<SEC-DOCUMENT>0000950123-22-008876.txt : 20221017
<SEC-HEADER>0000950123-22-008876.hdr.sgml : 20221017
<ACCEPTANCE-DATETIME>20220812170441
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-22-008876
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		30
FILED AS OF DATE:		20220812
<PUBLIC-REL-DATE>20221017
DATE AS OF CHANGE:		20220815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acrivon Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781174
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-06317
		FILM NUMBER:		221161110

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL WAY, SUITE 100
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-207-8979

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL WAY, SUITE 100
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on August&nbsp;12,
2022. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information
herein remains strictly confidential. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES
ACT OF 1933 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Acrivon Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Exact name of registrant as specified in its charter) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-5125532</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Primary Standard Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Classification Code Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Identification No.)</P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>480 Arsenal Way, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Watertown, Massachusetts 02472 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">207-8979</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Peter Blume-Jensen, M.D., Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer and President </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Acrivon Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>480 Arsenal Way, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Watertown, Massachusetts 02472 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">207-8979</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>Copies to: </I></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ryan Sansom</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mark
Ballantyne</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Katherine Denby</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>55 Hudson
Yards</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10001</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">479-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Edwin O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>William A. Magioncalda</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin Procter LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>620
Eighth Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10018</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">813-8800</FONT></B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after
this Registration Statement is declared effective. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)&nbsp;under the Securities Act,
please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and
&#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Large&nbsp;accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9744;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9746;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Smaller&nbsp;reporting&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9746;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Emerging&nbsp;growth&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">&#9746;</P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration
Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Arial Narrow" ALIGN="justify"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and
may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers
to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#de1a1e"><I>SUBJECT TO COMPLETION, DATED&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022
</I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#de1a1e"><I>PRELIMINARY PROSPECTUS </I></FONT></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>Shares </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g44x13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Common Stock </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>We are offering
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. This is our initial public offering, and no public market currently exists for shares of our common stock. We expect the initial public offering
price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. We intend to apply to list our common shares on the Nasdaq Global
Market under the symbol &#147;ACRV.&#148; </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an
&#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under federal securities laws, and, as such, will be subject to reduced public company reporting requirements for this prospectus and future filings. See the
section titled &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#148; Investing in our common stock involves risks. See the section titled &#147;<A HREF="#toc383050_4">Risk
Factors</A>&#148; beginning on page&nbsp;13. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT" ALIGN="justify"><B><I>Neither the Securities and Exchange Commission nor any state securities commission
has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Per&nbsp;Share</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Total</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Initial Public Offering Price</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Underwriting Discounts and
Commissions&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Proceeds, before expenses, to us</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>We refer you to &#147;Underwriting&#148; for additional information regarding total underwriter
compensation. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>We have granted the underwriters an option for a period of 30 days to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The underwriters expect to deliver the shares of common stock against payment in New York, New&nbsp;York on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><I>MORGAN&nbsp;STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>JEFFERIES</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>COWEN</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>PIPER&nbsp;SANDLER</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2022 </I></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_6">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_9">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_10">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_11">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_14">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_18">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_19">Certain Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_20">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_23">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc383050_24">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than
those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We
are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the
time of delivery of this prospectus or of any sale of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For investors outside of the United States: We
have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of
the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">OncoSignature is our trademark and is used in this prospectus. This prospectus also includes trademarks, tradenames and
service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus appear without the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&nbsp;symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable
licensor to these trademarks and tradenames. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This summary highlights, and is qualified in its entirety by, information contained elsewhere in this prospectus. This
summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes appearing elsewhere in this prospectus, before making an investment decision. As used in this prospectus, unless the
context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;the company,&#148; &#147;Acrivon&#148; and &#147;Acrivon Therapeutics&#148; refer to Acrivon Therapeutics, Inc. and, where appropriate, our
subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose
tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. Recently approved targeted oncology treatments, such as kinase inhibitors, have transformed the
cancer treatment landscape, and while the therapeutic benefit of these agents has provided significant benefit to patients, these targeted oncology treatments unfortunately only address the less than 10% of patients with cancers that harbor certain
easily-identifiable genetic mutations. Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or
AP3, to develop our pipeline of oncology drug candidates. Our AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates,
which we refer to as patient responders. We are currently advancing our lead candidate, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> a potent CHK1 and CHK2, or CHK1/2, inhibitor, in a potentially registrational Phase 2 trial across multiple
tumor types, which our AP3 platform predicts will have a high proportion of patient responders based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Our <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature test has been extensively validated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from patients with ovarian cancer treated with <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in past Phase&nbsp;2 clinical trials conducted by Eli Lilly and Company, or Lilly, and at the National Cancer Institute, or NCI, demonstrating robust enrichment of responders through our method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The AP3 approach is proteomics-based and designed to enable identification and treatment of the patients whose tumors are
sensitive to a specific drug or drug candidate based on direct protein measurement of critical tumor-driving mechanisms and independent of underlying genetic alterations. We believe our approach is applicable across stages of drug development and
across therapeutic modalities. Accordingly, the AP3 method is not limited to the typically very small subset of cancers driven by single gene driver mutations or susceptible to a synthetic lethal approach. Rather, we believe our method is broadly
applicable to the vast majority of cancers, in particular the majority of solid tumors, for which genetics-based approaches have proven insufficient to identify patient responders in many cases. In principle, we believe a much larger percentage of
tumors can be addressed therapeutically using agents attuned to the specific biochemical signaling pathways found in these tumors, which our AP3 platform was purposefully designed to enable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By applying our highly specific patient selection approach to drug development, we seek to both accelerate clinical
development and significantly increase the probability of successful treatment outcomes for patients. Our pipeline includes the Phase 2 lead program, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> also known as prexasertib, a targeted oncology
asset that has been demonstrated to potently inhibit CHK1/2. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been dosed in more than 400 patients at the recommended Phase 2 dose, or RP2D, with reported deep, durable responses, including complete
responses, or CRs, in a proportion of patients with solid tumors in past single center and multi-center Phase 2 clinical trials in tumor indications with high unmet need. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has also demonstrated a
favorable safety and tolerability </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
profile with primarily reversible hematological toxicity and very limited <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicity. We have received clearance from the U.S. Food and
Drug Administration, or FDA, for an Investigational New Drug, or IND, application to advance <FONT STYLE="white-space:nowrap">ACR-368</FONT> in Phase 2 single arm clinical trials conducted under the FDA program known as the master protocol, which
was developed to help expedite drug development in multiple tumor types for drugs with an established RP2D within the same overall trial structure. Initially, patients with platinum-resistant ovarian, endometrial, or bladder cancer will be treated
in this trial. Patients will be stratified for treatment based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> across multiple sites in the United States in this trial with registrational intent. Through the
use of our OncoSignature test, we believe we can significantly increase the overall response rate, or ORR, observed in previous trials that were conducted without a prospective patient responder identification method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also plan to study <FONT STYLE="white-space:nowrap">ACR-368</FONT> in additional indications, such as human papilloma virus
positive, or HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>, squamous cell carcinomas, including squamous cell cancer, or SCC, of head and neck, or SCCHN, anal, and cervical cancer, based on demonstrated clinical single agent activity in
SCCHN and anal cancer and OncoSignature-based prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in a proportion of patients. In addition to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we are also developing
internally-discovered preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response, or DDR, and cell cycle regulation pathways, including WEE1, a protein kinase, and a closely related, undisclosed serine/threonine
kinase.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our AP3 Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform is based on our proprietary approach developed to enable treatment of the patients who are most likely to
respond to any particular drug candidate based on dependency in the tumor on the upregulated specific biochemical pathways that each drug modulates. Hence, our approach is tumor-agnostic: if the pathways the tumor depends on for its survival and
growth, and that the drug candidate modulates, are upregulated, we predict that individual patient&#146;s tumor will be sensitive to the drug candidate. This applies regardless of the tumor origin and is independent of underlying genetic
alterations. We are applying AP3 broadly to clinically active drug candidates as well as carefully selected preclinical lead series with a strong clinical rationale, and for which there is no obvious patient selection path through standard companion
diagnostic approaches. We also intend to explore the use of AP3 with approved drugs to improve the ORR and outcomes for patients through our patient selection approach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One of the key outputs of our AP3 platform are our proprietary, response-predictive clinical tests that we refer to as
OncoSignature tests. These are drug-tailored, automated, quantitative proteomic tissue imaging tests applied to pretreatment tumor biopsies as a companion diagnostic, or CDx, to select and treat the patients predicted to benefit from the drug
candidate. Our OncoSignature tests encompass a signature of three classes of functionally-defined protein biomarkers assembled into a single signature assay. The quantitative levels for each of the three biomarkers are defined to determine whether a
patient&#146;s individual tumor has upregulated the biochemical signaling mechanisms that the drug modulates and that the tumor depends on for growth and/or survival. Our company name, Acrivon, is derived from Greek for &#147;accurate.&#148; We
chose it to embody how our OncoSignature tests are designed to accurately match our therapies with patients who will benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tumor-agnostic application of OncoSignature tests enables us to identify and focus on tumor types for which a high unmet
need for a treatment exists and that are predicted to be highly sensitive to our drug candidates. We achieve this by deploying our OncoSignature screening of human cancer samples across various tumor types. Through this process, we can identify new
tumor types predicted to be sensitive to a drug candidate and even estimate the percentage of predicted responders before entering clinical trials. For example, we have identified endometrial cancer and bladder cancer as two highly sensitive cancer
types for <FONT STYLE="white-space:nowrap">ACR-368,</FONT> and therefore will include patients with these tumor types in our Phase 2 trials. Moreover, we have found through this approach that a proportion of patients with HPV<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> cancers are predicted to be responsive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> consistent with </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
previously demonstrated clinical activity in a proportion of patients with SCCHN and anal cancer. Furthermore, we predicted that patients with squamous
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, or sqNSCLC, would not respond to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> consistent with an observed 0% ORR in patients with this tumor type in a past trial with <FONT
STYLE="white-space:nowrap">ACR-368.</FONT> Hence, through our OncoSignature screening approach, we can specifically avoid running clinical trials in cancer types predicted to have limited sensitivity to the drug candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are not only using our AP3 platform to generate drug-tailored, response-predictive clinical OncoSignature tests, but we
also use our AP3 platform to provide unbiased, quantitative analyses of <FONT STYLE="white-space:nowrap">off-target</FONT> effects on intracellular signaling using phosphoproteomic profiling, potentially enabling us to discover inhibitors that are
both highly potent and highly selective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that by leveraging our AP3 platform and clinical OncoSignature tests,
we will profoundly alter precision oncology drug development and the treatment landscape of patients suffering from cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g383050g10r11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Lead Clinical Candidate <FONT STYLE="white-space:nowrap">ACR-368</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">ACR-368</FONT> is a selective, potent inhibitor of CHK1/2 which are regulators of the cell
cycle and of DDR and have been validated as attractive drug targets in multiple preclinical models. Several CHK1/2 inhibitors including <FONT STYLE="white-space:nowrap">ACR-368,</FONT> previously known as prexasertib, have been investigated in the
clinic; however, none have been approved by the FDA. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has shown deep, durable single agent clinical activity, including CRs and partial responses, PRs, in a proportion of patients with solid tumors with
high unmet need for a treatment, such as platinum-resistant ovarian cancer, and SCCs, including SCCHN and anal cancer. More than 400 patients with these tumors have been treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy at the
RP2D in advanced single- and multi-center clinical trials conducted by Lilly, NCI, and at MD Anderson Cancer Center, or MDACC. The ORR in these trials without a predictive biomarker was 29% at the single center Phase 2 ovarian cancer trial at NCI in
the intent to treat, or ITT, population, and approximately 12% across the platinum-resistant ovarian cancer cohorts in the large Phase 2 multi-center international trial sponsored by Lilly. The median duration of response, or mDoR, at the
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
RP2D across trials to date have ranged from almost six months to over 12 months, and <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy demonstrated a generally favorable safety and
tolerability profile with primarily reversible hematological toxicity and very limited <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicity. Based on these two trials, encompassing over 200 patients with ovarian cancer, primarily
platinum-resistant, we believe the unenriched background ORR in a larger patient population of platinum-resistant ovarian cancer is somewhere between 15% and 20%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using our AP3 platform, we have developed a predictive OncoSignature test for <FONT STYLE="white-space:nowrap">ACR-368,</FONT>
called <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, that we believe can predict patient response to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy and therefore substantially improve the clinical ORR and, furthermore,
that, we believe, has the potential to enable expedited drug development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By applying our
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test for indication finding and expansion across human cancer types we have found that approximately 30% of samples from patients with ovarian cancer are
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive. Moreover, we observed that between 30% and 40% of patients with endometrial and bladder cancer are predicted highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT>
Patients with these two types of cancer were not previously treated in clinical trials. All three tumor types are therefore included in our upcoming Phase 2 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also used our AP3 platform to identify resistance mechanisms to <FONT STYLE="white-space:nowrap">ACR-368.</FONT>
Through phospho-proteomic profiling of human tumor cell lines that are either highly sensitive or highly resistant to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we uncovered key resistance mechanisms and found that very low dose gemcitabine,
or LDG, could be used to overcome resistance and further sensitize human tumor cells to <FONT STYLE="white-space:nowrap">ACR-368</FONT> through inducing increased DDR stress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on these results, we are initiating a Phase 2 clinical trial where we intend to treat patients with all three tumor
types: platinum-resistant ovarian, endometrial, and bladder cancer. <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients, which we believe will represent 30% to 40% of patients of each tumor type, will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> monotherapy in a single arm Phase 2b trial for each of the three tumor types. The <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients with these three tumor types will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> combined with LDG in a Phase 1b trial, followed by expansion into a Phase 2 trial with the combination in all three tumor types. As a result, all patients biopsied with these tumor types will have the
opportunity to receive therapy. This Phase 2 clinical trial design and protocol has been cleared by FDA and we anticipate beginning patient enrollment in the second half of 2022. We believe this trial, if successful, has the potential to be
registrational for <FONT STYLE="white-space:nowrap">ACR-368</FONT> in each of the three tumor types. We believe that use of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to select patients predicted to be sensitive to <FONT
STYLE="white-space:nowrap">ACR-368</FONT> for treatment will significantly increase the ORR, which has the potential to lead to accelerated approval for multiple cancers while avoiding treatment of patients with tumors that are not likely to
respond. We are planning to file an IND application amendment to add three additional cancer types under the same trial protocol design at a later time, including head and neck cancer, anal cancer, and cervical cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Preclinical Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also have two preclinical drug programs designed to take advantage of our AP3 platform and the ability to predict tumor
sensitivity based on custom OncoSignature tests. Both of these programs are structure-guided with rational medicinal chemistry efforts based on <FONT STYLE="white-space:nowrap">co-crystallography</FONT> of lead series with their respective targets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The first of these is directed at WEE1, a target that has been well-validated in preclinical studies described in the
literature, and a critical node in the DDR pathways. The second, equally advanced preclinical program is directed at a closely related serine/threonine kinase also serving critical functions in the cell cycle and DDR pathways. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on results from our AP3 platform, we believe that we can predict
drug-sensitivity using a proteomics-based OncoSignature test. We anticipate advancing our WEE1 inhibitor and an inhibitor against a closely related, undisclosed serine/threonine kinase into <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
studies in 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal is to be the leading biopharmaceutical company leveraging proteomic and phosphoproteomic data, which we access through
our proprietary AP3 platform, to unlock insights beyond genomic based approaches and discover and efficiently develop medicines to benefit patients with cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The key elements of our strategy summarized below are to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rapidly advance <FONT STYLE="white-space:nowrap">ACR-368,</FONT> our CHK1/2 inhibitor, through clinical
development in ovarian, bladder, and endometrial cancer by enrolling <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selectively pursue AP3 identified rational drug combinations with our drug candidates in
OncoSignature-negative patients, initially <FONT STYLE="white-space:nowrap">ACR-368</FONT> with <FONT STYLE="white-space:nowrap">low-dose</FONT> gemcitabine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discover and develop a pipeline of proprietary drug candidates by leveraging our AP3 platform and predictive
OncoSignature tests. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Acquire rights to drug candidates for which we believe our OncoSignature tests can increase the likelihood of
clinical success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Opportunistically enter into strategic <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships
around predictive OncoSignature tests to maximize the full potential of our AP3 platform. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were founded and are led by pioneers in oncogenic signaling, oncology precision medicine and the use of proteomic technology
to uncover intracellular biochemical signaling pathways with the goal of applying this knowledge to develop drug candidates and clinical diagnostics. Our founders have pioneered and established <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> including clinical implementation, for the underlying technologies in our AP3 platform. Our scientific advisors are thought leaders from leading global cancer and academic centers and are
actively involved in our drug development process. We are supported by leading healthcare investors, Wellington Management, Surveyor Capital, RA Capital, Perceptive Advisors, Sands Capital, HBM Partners, Marshall Wace, Pureos Bioventures, HealthCor,
Acorn Bioventures, Alexandria Venture Investments and Chione. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is subject to numerous risks that you should be aware of before making an investment decision. These risks are
described more fully in the section titled &#147;Risk Factors&#148; and include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant losses since our inception. We expect to incur losses over the next several years
and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and no history of commercializing products, which may make it difficult
for an investor to evaluate the success of our business to date and to assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will need additional funding to meet our financial obligations and to
pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned longer-term operations and the pursuit of our growth strategy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are highly dependent on the success of our lead drug candidate, ACR-368, as this is our first drug
candidate being developed for clinical development and regulatory approval. We may never obtain approval for <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other drug candidate. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business substantially depends upon the successful clinical development of drug candidates using our AP3
platform and OncoSignature companion diagnostics. If we are unable to obtain regulatory approval for, and successfully commercialize, drugs developed through the application of our AP3 platform and OncoSignature tests, our business may be materially
harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time
consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, on a timely basis or at all, our business will be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our relationships with customers, healthcare providers, including physicians, and third-party payors are
subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied,
with such laws, we could face substantial penalties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators,
contracted laboratories and contract research organizations, or CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be
able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The targeted oncology space is competitive, which may result in others discovering, developing or
commercializing products before or more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success depends on our ability to retain key executives and to attract, retain and motivate
qualified personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our success depends in part on our ability to obtain intellectual property rights for our proprietary
technologies and drug candidates, as well as our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend on intellectual property licensed from a third party and termination of this license could result in
the loss of significant rights, which would harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified material weaknesses in our internal control over financial reporting. If we are unable to
remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial
condition or results of operations, which may adversely affect our business. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a
Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our
Business Startups Act of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies.
These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, as amended, in the assessment of our internal control over financial reporting;</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes
on executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding
the communication of critical audit matters in the auditor&#146;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
may take advantage of these provisions until the last day of the fiscal year ending after the fifth anniversary of the completion of this offering or such earlier time that we no longer qualify as an emerging growth company. We will cease to qualify
as an emerging growth company on the date that is the earliest of: (1)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering, (2)&nbsp;the last day of the fiscal year in which we have
more than $1.07&nbsp;billion in total annual gross revenues, (3)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the rules of the U.S. Securities and Exchange Commission or (4)&nbsp;the date on which we have
issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over the prior three-year period. We will be deemed to be a &#147;large accelerated filer&#148; at such time that we (a)&nbsp;have an aggregate
worldwide market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of $700&nbsp;million or more as of the last business day of our most recently completed second fiscal quarter, (b)&nbsp;have been required to
file annual and quarterly reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, for a period of at least 12 months and (c)&nbsp;have filed at least one annual report pursuant to the Exchange Act. We may choose to take
advantage of some but not all of these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different than you might obtain from other
public companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, under the JOBS Act, emerging growth companies can delay
adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain
of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public
companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in this prospectus may be different than
the information you may receive from other public companies in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less
active trading market for our common stock and higher volatility in our share price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller
reporting company&#148; as defined under the Exchange Act. We may continue to be a smaller reporting company for so long as either (i)&nbsp;the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less
than $250&nbsp;million as of the last business day of our most recently completed second fiscal quarter or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our common
stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million as of the last business day of our most recently completed second quarter. If we are a smaller reporting company at the time we cease to be an
emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent
fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a
smaller reporting company with less than $100&nbsp;million in annual revenue, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were incorporated under the laws of the State of Delaware in March 2018. Our principal executive offices are located at 480
Arsenal Way, Suite 100, Watertown, Massachusetts 02472, and our telephone number is (617) <FONT STYLE="white-space:nowrap">207-8979.</FONT> Our website address is <I>www.acrivon.com</I>. The information contained on, or accessible through, our
website is not incorporated by reference into this prospectus. We have included our website in this prospectus solely as an inactive textual reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We have granted the underwriters an option for a period of 30&nbsp;days to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise in full their option to purchase additional shares).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the
underwriters exercise in full their option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock), assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We
currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, <U></U><B></B>(i)<B></B>&nbsp;to fund our ongoing and planned clinical development, including advancing our lead drug candidate
ACR-368 through initial Phase&nbsp;2 clinical readouts, as well as initiating our Phase&nbsp;2 trial in patients with HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> tumors, (ii)&nbsp;to enter IND-enabling stage for at least one of our
preclinical programs and fund continued development of our AP3 platform and (iii)&nbsp;the remainder for research and development activities, working capital and other general corporate purposes. See the section titled &#147;Use of Proceeds&#148;
beginning for additional information.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You should read the section titled &#147;Risk Factors&#148; for a discussion of factors you should consider carefully, together with all the other information included in this prospectus, before deciding to invest in our common
stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#147;ACRV&#148;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering is based on
31,835,656 shares of our common stock outstanding as of June&nbsp;30, 2022, after giving effect to the conversion of all outstanding shares of our preferred stock into an aggregate of 27,471,911 shares of common stock, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,111,703 shares of our common stock issuable upon the exercise of options outstanding as of June&nbsp;30,
2022 under our 2019 Stock Incentive Plan, or the 2019 Plan, at a weighted-average exercise price of $1.15 per share (which does not include options to purchase an aggregate of 410,000 shares of our common stock, at a weighted-average exercise price
of $1.65 per share, that were granted subsequent to June&nbsp;30, 2022); </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,474,989 shares of our common stock available for future issuance as of June&nbsp;30, 2022 under the 2019
Plan, which shares will cease to be available for issuance under the 2019 Plan at the time our 2022 Equity Incentive Plan, or the 2022 Plan, becomes effective and will be added to, and become available for issuance under, the 2022 Plan; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock reserved for future issuance under our 2022 Plan, which will become effective on the date of the underwriting agreement related to this offering, as well as any automatic increases in the number of shares of common stock reserved for
future issuance under the 2022 Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, all information contained in this
prospectus, including the number of shares of common stock that will be outstanding after this offering, assumes or gives effect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all outstanding shares of our preferred stock into 27,471,911 shares of our common stock,
which will occur upon the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stock</FONT></FONT> split of our common stock effected
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this
offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options referred to above after June&nbsp;30, 2022; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read the following summary consolidated financial data together with our consolidated financial statements and the
related notes appearing at the end of this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. The summary condensed consolidated statements of
operations data for the six months ended June&nbsp;30, 2022 and 2021 and the condensed consolidated balance sheet data as of June&nbsp;30, 2022 have been derived from our unaudited condensed consolidated financial statements appearing at the end of
this prospectus and have been prepared on the same basis as the audited consolidated financial statements. We have derived the consolidated statement of operations data for the years ended December&nbsp;31, 2021 and 2020 from our audited
consolidated financial statements appearing at the end of this prospectus. In the opinion of management, the unaudited data reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial
information in those statements. Our historical results are not necessarily indicative of the results that may be expected in any future period and the results for the six months ended June&nbsp;30, 2022 are not necessarily indicative of the results
to be expected for the fiscal year ending December&nbsp;31, 2022 or any other future period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#150; basic and
diluted<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (2.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (2.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (3.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (1.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common stock outstanding &#150; basic and diluted<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,363,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,237,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,299,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share &#150; basic and
diluted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average common stock outstanding &#150; basic and diluted<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,835,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,771,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">See Note 13 to our audited consolidated financial statements and Note 11 to our unaudited condensed
consolidated financial statements appearing at the end of this prospectus for details on the calculation of basic and diluted net loss per share attributable to common stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Pro forma basic and diluted net loss per share attributable to common stockholders has been prepared to give
effect to adjustments to our capital structure arising in connection with the completion of this offering </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and is calculated by dividing pro forma net loss attributable to common stockholders by the pro forma weighted-average common shares outstanding for the period. The unaudited pro forma net loss
attributable to common stockholders used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to common stockholders is equal to net loss attributable to common stockholders. The unaudited pro forma basic and
diluted weighted-average common shares outstanding used in the calculation of unaudited pro forma basic and diluted net loss per share for the six months ended June&nbsp;30, 2022 and year ended December&nbsp;31, 2021 have been prepared to reflect
the conversion of all of the outstanding shares of our convertible preferred stock into an aggregate of 27,471,911 shares of our common stock as if the offering had occurred on January&nbsp;1, 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma,<BR>As<BR>Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholder&#146;s (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;85,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Gives effect to the conversion of all of the outstanding shares of our preferred stock into an aggregate of
27,471,911 shares of our common stock upon the closing of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Gives further effect to the sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting fees and
commissions and estimated offering expenses payable by us. This pro forma as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00
increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase or decrease of 1.0&nbsp;million in the number of shares we are offering would increase or decrease the pro forma as adjusted amount of each
of cash and cash equivalents, working capital, total assets and stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public
offering price per share and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">We define working capital as current assets less current liabilities. See our consolidated financial
statements and related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties
described below, together with all of the other information in this prospectus, including our financial statements and related notes, before deciding whether to purchase shares of our common stock. The risks and uncertainties described below are not
the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks are realized, our business, financial
condition, results of operations and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Capital Needs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or
maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have incurred significant losses, and we expect to continue to
incur significant expenses and operating losses for the foreseeable future. Our net losses were $16.2&nbsp;million and $5.3&nbsp;million for the year ended December&nbsp;31, 2021 and 2020, respectively, and $13.0&nbsp;million and $9.5&nbsp;million
for the six months ended June&nbsp;30, 2022 and 2021, respectively. As of June&nbsp;30, 2022, we had an accumulated deficit of $37.9&nbsp;million. Since our inception, we have financed our operations with aggregate net proceeds of
$119.8&nbsp;million from the issuance of convertible notes and the sale of our Series A-1 convertible preferred stock and Series B convertible preferred stock. We have no products approved for commercialization and have never generated any revenue
from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our drug candidates are still in clinical and preclinical testing. We expect to continue to
incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to conduct our ongoing clinical trials of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> as well as
initiate and complete additional clinical trials of future drug candidates or current drug candidates in new indications or patient populations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to advance the preclinical development of our other drug candidates and our preclinical and discovery
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approval for any drug candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursue marketing approvals and reimbursement for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture material under current good manufacturing practices, or cGMP, for clinical trials and potential
commercial sales at our contracted manufacturing facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, establish and validate our commercial-scale cGMP manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, enforce, defend and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with regulatory requirements established by the applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish, either alone or with a third party, a sales, marketing and distribution infrastructure and scale up
external, or establish internal, manufacturing and distribution capabilities to commercialize any drug candidates for which we may obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire and retain additional personnel, including research, clinical, development, manufacturing quality
control, quality assurance, regulatory and scientific personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial, corporate development, management information systems and administrative
personnel, including personnel to support our product development and planned future commercialization efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting and other expenses in operating as a public company. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, we have not generated any revenue from the commercialization of any
drug candidate. To become and remain profitable, we must succeed in developing and eventually commercializing drug candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including
completing preclinical testing and clinical trials of our drug candidates, validating manufacturing processes, obtaining regulatory approval, and manufacturing, marketing and selling any drug candidates for which we may obtain regulatory approval,
as well as discovering and developing additional drug candidates. All of our drug candidates are in clinical or preclinical development. We may never succeed in these activities and, even if we do, may never generate any revenue or revenue that is
significant enough to achieve profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of the numerous risks and uncertainties associated with drug
candidate development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform clinical trials or preclinical studies in
addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our drug candidates, our expenses could increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our
failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain product approvals, diversify our offerings or continue our
operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have a limited
operating history and no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biopharmaceutical company with a limited operating history. We commenced operations in March 2018, and
our operations to date have been largely focused on organizing and staffing our company, business planning, raising capital, building our AP3 platform, developing our manufacturing capabilities and developing our clinical and preclinical drug
candidates, including undertaking preclinical studies and conducting clinical trials. To date, we have not yet demonstrated our ability to successfully complete pivotal clinical trials, obtain regulatory approvals, manufacture a product on a
commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization, and we may not be successful in doing so. Consequently, any predictions you make about our
future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties,
complications, delays and other known and unknown factors. We will eventually need to transition from a company with a research and clinical focus to a company, if any of our drug candidates are approved, capable of supporting commercial activities.
We may not be successful in such a transition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if this offering is successful, we will need additional funding to meet our
financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned longer-term operations and the pursuit of our growth strategy. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operations have consumed substantial amounts of cash since inception, and we expect to continue to incur significant
expenses and operating losses over the next several years as we continue to develop our drug candidate pipeline and, to a lesser extent, build out our manufacturing capabilities for our drug candidates, which, if approved, may not achieve commercial
success. Our revenue, if any, will be derived from sales of products that may not be commercially available for a number of years, if at all. If we obtain marketing approval for any drug candidates that we develop or otherwise acquire, we expect to
incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. We also expect an increase in our expenses associated with creating additional infrastructure to support operations as a public
company. Accordingly, we will need to obtain substantial additional funding in order to continue our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had cash and cash equivalents of
$83.9&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditure requirements
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . This estimate is based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We
plan to use the net proceeds from this offering to fund clinical development, manufacturing supply and initial commercialization costs for <FONT STYLE="white-space:nowrap">ACR-368,</FONT> and the remainder for working capital and other general
corporate purposes, including development of additional programs in our pipeline. The net proceeds from this offering, together with our existing cash and cash equivalents, may not be sufficient to fund any of our drug candidates through regulatory
approval. Changes may occur beyond our control that would cause us to consume our available capital before that time, including changes in and progress of our development activities, acquisitions of additional drug candidates and changes in
regulation. The timing and amount of our funding requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate of progress in the development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and our other drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies,
preclinical development, laboratory testing and clinical trials for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and future drug candidates and associated development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we develop, <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other drug
candidates and technologies in our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs as well as timing of process development and manufacturing <FONT
STYLE="white-space:nowrap">scale-up</FONT> and validation activities associated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> and our future drug candidates and other programs as we advance them through preclinical and clinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our AP3 platform to identify patient responders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and development requirements of drug candidates that we may pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our research and development capabilities and establish
a commercial infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and costs of securing sufficient capacity for commercial supply of our drug candidates, or the raw
material components thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales
and distribution, for any of our drug candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs necessary to obtain regulatory approvals, if any, for products in the United States and other
jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continuation of our existing licensing and collaboration arrangements and entry into new collaborations
and licensing arrangements, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need and ability to hire additional research, clinical, development, scientific and manufacturing
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs we incur in maintaining business operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to implement additional internal systems and infrastructure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological, product and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our drug candidates for which we receive marketing
approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business disruptions affecting the initiation, patient enrollment, development and operation of our clinical
trials, including a public health emergency, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or geopolitical events, including the ongoing Russian invasion of Ukraine, and related sanctions against Russia.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will require additional capital to achieve our business objectives. Additional funds may not be
available on a timely basis, on favorable terms or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Any additional fundraising efforts may divert our management from
their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our drug candidates. Further, our ability to raise additional capital
may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing Russian invasion of Ukraine
and related sanctions against Russia, and the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our
growth strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to
relinquish rights to our technologies or drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Until such time, if ever, as we can generate substantial
revenue, we may finance our cash needs through a combination of equity offerings, government or private-party grants, debt financings and license and collaboration agreements. We do not currently have any committed external source of funds. To the
extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect your
rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we raise additional funds through collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates, grant licenses on terms that may not be favorable to us or commit
to future payment streams. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights
to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Design and Development of
Our Drug Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are highly dependent on the success of our lead drug candidate, ACR-368, as this is our first drug
candidate being developed for clinical development and regulatory approval. We may never obtain approval for <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other drug candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future success is highly dependent on our ability to obtain regulatory approval for, and then successfully commercialize or
identify a strategic partner to commercialize, our lead drug candidate, <FONT STYLE="white-space:nowrap">ACR-368.</FONT> <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been dosed in more than 400 patients at the RP2D in past single center and
multi-center Phase 2 clinical trials. We have received clearance from the FDA for an IND application to advance <FONT STYLE="white-space:nowrap">ACR-368</FONT> in Phase 2 single arm clinical trials conducted under the FDA program known as the master
protocol. We currently have no products that are approved for sale in any jurisdiction. <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any of our other future drug candidates may not achieve success in their clinical trials or obtain regulatory
approval. If we do not obtain regulatory approval for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and successfully commercialize <FONT STYLE="white-space:nowrap">ACR-368</FONT> in one or more indications or if we experience significant delays in
doing so, we may never generate any revenue or become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to generate product revenues, which we do
not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or other future drug
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
candidates identified through the application of our AP3 platform and OncoSignature companion diagnostics. The success of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other future drug
candidate will depend on several factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely and successful enrollment of patients in, and completion of, clinical trials with favorable results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstration of safety, efficacy and acceptable risk-benefit profiles of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> and our future drug candidates to the satisfaction of the FDA and other regulatory agencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our AP3 platform-based OncoSignature tests to identify patient responders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the AP3 platform may not work equally well for all therapeutic targets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability, or that of our collaborators, to develop and obtain clearance or approval of companion
diagnostics, on a timely basis, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt and related terms of marketing approvals from applicable regulatory authorities for <FONT
STYLE="white-space:nowrap">ACR-368</FONT> and our future drug candidates, including the completion of any required post-marketing studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raising additional funds necessary to complete the clinical development of and commercialization of <FONT
STYLE="white-space:nowrap">ACR-368;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully identifying and developing, acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT>
additional drug candidates to expand our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of an IND application by the FDA or other similar clinical trial applications from other regulatory
authorities for clinical trials for future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory
exclusivity for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and our future drug candidates and our OncoSignature companion diagnostics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both
clinical and commercial supplies of our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if
approved, whether alone or in collaboration with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our products, if approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other therapies available on the market or in development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining third-party payor coverage and adequate reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of any products following regulatory approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of these factors are beyond our control, and it is possible that none of our drug candidates,
including <FONT STYLE="white-space:nowrap">ACR-368,</FONT> will ever obtain regulatory approval even if we expend substantial time and resources seeking such approval. If we experience significant delays or are otherwise unable to successfully
commercialize our drug candidates, it would materially harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business substantially depends upon the successful
clinical development of drug candidates using our AP3 platform and OncoSignature companion diagnostics. If we are unable to obtain regulatory approval for, and successfully commercialize, drugs developed through the application of our AP3 platform
and OncoSignature tests, our business may be materially harmed.</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using our AP3 platform, we have developed
predictive OncoSignature tests for our clinical drug candidate, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> as well as for two other clinical stage drug candidates. Negative results in the development of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<FONT STYLE="white-space:nowrap">ACR-368</FONT> may also impact our ability to successfully develop other drug candidates, either at all or within anticipated timeframes because, although other
drug candidates may target different indications, the underlying technology platform, and specifically the use of an OncoSignature test, to identify patient responders is the same for all of our drug candidates. Accordingly, a failure in any one
program may decrease trust in our AP3 program. In addition, if <FONT STYLE="white-space:nowrap">ACR-368</FONT> shows unexpected adverse events or a lack of efficacy in the indications we intend to treat, or if we experience other regulatory or
developmental issues, our development plans and business could be significantly harmed. We cannot guarantee the successful clinical development, approval and commercialization of ACR-368. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently
unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, on a timely basis or at all, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead drug candidate is currently in Phase&nbsp;2 clinical development under a master protocol designed for expedited drug
development using our ACR-368 OncoSignature test. Although we are using our OncoSignature test to specifically treat patients predicted to be sensitive to ACR-368, we cannot guarantee that we will achieve sufficient ORR for marketing approval. For
our preclinical drug candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidate in humans before obtaining marketing approval from regulatory
authorities. Clinical testing is expensive, difficult to design and implement, can take many&nbsp;years to complete and is uncertain as to the outcome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The length of time necessary to complete clinical trials and to submit an application for marketing approval for a decision by
a regulatory authority may be difficult to predict. The clinical trial requirements of the FDA and other comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a drug candidate vary
substantially according to the type, complexity, novelty and intended use and market of the drug candidate. As a result, the regulatory approval process for drug candidates such as ours is uncertain and may be more expensive and take longer than the
approval process for drug candidates based on other, better known or more extensively studied technologies. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our drug candidates in either
the United States or other comparable regions of the world or how long it will take to commercialize our drug candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential drug
candidate to market would adversely affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
drug candidates, including ACR-368, could fail to receive regulatory approval for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities
that a drug candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or
comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a drug candidate&#146;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our drug candidates may not be sufficient to support the submission
of a New Drug Application, or NDA, to the FDA or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or
facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or third-party collaborators may fail to obtain regulatory approval of companion diagnostic tests, if
required, on a timely basis, or at all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to obtaining approval
to commercialize a drug candidate in the United States or elsewhere, we or our collaborators must demonstrate with substantial evidence from one or more well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign
regulatory agencies, that such drug candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our
drug candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our drug
candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other studies required by the FDA or comparable foreign regulatory authorities, approval of any
regulatory approval applications that we submit may be delayed by several years, or may require us to expend significantly more resources than we have available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Of the large number of potential products in development, only a small percentage successfully complete the FDA or comparable
foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our drug candidates, which
would significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, as of May&nbsp;26, 2021, the
FDA noted it is continuing to ensure timely reviews of applications for medical products during the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in line with its user fee performance goals and conducting mission critical
domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a <FONT
STYLE="white-space:nowrap">pre-approval</FONT> inspection or an inspection of clinical sites is required and due to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and travel restrictions the FDA is unable to complete such
required inspections during the review period. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and <FONT
STYLE="white-space:nowrap">pre-approval</FONT> inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments
and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical
work, prioritize other higher-tiered inspectional needs (e.g., <FONT STYLE="white-space:nowrap">for-cause</FONT> inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. Should FDA determine that
an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it
generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the <FONT STYLE="white-space:nowrap">COVID-19</FONT> public health emergency, a
number of companies announced receipt of complete response letters due to the FDA&#146;s inability to complete required inspections for their applications. Regulatory authorities outside the United&nbsp;States may adopt similar restrictions or other
policy measures in response to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience delays in their regulatory activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, even if we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or
more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a post-marketing risk management strategy such as a Risk Evaluation and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Mitigation Strategy, or REMS, or the equivalent in another jurisdiction. Regulatory authorities may not approve the price we intend to charge for our products, may grant approval contingent on
the performance of costly post-marketing clinical trials, or may approve a drug candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing
scenarios could materially harm the commercial prospects for our drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Depending on our clinical trial results, we may
seek NDA approval for ACR-368 in the United States under FDA&#146;s accelerated approval pathway, but this pathway may not lead to faster development, regulatory review, or approval process and does not increase the likelihood that ACR-368 will
receiving marketing approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depending on our clinical trial results, we intend to seek approval for ACR-368 for
one or more indications, and we may seek approval of our future drug candidates, where applicable, under the FDA&#146;s accelerated approval pathway. A product may be eligible for accelerated approval if it is designed to treat a serious or
life-threatening disease or condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be
measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically
meaningful in the context of a given disease, such as IMM. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict
clinical benefit, but is not itself a measure of clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new product over available therapy may not be a direct therapeutic advantage, but is a clinically
important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to conduct adequate and well-controlled post-marketing clinical trials to confirm the
product&#146;s clinical benefit. These confirmatory trials must be completed with due diligence. If the sponsor fails to conduct such studies in a timely manner, or if such post-approval studies fail to verify the product&#146;s predicted clinical
benefit, the FDA may withdraw its approval of the product on an expedited basis. In addition, for products being considered for accelerated approval, the FDA currently requires, unless otherwise informed by the Agency, pre-approval of promotional
materials, which could adversely impact the timing of the commercial launch of the product. There can be no assurance that FDA would allow ACR-368 or any of the drug candidates we may develop to proceed on an accelerated approval pathway, and even
if FDA did allow such pathway, there can be no assurance that expedited development will occur or that FDA will review and approve such submission or application on a timely basis, or at all. Moreover, even if we received accelerated approval, any
post-marketing studies required to confirm clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. In addition, receiving accelerated approval does not assure that the product&#146;s accelerated
approval will eventually be converted to a traditional approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may incur additional costs or experience delays in completing,
or ultimately be unable to complete the development and/or commercialization of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our other future drug candidates identified through the application of our AP3 platform and OncoSignature companion
diagnostics. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any delays in the commencement or completion of our ongoing, planned or future clinical trials could
significantly increase our product development costs. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to obtain marketing approval or commercialize <FONT
STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates identified through the application of our AP3 platform and OncoSignature companion diagnostics, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, institutional review boards, or IRBs, or ethics committees, or ECs, may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA may disagree as to the design or implementation of our clinical trials or with our recommended doses
with respect to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> or any of our future drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or
clinical trial protocols with prospective contract research organizations, or CROs, and prospective trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials for <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates may produce
negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials, delay or halt clinical trials or abandon product development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials may be larger than we anticipate, enrollment in these
clinical trials may be slower than we anticipate or may be lower than we anticipate due to challenges in recruiting and enrolling suitable patients who meet the trial criteria, participants may drop out of these clinical trials at a higher rate than
we anticipate or the duration of these clinical trials may be longer than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition for clinical trial participants from investigational and approved therapies may make it more
difficult to enroll patients in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience difficulties in maintaining contact with patients after treatment, resulting in incomplete
data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or third-party collaborators may fail to obtain regulatory approval of companion diagnostic tests, if
required, on a timely basis, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at
all, or may fail to comply with regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have to suspend or terminate clinical trials for various reasons, including a finding by us or by a
Data Monitoring Committee for a trial that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates may have undesirable or
unexpected side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ECs to suspend or terminate the trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to clinical trial protocols; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates or
other materials necessary to conduct clinical trials may be insufficient or inadequate and result in delays or suspension of our clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may slow potential
enrollment, reduce the number of eligible patients for clinical trials, or reduce the number of patients who remain in our trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a
clinical trial or obtain timely marketing approvals. We do not know whether any of our planned preclinical studies or clinical trials will begin on a timely basis or at all, will need to be restructured or will be completed on schedule, or at all.
For example, the FDA may place a partial or full clinical hold on any of our current or future clinical trials for a variety of reasons, including safety concerns and noncompliance with regulatory requirements. If we are not able to complete
successful clinical trials, we will not be able to obtain regulatory approval and will not be able to commercialize <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right
to commercialize our drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our drug candidates, which would limit our future revenues and harm our commercial prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we or our companion diagnostic collaborator are unable to successfully develop and
obtain regulatory approval for our OncoSignature companion diagnostic tests for our drug candidates, or experience significant delays in doing so, we may not realize the commercial potential of our drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A key part of our development strategy for our drug candidates is to identify subsets of patients with specific types of
tumors. Identification of these patients will require the use and development of companion diagnostics. According to the FDA&#146;s 2014 guidance document on In Vitro Companion Diagnostic Devices, for novel therapeutic products that depend on the
use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product, the premarket application for the companion diagnostic device should be developed and approved or
cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion
diagnostic, the FDA&#146;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles for <FONT
STYLE="white-space:nowrap">co-development</FONT> of an in vitro companion diagnostic device with a therapeutic product. The draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic
product and its corresponding in vitro companion diagnostic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not have experience or capabilities in developing or
commercializing diagnostics and plan to rely in large part on our collaboration partner Akoya to perform these functions. Akoya has not commercialized or submitted or obtained Premarket Approval Application, or PMA, for any companion diagnostic, and
any setbacks they encounter could delay any commercial launch of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> if approved. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical
validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a drug candidate,
data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for,
manufacturing and commercializing companion diagnostics similar to those we face with respect to our drug candidates, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with
appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for our drug candidates, or experience delays in doing so, the development of these drug candidates may be adversely
affected, these drug candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that have or may obtain marketing approval. We may not be able to enter into arrangements with
another diagnostic company to develop and obtain regulatory approval for an alternative diagnostic test for use in connection with the development and commercialization of our drug candidates or do so on commercially reasonable terms, which could
adversely affect and/or delay the development or commercialization of our therapeutic candidates or therapeutics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices
and will likely require separate regulatory approval prior to commercialization. If we or third parties are unable to successfully develop companion diagnostics for our drug candidates, or experience delays in doing so: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of these drug candidates may be delayed because it may be difficult to identify patients for
enrollment in our clinical trials in a timely manner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">these drug candidates may not receive marketing approval if their safe and effective use depends on a
companion diagnostic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not realize the full commercial potential of these drug candidates that receive marketing approval if,
among other reasons, we are unable to appropriately identify patients or types of tumors targeted by these drug candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if our drug candidates and any associated companion diagnostics are approved for marketing, the need for companion
diagnostics may slow or limit adoption of our drug candidates. Although we believe companion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
diagnostic testing is becoming more prevalent in the diagnosis and treatment of cancer, our drug candidates may be perceived negatively compared to alternative treatments that do not require the
use of companion diagnostics, either due to the additional cost of the companion diagnostic or the need to complete additional testing prior to administering our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of these events were to occur, our business and growth prospects would be harmed materially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are
able to, the FDA may not permit us to proceed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we received clearance from the FDA for an IND to advance <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in Phase 2 single arm clinical trials conducted under the master protocol, we may not be able to file INDs for our other drug candidates on the timelines we expect. For example, we may experience, or our
partners may experience, manufacturing delays or other delays with <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin,
or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that
such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or
to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary
regulatory approval could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to initiate or continue our ongoing or
planned clinical trials if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. In addition, some of our competitors
currently have ongoing clinical trials for drug candidates that would treat the same patients as our lead clinical drug candidate, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our
competitors&#146; drug candidates. We rely on our external companion diagnostic partner, Akoya, to perform <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature testing in our clinical trial. If Akoya encounters delays or technical
challenges, enrollment in our clinical trials may be substantially delayed. Patient enrollment is also affected by other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators of appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the incidence and prevalence of our target indications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing studies or trials with similar eligibility criteria; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">invasive procedures required to enroll patients and to obtain evidence of the drug candidates&#146;
performance during clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability and efficacy of approved medications for the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility criteria defined in the protocol for the trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we are subject to a partial or full clinical hold on any of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reluctance of physicians to encourage patient participation in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our inability to enroll and maintain a sufficient number of patients for our clinical trials would result in significant
delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials, including due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may result in increased development costs, which
would cause the value of our company to decline, limit our ability to obtain additional financing and delay or limit our ability to obtain regulatory approval for our drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Unexpected adverse side effects or other safety risks associated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our other
future drug candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials or abandon further development, limit the commercial profile of an approved product or result in significant negative consequences following
marketing approval, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As is the case with small molecule therapeutics generally, side effects and adverse
events associated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> have been observed. Although <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been evaluated in approximately 1,000 patients in clinical trials to date with a generally
favorable tolerability profile, unexpected side effects may still arise in our ongoing or any future clinical trial. The side effects have included primarily reversible, manageable hematological toxicities, including neutropenia and thrombocytopenia
and limited non-hematological toxicities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our trials will be primarily based on the established RP2D dosing regimen used
in over 400 patients in past trials, where the above-described side effects were observed. However, our trials will also, in part, include testing of ACR-368 at RP2D in combination with low dose gemcitabine, which could result in greater severity
and prevalence of side effects or unexpected characteristics. Undesirable side effects could result in the delay, suspension or termination of clinical trials by us or regulatory authorities for a number of reasons. Furthermore, clinical trials by
their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our drug candidates or those of our competitors may only be uncovered with a
significantly larger number of patients exposed to the drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, due to the high mortality rates of the cancers
for which we are initially pursuing development and the pretreated nature of many patients in our ongoing clinical trial of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> a material&nbsp;percentage of patients in these clinical trials might die
during a trial for reasons unrelated to drug side effects. If we elect to, or are required to, delay, suspend or terminate any clinical trial, whether due to a patient death or otherwise, the commercial prospects of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates could be harmed and our ability to generate product revenues could potentially be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or
prevent market acceptance of our drug candidates, which would harm our commercial prospects our financial condition and our reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, if <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any of our future drug candidates are associated with
undesirable or unexpected side effects in clinical trials, we may elect to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or
more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the drug candidate, even if it is approved. We may also be required to modify our trial plans based on findings in our clinical trials. Side effects
could also affect patient recruitment or the ability of enrolled patients to complete a trial. Many drugs that initially showed promise in early stage testing have later been found to cause side effects that prevented further development. In
addition, regulatory authorities may draw different conclusions, require additional testing to confirm these determinations, require more restrictive labeling or deny regulatory approval of the drug candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that, as we test our drug candidates in larger, longer and more extensive clinical trials, including with
different dosing regimens, or as the use of our drug candidates becomes more widespread </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
following any regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in
previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if <FONT STYLE="white-space:nowrap">ACR-368</FONT> receives marketing approval, and we or others later identify
undesirable side effects caused by treatment with such drug, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approval of the drug; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a product or change the way the drug is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings in the labeling, such as a contraindication or a boxed
warning, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to implement a REMS, or create a medication guide outlining the risks of such side effects
for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional restrictions may be imposed on the marketing or promotion of the particular product or the
manufacturing processes for the product or any component thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to regulatory investigations and government enforcement actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the drug could become less competitive; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these events could prevent us from achieving or maintaining market acceptance of our drug candidates, if approved, and
could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preliminary, interim and topline
data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials, such as futility
analyses, ORR, or various primary and secondary clinical endpoints. These updates will be based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more
comprehensive review of the data related to the particular study or trial. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient
enrollment continues and more patient data becomes available. Therefore, positive interim results in any ongoing clinical trial may not be predictive of such results in the completed study or trial. We also make assumptions, estimations,
calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same
studies, or different conclusions or considerations may qualify such results, once additional data has been received and fully evaluated. Topline data also remains subject to audit and verification procedures that may result in the final data being
materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data is available. In addition, we may report interim analyses of only certain endpoints rather than all
endpoints. Adverse changes between preliminary or interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in
the price of our common stock after this offering. See the description of risks under the heading &#147;Risks Related to our Common Stock and This Offering&#148; for more disclosure related to the risk of volatility in our stock price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, others, including regulatory agencies, may not accept or agree with
our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug
candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others
may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions,
conclusions, views, activities or otherwise regarding a particular product, drug candidate or our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally,
other future clinical trials we conduct may be open-label trials in which both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved product or placebo. Open-label
clinical trials typically test only the investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in
open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#147;patient bias&#148; where patients perceive their symptoms to have improved merely due to their awareness of receiving an
experimental treatment. In addition, open-label clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received
treatment and may interpret the information of the treated group more favorably given this knowledge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the preliminary
or topline data that we report differs from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,
<FONT STYLE="white-space:nowrap">ACR-368,</FONT> or any other future drug candidates may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may in the future seek to
engage in strategic transactions to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional products, drug candidates or technologies. If we are unable to realize the benefits from such transactions, it may adversely affect our
ability to develop and commercialize an expanded pipeline of drug candidates, negatively impact our cash position, increase our expenses and present significant distractions to our management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset
purchases, joint ventures and <FONT STYLE="white-space:nowrap">in-licensing</FONT> of new products, drug candidates or technologies that we believe will complement or augment our existing business. For example, in 2021, we acquired our lead drug
candidate, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> pursuant to worldwide license agreement with Lilly which maintains certain open INDs with FDA for prexasertib being supplied to investigator-initiated studies. If we acquire assets with
promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are not able to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, testing,
manufacturing and marketing any new products resulting from a strategic acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example,
such transactions may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> or other charges, increase our near-term and long-term expenditures and pose significant integration or implementation challenges or disrupt our
management or business. These transactions would entail numerous operational and financial risks, including, but not limited to, exposure to unknown liabilities, disruption of our business and diversion of our management&#146;s time and attention in
order to manage a collaboration or develop acquired products, drug candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected acquisition or
integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the transaction or combining the operations and personnel of any acquired business, impairment of
relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, although there can be no assurance that we will undertake or
successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and could have a material and adverse effect on our business, financial condition, results of
operations and prospects. Conversely, any failure to enter any strategic transaction that would be beneficial to us could delay the development and potential commercialization of our drug candidates and could have a negative impact on the
competitiveness of any drug candidate that reaches market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may expend our limited resources to pursue a particular drug
candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we have limited financial and managerial resources, we focus on research programs and drug candidates that we identify
for specific indications. As a result, we may forego or delay pursuit of opportunities with other future drug candidates or for other indications that later prove to have greater commercial potential. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market
opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target
market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development
and commercialization rights to that drug candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our clinical development is focused on the development of precision oncology
medicines utilizing our proprietary precision medicine platform, which is based on a novel scientific approach and may never lead to marketable products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The development of precision oncology medicines for patients whose tumors are sensitive to a specific product or drug candidate
based on direct protein measurement is a rapidly emerging field, and the scientific discoveries that form the basis for our efforts to develop drug candidates are relatively new. Furthermore, our OncoSignature companion diagnostic is based on new
technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The scientific evidence to support the feasibility of developing drug candidates based on these discoveries is both
preliminary and limited. Although we believe, based on our clinical work, that our approach is applicable across stages of drug development and therapeutic modalities, clinical results may not confirm this hypothesis or may only confirm it for
certain tumor types. Therefore, we do not know if our approach will be successful, but if our approach is unsuccessful, our business will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Efforts to identify, acquire or <FONT STYLE="white-space:nowrap">in-license,</FONT> and then develop drug candidates require
substantial technical, financial and human resources, whether or not any drug candidates are ultimately identified. We apply our AP3 platform and OncoSignature companion diagnostic in our efforts to discover potential precision targets for which
drug candidates may be developed. Our efforts may initially show promise in identifying potential drug candidates, yet fail to yield drug candidates for clinical development, approved products or commercial revenues for many reasons, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the methodology used may not be successful in identifying potential drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render any drug candidates we develop obsolete;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any drug candidates we develop may nevertheless be covered by third parties&#146; patents or other exclusive
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a drug candidate may be shown to have harmful side effects or other characteristics that indicate it is
unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a drug candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a drug candidate may not be accepted as safe and effective by physicians, patients, the medical community or
third-party payors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Increasing demand for compassionate use of our drug candidates could negatively affect our
reputation and harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing drug candidates for the treatment of indications for which
there are currently limited or no available therapeutic options. It is possible for individuals or groups to target companies with disruptive social media campaigns related to a request for access to unapproved drugs for patients with significant
unmet medical need. If we experience a similar social media campaign regarding our decision to provide or not provide access to any of our current or future drug candidates under an expanded access policy, our reputation may be negatively affected
and our business may be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Recent media attention to individual patients&#146; expanded access requests has resulted
in the introduction and enactment of legislation at the local and national level referred to as &#147;Right to Try&#148; laws, such as the federal Right to Try Act of 2017 signed into law on May&nbsp;30, 2018, which are intended to allow patients
access to unapproved therapies earlier than traditional expanded access programs. A possible consequence of both activism and legislation in this area may be the need for us to initiate an unanticipated expanded access program or to make our drug
candidates more widely available sooner than anticipated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, some patients who receive access to drugs prior to
their commercial approval through compassionate use, expanded access programs or right to try access have life-threatening illnesses and have exhausted all other available therapies. The risk for serious adverse events in this patient population is
high, which could have a negative impact on the safety profile of our drug candidates if we were to provide them to these patients, which could cause significant delays or an inability to successfully commercialize our drug candidates, which could
materially harm our business. If we were to provide patients with any of our drug candidates under an expanded access program, we may in the future need to restructure or pause any compassionate use and/or expanded access programs for a variety of
reasons, which could prompt adverse publicity or other disruptions related to current or potential participants in such programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business and operations may be adversely affected by the evolving and ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT>
global pandemic. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business and operations may be adversely affected by the effects of the recent and evolving <FONT
STYLE="white-space:nowrap">COVID-19</FONT> virus, which was declared by the World Health Organization as a global pandemic, including the current resurgences as a result of the Omicron variant and related subvariants in various regions in the United
States and globally and other future resurgences. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease, including public health directives and orders
in the United States and globally that, among other things and for various periods of time, directed individuals to shelter at their places of residence, directed businesses and governmental agencies to cease
<FONT STYLE="white-space:nowrap">non-essential</FONT> operations at physical locations, prohibited certain <FONT STYLE="white-space:nowrap">non-essential</FONT> gatherings and events and ordered cessation of
<FONT STYLE="white-space:nowrap">non-essential</FONT> travel. Future remote work policies and similar government orders or other restrictions on the conduct of business operations related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic may negatively impact productivity; disrupt our ongoing research and development activities and our clinical programs and timelines; and cause disruptions to our supply chain, to the administrative functions of clinical trial sites and to
the operations of our other partners, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In the event that government
authorities were to enhance current restrictions, such orders also may impact the availability or cost of materials, which would disrupt our supply chain and manufacturing efforts and could affect our ability to conduct ongoing and planned clinical
trials and preparatory activities. We may also face difficulties in obtaining access to manufacturing slots for our drug candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although our ongoing and planned clinical trials have not been impacted by
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to date, we may experience related disruptions in the future that could severely impact our clinical trials, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or a suspension in clinical site initiation, including difficulties in recruiting
clinical site investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or interruptions in shipping and delivering in a timely manner supplies, samples or
products required for our clinical trials due to the impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the United States Postal Service, FedEx, United Parcel Service and/or other commercial shipping organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, difficulties or interruptions in obtaining the raw materials and other resources needed for our
operations, including due to <FONT STYLE="white-space:nowrap">government-led</FONT> diversion, reprioritization or appropriation of such resources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or interruptions in third-party or collaborator services, including due to <FONT
STYLE="white-space:nowrap">government-led</FONT> diversion, reprioritization or appropriation of such services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions in our ability to manufacture and deliver drug supply for trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of
hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the ongoing
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic that may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, and the ability or
willingness of subjects to travel to trial sites due to limitations on travel imposed or recommended by federal or state governments, employers and others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials,
including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review
and approval timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to accept data from clinical trials in these affected geographies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including new variants of the virus, such as the Omicron
variant and related subvariants, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, <FONT STYLE="white-space:nowrap">COVID-19</FONT> may be difficult
to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market
correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect our business and the value of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since the beginning of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, several vaccines for <FONT
STYLE="white-space:nowrap">COVID-19</FONT> have received Emergency Use Authorization by the FDA and a number of those later received marketing approval. Additional vaccines may be authorized or approved in the future. The resultant demand for
vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult and/or more costly to obtain materials or manufacturing
slots for the products needed for our clinical trials, which could lead to delays in these trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
continues to rapidly evolve. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our business and operations, including our clinical development and regulatory efforts, will depend on future developments that
are highly uncertain and cannot be predicted with confidence at the time of this prospectus, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of business disruptions and the short-term
effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat patients with the disease. Accordingly, we do not yet know
the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition, results of
operations and growth prospects. In addition, to the extent the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other
risks and uncertainties described in this &#147;Risk Factors&#148; section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our relationships with customers, healthcare providers, including physicians, and third-party payors are subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face
substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Healthcare providers, including physicians, and third-party payors in the United States and
elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants,
customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law
commonly referred to as the Physician Payments Sunshine Act and regulations promulgated under such laws. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs, and other interactions
with healthcare professionals. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not
limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities from knowingly
and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind in return for, or to induce, either the referral of an individual, or
the purchase, lease, order or arrangement for or recommendation of the purchase, lease, order or arrangement for any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the
Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an
exception or safe harbor. A person does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the ACA, signed into law in 2010, provides that the government may assert
that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including, without limitation, the federal False Claims Act,
which can be enforced by private citizens through civil whistleblower or qui tam actions, and the federal civil monetary penalty law which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented,
claims for payment or approval from the federal government, including Medicare, Medicaid and other government payors, that are false or fraudulent or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the
federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the United States federal government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly
providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of
products for unapproved, and thus <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional
federal criminal statutes which prohibit, among other things, a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and
willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal
Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or
HITECH, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on health plans, healthcare clearinghouses and certain healthcare
providers, known as &#147;covered entities&#148;, and their respective HIPAA &#147;business associates&#148;, which are independent contractors that perform certain services for or on behalf of covered entities or other business associates involving
the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys
general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency laws, including the federal Physician Payments Sunshine Act, which requires certain
manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#146;s Health Insurance Program, with specific exceptions, to report annually to Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to: (i)&nbsp;payments or other &#147;transfers of value&#146;&#146; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain
other healthcare providers (such as physicians assistants and nurse practitioners), and teaching hospitals, and (ii)&nbsp;ownership and investment interests held by physicians and their immediate family members.; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state and foreign laws and regulations that are analogous to each of the above federal laws; state laws that
require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state laws that require pharmaceutical companies to comply with the
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or that otherwise restrict payments that may be made to healthcare providers; state and local laws that
require the registration of pharmaceutical sales representatives; and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not
preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of the breadth of these laws and the
narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will
conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of
these laws or any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
governmental regulations that may apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines,
disgorgement, individual imprisonment, exclusion from participating in federal and state funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity
agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, diminished profits and future earnings, reputational harm and the curtailment or restructuring of
our operations, any of which could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The risk of our being found in violation of these laws is increased
by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply
with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our
management&#146;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting
requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we
obtain FDA approval of any of our drug candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying
regulatory requirements on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis regarding safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or
jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other
countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval
processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional
preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any drug
candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets
or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we receive regulatory approval of our current or future drug candidates, we will be subject to ongoing regulatory obligations
and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any drug candidate for which we obtain marketing approval will be subject to ongoing regulatory requirements for, among other
things, manufacturing processes, submission of post-approval clinical data and safety information, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, promotional activities and product
tracking and tracing. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents,
requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA and other federal and state agencies, including the Department of Justice, closely regulate compliance with all
requirements governing prescription drug and biologic products, including requirements pertaining to their marketing and promotion in accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP
requirements. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding <FONT
STYLE="white-space:nowrap">off-label</FONT> use and if we market our products for uses beyond their approved diseases, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. Violations of the Federal
Food, Drug, and Cosmetic Act, relating to the promotion of prescription drugs for unapproved uses may lead to enforcement actions and investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer
protection laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, later discovery of previously unknown adverse events or other problems with our products,
manufacturers or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various
results, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on manufacturing such products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning or untitled letters, or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA&#146;s policies, and the policies of foreign regulatory agencies, may change and additional government regulations may
be enacted that could prevent, limit or delay regulatory approval of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, executive orders or other actions could impose significant
burdens on, or otherwise materially delay, FDA&#146;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. If such executive
actions were to impose restrictions on FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business could be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or
the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects and ability to achieve or
sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Enacted and future healthcare legislation may increase the difficulty and cost for us
to progress our clinical programs and obtain marketing approval of and commercialize our drug candidates and may affect the prices we may set. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a
number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state
levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA,
was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since
its enactment, there have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, on June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is
unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress. Thus, the ACA will remain in effect in its current form. It is possible that the ACA will be subject to judicial or Congressional challenges in the
future. It is unclear how any such challenges and the health reform measures of the Biden administration will impact the ACA and our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In
August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to
the statute will remain in effect until 2031 unless additional action is taken by Congress. However, pursuant to <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief legislation, these Medicare sequester reductions were suspended from May&nbsp;1,
2020 through March&nbsp;31, 2022 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this
sequester .In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers,
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. It is also possible that additional governmental action is taken in response to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, payment methodologies may be subject to changes in
healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to
drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. For example, in July 2021, the Biden administration released an executive order, &#147;Promoting
Competition in the American Economy,&#148; with multiple provisions aimed at prescription drugs. In response to Biden&#146;s executive order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines
principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions
have been finalized to implement these principles. Additionally, on March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a
drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. In addition, Congress is considering drug pricing and other health reform initiatives. We expect that additional U.S.
federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our drug candidates or
additional pricing pressures and could negatively affect our customers and accordingly, our financial operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Individual states in the United States have also increasingly passed
legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of
operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their
prescription drug and other healthcare programs. This could reduce the ultimate demand for our drug candidates or put pressure on our product pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably
commercialize our drug candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or
obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for
national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In
general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and
national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to commercialize our drug
candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In markets outside of the United States and the European Union, reimbursement and healthcare
payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if
we or such third parties are not able to maintain regulatory compliance, our drug candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we or our third-party manufacturers and suppliers fail to comply with environmental, health and safety laws and regulations, we could
become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Although we do not currently manufacture our drug products or drug candidates on site, our research and development activities do involve the use of
biological and hazardous materials and produce hazardous waste products at small quantities. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these
materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly <FONT STYLE="white-space:nowrap">clean-up</FONT> and liabilities under
applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of
these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be
held liable for any resulting damages and such liability could exceed our resources and state or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change
frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental,
health and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties, or
other sanctions.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur
due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous
waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other
personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget
and funding levels, ability to hire and retain key personnel, accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government
funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by
necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory
agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Our business depends upon the ability of the FDA to accept and review our potential regulatory filings. If a prolonged government shutdown occurs,
it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our ability to advance clinical development of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process
our regulatory submissions, which could have a material adverse effect on our business. Further, future shutdowns of other government agencies, such as the U.S. Securities and Exchange Commission, or SEC, may also impact our business through review
of our public filings and our ability to access the public markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we obtain approval to commercialize any products outside of
the United States, a variety of risks associated with international operations could adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any of our other drug candidates are approved for commercialization, we
may seek to enter into agreements with third parties to market them in certain jurisdictions outside the United States. We expect that we would be subject to additional risks related to international pharmaceutical operations, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for drug and companion diagnostic approvals and rules governing drug and
companion diagnostic commercialization in foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and
other obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters
including earthquakes, typhoons, floods and fires, or from economic or political instability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater difficulty with enforcing our contracts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential noncompliance with the U.S. Foreign Corrupt Practices Act, or FCPA, the U.K. Bribery Act 2010 and
similar anti-bribery and anticorruption laws in other jurisdictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no prior experience in these areas. In addition, there are complex regulatory, tax,
labor and other legal requirements imposed by individual countries in Europe with which we will need to comply. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results
could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may develop our current and future drug candidates in combination with other therapies, and safety or supply
issues with <FONT STYLE="white-space:nowrap">combination-use</FONT> products may delay or prevent development and approval of our drug candidates.</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may develop our current or future drug candidates in combination with one or more cancer therapies, both approved and unapproved. Even if
any drug candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the
United States could revoke approval of the therapy used in combination with our drug candidates or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the
treatment of cancer, and we would be subject to similar risks if we develop any of our drug candidates for use in combination with other drugs or for indications other than cancer. Similarly, if the therapies we use in combination with our drug
candidates are replaced as the standard of care for the indications we choose for any of our drug candidates, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. The occurrence
of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also evaluate our drug candidates in combination with one or more cancer therapies that have not yet been approved for
marketing by the FDA or a similar regulatory authority outside of the United States. We may be unable to effectively identify and collaborate with third parties for the evaluation of our drug candidates in combination with their therapies. We will
not be able to market and sell any drug candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. The regulations prohibiting the promotion of products for unapproved uses are
complex and subject to substantial interpretation by the FDA and other government agencies. In addition, there are additional risks similar to the ones described for our products currently in development and clinical trials that result from the fact
that such cancer therapies are unapproved, such as the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the FDA or a similar regulatory authority outside of the United States does not approve these other drugs or revokes
approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with any drug candidate we develop, we may be unable to obtain approval of or market such product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to obtain or maintain orphan drug designation or exclusivity for
our drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulatory authorities in some jurisdictions, including the United States, may designate
drugs for relatively small patient populations as &#147;orphan drugs.&#148; Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat patients with a rare disease or condition, which is generally defined as
a patient population of fewer than 200,000 individuals in the United States, or if the disease or condition affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing the drug for
the type of disease or condition will be recovered from sales of the product in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Orphan drug
designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. Additionally, if a product that has orphan designation subsequently receives the first
FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for
seven&nbsp;years, except in certain circumstances, such as a showing of clinical superiority (i.e., another product is safer, more effective or makes a major contribution to patient care) over the product with orphan exclusivity or where the
manufacturer is unable to assure sufficient product quantity. Competitors, however, may receive approval of different products for the same indication for which the orphan product has exclusivity, or obtain approval for the same product but for a
different indication than that for which the orphan product has exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ACR-368 has been granted orphan drug
designation, or ODD, for the treatment of anal cancer. We may apply for an ODD in the United States or other geographies for <FONT STYLE="white-space:nowrap">ACR-368</FONT> for the treatment of other diseases or conditions or for our future drug
candidates. However, obtaining an orphan drug designation can be difficult, and we may not be successful in doing so. Even if we obtain orphan drug designation for a drug candidate in specific indications, we may not be the first to obtain
regulatory approval of the drug candidate for the orphan-designated indication, due to the uncertainties associated with developing drug products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an
indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for orphan designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to
meet the needs of patients with the rare disease or condition. Orphan drug designation does not ensure that we will receive marketing exclusivity in a particular market, and we cannot assure you that any future application for orphan drug
designation in any other geography or with respect to any other future drug candidate will be granted. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the
regulatory review or approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A Fast Track designation by the FDA, even if granted for our lead drug candidate, or any of
our future drug candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our drug candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At various times, we may seek Fast Track designation for one or more of our drug candidates. If a drug candidate is intended for the treatment
of a serious or life-threatening condition and the drug candidate demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA Fast Track designation for a particular indication. We may seek Fast
Track designation for our lead drug candidate and/or certain of our future drug candidates, but there is no assurance that the FDA will grant this status to any of our proposed drug candidates and we might only be successful in receiving a Fast
Track designation from the FDA for a drug candidate after applying on more than one occasion. Marketing applications filed by sponsors of products in Fast Track development may qualify for priority review under the policies and procedures offered by
the FDA, but the receipt of a Fast Track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant a Fast Track designation, so even if we believe a particular
drug candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive a Fast Track designation, we may not experience a faster development process, review or approval compared to
conventional FDA procedures, and receiving a Fast Track </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw a Fast Track designation if it believes that the designation is no longer supported by data from
our clinical development program. In addition, the FDA may withdraw any Fast Track designation at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A Breakthrough Therapy
designation by the FDA, even if granted for any of our current or future drug candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our drug candidates will receive
marketing approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may seek Breakthrough Therapy designation for our lead drug candidate and some or all of our future drug
candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drug candidates that have been designated as Breakthrough
Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs
designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe a drug candidate meets the criteria
for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such a designation. In any event, the receipt of a Breakthrough Therapy designation for a drug candidate may not result in a faster development
process, review or approval compared to candidate products considered for approval under <FONT STYLE="white-space:nowrap">non-expedited</FONT> FDA review procedures and does not assure ultimate approval by the FDA of a drug candidate. In addition,
even if a drug candidate qualifies as a Breakthrough Therapy, the FDA may later decide that the drug candidate no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for our lead drug
candidate and some or all of our future drug candidates for the treatment of various cancers, there can be no assurance that we will receive Breakthrough Therapy designations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely, and expect to continue to rely, on third parties, including independent clinical investigators, contracted laboratories and
CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug
candidates and our business could be substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have relied upon and plan to continue to rely upon
third parties, including independent clinical investigators, contracted laboratories and third-party CROs, to conduct our preclinical studies and clinical trials in accordance with applicable regulatory requirements and to monitor and manage data
for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each
of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our
third party contractors and CROs are required to comply with good laboratory practices, or GLPs, as applicable, and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of
our products in clinical development. Regulatory authorities enforce these GLPs and GCPs through periodic inspections of laboratories conducting GLP studies, trial sponsors, principal investigators and trial sites. If we, our investigators or any of
our CROs or contracted laboratories fail to comply with applicable GLPs and GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform
additional preclinical studies or clinical trials before approving our marketing applications. We cannot assure you </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our preclinical studies or clinical trials comply with applicable GLP or GCP
regulations. In addition, our clinical trials must be conducted with drug products produced in compliance with applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat preclinical studies or clinical trials,
which would delay the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, these laboratories, investigators and CROs are not our
employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our drug candidates and clinical trials. If independent laboratories, investigators or CROs fail to devote sufficient
resources to the development of our drug candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any drug candidates that we develop. In addition, the use of third-party
service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of
our CROs have an ability to terminate their respective agreements with us if we make a general assignment for the benefit of our creditors or if we are liquidated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of our relationships with these third-party laboratories, CROs or clinical investigators terminate, we may not be able
to enter into arrangements with alternative laboratories, CROs or investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs or clinical investigators do not successfully carry out their contractual
duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory
requirements or for other reasons, our preclinical or clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of
operations and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Switching or adding additional laboratories or CROs or investigators involves additional cost and requires management time and
focus. In addition, there is a natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage
our relationships with our contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business,
financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, clinical investigators may serve as scientific advisors or
consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the
financial relationship may have affected the interpretation of the preclinical study or clinical trial, the integrity of the data generated at the applicable preclinical study or clinical trial site may be questioned and the utility of the
preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from commercializing our clinical-stage drug candidate or any future drug
candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on third parties to supply and manufacture our drug candidates, and we expect
to continue to rely on third parties to manufacture our products, if approved. The development of such drug candidates and the commercialization of any products, if approved, could be stopped, delayed or made less profitable if any such third party
fails to provide us with sufficient quantities of drug candidates or products or fails to do so at acceptable quality levels or prices or fails to maintain or achieve satisfactory regulatory compliance. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not currently have the infrastructure or capability internally to manufacture all our drug candidates for use in the
conduct of our preclinical studies and clinical trials or for commercial supply, if our products are approved. We rely on, and expect to continue to rely on, contract manufacturing organizations, or CMOs. Any replacement of our CMOs could require
significant effort and expertise because there may be a limited number of qualified CMOs. This could be particularly problematic if we rely on a single-source supplier. Reliance on third-party providers may expose us to more risk than if we were to
manufacture our drug candidates ourselves. We are dependent on our CMOs for the production of our drug candidates in accordance with relevant regulations, such as cGMP, which includes, among other things, quality control, quality assurance and the
maintenance of records and documentation. Moreover, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting product development
activities that could harm our competitive position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our third-party manufacturers may be subject to damage or
interruption from, among other things, fire, natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disaster, war, disease outbreaks or public health pandemics, power loss, telecommunications failure, unauthorized entry, computer viruses, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, acts of terrorism, human error, vandalism or sabotage, financial insolvency, bankruptcy and similar events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we were to experience an unexpected loss of supply of or if any supplier were unable to meet our demand for any of our drug
candidates, we could experience delays in our research or ongoing and planned clinical trials or commercialization. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes who could meet our timelines at an
acceptable cost. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods necessary to switch manufacturers and suppliers, if
necessary, could significantly delay our preclinical studies, our clinical trials and the commercialization of our products, if approved, which could materially adversely affect our business, financial condition and results of operation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In complying with the applicable manufacturing regulations of the FDA and comparable foreign regulatory authorities, we and
our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the products meet applicable specifications and other regulatory
requirements. The failure to comply with these requirements could result in an enforcement action against us, including the seizure of products and shutting down of production. We and any of these third-party suppliers may also be subject to audits
by the FDA and comparable foreign regulatory authorities. If any of our third-party suppliers fails to comply with cGMP or other applicable manufacturing regulations, our ability to develop and commercialize the products could suffer significant
interruptions. We face risks inherent in relying on CMOs, as any disruption, such as a fire, natural hazards, vandalism or an outbreak of contagious disease affecting the CMO or any supplier of the CMO could significantly interrupt our manufacturing
capability. In case of a disruption, we will have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all. Additionally, we
would likely experience months of manufacturing delays as the CMO builds or locates replacement facilities and seeks and obtains necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis, if
at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our current and future partnerships will be important to our business. If we are unable to enter into new partnerships, or
if these partnerships are not successful, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have existing partnerships
and license agreements, including with Lilly for ACR-368 and with Akoya to co-develop, validate and commercialize our OncoSignature test. Moreover, a part of our business strategy is to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
carefully evaluate and, as deemed appropriate, potentially enter into partnerships in the future, including with major biotechnology or pharmaceutical companies. We have limited capabilities for
product development and do not yet have any capability for commercialization. Accordingly, we may enter into partnerships with other companies to provide us with additional drug candidates and funding for our programs and AP3 platform. If we fail to
enter into or maintain partnerships on reasonable terms or at all, our ability to develop our existing or future research programs and drug candidates or to identify future drug candidates through the application of our AP3 platform and
OncoSignature companion diagnostics could be delayed, the commercial potential of our product could change and our costs of development and commercialization could increase. Furthermore, we may find that our programs require the use of intellectual
property rights held by third parties, and the growth of our business may depend in part on our ability to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> these intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current partnerships, and any partnerships we may enter into in the future, may pose a number of risks, including, but not
limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners have significant discretion in determining the efforts and resources that they will apply;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners could independently develop, or develop with third parties, products that compete directly or
indirectly with our products and drug candidates if the partners believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners may fail to comply with applicable regulatory requirements regarding the development, manufacture,
distribution or marketing of a drug candidate or product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with partners, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or terminations of the research, development or commercialization of drug candidates, might lead to additional responsibilities for us with respect to drug candidates, or might result in litigation
or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners may infringe the intellectual property rights of third parties, which may expose us to litigation and
potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a partners of ours is involved in a business combination, the partner might deemphasize or terminate the
development or commercialization of any drug candidate licensed to it by us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships may be terminated by the partner, and, if terminated, we could be required to raise additional
capital to pursue further development or commercialization of the applicable drug candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our
partnerships do not result in the successful discovery, development and commercialization of drug candidates or if one of our partners terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments
under such partnership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of the risks relating to product development, regulatory approval and commercialization
described in this prospectus also apply to the activities of our partners. Additionally, if one of our partners terminates its agreement with us, we may find it more difficult to attract new partners and our perception in the business and financial
communities could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to negotiate partnerships on a timely basis, on acceptable
terms, or at all. Our ability to reach a definitive agreement for a partnership will depend, among other things, upon an assessment of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
partner&#146;s resources and expertise, the terms and conditions of the proposed partnership and the proposed partner&#146;s evaluation of a number of factors. These factors may include the
design or results of preclinical studies or clinical trials, the likelihood of regulatory approval, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the
potential of competing products, the existence of any uncertainty with respect to our ownership of technology (which can exist if there is a challenge to such ownership regardless of the merits of the challenge) and industry and market conditions
generally. The partner may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such a partnership could be more attractive than the one with us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Drug Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if any of our current or drug candidates receive marketing approval, they may fail to achieve the degree of market acceptance by
physicians, patients, third-party payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If <FONT
STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For
example, current cancer treatments, such as existing targeted therapies, chemotherapy, and radiation therapy, are well established in the medical community, and doctors may continue to rely on these treatments. If our drug candidates do not achieve
an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our drug candidates, if approved for commercial sale, will depend on a number of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy, safety and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acceptance of our drug candidates as front-line treatments for various indications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects, in particular compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the target patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity for our drug candidates and competing products and treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of distribution and/or use restrictions, such as through a REMS; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party payor coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any marketing approval in relation to other product approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">support from patient advocacy groups; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If the market opportunities for our drug candidates are smaller than we estimate or if any approval that we obtain is based on a
narrower definition of the patient population, then our revenue potential and ability to achieve profitability will be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total addressable market opportunity for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and any other future drug
candidates we may develop will ultimately depend upon, among other things, the proportion of patients identified as sensitive to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
treatments based on our OncoSignature tests in our target indications, acceptance by the medical community, patient access, drug and any related companion diagnostic pricing and their
reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may initially seek regulatory approval of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future
drug candidates as therapies for patients with platinum-resistant ovarian, bladder or endometrial cancer. The number of patients in our targeted commercial markets and elsewhere may turn out to be lower than expected, patients may not be otherwise
amenable to treatment with our drugs or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently have no marketing and sales organization and may have to invest significant resources to develop these capabilities. If we
are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently have no sales or marketing infrastructure or experience in the sale, marketing or distribution of drug products.
Our operations to date have been focused on developing and extensively validating our AP3 platform and our proprietary predictive OncoSignature tests, acquiring the rights to ACR-368, advancing our preclinical drug candidate programs, organizing and
staffing our company, business planning and raising capital. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales, marketing and distribution capabilities, either ourselves or through
collaboration or other arrangements with third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are risks involved with establishing our own sales and
marketing capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a drug candidate for which we recruit a sales force and establish marketing
capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts are expected to be costly, and our investment would be lost if we cannot retain or
reposition our sales and marketing personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Factors that may inhibit our efforts to commercialize our products on our
own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to raise financing necessary to build our commercialization infrastructure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or educate an adequate number of physicians as
to the benefits of our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable third-party payor coverage and reimbursement in any geography; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, developing a sales and marketing organization requires significant investment, is
time-consuming and could delay the launch of our drug candidate. We may not be able to build an effective sales and marketing organization in the United States, the European Union or other key global markets. If we are unable to build our own
distribution and marketing capabilities or to find suitable partners for the commercialization of our drug candidate, we may have difficulties generating revenue from them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we enter into arrangements with third parties to perform sales and marketing services, our product revenues and our
profitability, if any, are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to market and sell our drug candidates or
may be unable to do so on terms that are acceptable to us. We likely will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
have little control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not
establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing any drug candidate for which we receive marketing approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The targeted oncology space is competitive, which may result in others discovering, developing or commercializing products before or
more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The development and commercialization of drug products is highly competitive. We
face competition with respect to our current drug candidates and will face competition with respect to any drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical
companies and existing or emerging biotechnology companies, academic research institutions and governmental agencies and public and private research institutions worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate several biopharmaceutical companies will aim to develop precision oncology approaches for the larger subsets of
cancers where genetics has proven insufficient for patient responder identification over the next decade. We expect that the broader biopharmaceutical field will eventually recognize proteomics as the next era of precision medicine. There are
several competitors with CHK1/2 inhibitors and WEE1 inhibitors, including Sierra Oncology (SRA737), Astrazeneca/Merck (Adavosertib), Zentalis <FONT STYLE="white-space:nowrap">(Zn-c3),</FONT> Debiopharm (Debio0123), Impact Therapeutics (IMP7068) and
Shouya Holdings <FONT STYLE="white-space:nowrap">(SY-4835).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of the companies against which we are competing
or against which we may compete in the future, either alone or through collaborations, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials,
obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors.
Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified
scientific, management and sales and marketing personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, we also face competition more broadly across the oncology market for cost-effective and reimbursable cancer
treatments. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates, if
approved, may compete with these existing drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our drug candidates may not be competitive with them. Some of these drugs are
branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. As a result, obtaining market acceptance of,
and gaining significant share of the market for, our drug candidates may pose challenges. In addition, many companies are developing new oncology therapeutics, and we cannot predict what the standard of care will be as drug candidates progress
through clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial opportunity could be reduced or eliminated if our competitors develop and
commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or with a more favorable labeling than <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future
drug candidates. Our competitors also may obtain FDA, foreign regulatory authority, or other marketing or regulatory approval for their products more rapidly than any approval we may obtain for ours, which could result in our competitors
establishing a strong market position before we are able to enter the market, thereby limiting our potential for commercial success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we are able to commercialize any drug candidates, the products may become
subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from
country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug
before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial
that compares the cost-effectiveness of our drug candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a
result, we might obtain marketing approval for a drug candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues,
if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if such drug candidates obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to commercialize any drug candidates successfully also will depend in part on the extent to which coverage and
adequate reimbursement for these products and related treatments will be available from third-party payors, including government healthcare programs, private health insurers and other organizations. Third-party payors decide which medications they
will pay for and establish reimbursement levels. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS, which decides whether and to what extent a new medicine will be covered and
reimbursed under Medicare. Private payors often, but not always, follow CMS&#146;s decisions regarding coverage and reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to
control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for,
or the price of, any drug candidate for which we obtain marketing approval. Obtaining and maintaining coverage and adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify
coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any
drug candidate for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, companion diagnostic tests will be required to
obtain coverage and reimbursement separate and apart from the coverage and reimbursement we seek for our drug candidates, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be
more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or
at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may
not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments
for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where
they may be sold at lower prices than in the United States. Third-party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare
determinations. Our inability to promptly obtain coverage and adequate reimbursement rates from third-party payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital
needed to commercialize products and our overall financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also cannot predict the likelihood, nature or
extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we are not able to maintain regulatory compliance, our drug candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The market opportunities for any current or future drug candidate we develop, if and when approved, may be limited to those patients who
are ineligible for established therapies or for whom prior therapies have failed, and may be small. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cancer
therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone
therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We expect to
initially seek approval of our drug candidates we develop as a therapy for patients who have received one or more prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval
potentially as a first-line therapy, but there is no guarantee that drug candidates we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of patients who have the cancers we are targeting may turn out to be lower than expected. Additionally, the
potentially addressable patient population for our current programs or future drug candidates in both oncology and non-oncology indications may be limited, if and when approved. Even if we obtain significant market share for any drug candidate, if
and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products
that we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We face an inherent risk of product liability exposure related to the testing of our drug
candidates in human clinical trials and will face an even greater risk if we commercialize any products that we may develop. If we cannot successfully defend ourselves against any claims that our drug candidates or products caused injuries, we will
incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any drug candidates or products that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant time and costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management and scientific resources from our business operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced resources of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current product liability insurance coverage for the United States and certain other jurisdictions may not be adequate to
cover all liabilities that we may incur. We likely will need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or our future drug candidates.
Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. A successful product liability claim or series of claims brought
against us could decrease our cash and adversely affect our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Our Operations
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are highly dependent on the management, development, clinical, financial and business development expertise of
our executive officers, particularly Peter Blume-Jensen, M.D., Ph.D., our <FONT STYLE="white-space:nowrap">co-founder,</FONT> President and CEO, the inventor of our AP3 platform and OncoSignature patient selection method and a member of our board of
directors and Kristina Masson, Ph.D., our co-founder and President and CEO of our phosphoproteomics subsidiary in Lund, Sweden. Each of our executive officers may currently terminate their employment with us at any time. We do not currently maintain
&#147;key person&#148; insurance for any of our executives or employees<SUP STYLE="font-size:75%; vertical-align:top">.</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of our product
pipeline toward scaling up for commercialization, manufacturing and sales and marketing personnel, will also be critical to our success. The loss of the services of our executive officers or other key personnel, including any of our scientific
founders, could impede the achievement of our development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult
and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to
hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also
experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our
development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we
are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We
expect to expand our clinical development, manufacturing and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt
our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had 35 full-time employees and 1 part-time employee. As our
development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical product development, regulatory affairs and, if any of our drug candidates
receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and
train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. Our choice to focus on multiple therapeutic areas may negatively affect our ability to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
develop adequately the specialized capability and expertise necessary for operations. The expansion of our operations may lead to significant costs and may divert our management and business
development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may be
improperly classified and may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our endeavors to properly classify our employees as exempt or <FONT STYLE="white-space:nowrap">non-exempt</FONT> with respect
to wage and hour laws, including, but not limited to, for purposes of minimum wage, overtime and applicable meal and rest periods, and we monitor and evaluate such classifications. Although there are no current, pending, or threatened claims or
investigations against us asserting that any employees have been incorrectly classified as exempt, the possibility nevertheless exists that certain job roles could be deemed to have been incorrectly classified as exempt. In addition, we endeavor to
classify our workforce properly, and we monitor and evaluate such classifications. Although there are no current, pending, or threatened claims or investigations against us asserting that any independent contractors have been incorrectly classified,
the possibility nevertheless exists that certain contractors could be deemed to be employees </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to the risk
that our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless
and/or negligent conduct that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that
require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud,
kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious
harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we
are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation,
damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or
similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CROs&#146;,
manufacturers&#146; contractors&#146;, consultants&#146; or collaborators&#146; cybersecurity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Despite the
implementation of security measures, our internal computer systems, as well as those of third parties on which we rely, are vulnerable to damage from, among other things, computer viruses, malware, unauthorized access, natural disasters, terrorism,
war, telecommunication and electrical failures, system malfunctions, cyberattacks or cyber-intrusions over the Internet, attachments to emails, phishing attacks, persons inside our organization, or persons with access to systems inside our
organization. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and
sophistication of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could lead to the loss, destruction,
alteration, prevention of access to, disclosure, dissemination of, or damage or unauthorized access to, our data (including trade secrets or other confidential information, intellectual property, proprietary business information and personal data)
or data that is processed or maintained on our behalf, and cause interruptions in our operations, which could result in a material disruption of our drug candidate development programs. For example, the loss of preclinical study or clinical trial
data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a
loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of our drug candidates could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial
data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this
information is critical to our operations. Despite our security measures, we cannot ensure that our information technology and infrastructure will prevent breakdowns or breaches in our or their systems or other cybersecurity incidents that cause
loss, destruction, unavailability, alteration, dissemination of, or damage or unauthorized access to, our data, including personal data, assets and other data processed or maintained on our behalf, that could have a material adverse effect upon our
reputation, business, operations or financial condition. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed,
publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, and
such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay clinical development of our drug candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications,
or inappropriate disclosure of confidential or proprietary information or personal data, we could incur material legal claims and liability and damage to our reputation, and the further development of our drug candidates could be delayed. Any such
event could also compel us to comply with federal and state breach notification laws, and foreign law equivalents, subject us to mandatory corrective action and otherwise subject us to substantial liability under laws, rules, regulations and
standards that protect the privacy and security of personal data, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notifications and <FONT STYLE="white-space:nowrap">follow-up</FONT> actions related to a data breach or other security
incident could impact our reputation and cause us to incur significant costs, including significant legal expenses and remediation costs. We expect to incur significant costs in an effort to detect and prevent security incidents, and we may face
increased costs and requirements to expend substantial resources in the event of an actual or perceived security incident. However, we cannot guarantee that we will be able to detect or prevent any such incidents, or that we can remediate any such
incidents in an effective or timely manner. Our efforts to improve security and protect data from compromise may also identify previously undiscovered instances of data breaches or other cybersecurity incidents. To the extent that any data breach,
disruption or security incident were to result in any loss, destruction, or alteration of, damage, unauthorized access to or inappropriate or unauthorized disclosure or dissemination of, our data, including personal data, or other information that
is processed or maintained on our behalf, we could be exposed to litigation and governmental investigations and inquiries, the further development and commercialization of our drug candidates could be delayed and we could be subject to significant
fines or penalties for any noncompliance with applicable state, federal and foreign privacy and security laws, rules, regulations and standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Business disruptions could seriously harm our future revenue and financial condition
and increase our costs and expenses.</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operations, and those of our CROs, CMOs and other contractors and
consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or
<FONT STYLE="white-space:nowrap">man-made</FONT> disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and
increase our costs and expenses. We rely on third-party manufacturers to produce our drug candidates. Our ability to obtain clinical supplies of our drug candidates could be disrupted if the operations of these suppliers are affected by a <FONT
STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to a variety of
privacy and data security laws, rules, regulations, policies, industry standards and contractual obligations, and our failure to comply with them could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain a large quantity of sensitive information, including confidential business and personal information in connection
with the conduct of our clinical trials and related to our employees, and we are subject to laws and regulations governing the privacy and security of such information. In the United States, there are numerous federal and state privacy and data
security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws and federal and state
consumer protection laws. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business and is expected to
increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations could apply to our operations or the operations of our partners, including state data breach notification laws, state
health information privacy laws and federal and state consumer protection laws and regulations, including Section&nbsp;5 of the Federal Trade Commission Act, that govern the collection, use, disclosure and protection of health-related and other
personal information. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health Act, and the regulations promulgated thereunder. Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use or disclose individually
identifiable health information in a manner that is not authorized or permitted by HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In Europe, the General Data
Protection Regulation, or GDPR, took effect in May 2018. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of individuals within the European Economic Area, or EEA, including clinical trial data. Among
other things, the GDPR imposes requirements regarding the security of personal data and notification of data breaches to the competent national data processing authorities, requires having lawful bases on which personal data can be processed and
requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from the EEA to the United States and other
jurisdictions that the European Commission does not recognize as having &#147;adequate&#148; data protection laws; in July 2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA
to the United States by invalidating the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield and imposing further restrictions on the use of standard contractual clauses, which could increase our costs and our ability to efficiently
process personal data from the EEA. The GDPR imposes substantial fines for breaches and violations (up to the greater of &#128;20&nbsp;million or 4% of our consolidated annual worldwide gross revenue), and confers a private right of action on data
subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Relatedly, following the United Kingdom&#146;s withdrawal from the EEA and the European Union and the expiration of the
Transition Period, companies must comply with both the GDPR and the legislation similar to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the GDPR as incorporated into UK national law, which provides for significant fines of up to the greater of &pound;17.5&nbsp;million or 4% of global turnover and exposes companies to two parallel
regimes with potentially divergent enforcement actions for certain violations. On January&nbsp;1, 2021, the United Kingdom became a third country for purposes of the GDPR. The relationship between the United Kingdom and the European Union in
relation to certain aspects of data protection law remains unclear, for example with respect to how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. Pursuant to the <FONT
STYLE="white-space:nowrap">EU-UK</FONT> Trade and Cooperation Agreement of December&nbsp;24, 2020, transfers of personal data from the European Union to the United Kingdom may continue to take place without a need for additional safeguards during a
further transition period, which expires on the earlier of (i)&nbsp;the date on which an adequacy decision with respect to the United Kingdom is adopted by the European Commission; or (ii)&nbsp;the expiry of four months, which shall be extended by a
further two months unless either the European Union or the United Kingdom objects. On February&nbsp;19, 2021 the European Commission published its draft decision finding the United Kingdom to be adequate under the GDPR, though it remains unclear
whether the European Commission will formally adopt an adequacy decision with respect to the United Kingdom. In the absence of such decision, after the expiry of the additional transition period we may need to put in place additional safeguards for
transfers of personal data from the European Union to the United Kingdom, such as standard contractual clauses approved by the European Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive
process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely
affect our business, financial condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. In addition, states are constantly adopting new laws or amending
existing laws, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act, or CCPA, which took effect on January&nbsp;1, 2020, became enforceable by the California Attorney
General on July&nbsp;1, 2020 and has been dubbed the first &#147;GDPR-like&#148; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information
sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt out
of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act,
or CPRA, recently passed in California and will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk
data and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the
provisions will go into effect on January&nbsp;1, 2023, and additional compliance investment and potential business process changes may be required. Although the CCPA currently exempts certain health-related information, including clinical trial
data, the CCPA and the CPRA may increase our compliance costs and potential liability. Similar laws have been proposed in other states and at the federal level and, if passed, such laws may have potentially conflicting requirements that would make
compliance challenging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With the GDPR, CCPA, CPRA and other laws, regulations and other obligations relating to privacy
and data protection imposing new and relatively burdensome obligations, and with the substantial uncertainty over the interpretation and application of these and other obligations, we may face challenges in addressing their requirements and making
necessary changes to our policies and practices and may incur significant costs and expenses in an effort to do so. We are currently in the process of developing and updating our policies and procedures in accordance with requirements under
applicable data privacy and protection laws and regulations. We do not currently have any formal data privacy policies and procedures in place and have not completed formal assessments of whether we are in compliance with all applicable data privacy
laws and regulations. Additionally, if third parties with which we work, such as vendors or service providers, violate applicable laws, rules or regulations or our policies, such violations may also put our or our clinical trial and employee data,
including personal data, at risk, which could in turn have an adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our success depends in part on our ability to obtain intellectual property rights for our proprietary technologies and drug candidates,
as well as our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of
our proprietary technologies and our drug candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents, trademarks and trade
secrets against third-party challenges or violations. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our technologies and drug candidates is dependent upon the extent to which we have rights
under valid and enforceable patents that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our
competitors could develop and commercialize products and technologies similar or identical to ours, and our ability to commercialize any drug candidates and technologies we may develop may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable
patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify, or to file on, patentable aspects of our research
and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering drug
candidates and technologies that we license from or license to third parties and are reliant on our licensors or licensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can
be uncertain. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our drug candidates, technologies or uses thereof in the United States or in other
countries. Many of our technologies relate to diagnostics, such as for identifying subjects who are likely to respond to a particular drug due to biological characteristics of their tumors. Recent court decisions in the United States, such as
<I>Athena Diagnostics v. Mayo Collaborative Services, </I>915 F.3d 743 (Fed. Cir. 2019),<I> cert. denied, </I>140 S. Ct. 855 (2020) have invalidated certain patents in the diagnostics space as covering laws of nature. Some or all of our technologies
may similarly be found not eligible for patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we do successfully issue patents that cover our
products or technologies, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and
patent applications may not adequately protect our intellectual property or prevent others from designing around or otherwise avoiding our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to
our drug candidates is insufficient or is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our drug candidates and our technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, patents have limited terms. We may not be able to issue patents whose terms provide sufficient protection during the
commercial lifetime of our drug candidates or of our technologies. For example, if we encounter delays in our clinical trials, the period of time during which we could market our drug candidates under patent protection could be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some or all of our patents may have claims whose infringement is difficult to detect or to prove. Courts place the legal
burden of proving infringement on patent holders. If we cannot convince a court that we have met this burden of proof, then our patent may not provide useful protection even if valid and enforceable against infringers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since patent applications in the United States and most other countries are confidential for a period of time after filing, we
cannot be certain that we were the first to file any patent application related to our drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
candidates or technologies. Furthermore, for United States applications in which all claims are entitled to a priority date before March&nbsp;16, 2013, an interference proceeding can be provoked
by a third-party or instituted by the United States Patent and Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be certain that we are the first to invent the inventions covered by pending patent applications or issued patents
(collectively, our &#147;patent filings&#148;) and, if we are not, we may be subject to priority disputes or derivation challenges. We may be required to disclaim part or all of the term of certain patent filings. There may be prior art of which we
are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be
found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court or patent office to be valid or enforceable or that even if found valid and enforceable, a
competitor&#146;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in
relation to our drug candidates and technologies, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our drug candidates, our technologies or our
activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design
around or otherwise avoid the claims of patents that we have had issued that cover our products and technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is
possible that we do not perfect ownership of all of the patents, patent applications or other intellectual property upon which we rely. This possibility includes the risk that we do not identify all inventors, or identify incorrect inventors, which
may lead to claims disputing inventorship or ownership of our patents, patent applications or other intellectual property by former employees or other third parties. There is also a risk that we do not establish an unbroken chain of title from
inventors to us. Errors in inventorship or ownership can sometimes also impact priority claims. If we were to lose ability to claim priority for certain patent filings, intervening art or other events may preclude us from issuing patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act, or America Invents Act, enacted in 2013, the United States moved from a &#147;first to invent&#148; to a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the other requirements for patentability
are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant
changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a set of new patent office procedures for reviewing patents after issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The degree of future protection for our intellectual property rights is uncertain because legal means afford only limited
protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make or use compounds or formulations similar or equivalent our drug candidates, or to
develop technologies similar or comparable to ours, but that are not covered by the claims of any patents, should they issue, that we own or control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the active ingredients in our current drug candidates will eventually become commercially available in generic
drug products, and is it possible that patent protection may not be available with regard to formulation or method of use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or collaborators, as the case may be, may fail to meet our obligations to the U.S.
government in regards to any patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or collaborators, as the case may be, might not have been the first to invent, or the
first to file patent applications for our inventions, or may be found to have derived these inventions from others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights in a way that we can detect and prove; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not result in issued patents in jurisdictions where
we or our competitors operate commercially, in time to provide useful commercial protection, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the United States and other countries
that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive
products or technologies for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are prior public disclosures that could invalidate our patents or our
licensors&#146; patents, as the case may be, or parts of our or their patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that others may circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may
later issue with claims covering our products or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the laws of foreign countries may not protect our or our licensors&#146;, as the case may be, proprietary
rights to the extent required for us to benefit commercially, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the claims of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents or patent
applications, if and when issued, may not cover our drug candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents may not provide us with any
competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to detect or to prove infringement of our owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventors of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent
applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent
applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or
unenforceable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such
collaborators may develop adjacent or competing products or technologies to ours that are outside the scope of our patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies for which we can obtain patent protection;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file for patent protection in order to maintain certain trade secrets, and a third party
may subsequently obtain a patent covering such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that drug candidates or technologies we develop may be covered by third parties&#146; patents
or other exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to protect the confidentiality of key information, including trade secrets, that are required
for us to achieve or maintain our business goals; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to detect breaches of confidentiality obligations to us before significant damage is done
to our business, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to build brand identity in the marks we use to label our products or technologies, or third
parties may misuse them or create brand confusion, and our business may be negatively impacted. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Should
any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could harm our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on trade secrets to protect some of our technology and proprietary information, especially where
we believe patent protection is not appropriate or obtainable, or may not provide effective protection. However, trade secrets are difficult to protect. It can be difficult or impossible to detect trade secret breaches. Furthermore, litigating a
claim that a third party had illegally obtained and was using our trade secrets would be expensive and time consuming, and the outcome would be unpredictable. Moreover, if our competitors independently develop similar knowledge, methods and <FONT
STYLE="white-space:nowrap">know-how,</FONT> our business could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent terms may be inadequate to protect our competitive
position on our drug candidates for an adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have issued patents covering the
composition-of-matter and the salt form of ACR-368 through 2030 and 2037, respectively, without extension, and also seek protection through our OncoSignature method-of-use patents. We expect to seek extensions of patent terms in the United States
and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the
patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory
authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be
able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent term extensions in other countries may also be subject to certain procedural or administrative requirements including
adherence to certain strict timelines. A failure to meet such requirements may result in a loss of the extension in those countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental patent agencies require compliance with a
number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications
will have to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned patents and/or applications and any patent rights we may own or license in the future. We employ reputable law firms
and other professionals to help us comply with such requirements and fee payments. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited
to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
applications covering our products or technologies, we may not be able to stop a competitor from marketing products or technologies that are the same as or similar to our drug candidates or
technologies, which would have a material adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT
STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors
might be able to enter the market and this circumstance could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims challenging the
inventorship or ownership of our future patents and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also be subject to claims
that former employees, collaborators, or other third parties have an ownership interest in our patent applications, our future patents, or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from
conflicting obligations of consultants or others who are involved in developing our drug candidates and platform discovery. Although it is our policy to require our employees and contractors who may be involved in the conception or development of
intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we
cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be
self-executing or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may
become involved in lawsuits to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Competitors may infringe our present or future issued patents, trademarks, copyrights or other intellectual property. To
counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived
infringers could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents, trademarks, copyrights or other intellectual property. In addition, in a patent infringement proceeding, there is a
risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, or that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such
patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from making, using, selling, offering to sell or importing the invention at issue on the grounds that our
patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude
third parties from making, using, selling, offering to sell or importing similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or
that another party has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, there could be
public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
it could have a substantial adverse effect on the price of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such
infringement claims, which typically last for years before they are concluded. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and
more mature and developed intellectual property portfolios. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit
we receive as a result of the proceedings. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the
initiation and continuation of patent litigation or other proceedings could have a negative impact on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which
would be uncertain and could have a negative impact on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success
depends, in part, upon our ability and the ability of future collaborators, if any, to develop, use, manufacture, market and sell our drug candidates and our proprietary technologies without infringing the proprietary rights and intellectual
property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with,
adversarial proceedings or litigation regarding intellectual property rights with respect to our drug candidates and technology, including interference proceedings, derivation proceedings, ex parte reexamination, post grant review and inter partes
review before the USPTO or equivalent foreign regulatory authority. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third
parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are
valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future drug candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need
to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would
invalidate the claims of any such U.S. patent. Foreign courts will have similar burdens to overcome in order to successfully challenge a third party claim of patent infringement. If we are found to infringe a third party&#146;s valid and enforceable
intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our drug candidate(s) and technology. However, we may not be able to obtain any required license on
commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to
us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or drug candidate. In addition, we could
be found liable for monetary damages, including treble damages and attorneys&#146; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and
commercializing our drug candidates or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have
a similar negative impact on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may need to license
intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A third party may hold intellectual property rights, including patent rights, that are important or necessary to the
development of our drug candidates and technologies. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our drug candidates or our technologies, in which case we would be required to obtain a
license from these third parties. Such a license may not be available on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially reasonable terms, our business
could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We depend on intellectual property licensed from a third party and termination of this license could result in the
loss of significant rights, which would harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are dependent on patents, <FONT
STYLE="white-space:nowrap">know-how</FONT> and proprietary technology, both our own and licensed from others. In particular, we are dependent on our license agreement with Lilly. Any termination of this license could result in the loss of
significant rights and could harm our ability to commercialize our drug candidates. See the section titled &#147;Business&#151;License and Collaboration Agreements&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disputes may also arise between us and our current licensor or future licensors regarding intellectual property subject to a
license agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our drug candidates and technologies infringe intellectual property of the
licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development
and commercialization of our drug candidates, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our payment obligations with respect to licensed technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current or future
licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates and technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as
we are for intellectual property that we own, which are described below. If we, Lilly, or any future licensors fail to adequately protect any licensed intellectual property, our ability to commercialize products could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade
secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other
biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or
<FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any
such individual&#146;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in
our patents or patent applications, as a result of the work they performed on our behalf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Although it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to
us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face
of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to
bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby
impairing our ability to protect our future drug candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The United States Congress periodically enacts
legislation that significantly impacts the patent system. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent
owners in certain situations. Various decisions by the U.S. Supreme Court and other U.S. federal courts are widely considered to have reduced patent protections available to developers of diagnostic technologies. In addition to increasing
uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on actions by the U.S. Congress, the federal courts, and the
USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we own or have licensed, or that we might obtain in the future. Similarly, changes in
patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new
patents or to enforce patents that we own or have licensed or that we may obtain in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to protect our
intellectual property rights throughout the world, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Filing, prosecuting
and defending patents on drug candidates and technologies in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in
the United States. In some cases, we may not be able to obtain patent protection for certain technologies outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as
federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in
jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of
our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and
attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a
significant commercial advantage from the intellectual property that we develop or license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Reliance on third parties requires us to share our proprietary information, which
increases the possibility that such information will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we rely on third
parties for aspects of development, manufacture, or commercialization of our drug candidates and technologies, or if we collaborate with third parties for the development or commercialization of our future drug candidates and technologies, we must,
at times, share proprietary information with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements
with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential
information. Despite the contractual provisions employed when working with third parties, the need to share confidential information increases the risk that such information become known by our competitors, is inadvertently incorporated into the
technology of others, or is disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how,</FONT> a competitor&#146;s discovery of our <FONT
STYLE="white-space:nowrap">know-how</FONT> or other unauthorized use or disclosure could have an adverse effect on our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and
consultants to publish data potentially relating to our <FONT STYLE="white-space:nowrap">know-how.</FONT> Despite our efforts to protect our <FONT STYLE="white-space:nowrap">know-how,</FONT> we may not be able to prevent the unauthorized disclosure
or use of our technical <FONT STYLE="white-space:nowrap">know-how</FONT> by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential
information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the
collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. Moreover,
if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information.
Enforcing a claim that a third-party illegally obtained and is using our proprietary information, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes
less willing to protect proprietary information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Trademarks we own, license or may obtain may be infringed or successfully
challenged, resulting in harm to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on trademarks and expect to rely on future trademarks as
one means to distinguish our drug candidates that are approved for marketing and technologies from the products of our competitors. OncoSignature is trademarked. Once we select trademarks and apply to register them, our trademark applications may
not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in
loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, any proprietary name we propose to use with <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any future drug
candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the
potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that
would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Comparable foreign regulators may have similar requirements, and it is possible that different proprietary or <FONT
STYLE="white-space:nowrap">non-proprietary</FONT> names may be required in different jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to protect the confidentiality of our proprietary information, our
business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to seeking patent and trademark protection for our
drug candidates and technologies, we also rely on unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. We seek to protect our proprietary information, in
part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract
manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements
and disclose our proprietary information. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition,
we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated proprietary information is difficult, expensive and time-consuming, and the outcome is unpredictable. In
addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, our competitors may independently develop knowledge, methods and <FONT STYLE="white-space:nowrap">know-how</FONT>
equivalent to our proprietary information. Competitors may be able to obtain or reverse engineer information about our products or technologies that would permit them to replicate some or all of the competitive advantages we derive from our
development efforts for technologies on which we do not have patent protection. If any of our proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom
they communicate it, from using that technology or information to compete with us. If any of our proprietary information were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining
physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the
disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we
may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom
they communicate it, from using that technology or information to compete with us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we do not obtain patent term extension for
patents covering our drug candidates, our business may be materially harmed, and in any case, the terms of our patents may not be sufficient to effectively protect our drug candidates and business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patents have a limited term. In most countries, including the United States, the expiration of a patent is generally 20 years
after its first effective <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. However, depending upon the timing, duration and specifics of FDA marketing approval of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> our other drug
candidates or any future drug candidates, one or more of any U.S. patents we may be issued or have licensed may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as
the Hatch-Waxman Amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Hatch-Waxman Amendments permit a patent restoration term of up to five years as
compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a maximum of one patent to be extended per <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product as compensation
for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our drug
candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements.
Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors
may obtain approval of competing products following our patent expiration, and our competitive position, business, financial condition, results of operations, and prospects could be harmed, possibly materially. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If there are delays in obtaining regulatory approvals or other additional delays, the period of time during which we can
market our drug candidates under patent protection could be further reduced. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates might expire before or
shortly after such drug candidates are commercialized. Once the patent term has expired, we may be open to competition from similar or generic products. The launch of a generic version of one of our products in particular would be likely to result
in an immediate and substantial reduction in the demand for that product, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering, Ownership of our Common Stock and our Status as a Public Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>An active trading market for our common stock may not develop and you may not be able to resell your shares of our common stock at or
above the initial offering price, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our
common stock. The initial public offering price for our common stock was determined through negotiations with the underwriters and may not be indicative of the price at which our common stock will trade after the closing of this offering. Although
we anticipate that our common stock will be approved for listing on the Nasdaq Global Market, an active trading market for our shares may never develop or be sustained following this offering. If an active market for our common stock does not
develop or is not sustained, it may be difficult for you to sell shares you purchased in this offering at an attractive price or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our stock price may be volatile. The stock market in general and the market for biopharmaceutical companies in
particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for
the shares. The market price for our common stock may be influenced by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reporting of unfavorable preclinical results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment or results of our clinical trials of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> or any future clinical trials we may conduct, or changes in the development status of our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in our regulatory filings for <FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other drug
candidate we may develop, and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#146;s review of such filings, including without limitation the FDA&#146;s issuance of a &#147;refusal to
file&#148; letter or a request for additional information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results from, delays in or termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of <FONT STYLE="white-space:nowrap">ACR-368</FONT> or
any other drug candidate; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by us or by any equity research analysts who might cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions or trends in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in
the biopharmaceutical industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal
of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our relationships with our collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors&#146; general perception of our company and our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our
ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation or employee or independent contractor
litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The stock market in general, and the market for biotechnology companies in particular, have experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including recently in connection with the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the Russian invasion
of Ukraine, rising inflation and increasing interest rates, which have resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry
factors, including potentially worsening economic conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other
risks, including those described in this section, could have a significant and material adverse impact on the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies
following periods of volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#146;s attention and resources from our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near
future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the
perception in the market that the holders of a large number of shares intend to sell shares, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
could reduce the market price of our common stock. After this offering, we will have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
common stock outstanding based on the number of shares outstanding as of June&nbsp;30, 2022. This includes the shares that we are selling in this offering, which may be resold in the public market immediately. Following the consummation of this
offering, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares will be subject to a <FONT STYLE="white-space:nowrap">180-day</FONT>
<FONT STYLE="white-space:nowrap">lock-up</FONT> period provided under <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements executed in connection with this offering described in &#147;Underwriting&#148; and restricted from immediate resale
under the federal securities laws as described in &#147;Shares Eligible for Future Sale.&#148; All of these shares will, however, be able to be resold after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, as well as
pursuant to customary exceptions thereto or upon the waiver of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement by on behalf of the underwriters. We also intend to register shares of common stock that we may issue under our equity
compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. As restrictions on resale end, the market price of our stock
could decline if the holders of currently-restricted shares sell them or are perceived by the market as intending to sell them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If
you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
initial public offering price of our common stock will be substantially higher than the pro forma as adjusted net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay
a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this offering. To the extent outstanding options are exercised, you will incur further dilution. Based on an assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, you will experience
immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share as of June&nbsp;30, 2022, representing the difference between our pro forma as adjusted net tangible book value per
share, after giving effect to this offering, and the assumed initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as of
June&nbsp;30, 2022, there were outstanding options to purchase an aggregate of 5,111,703 shares of our common stock, at a weighted-average exercise price of $1.15 per share. To the extent that these outstanding options are exercised, you will incur
further dilution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about
us, our business or our market, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading market for our
common stock will be influenced by the research and reports that equity research analysts publish about us and our business. As a newly public company, we have only limited research coverage by equity research analysts. Equity research analysts may
elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the
analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research
analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our executive officers, directors and their affiliates, if they choose to act together, have the ability to significantly influence all
matters submitted to stockholders for approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, based on the number of common
stock outstanding as of June&nbsp;30, 2022, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, in the aggregate, hold common stock
representing approximately&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock. As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for
approval, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our
management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. Any of these actions could adversely affect the market price of our common stock.
This concentration of ownership control may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, defer, or prevent a change in control; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entrench our management and board of directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or prevent a merger, consolidation, takeover, or other business combination involving us that other
stockholders may desire. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Concentration of ownership of our common stock among our existing executive officers,
directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective
affiliates beneficially own over &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock prior to this offering and will continue to own a majority of our common stock following this offering. As a result, these persons, acting together, would be
able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders
purchased their shares at prices substantially below the current market price of our common stock and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may
want us to pursue strategies that deviate from the interests of other stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an &#147;emerging growth company&#148;
and a &#147;smaller reporting company&#148; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company&#148; as defined in the JOBS Act and we intend to take advantage of some
of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, as amended, in the assessment of our internal control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes
on executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding
the communication of critical audit matters in the auditor&#146;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an
emerging growth company until the last day of our fiscal year following the fifth anniversary of the completion of this offering or, if earlier, (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least
$1.07&nbsp;billion, (ii)&nbsp;the date on which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of
the prior June 30th, or (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have elected to take advantage of the extended transition period to comply with new or revised accounting
standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting
standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in this
prospectus may be different than the information investors may receive from other public companies in which they hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these
elections, which may result in a less active trading market for our common stock and higher volatility in our share price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even after we no longer qualify as an emerging growth company, we may, under certain circumstances, still qualify as a
&#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will have broad discretion in the use of proceeds from this offering and may invest or spend the proceeds in ways
with which you do not agree and in ways that may not increase the value of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will have broad
discretion over the use of proceeds from this offering. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. We expect to use the net proceeds to us from this offering, together with our
existing cash and cash equivalents, to fund our ongoing clinical development, including advancing our lead drug candidate ACR-368 through initial Phase&nbsp;2 clinical readouts, as well as initiating our Phase&nbsp;2 trial in patients with HPV<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> tumors, to enter IND-enabling stage for at least one of our preclinical programs and fund continued development of our AP3 platform, and the remainder for research and development activities, working
capital and other general corporate purposes. See the section titled &#147;Use of Proceeds.&#148; In addition, we may use a portion of the proceeds from this offering to pursue our strategy to <FONT STYLE="white-space:nowrap">in-license</FONT> or
develop additional drug candidates. Our failure to apply the net proceeds from this offering effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of
these net proceeds. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material
weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of
operations, which may adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A material weakness is a deficiency, or a combination of
deficiencies, in internal control over financial reporting such that it is reasonably possible that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely
manner commensurate with the financial reporting requirements of an SEC registrant. Prior to the completion of this offering, we have been a private company and therefore have not designed or maintained
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
internal controls over financial reporting commensurate with the financial reporting requirements of an SEC registrant. Accordingly, we have identified the following material weaknesses: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain an effective control environment commensurate with the financial reporting
requirements of a public company. Specifically, we lacked a sufficient complement of resources with (i)&nbsp;an appropriate level of accounting knowledge, experience and training to appropriately analyze, record and disclose accounting matters
timely and accurately as a public company, and (ii)&nbsp;an appropriate level of knowledge and experience to establish effective processes and controls. Additionally, the lack of a sufficient number of professionals resulted in an inability to
consistently design and maintain formal accounting policies, procedures and controls or establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives, as demonstrated by, among other things, insufficient
segregation of duties in our finance and accounting functions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls in response to the risks of material misstatement.
Specifically, changes to existing controls or the implementation of new controls were not sufficient to timely respond to changes to the risks of material misstatement to financial reporting due to changes in the complexity in the business.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These material weaknesses contributed to the following additional material weaknesses: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls to achieve complete, accurate and timely financial
accounting, reporting and disclosures, including controls over the preparation and review of account reconciliations and journal entries and the identification of and accounting for certain <FONT STYLE="white-space:nowrap">non-routine,</FONT>
unusual or complex transactions in a timely fashion, including the proper application of U.S. GAAP to such transactions.&nbsp;Specifically, we did not design and maintain controls to timely identify and account for preferred stock tranche rights,
convertible notes and the anti-dilution right valuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not design and maintain effective controls over information technology general controls for information
systems that are relevant to the preparation of its financial statements. Specifically, we did not design and maintain: (i)&nbsp;program change management controls to ensure that program and data changes are identified, tested, authorized and
implemented appropriately; (ii)&nbsp;user access controls to ensure appropriate segregation of duties and to adequately restrict user and privileged access to appropriate personnel; (iii)&nbsp;computer operations controls to ensure that processing
and transfer of data, and data backups and recovery are monitored; and (iv)&nbsp;program development controls to ensure that new software development is tested, authorized and implemented appropriately. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the material weaknesses described above resulted in misstatement to our consolidated financial statements. However,
the material weaknesses described above could result in a misstatement of one or more account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented
or detected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we are currently in the process of remediating the material weaknesses, we cannot assure you that
these efforts will remediate our material weaknesses in a timely manner, or at all. If we are unable to successfully remediate our material weaknesses, or identify any future material weaknesses, the accuracy and timing of our financial reporting
may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports, the market price of our stock may decline as a result, and we could be subject to sanctions or
investigations by the Nasdaq Global Market, the SEC, or other regulatory authorities. Failure to remediate any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required
of public companies, could also restrict our future access to the capital markets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our amended and restated certificate of incorporation provides that the Court of
Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain
a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated
certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us arising under the Delaware General Corporation Law, our amended and
restated certificate of incorporation, or our amended and restated bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our restated
certificate or our amended and restated bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any claim or cause of action as to which the Delaware General Corporation Law confers jurisdiction on the
Court of Chancery of the state of Delaware; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange
Act. Furthermore, Section&nbsp;22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have
jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of
incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have
determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert
the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be
no assurance that the provisions will be enforced by a court in those other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These exclusive forum
provisions may result in increased costs for investors to bring a claim. Further, these exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our
directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to
be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our
stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Provisions in our certificate of incorporation and our bylaws that will become effective upon the closing of this offering may
discourage, delay, or prevent a merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could
also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members
of our management team, these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of
directors. Among other things, these provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that directors are elected at the annual stockholder meeting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of our directors to be changed from time to time by our stockholders or our board
of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish requirements for stockholder proposals that can be acted on at stockholder meetings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and allow actions by
our stockholders by written consent, with certain requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to
institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware
General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15%
of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We could be subject to
securities class action litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past, securities class action litigation has often been brought against
a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it
could result in substantial costs and a diversion of management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to U.S. and certain foreign anti-corruption laws and regulations, export and import controls, sanctions and embargoes. We
could face liability and other serious consequences for violations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to anti-corruption laws and
regulations, including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act and other state and national anti-bribery laws in the countries in which we may conduct activities in the future.
Anti-corruption laws are interpreted broadly and generally prohibit companies and their employees, agents, contractors and other third-party collaborators from offering, promising, giving, or authorizing others to give anything of value, either
directly or indirectly through third parties, to any person in the public or private sector to obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions
of the corporation and to devise and maintain an adequate system of internal accounting controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business is heavily
regulated and therefore involves significant interaction with public officials, including officials of <FONT STYLE="white-space:nowrap">non-United</FONT> States governments. Additionally, in many other countries, the healthcare providers who
prescribe pharmaceuticals are employed by their government, and therefore will be considered foreign officials for purposes of the FCPA. We also expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain
necessary permits, licenses, patent registrations and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not
explicitly authorize or have actual knowledge of such activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also subject to export control and import laws and regulations,
including the U.S. Export Administration Regulations, U.S. Customs regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls. Compliance with applicable
regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export
control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments and persons targeted by U.S. sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors or collaborators, or those of
our affiliates, will comply with all applicable anti-corruption, export and import control, and sanctions laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in
fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned
countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing
or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to design and maintain effective internal control over financial reporting in the future, investors may lose
confidence in the accuracy and completeness of our financial reports and the market price of our common stock may decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ensuring that we have adequate internal control over financial reporting in place so that we can produce accurate financial
statements on a timely basis is a costly and time-consuming effort that needs to be <FONT STYLE="white-space:nowrap">re-evaluated</FONT> frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with this offering, we intend to begin the process of documenting, reviewing and
improving our internal control over financial reporting for compliance with Section&nbsp;404, which will require annual management assessment of the effectiveness of our internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Implementing any appropriate changes to our internal control over financial reporting may distract our officers and employees,
entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in establishing and maintaining the adequacy of our internal controls, and any failure to maintain that
adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. If we fail to remediate our identified material weaknesses, or identify additional material
weaknesses, in our internal control over financial reporting; if we are unable to comply with the requirements of Section&nbsp;404 in a timely manner; or if we are unable to assert that our internal control over financial reporting is effective,
investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline, and we could also become subject to investigations by the stock exchange on which our common stock is
listed, the SEC or other regulatory authorities, which could require additional financial and management resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be
able to utilize a significant portion of our net operating loss carryforwards and other tax attributes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of
December&nbsp;31, 2021, we had approximately $13.9&nbsp;million federal net operating loss carryforwards and $12.3&nbsp;million in state net operating loss carryforwards. The federal net operating loss carryforward can be carried forward
indefinitely while the state net operating loss carryforward will begin to expire in varying amounts in 2038. The net operating loss carryforwards subject to expiration could expire unused and be unavailable to offset future income tax liabilities.
Under the 2017 Tax Cuts and Jobs Act, or the Tax Act, as modified by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Coronavirus Aid, Relief and Economic Security Act, or CARES Act, federal net operating losses generated in taxable years beginning after December&nbsp;31, 2017 and in future taxable years, if
any, will not expire and may be carried forward indefinitely, but the deductibility of such federal net operating losses in taxable years beginning after December&nbsp;31, 2020 are limited to the lesser of the net operating loss carryover or 80% of
the corporation&#146;s adjusted taxable income (subject to Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code). There is variation in how states are responding to the Tax Act and CARES Act. In addition, for state income
tax purposes, there may be periods during which the use of net operating losses, or NOLs, is suspended or otherwise limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Separately, under Section&nbsp;382 of the Code, and corresponding provisions of state law, if a corporation undergoes an
&#147;ownership change,&#148; which is generally defined as a greater than 50 percentage point change, by value, in its equity ownership by certain stockholders over a rolling three-year period, the corporation&#146;s ability to use its <FONT
STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change income or taxes may be limited. The completion of this offering, together with
private placements and other transactions that have occurred since our inception, may trigger such an ownership change pursuant to Section&nbsp;382 of the Code. We have not completed a Section&nbsp;382 analysis, and therefore, there can be no
assurances that the NOLs carryforward are not already limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may experience ownership changes as a
result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it could harm our future operating results by
effectively increasing our future tax obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>New or future changes to tax laws could materially adversely affect our company.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tax regimes we are subject to or operate under, including with respect to income and <FONT
STYLE="white-space:nowrap">non-income</FONT> taxes, are unsettled and may be subject to significant change. Changes in tax laws, regulations, or rulings, or changes in interpretations of existing laws and regulations, could materially adversely
affect our company. For example, the Tax Act, together with the CARES Act, made broad and complex changes to the U.S. tax code, including changes to U.S. federal tax rates, additional limitations on the deductibility of interest, both positive and
negative changes to the utilization of future NOL carryforwards, allowing for the expensing of certain capital expenditures, and putting into effect the migration from a &#147;worldwide&#148; system of taxation to a territorial system. In addition,
many countries in Europe, as well as a number of other countries and organizations (including the Organization for Economic Cooperation and Development and the European Commission), have recently proposed, recommended, or (in the case of countries)
enacted or otherwise become subject to changes to existing tax laws or new tax laws that could significantly increase our tax obligations in the countries where we do business or require us to change the manner in which we operate our business.
Recently, in the United States, Congress and the Biden administration proposed legislation (which has not yet been enacted) to make various tax law changes. These proposals, recommendations and enactments include changes to the existing framework in
respect of income taxes that could apply to our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Unfavorable global political or economic conditions could adversely
affect our business, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our results of operations could be adversely
affected by general conditions in the global economy and in the global financial markets. The global credit and financial markets have experienced severe volatility and disruptions in the past several years. A severe or prolonged economic downturn,
such as the global financial crisis, could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. There can be no assurance that further deterioration in credit and
financial markets and confidence in economic conditions will not occur. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. In
addition, the current military conflict between Russia and Ukraine could disrupt or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have been or may in the future be initiated by nations including
the United States, the European Union or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with whom we conduct
business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will incur increased costs and demands upon management as a result of being a public company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a public company listed in the United States, we will incur significant additional legal, accounting and other expenses that
we did not incur as a private company, including the cost of director and officer liability insurance. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate
governance and public disclosure, including regulations implemented by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying
interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this
investment may result in increased general and administrative expenses and a diversion of management&#146;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws,
regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including
director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult
for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon completion of this offering, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure
controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and
reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These inherent limitations include the realities
that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an
unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking
statements are contained principally in the sections titled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Business&#148; and
elsewhere in this prospectus. In some cases, you can identify forward-looking statements by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148;
&#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; or &#147;would&#148; or the negative of these terms or other similar expressions intended to identify
statements about the future. These statements speak only as of the date of this prospectus and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and
financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include statements about the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of our preclinical studies and clinical trials of our drug candidates,
including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any IND submissions, initiation of clinical trials and timing of expected clinical results for <FONT
STYLE="white-space:nowrap">ACR-368</FONT> and our other future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any submission of filings for regulatory approval of, and our ability to obtain and maintain
regulatory approvals for, <FONT STYLE="white-space:nowrap">ACR-368</FONT> and any other drug candidates for any indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including new variants of the virus,
which could adversely impact our business, including our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify patients with the cancers treated by our drug candidates, and to enroll patients in
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the size of the patient populations, market acceptance and opportunity for and
clinical utility of our drug candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our manufacturing capabilities and strategy, including the scalability and commercial viability of our
manufacturing methods and processes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the scope of any approved indication for
<FONT STYLE="white-space:nowrap">ACR-368</FONT> or any other drug candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to leverage our AP3 platform to identify and develop future drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or
ability to obtain additional funding before we can expect to generate any revenue from drug sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations or strategic relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance upon intellectual property licensed from third parties and our ability to obtain such licenses on
commercially reasonable terms or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect and enforce our intellectual property position for our drug candidates, and the scope
of such protection; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development of and projections relating to our competitors or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding future revenue, expenses and needs for additional financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing list of risks is not exhaustive. Other sections of this prospectus may include additional
factors that could harm our business and financial performance. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and
uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks and other information we describe in the reports we will file from time to
time with the SEC after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because forward-looking statements are inherently subject to risks
and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis
for each forward-looking statement contained in this prospectus, the events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the
forward-looking statements. You should refer to the &#147;Risk Factors&#148; section of this prospectus for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our
forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should read this prospectus and the documents that we reference in this prospectus and
have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_6"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We obtained the industry, statistical and market data in this prospectus from our own internal estimates and research as well
as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this prospectus involve a number of assumptions and limitations, and the sources of such data cannot guarantee the
accuracy or completeness of such information. While we believe that each of these studies and publications is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors,
including those described in the section titled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the net proceeds from our issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters
exercise in full their option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares), assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase (decrease) in the assumed
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) the net proceeds to us from this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&nbsp;million in the number of shares we are offering would increase (decrease) the net proceeds to us from this offering,
after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming
the assumed initial public offering price stays the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had cash and cash equivalents of
$83.9&nbsp;million. We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund our ongoing and planned
clinical development, including advancing our lead drug candidate ACR-368 through initial Phase 2 clinical readouts, as well as initiating our Phase 2 trial in patients with HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> tumors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to enter IND-enabling stage for at least one of our preclinical programs and to fund continued development of our AP3 platform; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for research and development activities, working capital and other general corporate purposes.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our current operational plans and assumptions, we expect our cash and cash equivalents,
together with the net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We
believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will be insufficient to fund any of our drug candidates through regulatory approval, and we anticipate needing to raise additional capital to
complete the development of and commercialize our drug candidates. It is difficult to predict the cost and timing required to complete development and obtain regulatory approval of, and commercialize, our drug candidates due to, among other factors,
our limited experience with initiating, conducting and completing clinical trials, obtaining regulatory approval and commercializing our drug candidates, the rate of subject enrollment in our clinical trials, filing requirements with various
regulatory agencies, clinical trial results and the actual costs of manufacturing and supplying our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds
to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. We believe that opportunities may exist from time to time to expand our current business through licenses with or
acquisitions of, or investments in, complementary businesses, products or technologies, and we may use a portion of the net proceeds for these purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management will have broad discretion over the use of the net proceeds from this offering. The amounts and timing of our
expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing, cost and success of preclinical studies and clinical trials, the timing of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regulatory submissions, our ability to obtain additional financing, the amount of cash obtained through our existing collaborations and future collaborations, if any, and any unforeseen cash
needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pending any use described above, we intend to invest the net proceeds of this offering in short- and
intermediate-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our
capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the
discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem
relevant. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our cash and cash equivalents, and our capitalization as of June&nbsp;30, 2022: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to: (1)&nbsp;the conversion of all outstanding shares of our preferred
stock into an aggregate of 27,471,911 shares of our common stock upon the closing of this offering; and (2)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give effect to: (1)&nbsp;the pro forma adjustments described above; and
(2)&nbsp;our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts
and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma and pro forma as adjusted information
below is illustrative only, and our capitalization following the closing of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction
with our financial statements and the related notes appearing at the end of this prospectus, the sections of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and other
financial information contained in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.001 par value per share; 27,471,911 shares authorized, issued and
outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value per share; no shares authorized, issued or outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share; 40,013,683 shares authorized, 4,363,745 shares issued
and outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, 31,835,656 shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued and outstanding, pro&nbsp;forma as
adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
amount of each of cash and cash equivalents, additional paid in capital, total stockholders&#146; equity (deficit) and total capitalization by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
amount of each of cash and cash equivalents, additional paid in capital, total stockholders&#146; equity (deficit) and total capitalization by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of
shares of our common stock to be outstanding after this offering is based on 31,835,656 shares of our common stock outstanding as of June&nbsp;30, 2022, after giving effect to the conversion of all outstanding shares of our preferred stock into an
aggregate of 27,471,911 shares of common stock, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,111,703 shares of our common stock issuable upon the exercise of options outstanding as of June&nbsp;30,
2022 under the 2019 Plan, at a weighted-average exercise price of $1.15 per share (which does not include options to purchase an aggregate of 410,000 shares of our commons stock, at a weighted-average exercise price of $1.65 per share, that were
granted subsequent to June&nbsp;30, 2022); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,474,989 shares of our common stock available for future issuance as of June&nbsp;30, 2022 under the 2019
Plan, which shares will cease to be available for issuance under the 2019 Plan at the time the 2022 Plan becomes effective and will be added to, and become available for issuance under, the 2022 Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock reserved for future issuance under the 2022 Plan, which will become effective on the date of the underwriting agreement related to this offering, as well as any automatic increases in the number of shares of common stock reserved for
future issuance under the 2022 Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the
difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had a historical net tangible book deficit of $36.8&nbsp;million, or $8.43 per share of our
common stock. Our historical net tangible book deficit per share represents total tangible assets less total liabilities and the carrying values of our convertible preferred stock, which is not included within stockholders&#146; deficit divided by
the 4,363,745 shares of our common stock outstanding as of June&nbsp;30, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pro forma net tangible book value as
of June&nbsp;30, 2022 was $85.7&nbsp;million, or $2.69 per share of our common stock. Pro forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the conversion of all
outstanding shares of our preferred stock into an aggregate of 27,471,911 shares of our common stock, as if such conversion had occurred upon the closing of this offering. Pro forma net tangible book value per share represents pro forma net tangible
book value divided by the total number of shares outstanding as of June&nbsp;30, 2022, after giving effect to the pro forma adjustment described&nbsp;above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After giving further effect to the sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2022 would have been
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This amount represents an
immediate increase in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors in this offering. We determine dilution by subtracting the pro forma as adjusted net tangible book value per share after
this offering from the amount of cash that a new investor paid for a share of common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book deficit per share as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in historical net tangible book value per share attributable to the pro forma
transactions described in the preceding paragraphs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June 30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The dilution information discussed above is illustrative only and will change based on the
actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
net tangible book value per share after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , and dilution in pro forma net tangible book value per share to new investors
by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase of 1.0&nbsp;million shares in the number of shares we are offering would increase the pro forma as adjusted net tangible book value
per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and decrease the dilution per share to new investors participating in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , assuming no change in the assumed initial public offering price per share and after deducting the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
estimated underwriting discounts and commissions. A decrease of 1.0&nbsp;million shares in the number of shares we are offering would decrease the pro forma as adjusted net tangible book value
per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and increase the dilution per share to new investors participating in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts and commissions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares of our common stock in full, the pro forma as
adjusted net tangible book value after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in pro forma net tangible book value per share would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the dilution per share to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, in each case assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of
this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes, as of June&nbsp;30, 2022, on the pro forma as adjusted basis described
above, the differences between the number of shares purchased from us, the total consideration paid to us in cash and the average price per share that existing stockholders and new investors paid for such shares. The calculation below is based on an
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Price<BR>per&nbsp;Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering is based on
31,835,656 of shares of our common stock outstanding as of June&nbsp;30, 2022, after giving effect to the conversion of all outstanding shares of our preferred stock into an aggregate of 27,471,911 shares of common stock, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,111,703&nbsp;shares of our common stock issuable upon the exercise of options outstanding as of
June&nbsp;30, 2022 under the 2019 Plan, at a weighted-average exercise price of $1.15 per share (which does not include options to purchase an aggregate of 410,000 shares of our common stock, at a weighted-average exercise price of $1.65 per share,
that were granted subsequent to June&nbsp;30, 2022); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,474,989&nbsp;shares of our common stock available for future issuance as of June&nbsp;30, 2022 under the
2019 Plan, which shares will cease to be available for issuance under the 2019 Plan at the time the 2022 Plan becomes effective and will be added to, and become available for issuance under, the 2022 Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock reserved for future issuance under the 2022 Plan, which will become effective on the date of the underwriting agreement related to this offering, as well as any automatic increases in the number of shares of common stock reserved for
future issuance under the 2022 Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that stock options are exercised, new stock options
are issued under our equity incentive plan or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of
market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of
these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>You should read the following discussion and analysis of our financial
condition and results of operations together with our consolidated financial statements and related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set
forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including
those factors set forth in the &#147;Special Note Regarding Forward-Looking Statements&#148; and &#147;Risk Factors&#148; sections of this prospectus, our actual results could differ materially from the results described in or implied by the
forward-looking statements contained in the following discussion and analysis. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose
tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. Recently approved targeted oncology treatments, such as kinase inhibitors, have transformed the
cancer treatment landscape, and while the therapeutic benefit of these agents has provided significant benefit to patients, these targeted oncology treatments unfortunately only address the less than 10% of patients with cancers that harbor certain
easily-identifiable genetic mutations. Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, AP3, to develop our pipeline of oncology drug
candidates. Our AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates, which we refer to as patient responders. We
are currently advancing our lead candidate, ACR-368, a potent CHK1 and CHK2, or CHK1/2, inhibitor, in a potentially registrational Phase 2 trial across multiple tumor types, which our AP3 platform predicts will have a high proportion of patient
responders based on OncoSignature-predicted sensitivity to ACR-368. Our ACR-368 OncoSignature test has been extensively validated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor
biopsies collected from patients with ovarian cancer treated with ACR-368 in past Phase 2 clinical trials conducted by Eli Lilly and Company, or Lilly, and at the National Cancer Institute demonstrating robust enrichment of responders through our
method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception in 2018, we have devoted substantially all of our resources toward conducting discovery and
research activities, organizing and staffing our company, business planning, acquiring or discovering drug candidates, establishing and protecting our intellectual property portfolio, developing and progressing
<FONT STYLE="white-space:nowrap">ACR-368</FONT> and the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, preparing for and conducting preclinical studies and clinical trials, establishing arrangements with third parties for the
manufacture of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> the <FONT STYLE="white-space:nowrap">ACR-368</FONT> Oncosignature and component materials, as well as raising capital. We do not have any drug candidates approved for sale and have not
generated any revenue from drug sales. Since inception, we have funded our operations primarily through equity and convertible debt financings and have received aggregate net proceeds of $119.8&nbsp;million from the issuance of convertible notes and
the sale of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, and Series&nbsp;B convertible preferred stock, or Series B Preferred Stock, which
we refer to collectively as our Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred operating losses since inception. Our net losses for
the six months ended June&nbsp;30, 2022 and 2021 were $13.0&nbsp;million and $9.5&nbsp;million, respectively. Our net losses for the years ended December&nbsp;31, 2021 and 2020 were $16.2&nbsp;million and $5.3&nbsp;million, respectively. As of
June&nbsp;30, 2022, we had an accumulated deficit of $37.9&nbsp;million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our
operations. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, particularly if and as we: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to conduct preclinical studies and clinical trials for
<FONT STYLE="white-space:nowrap">ACR-368;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and conduct additional preclinical studies and clinical trials for
<FONT STYLE="white-space:nowrap">ACR-368;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to discover and develop additional drug candidates and the
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature tests; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire <FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;other</FONT> drug candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical and scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop and refine the manufacturing processes for <FONT STYLE="white-space:nowrap">ACR-368,</FONT>
the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature or any future drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals and pursue commercialization for any drug candidates that successfully complete
clinical trials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial, and management information systems and personnel, including personnel to support
our drug development and planned future commercialization efforts, as well as to support our transition to a public reporting company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the closing of this offering, we expect to incur additional costs associated with operating as a public company,
including significant legal, accounting, insurance, investor relations and other expenses that we did not incur as a private company. Furthermore, we will not generate revenue from drug sales until we successfully complete clinical development and
obtain regulatory approval for a drug candidate. In addition, if we obtain regulatory approval for a drug candidate and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our
commercialization capability to support drug sales, marketing, manufacturing and distribution activities. Our net losses may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our planned clinical
studies and our expenditures on other research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result, we will need substantial
additional funding to support our continuing operations and pursue our growth strategy. Until such time that we can generate significant revenue from drug sales, if ever, we expect to finance our operations through the sale of equity, debt
financings or other capital sources, including potential collaborations with other companies or other strategic transactions. If we are unable to raise capital as needed, this could have a negative impact on our financial condition and ability to
pursue our business strategies including requiring us to delay, reduce or eliminate drug development or future commercialization efforts. The amount and timing of our future funding requirements will depend on many factors including the successful
advancement of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, or any future drug candidates. Our ability to raise additional funds may also be adversely impacted by potential
worsening global economic conditions, and disruptions to, and volatility in the credit and financial markets in the United States and worldwide, such as those resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and
the hostilities in Ukraine. There can be no assurances that the current operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had cash and cash equivalents of $83.9&nbsp;million. We believe that the anticipated net proceeds
from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements through
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See
the section titled &#147;&#151;Liquidity and Capital Resources.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Eli Lilly and Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, we entered into a license agreement and stock issuance agreement, or, collectively, the Lilly Agreement, with
Lilly, pursuant to which we have been granted an exclusive, royalty-bearing sublicensable license to certain intellectual property rights owned or controlled by Lilly, to commercially develop, manufacture, use, distribute and sell therapeutic
products containing the compound prexasertib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the agreement, we paid Lilly an initial upfront fee
payment of $5.0&nbsp;million. In connection with entering into the agreement, we also entered into a common stock issuance agreement with Lilly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
pursuant to which we issued Lilly 829,995 shares of our common stock and 46,058 shares of Series B Preferred Stock. As additional consideration for the license, we are required to pay Lilly
aggregate&nbsp;development and commercial&nbsp;milestone payments of up to $168.0&nbsp;million, of which $5.0&nbsp;million is due prior to NDA.&nbsp;No development or commercial milestones have been achieved to date under the Lilly Agreement. We are
also obligated to pay a tiered percentage royalty on annual net sales ranging from a low single-digit up to&nbsp;low double-digits,&nbsp;subject to certain specified reductions. Royalties are payable by&nbsp;us on a licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of the expiration of
the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in
such country, provided, that our obligation to pay royalties for a given licensed product in a given country will expire earlier upon achievement of certain sales thresholds by generic products in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For a more detailed description of this agreement, see the section titled &#147;Business&#151;Licensing and
Collaborations&#148; and Note 7 to our consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Companion Diagnostic Agreement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, we entered into a companion diagnostic agreement with Akoya Biosciences, Inc., or Akoya, pursuant to
which we agreed to <FONT STYLE="white-space:nowrap">co-develop,</FONT> validate, and commercialize our proprietary <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test, the companion diagnostic that will be used to identify patients
with cancer most likely to respond to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the agreement, we paid
Akoya a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> upfront payment in the amount of $0.6&nbsp;million. We are obligated to pay
Akoya up to low double-digit million dollars upon the achievement of specified development milestones. To date, development milestones have been achieved under the agreement, resulting in payments of $2.0&nbsp;million by us to Akoya. Other than
certain specified pass-through costs, each party is responsible for its own costs associated with the development of the companion diagnostic.&nbsp;Akoya will procure and manufacture necessary supplies to perform the
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to support our clinical development and commercial requirements, in accordance with a supply agreement to be mutually agreed upon by the parties.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For a more detailed description of this agreement, see the sections titled &#147;Business&#151;Licensing and
Collaborations&#148; and &#147;&#151;Contractual Obligations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;on</FONT> Our
Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The extent of the impact of the novel coronavirus, or <FONT STYLE="white-space:nowrap">COVID-19,</FONT>
pandemic on our business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on our CMOs, CROs, and other third parties with
whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. While we continue to conduct our research and development activities,
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> may cause disruptions that impact the timing of our preclinical studies and clinical trials <FONT STYLE="white-space:nowrap">of&nbsp;ACR-368</FONT> and affect our ability to
complete preclinical studies, future clinical trials or to procure items that are essential for our research and development activities. We expect to continue to take actions as may be required or recommended by government authorities or as we
determine are in the best interests of our employees and other business partners in light of the pandemic. To date, there has not been a significant impact on the <FONT STYLE="white-space:nowrap">development&nbsp;of&nbsp;ACR-368</FONT> and the <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature&nbsp;or the rest of our pipeline; however, we cannot at this time predict the specific extent, duration, or full impact that
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> could potentially have on our ongoing business plan, financial condition and operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date,
we have not generated any revenue, and we do not expect to generate any revenue in the foreseeable future from drug sales. We may in the future generate revenue from payments received under collaboration agreements, which includes payments of
upfront fees, license fees, milestone-based payments and reimbursements for research and development efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The majority of our expenses has been research and development expenses, which consist primarily of costs incurred in
connection with our research and development activities, including our drug discovery efforts and the development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature. We expense
research and development costs as incurred, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct cost for conducting internal research and development to generate preclinical validation data for <FONT
STYLE="white-space:nowrap">ACR-368</FONT> including the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, and for our internal preclinical drug discovery programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to obtain and maintain licenses to intellectual property, such as those with Lilly and related future
payments should certain milestones be achieved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external research and development expenses incurred under agreements with CROs, as well as investigative sites
and consultants that conduct our clinical trials and other scientific development services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to manufacturing material for our clinical trials, including fees paid to CMOs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">manufacturing&nbsp;scale-up&nbsp;expenses</FONT> and the cost of acquiring
and manufacturing clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, bonuses, benefits, stock-based compensation and other related
costs for those employees involved in research and development efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses to acquire technologies, such as intellectual property, to be used in research and development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upfront and maintenance fees incurred under license, acquisition and other third-party agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to regulatory activities, including filing fees paid to regulatory agencies and compliance with
regulatory requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent,
maintenance of facilities and equipment and software. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Costs for certain activities are recognized based
on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our discovery studies or other services performed. Significant judgment and estimates are
made in determining the accrued expense balances at the end of any reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We characterize research and
development costs incurred prior to the identification of a drug candidate as discovery costs. Once a drug candidate has been identified, research and development costs incurred are allocated as drug candidate costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our direct, internal research and development costs consist primarily of costs for reagents and material supplies for our <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test and for cellular and human tissue samples and reagents necessary for our preclinical drug discovery programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our external research and development expenses consist primarily of fees
paid to outside consultants, CROs, CMOs and research laboratories in connection with our process development, manufacturing, and clinical development activities. Our direct external research and development expenses also include fees incurred under
license and intellectual property purchase agreements. We track these external research and development costs on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;program-by-program&nbsp;basis</FONT></FONT> once we have
identified a drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A significant portion of our research and development costs to date have been third-party
costs, which we track on an individual drug candidate basis after a clinical drug candidate has been identified. Currently, our sole clinical drug candidate is <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our indirect research and development costs are primarily personnel-related costs, facilities, which is offset by a portion of
our allocable sublease rent income, and other costs. Employees and infrastructure are not directly tied to any one program and are deployed across our programs. As such, we do not track these costs on a specific program basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not allocate employee costs associated with our discovery efforts, or facility costs, including depreciation or other
indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources and third-party consultants primarily to conduct our research and discovery
activities as well as for managing our process development, manufacturing and clinical development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
successful development of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> and <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test or any other future drug candidates is highly uncertain. We plan to substantially increase our
research and development expenses for the foreseeable future as we continue the development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and manufacturing processes and conduct discovery and research activities for our clinical programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot determine with certainty the timing of initiation, the duration, or the completion costs of current or future
clinical trials of our drug candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We
anticipate that we will make determinations as to which drug candidates to pursue and how much funding to direct to each drug candidate on an ongoing basis in response to the results of ongoing and future clinical trials, regulatory developments and
our ongoing assessments as to each drug candidate&#146;s commercial potential. We will need to raise substantial additional capital in the future. Our clinical development costs are expected to increase significantly with our ongoing clinical
trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing drug candidates, including the uncertainty of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress and expenses of our ongoing research activities and clinical trials and other
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">confirming the appropriate safety profile established in past clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our drug candidates show efficacy with an increased objective response rate through patient responder
identification in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we establish additional collaboration or license agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing drug candidates, if and when approved, whether alone or in collaboration with others; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued acceptable safety profile of the products following any regulatory approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any changes in the outcome of any of these variables with respect to the development of our drug candidates in clinical
development could mean a significant change in the costs and timing associated with the development of these drug candidates. We may never succeed in achieving regulatory approval for any of our drug candidates. We may obtain unexpected results from
our clinical trials. We may elect to discontinue, delay or modify clinical trials of some drug candidates or focus on others. For example, if the U.S. Food and Drug Administration, European Medicines Agency or another regulatory authority were to
delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be
required to expend significant additional financial resources and time on the completion of clinical development of that drug candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and
Administrative </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist primarily of employee-related costs, including salaries,
bonuses, benefits, and stock-based compensation expenses for personnel in executive, finance, accounting, human resources and other administrative functions. Other significant general and administrative expenses include legal fees relating to
patent, intellectual property and corporate matters, fees paid for accounting, audit, consulting and other professional services, and expenses for rent, insurance and other operating costs. An allocated portion of sublease rent income is recorded as
an offset to general and administrative expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate that our general and administrative expenses will increase
in the future as we increase our headcount to support our continued research activities and development of our drug candidates. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and
director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Other
Income (Expense), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income primarily consists of interest income, which is earned on cash equivalents that generate interest on a monthly
basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Convertible Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The convertible notes, or the Notes, were related to our obligation to issue shares of Preferred Stock to investors, which were
converted into Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in October 2020. We elected the fair value option to account for the Notes. The Notes were classified as a liability on our consolidated balance sheets and initially
recorded at fair value. The Notes were subsequently revalued with changes in fair value for each reporting period recognized in other income (expense), net until converted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Preferred Stock Tranche Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preferred stock tranche rights, or Preferred Stock Tranche Rights, were related to our obligation to issue shares of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in subsequent second and third closings upon the occurrence of one of four milestones. This obligation was fully satisfied in January 2021 when the third and final tranche of the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock was closed. The Preferred Stock Tranche Rights were classified as a liability on our consolidated balance sheets and initially recorded at fair value. The Preferred Stock Tranche Rights were
subsequently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
revalued until the tranches were settled, with changes in fair value for each reporting period recognized in other income (expense), net. Upon the issuance of the Preferred Stock Tranche Right
shares, the fair value of the related Preferred Stock Tranche Rights was reclassified to Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Anti-dilution Right </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The anti-dilution right, or Anti-dilution Right, related to our obligation to issue capital stock to Lilly for no consideration
upon a future financing. We determined that the Anti-dilution Right was a freestanding financial instrument, and it was classified as a liability on our consolidated balance sheets and initially recorded at fair value. We determined that the Lilly
Agreement represented an asset acquisition of in process research and development, or IPR&amp;D, assets with no alternative future use and recognized the aggregate acquisition cost as acquired IPR&amp;D expense in the consolidated statements of
operations and comprehensive loss. The Anti-dilution Right was subsequently revalued until anti-dilution shares were issued and the Anti-dilution Right was settled, with changes in fair value for each reporting period recognized in other income
(expense), net. Upon issuance of the anti-dilution shares in November 2021, the fair value of the Anti-dilution Right was reclassified to Series B Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have not recorded any income tax benefits for the net losses we have incurred or for the research and
development tax credits earned in each year and interim period, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credit carryforwards will not be
realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, we had $13.9&nbsp;million and $12.3&nbsp;million of federal and state operating
loss carryforwards, respectively. The federal NOLs are not subject to expiration and the state NOLs begin to expire in 2038. These loss carryforwards are available to reduce future federal taxable income, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Six Months
Ended June&nbsp;30, 2022 and 2021 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our results of operations (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our research and development expenses (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ACR-368</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated research and development expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other drug discovery programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, supplies and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses were $10.1&nbsp;million for the six months ended
June&nbsp;30, 2022, compared to $8.4&nbsp;million for the six months ended June&nbsp;30, 2021. The increase of $1.7&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.7&nbsp;million decrease in costs related to the development
<FONT STYLE="white-space:nowrap">of&nbsp;ACR-368,</FONT> primarily due to a $5.5&nbsp;million decrease from the upfront fees associated with the Lilly Agreement in the prior year, offset by increased costs of $3.8&nbsp;million related to the
development of ACR-368, which included $2.0&nbsp;million from increased activity in the outsourcing of manufacturing and the development of clinical trials, and an increase of $1.8&nbsp;million in costs related to the onboarding of CROs in clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $2.1&nbsp;million increase in personnel-related costs, including $0.5&nbsp;million of recruiting expense and
$0.1&nbsp;million of stock-based compensation expense, primarily due to an increase in headcount in support of research activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.3&nbsp;million increase in costs related to discovery activities as a result of increased efforts toward
identifying drug candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our general and administrative expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, supplies and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $3.0&nbsp;million for the six months ended
June&nbsp;30, 2022, compared to $0.8&nbsp;million for the six months ended June&nbsp;30, 2021. The increase of $2.2&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.4&nbsp;million increase in payroll and personnel-related costs, primarily due to an increase in
headcount, including the hiring of our chief financial officer; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.8&nbsp;million increase in legal, accounting and professional fees, primarily due to preparation for our
initial public offering, or IPO. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Total Other Income (Expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total other income, net was $0.1&nbsp;million for the six months ended June&nbsp;30, 2022, compared to total other expense, net
of $0.2&nbsp;million for the six months ended June&nbsp;30, 2021. The change of $0.3&nbsp;million is primarily </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
attributable to a $0.2&nbsp;million loss attributable to the change in the fair value of the Anti-dilution Right upon remeasurement as of June&nbsp;30, 2021 prior to settlement in November 2021,
a $0.1&nbsp;million loss attributable to the change in the fair value of the Preferred Stock Tranche Rights upon remeasurement immediately prior to settlement in January 2021, and an increase of $0.1&nbsp;million in other income, net primarily
related to an increase in interest income on our cash equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2021 and 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our results of operations (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our research and development expenses (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct research and development expenses by program:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ACR-368</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated research and development expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other drug discovery programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, supplies and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses were $13.7&nbsp;million for the year ended December&nbsp;31,
2021, compared to $1.9&nbsp;million for the year ended December&nbsp;31, 2020. The increase of $11.8&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $7.3&nbsp;million increase in costs related to the development
<FONT STYLE="white-space:nowrap">of&nbsp;ACR-368,</FONT> primarily due to costs associated with the Lilly Agreement, including the upfront payment to Lilly of $5.0&nbsp;million, the initial fair value of the Anti-dilution Right of $0.2&nbsp;million,
and the issuance of common stock to Lilly of $0.3&nbsp;million, an increase of $1.1&nbsp;million due to the increased activity in outsourcing of manufacturing and the development of clinical trials, and an increase of $0.7&nbsp;million due to
increased costs related to the onboarding of CROs in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $2.3&nbsp;million increase in costs related to discovery activities as a result of increased efforts toward
identifying drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.5&nbsp;million increase in personnel-related costs, including $0.4&nbsp;million of stock-based
compensation expense, primarily due to an increase in headcount in support of research activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.7&nbsp;million increase in facilities, supplies and other expenses, primarily due to a $1.0&nbsp;million
increase in facilities, rent, travel and equipment driven by an increase in headcount in support of research activities, offset by a $0.3&nbsp;million increase in allocated sublease rent income, which is recorded as an offset to research and
development expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our general and administrative expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities, supplies and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $2.5&nbsp;million for the year ended
December&nbsp;31, 2021, compared to $1.3&nbsp;million for the year ended December&nbsp;31, 2020. The increase of $1.2&nbsp;million was primarily due to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.7&nbsp;million increase in payroll and personnel-related costs, including $0.1&nbsp;million of
stock-based compensation, primarily due to an increase in headcount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million increase in legal, accounting and professional fees; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.3&nbsp;million increase in facilities, supplies, and other expenses, primarily due to a $0.4&nbsp;million
increase in facilities, rent, travel and equipment driven by an increase in headcount, offset by a $0.1&nbsp;million increase in allocated sublease rent income, which is recorded as an offset to general and administrative expenses.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Total Other Expense, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total other expense, net was $0.1&nbsp;million for the year ended December&nbsp;31, 2021, compared to total other expense, net
of $2.1&nbsp;million for the year ended December&nbsp;31, 2020. The decrease of $2.0&nbsp;million is primarily attributable to a $2.1&nbsp;million loss attributable to the change in the fair value of the Notes upon remeasurement in October 2020,
prior to conversion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have not recognized any revenue and have incurred significant losses in each period and on an aggregate
basis. We have not yet commercialized any drug candidates, and we do not expect to generate revenue from sales of any drug candidates or from other sources for several years, if at all. As of June&nbsp;30, 2022, we had $83.9&nbsp;million in cash and
cash equivalents, and we had an accumulated deficit of $37.9&nbsp;million. We have funded our operations primarily with net proceeds of $119.8&nbsp;million from the issuance of convertible notes and sales of our Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our cash flows for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $14.2&nbsp;million for the six months ended June&nbsp;30, 2022, reflecting a net loss
of $13.0&nbsp;million and a net change of $2.0&nbsp;million in our net operating assets and liabilities, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.8&nbsp;million.
<FONT STYLE="white-space:nowrap">Non-cash&nbsp;charges</FONT> primarily consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $0.4&nbsp;million, stock-based compensation expense of $0.3&nbsp;million, and depreciation of
$0.1&nbsp;million. The change in our net operating assets and liabilities was primarily due to a $2.5&nbsp;million increase in prepaid expenses and other current assets and a $0.3&nbsp;million decrease in operating lease liabilities, partially
offset by a $0.4&nbsp;million increase in accounts payable and a $0.4&nbsp;million increase in accrued expenses and other liabilities. The increase in prepaid expenses and other current assets was primarily due to the timing of payments to vendors,
the decrease in operating lease liabilities was due to lease payments on our leases, the increase in accounts payable and accrued expenses and other liabilities was primarily due to an increase in research and development costs and an increase in
headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $8.0&nbsp;million for the six months ended June&nbsp;30, 2021,
reflecting a net loss of $9.5&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.3&nbsp;million and a net change of $0.1&nbsp;million in our net operating assets and liabilities. <FONT
STYLE="white-space:nowrap">Non-cash&nbsp;charges</FONT> primarily consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $0.3&nbsp;million, the cost of the Lilly Agreement paid for in common stock of $0.3&nbsp;million,
stock-based compensation expense of $0.2&nbsp;million, the cost of the Anti-dilution Right assumed with the Lilly Agreement of $0.2&nbsp;million, and the change in the fair value of the Anti-dilution right of $0.2&nbsp;million. The change in our net
operating assets and liabilities was primarily due to a $0.2&nbsp;million increase in accrued expenses and other liabilities and a $0.1&nbsp;million increase in accounts payable, partially offset by a $0.2&nbsp;million decrease in operating lease
liabilities. The increase in accounts payable and accrued expenses and other liabilities was primarily due to an increase in research and development costs and an increase in headcount, and the decrease in operating lease liabilities was due to
lease payments on our leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $14.0&nbsp;million for the year ended
December&nbsp;31, 2021, reflecting a net loss of $16.2&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.9&nbsp;million and a net change of $0.3&nbsp;million in our net operating assets and liabilities.
<FONT STYLE="white-space:nowrap">Non-cash&nbsp;charges</FONT> primarily consisted of <FONT STYLE="white-space:nowrap">non-cash</FONT> lease expense of $0.8&nbsp;million, stock-based compensation expense of $0.5&nbsp;million, the cost of the Lilly
Agreement paid for in common stock of $0.3&nbsp;million, and the cost of the Anti-dilution Right assumed with the license agreement of $0.2&nbsp;million. The change in our net operating assets and liabilities was primarily due to a $0.9&nbsp;million
increase in accrued expenses and other liabilities and a $0.8&nbsp;million increase in accounts payable, partially offset by a $0.8&nbsp;million increase in prepaid expenses and other current assets and a $0.6&nbsp;million decrease in operating
lease liabilities. The increase in accounts payable was primarily due to an increase in research and development costs, the increase in accrued expenses and other liabilities was primarily due to an increase in research and development costs and an
increase in headcount, the increase in prepaid expenses and other current assets was primarily due to the timing of payments to vendors, and the decrease in operating lease liabilities was due to lease payments on our leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $2.8&nbsp;million for the year
ended December&nbsp;31, 2020, reflecting a net loss of $5.3&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $2.2&nbsp;million and a net change of $0.3&nbsp;million in our net operating assets and
liabilities. <FONT STYLE="white-space:nowrap">Non-cash&nbsp;charges</FONT> primarily consist of a change in fair value of the Notes of $2.1&nbsp;million and the change in the fair value of Preferred Stock Tranche Rights of $0.1&nbsp;million. The
change in our net operating assets and liabilities was primarily due to a $0.4&nbsp;million increase in accrued expenses and other liabilities and a $0.1&nbsp;million increase in accounts payable, partially offset by a $0.1&nbsp;million increase in
prepaid expenses and other current assets. The increase in accrued expenses and other liabilities was primarily due to an increase in research and development costs and an increase in headcount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities was $1.5&nbsp;million and $0.1&nbsp;million for the six months ended June&nbsp;30, 2022
and 2021, respectively, and resulted from our purchases of property and equipment, consisting largely of laboratory equipment purchases to support our expanded headcount and continued research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities was $0.2&nbsp;million and $15,000 for the year ended December&nbsp;31, 2021 and 2020,
respectively, and resulted from our purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Cash (Used in) Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in financing activities was $11,000 for the six months ended June 30, 2022, resulting from the payment of
deferred offering costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities was $12.5&nbsp;million for the six months ended
June&nbsp;30, 2021, resulting from proceeds received from the issuance and sale of shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, net of issuance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities was $112.2&nbsp;million for the year ended December&nbsp;31, 2021, resulting from
proceeds received from the issuance and sale of shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, net of issuance costs, of $12.5&nbsp;million and from the issuance and sale of our Series B Preferred Stock, net of
issuance costs, of $99.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities was $2.9&nbsp;million for the year ended
December&nbsp;31, 2020, resulting from proceeds received from the issuance and sale of shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, net of issuance costs of $2.8&nbsp;million and proceeds from the issuance of our
payment protection program loan of $0.1&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, our cash and cash equivalents were $83.9&nbsp;million. We believe that the net proceeds from this
offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
We have based this estimate on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to incur significant expenses and operating losses for the foreseeable future as we advance our drug candidates
through clinical development, seek regulatory approval and pursue commercialization of any approved drug candidates. We expect that our research and development and general and administrative costs will increase in connection with our planned
research and clinical activities. In addition, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses
that we did not incur as a private company. If we receive regulatory approval for any of our drug candidates, we expect to incur significant commercialization expenses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
related to drug manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We may also require additional capital to
<FONT STYLE="white-space:nowrap">pursue&nbsp;in-licenses&nbsp;or</FONT> acquisitions of other drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of
the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drug candidates, we are unable to accurately predict the amount of our operating expenditures. Our future capital requirements will
depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress, results and costs of preclinical and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of future activities, including drug sales, medical affairs, marketing, manufacturing and
distribution, for any drug for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of establishing and maintaining arrangements with third party manufacturers for the commercial
supply of products that receive marketing approval, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sale of our products, should any drug candidates receive
marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cash requirements of any future acquisitions or discovery of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of attracting, hiring and retaining skilled personnel to support our operations and
continued growth; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of implementing operational, financial and management systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations, strategic partnerships or marketing, distribution,
licensing or other strategic arrangements with third parties on favorable terms, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, current or
future drug candidates, if any; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A change in the outcome of any of these or other variables with respect to the development of
<FONT STYLE="white-space:nowrap">ACR-368,</FONT> the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, or any drug or development candidate we may develop in the future could significantly change the costs and timing associated with our
development plans. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Until such time, if ever, as we can generate substantial drug revenues to support our expenses, we expect to finance our cash
needs through a combination of equity offerings, debt financings, collaborations and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our
stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar
arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of
our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop
and market our drug candidates even if we would otherwise prefer to develop and market such drug candidates ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Leases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We lease
laboratory and office space in Watertown, Massachusetts. This lease is classified as an operating lease, and will expire in April 2028, with an option to extend the term for an additional five years at then-market rental rates. Additionally, we also
lease laboratory and office space in Lund, Sweden. This lease is classified as an operating lease, and will expire in September 2023, with an option to extend the term for an additional three years. Future minimum commitments under these leases are
$7.2&nbsp;million as of December&nbsp;31, 2021. Of the $7.2&nbsp;million, $1.1&nbsp;million is due in less than 12 months. See Note 6 in our unaudited condensed consolidated financial statements appearing at the end of this prospectus for more
information on our lease obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may incur contingent royalty and milestone payments that we are required to make under our license agreement with Lilly,
pursuant to which we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> certain intellectual property. We are required to pay Lilly aggregate&nbsp;development and commercial&nbsp;milestone payments of up to $168.0&nbsp;million, of which
$5.0&nbsp;million is due prior to NDA. Due to the uncertainty of the achievement and timing of the events requiring payment under our license agreement with Lilly, the amounts to be paid by us are not fixed or determinable at this time. We are also
obligated to pay a tiered percentage royalty on annual net sales ranging from a low single-digit up to&nbsp;low double-digits,&nbsp;subject to certain specified reductions. For additional information, see the section titled
&#147;Business&#151;Licensing and Collaborations.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Companion Diagnostic Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may incur contingent milestone payments that we are required to make under our companion diagnostic agreement with Akoya
pursuant to which we agreed to <FONT STYLE="white-space:nowrap">co-develop,</FONT> validate, and commercialize our proprietary ACR-368 OncoSignature test. We are obligated to pay Akoya up to low double-digit million dollars upon the achievement of
specified development milestones. Due to the uncertainty of the achievement and timing of the events requiring payment under our companion diagnostic agreement with Akoya, the amounts to be paid by us and when are not determinable at this time.
While the achievement and timing of such milestones are uncertain, it is reasonably possible that up to $2.3&nbsp;million in milestone payments could be achieved in the next 12 months. To date, development milestones have been achieved under our
companion diagnostic agreement, resulting in payments of $2.0&nbsp;million by us to Akoya. For additional information, see the section titled &#147;Business&#151;Licensing and Collaborations.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase and Other Obligations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We enter into contracts in the normal course of business with CROs and other third-party vendors for clinical trials and
testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, <FONT
STYLE="white-space:nowrap">including&nbsp;non-cancelable&nbsp;obligations</FONT> of our service provided up to one year after the date of cancellation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our consolidated financial statements are prepared in accordance with&nbsp;accounting principles generally accepted in the
United States, or U.S. GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our
estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While our significant accounting policies are described in more detail in
Note&nbsp;2 to our audited consolidated financial statements appearing elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated
financial statements.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and
development expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel and with vendors to identify services that have been performed on our behalf and estimating the
level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or
when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers
and make adjustments if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We base our expenses related to research and development activities on our estimates
of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and
may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the
time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance <FONT
STYLE="white-space:nowrap">accordingly.&nbsp;Non-refundable&nbsp;advance</FONT> payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have
been received rather than when the payment is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we do not expect our estimates to be materially different
from amounts incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To
date, there have been no material differences between our estimates of such expenses and the amounts incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Rights and
Anti-dilution Right </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial fair value of the Preferred Stock Tranche Rights recognized in connection with the
issuance of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in August 2020 and the Anti-dilution Right issued to Lilly in January 2021 were determined based on significant inputs not observable in the market, which represent
Level&nbsp;3 measurements within the fair value hierarchy. These obligations were remeasured prior to the issuance of subsequent tranches in January 2021 and anti-dilution shares in November 2021 and at each interim reporting period. See Note 9 to
our audited consolidated financial statements included elsewhere in this prospectus for additional information regarding our issuances of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock Tranche Rights and Anti-dilution Right were valued as forward contracts. The values were determined using
a probability-weighted present value calculation. In determining the fair values, estimates and assumptions impacting fair value included the future value of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, risk free interest
rates, estimated years to liquidity and probability of each milestone being achieved. We determined the per share future value of the shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by back-solving to the initial
proceeds of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing. We remeasured each Tranche Right and Anti-dilution Right at each reporting period and prior to settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We issued the Notes in 2018 and 2019 to investors, which were subsequently converted in October 2020. We elected the fair value
option to account for the Notes. The fair value of the Notes was based on significant inputs not observable in the market, which represented a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the
valuation of the Notes could have a significant impact on the value of the obligation. The value was determined using a probability-weighted present value calculation. In determining the fair value of the Notes, estimates and assumptions impacting
the fair value included the estimated future values of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, discount rates, estimated time to conversion, and probability of conversion upon certain events. We remeasured the Notes
at each reporting period and prior to the conversion of the Notes. There were no convertible notes outstanding during the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We measure stock-based compensation based on the grant date fair value of the stock-based awards and recognize stock-based
compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur.
<FONT STYLE="white-space:nowrap">For&nbsp;non-employee&nbsp;awards,</FONT> compensation expense is recognized as the services are provided, which is generally ratably over the vesting period. At inception, prior to the issuance of any stock option
grants, we adopted the guidance of Accounting Standards Update, or ASU, <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT><I>&nbsp;Compensation&#151;Stock Compensation</I>&nbsp;(Topic 718):<I>&nbsp;Improvements to</I><I></I><I><FONT
STYLE="white-space:nowrap">&nbsp;Non-employee</FONT></I><I></I><I>&nbsp;Share-based Payment Accounting</I>, <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07,&nbsp;and</FONT> account for awards
<FONT STYLE="white-space:nowrap">to&nbsp;non-employees&nbsp;using</FONT> the grant date fair value without subsequent periodic remeasurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense is classified in our consolidated statements of operations based on the function to which the
related services are provided or in the same manner in which the grantee&#146;s payroll costs are classified or in which the grantee&#146;s service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model,
which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our
expected dividend yield. As there is currently no public market for our common stock, we determined the volatility for awards granted based on an analysis of reported data for a group of guideline companies that issued options with substantially
similar terms. The expected volatility has been determined using a weighted-average of the historical volatility measures of this group of guideline companies. We expect to estimate expected volatility based on the group of guideline companies until
we have adequate historical data regarding the volatility of our own traded stock price. The expected term of our stock options granted to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> has been determined utilizing the
&#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods
approximately equal to the expected term of the award. We have not paid, and do not anticipate paying, dividends on our common stock; therefore, the expected dividend yield is assumed to be zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Determination of Fair Value of Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As there has been no public market for our common stock to date, the historical estimated fair value of our common stock has
been determined by our board of directors, considering our most recently available independent third-party valuations of common stock. In accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146;
Accounting and Valuation Guide,<I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>,&nbsp;a third-party valuation firm prepared valuations of our common stock using either an option pricing method, or OPM, or a
hybrid method, both of which used market approaches to estimate our enterprise value. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which
the allocation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
among the various holders of a company&#146;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of
the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.
The hybrid method is a probability-weighted expected return method, or PWERM, where the equity value in one or more scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based
upon an analysis of our future values, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the
rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability-weighted to arrive at an indication of value for the common
stock. These third-party valuations were performed at various dates, which resulted in valuation of our common stock of $1.57 per share as of November&nbsp;9, 2021, $1.47 per share as of April&nbsp;15, 2022 and $1.65 per share as of July&nbsp;22,
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to considering the results of the third-party valuations, our board of directors considered various
objective and subjective factors to determine the fair value of our common stock as of each grant date, which may be a date later than the most recent third-party valuation date, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold Preferred Stock and the superior rights and preferences of the Preferred Stock
relative to our common stock at the time of each grant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise future financings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development efforts, including the status of clinical studies for our drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of liquidity of our equity as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the achievement of enterprise milestones, including entering into collaboration and license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently
completed mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any external market conditions affecting the biotechnology industry and trends within the biotechnology
industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our Preferred Stock and holders of our common
stock, such as an IPO, or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are significant judgments and estimates inherent in these valuations. These judgments and
estimates include assumptions regarding our future operating performance, the stage of development of our drug candidates, the timing of a potential IPO or other liquidity event and the determination of the appropriate valuation methodology at each
valuation date. The assumptions underlying these valuations represent management&#146;s best estimates, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use
significantly different assumptions or estimates, our stock-based compensation expense could be materially different. Following the completion of this offering, the fair value of our common stock will be determined based on the quoted market price
of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Options Granted </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth, by grant date, the number of shares underlying options granted from January&nbsp;1, 2022
through the date of this prospectus, the per share exercise price of the options, the fair value per share of common stock on each grant date and the weighted-average estimated per share fair value of the options granted during the period: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number
of<BR>Shares<BR>Subject to<BR>Options&nbsp;Granted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share<BR>Exercise&nbsp;Price<BR>of<BR>Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share&nbsp;Value&nbsp;of<BR>Common&nbsp;Stock on<BR>Grant
Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Estimated Per<BR>Share Fair Value<BR>of Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;6, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,752,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;29, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;5, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of our common stock of $1.57 per share on April&nbsp;6, 2022 was determined by
our board of directors, based, in part, on the $1.57 per share value indicated in the third-party valuation prepared as of November&nbsp;9, 2021. In particular, the valuation determined our enterprise value using an OPM backsolve approach that was
based on the $5.71 price per share paid by new and existing investors in the closing of our Series B Preferred Stock financing in November 2021. A DLOM of the common stock was then applied to arrive at an indication of fair value for our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of our common stock of $1.47 per share on June&nbsp;29, 2022 was determined by us, based, in part,
on the $1.47 per share value indicated in the third-party valuation prepared as of April&nbsp;15, 2022. In particular, the valuation determined our enterprise value using the hybrid method, which included a PWERM, with an IPO scenario, and a sale
scenario. Our enterprise value in the IPO scenario was based on guideline IPO transactions identified within the last one to two years, which was adjusted by a risk-adjusted discount rate. The IPO scenario also assumed an estimated timeline for the
IPO to occur. Our enterprise value for the sale scenario was based on an OPM market-adjusted backsolve method based on the $5.71 price per share paid by new and existing investors in the closing of our Series B Preferred Stock financing in November
2021. The market adjustment applied to the equity value considered the performance of guideline public companies and the biotech indices since the most recent sale of our preferred stock through the valuation date. A DLOM of the common stock was
then applied to arrive at an indication of fair value for our common stock. In addition, the board determined that the fair value of our common stock remained at $1.47 per share through June&nbsp;29, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of our common stock of $1.65 per share on August 5, 2022 was determined by us, based, in part, on the $1.65 per
share value indicated in the third-party valuation prepared as of July 22, 2022. In particular, the valuation determined our enterprise value using the hybrid method, which included a PWERM, with an IPO scenario, and a sale scenario. Our enterprise
value in the IPO scenario was based on guideline IPO transactions identified within the last one to two years, which was adjusted by a risk-adjusted discount rate. The IPO scenario also assumed an estimated timeline for the IPO to occur. Our
enterprise value for the sale scenario was based on an OPM market-adjusted backsolve method based on the $5.71 price per share paid by new and existing investors in the closing of our Series B Preferred Stock financing in November 2021. The market
adjustment applied to the equity value considered the performance of guideline public companies and the biotech indices since the most recent sale of our preferred stock through the valuation date. A DLOM of the common stock was then applied to
arrive at an indication of fair value for our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A description of recent issued accounting pronouncements that may potentially impact our financial position and results of
operations is disclosed in Note 2 to our unaudited condensed consolidated financial statements appearing at the end of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the audit of our financial statements for the year ended December&nbsp;31, 2021 and 2020, we identified
material weaknesses in our internal control over financial reporting that existed as of those periods. See the section titled &#147;Risk factors&#151;We have identified material weaknesses in our internal control over financial reporting. If we are
unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our
financial condition or results of operations, which may adversely affect our business.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Qualitative and Quantitative Disclosures about Market
Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our primary exposure to market risk is interest rate sensitivity, which is impacted by changes to the general level of U.S.
interest rates, particularly because our cash equivalents are in the form of money market funds that are invested in U.S. Treasury securities. As of June&nbsp;30, 2022 and December&nbsp;31, 2021, we had cash and cash equivalents of
$83.9&nbsp;million and $99.6&nbsp;million, respectively. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, an immediate 10% change in interest rates would not have a
material effect on the fair market value of our investment portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and December&nbsp;31,
2021, we had no debt outstanding, and therefore we are not subject to interest rate risk related to debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Exchange Risk
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our reporting currency is the U.S. dollar, or USD. Our functional currency for Acrivon AB, our wholly-owned
subsidiary in Sweden, is the USD. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the functional currency are included in other income (expense), net in the consolidated statements of operations
and comprehensive loss as incurred. We have not recognized material currency transaction gains or losses during the six months ended June&nbsp;30, 2022 and year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not currently engage in currency hedging activities in order to reduce our currency exposure, but we may begin to do so
in the future. Instruments that may be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected
against material foreign currency fluctuations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effects of Inflation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We believe that inflation has not had
a material effect on our consolidated financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting
Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The JOBS Act provides that, among other things, an &#147;emerging growth company&#148; can take
advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to
private companies.&nbsp;As an emerging growth company, we have elected not to &#147;opt out&#148; of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards and, as a result, we will
comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required&nbsp;for&nbsp;private companies on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;case-by-case&nbsp;basis</FONT></FONT> until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer
qualify as an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
emerging growth company. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company
effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. We intend to rely on&nbsp;certain of&nbsp;the other exemptions and reduced reporting requirements
provided by the JOBS Act. As an emerging growth company, we are not required to, among other things, (i)&nbsp;provide an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404(b),
and (ii)&nbsp;comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor
discussion and analysis). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock
held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;plus</FONT> the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million
during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less
than $250&nbsp;million or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less
than $700&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are a smaller reporting company at the time we cease to be an emerging growth company, we
may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited
financial statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and,</FONT> similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder
identification platform. Recently approved targeted oncology treatments, such as kinase inhibitors, have transformed the cancer treatment landscape, and while the therapeutic benefit of these agents has provided significant benefit to patients,
these targeted oncology treatments unfortunately only address the less than 10% of patients with cancers that harbor certain easily-identifiable genetic mutations. Our approach is designed to overcome the limitations of genomics-based patient
selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or AP3, to develop our pipeline of oncology drug candidates. Our AP3 platform enables the creation of drug-specific
proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates, which we refer to as patient responders. We are currently advancing our lead candidate, <FONT
STYLE="white-space:nowrap">ACR-368,</FONT> a potent CHK1 and CHK2, or CHK1/2, inhibitor, in a potentially registrational Phase 2 trial across multiple tumor types, which our AP3 platform predicts will have a high proportion of patient responders
based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Our ACR-368 OncoSignature test has been extensively validated in preclinical studies, including in two separate, blinded, prospectively-designed studies
on pretreatment tumor biopsies collected from patients with ovarian cancer treated with ACR-368 in past Phase 2 clinical trials conducted by Eli Lilly and Company, or Lilly, and at the National Cancer Institute, or NCI, demonstrating robust
enrichment of responders through our method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The AP3 approach is proteomics-based and designed to enable identification
and treatment of the patients whose tumors are sensitive to a specific drug or drug candidate based on direct protein measurement of critical tumor-driving mechanisms and independent of underlying genetic alterations. We believe our approach is
applicable across stages of drug development and across therapeutic modalities. Accordingly, the AP3 method is not limited to the typically very small subset of cancers driven by single gene driver mutations or susceptible to a synthetic lethal
approach. Rather, we believe our method is broadly applicable to the vast majority of cancers, in particular the majority of solid tumors, for which genetics-based approaches have proven insufficient to identify patient responders in many cases. In
principle, we believe a much larger percentage of tumors can be addressed therapeutically using agents attuned to the specific biochemical signaling pathways found in these tumors, which our AP3 platform was purposefully designed to enable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By applying our highly specific patient selection approach to drug development, we seek to both accelerate clinical
development and significantly increase the probability of successful treatment outcomes for patients. Our pipeline includes the Phase 2 lead program, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> also known as prexasertib, a targeted oncology
asset that has been demonstrated to potently inhibit CHK1/2. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been dosed in more than 400 patients at the recommended Phase 2 dose, or RP2D, with reported deep, durable responses, including complete
responses, or CRs, in a proportion of patients with solid tumors in past single center and multi-center Phase 2 clinical trials in tumor indications with high unmet need. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has also demonstrated a
generally favorable safety and tolerability profile with primarily reversible hematological toxicity and very limited <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicity. We have received clearance from the U.S. Food and Drug
Administration, or FDA, for an Investigational New Drug, or IND, application to advance <FONT STYLE="white-space:nowrap">ACR-368</FONT> in Phase 2 single arm clinical trials conducted under the FDA program known as the master protocol, which was
developed to help expedite drug development in multiple tumor types for drugs with an established RP2D within the same overall trial structure. Initially, patients with platinum-resistant ovarian, endometrial, or bladder cancer will be treated in
this trial. Patients will be stratified for treatment based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> across multiple sites in the United States in this trial with registrational intent. Through the
use of our OncoSignature test, we believe we can significantly increase the overall response rate, or ORR, observed in previous trials that were conducted without a prospective patient responder identification method. We also plan to study <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in additional indications, such as human papilloma virus positive, or HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>, squamous cell carcinomas, including squamous cell cancer, or SCC, of head
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and neck, or SCCHN, anal, and cervical cancer, based on demonstrated clinical single agent activity in SCCHN and anal cancer and OncoSignature-based prediction of sensitivity to <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in a proportion of patients. In addition to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we are also developing internally-discovered preclinical stage pipeline programs targeting critical nodes in the
DNA Damage Response, or DDR, and cell cycle regulation pathways, including WEE1, a protein kinase, and a closely related, undisclosed serine/threonine kinase.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were founded and are led by pioneers in oncogenic signaling, oncology precision medicine and the use of proteomic
technology to uncover intracellular biochemical signaling pathways with the goal of applying this knowledge to develop drug candidates and clinical diagnostics. Our founders have established <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> including clinical implementation, for the underlying technologies in our AP3 platform. Our scientific advisors are thought leaders from leading global cancer and academic centers and are
actively involved in our drug development process. We are supported by leading healthcare investors, including Wellington Management, Surveyor Capital, RA Capital, Perceptive Advisors, Sands Capital, HBM Partners, Marshall Wace, Pureos Bioventures,
HealthCor, Acorn Bioventures, Alexandria Venture Investments and Chione. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our AP3 Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform is based on our proprietary approach developed to enable treatment of the patients who are most likely to
respond to any particular drug candidate based on dependency in the tumor on the upregulated specific biochemical pathways that each drug modulates. Hence, our approach is tumor-agnostic: if the pathways the tumor depends on for its survival and
growth, and that the drug candidate modulates, are upregulated, we predict that individual patient&#146;s tumor will be sensitive to the drug candidate. This applies regardless of the tumor origin and is independent of underlying genetic
alterations. We are applying AP3 broadly to clinically active drug candidates as well as carefully selected preclinical lead series with a strong clinical rationale, and for which there is no obvious patient selection path through standard companion
diagnostic approaches. We also intend to explore the use of AP3 with approved drugs to improve the ORR and outcomes for patients through our patient selection approach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One of the key outputs of our AP3 platform are our proprietary response-predictive clinical tests that we refer to as
OncoSignature tests. These are drug-tailored, automated, quantitative proteomic tissue imaging tests applied to pretreatment tumor biopsies as a companion diagnostic, or CDx, to select and treat the patients predicted to benefit from the drug
candidate. Our OncoSignature tests encompass a signature of three classes of functionally-defined protein biomarkers assembled into a single signature assay. The quantitative levels for each of the three biomarkers are defined to determine whether a
patient&#146;s individual tumor has upregulated the biochemical signaling mechanisms that the drug modulates and that the tumor depends on for growth and/or survival. Our company name, Acrivon, is derived from Greek for &#147;accurate.&#148; We
chose it to embody how our OncoSignature tests are designed to accurately match our therapies with patients who will benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tumor-agnostic application of OncoSignature tests enables us to identify and focus on tumor types for which a high unmet
need for a treatment exists and that are predicted to be highly sensitive to our drug candidates. We achieve this by deploying our OncoSignature screening of human cancer samples across various tumor types. Through this process, we can identify new
tumor types predicted to be sensitive to a drug candidate and even estimate the percentage of predicted responders before entering clinical trials. For example, we have identified endometrial cancer and bladder cancer as two highly sensitive cancer
types for ACR-368, and therefore will include patients with these tumor types in our Phase 2 trials. Moreover, we have found through this approach that a proportion of patients with HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> cancers
are predicted to be responsive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> consistent with previously demonstrated clinical activity in a proportion of patients with SCCHN and anal cancer. Furthermore, we predicted that patients with
squamous non-small cell lung cancer, or sqNSCLC, would not respond to ACR-368, consistent with an observed ORR of 0% in patients with this tumor type in a past trial with ACR-368. Hence, through our OncoSignature screening approach, we can
specifically avoid running clinical trials in cancer types predicted to have limited sensitivity to the drug candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are not only using our AP3 platform to generate drug-tailored,
response-predictive clinical OncoSignature tests, but we also use our AP3 platform to provide unbiased, quantitative analyses of <FONT STYLE="white-space:nowrap">off-target</FONT> effects on intracellular signaling using phosphoproteomic profiling,
potentially enabling us to discover inhibitors that are both highly potent and highly selective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that by
leveraging our AP3 platform and clinical OncoSignature tests, we will profoundly alter precision oncology drug development and the treatment landscape of patients suffering from cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g10r11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 1</B>. Acrivon&#146;s internal pipeline including the clinically advanced <FONT
STYLE="white-space:nowrap">ACR-368</FONT> and two preclinical programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Lead Clinical Candidate <FONT STYLE="white-space:nowrap">ACR-368</FONT>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">ACR-368</FONT> is a selective, potent inhibitor of CHK1/2, which are regulators of
the cell cycle and of DDR and have been validated as attractive drug targets in multiple preclinical models. Several CHK1/2 inhibitors including <FONT STYLE="white-space:nowrap">ACR-368,</FONT> previously known as prexasertib, have been investigated
in the clinic; however, none have been approved by the FDA. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has shown deep, durable single agent clinical activity, including CRs and partial responses, or PRs, in a proportion of patients with solid
tumors with high unmet need for a treatment, such as platinum-resistant ovarian cancer, and SCCs, including SCCHN and anal cancer. More than 400 patients with these tumors have been treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT>
monotherapy at the RP2D in advanced single- and multi-center clinical trials conducted by Lilly, NCI, and at MD Anderson Cancer Center, or MDACC. The ORR in these trials without a predictive biomarker was 29% at the single center Phase 2 ovarian
cancer trial at NCI in the intent to treat, or ITT, population, and approximately 12% across the platinum-resistant ovarian cancer cohorts in the large Phase 2 multi-center international trial sponsored by Lilly. The median duration of response, or
mDOR, at the RP2D across trials to date have ranged from almost six months to over 12 months, and <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy demonstrated a generally favorable safety and tolerability profile with primarily
reversible hematological toxicity and very limited <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicity. Based on these two trials, encompassing over 200 patients with ovarian cancer, primarily platinum-resistant, we believe the
unenriched background ORR in a larger patient population of platinum-resistant ovarian cancer is somewhere between 15% and 20%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using our AP3 platform, we have developed a predictive OncoSignature test for <FONT STYLE="white-space:nowrap">ACR-368,</FONT>
called <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature, that we believe can predict patient response to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy and therefore substantially
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
improve the clinical ORR and, furthermore, that we believe, has the potential to enable expedited drug development. Predicted patient responders are referred to as
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive and predicted <FONT STYLE="white-space:nowrap">non-responders</FONT> are referred to as <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative. The <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test has been extensively validated in both patient-derived xenograft, or PDX, mouse tumor models as well as in two separate blinded, prospectively designed preclinical studies of <FONT
STYLE="white-space:nowrap">pre-treatment</FONT> tumor biopsies collected from patients with ovarian cancer that received <FONT STYLE="white-space:nowrap">ACR-368</FONT> in previous clinical trials. Based on the preclinical study results, we believe
the ORR in the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients will be increased significantly when compared to the unenriched ORR observed in previous trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By applying our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test for indication finding and expansion across
human cancer types, as described below, we have found that approximately 30% of samples from patients with ovarian cancer are <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive. Moreover, we observed that between 30% and 40% of
patients with endometrial and bladder cancer are predicted to be highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Patients with these two types of cancer were not previously treated in
<FONT STYLE="white-space:nowrap">ACR-368</FONT> clinical trials. All three tumor types are therefore included in our upcoming Phase 2 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also used our AP3 platform to identify resistance mechanisms to <FONT STYLE="white-space:nowrap">ACR-368.</FONT>
Through phospho-proteomic profiling of human tumor cell lines that are either highly sensitive or highly resistant to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we uncovered key resistance mechanisms and found that very low dose gemcitabine,
or LDG, could be used to overcome resistance and further sensitize human tumor cells to <FONT STYLE="white-space:nowrap">ACR-368</FONT> through inducing increased DDR stress. Moreover, the use of LDG was observed to enhance sensitivity to <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in the already sensitive cells. We expect this may enable <FONT STYLE="white-space:nowrap">ACR-368</FONT> in combination with LDG to be an important treatment for
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients who would otherwise be excluded from <FONT STYLE="white-space:nowrap">ACR-368</FONT> treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on these results, we are initiating a Phase 2 clinical trial where we intend to treat patients with all three tumor
types: platinum-resistant ovarian, endometrial, and bladder cancer. <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients, which we believe will represent 30% to 40% of patients of each tumor type, will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> monotherapy in a single arm Phase 2b trial for each of the three tumor types. The <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients with one of these three tumor types will
receive <FONT STYLE="white-space:nowrap">ACR-368</FONT> combined with LDG in a Phase 1b trial, followed by expansion into a Phase 2 trial with the combination in all three tumor types. As a result, all patients with these tumor types that have been
biopsied will be eligible to receive therapy. This Phase 2 clinical trial design and protocol has been cleared by FDA and we anticipate beginning patient enrollment in the second half of 2022. We believe this trial, if successful, has the potential
to be registrational for <FONT STYLE="white-space:nowrap">ACR-368</FONT> in each of the three tumor types. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are
carrying out our trial under the auspices of the master protocol guidance issued by FDA in March 2022 to enable expedited drug development. This guidance provides sponsors of drugs or biologics for the treatment of cancer and for which the RP2D has
been established in prior studies, the opportunity to simultaneously evaluate more than one investigational drug and/or multiple cancer subpopulations within the same overall trial structure under master protocol in adult and pediatric cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that use of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to select patients predicted to
be sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> for treatment will significantly increase the ORR, which has the potential to lead to accelerated approval for multiple cancers while avoiding treatment of patients with tumors that are
not likely to respond. We are planning to file an IND application amendment to add three additional cancer types under the same trial protocol design at a later time, including head and neck cancer, anal cancer, and cervical cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Preclinical Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also have two preclinical drug programs designed to take advantage of our AP3 platform and the ability to predict tumor
sensitivity based on custom OncoSignature tests. Both of these programs are structure-guided with rational medicinal chemistry efforts based on <FONT STYLE="white-space:nowrap">co-crystallography</FONT> of lead series with their respective targets.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The first of these is directed at WEE1, a target that has been
well-validated in preclinical studies described in the literature, and a critical node in the DDR pathways. Promising antitumor activity has been reported from early clinical trials of WEE1 inhibitors developed by competitors; however, the ORRs have
been relatively low and we believe will be insufficient for approval without a patient selection method. Similar to the case with <FONT STYLE="white-space:nowrap">ACR-368,</FONT> to our knowledge, no genetic biomarkers have been identified that can
reliably predict drug sensitivity. Multiple lead compounds have been synthesized and <FONT STYLE="white-space:nowrap">co-crystallized</FONT> with WEE1 at high resolution, resulting in four novel lead series with potent compounds (IC<SUB
STYLE="font-size:75%; vertical-align:bottom">50 </SUB>&lt;10 nM) that have preclinical pharmacokinetic, or PK, studies ongoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The second, equally advanced preclinical program is directed at a closely related serine/threonine kinase also serving
critical functions in the cell cycle and DDR pathways. Similar to the WEE1 program, many high resolution <FONT STYLE="white-space:nowrap">co-crystals</FONT> have been generated between our lead series and our undisclosed target, resulting in two
promising, equally potent, novel lead series with PK studies ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on results from our AP3 platform, we believe
that we can predict drug-sensitivity using a proteomics-based OncoSignature test. We anticipate advancing our WEE1 inhibitor and an inhibitor against a closely related, undisclosed serine/threonine kinase into
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AP3 Potential for Broad Clinical Impact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform is based on two integrated technology pillars, mass spectrometry-based proteomic profiling and our automated
tumor imaging biomarker platform. Mass spectrometry, or MS, enables a systematic, unbiased quantitative analysis of the proteins inside a cell or entire tissues and is used to identify our biomarker candidates. These are validated using our
biomarker platform which is also used to run our OncoSignature tests. AP3 is designed to generate multiple clinically-actionable, valuable outputs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Predictive biomarkers and patient responder identification:</U> Our OncoSignature tests are designed to
enable identification and treatment of patients predicted to be sensitive to the drug candidate, while avoiding treatment of patients predicted not to benefit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Indication finding and expansion:</U> OncoSignature screening of human patient tumor samples is used to
predict what proportion of various tumor types are expected to be highly sensitive to our drug candidates. This enables indication expansion and could potentially increase the response rates in clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Identification of resistance mechanisms:</U> AP3 is a powerful technology to identify either <FONT
STYLE="white-space:nowrap">pre-existing</FONT> (intrinsic) resistance or acquired (therapy-induced) resistance to drugs demonstrated in prior studies. We intend to apply this technology to develop combination therapy candidates that target the
druggable resistance mechanisms and <FONT STYLE="white-space:nowrap">re-sensitize</FONT> tumors and to prevent resistance development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Identification of rational drug combinations:</U> Through our AP3 platform, we uncover the entire protein
signaling pathways underlying resistance. The druggable targets on such pathways are a basis for rational drug combinations and we believe can efficiently overcome resistance demonstrated in multiple prior studies. We intend to apply this for
indication expansion and confirmatory trials for our drug candidate pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Unbiased drug target engagement and pharmacodynamic biomarker discovery:</U> Through our high resolution
phosphoproteomic drug profiling, we uncover thousands of <FONT STYLE="white-space:nowrap">on-</FONT> and <FONT STYLE="white-space:nowrap">off-target</FONT> interactions and drug-regulated pharmacodynamic, or PD, biomarkers for each drug candidate.
These can be used to guide selectivity optimization of preclinical lead series and to measure drug target engagement in patient tumor tissues during clinical trials, and hence guide dose optimization. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform deploys high resolution, high throughput MS resulting in large datasets reflecting differentially
drug-regulated phosphorylation sites and signaling pathways inside sensitive and resistant cells for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
each drug candidate we profile. The data are highly structured and amenable to machine learning, which has enabled us to create a streamlined process and to integrate all the analytical steps
into a single workflow. We intend to apply our AP3 platform to both our existing and future pipeline of drug candidates addressing prevalent, high unmet need cancers and where patient responder identification has proven challenging, as further
described below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><U>


<IMG SRC="g383050g20a22.jpg" ALT="LOGO">
 </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 2</B>. AP3 has potential for broad impact across the drug discovery and development process.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were
founded and are led by pioneers in oncogenic signaling, oncology precision medicine, and the use of proteomic technology to uncover intracellular biochemical signaling pathways and to apply this knowledge to develop drug candidates and clinical
diagnostics. Peter Blume-Jensen, MD, PhD, our <FONT STYLE="white-space:nowrap">co-founder,</FONT> President and Chief Executive Officer, is the inventor of our AP3 platform and OncoSignature patient selection method. He has extensive experience in
oncology drug discovery and development at leading pharmaceutical companies including Serono, Merck&nbsp;&amp; Co. and Daiichi Sanyo. While Chief Scientific Officer at Metamark Genetics, Dr.&nbsp;Blume-Jensen led the development of an automated,
proteomics-based predictive clinical diagnostic for prostate cancer which was validated through blinded clinical trials and included as the only stand-alone test under National Comprehensive Cancer Network, or NCCN, guidelines and reimbursement in
2015. Kristina Masson, PhD, <FONT STYLE="white-space:nowrap">co-founder,</FONT> Executive Vice President, Business Operations and head of our discovery research site in Sweden, previously founded and operated OncoSignature AB, a biotech company
which established the phosphoproteomics and drug discovery infrastructure, and which we subsequently acquired. Jesper Olsen, PhD, our academic <FONT STYLE="white-space:nowrap">co-founder,</FONT> is Professor of Quantitative Proteomics at the
University of Copenhagen and Vice Director of the Novo Nordisk Foundation for Protein Research and a recognized pioneer of <FONT STYLE="white-space:nowrap">MS-based</FONT> quantitative phosphoproteomics. Rasmus Holm-Jorgensen, our Chief Financial
Officer, has over 20 years of experience in the biopharmaceutical industry, most recently as Chief Strategy&nbsp;&amp; Portfolio Officer and part of the founding team at Kiniksa Pharmaceuticals. Erick Gamelin, MD, PhD, our Chief Medical Officer, has
led over 100 Phase 1 through Phase 3 oncology clinical trials and most recently served as Chief Medical Officer of Step Pharma. Eric Devroe, PhD, our Chief Operating Officer, has extensive experience in operations and business development leadership
from his time at Metamark Genetics, MDACC, and several <FONT STYLE="white-space:nowrap">start-up</FONT> companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
founders have pioneered and established <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> including clinical implementation, for the underlying technologies in our AP3 platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal is to be the leading biopharmaceutical company leveraging proteomic and phosphoproteomic data, which we access through
our proprietary AP3 platform, to unlock insights beyond genomic-based approaches and discover and efficiently develop medicines to benefit patients with cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While our AP3 approach is broadly applicable across disease areas, we are initially committed to oncology. Our goal is to
treat patients with cancer with clinically active therapeutics that have a high likelihood of success based on predicted sensitivity to our drug candidates. Oncology is an area of high unmet clinical need, in which only a small fraction of patients
currently benefit from existing predictive biomarkers, such as next-generation sequencing, or NGS. We are currently applying the AP3 technology to both <FONT STYLE="white-space:nowrap">in-licensed</FONT> clinical stage and to internally developed
drug candidates for tumors that do not harbor single gene driver mutations, which is estimated to be more than 90% of all human cancers. The relevant drug target classes in these tumors that we believe are well-suited for our AP3 approach include
but are not limited to DDR pathways, DNA replication stress, super enhancers, and cell cycle and transcriptional regulators. We are initially focused on expedited clinical development of our clinically advanced asset
<FONT STYLE="white-space:nowrap">ACR-368,</FONT> in our upcoming Phase 2 trial in patients with platinum-resistant ovarian, endometrial, or bladder cancers, followed by staggered development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> in HPV<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> cancers. This trial is based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> and has recently been cleared by the FDA to be conducted under a master
protocol. In addition, we intend to leverage AP3 for our internally developed preclinical programs targeting WEE1 and a closely related, undisclosed serine/threonine kinase. The key elements of our strategy summarized below are to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Rapidly advance <FONT STYLE="white-space:nowrap">ACR-368,</FONT> our CHK1/2 inhibitor, through clinical
development in ovarian, bladder, and endometrial cancer by enrolling <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive patients</B>. Our lead program, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> has already demonstrated
deep, durable antitumor activity, including CRs, in patients with ovarian cancer in past clinical trials. Based on our robust preclinical data, including in two blinded, prospective studies on pretreatment tumor biopsies from past ovarian cancer
trials with <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we believe that our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test will lead to significant improvement in ORRs in ovarian cancer as compared to the ORR seen in the
previous trials. Based on human tumor sample profiling, we expect around 30% of patients with ovarian cancer to be <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive and these patients will receive
<FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy in a single arm Phase 2 clinical trial. Additionally, through screening with our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test we predict that patients with other solid
tumor types of high clinical unmet need, including 30% to 40% of patients with endometrial and bladder cancer, could benefit from <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy. We have further validated this prediction in PDX models of
these two tumor types where we observed that these tumors were highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> and that our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test was able to prospectively identify
which models are the most sensitive. We expect to enroll patients into Phase 2 clinical trials in these three tumor types in the second half of 2022 and report initial clinical data from this trial during the second half of 2023. Pending the results
and discussions with FDA, we intend to enter the registrational phase during 2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Selectively pursue AP3 identified rational drug combinations with our drug</B> <B>candidates in
OncoSignature-negative patients, initially ACR-368 with LDG</B>. Our AP3 platform is able to elucidate pathways of underlying tumor resistance mechanisms, both <FONT STYLE="white-space:nowrap">pre-existing</FONT> (intrinsic) and acquired
(therapy-induced). This allows us to identify rational drug combinations that can <FONT STYLE="white-space:nowrap">re-sensitize</FONT> <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients to our drug candidates in
resistant tumors. For example, we have shown that LDG was highly synergistic with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in resistant human tumor cell lines and was able to <FONT STYLE="white-space:nowrap">re-sensitize</FONT> <FONT
STYLE="white-space:nowrap">ACR-368</FONT> resistant tumors to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> in ovarian, bladder, and endometrial cancers. Based on these findings, we will conduct a clinical trial with <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in combination with LDG for patients that are <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative within these tumor types, and subsequently in patients with HPV<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> cancers. We expect to enroll patients into a Phase 1b dose escalation arm in the second half of 2022, in order to determine the optimal dosage of LDG with the RP2D of
<FONT STYLE="white-space:nowrap">ACR-368,</FONT> and then expand into a Phase 2 trial. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Discover and develop a pipeline of proprietary drug candidates by leveraging our AP3 platform and
predictive OncoSignature tests</B>. We are applying our AP3 platform in multiple ways to build and rapidly advance a pipeline of structure-guided, wholly owned precision oncology drug candidates. Our first earlier stage pipeline program is targeting
WEE1. While WEE1 is a validated target and WEE1 inhibitors have shown single agent clinical activity across patients with solid tumors of high unmet need, the ORR so far has been insufficient for approval and, despite significant efforts in
identifying patient responders, these efforts have not been fruitful to date. We believe that with our AP3 platform and OncoSignature patient selection strategy, we can significantly enrich the ORR for responders sufficient for approval. Our WEE1
program is currently in preclinical stage and we expect to enter <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies during 2023. We are also developing an additional preclinical stage lead series in parallel against a closely related,
undisclosed serine/threonine kinase and expect to enter <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for that program in 2023. All of our internally derived drug candidates will leverage AP3 phosphoproteomic drug candidate profiling
to guide and optimize drug potency and selectivity. We believe that this approach will help ensure that our drug candidates directly affect the pathways of interest while minimizing <FONT STYLE="white-space:nowrap">off-target</FONT> effects, an
approach that is highly differentiated from traditional drug discovery programs. Secondly, by developing OncoSignature tests tailored for our pipeline drug candidates we believe we can identify patients with highly sensitive tumor types of high
unmet clinical need for treatment before initiation of our clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Acquire rights to drug</B> <B>candidates for which we believe our OncoSignature tests can increase the
likelihood of clinical success</B>. We <FONT STYLE="white-space:nowrap">in-licensed</FONT> <FONT STYLE="white-space:nowrap">ACR-368</FONT> after successfully developing a predictive <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test
to increase the probability of clinical success. We intend to take a similar approach and <FONT STYLE="white-space:nowrap">in-license</FONT> other attractive drug candidates where genetics-based patient selection is challenging or impossible, and
develop drug-tailored OncoSignature tests for these drug candidates. We intend to pursue only the opportunities that, similar to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> have high clinical potential and where we believe we can successfully
select patients who are likely to respond to such specific drug candidates, based on our proprietary OncoSignature tests. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Opportunistically enter into strategic <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships
around predictive OncoSignature tests to maximize the full potential of our AP3 platform</B>. We believe that there are opportunities to partner with organizations that have approved drugs or drug candidates in development under competitive pressure
and where the availability of a highly predictive OncoSignature test to achieve high ORRs can potentially provide an advantage in obtaining regulatory approval and market share. Moreover, we believe that identification of rational drug combinations
for such drugs to improve ORR and clinical benefit are of high value to prospective partners. We intend to pursue such partnerships where we can realize the value that OncoSignature and our AP3 platform can bring to the drug candidate through early <FONT
STYLE="white-space:nowrap">co-development.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Urgent Need for Precision Oncology Approaches that Transcend the Limitations of
Genomics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cancer is a disease of dysregulated protein activity, which occurs as a result of underlying genetic changes.
The majority of precision medicine efforts in oncology have been focused on identifying patients who are most likely to respond based either on genetic changes in their tumors, such as specific mutations, gene amplifications, and gene
translocations, or on the patient&#146;s own genetic background. The availability of genomic sequences from tens of thousands of tumors has begun to transform oncology treatment away from the use of broad cytotoxic drugs approved based on tumor
location towards precision medicines that address tumors with specific genetic alterations. However, while this approach has led to the recent approval of a number of targeted therapies, their use is limited to a very small fraction of patients with
these mutations. It is estimated that only 9% of all patients with cancer have tumors with genetic profiles that make them eligible for an available precision oncology medicine, <FONT STYLE="white-space:nowrap">so-called</FONT> genetically-defined
cancers, and only 5% of all patients with cancer are likely to benefit from available therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><U>


<IMG SRC="g383050g20a23.jpg" ALT="LOGO">
 </U></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 3. </B>Proteomic biomarkers have the potential to be broadly applicable across the vast
majority of cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proteomic biomarkers have the potential to be broadly applicable for the vast majority of cancers
where more traditional genetics-based approaches have proven challenging. In this small subset of genetically defined cancers, most often the alterations in the gene lead to drug target protein dysregulation that drives the cancer, which are
potential targets of cancer therapies. There are three main types of such recurrent single driver <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gain-of-function,</FONT></FONT> or GOF, gene alterations known in human cancer: point
mutations, gene fusions, and amplifications, which represents less than 10% of all cancers. These most easily addressable GOF mutation-driven cancers have been the obvious focus of drug discovery and development for more than two decades. Examples
of such approved drugs include Vemurafenib for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B-RAF-V600E-mutant</FONT></FONT> melanoma, Imatinib for KIT and PDGFR-alpha mutant GIST, Crizotinib for
<FONT STYLE="white-space:nowrap">EML4-ALK+</FONT> lung cancer, Trastuzumab for HER2 amplified breast cancer, and recently Larotrectinib for solid tumors with <FONT STYLE="white-space:nowrap">N-TRK</FONT> fusions. However, more than 90% of cancers
have tumor-driving targets that do not harbor underlying single genetic alterations. Such tumor-driving drug targets are activated through post-translational modifications, including phosphorylation, due to complex genetic alterations elsewhere in
the genome of tumor cells, rather than in the drug target itself. Successful clinical development of inhibitors for these targets is highly challenging as prevailing predictive methods such as NGS, polymerase chain reaction, or PCR, fluorescent <I><FONT
STYLE="white-space:nowrap">in-situ</FONT></I> hybridization, or FISH, immunohistochemistry, or IHC, and transcriptomics have not been successful in identifying patients that would significantly benefit from the drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, while a powerful tool to uncover underlying mechanisms of disease, the utility of genomics for patient selection
is limited when it comes to drug response prediction in oncology. Additionally, the lack of therapeutic efficacy for a given drug, due to inability to identify patient responders, is still a top attrition factor in drug development. The vast
majority of cancers contain multiple, complex genomic alterations resulting in the dysregulated, tumor-driving protein activity. Relatively few genetic alterations are common to a broad percentage of patients with cancer, such as mutations in the <FONT
STYLE="white-space:nowrap">K-RAS</FONT> or p53 genes. However, precision medicines against these targets have been difficult to develop and, because of the complex genetic alterations often <FONT STYLE="white-space:nowrap">co-existing</FONT> in
tumors, treatment often does not elicit expected clinical benefit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The AP3 Solution: Matching Drug Action to the Disease-driving Mechanisms in
Patients&#146; Tumors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform has been developed over the last decade to be an efficient process and workflow
to determine sensitivity to drugs based on the biological signaling pathways that are activated in diseased cells and are required for their survival. Our AP3 platform leverages proteomic biomarkers which enable direct measurement of disease-driving
mechanisms independent of target gene alterations, and allow for accurate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
matching with the mechanism of action of a particular drug. We have designed our proprietary AP3 platform to be agnostic to the underlying genetic alterations in the genome and enable
identification and treatment of patients based on direct measurement of the disease-driving mechanisms that are regulated by and sensitive to the drug. Hence, in contrast to measuring genetic alterations in a patient&#146;s tumor, which is only a
surrogate <FONT STYLE="white-space:nowrap">read-out</FONT> for protein dysregulation, and having to infer whether the drug will act on the inferred protein dysregulation, the AP3 method directly reveals the dysregulated proteins and pathways driving
the tumor that the drug acts on. The AP3 method is drug-centric, and we believe enables an accurate match <I>(</I>Acrivon is derived from Greek for &#147;accurate&#148;)<I> </I>between the mechanism of the drug action with the disease-driving
mechanisms in the patient&#146;s tumor. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g23s23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 4.</B> We are applying AP3 to develop drug candidates with the potential to serve the high unmet
clinical needs of the 95% of patients currently unaddressed by precision oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform is fundamentally
different from genetics-based methods to identify patient responders and we believe it is particularly applicable to the majority of cancers without genetic alterations in the drug target itself. It specifically focuses on the proteins and pathways
that drive tumor growth and survival and enable drug action, rather than exploring complex biology and accumulated genetic alterations that have proven very difficult to connect to drug response. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While the principles and technology behind AP3 are not limited to cancer, we
are initially committed to oncology, where we are applying AP3 to develop drug candidates with the potential to transform the treatment of solid tumors of high unmet clinical need. Strategically, we are applying AP3 to drug classes where genetics
has proven difficult or insufficient for response prediction, and that are active in major fractions of solid tumors, but where the ORR is insufficient for approval without a prospective patient responder identification method. In addition to DDR
pathway inhibitors such as ATR, ATM, WEE1, and CHK1/2, examples of drug classes that we believe would benefit from our AP3 platform include cell cycle regulators (such as CDK2, 4, 6), mitotic regulators (such as Aurora kinases), transcriptional
regulators, DNA replication modulators, such as CDC7, super enhancer kinases (such as CDK7, 9, 12), and inhibitors of mutated forms of <FONT STYLE="white-space:nowrap">K-RAS.</FONT> We believe our ability to apply AP3 to these drug classes allows us
to open up the potential of precision medicine approaches to a much larger fraction of patients than has been possible using exclusively genetics-based approaches. We are initially progressing a pipeline of DDR drug candidates, but intend to broaden
our pipeline to some of these other drug classes and targets through OncoSignature patient responder identification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
AP3 platform is based on two underlying technology pillars typically executed in two sequential steps: the first step, a high-resolution MS for biomarker identification which is integrated with, the second step, our automated tumor biopsy-imaging
biomarker platform that enables biomarker validation and which is also used to run our OncoSignature tests. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g11m11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 5. </B>Our AP3 platform is based on unbiased biomarker identification using global
phosphoproteomic profiling by MS and an automated biomarker platform for our clinical OncoSignature tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">MS enables a
systematic, unbiased quantitative measurement and analysis of the proteins inside a cell or entire tissues. We specifically use it to identify and measure in an unbiased manner the effects of any given drug or drug candidate on the activity state of
the protein signaling networks inside a cell through analysis of the phosphorylation state and levels of proteins inside a tumor cell. Phosphorylation is the best-studied, allosteric <FONT STYLE="white-space:nowrap">on-off</FONT> switch regulatory
mechanism for protein activity involved in all forms of intracellular signaling. Analysis of the entire phospho-proteome before and after drug treatment, <FONT STYLE="white-space:nowrap">so-called</FONT> phosphoproteomic drug profiling, enables us
to objectively identify the global effect of any drug on the activity state of the protein signaling network. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our MS
efforts allow us to identify attractive drug-regulated biomarker candidates, which include identifying changes in overall protein levels as well as in post-translational modifications of proteins, such as those that involve phosphorylation and are
involved in activation or inhibition of protein function in biological signaling pathways. Our data-independent acquisition, label-free phosphoproteomic methods provide for very high resolution. Starting with lists of thousands of potential
biomarker candidates that correlate with drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
sensitivity and resistance, our proprietary algorithms and workflows distill biomarker candidates into three functionally defined classes. The biomarkers are further validated in tumor models and
through quantitative measurements on PDX models as well as on patient tumor samples and, when available, clinical trial biopsies, as we have done with <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of our AP3 platform to develop drug-tailored, predictive OncoSignature tests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One of the key outputs of our AP3 platform are our drug-tailored OncoSignature tests, which are based on an assembly of
biomarkers from each of the three classes selected by the process described above, resulting in a single, quantitative signature test. They are automated, quantitative protein imaging tests designed to be applied to pretreatment tumor biopsies as a
CDx to select and treat the patients predicted to benefit from the specific drug candidate for which they are developed. The tests are developed for routine-processed, paraffin-fixed biopsy tissue and stained with fluorescently labeled antibodies
against the OncoSignature biomarkers. Digital images of these stained tissues are then processed by proprietary software that identifies both tumor cells and tumor cell nuclei. They are quantitatively measured in only defined tumor tissue regions of
a patient biopsy where they function, called the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;region-of-interest,&#148;</FONT></FONT> or ROI. A proprietary algorithm assesses the quantitative level of each biomarker and
combines them to predict the likely response to a drug or drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The AP3 approach is designed to provide a
streamlined, rationale-driven workflow to identify and validate biomarkers. Every OncoSignature test is drug-tailored. Our process to generate an OncoSignature test, including technical biomarker validation, can be completed in approximately two to
three months. It measures three functionally defined classes of biomarkers that in combination are predictive of sensitivity to the particular drug. Each biomarker class can contain more than one biomarker, but we typically measure only one in each
class for a total of three biomarkers. A key rationale is that patients whose tumors do not harbor the specific protein disease-driving mechanisms that are sensitive to the drug are predicted to be unlikely to respond to a particular drug or drug
candidate and hence can be excluded from treatment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><U>


<IMG SRC="g383050g24s24.jpg" ALT="LOGO">
 </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 6</B>. AP3 approach for streamlined development and validation of predictive OncoSignature
tests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to create an OncoSignature test that can be readily performed on
clinical samples, we qualify monoclonal antibodies for the prioritized set of three biomarkers. These antibodies are chosen based on our systematic evaluation of their specificity and sensitivity including correlation in changes in biomarker levels
with drug sensitivity in cell lines and, most importantly, their technical performance on human intended use FFPE-processed cancer tissues as well. This technical validation ensures specificity (that it only recognizes the biomarker of interest),
dynamic range (the fold changes of the biomarker level across tumor samples), and proper intensity. The technically validated antibodies are then assembled into a final drug-tailored predictive OncoSignature test that is functionally validated in a
blinded, prospectively designed manner in various preclinical studies. These include prediction of drug sensitivity across human tumor cell lines, in PDX models, and across human tumor samples, and, when available, on pretreatment tumor biopsies
collected from past trials with the drug or drug candidate. Using our AP3 platform workflow, we have developed and validated an OncoSignature predictive test for <FONT STYLE="white-space:nowrap">ACR-368,</FONT> as further described below. We have
also developed and done preliminary validation for two prototype OncoSignature tests for two other clinical stage assets, a CDK7 and a CDC7 inhibitor, for which genetics-based patient selection has also proven challenging. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test will be conducted under an exclusive license with our
external companion diagnostic partner, who will also commercialize the test, pending approval. The tests are performed on a standard, routine processed <FONT STYLE="white-space:nowrap">pre-treatment</FONT> tumor biopsy with an expected turnaround
time of five to seven business days. We intend to protect all our drug-tailored OncoSignature tests via patents for their tumor-agnostic usage across cancers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g11i11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 7.</B> Our OncoSignature tests are applied to pretreatment tumor biopsies and will be offered by
our CDx partner with an anticipated turn-around time of five to seven business days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enablement of AP3 through our team&#146;s expertise
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The enablement of the AP3 approach as a means to realize the potential of proteomic drug profiling and protein
signature tests in precision medicine is the result of the vision of our founders and their long-standing expertise in the field, including pioneering the underlying AP3 technologies and implementation experience. Three critical aspects behind AP3
are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Founding concept and vision</B>. Our founders are leaders and respected authorities in the understanding of
oncogenic kinase signaling, protein dysregulation through tyrosine phosphorylation, and the relationship of each to human cancer. Our vision was embedded in the 2001 <I>Nature</I> review article, &#147;Oncogenic kinase signaling,&#148; by our
founder Peter Blume-Jensen, which became a citation classic in the field of medicine. It described how cancer and other diseases are inevitably driven by dysregulated protein signaling resulting from either very simple or complex underlying genetic
alterations. The </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
paper linked simple GOF mutations in a class of proteins called tyrosine kinases with their disease-driving dysregulation and involvement in a certain small subset of human cancers. Our founding
vision is that proteomic biomarkers enable direct measurement of the disease-driving mechanisms and allow for accurate matching with drug action, independent of underlying genetic alterations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Technical expertise and implementation experience</B>. The two underlying technologies used in a stepwise
manner in our AP3 platform, (1)&nbsp;high resolution MS for quantitative protein and protein phosphorylation analysis and (2)&nbsp;the automated biomarker platform, have been pioneered and established by our founders and team and integrated into a
content system and approach. Jesper Olsen, our academic <FONT STYLE="white-space:nowrap">co-founder,</FONT> is a recognized world leader in the use of <FONT STYLE="white-space:nowrap">MS-based</FONT> phosphoproteomics, or the study of protein
phosphorylation and its impact on biology. Dr.&nbsp;Olsen is one of the most highly cited authors in this field. Our <FONT STYLE="white-space:nowrap">co-founder,</FONT> Kristina Masson, has established the entire infrastructure for phosphoproteomics
at our subsidiary in Medicon Village, Lund, Sweden in close proximity with Dr.&nbsp;Olsen&#146;s laboratory in Copenhagen, Denmark. Our OncoSignature technology is enabled by this comprehensive proteomics infrastructure and demonstrated <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for the first unbiased MS step in the AP3 approach, resulting in identification of resistance mechanisms and rational drug combinations with the potential to
be tested in controlled clinical trials with the drug selinexor in acute myeloid leukemia. This work was published in <I>Cell Reports </I>on August&nbsp;9, 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Peter Blume-Jensen, led the first
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for unbiased identification of drug-regulated PD biomarkers for PI3&#146;K pathway-targeted agents through an
<FONT STYLE="white-space:nowrap">MS-based</FONT> phosphoproteomics approach. Under his leadership, our team also led the establishment of our automated biomarker platform and the research and development of ProMark, a proteomics eight biomarker
imaging test for prostate cancer outcome prediction launched by Metamark. That test was validated in a blinded trial and was subsequently included in the NCCN Clinical Practice Guidelines. Through this experience, we understand the technical and
regulatory challenges involved in developing and implementing a clinically meaningful proteomic test, and we fully leverage and factor these insights into the design of our OncoSignature tests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ACR-368,</FONT> Our Phase 2 Lead Candidate </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead drug candidate, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> also known as prexasertib, is a potent selective
inhibitor of CHK1/2. <FONT STYLE="white-space:nowrap">ACR-368</FONT> was originally discovered by Array BioPharma and acquired by Lilly, who evaluated the compound in over 1,000 patients across 18 clinical trials, where it demonstrated deep, durable
single agent activity, including CRs, in a proportion of patients across several Phase 2 studies of platinum-resistant ovarian cancer and other solid tumors. Despite the demonstrated clinical activity in a proportion of patients, there was no
obvious patient selection strategy to improve responses sufficient for approval. We chose to <FONT STYLE="white-space:nowrap">in-license</FONT> <FONT STYLE="white-space:nowrap">ACR-368,</FONT> prioritizing it over other carefully evaluated
candidates, based on multiple criteria, including its proven clinical single agent activity, extensive safety data set and extensive comparison work and <FONT STYLE="white-space:nowrap">in-house</FONT> AP3 profiling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have initiated a Phase 2 trial of <FONT STYLE="white-space:nowrap">ACR-368</FONT> in patients with ovarian, endometrial, or
bladder cancer based on OncoSignature-predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> We expect to enroll patients with these three tumor types in the second half of 2022 and report initial clinical data from this trial
during the second half of 2023. Pending results and discussions with the FDA, we intend to enter the registrational phase during 2024. Patients who test <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> monotherapy in a single arm Phase 2 trial, while <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients will receive <FONT STYLE="white-space:nowrap">ACR-368</FONT> in combination
with LDG in a Phase 1b/2 single arm trial. We also plan to study <FONT STYLE="white-space:nowrap">ACR-368</FONT> in additional indications, such as HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> squamous cell carcinomas, including SCCHN,
anal, and cervical cancer, based on demonstrated clinical single agent activity in SCCHN and anal cancer and OncoSignature-based prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in a proportion of patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">ACR-368,</FONT> a selective inhibitor of CHK1 and CHK2, key DDR regulators </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHK1 and CHK2 are checkpoint proteins that prevent cell replication when DNA damage is present. In the absence of DNA damage,
CHK1 and CHK2 are largely inactive. Most normal tissues, other than certain dividing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cells such as those in bone marrow, are not reliant on DDR mechanisms such as CHK1 and CHK2, and hence not subject to the negative side effects from such inhibitors. In contrast, inhibition of
the kinase activity of these proteins or knockdown of their expression by RNA interference in certain G1/S checkpoint-deficient tumor cells has been shown to prevent repair of double-strand DNA breaks resulting in cell death. Treatment of cells with
DNA damaging agents or inhibitors of other proteins involved in the DDR, sensitizes them to cell killing by CHK1 and CHK2 inhibitors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g28m28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 8.</B> CHK1 functions as a cell cycle checkpoint to inhibit DNA replication when DNA damage is
present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">ACR-368</FONT> is a selective CHK1/2 inhibitor with a potency of less than 1 nM
against CHK1 and 8 nM against CHK2. In preclinical studies, <FONT STYLE="white-space:nowrap">ACR-368</FONT> inhibited growth with a potency of less than 100 nM in over 75% of 600 cancer cell lines screened, including a potency of less than 50 nM in
16 of 23 tested ovarian cancer cell lines. <FONT STYLE="white-space:nowrap">ACR-368</FONT> as a single agent led to complete tumor regression in approximately 40% of 38 ovarian cancer PDX models tested. Significant antitumor activity was also
observed in other tumor models such as sarcomas and neuroblastoma. The antitumor activity of <FONT STYLE="white-space:nowrap">ACR-368</FONT> was enhanced in preclinical models when it was combined with DNA damaging agents such as cisplatin and
gemcitabine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Clinical development of <FONT STYLE="white-space:nowrap">ACR-368</FONT> for patients with ovarian and other solid
cancers of high unmet treatment need </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing <FONT STYLE="white-space:nowrap">ACR-368</FONT> for the
treatment of patients with advanced solid tumors including ovarian, endometrial, and bladder cancers. <FONT STYLE="white-space:nowrap">ACR-368</FONT> has demonstrated deep, durable single agent anti-tumor clinical activity, including CRs, in a
proportion of more than 400 patients treated at RP2D in past clinical trials conducted by Lilly, its previous sponsor, and in several investigator-initiated trials, including at the NCI and at MDACC. Importantly, ACR-368 was well-tolerated in these
trials, exhibiting primarily reversible, manageable hematological toxicities and limited dose-limiting <FONT STYLE="white-space:nowrap">non-hematological</FONT> toxicities. Accordingly, there have been no clinical or regulatory holds reported and
less than 2% drug-related discontinuations across all trials to date. While the ORR in the single center Phase 2 study at NCI was 29%, the confirmed ORR in a <FONT STYLE="white-space:nowrap">169-patient</FONT> Phase 2 trial conducted in 46 centers
across eight countries in platinum-resistant ovarian cancer was only approximately 12%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By pairing <FONT
STYLE="white-space:nowrap">ACR-368</FONT> with our compound-specific OncoSignature test, we believe we can significantly increase the ORR by targeting treatment to the patients that are predicted to be most dependent on CHK1/2, and therefore more
likely to respond. Based on our preclinical studies, which include validation of <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test on pretreatment tumor biopsies collected from patients treated with
<FONT STYLE="white-space:nowrap">ACR-368</FONT> in the past ovarian trials, we expect 30% to 40% of patients in our three lead indications, platinum-resistant ovarian, endometrial, and bladder cancer, will be
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive. We expect the ORR to be significantly amplified and, if the data are sufficient, we will aim for single-agent, <FONT STYLE="white-space:nowrap">single-arm</FONT> approval. These
patients will be treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in a Phase 2 trial at the RP2D. The remaining 60% to 70% of <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients will receive <FONT
STYLE="white-space:nowrap">ACR-368</FONT> at the RP2D with LDG, which we have found to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
highly synergistic with <FONT STYLE="white-space:nowrap">ACR-368</FONT> using our AP3 platform in preclinical studies. The IND application for our Phase 2 master protocol trial has been cleared.
We expect to enroll patients into Phase 2 clinical trials in these three tumor types in the second half of 2022 and report initial clinical data from this trial during the second half of 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ovarian cancer background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ovarian cancer is the fifth deadliest cancer in women. An estimated 19,880 women in the United States are projected to be
diagnosed with ovarian cancer and approximately 12,810 will die from this disease in 2022 based on projections from the NCI. The overall five-year survival rate in patients with ovarian cancer is 50% but drops to 31% in patients with metastatic
disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surgery and cytotoxic chemotherapies are widely used to treat patients with ovarian cancer. One of the primary
chemotherapies involves the use of platinum containing regimens such as carboplatin or cisplatin. Approximately 85% to 90% of patients with ovarian cancer initially respond to these drugs, but in over 80% of cases, these cancers return and are
considered platinum-resistant. For these patients, there are few remaining treatment options, including bevacizumab with chemotherapy or PARP inhibitor as maintenance therapy for some patients. Only about 12% of platinum-resistant patients achieve
tumor shrinkage and, on average, people with platinum-resistant ovarian cancer survive for no longer than a year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Endometrial cancer background
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Endometrial cancer is a cancer of the lining of the uterus that primarily affects post-menopausal women. The
American Cancer Society estimates that in the United States there will be 65,950 new cases of endometrial cancer and approximately 12,550 patients will die of this disease in 2022. First-line treatment for patients with localized, early-stage
disease is surgery. Patients with more advanced disease, stages III or IV, are treated with chemotherapy, typically with platinum-based drugs. Approximately 60% of patients with endometrial cancer initially respond to these treatments; however,
similar to ovarian cancer, resistance develops to these drugs. These platinum-resistant patients are treated with radiation therapy or may be eligible for immunotherapy treatments with lenvatinib, an angiogenesis inhibitor. Five-year survival for
patients with metastatic endometrial cancer is approximately 20%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bladder cancer background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Bladder cancer is the most common malignancy involving the urinary system, and 90% of bladder cancer cases are urothelial
carcinomas. The five-year survival for patients with early-stage disease is 96%; however, for patients with advanced metastatic disease the five-year survival drops sharply to less than 10%. The NCI estimates that there will be 81,180 new cases of
bladder cancer and 17,100 deaths in the United States in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The most common treatment for patients diagnosed with
advanced or metastatic bladder cancer is chemotherapy with platinum-based drugs such as carboplatin or cisplatin in combination with gemcitabine. Patients with metastatic disease that progress during or after platinum-based chemotherapy are
increasingly being treated with immune checkpoint inhibitor therapy. A number of <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT STYLE="white-space:nowrap">PD-L1</FONT> checkpoint inhibitors have been approved by the FDA for use in refractory
bladder cancer. Objective ORRs in clinical trials with checkpoint inhibitors have been approximately 15%. On July&nbsp;9, 2021, enfortumab vedotin, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">nectin-4-directed</FONT></FONT>
antibody drug conjugate was approved for patients that have progressed after treatment with immune checkpoint inhibitors <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> and a platinum-containing
chemotherapy. The ORR is about 40%, but eventually the disease progresses and the median overall survival is approximately 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Only an estimated 20% of patients with bladder cancer have alterations in the FGFR2 or FGFR3 genes. In clinical testing,
erdafitinib, an FGFR-targeted drug, has demonstrated a 32% ORR with 2% of patients achieving CRs. Despite the availability of these therapies, the prognosis for patients with metastatic bladder cancer is still poor with a five-year survival rate of
only 8%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> squamous cell carcinoma background
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Squamous cell carcinomas are cancers that develop in the squamous cells that make up the outermost layer of the
skin. More than 90% of anal cancers and cervical cancers and about 70% of SCCHN in the oropharynx, or the back of the throat, are linked to infections with HPV. There are over 46,000
HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>-associated cancers diagnosed in the United States each year and up to 5% of cancers worldwide are potentially caused by HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> infections.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unlike many cancers, HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> cancers are not typically driven by high
levels of genomic instability but rather by alterations in cell cycle regulation, including upregulation of DDR pathways. Certain HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> cancers, primarily SCCHN and cervical cancer, respond to <FONT
STYLE="white-space:nowrap">PD-1</FONT> or <FONT STYLE="white-space:nowrap">PD-L1</FONT> immune checkpoint inhibitor therapies with ORRs of approximately 20%. While these and other targeted therapies are still in development for these cancers, the
primary treatment is with surgery and chemotherapy regimens typically composed of a backbone of <FONT STYLE="white-space:nowrap">5-fluorouracil</FONT> and cisplatin, and radiation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sarcoma background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to previously demonstrated clinical activity in the above tumor types as monotherapy, <FONT
STYLE="white-space:nowrap">ACR-368</FONT> has also shown clinical activity in patients with sarcomas in combination with various chemotherapeutic agents. Patients with sarcomas have very limited treatment options, primarily surgery, chemotherapy,
and radiation. The five-year survival for patients with metastatic soft tissue sarcomas is approximately 17%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Previous clinical trials of <FONT
STYLE="white-space:nowrap">ACR-368</FONT> have demonstrated compelling, durable single agent activity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT
STYLE="white-space:nowrap">ACR-368</FONT> has demonstrated deep, durable single agent activity, including CRs, in a proportion of more than 400 patients with high-grade serous, primarily platinum-resistant, ovarian cancer and SCC treated at RP2D.
Overall, <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been tested in 18 clinical trials as monotherapy or in combination with both targeted agents and chemotherapy in over 1,000 patients across primarily solid tumor types and has shown a
generally favorable safety profile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1a/b trial in squamous cell carcinoma established single agent clinical activity and the RP2D </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A <FONT STYLE="white-space:nowrap">146-patient</FONT> Phase 1 multicenter trial was conducted in patients with refractory or
recurrent squamous cell carcinoma and led by Dr.&nbsp;David Hong at MDACC. The trial included patients with SCCHN, sqNSCLC, and anal cancer. The primary objective of the Phase 1b expansion cohorts was to determine the safety, toxicity, and RP2D of <FONT
STYLE="white-space:nowrap">ACR-368.</FONT> In addition, the ORR according to Response Evaluation Criteria in Solid Tumors, or RECIST, version 1.1 for patients with specific types of SCC was recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The RP2D was established at 105 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> given as an intravenous infusion
every 14 days, and used in the expansion phase for 101 patients. The study demonstrated clinical monotherapy activity of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> with a 5% ORR in SCCHN and 15% ORR in anal cancer. The mDoR was seven months
and over 12 months, respectively, including a CR in anal cancer. Based on these results and the lack of highly effective treatments, <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been granted FDA Orphan Drug Designation, or ODD, for the
treatment of anal cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Of note, approximately half of the patients with SCCHN were HPV<SUP
STYLE="font-size:75%; vertical-align:top">+</SUP> and showed a significantly higher ORR of 19% in response to <FONT STYLE="white-space:nowrap">ACR-368&#151;a</FONT> similar finding to the ORR recorded in patients with anal cancer, which is almost
obligate HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP>. This was reflected in a markedly longer progression-free survival, or PFS, in HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> compared to
<FONT STYLE="white-space:nowrap">HPV-negative,</FONT> or HPV<SUP STYLE="font-size:75%; vertical-align:top">-</SUP>, patients, with some HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> patients benefiting from therapy well over 12 months
while no HPV<SUP STYLE="font-size:75%; vertical-align:top">-</SUP> patients had benefit beyond five months (Fig. 9.). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g29k08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 9.</B> <FONT STYLE="white-space:nowrap">ACR-368</FONT> treatment resulted in a significant
improvement in progression-free survival in patients with HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> SCCHN compared to patients with HPV<SUP STYLE="font-size:75%; vertical-align:top">-</SUP> SCCHN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In this trial, as in most of the other clinical trials with <FONT STYLE="white-space:nowrap">ACR-368,</FONT> an attempt was
made to identify biomarkers predictive for response to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in pretreatment tissue samples by NGS. In an analysis of genetic changes in 24 genes involved in DDR or increased replication stress, no obvious
correlation with clinical response was observed. This lack of correlation between genetic changes and clinical response underscores the need for an alternative patient responder identification method, such as AP3. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g22j00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 10.</B> Maximal percentage change in tumor size from baseline by best ORR across all expansion
cohorts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2, single center NCI trial in patients with high-grade serous ovarian cancer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A Phase 2 trial of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> led by Dr.&nbsp;Lee at NCI, enrolled 28 women with
high-grade serous ovarian cancer. <FONT STYLE="white-space:nowrap">ACR-368</FONT> was administered at the RP2D every 14 days until disease progression, an event of unacceptable toxicity, or withdrawal of consent. Twenty-four women had evaluable
responses after three withdrew consent because of travel inconvenience and one developed an intervening illness that prevented radiological evaluation of tumor progression. All patients in this trial had failed at least one round of prior cytotoxic
chemotherapy and three quarters of the patients had failed three or more prior lines of therapy. The primary endpoint in this single center trial was investigator assessed tumor response based on RECIST v1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the analysis of the ITT population of 28 patients, an ORR of 29% was achieved. The mean duration of response in patients
with platinum-resistant ovarian cancer was over ten months, with some patients remaining on <FONT STYLE="white-space:nowrap">ACR-368</FONT> therapy for over 16 months (Fig. 11). </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g19a20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 11.</B> Duration of response with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in a <FONT
STYLE="white-space:nowrap">28-patient</FONT> ovarian cancer Phase 2 trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Similar to the findings reported for
<FONT STYLE="white-space:nowrap">ACR-368</FONT> in SCC, there was no correlation observed between clinical response and alterations or the expression of potential biomarker genes (Fig. 12). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g93i64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 12</B>. No correlation was observed between <FONT STYLE="white-space:nowrap">ACR-368</FONT>
response and genetic alterations or potential biomarker expression in patients with ovarian cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2 multicenter trial in advanced, high-grade
serous ovarian cancer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A large Phase 2 trial of <FONT STYLE="white-space:nowrap">ACR-368</FONT> in patients with
platinum-resistant and platinum-refractory ovarian cancer sponsored by Lilly was conducted in 46 centers across eight countries. The 169 patients enrolled in this trial had failed two to four prior systemic therapies and 90% of patients had stage
III or stage IV disease. The trial included patients with either an altered BRCA1 or BRCA2 gene, or BRCA-positive, or unaltered BRCA1 or BRCA2 gene, or BRCA-negative, ovarian cancer and was divided into four cohorts. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 1: patients with platinum-resistant, BRCA negative ovarian cancer with at least three lines of prior
therapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 2: patients with BRCA negative platinum-resistant ovarian cancer with no more than two lines of prior
therapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 3: patients with platinum-resistant BRCA mutant ovarian cancer with any line of prior therapy, but with
obligatory prior PARP inhibitor therapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cohort 4: patients with platinum-refractory BRCA negative or BRCA mutant ovarian cancer and any line of prior
therapy. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g13p30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 13. </B>ORR and Disease Control Rate in each of the four cohorts of patients with
platinum-resistant and platinum-refractory ovarian cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary outcome in this study was ORR. Results from this
trial showed that a subset of patients with ovarian cancer treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> across all four cohorts achieved durable PRs. However, the ORR in the 140 patients with platinum-resistant ovarian cancer was
only 19% (12% confirmed, 7% unconfirmed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Secondary outcomes included Disease Control Rate, or DCR, which is the
percentage of patients with a best overall response of CR, PR, or stable disease, or SD, for at least four months. The DCR was over 50% across all four cohorts, varying from 52% in patients with platinum-refractory disease to 74% in patients with
platinum-resistant disease with at least three lines of prior failed therapies. The median duration of response was 5.8 months and median duration of survival was 13.3 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Consistent with previous observations, retrospective analyses of patient pretreatment tumor samples by both NGS and by IHC
failed to identify biomarkers that strongly correlated with clinical response. Despite the demonstrated clinical activity, these data underscore the need for an effective patient responder enrichment method. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">ACR-368</FONT> has been generally well-tolerated with manageable side effects </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There have been eight Lilly-sponsored clinical trials with <FONT STYLE="white-space:nowrap">ACR-368.</FONT> In these trials, <FONT
STYLE="white-space:nowrap">ACR-368</FONT> was administered to a total of 681&nbsp;subjects, to 479&nbsp;subjects as monotherapy and to 202&nbsp;subjects in combination with other treatments. In addition, there have been 10 Investigator-Initiated
Trials, or IITs, where <FONT STYLE="white-space:nowrap">ACR-368</FONT> was administered to a total of 283&nbsp;patients as either monotherapy or in combination. The primary adverse events observed in these trials were hematological, including
transient neutropenia and thrombocytopenia, both of which were generally reversible and manageable. The neutropenia and thrombocytopenia are thought to be part of the mechanism-based suppression of cells in the bone marrow, or myelosuppression,
which is also seen with other DDR inhibitors. However, by dosing <FONT STYLE="white-space:nowrap">ACR-368</FONT> at the established RP2D once every 14 days it was found that in most patients who experienced drug-related hematologic toxicities such
as neutropenia had already begun to recover by the 14th day after dosing. Hence, granulocyte colony-stimulating factor and platelet infusions to correct for neutropenia and thrombocytopenia, respectively, were not mandated but were used at the
discretion of the treating physicians in these trials. Nonhematologic toxicities deemed related to ACR-368 treatment occurred at a much lower frequency and severity as summarized below, with fatigue, nausea, and diarrhea being the mostly commonly
observed events. In addition, in a few patients, an association was identified between increasing ACR-368 plasma concentration following monotherapy and transient QTcF prolongation. None of these episodes led to clinical manifestations. Accordingly,
drug-related discontinuations were between only 1% to 2% across all patients. A proportion of patients experienced very durable responses, and in a few cases remained on therapy for several years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of adverse events from published reports on clinical trials with ACR-368 monotherapy dosed
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>at RP2D </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Study Number <BR>NCT Number <BR>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Study Design<BR>Monotherapy</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">ACR-368&nbsp;Dosing</FONT><BR>Regimen and<BR>Schedule</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of<BR>Subjects</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Summary of Safety Data</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="9"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>Ovarian Carcinoma</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">NCI Phase 2 single center study in platinum-resistant or refractory recurrent ovarian cancer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Single arm study in BRCA-negative, primarily platinum-resistant, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma (Lee et al, Lancet Oncology, 2018)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">RP2D: 105 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> every 14&nbsp;days</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">28 intent to treat platinum resistant (N=21), platinum-sensitive (N=6), and platinum-refractory (N=1) patients.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Most frequent treatment related AEs &#8805; Grade 3: neutropenia measured at day 8, 26 (93%), leukopenia 23 (82%), thrombocytopenia 7 (25%),
anemia 3 (11%), febrile neutropenia 2 (7%); most frequent treatment related non hematological AEs &#8805; Grade 3: fatigue 2 (7%), vomiting 1 (4%), diarrhea 2 (7%).</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">No deaths and no treatment discontinuation due to AEs reported. Note: in this trial, neutropenia and thrombocytopenia were measured at day 8 after infusion,
which is nadir for neutropenia, to specifically assess highest degree of neutropenia, not at end of each dosing cycle, which is standard clinical practice.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="9"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>Other Cancer Types</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I4D-MC-JTJA</FONT></FONT> (JTJA)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">NCT01115790 Completed</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Phase 1 open-label, multicenter</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Non randomized, cohort expansion in subjects advanced squamous cell carcinomas (Hong et al, Clin Cancer Res 2018)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">RP2D: 105 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> every 14&nbsp;days</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Total: 101</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Anus: 26</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">H&amp;N: 57</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">NSCLC: 16</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">+ 2 subjects skin and vaginal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Most frequent treatment related AEs &#8805; Grade 3: 93/101&nbsp;(92%) subjects; neutropenia at day 8, 90 (89%), leukopenia 26 (26%),
thrombocytopenia 16 (16%), febrile neutropenia 12 (12%), anemia 14 (14%). Most frequent treatment related non-hematological AEs &#8805; Grade 3: fatigue 2 (2%), and headache 1(1%).</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Dose reductions in 10 subjects (10%) and dose delays in 22 (22%) due to neutropenia. No deaths and no treatment discontinuation due to AEs reported.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Note: in this trial, neutropenia and thrombocytopenia were measured at day 8 after infusion, which is nadir for neutropenia, to specifically assess highest
degree of neutropenia, not at end of each dosing cycle, which is standard clinical practice.</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I4D-MC-JTJH</FONT></FONT> (JTJH)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">NCT02735980 Phase 2 multicenter, nonrandomized</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Parallel cohort study in subjects with extensive-Small Cell Lung Cancer who had either</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">platinum-sensitive or platinum-resistant/refractory disease (Byers et al, Clin Lung Cancer 2021)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Cohort 1: platinum-sensitive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Cohort 2:
platinum-resistant/refractory</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">RP2D: 105 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> every 14&nbsp;days</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Total: 116</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Cohort 1: 58</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Cohort 2: 60</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Treatment related AEs &#8805; Grade 3: 89/116&nbsp;(76.7%) subjects; neutropenia 75 (64.7%), leukopenia 30 (25.9%), thrombocytopenia 30
(25.9%), febrile neutropenia 12 (10.3%), anemia 14 (12.1%). <FONT STYLE="white-space:nowrap">Non-heme</FONT> AEs: fatigue 5 (4.3%), and decreased appetite 2 (1.7%).</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Dose reductions in 8 subjects (13.3%). Dose delays in 19 (31%) due to neutropenia or thrombocytopenia, and 2 possibly drug related treatment discontinuations
due to Gr3 pneumonia and Gr2 leukopenia. Mean relative dose-intensity 98.26%. </P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Three deaths (5.4%) in cohort 1 deemed possibly related to study
treatment.</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Using Our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature Test For Prediction of Sensitivity to <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in Our Upcoming Phase&nbsp;2 Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using the AP3 streamlined process as
described above, we have developed a predictive OncoSignature test for <FONT STYLE="white-space:nowrap">ACR-368,</FONT> called <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature. We will be using this in our upcoming Phase&nbsp;2 trial to
treat patients with ovarian, endometrial, or bladder cancer based on predicted sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> We have extensively validated our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test in
various preclinical studies and models demonstrating the ability to predict sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> across multiple human
ovarian tumor samples </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Two key questions facing companies entering clinical trials is whether the chosen tumor
types in a particular trial will be sensitive to the drug candidate and, if so, what percentage of patients with each of these tumor types are expected to be sensitive to the drug candidate. To acquire this important information, we use our
OncoSignature tests to screen across human patient tumor samples and multiple tumor types to predict not only which tumors are sensitive to our drug candidates, but also what percentage of patients with these tumor types are predicted to respond. We
have used our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test in this manner to screen across commercially available human patient tumor samples and across tumors that have been routine-processed by formalin-fixation and paraffin
embedding, or FFPE, just like the pretreatment tumor biopsies collected from patient tumors will be processed in our upcoming clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using automated image acquisition software, the biomarkers in our <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature tests are measured quantitatively within the ROI, which is where they are informative and exert their biological function. Patient tumor samples with a minimal predictive threshold of each of the three biomarkers present predicts
sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Conversely, patients without presence of any of the three biomarkers are predicted to not benefit from <FONT STYLE="white-space:nowrap">ACR-368</FONT> and will be excluded from the
monotherapy arm in our upcoming clinical trials. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g13p40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 14.</B> Screening with our ACR-368 OncoSignature across human patient tumor samples is used to
predict which patients are believed to be sensitive and resistant to ACR-368, in this example using human ovarian and anal tumor samples. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Through our analysis of patient tumor samples acquired from biorepositories, we have found that in high-grade serous ovarian
cancer approximately 30% of all patient tumor samples have each of the three biomarkers present above the minimal predictive threshold. This result, combined with the results described below, suggests that approximately 30% of patients could
potentially benefit from treatment with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g23n00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 15.</B> Our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature provides quantitative
scores that we use to objectively predict tumor response. Patient tumor samples with all three biomarkers above a certain minimum level on the heatmap are predicted to benefit from <FONT STYLE="white-space:nowrap">ACR-368</FONT> therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in human tumor cell lines </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Human tumor cell lines are very different from human intact tumor tissue, but are still widely used to assess anti-tumor
efficacy. To date, it has been very challenging to predict sensitivity to DDR inhibitors with prevailing genetics-based methods in human tumor cell lines. However, by applying our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature to a
small panel of human tumor cell lines, we demonstrated our ability to predict sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> with a high degree of certainty. The presence of all three biomarkers above a minimal level predicted
sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in all cells that are highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in viability assays, except for one. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g23r43.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 16</B>. Prediction of <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity across human tumor cell lines. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB>: concentration of <FONT STYLE="white-space:nowrap">ACR-368</FONT> resulting in 50%
inhibition of tumor cell survival. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">R = predicted responder and NR = predicted <FONT STYLE="white-space:nowrap">non-responder.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in ovarian PDX models </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To demonstrate that we can also predict responders to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in PDX models, we
obtained untreated tumor tissue samples from 20 PDX models of ovarian cancer and generated quantitative biomarker scores with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test. Using the same approach, we assessed whether the tumor samples with a minimal level of each of the three biomarkers would
predict sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> We found that our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature was able to capture 80% of responders in PDX models while improving the ORR to approximately 55%
compared to an approximated 20% baseline response rate.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g35a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 17.</B> Our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature accurately
distinguished responders from <FONT STYLE="white-space:nowrap">non-responders</FONT> in PDX models; sensitivity and specificity plotted as an area under receiver operator curve, or AUC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Blinded, prospectively designed prediction of <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity in two separate studies of
pretreatment tumor biopsies from past Phase 2 trials with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in patients with high grade serous ovarian cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our OncoSignature tests are developed using only tumor cells independent of any input from clinical results. The tests are
dictated by a mechanistic, functional definition of each of the three classes of biomarkers based on a strong scientific and clinical rationale as well as on our insights into biological signaling. Based on our approach, we believe we can predict
that if all three classes of biomarkers are present at a minimal level in a tumor sample, the tumor depends on upregulation of the drug target signaling axis for its growth and survival. Moreover, from our phosphoproteomic drug profiling of tumor
cells, we have found that this upregulated signaling axis is modulated by the drug candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To test our <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature for its ability to identify the patients that benefit from monotherapy with <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we conducted two separate studies on pretreatment tumor biopsy
samples collected from patients treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in past trials. Importantly, the studies were blinded to any treatment outcome annotation, the analyses were prospectively defined, and results were
analyzed by an independent third-party statistician. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were able to obtain
<FONT STYLE="white-space:nowrap">pre-treatment</FONT> biopsy samples from a subset of patients with ovarian cancer treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> in the prior clinical Phase 2 trials: patients treated at NCI and in the
multi-center trial sponsored by Lilly. We generated OncoSignature scores on these biopsy samples blinded to treatment outcome and handed these over to the third-party biostatistician, who received the treatment outcome annotation separately. The
results of both of these studies showed that use of our tumor-agnostic <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test was able to significantly improve the response rate, to 47% and 58%, respectively. Moreover, the results also
demonstrated that a negative <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature largely eliminated patients who are less responsive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> hence sparing these patients from a <FONT
STYLE="white-space:nowrap">ACR-368</FONT> single-agent treatment from which they would not benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g24m45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 18.</B> Blinded OncoSignature scoring of <FONT STYLE="white-space:nowrap">pre-treatment</FONT>
tumor biopsies from prior clinical trials of <FONT STYLE="white-space:nowrap">ACR-368</FONT> was able to segregate responders from <FONT STYLE="white-space:nowrap">non-responders.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patients predicted to be sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> had a median PFS, or mPFS, of 7.9 months
compared to 2.2 months for those predicted to be <FONT STYLE="white-space:nowrap">non-responders.</FONT> This reflects the fact that not only the patients with PR or CR, but also with SD predicted by <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature to be responders to <FONT STYLE="white-space:nowrap">ACR-368</FONT> treatment did indeed benefit for longer periods of time than the predicted <FONT STYLE="white-space:nowrap">non-responders.</FONT> This could be valuable for
confirmatory trials where mPFS is typically a primary endpoint. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g09m65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 19.</B> Patients with OncoSignature positive scores had improved PFS compared to OncoSignature
negative patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prediction of <FONT STYLE="white-space:nowrap">ACR-368</FONT> clinical activity in additional cancer indications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To identify tumor types predicted to be sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> we used our <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to screen across large numbers of human patient tumor samples across tumor types obtained from biorepositories. Through this tumor-agnostic usage of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature we found that between 30% and 40% of samples from patients with endometrial cancer and bladder cancer were predicted to be sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> In
addition to validating the positive predictive value of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test, we have also demonstrated the high negative predictive value of our <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature test. For example, in sqNSCLC our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test predicted that none of the patient samples would be sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> which is consistent
with the Phase 1 trial that was conducted in SCC types and described above, which showed an ORR of 0% in sqNSCLC. Based on these findings, which were further confirmed in PDX models of endometrial and bladder cancer, as described below, we predict
that a significant proportion of patients with endometrial and bladder cancer will also be sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy, and these two tumor types are therefore included together with ovarian cancer in our
upcoming Phase 2 trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g12s26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 20.</B> <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature screening across human
routine-processed FFPE patient tumor samples predicts which tumor types and what proportion of these are sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Confirmation of activity in PDX models of predicted tumor types </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to confirm our prediction based on screening of human patient tumor samples that a proportion of patients with bladder
and endometrial cancer are sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy, we generated PDX models of these two tumor types and assessed anti-tumor activity of <FONT STYLE="white-space:nowrap">ACR-368</FONT> in these
tumors. Fresh tumor tissues from mice bearing established primary human endometrial and bladder cancer tissues from 20 and 18 patients, respectively, were harvested and small pieces inoculated into mice randomized into two groups, receiving vehicle
control and <FONT STYLE="white-space:nowrap">ACR-368,</FONT> respectively, as well as a PD group used to predict <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity on the tumor tissue prior to treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mice were treated in a <FONT STYLE="white-space:nowrap">three-days-on,</FONT>
<FONT STYLE="white-space:nowrap">four-days-off</FONT> weekly schedule for four weeks at 10 mg/kg. Mice were sacrificed either four days after last dosing or when the tumor volume in one of the arms reached 2,000 mm, whichever came first. <FONT
STYLE="white-space:nowrap">ACR-368</FONT> demonstrated a potent anti-tumor single agent activity in a proportion of models while others were less sensitive, consistent with the prediction obtained from screening of human patient tumor samples. This
result in these preclinical studies confirmed the predicted single agent activity of <FONT STYLE="white-space:nowrap">ACR-368</FONT> in endometrial and bladder cancer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g17s56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 21.</B><B><I> </I></B>Assessment of anti-tumor activity of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> in PDX models of endometrial cancer (left two columns) and bladder cancer (right two columns) confirm that a proportion are sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Blinded, prospectively designed prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in endometrial PDX models </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To further demonstrate the predictive power of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test, we were
able to obtain <FONT STYLE="white-space:nowrap">de-identified</FONT> FFPE tissue samples from the PD arm of the endometrial cancer PDX model study. <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature biomarker scores were generated for 18
out of 20 PDX models, as two PDX models lacked cytokeratin expression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using the same minimal biomarker levels
established and evaluated in all our other studies summarized above, we found that eight PDX models were <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive and predicted to be sensitive to
<FONT STYLE="white-space:nowrap">ACR-368.</FONT> After unblinding of the data and analysis by a third-party biostatistician, we showed that these models all were sensitive and experienced tumor growth inhibition, or TGI, in response to treatment
with <FONT STYLE="white-space:nowrap">ACR-368.</FONT> The <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative models, which are predicted less sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> contained all the <FONT
STYLE="white-space:nowrap">non-responsive</FONT> PDX models as well as some models with overall less pronounced TGI. The segregation of <FONT STYLE="white-space:nowrap">non-responders</FONT> from responders was statistically significant, and a
sensitivity and specificity analysis demonstrated an AUC of 0.88. Despite the well-known observation that PDX models in general tend to show a much higher percentage of responders compared to human patients, as also demonstrated in our ovarian PDX
model study above, this result nevertheless confirmed the ability of our <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to segregate the most sensitive from <FONT STYLE="white-space:nowrap">non-sensitive</FONT> PDX models in a
blinded, prospectively designed manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g91s91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 22</B>.<B> </B>Blinded, prospectively designed prediction of
<FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity with our OncoSignature test demonstrates segregation of responders and <FONT STYLE="white-space:nowrap">non-responders</FONT> with a p-value = 0.003 and an AUC of 0.88. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AP3 Platform Prediction of LDG as a Rational Combination to Circumvent <FONT STYLE="white-space:nowrap">ACR-368</FONT> Resistance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Not all tumors are sensitive to <FONT STYLE="white-space:nowrap">ACR-368,</FONT> and those that are sensitive can develop
resistance to treatment. We used our AP3 platform to identify pathways that drive resistance to <FONT STYLE="white-space:nowrap">ACR-368</FONT> and to propose potential combination therapies to circumvent these resistance pathways. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As an example, we generated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ACR-368-resistant</FONT></FONT>
ovarian cancer cell lines by growing five different human tumor cell lines, including OVCAR3, that are normally sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in the presence of a clinically relevant dose (50 nM) of <FONT
STYLE="white-space:nowrap">ACR-368</FONT> for over ten weeks. While most cells died, a few cells developed resistance to <FONT STYLE="white-space:nowrap">ACR-368</FONT> and were able to grow in the presence of the drug candidate. In general,
resistant cells were at least <FONT STYLE="white-space:nowrap">1,000-fold</FONT> less sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> than the parental cell lines. Removal of <FONT STYLE="white-space:nowrap">ACR-368</FONT> for up to two
months in the cell lines did not alter this level of resistance, and resistance was maintained in the presence of drug efflux inhibitors, suggesting that the resistance was not due to drug efflux from the cells, but rather permanent change in cell
signaling in these cell lines drove the development of resistance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using AP3, we conducted global proteomic analyses
comparing <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitive and resistant OVCAR3 cells, identifying thousands of differentially expressed proteins and phosphoproteins in these cells. Pathway mapping and analyses of these proteins and
phosphoproteins showed that the activity state of proteins involved in DNA damage repair were significantly downregulated, with a compensatory upregulation of proteins involved in cell cycle progression. These changes demonstrate a low level of
active DNA damage repair and hence we believe that they allowed these <FONT STYLE="white-space:nowrap">ACR-368</FONT> resistant cells to continue to progress through the cell cycle regardless of the presence of the drug. Furthermore, we found that
cells treated with low doses of gemcitabine led to reversal of these changes, upregulating the activity of the core DNA damage repair pathways, consistent with potentially identifying a means of reversing
<FONT STYLE="white-space:nowrap">ACR-368</FONT> resistance. This was in line with our quantitative phosphoproteomic data, which showed that treatment of <FONT STYLE="white-space:nowrap">ACR-368</FONT> resistant cells with LDG resulted in an
upregulation of the three OncoSignature biomarkers, rendering the tumor cells more <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive after treatment with LDG. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g14s30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 23</B>. Proteomic analyses of <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitive and
resistant ovarian cell lines identified activation of proteins that regulate cell cycle progression and inactivation of proteins in the DNA damage repair pathways. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These findings suggested that tumor cells that are resistant to <FONT STYLE="white-space:nowrap">ACR-368</FONT> should be
sensitized by treatments such as gemcitabine that function by disrupting cell cycle progression. We tested this hypothesis in cell-killing assays. The five parental human ovarian tumor cell lines were highly sensitive to <FONT
STYLE="white-space:nowrap">ACR-368</FONT> killing with a concentration required for 50% inhibition, or EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> between ten to 30 nM. The
EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> for OVCAR3 was 15 nM <FONT STYLE="white-space:nowrap">ACR-368.</FONT> By contrast, the resistant OVCAR3 cells had an EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> of over 10
&micro;M, which means they were over <FONT STYLE="white-space:nowrap">1,000-fold</FONT> less sensitive to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> Treatment of these cells with 0.53 nM gemcitabine, lowered the EC<SUB
STYLE="font-size:75%; vertical-align:bottom">50</SUB> for <FONT STYLE="white-space:nowrap">ACR-368</FONT> to 100 nM. A further increase in gemcitabine concentration to 2.7 nM lowered the EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB>
for <FONT STYLE="white-space:nowrap">ACR-368</FONT> to 6 nM. These findings of synergy between <FONT STYLE="white-space:nowrap">ACR-368</FONT> and LDG were extended into other human tumor cell lines, including endometrial and bladder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Support for the synergistic action of <FONT STYLE="white-space:nowrap">ACR-368</FONT> and gemcitabine comes from the
observation that gemcitabine alone does not induce potent cell death in OVCAR3 cells: at 0.53 and at 2.7 nM of gemcitabine there was no effect on cell survival, and more than half of treated cells survived at concentrations exceeding 30 &micro;M.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g14s40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 24.</B> Low concentrations of gemcitabine sensitize a highly resistant ovarian cancer cell line
to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on these results, we intend to treat patients who are predicted
to be resistant to <FONT STYLE="white-space:nowrap">ACR-368</FONT> in our clinical trials with LDG in combination with <FONT STYLE="white-space:nowrap">ACR-368</FONT> to potentially overcome resistance to
<FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upcoming Phase 2 Clinical Trials of <FONT STYLE="white-space:nowrap">ACR-368</FONT> Based on <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-predicted Drug Sensitivity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The IND for our upcoming Phase 2
clinical trial of <FONT STYLE="white-space:nowrap">ACR-368</FONT> with cohorts of patients with advanced or metastatic recurrent platinum-resistant high-grade ovarian, endometrial, and bladder cancers has cleared. The trial will be conducted under
the master protocol guidance by FDA published in March 2022, which aims to enable expedited drug development in multiple cancer types of drugs for which the RP2D has been established in prior studies. The Phase 2 trial will be based on <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature prediction of sensitivity to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy on freshly sampled pretreatment tumor biopsies. Patients with
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive tumors of all three tumor types will be enrolled in an arm to be treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy at RP2D in a Simon <FONT
STYLE="white-space:nowrap">two-stage,</FONT> single arm design. Patients who have OncoSignature negative tumors of all three tumor types are predicted not to be highly sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy. These
patients will be treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> at RP2D plus LDG in a single arm design based on our expectation that LDG will increase <FONT STYLE="white-space:nowrap">ACR-368</FONT> sensitivity in a proportion of
these <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the <FONT
STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-positive arm, up to 23 patients of each of the three tumor types will receive <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy at RP2D. Although not expected to be necessary, the
trial does incorporate an opportunity to refine the OncoSignature biomarker patient selection threshold based on the first 12 patients treated with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy. An interim futility analysis will be
used to exclude the <FONT STYLE="white-space:nowrap">non-interesting</FONT> response rate and assess the ORR. Based on this result, the study is designed to enroll up to an additional 48 patients with these tumor types with a registrational intent.
The <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients of all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
three tumor types will receive <FONT STYLE="white-space:nowrap">ACR-368</FONT> at RP2D with increasing doses of LDG in a Phase 1b dose escalation component of the trial. Once the RP2D for LDG
with <FONT STYLE="white-space:nowrap">ACR-368</FONT> has been found, the plan is to expand the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature-negative patients at the RP2D for the combination into a Phase 2 trial component for all
three tumor types in a single arm design. Antitumor activity will be assessed by RECIST. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g23a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 25</B>. Design of the single arm Phase 2 ACR-368 monotherapy and single arm Phase 1b/2 ACR-368
with low dose gemcitabine combination trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to expand our master protocol, at a later point to include
patients with HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> squamous cell carcinomas, including SCCHN, anal, and cervical cancer. The prior studies in SCCHN and anal cancer, described above, have demonstrated an unenriched ORR of 19% in
patients with HPV<SUP STYLE="font-size:75%; vertical-align:top">+</SUP> SCCHN, and 15% in patients with anal cancer. Moreover, the mDoR was seven months for SCCHN and above 12 months in anal cancer. The FDA has granted ODD for <FONT
STYLE="white-space:nowrap">ACR-368</FONT> for anal cancer. Preclinical screening on human patient tumor samples suggests that approximately 25% of cases of these cancers have activated biochemical signaling pathways that are consistent with
sensitivity to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> We plan to file an IND application amendment to add three additional tumor types under the same master protocol and clinical trial design described above at a later date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patients with additional tumor types, including sarcomas, have been observed to be sensitive to <FONT STYLE="white-space:nowrap">ACR-368</FONT>
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Several investigator-initiated trials, or IITs, have demonstrated clinical activity of <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in combination with various chemotherapeutic agents in patients with different types of sarcomas. These are of high unmet need for improved treatments, and only 17% of patients with metastatic soft tissue
sarcomas survive more than five years. Importantly, these IITs have not only demonstrated clinical activity of <FONT STYLE="white-space:nowrap">ACR-368,</FONT> but have also demonstrated that combination with chemotherapy is generally well-tolerated
in these patients. For example, in a Phase 1/2 trial in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma conducted at Memorial Sloan Kettering Cancer Center it was reported that <FONT
STYLE="white-space:nowrap">ACR-368</FONT> in combination with irinotecan resulted in a 32% ORR and mPFS of over 5.5 months. The combination was generally well-tolerated, leading to primarily hematological adverse events, which were manageable. We
intend to initiate certain carefully selected trials in patients with sarcomas that have demonstrated promising preliminary clinical results in past trials at a later date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Proprietary, Internal Preclinical Programs Targeting Critical Nodes in the DDR Pathways </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to leverage our AP3 platform and OncoSignature tests to aim for enrichment of patient responders for our internal
preclinical programs. We strategically work on drug targets for which early-stage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clinical programs from other companies have demonstrated clinical activity or where there is a strong rationale for clinical activity, and where we believe genetics-based approaches are
insufficient for patient responder identification. Our programs include WEE1 and a closely related, undisclosed serine/threonine kinase. The field designing drugs that target the DDR pathway is rapidly expanding to include a number of drug
candidates in development against targets such as ATR, ATM, <FONT STYLE="white-space:nowrap">DNA-PK,</FONT> CHK1/2, and WEE1. Although several of these candidates have demonstrated antitumor activity in the clinic, the ORRs to treatment with these
candidates have been relatively low. We believe that our AP3 platform provides us with the opportunity to not only develop OncoSignature tests to improve the response rates of existing drug candidates but can also guide the design and optimization
of novel drug candidates as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are using
<FONT STYLE="white-space:nowrap">co-crystallography-guided</FONT> drug design and use of cellular drug target engagement imaging assays that incorporate insights derived from our AP3 platform, aiming to accelerate the advancement, and maximally
improve the likelihood of success of, these internal programs. We are not only using our AP3 platform to generate drug-tailored, response-predictive clinical OncoSignature tests, but we also use our AP3 platform to provide unbiased, quantitative
analyses of <FONT STYLE="white-space:nowrap">off-target</FONT> effects on intracellular signaling using phosphoproteomic profiling, potentially enabling us to discover inhibitors that are both highly potent and highly selective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In our WEE1 program, we have multiple lead compounds synthesized and <FONT STYLE="white-space:nowrap">co-crystallized</FONT>
with WEE1 at resolutions observed between 2.1 &Aring; to 2.6 &Aring;. As a result of these experiments, we have synthesized over 400 compounds and discovered four novel lead series. Multiple compounds have been identified with IC<SUB
STYLE="font-size:75%; vertical-align:bottom">50</SUB>&#146;s less than 10 nM. We have observed encouraging drug target engagement in cells and evaluation of their PK properties is currently underway. In parallel, we are developing a target and drug
tailored OncoSignature test for patient selection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our second, closely related preclinical program directed at an
undisclosed target is equally advanced as our WEE1 program. We have synthesized multiple lead compounds and <FONT STYLE="white-space:nowrap">co-crystallized</FONT> these compounds with the target providing resolutions between 1.8 &Aring; to 2.1
&Aring;. As a result of these experiments, we have identified two novel lead series. Multiple compounds have been identified with IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB>&#146;s less than 10 nM. We have also observed encouraging
drug target engagement in cells and evaluation of their PK properties is currently underway. In parallel, we are developing a target and drug tailored OncoSignature test for patient selection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate nominating a development candidate and entering <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for
either of these programs by the end of 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expansion of Our Pipeline Through Application of AP3 and OncoSignature Tests </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have shown that our AP3 platform is capable of generating OncoSignature tests that can predict preclinical sensitivity to a
number of potential cancer therapies. We are applying the power of this technology to expand our pipeline in several ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Selectively pursue carefully selected in-licensing candidates for which we believe a genetics-based patient
selection method is challenging and where we believe an OncoSignature predictive test can be developed that will significantly improve response rates, similar to how we identified ACR-368. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop our own proprietary inhibitors of targets that we believe are highly amenable to use with an
OncoSignature test. We have found that a number of DDR targets fall into this class. We have already initiated preclinical programs for two such targets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establish carefully selected <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships with leading
biopharmaceutical organizations that either have approved products or attractive drug candidates under competitive pressure where the availability of an OncoSignature test could significantly increase response rates, leading to new drug approvals,
label expansions and the ability to deliver effective therapies to the right patients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Broad Utility and Applications of Our AP3 Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our extensive studies, we have demonstrated that our AP3 platform has many high impact applications, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Predictive biomarkers and patient responder identification. </U>Our AP3 platform enables identification of
predictive biomarkers that are assembled into OncoSignature tests used to select patients to be treated that are predicted to be sensitive to a drug or drug candidate, <FONT STYLE="white-space:nowrap">so-called</FONT> patient responders. This
capability has been demonstrated in the studies described above. Using this approach, we have also developed predictive OncoSignature tests for a clinical stage CDK7 inhibitor and a clinical stage CDC7 inhibitor. The goal is to only treat patients
most likely to benefit from the drug and avoid overtreatment of patients that do not benefit from it with the potential for side effects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Indication finding and expansion</U>. The drug-tailored OncoSignature tests are also used to identify tumor
types predicted to be sensitive to a drug or drug candidate. By screening across human patient tumor samples across tumor types, one can estimate the proportion of predicted responders within these samples in a matter of weeks. The goal is to
identify and treat patients with attractive, high unmet need tumor types with an appropriate proportion of predicted responders and to avoid treatment of patients with tumor types that are predicted to be unresponsive to the drug or drug candidate.
This is applicable to both clinical stage drug candidates and preclinical lead series. For example, through this approach we were able to identify endometrial and bladder cancer as two predicted highly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ACR-368-sensitive</FONT></FONT> tumor types, which are now included in our upcoming Phase 2 clinical trials. Conversely, we also found that sqNSCLC is predicted <FONT STYLE="white-space:nowrap">non-sensitive</FONT> to the
drug candidate, consistent with the clinical trial conducted by Lilly, which showed 0% ORR in their prior clinical trial in sqNSCLC. Likewise, for preclinical stage lead series, our AP3 platform enables us to know and plan for exactly which tumor
types to include in any future clinical trials. This enables indication expansion and could potentially increase the response rates in clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Identification of resistance mechanisms.</U> The AP3 approach is also used to identify resistance
mechanisms in human cancer, preventing a desirable drug response. Resistance mechanisms can be divided into two main categories: na&iuml;ve, or intrinsic, resistance and therapy-induced, or acquired, resistance. For example, we have shown that the <FONT
STYLE="white-space:nowrap">IRS-2</FONT> adaptor protein is a key mediator of <FONT STYLE="white-space:nowrap">ALK-driven</FONT> tumor cell survival in neuroblastoma and can serve as an intrinsic resistance mechanism to ALK inhibition. As an example
of therapy-induced resistance we have shown that protein kinase <FONT STYLE="white-space:nowrap">C-delta,</FONT> or <FONT STYLE="white-space:nowrap">PKC-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>, is a resistance mechanism to Notch1
inhibition in leukemia. Moreover, in studies deploying advanced MS with <FONT STYLE="white-space:nowrap">so-called</FONT> spatial phosphoproteomics to quantify phosphopeptides with high accuracy in the nucleus and cytoplasm of cells, a method
developed in <FONT STYLE="white-space:nowrap">co-founder</FONT> Jesper Olsen&#146;s lab, we found that upregulated <FONT STYLE="white-space:nowrap">AKT-Foxo3</FONT> signaling and p53
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">loss-of-function</FONT></FONT> are acquired and intrinsic resistance mechanisms to selinexor, a selective inhibitor of the nuclear export protein XPO1, in patients with AML.
Understanding of resistance mechanisms is often clinically actionable, as such patients can either effectively be excluded from therapy or, as described in next paragraph, receive rational drug combinations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g46m46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 26. </B>Spatial phosphoproteomics conducted in two human AML cell lines quantifies the nuclear
and cytoplasmic levels of more than 35,000 phosphopeptides and identifies upregulated, nuclear signaling of <FONT STYLE="white-space:nowrap">AKT-FOXO3A</FONT> as a resistance mechanism to Selinexor. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Identification of rational drug combinations.</U> To the extent that identified resistance mechanisms
include druggable targets, these can be the basis for rational drug combinations. For example, in the studies referenced above, the uncovered resistance mechanisms included the druggable targets <FONT STYLE="white-space:nowrap">PKC-</FONT><FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>, AKT, and MDM2. Accordingly, it was demonstrated that (i)&nbsp;combination with the PKC inhibitor sotrastaurin overcame Notch inhibitor resistance in leukemia, (ii)&nbsp;combination with the AKT inhibitor <FONT
STYLE="white-space:nowrap">MK-2206</FONT> overcame selinexor resistance, and (iii)&nbsp;combination with the MDM2 inhibitor, nutlin, which enhances p53 activity, enhanced selinexor sensitivity in AML. These results demonstrate the wider
applicability of our AP3 platform to a number of drug target classes beyond DDR, including targets for which there is currently only limited understanding of their biological mechanisms of action. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Unbiased drug target engagement and PD biomarker discovery.</U> Through our high resolution
phosphoproteomic drug profiling we uncover and quantify typically in the order of approximately 6,000 statistically significantly regulated phosphoproteomic changes that correlate with drug exposure. This provides a rich source of potential
clinically useful biomarkers that can be developed to quantify PD drug target exposure. Such biomarkers can be used for dose-optimization through measure of the drug target engagement in patient tumor tissue in dose-finding Phase 1 clinical trials.
Moreover, they can inform whether the drug candidate elicits the predicted changes in biological signaling pathways in a patient&#146;s tumor. Typically at least one of our three classes of biomarkers in our OncoSignature tests is a key PD biomarker
for our drug target. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In summary, the AP3 method is broadly applicable across products and drug
candidates and is developed and designed to be a transformative, efficient method to accurately match the right therapy to the right patient. Given the highly structured data resulting from AP3, we have been able to engineer it as a machine learning
pipeline, aiming for high throughput and reproducible results. We expect this to be highly beneficial in our pursuit of expanding our proprietary pipeline and portfolio through continued <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT
STYLE="white-space:nowrap">co-development</FONT> pharmaceutical partnerships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Protection </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our AP3 platform and OncoSignature methodology has been developed and implemented for over a decade by our founding scientific
team as an expert system. As such, we have multiple layers of protection. Firstly, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
have over the years established a number of tools and trade secrets that we keep as proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> <FONT STYLE="white-space:nowrap">in-house.</FONT>
Secondly, we file concrete, tumor-agnostic <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patents for our drug-tailored OncoSignature tests. For example, we have filed an
<FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent claiming treatment of patients with <FONT STYLE="white-space:nowrap">ACR-368</FONT>
OncoSignature-positive tumors with <FONT STYLE="white-space:nowrap">ACR-368</FONT> monotherapy based on predicted sensitivity to the drug. Finally, through an exclusive license arrangement with our CDx partner who will be conducting the clinical
development for our test and, pending successful market approval, commercialize it, we believe we have ensured that the test cannot be offered for other DDR inhibitors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
acquired sufficient <FONT STYLE="white-space:nowrap">ACR-368</FONT> drug substance and drug product from Lilly to treat several hundred patients. Aside from this material, we expect to rely on, for the foreseeable future, third-party contract
manufacturing organizations, or CMOs, to produce our drug candidates for preclinical studies and clinical trials, as well as for future commercial manufacture of any drugs, if approved. We require all our CMOs to conduct manufacturing activities in
compliance with current good manufacturing practice, or cGMP, requirements. We have assembled a team of experienced employees and consultants who provide the necessary technical, quality and regulatory oversight to ensure the cGMP compliance of our
CMOs. Currently, we have manufacturing agreements in place with three CMOs for the manufacture of <FONT STYLE="white-space:nowrap">ACR-368.</FONT> To date we have successfully completed three familiarization and one cGMP campaign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We plan to continue to rely on third-party manufacturers for any future trials and commercialization, if approved, of <FONT
STYLE="white-space:nowrap">ACR-368</FONT> and any future drug candidates. We anticipate that these CMOs will have the capacity to support commercial scale production, but do not have any formal agreements in place at this time. If needed, we believe
we can identify and engage additional CMOs to provide active pharmaceutical ingredient and finished drug product without significant disruption to our business or clinical development timelines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Licensing and Collaborations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement
with Lilly </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, we entered into a license agreement and stock issuance agreement, or, collectively,
the Lilly Agreement, with Lilly, pursuant to which we have been granted an exclusive, royalty-bearing sublicensable license to certain intellectual property rights owned or controlled by Lilly, to commercially develop, manufacture, use, distribute
and sell therapeutic products containing the compound prexasertib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the agreement, we paid Lilly an
initial upfront fee payment of $5.0&nbsp;million. In connection with entering into the agreement, we also entered into a common stock issuance agreement with Lilly pursuant to which we issued Lilly 829,995 shares of our common stock and 46,058
shares of Series B convertible preferred stock. As additional consideration for the license, we are required to pay Lilly aggregate&nbsp;development and commercial&nbsp;milestone payments of up to $168.0&nbsp;million, of which $5.0&nbsp;million is
due prior to NDA.&nbsp;We are also obligated to pay a tiered percentage royalty on annual net sales ranging from a low single-digit up to&nbsp;low double-digits subject to certain specified reductions. Royalties are payable by&nbsp;us on a licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the later of the expiration of
the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in
such country, provided, that our obligation to pay royalties for a given licensed product in a given country will expire earlier upon achievement of certain sales thresholds by generic products is such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also&nbsp;have provided Lilly&nbsp;with certain, limited rights of first negotiation with us for reacquisition of the <FONT
STYLE="white-space:nowrap">ACR-368</FONT> program with such right expiring 45 days following the completion of certain clinical milestones.&nbsp;The right to first negotiation expressly does not restrict any potential Change of Control transaction
or IPO of our company (as each such term is&nbsp;contractually&nbsp;defined in the agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Companion Diagnostic Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, we entered into a companion diagnostic agreement with Akoya Biosciences, Inc., or Akoya, pursuant to which we
agreed to <FONT STYLE="white-space:nowrap">co-develop,</FONT> validate, and commercialize our proprietary <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test, the CDx that will be used to identify patients with cancer most likely to
respond to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the agreement, Akoya, in partnership with us,
will develop, clinically validate, seek regulatory approval for, and, pending <FONT STYLE="white-space:nowrap">ACR-368</FONT> approval, commercialize the OncoSignature test required for prescribing
<FONT STYLE="white-space:nowrap">ACR-368.&nbsp;Development</FONT> of the CDx will be overseen by a joint steering committee.&nbsp;Each party is required to use commercially reasonable efforts to carry out its activities under the agreement.&nbsp;The
agreement contains certain mutual exclusivity obligations of the parties with respect to the biomarkers and drug target, subject to certain specified limitations, including in the event that Akoya is unable to sufficiently supply commercial needs of
such CDx.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the agreement, we paid Akoya a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> upfront payment in the amount of $0.6&nbsp;million. The Company is obligated to pay Akoya up to low double-digit million dollars upon the
achievement of specified development milestones. To date, development milestones have been achieved under the agreement, resulting in payments of $2.0&nbsp;million by the Company to Akoya. Other than certain specified pass-through costs, each party
is responsible for its own costs associated with the development of the companion diagnostic.&nbsp;Akoya will procure and manufacture necessary supplies to perform the <FONT STYLE="white-space:nowrap">ACR-368</FONT> OncoSignature test to support our
clinical development and commercial requirements, in accordance with a supply agreement to be mutually agreed upon by the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
agreement shall, unless terminated early, continue in perpetuity.&nbsp;Either party may terminate the agreement in the event of an uncured, material breach by the other party or insolvency of the other party.&nbsp;Additionally, we may terminate the
agreement for any reason subject to a specified notice period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We pursue a layered intellectual property strategy, including patents, trademarks, and trade secret rights, to protect our AP3
platform, the OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>tests we develop with it, and the drug candidates<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>we work to commercialize. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the early stage of development of our drug candidates, we cannot be certain that any of our intellectual property rights
will provide protection for any drug candidate that may ultimately be commercialized. <FONT STYLE="white-space:nowrap">ACR-368</FONT> is our only drug candidate that has advanced to clinical testing, and there can be no certainty that its clinical
development will be successful, or that significant modification or adjustment will not be required for successful commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future commercial success depends, in part, on our abilities to obtain and maintain patent and other proprietary
protection for commercially important technology, inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business; to defend and enforce our patents and other intellectual property; to preserve the confidentiality of our
trade secrets; and to operate without infringing, misappropriating or violating the valid and enforceable patents and other intellectual property rights of third parties. Our ability to stop third parties from making, using, selling, offering to
sell or importing our products, or from developing competing diagnostic technologies, may depend on the extent to which we have rights under valid and enforceable patents, trade secrets or other intellectual property rights that cover these
activities. We cannot be sure that patents will issue with respect to any of the owned or licensed pending patent applications or, with respect to any patent applications that we may file or license in the future, nor can we be sure that any of our
owned or licensed patents or any patents that may be issued now or in the future will be commercially useful in protecting any products that we ultimately attempt to commercialize, or any method of making or using such products. Moreover, we may be
unable to obtain patent protection for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
certain of our drug candidates, or for our OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>tests or AP3 platform. See the section titled &#147;Risk Factors&#151;Risks Related
to Intellectual Property&#148; for a more comprehensive description of risks related to our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An issued patent provides its owner (or its licensee) with a right to exclude others from making, using or selling that which
is claimed in the patent, for a specified period of time (the &#147;term&#148; of the patent), in the jurisdiction in which the patent is issued. In the United States, and in many other countries, patents have a presumptive term of 20&nbsp;years
from their effective filing date (which is the earliest <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date to which the patent claims priority). However, many jurisdictions, including the United States, require the payment of
periodic maintenance fees in order for patents to remain in force for the full <FONT STYLE="white-space:nowrap">20-year</FONT> term; some jurisdictions require periodic annuities to be paid even to maintain pendency of an application. The United
States also has provisions that require a patent term to be shortened if its claims are too similar to another patent owned by the same party that has a shorter term. The United States and certain other jurisdictions also have provisions that permit
extension of patent term for patents that claim a drug or drug product, or its approved use, if the patent was issued before clinical trials were completed and certain other requirements were satisfied. In the United States, such extension is called
a Patent Term Extension, or PTE, and it is limited to a period of not more than five years, or a period that would extend the patent so that the total patent term including the PTE does not exceed 14 years after the date of regulatory approval; only
one patent can be extended per product approval. The United States also offers a different form of patent term extension, known as Patent Term Adjustment, or PTA, whereby a particular patent&#146;s term is automatically extended beyond the <FONT
STYLE="white-space:nowrap">20-year</FONT> date if the United States Patent and Trademark Office, or the USPTO, caused delay during its examination; however, potentially available PTA is reduced by any amount of any delay caused by the patent
applicant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our patent portfolio includes both <FONT STYLE="white-space:nowrap">in-licensed</FONT> and owned patent
filings, as discussed in more detail below. Particularly given our <FONT STYLE="white-space:nowrap">pre-commercial</FONT> state of development, we cannot be certain that any of the patent filings in our portfolio will provide meaningful protection
for any drug or OncoSignature test we ultimately attempt to commercialize. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have
<FONT STYLE="white-space:nowrap">in-licensed</FONT> from Lilly a portfolio including three families of patent filings relating to <FONT STYLE="white-space:nowrap">ACR-368.</FONT> See the section titled &#147;Business&#151;Licensing and
Collaborations.&#148; The first family, with a presumptive twenty-year term extending into 2029, includes issued patents in the United States (US patent 8,314,108, which, due to PTA, will expire in 2030) and certain other jurisdictions that claim
the <FONT STYLE="white-space:nowrap">ACR-368</FONT> compound itself. The second family, with a presumptive twenty-year term extending into 2036, includes issued patents in the United States (US patent 11,123,326, which, due to PTA, will expire in
2037) and other jurisdictions, and a pending application in the United States, that claim use of <FONT STYLE="white-space:nowrap">ACR-368</FONT> to treat certain particular types of cancer. The third family, with a presumptive twenty-year term
extending into late 2036, includes issued patents in the United States (US patent 10,189,818, which, due to PTA, will expire in 2037) and other jurisdictions, that claim the commercially-relevant salt of
<FONT STYLE="white-space:nowrap">ACR-368.</FONT> We may be able to pursue patent term extension in one or more jurisdictions for patents in this <FONT STYLE="white-space:nowrap">in-licensed</FONT> portfolio to provide extended protection to <FONT
STYLE="white-space:nowrap">ACR-368.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have also <FONT STYLE="white-space:nowrap">in-licensed</FONT> from our
founder a patent family with a presumptive twenty-year term extending into 2028 that includes issued EP and pending US filings that claims aspects of our AP3 platform relating to methods of identifying responder populations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We own a patent filing directed to our OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>test for <FONT
STYLE="white-space:nowrap">ACR-368,</FONT> including claims to methods of treating patients identified by the OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>test with <FONT STYLE="white-space:nowrap">ACR-368;</FONT> this filing
has a presumptive twenty-year term extending into 2043. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to pursue patent protection, whether through <FONT
STYLE="white-space:nowrap">in-licensing</FONT> or our own development, for future drug candidates and OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>tests. We may also pursue additional patent protection for features of our AP3
platform, though we will rely on confidentiality and trade secret protections for certain aspects of that platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have registered our rights in the OncoSignature<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>mark in the United
States and various other jurisdictions. We expect to pursue trademark protection for additional marks in the future for products and assays that we commercialize. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets and Confidential Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For certain of our technologies, including aspects of our AP3 platform and how we use it to develop OncoSignature<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>tests, we rely on unpatented trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and maintain our competitive position. However, trade secrets are notoriously
difficult to protect. Breaches of trade secret or confidentiality provisions can be challenging to detect, and even more challenging to prove. We seek to protect our proprietary information, in part, through confidentiality and <FONT
STYLE="white-space:nowrap">non-competition</FONT> agreements with employees, consultants, partners, and other advisors. These agreements may be breached and we may not be able to successfully defend our rights. Moreover, we may not be able to secure
adequate remedies for harm caused by such breach. Furthermore, our trade secrets or confidential information may be independently developed by a third party, and we may not have any ability to restrain or secure any remedy from them. As a result, we
may be unable to meaningfully protect our trade secrets and proprietary information. See the section titled &#147;Risk Factors&#151;Risks Related to Intellectual Property&#148; for a more comprehensive description of risks related to our trade
secrets and confidential information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The biopharmaceutical industry is characterized by the rapid evolution of technologies and understanding of precision medicine
in oncology, intense competition and a strong emphasis on intellectual property. As one of the first companies to adopt a phosphoproteomics-based approach with a platform designed to develop predictive protein signature tests for patient responder
identification, we believe that our differentiated approach, strategy, as well as our scientific capabilities, <FONT STYLE="white-space:nowrap">know-how</FONT> and experience provide us with significant competitive advantages. However, in the
future, we expect competition from multiple sources, including major pharmaceutical, specialty pharmaceutical, and existing or emerging biotechnology companies, academic research institutions and governmental agencies and public and private research
institutions worldwide. Many of our competitors, either alone or with their collaborators, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials,
obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment
in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At present, we do not believe we face competition from segments of the pharmaceutical, biotechnology and other related markets
that pursue the development of targeted oncology therapies for the smaller subsets of patients with genetically-defined cancers. However, we anticipate several biopharmaceutical companies will aim to develop precision oncology approaches for the
larger subsets of cancers where genetics has proven insufficient for patient responder identification. We expect that the broader biopharmaceutical field will eventually recognize proteomics as the next era of precision medicine, but we believe it
will take some time before significant competition will truly emerge in this space. There are several competitors with CHK1/2 inhibitors and WEE1 inhibitors, including Sierra Oncology (SRA737), Astrazeneca/Merck (Adavosertib), Zentalis <FONT
STYLE="white-space:nowrap">(Zn-c3),</FONT> Debiopharm (Debio0123), Impact Therapeutics (IMP7068) and Shouya Holdings <FONT STYLE="white-space:nowrap">(SY-4835).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, like other targeted oncology precision medicine companies, face competition more broadly across the oncology market for
cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy, biologic </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
therapy, such as monoclonal and bispecific antibodies, immunotherapy, cell-based therapy and targeted therapy, or a combination of any such methods. There are a variety of available drug
therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our drug candidates, if any are approved, may compete with these existing drugs and other therapies, to the extent they are
ultimately used in combination with or as an adjunct to these therapies, our drug candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers
and other third-party payors may also encourage the use of generic products or specific branded products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our drug candidates that we successfully
introduce to the market may pose challenges. In addition, many companies are developing new oncology therapeutics, and we cannot predict what the standard of care will be as our drug candidates progress through clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We could see a reduction or elimination in our commercial opportunity if our competitors develop and commercialize drugs that
are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or with a more favorable label than our drug candidates. Our competitors also may obtain FDA or other regulatory approval for
their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our drug
candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial
requirements upon the clinical development, manufacture and marketing of pharmaceutical and diagnostic products. These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture,
quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of drug and diagnostic products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Government Regulation of Drug Products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to
comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#146;s refusal to
approve a pending New Drug Application, or NDA, withdrawal of an approval, imposition of a clinical hold, issuance of untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of
production or distribution, injunctions, debarment, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The process required by the FDA before drug candidates may be marketed in the United States generally involves the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">nonclinical laboratory and animal tests that must be conducted in accordance with applicable regulations,
including good laboratory practices, or GLPs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an investigational new drug, or IND, application, which must become effective before
clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each
trial may be initiated; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug
candidate for its intended use, performed in accordance with good clinical practices, or GCPs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA and payment of user fees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of manufacturing facilities and selected
clinical investigators for their compliance with cGMPs and GCPs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity
of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of an NDA to permit commercial marketing for particular indications for use; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk
Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The testing and approval process requires substantial time, effort and financial resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology, toxicity and drug product
formulation, as well as animal studies to assess potential safety and efficacy. Prior to commencing the first clinical trial with a drug candidate, a sponsor must submit the results of the preclinical tests and preclinical literature, together with
manufacturing information, analytical data and any available clinical data or literature, among other required information, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically
becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or questions about the conduct of the clinical trial and imposes a clinical hold. In
such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA also may impose a partial clinical hold that would limit a trial, for example, to certain doses or for a certain length of
time or to a certain number of subjects. As a result, submission of an IND may not result in FDA authorization to commence a clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified
investigators in accordance with GCP requirements. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials.
Further, an independent IRB for each institution participating in the clinical trial must review and approve the plan for any clinical trial, its informed consent form and other communications to study subjects before the clinical trial commences at
that site. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated
benefits. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds,
including a finding that the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#146;s or the IRB&#146;s requirements, or if the drug has been associated with unexpected
serious harm to subjects. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determines that there is an
unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, for purposes of NDA approval, human clinical trials are
typically conducted in three sequential phases that may overlap. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Phase 1</I>. Studies are initially conducted to test the drug
candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease or condition. If possible, Phase 1 clinical
trials may also be used to gain early evidence of product effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Phase 2</I>. Controlled studies are conducted with groups of
subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase 2 clinical trials may be conducted to obtain information
prior to beginning larger and more expansive Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Phase 3</I>. These clinical trials are generally undertaken in
larger subject populations to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites. These clinical trials are intended to establish the
overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These clinical trials may be done at trial sites outside the United States as long as the global sites are also representative of the U.S. population and
the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
FDA may require, or companies may pursue, additional clinical trials after a product is approved. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a condition to be satisfied after approval. The results of Phase 4
studies can confirm the effectiveness of a drug candidate and can provide important safety information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to
proceed with the design and conduct of certain of our clinical trials under the FDA&#146;s master protocol guidance. This guidance is intended to provide recommendations to sponsors of drugs or biologics for the treatment of cancer to expedite the
development of such products by simultaneously evaluating more than one investigational drug and/or more than one cancer type within the same overall trial structure (master protocols) in adult and pediatric cancers. In general, the RP2D should have
been established for an investigational drug or drugs evaluated in a master protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials must be conducted
under the supervision of qualified investigators in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, and the review
and approval of the study by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among
other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan. Information about some clinical trials, including a
description of the trial and trial results, must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials
must be submitted at least annually to the FDA and the IRB and more frequently if serious adverse events occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA
relating to their labeling and distribution. Further, the export of investigational drug products outside of the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the FDCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional
information about the chemistry and physical characteristics of the drug candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable
of consistently producing quality batches of the drug candidate and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and
stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special
FDA Expedited Review and Approval Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA has various programs, including fast track designation,
breakthrough therapy designation, accelerated approval, and priority review, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening
diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the fast track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a
specific indication as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to
treat patients with a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none
exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional opportunities for interaction with the FDA&#146;s review team and may allow for rolling
review of NDA components before the completed application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable,
and the sponsor pays any required user fees upon submission of the first section of the NDA. However, the FDA&#146;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. The FDA may decide to
rescind the fast track designation if it determines that the qualifying criteria no longer apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, a sponsor
can request breakthrough therapy designation for a drug if it is intended, alone or in combination with one or more other drugs, to treat patients with a serious or life-threatening disease or condition, and preliminary clinical evidence indicates
that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies
are eligible for intensive guidance from the FDA on an efficient drug development program, organizational commitment to the development and review of the product including involvement of senior managers, and, like fast track products, are also
eligible for rolling review of the NDA. Both fast track and breakthrough therapy products may be eligible for accelerated approval and/or priority review, if relevant criteria are met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the FDA&#146;s accelerated approval regulations, the FDA may approve a drug for a serious or life threatening illness
that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of
alternative treatments. A drug candidate approved on this basis is subject to rigorous post marketing compliance requirements, including the completion of Phase 4 or post approval clinical trials to confirm the effect on the clinical endpoint.
Failure to conduct required post approval studies, or confirm a clinical benefit during post marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. In addition, for products being considered for accelerated
approval, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review
during the pre-approval review period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once an NDA is submitted for a product intended to treat patients with a serious
condition, the FDA may assign a priority review designation if FDA determines that the product, if approved, would provide a significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
improvement in safety or effectiveness. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under the
Prescription Drug User Fee Act, or PDUFA, guidelines. Under the current PDUFA performance goals, these six and ten month review periods are measured from the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date rather than the receipt date for
NDAs for new molecular entities, which typically adds approximately two months to the timeline for review from the date of submission. In addition, the FDA may review applications under Real-Time Oncology Review, or RTOR, which, according to the
FDA, aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as early as possible, while maintaining and improving review quality. Drugs considered for review under RTOR must be likely
to demonstrate substantial improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same or other indications, and must have straightforward study designs and endpoints that can be
easily interpreted. RTOR allows the FDA to review much of the data in a NDA earlier, before the applicant formally submits the complete application. This analysis of the <FONT STYLE="white-space:nowrap">pre-submission</FONT> package gives the FDA
and applicants an early opportunity to address data quality and potential review issues and allows the FDA to provide early feedback regarding the most effective way to analyze data to properly address key regulatory questions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the
conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational drug for a serious or life threatening disease is required to make available, such as
by posting on its website, its policy on responding to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority review do not change the standards for approval and may not
ultimately expedite the development or approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NDA Submission and Review by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product
development, including chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the
FDA. These user fees must be filed at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances. One basis for a waiver of the
application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into
interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy
of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric
data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active
ingredients, that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee. The FDA may also refer drugs which present difficult
questions of safety or efficacy to an advisory committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation as to whether the application should be approved and under
what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA reviews applications to determine, among other things, whether a
product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product&#146;s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the facility or
facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit
a substantive review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the NDA. Under the goals and policies agreed to by the FDA
under PDUFA, the FDA has set the review goal of 10 months from the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date to complete its initial review of a standard NDA for a new molecular entity, or NME, and make a decision on the
application. For priority review applications, the FDA has set the review goal of reviewing NME NDAs within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date. Such deadlines are referred to as the PDUFA date. The PDUFA
date is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the
submission during the review period that amends the original application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once the FDA&#146;s review of the application
is complete, the FDA will issue either a Complete Response Letter, or CRL, or an approval letter. A CRL indicates that the review cycle of the application is complete and the application is not ready for approval. A CRL generally contains a
statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing, or other information or analyses in order for the FDA to reconsider the application in the
future. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA
may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing
or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or other risk management mechanisms. For example, the FDA may require a
REMS as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product, or impose additional post-marketing
requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject
to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA notification may be required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such
product may be marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a boxed warning. A boxed warning is the strictest warning put in the labeling of prescription drugs or drug products by
the FDA when there is reasonable evidence of an association of a serious hazard with the drug. The FDA also may not approve the inclusion of all labeling claims sought by an applicant. Once approved, the FDA may withdraw the product approval if
compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4 post-marketing studies to
monitor the effect of approved products, and may limit further marketing of the product based on the results of these post-marketing studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat patients with a rare
disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more than individuals in the United States for which there is no reasonable expectation that the cost of developing
and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA. After
the FDA grants Orphan Drug Designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the
regulatory review or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a product that has Orphan Drug Designation subsequently receives the first FDA
approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA, to market the same drug
for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the holder of the orphan drug exclusivity cannot assure the availability of
sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease
or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the NDA application fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the
indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to
assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Post-Approval Requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by
the FDA, including periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and
surveillance, recordkeeping and reporting requirements, including adverse experiences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After approval, most changes to
the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program fee requirements for approved products, as well as new application fees for
supplemental applications with clinical data. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products, and are subject to periodic announced
and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which impose procedural and documentation requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented, or
FDA notification. FDA regulations also require investigation and correction of any deviations from cGMPs and specifications, and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may
decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Manufacturers and other parties involved in the drug supply chain for prescription
drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United
States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Later discovery of previously unknown problems with a product, including
adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new safety
information or other limitations, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS program, among other consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and
efficacy that are consistent with the FDA approved labeling. Physicians, in their independent professional medical judgment, may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from
those tested by us and approved by the FDA. However, manufacturers and third parties acting on their behalf are prohibited from marketing or promoting drugs in a manner inconsistent with the approved labeling. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to
significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Failure to comply with any of the FDA&#146;s requirements could result in significant adverse
enforcement actions. These include a variety of administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of
clinical trials, warning letters, untitled letters, modification of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution,
debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution,
disgorgement or civil or criminal penalties, including fines and imprisonment. It is also possible that failure to comply with the FDA&#146;s requirements relating to the promotion of prescription drugs may lead to investigations alleging violations
of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Any of these sanctions could result in adverse publicity, among other adverse consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA provides periods of <FONT STYLE="white-space:nowrap">non-patent</FONT> regulatory exclusivity, which provides the
holder of an approved NDA limited protection from new competition in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&#146;s approval of the NDA. Five years of exclusivity are
available to new chemical entities, or NCEs. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety. An active moiety is the molecule or ion, excluding those appended portions of the molecule
that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent, or not involving the sharing of electron pairs between atoms, derivatives, such as a complex (i.e., formed by the chemical
interaction of two compounds), chelate (i.e., a chemical compound), or clathrate (i.e., a polymer framework that traps molecules), of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the
FDA may not accept for review or approve an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted
one year before NCE exclusivity expires if a Paragraph IV certification is filed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Companion Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that the success of ACR-368 and certain of our drug candidates may depend, in part, on the development and
commercialization of OncoSignature, a companion diagnostic candidate. Companion diagnostics identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side
effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics
are regulated as medical devices by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development,
preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or
FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are
premarket notification, also called 510(k) clearance, and approval of a premarket, or PMA approval. We intend to seek PMA approval of our OncoSignature companion diagnostic candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical,
preclinical, clinical and manufacturing data, to demonstrate to the FDA&#146;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data regarding analytical and clinical validation
studies. As part of its review of the PMA, the FDA will conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation, or QSR, which
requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. The FDA&#146;s review of an initial PMA application is required by statute to take between six to ten months, although the process
typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually
contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not
approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with
post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On July&nbsp;31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#147;In
Vitro Companion Diagnostic Devices.&#148; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the
corresponding therapeutic product, the premarket application for the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when
contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#146;s guidance indicates it will generally not approve the drug without the approval or
clearance of the diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles for <FONT STYLE="white-space:nowrap">co-development</FONT> of an in vitro companion diagnostic device with a therapeutic product. The
draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding in vitro companion diagnostic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the
requirements of FDA&#146;s QSR, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug and biologic makers, companion diagnostic makers are subject to unannounced FDA inspections at any
time during which the FDA will conduct an audit of the product(s) and the company&#146;s facilities for compliance with its authorities </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation
Outside the United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to market any product outside of the United States, we would need to comply
with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety, and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our
products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, the
approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be
longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may
negatively impact the regulatory process in others. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business activities, including but not limited to, research, sales, promotion, distribution, medical education and other
activities are subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including the Department of Justice, the Department of Health and Human Services, or HHS, and its various
divisions, including Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense and state and local governments. Our business
activities must comply with numerous healthcare laws and regulations, including those described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal
Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward,
or in return for, the referral of an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable under Medicare, Medicaid or other federal healthcare programs.
The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. The term remuneration has been interpreted broadly to
include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer
protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the
requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the
Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amended the intent requirement of the federal Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer needs to have
actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it, to have violated the statute. The ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower
to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act, or FCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal civil and criminal false claims laws, including the FCA, prohibit, among other things, any person or entity from
knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the U.S. federal government, including the Medicare and Medicaid programs, or knowingly making, using, or causing to be made or used a false record or
statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any
request or demand&#148; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the
submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. FCA
liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties. Government enforcement agencies and private whistleblowers have investigated
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
pharmaceutical companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free products to customers with the expectation
that the customers would bill federal programs for the products; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT>
uses; and submitting inflated best price information to the Medicaid Rebate Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or
obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private,
knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or
device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Additionally, the ACA amended the
intent requirement of some of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under
Section&nbsp;6002 of the ACA and its implementing regulations, requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program
(with specified exceptions) to report annually information related to specified payments or other transfers of value provided to physicians, as defined by such law, certain other healthcare providers (such as physician assistants and nurse
practitioners) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually specified ownership and investment interests held by physicians and
their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which
we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements relating to the privacy, security and transmission of
individually identifiable health information held by covered entities and their business associates. Among other things, HITECH makes HIPAA&#146;s security standards directly applicable to business associates, defined as independent contractors or
agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created new tiers of civil monetary penalties, amended HIPAA
to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek
attorneys&#146; fees and costs associated with pursuing federal civil actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many states have also adopted laws similar
to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply
with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state laws that require drug manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and
security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and
regulations will likely be costly. It is possible that governmental authorities will conclude </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, possible
exclusion from government funded healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other
agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment of our operations, any of which could substantially disrupt our operations. If the physicians or other providers or entities
with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate
reimbursement for the procedures utilizing our drug candidates, performed by health care providers, once approved, will be available from government health administration authorities, private health insurers and other organizations. Government
authorities and other third-party payors, such as private health insurers and health maintenance organizations, determine which procedures, and the products utilized in such procedures, they will cover and establish reimbursement levels. Assuming
coverage is obtained for procedures utilizing a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably
high. Patients who undergo procedures for the treatment of their conditions, and their treating physicians, generally rely on third-party payors to reimburse all or part of the costs associated with the procedures which utilize our products.
Treating physicians are unlikely to use and order our products unless coverage is provided and the reimbursement is adequate to cover all or a significant portion of the cost of the procedures which utilize our products. Therefore, coverage and
adequate reimbursement for procedures which utilize new products is critical to the acceptance of such new products. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost
therapeutic alternatives are already available or subsequently become available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Government authorities and other
third-party payors are developing increasingly sophisticated methods of cost containment, such as including price controls, restrictions on coverage and reimbursement and requirements for substitution of less expensive products and procedures.
Government and other third-party payors are increasingly challenging the prices charged for health care products and procedures, examining the cost effectiveness of procedures, and the products used in such procedures, in addition to their safety
and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement. Further, no uniform policy requirement for coverage and reimbursement exists among third-party payors in the United States, which causes significant
uncertainty related to the insurance coverage and reimbursement of newly approved products, and the procedures which may utilize such newly approved products. Therefore, coverage and reimbursement can differ significantly from payor to payor and
health care provider to health care provider. As a result, the coverage determination process is often a time-consuming and costly process that requires the provision of scientific and clinical support for the use of new products to each payor
separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we may develop, either by ourselves or with collaborators, companion diagnostic tests for our lead drug
candidate for certain indications. We, or our collaborators, if any, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug candidates, if approved. While we
have not yet developed any companion diagnostic test for our drug candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons that are applicable to our drug
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There may also be significant delays in obtaining coverage and reimbursement for newly approved products, and
coverage may be more limited than the purposes for which the product is approved by the FDA. Moreover, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
eligibility for coverage and reimbursement does not imply that a product, or the procedures which utilize such product, will be paid for in all cases or at a rate which the health care providers
who purchase those products will find cost effective. Additionally, we expect pricing pressures in connection with the sale of any of our drug candidates due to the trend toward managed healthcare, the increasing influence of health maintenance
organizations, and additional legislative changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be sure that coverage and reimbursement will be available
for any product that we commercialize, or the procedures which utilize such product, and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any drug
candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any drug candidate for which we obtain marketing approval.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory
proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare
systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the biopharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and
state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control
of drug pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By way of example, in March 2010, the ACA was signed into law, intended to broaden access to health
insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the healthcare industry and impose
additional health policy reforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There have been executive, judicial and Congressional challenges to certain aspects of
the ACA. For example, on June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress. Thus, the ACA
will remain in effect in its current form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other legislative changes have been proposed and adopted in the United States
since the ACA. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013 and, following passage of the
BBA and the Infrastructure Investment and&nbsp;Jobs Act, will remain in effect until 2031 unless additional Congressional action is taken. However, <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief support legislation suspended the 2% Medicare
sequester from May&nbsp;1, 2020 through March&nbsp;31, 2022. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. In January 2013, the American Taxpayer
Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The heightened governmental scrutiny in
the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics, also has resulted in executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, in July 2021, the Biden
administration released an executive order, &#147;Promoting Competition in the American Economy,&#148; with multiple </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
provisions aimed at prescription drugs. In response to Biden&#146;s executive order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines
principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions
have been finalized to implement these principles. Additionally, on March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a
drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. In addition, Congress is considering drug pricing and other health reform initiatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the state level, individual states in the United States have increasingly passed legislation and implemented regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. Some third-party payors also <FONT STYLE="white-space:nowrap">require&nbsp;pre-approval&nbsp;of</FONT> coverage for new or innovative devices or therapies before they will
reimburse healthcare providers that use such therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that these initiatives, as well as other healthcare
reform measures that may be adopted in the future, as well as the trend toward managed healthcare and increasing influence of managed care organizations, may result in more rigorous coverage criteria and lower reimbursement, and in additional
downward pressure on the price that we receive for any approved product. It is also possible that additional governmental action is taken in response to <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> Any reduction in
reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of current and future cost containment measures or other healthcare reforms may adversely affect
our operations and prevent us from being able to generate revenue, attain profitability or commercialize our drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and
Security </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of our business, we collect, process and store confidential and sensitive
information, including personal information, intellectual property, trade secrets, and proprietary information owned or controlled by ourselves or other third parties. We, and third parties upon whom we rely, use sophisticated information
technology, software and services to process, store, use, generate, transfer and disclose information, as well as other sensitive information controlled by ourselves or other third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also be subject to federal, state, and foreign data privacy and security laws and regulations. In the United States,
numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section&nbsp;5 of the FTC Act), govern the
collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners, vendors, or other third parties on whom we rely. The legislative and regulatory framework
related to the collection, use, retention, safeguarding, disclosure, sharing, transfer, security and other processing of personal data worldwide is rapidly evolving. The number and scope of data protection laws and regulations is changing, subject
to differing applications and interpretations, and may be inconsistent among jurisdictions, or in conflict with other rules, laws or other data processing obligations. Efforts to ensure that our current and future business arrangements, including
our relationship with our CROs or other vendors who process data on our behalf, comply with applicable data privacy and data security laws and regulations will involve substantial costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, HIPAA, as amended by HITECH, and its implementing regulations, impose requirements relating to the privacy,
security and transmission of individually identifiable health information on certain health care providers, health plans and health care clearinghouses, known as covered entities, as well as their business associates and covered subcontractors that
perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA as the result of a
breach of unsecured protected health information, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if
required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of <FONT STYLE="white-space:nowrap">HIPAA&nbsp;non-compliance.&nbsp;Further,</FONT> entities that knowingly obtain, use, or disclose individually
identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to civil and criminal penalties. Even when HIPAA does not apply, according to the FTC, violating
consumers&#146; privacy rights or failing to take appropriate steps to keep consumers&#146; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5 of the FTC Act. The FTC expects a
company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce
vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Likewise, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy
and data protection in the United States, the EU and other jurisdictions, such as the California Consumer Privacy Act of 2018 (CCPA), which has been characterized as the first &#147;GDPR-like&#148; privacy statute to be enacted in the United States.
Although the CCPA exempts certain data processed in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to the personal information
we maintain about California residents. The CCPA among other effects, creates individual privacy rights for California consumers (as defined in the law), places increased privacy and security obligations on entities handling certain personal data of
consumers or households, requires covered companies to provide disclosures to consumers regarding data collection, use and sharing practices, requires covered companies to allow users <FONT STYLE="white-space:nowrap">to&nbsp;opt-out&nbsp;of</FONT>
certain sales or transfers of personal information, and provides consumers with a private right of action for certain data breaches. The CCPA became effective on January&nbsp;1, 2020, and the California Attorney General&#146;s authority to begin
bringing enforcement actions began July&nbsp;1, 2020. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected
health information. Further, the California Privacy Rights Act (CPRA) was recently voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on covered companies doing business
in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased
regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA will go into effect on January&nbsp;1, 2023, and become enforceable on July&nbsp;1, 2023. A
similar law, the Consumer Data Protection Act (CDPA), was recently passed in Virginia and goes into effect on January&nbsp;1, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also are or will become subject to privacy laws in the jurisdictions in which we are established or in which we sell or
market our products or run clinical trials. For example, in the EU, we are subject to Regulation (EU) 2016/679, the GDPR, in relation to our collection, control, processing, and other use of personal data (i.e. data relating to an identified or
identifiable living individual). We process personal data in relation to participants in our clinical trials in the European Economic Area (EEA), including the health and medical information of these participants. The GDPR is directly applicable in
each EU and EEA Member State, however, it provides that EU and EEA Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical
information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. As noted above, the GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of
their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their
personal information is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized <FONT STYLE="white-space:nowrap">(i.e.,&nbsp;key-coded)&nbsp;data;</FONT> introduces mandatory data breach notification
requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. We are also subject to EEA rules with respect to cross-border transfers of personal data out
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of the EEA. As noted above, recent legal developments in the EU have created complexity and uncertainty regarding transfers of personal data from the EEA to the United States, e.g. on
July&nbsp;16, 2020, the Court of Justice of the European Union (CJEU), invalidated <FONT STYLE="white-space:nowrap">the&nbsp;EU-U.S.&nbsp;Privacy</FONT> Shield Framework, or the Privacy Shield, under which personal data could be transferred from the
EEA to U.S. entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data
transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;case-by-case&nbsp;basis</FONT></FONT> taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals
and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. On June&nbsp;4, 2021, the European Commission adopted new standard contractual clauses under
the GDPR for data transfers from entities that are subject to the GDPR to transfer personal data outside of the EEA. The new standard contractual clauses impose additional obligations, including the obligation to conduct a transfer impact assessment
and, depending on a party&#146;s role in the transfer, to implement additional security measures and to update internal privacy practices. If we elect to rely on the standard contractual clauses for data transfers, we may be required to incur
significant time and resources to update our contractual arrangements and to comply with new obligations. Additionally, on September&nbsp;8, 2020, the Swiss Data Protection Authority (the Federal Data Protection and Information Commissioner)
concluded that <FONT STYLE="white-space:nowrap">the&nbsp;Swiss-U.S.&nbsp;Privacy</FONT> Shield does not provide an adequate level of protection for personal data transfer from Switzerland to the U.S. pursuant to the Swiss Federal Act on Data
Protection. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional
costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the
geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or
otherwise subject to the GDPR. Fines for certain breaches of the GDPR are significant: up to the greater of &#128;20.0&nbsp;million or 4% of total global annual turnover. Further, following the withdrawal of the United Kingdom from the EU on
January&nbsp;31, 2020, pursuant to the transitional arrangements agreed between the United Kingdom and the EU, we will have to comply with the GDPR and separately the GDPR as implemented in the United Kingdom, each regime having the ability to fine
up to the greater of &#128;20&nbsp;million / &pound;17&nbsp;million or 4% of global turnover. Following December&nbsp;31, 2020, and the expiry of the post-Brexit transitional arrangements between the United Kingdom and EU, although it is likely that
the data protection obligations of the GDPR will continue to apply <FONT STYLE="white-space:nowrap">to&nbsp;UK-related&nbsp;processing</FONT> of personal data in substantially unvaried form and fashion, for at least the short term thereafter, the
relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear. For example, it is not yet clear whether the United Kingdom will be the subject of
<FONT STYLE="white-space:nowrap">a&nbsp;so-called&nbsp;adequacy</FONT> decision of the European Commission, and it is therefore unclear how data transfers between EU/EEA Member States and the United Kingdom will be treated. Any changes relating to
the UK and EU position regarding aspects of data protection law may lead to additional compliance costs and could increase our overall risk. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and
regulations could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, an inability to process personal data or to operate in certain jurisdictions, or potential civil claims
including class action type litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, we use third-party service providers and subprocessors to help us
operate our business and engage in processing on our behalf. If we, our service providers, partners, or other relevant third-parties have experienced, or in the future experience, any security incident(s) that result in any data loss, deletion or
destruction, unauthorized access to, loss of, unauthorized acquisition or disclosure of, or inadvertent exposure or disclosure of sensitive information, or compromise related to the security, confidentiality, integrity of our (or their) information
technology, software, services, communications or data, it may result in a material adverse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
impact, including without limitation, regulatory investigations or enforcement actions, litigation, or an inability to process data in some jurisdictions. Furthermore, applicable data protection
laws, privacy policies and data protection obligations may require us to notify relevant stakeholders of security breaches, including affected individuals, customers, and regulators. Such disclosures are costly, and the disclosure or the failure to
comply with such requirements, could result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For more information on the potential impact of the GDPR, and associated EEA data protection laws, on our business, see the
section titled &#147;Risk Factors&#151;Risks Related to Employee Matters and Our Operations&#151;We are subject to a variety of privacy and data security laws, rules, regulations, policies, industry standards and contractual obligations, and our
failure to comply with them could harm our business.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the
Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive
substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been
adopted in other countries that impose similar obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Corrupt Practices Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing
payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in
obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the companies to maintain books and records that accurately and fairly reflect all
transactions of the companies, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our principal
executive office is located in Watertown, Massachusetts, where we lease a total of 13,711 square feet of office and laboratory space that we use for our administrative, research and development and other activities under a lease that currently
expires in April 2028, with an option to extend the term for an additional five years at then-market rental rates. Additionally, we also lease laboratory and office space in Lund, Sweden, which will expire in September 2023, with an option to extend
the term for an additional three years. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had 35 full-time employees and one part-time employee. Of our 36 full- and part-time employees,
approximately 23 have Ph.D. or M.D. degrees and 32 are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our
employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining,
incentivizing and integrating our employees. We believe our success depends on our ability to attract, retain, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
develop and motivate diverse highly skilled personnel. In particular, we depend upon the personal efforts and abilities of the principal members of our senior management to partner effectively as
a team, and to provide strategic direction, develop our business, manage our operations and maintain a cohesive and stable work environment. We also rely on qualified managers and skilled employees, such as scientists, engineers and laboratory
technicians, with technical expertise in operations, scientific knowledge, engineering skills and quality management experience in order to operate our business successfully. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation program is designed to retain, motivate and, as needed, attract highly qualified employees. Accordingly, we
use a mix of competitive base salary, cash-based annual incentive compensation, performance-based equity compensation awards and other employee benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From
time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides information regarding our current executive officers and directors, including their ages as of
June&nbsp;30, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position(s)</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, President and Chairman of the Board</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rasmus Holm-Jorgensen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erick Gamelin, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristina Masson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Business Operations, Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Devroe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">44</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek DiRocco, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sharon Shacham, Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Peter Blume-Jensen, M.D., Ph.D.</I></B>, is our main founder and has served as our Chief Executive Officer, acting Chief
Scientific Officer, President, and as a member of our board of directors since March 2018, including as chairman of our board of directors since October 2020. Dr.&nbsp;Blume-Jensen previously served as Chief Scientific Officer at XTuit
Pharmaceuticals, Inc., a biopharmaceutical company, from 2014 to March 2018 and before that as Chief Scientific Officer at Metamark Genetics, Inc., a biopharmaceutical company, from 2010 to 2014. Prior to that he held several leadership positions in
various pharmaceutical companies, including most recently as Vice President, External Scientific Affairs and Global Therapeutic Area Advisor for Oncology at Daiichi Sankyo from 2008 to 2010. He was Department Head, Senior Director, Molecular
Oncology at Merck&nbsp;&amp; Co., Inc. from 2005 to 2008 and before that Department Head, Director of Molecular Oncology at EMD Serono, a biopharmaceutical division of Merck KGaA, from 2001 to 2005. He received an M.D. from Copenhagen University
Medical School, Denmark, a Ph.D. from The Ludwig Institute for Cancer Research, Uppsala University, Uppsala, Sweden, and conducted his Post-Doctoral Fellowship under Tony Hunter at the Salk Institute. Our board of directors believes that
Dr.&nbsp;Blume-Jensen is qualified to serve as a director based on his knowledge of our business as our main founder and chief executive officer, inventor of the founding AP3 platform and his extensive experience in oncology research and development
and oncogenic kinase signaling. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Rasmus Holm-Jorgensen</I></B> has served as our Chief Financial Officer since April
2022. Previously, he served as Senior Vice President, Chief Strategy&nbsp;&amp; Portfolio Officer at Kiniksa Pharmaceuticals, Inc., a biopharmaceutical company, from 2015 to April 2022. Prior to that, Mr.&nbsp;Holm-Jorgensen served as Group Vice
President and General Manager at Synageva BioPharma Corp. from 2011 to 2015. Mr.&nbsp;Holm-Jorgensen received an M.S. in economics from the University of Copenhagen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Erick Gamelin, M.D., Ph.D.</I></B>, has served as our Chief Medical Officer since March 2021. Previously, he served as
Chief Medical Officer at Step Pharma, a biotechnology company, from November 2019 to January 2021, Vice President, Oncology at Dynavax Technologies Corporation, a biopharmaceutical company, from March 2018 to October 2019, Vice President at
MacroGenics, Inc., a biopharmaceutical company, from August 2017 to March 2018, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and in various leadership positions in the Oncology Vaccine department at Pfizer Inc., a pharmaceutical company, from 2015 to July 2017. Dr. Gamelin is a medical oncologist, former professor of
Medical Oncology and CEO of a University Cancer Center, ICO, and a Knight of the French National Order of Merit, appointed by the French Minister of Health. He has co-authored more than 135 international scientific articles in peer-reviewed journals
and has founded and led an academic research team: &#147;Genomics and mechanisms of cancer resistance.&#148; Dr.&nbsp;Gamelin received a Ph.D. in molecular pharmacology from Bordeaux University and conducted his Post-Doctoral studies in the
Molecular Therapeutics Section, Medical Branch, at the National Institutes of Health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Kristina Masson,
Ph.D.</I></B>, is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our President, CEO and Site Head of our subsidiary Acrivon AB and as a member of our board of directors since March 2018. Dr.&nbsp;Masson has also served as
our Executive Vice President, Business Operations since August 2022 and previously served as our Senior Vice President, Operations from March 2018 to August 2022. In November 2016, Dr.&nbsp;Masson founded OncoSignature AB, a biotechnology company,
which she led until its acquisition by Acrivon AB in March 2018. Dr.&nbsp;Masson received an MSc and a Ph.D. from Lund University and conducted her Post-Doctoral Fellowship at the Broad Institute of MIT and Harvard. Our board of directors believes
that Dr.&nbsp;Masson is qualified to serve as a director based on her knowledge of our business as a <FONT STYLE="white-space:nowrap">co-founder</FONT> of the company and OncoSignature AB and her extensive experience in oncology research and
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Eric Devroe, Ph.D.</I></B>, has served as our Chief Operating Officer since August 2022 and previously
served as our Senior Vice President, Business Operations from October 2020 to August 2022. Dr. Devroe has also served as our Corporate Secretary since January 2021. Previously, Dr.&nbsp;Devroe served as Founder&nbsp;&amp; Chief Executive Officer of
Xione Therapeutics, Inc., an oncology company, from August 2019 to September 2021, Strategic Advisor, Therapeutics Discovery at the MDACC from May 2018 to October 2019, and Founder&nbsp;&amp; Chief Executive Officer of Opsonix, Inc., an infectious
diseases company, from 2015 to May 2018. Dr.&nbsp;Devroe received a B.S. in microbiology from the University of Texas at Austin and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Derek DiRocco, Ph.D.</I></B>, has served on our board of directors since November 2021. Dr.&nbsp;DiRocco has been a
partner at RA Capital Management, LLC, an investment manager, since December 2020 and previously served as principal from December 2017 to December 2020, an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015.
Dr.&nbsp;DiRocco has served on the board of directors of 89bio, Inc. since April 2018, iTeos Therapeutics, Inc. since March 2020, Connect Biopharma Holdings Limited since August 2020, and Werewolf Therapeutics, Inc. since December 2020. He
previously served on the board of directors of Achilles Therapeutics plc from September 2019 to May 2022. Dr.&nbsp;DiRocco holds a B.A. in biology from College of the Holy Cross and a Ph.D. in pharmacology from the University of Washington, and
conducted his postdoctoral research at Brigham and Women&#146;s Hospital/Harvard Medical School. Our board of directors believes that Dr.&nbsp;DiRocco is qualified to serve as a director because of his experience as an investor in biotechnology
companies and experience as a director of multiple private and public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sharon Shacham, Ph.D.,
M.B.A.</I></B>, has served on our board of directors since October 2020. Dr.&nbsp;Shacham founded Karyopharm Therapeutics Inc. in 2008, where she served as Chief Scientific Officer and President from December 2012 to April 2021 and as Chief
Scientific Officer through May 2022. Dr.&nbsp;Shacham currently serves on Karyopharm&#146;s Scientific Advisory Board. Dr.&nbsp;Shacham led the scientific and clinical work that led to the discovery, development and regulatory approval of selinexor
(Xpovio). Xpovio is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> oral exportin 1 (XPO1) inhibitor and is approved in the United States in multiple oncology indications. Prior to joining
Karyopharm, Dr.&nbsp;Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, where
she led the company&#146;s efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials. Dr.&nbsp;Shacham holds a B.S. in chemistry, a Ph.D. in biophysical chemistry, and an M.B.A. from Tel Aviv University.
Our board of directors believes that Dr.&nbsp;Shacham is qualified to serve as a director because of her extensive experience as an executive officer in the biopharmaceutical industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business and affairs are managed under the direction of our board of directors, which currently consists of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; members. Our directors were elected to, and currently serve on, the board pursuant to a voting agreement among us and
substantially all of our stockholders and voting rights granted by our current amended and restated certificate of incorporation. The voting agreement will terminate upon the closing of this offering, after which there will be no further contractual
obligations regarding the election of our directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with our amended and restated certificate of
incorporation that will be in effect upon the closing of this offering, our board of directors will be divided into three classes, each of which will consist, as nearly as possible, of <FONT STYLE="white-space:nowrap">one-third</FONT> of the total
number of directors constituting our entire board and which will serve staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and
qualification until the third annual meeting following election. Our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I, which will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our first annual
meeting of stockholders to be held after the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II, which will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our second annual
meeting of stockholders to be held after the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III, which will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our third annual
meeting of stockholders to be held after the closing of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws,
which will become effective upon the closing of this offering, will provide that the authorized number of directors may be changed only by resolution approved by a majority of our board of directors. Any additional directorships resulting from an
increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors
into three classes with staggered three-year terms may delay or prevent a change of our management or a change of control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Applicable Nasdaq rules, or the Nasdaq Listing Rules, require a majority of a listed company&#146;s board of directors
to be composed of independent directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate
governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act of 1934, as amended, or the Exchange Act. The Nasdaq
independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees, that neither the director nor any of his family members has engaged in various types of
business dealings with us and that the director is not associated with the holders of more than 5% of our common stock. In addition, under applicable Nasdaq rules, a director will only qualify as an &#147;independent director&#148; if, in the
opinion of the listed company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has determined that all of our directors other than Peter Blume-Jensen, M.D., Ph.D., and Kristina
Masson, Ph.D., representing two of our &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;directors, are &#147;independent directors&#148; as defined under applicable Nasdaq rules.
In making such determination, our board of directors considered the current and prior relationships that each such director has with our company and all other facts and circumstances that our board of directors deemed relevant in determining his or
her independence, including the beneficial ownership of our capital stock by each director and the transactions described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no family relationships among any of our directors or executive
officers except that Dr. Blume-Jensen and Dr. Masson are married. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors
does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of our board of directors that address risks
inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure. Following the completion of this offering, we intend for our audit committee to have the
responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management
is undertaken. The audit committee will also monitor compliance with legal and regulatory requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has established an audit committee, compensation committee and a nominating and corporate governance
committee, each of which operate pursuant to a committee charter. Our board of directors may establish other committees to facilitate the management of our business. The composition and functions of each committee are described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the
completion of this offering, our audit committee will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serving as chair of the audit committee. Our board of directors has determined that each of these individuals meets the independence requirements
of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, or the Exchange Act, and the applicable listing standards of Nasdaq. Each member of our audit committee can read and understand fundamental financial
statements in accordance with Nasdaq audit committee requirements. Our board of directors has also determined that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; qualifies as an audit committee
financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the Nasdaq Listing Rules. In arriving at these determinations, the board has examined each audit committee member&#146;s scope of
experience and the nature of their prior and/or current employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The functions of this committee include, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve
as the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and reviewing a report by the independent registered public accounting firm at least annually that
describes our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that the composition and functioning of our audit committee will
comply with all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, our compensation committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serving as chair of the compensation committee.
Each of these individuals is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and is an &#147;outside director,&#148; as defined
pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code. Our board of directors has determined that each of these individuals is &#145;&#145;independent&#146;&#146; as defined under the applicable listing
standards of Nasdaq, including the standards specific to members of a compensation committee. The functions of this committee include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of
directors regarding) our overall compensation strategy and policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to the full board of directors regarding the compensation and other terms of employment
of our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding performance goals and objectives
relevant to the compensation of our executive officers and assessing their performance against these goals and objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors
regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating risks associated with our compensation policies and practices and assessing whether risks arising
from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the type and amount of
compensation to be paid or awarded to our <FONT STYLE="white-space:nowrap">non-employee</FONT> board members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to votes by our stockholders to approve executive compensation to the
extent required by Section&nbsp;14A of the Exchange Act and, if applicable, determining our recommendations regarding the frequency of advisory votes on executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as
required by Section&nbsp;10C of the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to equity compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our
compensation policy and strategy in achieving expected benefits to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the full board of directors regarding the terms of any employment
agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and approving our disclosures under the caption &#147;Compensation Discussion and
Analysis&#148; in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating on an annual basis the performance of the compensation committee and the compensation
committee charter. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that the composition and functioning of our compensation
committee will comply with all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, our nominating and corporate governance committee will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serving as chair of the nominating and corporate governance committee. Our board of directors has
determined that each of these individuals is &#145;&#145;independent&#146;&#146; as defined under the applicable listing standards of Nasdaq and SEC rules and regulations. The functions of this committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing and evaluating candidates to serve on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the minimum qualifications for service on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating director performance on the board and applicable committees of the board and determining whether
continued service on our board is appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating, nominating and recommending individuals for membership on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating nominations by stockholders of candidates for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and assessing the independence of members of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a set of corporate governance policies and principles and recommending to our board of directors
any changes to such policies and principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the board of directors with respect to management succession planning;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering questions of possible conflicts of interest of directors as such questions arise; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating on an annual basis the performance of the nominating and corporate governance
committee and the nominating and corporate governance committee charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that the
composition and functioning of our nominating and corporate governance committee will comply with all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of our directors who serve as a member of our compensation committee is, or has at any time during the past year been, one
of our officers or employees. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving on our
board of directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective upon the closing of this offering, we will adopt a Code of Business Conduct and Ethics, or the Code of Conduct,
applicable to all of our employees, executive officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. Following the
closing of this offering, the full text of the Code of Conduct will be available on our website at <I>www.acrivon.com</I>. We intend to post on our website all disclosures that are required by law or the listing standards of the Nasdaq Stock Market
concerning any amendments to, or waivers from, any provision of the Code of Conduct. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider
information on our website to be part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We did not pay compensation to any of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended
December&nbsp;31, 2021. Dr.&nbsp;Blume-Jensen, our Chief Executive Officer and President, and Dr.&nbsp;Masson, our Executive Vice President, Business Operations, are also members of our board of directors, but did not receive any additional
compensation for their service as a director during this period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to adopt a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, pursuant to which our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be eligible to receive compensation for service on our board of directors
and committees of our board of directors, to be effective following the completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers for the fiscal year ended December&nbsp;31, 2021, consisting of our principal executive officer
and the next two most highly compensated executive officers, were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Peter Blume-Jensen, M.D., Ph.D., who currently serves as our Chief Executive Officer and President and as a
member of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Erick Gamelin, M.D., Ph.D., who currently serves as our Chief Medical Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Eric Devroe, Ph.D., who currently serves as our Chief Operating Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding compensation awarded to, earned by and paid to our named executive
officers with respect to the year ended December&nbsp;31, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>Incentive Plan</B><br><B>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">430,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">756,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer, President and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erick Gamelin, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Devroe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Option awards in this column are reported at the aggregate grant date fair value in accordance with FASB ASC
Topic 718. Assumptions used in the calculation of these amounts are included in Note 11 to our audited consolidated financial statements included in this registration statement. This amount does not reflect the actual economic value that may be
realized by the named executive officer. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to the Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Annual Base Salary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers receive a base salary to compensate them for services rendered to us. The base salary payable to
each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and responsibilities. Dr.&nbsp;Blume-Jensen&#146;s, Dr.&nbsp;Gamelin&#146;s and Dr.&nbsp;Devroe&#146;s
respective annual base salaries were $430,000, $360,000 and $300,000 for the year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT
STYLE="white-space:nowrap">Non-Equity&nbsp;Incentive</FONT> Plan Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers are
eligible to receive annual incentive compensation based on the satisfaction of individual and corporate performance objectives established by the Board. Each Named Executive Officer has a target annual incentive opportunity, calculated as a
percentage of annual base salary. For 2021, the target annual incentive opportunities as a percentage of base salary for our named executive officers were 50% for Dr.&nbsp;Blume-Jensen, 40% for Dr.&nbsp;Gamelin and 25% for Dr. Devroe. The amounts of
any annual incentives earned are determined after the end of the year, based on the achievement of the designated corporate and individual performance objectives, and may be paid in cash or equity. For 2021, our board of directors determined that
the corporate performance goals had been achieved at a 100% level, which resulted in the aggregate payouts for each named executive officer in the amounts reflected in the column of the Summary Compensation Table above
<FONT STYLE="white-space:nowrap">entitled&nbsp;&#147;Non-Equity&nbsp;Incentive</FONT> Plan Compensation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Incentive Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that equity awards provide our executives with a strong link to our long-term performance, create an ownership
culture and help to align the interests of our executives and our stockholders. To date, we have only used stock option grants for this purpose because we believe they are an effective means by which to align the long-term interests of our executive
officers with those of our stockholders. The use of stock options also can provide tax and other advantages to our executive officers relative to other forms of equity compensation. We believe that our equity awards are an important retention tool
for our executive officers, as well as for our other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We award stock options broadly to our employees, <FONT
STYLE="white-space:nowrap">including&nbsp;to&nbsp;our&nbsp;non-executive&nbsp;employees.&nbsp;Grants&nbsp;to</FONT> our executives and other employees are made at the discretion of our board of directors and are not made at any specific time period
during a year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, all of the stock options we have granted were made pursuant to our 2019 Plan.
Following this offering, we will grant equity incentive awards under the terms of our 2022 Plan. The terms of our equity plans are described under the section titled &#147;Executive Compensation&#151;Equity Incentive Plans&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal Year End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth certain information about outstanding equity awards granted to our named executive officers that
were outstanding as of December&nbsp;31, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/14/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,562</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/13/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer, President and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erick Gamelin, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/25/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/24/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Devroe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/14/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/5/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,250</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/13/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">All of the option awards were granted under the 2019 Plan. All of the option awards were granted with a per
share exercise price equal to the fair market value of one share of our common stock on the date of grant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The unvested shares underlying this option vest in 36 equal monthly installments until October&nbsp;31,
2023, subject to the officer&#146;s continued service through each applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The unvested shares underlying this option vest in 16 equal quarterly installments until March&nbsp;1, 2025,
subject to the officer&#146;s continued service through each applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The unvested shares underlying this option vest in 16 equal monthly installments until October&nbsp;5, 2024,
subject to the officer&#146;s continued service through each applicable vesting date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Employment Agreements with Named Executive Officers and Potential Payments and Benefits
Upon Termination or Change in Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into employment agreements with our named executive officers,
and in connection with this offering, we expect to enter into amended and restated employment agreements with our named executive officers to supersede their prior employment agreements. The key terms of the current agreements are described below.
For a discussion of the severance pay and other benefits to be provided in connection with a termination of employment or a change in control under the arrangements with our named executive officers, please see the section titled &#147;Potential
Payments Upon Termination of Employment or Change in Control in the Prior Employment Agreements&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements with our Named
Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Peter Blume-Jensen, M.D., Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Blume-Jensen&#146;s employment agreement originally included a base salary of $430,000 and an annual target bonus of
50% of his base salary. In March 2022, our board of directors approved an increase to <FONT STYLE="white-space:nowrap">Dr.&nbsp;Blume-Jensen&#146;s</FONT> base salary to $520,000, effective retroactively to January 1, 2022. The annual bonus will be
determined by the board of directors based on achievement of targets and milestones for our performance and Dr.&nbsp;Blume-Jensen&#146;s performance for the applicable calendar year. The employment agreement provides for standard benefits, such as
vacation, reimbursement of business expenses, and participation in our employee benefit plans and programs. Upon a termination without cause, we have agreed to provide Dr.&nbsp;Blume-Jensen a minimum of sixty days&#146; notice of such termination.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Erick Gamelin, M.D., Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Gamelin&#146;s employment agreement originally included a base salary of $360,000 and an annual target bonus of 40% of
his base salary. In March 2022, our board of directors approved an increase to Dr. Gamelin&#146;s base salary to $410,000, effective retroactively to January 1, 2022. The annual bonus will be determined by the board of directors based on our and
Dr.&nbsp;Gamelin&#146;s performance against corporate goals for the applicable calendar year. The employment agreement provides for standard benefits, such as vacation and participation in our employee benefit plans and programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Eric Devroe, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Devroe&#146;s employment agreement originally included a base salary of $300,000 and an annual target bonus of 25% of
his base salary. In March 2022, our board of directors approved an increase to Dr. Devroe&#146;s base salary to $370,000, effective retroactively to January 1, 2022. The annual bonus will be determined by the board of directors based on our and
Dr.&nbsp;Devroe&#146;s performance against corporate goals for the applicable calendar year. The employment agreement provides for standard benefits, such as vacation and participation in our employee benefit plans and programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Potential Payments Upon Termination of Employment or Change in Control in the Prior Employment Agreements </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Blume-Jensen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that Dr.&nbsp;Blume-Jensen&#146;s employment terminates, other than during the Change of Control Period, by us
without &#147;cause&#148; or by Dr.&nbsp;Blume-Jensen for &#147;good reason&#148; (as defined in the employment agreement), and subject to Dr.&nbsp;Blume-Jensen&#146;s execution of a separation agreement with a general release of claims in our
favor, and standard terms relating to <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> confidentiality cooperation and the like (the &#147;CEO Severance Conditions&#148;), Dr.&nbsp;Blume-Jensen will receive (i)&nbsp;cash severance in the
form of continuation of his base salary for a period of twelve months; (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of his target bonus for the year in which termination occurs; (iii)&nbsp;continuation of health benefits for
a period of up to twelve months; and (iv)&nbsp;continued vesting of all outstanding time-based equity awards that would otherwise have vested had he remained employment for an additional twelve months after the separation date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that Dr.&nbsp;Blume-Jensen&#146;s employment terminates without
cause or upon Dr.&nbsp;Blume-Jensen&#146;s resignation for good reason within the Change of Control Period, and subject to Dr.&nbsp;Blume-Jensen&#146;s satisfaction of the CEO Severance Conditions, Dr.&nbsp;Blume-Jensen will receive (i)&nbsp;cash
severance in the form of a lump sum payment equal to eighteen months of his base salary; (ii) 100% of his target bonus; (iii)&nbsp;continuation of health benefits for a period of up to eighteen months; and (iv)&nbsp;full acceleration of all
outstanding time-based equity awards held by Dr.&nbsp;Blume-Jensen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr. Gamelin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that Dr.&nbsp;Gamelin&#146;s employment terminates, other than during the period ending twelve months after a
change of control, or the Change of Control Period, by us without &#147;cause&#148; or by Dr.&nbsp;Gamelin for &#147;good reason&#148; (as defined in the employment agreement), and subject to Dr.&nbsp;Gamelin&#146;s execution of a general release of
claims, Dr.&nbsp;Gamelin will receive cash severance in the form of continuation of his base salary for a period of six months. In the event that Dr.&nbsp;Gamelin&#146;s employment terminates without cause or upon Dr.&nbsp;Gamelin&#146;s resignation
for good reason within the Change of Control Period, and subject to Dr.&nbsp;Gamelin&#146;s execution of a general release of claims in our favor, Dr.&nbsp;Gamelin will receive (i)&nbsp;cash severance in the form of a lump sum payment equal to six
months of his base salary and (ii)&nbsp;full acceleration of all unvested shares and unexercised options held by Dr.&nbsp;Gamelin as of the date of termination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Devroe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that Dr.&nbsp;Devroe&#146;s employment terminates, other than during the Change of Control Period, by us without
&#147;cause&#148; or by Dr.&nbsp;Devroe for &#147;good reason&#148; (as defined in the employment agreement), and subject to Dr.&nbsp;Devroe&#146;s execution of a separation agreement with a general release of claims in our favor, Dr.&nbsp;Devroe
will receive cash severance in the form of continuation of his base salary for a period of six months. In the event that Dr.&nbsp;Devroe&#146;s employment terminates, within the Change of Control Period, by us without &#147;cause&#148; or by
Dr.&nbsp;Devroe for &#147;good reason&#148; (as defined in the employment agreement), and subject to Dr.&nbsp;Devroe&#146;s execution of a separation agreement with a general release of claims in our favor, Dr.&nbsp;Devroe will receive (i)&nbsp;cash
severance in the form of a lump sum payment equal to six months of his base salary in effect at the time of his separation and (ii)&nbsp;full acceleration of all unvested shares and unexercised options held by Dr.&nbsp;Devroe as of the date of
termination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Retirement Benefits and Other Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers are eligible to participate in our employee benefits, including health insurance and group life
insurance benefits, on the same basis as our other employees. In addition, we maintain a 401(k) profit sharing plan pursuant to Section&nbsp;401(k) of the Code covering all eligible employees. We make profit sharing contributions to qualifying
participants pursuant to a discretionary formula. We generally do not provide other perquisites or personal benefits except in limited circumstances, and we did not provide any such perquisites or personal benefits to our named executive officers in
2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 Equity
Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors intends to adopt the 2022 Plan, which will become effective on the date of
the underwriting agreement related to this offering. Our 2022 Plan will come into existence upon its adoption by our board of directors, but no grants will be made under our 2022 Plan prior to its effectiveness. Once our 2022 Plan becomes effective,
no further grants will be made under our 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Types of Awards</I>. Our 2022 Plan provides for the grant of
incentive stock options, or ISOs, nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based awards and other awards, or collectively, awards. ISOs may be granted only to
our employees, including our officers, and the employees of our affiliates. All other awards may be granted to our employees, including our officers, <FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors</FONT> and consultants and
the employees and consultants of our affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Authorized Shares</I>. The maximum number of shares of common stock that
may be issued under our 2022 Plan is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, which is the sum of: (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new shares, plus (ii)&nbsp;up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock subject to awards granted under our 2019 Plan that, after the effective date of our 2022 Plan, expire or otherwise terminate without having been exercised in full or are
forfeited to or repurchased by us. The number of shares of common stock reserved for issuance under our 2022 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2023, and continuing through and including
January&nbsp;1, 2032, by &nbsp;&nbsp;&nbsp;&nbsp;% of the aggregate number of shares of common stock of all classes issued and outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of
directors prior to the applicable January 1. The maximum number of shares that may be issued upon the exercise of ISOs under our 2022 Plan is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares issued under our 2022 Plan will be authorized but unissued or reacquired shares of common stock. Shares subject to
awards granted under our 2022 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under our 2022 Plan. Additionally, shares
issued pursuant to awards under our 2022 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of an award or to satisfy the tax withholding obligations to an award, will become available for future grant
under our 2022 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The maximum number of shares of common stock subject to stock awards granted under the 2022 Plan or
otherwise during any calendar year beginning in 2023 to <FONT STYLE="white-space:nowrap">any&nbsp;non-employee&nbsp;director,</FONT> taken together with any cash fees paid by us to
<FONT STYLE="white-space:nowrap">such&nbsp;non-employee&nbsp;director</FONT> during such calendar year for service on the board of directors, will not exceed $&nbsp;&nbsp;&nbsp;&nbsp; in total value (calculating the value of any such stock awards
based on the grant date fair value of such stock awards for financial reporting purposes), or, with respect to the calendar year in which <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> is first appointed or elected to our
board of directors, $&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Administration</I>. Our board of directors, or a duly authorized
committee of our board, may administer our 2022 Plan. Our board of directors has delegated concurrent authority to administer our 2022 Plan to the compensation committee under the terms of the compensation committee&#146;s charter. We sometimes
refer to the board of directors, or the applicable committee with the power to administer our equity incentive plans, as the administrator. The administrator may also delegate to one or more of our officers the authority to (1)&nbsp;designate
employees (other than officers) to receive specified awards, and (2)&nbsp;determine the number of shares subject to such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike
price of awards, if any, the number of shares subject to each award, the fair market value of a share of common stock, the vesting schedule applicable to the awards, together with any vesting acceleration, and the form of consideration, if any,
payable upon exercise or settlement of the award and the terms of the award agreements for use under our 2022 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, subject to the terms of the 2022 Plan, the administrator also has the power to modify outstanding awards under our 2022 Plan, including the authority to reprice any outstanding option or stock appreciation right, cancel <FONT
STYLE="white-space:nowrap">and&nbsp;re-grant&nbsp;any</FONT> outstanding option or stock appreciation right in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally
accepted accounting principles, with the consent of any materially adversely affected participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Options</I>.
ISOs and NSOs are granted pursuant to stock option agreements adopted by the administrator. The administrator determines the exercise price for a stock option, within the terms and conditions of the 2022 Plan, provided that the exercise price of a
stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2022 Plan vest at the rate specified in the stock option agreement as specified in the stock option
agreement by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator determines the term of stock options granted under the 2022 Plan, up to
a maximum of ten years. Unless the terms of an optionholder&#146;s stock option agreement provide otherwise, if an optionholder&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of
three months following the cessation of service. The option term may be extended in the event that either an exercise of the option or an immediate sale of shares acquired upon exercise of the option following such a termination of service is
prohibited by applicable securities laws or our insider trading policy. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following
cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, options generally
terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the
administrator and may include (1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of common stock previously owned by the optionholder, (4)&nbsp;a net exercise of the option if
it is an NSO and (5)&nbsp;other legal consideration approved by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options may not be transferred to
third-party financial institutions for value. Unless the administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution or pursuant to a domestic relations order. An optionholder may
designate a beneficiary, however, who may exercise the option following the optionholder&#146;s death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Tax Limitations
on ISOs</I>. The aggregate fair market value, determined at the time of grant, of common stock with respect to ISOs that are exercisable for the first time by an option holder during any calendar year under all of our stock plans may not exceed
$100,000. Options or portions thereof that exceed such limit will be treated as NSOs. No ISOs may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or
that of any of our parent or subsidiary corporations, unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2)&nbsp;the term of the ISO does not exceed five
years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Awards</I>. Restricted stock awards are granted pursuant to restricted
stock award agreements adopted by the administrator. Restricted stock awards may be granted in consideration for cash, check, bank draft or money order, services rendered to us or our affiliates or any other form of legal consideration. Common stock
acquired under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the administrator. A restricted stock award may be transferred only upon such
terms and conditions as set by the administrator. Except as otherwise provided in the applicable award agreement, restricted stock awards that have not vested may be forfeited or repurchased by us upon the participant&#146;s cessation of continuous
service for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Unit Awards</I>. Restricted stock unit awards are granted pursuant to
restricted stock unit award agreements adopted by the administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a
combination of cash and stock as deemed appropriate by the administrator or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by
a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s cessation of continuous service for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Appreciation Rights</I>. Stock appreciation rights are granted pursuant to stock appreciation right grant agreements
adopted by the administrator. The administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of common stock on the date of grant. Upon the exercise of a stock
appreciation right, we will pay the participant an amount equal to the product of (1)&nbsp;the excess of the per share fair market value of common stock on the date of exercise over the strike price,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
multiplied by (2)&nbsp;the number of shares of common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2022 Plan vests at the
rate specified in the stock appreciation right agreement as determined by the administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator determines
the term of stock appreciation rights granted under the 2022 Plan, up to a maximum of ten years. Unless the terms of a participant&#146;s stock appreciation right agreement provide otherwise, if a participant&#146;s service relationship with us or
any of our affiliates ceases for any reason other than cause, disability or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation
right term may be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant&#146;s service relationship with us, or any of our
affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the
event of disability and 18 months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause.
In no event may a stock appreciation right be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Performance Awards</I>. Our
2022 Plan permits the grant of performance-based stock and cash awards. The compensation committee can structure such awards so that the stock or cash will be issued or paid pursuant to such award only following the achievement of <FONT
STYLE="white-space:nowrap">certain&nbsp;pre-established&nbsp;performance</FONT> goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by
reference to, or otherwise based on, the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The performance goals may be based on any measure of performance
selected by the board of directors. The compensation committee may establish performance goals on a company-wide basis, with respect to one or more business units, divisions, affiliates or business segments, and in either absolute terms or relative
to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i)&nbsp;in the award agreement at the time the award is granted or (ii)&nbsp;in such other document setting forth
the performance goals at the time the goals are established, the compensation committee will appropriately make adjustments in the method of calculating the attainment of the performance goals as follows: (1)&nbsp;to exclude restructuring and/or
other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates;
(5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint
ventures; (7)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding
shares of common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, <FONT STYLE="white-space:nowrap">consolidation,&nbsp;spin-off,&nbsp;combination</FONT> or exchange of shares or other
similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock-based compensation and the award of bonuses under our bonus plans; (10)&nbsp;to exclude costs incurred
in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded
under generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Awards</I>. The administrator may grant other awards based in
whole or in part by reference to common stock. The administrator will set the number of shares under the award and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes to Capital Structure</I>. In the event there is a specified type of change in our capital structure, such as a
stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2022 Plan; (2)&nbsp;the class and maximum number of shares by which the
share reserve may increase automatically each year; (3)&nbsp;the class and maximum number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
shares that may be issued upon the exercise of ISOs and (4)&nbsp;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate Transactions</I>. The following applies to stock awards under the 2022 Plan in the event of a corporate
transaction, unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time of grant. Under the 2022 Plan, a
corporate transaction is generally the consummation of (1)&nbsp;a sale or other disposition of all or substantially all of our assets, (2)&nbsp;a sale or other disposition of at least 50% of our outstanding securities, (3)&nbsp;a merger,
consolidation or similar transaction following which we are not the surviving corporation or (4)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of common stock outstanding
immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the
event of a corporate transaction, any stock awards outstanding under the 2022 Plan may be assumed, continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us
with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i)&nbsp;with respect to
any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards
will be accelerated in full to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the
effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the corporate transaction), and (ii)&nbsp;any such stock awards
that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such
stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. In addition, the plan administrator may also provide, in its sole discretion, that the holder of a stock award that will terminate upon the
occurrence of a corporate transaction if not previously exercised will receive a payment, if any, equal to the excess of the value of the property the participant would have received upon exercise of the stock award over the exercise price otherwise
payable in connection with the stock award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A stock award may be subject to additional acceleration of vesting and
exercisability upon or after a change in control as may be provided in an applicable award agreement or other written agreement, but in the absence of such provision, no such acceleration will occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Transferability</I>. A participant may not transfer awards under our 2022 Plan other than by will, the laws of descent and
distribution or as otherwise provided under our 2022 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Amendment or Termination</I>. Our board has the
authority to amend, suspend or terminate our 2022 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the
approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our board adopted our 2022 Plan. No awards may be granted under our 2022 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors adopted, and our stockholders approved, our 2019 Plan in June 2019. No further stock awards will be
granted under our 2019 Plan on or after the effectiveness of our 2022 Plan; however, awards outstanding under our 2019 Plan will continue to be governed by their existing terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Types of Awards</I>. Our 2019 Plan allows us to grant ISOs, NSOs, stock
appreciation rights, restricted stock awards, restricted stock units and other awards to eligible employees, directors, officers, consultants and advisors of ours and any parent or subsidiary of ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Authorized Shares</I>. An aggregate of 7,587,942 shares of our common stock were reserved for issuance under our 2019 Plan.
As of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022, options to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock remained outstanding under our 2019 Plan. In
the event that an outstanding option, restricted stock award or other award for any reason expires or is canceled, the shares allocable to such award shall be added to the number of shares then available for issuance under our 2022 Plan once adopted
by our board of directors and approved by our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan Administration</I>. Our board of directors or a
committee of our board administers our 2019 Plan. Subject to the provisions of the 2019 Plan, the administrator has the full authority and discretion to take any actions it deems necessary or advisable for the administration of the 2019 Plan. All
decisions, interpretations and other actions of the administrator are final and binding on all participants in the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Options</I>. Stock options have been granted under our 2019 Plan. Subject to the provisions of our 2019 Plan, the
administrator determines the term of an option, the number of shares subject to an option, and the time period in which an option may be exercised. The term of an option is stated in the applicable award agreement, but the term of an option may not
exceed 10 years from the grant date. The administrator determines the exercise price of options, which may not be less than 100% of the fair market value of our common stock on the grant date. To the extent that the aggregate fair market value of
the shares with respect to which ISOs are exercisable for the first time by an employee during any calendar year (under all our plans and any parent or subsidiary) exceeds $100,000, such options will be treated as NSOs. The administrator determines
how a participant may pay the exercise price of an option, and the permissible methods are generally set forth in the applicable award agreement. If a participant&#146;s employment, or relationship with us as a director, consultant or advisor,
terminates, that participant may exercise the vested portion of his or her option for the period of time stated in the applicable award agreement. Vested options generally will remain exercisable for 90 days or such longer period of time as set
forth in the applicable award agreement if a participant&#146;s service to us terminates for a reason other than death, disability or for &#147;cause.&#148; If a participant&#146;s continuous service terminates due to disability or death, then
vested options generally remain exercisable for one year from the date of termination (or such longer period as set forth in the applicable award agreement). In no event will an option remain exercisable beyond its original term. If a participant
does not exercise his or her option within the time specified in the award agreement, the option will terminate. Except as described above, the administrator has the discretion to determine the post-termination exercisability periods for an option.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Certain Adjustments</I>. In the event of any change that is made in, or other events that occur with respect to, the
common stock subject to the 2019 Plan without the receipt of consideration by us through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash
dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restricting transaction (but excluding the conversion of any of our convertible
securities), the administrator will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the 2019 Plan, (ii)&nbsp;the class(es) and maximum number of securities that may be issued pursuant to
the exercise of ISOs and (iii)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Reorganization Events</I>. The following applies to awards under the 2019 Plan in the event of a reorganization event,
unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time of grant. Under the 2019 Plan, a
reorganization event is generally (1)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation, (2)&nbsp;any transfer or disposition of all of the shares of our common stock, or (3)&nbsp;any
liquidation or dissolution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of a reorganization event, our administrator generally may take
one or more of the following actions, contingent upon the closing or completion of such reorganization event: (i)&nbsp;arrange for the surviving corporation or acquiring corporation (or parent company) to assume or continue the award or substitute a
similar award, (ii)&nbsp;provide for the termination of all unexercised awards immediately prior to the consummation of the reorganization event, (iii)&nbsp;accelerate the vesting, in whole or in part, of the stock award to a date prior to or upon
the effective time of such reorganization event as our administrator determines, (iv)&nbsp;make a payment, in such form as may be determined by our administrator, equal to the excess, if any, of (A)&nbsp;the value of the property the participant
would have received upon exercise of the award immediately prior to the effective time of the reorganization event over (B)&nbsp;any exercise price payable, or (v)&nbsp;in connection with a liquidation or dissolution, provide that awards will
convert into the right to receive liquidation proceeds (net of any applicable exercise or purchase price). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Transferability of Awards</I>. Unless our administrator provides otherwise, our 2019 Plan generally does not allow for the
transfer or assignment of awards, except by will or by the laws of descent and distribution. Shares issued upon exercise or settlement of an award will be subject to such terms and conditions as the administrator may determine, including rights of
first refusal and other transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Amendment; Termination</I>. Our board of directors may amend, suspend
or terminate our 2019 Plan at any time, provided that such action does not materially and adversely affect a participant&#146;s rights under outstanding awards without such participant&#146;s written consent. As noted above, in connection with this
offering, our 2019 Plan will be terminated and no further awards will be granted thereunder. All outstanding awards will continue to be governed by their existing terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, our amended and restated certificate of incorporation will contain provisions that limit the
liability of our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary
duties as directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These limitations of liability do not apply to liabilities arising under federal securities laws and does not affect the
availability of equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of
incorporation and our amended and restated bylaws that will be in effect upon the closing of this offering will provide that we are required to indemnify our directors to the fullest extent permitted by Delaware law. Our amended and restated bylaws
will also provide that, upon satisfaction of certain conditions, we are required to advance expenses incurred by a director in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer,
director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. Our amended and restated
bylaws will also provide our board of directors with discretion to indemnify our officers, employees and other agents when determined appropriate by the board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we expect to enter into indemnification
agreements with each of our directors and executive officers. With certain exceptions, these agreements will provide for indemnification for related expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement
amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. We maintain
directors&#146; and officers&#146; liability insurance and will obtain customary directors&#146; and officers&#146; liability insurance prior to the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and
amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an
action, if successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by
these indemnification provisions. At present, there is no pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened litigation that may result in
claims for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted
for our directors, executive officers or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a description of transactions since January&nbsp;1, 2019 to which we have been a participant in which the
amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets at year end for the last two completed fiscal years, and in which any of our directors, executive officers or holders of more than 5% of our voting
securities, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements which are described under &#147;Executive Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placements of Our Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible
Promissory Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June and December 2019, we issued and sold convertible promissory notes, or the Convertible
Notes, in the aggregate principal amount of $3,000,000. The Convertible Notes accrued interest at a rate of 8% per annum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the aggregate principal amount of the Convertible Notes issued to our directors, officers and
holders of more than 5% of our capital stock and their affiliates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Principal<BR>Amount</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chione Limited<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Marcin Czernik, a former member of our board of directors, is a director of Chione Limited. Chione Limited
holds more than 5% of our capital stock prior to this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, we entered into a Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred
stock purchase agreement, or the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Purchase Agreement, with certain investors, including a beneficial owner of greater than 5% of our capital stock and an affiliate of a member of our board of
directors, pursuant to which we issued and sold to such investors an aggregate of 1,315,789 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock, par value $0.001 per share, or Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, at a purchase price of $2.28 per share for aggregate gross proceeds of $3.0&nbsp;million and issued 3,106,561 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock upon conversion of outstanding convertible promissory notes, including the Convertible Notes, to the holders thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Purchase Agreement, Chione was required to purchase up to
$12,000,000 of additional shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon our achievement of certain milestones, provided that a third-party investor mutually acceptable to us and Chione could purchase all or
any portion of such additional shares and the aggregate amount and price per share of such additional shares could be increased upon the mutual agreement of the purchasers of such shares and us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, upon the achievement of certain milestones, we issued and sold to such investors an aggregate of 5,482,456
shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock at a purchase price of $2.28 per share for aggregate gross proceeds of $12.5&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below sets forth the aggregate number of shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock issued to our related parties in this financing: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT><BR>Preferred<BR>Stock (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chione Limited<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,497,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,005,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 16, LP<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,187,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,166,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Marcin Czernik, a former member of our board of directors, is a director of Chione Limited. Chione Limited
holds more than 5% of our capital stock prior to this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">New Enterprise Associates 16, LP became a beneficial owner of more than 5% of our capital stock in
connection with this transaction. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement of Expenses Related to Patent License Agreement with Peter Blume-Jensen
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, we entered into a patent license agreement, or the Blume-Jensen License, with Peter Blume-Jensen,
our Chief Executive Officer and President, that granted us an exclusive, worldwide, irrevocable, perpetual, royalty-free license under certain licensed patents for any and all purposes and uses, including without limitation and rights to sublicense
through multiple tiers. Under the terms of the Blume-Jensen License, we were obligated to reimburse Dr.&nbsp;Blume-Jensen the sum of $150,000, which represented the parties&#146; agreed upon estimate of unreimbursed past expenses incurred by
Dr.&nbsp;Blume-Jensen with respect to the preparation, filing, prosecution, protection and maintenance of the licensed patents, within 30 days following the closing of an equity financing by us with gross proceeds of at least $2,000,000. Following
the closing of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing, we paid Dr.&nbsp;Blume-Jensen $150,000 in October 2020 to satisfy this obligation under the Blume-Jensen License. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, we entered into a Series B preferred stock purchase agreement, or the Series B Purchase Agreement, with
certain investors, including beneficial owners of greater than 5% of our capital stock and affiliates of certain members of our board of directors, pursuant to which we issued and sold to such investors an aggregate of 17,521,047 shares of our
Series B preferred stock, par value $0.001 per share, or Series B Preferred Stock, at a purchase price of $5.70742 per share for aggregate gross proceeds of $100.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table below sets forth the aggregate number of shares of Series B preferred stock issued to our related parties in this
financing: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Preferred<BR>Stock (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chione Limited<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,190,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,499,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,978,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital
Management<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,504,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sands Capital Life Sciences Pulse Fund II, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,102,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Biomedical Innovation Master Investors (Cayman) I L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,190,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,499,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Marcin Czernik, a former member of our board of directors, is a director of Chione Limited. Chione Limited
holds more than 5% of our capital stock prior to this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Derek DiRocco, Ph.D., a member of our board of directors, is a partner at RA Capital Management. Entities
affiliated with RA Capital Management hold more than 5% of our capital stock prior to this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights, Voting, Right of First Refusal and
<FONT STYLE="white-space:nowrap">Co-Sale,</FONT> and Management Rights Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with our convertible
preferred stock financings, we entered into investors&#146; rights, voting, right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> and management rights agreements containing registration rights, information rights, rights of
first offer, voting rights and rights of first refusal, among other things, with certain holders of our capital stock, including Chione Limited, New Enterprise Associates 16, LP, entities affiliated with RA Capital Management, Citadel Multi-Strategy
Equities Master Fund Ltd., Perceptive Life Sciences Master Fund, Ltd., Entities affiliated with RA Capital Management, Sands Capital Life Sciences Pulse Fund II, L.P., and Wellington Biomedical Innovation Master Investors (Cayman) I L.P. Marcin
Czernik, a former member of our board of directors, is a director of Chione Limited. Derek DiRocco, Ph.D., a member of our board of directors, is a partner at RA Capital Management. Peter Blume-Jensen, M.D., Ph.D., our
<FONT STYLE="white-space:nowrap">co-founder,</FONT> Chief Executive Officer and President and a member of our board of directors, and Kristina Masson, Ph.D., our <FONT STYLE="white-space:nowrap">co-founder</FONT> and Executive Vice President,
Business Operations, are party to certain of these agreements in their capacity as a stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing
stockholder agreements will terminate upon the closing of this offering, except for the registration rights granted under our investors&#146; rights agreement, as more fully described in the section titled &#147;Description of Capital
Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into employment agreements or offer letter agreements with certain of our executive officers. For more
information regarding our employment agreements with our named executive officers, see the section titled &#147;Executive Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation that will be in effect upon the closing of this offering will contain
provisions limiting the liability of directors, and our amended and restated bylaws will provide that we will indemnify each of our directors to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation
and amended and restated bylaws will also provide our board of directors with discretion to indemnify our officers, employees and other agents when determined appropriate by the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in connection with this offering, we expect to enter into indemnification agreements with each of our directors
and our executive officers prior to the closing of this offering. For more information regarding these agreements, see the section titled &#147;Executive Compensation&#151;Limitations on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, we have not had a formal policy regarding approval of transactions with related parties. In connection
with this offering, we will adopt a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions, which policy will become effective
immediately upon the execution of the underwriting agreement for this offering. For purposes of our policy only, a related person transaction will be a transaction, arrangement or relationship, or any series of similar transactions, arrangements or
relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director will not be covered by this
policy. A related person will be any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not
a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to
our audit committee, or, if audit committee approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
would be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification. The presentation must include a description of, among other
things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an
unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to
identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Conduct that we expect to adopt prior to the closing of this offering, our employees and directors will have an
affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our board
of directors, will take into account the relevant available facts and circumstances including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate
family member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The policy will require that, in determining whether to approve, ratify or reject a related person
transaction, our audit committee, or other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as
our audit committee, or other independent body of our board of directors, determines in the good faith exercise of its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of the transactions described in this section were entered into prior to the adoption of this policy. Although we have not
had a written policy for the review and approval of transactions with related persons, our board of directors has historically reviewed and approved any transaction where a director or officer had a financial interest, including the transactions
described above. Prior to approving such a transaction, the material facts as to a director&#146;s or officer&#146;s relationship or interest in the agreement or transaction were disclosed to our board of directors. Our board of directors took this
information into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of
June&nbsp;30, 2022: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have determined beneficial ownership in accordance with the rules of the SEC, and therefore it
represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all
shares that they beneficially owned, subject to community property laws where applicable. We have deemed shares of common stock subject to options that are currently exercisable or exercisable within 60 days of June&nbsp;30, 2022, to be outstanding
and to be beneficially owned by the person holding the option for the purpose of computing the percentage ownership of that person but have not treated them as outstanding for the purpose of computing the percentage ownership of any other person.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have based percentage ownership of common stock before this offering on 31,835,656 shares of common stock outstanding
as of June&nbsp;30, 2022, which includes 27,471,911 shares of common stock resulting from the conversion of all outstanding shares of preferred stock immediately upon the closing of this offering, as if this conversion had occurred as of
June&nbsp;30, 2022. Percentage ownership of common stock after this offering assumes the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering and no exercise of the underwriters&#146; option to purchase
additional shares of common stock from us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, the address for each beneficial owner listed in
the table below is c/o Acrivon Therapeutics, Inc., 480 Arsenal Way, Suite 100, Watertown, MA 02472. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Greater than 5% Stockholders:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chione Limited<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,523,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA Capital
Management<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,504,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund,
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,978,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,190,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Biomedical Innovation Master Investors (Cayman) I L.P.<SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,190,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sands Capital Life Sciences Pulse Fund II,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,102,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,341,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek DiRocco, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,504,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristina Masson, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,341,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sharon Shacham, Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erick Gamelin<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Devroe, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (7 persons)<SUP
STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,079,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The following description of our capital stock, certain provisions of our amended and restated certificate of incorporation
and amended and restated bylaws, as each will be in effect following the completion of this offering, and certain provisions of Delaware law are summaries. You should also refer to the amended and restated certificate of incorporation and the
amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, our amended and restated certificate of incorporation will authorize us to issue up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, $0.001 par value per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock, $0.001 par value per share, all of which shares of preferred stock
will be undesignated. Our board of directors may establish the rights and preferences of the preferred stock from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, we had outstanding 4,363,745 shares of common stock, held by seven stockholders of record. As of
June&nbsp;30, 2022, after giving effect to the conversion of all of the outstanding shares of our convertible preferred stock, including shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series B Preferred Stock,
into 27,471,911 shares of common stock, there would have been 31,835,656 shares of common stock issued and outstanding, held by 48 stockholders of record. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders,
including the election of directors. The affirmative vote of holders of at least 66<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>% of the voting power of all of the then-outstanding
shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified
board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive forum. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject
to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available
funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the
net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund
provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the right of the holders of shares of any series of preferred stock that we may
designate in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022, there were 27,471,911 shares of preferred stock outstanding, consisting of 9,904,806 shares of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and 17,567,105 shares of Series B convertible preferred stock. All currently outstanding shares of convertible preferred stock will be converted into an aggregate of 27,471,911
shares of common stock upon the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the closing of this offering, our board of directors
will have the authority under our amended and restated certificate of incorporation, without further action by our stockholders, to issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock in one or more series, to
establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to
increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely
affect the voting power or other rights of the holders of our common stock. The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote
on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in
control of us and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock on the
rights of holders of common stock until the board of directors determines the specific rights attached to that preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no present plans to issue any shares of preferred stock following completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of
June&nbsp;30, 2022, there were options to purchase 5,111,703 shares of common stock outstanding under our 2019 Plan. For additional information regarding the terms of our 2019 Plan, see the section titled &#147;Executive Compensation&#151;Equity
Incentive Plans.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, the holders of our existing convertible preferred stock and certain holders of our existing common stock have entered into
an amended and restated investors&#146; rights agreement. The registration rights provisions of this agreement provide those holders with demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights with respect to
the shares of common stock currently held by them and issuable to them upon conversion of our convertible preferred stock in connection with our initial public offering. These shares are collectively referred to herein as registrable securities.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time beginning 180 days following the effective date of the registration statement of which this prospectus is a part,
the holders of a majority of registrable securities then outstanding have the right to demand that we file a registration statement covering registrable securities then outstanding having an aggregate offering price in excess of $15.0&nbsp;million,
net of certain selling expenses. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified
circumstances. Upon such a request, we are required to effect the registration as soon as practicable, but in any event no later than 60 days after the receipt of such request. An aggregate of 28,301,906 shares of common stock will be entitled to
these demand registration rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we propose to register any of our securities under the Securities Act either for our own account or for the account of other
stockholders, the holders of registrable securities will each be entitled to notice of the registration and will be entitled to include their shares of common stock in the registration statement. These piggyback registration rights are subject to
specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under specified circumstances. An aggregate of 28,301,906 shares of common stock will be entitled to these
piggyback registration rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time after we become eligible to file&nbsp;a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> the holders of at least 30% of the registrable securities then outstanding will be entitled to request to have such shares registered by us on a
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration statement. These <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights are subject to other specified conditions and limitations, including the condition that the
anticipated aggregate offering price, net of certain selling expenses, is at least $5.0&nbsp;million. Upon receipt of this request, the holders of registrable securities will each be entitled to participate in this registration. An aggregate of
28,301,906 shares of common stock will be entitled to these <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of
Registration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are required to pay all expenses, including fees and expenses of one counsel to represent the
selling stockholders (up to $50,000 total), relating to any demand, piggyback or <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration, other than underwriting discounts and commissions, stock transfer taxes and any additional fees of
counsel for the selling stockholders, subject to specified conditions and limitations. We are not required to pay registration expenses if a demand registration request is withdrawn at the request of a majority of holders of registrable securities
to be registered, unless holders of a majority of the registrable securities agree to forfeit their right to one demand registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The amended and restated investors&#146; rights agreement contains customary cross-indemnification provisions, pursuant to
which we are obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the applicable registration statement attributable to us, and the selling stockholders are obligated to indemnify us for material
misstatements or omissions in the registration statement attributable to them, subject to certain limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Registration Rights
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The registration rights granted under the investors&#146; rights agreement will terminate with respect to any
particular stockholder upon the earlier of (a)&nbsp;the closing of a deemed liquidation event, as defined in our certificate of incorporation, (b)&nbsp;the fifth anniversary of the closing of this offering and (c)&nbsp;with respect to each
stockholder, at such time such stockholder is able to sell all of its shares without limitation pursuant to Rule 144 or another similar exemption under the Securities Act during a three-month period without registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the
Delaware General Corporation Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which
prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an
annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the outstanding voting stock that is not
owned by the interested stockholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines a &#147;business
combination&#148; to include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation or any direct or indirect majority-owned subsidiary of
the corporation and the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the
corporation or of any direct or indirect majority-owned subsidiary involving the interested stockholder (in one transaction or a series of transactions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation or
by any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the
corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation or any such subsidiary beneficially owned by the interested stockholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation or any direct or indirect majority-owned subsidiary. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity or person who, together with the
person&#146;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation to be in effect upon the completion of this offering, or our restated
certificate, will provide for our board of directors to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the
remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our restated
certificate and our amended and restated bylaws to be effective upon the completion of this offering, or our restated bylaws, will also provide that directors may be removed by the stockholders only for cause upon the vote of 66<SUP
STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% or more of our outstanding common stock. Furthermore, the authorized number of directors may be changed only by resolution of the board of directors, and vacancies
and newly created directorships on the board of directors may, except as otherwise required by law or determined by the board and subject to the rights of any series of then-outstanding preferred stock, only be filled by a majority vote of the
directors then serving on the board, even though less than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under our restated certificate of incorporation and
amended and restated bylaws our stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for
election, if they should so choose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our restated certificate and restated bylaws will also provide that all
stockholder actions must be effected at a duly called meeting of stockholders and will eliminate the right of stockholders to act by written consent without a meeting. Our restated bylaws will also provide that only our Chairman of the board, Chief
Executive Officer or the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors may call a special meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our restated bylaws will also provide that stockholders seeking to present proposals before a meeting of stockholders to
nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and will specify requirements as to the form and content of a stockholder&#146;s notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our restated certificate and restated bylaws will provide that the stockholders cannot amend many of the provisions described
above except by a vote of 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% or more of our outstanding common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As described in &#147;&#151;Preferred Stock&#148; above, our restated certificate will give our board of directors the
authority, without further action by our stockholders, to issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock in one or more series, with any rights, preferences and privileges as they may designate, including the
right to approve an acquisition or other change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The combination of these provisions will make it more
difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers,
these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue
preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors
and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights.
However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations
in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly
or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
amended and restated certificate of incorporation will provide that the Court of Chancery of the state of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our restated
certificate, or our amended and restated bylaws; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us that is governed by the internal affairs doctrine.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The provision would not apply to suits brought to enforce a duty or liability created by the Exchange
Act. Furthermore, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated
certificate of incorporation will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a
cause of action arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While the Delaware courts have determined that such choice of forum
provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of
the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be
enforced by a court in those other jurisdictions </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These exclusive forum provisions may limit a stockholder&#146;s ability
to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find
either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other
jurisdictions, all of which could seriously harm our business.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated
certificate of incorporation will further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and
contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transfer agent and registrar for our common stock
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent&#146;s address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to
apply for listing of our common stock on the Nasdaq Global Market under the trading symbol &#147;ACRV.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, no public market existed for our common stock. Future sales of our common stock in the public market,
or the availability of such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to
contractual and legal restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time
and our ability to raise equity capital in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on the number of shares outstanding as of June&nbsp;30,
2022, upon the closing of this offering and assuming no exercise of the underwriters&#146; option to purchase additional shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
will be outstanding, assuming no outstanding options are exercised. All of the shares of common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except for any shares sold to
our &#147;affiliates,&#148; as that term is defined under Rule 144 under the Securities Act. The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock held by existing
stockholders are &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. Restricted securities may be sold in the public market only if registered or if their resale qualifies for exemption from registration
described below under Rule 144 promulgated under the Securities Act or another available exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below and the provisions of Rules 144 and 701 under the Securities Act, the shares of common stock that will be deemed restricted securities after this offering will be available for
sale in the public market as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">none of the existing shares will be eligible for immediate sale upon the completion of this offering; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be eligible for sale in
the public market upon expiration of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements 180 days after the date of this prospectus, subject in certain circumstances to the volume, manner of sale and other limitations under Rule 144 and
Rule&nbsp;701 under the Securities Act, which are summarized below. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, <FONT STYLE="white-space:nowrap">non-affiliate</FONT> persons who have beneficially owned restricted shares of our
common stock for at least six months, and any of our affiliates who owns either restricted or unrestricted shares of our common stock, are entitled to sell their securities without registration with the SEC under an exemption from registration
provided by Rule 144 under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliates</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any person who is not deemed to have been one of our affiliates at the time of, or at any time during the three months
preceding, a sale may sell an unlimited number of restricted securities under Rule&nbsp;144 if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the restricted securities have been held for at least six months, including the holding period of any prior
owner other than one of our affiliates (subject to certain exceptions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are current in our Exchange Act reporting at the time of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any person who is not deemed to have been an affiliate of ours at the time of, or at any time during the three months
preceding, a sale and has held the restricted securities for at least one year, including the holding period of any prior owner other than one of our affiliates, will be entitled to sell an unlimited number of restricted securities without regard to
the length of time we have been subject to Exchange Act periodic reporting or whether we are current in our Exchange Act reporting. <FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume
limitation or notice filing provisions of Rule 144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Persons seeking to sell restricted securities who are our affiliates at the time of, or any time during the three months
preceding, a sale, would be subject to the restrictions described above. They are also subject to additional restrictions, by which such person would be required to comply with the manner of sale and notice provisions of Rule 144 and would be
entitled to sell within any three-month period only that number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after the completion of this offering based on the number of shares outstanding as of June&nbsp;30, 2022; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on the stock exchange on which our shares are listed
during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, persons who are our affiliates at the time of, or any time during the three months preceding, a sale may sell
unrestricted securities under the requirements of Rule 144 described above, without regard to the <FONT STYLE="white-space:nowrap">six-month</FONT> holding period of Rule 144, which does not apply to sales of unrestricted securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rule 701 under
the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees,
executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of
this prospectus before selling their shares. However, substantially all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section titled &#147;Underwriting&#148; and will become
eligible for sale upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT>
under the Securities Act to register all shares of common stock subject to outstanding stock options and common stock issued or issuable under our equity plans. We expect to file the registration statement covering shares offered pursuant to our
stock plans as soon as practicable after the closing of this offering, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by
affiliates in the public market, subject to compliance with the resale provisions of Rule 144 and expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, our executive officers and directors and substantially all of the holders of our common stock outstanding on the date of
this prospectus have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters or otherwise agreed, subject to certain exceptions, that we and they will not, directly or indirectly, offer, sell, contract to sell,
pledge, grant any option to purchase, make any short sale, or otherwise dispose of or hedge any of our shares of common stock, any options or warrants to purchase shares of our common stock, or any securities convertible into, or exchangeable for or
that represent the right to receive shares of our common stock, without the prior written consent of Morgan Stanley &amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC for a period of 180 days from the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the restrictions contained in the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described above, we have entered into an agreement with the holders of our preferred stock that contains market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions imposing restrictions
on the ability of such security holders to sell or otherwise transfer or dispose of any registrable securities for a period of 180 days following the date of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon
the closing of this offering, the holders of 28,301,906&nbsp;shares of our common stock, including common stock issuable upon the conversion of our convertible preferred stock, or their transferees, will be entitled to specified rights with respect
to the registration of their registrable shares under the Securities Act, subject to certain limitations and the expiration, waiver or termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Registration of these shares under
the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act immediately upon effectiveness of the registration. See the section titled &#147;Description of Capital Stock&#151;Registration
Rights&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_19"></A>CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following summary describes certain material U.S. federal
income tax consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the, ownership and disposition of our common stock acquired in this offering. The summary below is based upon the provisions of the U.S.
Internal Revenue Code of 1986, as amended, or the Code, and Treasury Regulations, rulings and judicial decisions thereunder as of the date hereof, and such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in
U.S. federal income tax consequences different from those discussed below. We have not requested and will not request a ruling from the U.S. Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the
following summary, and there can be no assurance that the IRS will agree with such statements and conclusions. This discussion assumes that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds our common stock as a &#147;capital
asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This summary is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, and does not address <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> or U.S. state and local consequences that may be relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders in light of their particular circumstances, nor does it address U.S. federal tax
consequences (such as gift and estate taxes) other than income taxes. This summary also does not address the alternative minimum tax, the Medicare contribution tax on net investment income, the special tax accounting rules under Section&nbsp;451(b)
of the Code, or the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code. Special rules different from those described below may apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
that are subject to special treatment under the Code, such as financial institutions, insurance companies, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, broker-dealers and traders in securities, U.S. expatriates, &#147;controlled
foreign corporations,&#148; &#147;passive foreign investment companies,&#148; corporations that accumulate earnings to avoid U.S. federal income tax, corporations organized outside of the United States, any state thereof and the District of Columbia
that are nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes, persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;synthetic security&#148; or
integrated investment or other risk reduction strategy, persons who acquire our common stock through the exercise of an option or otherwise as compensation, persons that hold more than 5% of our outstanding common stock, directly or indirectly
during the applicable testing period (except to the extent specifically set forth below), &#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which are held by one or more
qualified foreign pension funds, persons deemed to sell our common stock under the constructive sale provisions of the Code, partnerships and other pass-through entities or arrangements, and investors in such pass-through entities or arrangements. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax
treatment of a partner in the partnership (or entity or arrangement treated as partnership for U.S. federal income tax purposes) will depend on the status of the partner, the activities of the partnership and certain determinations made at the
partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PERSONS CONSIDERING THE PURCHASE OF OUR COMMON
STOCK PURSUANT TO THIS OFFERING SHOULD CONSULT THEIR TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME, ESTATE AND OTHER TAX CONSEQUENCES OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK IN LIGHT OF THEIR PARTICULAR SITUATIONS AS WELL AS ANY
CONSEQUENCES ARISING UNDER THE LAWS OF ANY OTHER TAXING JURISDICTION, INCLUDING ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this discussion, the term
<FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; means a beneficial owner of our common stock (other than a partnership or other entity or arrangement treated as a partnership for U.S. federal income tax purposes regardless of its
place of organization or formation) that is not, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or
more U.S. persons have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Distributions, if any, made on our common stock to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder to the extent made
out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) generally will constitute dividends for U.S. federal income tax purposes. If a distribution exceeds our current and accumulated earnings
and profits, the excess will constitute a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common
stock, but not below zero. Any remaining excess will be treated as capital gain and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussion below on effectively connected income, backup withholding and foreign accounts, dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s entitlement to benefits
under such income tax treaty). This certification must be provided to us or our paying agent prior to the payment of dividends and must be updated periodically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are treated as effectively connected with the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a
permanent establishment in the United States to which such dividends are attributable), are generally exempt from the 30% U.S. federal withholding tax described above if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder delivers to us (or,
if stock is held through a financial institution or other agent, to such agent) a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are effectively connected with the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, such effectively connected dividends will be subject to U.S. federal income tax, on a <FONT
STYLE="white-space:nowrap">net-income</FONT> basis at the regular rates applicable to U.S. persons (as defined in the Code). A corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder receiving effectively connected dividends may also be
subject to an additional &#147;branch profits tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on the corporate
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s effectively connected earnings and profits, subject to certain adjustments. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any
applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and does not timely file the required certification, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussions below regarding backup withholding and foreign accounts, a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income tax with respect to gain recognized on a sale or other disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with a trade or business of such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains in the United States);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual and is treated,
for U.S. federal income tax purposes, as present in the United States for a period or periods aggregating to 183 or more days in the taxable year of the disposition and certain other conditions are met; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are, or have been at any time during the five-year period preceding such disposition (or the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period, if shorter), a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market (as defined under applicable
Treasury Regulations) and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder held no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the five year period ending on the date of the disposition or
the period that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder held our common stock. If we are determined to be a U.S. real property holding corporation and the foregoing exception does not apply, then the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be taxed on its net gain derived from the disposition of our common stock generally in the same manner as gain that is effectively connected with the conduct of a trade or business in
the United States, at the U.S. federal income tax rates applicable to U.S. persons (as defined in the Code), except that the branch profits tax generally will not apply. Generally, a corporation is a &#147;United States real property holding
corporation&#148; if the fair market value of its &#147;United States real property interests&#148; equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a
trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a &#147;U.S. real property holding corporation&#148; for U.S. federal income tax purposes. No assurance can be provided
that our common stock will be regularly traded on an established securities market for purposes of the rule described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in the first bullet point above generally will be subject
to U.S. federal income tax on a net income basis at the regular rates, and corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders described in the first bullet point above may be subject to the additional branch profits tax at a 30% rate
or such lower rate as may be specified by an applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in second bullet point above
will be subject to U.S. federal income tax at a flat 30% rate, which gain may be offset by certain U.S.-source capital losses (even though the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United
States), provided that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax
treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting Requirements and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, we must report annually information to the IRS and to each <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
the gross amount of the distributions we pay on our common stock (even if the payments are exempt from withholding), including the amount of any such distributions, the name and address of the recipient and the amount, if any, of tax withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividends paid by us (or our paying agents) to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject
to U.S. backup withholding (currently at a rate of 24%). U.S. backup withholding generally will not apply to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
who provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or IRS
Form <FONT STYLE="white-space:nowrap">W-ECI</FONT> (as applicable), or otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if the withholding agent has actual knowledge, or reason to know, that the holder
is a U.S. person (as defined in the Code) who is not an exempt recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">U.S. information reporting and backup
withholding requirements generally will apply to the proceeds of a disposition of our common stock by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder effected by or through a U.S. office of any broker, U.S. or foreign, unless the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or otherwise
meets documentary evidence requirements for establishing <FONT STYLE="white-space:nowrap">non-U.S.</FONT> person status or otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply
to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> broker. Information reporting and backup withholding requirements may, however, apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact,
a U.S. person. For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner similar to U.S. brokers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding the application of the
information reporting and backup withholding rules to them. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder&#146;s resides or is incorporated. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be refunded or credited against the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
U.S. federal income tax liability, if any, provided that the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sections 1471 through 1474 of the Code (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain
payments, made to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institution (as specifically defined by applicable rules) unless (i)&nbsp;if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity is a &#147;foreign financial
institution,&#148; such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity undertakes certain due diligence, reporting, withholding and certification obligations, (ii)&nbsp;if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity is not a
&#147;foreign financial institution,&#148; such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity identifies certain of its U.S. investors, if any or (iii)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity is otherwise exempt
under FATCA. FATCA currently applies dividends paid on our common stock. FATCA also applies to gross proceeds from the sale or other disposition of our common stock, but the U.S. Treasury released proposed regulations which, if finalized in their
present form, would eliminate the federal withholding tax of 30% applicable to the gross proceeds of a sale or other disposition of our common stock. In the preamble to such proposed regulations, the U.S. Treasury stated that taxpayers may generally
rely on the proposed regulations until final regulations are issued. Under certain circumstances, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be eligible for refunds or credits of this withholding tax. An intergovernmental
agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding the possible
implications of this legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the
imposition of the 30% withholding tax under FATCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING
THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters
named below, for whom Morgan Stanley&nbsp;&amp; Co. LLC, Jefferies LLC, Cowen and Company, LLC and Piper Sandler&nbsp;&amp; Co. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the
number of shares of common stock indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and the representatives are collectively referred to as the
&#147;underwriters&#148; and the &#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides
that the obligations of the several underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The
underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146;
option to purchase additional shares described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters initially propose to offer part of the shares of
common stock directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $ &nbsp;&nbsp;&nbsp;&nbsp; per share under the public offering
price. After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each underwriter will become
obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of shares of common
stock listed next to the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the per share and
total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="0%"></TD>
<TD nowrap style="width:10pt"></TD>
<TD></TD>
<TD></TD>
<TD nowrap style="width:10pt"></TD>

<TD VALIGN="bottom" WIDTH="0%"></TD>
<TD nowrap style="width:10pt"></TD>
<TD></TD>
<TD></TD>
<TD nowrap style="width:10pt"></TD>

<TD VALIGN="bottom" WIDTH="0%"></TD>
<TD nowrap style="width:10pt"></TD>
<TD></TD>
<TD></TD>
<TD nowrap style="width:10pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The estimated offering expenses payable by us, exclusive of the underwriting discounts and
commissions, are approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have agreed to reimburse the underwriters for expenses of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; relating to the clearance of this offering with
the Financial Industry Regulatory Authority, Inc., compliance with state securities or &#147;blue sky&#148; laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have informed us that they do not intend sales to
discretionary accounts to exceed 5% of the total number of shares of common stock offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to apply to
list our common stock on the Nasdaq Global Market under the trading symbol &#147;ACRV.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and all of our directors
and officers and the holders of all of our outstanding common stock, stock options and other securities convertible into, exercisable or exchangeable for our common stock outstanding immediately prior to the closing of this offering have agreed
that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 180
days after the date of this prospectus, or the restricted period: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the Securities and Exchange Commission relating to the offering of any
shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">whether any such transaction described above is to be settled by
delivery of common stock or such other securities, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of the representatives on behalf of the underwriters, we or such other person will not,
during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions described in the immediately preceding paragraph to do not apply to our directors, officers and
securityholders with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions relating to shares of our common stock or other securities acquired in this offering or in open
market transactions after the completion of this offering, provided that no filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of our common stock shall be voluntarily made during the restricted period in
connection with subsequent sales of our common stock or other securities acquired in this offering or in such open market transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers or distributions of shares of our common stock or any security convertible into or exercisable or
exchangeable for our common stock (i) as a bona fide gift or charitable contribution, (ii) by will or intestacy or to any immediate family or to a trust for the direct or indirect benefit of the stockholder and/or any immediate family, (iii) to
limited partners, members, stockholders or holders of similar equity interests in the stockholder or (iv) if the stockholder is a corporation, to another corporation, partnership, limited liability company, trust or other business entity that is an
affiliate (as defined in Rule 405 promulgated under the Securities Act) of the stockholder, or to any investment fund or other entity controlled or managed by such stockholder or affiliates of such stockholder; provided that (A) each transferee,
donee or distributee shall sign and deliver a lock up agreement and (B) no filing under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of our common stock, shall be required or shall be voluntarily made
during the restricted period, and provided further that any such transfer shall not involve a disposition for value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of our common stock or any security convertible into or exercisable or exchangeable for our common
stock by operation of law pursuant to a qualified domestic order or other court order or in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
connection with a divorce settlement; provided that (i) any filing under Section 16(a) of the Exchange Act made during the restricted period shall clearly indicate in the footnotes thereto that
(A) the filing relates to the circumstances described in this clause and (B) no securities were sold by such stockholder, and (ii) such stockholder does not otherwise voluntarily effect any other public filing or report regarding such transfers
during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by such stockholder from us of shares of our common stock upon the transfer or disposition of
shares of our common stock or any securities convertible into our common stock to us upon a vesting or settlement event of our securities or vesting of restricted stock unit awards or upon the exercise of options to purchase our securities on a
&#147;cashless&#148; or &#147;net exercise&#148; basis, in each case pursuant to any equity incentive plan of us described in this prospectus and to the extent permitted by the instruments representing such restricted stock unit awards or options
outstanding as of the date of this prospectus (and solely to cover withholding tax obligations in connection with such transaction and any transfer to us for the payment of taxes as a result of such transaction), provided that (i) the shares
received upon exercise or settlement of the option are subject to the terms of this agreement, (ii) no public disclosure or filing under Section 16(a) of the Exchange Act shall be voluntarily made during the restricted period and (iii) to the extent
a filing under Section 16(a) of the Exchange Act is required during the restricted period as a result of transfers in this clause, it shall clearly indicate that (A) the filing relates to the circumstances described in this clause, including that
the securities remain subject to the terms of this agreement and (B) no securities were sold by such stockholder other than pursuant to this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers to us to the extent required in order to satisfy the exercise price and/or any income, employment
tax withholding and remittance obligations upon the vesting or exercise of an option or other award granted under an equity incentive plan or share purchase plan of us described in this prospectus or the conversion or exercise of a warrant of us
described in this prospectus; provided that (i) any filing under Section 16(a) of the Exchange Act made during the restricted period shall clearly indicate in the footnotes thereto that (A) the filing relates to the circumstances described in this
paragraph and (B) no securities were sold by such stockholder, and (ii) such stockholder does not otherwise voluntarily effect any other public filing or report regarding such transfers during the restricted period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers to us in connection with the repurchase of our common stock in connection with the termination of
such stockholder&#146;s employment with us pursuant to contractual agreements with us as in effect as of the date of this prospectus, provided that no public disclosure or filing under Section 16(a) of the Exchange Act shall be required or shall be
voluntarily made during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of the outstanding preferred stock of us described in this prospectus into shares of our common
stock of us, provided that such shares of our common stock remain subject to the terms of the lock-up agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating the establishment of a trading plan on behalf of a stockholder, officer or director of us
pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of our common stock, provided that (i) such plan does not provide for the transfer of our common stock during the restricted period and (ii) to the extent a public
announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of such stockholder or us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no
transfer of our common stock may be made under such plan during the restricted period; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers pursuant to a bona fide third-party tender offer for all outstanding our common stock or securities
convertible into or exchangeable for our common stock of us, merger, consolidation or other similar transaction approved by our board of directors and made to all holders of our securities involving a change of control of us (including, without
limitation, the entering into any lock-up, voting or similar agreement pursuant to which such stockholder may agree to transfer, sell, tender or otherwise dispose of our common stock or other such securities in connection with such transaction, or
vote any our common stock or other such securities in favor of any such transaction); provided that in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by such stockholder shall remain subject to the provisions of the lock-up
agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions on transfers or other dispositions by us described above do not apply to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares to be sold in this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of shares of common stock upon the exercise of an option or warrant or the conversion of a
security outstanding on the date hereof as described in this prospectus; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating the establishment of a trading plan on behalf of one of our stockholders, officers or directors
pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of common stock, provided that (i)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and
(ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no
transfer of common stock may be made under such plan during the restricted period. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan
Stanley&nbsp;&amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC, in their sole discretion, may release the common stock and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or
in part at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to facilitate the offering of the common stock, the underwriters may engage in transactions
that stabilize, maintain or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered
if the short position is no greater than the number of shares available for purchase by the underwriters under the option to purchase additional shares described above. The underwriters can close out a covered short sale by exercising such option or
purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under such option. The
underwriters may also sell shares in excess of such option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this
offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels
or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A prospectus in electronic format may be made available on websites maintained by one or more
underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions
will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which
may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective
affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the ordinary course of their various business activities,
the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account
and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective
affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such
securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. The initial public offering price will be
determined by negotiations between us and the representatives. Among the factors to be considered in determining the initial public offering price are our future prospects and those of our industry in general, our results of operations and certain
other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by
the government of a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI
<FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to each Member State of the European Economic Area and the United Kingdom, each, a Relevant State, no securities
have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Relevant State or,
where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of securities may be made to the public in that Relevant State
at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares shall require us or any of our representatives to publish a prospectus pursuant to Article&nbsp;3 of the
Prospectus Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the
purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to
be offered so as to enable an investor to decide to purchase any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU)&nbsp;2017/1129 (as amended). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000, or the FSMA) received by it in connection with the issue or sale of the shares of our common stock in
circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it
in relation to the shares of our common stock in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No registration pursuant to Article&nbsp;4, paragraph&nbsp;1 of the Financial Instruments and Exchange Law of Japan (Law
No.&nbsp;25 of 1948, as amended), or the FIEL, has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly or
indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or <FONT STYLE="white-space:nowrap">re-sale,</FONT> directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration
requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For Qualified Institutional
Investors, or QII </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please note that the solicitation for newly-issued or secondary securities (each as described in
Paragraph&nbsp;2, Article&nbsp;4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph&nbsp;1, <FONT
STYLE="white-space:nowrap">Article&nbsp;23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph&nbsp;1, Article&nbsp;4 of the FIEL, has not been made in relation to the shares of common stock.
The shares of common stock may only be transferred to QIIs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph&nbsp;2,
Article&nbsp;4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;small number private </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph&nbsp;4, <FONT STYLE="white-space:nowrap">Article&nbsp;23-13</FONT> of the FIEL).
Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph&nbsp;1, Article&nbsp;4 of the FIEL, has not been made in relation to the shares of common stock. The shares of common stock may only be transferred en bloc without
subdivision to a single investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of our common stock may not be offered or sold by means of any document other than (i)&nbsp;in circumstances which do
not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), (ii) to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and
any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation, or
document relating to shares of our common stock may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be
accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares of our common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This
prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares
of our common stock may not be circulated or distributed, nor may the shares of our common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other
than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the
conditions, specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where shares of our common stock are subscribed or purchased under Section&nbsp;275 by a relevant person which is: (i)&nbsp;a
corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (ii)&nbsp;a trust (where the
trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures, and units of shares and debentures of that corporation or the beneficiaries&#146; rights and
interest in that trust shall not be transferable for 6 months after that corporation or that trust has acquired shares of our common stock under Section&nbsp;275 except: (a)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a
relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in Section&nbsp;275 of the SFA; (b)&nbsp;where no consideration is given for the transfer; or (c)&nbsp;by operation of law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
shares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard
to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other
stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland.
Neither this document </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
nor any other offering or marketing material relating to the offering, us, or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this
document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective
Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services
Authority, or DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this
prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The validity of the shares of common stock offered hereby will be passed upon for us by Cooley LLP, New&nbsp;York, New York.
Certain legal matters will be passed upon for the underwriters by Goodwin Procter LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial statements as of December&nbsp;31, 2021 and 2020 and for each of the years then ended, included in this
prospectus have been so included in reliance on the report (which contains an emphasis of matter paragraph regarding the Company&#146;s significant operating losses and negative cash flows from operations since its inception, and management&#146;s
evaluation of the events and conditions and management&#146;s plans to mitigate these matters, as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the
authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc383050_23"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities
Act with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For
further information with respect to our company and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other
document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this
reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You can read our SEC filings, including the registration statement, over the internet at the SEC&#146;s
website at <I>www.sec.gov</I>. Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy
statements and other information will be available at <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also maintain a website at
<I>www.acrivon.com</I>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our
website is not part of, and is not incorporated into, this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc383050_24"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Financial Statements for the Years Ended December&nbsp;31, 2021 and 2020: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_3">Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_4">Consolidated Statements of Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the Board of Directors and Stockholders of Acrivon Therapeutics, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have audited the accompanying consolidated<B> </B>balance sheets of Acrivon Therapeutics, Inc. and its subsidiaries (the
&#147;Company&#148;) as of December&nbsp;31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and stockholders&#146; deficit and of cash flows for the years then ended,
including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated<B> </B>financial statements present fairly, in all material respects, the financial position of the Company
as of December&nbsp;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United&nbsp;States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to
express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&nbsp;States) (PCAOB) and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB and in
accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material
misstatement, whether due to error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audits included performing procedures to assess the risks of material
misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe
that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emphasis of Matter </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As discussed in Note 1 to the consolidated financial statements, the Company has incurred significant operating losses and
negative cash flows from operations since its inception. Management&#146;s evaluation of the events and conditions and management&#146;s plans to mitigate these matters are also described in Note 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;12, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have served as the
Company&#146;s auditor since 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_2"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 99,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, par value $0.001;
9,904,806 and 9,685,508 shares authorized as of December&nbsp;31, 2021 and 2020, respectively; 9,904,806 and 4,422,350 shares issued and outstanding as of December&nbsp;31, 2021 and 2020, respectively; liquidation preference of $22.6&nbsp;million as
of December&nbsp;31, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, par value $0.001; 17,567,105 and 0 shares authorized, issued
and outstanding as of December&nbsp;31, 2021 and 2020, respectively; liquidation preference of $100.3&nbsp;million as of December&nbsp;31, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.001; 40,013,683 and 20,000,000 shares authorized as of December 31,
2021 and 2020, respectively; 4,363,745 and 3,532,500 shares issued and outstanding as of December&nbsp;31, 2021 and 2020, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_3"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 13,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,299,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_4"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, net
of preferred stock tranche rights and issuance costs of $247 and $169, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock
related to conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,106,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of common stock related to license agreement with Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">829,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, net
of issuance costs of $33</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,321,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock
related to settlement of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock, net of issuance costs of $247</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,521,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock related to settlement of anti-dilution
right</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,363,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
<P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_5"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">License agreement paid for with common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Anti-dilution right assumed with license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Gain upon extinguishment of PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock and
preferred stock tranche obligations in first closing, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock in
second and third closings, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of Series B preferred stock, net of issuance costs and settlement of
anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net increase in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 99,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Fair value of convertible notes recognized as Series <FONT STYLE="white-space:nowrap">A-1</FONT>
preferred stock upon conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Fair value of preferred stock tranche rights recognized as Series
<FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock upon issuance of milestone shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Fair value of anti-dilution right recognized as Series B preferred stock upon issuance of
anti-dilution shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Reconciliation of cash, cash equivalents and restricted cash:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_6"></A>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Acrivon Therapeutics, Inc., (the &#147;Company&#148;) is a clinical stage biopharmaceutical company developing oncology
medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The Company&#146;s pipeline includes the Phase&nbsp;2
lead program, <FONT STYLE="white-space:nowrap">ACR-368,</FONT> referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation
pathways, including WEE1, a protein kinase, and a closely related, undisclosed serine/threonine kinase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company was
incorporated in March 2018 under the laws of the state of Delaware, and its principal offices are in Watertown, Massachusetts. Also in March 2018, the Company formed Acrivon AB, a wholly-owned subsidiary of the Company, established in Lund, Sweden.
In December 2021, the Company formed Acrivon Securities Corporation, a wholly-owned subsidiary, established in Massachusetts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise
substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date the accompanying consolidated financial statements were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and
staffing the Company, business planning, raising capital, establishing its intellectual property portfolio, acquiring or discovering drug candidates, research and development activities for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and other
compounds, establishing arrangements with third parties for the manufacture of its drug candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant
operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its inception, the Company has funded its operations primarily with proceeds from the sales of shares of its convertible
preferred stock and the issuance of convertible notes. The Company has incurred recurring losses since its inception, including net losses of $16.2&nbsp;million and $5.3&nbsp;million for the years ended December&nbsp;31, 2021, and 2020,
respectively. As of December&nbsp;31, 2021, the Company had an accumulated deficit of $24.9&nbsp;million. To date the Company has not generated any revenues and expects to continue generating operating losses for the foreseeable future as it
continues to expand its research and development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company expects that its existing cash and cash equivalents
of $99.6&nbsp;million as of December&nbsp;31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date these consolidated financial statements were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will need additional funding to support its planned operating activities. There can be no assurances, however,
that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development
efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is seeking to complete an initial public offering (&#147;IPO&#148;) of its common stock. Immediately prior to the
closing of a qualifying public offering on specified terms, the Company&#146;s outstanding convertible preferred stock will automatically convert into common stock (see Note 9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event the Company does not complete an IPO, the Company expects to seek additional funding through private equity
financings, government or private-party grants, debt financings or other capital sources, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to
enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of
its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue
these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and
classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the
Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2020, the World Health Organization declared the outbreak of the novel coronavirus,
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> a pandemic. The pandemic has resulted in the closing of borders, enhanced health screenings, health care service preparation and delivery, quarantines, cancellations, disruptions to supply chains, as
well as general concern and uncertainty. The Company cannot predict the future progression or full impact of the outbreak and its effects on the Company&#146;s business and operations. Additionally, <FONT STYLE="white-space:nowrap">COVID-19</FONT>
has resulted in substantial market volatility and may result in a significant economic downturn. The Company will continue to actively monitor the current international and domestic impacts of and responses to
<FONT STYLE="white-space:nowrap">COVID-19</FONT> and its related risks. The Company considered the potential effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its financial statements and noted that there is no material
effect on the consolidated financial statements as of December&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally
accepted in the United States of America (&#147;U.S. GAAP&#148;) and include the operations of Acrivon Therapeutics, Inc. and its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in consolidation.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of the Company&#146;s financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant
estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, and the valuations of common stock, stock-based awards, preferred stock tranche rights,
convertible notes and anti-dilution right. The Company bases its estimates on historical experience when available, known trends and other market specific data, or other relevant factors that it believes to be reasonable under the circumstances. On
an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could
differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating segments are defined as components of an enterprise for which separate and discrete information is available for
evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company&#146;s focus is the research and development of precision oncology therapies. The
Company&#146;s chief operating decision maker, its chief executive officer, manages the Company&#146;s operations on a consolidated basis for the purpose of allocating resources. As the Company has one reportable segment, all required segment
financial information is presented in the consolidated financial statements. As of December&nbsp;31, 2021, the majority of the Company&#146;s long-lived assets are held in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be
cash equivalents. Cash and cash equivalents include standard checking accounts and amounts held in money market funds. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a
bank, which serve as collateral for a letter of credit issued to the landlord of the Company&#146;s leased facility for a security deposit. The Company classified this amount as restricted cash in the accompanying consolidated balance sheets within <FONT
STYLE="white-space:nowrap">non-current</FONT> assets based on the release date of restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with <FONT
STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering,
either as a reduction of the carrying value of the preferred stock or in stockholders&#146; deficit as a reduction of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering. Should the <FONT
STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. There were no deferred
offering costs capitalized as of December&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk and Significant Suppliers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and
cash equivalents. The Company has not experienced any credit losses on its cash or cash equivalents. The Company maintains its cash and cash equivalents at a high-quality financial institution. Management believes that such funds are not exposed to
any significant credit or concentration risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is dependent on third-party contract research organizations
(&#147;CROs&#148;) and contract manufacturing organizations to supply certain intellectual property and services for research activities in its drug candidates. In particular, the Company relies and expects to continue to rely on a small number of
these organizations to supply it with its requirements for key raw materials related to these programs. These drug candidates could be adversely affected by a significant interruption in the supply of key raw materials. Additionally, the Company
relies on a single companion diagnostic collaborator to perform ACR-368 OncoSignature tests in the Company&#146;s clinical trials (see Note&nbsp;17). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Comprehensive loss includes net loss as well as other changes in stockholders&#146; deficit that result from transactions and
economic events other than those with stockholders. For the years ended December&nbsp;31, 2021 and 2020, there was no difference between net loss and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ASC Topic 820, <I>Fair Value Measurement</I> (&#147;ASC 820&#148;), establishes a fair value hierarchy for instruments measured
at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#146;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or
liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the asset or liability and are
developed based on the best information available in the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ASC 820 identifies fair value as the exchange
price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value
measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Level</I><I></I><I>&nbsp;1</I>&#151;Quoted prices in active markets for identical assets or liabilities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Level</I><I></I><I>&nbsp;2</I>&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in
active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Level</I><I></I><I>&nbsp;3</I>&#151;Unobservable inputs that are supported by little or no market activity and that are
significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the
determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level within the fair
value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company&#146;s convertible notes, preferred stock tranche rights and anti-dilution right were carried at fair value, determined
according to Level&nbsp;3 inputs in the fair value hierarchy described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment are stated at cost, less accumulated depreciation. Costs of major additions and betterments are
capitalized. Maintenance and repairs which do not improve or extend the life of the respective assets are charged to expense as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which
range from five to seven years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. The Company had no leasehold improvements as of December&nbsp;31, 2021 and 2020. When an item
is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to the consolidated statement of operations and comprehensive loss. Property and equipment to be
disposed of are carried at fair value less costs to sell. The estimated useful lives of the Company&#146;s property and equipment are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Useful Life (in Years)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5-7</FONT> years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Lesser&nbsp;of&nbsp;asset&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease&nbsp;term</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes an impairment loss in loss from operations only if the carrying amount of a long-lived asset is not
recoverable based on its undiscounted future cash flows and in such case, measures an impairment loss as the difference between the carrying amount and the fair value of the asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company tests long-lived assets to be held and used, including property and equipment and operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully
recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover
the carrying amount of the assets, the assets are written down to their fair values. The Company has not recognized any impairment losses during the years ended December&nbsp;31, 2021 and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs include (i)&nbsp;employee-related expenses, including salaries, benefits, and stock-based
compensation expense; (ii)&nbsp;external research and development expenses incurred under arrangements with third parties, such as CRO agreements and consultants; (iii)&nbsp;costs associated with preclinical activities; and (iv)&nbsp;lab supplies,
lab expenses and an allocation of rent, depreciation, and infrastructure. Costs incurred in connection with research and development activities are expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company enters into various consulting, research, and other agreements with commercial firms, researchers, universities
and other external parties for the provision of goods and services. Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using
information and data provided by the Company&#146;s clinical sites and vendors. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of
the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#146;s estimates of the work
performed under service agreements, milestones achieved, and experience with similar contracts. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is
determined to be probable of achievement and the related amount is reasonably estimable. The Company monitors each of these factors and adjusts estimates accordingly. The Company has not experienced any material differences between accrued costs and
actual costs incurred since its inception. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Acquisitions and Acquired <FONT STYLE="white-space:nowrap">In-Process</FONT> Research and
Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for acquisitions of assets or a group of assets that do not meet the
definition of a business as asset acquisitions based on the cost to acquire the asset or group of assets, which include certain transaction costs. In an asset acquisition, the cost to acquire is allocated to the identifiable assets acquired and
liabilities assumed based on their relative fair values as of the acquisition date. No goodwill is recorded in an asset acquisition. Assets that are acquired in an asset acquisition for use in research and development activities that have an
alternative future use are capitalized as in process research and development (&#147;IPR&amp;D&#148;). Acquired IPR&amp;D that has no alternative future use as of the acquisition date is recognized as research and development expense as of the
acquisition date. The Company will recognize additional research and development expenses in the future if and when the Company becomes obligated to make contingent milestone payments under the terms of the agreements by which it acquired the
IPR&amp;D assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Contingent consideration in asset acquisitions is measured and recognized when payment becomes probable
and reasonably estimable. Subsequent changes in the accrued amount of contingent consideration are measured </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and recognized at the end of each reporting period and upon settlement as an adjustment to the cost basis of the acquired asset or group of assets, or, if related to IPR&amp;D with no alternative
future use, charged to expense. For the year ended December&nbsp;31, 2021, the Company recognized $5.5&nbsp;million of IPR&amp;D expense in connection with the consideration due under the Lilly Agreement (see Note 7), included within research and
development expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application
fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company&#146;s consolidated
statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The functional currency for the Company&#146;s wholly-owned foreign subsidiary, Acrivon AB, is the United States dollar. All
foreign currency transaction gains and losses are recognized in the consolidated statements of operations and comprehensive loss through other income (expense). The Company has not recognized material currency transaction gains or losses during the
years ended December&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to January&nbsp;1, 2021, the Company accounted for leases in accordance with Financial Accounting Standards Board
(&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 840, <I>Leases </I>(&#147;ASC 840&#148;). At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company
recognized rent expense, inclusive of rent escalations, on a straight-line basis over the lease term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective on
January&nbsp;1, 2021, the Company accounts for leases in accordance with ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases</I>, as subsequently amended (collectively, &#147;ASC 842&#148;). In accordance with ASC 842, the
Company determines whether an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The
Company classifies leases at the lease commencement date, when control of the underlying asset is transferred from the lessor to the lessee, as operating or finance leases and records a ROU asset and a lease liability on the consolidated balance
sheets for all leases with an initial lease term of greater than 12 months. The Company has elected to not recognize leases with a lease term of 12 months or less, but payments are recognized as expense on a straight-line basis over the lease term.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company enters into contracts that contain both lease and <FONT STYLE="white-space:nowrap">non-lease</FONT>
components. <FONT STYLE="white-space:nowrap">Non-lease</FONT> components may include maintenance, utilities, and other operating costs. For leases of real estate, the Company combines the lease and associated
<FONT STYLE="white-space:nowrap">non-lease</FONT> components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of
the lease payments over the lease term using the discount rate implicit in the lease if readily determinable. If the rate implicit is not readily determinable, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at
which the Company could borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. ROU assets are further adjusted for initial direct costs, prepaid rent, or incentives received.
Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#146;s lease terms may include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Finance lease assets are amortized to depreciation expense using the
straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i)&nbsp;a portion that is recorded as interest expense using the effective interest method and (ii)&nbsp;a
portion that reduces the finance liability associated with the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Company examines other contracts
with suppliers, vendors and outside parties to identify whether such contracts contain an embedded lease and, as applicable, records such embedded leases in accordance with ASC 842. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s convertible preferred stock is classified as temporary equity in the accompanying consolidated balance
sheets and excluded from stockholders&#146; deficit as the potential redemption of such stock is outside the Company&#146;s control and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock
is not redeemable except for in the event of a liquidation, dissolution, or winding up of the Company (see Note 9). Costs incurred in connection with the issuance of convertible preferred stock, as well as the recognition of the preferred stock
tranche liability, are recorded as a reduction of gross proceeds from issuance. The Company does not accrete the carrying values of the preferred stock to the redemption values since the occurrence of these events was not considered probable as of
December&nbsp;31, 2021 and 2020. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only when it becomes probable that these events will occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for all share-based payment awards granted to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> as stock-based compensation expense at fair value, based on the date of the grant, and recognizes compensation expense for those awards over the requisite service period, which is generally the
vesting period of the respective award. The Company&#146;s share-based payments include stock options and grants of common stock. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as
expense over the employees&#146; requisite service period, which is the vesting period, on a straight-line basis. The Company adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation (Topic 718):
Improvements to Nonemployee Share-Based Payment Accounting </I>(&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07&#148;)</FONT> at inception of the 2019 Stock<I> </I>Incentive Plan, prior to the issuance of any stock option grants. The
measurement date for <FONT STYLE="white-space:nowrap">non-employee</FONT> awards<I> </I>is the date of grant, and stock-based compensation costs<I> </I>for <FONT STYLE="white-space:nowrap">non-employees</FONT> are recognized as expense over the
vesting period on a straight-line basis.<I> </I>The Company accounts for forfeitures as they occur. Stock-based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive loss in the same manner in
which the award recipient&#146;s payroll costs are classified or in which the award recipients service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model,
which requires inputs based on certain subjective assumptions. The Company&#146;s board of directors determines the fair value of the Company&#146;s common stock, taking into consideration its most recently available third-party valuations of common
stock and as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the grant date. The Company has historically been a private company and lacks company-specific historical and implied
volatility information. The Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of representative companies and expects to continue to do so until such time as it has adequate historical data
regarding the volatility of its own traded stock price. The expected term of the Company&#146;s stock options has been determined utilizing the &#147;simplified&#148; method for awards that qualify as &#147;plain-vanilla&#148; options. The risk-free
interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the
Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during
the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to
common stockholders is calculated using the <FONT STYLE="white-space:nowrap">two-class</FONT> method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#146;s common shares and participating
securities. The Company&#146;s convertible preferred stock contains participation rights in any dividend paid by the Company and is deemed to be a participating security. Net loss attributable to common stockholders and participating preferred
shares are allocated to each share <FONT STYLE="white-space:nowrap">on&nbsp;an&nbsp;as-converted&nbsp;basis&nbsp;as</FONT> if all of the earnings for the period had been distributed. The participating securities do not include a contractual
obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Diluted net loss per share is computed using the more dilutive
<FONT STYLE="white-space:nowrap">of&nbsp;(a)&nbsp;the&nbsp;two-class&nbsp;method&nbsp;or</FONT> <FONT STYLE="white-space:nowrap">(b)&nbsp;the&nbsp;if-converted&nbsp;method.</FONT> The Company allocates earnings first to preferred stockholders based
on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss per share gives effect to all potentially dilutive common
equivalent shares, including outstanding stock options and preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Common stock equivalent shares are excluded
from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as
basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is antidilutive. The Company reported a net loss attributable to common stockholders for the years ended
December&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax
assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or the Company&#146;s tax returns. Under this method, deferred tax assets and liabilities are determined based on the
differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more
likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a
&#147;more likely than not&#148; threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are no unrecognized tax benefits included in the Company&#146;s consolidated
balance sheets as of December&nbsp;31, 2021 and 2020. The Company&#146;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its consolidated
statements of operations and comprehensive loss since inception. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> Leases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2016, the FASB issued ASC 842, which sets out the principles for the recognition, measurement, presentation and
disclosure of leases for both parties to a contract (i.e., lessees and lessors), and replaces the existing guidance in ASC 840. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The new standard requires lessees to apply a dual approach, classifying
leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine the recognition pattern of lease expense over the term of the lease.
In addition, a lessee is required to record (i)&nbsp;a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability on its balance sheets for all leases with accounting lease terms of more
than 12 months regardless of whether it is an operating or financing lease and (ii)&nbsp;lease expense in its consolidated statements of operations and comprehensive loss for operating leases and amortization and interest expense in its consolidated
statements of operations and comprehensive loss for financing leases. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases under ASC 840. In July 2018, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-11,</FONT> <I>Leases </I>(Topic 842), which added an optional transition method that allows companies to adopt the standard as of the beginning of the year of adoption as opposed to the earliest comparative
period presented. This guidance is effective for the Company for fiscal years beginning after December&nbsp;15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022. Early application is permitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company early adopted ASC 842, with an effective date of January&nbsp;1, 2021, using the modified retrospective transition
approach which uses the effective date as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. The Company has elected to apply the package of practical expedients requiring
no reassessment of whether any expired or existing contracts are or contain leases, the lease classification of any expired or existing leases, or the capitalization of initial direct costs for any existing leases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon its adoption of ASC 842 on January&nbsp;1, 2021, the Company recorded a lease liability and its corresponding ROU asset
based on the present value of lease payments over the remaining lease term. The adoption of ASC 842 resulted in the recognition of operating lease liabilities of $0.4&nbsp;million and ROU assets of $0.4&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT> Debt </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January&nbsp;1, 2021, the Company early adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT>
<I>Debt&#151;Debt with Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging&#151;Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40):</FONT>
Accounting for Convertible Instruments and Contracts in an Entity&#146;s Own Equity</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2020-06&#148;),</FONT> which simplifies the accounting for certain financial instruments with characteristics of
liabilities and equity, including convertible instruments and contracts on an entity&#146;s own equity. Specifically, ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> simplifies accounting for the issuance of convertible instruments by removing
major separation models required under current U.S. GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share
calculation in certain areas. The adoption of this standard did not have a material effect on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-10,</FONT> Codification Improvements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-10,</FONT> <I>Codification
Improvements</I>, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#146;s regulations. The Company adopted this accounting standard as of January&nbsp;1, 2021 with no material impact
on its consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Emerging Growth Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Jumpstart Our Business Startups Act of 2012 permits an &#147;emerging growth company&#148; to take advantage of an extended
transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company has elected not to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
&#147;opt out&#148; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company
will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that the Company either (i)&nbsp;irrevocably elects to &#147;opt out&#148; of such extended transition period or
(ii)&nbsp;no longer qualifies as an emerging growth company. As a result of this election, the Company&#146;s financial statements may not be comparable to other public companies that comply with new or revised accounting pronouncements as of public
company effective dates. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies<B><I>.</I></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> Simplifying the Accounting for Income Tax </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Simplifying the Accounting
for Income Tax </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;).</FONT> The standard contains several provisions that reduce financial statement complexity including removing the exception to the incremental approach for intra-period
tax expense allocation when a company has a loss from continuing operations and income from other items not included in continuing operations. The new guidance is effective for the year beginning January&nbsp;1, 2022, with optional adoption prior to
the effective date. The Company does not expect that the new standard will have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a
recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>December&nbsp;31, 2021 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at<BR>December&nbsp;31, 2020 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, the Company&#146;s cash equivalents consisted of money market
funds, classified as Level&nbsp;1 financial assets, as these assets are valued using quoted market prices in active markets without any valuation adjustment. As of December&nbsp;31, 2020, the Company had Level&nbsp;3 financial liabilities that were
measured at fair value on a recurring basis. The Company&#146;s preferred stock tranche rights, convertible notes and anti-dilution right were carried at fair value determined using Level&nbsp;3 inputs in the fair value hierarchy. As of
December&nbsp;31, 2021, the preferred stock tranche rights, convertible notes and anti-dilution right have been satisfied, and as such, there are no liabilities recorded as of December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the years ended December&nbsp;31, 2021 and 2020, there were no transfers between levels. The Company uses the carrying
amounts of its restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses to approximate their fair value due to the short-term nature of these amounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Company issued Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock
(&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock&#148;). According to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock subscription agreement, the Company was obligated to issue second and third
tranches of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon the Company&#146;s successful completion of future science-driven milestone events, such as entering into <FONT STYLE="white-space:nowrap">in-licensing</FONT>
agreements, contracting with a CRO to conduct phase 2 clinical trials, and identifying compounds for lead drug candidates. As a result, the Company&#146;s obligation to issue additional Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock was recognized as a tranche obligation (the &#147;Preferred Stock Tranche Rights&#148;), which was subject to revaluation at each balance sheet date. Changes in fair value were recorded as a component of other income (expense), net in the
consolidated statements of operations and comprehensive loss until the Preferred Stock Tranche Rights were settled (see Note 9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Preferred Stock Tranche Rights are freestanding financial instruments. The freestanding
financial instruments were classified as a liability on the Company&#146;s consolidated balance sheets and initially recorded at fair value. The liability was subsequently remeasured to fair value at each reporting date until settled,&nbsp;and
changes in the fair value of the preferred stock tranche liability were recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The fair value of the Preferred Stock Tranche Rights was
based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the valuation of the Preferred Stock Tranche Rights could have a
significant impact on the value of the obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred Stock Tranche Rights were valued as a forward contract.
The value was determined using a probability-weighted present value calculation. In determining the fair value of the tranche rights obligation, estimates and assumptions impacting the fair value included the per share estimated fair value of the
Company&#146;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, discount rates, estimated time to tranche closing, and probability of each tranche closing. The Company determined the per share estimated fair value of the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by back-solving to the initial proceeds of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing. The Company remeasured the Preferred Stock Tranche Rights at each
reporting period and prior to the settlement of the Preferred Stock Tranche Rights in January 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following
reflects the ranges of significant quantitative inputs used in the valuation of the Preferred Stock Tranche Rights during the years ended December&nbsp;31, 2021 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Implied fair value of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to milestone event (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.12&nbsp;-&nbsp;0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of tranche closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">70%&nbsp;-&nbsp;90%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Preferred Stock Tranche Rights
measured at fair value on a recurring basis using Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Preferred Stock Tranche Rights to purchase Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value recognized as Series A-1 Preferred Stock upon settlement of Preferred Stock Tranche
Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2018 and 2019, the Company entered into convertible notes purchase agreements (collectively, the &#147;Notes&#148;) for a
total aggregate borrowing amount of $4.8&nbsp;million (see Note 8). The Notes contained various conversion features including mandatory conversion upon the occurrence of a qualified financing at a 20% or 50% discount. Upon the occurrence of a <FONT
STYLE="white-space:nowrap">non-qualified</FONT> financing, the holders of convertible notes issued in 2019 had the option to convert at the same terms as described above for a qualified financing. The Company elected the fair value option to account
for the Notes. Changes in fair value were recorded as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss until the Notes converted in October 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Notes were classified as a liability on the Company&#146;s consolidated balance sheets and initially recorded at fair
value. The fair value of the Notes was based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the valuation of the Notes could
have a significant impact on the value of the obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The value of the Notes was determined using a
probability-weighted present value calculation. In determining the fair value of the Notes, estimates and assumptions impacting the fair value primarily included the per share estimated fair value of the Company&#146;s Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. The Company remeasured the Notes at each reporting period and prior to the conversion of the Notes in October 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Immediately prior to conversion, the Notes were marked to fair value using the Series
<FONT STYLE="white-space:nowrap">A-1</FONT> price of $2.28 per share. No gain or loss was recorded upon extinguishment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Notes measured at fair value on a recurring basis using
Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value recognized as Series A-1 Preferred Stock upon conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,083</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-dilution Right </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with a license agreement and stock issuance agreement between Eli Lilly and Company (&#147;Lilly&#148;) and the
Company (collectively, the &#147;Lilly Agreement&#148;) entered into in January 2021, the Company was obligated to issue capital stock in a subsequent financing to Lilly in order to maintain a specified, single-digit percentage ownership of the
Company upon specified conditions (the &#147;Anti-dilution Right&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Anti-dilution
Right is a freestanding financial instrument. The freestanding financial instrument was classified as an asset or liability on the Company&#146;s consolidated balance sheets and initially recorded at fair value. The fair value of the Anti-dilution
Right was based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the valuation of the Anti-dilution Right could have a significant
impact on the value of the obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Anti-dilution Right was valued as a forward contract. The value was determined
using a probability-weighted present value calculation. In determining the fair values of the obligation, estimates and assumptions impacting fair value included the per share estimated fair value of the Company&#146;s Series B convertible preferred
stock (&#147;Series B Preferred Stock&#148;), discount rates, estimated time to share issuance and probability of each share issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Anti-dilution Right was subsequently revalued until anti-dilution shares
were issued, with changes in fair value for each reporting period recognized in other income (expense), net in the consolidated statements of operations and comprehensive loss. Upon issuance of the anti-dilution shares, the fair value of the
Anti-dilution Right was recognized as Series B Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the Anti-dilution Right, the Company
issued Lilly 46,058 shares of Series B Preferred Stock in November 2021 in full satisfaction of the obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
following reflects the ranges of significant quantitative inputs used in the valuation of the Anti-dilution Right during the year ended December&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.0%&nbsp;-&nbsp;0.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Implied issuance price of Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">$0.84&nbsp;-&nbsp;$6.11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10%&nbsp;-&nbsp;100%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Anti-dilution Right measured at
fair value on a recurring basis using Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value recognized as Series B Preferred Stock upon settlement of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, net consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depreciation expense related to property and equipment for the years ended December&nbsp;31,
2021 and 2020 was $37,000 and $13,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued legal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PPP loan payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, the Company entered into a lease agreement for laboratory and office space located at 700 N. Main Street,
Cambridge, Massachusetts. The lease term, which commenced in April 2018 and was set to expire in April 2020, was extended in March 2020 for an additional <FONT STYLE="white-space:nowrap">one-year</FONT> period. The lease was cancellable with 30
days&#146; notice. The Company elected the short-term lease measurement and recognition exemption under ASC 842 for the <FONT STYLE="white-space:nowrap">one-year</FONT> period extension and therefore did not recognize the lease on the Company&#146;s
consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2020, the Company entered into an operating lease agreement, denominated in
Swedish Krona, for office space located in Lund, Sweden. The term of the lease commenced in October 2020 and is scheduled to expire in September 2023, with lease payments being made on a quarterly basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2020, the Company entered into a lease agreement for laboratory and office space located at 480 Arsenal Way,
Watertown, Massachusetts (the &#147;Arsenal Way Lease&#148;). The term of the lease commenced in April 2021. The lease has an initial term from the rent commencement date, which is a month after the lease commencement date, of approximately seven
years, with an option to extend the term for an additional five years at then-market rental rates. In connection with the execution of the lease agreement, the Company delivered a letter of credit of $0.3&nbsp;million to the landlord, which is
included in restricted cash in the accompanying consolidated balance sheets. The landlord contributed an aggregate of $0.7&nbsp;million toward the cost of tenant improvements for the premises. Under the terms of the lease, the base rent is
$1.0&nbsp;million, subject to a 3% annual rent increase, plus an allocation of operating expenses and taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In May 2021,
the Company entered into an agreement to sublease 6,330 rentable square feet of its Arsenal Way Lease to a subtenant through March 2023. Sublease income is recognized on a straight-line basis over the term of the sublease agreement. Sublease rent
income was $0.4&nbsp;million for the year ended December&nbsp;31, 2021, which was allocated and recorded as a reduction to general and administrative expenses and research and development expenses. The Company was not relieved of its primary
obligation under the Arsenal Way Lease as a result of the sublease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes monthly operating lease
expense on a straight-line basis over the term of the lease as research and development or general and administrative expenses in the consolidated statement of operations and comprehensive loss. Variable lease expense relates primarily to office
lease common area maintenance, insurance, and property taxes, is expensed as incurred, and is excluded from the calculation of the lease liabilities and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use-assets.</FONT></FONT></FONT> Variable lease expense for the year ended December&nbsp;31, 2021 was $0.3&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the presentation of the Company&#146;s
operating leases on its consolidated balance sheet (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Leases</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Balance sheet classification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease liability, current</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease liability, long-term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The components of lease cost under ASC 842 included within research and development expenses
and general and administrative expenses in the Company&#146;s consolidated statement of operations and comprehensive loss for the year ended December&nbsp;31, 2021 were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Lease cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, the weighted-average remaining lease term for operating leases
was 6.3 years and the weighted-average discount rate was 7.85%. Cash paid for amounts included in the measurement of lease liabilities was $0.9&nbsp;million for the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future minimum annual lease commitments under the Company&#146;s <FONT STYLE="white-space:nowrap">non-cancellable</FONT>
operating leases as of December&nbsp;31, 2021 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Disclosures under ASC 840 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes rent expense on a straight-line basis over the respective lease period. During the year ended
December&nbsp;31, 2020, rent expense was $0.4&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future minimum rental commitments to be paid by the Company at
December&nbsp;31, 2020 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected future lease payments of $7.7 million related to the Arsenal Way lease are not
included in the table above. This lease agreement was signed in December 2020 and had not commenced as of December 31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. License Agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, the Company entered into the Lilly Agreement with Lilly, pursuant to which the Company has been
granted an exclusive, royalty-bearing sublicensable license to certain intellectual property rights owned or controlled by Lilly, to commercially develop, manufacture, use, distribute and sell therapeutic products containing the compound
prexasertib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As initial consideration for the license, the Company made a
<FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $5.0&nbsp;million. As additional consideration for the license, the
Company is required to pay Lilly aggregate development and commercial milestone payments of up to $168.0 million, of which $5.0 million is due prior to a new drug application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is also obligated to pay a tiered percentage royalty on annual net sales ranging from a low single-digit up to low
double-digits, subject to certain specified reductions. Royalties are payable by the Company on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed
product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country, provided, that the
Company&#146;s obligation to pay royalties for a given licensed product in a given country will expire earlier upon achievement of certain sales thresholds by generic products in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the cash consideration described above, the Company issued 829,995 shares of its common stock to Lilly in an
amount equal to 5.0% of the Company&#146;s capital stock on a fully diluted basis as of the date of the Lilly Agreement. The Company agreed to issue its capital stock to Lilly pursuant to the Anti-dilution Right (see Note 3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, the Company completed its Series B Preferred Stock financing. The financing triggered the settlement of the
Anti-dilution Right, resulting in the issuance of 46,058 shares of Series B Preferred Stock to Lilly with a then fair value of $0.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Lilly Agreement represented an asset acquisition of IPR&amp;D assets with no alternative
future use and recognized the aggregate acquisition cost as acquired IPR&amp;D expense in the consolidated statements of operations and comprehensive loss. For the year ended December&nbsp;31, 2021, the Company recognized $5.5&nbsp;million of
research and development expense in connection with the consideration due under the Lilly Agreement. The $5.5&nbsp;million consisted of (i) $0.2&nbsp;million initial recognition of the Anti-dilution Right, (ii) $0.3&nbsp;million fair value for the
829,995 shares of common stock issued to Lilly and (iii)&nbsp;the upfront cash consideration for the license arrangement of $5.0&nbsp;million. To date, no milestones have been achieved and no royalties have been incurred related to the Lilly
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PPP Loan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April
2020, the Company issued a promissory note to Silicon Valley Bank, pursuant to which it received loan proceeds of $0.1&nbsp;million (the &#147;PPP Loan&#148;) provided under the Paycheck Protection Program (&#147;PPP&#148;), which was established
under the Coronavirus Aid, Relief and Economic Security Act and guaranteed by the Small Business Administration (&#147;SBA&#148;). The PPP loan was recorded within accrued expenses and other current liabilities on the Company&#146;s consolidated
balance sheets. In February 2021, the Company received notice from the SBA that the PPP Loan was forgiven. Accordingly, the Company was no longer required to repay the $0.1&nbsp;million in principal and immaterial accrued interest borrowed under the
PPP Loan. A gain on extinguishment of the PPP Loan of $0.1&nbsp;million was recorded as other income (expense), net for the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, the Company commenced an offering to issue $1.8&nbsp;million of convertible notes (the &#147;2018 Notes&#148;)
to certain investors with a maturity date in April 2020. The 2018 Notes carried an interest rate of 4.0% per annum. The 2018 Notes carried both a voluntary conversion feature and an automatic conversion feature. Under the terms of the 2018 Notes,
the 2018 Notes were automatically converted into shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock at price per share equal to between 50% and 80% of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock
price of $2.28 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2019, the Company commenced an offering to issue up to $3.0&nbsp;million of convertible
notes (the &#147;2019 Notes&#148;) to certain investors with a maturity date in June 2020, which was subsequently extended to December&nbsp;31, 2020. In June 2019, the Company issued an initial $1.5&nbsp;million of convertible notes. Subsequently,
the Company issued an additional $1.5&nbsp;million of convertible notes in December 2019. The 2019 Notes were secured by specific assets of the Company and carried an interest rate of 8.0% per annum. The 2019 Notes carried both a voluntary
conversion feature and an automatic conversion feature. Under the terms of the 2019 Notes, the 2019 Notes were optionally converted into shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock at price per share equal to 80% of
the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock price of $2.28 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company elected the
fair value option to account for the Notes, whereby the Company recognized the Notes as liabilities at fair value, with subsequent changes in the fair value recognized in other income (expense), net on the consolidated statements of operations and
comprehensive loss. At issuance, the fair value of the 2019 Notes and 2018 Notes was determined to be $1.8&nbsp;million and $3.0&nbsp;million, respectively. The Company incurred an immaterial amount of fees related to the issuance of the Notes,
which was expensed to general and administrative expense on the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Company entered into the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock purchase
agreement (the &#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Agreement&#148;). As part of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock issuance, the Company settled the outstanding principal of the 2018 Notes and
2019 Notes of $4.8&nbsp;million plus accrued interest of $0.4&nbsp;million through the issuance of 3,106,561 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company had no debt outstanding as of December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Convertible Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Board of Directors (the &#147;Board&#148;)
authorized the sale and issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in three closings. In October 2020, as part of the first closing of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the
Company issued 1,315,789 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock with a par value of $0.001 and a purchase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
price of $2.28 per share, and an additional 3,106,561 shares of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon conversion of the Company&#146;s convertible notes (see
Note 8). The second and third closings of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing were dependent upon the Company&#146;s successful completion of future science-driven milestone events, such as entering into <FONT
STYLE="white-space:nowrap">in-licensing</FONT> agreements, contracting with a CRO to conduct phase 2 clinical trials, and identifying compounds for lead drug candidates. The obligations to issue additional shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in subsequent financings, or Preferred Stock Tranche Rights, were recorded as a liability (see Note 3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, upon effectiveness of the Lilly Agreement, the Company completed the second and third closings and issued an
aggregate of 5,482,456 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock issued in the second and third closings had a par value of $0.001 and had a
purchase price of $2.28 per share, which was equal to fair value as estimated by the Company&#146;s management by taking into consideration the results obtained from a third-party valuation, among other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company incurred issuance costs of $0.2&nbsp;million in connection with these transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series B Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, the Board authorized the sale and issuance of Series B Preferred Stock. In November 2021, the Company issued
17,521,047 shares of Series B Preferred Stock, with a par value of $0.001 and a purchase price of $5.70742 per share, and an additional 46,058 shares of Series B Preferred Stock to settle the Company&#146;s Anti-dilution Right in connection with the
Lilly Agreement (see Note 3). The Company incurred issuance costs of $0.2&nbsp;million in connection with this transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series B Preferred Stock
(collectively, &#147;Preferred Stock&#148;), the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preferred Stock consisted of the following as of the dates presented (in thousands, except share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Stock<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,685,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,685,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of Preferred Stock have the following rights, preferences and privileges: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holder of
each share of Preferred Stock is entitled to one vote for each share of common stock into which it would convert and to vote with the common stock on all matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Preferred Stock is convertible, at the option of the holder, at any time and from time to time, and without the
payment of additional consideration by the holder thereof, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock as is determined by dividing the original issue price by the conversion price
for each series of Preferred Stock (as defined below). The conversion price, and the rate at which each series of preferred stock may be converted into common stock, are subject to adjustment from time to time to reflect future share dividends,
splits, combinations, recapitalizations and similar events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, each share of Preferred Stock shall automatically be
converted into shares of common stock at the conversion rate at the time in effect for such series of Preferred Stock immediately upon either of: (i)&nbsp;the closing of the Company&#146;s sale of common stock to the public at a price per share of
at least $11.4148 per share in an IPO (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the applicable class of common stock), resulting in at least
$50.0&nbsp;million of proceeds, net of the underwriting discount and commissions; or (ii)&nbsp;the date and time, or occurrence of an event, specified by vote or written consent of the requisite holders of at a majority of the combined voting power
of the shares of Preferred Stock then outstanding as calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of
the Preferred Stock are entitled to receive dividends at the rate of 6% of the applicable original issue price per annum, as potentially adjusted for certain <FONT STYLE="white-space:nowrap">non-dilutive</FONT> transactions. Dividends shall not be
cumulative or compounded and shall be payable only when, as and if declared by the Board and in preference and in priority to any dividends on common stock. There have been no dividends declared by the Board as of December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Preference </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of any liquidation, dissolution, or winding up of the Company (&#147;Liquidation Event&#148;), the holders of
Preferred Stock (first to the holders of Series B Preferred Stock, then to the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock) are entitled to receive prior and in preference to the holders of common stock, an amount
equal to an amount per share equal to the greater of the original issue price, as potentially adjusted for certain <FONT STYLE="white-space:nowrap">non-dilutive</FONT> transactions, plus all declared and unpaid dividends on the Preferred Stock or
the price per share that would be received if the Preferred Stock were converted to common stock. If the assets and funds available to be distributed to all holders of Preferred Stock are insufficient to permit the payment, in full, of any of the
liquidation preferences, then the entire assets and funds legally available for distribution to holders of the Preferred Stock shall be distributed ratably among the holders of Preferred Stock, acting as a single class, at the time outstanding,
ratably in proportion to the full amounts to which they would otherwise be respectively entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the payment of
the full liquidation preference of the Preferred Stock as set forth above, the remaining assets of the Company legally available for distribution in such Liquidation Event shall be distributed ratably to the holders of shares of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred
Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Liquidation Event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021 and 2020, the Company&#146;s Amended and Restated Certificate of Incorporation authorized the
Company to issue 40,013,683 and 20,000,000 shares of common stock, respectively, with a par value of $0.001. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The voting, dividend and liquidation rights of the holders of the
Company&#146;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock as set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders
(and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the
Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, and 2020, the Company has reserved the following shares of common stock for the potential
conversion of outstanding preferred stock and exercise of stock options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining shares reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,412,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,217,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,058,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,754,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company adopted the 2019 Stock Incentive Plan (the &#147;2019 Plan&#148;) in June 2019 pursuant to which the Company can
issue incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. Recipients of stock options or stock appreciation
rights shall be eligible to purchase shares of the Company&#146;s common stock at an exercise price equal to the estimated fair market value of such stock on the date of grant. The exercise price may be less than fair market value if the stock award
is granted pursuant to an assumption or substitution for another stock award in the event of a merger or sale of the Company. The maximum term of options granted under the 2019 Plan is ten years, and stock options typically vest over a four-year
period. The Board may assign vesting terms to the stock option grants as deemed appropriate. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. At the discretion
of the Board, unvested shares held by employees may accelerate vesting in the event of a change of control of the Company unless assumed or substituted by the acquirer or surviving entity. The original Plan provided for the issuance of up to
1,042,500 shares of common stock, which was subsequently amended in November 2021 to allow for the issuance of up to 7,587,942 shares of common stock as of December&nbsp;31, 2021, of which 5,412,619 shares of common stock remain available for future
grant under the 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of unused common stock that cover awards that are expired, terminated, surrendered or
canceled under the 2019 Plan without having been fully exercised will be available for future awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has granted stock options with service-based vesting conditions. Stock options typically vest over four years and
have a maximum term of ten years. The Company typically grants stock options to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> at exercise prices deemed by the Board to be equal to the fair value of the common stock at the time
of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The assumptions that the Company used in the Black-Scholes option-pricing
model to determine the grant date fair value of stock options granted were as follows. No options were granted in the year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.49%&nbsp;-&nbsp;1.33%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of options (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.0&nbsp;-&nbsp;6.2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility rate range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">70.77%&nbsp;-&nbsp;79.18%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock range</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">$0.42&nbsp;-&nbsp;$1.57</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Company&#146;s stock option activity under the 2019 Plan:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining<BR>Contractual Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Intrinsic<BR>Value<BR>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,120,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and exercisable as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,068,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate intrinsic value of options is calculated as the difference between the exercise
price of the stock options and the fair value of the Company&#146;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the reporting period. There was no aggregate intrinsic
value of options exercised during the years ended December&nbsp;31, 2021 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The weighted-average grant date fair
value of the Company&#146;s stock options granted during the year ended December&nbsp;31, 2021 was $0.42 per option. As of December&nbsp;31, 2021, there was $0.4&nbsp;million of unrecognized stock-based compensation expense related to the
share-based compensation arrangements under the 2019 Plan. The Company expects to recognize this amount over a weighted-average period of 2.6 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total fair value of options vested during the years ended December&nbsp;31, 2021 and 2020, was $0.5&nbsp;million and an
insignificant amount, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense included in the Company&#146;s consolidated statements of operations and comprehensive loss is
as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the years ended December&nbsp;31, 2021 and 2020, the Company recorded no income tax benefits for the net operating losses
incurred or for the research and development tax credits generated in each period, due to its uncertainty of realizing a benefit from those items. The Company&#146;s operating losses since inception have been generated in the United States and
Sweden. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Loss before provision for income taxes consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred Tax Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D credit carryovers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred Tax Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following reconciles the differences between income taxes computed at the federal
statutory rate and the provision for income taxes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax effected at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other permanent adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes revaluation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal R&amp;D credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has had no income tax expense due to operating losses incurred
since inception. The Company has evaluated the positive and negative evidence bearing upon the reliability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets
as the realization of the deferred tax assets is not determined to be more likely than not. During the years ended December&nbsp;31, 2021 and 2020, the valuation allowance increased by $4.4&nbsp;million and $0.7&nbsp;million, respectively, primarily
due to the increase in the Company&#146;s net operating loss carryovers (&#147;NOLs&#148;) during the period. The changes in the valuation allowance were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases (decreases) recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021, the Company had $13.9&nbsp;million and $12.3&nbsp;million of
federal and state operating loss carryforwards, respectively. The federal NOLs are not subject to expiration and the state NOLs begin to expire in 2038. These loss carryforwards are available to reduce future federal taxable income, if any. These
loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the
company&#146;s ultimate parent. The Company has not conducted a Section&nbsp;382 study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and
cost associated with such a study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;18, 2015, the Protecting Americans from Tax Hikes (&#147;PATH&#148;)
Act of 2015 was signed into law. The PATH Act has created several R&amp;D credit provisions, including allowing qualified small business to utilize the research credit against the employer portion of payroll tax (i.e., FICA tax) not exceeding
$250,000 per year. This provision is available for credits generated in tax years beginning after 2015. The company qualifies as small business for 2021, and will elect to make a small business election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company follows the provisions of ASC <FONT STYLE="white-space:nowrap">740-10,</FONT> &#147;Accounting for Uncertainty in
Income Taxes,&#148; which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax
positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions. As of December&nbsp;31, 2021 and 2020, the Company has not recorded any amounts for uncertain tax positions. As of
December&nbsp;31, 2021 and 2020, the Company had no reserves for uncertain tax positions. For the years ended December&nbsp;31, 2021 and 2020, no estimated interest or penalties were recognized on uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s tax returns for the years ended December&nbsp;31, 2018 to December&nbsp;31, 2021 remain open and subject to
examination by the Internal Revenue Service, state, and applicable foreign taxing authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Net Loss per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share
and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in net loss per share - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,299,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s potentially dilutive securities, which include Preferred Stock and stock
options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net
loss per share attributable to common stockholders is the same. The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of December&nbsp;31, 2021 and 2020 because including
them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company&#146;s commitments under its operating leases are described in Note 6. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company entered into a license agreement under which it is obligated to make fixed and contingent payments (see Note 7).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors,
business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has
entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as directors. The
maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The
Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its financial statements as of December&nbsp;31, 2021 and 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well
as information gathering requests, inquiries and investigations. As of December&nbsp;31, 2021 and 2020, there were no matters which would have a material impact on the Company&#146;s financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Contracts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company enters into contracts in the normal course of business with various third parties for preclinical research studies,
clinical trials, testing, manufacturing and other services. These contracts generally provide for termination upon notice and are cancelable without significant penalty or payment, and do not contain any minimum purchase commitments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Employee Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective January&nbsp;1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under
Section&nbsp;401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) Plan within statutory and 401(k) Plan limits. Since inception of the 401(k) Plan and through the year ended December&nbsp;31, 2021 the
Company has not made any contributions to the 401(k) Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The chief executive officer of the Company received a payment of $0.2&nbsp;million from the Company during the year ended
December&nbsp;31, 2020, which was recorded as a general and administrative expense. The payment was in accordance with a founder patent license agreement, executed in April 2018, that granted an exclusive, worldwide, irrevocable, perpetual,
royalty-free license under certain licensed patents for any and all purposes and uses, including without limitation and rights to sublicense through multiple tiers, for the reimbursement of agreed, estimated unreimbursed expenses incurred by the
chief executive officer prior to the effective date of such agreement with respect to the preparation, filing, prosecution, protection and maintenance of certain licensed patents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For its annual consolidated financial statements as of December&nbsp;31, 2021 and for the year then ended, the Company
evaluated subsequent events through August&nbsp;12, 2022, the date on which those financial statements were issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Grants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2022, the Company granted options for the purchase of an aggregate of 1,752,630 shares of common stock, at an exercise
price of $1.57 per share. The aggregate grant-date fair value of the options granted is $1.8&nbsp;million, which is expected to be recognized as stock-based compensation expense over a weighted-average period of 3.8 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, the Company granted options for the purchase of an aggregate of 1,200,000 shares of common stock, at an exercise
price of $1.47 per share. The aggregate grant-date fair value of the options granted is $1.3&nbsp;million, which is expected to be recognized as stock-based compensation expense over a weighted-average period of 3.8 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2022, the Company granted options for the purchase of an aggregate 410,000 shares of common stock, at an exercise
price of $1.65 per share. The aggregate grant-date fair value of the options granted is $0.4&nbsp;million, which is expected to be recognized as stock-based compensation expense over a weighted-average period of 4.0 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Companion Diagnostic Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, the Company entered into a Companion Diagnostic Agreement (the &#147;Akoya Agreement&#148;) with Akoya
Biosciences, Inc. (&#147;Akoya&#148;). Pursuant to the Akoya Agreement, Akoya has agreed to co-develop, validate, and commercialize the Company&#146;s proprietary ACR-368 OncoSignature test, the companion diagnostic that will be used to identify
patients with cancer most likely to respond to ACR-368. Subject to the terms of the Akoya Agreement, the Company paid Akoya a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT
STYLE="white-space:nowrap">non-creditable</FONT> upfront payment in the amount of $0.6&nbsp;million. The Company is obligated to pay Akoya up to low double-digit million dollars upon the achievement of specified development milestones. To date,
development milestones have been achieved under the Akoya Agreement, resulting in aggregate payments of $2.0&nbsp;million by the Company to Akoya. In addition, the Company will reimburse Akoya for certain pass-through costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc1"></A><A NAME="toc1"></A>INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited Condensed Consolidated Financial Statements for the Six Months Ended June&nbsp;30, 2022 and 2021: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_7">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_8">Condensed Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_9">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_10">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-37</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin383050_11">Notes to Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-38</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_7"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands,
except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 99,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 94,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, par value $0.001;
9,904,806 shares authorized, issued and outstanding as of June&nbsp;30, 2022 and December&nbsp;31, 2021; liquidation preference of $22.6&nbsp;million as of June&nbsp;30, 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, par value $0.001; 17,567,105 shares authorized, issued and
outstanding as of June&nbsp;30, 2022 and December&nbsp;31, 2021; liquidation preference of $100.3 million as of June&nbsp;30, 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.001; 40,013,683 shares authorized as of June&nbsp;30, 2022 and
December&nbsp;31, 2021; 4,363,745 shares issued and outstanding as of June&nbsp;30, 2022 and December&nbsp;31, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 94,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_8"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands,
except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common stock outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,363,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,237,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_9"></A>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands,
except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,363,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,363,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,422,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock related to license agreement with Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">829,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock, net of
issuance costs of $33</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,321,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock related
to settlement of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,362,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_10"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands)
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License agreement paid for with common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anti-dilution right assumed with license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of anti-dilution right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain upon extinguishment of PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,242</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock in
second and <BR>third closings, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 84,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of preferred stock tranche rights recognized as Series
<FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock upon issuance of milestone shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of cash, cash equivalents, and restricted cash:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 84,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin383050_11"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Acrivon Therapeutics, Inc., (the &#147;Company&#148;) is a clinical stage biopharmaceutical company developing
oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The Company&#146;s pipeline includes the Phase
2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase,
and a closely related, undisclosed serine/threonine kinase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company was incorporated in March 2018 under the laws of
the state of Delaware, and its principal offices are in Watertown, Massachusetts. Also in March 2018, the Company formed Acrivon AB, a wholly-owned subsidiary of the Company, established in Lund, Sweden. In December 2021, the Company formed Acrivon
Securities Corporation, a wholly-owned subsidiary, established in Massachusetts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt
about the Company&#146;s ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and
staffing the Company, business planning, raising capital, establishing its intellectual property portfolio, acquiring or discovering drug candidates, research and development activities for <FONT STYLE="white-space:nowrap">ACR-368</FONT> and other
compounds, establishing arrangements with third parties for the manufacture of its drug candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant
operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its inception, the Company has funded its operations primarily with proceeds from the sales of shares of its convertible
preferred stock and the issuance of convertible notes. The Company has incurred recurring losses since its inception, including net losses of $13.0&nbsp;million and $9.5&nbsp;million for the six months ended June&nbsp;30, 2022, and 2021,
respectively. As of June&nbsp;30, 2022, the Company had an accumulated deficit of $37.9&nbsp;million. To date, the Company has not generated any revenues and expects to continue generating operating losses for the foreseeable future as it continues
to expand its research and development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company expects that its existing cash and cash equivalents of
$83.9&nbsp;million as of June&nbsp;30, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date these condensed consolidated financial statements were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will need additional funding to support its planned operating activities. There can be no assurances, however,
that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development
efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is seeking to complete an initial public offering (&#147;IPO&#148;) of its common stock. Immediately prior to the
closing of a qualifying public offering on specified terms, the Company&#146;s outstanding convertible preferred stock will automatically convert into common stock (see Note 8). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event the Company does not complete an IPO, the Company expects to
seek additional funding through private equity financings, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to
obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of
its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue
these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and
classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes
the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2020, the World Health Organization declared the outbreak of the novel coronavirus,
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> a pandemic. The pandemic has resulted in the closing of borders, enhanced health screenings, health care service preparation and delivery, quarantines, cancellations, disruptions to supply chains, as
well as general concern and uncertainty. The Company cannot predict the future progression or full impact of the outbreak and its effects on the Company&#146;s business and operations. Additionally, <FONT STYLE="white-space:nowrap">COVID-19</FONT>
has resulted in substantial market volatility and may result in a significant economic downturn. The Company will continue to actively monitor the current international and domestic impacts of and responses to
<FONT STYLE="white-space:nowrap">COVID-19</FONT> and its related risks. The Company considered the potential effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its financial statements and noted that there is no material
effect on the condensed consolidated financial statements as of June&nbsp;30, 2022 and 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s significant accounting policies are disclosed in the audited financial statements for the years ended
December&nbsp;31, 2021 and 2020, included elsewhere in this prospectus. There have been no changes to the Company&#146;s significant accounting policies, except as noted below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I></I></B>The accompanying consolidated financial statements have been prepared in conformity with accounting principles
generally accepted in the United States of America (&#147;U.S. GAAP&#148;) and include the operations of Acrivon Therapeutics, Inc. and its wholly-owned subsidiaries. All intercompany accounts, transactions and balances have been eliminated in
consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The condensed consolidated interim financial statements have been prepared on the same basis as the
audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair presentation of the Company&#146;s financial position at June&nbsp;30, 2022 and
the results of its operations and its cash flows for the six months ended June&nbsp;30, 2022 and 2021. The condensed balance sheet as of December&nbsp;31, 2021 was derived from audited annual financial statements but does not include all disclosures
required by U.S. GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The results for the six months ended June&nbsp;30, 2022 are not necessarily indicative of results
to be expected for the full year or for any other subsequent interim period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> Simplifying the Accounting for Income Tax </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Simplifying the Accounting
for Income Tax</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2019-12&#148;).</FONT> The standard contains several provisions that reduce financial statement complexity including removing the exception to the incremental approach for intra-period
tax expense allocation when a company has a loss from continuing operations and income from other items not included in continuing operations. The Company adopted this accounting standard as of January&nbsp;1, 2022, with no material impact on its
condensed consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a
recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at June&nbsp;30, 2022 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2021 Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and December&nbsp;31, 2021, the Company&#146;s cash equivalents
consisted of money market funds, classified as Level&nbsp;1 financial assets, as these assets are valued using quoted market prices in active markets without any valuation adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the six months ended June&nbsp;30, 2022 and year ended December&nbsp;31, 2021, there were no transfers between levels.
The Company uses the carrying amounts of its restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses to approximate their fair value due to the short-term nature of these amounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Company issued Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock
(&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock&#148;). According to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock subscription agreement, the Company was obligated to issue second and third
tranches of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon the Company&#146;s successful completion of future science-driven milestone events, such as entering into <FONT STYLE="white-space:nowrap">in-licensing</FONT>
agreements, contracting with a CRO to conduct phase 2 clinical trials, and identifying compounds for lead drug candidates. As a result, the Company&#146;s obligation to issue additional Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock was recognized as a tranche obligation (the &#147;Preferred Stock Tranche Rights&#148;), which was subject to revaluation at each balance sheet date. Changes in fair value were recorded as a component of other income (expense), net in the
consolidated statements of operations and comprehensive loss until the Preferred Stock Tranche Rights were settled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company determined that the Preferred Stock Tranche Rights are freestanding financial instruments. The freestanding financial instruments were classified as a liability on the Company&#146;s consolidated balance
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
sheets and initially recorded at fair value. The liability was subsequently remeasured to fair value at each reporting date until settled in January 2021,&nbsp;and changes in the fair value of
the preferred stock tranche liability were recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The fair value of the Preferred Stock Tranche Rights was based on significant inputs
not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred
Stock Tranche Rights were valued as a forward contract. The value was determined using a probability-weighted present value calculation. In determining the fair value of the tranche rights obligation, estimates and assumptions impacting the fair
value included the per share estimated fair value of the Company&#146;s Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, discount rates, estimated time to tranche closing, and probability of each tranche closing. The Company
determined the per share estimated fair value of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by back-solving to the initial proceeds of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing. The
Company remeasured the Preferred Stock Tranche Rights at each reporting period and prior to the settlement of the Preferred Stock Tranche Rights in January 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following reflects the ranges of significant quantitative inputs used in the valuation of the Preferred Stock Tranche
Rights during the six months ended June&nbsp;30, 2021, which reflects the inputs used at remeasurement prior to settlement in January 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Implied fair value of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time to milestone event (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of tranche closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Preferred Stock Tranche Rights
measured at fair value on a recurring basis using Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value recognized as Series A-1 Preferred Stock upon settlement of Preferred Stock Tranche
Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-dilution Right </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with a license agreement and stock issuance agreement between Eli Lilly and Company (&#147;Lilly&#148;) and the
Company (collectively, the &#147;Lilly Agreement&#148;) entered into in January 2021, the Company was obligated to issue capital stock in a subsequent financing to Lilly in order to maintain a specified, single-digit percentage ownership of the
Company upon specified conditions (the &#147;Anti-dilution Right&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Anti-dilution
Right is a freestanding financial instrument. The freestanding financial instrument was classified as an asset or liability on the Company&#146;s consolidated balance sheets and initially recorded at fair value. The fair value of the Anti-dilution
Right was based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. A change in the assumptions related to the valuation of the Anti-dilution Right could have a significant
impact on the value of the obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Anti-dilution Right was valued as a forward contract. The value was
determined using a probability-weighted present value calculation. In determining the fair values of the obligation, estimates and assumptions impacting fair value included the per share estimated fair value of the Company&#146;s Series B
convertible preferred stock (&#147;Series B Preferred Stock&#148;), discount rates, estimated time to share issuance and probability of each share issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Anti-dilution Right was subsequently revalued until anti-dilution shares were issued in November 2021, with changes in
fair value for each reporting period recognized in other income (expense), net in the consolidated statements of operations and comprehensive loss. Upon issuance of the anti-dilution shares, the fair value of the Anti-dilution Right was recognized
as Series B Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In full satisfaction of the Anti-dilution Right, the Company issued Lilly 46,058 shares of
Series B Preferred Stock in November 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following reflects the ranges of significant quantitative inputs used in
the valuation of the Anti-dilution Right during the six months ended June&nbsp;30, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0%&nbsp;-&nbsp;0.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Implied issuance price of Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.84&nbsp;-&nbsp;$6.11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10%&nbsp;-&nbsp;40%</FONT></TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following provides a roll forward of the fair value of the Anti-dilution Right measured at
fair value on a recurring basis using Level&nbsp;3 significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Anti-dilution Right</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, net consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(179</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depreciation expense related to property and equipment for the six months ended June&nbsp;30,
2022 and 2021 was $0.1&nbsp;million and $15,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued legal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, the Company entered into a lease agreement for laboratory and office space located at 700 N. Main Street,
Cambridge, Massachusetts. The lease term, which commenced in April 2018 and was set to expire in April 2020, was extended in March 2020 for an additional <FONT STYLE="white-space:nowrap">one-year</FONT> period. The lease was cancellable with 30
days&#146; notice. The Company elected the short-term lease measurement and recognition exemption under ASC 842 for the <FONT STYLE="white-space:nowrap">one-year</FONT> period extension and therefore did not recognize the lease on the Company&#146;s
condensed consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2020, the Company entered into an operating lease agreement,
denominated in Swedish Krona, for office space located in Lund, Sweden. The term of the lease commenced in October 2020 and is scheduled to expire in September 2023, with lease payments being made on a quarterly basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2020, the Company entered into a lease agreement for laboratory and office space located at 480 Arsenal Way,
Watertown, Massachusetts (the &#147;Arsenal Way Lease&#148;). The term of the lease commenced in April 2021. The lease has an initial term from the rent commencement date, which is a month after the lease commencement date, of approximately seven
years, with an option to extend the term for an additional five years at then-market rental rates. In connection with the execution of the lease agreement, the Company delivered a letter of credit of $0.3&nbsp;million to the landlord, which is
included in restricted cash in the accompanying condensed consolidated balance sheets. The landlord contributed an aggregate of $0.7&nbsp;million toward the cost of tenant improvements for the premises. Under the terms of the lease, the base rent is
$1.0&nbsp;million, subject to a 3% annual rent increase, plus an allocation of operating expenses and taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In May 2021,
the Company entered into an agreement to sublease 6,330 rentable square feet of its Arsenal Way Lease to a subtenant through March 2023. Sublease income is recognized on a straight-line basis over the term of the sublease agreement. Sublease rent
income was $0.4&nbsp;million and an insignificant amount for the six months ended June&nbsp;30, 2022 and 2021, respectively, which was allocated and recorded as a reduction to general and administrative expenses and research and development
expenses. The Company was not relieved of its primary obligation under the Arsenal Way Lease as a result of the sublease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes monthly operating lease expense on a straight-line basis over the term of the lease as research and
development or general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. Variable lease expense relates primarily to office lease common area maintenance, insurance, and property taxes, is
expensed as incurred, and is excluded from the calculation of the lease liabilities and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use-assets.</FONT></FONT></FONT> Variable lease
expense for the six months ended June&nbsp;30, 2022 and 2021 was $0.3&nbsp;million and $0.1&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the presentation of the Company&#146;s
operating leases on its condensed consolidated balance sheet (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Leases</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Balance sheet classification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease liability, current</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Operating lease liability, long-term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The components of lease cost under ASC 842 included within research and development expenses
and general and administrative expenses in the Company&#146;s condensed consolidated statement of operations and comprehensive loss for the six months ended June&nbsp;30, 2022 were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Lease cost</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and 2021, the weighted-average remaining lease term for operating
leases was 5.8 years and 6.6 years, respectively, and the weighted-average discount rate was 7.85% and 7.79%, respectively. Cash paid for amounts included in the measurement of lease liabilities was $0.5&nbsp;million and $0.3&nbsp;million for the
six months ended June&nbsp;30, 2022 and 2021, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future minimum annual lease commitments under the
Company&#146;s <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating leases as of June&nbsp;30, 2022 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 (remaining 6 months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. License Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, the Company entered into a license agreement and stock issuance agreement (collectively, the &#147;Lilly
Agreement&#148;) with Eli Lilly and Company (&#147;Lilly&#148;), pursuant to which the Company has been granted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
an exclusive, royalty-bearing sublicensable license to certain intellectual property rights owned or controlled by Lilly, to commercially develop, manufacture, use, distribute and sell
therapeutic products containing the compound prexasertib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As initial consideration for the license, the Company made a <FONT
STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $5.0&nbsp;million. As additional consideration for the license, the Company
is required to pay Lilly aggregate development and commercial milestone payments of up to $168.0 million, of which $5.0 million is due prior to a new drug application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is also obligated to pay a tiered percentage royalty on annual net sales ranging from single-digit up to low
double-digits, subject to certain specified reductions. Royalties are payable by the Company on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed
product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country, provided, that the
Company&#146;s obligation to pay royalties for a given licensed product in a given country will expire earlier upon achievement of certain sales thresholds by generic products in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the cash consideration described above, the Company issued 829,995 shares of its common stock to Lilly in an
amount equal to 5.0% of the Company&#146;s capital stock on a fully diluted basis as of the date of the Lilly Agreement. The Company agreed to issue its capital stock to Lilly pursuant to the Anti-dilution Right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, the Company completed its Series B Preferred Stock financing. The financing triggered the settlement of the
Anti-dilution Right, resulting in the issuance of 46,058 shares of Series B Preferred Stock to Lilly with a then fair value of $0.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the Lilly Agreement represented an asset acquisition of IPR&amp;D assets with no alternative
future use and recognized the aggregate acquisition cost as acquired IPR&amp;D expense in the condensed consolidated statements of operations and comprehensive loss. During the six months ended June&nbsp;30, 2021, the Company recognized
$5.5&nbsp;million of research and development expense in connection with the consideration due under the Lilly Agreement. The $5.5&nbsp;million consisted of (i) $0.2&nbsp;million initial recognition of the Anti-dilution Right, (ii) $0.3&nbsp;million
fair value for the 829,995 shares of common stock issued to Lilly and (iii)&nbsp;the upfront cash consideration for the license arrangement of $5.0&nbsp;million. To date, no milestones have been achieved and no royalties have been incurred related
to the Lilly Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, the Board of Directors (the &#147;Board&#148;) authorized the sale and issuance of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in three closings. In October 2020, as part of the first closing of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Company issued 1,315,789 shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock with a par value of $0.001 and a purchase price of $2.28 per share, and an additional 3,106,561 shares of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock upon conversion of
the Company&#146;s convertible notes. The second and third closings of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock financing were dependent upon the Company&#146;s successful completion of future science-driven milestone
events, such as entering into <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreements, contracting with a CRO to conduct phase 2 clinical trials, and identifying compounds for lead drug candidates. The obligations to issue additional shares
of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock in subsequent financings, or Preferred Stock Tranche Rights, were recorded as a liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, upon effectiveness of the Lilly Agreement, the Company completed the second and third closings and issued an
aggregate of 5,482,456 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock. Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
issued in the second and third closings had a par value of $0.001 and had a purchase price of $2.28 per share, which was equal to fair value as estimated by the Company&#146;s management by
taking into consideration the results obtained from a third-party valuation, among other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company incurred
issuance costs of $0.2&nbsp;million in connection with these transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series B Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, the Board authorized the sale and issuance of Series B Preferred Stock. In November 2021, the Company issued
17,521,047 shares of Series B Preferred Stock, with a par value of $0.001 and a purchase price of $5.70742 per share, and an additional 46,058 shares of Series B Preferred Stock to settle the Company&#146;s Anti-dilution Right in connection with the
Lilly Agreement. The Company incurred issuance costs of $0.2&nbsp;million in connection with this transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the
issuance of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Series B Preferred Stock (collectively, &#147;Preferred Stock&#148;), the Company assessed the embedded conversion and liquidation features of the shares and
determined that such features did not require the Company to separately account for these features. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preferred Stock
consisted of the following as of June&nbsp;30, 2022 and December&nbsp;31, 2021 (in thousands, except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Stock<BR>Issued&nbsp;and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="20"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,567,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of Preferred Stock have the following rights, preferences and privileges: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holder of
each share of Preferred Stock is entitled to one vote for each share of common stock into which it would convert and to vote with the common stock on all matters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of
Preferred Stock is convertible, at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock as is determined by dividing the original issue price by the conversion price for each series of Preferred Stock (as defined below). The conversion price, and the rate at
which each series of preferred stock may be converted into common stock, are subject to adjustment from time to time to reflect future share dividends, splits, combinations, recapitalizations and similar events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, each share of Preferred Stock shall automatically be converted into
shares of common stock at the conversion rate at the time in effect for such series of Preferred Stock immediately upon either of: (i)&nbsp;the closing of the Company&#146;s sale of common stock to the public at a price per share of at least
$11.4148 per share in an IPO (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the applicable class of common stock), resulting in at least
$50.0&nbsp;million of proceeds, net of the underwriting discount and commissions; or (ii)&nbsp;the date and time, or occurrence of an event, specified by vote or written consent of the requisite holders of at a majority of the combined voting power
of the shares of Preferred Stock then outstanding as calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of
the Preferred Stock are entitled to receive dividends at the rate of 6% of the applicable original issue price per annum, as potentially adjusted for certain <FONT STYLE="white-space:nowrap">non-dilutive</FONT> transactions. Dividends shall not be
cumulative or compounded and shall be payable only when, as and if declared by the Board and in preference and in priority to any dividends on common stock. There have been no dividends declared by the Board as of June&nbsp;30, 2022 and
December&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Preference </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of any liquidation, dissolution, or winding up of the Company (&#147;Liquidation Event&#148;), the holders of
Preferred Stock (first to the holders of Series B Preferred Stock, then to the holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock) are entitled to receive prior and in preference to the holders of common stock, an amount
equal to an amount per share equal to the greater of the original issue price, as potentially adjusted for certain <FONT STYLE="white-space:nowrap">non-dilutive</FONT> transactions, plus all declared and unpaid dividends on the Preferred Stock or
the price per share that would be received if the Preferred Stock were converted to common stock. If the assets and funds available to be distributed to all holders of Preferred Stock are insufficient to permit the payment, in full, of any of the
liquidation preferences, then the entire assets and funds legally available for distribution to holders of the Preferred Stock shall be distributed ratably among the holders of Preferred Stock, acting as a single class, at the time outstanding,
ratably in proportion to the full amounts to which they would otherwise be respectively entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the payment of
the full liquidation preference of the Preferred Stock as set forth above, the remaining assets of the Company legally available for distribution in such Liquidation Event shall be distributed ratably to the holders of shares of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Preferred
Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Liquidation Event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and December&nbsp;31, 2021, the Company&#146;s Amended and Restated Certificate of Incorporation
authorized the Company to issue 40,013,683 shares of common stock, respectively, with a par value of $0.001. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The voting,
dividend and liquidation rights of the holders of the Company&#146;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock as set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders
(and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the
Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Certificate of Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2022 and December&nbsp;31, 2021, the Company has
reserved the following shares of common stock for the potential conversion of outstanding preferred stock and exercise of stock options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,111,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining shares reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,474,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,412,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,058,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,058,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company adopted the 2019 Stock Incentive Plan (the &#147;2019 Plan&#148;) in June 2019 pursuant to which the Company can
issue incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. Recipients of stock options or stock appreciation
rights shall be eligible to purchase shares of the Company&#146;s common stock at an exercise price equal to the estimated fair market value of such stock on the date of grant. The exercise price may be less than fair market value if the stock award
is granted pursuant to an assumption or substitution for another stock award in the event of a merger or sale of the Company. The maximum term of options granted under the 2019 Plan is ten years, and stock options typically vest over a four-year
period. The Board may assign vesting terms to the stock option grants as deemed appropriate. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. At the discretion
of the Board, unvested shares held by employees may accelerate vesting in the event of a change of control of the Company unless assumed or substituted by the acquirer or surviving entity. The original Plan provided for the issuance of up to
1,042,500 shares of common stock, which was subsequently amended in November 2021 to allow for the issuance of up to 7,587,942 shares of common stock as of June&nbsp;30, 2022, of which 2,474,989 shares of common stock remain available for future
grant under the 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of unused common stock that cover awards that are expired, terminated, surrendered or
canceled under the 2019 Plan without having been fully exercised will be available for future awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has granted stock options with service-based vesting conditions. Stock options typically vest over four years and
have a maximum term of ten years. The Company typically grants stock options to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> at exercise prices deemed by the Board to be equal to the fair value of the common stock at the time
of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Company&#146;s stock option activity under the 2019 Plan: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining<BR>Contractual Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value<BR>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,952,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,111,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,111,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and exercisable as of June&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate intrinsic value of options is calculated as the difference
between the exercise price of the stock options and the fair value of the Company&#146;s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The weighted-average grant date fair value of the Company&#146;s stock options granted during the six months ended
June&nbsp;30, 2022 was $1.03 per option. As of June&nbsp;30, 2022, there was $3.1&nbsp;million of unrecognized stock-based compensation expense related to the share-based compensation arrangements under the 2019 Plan. The Company expects to
recognize this amount over a weighted-average period of 3.3 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total fair value of options vested during the six
months ended June&nbsp;30, 2022 and 2021, was $0.2&nbsp;million and $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense included in the Company&#146;s condensed consolidated statements of operations and
comprehensive loss is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Net Loss per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share
and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,363,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,237,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s potentially dilutive securities, which include Preferred Stock and stock
options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net
loss per share attributable to common stockholders is the same. The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of June&nbsp;30, 2022 and 2021 because including them
would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,471,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,904,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,111,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,740,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company&#146;s commitments under its operating leases are described in Note 6. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company entered into a license agreement under which it is obligated to make fixed and contingent payments (see Note 7).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Companion Diagnostic Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2022, the Company entered into a companion diagnostic agreement (the &#147;Akoya Agreement&#148;) with Akoya
Biosciences, Inc. (&#147;Akoya&#148;), pursuant to which the Company has engaged Akoya to co-develop, validate, and commercialize the Company&#146;s proprietary ACR-368 OncoSignature test, the companion diagnostic that will be used to identify
patients with cancer most likely to respond to ACR-368. Subject to the terms of the Akoya Agreement, the Company paid Akoya a one-time, non-refundable, non-creditable upfront payment in the amount of $0.6&nbsp;million. The Company is obligated to
pay Akoya up to low double-digit million dollars upon the achievement of specified development milestones. Through the issuance date of the unaudited condensed consolidated financial statements, milestones under the Akoya Agreement were achieved and
the Company has made aggregate payments of $2.0&nbsp;million to Akoya. Of the $2.0&nbsp;million aggregate milestone payments, $1.6&nbsp;million, which was recorded as research and development expense, was paid through June&nbsp;30, 2022 and the
remaining $0.4&nbsp;million was paid in the third quarter of 2022 when an additional milestone was achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors,
lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the
Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as
directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such
indemnifications. The Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its financial statements as of June&nbsp;30, 2022 and December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well
as information gathering requests, inquiries and investigations. As of June&nbsp;30, 2022 and 2021, there were no matters which would have a material impact on the Company&#146;s financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Contracts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company enters into contracts in the normal course of business with various third parties for preclinical research studies,
clinical trials, testing, manufacturing and other services. These contracts generally provide for termination upon notice and are cancelable without significant penalty or payment, and do not contain any minimum purchase commitments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Employee Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective January&nbsp;1, 2019, the Company adopted a 401(k) Plan for its employees, which is designed to be qualified under
Section&nbsp;401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the 401(k) Plan within statutory and 401(k) Plan limits. Since inception of the 401(k) Plan and through the six months ended June&nbsp;30, 2022, the Company has not made any contributions to the
401(k) Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For its condensed consolidated financial statements as of the six months ended June&nbsp;30, 2022 and for the period then
ended, the Company evaluated subsequent events through August&nbsp;12, 2022, the date on which those financial statements were issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option
Grants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2022, the Company granted options for the purchase of an aggregate 410,000 shares of common
stock, at an exercise price of $1.65 per share. The aggregate grant-date fair value of the options granted is $0.4&nbsp;million, which is expected to be recognized as stock-based compensation expense over a weighted-average period of 4.0 years. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </I></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g383050g44x13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Common Stock </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>PROSPECTUS </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><I>MORGAN&nbsp;STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>JEFFERIES</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>COWEN</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><I>PIPER&nbsp;SANDLER</I></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other&nbsp;Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table indicates the expenses to be incurred in connection with the offering described in this registration
statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or
FINRA, filing fee and the Nasdaq Global Market initial listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To be provided by amendment </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are incorporated under the laws of the State of Delaware. Section&nbsp;102 of the Delaware General Corporation Law permits a
corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to
act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director,
officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlements actually and
reasonably incurred by the person in connection with an action, suit or proceeding to which he is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or
not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no
indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines
that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As permitted by the Delaware General Corporation Law, our amended and restated certificate of incorporation and bylaws to be
in effect upon the closing of this offering will provide that: (i)&nbsp;we are required to indemnify our directors to the fullest extent permitted by the Delaware General Corporation Law; (ii)&nbsp;we may, in our discretion, indemnify our officers,
employees and other agents as set forth in the Delaware General Corporation Law; (iii)&nbsp;we are required, upon satisfaction of certain conditions, to advance all expenses incurred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
by our directors in connection with certain legal proceedings; (iv)&nbsp;the rights conferred in the bylaws are not exclusive; and (v)&nbsp;we are authorized to enter into indemnification
agreements with our directors, officers, employees and agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we expect to enter into
indemnification agreements with each of our directors and executive officers that require us to indemnify them against expenses, judgments, fines, settlements and other amounts that any such person becomes legally obligated to pay (including with
respect to a derivative action) in connection with any proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that such person is or was a director or officer of us or any of our affiliates, provided
such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, our best interests. The indemnification agreements will also set forth certain procedures that will apply in the event of a claim for
indemnification thereunder. At present, no litigation or proceeding is pending that involves any of our directors or officers regarding which indemnification is sought, nor are we aware of any threatened litigation that may result in claims for
indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain a directors&#146; and officers&#146; liability insurance policy. The policy insures
directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and officers. The policy
contains various exclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the underwriting agreement filed as Exhibit 1.1 to this Registration Statement
provides for indemnification by the underwriters of us and our officers and directors for certain liabilities arising under the Securities Act, or otherwise. Our amended and restated investors&#146; rights agreement with certain investors also
provides for cross-indemnification in connection with the registration of our common stock on behalf of such investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of
Unregistered Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following list sets forth information regarding all unregistered securities sold by us
since our inception through the date of the prospectus that forms a part of this registration statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, we issued 2,150,000 shares of our common stock to one accredited investor as consideration for a license to
certain patent rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April 2018, we issued an aggregate of 825,000 shares of our common stock to one accredited
investor and one unaccredited investor at a purchase price of $0.001 per share, for aggregate consideration of $825.00. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2018, we issued 457,500 shares of our common stock to one sophisticated unaccredited investor at a purchase price of
$0.001 per share, for aggregate consideration of $457.50. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2018, we issued 686,250 shares of our common stock to
one sophisticated unaccredited investor at a purchase price of $0.001 per share, for aggregate consideration of $686.25, of which 586,250 shares were repurchased in April 2019 in connection with the termination of such investor&#146;s consulting
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, we issued 829,995 shares of our common stock to one accredited investor as partial
consideration for a license to certain patent rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2021, we issued 1,250 shares of our common stock to
one employee upon exercise of an option granted under our stock incentive plan at an exercise price of $0.42 per share, for aggregate consideration of $525.00. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2020, we issued (a) 1,315,789 shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible
preferred stock to one investor at a purchase price of $2.28 per share, for aggregate consideration of $3.0&nbsp;million, (b) 1,918,745 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock to one investor upon
conversion of outstanding convertible notes in aggregate principal amount of $2,750,000 at a conversion price of $1.57 per share, and (c) 1,187,816 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock to one
investor upon conversion of outstanding convertible notes in aggregate principal amount of $2,000,000 at a conversion price of $1.82 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, we issued an aggregate of 5,482,456 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT>
convertible preferred stock to two investors at a purchase price of $2.28 per share, for aggregate consideration of $12.5&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In November 2021, we issued (a)&nbsp;an aggregate of 17,521,047 shares of our Series B convertible preferred stock to 13
investors at a purchase price of $5.70742 per share, for aggregate consideration of $100.0&nbsp;million, and (b) 46,058 shares of our Series B convertible preferred stock to one accredited investor in satisfaction of a contractual obligation
contained in a license to certain patent rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances Pursuant to our Equity Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From March&nbsp;13, 2018 (the date of our inception) through the date of this registration statement, we granted options under
our 2019 Stock Incentive Plan to purchase an aggregate of 5,597,703 shares of common stock, at a weighted-average exercise price of $1.18 per share, to our employees, directors and consultants. Of these, 1,250 shares have been issued upon the
exercise of options for aggregate consideration of $525.00 and options for the purchase of 236,000 shares of common stock have been forfeited, expired or canceled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering.
Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section&nbsp;4(a)(2) of the Securities Act (and Regulation D or Regulation S promulgated thereunder) or Rule 701
promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in
each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates
issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16.</B><B><I> </I></B><B>Exhibits and Financial Statement Schedules</B><B><I>.</I></B><B>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Exhibits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exhibits listed below are filed as part of this registration. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amended and Restated Certificate of Incorporation of the Registrant (as amended and currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws of the Registrant (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investors&#146; Rights Agreement, by and among the Registrant and certain of its stockholders, dated November&nbsp;9, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Cooley LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2019 Stock Incentive Plan and Forms of Stock Option Agreement and Notice of Exercise</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2022 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Notice of Exercise, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement with Executive Officers and Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement, by and between the Registrant and Eli Lilly and Company, dated January&nbsp;27, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">OncoSignature Companion Diagnostic Agreement, by and between the Registrant and Akoya Biosciences, Inc., dated June&nbsp;17, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, by and between the Registrant and Peter Blume-Jensen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, by and between the Registrant and Erick Gamelin, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, by and between the Registrant and Eric Devroe, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">List of Subsidiaries</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Cooley LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Filing Fee Table</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> Item 601(b)(10)(iv). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To be filed by amendment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Financial Statement Schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is
shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Filing Fee Table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The information required to be furnished by paragraph (c)&nbsp;of this Item is incorporated herein by reference to Exhibit
107. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings</B><B><I>.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned Registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this Registration Statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized in the City of Watertown, Commonwealth of Massachusetts, on this &nbsp;&nbsp;&nbsp;&nbsp;day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>ACRIVON THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Peter Blume-Jensen, M.D., Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Executive Officer and President</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Peter Blume-Jensen
and Rasmus Holm-Jorgensen, and each of them, as his or her true and lawful agents, proxies and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> with full power of substitution and resubstitution, for
him or her and in his or her name, place and stead, in any and all capacities, to (i)&nbsp;act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration statement
together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii)&nbsp;act on, sign and file
such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii)&nbsp;act on and file any supplement to any prospectus included in this registration statement or any such amendment or
any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and (iv)&nbsp;take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he
might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> or any of his substitutes may lawfully do or
cause to be done by virtue thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, this registration
statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Blume-Jensen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Executive Officer, President and Chairman of the Board <I>(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rasmus Holm-Jorgensen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Financial Officer<I> (Principal Financial and Accounting Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek DiRocco, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristina Masson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Executive Vice President, Business Operations, Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sharon Shacham, Ph.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">, 2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i)&nbsp;is not material and (ii)&nbsp;is
the type that the registrant treats as private or confidential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Copy </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
<B>L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this &#147;<B>Agreement</B>&#148;), effective as of January&nbsp;27, 2021 (the &#147;<B>Effective Date</B>&#148;), is entered into by and between <B>A<SMALL>CRIVON</SMALL>
T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation with a place of business at Lab Central, 700 North Main St, Cambridge, MA 02139 (&#147;<B>Acrivon</B>&#148;), and <B>E<SMALL>LI</SMALL> L<SMALL>ILLY</SMALL>
<SMALL>AND</SMALL> C<SMALL>OMPANY</SMALL></B><SMALL></SMALL>, an Indiana corporation with a place of business at Lilly Corporate Center, Indianapolis, Indiana, 46285 (&#147;<B>Lilly</B>&#148;). Acrivon and Lilly may be referred to herein
individually as a &#147;<B>Party</B>&#148; or collectively as the &#147;<B>Parties</B>&#148;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recitals: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Lilly has developed and controls certain technology, patent rights and proprietary materials related to a certain compound that is known
internally by Lilly as [***] or prexasertib. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Lilly wishes to grant to Acrivon, and Acrivon wishes to receive, an exclusive license in
the Field for the Territory to such technology, patent rights and proprietary materials under the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Agreement: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, in consideration of the mutual agreements and covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties, intending to be legally bound hereby,
agree to the foregoing and as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. DEFINITIONS </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective
meanings set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.1 &#147;<B>Acrivon</B>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2 &#147;<B>Acrivon Indemnitee(s)</B>&#148; has the meaning set forth in Section&nbsp;7.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.3 &#147;<B>Acrivon <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any and all <FONT STYLE="white-space:nowrap">Know-How</FONT> (other than
Licensed <FONT STYLE="white-space:nowrap">Know-How)</FONT> that (a)&nbsp;is Controlled by Acrivon or any of its Affiliates as of the Effective Date, comes under the Control of Acrivon or any of its Affiliate thereafter and (b)&nbsp;reasonably
necessary or useful for, or was actually used or generated by or on behalf of Acrivon or any of its Affiliates in, the Manufacture, Development, Commercialization, or use of any Licensed Compound or Licensed Product, in each case, (i)&nbsp;including
<FONT STYLE="white-space:nowrap">Know-How</FONT> that is necessary or reasonably useful for all usage of the Product Tailored OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay and (ii)&nbsp;excluding any <FONT
STYLE="white-space:nowrap">Know-How</FONT> that constitutes trade secrets of Acrivon or other <FONT STYLE="white-space:nowrap">Know-How</FONT> that is, in either case, of general applicability to the AP3 Method or the OncoSignature<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay, and is not specific to the Licensed Product or necessary to practice the Product Tailored OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.4 &#147;<B>Acrivon Licensed Foreground IP</B>&#148; means Foreground Intellectual Property Rights that (i)&nbsp;(a) are generated prior to the expiration of
the ROFN Term or (b)&nbsp;constitute Patents coming under the ownership or Control of Acrivon or an Affiliate thereof and Covering Foreground Intellectual Property Rights referred to under clause (a), (ii) do not constitute Acrivon <FONT
STYLE="white-space:nowrap">Know-How</FONT> generated by the AP 3 Method, OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay, or Product Tailored OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay, and
(iii)&nbsp;do not directly relate to the AP 3 Method, the OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay, or Product Tailored OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.5 &#147;<B>Acrivon Patents</B>&#148; means any and all Patents (other than Licensed Patents) Controlled by
Acrivon or any Affiliate thereof as of the Effective Date, coming under the Control of Acrivon or any Affiliate thereof during the term of this Agreement that, in each case, Covers any Licensed Compound or Licensed Product, in each case,
(i)&nbsp;including the Patents that Cover the Product Tailored OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay and (ii)&nbsp;excluding any Patents that Cover the AP3 Method or OncoSignature<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay, and are not specific to the Licensed Product or necessary to practice the Product Tailored OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.6 &#147;<B>Act</B>&#148; means, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq., and/or the Public
Health Service Act, 42 U.S.C. &#167;&#167; 262 et seq., as such may be amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.7 &#147;<B>Affiliate</B>&#148; means, with respect to
any Party, any person or entity controlling, controlled by or under common control with such Party. For purposes of this Section&nbsp;1.7, &#147;control&#148; means (a)&nbsp;in the case of a corporate entity, direct or indirect ownership of fifty
percent (50%) or more of the stock or shares having the right to vote for the election of directors of such corporate entity and (b)&nbsp;in the case of an entity that is not a corporate entity, the possession, directly or indirectly, of the power
to direct, or cause the direction of, the management or policies of such entity, whether through the ownership of voting securities, by contract or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.8 &#147;<B>Annual Net Sales</B>&#148; means the total Net Sales of all Licensed Products in any Calendar Year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.9 &#147;<B>AP3 Method</B>&#148; means the Acrivon Predictive Precision Proteomics Method to identify, develop, and validate OncoSignature<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> Assays. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.10 &#147;<B>Applicable Laws</B>&#148; means all statutes, ordinances, regulations, rules or
orders of any kind whatsoever of any Governmental Authority that may be in effect from time to time and applicable to the activities contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.11 &#147;<B>Business Day</B>&#148; means any day other than a Saturday or a Sunday on which the banks in New York, New York are open for business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.12 &#147;<B>Calendar Quarter</B>&#148; means the respective periods of three (3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30,
September&nbsp;30 and December 31. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.13 &#147;<B>Calendar Year</B>&#148; means the respective periods of twelve (12)&nbsp;months commencing on
January&nbsp;1 and ending on December 31. The first Calendar Year under this Agreement shall commence as of the Effective Date and end on December&nbsp;31 of the same year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.14 &#147;<B>Challenge</B>&#148; means with respect to any Licensed Patent, to challenge the validity, patentability or enforceability of such Patent in whole
or in part, or otherwise oppose any such Patent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.15 &#147;<B>Change of Control</B>&#148; FP HI, with respect to either Party: (a)&nbsp;the acquisition by a
Third Party, in one transaction or a series of related transactions, of direct or indirect beneficial ownership of more than fifty percent (50%) of the outstanding voting equity securities of such Party (excluding, for clarity, an acquisition by a
Third Party where the equity holders of such acquired Party immediately prior to such transaction hold a majority of the voting shares of outstanding capital stock of the surviving entity immediately following such transaction); (b) a merger or
consolidation involving such Party, as a result of which a Third Party acquires direct or indirect beneficial ownership of more than fifty percent (50%) of the voting power of the surviving entity immediately after such merger, reorganization or
consolidation; or (c)&nbsp;a sale of all or substantially all of the assets of such Party in one transaction or a series of related transactions to a Third Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.16 &#147;<B>Claim</B>&#148; has the meaning set forth in Section&nbsp;7.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.17 &#147;<B>Combination Product</B>&#148; means a Licensed Product containing one or more Licensed Compounds and one or more additional active pharmaceutical
ingredients that are not licensed hereunder (a separately saleable product incorporating such an additional ingredient, an &#147;<B>Other Product</B>&#148;), whether <FONT STYLE="white-space:nowrap">co-formulated</FONT> or <FONT
STYLE="white-space:nowrap">co-packaged.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.18 &#147;<B>Commercialization</B>&#148; or &#147;<B>Commercialize</B>&#148; means activities taken before
and after obtaining Regulatory Approval relating specifically to the <FONT STYLE="white-space:nowrap">pre-launch,</FONT> launch, promotion, marketing, sales force recruitment, pricing determination, Manufacture, importation, offering for sale, sale
and distribution for commercial sale, of a pharmaceutical product and post-launch medical activities, including without limitation: (a)&nbsp;Manufacture, importation and distribution for commercial sale; (b)&nbsp;strategic marketing, sales force
detailing, advertising, and market and product support; (c)&nbsp;medical education and liaison and any Phase IV clinical trials; (d)&nbsp;all customer support and product distribution, invoicing and sales activities; (e)&nbsp;all post-approval
regulatory activities, including those necessary to maintain Regulatory Approvals; (f)&nbsp;expanded target product profile activities after receipt of initial Regulatory Approval for the relevant product; and (g)&nbsp;pricing, formulary and
reimbursement related activities, including pricing and reimbursement approvals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.19 &#147;<B>Commercially Reasonable Efforts</B>&#148; means, with
respect to Acrivon, those efforts and resources commensurate with those efforts [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.20 &#147;<B>Compound</B>&#148; either of the [***] identified by
Lilly internally as [***] with the chemical names and structures set forth on <B>Exhibit A</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.21 &#147;<B>Confidential Information</B>&#148; means all
information disclosed or made available by a Party (the &#147;<B>Disclosing Party</B>&#148;) or its Representatives to the other Party (the &#147;<B>Receiving Party</B>&#148;) or its Representatives pursuant to, or in connection with, this Agreement
or pursuant to the Confidentiality Agreement, whether, in each case, in written, oral, graphic, electronic or other form. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.22 &#147;<B>Confidentiality
Agreement</B>&#148; means the Confidentiality Agreement between the Parties dated October&nbsp;21, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.23 &#147;<B>Control</B>&#148;, &#147;<B>Controls</B>&#148; or &#147;<B>Controlled by</B>&#148; means
(except as used in Section&nbsp;1.7, above), with respect to any item of or right under Patents or <FONT STYLE="white-space:nowrap">Know-How,</FONT> the ability of the specified Party or any of its Affiliates, whether through ownership, license or
other right (other than pursuant to this Agreement), to grant access to, license or sublicense such item or right without violating the terms of any agreement or other arrangement with any Third Party or incurring any payment obligation to any Third
Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.24 &#147;<B>Cover</B>&#148; means, with respect to a Licensed Compound or Licensed Product in a particular country, that the research,
Development, Manufacture, use, sale, importation, or other Commercialization of such Licensed Compound or Licensed Product, as applicable, in such country would, but for any licenses granted under any Patent, infringe such Patent (considering claims
of patent applications to be issued as then pending). &#147;<B>Covering</B>&#148; has a corresponding meaning. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.25 &#147;<B>Data Exclusivity
Period</B>&#148; means, with respect to any Licensed Product in the Territory, the period during which any additional market protection, other than patent protection, granted by a Regulatory Authority within the Territory confers an exclusive
Commercialization period during which Acrivon, its Affiliates and Sublicensees have the exclusive right to market and sell such Licensed Product in the Field and in a country of the Territory through a regulatory exclusivity right (including new
chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug exclusivity, pediatric exclusivity, or any applicable data exclusivity right). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.26 &#147;<B>Develop</B>&#148; or &#147;<B>Development</B>&#148; or &#147;<B>Developing</B>&#148; means research, discovery, process development, preclinical
or clinical manufacturing and importation for preclinical and clinical uses, and preclinical and clinical drug or biological development activities, including, without limitation, test method development and stability testing, toxicology,
formulation, quality assurance/quality control development, statistical analysis, preclinical and clinical studies and regulatory affairs, in each case, of a Licensed Compound use in the Field, and to the extent normally undertaken during the
development (as opposed to Commercialization) phase of such Licensed Compound&#146;s life cycle. Development shall exclude all Phase IV clinical trials. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.27 &#147;<B>EMA</B>&#148; means the European Medicines Agency or any successor agency thereto in the EU having substantially the same function. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.28 &#147;<B>EU</B>&#148; means the European Union. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.29
&#147;<B>Existing 3 INDs</B>&#148; means IND Nos. [***] and [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.30 &#147;<B>FDA</B>&#148; means the United States Food and Drug Administration or any
successor agency thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.31 &#147;<B>Field</B>&#148; means any and all human uses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.32 &#147;<B>First Commercial Sale</B>&#148; means, with respect to any Licensed Product, the first sale to a Third Party for end use or consumption of such
Licensed Product in a country after Regulatory Approval (including pricing and reimbursement approval in jurisdictions where such approval is required for sale or marketing of a Licensed Product) has been granted by the Regulatory Authority of such
country, if such Regulatory Approval is required, or, if Regulatory Approval is not required, upon the first such sale; provided that the following shall not constitute a First </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Commercial Sale: (a)&nbsp;any sale, transfer or disposition of a Licensed Product at no more than a de minimis charge for academic research, preclinical, clinical, or regulatory purposes; or
(b)&nbsp;any sale, transfer or disposition of a Licensed Product for use in clinical trials, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or other research or Development activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.33 &#147;<B>First Indication</B>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) with respect to the conduct of a Phase III Clinical Trial, the Indication specified as being the subject of such trial in the protocol
pursuant to which such trial is being conducted; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) with respect to the initial NDA filed, or Regulatory Approval obtained, with
respect to a Licensed Product in a country or jurisdiction, the specified Indication(s) for which marketing, sale, or use of such Licensed Product were sought or obtained thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.34 &#147;<B>GAAP</B>&#148; means US Generally Accepted Accounting Principles as the same may be in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.35 &#147;<B>GCP</B>&#148; means all applicable current Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing,
recording, analyses and reporting of clinical trials, including, as applicable, (a)&nbsp;as set forth in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#147;ICH&#148;) E6
and any other guidelines for good clinical practice for trials on medicinal products in the Territory, (b)&nbsp;the Declaration of Helsinki (2004)&nbsp;as last amended at the 52nd World Medical Association in October 2000 and any further amendments
or clarifications thereto, (c)&nbsp;U.S. Code of Federal Regulations Title 21, Parts 50, 54, 56, 312 and 314, as may be amended from time to time, and (d)&nbsp;the equivalent Applicable Laws in any relevant country, each as may be amended and
applicable from time to time and in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.36 &#147;<B>Generic Product</B>&#148; means, with respect to a particular country in the Territory, any pharmaceutical product that (a)&nbsp;is sold or
marketed for sale by a Third Party not authorized by Acrivon, any Affiliate thereof, or any Sublicensee, (b)&nbsp;receives Regulatory Approval (with or without pricing or reimbursement approval) in such country in full or partial reliance on the
Regulatory Approval (but not necessarily pricing or reimbursement approval) held by Acrivon, any Affiliate thereof, or any Sublicensee for a Licensed Product, (c)&nbsp;is determined by a Regulatory Authority in such country to be therapeutically
equivalent to a Licensed Product, and (d)&nbsp;may be freely and legally substituted by pharmacies in such country for the Licensed Product sold by Acrivon, any Affiliate thereof, or any Sublicensee in such country when filling a prescription
written therefor without having to seek authorization to do so from the physician or other health care provider writing such prescription. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.37
&#147;<B>GLP</B>&#148; means the then-current standards for laboratory activities for pharmaceuticals, as set forth in the FDA&#146;s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58, the Council Directive 87/18/EEC, as amended,
the principles for Good Laboratory Practice and/or the Good Laboratory Practice principles of the Organization for Economic <FONT STYLE="white-space:nowrap">Co-Operation</FONT> and Development (&#147;<B>OECD</B>&#148;), and such standards of good
laboratory practice as are required by the European Union and other organizations and governmental agencies in countries in which a Licensed Product is intended to be sold, to the extent such standards are not less stringent than United States Good
Laboratory Practice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.38 &#147;<B>GMP</B>&#148; means all applicable current Good Manufacturing Practices including, as
applicable, (a)&nbsp;the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, 601, 610 and 820, (b) European Directive 2003/94/EC and Eudralex 4, (c) the principles detailed in the WHO TRS 986 Annex 2,
TRS 961 Annex 6, TRS 957 Annex 2 and TRS 999 Annex 2,(d) ICH Q7 guidelines, and (e)&nbsp;the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.39 &#147;<B>Government or Public Official</B>&#148; means: (i)&nbsp;any officer or employee of: (a)&nbsp;a government, or any department or agency thereof;
(b)&nbsp;a government-owned or controlled company, institution, or other entity, including a government-owned hospital or university; or (c)&nbsp;a public international organization (such as the United Nations, the International Monetary Fund, the
International Committee of the Red Cross, and the World Health Organization), or any department or agency thereof; (ii)&nbsp;any political party or party official or candidate for public or political party office; and (iii)&nbsp;any person acting in
an official capacity on behalf of any of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.40 &#147;<B>Governmental Authority</B>&#148; means any agency, bureau, branch, office, court,
commission, authority, department, ministry, official or other instrumentality of, or being vested with public authority under any law of, any country, state or local authority or any political subdivision thereof, or any association of countries.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.41 &#147;<B>IND</B>&#148; means a submission for approval in the Territory to conduct human clinical investigations filed with or submitted to a
Regulatory Authority for a country in the Territory in conformance with the requirements of such Regulatory Authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.42 &#147;<B>Indication</B>&#148;
means a discrete, clinically recognized form of a disease or health condition in the Field, provided that, following the initial Regulatory Approval of a Licensed Product in a particular country, an Indication shall only be considered a distinct,
additional Indication from the Indication(s) for which such Licensed Product received its initial Regulatory Approval in such country if such additional Indication requires conduct of an additional Phase III Clinical Trial to obtain Regulatory
Approval of such Licensed Product for such Indication in such country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.43 &#147;<B>Internal Compliance Codes</B>&#148; means a Party&#146;s internal
policies and procedures intended to ensure that a Party complies with Applicable Laws, Party Specific Regulations, and such Party&#146;s internal ethical, medical and similar standards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.44 &#147;<B>Investigator-Sponsored Trials</B>&#148; means the clinical trials described on <B>Exhibit B</B> under the heading Investigator-Sponsored Trials.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.45 &#147;<B>IPO</B>&#148; means the first underwritten public offering of equity securities of Acrivon (or any successor thereto formed for the purpose
of pursuing an initial public offering) pursuant to an effective registration statement filed with the United States Securities and Exchange Commission (or any successor form or foreign equivalent thereof), including a transaction with a special
purpose acquisition company, plan of arrangement, amalgamation, direct listing, reverse take-over or other business combination pursuant to which the securities of Acrivon, or any resulting issuer or parent entity thereof, are listed on a stock
exchange; provided that an IPO shall not include any registration of the issuance of securities to existing securityholders or employees of Acrivon on Form <FONT STYLE="white-space:nowrap">S-4</FONT> or Form
<FONT STYLE="white-space:nowrap">S-8</FONT> (or any successor forms). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.46 &#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means any proprietary and
confidential scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including any of the foregoing that are databases, safety information, practices, methods, techniques,
specifications, formulations, formulae, knowledge, <FONT STYLE="white-space:nowrap">know-how,</FONT> skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test
data, analytical and quality control data, stability data, studies and procedures, manufacturing process and development information, results or data. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.47 &#147;<B>Licensed Compound(s)</B>&#148; means either Compound and any salt, free acid form, free base form, hydrate, solvate, polymorph, amorphous form,
or <FONT STYLE="white-space:nowrap">co-crystal</FONT> of either Compound. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.48 &#147;<B>Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all <FONT STYLE="white-space:nowrap">Know-How</FONT> (excluding any <FONT STYLE="white-space:nowrap">Know-How</FONT> covered by a claim of any published Licensed Patent) that
(a)&nbsp;is Controlled as of the Effective Date by Lilly or any of its Affiliates and is explicitly described on <B>Exhibit C</B>, or comes under the Control of Lilly or any Affiliate thereof following the Effective Date and constitutes data
generated through the conduct of the Lilly Trials, and (b)&nbsp;is reasonably necessary for the Manufacture, Development, or Commercialization of any Licensed Compound or Licensed Product, provided that, notwithstanding anything to the contrary,
Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> shall not include any <FONT STYLE="white-space:nowrap">Know-How</FONT> concerning any active pharmaceutical ingredient or compound other than a Licensed Compound. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.49 &#147;<B>Licensed Patents</B>&#148; means (a)&nbsp;the Listed Patents and (b)&nbsp;any Patents Controlled by Lilly or any Affiliate thereof during the
Term that claim priority to the Listed Patents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.50 &#147;<B>Licensed Product</B>&#148; means any pharmaceutical composition or preparation containing or
comprising any Licensed Compound (whether or not as the sole active ingredient), including all formulations and dosage forms thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.51
&#147;<B>Licensed Technology</B>&#148; means Licensed Patents and Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.52 &#147;<B>Lilly</B>&#148;
has the meaning set forth in the Preamble. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.53 &#147;<B>Lilly CMO Agreements</B>&#148; means those agreements between Lilly and various Third Parties
described on Exhibit D. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.54 &#147;<B>Lilly Trials</B>&#148; means the clinical trials described on <B>Exhibit E</B> under the heading Lilly Trials. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.55 &#147;<B>Listed Patents</B>&#148; means the Patents listed in <B>Exhibit F</B> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.56 &#147;<B>Manufacture</B>&#148; and &#147;<B>Manufacturing</B>&#148; mean all activities related to the production, manufacture, processing, filling,
finishing, packaging, labeling, shipping and holding of Licensed Compound or Licensed Product, or any intermediate of either of the foregoing, including process development, process qualification and validation,
<FONT STYLE="white-space:nowrap">scale-up,</FONT> <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.57 &#147;<B>NDA</B>&#148; means the application or submission for approval to market and sell a human
pharmaceutical product filed with the governing Regulatory Authority for a country in the Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.58 &#147;<B>Net Sales</B>&#148; means, [***]: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) [***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) [***]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) [***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) [***]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) [***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) [***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.59 &#147;<B>OncoSignature</B><B><SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP></B><B> Assay</B>&#148; means the proprietary predictive protein
multiplex assay developed and owned by Acrivon (and which incorporates or requires the use of <FONT STYLE="white-space:nowrap">Know-How</FONT> owned or controlled by Acrivon and is Covered by Patents owned or controlled by Acrivon) to identify and
select patients likely to respond to a pharmaceutical product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.60 &#147;<B>Party Specific Regulations</B>&#148; shall mean all judgments, decrees,
orders or similar decisions issued by any Governmental Authority specific to a Party or any Affiliate thereof, and all consent decrees, corporate integrity agreements, or other agreements or undertakings of any kind by a Party or any Affiliate
thereof with any Governmental Authority, in each case as the same may be in effect from time to time and applicable to a Party&#146;s or its Affiliates&#146; activities contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.61 &#147;<B>Patent(s)</B>&#148; means all patents and patent applications in any country or supranational jurisdiction, including any provisionals,
substitutions, divisions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, renewals, registrations, confirmations, reexaminations, extensions, any other <FONT
STYLE="white-space:nowrap">pre-</FONT> or post-grant forms of any of the foregoing, any confirmation patents or registration patents or patents of addition, utility models, patent term extensions or restorations, and supplementary protection
certificates or requests for continued examinations and the like, including any and all foreign counterparts of any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.62 &#147;<B>Patent Prosecution</B>&#148; or &#147;<B>Prosecution</B>&#148; means, with respect to a
Patent, (a)&nbsp;preparing, filing and prosecuting applications (of all types) for such Patent, (b)&nbsp;paying filing, issuance and maintenance fees relating to such Patent, (c)&nbsp;managing and conducting any interference, opposition,
invalidation, <FONT STYLE="white-space:nowrap">re-issue,</FONT> reexamination, revocation, nullification, post-grant review, inter partes review, derivation proceeding, cancellation proceeding or other similar administrative proceeding or
administrative appeal thereof with respect to such Patent, and (d)&nbsp;settling any interference, opposition, revocation, nullification or cancellation proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.63 &#147;<B>Person</B>&#148; means any individual, corporation, association, partnership (general or limited), joint venture, trust, estate, limited
liability company, limited liability partnership, unincorporated organization, government (or any agency or political subdivision thereof) or other legal entity or organization, other than Lilly or Acrivon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.64 &#147;<B>Personal Information</B>&#148; means, in addition to any definition for any similar term (e.g., &#147;personal data&#148; or &#147;personally
identifiable information&#148; or &#147; PII&#148; ) provided by Applicable Laws, or by either Party in any of its own privacy policies, notices or contracts, all information that identifies, could be used to identify or is otherwise associated with
an individual person, whether or not such information is associated with an identified individual person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.65 &#147;<B>Phase IIB Clinical Trial</B>&#148;
means (i)&nbsp;a human clinical trial of a Licensed Product designed to test the safety, dose range and efficacy of such Licensed Product and demonstrate whether such Licensed Product has a clinically meaningful <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">benefit-to-risk</FONT></FONT> profile in treating a specific indication that would satisfy the requirements of 21 C.F.R. &#167; 312.21(b), as amended from time to time for such clinical trial conducted in the U.S., (ii)
any analogous clinical trial described or defined in Applicable Laws and guidelines for a clinical trial conducted in another country in the Territory, or (iii)&nbsp;any other clinical trial the results of which are intended to support the conduct
of a deemed clinical trial without the need for subsequent additional clinical trials. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.66 &#147;<B>Phase III Clinical Trial</B>&#148; means a human
clinical trial designed as a pivotal study to confirm, with statistical significance, the efficacy and safety of a Licensed Product with respect to a particular indication, which trial is performed for purposes of filing an NDA or similar
application to obtain Regulatory Approval for such Licensed Product in any country or regulatory jurisdiction, as defined in 21 C.F.R. &#167; 312.21(c), as amended from time to time, or any analogous clinical trial described or defined in Applicable
Laws and guidelines for a clinical trial conducted in another country in the Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.67 &#147;<B>Product Marks</B>&#148; means all trademarks,
including trade names, trade dresses, branding, and logos, owned, controlled, or used by or on behalf of Acrivon or any Affiliate thereof during the Term with respect to any Licensed Product, other than those representing Acrivon or its Affiliates
generally. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.68 &#147;<B>Product-Related Materials</B>&#148; means all advertising and promotional materials (including but not limited to flyers,
brochures, pamphlets and electronic media), labeling and packaging materials, and any materials or items similar to the foregoing to the extent, in each case, pertaining exclusively to the Licensed Products and in the possession or control of
Acrivon or any Affiliate thereof, and all copyright and similar rights to the contents thereof, provided that the foregoing rights shall not include any rights to any trademark, logos, or the like other than Product Marks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.69 &#147;<B>Product Tailored
OncoSignature</B><B><SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP></B><B> Assay</B>&#148; means the OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Assay specifically developed by Acrivon for the Licensed
Product to identify and select patients likely to respond to the Licensed Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.70 &#147;<B>Regulatory Applications</B>&#148; means any and all
applications that are necessary and appropriate to obtain a Regulatory Approval with respect to a Licensed Product, including, without limitation, all required documents, data and information concerning a Licensed Product, filed or required to be
filed with or, otherwise submitted to, a Regulatory Authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.71 &#147;<B>Regulatory Approval</B>&#148; means all approvals from the relevant
Regulatory Authority necessary to market and sell a pharmaceutical product in the Territory (excluding all applicable pricing and reimbursement approvals). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.72 &#147;<B>Regulatory Authority</B>&#148; means any applicable government regulatory authority involved in granting approvals for the conduct of clinical
trials or the manufacturing, marketing, sale, reimbursement or pricing of a Licensed Product in the Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.73 &#147;<B>Regulatory
Materials</B>&#148; means all Regulatory Approvals, Regulatory Applications and other regulatory submissions in the Territory for any Licensed Compound or Licensed Product, and all correspondence with such Regulatory Authorities relating to any
Licensed Compound or Licensed Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.74 &#147;<B>Related Party</B>&#148; means any Affiliate of Acrivon or any Sublicensee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.75 &#147;<B>Representatives</B>&#148; means, with respect to a Party, such Party&#146;s Affiliates, and such Party&#146;s and its Affiliates&#146; directors,
officers, employees, agents and other representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.76 &#147;<B>Royalty Term</B>&#148; means the period of time commencing on the Effective Date and
ending, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, on the
latest of the following: [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.77 &#147;<B>Second Indication</B>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) with respect to the conduct of a Phase III Clinical Trial, the Indication, other than the First Indication, specified as being the subject
of such trial in the protocol pursuant to which such trial is being conducted; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) with respect to an NDA, or amendment or supplement
thereto, filed with respect to a Licensed Product in a country or jurisdiction, any Indication, other than the First Indication, for which marketing, promotion, sale, or use of such Licensed Product is sought under such NDA or amendment or
supplement thereto; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) with respect to Regulatory Approval of a Licensed Product in a country or jurisdiction, any Indication, other
than the First Indication, for which marketing, promotion, sale, or use of such Licensed Product is obtained thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.78 &#147;<B>Sublicense</B>&#148; means any agreement entered into by Acrivon, any Affiliate thereof, or
any prior Sublicensee with a Sublicensee pursuant to which such Sublicensee obtains a sublicense to any of the rights granted to Acrivon under the Licensed Patents or Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.79 &#147;<B>Sublicensee</B>&#148; means any Third Party to which Acrivon, an Affiliate thereof, or a Sublicensee grants a sublicense of the rights granted to
Acrivon under the Licensed Patents or Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.80 &#147;<B>Territory</B>&#148; means worldwide. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.81 &#147;<B>Third Indication</B>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) with respect to the conduct of a Phase III Clinical Trial, the Indication, other than the First Indication or Second Indication, specified
as being the subject of such trial in the protocol pursuant to which such trial is being conducted; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) with respect to an NDA, or
amendment or supplement thereto, filed with respect to a Licensed Product in a country or jurisdiction, any Indication, other than the First Indication or Second Indication, for which marketing, promotion, sale, or use of such Licensed Product is
sought under such NDA or amendment or supplement thereto; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) with respect to Regulatory Approval of a Licensed Product in a country
or jurisdiction, any Indication, other than the First Indication or Second Indication, for which marketing, promotion, sale, or use of such Licensed Product is obtained thereunder </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.82 &#147;<B>Third Party</B>&#148; means an entity other than (a)&nbsp;Lilly and its Affiliates, and (b)&nbsp;Acrivon and its Affiliates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.83 &#147;<B>Transferred Clinical Compound</B>&#148; means the Transferred Compound identified on <B>Exhibit G</B> as the &#147;Clinical Compound&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.84 &#147;<B>Transferred Compound</B>&#148; means the Licensed Compound identified on <B>Exhibit G</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.85 &#147;<B>Transferred Materials</B>&#148; means, collectively, the Transferred Clinical Compound, the Transferred Compound, the Transferred Product and
other materials set forth on <B>Exhibit G</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.86 &#147;<B>Transferred Product</B>&#148; means the Licensed Product identified on <B>Exhibit G</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.87 &#147;<B>Transferred Samples</B>&#148; means those [***] collected under the Lilly Trials that are described in Exhibit H. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.88 &#147;<B>Valid Claim</B>&#148; [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.89
&#147;<B>Vendor</B>&#148; means a Third Party engaged by Acrivon to perform development or commercialization activities on Acrivon&#146;s behalf, including a clinical research organization, contract manufacturing organization, a distributor, a
subcontractor, a consultant or other service provider. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Definitions</B>. Each of the following definitions is set forth in the Section of this
Agreement indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Defined Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acrivon</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acrivon Indemnitee(s)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bankruptcy Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;9.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Claim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Commercial Milestone Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Competitive Infringement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;8.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Controlling Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;8.4(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Development Milestone Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Diligence Milestone</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.4(c)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Disclosing Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effective Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FCPA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;10.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Foreground Intellectual Property Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;8.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnifying Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnitee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Infringement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;8.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Initial Development Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.4(c)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Licensed Subproduct(s)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.58</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lilly</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lilly Indemnitee(s)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Losses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;8.4(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">OECD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.37</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other Product</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.17</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Party or Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Patent Certification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;8.4(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Product-Related Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;9.5(d)(ii)(2)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Product-Related Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;9.5(d)(ii)(1)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Receiving Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.21</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ROFN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ROFN Exercise Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.5(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ROFN Negotiation Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.5(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ROFN Notice of Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.5(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ROFN Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.5(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stock Issuance Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;9.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Termination Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;9.5(d)(v)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Third Party License</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.6(b)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <B>LICENSE; RIGHT OF FIRST NEGOTIATION; DILIGENCE</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1 <B>License to Acrivon</B>. Lilly hereby grants to Acrivon an exclusive (even as to Lilly and its Affiliates, except as described below), royalty-bearing
license, with the right to grant sublicenses (subject to Section&nbsp;2.2), under the Licensed Patents and Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> to Develop, Commercialize, Manufacture, and otherwise exploit Licensed Compound and
Licensed Products in the Field in the Territory; provided that, notwithstanding the foregoing, Lilly and its Affiliates retain a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, without the right to sublicense, under the Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> and the Licensed Patents to make, have made, and use (i)&nbsp;Licensed Compounds for internal research and development purposes (which, for clarity, shall exclude administration of any Licensed Product to
any human) and (ii)&nbsp;Licensed Products for purposes of the conduct, wind-down and completion of the Lilly Trials and Investigator-Sponsored Trials. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.2 <B>Sublicenses</B>. The rights and licenses granted to Acrivon in Section&nbsp;2.1 include the right to grant sublicenses, directly or through multiple
tiers to Affiliates or Third Parties; provided that (a)&nbsp;any sublicense granted by Acrivon under this Agreement (directly or indirectly through its Affiliate) to a Third Party shall be (i)&nbsp;in writing, (ii)&nbsp;subject in applicable
respects to the provisions contained in this Agreement, (iii)&nbsp;consistent with, and not conflict with, the terms of this Agreement, and (iv)&nbsp;contain terms sufficient to ensure Acrivon&#146;s compliance with this Agreement; and
(b)&nbsp;Acrivon shall not, without Lilly&#146;s written consent, grant any Third Party any sublicense of the rights granted under Section&nbsp;2.1 (or option or similar right to obtain such a license) prior to the expiration of the ROFN Term in
accordance with Section&nbsp;2.5(a), and, thereafter, Acrivon may grant sublicenses to Third Parties without the prior written consent of Lilly. Notwithstanding the foregoing, the prior consent of Lilly shall not be required in connection with a
grant of a Sublicense to a Third Party in its capacity as a Vendor. Acrivon shall provide Lilly with full, complete, and accurate copies of all Sublicenses (other than any Sublicense to an Affiliate or Vendor) promptly following the execution
thereof; provided that the financial and other terms of such Sublicenses may be redacted to the extent such redactions do not prevent Lilly from ensuring such Sublicense complies with the requirements set forth in this Section&nbsp;2.2. Acrivon
shall be responsible for the compliance of its Sublicensees, and shall ensure that Sublicensees comply, with the applicable provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.3 <B>Third Party Contractors</B>. Acrivon and its Affiliates shall have the right to retain one or more Third Party contractors to perform any activities in
connection with Acrivon&#146;s or its Affiliates&#146; exercise of any rights granted under Section&nbsp;2. 1, where such activity is to be performed at the direction and control and for the sole benefit of Acrivon or its Affiliates. Such retention
of the Third Party contractor is not a sublicense within the meaning of Section&nbsp;2.2 but is considered an activity of Acrivon under the license granted under Section&nbsp;2.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.4 <B>Lilly Trials and Investigator-Sponsored Trials; Regulatory Interactions; Responsibility to Develop and Commercialize</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Lilly Trials and Investigator-Sponsored Trials</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Pursuant to Lilly&#146;s reserved right set forth in Section&nbsp;2.1, Lilly shall be
responsible for the conduct of the Lilly Trials or facilitation of the Investigator-Sponsored Trials (and may wind-down or cease such conduct or facilitation) as it may determine in its sole discretion and at its sole expense, in accordance with the
applicable protocols and Applicable Laws. Notwithstanding the foregoing, Lilly shall (A)&nbsp;in good faith use reasonable efforts to coordinate with the principal investigators responsible for each of the Investigator-Sponsored Trials to complete
such Investigator-Sponsored Trials as promptly as practicable following the Effective Date, consistent with the applicable protocol(s), Applicable Laws (including GCPs and medical and ethical standards), and Investigator-Sponsored Trial agreements,
(B)&nbsp;undertake all activities reasonably necessary for the completion or discontinuation of the Lilly Trials as promptly as reasonably practicable following the Effective Date, and (C)&nbsp;not begin any clinical trials relating to the Licensed
Compounds or Licensed Products after the Effective Date. Lilly shall maintain responsibility for all regulatory activities and interactions required of Lilly with respect to the conduct, wind-down, or discontinuation of the Lilly Trials or
Investigator-Sponsored Trials. Acrivon shall promptly provide Lilly with any Acrivon <FONT STYLE="white-space:nowrap">Know-How</FONT> requested by Lilly that is required for compliance with, and solely for use to comply with, Applicable Laws (or any
agreement entered into by Lilly or any Affiliate thereof with any Third Party) with respect to the conduct, facilitation, wind-down, or discontinuation, as applicable, of the Lilly Trials and Investigator-Sponsored Trials. [***]. For clarity,
Acrivon shall not be responsible for any activities of Lilly with respect to the Licensed Compound to the extent occurring prior to the Effective Date or resulting from activities regarding the Lilly Trials or Investigator-Sponsored Trials. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Promptly following receipt of written notice from Lilly confirming the completion and/or discontinuation of all Lilly Trials and
Investigator-Sponsored Trials, upon Acrivon&#146;s written request received by Lilly within [***] of such notice from Lilly, Lilly will [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Regulatory Interactions</U>. Subject to the terms of this Agreement, including Section&nbsp;2.4(a), Acrivon, its Affiliates or
Sublicensees, or its or their designees will have the right to conduct, and shall be responsible for, all regulatory activities and interactions, at their cost, concerning the Licensed Compounds, Licensed Products, and the Development, Manufacture,
or Commercialization of any of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Development and Commercialization</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Acrivon, itself or through its Affiliates and Sublicensees, will use Commercially Reasonable Efforts to (A)&nbsp;Develop and Commercialize
at least one Licensed Product in the Field in the Territory and (B)&nbsp;achieve each of the events set forth on Exhibit I (each such event, a &#147;<B>Diligence Milestone</B>&#148;) by the date set forth thereon for such Diligence Milestone.
Acrivon may request in writing [***] extension of the due date for achieving a particular Diligence Milestone by up to [***], setting forth the basis for the requested extension, which extension will be granted by Lilly unless [***]. The extension
of a Diligence Milestone in accordance with this Section&nbsp;2.4(c) shall automatically extend the deadline for subsequent Diligence Milestones with respect to the same subject matter by the same time period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Acrivon&#146;s Development of Licensed Products prior to the expiration of the ROFN Term shall be performed in accordance with the
development plan attached hereto as <B>Exhibit J</B> (the &#147;<B>Initial Development Plan</B>&#148;). Acrivon will provide Lilly any proposed material revisions to the Initial Development Plan and will consider in good faith any comments made by
Lilly with respect thereto, but, except with respect to the Lilly Trials as set forth above, Acrivon shall have sole responsibility for and final decision-making authority with respect to, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Development and Commercialization of Licensed Products; provided that no changes to the Initial Development Plan shall change the deadline set forth on <B>Exhibit I</B> for each Diligence
Milestone, unless Lilly has granted an extension thereof pursuant to Section&nbsp;2.4(c)(i) or as otherwise agreed to in writing by Lilly. Acrivon will be responsible for all costs and expenses associated with Development, regulatory and
Commercialization activities, except with respect to the Lilly Trials as set forth above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>GCP and GLP Compliance</U>. The
Development of Licensed Products shall be conducted by Acrivon (and Acrivon shall ensure that its Affiliates and Sublicensees conduct Development of Licensed Products) in accordance with GCP and GLP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Compliance with Animal Care and Use Requirements</U>. Acrivon shall comply with all Applicable Laws pertaining to the care and use of
experimental animals and that all animals used in experiments with Licensed Compound and shall be provided humane care and treatment in accordance with the current applicable veterinary practices. Acrivon shall also comply with the Lilly animal care
and use requirements referenced in the attached <B>Exhibit K</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Safety Agreement</U>. The Parties shall use reasonable, good
faith efforts to negotiate and enter into a safety-regulatory agreement concerning the subject matter hereof within [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.5 <B>Lilly&#146;s Right of
First Negotiation</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions of this Section&nbsp;2.5, Lilly shall have an exclusive right of first
negotiation to reacquire all rights to the Licensed Products, under the Licensed Technology, Acrivon Patents, Acrivon <FONT STYLE="white-space:nowrap">Know-How,</FONT> the Product Tailored
OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay, and Product-Related Contracts related thereto, via acquisition, license or otherwise (the &#147;<B>ROFN</B>&#148;). The ROFN shall expire upon the earliest to occur of the
following: (i)&nbsp;expiration of the ROFN Exercise Period without written exercise of the ROFN by Lilly, (ii)&nbsp;delivery of written notice from Lilly electing not to exercise the ROFN prior to the expiration of the ROFN Exercise Period,
(iii)&nbsp;if Lilly provides a ROFN Notice of Interest prior to the end of the ROFN Exercise Period, the expiration of ROFN Negotiation Period without the Parties&#146; execution of a definitive agreement with respect thereto (the period from the
Effective Date until the applicable such expiration described in the preceding clause (i), (ii), or (iii), the &#147;<B> ROFN Term</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Lilly shall have from the Effective Date until [***] (the period from the Effective Date until [***], the &#147;<B>ROFN Exercise
Period</B>&#148;) to exercise the ROFN by delivering to Acrivon a written notice of such exercise (the &#147;<B>ROFN Notice of Interest</B>&#148;). The ROFN Notice of Interest shall set forth Lilly&#146;s initial proposed material terms on which
Lilly would reacquire such rights in the Licensed Products, including transaction structure, purchase price and other financial terms, and closing conditions. If Lilly exercises the ROFN during the ROFN Exercise Period, then the Parties shall
negotiate in good faith and on an exclusive basis for up to an additional [***] from the date of the ROFN Notice of Interest (such period, the &#147;<B>ROFN Negotiation Period</B>&#148;) to execute definitive documentation pursuant to which Lilly
would reacquire rights in the Licensed Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Effective upon the expiration of the ROFN Term, Lilly shall be deemed have irrevocably
waived the ROFN. If Lilly is deemed to have irrevocably waived the ROFN pursuant to the preceding sentence then, effective upon such expiration of the ROFN Term, (i)&nbsp;the ROFN shall terminate and be of no further force or effect, (ii)&nbsp;Lilly
shall have no further right to reacquire rights to Licensed Products as contemplated under this Section&nbsp;2.5, and (iii)&nbsp;Acrivon shall no longer be prohibited from entering into an agreement granting or assigning any Third Party rights to
one or more Licensed Products; provided that, in the case of an expiration of the ROFN Term pursuant to clause (iii)&nbsp;of Section&nbsp;2.5(a), for a period of [***] days from the expiration of the ROFN Negotiation Period, Acrivon shall not enter
into an agreement with a Third Party with respect to the Licensed Product set forth in the ROFN Notice of Interest on economic conditions and terms that, [***], are less favorable to Acrivon as compared to those last offered by Lilly with respect to
the applicable rights to Licensed Products during the ROFN Negotiation Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) For the avoidance of doubt, and without limitation of
Section&nbsp;11.2, Lilly&#146;s rights under this Section&nbsp;2.5 shall not restrict Acrivon from undertaking and closing (i)&nbsp;an IPO of Acrivon or Affiliates or (ii)&nbsp;a Change of Control of Acrivon, provided that the ROFN (and obligations
related thereto) shall survive the closing of an IPO or a Change of Control. Notwithstanding the foregoing, and subject to Applicable Laws and confidentiality restrictions, [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.6 <B>Progress Reports</B>. From and after the Effective Date until the date [***] after the First Commercial Sale of a Licensed Product [***], Acrivon shall
keep Lilly regularly informed in reasonable detail of the progress of its, its Affiliates&#146;, and Sublicensees&#146; efforts to Develop or Commercialize Licensed Products, including providing [***] written updates to Lilly within [***] during the
Term of this Agreement, beginning with [***], including a summary of [***]. In addition, from and after the Effective Date until [***] after the First Commercial Sale of a Licensed Product [***], upon the reasonable request of Lilly, but no more
frequently than [***], Lilly and Acrivon shall meet by telephone, videoconference, or <FONT STYLE="white-space:nowrap">in-person</FONT> at a mutually agreeable location to discuss the topics described in the progress reports, and such other topics
related to Licensed Compound and/or Licensed Product as Lilly may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.7 <B>License to Lilly</B>. Acrivon, on behalf of itself and its
Affiliates, hereby grants to Lilly and its Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, perpetual, irrevocable, royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> license, with the right to grant
sublicenses and transferable with this Agreement, (i)&nbsp;under the Acrivon Licensed Foreground IP for internal research purposes (which shall not include the conduct of human clinical trials) and (ii)&nbsp;under such applicable component of
Acrivon <FONT STYLE="white-space:nowrap">Know-How</FONT> required to comply with Applicable Law or any contractual obligations with respect to the Lilly Trials or Investigator-Sponsored Trials for purposes of, in the case of this clause (ii), such
compliance. The licenses granted to Lilly in this paragraph shall survive termination and/or expiration of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <B>TECHNOLOGY AND COMPOUND
TRANSFER</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1 <B>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></B>. Within [***] of the Effective Date, Lilly will provide and transfer to
Acrivon copies of the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> relating to the Licensed Compound to extent such <FONT STYLE="white-space:nowrap">Know-How</FONT> is specifically identified on <B>Exhibit C</B> and has not previously
been provided to Acrivon. Unless Lilly otherwise agrees, all such Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> will be transferred in its current form and will not be <FONT STYLE="white-space:nowrap">re-formatted</FONT> or otherwise
modified for Acrivon&#146;s benefit. Notwithstanding anything to the contrary in this Agreement, Lilly will have no obligation under this Agreement to transfer any Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> or material existing as of
the Effective Date other than the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> specifically described on <B>Exhibit C</B> and Acrivon will cooperate to facilitate such transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2 <B>Technology Transfer Assistance</B>. Lilly will provide written or verbal responses to reasonable
questions relating to the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> for a period of [***] following the Effective Date provided under no circumstance shall such assistance exceed [***]. For clarity, except as specifically provided in
this Article 3, Lilly shall have no other obligations to provide any assistance in connection with technology transfer under this Agreement. Acrivon may reasonably request additional hours of assistance from Lilly. Lilly may agree to provide such
additional assistance at Lilly&#146;s reasonable discretion and subject to payment by Acrivon of the rate of [***] for the provision of such additional assistance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.3 <B>Transferred Materials and Transferred Samples</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transferred Materials</U>. [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Transferred Samples</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) Acrivon will use the Transferred Samples solely for the Development, Commercialization, and other exploitation of the
Licensed Compound and Licensed Products in the Field in the Territory, and in every case, such use will be in accordance with Applicable Law and, for each Transferred Sample, the informed consent form under which such Transferred Sample was
obtained. If any Transferred Samples or information derived from the use of thereof is transferred out of the United States by Acrivon, Acrivon will communicate with all applicable governmental agencies for any regulations which may apply to the
exportation, handling, storage, and transfer of Transferred Samples (or data derived from the use thereof) out of the United States and shall comply with laws and regulations applicable to the transfer of the Transferred Samples or data derived from
the Transferred Samples out of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) Acrivon assumes full responsibility for any claims or liabilities
which may arise as a result of Acrivon&#146;s use, handling or possession of Transferred Samples, except as prohibited by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(4) Acrivon agrees to retain control over and not transfer, sell, or distribute the Transferred Samples to anyone other than
Acrivon&#146;s employees and in each case solely as needed for the purposes set forth in subsection (2)&nbsp;above. Acrivon shall exercise at a minimum the same degree of care it would exercise to protect its own similar material (and in no event
less than a reasonable standard of care). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(5) [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.4 <B>Lilly CMO Agreements</B>. Lilly shall, promptly following any written request given by Acrivon within [***] after the Effective Date, execute and
provide to Acrivon an authorization letter similar to the form included in Exhibit D for each requested Lilly CMO Agreement which Acrivon shall be entitled to provide to the applicable Third Party manufacturer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.5 <B>Orphan Drug Designation</B>. [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <B>PAYMENTS; EQUITY</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1 <B>Upfront Payment</B>. Acrivon
shall pay Lilly a <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment of five million dollars ($5,000,000) within [***] of the Effective Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.2 <B>Equity</B>. Within [***] of the Effective Date, Acrivon will issue to Lilly eight hundred twenty-ninie thousand nine hundred ninety-five (829,995)
shares of Common Stock, par value $0.001 per share, of Acrivon, [***], in accordance with a common stock issuance agreement, substantially in the form attached hereto as <B>Exhibit L</B> (the &#147;<B>Stock Issuance Agreement</B>&#148;), which shall
include [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.3 <B>Development Milestone Payments</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Within [***] after the initial achievement of each of the milestone events set forth in the table below (each, a &#147;<B>Development
Milestone Event</B>&#148;) with respect to the first Licensed Product to achieve such Development Milestone Event, Acrivon will notify Lilly in writing of such achievement and make the corresponding
<FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment to Lilly. The maximum aggregate amount that can become payable under this <U>Section</U><U></U><U>&nbsp;4.3</U> is [***]. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Development Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>First<BR>Indication</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Second<BR>Indication</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Third<BR>Indication</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) each milestone payment set forth in this Section&nbsp;4.3 shall be paid only once for the first achievement of the corresponding
Development Milestone Event by a Licensed Product for the First Indication, Second Indication, and Third Indication therefor, regardless of the number of Licensed Products to achieve any of the Development Milestone Event for a particular
Indication; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) [***]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) [***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.4 <B>Commercial Milestone Payments</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Within [***] after the end of the Calendar Quarter in which Acrivon, its Affiliates or
their Sublicensees has first achieved each of the milestone events set forth in the table below (each, a &#147;<B>Commercial Milestone Event</B>&#148;), Acrivon will notify Lilly in writing of such achievement and make the corresponding <FONT
STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment to Lilly. The maximum aggregate amount that can become payable under this Section&nbsp;4.4 is [***]. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Commercial Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.5
<B>Royalties</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;4.6, Acrivon will pay Lilly a tiered royalty based on Annual Net Sales in each Calendar Year,
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="41%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Portion of Annual Net Sales in a particular Calendar
Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate&nbsp;Applicable&nbsp;to&nbsp;Such&nbsp;Portion&nbsp;of<BR>Annual Net Sales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an example of the royalties contemplated by this Section&nbsp;4.5 (without taking into account any of the
adjustments set forth below), if Annual Net Sales in a particular Calendar Year total [***], the total royalties due for such Calendar Year would be [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Royalty obligations under this Section&nbsp;4.5 (subject to adjustment pursuant to Section&nbsp;4.6) shall only apply to Net Sales of a
Licensed Product sold in a country during the Royalty Term applicable to such Licensed Product in such country. Following the expiration of the Royalty Term with respect to a Licensed Product in a country, the licenses and rights granted to Acrivon
hereunder with respect to such Licensed Product in such country shall become fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, and nonexclusive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.6 <B>Royalty Reductions</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Step-Down
for No Valid Claims</U>. [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Third Party Licenses</U>. If Acrivon or any Affiliate thereof reasonably determines in good faith,
[***], that it is reasonably necessary to obtain a license or other right from a Third Party under any intellectual property rights Covering any Licensed Product (including in connection with the settlement of a patent infringement claim) (in each
case, a 3 710d PL y License&#146;), then Acrivon may deduct [***] of the Third Party License costs actually paid by Acrivon or any of its Affiliates to such Third Party with respect to any particular Licensed Product in a particular country from the
royalties otherwise payable to Lilly under Section&nbsp;4.5 with respect to Net Sales of such Licensed Products in such country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Royalty Reduction Cap</U>. Notwithstanding anything in this Section&nbsp;4.6 to the
contrary, in no case shall the royalties payable by Acrivon to Lilly under Section&nbsp;4.5 with respect to Net Sales of a particular Licensed Product in a particular country be reduced by more than an aggregate of [***] in any Calendar Quarter as a
result of any and all reductions or offsets under this Section&nbsp;4.6. Any portion of the Third Party License payments payable to such Third Party with respect to such Licensed Product in such country that Acrivon would, but for the foregoing
limitation on royalty reductions, be entitled to deduct under Section&nbsp;4.6(b) may be carried over and applied against royalties payable to Lilly in respect of Net Sales of such Licensed Product in such country in subsequent Calendar Quarters if
the same can be accomplished without exceeding the [***] limitation as set forth above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.7 <B>Reports; Payment of Royalty</B>. During the Term, beginning
with the Calendar Quarter during which the First Commercial Sale of a Licensed Product occurs, Acrivon shall furnish to Lilly a quarterly written report for each Calendar Quarter showing the Net Sales of Licensed Products subject to royalty payments
sold by Acrivon and its Related Parties and broken down between Acrivon, its Affiliates, and any Sublicensees during the reporting period and the royalties payable under this Agreement. [***]. Reports shall be due within [***] following the close of
each Calendar Year. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due. Acrivon will mail such reports to the attention of: [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.8 <B>Records; Financial Audits</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
Acrivon will keep and maintain complete and accurate (and cause its Affiliates and Sublicensees to keep and maintain complete and accurate) records and books which may be necessary to ascertain properly and to verify the payments owed hereunder.
Such records need only be kept and maintained for up to [***] after the end of any Calendar Year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Upon the written request of Lilly
and not more than once in each Calendar Year, Acrivon shall permit (and Lilly shall have the right to have) an [***], to have access during normal business hours to inspect the records of Acrivon, its Affiliates, and Sublicensees as may be
reasonably necessary to verify the accuracy of the royalty reports hereunder for any Calendar Year ending not more than [***] prior to the date of such request. Any given period may not be audited more than once. [***]. The accounting firm shall
disclose to Lilly and Acrivon only whether the royalty reports are correct or incorrect [***]. This right to audit shall remain in effect throughout the Term of this Agreement and for a period of [***] after the end of the Calendar Year in which the
termination of this Agreement occurs. If such accounting firm identifies an underpayment of royalties by Acrivon during such period, Acrivon shall pay Lilly the amount of the underpayment within [***] of the date the accounting firm delivers to
Acrivon such accounting firm&#146;s written report so concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting firm shall be paid by Lilly unless the underpayment exceeded [***]. Acrivon shall pay interest on any
underpayment at the rate set forth in Section&nbsp;4.10. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Acrivon shall ensure that all Sublicenses granted pursuant to this Agreement include a
provision requiring the Sublicensee to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by Lilly&#146;s independent accountant to the same extent required of Acrivon under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Lilly shall treat all financial information subject to review as Acrivon&#146;s Confidential Information in accordance with Article 5 of
this Agreement, and shall, if and as requested by Acrivon, cause its accounting firm(s) to enter into a reasonable and customary form of confidentiality agreement with Acrivon, its Affiliate or Sublicensee, as applicable, obligating them to retain
all such information in confidence pursuant to such confidentiality agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.9 Payment Method. All payments to be made by Acrivon to Lilly under this
Agreement shall be made in United States dollars by bank wire transfer in immediately available funds to a bank account designated in writing by Lilly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.10 Late Payment. All late payments under the Agreement shall bear interest at the rate of prime (as reported in The Wall Street Journal (Eastern U.S.
edition)) plus [***], or, if lower, the highest rate permitted by Applicable Law, until the date such payment is made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.11 Tax Withholding. If Applicable
Laws require Acrivon or any Related Party to withhold income taxes or other taxes imposed upon payments due hereunder, Acrivon or such Related Party shall promptly notify Lilly in writing of such requirement, shall make such withholding payments as
required, [***]. For clarity, Acrivon (including its Affiliates and Sublicensees) is solely responsible for any income tax due in connection with its income under this Agreement. [***]. Each Party shall provide the other with reasonable assistance
to enable the recovery, as permitted by Applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax
or value added taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <B>CONFIDENTIALITY; PUBLICATION</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1 <B>Nondisclosure Obligation</B>. Except to the extent expressly authorized by this Agreement, during the Term and for [***] thereafter, the Receiving Party
shall keep confidential, and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement, the Confidential Information of the Disclosing Party. The Receiving Party may use
Confidential Information only to the extent required to accomplish the purposes of this Agreement. Each Party agrees that during the term of this Agreement, without limiting its obligations hereunder, each Party shall implement technical and
organizational measures to protect all information under the Agreement that are appropriate, reasonable, and that provide no less protection than its measures to protect its own information of a similar nature or importance. The Receiving Party
shall promptly notify the Disclosing Party upon discovery of any unauthorized use or unauthorized disclosure of the Disclosing Party&#146;s Confidential Information by the Receiving Party or any of its Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.2 <B>Exceptions</B>. The Receiving Party&#146;s obligations under Section&nbsp;5.1 shall not apply to any
information that the Receiving Party can show by competent evidence: (i)&nbsp;is already known to it or its Affiliates at the time it is disclosed to any of them, as evidenced by the Receiving Party&#146;s written records; (ii)&nbsp;is or becomes
generally known to the public through no act or omission of the Receiving Party or any of its Affiliates in violation of the terms of this Agreement; (iii)&nbsp;has been lawfully received by the Receiving Party or any of its Affiliates from a Third
Party without restriction on its disclosure and without, to the knowledge of the Receiving Party, a breach by such Third Party of an obligation of confidentiality to the Disclosing Party or any of its Affiliates; or (iv)&nbsp;has been independently
developed by the Receiving Party or any of its Affiliates without use of or reference to the Confidential Information of the Disclosing Party or any of its Affiliates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.3 <B>Authorized Disclosure</B>. Notwithstanding the provisions of Section&nbsp;5. 1, the Receiving Party may disclose Confidential Information of the
Disclosing Party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) filing or prosecuting Patents as permitted by this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) enforcing the Receiving Party&#146;s rights under this Agreement and performing the Receiving Party&#146;s obligations under this
Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) prosecuting or defending litigation as permitted by this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) complying with applicable court or governmental orders, or Applicable Laws, including Applicable Laws related to securities laws disclosure
requirements or any disclosure requirements of any applicable stock market or securities exchange on which the Receiving Party&#146;s or any of its Affiliates&#146; securities are traded, provided the Receiving Party gives the Disclosing Party
sufficient written notice, to the extent reasonably possible, to permit the Disclosing Party to seek a protective order or other confidential or protective treatment with respect to such Confidential Information; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) in the case of Acrivon as the Receiving Party during the Term or after expiration (but not earlier termination) of this Agreement,
disclosure in submissions to or filings with any Regulatory Authority (including, without limitation, in INDs and NDAs) with respect to any Licensed Compound or Licensed Product, and in correspondence with any Regulatory Authority in the Territory
regarding any Licensed Compound or Licensed Product or any of the foregoing submissions or filings in the Territory; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) disclosure to the
Receiving Party&#146;s Affiliates, to actual or potential Sublicensees (in the case of Acrivon as the Receiving Party during the Term or after expiration, but not earlier termination, of this Agreement), and to the Receiving Party&#146;s
Representatives who, in each case, have a need to know such information in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement, provided, in each case, that any such Affiliate, actual or potential
Sublicensee, or Representative agrees to be bound by terms of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as restrictive as those set forth in this Article 5; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) disclosure to Third Parties in connection with due diligence or similar investigations by such Third Parties, and disclosure to potential
Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by reasonable obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use;</FONT> and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) disclosure, by Lilly, of a copy of the Agreement in response to a request from a taxing
authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing
Party&#146;s Confidential Information pursuant to Section&nbsp;5.3(d) or 5.3(e) (but, for clarity, not under Section&nbsp;5.3(h) where, notwithstanding anything to the contrary, Lilly may freely disclose a copy of the Agreement in response to a
valid request from a taxing authority), it will, except in the case where it is impractical to do so (i)&nbsp;give reasonable advance notice to the Disclosing Party of such required disclosure, and (ii)&nbsp;at the Disclosing Party&#146;s request
and expense, shall cooperate with the Disclosing Party&#146;s efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or
the law or regulation required, and/or to obtain other confidential treatment of such Confidential Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.4 Publication. Acrivon and its
Affiliates shall have the right to publish or present, and to authorize Sublicensees to publish or present, the results of any study or clinical trial, or other Development activities with respect to, any Licensed Compound or Licensed Product
conducted by or on behalf of Acrivon, its Affiliates or Sublicensees, without the prior review or approval of Lilly. During the Term, Lilly and its Affiliate shall not have the right to, and shall not, publish or present any Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> without the prior written review of Acrivon; provided that, notwithstanding anything to the contrary, nothing in this Agreement shall in any event be construed to prohibit the publication or presentation by
or on behalf of Lilly or any Affiliate thereof of any of the manuscripts or abstracts listed in <B>Exhibit M</B> hereto. In addition, with respect to the Investigator-Sponsored Trials, Lilly will use reasonable efforts, subject to the
confidentiality and other obligations in any agreements with the relevant clinical sites, to provide, prior to submission or public disclosure, a copy of any publication, manuscript or presentation of the results of any Investigator-Sponsored Trial
by the applicable investigators to Acrivon for its review and comment. Acrivon shall have a period of [***] to review in advance any such manuscript, abstract or presentation and Lilly will, and will, subject to the terms of the applicable
agreements with the relevant clinical sites, use reasonable efforts to cause the applicable investigators or clinical sites to, consider in good faith any comments made by Acrivon with respect thereto; provided that if Acrivon reasonably determines
that such manuscript, abstract or presentation contains Confidential Information of Acrivon, Lilly shall, subject to the terms of the applicable agreements with the relevant clinical sites, remove, or cause to be removed, such Confidential
Information from the proposed manuscript, abstract or presentation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.5 <B>Publicity</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Public Announcements</U>. Except as required by applicable securities laws or the listing rules of any stock exchange on which
securities issued by a Party or its Affiliates are traded, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the other Party; <I>provided</I> that each Party may make any public statement
in response to questions by the press, analysts, investors or those attending industry conferences or financial analyst calls, respond to queries by any exchange on which such Party&#146;s securities are traded, or issue press releases, so long as
any such public statement, response, or press release is not inconsistent with prior public disclosures or public statements made in accordance with this Section&nbsp;5.5 and which do not reveal <FONT STYLE="white-space:nowrap">non-public</FONT>
information about the other Party. In the event of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a required public announcement concerning this Agreement, to the extent practicable under the circumstances, the Party making such announcement shall use reasonable efforts to provide the other
Party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment upon the proposed text, unless the proposed text is substantially
the same as that used in any prior public disclosure, press release or public statement made in accordance with this Section&nbsp;5.5. Following the Effective Date, Acrivon intends to have a corporate launch (including a website) and shall be
entitled to issue a press release regarding its launch and/or announcing the execution of this Agreement. Acrivon shall provide Lilly an advance copy of any launch materials that reference Lilly or relate to this Agreement for Lilly&#146;s review
and approval, which approval will not be unreasonably withheld, conditioned or delayed. Once any launch materials are approved, then those materials or the substantially same content as those materials may be used repeatedly without seeking
additional consent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Filing of this Agreement</U>. The Parties shall coordinate in advance with each other in connection with the
filing of this Agreement (including redaction of certain provisions of this Agreement) with any securities authority or with any stock exchange on which securities issued by a Party or its Affiliate are traded, and each Party shall use reasonable
efforts to seek confidential treatment for the terms proposed to be redacted; <U>provided</U> that each Party shall ultimately retain control over what information to disclose to any securities authority or stock exchange, as the case may be, and
provided further that the Parties shall use their reasonable efforts to file redacted versions with any governing bodies which are consistent with redacted versions previously filed with any other governing bodies. Other than such obligation,
neither Party (nor any of its Affiliates) shall be obligation to consult with or obtain approval from the other Party with respect to any filings to any securities authority or stock exchange. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.6 <B>Prior Confidentiality Agreement</B>. As of the Effective Date, the terms of this Article 5 shall supersede the Confidentiality Agreement, and any
information disclosed by a Party pursuant to the Confidentiality Agreement shall be deemed Confidential Information of such Party for purposes of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <B>REPRESENTATIONS AND WARRANTIES</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1 <B>Mutual
Representations and Warranties</B>. Each Party represents and warrants to the other that, as of the Effective Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) it has the full
right, power and authority to enter into this Agreement, and its execution of this Agreement, the fulfillment of its obligations and performance of its activities hereunder do not conflict with, violate, or breach, or constitute a default under, any
material agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction
over it; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full
corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) it is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) this Agreement is legally binding upon it, enforceable in accordance with its terms; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) all necessary consents, approvals and authorizations of all Governmental Authorities and other persons required to be obtained by such
Party as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2 <B>Representations and
Warranties of Acrivon</B>. Acrivon represents and warrants to Lilly that, as of the Effective Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) neither Acrivon nor any of its
Affiliates is debarred or disqualified under the Act or comparable Applicable Laws outside of the United States; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) no current
employee of Acrivon or any of its Affiliates is debarred or disqualified under United States law, including 21 U.S.C. &#167;335a, or any foreign equivalent thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.3 <B>Representations and Warranties of Lilly</B>. Lilly represents and warrants to Acrivon that, as of the Effective Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Listed Patents constitute all Patents owned or Controlled by Lilly or any of its Affiliates as of the Effective Date in the Territory
that contain one or more claims Covering any Licensed Compound; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Transferred Materials shall, upon being made available for
delivery to Acrivon, materially conform to the respective specifications therefor (if any) set forth in <B>Exhibit G</B>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Lilly has
provided or otherwise made available to Acrivon current, true and complete copies of all unpublished Listed Patents; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) all documents
required to be filed and all payments required to be made in order to prosecute and maintain each of the Listed Patents prior to the Effective Date in the Territory have been filed or made, as the case may be, in a timely manner, and no action has
been taken that would constitute waiver, abandonment or any similar relinquishment of such rights; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) no Listed Patent in the Territory
is or has been involved in any interference, opposition, reissue, reexamination, revocation, inter partes review, post-grant review, post-grant proceeding, or equivalent proceeding in which the scope, validity or enforceability of any such Listed
Patent is being or has been contested or challenged, and, to Lilly&#146;s knowledge, no such proceeding has been threatened with respect to any Listed Patent in the Territory; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) no Listed Patent in the Territory has been adjudged invalid or unenforceable in whole or part, or, in the case of pending patent
applications within the Listed Patents in the Territory, has been the subject of a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> finding of unpatentability; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Lilly has the full right, power and authority to grant the rights and licenses it
purports to grant hereunder, and neither Lilly nor any of its Affiliates has granted any Third Party any rights or licenses that would interfere or be inconsistent with Acrivon&#146;s rights and licenses hereunder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) to the knowledge of Lilly, there are no legal claims or litigation, threatened or pending, against Lilly or any Affiliate thereof alleging
that the Manufacture or use of the Licensed Compound or Licensed Products in the Field within the Territory infringes, misappropriates or otherwise violates the intellectual property rights of a Third Party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) neither Lilly nor any of its Affiliates has received written notice from any Third Party claiming that the Development, Manufacture, use,
Commercialization or other exploitation of any Licensed Compound or Licensed Products infringes or misappropriates, or would infringe or misappropriate, the Patents or other intellectual property rights of any Third Party, and, to Lilly&#146;s
knowledge, without duty of inquiry or investigation, none of the Development, Manufacture, use, Commercialization or other exploitation of Licensed Compound or Licensed Product infringes the Patents, or misappropriates any other intellectual
property rights, of any Third Party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) to the knowledge of Lilly, Lilly has performed all Lilly Trials in material compliance with the
applicable protocol, GCPs and Applicable Laws and materially complied with its obligations, if any, under any agreements regarding the Investigator-Sponsored Trials; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) to the knowledge of Lilly, there is no claim pending or threatened by Lilly alleging that a Third Party is or was infringing,
misappropriating or otherwise violating any Licensed Technology in the Field within the Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.4 <B>Covenants</B>. Each Party shall inform the other
Party in writing promptly upon learning that it or any Person who has performed activities with respect to the Licensed Compound prior to the Effective Date is debarred or is the subject of a conviction described in Section&nbsp;306 of the Act, or
upon learning that any action is pending or threatened relating to the debarment or conviction of such Party or any Person used in any capacity by such Party or any of its Affiliates in connection with the Development or Commercialization of the
Licensed Compound or Licensed Products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.5 <B>No Other Representations or Warranties</B>. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO
REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT,</FONT> OR <FONT
STYLE="white-space:nowrap">NON-MISAPPROPRIATION</FONT> OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY AND ALL SUCH OTHER REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE
HEREBY EXPRESSLY EXCLUDED. FURTHER, WITHOUT LIMITATION OF THE FOREGOING, AND EXCEPT AS SET FORTH IN SECTION 6.3(B), (I) LILLY MAKES NO REPRESENTATIONS, AND EXTENDS NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO ANY TRANSFERRED
MATERIALS, (II)&nbsp;THE TRANSFERRED MATERIALS ARE SUPPLIED &#147;AS IS&#148;, AND (III)&nbsp;LILLY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.6 <B>Limitation of Liability</B>. EXCEPT FOR A PARTY&#146;S WILLFUL MISCONDUCT OR FRAUD, NEITHER PARTY
SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES, LOST PROFITS, LOST OPPORTUNITY OR LOST SALES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE
POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 6.6 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 7, OR DAMAGES AVAILABLE FOR A PARTY&#146;S BREACH
OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <B>INDEMNIFICATION</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.1 <B>By Lilly</B>. Lilly agrees to indemnify, defend and hold harmless Acrivon, its Affiliates, and their respective Representatives (individually and
collectively, the &#147;<B>Acrivon Indemnitee(s)</B>&#148;) from and against any claim, demand, action or other proceeding by any Third Party (each, a &#147;<B>Claim</B>&#148;) against any Acrivon Indemnitee, and all associated losses, liabilities,
damages and expenses, including reasonable attorneys&#146; fees and costs (individually and collectively, &#147;<B>Losses</B>&#148;), arising out of (a)&nbsp;Lilly&#146;s breach of any of Lilly&#146;s representations, warranties or covenants under
this Agreement; (b)&nbsp;the gross negligence, willful misconduct, or failure to comply with Applicable Laws on the part of Lilly or any Lilly Indemnitee; (c)&nbsp;personal injury directly resulting from the clinical development conducted by Lilly
with respect to the Licensed Compound or Licensed Product prior to the Effective Date; (d)&nbsp;Lilly&#146;s or its Affiliates&#146; breach of any contractual obligations of Lilly or its Affiliates to Third Parties related to the Licensed Product,
Transferred Materials, Lilly Trials, or Investigator-Sponsored Trials; or (e)&nbsp;personal injury directly resulting from the conduct, completion, or wind-down of the Lilly Trials following the Effective Date; except, in each case, to the extent
such Claims or Losses arise out of any Acrivon Indemnitee&#146;s negligence, illegal conduct, willful misconduct, failure to comply with Applicable Laws, or breach of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.2 <B>By Acrivon</B>. Acrivon agrees to indemnify, defend and hold harmless Lilly, its Affiliates, and their respective Representatives (individually and
collectively, the &#147;<B>Lilly Indemnitee(s)</B>&#148;) from and against all Losses to which any Lilly Indemnitee may become subject as a result of any Claim, to the extent such Losses arise out of (a)&nbsp;the gross negligence, willful
misconduct, or failure to comply with Applicable Laws on the part of Acrivon or any Acrivon Indemnitee; (b)&nbsp;the use, Development, Manufacture, Commercialization or other disposition or exploitation of any Licensed Compound or Licensed Product,
or the use of any Transferred Sample or <FONT STYLE="white-space:nowrap">Know-How</FONT> derived therefrom, by or on behalf of Acrivon or any of its Related Parties, including without limitation any product liability claim; or
(c)&nbsp;Acrivon&#146;s breach of this Agreement; except, in each case, to the extent such Losses arise out of any Lilly Indemnitee&#146;s negligence, illegal conduct, willful misconduct, or failure to comply with Applicable Laws or breach of this
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3 <B>Defined Indemnification Terms</B>. Either the Lilly Indemnitee or the Acrivon Indemnitee that is the
beneficiary of the obligation to indemnify, defend, and hold harmless under Section&nbsp;7.1 or 7.2, as applicable, shall be an &#147;<B>Indemnitee</B>&#148; for the purpose of this Article 7, and the Party that is obligated to indemnify the
Indemnitee under Section&nbsp;7.1 or Section&nbsp;7.2, as applicable, shall be the &#147;<B>Indemnifying Party</B>&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.4 <B>Defense</B>. The
Indemnifying Party shall have the right to assume direction and control of the defense of the Claim at the Indemnifying Party&#146;s sole expense by counsel selected by Indemnifying Party and reasonably acceptable to the Indemnitee, provided that
the Indemnitee may, at its own expense, also be represented by counsel of its own choosing. The Indemnifying Party shall have the sole right to control the defense of any such Claim subject to the terms of this Article 7, but shall consider in good
faith all reasonable suggestions of the Indemnitee. Notwithstanding the foregoing, if the Indemnifying Party does not assume direction and control of the defense of the Claim within [***] after receiving notice of the Claim from the Indemnitee, the
Indemnitee shall have the right to assume direction and control of such defense by counsel selected by the Indemnitee, and, without limiting the ,Indemnifying Party&#146;s indemnification obligations, the Indemnifying Party shall reimburse the
Indemnitee for all reasonable and documented costs, including reasonable attorney fees, incurred by the Indemnitee in defending itself within [***] after receipt of any invoice therefor from the Indemnitee. If the Indemnitee assumes direction and
control of the defense of such Claim in accordance with the preceding sentence, the Indemnifying Party may, at its own expense, participate in and monitor such defense with counsel of its own choosing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.5 <B>Settlement</B>. The Indemnifying Party shall be entitled to settle any such Claim or otherwise consent to an adverse judgment with respect to such Claim
(a)&nbsp;with prior written notice to the Indemnitee but without the consent of the Indemnitee where (i)&nbsp;there is no admission of legal wrongdoing on the part of the Indemnitee or (ii)&nbsp;the only liability or other obligation imposed on the
Indemnitee is the payment of money and the Indemnifying Party is obligated to make such payment under this Article 7 and actually makes such payment or (b)&nbsp;in all other cases, only with the prior written consent of the Indemnitee, such consent
not to be unreasonably withheld, provided that, notwithstanding anything to the contrary, Acrivon shall not enter into any settlement or consent to an adverse judgment with respect to any Claim in any matter that would, in either case, reasonably be
anticipated to adversely affect any Licensed Technology or either Party&#146;s ability to Develop or Commercialize Licensed Products without Lilly&#146;s prior written consent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.6 <B>Notice</B>. In connection with any Claim for which an Indemnitee seeks indemnification from the Indemnifying Party pursuant to this Agreement, the
Indemnitee shall: (a)&nbsp;notify the Indemnifying Party promptly in writing of such Claim; provided, however, that failure to provide such notice will not relieve the Indemnifying Party from its liability or obligation hereunder, except to the
extent of any material prejudice as a direct result of such failure; (b)&nbsp;reasonably cooperate with all reasonable requests of the Indemnifying Party with respect to such Claim and the defense or settlement thereof at the Indemnifying
Party&#146;s expense; and (c)&nbsp;permit the Indemnifying Party to control the defense and settlement of the Claim as set forth above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.7 <B>Permission
by Indemnifying Party</B>. The Indemnitee may not settle, consent to an adverse judgment, or make any admission as to liability or fault with respect to any Claim subject to indemnification without the express written permission of the Indemnifying
Party, which will not be unreasonably withheld or delayed, except in the case of any settlement, consent, or admission that would reasonably be anticipated to adversely affect any Licensed Technology or either Party&#146;s ability to Develop or
Commercialize Licensed Products, which shall, in each case, require Lilly&#146;s prior written consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <B>INVENTIONS; PATENT PROVISIONS</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.1 <B>Ownership of Inventions</B>. As between the Parties, and subject to Section&nbsp;9.5(d), Acrivon shall own the entire right, title and interest in and
to any and all information and inventions, whether or not patentable, discovered, created, identified or made solely by or on behalf of Acrivon, any of its Representatives, any Sublicensees, or any contractors of any of the foregoing in the course
of performing Acrivon&#146;s obligations or exercising any rights granted under this Agreement, or as a result of the Development, Manufacture, Commercialization, or use of Licensed Compound or Licensed Product or other use of Lilly&#146;s
Confidential Information, and all intellectual property rights in any of the foregoing (collectively, all of the foregoing, &#147;<B>Foreground Intellectual Property Rights</B>&#148;). Inventorship shall be determined in accordance with U.S. patent
laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.2 <B>Patent Filing, Prosecution and Maintenance</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Within [***] after the Effective Date, Lilly shall inform in writing any outside patent counsel and all local patent representatives used
by Lilly or any of its Affiliates to Prosecute any Licensed Patent that (i)&nbsp;the Licensed Patents have been exclusively licensed to Acrivon, (ii)&nbsp;Acrivon has the first right to Prosecute the Licensed Patents, and (iii)&nbsp;a copy of all
future correspondence regarding the Licensed Patents should be sent to both Acrivon and Lilly, and Lilly shall forward copies of any correspondence it or any of its Affiliates receives from any such outside patent counsel or local patent
representative or any patent office or other governmental body regarding the Licensed Patents to Acrivon. Upon Acrivon&#146;s written request, for a period of up to [***] following the Effective Date, Lilly will be responsible for Prosecuting the
Licensed Patents on Acrivon&#146;s behalf at Acrivon&#146;s cost (which shall be reimbursed to Lilly within [***] of Acrivon&#146;s receipt of an invoice therefor). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Acrivon shall have the first right, but not the obligation, to Prosecute the Licensed Patents, at its sole cost and expense using outside
counsel mutually acceptable to the Parties (such acceptance not to be unreasonably withheld). In the event that Acrivon desires to abandon or cease Prosecution of any Licensed Patent, Acrivon shall provide written notice to Lilly thereof at least
[***] prior to the next deadline for any action that must be taken with respect to such Licensed Patent in the relevant patent office. In such case, Lilly shall have the right, in its discretion, exercisable upon written notice to Acrivon delivered
no later than sixty (60)&nbsp;days after receipt of notice from Acrivon, to assume responsibility for and control of Prosecution of such Licensed Patent, at its sole cost and expense. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Acrivon shall keep Lilly reasonably informed regarding Acrivon&#146;s Prosecution activities with respect to Licensed Patents, including
periodic updates and advance notice of and reasonable opportunity to review material Patent filings prior to the time they are made. Acrivon shall consider in good faith any comments Lilly may make with respect to Acrivon&#146;s Prosecution
activities with respect to Licensed Patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If Lilly assumes control of the Prosecution of any Licensed Patent pursuant to
Section&nbsp;8.2(b), and thereafter decides to abandon or cease Prosecution of such Licensed Patent, Lilly shall provide written notice to Acrivon thereof at least [***] prior to the next deadline for any action that must be taken with respect to
such Licensed Patent in the relevant patent office. In such case, Acrivon shall have the right, in its discretion, exercisable upon written notice to Lilly delivered no later than [***] days after receipt of notice from Lilly, to assume
responsibility for and control of Prosecution of such Licensed Patent, at its sole cost and expense (in which case Sections 8.2(b) and 8.2(c) shall again then apply to such Licensed Patent). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.3 <B>Cooperation</B>. Each Party agrees to cooperate in the Prosecution of Licensed Patents under Section&nbsp;8.2. Such cooperation includes, but is not
limited to: (a)&nbsp;executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, that may be reasonably required so as to enable the other Party to Prosecute patent applications in any
country as permitted by Section&nbsp;8.2; and (b)&nbsp;promptly informing the other Party of any request for, or filing or declaration of, any interference, opposition, reissue, reexamination, revocation, inter partes review, post-grant review,
post-grant proceeding or similar proceeding relating to any Licensed Patent received by the Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.4 <B>Enforcement and Defense of Patent Rights</B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Notice</U>. Each Party shall notify the other Party in writing within [***] (except as expressly set forth below) of becoming aware
of any alleged or threatened infringement by a Third Party of a Licensed Patent (&#147;<B>Infringement</B>&#148;), including (i)&nbsp;any such alleged or threatened Infringement on account of a Third Party&#146;s Manufacture, use or sale of any
Licensed Compound or Licensed Product in the Field, (ii)&nbsp;any certification filed in the United States under 21 U.S.C. &#167;355(b)(2) or 21 U.S.C. &#167;355(j)(2) or similar provisions in other jurisdictions in connection with an ANDA (an
Abbreviated New Drug Application in the United States or a comparable application for marketing approval under Applicable Laws in any country other than the United States) or other NDA for a Licensed Product (in either case, a &#147;<B>Patent
Certification</B>&#148;), and (iii)&nbsp;any declaratory judgment action filed by a Third Party that is developing, manufacturing or commercializing Licensed Compound or Licensed Product in the Field alleging the invalidity, unenforceability or <FONT
STYLE="white-space:nowrap">non-infringement</FONT> of any Licensed Patent ((i), (ii), or (iii), collectively, &#147;<B>Competitive Infringement</B>&#148;); provided, however, that each Party shall notify the other Party of any Patent Certification
regarding any Licensed Patent that it receives, and such Party shall provide the other Party with a copy of such Patent Certification, within [***] of receipt. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Right to Enforce and Defend</U>. Acrivon shall have the first right, but not the obligation, to bring (or defend) and control any action
or proceeding with respect to Competitive Infringement of a Licensed Patent, at Acrivon&#146;s expense and by counsel of its choice, and Lilly shall have the right to be represented in any such action or proceeding, at Lilly&#146;s expense and by
counsel of its choice. If Acrivon fails to bring any such action or proceeding with respect to Competitive Infringement of any Licensed Patent within [***] following the notice of alleged Competitive Infringement, Lilly shall have the right to bring
(or defend) and control any such action at its expense and by counsel of its choice, and Acrivon shall have the right, at its own expense, to be represented in any such action at its expense and by counsel of its choice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Cooperation</U>. In the event a Party brings (or defends) an infringement action in
accordance with this Section&nbsp;8.4, or in the event a Party is entitled to bring (or defend) an infringement action in accordance with this Section&nbsp;8.4 but lacks standing to do so, the other Party shall cooperate fully, including, if
required to bring (or defend) such action, the furnishing of a power of attorney or being named as a party. Neither Party shall enter into any settlement or compromise of any action under this Section&nbsp;8.4 which would in any manner alter,
diminish, or be in derogation of the other Party&#146;s rights under this Agreement without the prior written consent of such other Party, which shall not be unreasonably withheld. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Recovery</U>. Except as otherwise agreed by the Parties in connection with a cost-sharing arrangement, any recovery realized by a Party
as a result of any action or proceeding pursuant to this Section&nbsp;8.4 with respect to Competitive Infringement, whether by way of settlement or otherwise, shall be applied [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.5 <B>Patent Term Extensions</B>. Acrivon shall have the right to determine the Licensed Patents for which it will apply for patent extension in any country
for any Licensed Product. Acrivon shall file for any such extension at Acrivon&#146;s cost and expense. Lilly shall provide all reasonable assistance to Acrivon in connection with such filings, provided that Acrivon shall pay or reimburse any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by Lilly in providing such assistance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.6
<B>Infringement of Third Party Rights</B>. Each Party shall promptly notify the other in writing of any allegation by a Third Party that the activity of either Party pursuant to this Agreement infringes or may infringe the intellectual property
rights of such Third Party. Neither Party shall have the right to settle any patent infringement litigation under this Section&nbsp;8.6 in a manner that materially diminishes the rights or interests of the other Party with respect to Licensed
Compounds or Licensed Products without the written consent of such other Party (which shall not be unreasonably withheld). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.7 <B>Patent Markings</B>.
Acrivon and its Affiliates shall (and ensure that all Sublicensees) mark all Licensed Products or Licensed Product packaging or advertising (as may be permitted) with the appropriate patent number reference for any applicable Licensed Patent(s) in
compliance with the requirements of 35 U.S.C. &#167; 287 and equivalent foreign laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.8 <B>Trademarks</B>. As between the Parties, Acrivon shall be
responsible for selecting, in its sole discretion, and shall own all right, title and interest in and to any trademarks adopted by Acrivon for use with the Licensed Products anywhere in the world (including all goodwill accruing with respect to such
use), and shall be responsible for the registration, filing, maintenance and enforcement thereof. Acrivon shall have no right to use any trademark, tradename, or corporate name of Lilly or any of its Affiliates with the Licensed Products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <B>TERM AND TERMINATION</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.1 <B>Term and Expiration</B>.
This Agreement shall be effective as of the Effective Date and, unless earlier terminated pursuant to Sections 9.2, 9.3 or 9.4, continue until the expiration of the <FONT STYLE="white-space:nowrap">last-to-expire</FONT> Royalty Term for any and all
Licensed Products (the period during which this Agreement is effective, the &#147;<B>Term</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.2 <B>Termination on Mutual Agreement</B>. This Agreement may be terminated by the mutual written agreement
of the Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.3 <B>Unilateral Termination by Acrivon</B>. Acrivon shall have the right to terminate this Agreement, in its entirety, in its sole
discretion by giving [***] advance written notice to Lilly; provided, however, that if Acrivon (or its Related Parties) is conducting clinical trials or Commercializing the Licensed Product at the time of termination, the notice period shall be
[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.4 <B>Termination for Cause</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Material Breach</U>. This Agreement may be terminated by a Party at any time during the Term upon written notice to the other Party if
such other Party is in material breach of its obligations under this Agreement and has not cured such breach within (i) [***] of such notice in the case of any failure to make when due any payment hereunder and (ii) [***] of such notice in the case
of any other breach. A material breach shall, notwithstanding anything to the contrary, include failure of Acrivon to timely achieve a Diligence Milestone by the applicable date therefor set forth on Exhibit I (as may be extended pursuant to
Section&nbsp;2.4(c)), provided that, notwithstanding anything to the contrary, if Acrivon has requested, and Lilly has granted, two extensions under Section&nbsp;2.4(c), no cure period shall thereafter apply hereunder to any failure to timely
achieve a Diligence Milestone and Lilly shall be entitled to immediately terminate this Agreement upon written notice to Acrivon. Any such termination shall become effective at the end of such [***] or [***] period unless the breaching Party has
cured such breach prior to the end of such period. Any right to terminate under this Section&nbsp;9.4(a) shall be stayed and the cure period tolled in the event that, during any cure period, the Party alleged to have been in material breach shall
have in good faith initiated dispute resolution with respect to the alleged breach, which stay and tolling shall continue until such dispute has been resolved. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Bankruptcy or Insolvency</U>. In the event that either Party files for protection under bankruptcy laws, makes an assignment for the
benefit of creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not discharged within [***] of the filing
thereof, then the other Party may terminate this Agreement effective immediately upon written notice to such Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for
Patent Challenge</U>. Except to the extent unenforceable under the Applicable Laws of a particular jurisdiction where the applicable Patent within the Licensed Patents is pending or has issued, Lilly may terminate this Agreement by written notice to
Acrivon in the event that (i)&nbsp;Acrivon or any of its Affiliates Challenges any Licensed Patent or (ii)&nbsp;any Sublicensee Challenges any Licensed Patent; provided such Challenge is not withdrawn within [***] of notice thereof or, in the case
of clause (ii), Acrivon does not terminate its all Sublicenses with such Sublicensee who commenced such Challenge. Notwithstanding the foregoing, Lilly shall have no such right to terminate this Agreement as a result of (A)&nbsp;any Challenge made
by Acrivon or any of its Related Parties, respectively, as a defense in any infringement proceeding brought against Acrivon or such Related Party, respectively, by Lilly, any of its Affiliates, or any of their respective licensees under the Patents
forming the basis for such Challenge, (y)&nbsp;any Challenge by Acrivon or any of its Related Parties challenging the validity or enforceability of any Patent owned or otherwise Controlled by Lilly that was or is not included in the Licensed
Patents, or (z)&nbsp;any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Challenge made or brought by any Person which becomes an Affiliate of Acrivon after the Effective Date which was initiated before the signing of the definitive document(s) whereby such Third
Party becomes such an Affiliate; provided, that (1)&nbsp;neither Acrivon nor any of its Affiliates, directly or indirectly, played any role in such Challenge and (2)&nbsp;such Challenge shall be dismissed as soon as reasonably possible (but in any
event no later than [***]) after such Person becomes an Affiliate of Acrivon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Damages</U>. If either Party has the right to
terminate this Agreement under this Section&nbsp;9.4, it may at its sole option, elect either to (i)&nbsp;terminate this Agreement and pursue any legal or equitable remedy available to it or (ii)&nbsp;maintain the Agreement in effect and pursue any
legal or equitable remedy available to it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.5 <B>Effect of Expiration or Termination</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Expiration</U>. Upon expiration (but not earlier termination under Section&nbsp;9.2, 9.3 or 9.4) of the Term of this Agreement, the
license and rights under Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> granted by Lilly to Acrivon pursuant to this Agreement shall survive on a nonexclusive, royalty-free, fully-paid, irrevocable, perpetual basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Upon any termination of this Agreement, Acrivon shall, unless otherwise agreed in writing by the Parties, destroy or properly dispose of
any Transferred Samples in its possession or control, as directed by Lilly, within [***] following termination and, in the case of destruction thereof, Acrivon shall also provide Lilly with written certification of the Transferred Samples&#146;
destruction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination by Acrivon for Cause</U>. In the event that Acrivon terminates this Agreement pursuant to
Section&nbsp;9.4(a) or Section&nbsp;9.4(b), the following shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all licenses and rights granted by Lilly to Acrivon pursuant to
this Agreement shall automatically terminate and Acrivon, its Affiliates, and, except to the extent any Sublicensees&#146; rights survive termination hereof pursuant to Section&nbsp;9.5(d), any Sublicensees shall cease Development, Manufacture, and
Commercialization of all Licensed Products; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Acrivon shall have the right to sell its remaining inventory of Licensed Product so long
as Acrivon has fully paid, and continues to pay when due, all royalties and milestone payments owed to Lilly, and Acrivon is not otherwise in material breach of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by Lilly for Cause or Acrivon for Convenience</U>. In the event that (x)&nbsp;Lilly terminates this Agreement pursuant to
Section&nbsp;9.4 or (y)&nbsp;Acrivon terminates this Agreement pursuant to Section&nbsp;9.3, then the following shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all
licenses and rights granted by Lilly to Acrivon pursuant to this Agreement shall automatically terminate and Acrivon, its Affiliates, and, except to the extent any Sublicensees&#146; rights survive termination hereof pursuant to Section&nbsp;9.5(d),
any Sublicensees shall cease Development, Manufacture, and Commercialization of all Licensed Products; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Acrivon and its Affiliates shall promptly (and, in any event, no later than within
[***] of termination) provide to Lilly the following information, in each case, (A)&nbsp;to the extent reasonably necessary or useful for Lilly to continue using, Developing, Commercializing and otherwise exploiting the Licensed Compounds and the
Licensed Products (including such information related to or generated after the Effective Date by the Product Tailored OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay) and (B)&nbsp;excluding any information or trade
secrets related to the AP3 Method or the OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay generally (and not specific to the Product Tailored OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Assay or
Licensed Product): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) all material information that is Controlled by Acrivon or its Affiliates concerning Licensed Compounds, Licensed
Products, Licensed Products and Licensed Compounds inventory, Acrivon <FONT STYLE="white-space:nowrap">Know-How,</FONT> Acrivon Patents, Product Marks, Product-Related Materials, Regulatory Materials, and Regulatory Approvals for Licensed Products
(all such information, &#147;<B>Product-Related Information</B>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) all material information reasonably requested by Lilly
concerning any manufacturing, supplier, distributor, research, development, clinical study, or other contracts, to the extent, in each case, related to the Development, Manufacture, or Commercialization of Licensed Compounds or Licensed Products,
entered into by Acrivon or its Affiliates with Third Parties (&#147;<B>Product-Related Contracts</B>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) upon written election
by Lilly within [***] of Lilly&#146;s receipt of all of the information Acrivon is obligated to provide under Section&nbsp;9.5(d)(ii)) and Acrivon&#146;s written notice to Lilly confirming its delivery to Lilly of all such information; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) [***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) [***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) [***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Except as Lilly
may otherwise elect to carry out on its own as described below in this paragraph, Acrivon shall be solely responsible to continue, wind-down or cease any ongoing clinical trials that it has commenced prior to such termination. Such continuation,
wind-down or cessation shall be carried out, in all instances, in full compliance with Applicable Laws, ethical standards and any regulatory requirements of applicable Regulatory Authorities, In the event Lilly notifies Acrivon in writing that it is
electing to carry out such ongoing clinical trials, Acrivon shall, in good faith, work with Lilly, at its cost, to transition such ongoing clinical trials to Lilly pursuant to a mutually agreed upon transition plan; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Notwithstanding anything to the contrary, (1)&nbsp;Acrivon and its Affiliates shall, for a period [***] following termination and only in
the case of a termination other than a termination by Lilly under Section&nbsp;9.4, have the privilege, subject to the payment of royalties and milestones as required under Article 4, of selling all finished Licensed Products or Licensed Products in
the process of Manufacture as of the date this Agreement is terminated (the &#147;<B>Termination Date</B>&#148;), (2) any assignment of any tangible or intangible assets to Lilly by Acrivon pursuant to Section&nbsp;9.5(d)(iii) shall be made subject
to the rights any Sublicensee may have with respect to such assets under any commercially reasonable sublicense entered into in accordance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with this Agreement and surviving such termination in accordance with Section&nbsp;9.5(d) below, and (3)&nbsp;with respect to any Licensed Product inventory or Licensed Product in the process of
Manufacture that Acrivon does not elect to (or cannot) sell in accordance with this Section&nbsp;9.5(d)(v) and Lilly elects to have transferred to it as contemplated above, (A)&nbsp;Lilly shall pay Acrivon a commercially reasonable amount as
consideration for the assignment and transfer of any Licensed Product inventory or Licensed Product in the process of Manufacture, with such amount to be negotiated in good faith by the Parties based on the facts and circumstances at such time and
which amount shall not, in any event, exceed Acrivon&#146;s reasonable, documented direct costs of manufacturing or procuring such Licensed Product inventory or Licensed Product in the process of Manufacture and (B)&nbsp;Lilly shall, at any time
prior to the delivery or assignment of such Licensed Product inventory or Licensed Product in the process of Manufacture have the right to decline its right to have any of the foregoing assigned to it (and thereby not be obligated to make any
payments with respect thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding any provision herein to the contrary, in the event (A)&nbsp;Acrivon or an Affiliate
thereof has entered into any Sublicense granting any Third Party rights to Develop and/or Commercialize Licensed Products as permitted by this Agreement (but which agreement must, in any event, include rights for such Third Party to Commercialize
Licensed Products), (B) this Agreement is terminated by Lilly pursuant to Section&nbsp;9.4, (C) the applicable Sublicensee provides written notice to Lilly, within five (5)&nbsp;Business Days of the termination of this Agreement, of the survival and
assignment of its Sublicense to Lilly and, in such notice, agrees to comply with the terms thereof and permit Lilly to enforce such terms following such assignment, and (D)&nbsp;the applicable Sublicensee is not in material breach of such
Sublicense: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) such sublicense (including any rights to payment thereunder) shall, to the extent concerning the Licensed Technology, not
imposing obligations on Lilly in excess of those contained in this Agreement, providing for payments with respect to the Licensed Technology and Licensed Products at least as favorable to Lilly as those provided herein, and provided for in such
Sublicense, be automatically assigned to Lilly; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Lilly shall grant such Third Party the rights granted with respect to Licensed
Technology under the assigned Sublicense, subject to such Third Party&#146;s compliance with its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.6 <B>Accrued Obligations; Survival</B>. Neither
expiration nor any termination of this Agreement shall relieve either Party of any obligation or liability accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement preclude either Party from
pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement. The following provisions (in addition to any provision that explicitly indicates herein that it shall survive
termination/expiration) shall survive the termination or expiration of this Agreement for any reason: 1, 2.7, 4.7, 4.8, 4.9, 4.10, 4.11, 5.1, 5.2, 5.3, 5.5, 5.6, 6.5, 6.6, 7, 8.1, 9.5, 9.6, 9.7, 10.1, 10.2, 10.3, 10.4, and 11. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.7 <B>Rights Upon Bankruptcy</B>. All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes
of Section&nbsp;365(n) of Title 11 of the United States Code and other similar laws in any jurisdiction outside the US (collectively, the &#147;<B>Bankruptcy Laws</B>&#148;), licenses of rights to be &#147;intellectual property&#148; as defined
under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Bankruptcy Laws. If a case is commenced during the Term by or against a Party under Bankruptcy Laws then, unless and until this Agreement is rejected as provided in such Bankruptcy Laws, such
Party (in any capacity, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debtor-in-possession)</FONT></FONT> and its successors and assigns (including a trustee) shall perform all of the obligations provided in this
Agreement to be performed by such Party. If a case is commenced during the Term by or against a Party under the Bankruptcy Laws, this Agreement is rejected as provided in the Bankruptcy Laws and the other Party elects to retain its rights hereunder
as provided in the Bankruptcy Laws, then the Party subject to such case under the Bankruptcy Laws (in any capacity, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debtor-in-possession)</FONT></FONT> and its successors
and assigns (including a Title 11 trustee), shall provide to the other Party copies of all information necessary for such other Party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly upon such other Party&#146;s
written request therefor. All rights, powers and remedies of the <FONT STYLE="white-space:nowrap">non-bankrupt</FONT> Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or
hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <B>COVENANTS</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.1 <B>Compliance with Applicable
Laws</B>. Each Party shall, and shall require its Affiliates, sublicensees, agents and subcontractors to comply in all material respects with all Applicable Laws in connection with the performance of their obligations and the exercise of their
rights under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.2 <B>Compliance with Party Specific Regulations</B>. The Parties agree to cooperate with each other (and cause their
Affiliates to cooperate) as may reasonably be requested to ensure that each Party and its Affiliates is able to fully meet its obligations with respect to the Party Specific Regulations applicable to it. Neither Party nor any Affiliate thereof shall
be obligated to pursue any course of conduct that would result in such Party or any Affiliate thereof being in material breach of any Party Specific Regulation applicable to it. All Party Specific Regulations are binding only in accordance with
their terms and only upon the Party or its Affiliate to which they relate. This Section&nbsp;10.2 shall apply subject to notification by a Party to the other Party of any such applicable Party Specific Regulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.3 <B>Compliance with Internal Compliance Codes</B>. All Internal Compliance Codes shall apply only to the Party (and Affiliates thereof) to which they
relate. The Parties agree to cooperate with each other (and to cause their Affiliates to cooperate) as may be reasonably requested to allow each Party and its Affiliates to comply in all material respects with the substance of its respective
Internal Compliance Codes and, to the extent practicable, to operate in a manner consist with its usual compliance-related processes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.4 <B>Compliance
with Anti-Corruption and Privacy Laws</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Anti-Corruption and Privacy</U>. In connection with this Agreement, each Party and each
of its Affiliates has complied and will comply with all Applicable Laws and industry codes dealing with data protection and privacy of personal information and with government procurement, conflicts of interest, corruption or bribery, including, if
applicable, the U.S. Foreign Corrupt Practices Act of 1977 (&#147;<B>FCPA</B>&#148;), as amended, and any laws enacted to implement the Organisation of Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in
International Business Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Privacy</U>. Each Party shall at all times comply (and cause its Affiliates to
comply) with all Applicable Laws and all applicable contractual obligations with respect to the receipt, collection, compilation, use, storage, processing, sharing, safeguarding, security (technical, physical and administrative), disposal,
destruction, disclosure, or transfer (including cross-border) of Personal Information in connection with this Agreement, including providing any notice, obtaining any consent and/or prior authorization, and conducting any assessment required under
Applicable Laws, with respect thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Bribery</U>. In connection with this Agreement, neither Party, nor any of its Affiliates,
has made, offered, given, promised to give, or authorized, nor will make, offer, give, promise to give, or authorize, in a manner that violates Applicable Laws, any bribe, kickback, payment or transfer of anything of value, directly or indirectly,
to any person or to any Government or Public Official for the purpose of: (i)&nbsp;improperly influencing any act or decision of the person or Government or Public Official; (ii)&nbsp;inducing the person or Government or Public Official to do or
omit to do an act in violation of a lawful or otherwise required duty; (iii)&nbsp;securing any improper advantage; or (iv)&nbsp;inducing the person or Government or Public Official to improperly influence the act or decision of any organization,
including any government or government instrumentality, in order to assist Acrivon or Lilly, as applicable, in obtaining or retaining business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.
<B>MISCELLANEOUS</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.1 <B>Force Majeure</B>. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached
this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including, but not limited to,
embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, epidemic, pandemic, fire, flood, earthquake, tornado, tsunami, explosion, storm,
or other acts of God, failure of public utilities or common carriers, or acts, omissions or delays in acting by any Governmental Authority. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably
practical and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.2 <B>Assignment</B>. Neither Party
may assign its rights and obligations under this Agreement without the prior written consent of the other Party, such consent not to unreasonably withheld; provided that: (i)&nbsp;Lilly may, at any time, and (ii)&nbsp;Acrivon may, only after the
expiration of the ROFN Term, assign this Agreement and its rights and obligations hereunder, without the other Party&#146;s consent: (X)&nbsp;to any of its Affiliates (provided that the assigning Party shall remain jointly and severally (with the
assignee) liable and responsible to the <FONT STYLE="white-space:nowrap">non-assigning</FONT> Party for the performance and observance of all such duties and obligations by such Affiliate); or (Y)&nbsp;in connection with the transfer or sale of all
or substantially all of the business or assets of such Party (or that portion thereof to which this Agreement relates) to a Third Party, whether by merger, sale of stock, sale of assets, or otherwise. The rights and obligations of the Parties under
this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#146;s successors and permitted assigns
to the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.3 <B>Severability</B>. If any one or more of the provisions contained in this Agreement is held invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely
affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical,
implement the purposes of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.4 <B>Notices</B>. All notices which are required or permitted hereunder shall be in writing and sufficient if
delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; font-size:10pt; font-family:Times New Roman">if to Acrivon, to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Acrivon Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; font-size:10pt; font-family:Times New Roman">with copy (which shall not</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hogan Lovells US LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; font-size:10pt; font-family:Times New Roman">constitute notice) to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; font-size:10pt; font-family:Times New Roman">if to Lilly, to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Eli Lilly and Company</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; font-size:10pt; font-family:Times New Roman">with copy (which shall not</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Eli Lilly and Company</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; font-size:10pt; font-family:Times New Roman">constitute notice) to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. Any such notice shall be deemed to have been given: (a)&nbsp;when delivered if personally delivered or sent by facsimile on a Business Day (provided that if given by facsimile, the transmitting Party received confirmation of
complete transmission); (b) on the Business Day after dispatch if sent by nationally-recognized overnight courier; or (c)&nbsp;on the [***] Business Day following the date of mailing if sent by mail. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.5 <B>Governing Law</B>. This Agreement shall be governed by and construed in accordance with the laws of
the United States federal law and New York state law, without reference to any rules of conflict of laws that would result in the application of the laws of any other jurisdiction. The United Nations Convention on Contracts for the International
Sale of Goods shall not apply to the transactions contemplated by this Agreement. Each Party hereby irrevocably and unconditionally (a)&nbsp;consents to submit to the exclusive jurisdiction of the federal courts located in New York, New York, for
any actions, suits or proceedings arising out of or relating to this Agreement and (b)&nbsp;waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated hereby in the
federal courts of New York, New York, and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. Each Party waives personal service of any summons,
complaint or other process in connection with such action and agree that service may be made by any means permitted or prescribed in this Agreement for delivery of notices or by any means permitted by Applicable Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.6 <B>Waiver of Jury Trial</B>. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN
ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES. THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.7 <B>Entire Agreement; Amendments</B>. The Agreement contains the entire understanding of the Parties with respect to the rights and licenses granted
hereunder. All express or implied agreements and understandings, either oral or written, with regard to the rights and licenses granted hereunder are superseded by the terms of this Agreement, including the prior Confidentiality Agreement. The
Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.8
<B>Headings</B>. The captions to the several Articles and Sections hereof are for convenience of reference only, are not a part of the Agreement, and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of
any provision contained in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.9 <B>Independent Contractors</B>. It is expressly agreed that Acrivon and Lilly shall be independent
contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Acrivon nor Lilly shall have the authority to make any statements, representations or commitments of any kind, or to
take any action, which shall be binding on the other Party, without the prior written consent of the other Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.10 <B>Waiver</B>. The failure by
either Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement or any breach hereof by the other Party shall neither impair such provision or right nor constitute a waiver of
that provision or right, in whole or in part, in that instance or any other. No waiver by a Party of a particular provision or right shall be effective unless in writing, specific as to a particular matter and, if applicable, for a particular period
of time, and signed by such Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.11 <B>Cumulative Remedies</B>. Except as expressly set forth herein, no remedy referred to in this Agreement is
intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available at law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.12 <B>Waiver of Rule of Construction</B>. Each Party has had the opportunity to consult with counsel in
connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.13 <B>Construction</B>. Except where the context otherwise requires, wherever used, the singular will include the plural, the plural the singular, and the
use of any gender will be applicable to all genders. The term &#147;including&#148; as used herein means including, without limiting the generality of any description that precedes such term, and shall be deemed to be followed by the phrase &#147;
but not limited to,&#148; &#147;without limitation&#148; or words of similar import regardless of whether such words are actually written there (and drawing no implication from the actual inclusion of such phrase in some instances after the word
&#147;including&#148; but not others). References to &#147;Article&#148;, &#147;Articles&#148;, &#147;Section&#148;, &#147;Sections&#148;, &#147;Exhibit&#148; or &#147;Exhibits&#148; are references to the numbered Article(s) or lettered Exhibit(s)
of this Agreement, unless expressly stated otherwise. Except where the context otherwise requires, (a)&nbsp;references to a particular law, rule or regulation mean such law, rule or regulation as in effect as of the relevant time, including all
rules and regulations thereunder and any successor law, rule or regulation in effect as of the relevant time, and including the then-current amendments thereto; (b)&nbsp;the word &#147;or&#148; has the inclusive meaning that is typically associated
with the phrase &#147;and/or&#148;; (c) whenever this Agreement refers to a number of days, such number will refer to calendar days unless Business Days are specified, and if a period of time is specified and dates from a given day or Business Day,
or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day; (d)&nbsp;references to a particular person or entity include such person&#146;s or entity&#146;s successors and assigns to the extent not
prohibited by this Agreement; (e)&nbsp;a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein shall be interpreted in a correlative manner; and (f)&nbsp;the words
&#147;hereof,&#148; &#147;herein,&#148; &#147;hereby&#148; and derivative or similar words refer to this Agreement (including any Exhibits). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.14 <B>Use
of Third Parties</B>. Notwithstanding any delegation of obligations under this Agreement by a Party or its Affiliates or to a Third Party, such Party shall remain primarily liable and responsible for the performance of all of its obligations under
this Agreement and for causing such Affiliates or Third Parties to act in a manner consistent herewith, to the extent applicable. No Party contracting with any Third Party shall agree to any term that would make it unable to comply with its
obligations under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.15 <B>Further Action</B>. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do
all such other acts, as may be reasonably necessary or appropriate in order to carry out the purposes and intent of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.16
<B>Counterparts</B>. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Each Party shall be entitled to rely on the delivery
of executed facsimile copies of counterpart execution pages of this Agreement and such facsimile copies shall be legally effective to create a valid and binding agreement among the Parties. Signatures provided by facsimile transmission or in Adobe<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> Portable Document Format (PDF) sent by electronic mail shall be deemed to be original signatures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page Follows </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have caused this Agreement to be executed by their
duly authorized representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACRIVON THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Blume-Jensen, MD, PhD</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Peter Blume-Jensen, MD, PhD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President and CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ELI LILLY AND COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Skovronsky, MD, PhD</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Daniel Skovronsky, MD, PhD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President Lilly Research Laboratories</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chief Scientific Officer, Eli Lilly and Company</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Compound </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Investigator-Sponsored Trials </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Existing Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Index</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Index</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Additional items</U>: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lilly CMO Agreements and Authorization Letter </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lilly Trials </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Listed Patents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lilly</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Project</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Appl&nbsp;Ser.&nbsp;#</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Transferred Materials </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Clinical
Compound</U>: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Transferred Product</U>:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Additional Transferred Materials</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Drug Substance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Rationale</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Transferred Samples </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Diligence Milestones </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Target Date of Completion</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Back-Up</FONT> Date of
Completion</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***]</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT J </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Initial Development Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT K </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lilly Animal Care and Use Requirements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT L </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Stock
Issuance Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACRIVON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK ISSUANCE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Common Stock Issuance Agreement (the &#147;<B><I>Agreement</I></B>&#148;) is made as of this [&#149;] day of January, 2021 (the
&#147;<B><I>Effective Date</I></B>&#148;), by and between Acrivon Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148; or &#147;<B><I>Acrivon</I></B>&#148; ) and Eli Lilly and Company, an Indiana corporation (the
&#147;<B><I>Purchaser</I></B>&#148; or &#147;<B><I>Lilly</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Purchaser has entered into that certain License Agreement with the Company, dated as of January [&#149;], 2021 (the
&#147;<B><I>License Agreement</I></B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in accordance with Section&nbsp;4.2 of the License Agreement and in
partial consideration for the rights and licenses granted to the Company thereunder, the Company wishes to issue to Purchaser and Purchaser wishes to obtain from the Company, an aggregate of 829,995 shares of Common Stock of the Company, par value
$0.001 per share (the &#147;<B><I>Initial Shares</I></B>&#148;, and, together with any Additional Shares (as defined below), the &#147;<B><I>Shares</I></B>&#148;), effective as of the Effective Date on the terms and conditions set forth herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW,
THEREFORE</B>, in consideration of the foregoing recitals and the mutual covenants and representations set forth below, the Company and the Purchaser agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>Purchase and Sale of the Shares</B>. Subject to the terms and conditions of this Agreement, the Company hereby issues to the Purchaser,
and the Purchaser hereby accepts from the Company, on the Effective Date the Initial Shares in exchange for Purchaser&#146;s execution and delivery of the License Agreement (the &#147;Transaction&#148;). The Company will issue, as promptly hereafter
as practicable, a stock certificate registered in the name of the Purchaser, or a notice of issuance of uncertificated stock, as applicable, reflecting the Initial Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Company Representations and Warranties as of the Effective Date</B>. As of the Effective Date, the Company hereby represents and warrants
to the Purchaser as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. Upon issuance, the Initial Shares will constitute [***] of the fully diluted capitalization of the Company
(including any shares issuable upon exercise, conversion or exchange of other securities of the Company exercisable for, convertible into, or exchangeable shares) and including authorized but unissued shares reserved pursuant to the Company&#146;s
2019 Stock Incentive Plan, duly adopted by the Board of Directors of the Company (the &#147;<B><I>Board</I></B>&#148;) and approved by the Company stockholders (the &#147;<B><I>Stock Plan</I></B>&#148;). The calculation of the percentage that the
Initial Shares constitute of the Company&#146;s fully diluted capitalization is set forth on <B>Schedule 2.A</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. The authorized
capital of the Company consists, immediately prior to the Effective Date, of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) [***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Except for
the shares described as issued and outstanding under clauses (i)&nbsp;through (iii) of this <B>Section</B><B></B><B>&nbsp;2.B</B>, the Company has not issued or agreed to issue any (a)&nbsp;shares of capital stock or other equity, ownership, or
voting interests; (b)&nbsp;securities or instruments convertible into or exchangeable or exercisable for shares of capital stock or other equity, ownership, or voting interests; or (c)&nbsp;equity-equivalents, earnings, profits, or revenue-based or
equity-based rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C. <B>Schedule 2.A</B> sets forth an accurate and complete <I>pro forma</I> capitalization table as of immediately
following the issuance of the Initial Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">D. The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware. The Company has the requisite corporate power to own and operate its properties and assets and to carry on its business as now conducted, and to execute and deliver this Agreement and to carry out and perform its
obligations under the terms of the Agreement. The Company is duly qualified and is authorized to do business and is in good standing in all jurisdictions in which the nature of its activities and of its properties (both owned and leased) makes such
qualification necessary, except for those jurisdictions in which failure to do so would not have a material adverse effect on the Company or its business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">E. All corporate action on the part of the Company and its stockholders necessary for the authorization of the Agreement and the execution,
delivery and performance of all obligations of the Company under the Agreement, including the issuance and delivery of the Initial Shares, has been taken by the Company. The Agreement, when executed and delivered by the Company, shall constitute a
valid and binding obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency, the relief of debtors and, with respect to rights to indemnity, subject to federal and
state securities laws. Upon issuance the Shares issued pursuant to this Agreement will be validly issued, fully paid and nonassessable and free of any liens or encumbrances other than as explicitly provided hereinafter, and issued in compliance with
all applicable federal and securities laws, subject to the making of any required filings under applicable federal and state securities laws and the accuracy of the Purchaser&#146;s representations in Section&nbsp;3, and the offer, issue, and sale
of the Shares are and will be exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), and have been registered or qualified (or are exempt from
registration and qualification) under the registration, permit, or qualification requirements of all applicable state securities laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">F.
The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the transactions contemplated hereby do not and will not (a)&nbsp;violate any provision of the certificate of incorporation or bylaws of
the Company; (b)&nbsp;violate any federal, state or local statute, law, regulation, order, injunction or decree (&#147;<B><I>Law</I></B>&#148;) applicable to the Company, subject to such filings required under applicable state securities laws and
the rules thereunder and Regulation D of the Securities Act; (c)&nbsp;conflict with, create a breach or default under, require any consent of or notice to or give to any third party any right of modification, acceleration or cancellation, or result
in the creation of any encumbrance upon any property or right of the Company pursuant to, any contract, agreement, license, permit or other instrument to which the Company is a party or by which the Company or any of the Company&#146;s properties,
assets or rights may be bound, affected or benefited; (d)&nbsp;allow the imposition of any fees or penalties or require the offering or making of any payment to a third party on the part of the Company; or (e)&nbsp;require any consent or approval
of, registration or filing with, or notice to any federal, state or local governmental authority or any agency or instrumentality thereof, other than such filings required under applicable state securities laws and the rules thereunder and
Regulation D of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">G. Except as set forth on <B>Schedule 2.G</B>, the Company does not presently own or
control, directly or indirectly, any interest in any other entity of any type. The Company is not a participant in any joint venture, partnership or similar arrangement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">H. There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or to the Company&#146;s knowledge,
currently threatened (i)&nbsp;against the Company or any officer, director or key employee of the Company arising out of their employment or board relationship with the Company; or (ii)&nbsp;to the Company&#146;s knowledge, that questions the
validity of this Agreement or the License Agreement or the right of the Company to enter into them, or to consummate the transactions contemplated by this Agreement or the License Agreement; or (iii)&nbsp;to the Company&#146;s knowledge, that would
reasonably be expected to have, either individually or in the aggregate, a material adverse effect. Neither the Company nor, to the Company&#146;s knowledge, any of its officers, directors or key employees is a party or is named as subject to the
provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers, directors or key employees, such as would affect the Company). There is no action, suit, proceeding or
investigation by the Company pending or which the Company intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any basis therefor known to the Company)
involving the prior employment of any of the Company&#146;s employees, their services provided in connection with the Company&#146;s business, any information or techniques allegedly proprietary to any of their former employers or their obligations
under any agreements with prior employers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I. The Company is not in violation or default (i)&nbsp;of any provisions of its certificate of
incorporation or bylaws, (ii)&nbsp;of any instrument, judgment, order, writ or decree, (iii)&nbsp;under any note, indenture or mortgage, (iv)&nbsp;under any lease, agreement, contract or purchase order to which it is a party or by which it is bound,
or (v)&nbsp;to its knowledge, of any provision of federal or state statute, rule or regulation applicable to the Company, the violation of which would have a material adverse effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">J. The Company has all franchises, permits, government licenses and any similar authority necessary for the conduct of its business, the lack
of which could reasonably be expected to have a material adverse effect. The Company is not in default in any material respect under any of such franchises, permits, government licenses or other similar authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">K. The certificate of incorporation and bylaws of the Company are in the form made available to the Purchaser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">L. Neither the Company, nor any of its officers, directors, employees or agents, has either directly or indirectly, including through a broker
or finder, (i)&nbsp;engaged in any general solicitation or (ii)&nbsp;published any advertisement in connection with the offer and sale of the Initial Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">M. Neither the Company nor, to the knowledge of the Company, any director, officer, employee, or person acting on behalf of the Company is
currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">N. Neither
the Company nor any of the Company&#146;s directors, officers, employees, or agents have, directly or indirectly, made, offered, promised, or authorized any payment or gift of any money or anything of value to or for the benefit of any &#147;foreign
official&#148; (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#147; <B><I>FCPA</I></B>&#148; )), foreign political party or official thereof, or candidate for foreign political office for the purpose of
(i)&nbsp;influencing any official act or decision of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
official, party, or candidate, (ii)&nbsp;inducing such official, party, or candidate to use his, her, or its influence to affect any act or decision of a foreign governmental authority, or
(iii)&nbsp;securing any improper advantage, in the case of (i), (ii), and (iii)&nbsp;above in order to assist the Company or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the
Company nor any of its directors, officers, employees, or agents have made or authorized any bribe, rebate, payoff, influence payment, kickback, or other unlawful payment of funds or received or retained any funds in violation of any law, rule, or
regulation. Neither the Company, nor, to the Company&#146;s knowledge, any of its officers, directors, or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution, or other enforcement action related to the FCPA
or any other anti-corruption law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">O. The operation of the Company is and has been conducted at all times in compliance with the money
laundering statues of applicable jurisdictions, the rules and regulations thereunder, and any related or similar rules, regulations, or guidelines, issued, administered, or enforced by any applicable governmental agency (collectively, the
&#147;<B><I>Money Laundering Laws</I></B>&#148;), and no action suit, or proceeding by or before any court of governmental agency, authority, or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending, or to
the Company&#146;s knowledge, threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">P. There are no federal, state, county, local, or foreign taxes due and payable by the Company
which have not been timely paid. There are no accrued and unpaid federal, state, county, local ,or foreign taxes of the Company which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or
reports by any applicable federal, state, local, or foreign governmental agency. The Company has duly and timely filed all federal, state, county, local, and foreign tax returns required to have been filed by it and there are in effect no waivers of
applicable statutes of limitations with respect to taxes for any year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>Purchaser Representations and Warranties as of the Effective
Date</B>. As of the Effective Date, the Purchaser hereby represents and warrants to the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. Purchaser understands that
the Company&#146;s sale of the Shares to Purchaser has not been registered under the Securities Act, because the Company believes, relying in part on Purchaser&#146;s representations in this Agreement, that an exemption from such registration
requirement is available for such sale. Purchaser understands that the availability of this exemption depends upon the representations it is making to the Company in this Agreement being true and correct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. This Agreement, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser,
enforceable in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors&#146; rights generally,
and as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C. Purchaser
is purchasing the Shares solely for investment purposes, and not for further distribution. Purchaser&#146;s entire legal and beneficial ownership interest in the Shares is being purchased and shall be held solely for its account. Purchaser is not a
party to, and does not presently intend to enter into, any contract or other arrangement with any other person or entity involving the resale, transfer, grant of participation with respect to or other distribution of any of the Shares.
Purchaser&#146;s investment intent is not limited to its present intention to hold the Shares for the minimum capital gains period specified under any applicable tax law, for a deferred sale, for a specified increase or decrease in the market price
of the Shares, or for any other fixed period in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">D. Purchaser can properly evaluate the merits and risks of an investment in the Shares and
can protect its own interests in this regard, whether by reason of its own business and financial expertise, the business and financial expertise of certain professional advisors unaffiliated with the Company with whom Purchaser has consulted, or
Purchaser&#146;s preexisting business or personal relationship with the Company or any of its officers, directors or controlling persons. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">E. Purchaser is sufficiently aware of the Company&#146;s business affairs and financial condition to reach an informed and knowledgeable
decision to acquire the Shares. Purchaser has had an opportunity to discuss the plans, operations, and financial condition of the Company with its officers, directors or controlling persons, and has received all information it deems appropriate for
assessing the risk of an investment in the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">F. Purchaser realizes that the purchase of the Shares involves a high degree of risk,
and that the Company&#146;s future prospects are uncertain. Purchaser is able to hold the Shares indefinitely if required, and is able to bear the loss of its entire investment in the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">G. Purchaser understands that the Shares are &#147;restricted securities&#148; in that the Company&#146;s sale of the Shares to Purchaser has
not been registered under the Securities Act in reliance upon an exemption for <FONT STYLE="white-space:nowrap">non-public</FONT> offerings. In this regard, Purchaser also understands and agrees that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) Purchaser must hold the Shares indefinitely, unless any subsequent proposed resale by it is registered under the Securities Act, or unless
an exemption from registration is otherwise available (such as Rule 144); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) the Company is under no obligation to register any
subsequent proposed resale of the Shares by Purchaser; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) the certificate evidencing the Shares (or the notice of issuance of
uncertificated stock, as applicable) will be imprinted with a legend which prohibits the transfer of the Shares unless such transfer is registered or such registration is not required in the opinion of counsel for the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">H. Purchaser is familiar with Rule 144 adopted under the Securities Act, which in some circumstances permits limited public resales of
&#147;restricted securities&#148; like the shares acquired from an issuer in a <FONT STYLE="white-space:nowrap">non-public</FONT> offering. Purchaser understands that its ability to sell the Shares under Rule 144 in the future is uncertain, and may
depend upon, among other things: (i)&nbsp;the availability of certain current public information about the Company; (ii)&nbsp;the resale occurring more than a specified period after Purchaser&#146;s purchase and full payment (within the meaning of
Rule 144) for the Shares; and (iii)&nbsp;if Purchaser is an affiliate of the Company (A)&nbsp;the sale being made in an unsolicited &#147;broker&#146;s transaction,&#148; transactions directly with a market maker or riskless principal transactions,
as those terms are defined under the Securities Exchange Act of 1934, as amended, (B)&nbsp;the amount of shares being sold during any three-month period not exceeding the specified limitations stated in Rule 144, and (C)&nbsp;timely filing of a
notice of proposed sale on Form 144, if applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I. Purchaser understands that the requirements of Rule 144 may never be met, and that
the Shares may never be saleable under the rule. Purchaser further understands that at the time it wishes to sell the Shares, there may be no public market for the Company&#146;s stock upon which to make such a sale, or the current public
information requirements of Rule 144 may not be satisfied, either of which may preclude Purchaser from selling the Shares under Rule 144 even if the relevant holding period had been satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">J. Purchaser understands that in the event Rule 144 is not available to it, any future
proposed sale of any of the Shares by Purchaser will not be possible without prior registration under the Securities Act, compliance with some other registration exemption (which may or may not be available), or each of the following:
(i)&nbsp;Purchaser&#146;s written notice to the Company containing detailed information regarding the proposed sale, (ii)&nbsp;Purchaser providing an opinion of its counsel to the effect that such sale will not require registration, and
(iii)&nbsp;the Company notifying Purchaser in writing that Company&#146;s counsel concurs in such opinion. Purchaser understands that neither the Company nor its counsel is obligated to provide Purchaser with any such opinion. Purchaser understands
that although Rule 144 is not exclusive, the staff of the SEC has stated that persons proposing to sell private placement securities other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing
that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">K. The Purchaser understands that no public market now exists for the Shares, and that the Company has made no assurances that a public market
will ever exist for the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">L. The Purchaser understands that the Shares and any securities issued in respect of or exchange for the
Shares, may be notated with one or all of the following legends: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The legend set forth below; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT
WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) Any legend required by the securities laws of any state to the
extent such laws are applicable to the Shares represented by the certificate, instrument, or book entry so legened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">M. The Purchaser is an
accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">N. Purchaser understands that the
Board believes its valuation of the Shares represents a fair appraisal of their worth, but that it remains possible that, with the benefit of hindsight, the Internal Revenue Service (&#147;IRS&#148;) may successfully assert that the value of the
Shares on the date of Purchaser&#146;s purchase is substantially greater than the Board&#146;s appraisal. Purchaser understands that any additional value ascribed to the Shares by such an IRS determination will constitute ordinary income to
Purchaser as of the purchase date, and that any additional taxes and interest due as a result will be Purchaser&#146;s sole responsibility payable only by Purchaser, and that the Company need not and will not reimburse Purchaser for that tax
liability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">O. The address of Purchaser&#146;s principal place of business is set forth on the signature page to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">P. Neither the Purchaser, nor any of its officers, directors, employees, agents, or partners has either directly or indirectly, including,
through a broker or finder (a)&nbsp;engaged in any general solicitation, or (b)&nbsp;published any advertisement in connection with the offer and sale of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Q. Neither Purchaser nor any person that would be deemed a beneficial owner of the Shares
(in accordance with Rule 506(d) of the Securities Act) is subject to any of the &#147; bad actor&#148; disqualifications described in Rule 506(d)(1)(i) through (viii)&nbsp;under the Securities Act, except as set forth in Rule 506(d)(2)(ii) or
(iii)&nbsp;or (d)(3) under the Securities Act and disclosed, reasonably in advance of the purchase or acquisition of the Shares, in writing in reasonable detail to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B>Additional Agreements.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. <B><I>Anti-Dilution</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) As partial consideration for the exclusive license rights granted by the Purchaser to the Company under the License Agreement, and subject
to Section&nbsp;4.A.2, until the Aggregate Equity Value reaches [***] (the &#147;Valuation Threshold&#148;), the Company shall issue to the Purchaser a number of shares of Capital Stock (i)&nbsp;upon completion of a Preferred Financing;
(ii)&nbsp;within [***] following each issuance of Capital Stock (as defined below) after the date hereof (excluding issuances in a Preferred Financing for which Additional Shares are issued pursuant to clause (i)&nbsp;and excluding any shares of
Capital Stock issued upon exercise or conversion of options or warrants set forth on Schedule 2.A or any warrants, options or convertible securities for which Additional Shares are issued pursuant to clauses (iii)&nbsp;and (iv)); (iii) within [***]
following an issuance of any warrant or security exercisable for Capital Stock (other than the issuance of any options or shares of stock pursuant to the Company&#146;s equity incentive plan); and (iv)&nbsp;within [***] after any increase in the
Company&#146;s employee stock option plan (each event set forth in clauses (i)-(iv), a &#147;Trigger Event&#148;), such that the Purchaser holds, in each case, in aggregate and on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">as-converted-to-Common</FONT></FONT></FONT> Stock basis, [***] of the Company&#146;s Fully Diluted Equity immediately following such Trigger Event (such shares of Company stock, the &#147;Additional Shares&#148;). The
Additional Shares shall be, as applicable: (a)&nbsp;the same security as issued in any Preferred Financing with identical rights, preferences and privileges as the other securities issued in the Preferred Financing in the case of issuing Additional
Shares upon completion of a Preferred Financing and (b)&nbsp;Common Stock in the case of any other issuance of Additional Shares. Simultaneously with the Company&#146;s delivery of any Additional Shares to the Purchaser, which shall occur no later
than [***] after the event requiring such issuance, the Company shall provide Purchaser a written description of the calculation of the number of Additional Shares. Such written description shall include, as of the date of issuance of the Additional
Shares, the Company&#146;s Fully Diluted Equity, shown in at least the same degree of detail as shown in Schedule 2.A, the Applicable Price Per Share, and a reference to the source of the Applicable Price Per Share. Sample calculations of the
Additional Shares in connection with a Preferred Financing are attached as Schedule 4.A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) If the Additional Shares are issued in
connection with a Preferred Financing, the Purchaser shall execute and deliver to the Company, and shall be bound upon such issuance by the obligations in all transaction documents entered into by the purchasers participating in the Preferred
Financing, as applicable; provided, however, that (1)&nbsp;all other investors participating in such Preferred Financing also execute such agreements and other documents; (2)&nbsp;the obligations of Purchaser with respect to the Additional Shares
issued to the Purchaser shall be no more restrictive or burdensome than the obligations of the other purchasers of the preferred securities and (3)&nbsp;in no event will the Purchaser or any of its affiliates be required, in connection with any sale
of the Company (including pursuant to an exercise of any drag-along provisions set forth in any agreement to which Purchaser is a party) or otherwise, to enter into, or be bound by or subject to any provisions in (or agree or commit to enter into or
be bound by or subject to), any agreement that, directly or indirectly, (A)&nbsp;would limit or restrict the Purchaser&#146;s or any of its affiliates&#146; freedom to engage in any business or investment activity, whether or not it may be
competitive with the Company or its affiliates (including, without limitation, requiring the Purchaser or any of its affiliates to enter into any <FONT STYLE="white-space:nowrap">non-competition</FONT> or
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, or any other restrictive covenant); (B) would require the Purchaser or any of its affiliates to waive or release any claim against the Company in connection with a sale of the
Company other than those arising solely in its capacity as a holder of Capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock; (C)&nbsp;would require the Purchaser or any of its affiliates to amend, extend, or terminate any contractual or other relationship with the Company, the acquirer of the Company or their
respective affiliates, except that the Purchaser and its affiliates may be required to agree to terminate the investment-related documents between or among the Purchaser, the Company, and the other stockholders of the Company; (D)&nbsp;would require
the Purchaser or any of its affiliates to make any representations or warranties in connection with the sale of the Company other than those related to authority, ownership, and the ability to convey title to the shares of capital stock of the
Company then held by the Purchaser, or (E)&nbsp;would require the Purchaser or any of its affiliates to be liable for indemnification with respect to any inaccuracy of any representations or warranties made by the Company or any other stockholder
unless such indemnification is several and not joint and is pro rata in proportion to, and does not exceed, the amount of consideration paid to the Purchaser and its affiliates in connection with such sale of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) The Company&#146;s obligation to issue Additional Shares to the Purchaser pursuant to Section&nbsp;4.A shall terminate upon the earlier of
(i)&nbsp;Company&#146;s issuance of Additional Shares to the Purchaser following the achievement of the Valuation Threshold or (ii)&nbsp;the closing of any Preferred Financing of the Company where the Aggregate Equity Value determined immediately
prior to the completion of such Preferred Financing exceeds the Valuation Threshold. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) For the purposes of this Section&nbsp;4.A: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">i. the term &#147;Aggregate Equity Value&#148; means the product of (i)&nbsp;the Fully Diluted Equity and (ii)&nbsp;the Applicable Price Per
Share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">ii. The term &#147;Applicable Price Per Share&#148; means (i)&nbsp;with respect to the common stock (including any options or
warrants exercisable for common stock), the price per share set forth in the Company&#146;s most recent 409A valuation, (ii)&nbsp;with respect to any preferred stock then-outstanding, the price per share paid in the most recently completed Qualified
Preferred Financing, (ii)&nbsp;with respect to any preferred stock issuable in a Qualified Preferred Financing following the Effective Date, the price per share paid by the investors in the applicable Qualified Preferred Financing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">iii. the term &#147;Capital Stock&#148; means the capital stock of the Company (including Common Stock and preferred stock). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">iv. the term &#147;Fully Diluted Equity&#148; means the total outstanding common stock and preferred stock as of a given date after giving
effect to the conversion into capital stock of all outstanding convertible securities of the Company (assuming the issuance of Capital Stock authorized and reserved for issuance under the employee incentive compensation and other stock option plans
of the Company). For clarity, the Fully Diluted Equity shall not take into account any debt securities or other convertible securities issued by the Company that will convert into Capital Stock in connection with a Preferred Financing until and
unless those debt securities are converted to Capital Stock. For further clarity, for purposes of calculating the Aggregate Equity Value for purposes of determining whether the Valuation Threshold has been met, the Fully Diluted Equity shall include
only the equity set forth on Schedule 2.A and any equity issued by the Company in connection with a Trigger Event and for which Purchaser actually received Additional Shares pursuant to Section&nbsp;4.A.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">v. the term &#147;Preferred Financing&#148; means the issuance and sale of preferred stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">vi. the term &#147;Qualified Preferred Financing&#148; means the issuance and sale of preferred stock in a bona fide equity financing led by a
family office private wealth management firm, institutional investor, venture capital fund, private equity fund or other professional investor, in a single transaction or series of transactions, or in one or more closings, with a price per share set
based on agreement with investor(s) in such financing with gross proceeds, including the forgiveness of debt, to the Company of not less than [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. <B><I>Restrictions on Transfer</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The Shares shall not be sold, pledged or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer
instructions to its transfer agent with respect to any such sale, pledge or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. If the
Purchaser intends to sell, pledge or otherwise transfer any of the Shares, the Purchaser will cause any proposed purchaser, pledgee or transferee of the Shares to agree to take and hold such securities subject to the provisions and upon the
conditions specified in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) Each certificate, instrument, or book entry representing (i)&nbsp;the Shares, and
(ii)&nbsp;any other securities issued in respect of the Shares, upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event (the &#147;<B><I>Restricted Securities</I></B>&#148;), shall (unless otherwise permitted
by the provisions of <B>Section</B><B></B><B>&nbsp;4.B.3</B>) be notated with a legend substantially in the following form: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">THE
SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE
REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE
WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">The Purchaser consents to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted
Securities in order to implement the restrictions on transfer set forth in this Section&nbsp;4.B. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) The holder of the Restricted
Securities (the &#147;<B><I>Holder</I></B>&#148;), by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this <B>Section</B><B></B><B>&nbsp;4</B>. Before any proposed sale, pledge, or transfer of any Restricted
Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of
such Holder&#146;s intention to effect such sale, pledge, or transfer, provided that no such notice shall be required in connection if the intended sale, pledge or transfer complies with SEC Rule 144. Each such notice shall describe the manner and
circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder&#146;s expense by either (i)&nbsp;a written opinion of legal counsel chosen by Lilly, who
may be a qualified <FONT STYLE="white-space:nowrap">in-house</FONT> legal counsel, addressed to the Company and reasonably satisfactory to the Company, to the effect that the proposed transaction may be effected without registration under the
Securities Act; (ii)&nbsp;a &#147;no action&#148; letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that
action be taken with respect thereto; or (iii)&nbsp;any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration
under the Securities Act, whereupon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The
Company will not require such a notice, legal opinion or &#147;no action&#148; letter (x)&nbsp;in any transaction in compliance with SEC Rule 144; (y) in any transaction in which such Holder distributes Restricted Securities to an affiliate of such
Holder for no consideration; provided that with respect to transfers under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of this <B>Section</B><B></B><B>&nbsp;4.B</B>. Each certificate, instrument, or book
entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in <B>Section</B><B></B><B>&nbsp;4.B.2</B>,
except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions
of the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C. <B><I>Market Standoff Agreement</I></B>. The Purchaser shall enter into a customary <FONT
STYLE="white-space:nowrap">lock-up</FONT> or market standoff agreement of not less than one hundred eighty (180)&nbsp;days following the Company&#146;s initial public offering pursuant to a registration statement filed with the Securities and
Exchange Commission under the Securities Act; provided, however, that this <B>Section</B><B></B><B>&nbsp;4.C</B> shall only be applicable to the Purchaser if all officers, directors and stockholders individually owning more than one percent (1%) of
the Company&#146;s outstanding Common Stock (after giving effect to the conversion into Common Stock of all outstanding preferred stock) are subject to the same restrictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">D. <B><I>Financial Statements</I></B>. For so long as the Purchaser holds the Shares, the Company shall deliver to the Purchaser periodic
financial statements of the Company at the same time and in the same form as the Company is required to deliver pursuant to Section&nbsp;3.1 of the Investors&#146; Rights Agreement, dated as of October&nbsp;5, 2020, by and among the Company and the
investors party thereto (the &#147;<B><I>IRA</I></B>&#148;) to the Major Investors (as defined in the IRA). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">E. <B><I>Removal of
Restrictive Legend</I></B>. At the time of the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, the Company shall use commercially reasonable efforts to cause to be prepared and delivered to the Company&#146;s transfer agent
at least five days in advance of the expiration date of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period a legal opinion of the Company&#146;s counsel regarding the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period
and instructions to the Company&#146;s transfer agent to remove any restrictive legends applicable to the registrable securities of the Purchaser (provided that the Purchaser has provided any representations and certifications reasonably requested
by the Company or the Company&#146;s transfer agent or counsel to verify satisfaction with any of the conditions of Rule 144), which opinion shall be delivered to the transfer agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">F. <B><I>Drag -Along</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) <I>Definitions</I>. A &#147;<B><I>Sale of the Company</I></B>&#148; shall mean either: (i)&nbsp;a transaction or series of related
transactions in which a person, or a group of related persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a &#147;Stock Sale&#148;); or (ii)&nbsp;a
transaction that qualifies as a &#147;<B><I>Deemed Liquidation Event</I></B>&#148; as defined in the Amended and Restated Certificate of Incorporation of the Company in effect as of the Effective Date (the &#147;<B><I>Restated
Certificate</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) <I>Actions to be Taken</I>. In the event that (a)&nbsp;the holders of at least a majority of the shares
of Common Stock then issued or issuable upon conversion of the shares of Preferred Stock (the &#147;<B><I>Selling Investors</I></B>&#148;), and (b)&nbsp;the Board, approve a Sale of the Company (which approval of the Selling Investors must be in
writing), specifying that the provisions of Section&nbsp;3 of that certain Voting Agreement made and entered into as of October&nbsp;5, 2020, by and among the Company and certain stockholders of the Company (the &#147;<B><I>Voting
Agreement</I></B>&#148;) shall apply to such transaction, then, subject to the satisfaction of each of the conditions set forth in Section&nbsp;4.F.3 below, the Purchaser and the Company hereby agree: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">i. if such transaction requires stockholder approval, with respect to all Shares that the
Purchaser owns or over which the Purchaser otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all Shares in favor of, and adopt, such Sale of the Company (together with any related
amendment or restatement to the Restated Certificate required to implement such Sale of the Company) and to vote in opposition to any and all other proposals that could reasonably be expected to delay or impair the ability of the Company to
consummate such Sale of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">ii. if such transaction is a Stock Sale, to sell the same proportion of shares of capital stock of
the Company beneficially held by the Purchaser as is being sold by the Selling Investors to the person to whom the Selling Investors propose to sell their shares of capital stock of the Company, and, except as permitted in
<B>Section</B><B></B><B>&nbsp;4.F.3</B> below, on the same terms and conditions as the other stockholders of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">iii. to execute
and deliver all related documentation and take such other action in support of the Sale of the Company as shall reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this
<B>Section</B><B></B><B>&nbsp;4.F</B>, including, without limitation, executing and delivering instruments of conveyance and transfer, and any purchase agreement, merger agreement, any associated indemnity agreement, or escrow agreement, any
associated voting, support, or joinder agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and encumbrances), and any similar or related documents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">iv. not to deposit, and to cause its affiliates not to deposit, except as provided in this Agreement, any Shares of the Company owned by
Purchaser or its affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by the acquirer in connection with the Sale of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">v. to refrain from (a)&nbsp;exercising any dissenters&#146; rights or rights of appraisal under applicable law at any time with respect to
such Sale of the Company, or (b); asserting any claim or commencing any suit (x)&nbsp;challenging the Sale of the Company, or (y)&nbsp;alleging a breach of any fiduciary duty of the Selling Investors or any affiliate or associate thereof (including,
without limitation, aiding and abetting breach of fiduciary duty) in connection with the evaluation, negotiation or entry into the Sale of the Company, or the consummation of the transactions contemplated thereby; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">vi. if the consideration to be paid in exchange for the Shares pursuant to this <B>Section</B><B></B><B>&nbsp;4.F</B> includes any securities
and due receipt thereof by Purchaser would require under applicable law (a)&nbsp;the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (b)&nbsp;the provision to the
Purchaser of any information other than such information as a prudent issuer would generally furnish in an offering made solely to &#147;accredited investors&#148; as defined in Regulation D promulgated under the Securities Act of 1933, as amended
(the &#147;<B><I>Securities Act</I></B>&#148;), the Company may cause to be paid to the Purchaser in lieu thereof, against surrender of the Shares which would have otherwise been sold by the Purchaser, an amount in cash equal to the fair value (as
determined in good faith by the Board) of the securities which the Purchaser would otherwise receive as of the date of the issuance of such securities in exchange for the Shares; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">vii. in the event that the Selling Investors, in connection with such Sale of the Company, appoint a stockholder representative (the
&#147;<B><I>Stockholder Representative</I></B>&#148;) with respect to matters affecting the stockholders under the applicable definitive transaction agreements following consummation of such Sale of the Company, (a)&nbsp;to consent to (x)&nbsp;the
appointment of such Stockholder Representative, (y)&nbsp;the establishment of any applicable escrow, expense or similar fund in connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any indemnification or similar obligations, and (z)&nbsp;the payment of the Purchaser&#146;s pro rata portion (from the applicable escrow or expense fund or otherwise) of any and all reasonable
fees and expenses to such Stockholder Representative in connection with such Stockholder Representative&#146;s services and duties in connection with such Sale of the Company and its related service as the representative of the stockholders, and
(b)&nbsp;not to assert any claim or commence any suit against the Stockholder Representative or any other stockholder with respect to any action or inaction taken or failed to be taken by the Stockholder Representative, within the scope of the
Stockholder Representative&#146;s authority, in connection with its service as the Stockholder Representative, absent fraud, bad faith, gross negligence or willful misconduct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) <I>Conditions</I>. Notwithstanding anything to the contrary set forth herein, the Purchaser will not be required to comply with
<B>Section</B><B></B><B>&nbsp;4.F.2</B> above in connection with any proposed Sale of the Company (the &#147;<B><I>Proposed Sale</I></B>&#148;), unless: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">i. any representations and warranties to be made by the Purchaser in connection with the Proposed Sale are limited to representations and
warranties related to authority, ownership and the ability to convey title to such Shares, including, but not limited to, representations and warranties that (a)&nbsp;the Purchaser holds all right, title and interest in and to the Shares the
Purchaser purports to hold, free and clear of all liens and encumbrances, (b)&nbsp;the obligations of the Purchaser in connection with the transaction have been duly authorized, if applicable, (c)&nbsp;the documents to be entered into by the
Purchaser have been duly executed by the Purchaser and delivered to the acquirer and are enforceable (subject to customary limitations) against the Purchaser in accordance with their respective terms; and (d)&nbsp;neither the execution and delivery
of documents to be entered into by the Purchaser in connection with the transaction, nor the performance of the Purchaser&#146;s obligations thereunder, will cause a breach or violation of the terms of any agreement to which the Purchaser is a
party, or any law or judgment, order or decree of any court or governmental agency that applies to the Purchaser; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">ii. the Purchaser is
not required to agree (unless the Purchaser is a Company officer or employee) to any restrictive covenant in connection with the Proposed Sale (including, without limitation, any covenant not to compete or covenant not to solicit customers,
employees or suppliers of any party to the Proposed Sale) or any release of claims other than a release in customary form of claims arising solely in the Purchaser&#146;s capacity as a stockholder of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">iii. the Purchaser and its affiliates are not required to amend, extend or terminate any contractual or other relationship with the Company,
the acquirer or their respective affiliates, except that the Purchaser may be required to agree to terminate the investment-related documents between or among the Purchaser and the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">iv. the Purchaser is not liable for the breach of any representation, warranty or covenant made by any other person in connection with the
Proposed Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company as well as breach by any stockholder of any of identical
representations, warranties and covenants provided by all stockholders); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">v. liability shall be limited to the Purchaser&#146;s applicable
share (determined based on the respective proceeds payable to each stockholder in connection with such Proposed Sale in accordance with the provisions of the Restated Certificate) of a negotiated aggregate indemnification amount that applies equally
to all stockholders but that in no event exceeds the amount of consideration otherwise payable to the Purchaser in connection with such Proposed Sale, except with respect to claims related to fraud by the Purchaser, the liability for which need not
be limited as to the Purchaser; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">vi. upon the consummation of the Proposed Sale (a)&nbsp;each holder of each class or series
of the capital stock of the Company will receive the same form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same class or series of stock, and if any holders of any
capital stock of the Company are given a choice as to the form of consideration to be received as a result of the Proposed Sale, all holders of such capital stock will be given the same option, (b)&nbsp;each holder of a series of Preferred Stock
will receive the same amount of consideration per share of such series of Preferred Stock as is received by other holders in respect of their shares of such same series, (c)&nbsp;each holder of Common Stock will receive the same amount of
consideration per share of Common Stock as is received by other holders in respect of their shares of Common Stock, and (d)&nbsp;unless waived pursuant to the terms of the Restated Certificate and as may be required by law, the aggregate
consideration receivable by all holders of the Preferred Stock and Common Stock shall be allocated among the holders of Preferred Stock and Common Stock on the basis of the relative liquidation preferences to which the holders of each respective
series of Preferred Stock and the holders of Common Stock are entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a Deemed Liquidation Event) in accordance with the Company&#146;s Restated Certificate in
effect immediately prior to the Proposed Sale; provided, however, that, notwithstanding the foregoing provisions of this <B>Section</B><B></B><B>&nbsp;4.F.3.vi</B>, if the consideration to be paid in exchange for the Shares held by the Purchaser,
pursuant to this <B>Section</B><B></B><B>&nbsp;4.F.3.vi</B> includes any securities and due receipt thereof by the Purchaser would require under applicable law (x)&nbsp;the registration or qualification of such securities or of any person as a
broker or dealer or agent with respect to such securities; or (y)&nbsp;the provision to the Purchaser of any information other than such information as a prudent issuer would generally furnish in an offering made solely to &#147;accredited
investors&#148; as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to the Purchaser in lieu thereof, against surrender of the Shares held by the Purchaser, which would have otherwise been sold by the
Purchaser, an amount in cash equal to the fair value (as determined in good faith by the Board) of the securities which the Purchaser would otherwise receive as of the date of the issuance of such securities in exchange for the Shares held by the
Purchaser; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">vii. subject to clause (vi)&nbsp;above, requiring the same form of consideration to be available to the holders of any single
class or series of capital stock, if any holders of any capital stock of the Company are given an option as to the form and amount of consideration to be received as a result of the Proposed Sale, all holders of such capital stock will be given the
same option; provided, however, that nothing in this <B>Section</B><B></B><B>&nbsp;4.F.3.vii</B> shall entitle the Purchaser to receive any form of consideration that such holder would be ineligible to receive as a result of the Purchaser&#146;s
failure to satisfy any condition, requirement or limitation that is generally applicable to the Company&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4)
<I>Restrictions on Sales of Control of the Company</I>. The Purchaser shall not be a party to any Stock Sale unless (i)&nbsp;all holders of Preferred Stock are allowed to participate in such transaction(s) and (ii)&nbsp;the consideration received
pursuant to such transaction is allocated among the parties thereto in the manner specified in the Company&#146;s Restated Certificate in effect immediately prior to the Stock Sale (as if such transaction(s) were a Deemed Liquidation Event), unless
the holders of at least the requisite percentage required to waive treatment of the transaction(s) as a Deemed Liquidation Event pursuant to the terms of the Restated Certificate, elect to allocate the consideration differently by written notice
given to the Company at least ten (10)&nbsp;days prior to the effective date of any such transaction or series of related transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B>Tax Consequences</B>. The Purchaser has reviewed with the Purchaser&#146;s own tax advisors the federal, state, local and foreign tax
consequences of this investment and the transactions contemplated by this Agreement. The Purchaser is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B>General Provisions.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A. <B><I>Integration</I></B>. This Agreement and the License Agreement, including all exhibits hereto and thereto, represent the entire
agreement between the parties with respect to the purchase of the Shares by the Purchaser and rights granted to Purchaser and supersede and replace any and all prior written or oral agreements regarding the subject matter of the Agreement and
License Agreement. For the avoidance of doubt, this Agreement does not supersede or replace any of the rights granted to Purchaser under the License Agreement, including but not limited to, those rights under Section&nbsp;6 of the License Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">B. <B><I>Notices</I></B>. Any notice, demand, offer, request or other communication required or permitted to be given by either the
Company or the Purchaser pursuant to the terms of this Agreement shall be in writing and shall be deemed effectively given the earlier of (i)&nbsp;when received, (ii)&nbsp;when delivered personally, (iii)&nbsp;one business day after being delivered
by facsimile (with receipt of appropriate confirmation), (iv) one business day after being deposited with an overnight courier service or (v)&nbsp;four days after being deposited in the U.S. Mail, First Class&nbsp;with postage prepaid and return
receipt requested, and addressed to the parties at the addresses provided to the Company (which the Company agrees to disclose to the other parties upon request) or such other address as a party may request by notifying the other in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to the limitations set forth in Section&nbsp;232(e) of the Delaware General Corporation Law, the Purchaser consents to the delivery of
any notice to stockholders given by the Company under the Delaware General Corporation Law or the Company&#146;s certificate of incorporation or bylaws by (i)&nbsp;facsimile telecommunication to the facsimile number set forth on the signature page
(or to any other facsimile number for the Purchaser in the Company&#146;s records), (ii) electronic mail to the electronic mail address set forth on the signature page (or to any other electronic mail address for the Purchaser in the Company&#146;s
records), (iii) posting on an electronic network together with separate notice to the Purchaser of such specific posting or (iv)&nbsp;any other form of electronic transmission (as defined in the Delaware General Corporation Law) directed to the
Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C. <B><I>Successors</I></B>. Any successor to the Company (whether direct or indirect and whether by purchase, merger,
consolidation, liquidation or otherwise) to all or substantially all of the Company&#146;s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same
manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term &#147;Company&#148; shall include any successor to the Company&#146;s business
and/or assets that becomes bound by the terms of this Agreement by operation of law. Subject to the restrictions on transfer set forth in this Agreement, this Agreement shall be binding upon the Purchaser and its successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">D. <B><I>Assignment; Transfers</I></B>. Except as set forth in this Agreement, this Agreement, and any and all rights, duties and obligations
hereunder, shall not be assigned, transferred, delegated or sublicensed by the Purchaser without the prior written consent of the Company. Any attempt by the Purchaser without such consent to assign, transfer, delegate or sublicense any rights,
duties or obligations that arise under this Agreement shall be void. Except as set forth in this Agreement, any transfers in violation of any restriction upon transfer contained in any section of this Agreement shall be void, unless such restriction
is waived in accordance with the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">E. <B><I>Amendment; Waiver</I></B>. Except as expressly provided herein,
neither this Agreement nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument referencing this Agreement and signed by the Company and the Purchaser. Either party&#146;s failure to enforce any
provision of this Agreement shall not in any way be construed as a waiver of any such provision, nor prevent that party from thereafter enforcing any other provision of this Agreement. The rights granted both parties hereunder are cumulative and
shall not constitute a waiver of either party&#146;s right to assert any other legal remedy available to it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">F. <B><I>Severability</I></B>. Should any provision of this Agreement be found to be illegal
or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable to the greatest extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">G. <B><I>Rights as Stockholder</I></B>. Subject to the terms and conditions of this Agreement, the Purchaser shall have all of the rights of a
stockholder of the Company with respect to the Shares from and after the date that the Purchaser delivers a fully executed copy of this Agreement (including the applicable exhibits and attachments to this Agreement) and of the License Agreement to
the Company, and until such time as the Purchaser disposes of the Shares in accordance with this Agreement. Upon such transfer, the Purchaser shall have no further rights as a holder of the Shares so purchased except (in the case of a transfer to
the Company) the right to receive payment for the Shares so purchased in accordance with the provisions of this Agreement, and the Purchaser shall forthwith cause any certificate(s) evidencing the Shares so purchased to be surrendered to the Company
for transfer or cancellation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">H. <B><I>Adjustment for Stock Split</I></B>. All references to the number of Shares in this Agreement shall
be adjusted to reflect any stock split, stock dividend or other change in the Shares which may be made after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">I. <B><I>Governing Law and Waiver of Jury Trial</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) <I>Governing Law</I>. This Agreement shall be governed by and construed in accordance with the laws of the United States federal law and
New York state law, without reference to any rules of conflict of laws that would result in the application of the laws of any other jurisdiction. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to the
transactions contemplated by this Agreement. Each party hereby irrevocably and unconditionally (a)&nbsp;consents to submit to the exclusive jurisdiction of the federal courts located in New York, New York, for any actions, suits or proceedings
arising out of or relating to this Agreement and (b)&nbsp;waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated hereby in the federal courts of New York, New
York, and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. Each party waives personal service of any summons, complaint or other process in
connection with such action and agree that service may be made by any means permitted or prescribed in this Agreement for delivery of notices or by any means permitted by applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) <I>Waiver of Jury Trial</I>. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A
TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES. THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) <I>Availability of Injunctive Relief</I>. BOTH PARTIES AGREE THAT EITHER PARTY MAY PETITION A COURT FOR INJUNCTIVE RELIEF AS PERMITTED BY
LAW INCLUDING, BUT NOT LIMITED TO, WHERE EITHER PARTY ALLEGES OR CLAIMS A VIOLATION OF ANY OF THIS AGREEMENT OR THE LICENSE AGREEMENT REGARDING TRADE SECRETS, CONFIDENTIAL INFORMATION, OR <FONT STYLE="white-space:nowrap">NON-SOLICITATION.</FONT>
BOTH PARTIES UNDERSTAND THAT ANY SUCH BREACH OR THREATENED BREACH OF SUCH AN AGREEMENT WILL CAUSE IRREPARABLE INJURY AND THAT MONEY DAMAGES WILL NOT PROVIDE AN ADEQUATE REMEDY THEREFOR AND BOTH PARTIES HEREBY CONSENT TO THE ISSUANCE OF AN
INJUNCTION. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">J. <B><I>Cross Default</I></B>. A material breach by the Company of this Agreement that is
not cured (if capable of being cured) within thirty (30)&nbsp;days written notice thereof shall constitute a material breach by the Company of the License Agreement and, without limitation of any other rights and remedies that may be available to
Purchaser at law or in equity, gives rise to Purchaser&#146;s rights and remedies under the License Agreement upon the occurrence of a material breach thereof. Notwithstanding the foregoing, a material breach of this Agreement will not be actionable
as a material breach of the License Agreement if the material breach of this Agreement does not adversely affect Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">K.
<B><I>Counterparts</I></B>. This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages shall
be binding originals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>signature page follows</I>) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties represent that they have read this Agreement in its entirety, have had an
opportunity to obtain the advice of counsel prior to executing this Agreement and fully understand this Agreement. The Purchaser agrees to notify the Company of any change in its contact information below. The parties are signing this Agreement as
of the date stated in the introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ELI LILLY&nbsp;AND&nbsp;COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Address</I>:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Email</I>:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ACRIVON THERAPEUTICS,&nbsp;INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2.A </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FULLY
DILUTED CAPITALIZATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fully&nbsp;Diluted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>% FD</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">[***]</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2.B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAPITALIZATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***]
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2.G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBSIDIARIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4.A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SAMPLE ANTI-DILUTION CALCULATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTATED CERTIFICATE AND FORM OF AMENDMENT TO BE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FILED ON EFFECTIVE DATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT M </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Permitted Publications </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information has been excluded from this agreement (indicated by &#147;[***]&#148;) because such information (i)&nbsp;is not material and (ii)&nbsp;is
the type that the registrant treats as private or confidential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ONCOSIGNATURE
COMPANION DIAGNOSTIC AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>O<SMALL>NCOSIGNATURE</SMALL> C<SMALL>OMPANION</SMALL> D<SMALL>IAGNOSTIC</SMALL>
A<SMALL>GREEMENT</SMALL> </B>(this &#147;<B><I>Agreement</I></B>&#148;), effective as of June&nbsp;17, 2022 (the &#147;<B><I>Effective Date</I></B>&#148;), is made by and between <B>A<SMALL>CRIVON</SMALL> T<SMALL>HERAPEUTICS</SMALL>,
I<SMALL>NC</SMALL>.</B>, a Delaware corporation with its principal place of business at 480 Arsenal Way, Suite 100, Watertown, MA 02472 (&#147;<B><I>Acrivon</I></B>&#148;), and <B>A<SMALL>KOYA</SMALL> B<SMALL>IOSCIENCES</SMALL>,
I<SMALL>NC</SMALL>.</B>, a Delaware corporation with its principal place of business at 100 Campus Drive, 6<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> floor, Marlborough, MA 01752 (&#147;<B><I>Akoya</I></B>&#148;). Acrivon and Akoya are
sometimes referred to herein individually as a &#147;<B><I>Party</I></B>&#148; and collectively as the &#147;<B><I>Parties.</I></B>&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Acrivon is a company with a proprietary proteomics-based patient selection platform, Acrivon
Predictive Precision Proteomics (AP3), designed for the identification, development, and preclinical validation of drug-tailored patient selection OncoSignature<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> tests for patient responder
identification; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Acrivon is a company engaged in the development and commercialization of
therapeutics based on responder enrichment using the patient selection OncoSignature test and <FONT STYLE="white-space:nowrap">co-registration</FONT> approval with the patient selection OncoSignature test as a companion diagnostic; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Acrivon is developing the drug candidate known as Prexasertib using a preclinically validated
Prexasertib OncoSignature Assay (defined below) for patient selection; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Akoya is a company
having a proprietary platform for the development and commercialization of complete workflow solutions aimed at the discovery and translation of spatial biomarkers; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Acrivon and Akoya are parties to that certain Master Services Agreement [***] (collectively, the
&#147;<B><I>Prior Agreements</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Acrivon and Akoya desire to further
collaborate for Akoya to develop, validate, obtain regulatory approval for, and commercialize a companion diagnostic test for use with Prexasertib, using Akoya&#146;s platform technology and incorporating the Prexasertib OncoSignature Assay, and as
a result become the provider of such companion diagnostic test; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Master Services
Agreement and the MNDA are terminated on the Effective Date, and the activities commenced under the Master Services Agreement will continue to be conducted under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the foregoing premises and the mutual covenants
contained herein, the receipt and sufficiency of which are hereby acknowledged, Acrivon and Akoya hereby agree as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. D<SMALL>EFINITIONS</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acquired Party</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;16.6(c)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acrivon</I></B>&#148; shall have the meaning ascribed to it in the Preamble of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acrivon Background Intellectual Property</I></B>&#148; means any and all Intellectual Property Rights that are (a)&nbsp;Controlled by Acrivon or
its Affiliates and exist as of the Effective Date (including Intellectual Property Rights Controlled by Acrivon pursuant to the Master Services Agreement) or (b)&nbsp;discovered, created, generated,
<FONT STYLE="white-space:nowrap">in-licensed,</FONT> acquired, or otherwise Controlled by Acrivon or its Affiliates during the Term outside of the scope of this Agreement and without use of Akoya&#146;s Confidential Information, including any and
all Intellectual Property Rights Controlled by Acrivon and Covering or otherwise directed to the Acrivon Biomarker Identification Platform or the Prexasertib OncoSignature Assay (including the applicable trademark, OncoSignature<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and goodwill of the business symbolized by or associated therewith), in each case, to the extent necessary or reasonably useful for the Exploitation of the Prexasertib OncoSignature CDx. Acrivon
Background Intellectual Property includes the Intellectual Property Rights set forth on Exhibit A, which may be updated from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acrivon Biomarker Identification Platform</I></B>&#148; means methods for (a)&nbsp;identifying functional classes of predictive biomarkers or drug
targets using approaches, methods, processes, and trade secrets to identify and validate individual biomarkers (referred to as &#147;OncoSignature biomarkers&#148;), and (b)&nbsp;assembling, identifying, validating, and optimizing resulting assays
(referred to as &#147;OncoSignature assays&#148;), that are (i)&nbsp;Controlled by Acrivon or its Affiliates as of the Effective Date or (ii)&nbsp;discovered, generated, developed, <FONT STYLE="white-space:nowrap">in-licensed</FONT> or otherwise
acquired by Acrivon or its Affiliates during the Term outside the scope of this Agreement and without use of Akoya&#146;s Confidential Information. For clarity, Acrivon Biomarker Identification Platform includes the methods described in [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acrivon Collaboration Intellectual Property</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;9.2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acrivon Indemnitee</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;13.1(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acrivon Intellectual Property</I></B>&#148; means the Acrivon Background Intellectual Property and the Acrivon Collaboration Intellectual
Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Acrivon Materials</I></B>&#148; means any tangible materials, [***], provided by or on behalf of Acrivon to Akoya for use under
this Agreement (and any modifications or derivatives thereof) as provided in the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; means, as to any
Person, any other Person that (directly or indirectly), controls, is controlled by, or is under common control with, such Person for the duration of such control, where &#147;control&#148; means (a)&nbsp;beneficial ownership of more than fifty
percent (50%) of the voting equity interests in such Person or (b)&nbsp;the possession, directly or indirectly, of the power to independently direct or cause the direction of the management and policies of a Person, whether through the ownership of
a voting equity interest, by contract or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Agreement</I></B>&#148; shall have the meaning ascribed to it in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Akoya</I></B>&#148; shall have the meaning ascribed to it in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Akoya Background Intellectual Property</I></B>&#148; means any and all Intellectual Property Rights that are (a)&nbsp;Controlled by Akoya or its
Affiliates and exist as of the Effective Date (including Intellectual Property Rights Controlled by Akoya pursuant to the Master Services Agreement) or (b)&nbsp;discovered, created, generated, <FONT STYLE="white-space:nowrap">in-licensed,</FONT>
acquired, or otherwise Controlled by Akoya or its Affiliates during the Term outside of the scope of this Agreement and without use of Acrivon&#146;s Confidential Information, including any and all Intellectual Property Rights Controlled by Akoya
and Covering or otherwise directed to Akoya Platform (including the Akoya Biomarker Detection Platform). Akoya Background Intellectual Property includes the Intellectual Property Rights set forth on Exhibit B, which may be updated from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> by the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Akoya Biomarker Detection
Platform</I></B>&#148; means Akoya&#146;s proprietary reagents and methods for staining biological samples and the hardware, software and statistical analysis used to detect and quantify certain biomarkers in such samples that are
(a)&nbsp;Controlled by Akoya or its Affiliates as of the Effective Date or (b)&nbsp;discovered, generated, <FONT STYLE="white-space:nowrap">in-licensed</FONT> or acquired by Akoya or its Affiliates during the Term outside the scope of this
Agreement, to the extent not in breach of Akoya&#146;s exclusivity obligations pursuant to Section&nbsp;10.2 and without use of Acrivon&#146;s Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Akoya Collaboration Intellectual Property</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;9.2(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Akoya Indemnitee</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;13.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Akoya Intellectual Property</I></B>&#148; means the Akoya Background Intellectual Property and the Akoya Collaboration Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Akoya Materials</I></B>&#148; means any tangible materials that are provided by Akoya to Acrivon for use under this Agreement (including any
modifications or derivatives thereof) as provided in the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Akoya Platform</I></B>&#148; means Akoya&#146;s proprietary
instruments, hardware, software, reagents and other materials, and Akoya&#146;s proprietary methods and processes relating thereto, including Akoya&#146;s proprietary sample preparation, monoplex or multiplex assay procedures and methods and
processes, readout, analysis, algorithmic determination, and reporting, in each case that are Controlled by Akoya or its Affiliates during the Term outside of the scope of this Agreement and that are developed without use of Acrivon&#146;s
Confidential Information. For clarity, &#147;Akoya Platform&#148; includes the Akoya Biomarker Detection Platform, [***] or commercially available reagents or methods or processes that are not proprietary to Akoya (e.g., methods or processes that
are initially developed by Acrivon). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Alliance Manager</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;2.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Antibody Reagents</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;5.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Applicable Law</I></B>&#148; means, individually and collectively, any and all applicable laws,
statutes, ordinances, rules, directives, administrative circulars and regulations of any kind whatsoever of any Governmental Authority within the applicable jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Approval</I></B>&#148; and &#147;<B><I>Approved</I></B>&#148; means, with respect to a particular product in a particular regulatory jurisdiction,
the approval (including the clearance, certification or <FONT STYLE="white-space:nowrap">non-objection,</FONT> as applicable) from the applicable Regulatory Authority (or in regulatory jurisdictions where no approval is required, completion of all
conformity assessment, certification or other regulatory procedures in compliance with Applicable Laws) required for the distribution, use, promotion and sale of such product in such jurisdiction in accordance with Applicable Laws, including receipt
of pricing and reimbursement approvals, where applicable and relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Assignee</I></B>&#148; shall have the meaning ascribed to it in
Section&nbsp;16.6(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Bankruptcy Code</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;14.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Bankruptcy Event</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;14.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Biomarker</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;10.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means a day, other than Saturday, Sunday or any day on which commercial banks located in the Commonwealth of
Massachusetts, USA, are authorized or obligated by Applicable Laws to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Calendar Quarter</I></B>&#148; means the respective periods of
three (3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 and December 31; provided that (a)&nbsp;the first &#147;Calendar Quarter&#148; of the Term shall extend from the Effective Date to the end of the
first complete period of three (3)&nbsp;consecutive calendar months thereafter that ends on the first to occur of March&nbsp;31, June&nbsp;30, September&nbsp;30 and December&nbsp;31 and (b)&nbsp;the last &#147;Calendar Quarter&#148; of the Term
shall end upon the expiration or termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Calendar Year</I></B>&#148; means (a)&nbsp;for the first year of the Term,
the period beginning on the Effective Date and ending on December&nbsp;31, 2022, and (b)&nbsp;for each year of the Term thereafter, each successive period beginning on January&nbsp;1 and ending twelve (12)&nbsp;consecutive calendar months later on
December&nbsp;31, except that the last &#147;Calendar Year&#148; of the Term shall end on the effective date of expiration or termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Claim Notice</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;13.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Claims</I></B>&#148; means all liability, loss, damage, claim, injury, costs or expenses (including reasonable attorneys&#146; fees and expenses
of litigation) of any kind arising from Third Party demands, claims, actions and proceedings (whether criminal or civil, in contract, tort or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Clinical Trial</I></B>&#148; means a human clinical trial conducted to obtain information relating to patient outcomes or patient selection for
therapy with respect to a product (including Prexasertib). For the avoidance of doubt, a Clinical Trial can be one that was completed on or before the Effective Date, is being conducted on the Effective Date and continues thereafter or is commenced
after the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Collaboration Intellectual Property</I></B>&#148; means any and all Intellectual Property Rights
invented or generated by or on behalf of a Party or jointly by or on behalf of the Parties, as applicable, in the course of and as a result of the activities under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commercial Market</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;5.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commercialization</I></B>&#148; means all activities undertaken before and after obtaining Approval relating specifically to the <FONT
STYLE="white-space:nowrap">pre-launch,</FONT> launch, promotion, detailing, medical education and medical liaison activities, marketing, pricing, reimbursement, sale, import, export and distribution of any product, including strategic marketing,
sales force detailing, advertising, all customer support, distribution and invoicing and sales activities, including any Clinical Trials conducted after Approval for a product (including Prexasertib or the Prexasertib OncoSignature CDx as
applicable). &#147;Commercialize&#148; and &#147;Commercializing&#148; shall have the correlative meanings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commercialization
Milestones</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;5.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commercialization Plan</I></B>&#148; shall have the
meaning ascribed to it in Section&nbsp;5.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commercially Reasonable Efforts</I></B>&#148; means, with respect to either Party in relation to
this Agreement, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Control</I></B>&#148; or &#147;<B><I>Controlled</I></B>&#148; means, with respect to any Intellectual Property Right,
that a Party has the legal authority or right (whether by ownership, license or otherwise, other than pursuant to a license granted to such Party under this Agreement) to grant a license, sublicense, access or right to use (as applicable) to or
under such Intellectual Property Right to the other Party on the terms and conditions set forth herein at the time such Party would first be required hereunder to grant the other Party such license, sublicense, access or right to use (as
applicable), in each case without breaching the terms of any agreement with a Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cover</I></B>&#148; or
&#147;<B><I>Covering</I></B>&#148; means, (a)&nbsp;as to a method, compound or product and Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, offering for sale or importation of such
method, compound or product would infringe any claim of such Patent or, as to a pending claim included in such Patent, the making, using, selling, offering for sale or importation of such method, compound or product would infringe the claim of such
Patent if such pending claim were to issue in an issued patent without modification, and (b)&nbsp;as to <FONT STYLE="white-space:nowrap">know-how</FONT> and a Patent, that, in the absence of a license granted under, or ownership of, such Patent, the
use or practice of such <FONT STYLE="white-space:nowrap">know-how</FONT> would infringe such Patent or, as to a pending claim included in such Patent, the use or practice of such <FONT STYLE="white-space:nowrap">know-how</FONT> would infringe such
Patent if such pending claim were to issue in an issued patent without modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Development Plan</I></B>&#148; shall have the meaning
ascribed to it in Section&nbsp;3.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Disclosing Party</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;11.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Dollars</I></B>&#148; means the U.S. dollar, and &#147;$&#148; shall be interpreted accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Effective Date</I></B>&#148; shall have the meaning ascribed to it in the Preamble. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Executive Officers</I></B>&#148; means the Chief Executive Officer of Acrivon and the Chief
Executive Officer of Akoya. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exploit</I></B>&#148; or &#147;<B><I>Exploitation</I></B>&#148; means to make, have made, import, export, use,
sell, or offer for sale, including to research, discover, develop, Commercialize, register, manufacture, have manufactured, hold or keep (whether for disposal or otherwise), formulate, optimize, modify, have used, export, transport, distribute,
promote, market, have sold or otherwise dispose of any technology, a compound, molecule, construct or product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FDA</I></B>&#148; means the
United States Food and Drug Administration and any successor agency(ies) or authority having substantially the same function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FFDCA</I></B>&#148; means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167; 301 et seq., as amended from time to time,
together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Force Majeure</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;16.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Good Reason</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;3.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Governmental Authority</I></B>&#148; means any federal, state, national, state, provincial or local government, or political subdivision thereof,
or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or
division thereof, or any governmental arbitrator or arbitral body). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>H&amp;E</I></B>&#148; shall have the meaning ascribed to it in
Section&nbsp;3.8(c)(i)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>IND</I></B>&#148; means an application filed with a Regulatory Authority for authorization to commence Clinical
Trials, including (a)&nbsp;an Investigational New Drug Application as defined in the FFDCA or any successor application or procedure filed with the FDA, (b)&nbsp;any equivalent thereof in other countries or regulatory jurisdictions, (e.g., a
Clinical Trial Application (CTA) in the European Union) and (c)&nbsp;all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect to the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Indemnified Party</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;13.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Indemnify</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;13.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Indemnifying Party</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;13.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Independent Activities</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;10.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Indication</I></B>&#148; means the statement of the indication of use of the Prexasertib OncoSignature CDx, as set forth in the Development Plan.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Intellectual Property Rights</I></B>&#148; means all right, title and interest in and to any
intellectual property, including patent rights (pending or issued), <FONT STYLE="white-space:nowrap">know-how,</FONT> materials, method, processes, protocols, inventions or discoveries (whether or not patentable), trademarks, utility models,
registered designs, design rights, copyrights, copyright registrations, trade secret and other confidential information, and similar intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Joint Collaboration Intellectual Property</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;9.2(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Joint Collaboration Patents</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;9.4(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Joint Steering Committee</I></B>&#148; and &#147;<B><I>JSC</I></B>&#148; shall have the meaning ascribed to each in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Labeling</I></B>&#148; means the statement of the intended use, the Indication or the labeling for the Prexasertib OncoSignature CDx in any
Regulatory Submission or otherwise proposed to or by the Regulatory Authority in connection with any Regulatory Submission for the Prexasertib OncoSignature CDx. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Lilly Agreement</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;16.6(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Losses</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;13.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Master Services Agreement</I></B>&#148; shall have the meaning ascribed to it in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>MNDA</I></B>&#148; shall have the meaning ascribed to it in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>NDA</I></B>&#148; means: (a)&nbsp;in the United States, as applicable, a New Drug Application (as more fully described in the FFDCA) filed with
the FDA, or abbreviated processes relating to either of the foregoing (e.g. an Abbreviated New Drug Application) or any successor application to the foregoing; or (b)&nbsp;in any other country or group of countries, the equivalent application or
submission for approval to market a pharmaceutical product filed with the Regulatory Authority in such country or group of countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Publishing</FONT> Party</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;11.6(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Party</I></B>&#148; and &#147;<B><I>Parties</I></B>&#148; shall have the meaning ascribed to each in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Patents</I></B>&#148; means (a)&nbsp;all national, regional and international patents and patent applications, including provisional patent
applications and any and all rights to claim priority thereto, (b)&nbsp;all patent applications filed either from such patents, patent applications, or provisional applications or from an application claiming priority from either of these, including
divisionals, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> provisionals, converted provisionals, and continued prosecution applications, (c)&nbsp;any and all patents that have
issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents, and design patents and certificates of invention, (d)&nbsp;any and all extensions or restorations by existing or future
extension or restoration mechanisms, including revalidations, reissues, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent
applications or other patents resulting from post-grant proceedings ((a), (b), and (c)), and (e)&nbsp;any similar patent rights, including <FONT STYLE="white-space:nowrap">so-called</FONT> pipeline protection or any importation, revalidation,
confirmation, or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Patient Data</I></B>&#148; means patient demographical information associated with each Patient
Sample. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Patient Sample Requirements</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;3.8(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Patient Samples</I></B>&#148; means any human tissue, blood, serum or other human sample collected in accordance with the protocol of any Clinical
Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means any person or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>PMA</I></B>&#148; means (a)&nbsp;a premarket approval application (including a supplement thereto) made to the FDA for a medical device in
accordance with section 515 of the FFDCA and the applicable regulations including 21 CFR Part 814, or (b)&nbsp;any analogous application to the application set forth in (a)&nbsp;that is filed with the relevant Regulatory Authority in a country or
region outside the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Post Signing Notice</I></B>&#148; shall have the meaning ascribed to it in the definition of &#147;Acrivon Biomarker
Identification Platform&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Prexasertib</I></B>&#148; means Acrivon&#146;s proprietary product comprising
<FONT STYLE="white-space:nowrap">ACR-368</FONT> or prexasertib, a small molecule inhibitor of the DNA damage response checkpoint kinases CHK1 and CHK2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Prexasertib OncoSignature Assay</I></B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Prexasertib OncoSignature CDx</I></B>&#148; means an in vitro diagnostic (IVD) test that is based on the Prexasertib OncoSignature Assay and
developed to run on the Akoya Platform, and is intended to be Commercialized, subject to Approval, as a predictive test used to select patients eligible for treatment with Prexasertib (companion diagnostic claim). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Prior Agreements</I></B>&#148; shall have the meaning ascribed to it in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Prosecution and Maintenance</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;9.4(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Publishing Party</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;11.6(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Quality Agreement</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;4.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>RDS Notice</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;5.2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Receiving Party</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;11.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Regulatory Authority</I></B>&#148; means any applicable Governmental Authority or other authority having the administrative authority to regulate
the development or marketing of pharmaceutical or biologic products in any applicable country or other jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Regulatory Documentation</I></B>&#148; means all (a)&nbsp;applications (including all INDs),
registrations, licenses, authorizations, and approvals (including PMAs, NDAs and Approvals), (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any
communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, adverse event files, and complaint files, and (c)&nbsp;clinical data and data
contained or relied upon in any of the foregoing, in each case ((a), (b), and (c)) to the extent relating to the Prexasertib OncoSignature CDx or Prexasertib, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Regulatory Submission</I></B>&#148; means any submissions to or filings with any Regulatory Authority relating to the Prexasertib OncoSignature
CDx or Prexasertib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Replacement Diagnostic Solution</I></B>&#148; means an alternative arrangement (to the arrangement described in this
Agreement) on commercially reasonable terms (including, subject to and without limiting Section&nbsp;5.2(d), financial terms) to ensure the continuing development, supply and Commercialization of the Prexasertib OncoSignature CDx (as applicable) in
the applicable Commercial Market(s), such as: [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Reserved Patient Sample</I></B>&#148; [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Results</I></B>&#148; means, as part of the Collaboration Intellectual Property, any and all data, information and reports that are developed or
produced by or on behalf of Akoya or Acrivon (solely or jointly) in the course of and as a result of the Parties&#146; activities under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Sale Transaction</I></B>&#148; shall have the meaning ascribed to in Section&nbsp;16.6(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Supply Agreement</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Term</I></B>&#148; shall have the meaning ascribed to it in Section&nbsp;14.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Third Party</I></B>&#148; means any party other than Akoya, Acrivon, or an Affiliate of either Akoya or Acrivon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Third Party Acquirer</I></B>&#148; shall have the meaning ascribed to in Section&nbsp;16.6(c). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>G<SMALL>OVERNANCE</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Joint Steering Committee. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Formation; Membership</B>. Within [***] following the Effective Date, the Parties shall establish a joint steering committee (the
&#147;<B><I>Joint Steering Committee</I></B>&#148; or the &#147;<B><I>JSC</I></B>&#148;), composed of three (3)&nbsp;representatives from each Party. Each representative shall have the requisite experience and seniority to enable such person to make
decisions on behalf of the applicable Party with respect to the issues falling within the decision-making authority of the JSC. From time to time, each Party may substitute one (1)&nbsp;or more of its representatives to the JSC on written notice to
the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Responsibilities</B>. The JSC shall oversee the overall conduct and progress of the
Parties&#146; activities in accordance with the Development Plan and shall serve as a decision-making forum and as a forum for the coordination of such activities. In particular, the JSC shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>[***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)
</B>[***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>review, discuss and approve the Development Plan, and review and approve any amendment thereto (provided that the
initial Development Plan attached to this Agreement as Schedule 3.2 shall be deemed approved as of the Effective Date); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)
</B>review, discuss and approve the Commercialization Plan and any amendment thereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>[***]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi) </B>appointing working groups to be made of representatives of each Party to address such matters as the JSC may determine; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii) </B>discuss and monitor access and reimbursement for the Prexasertib OncoSignature CDx; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(viii) </B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)
Conduct</B>. Each Party shall be responsible for ensuring that, at all times during the existence of the JSC, its representatives on the JSC act reasonably and in good faith in carrying out their respective responsibilities hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) Meetings and Minutes</B>. The JSC shall meet at least [***] per Calendar Quarter, [***]. Each Party shall make all proposals for agenda
items and shall provide all appropriate information with respect to such proposed items at least [***] in advance of the applicable meeting. Akoya&#146;s Alliance Manager shall prepare and circulate to Acrivon&#146;s Alliance Manager draft minutes
of each meeting within [***] after the meeting for the Parties&#146; review and approval. The Parties shall agree on the minutes of each JSC meeting promptly, but in no event later than [***] following circulation of the draft minutes; provided,
that, to the extent applicable, any final minutes will note any disagreements that the Parties cannot resolve. Each Party will bear all costs and expenses incurred by its members and other representatives in connection with participating in all
meetings of the JSC, including all travel and living expenses. In addition, each Party may, with the consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, invite a reasonable number of <FONT
STYLE="white-space:nowrap">non-voting</FONT> employees, consultants or scientific advisors to attend the meetings of the JSC, provided such invitees are bound by appropriate (i.e., consistent with Article 11) confidentiality obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) Decision-Making</B>. All JSC decisions shall be made by unanimous vote, with each Party&#146;s representatives collectively having one
(1)&nbsp;vote. The presence of at least one (1)&nbsp;of each Party&#146;s JSC representatives constitutes a quorum for the conduct of business at any JSC meeting, and no vote of the JSC may be taken without a quorum present. If, after reasonable
discussion and good faith consideration of each Party&#146;s view on a particular matter, the JSC representatives of the Parties cannot reach an agreement as to such matter within [***] then either Party may, by written notice to the other Party,
have such issue referred to the Executive Officers for resolution. The Parties&#146; respective Executive Officers shall discuss within [***] after such matter is referred to them, and shall negotiate in good faith to resolve the matter. If the
Executive Officers are unable to resolve the matter within [***] thereafter, then: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>Akoya shall have final casting vote on [***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Acrivon shall have final casting vote on [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2 Limitations on Authority</B>. The JSC&#146;s decision-making authority shall be limited to those matters expressly delegated to it in
this Agreement. Each Party shall retain the rights, powers, and discretion granted to it under this Agreement, and no such rights, powers, or discretion shall be delegated to or vested in the JSC unless such delegation or vesting of rights is
expressly provided for in this Agreement or the Parties expressly agree in writing. In addition to any other exclusions from or limitations on its authority set forth in this Article 2 or elsewhere in this Agreement, the JSC shall have no right,
power or authority to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>interpret, modify, amend, or waive compliance with any provision of, or any right or remedy under, this
Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>determine whether or not a Party has complied with any of its obligations under this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>determine any issue in a manner that would conflict with the express terms of this Agreement; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>make any decision or approve any matter that is expressly stated to require the mutual agreement or mutual written agreement of the
Parties or the written consent or written approval of a Party or of both Parties, without having received such agreement or consent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 Discontinuation of the JSC</B>. The JSC may be disbanded by the mutual written agreement by the Parties. After disbandment of the JSC,
each Party shall designate a contact person for the exchange of information under this Agreement, and decisions of the JSC shall be decisions as between the Parties, subject to the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4 Alliance Management</B>. Within [***] of the Effective Date, each Party will appoint one representative to act as its alliance manager
under this Agreement (each, an &#147;<B><I>Alliance Manager</I></B>&#148;). The role of the Alliance Manager is to act as a primary point of contact between the Parties to assure a successful relationship between the Parties. The Alliance Managers
will attend all meetings of the JSC to support the JSC in the discharge of its responsibilities (for clarity, a Party&#146;s Alliance Manager may, but need not, be a member of the JSC; if an Alliance Manager is not a JSC member, then such Alliance
Manager shall have no vote on JSC matters). An Alliance Manager may bring any matter concerning a Party&#146;s performance under this Agreement to the attention of the JSC if the Alliance Manager reasonably believes that such attention is warranted.
Each Party may change its designated Alliance Manager from time to time upon written notice to the other Party. Any Alliance Manager may designate a substitute to temporarily perform the functions of such Alliance Manager upon written notice to the
other Party&#146;s Alliance Manager. Each Alliance Manager will be charged with creating and maintaining a collaborative work environment within the JSC. Each Alliance Manager also will: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>identify and bring disputes to the attention of the JSC (or the Parties, as
applicable) in a timely manner and be the point of first referral in all matters of conflict resolution; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>provide a single point
of communication for seeking consensus both internally within the Parties&#146; respective organizations and between the Parties regarding issues that arise [***]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>plan and coordinate cooperative efforts and internal and external communications in relation to the Development Plan; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>[***]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>EVELOPMENT</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1 Overview</B>. During the Term, the Parties shall perform the activities set out in a development plan that defines the scope and
responsible Party for activities related to the development, clinical validation, registration, manufacture, and ultimate commercialization of the Prexasertib OncoSignature CDx for use as an aid in (a)&nbsp;identifying responders to Prexasertib and
(b)&nbsp;the selection of patients for treatment with Prexasertib, [***] (the &#147;<B><I>Development Plan</I></B>&#148;). [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2
Development Plan</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Development Plan shall set forth: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>[***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)
</B>[***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>[***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)
</B>The Development Plan as of the Effective Date is attached to this Agreement as <U>Schedule 3.2</U>, as may be later supplemented or amended as set forth in Section&nbsp;3.2(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B><B></B>&nbsp;(i) Acrivon shall use Commercially Reasonable Efforts to develop Prexasertib, and (ii)&nbsp;Akoya shall use Commercially
Reasonable Efforts to develop Prexasertib OncoSignature CDx, in each of (i)&nbsp;and (ii), including the related manufacturing activities, all in good scientific manner and in compliance with Applicable Laws, standards of care and skill to be
reasonably expected in the pharmaceutical or diagnostics field, as applicable, and in accordance with the timelines set forth in the Development Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) Updates to the Development Plan</B>. During the Term, either Party may propose, through the JSC, amendments to the Development Plan. The
Parties will discuss any such proposed amendment through the JSC, including the impact of any such amendment on the scope, timing, or cost of the activities under the Development Plan, and any such amendment shall be only effective upon the approval
of the JSC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3 Development Responsibilities</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Development of Prexasertib. As between the Parties, Acrivon shall be solely responsible for the development of Prexasertib,
including the conduct of Clinical Trials therefor, all at its sole cost and expense. [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Development of Prexasertib
OncoSignature CDx</B>. Akoya shall be solely responsible for the development of Prexasertib OncoSignature CDx, including the implementation of the Prexasertib OncoSignature CDx within a Clinical Trial, either by itself or through use of a Third
Party test laboratory as a Subcontractor. [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4 Development Costs</B>. Without limiting the payments listed in Section&nbsp;7.1
and Section&nbsp;7.2, each Party shall bear its own costs incurred in connection with its activities under the Development Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5
Development Milestones</B>. Akoya shall meet the development milestones (i.e., achieve and pass the mutually agreed-upon technical acceptance criteria specified in associated statistical analysis plans for each milestone) set forth in Schedule 3.5
(&#147;<B><I>Development Milestones</I></B>&#148;) in accordance with the timelines set forth therein (and otherwise in accordance with the Development Plan); [***]. A failure to use Commercially Reasonable Efforts to pursue the Development
Milestones shall be deemed a material breach of this Agreement subject to Section&nbsp;14.2, except to the extent such failure results from (a)&nbsp;Acrivon&#146;s action or omission (including through its final decision making pursuant to
Section&nbsp;2.1(e)(ii)), (b) a delay in the development of Prexasertib, (c)&nbsp;Force Majeure, (d)&nbsp;Regulatory Authority actions, or (e)&nbsp;Acrivon&#146;s gross negligence or willful misconduct (collectively (a), (b), (c), (d) and (e);
&#147;<B><I>Good Reason</I></B>&#148;). [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6 Results. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Ownership</B>. As part of the Collaboration Intellectual Property, ownership of Results will follow the determination of the ownership
of Collaboration Intellectual Property. Results solely owned by a Party will be deemed Confidential Information of such Party, and Results jointly owned by the Parties will be deemed Confidential Information of both Parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Disclosure</B>. Each Party will report to the other Party all Results conceived, generated, discovered, or made by such Party together
with other related information in such Party&#146;s possession or Control that is reasonably necessary to verify and evaluate the Results. Such Results and other related information will be disclosed to the other Party promptly after they are
generated at JSC meetings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7 Subcontractors</B>. Akoya may perform any of the activities allocated to it under the Development Plan
through its Affiliates or, subject to Acrivon&#146;s prior written consent, not to be unreasonably withheld, delayed or conditioned, Third Party subcontractors (&#147;<B><I>Subcontractors</I></B>&#148;), provided that (a)&nbsp;Akoya will remain
responsible for the work allocated to such Affiliates or Subcontractors to the same extent it would if it had done such work itself, (b)&nbsp;each Affiliate or Subcontractor shall be bound by terms and conditions (including the <FONT
STYLE="white-space:nowrap">non-use</FONT> and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> obligations set forth in Article 11 and debarment covenants set forth in Section&nbsp;12.4(a)) consistent with those set forth in this Agreement,
and (c)&nbsp;each Affiliate or Subcontractor agrees in writing to assign to Akoya its rights in any Intellectual Property Rights conceived and reduced to practice by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Affiliate or Subcontractor in the course of performing such work, provided that such Intellectual Property Rights are not an improvement to such Subcontractor&#146;s background Intellectual
Property Rights and are otherwise generically applicable to the Subcontractor&#146;s business, in which case it will be acceptable for the applicable Party to obtain a sublicenseable license to such Intellectual Property Rights for use with
deliverables arising from its engagement. Akoya shall be solely responsible and liable for acts and omissions of its Affiliates or Subcontractors hereunder and any and all failures by such Affiliate or Subcontractor to comply with the terms of this
Agreement. Without limiting the foregoing, the Subcontractors that are listed in the Development Plan are deemed approved by Acrivon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.8 Acrivon Materials, Akoya Materials and Patient Samples</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Acrivon Materials</B>. Acrivon shall transfer to Akoya the Acrivon Materials as provided in the Development Plan. Akoya shall use the
Acrivon Materials solely for the purpose of carrying out the activities under the Development Plan. Akoya agrees that such Acrivon Materials shall be used in compliance with Applicable Law and the terms and conditions of this Agreement. Akoya shall
not transfer any Acrivon Materials to any Third Party without Acrivon&#146;s prior written consent. Akoya may not modify, analyze, sequence, derivatize, nor attempt to determine the structure of any Acrivon Material except to the extent described in
the Development Plan or otherwise agreed in writing by Acrivon. Acrivon will retain ownership of the Acrivon Materials at all times. This Agreement may not be construed as granting any rights to Acrivon&#146;s rights, title or interests in or to the
Acrivon Materials, their Commercialization, or any other uses thereof except to the extent described in the Development Plan. Akoya may not use the Acrivon Materials for testing in, or treatment of, human subjects except to the extent described in
the Development Plan. Upon termination of this Agreement, upon Acrivon&#146;s election at its sole discretion, Akoya shall either (i)&nbsp;return such Acrivon Materials to Acrivon or (ii)&nbsp;destroy such Acrivon Materials and deliver to Acrivon a
written confirmation thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Akoya Materials</B>. Akoya shall transfer to Acrivon the Akoya Materials as provided in the
Development Plan. Acrivon shall use the Akoya Materials solely for the purpose of carrying out the activities under the Development Plan. Acrivon agrees that such Akoya Materials shall be used in compliance with Applicable Law and the terms and
conditions of this Agreement. Acrivon shall not transfer any Akoya Materials to any Third Party without Akoya&#146;s prior written consent. Acrivon may not modify, analyze, sequence, derivatize, nor attempt to determine the structure of any Akoya
Material except to the extent described in the Development Plan or otherwise agreed in writing by Akoya. Akoya will retain ownership of the Akoya Materials at all times. This Agreement may not be construed as granting any rights to Akoya&#146;s
rights, title or interests in or to the Akoya Materials, their Commercialization, or any other uses thereof except to the extent described in the Development Plan. Acrivon may not use the Akoya Materials for testing in, or treatment of, human
subjects except to the extent described in the Development Plan. Upon termination of this Agreement, upon Akoya&#146;s election at its sole discretion, Acrivon shall either (i)&nbsp;return such Akoya Materials to Akoya or (ii)&nbsp;destroy such
Akoya Materials and deliver to Akoya a written confirmation thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) Patient Samples</B>. [***]: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>[***]: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(1) </B>[***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(2)
</B>[***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(3) </B>[***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(4) </B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)
</B>[***]: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(1) </B>[***]; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(2) </B>[***]; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(3)
</B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>[***]: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(1) </B>[***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(2)
</B>[***]; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(3) </B>[***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)
</B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) Disclaimer</B>.
EXCEPT AS SET FORTH IN THIS AGREEMENT OR THE DEVELOPMENT PLAN, THE RECEIVING PARTY ACKNOWLEDGES THAT THE ACRIVON MATERIALS, AKOYA MATERIALS AND PATIENT SAMPLES ARE BEING SUPPLIED <FONT STYLE="white-space:nowrap">AS-IS</FONT> WITH NO WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIALS WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS OF ANY THIRD PARTY. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>EGULATORY</SMALL> M<SMALL>ATTERS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1 Responsibility for Regulatory Submissions Approvals</B>. Acrivon shall be responsible for the preparation and filing of all Regulatory
Submissions for Prexasertib and for obtaining all Approvals for Prexasertib, at, as between the Parties, Acrivon&#146;s sole cost and expense. Akoya shall be responsible for the preparation and filing of all Regulatory Submissions for the
Prexasertib OncoSignature CDx and for obtaining all Approvals for the Prexasertib OncoSignature CDx [***]. Each Party shall provide to the other Party all Results in its Control necessary and relevant for the other Party to obtain Approval and other
permissions or authorizations from Regulatory Authorities as set forth above and will provide reasonable assistance to such other Party in connection therewith. [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2 Regulatory Activities and Submissions Generally</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Parties will confer and cooperate with one another, including through the JSC, regarding all aspects of Approval for the
Prexasertib OncoSignature CDx, including those relating to Prexasertib. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>[***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)
</B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>[***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3
Meetings and Correspondence with Regulatory Authorities. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Parties shall notify one another in advance of any request for
a meeting or substantive discussion with any Regulatory Authority relating to any Regulatory Submission or other regulatory filing or correspondence for or with respect to the Regulatory Submission for the Prexasertib OncoSignature CDx that the
Parties reasonably believe could adversely impact the Approval or the timing of the Approval of the Prexasertib OncoSignature CDx. Such notification shall be provided as soon as possible, and, in any case, no later than [***] prior to any such
meeting or substantive discussion. The foregoing obligations apply with respect to meetings or discussions initiated by a Party or by a Regulatory Authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Akoya shall have sole responsibility for all communications with the Regulatory Authorities with respect to the Prexasertib
OncoSignature CDx and Acrivon shall have sole responsibility for all communications with the Regulatory Authorities with respect to Prexasertib. At Acrivon&#146;s request and reasonable expense, Akoya shall provide reasonable assistance to Acrivon
and participate in meetings with Regulatory Authorities in connection with the development and Approval of Prexasertib, where such development and Approval involve the Prexasertib OncoSignature CDx. Upon request by Akoya, subject to
Section&nbsp;10.2, Acrivon shall provide reasonable assistance to Akoya and participate in meetings with Regulatory Authorities in connection with the development and Approval of Prexasertib OncoSignature CDx. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4 Regulatory Activities and Submissions</B>. Akoya will be responsible for the preparation of all documentation necessary for a complete
Regulatory Submission for the Approval of Prexasertib OncoSignature CDx (including the Labeling) in accordance with this Agreement. With Acrivon&#146;s assistance, including providing required materials, Akoya shall be responsible for providing, in
the format required by the FDA, the data and information required to be submitted in connection with the Regulatory Submissions required for Approval of the Prexasertib OncoSignature CDx. The Regulatory Submission shall be filed by Akoya in
Akoya&#146;s name, and Akoya shall be the owner of all Regulatory Submissions and any and all Approvals for the Prexasertib OncoSignature CDx. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5 Right of Reference</B>. Acrivon shall have the right to use and reference Akoya&#146;s
Regulatory Documentation for the Prexasertib OncoSignature CDx in connection with the development (including regulatory filings) and Commercialization of Prexasertib. In the event that Acrivon makes any Regulatory Submissions, Akoya shall have the
right to use and reference such Regulatory Submissions in connection with the development (including regulatory filings) and Commercialization of the Prexasertib OncoSignature CDx. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6 Quality Agreement</B>. No later than [***] after the Effective Date (or such later date as may be otherwise agreed upon by the Parties
in writing), the Parties shall enter into a quality agreement (&#147;<B><I>Quality Agreement</I></B>&#148;) defining the commitments of both Parties to ensure that the Prexasertib OncoSignature CDx developed and Commercialized under this Agreement
satisfy the quality and regulatory requirements required by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7 Medical Device Reporting Events</B>. Akoya shall be
responsible for reporting any medical device reporting events for the Prexasertib OncoSignature CDx to the applicable Regulatory Authority(ies), with a copy of such report to Acrivon, in accordance with 21 C.F.R. Part 803.1 in the United States, and
corresponding regulatory standards as may be required by other Regulatory Authorities as applicable, and in all cases as appropriate for the stage of development or commercialization of the Prexasertib OncoSignature CDx at the relevant time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8 Technical and Medical Inquiries</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Technical questions and inquiries from consumers regarding Prexasertib OncoSignature CDx shall be directed to Akoya. Acrivon shall
comply with the directions and policies reasonably established by Akoya in connection therewith, including routing all requests for written responses to technical inquiries regarding the Prexasertib OncoSignature CDx or any other Akoya product to
Akoya for answers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>As between the Parties, Acrivon shall be solely responsible, at its cost, for responding to and answering
medical questions and inquiries from members of the medical profession and consumers regarding Prexasertib. Akoya shall comply with the directions and policies reasonably established by Acrivon and provided to Akoya in connection therewith,
including routing all requests for written responses to medical inquiries regarding Prexasertib to Acrivon for answers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>If
representatives of a Party are asked questions or asked for information that is beyond the information provided in the Prexasertib OncoSignature CDx promotional materials developed in consultation with the JSC or the Labeling for the Prexasertib
OncoSignature CDx, such representatives shall refer (i)&nbsp;Prexasertib related questions or requests to Acrivon&#146;s contacts as designated by Acrivon and (ii)&nbsp;Prexasertib OncoSignature CDx related questions or requests to Akoya&#146;s
contact as designated by Akoya. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.9 Prexasertib OncoSignature CDx and Drug Complaints. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Parties each agree to share with each other any complaints relating to the Prexasertib OncoSignature CDx (including Regulatory
Authority inquiries regarding the Prexasertib OncoSignature CDx complaints) as soon as practicable following its receipt of such information, but in any event within [***] of becoming aware of any such complaint. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Subject to the terms and conditions of the Quality Agreement, Akoya shall have
responsibility for [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>As between the Parties, Acrivon shall have the sole authority and responsibility for: [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.10 Recalls</B>. The Parties each agree to share with each other any information that might lead to field corrections, recalls, and market
withdrawals of the Prexasertib OncoSignature CDx as soon as practicable following its receipt of such information. Akoya shall have the sole authority and responsibility to handle [***]. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ANUFACTURE</SMALL> <SMALL>AND</SMALL> C<SMALL>OMMERCIALIZATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1 Manufacture and Supply of Prexasertib OncoSignature CDx</B>. Unless the Parties otherwise agree in writing, Akoya shall be responsible
for the manufacture or procurement of adequate supplies of Prexasertib OncoSignature CDx as forecasted by Acrivon for clinical development in the Development Plan and commercial supply (including launch) in accordance with a commercial supply
agreement to be negotiated and entered into between the Parties prior to the start of the registration study for Prexasertib (the &#147;<B><I>Supply Agreement</I></B>&#148;). [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2 Replacement Diagnostic Solution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>In addition to other remedies set forth in the Supply Agreement, [***], Acrivon shall then have the right to provide Akoya notice of
such failure (the &#147;<B><I>RDS Notice</I></B>&#148;) and the Parties will negotiate in good faith a Replacement Diagnostic Solution for such Commercial Market as set forth in this Section&nbsp;5.2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)
</B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>[***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3 Commercialization Plan</B>. [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4 Responsibility for Prexasertib OncoSignature CDx</B>. Except as expressly set forth in this Agreement, Akoya shall have sole
responsibility and authority with respect to the Commercialization of the Prexasertib OncoSignature CDx in accordance with the Commercialization Plan at its sole cost and expense, including the marketing, promotion, distribution, sale and other
Commercialization activities, and shall book sales and retain all revenue received from such sales; provided, that Akoya shall ensure that the Prexasertib OncoSignature CDx is widely accessible and can meet clinical development and commercial needs
in the United States initially and globally thereafter as forecasted by Acrivon. Notwithstanding the foregoing, in recognition that health economics studies will enable value-based Third Party payor coverage and reimbursement levels, Akoya commits
to conducting (or having conducted), using Commercially Reasonable Efforts, such customary health economics studies. [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5
</B>[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6 Responsibility for Prexasertib</B>. For the avoidance of doubt, Akoya and the JSC
shall have no authority over decisions regarding the marketing, promotion, distribution, sale and other commercialization activities and decisions for Prexasertib. [***]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>ECORDS</SMALL>; A<SMALL>UDITS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1 Records; Audits</B>. Akoya shall maintain complete, current, and accurate records of all activities performed by it in the performance
of this Agreement, including pursuant to the Development Plan and the Commercialization Plan and with respect to any Results. Such records shall fully and properly reflect all work performed and results achieved in the performance of this Agreement,
including under the Development Plan and Commercialization Plan in good scientific manner appropriate for regulatory and patent purposes. During the Term and for a period of [***] thereafter, representatives of Acrivon who have been authorized by
Akoya (which authorization will not be unreasonably withheld, conditioned or delayed) will have the right to perform a quality management system audit of Akoya facilities and to inspect the facilities and records that relate to the performance of
the Development Plan and Commercialization Plan and compliance under this Agreement. Such audit by Acrivon will be: (a)&nbsp;on at least [***] prior written notice, with Acrivon providing a written audit plan to Akoya at least [***] before the
audit, or [***] prior written notice for <FONT STYLE="white-space:nowrap">for-cause</FONT> audits, (b)&nbsp;during [***] Akoya regular business hours, (c)&nbsp;not unreasonably disruptive to Akoya business operations, (d)&nbsp;reasonable in
duration, (e)&nbsp;not unduly burdensome to Akoya&#146;s personnel, (f)&nbsp;not more than [***] except as required by Applicable Law or for <FONT STYLE="white-space:nowrap">for-cause</FONT> audits, and (g)&nbsp;subject to Akoya&#146;s generally
applicable confidentiality, security and safety procedures, as well as quality management system procedures to the extent such procedures are made available during such Third Party audits. [***]. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>P<SMALL>AYMENTS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1 Upfront Development Fee</B>. Acrivon shall pay Akoya a <FONT STYLE="white-space:nowrap">one-time,</FONT>
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> upfront payment equal to Six Hundred Thousand Dollars ($600,000), towards which payment of Six Hundred Thousand Dollars ($600,000) made by
Acrivon to Akoya under the Master Services Agreement shall be fully credited. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2 Development Milestone Payments by Acrivon</B>.
Acrivon shall pay to Akoya the <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payments corresponding to Akoya&#146;s achievement of diligence obligations as set forth in
Schedule 3.5; provided, that Akoya shall provide written notice to Acrivon regarding achievement of each such milestone and an invoice for the milestone payment due. [***]. Notwithstanding anything to the contrary, the Parties agree that the
milestone &#147;Initial PMA Planning&#148; has been achieved as of the Effective Date and the corresponding milestone payment in the amount of Five Hundred Thousand Dollars ($500,000) will be fully due and payable after Acrivon receives an invoice
from Akoya therefor, which invoice may be issued by Akoya immediately after the Effective Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3 Other Costs</B>. Except for the
development payments payable by Acrivon to Akoya under Sections 7.1 and 7.2, each Party shall be responsible for all costs and expenses it incurs related to the performance of its activities under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4 Mode of Payment</B>. All payments by Acrivon to Akoya under this Agreement shall be
made in Dollars via electronic funds transfer in the requisite amount to such bank account as Akoya may from time to time designate by notice in writing to Acrivon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5 Interest on Late Payments</B>. If any payment due to Akoya under this Agreement for activities properly performed and correctly invoiced
by Akoya is not paid when due, then Acrivon shall pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of [***], such interest to run from the date on which payment of such sum became
due until payment thereof in full together with such interest; provided, that Akoya shall first provide Acrivon with at least [***] prior written notice that an amount remains outstanding and will become subject to interest payments if not paid on
time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6 Taxes</B>. All amounts payable by Acrivon to Akoya pursuant to this Agreement will be paid free and clear of any and all
taxes, except for any withholding taxes required by Applicable Law to be remitted by Acrivon. Except as provided in this Section&nbsp;7.6, Akoya will be solely responsible for paying any and all taxes (other than withholding taxes required by
Applicable Law to be deducted from such payments and remitted by Acrivon) levied on account of, or measured in whole or in part by reference to, any payments it receives. Acrivon will deduct or withhold from payments to Akoya any taxes that it is
required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if Akoya is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it will deliver to Acrivon or the
appropriate Governmental Authority (with the assistance of Acrivon to the extent reasonably requested in writing by Akoya) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Acrivon of its obligation to
withhold such tax and Acrivon will apply the reduced rate of withholding or dispense with withholding, as the case may be; provided, however, that Akoya shall indemnify, defend and hold harmless the Acrivon Indemnitees from and against any and all
Losses and Claims arising from the application of any such reduced rate of withholding taxes. If, in accordance with the foregoing, Acrivon withholds any amount, it will pay to Akoya the balance when due, make timely payment to the proper taxing
authority of the withheld amount and send to Akoya proof of such payment within [***] following such payment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>L<SMALL>ICENSES</SMALL>; G<SMALL>RANTS</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL>
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1 License to Acrivon</B>. Subject to the terms and conditions of this Agreement, during the Term, Akoya hereby
grants to Acrivon a limited, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free license, with the right to grant sublicenses in accordance with Section&nbsp;8.3,
under the Akoya Intellectual Property (a)&nbsp;for the sole purpose of performing the activities under the Development Plan allocated to Acrivon or (b)&nbsp;to the extent necessary to develop, make, use, sell, offer for sale, and import Prexasertib
in connection with the use of the Prexasertib OncoSignature CDx. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2 License to Akoya</B>. Subject to the terms and conditions of this
Agreement, Acrivon hereby grants to Akoya (a)&nbsp;a limited, worldwide, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free license, with the right to grant sublicenses in accordance with Section&nbsp;8.3 under the Acrivon
Collaboration Intellectual Property and (b)&nbsp;a limited, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free license, with the right to grant sublicenses in
accordance with Section&nbsp;8.3 under the Acrivon Background Intellectual Property, in each case of (a)&nbsp;and (b), (i) for the sole purpose of performing the activities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Development Plan allocated to Akoya and (ii)&nbsp;to the extent necessary to develop, make, use, sell, offer for sale, and import the Prexasertib OncoSignature CDx. The foregoing
license grant under clause (a)&nbsp;shall be exclusive for so long as (x)&nbsp;Akoya meets the Development Milestones and Commercialization Milestones and (y)&nbsp;Acrivon does not provide Akoya with an RDS Notice in accordance with
Section&nbsp;5.2(a); provided that, for clarity, (1)&nbsp;if any Development Milestones or Commercialization Milestones, as applicable, are not met when due (subject to extension as set forth in Section&nbsp;3.5), upon Acrivon&#146;s written notice,
in lieu of Acrivon exercising its right to terminate this Agreement for material breach in accordance with this Agreement, such license grant shall, at Acrivon&#146;s option, convert to <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> and
(2)&nbsp;such license grant shall convert to <FONT STYLE="white-space:nowrap">non-exclusive</FONT> if Acrivon provides Akoya with an RDS Notice in accordance with Section&nbsp;5.2(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3 Sublicenses</B>. Acrivon will have the right to grant sublicenses under the license granted to Acrivon in Section&nbsp;8.1 with
Akoya&#146;s prior written consent solely to perform activities for or on behalf of Acrivon under this Agreement. Akoya shall have the right to grant sublicenses under the license granted to Akoya in Section&nbsp;8.2 to its Affiliates and
Subcontractors solely to perform activities for or on behalf of Akoya under the Development Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4 No Other Rights</B>. Each Party
acknowledges that the licenses and other rights granted to it under this Article 8 and elsewhere in this Agreement are limited to the scope expressly granted and each Party covenants and agrees not to exploit any Intellectual Property Rights or
Results so licensed under this Agreement outside the scope of the licenses and other rights granted to such Party. Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever with
respect to any Intellectual Property Right of the other Party is granted whether by implication, estoppel, reliance, or otherwise, by the other Party to such Party. All rights that are not specifically granted herein are reserved to and retained by
the Controlling or possessing Party. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>I<SMALL>NTELLECTUAL</SMALL> P<SMALL>ROPERTY</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1 Ownership of Background Intellectual Property</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Acrivon Background Intellectual Property</B>. Acrivon shall retain all right, title and interest in and to the Acrivon Background
Intellectual Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Akoya Background Intellectual Property</B>. Akoya shall retain all right, title and interest in and to the
Akoya Background Intellectual Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2 Ownership of Collaboration Intellectual Property. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Disclosure</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)
</B>During the Term, Acrivon shall disclose to Akoya all Collaboration Intellectual Property that is conceived, discovered, developed or otherwise made by or on behalf of Acrivon or its Affiliates (including Subcontractors thereof), whether solely
or jointly with Akoya or its Affiliates (including Subcontractors thereof) and Akoya shall disclose to Acrivon any Collaboration Intellectual Property that is conceived, discovered, developed or otherwise made by or on behalf of Akoya or its
Affiliates (including Subcontractors thereof), whether solely or jointly with Acrivon or its Affiliates (including Subcontractors thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>During the Term, each Party will disclose to the other Party all Joint
Collaboration Intellectual Property that is conceived, discovered, developed or otherwise made solely or jointly by or on behalf of such Party or its Affiliates (including Subcontractors thereof). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>Any disclosure required by this Section&nbsp;9.2(a) shall (A)&nbsp;be made promptly and in any event reasonably prior to the
filing of any patent application with respect to such Collaboration Intellectual Property, (B)&nbsp;include all invention disclosures or other similar documents submitted to such Party by its or its Affiliates&#146; employees, agents or independent
contractors relating thereto, and (C)&nbsp;be treated as Confidential Information in accordance with Article 11 herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)
Inventorship</B>. The determination of inventorship and whether Collaboration Intellectual Property is conceived, reduced to practice, discovered, developed or otherwise made under this Agreement solely by a Party or jointly with the other Party for
the purpose of allocating proprietary rights (including Patent, copyright or other Intellectual Property Rights) therein, shall, for purposes of this Agreement, be made in accordance with the United States patent law irrespective of where such
conception, reduction to practice, discovery, development or making occurs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>[***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) Joint
Collaboration Intellectual Property</B>. Acrivon and Akoya shall jointly own all right, title, and interest in and to any and all Collaboration Intellectual Property that (i)&nbsp;regardless of inventorship, pertains to (A)&nbsp;sample staining
protocol, (B)&nbsp;analysis algorithm and imagery scoring system, or (C)&nbsp;data conformation through control sample imagery analysis or (ii)&nbsp;subject to Section&nbsp;9.2(c)(i) and Section&nbsp;9.2(d)(i), is conceived, invented, discovered,
developed or otherwise made jointly by or on behalf of Acrivon or its Affiliates (including Subcontractors thereof), on the one hand, and by or on behalf of Akoya or its Affiliates (including Subcontractors thereof), on the other hand
(&#147;<B><I>Joint Collaboration Intellectual Property</I></B>&#148;). Each Party shall own an equal, undivided interest in and to such Joint Collaboration Intellectual Property. Subject to each Party&#146;s obligations under this Article 9 and
Article 10, each Party shall have the right to Exploit the Joint Collaboration Intellectual Property without a duty of seeking consent from or accounting to the other Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f) Patents and Patent Applications Disclosing Both Acrivon Collaboration Intellectual Property and Akoya Collaboration Intellectual
Property</B>. If any Patent (including any application for patent) contains claims which represent both Acrivon Collaboration Intellectual Property and Akoya Collaboration Intellectual Property, Akoya and Acrivon shall make efforts to separate
Acrivon Collaboration Intellectual Property and Akoya Collaboration Intellectual Property into different filings (e.g., using divisional applications or other appropriate procedures). If the Parties mutually agree that it is impossible to separate
Acrivon Collaboration Intellectual Property from Akoya Collaboration Intellectual Property in a Patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without adversely affecting each Party&#146;s Intellectual Property Rights therein, such Patent shall be owned by Acrivon and Acrivon shall (i)&nbsp;grant to Akoya an exclusive, fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> perpetual and irrevocable, worldwide right and license (with the right to grant <FONT STYLE="white-space:nowrap">sub-licenses)</FONT> to any portion of the patent or application that represents Akoya
Collaboration Intellectual Property; and (ii)&nbsp;furnish Akoya with copies of applications for such Patent, amendments thereto and other related correspondence to and from patent offices, and shall permit Akoya a reasonable opportunity to review
and offer comments with respect thereto, which comments Acrivon shall incorporate in good faith, to the extent related to Akoya Collaboration Intellectual Property, and, to the extent not related to Akoya Collaboration Intellectual Property,
consider in good faith; provided that neither Party shall intentionally file or prosecute its Patents under this Section&nbsp;9.2(f) in a way that claims any Invention owned by the other Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3 Assignment of Rights</B>. Each Party shall cause all Persons who perform activities for such Party under this Agreement to be under an
obligation to assign (or, if such Party is unable to cause such Person to agree to such assignment obligation despite such Party using commercially reasonable efforts to negotiate such assignment obligation, provide a license under) their rights in
any Intellectual Property Rights resulting therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT>
and public institutions which have standard policies against such an assignment (in which case a suitable license, or right to obtain such a license, shall be obtained). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4 Patent Prosecution and Maintenance</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Acrivon</B>. Acrivon shall have the sole right (but not the obligation) to control the preparation, filing, prosecution and maintenance
(including any oppositions, interferences, reissue proceedings, reexaminations, post-grant proceedings, supplemental examinations, post grant review proceedings, inter partes review proceedings, patent interference proceedings, opposition
proceedings, derivation proceedings, reissue and reexamination, maintenance and defense) (such activities collectively, the &#147;<B><I>Prosecution and Maintenance</I></B>&#148;) of Patents Covering the Acrivon Background Intellectual Property or
the Acrivon Collaboration Intellectual Property on a worldwide basis, at Acrivon&#146;s sole cost and expense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Akoya</B>. Akoya
shall have the sole right (but not the obligation) to control the Prosecution and Maintenance of Patents Covering the Akoya Background Intellectual Property or the Akoya Collaboration Intellectual Property on a worldwide basis, at Akoya&#146;s sole
cost and expense; provided that if Akoya decides to abandon the Prosecution and Maintenance of any filed Patents Covering the Akoya Collaboration Intellectual Property, then Akoya shall provide notice of such decision at least [***] prior to the
next required office action involving any such Akoya Collaboration Intellectual Property, and Acrivon shall have the right to assume responsibility for the filing or further Prosecution and Maintenance of any such Patent(s), on Akoya&#146;s behalf,
including all costs associated therewith, by providing notice to Akoya indicating Acrivon&#146;s desire to assume responsibility for such activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) Joint Collaboration Intellectual Property</B>. The Parties, using outside patent counsel acceptable to both Parties, shall be
responsible for Prosecution and Maintenance of Patents Covering the Joint Collaboration Intellectual Property (&#147;<B><I>Joint Collaboration Patents</I></B>&#148;) and shall equally share in the costs and expenses in relation thereto. Each Party
shall keep the other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party advised as to material developments and all steps to be taken with respect to any such Joint Collaboration Patents and shall furnish the other Party with copies of applications for Joint
Collaboration Patents, amendments thereto and other related correspondence to and from patent offices, and shall permit the other Party a reasonable opportunity to review and offer comments. The Parties shall reasonably assist and cooperate with one
another in the Prosecution and Maintenance of the Joint Collaboration Patents. In the event that a Party determines either (A)&nbsp;not to continue the Prosecution and Maintenance of any Joint Collaboration Patent or (B)&nbsp;not to file any new
patent application requested to be filed by the other Party, the applicable Party shall provide the other Party with notice of its decision at least [***] prior to any pending lapse or abandonment thereof. In such event, the applicable Party shall
provide the other Party with an opportunity to assume responsibility for all costs associated with the filing or further Prosecution and Maintenance of such Joint Collaboration Patent (such filing to occur prior to the issuance of the Joint
Collaboration Patent to which the application claims priority or expiration of the applicable filing deadline, as set forth above). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5
Cooperation</B>. Each Party shall provide the other Party all reasonable assistance and cooperation in the Patent Prosecution and Maintenance efforts under Section&nbsp;9.4, including providing any necessary powers of attorney and executing any
other required documents or instruments for such Prosecution and Maintenance, without further compensation or consideration of any kind. The Party assuming such Prosecution and Maintenance responsibilities (in the case of Section&nbsp;9.4(a) and
9.4(b)) shall have the right to engage its own counsel to perform such activities and the Party providing assistance shall have the right to engage its own counsel. Each Party shall assist the other Party in all other reasonable ways that are
necessary for the issuance of those Patents for which such other Party is responsible, as well as for the Prosecution and Maintenance of such Patents. Each Party shall bear its own costs in exercising its rights and performing its obligations under
this Section&nbsp;9.5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6 Patent Enforcement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Enforcement Rights.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) Acrivon</B>. Acrivon shall have the sole right (but not the obligation) to prosecute infringement of the Acrivon Background
Intellectual Property and Acrivon Collaboration Intellectual Property at its sole cost and expense and Acrivon shall retain control of the prosecution of such claim, suit or proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) Akoya</B>. Akoya shall have the sole right, but not the obligation, to prosecute any infringement of the Akoya Background Intellectual
Property and Akoya Collaboration Intellectual Property at its sole cost and expense and Akoya shall retain control of the prosecution of such claim, suit or proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) Joint Collaboration Intellectual Property</B>. Acrivon shall have the first right (but not the obligation) to prosecute infringement
of the Joint Collaboration Intellectual Property within [***] from the date of notice and to join Akoya as a party plaintiff. Acrivon shall bear all the expenses of any suit brought by it claiming infringement of any Joint Collaboration Intellectual
Property. Akoya will reasonably cooperate with Acrivon, at Akoya&#146;s expense, in any such suit and shall have the right to consult with Acrivon and to participate in and be represented </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by independent counsel in such litigation at its own expense. If, after the expiration of such [***] period (or, if earlier, the date upon which Acrivon provides written notice that it does not
plan to bring suit), Acrivon has not obtained a discontinuance of infringement of the Joint Collaboration Intellectual Property or filed suit against any such Third Party infringer of the Joint Collaboration Intellectual Property, then Akoya shall
have the right, but not the obligation, to bring suit against such Third Party infringer of Joint Collaboration Intellectual Property, provided that Akoya shall bear all the expenses of such suit. Acrivon will reasonably cooperate with Akoya, at
Acrivon&#146;s expense, in any such suit for infringement of a Joint Collaboration Intellectual Property brought by Akoya against a Third Party, and shall have the right to consult with Akoya and to participate in and be represented by independent
counsel in such litigation at its own expense. Any recoveries obtained by Acrivon or Akoya, as applicable, as a result of any proceeding against such a Third Party infringer shall be allocated as follows: (A)&nbsp;such recovery shall first be used
to reimburse each Party for all reasonable attorney fees and other litigation costs actually incurred in connection with such litigation by that Party, and (B)&nbsp;any remainder shall [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Cooperation</B>. The Parties agree to reasonably cooperate in any infringement action pursuant to this Section&nbsp;9.6 that involves
Collaboration Intellectual Property. Unless otherwise set forth herein, the Party entitled to bring any patent infringement litigation in accordance with this Section&nbsp;9.6 shall have the right to settle such claim; provided that neither Party
shall have the right to settle any patent infringement litigation under this Section&nbsp;9.6 in a manner that materially diminishes or has a material adverse effect on the rights or interest of, imposes any costs or liability on, or involves any
admission by, the other Party, without the express written consent of such other Party. The Party commencing the litigation shall provide the other Party with copies of all pleadings and other documents filed with the court if doing so would not
waive any privilege or violate any court order or Applicable Law and shall consider reasonable input from the other Party during the course of the proceedings. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.7 Inventor&#146;s Remuneration</B>. Each Party shall be solely responsible for any remuneration that may be due such Party&#146;s
inventors under any applicable inventor remuneration laws. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>E<SMALL>XCLUSIVITY</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1 Acrivon</B>. [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2 Akoya</B>. [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3 Enforceability</B>. It is the desire and intent of the Parties that the restrictive covenants contained in this Article 10 be enforced
to the fullest extent permissible under Applicable Laws and public policies applied in each jurisdiction in which enforcement is sought. Acrivon and Akoya believe that the restrictive covenants in this Article 10 are valid and enforceable. However,
if any restrictive covenant should for any reason become or be declared by a competent court or competition authority to be invalid or unenforceable in any jurisdiction, such restrictive covenant shall be deemed to have been amended to the extent
necessary in order that such provision be valid and enforceable, and such amendment shall apply only with respect to the operation of such provision of this Article 10 in the particular jurisdiction in which such declaration is made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>ONFIDENTIALITY</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1 Confidential Information</B>. &#147;<B><I>Confidential Information</I></B>&#148; means all information and data of a financial,
commercial, business, operational or technical nature that is disclosed by or on behalf of a Party (the &#147;<B><I>Disclosing Party</I></B>&#148;) or any of its Affiliates or otherwise made available to the other Party (the &#147;<B><I>Receiving
Party</I></B>&#148;) or any of its Affiliates, in each case in connection with this Agreement (including under the Prior Agreements), whether made available orally, visually, in writing or in electronic form. Notwithstanding the foregoing,
(a)&nbsp;the Acrivon Intellectual Property shall be Acrivon&#146;s Confidential Information, (b)&nbsp;the Akoya Intellectual Property shall be Akoya&#146;s Confidential Information, and (c)&nbsp;Joint Collaboration Intellectual Property shall be the
Confidential Information of both Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2 Confidentiality and <FONT STYLE="white-space:nowrap">Non-Use</FONT> Obligations</B>.
Subject to the other provisions of this Article 11, during the Term and for [***] thereafter: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>except to the extent expressly
authorized by this Agreement, the Receiving Party shall maintain all Confidential Information of the Disclosing Party in confidence and not publish or otherwise disclose Confidential Information of the Disclosing Party to a Third Party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>the Receiving Party will treat all Confidential Information of the Disclosing Party with the same degree of care as the Receiving
Party uses for its own similar information, but in no event less than a reasonable degree of care; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>the Receiving Party may only
use any Confidential Information of the Disclosing Party for the purposes of performing its obligations or exercising its rights under this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>a Receiving Party may disclose Confidential Information of the Disclosing Party to such Receiving Party&#146;s Affiliates,
employees, agents, consultants, Subcontractors, licensees, and sublicensees to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement; provided that (i)&nbsp;such Persons are bound by
legally enforceable obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> with respect to the Confidential Information of the Disclosing Party no less stringent than the obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> set forth in this Agreement and (ii)&nbsp;each Party remains responsible for any failure by its Affiliates, employees, agents, consultants, Subcontractors, licensees and sublicensees to treat such
Confidential Information as required under this Section&nbsp;11.2; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>each Receiving Party will promptly notify the Disclosing
Party of any misuse or unauthorized disclosure of the Confidential Information of the Disclosing Party that the Receiving Party is or becomes aware of. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3 Exceptions</B>. The obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> of a Receiving Party with
respect to the Confidential Information of such Disclosing Party shall not apply with respect to any Confidential Information to the extent that the Receiving Party can demonstrate through competent documentary evidence that such Confidential
Information: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>is known by the Receiving Party or any of its Affiliates without an obligation of confidentiality at the time of
disclosure by or on behalf of the Disclosing Party, and not through a prior disclosure by or on behalf of the Disclosing Party, as documented by the Receiving Party&#146;s business records; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>is generally available to the public before its receipt from the Disclosing Party;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>became generally available to the public or otherwise part of the public domain after its disclosure by the Disclosing Party
and other than through any act or omission of the Receiving Party or any of its Affiliates or disclosees in breach of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>is subsequently disclosed to the Receiving Party or any of its Affiliates without obligation of confidentiality by a Third Party who
may rightfully do so and is not under a conflicting obligation of confidentiality to the Disclosing Party; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>is developed by
the Receiving Party or any of its Affiliates independently and without use of or reference to any Confidential Information of the Disclosing Party, as documented by the Receiving Party&#146;s contemporaneous written records. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">No combination of features or disclosures will be deemed to fall within the foregoing exclusions merely because individual features are
published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the
Receiving Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4 Authorized Use and Disclosure</B>. Notwithstanding the obligations set forth in Section&nbsp;11.2, the Receiving
Party may disclose the Confidential Information of the Disclosing Party to the extent such disclosure is reasonably necessary in the following situations: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B><B></B>&nbsp;(i) the Prosecution and Maintenance of Patents, as contemplated by this Agreement; or (ii)&nbsp;Regulatory Submissions
and other filings with Governmental Authorities (including Regulatory Authorities), as necessary for the Exploitation of the Prexasertib OncoSignature CDx in the case of Akoya and Prexasertib in the case of Acrivon; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>disclosure of this Agreement, its terms, and the status and results of Exploitation of the Prexasertib OncoSignature CDx to actual
or bona fide potential investors in connection with acquisition of equity of the Receiving Party, acquirors, lenders, and royalty factoring partners, and their respective attorneys, accountants, banks, investors, and advisors, solely for the purpose
of evaluating or carrying out an actual or potential investment, acquisition, debt or royalty factoring transaction; provided that, any such Persons are bound by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at
least as stringent as those set forth in this Article 11 or otherwise customary for such type and scope of disclosure, and that any such disclosure is limited to the maximum extent practicable for the particular context in which it is being
disclosed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>such disclosure is required to comply with Applicable Law (whether generally or in pursuit of an application for
listing of securities, including those regulations promulgated by the United States Securities and Exchange Commission) or otherwise required by judicial or administrative process; provided that, in each such event, as promptly as reasonably
practicable and to the extent not prohibited by Applicable Law or judicial or administrative process, such Receiving Party will (i)&nbsp;notify the Disclosing Party of such required disclosure, (ii) </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
take all steps reasonably necessary, including seeking of confidential treatment or a protective order, to ensure the continued confidential treatment of such Confidential Information, and
(iii)&nbsp;only disclose that portion of Confidential Information that is legally required to be disclosed. Any Confidential Information that is disclosed in order to comply with Applicable Law or by judicial or administrative process pursuant to
this Section&nbsp;11.4(c) will remain otherwise subject to the confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> provisions of this Article 11 with respect to such Receiving Party disclosing such Confidential Information; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>disclosure pursuant to Section&nbsp;11.6 (in accordance with the process set forth therein) and Section&nbsp;11.7. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.5 Prior Agreements</B>. This Agreement supersedes the Prior Agreements with respect to any information disclosed thereunder. All
information provided by a Party under the Prior Agreements shall be deemed Confidential Information of such Party as the Disclosing Party and shall be subject to the terms and conditions of this Article 11. Notwithstanding the foregoing, all
&#147;<B><I>Akoya Background Intellectual Property</I></B>&#148; and &#147;<B><I>Client Intellectual Property</I></B>&#148; (each, as defined in the Master Services Agreement) developed under the Master Services Agreement prior to the Effective Date
shall continue to be owned in accordance with Section&nbsp;5 of the Master Services Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.6 Publications. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Acrivon and its Affiliates shall have the right to publish, present (including presentation at any scientific meeting) or otherwise
disclose information related to Prexasertib and patient responder identification without the prior review and approval of Akoya, subject to Section&nbsp;11.6(b) with respect to the portions of such publications or presentations that specifically
relate to the Prexasertib OncoSignature CDx. Subject to the foregoing, neither Party will make any academic, scientific, medical or other publication or public presentation related to any activities conducted pursuant to this Agreement, in each
case, without the other Party&#146;s prior written consent and review in accordance with Section&nbsp;11.6(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>If either Party
intends to publish, present (including presentation at any scientific meeting) or otherwise disclose information specifically related to the Prexasertib OncoSignature CDx, such Party (the &#147;<B><I>Publishing Party</I></B>&#148;) shall provide the
other Party (the &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Publishing</FONT> Party</I></B>&#148;) with such proposed publication, presentation or disclosure at least [***] prior to the intended submission date for publication. The <FONT
STYLE="white-space:nowrap">Non-Publishing</FONT> Party will have the right to reasonably review and comment on such publication, presentation or disclosure within [***] following receipt thereof. When Akoya is the Publishing Party it shall
incorporate comments provided by Acrivon with respect to any such publication, presentation or disclosure; when Acrivon is the Publishing Party it shall consider in good faith comments made by Akoya, but Acrivon shall be under no obligation to
incorporate Akoya&#146;s comments unless Akoya reasonably demonstrates that elements of the applicable publication are reasonably likely to negatively impact the Commercialization of the Prexasertib OncoSignature CDx or will otherwise materially
adversely impact Akoya&#146;s business. Notwithstanding the foregoing, if a publication, presentation or disclosure contains Confidential Information of the <FONT STYLE="white-space:nowrap">Non-Publishing</FONT> Party, then upon the <FONT
STYLE="white-space:nowrap">Non-Publishing</FONT> Party&#146;s request during such [***] period, the Publishing Party shall delete any such information identified by the <FONT STYLE="white-space:nowrap">Non-Publishing</FONT> Party. If the <FONT
STYLE="white-space:nowrap">Non-Publishing</FONT> Party wishes to request </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a reasonable delay in publication or presentation in order to protect patentable information, the Publishing Party shall delay the publication or presentation for a period of no more than [***]
to enable patent applications to be filed in accordance with Section&nbsp;9.4 to protect Collaboration Intellectual Property disclosed in such publication or presentation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>For clarity, if the <FONT STYLE="white-space:nowrap">Non-Publishing</FONT> Party fails to notify the Publishing Party during the
[***] previewing period as provided under this Section&nbsp;11.6(b), the Publishing Party shall be free to proceed with the proposed publication or presentation of such Confidential Information. Without limiting the foregoing, should the Parties
decide to publish, present or otherwise disclose information related to the Prexasertib OncoSignature CDx jointly, the Parties will work together in good faith to do so. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.7 Public Announcements</B>. The Parties have agreed on the press release announcing this Agreement, in the form substantially as set
forth on Schedule 11.7, to be issued by either or both Parties on such date and time as the Parties may agree. Other than such initial press release, except for any such disclosure permitted under Section&nbsp;11.4 or Section&nbsp;11.6, the Parties
agree that the portions of any other news release or other public announcement relating to this Agreement or the performance hereunder that would disclose information other than that already in the public domain will first be reviewed and approved
by both Parties (with such approval not to be unreasonably withheld, conditioned, or delayed). Notwithstanding the foregoing, (a)&nbsp;Akoya shall be free to issue any public announcement, press release, or other public disclosure related to
(i)&nbsp;the Akoya Platform that does not specifically relate to Prexasertib, (ii)&nbsp;other diagnostics products under development by Akoya that utilize the Akoya Platform, or (iii)&nbsp;any publication, presentation or disclosure that was
permitted under Section&nbsp;11.6; provided that any such disclosure under each of the foregoing ((i) through (iii)) does not contain any Confidential Information of Acrivon or mention of Acrivon and (b)&nbsp;Acrivon shall be free to issue any
public announcement, press release or other public disclosure related to (i)&nbsp;the Acrivon Biomarker Identification Platform or Prexasertib that does not specifically relate to the Prexasertib OncoSignature<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> CDx, (ii)&nbsp;other diagnostics products under development by Acrivon that utilize the Acrivon Biomarker Identification Platform, or (iii)&nbsp;any publication, presentation or disclosure that
was permitted under Section&nbsp;11.6; provided that any such disclosure under each of the foregoing ((i) through (iii)) does not contain any Confidential Information of Akoya or mention of Akoya. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.8 Use of Names. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)
</B>Each Party and its Affiliates will retain all right, title and interest in and to its and their respective corporate names and trademarks. Akoya will ensure that its, and its Affiliates&#146;, references to Acrivon (and any product (including
Prexasertib), trademark, logo, or corporate name of Acrivon or any of its Affiliates) in connection with the Prexasertib OncoSignature CDx (including any use in any Labeling, the Prexasertib OncoSignature CDx description, technical information,
instructions for use, promotional material, advertising and other information and messaging to be included with the Prexasertib OncoSignature CDx or otherwise to be provided by Akoya to potential purchasers or users of the Prexasertib OncoSignature
CDx) will only be as approved in advance in writing by Acrivon and only to the extent as specifically agreed to in advance in writing by Acrivon, provided that such approval or agreement may not be unreasonably withheld, conditioned, or delayed.
Without limiting the foregoing, Akoya shall include the OncoSignature trademark in all Labeling. Likewise, Acrivon will ensure that its, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its Affiliates&#146;, references to Akoya (and any product, trademark, logo, or corporate name of Akoya or any of its Affiliates) in connection with Prexasertib (including any use in any
Labeling, the Prexasertib description, technical information, instructions for use, promotional material, advertising and other information and messaging to be included with Prexasertib or otherwise to be provided by Acrivon to potential purchasers
or users of Prexasertib) will only be as approved in advance in writing by Akoya and only to the extent as specifically agreed to in advance in writing by Akoya, provided that such approval or agreement may not be unreasonably withheld, conditioned
or delayed. The Parties will in good faith negotiate any necessary trademark licenses that either Party would like to uniquely memorialize. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The Parties shall have the right to exercise quality control over the use of their names and trademarks to the degree necessary to
maintain the validity of trademarks and to protect the goodwill associated therewith. Except as permitted under Section&nbsp;11.7, or with the prior express written permission of the other Party, neither Party will use the corporate name or
trademark of the other Party or its Affiliates or their respective employees in any publicity, promotion, news release, or disclosure relating to this Agreement or its subject matter except as may be required by Applicable Law. Each Party will use
the other Party&#146;s corporate name in all publicity relating to this Agreement, including the initial press release and all subsequent press releases. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.9 Injunctive Relief</B>. Each Party acknowledges that its breach of this Article 11 will cause irreparable harm to the other Party, which
cannot be reasonably or adequately compensated in damages in an action at law. By reasons thereof, each Party shall be entitled, in addition to any other right or remedy it may have at law or in equity, to seek injunctive and other equitable relief,
in any court of competent jurisdiction, enjoining or restraining the other Party or its Affiliates from any violation or threatened violation of this Article 11. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1 Representations and Warranties of Each Party</B>. Acrivon and Akoya each represents and warrants to the other, as of the Effective
Date, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>it is a corporation duly incorporated, validly existing, and in good standing under the laws of the
jurisdiction of its incorporation, and has all requisite corporate power and authority, to execute, deliver, and perform its obligations under this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>the execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly
authorized by all necessary corporate action, and do not violate (i)&nbsp;such Party&#146;s charter documents, bylaws, or other organizational documents, (ii)&nbsp;in any material respect, any agreement, instrument, or contractual obligation to
which such Party is bound, (iii)&nbsp;any requirement of any Applicable Law, or (iv)&nbsp;any order, writ, judgment, injunction, decree, determination, or award of any court or governmental agency presently in effect applicable to such Party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>this Agreement is a legal, valid, and binding obligation of such Party enforceable against it in accordance with its terms and
conditions, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, and general principles of equity
(whether enforceability is considered a proceeding at law or equity); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>it is not under any obligation, contractual or otherwise, to any Person that
conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2 Additional Representations and Warranties of Acrivon</B>. Acrivon represents and warrants to Akoya, as of the Effective Date, as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>it has the rights in and to the Acrivon Background Intellectual Property existing as of the Effective Date and
necessary to perform the activities allocated to it under the Development Plan as contemplated as of the Effective Date, and to grant the licenses to Akoya under such Acrivon Background Intellectual Property that Acrivon purports to grant pursuant
to this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>it has not granted to any Third Party any rights under the Acrivon Background Intellectual Property existing
as of the Effective Date that would otherwise interfere or be inconsistent with Akoya&#146;s rights hereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>[***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>[***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3
Additional Representations and Warranties of Akoya</B>. Akoya represents and warrants to Acrivon, as of the Effective Date, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>it has the rights in and to the Akoya Background Intellectual Property existing as of the Effective Date necessary to perform the
activities allocated to it under the Development Plan as contemplated as of the Effective Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>it has not granted to any Third
Party any rights under the Akoya Background Intellectual Property existing as of the Effective Date that would otherwise interfere or be inconsistent with Acrivon&#146;s rights hereunder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>[***]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>it
has or will have (at the appropriate time) the capacity and resources to develop (including filing for, obtaining and maintaining, Approval, as applicable), manufacture and commercialize the Prexasertib OncoSignature CDx in accordance with this
Agreement, including in accordance with the Development Plan and Commercialization Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>from and after the receipt of Approval
therefor, each Prexasertib OncoSignature CDx will conform to its applicable specifications and have been and will be manufactured and supplied in accordance with Applicable Laws; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.4 Mutual Covenants</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) No Debarment</B>. In the course of conducting the Development Plan and the Exploitation of Prexasertib or the Prexasertib OncoSignature
CDx hereunder, neither Party nor its Affiliates shall use any employee or Third Party who has been debarred by any Regulatory Authority, or, to such Party&#146;s or its Affiliates&#146; knowledge, is the subject of debarment proceedings by a
Regulatory Authority. Each Party shall notify the other Party promptly upon becoming aware that any of its or its Affiliates&#146; employees or consultants has been debarred or is the subject of debarment proceedings by any Regulatory Authority.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Compliance</B>. Each Party and its Affiliates shall comply in all material respects with all Applicable Laws (including all
anti-corruption and anti-bribery laws) in relation to the conduct of the Development Plan and performance of its obligations under this Agreement, including (in the case of Akoya) the Exploitation of the Prexasertib OncoSignature CDx and (in the
case of Acrivon) the Exploitation of Prexasertib. Each Party and its Affiliates shall, in connection with its activities hereunder, use its best efforts to comply with all applicable (i)&nbsp;U.S. laws prohibiting the
<FONT STYLE="white-space:nowrap">re-export,</FONT> directly or indirectly, of certain controlled U.S.-origin items without a license to parties located in certain countries or appearing on certain U.S. Government lists of restricted parties;
(ii)&nbsp;U.S. laws prohibiting participation in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> boycotts that the United States does not support; and (iii)&nbsp;U.S. laws prohibiting the sale of products to parties from any country subject to U.S.
economic sanctions or who are identified on related U.S. Government lists of restricted parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) Assignment of Collaboration
Intellectual Property</B>. Each Party and each of its Affiliates have obtained from each of its current employees, consultants, contractors and agents, and will obtain from each of its future employees, consultants, contractors and agents, in each
case who perform activities pursuant to this Agreement, written agreements containing obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> (that is substantially consistent with the provisions of Article 11 hereunder)
and an assignment to such Party or its Affiliates of all Collaboration Intellectual Property (and all of such Person&#146;s rights thereto) for which Acrivon or Akoya is intended to have ownership or license rights under this Agreement such that no
such employee, contractor, consultant or agent shall retain any rights to such Collaboration Intellectual Property that would prevent or conflict with the other Party&#146;s rights of ownership or use of such Collaboration Intellectual Property
contemplated by or arising under the development activities pursuant to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.5 Warranty Disclaimer</B>. EXCEPT AS SET
FORTH IN THIS ARTICLE 12, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER
WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT>
OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>I<SMALL>NDEMNITY</SMALL>; I<SMALL>NSURANCE</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1 Indemnification</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Indemnification by Acrivon</B>. Acrivon hereby agrees to defend, hold harmless and indemnify (collectively,
&#147;<B><I>Indemnify</I></B>&#148;) Akoya and its Affiliates, and its and their respective directors, officers, employees, and agents (each, a &#147;<B><I>Akoya Indemnitee</I></B>&#148;) from and against any and all losses, damages, liabilities,
penalties, settlements, costs, and expenses (including reasonable attorneys&#146; fees and other expenses of litigation) (collectively, &#147;<B><I>Losses</I></B>&#148;) in connection with any Claims against any Akoya Indemnitee to the extent
arising from or occurring as a result of (i)&nbsp;any breach of any representation or warranty made by Acrivon, or any breach or violation of any covenant or agreement of Acrivon, in this Agreement; (ii)&nbsp;the Exploitation of Prexasertib by or on
behalf of Acrivon, its Affiliates and sublicensees (including, for clarity, any claims of infringement of Patents Controlled by a Third Party based upon [***] the Exploitation of Prexasertib), or (iii) [***]; except in each case of ((i), (ii), and
(iii)), to the extent such Claim arises from a circumstance for which Akoya has an obligation to indemnify Acrivon pursuant to Section&nbsp;13.1(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Indemnification by Akoya</B>. Akoya hereby agrees to Indemnify Acrivon and its Affiliates, and its and their respective directors,
officers, employees, and agents (each, a &#147;<B><I>Acrivon Indemnitee</I></B>&#148;) from and against any and all Losses in connection with any Claims against any Acrivon Indemnitee to the extent arising from or occurring as a result of:
(i)&nbsp;any breach of, or inaccuracy in, any representation or warranty made by Akoya in this Agreement, or any breach or violation of any covenant or agreement of Akoya in or pursuant to this Agreement; or (ii) [***] or (iii)&nbsp;the Exploitation
of the Prexasertib OncoSignature CDx by or on behalf of Akoya or its Affiliates (including, for clarity, any claims of infringement of Patents Controlled by a Third Party based upon Exploitation of the Prexasertib OncoSignature CDx [***]; except in
each case of ((i)-(iii)), to the extent such Claim arises from a circumstance for which Acrivon has an obligation to indemnify Akoya pursuant to Section&nbsp;13.1(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2 Indemnification Procedure</B>. All indemnification claims in respect of a Party, its Affiliates, or its or their respective directors,
officers, employees and agents shall be made solely by such Party to this Agreement. The Party claiming indemnity under Section&nbsp;13.1(a) or Section&nbsp;13.1(b) (the &#147;<B><I>Indemnified Party</I></B>&#148;) shall give the other Party (the
&#147;<B><I>Indemnifying Party</I></B>&#148;) prompt written notice (a &#147;<B><I>Claim Notice</I></B>&#148;) of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under Article 13,
provided that any delay in providing such notice shall not constitute a waiver or release of, or otherwise limit, the Indemnified Party&#146;s rights to indemnification, except to the extent that such delay materially prejudices the Indemnifying
Party&#146;s ability to defend against the relevant claims. Each Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The
Indemnified Party shall furnish promptly to the Indemnified Party copies of all papers and official documents received in respect of any Losses and Claims. The Indemnifying Party may assume and control, with the sole power to direct, the defense of
the Claim at its own cost and expense with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. If the Indemnifying Party does not assume control of the defense of the Claim as described in this
Section&nbsp;13.2, the Indemnified Party shall control such defense at the Indemnifying Party&#146;s cost and expense. The Party not controlling such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defense may participate therein at its own cost and expense. Neither the Indemnifying Party nor the Indemnified Party shall admit fault on behalf of the other Party without the written consent of
such other Party. The Indemnified Party shall not settle or compromise any Claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, conditioned or delayed. The Indemnifying Party shall not settle
or compromise a Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto or that imposes any liability or obligation on the
Indemnified Party for which the Indemnified Party is not indemnified under this Agreement, without the prior written consent of the Indemnified Party. The Party controlling the defense of a Claim under this Section&nbsp;13.2 shall keep the other
Party advised of the status of such Claim and the defense thereof and shall reasonably consider recommendations made by the other Party with respect thereto. Each Party shall cooperate fully with the Party controlling such defense and shall make
available all pertinent information under its control, which information shall be subject to Article 11, and cause its employees to be available in a deposition, hearing or trial. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.3 Insurance</B>. Each Party shall acquire and maintain, at its own expense, insurance as reasonably necessary to cover potential
liabilities and risk arising out of activities to be performed under this Agreement. Within [***] following written request from the other Party, each Party shall furnish to such other Party a certificate of insurance evidencing such coverage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.4 Limitation of Liability</B>. EXCEPT WITH RESPECT TO (A)&nbsp;A BREACH OF EITHER PARTY&#146;S CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE
11, (B) A BREACH OF ARTICLE 9, ARTICLE 10 OR ARTICLE 11, (C) WILLFUL MISCONDUCT OR FRAUD OF A PARTY UNDER THIS AGREEMENT, OR (D)&nbsp;THE PARTIES&#146; INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 13, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT, OR INCIDENTAL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT, INCLUDING LOSS OF PROFITS OR ANTICIPATED SALES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>ERM</SMALL>; T<SMALL>ERMINATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.1 Term</B>. The term of this Agreement shall commence on the Effective Date, and shall continue in full force and effect until earlier
terminated in accordance with this Article 14 (the &#147;<B><I>Term</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.2 Termination for Material Breach</B>. Either
Party may terminate this Agreement by written notice referencing this Section&nbsp;14.2 and specifying the breach to the other Party if the other Party is in material breach of this Agreement and has not cured such breach within [***] after notice
requesting cure of the breach; provided that in the event of a good faith dispute with respect to the existence of a material breach, this Agreement shall not be terminated unless it is finally determined under Article 15 that this Agreement was
materially breached, and the breaching Party fails to cure such breach within [***] after such determination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.3 Termination for Insolvency</B>. If, at any time during the Term, (a)&nbsp;a case is
commenced by or against either Party under Title 11, United States Code, as amended, or analogous provisions of Applicable Law outside the United States (the &#147;<B><I>Bankruptcy Code</I></B>&#148;) and, in the event of an involuntary case under
the Bankruptcy Code, such case is not dismissed within [***] after the commencement thereof, (b)&nbsp;either Party files for or is subject to the institution of bankruptcy, liquidation or receivership proceedings (other than a case under the
Bankruptcy Code), (c) either Party assigns all or a substantial portion of its assets for the benefit of creditors, (d)&nbsp;a receiver or custodian is appointed for either Party&#146;s business, or (e)&nbsp;a substantial portion of either
Party&#146;s business is subject to attachment or similar process (each of ((a) through (e)), a &#147;<B><I>Bankruptcy Event</I></B>&#148;); then, in any case of ((a) through (e)), the other Party may terminate this Agreement upon written notice to
the extent permitted under Applicable Law. All rights and licenses granted under or pursuant to this Agreement by each Party to the other Party, as applicable, are and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the
Bankruptcy Code, licenses of rights to &#147;intellectual property&#148; as defined under Article 101(35A) of the Bankruptcy Code. The Parties agree that each Party, as a licensee of such Intellectual Property Rights under this Agreement, shall
retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code or analogous
provisions of Applicable Laws outside the United States, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any Intellectual Property Rights licensed to such Party and all embodiments of such
Intellectual Property Rights, which, if not already in such Party&#146;s possession, will be promptly delivered to it (i)&nbsp;upon any such commencement of a bankruptcy proceeding upon such Party&#146;s written request therefor, unless the Party in
the bankruptcy proceeding elects to continue to perform all of its obligations under this Agreement or (ii)&nbsp;if not delivered under clause (i), following the rejection of this Agreement in the bankruptcy proceeding, upon written request therefor
by the other Party. The Parties further agree that, upon the occurrence of a Bankruptcy Event with respect to a Party, each Party shall have the right to retain and enforce their rights under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.4 Termination For Convenience</B>. Acrivon may terminate this Agreement at its convenience at any time upon [***] prior written notice to
Akoya; [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.5 Termination Upon Agreement</B>. The Parties may terminate this Agreement at any time upon mutual written agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.6 Effects of Termination</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Termination of Licenses; Granting of License</B>. All licenses, options, and other rights granted under Article 8 shall terminate as of
the effective date of expiration or termination; provided, that, upon any termination of this Agreement, other than termination by Akoya pursuant to Section&nbsp;14.2 or 14.3, Akoya hereby grants Acrivon a perpetual, irrevocable sublicense, with
right to grant sublicenses, under, in and to, all rights Controlled by Akoya pertaining [***] subject to Acrivon&#146;s compliance with the terms and conditions under the applicable upstream agreement applicable to and attributed to Acrivon&#146;s
exercise of such sublicense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Wind-Down</B>. The Parties shall cooperate in good faith to wind down any then-ongoing activities
under the Development Plan prior to the effective date of termination unless the Parties otherwise agree in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) Return of Confidential Information and Materials</B>. Upon any expiration or
termination of this Agreement, or upon either Party&#146;s earlier written request, each Party shall destroy all Confidential Information and materials provided to it by the other Party and all copies and embodiments thereof, and shall certify in
writing such destruction, provided that such other Party shall be permitted to retain one (1)&nbsp;copy of such Confidential Information for the sole purpose of performing any continuing obligations or exercising any surviving rights hereunder, as
required by Applicable Law, or for litigation or archival purposes. Notwithstanding the foregoing, such other Party also shall be permitted to retain such additional copies of or any computer records or files containing such Confidential Information
that have been created solely by such Party&#146;s automatic archiving and <FONT STYLE="white-space:nowrap">back-up</FONT> procedures, to the extent created and retained in a manner consistent with such other Party&#146;s standard archiving and <FONT
STYLE="white-space:nowrap">back-up</FONT> procedures, but not for any other use or purpose. Any Confidential Information so retained under this Section&nbsp;14.6(c) shall continue to be subject to the obligations of
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-use</FONT> set forth in Article 11. Without limiting the foregoing, Akoya shall promptly following the effective date of termination transfer to Acrivon
any and all Reserved Patient Samples remaining in its possession. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.7 Accrued Obligations; Survival</B>. Any expiration or termination
of this Agreement for any reason shall not release either Party of any obligation or liability which, at the time of such expiration or termination, has already accrued to such Party or which is attributable to a period prior to such expiration or
termination. Without limiting the generality of the foregoing, Articles 1, 6 (for a period of [***] except with respect to the last sentence thereof which shall survive indefinitely), 11 (for a period of [***] except with respect to Sections 11.5,
11.7, 11.8 and 11.9 which shall survive indefinitely, and except with respect to Section&nbsp;11.6 which shall survive, to the extent relevant, until expiration of the last Patent referenced in the final sentence of the Acrivon Biomarker
Identification Platform definition), 15, and 16 and Sections 3.6, 3.8, 9.1, 9.2, 9.3, 10.2(b) (for a period of [***], 10.3, 12.5, 13.1, 13.2, 13.4, 14.6, 14.7, and 14.8 shall survive any termination or expiration of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.8 <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedy</B>. Notwithstanding anything herein to the contrary, termination of this
Agreement under this Article 14 shall be without prejudice to other remedies each Party may have at law or in equity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>D<SMALL>ISPUTE</SMALL> R<SMALL>ESOLUTION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.1 Disputes</B>. Except as otherwise provided under Section&nbsp;2.1(e), if the Parties, in consultation with each Party&#146;s Alliance
Managers, are unable to resolve any dispute arising out of or in connection with this Agreement, either Party may, by written notice to the other, have such dispute referred to the Executive Officers of each of Acrivon and Akoya, or their respective
equivalents or designees, for attempted resolution by good faith negotiations within [***] after such notice is received. In such event, the Parties shall cause their Executive Officers or their designees to meet and be available to attempt to
resolve such issue. If the Parties are unable to resolve any dispute under this Section&nbsp;15.1, such remaining dispute shall be resolved pursuant to Section&nbsp;15.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.2 Arbitration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>If the Parties are unable to resolve any dispute pursuant to Section&nbsp;15.1, then, subject to Section&nbsp;15.3, such dispute
shall settled by arbitration pursuant to this Section&nbsp;15.2. Any arbitration under this Section&nbsp;15.2 shall be administered under the [***] as then in effect, except as modified herein. Any disputes concerning the propriety of the
commencement of arbitration or the scope or applicability of this agreement to arbitrate shall be finally settled by the arbitral tribunal. The arbitral tribunal shall be comprised of a panel of three (3)&nbsp;independent and neutral experienced
arbitrators appointed in accordance with such rules. Each Party shall nominate one (1)&nbsp;arbitrator, and the two (2)&nbsp;arbitrators so nominated shall nominate a third (3rd) arbitrator, who shall act as the chairperson of the tribunal. Each
Party shall select its arbitrator within ten (10)&nbsp;days of one Party notifying the other Party that it is exercising its rights under this Section&nbsp;15.2, and the two (2)&nbsp;arbitrators shall select the third arbitrator within five
(5)&nbsp;days of their selection. The seat, or legal place, of arbitration shall be [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The language to be used in the
arbitral proceedings will be English. The Parties acknowledge that this Agreement evidences a transaction involving interstate commerce. Notwithstanding the provision in Section&nbsp;16.1 with respect to applicable substantive law, any arbitration
conducted pursuant to the terms of this Agreement shall be governed by the Federal Arbitration Act (9 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1-16).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Based on the materials submitted, the arbitrators shall determine whether any discovery process is necessary, and, if it is, the
parameters of such process with the intent of resolving the arbitration as expeditiously as possible (e.g., limiting the number of depositions and the time discovery is permitted to take). The Parties and arbitrators shall employ procedures designed
to resolve the conflict by arbitration within [***] of the dispute being referred for arbitration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>The arbitrators shall have
no authority to award punitive or any other type of damages not measured by a Party&#146;s compensatory damages and the arbitrators shall have no authority to grant any award or remedy other than such awards or remedies that are available under the
Applicable Law. Except to the extent necessary to prepare for or conduct the arbitration, to challenge, confirm or enforce an arbitral award, as may be required in connection with a court application for interim relief in aid of arbitration, or as
may be required by law, neither a Party nor any arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Acrivon and Akoya. In no event shall arbitration be initiated after the date when
commencement of a legal or equitable proceeding based on the dispute, controversy or claim would have been barred by the applicable statute of limitations under the laws of the State of Delaware. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Each Party shall bear its own attorneys&#146; fees, costs and disbursements arising out of the arbitration, and shall pay an equal
share of the fees and costs of the arbitrators; provided that the arbitrators shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party reimbursement for its reasonable attorneys&#146;
fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges, travel expenses, etc.) or the fees and costs of the arbitrators. Each Party agrees to fully perform and satisfy any arbitration award made
against it within [***] of the service of the award. Judgment on the award may be entered in any court of competent jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.3 Patent and Trademark Disputes</B>. As between the Parties, any dispute, controversy,
or claim relating to the scope, validity, enforceability, or infringement of any Patents Covering Prexasertib or the Prexasertib OncoSignature CDx, or Patents within Acrivon Background Intellectual Property or Akoya Background Intellectual Property,
or of any trademark relating to Prexasertib, &#147;<B><I>OncoSignature</I></B>&#148; or the Prexasertib OncoSignature CDx shall be submitted to a court of competent jurisdiction in the country or jurisdiction in which such Patent or trademark were
granted or arose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.4 Injunctive Relief</B>. Nothing contained in this Agreement shall preclude either Party from seeking interim or
other provisional equitable relief from any court of competent jurisdiction anywhere in the world to preserve the status quo or prevent irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing good faith
negotiations by the Executive Officers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.1 Governing Law</B>. This Agreement shall be governed in all respects by the laws of the State of Delaware exclusively, without regard to
any conflict of law rule that would result in the application of the laws of any jurisdiction other than the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.2
</B>Compliance with Law. In performing its duties under this Agreement, each Party shall at all times comply with all applicable international, federal, state and local laws. Without limiting any of the foregoing, each Party agrees that it shall not
download, export, or <FONT STYLE="white-space:nowrap">re-export</FONT> any software or technical data received hereunder, regardless of the manner in which received, (a)&nbsp;into, or to a national or resident of, any country to which the United
States has embargoed goods, or (b)&nbsp;to anyone on the United States Treasury Department&#146;s list of Specially Designated Nationals or the U.S. Commerce Department&#146;s Table of Denial Orders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.3 Entire Agreement</B>. This Agreement with its Schedules and the Quality Agreement (from and after its effective date)&nbsp;(a)
constitutes the entire agreement and supersedes, as of the Effective Date, all prior and contemporaneous agreements, negotiations, arrangements and understandings, both written and oral, between the Parties with respect to the subject matter hereof,
including the Prior Agreements (provided that the Master Services Agreement shall govern all activities performed prior to the Effective Date and all &#147;<B><I>Akoya Background Intellectual Property</I></B>&#148; and &#147;<B><I>Client
Intellectual Property</I></B>&#148; (each, as defined in the Master Services Agreement) developed under the Master Services Agreement prior to the Effective Date shall continue to be owned in accordance with Section&nbsp;5 of the Master Services
Agreement) and (b)&nbsp;is not intended to confer upon any person or entity, other than the Parties, any rights, benefits, or remedies of any nature whatsoever. No subsequent alteration, amendment, change or addition to this Agreement shall be
binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.4 Force Majeure</B>. Neither Party shall be liable to the other for failure or delay in
the performance of any of its obligations under this Agreement (including payment obligations if the payment process (including method of payment) is so affected) for the time and to the extent such failure or delay is caused by earthquake, riot,
civil commotion, war, terrorist acts, strike, flood, or governmental acts or restriction, or other cause that is beyond the reasonable control of the respective Party (&#147;<B><I>Force Majeure</I></B>&#148;). The Party affected by such Force
Majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and shall use commercially
reasonable efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable. If the performance of any such obligation under this Agreement is delayed owing to such a Force Majeure for any
continuous period of more than [***], the Parties shall consult with respect to an equitable solution, including the possibility of the mutual termination of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.5 Independent Contractors</B>. The Parties agree that the relationship of Acrivon and Akoya established by this Agreement is that of
independent contractors. Furthermore, the Parties agree that this Agreement does not, is not intended to, and shall not be construed to, establish an employment, agency or any other relationship. Except as may be specifically provided herein,
neither Party shall have any right, power or authority, nor shall they represent themselves as having any authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act
as an agent for the other Party for any purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.6 Assignment</B>. Except as expressly provided in this Section&nbsp;16.6, neither
this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld conditioned or delayed); provided
that a Party may assign this Agreement and all of its rights and obligations hereunder, without the written consent of the other Party: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>to an Affiliate of such Party (for so long as such Affiliate remains an Affiliate of such Party), provided that the assigning Party
shall remain responsible and liable to the <FONT STYLE="white-space:nowrap">non-assigning</FONT> Party for the performance of this Agreement by such Affiliate, notwithstanding such assignment, and that the assigning Party shall promptly notify the
other Party in writing of such assignment within ten (10)&nbsp;days following the consummation of such assignment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>[***]; or
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>in connection with the transfer or sale of all or substantially all of such Party&#146;s business to which this Agreement
relates to a Third Party (&#147;<B><I>Third Party Acquirer</I></B>&#148;), whether by merger, reorganization, consolidation, sale of stock, sale of assets or otherwise (in each case, a &#147;<B><I>Sale Transaction</I></B>&#148;), provided that in
the event of a Sale Transaction (whether this Agreement is actually assigned or is assumed by the Third Party Acquirer or the surviving entity resulting from such Sale Transaction (in either case, the &#147;<B><I>Assignee</I></B>&#148;) by operation
of law (e.g., in the context of a reverse triangular merger)): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>such Party (the &#147;<B><I>Acquired Party</I></B>&#148;) shall promptly notify
the other Party in writing of such Sale Transaction within ten (10)&nbsp;days following the consummation of such Sale Transaction; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Intellectual Property Rights of the Third Party Acquirer or any of its Affiliates that existed prior to the Sale Transaction
(A)&nbsp;shall not be included within the Intellectual Property Rights licensed to the other Party hereunder, (B)&nbsp;shall not be deemed to be Controlled by the Assignee, and (C)&nbsp;shall not otherwise become subject to this Agreement; except,
in each case, to the extent such Intellectual Property Rights (1)&nbsp;were Controlled by the Acquired Party immediately prior to the consummation of such Sale Transaction or (2)&nbsp;are used by or on behalf of the Assignee after the consummation
of such Sale Transaction in the performance of activities pursuant to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms and conditions of this Agreement shall be binding on and
inure to the benefit of the permitted successors and assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#146;s successors and permitted assigns to the extent necessary to carry out the
intent of this Section&nbsp;16.6. Any attempted assignment or transfer of this Agreement not in accordance with this Section&nbsp;16.6 shall be null and void. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.7 Representation by Legal Counsel</B>. Each Party represents that it has been represented by legal counsel in connection with this
Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party that drafted such
terms and provisions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.8 Waiver</B>. Neither Party may waive or release any of its rights or interests in this Agreement except in
writing. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or
condition. No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.9 Notices</B>. Any notice required or permitted to be given under this Agreement shall be in writing, shall make specific reference to
this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section&nbsp;16.9, and shall be deemed to have been given for
all purposes (a)&nbsp;when received, if hand-delivered or sent by a reputable overnight delivery service, (b)&nbsp;on the day of sending by facsimile or email (with documented confirmation of receipt), if followed by mailing by first class certified
or registered mail, postage prepaid, return receipt requested, or (c)&nbsp;five (5) days after mailing, if mailed by first class certified or registered mail, postage prepaid, return receipt requested. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">If to Acrivon, addressed to: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">With a copy to: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">If to Akoya, addressed to: [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">With a copy to: [***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***]
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.10
Severability</B>. Any term or provision of this Agreement that is held to be invalid, void, or unenforceable in any situation in any jurisdiction will not affect the validity or enforceability of the remaining terms and provisions hereof or the
validity or enforceability of the invalid, void, or unenforceable term or provision in any other situation or in any other jurisdiction. If any term or provision of this Agreement is declared invalid, void, or unenforceable, the Parties agree that
the authority making such determination will have the power to and shall, subject to the discretion of such authority, reduce the scope, duration, area or applicability of the term or provision, to delete specific words or phrases, or to replace any
invalid, void, or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the original intention of the invalid or unenforceable term or provision. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.11 Interpretation</B>. The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in
construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Articles, Sections or Schedules mean the particular Articles, Sections or Schedules to this Agreement and references to this
Agreement include all Schedules hereto. Unless context otherwise clearly requires, whenever used in this Agreement: (a)&nbsp;the words &#147;include&#148; or &#147;including&#148; shall be construed as incorporating, also, &#147;but not limited
to&#148; or &#147;without limitation&#148;; (b) the word &#147;day&#148; or &#147;year&#148; means a calendar day or year unless otherwise specified; (c)&nbsp;the word &#147;notice&#148; means notice in writing (whether or not specifically stated)
and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (d)&nbsp;the words &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby&#148; and derivative or similar words refer to this Agreement
(including any Schedules); (e) the word &#147;or&#148; shall be construed as the inclusive meaning identified with the phrase &#147;and/or&#148;; (f) provisions that require that a Party, the Parties or a committee hereunder &#147;agree,&#148;
&#147;consent&#148; or &#147;approve&#148; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise; (g)&nbsp;words of any gender include the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B></B>EXECUTION COPY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Confidential </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other gender; (h)&nbsp;words using the singular or plural number also include the plural or singular number, respectively; (i)&nbsp;references to any Applicable Laws, or article, section or other
division thereof, shall be deemed to include the then-current amendments thereto or any replacement Applicable Laws thereto; (j)&nbsp;neither Party or its Affiliates shall be deemed to be acting &#147;on behalf of&#148; or &#147;under authority
of&#148; the other Party under this Agreement; and (k)&nbsp;the phrases <FONT STYLE="white-space:nowrap">&#147;non-refundable&#148;</FONT> and <FONT STYLE="white-space:nowrap">&#147;non-creditable&#148;</FONT> are not intended to prevent a Party
from pursuing and obtaining damages related to a breach. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.12 Counterparts</B>. This Agreement may be executed in two or more
counterparts (whether delivered by email via .pdf format, facsimile or otherwise), each of which will be considered one and the same agreement and will become effective when counterparts have been signed by each of the Parties and delivered to the
other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their
authorized representatives as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Acrivon Therapeutics, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Akoya Biosciences, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Blume-Jensen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian McKelligon</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Peter Blume-Jensen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brian McKelligon</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">C.E.O.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to OncoSignature Companion Diagnostic Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Appendices </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Exhibit A</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Acrivon Background Intellectual Property</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Exhibit B</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Akoya Background Intellectual Property</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Schedule 3.2</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Development Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Schedule 3.5</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Development Milestones; Development Milestone Payments</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Schedule 11.7</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Acrivon Background Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Akoya Background Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Development Plan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 3.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Development Milestones; Development Milestone Payments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 11.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Proposed Press Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g383050g09m65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g09m65.jpg
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M 0$! 0$! 0$! 0$! 0$!_\  $0@!BP)= P$1  (1 0,1 ?_$ !\  0 " P$
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M8K[GTX3+QYR:Z/@>SAV!FYA\!*AYY7A[[#UTO$2]\Z)V4Q7W/IPF7CSDUT?
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MF>$O@'B+]%;7O\/9Z]G??1 _Z1(/<FG!!7><J3^],]E#MF>$O@'B+]%;7O\
M#V>O9WWT0/\ I$@]R:<$%=YRI/[TSV4.V9X2^ >(OT5M>_P]GKV=]]$#_I$@
M]R:<$%=YRI/[TSV4.V9X2^ >(OT5M>_P]GKV=]]$#_I$@]R:<$%=YRI/[TSV
M4.V9X2^ >(OT5M>_P]GKV=]]$#_I$@]R:<$%=YRI/[TSV4.V9X2^ >(OT5M>
M_P /9Z]G??1 _P"D2#W)IP05WG*D_O3/90[9GA+X!XB_16U[_#V>O9WWT0/^
MD2#W)IP05WG*D_O3/90[9GA+X!XB_16U[_#V>O9WWT0/^D2#W)IP05WG*D_O
M3/90[9GA+X!XB_16U[_#V>O9WWT0/^D2#W)IP05WG*D_O3/90[9GA+X!XB_1
M6U[_  ]GKV=]]$#_ *1(/<FG!!7><J3^],]E#MF>$O@'B+]%;7O\/9Z]G??1
M _Z1(/<FG!!7><J3^],]E#MF>$O@'B+]%;7O\/9Z]G??1 _Z1(/<FG!!7><J
M3^],]E#MF>$O@'B+]%;7O\/9Z]G??1 _Z1(/<FG!!7><J3^],]E#MF>$O@'B
M+]%;7O\ #V>O9WWT0/\ I$@]R:<$%=YRI/[TSV4.V9X2^ >(OT5M>_P]GKV=
M]]$#_I$@]R:<$%=YRI/[TSV4.V9X2^ >(OT5M>_P]GKV=]]$#_I$@]R:<$%=
MYRI/[TSV4.V9X2^ >(OT5M>_P]GKV=]]$#_I$@]R:<$%=YRI/[TSV4.V9X2^
M >(OT5M>_P /9Z]G??1 _P"D2#W)IP05WG*D_O3/90[9GA+X!XB_16U[_#V>
MO9WWT0/^D2#W)IP05WG*D_O3/90[9GA+X!XB_16U[_#V>O9WWT0/^D2#W)IP
M05WG*D_O3/90[9GA+X!XB_16U[_#V>O9WWT0/^D2#W)IP05WG*D_O3/90[9G
MA+X!XB_16U[_  ]GKV=]]$#_ *1(/<FG!!7><J3^],]E#MF>$O@'B+]%;7O\
M67TZX*\^ZY;,Q%-KJE.'UQOQXXQUE42F^.],EDZ *C*B;B$0Q46H1)7&L*>#
M$OT@V!AS>&?)G?+P<<LW;>&=7HM<IU4D3Z:ZS#>4XXVRJ4;JB-IQO)&G'0C/
M-9'W2B+(CVYCE&.6[UPWQ1PGO:P*/9][T^IW/2VX$294FZ"4&.XB?#EFN2<6
MLR)!(-$=22U3+BM)2>YRS,NE&NUCY4A0 H 4 * % "@!0 H 4 * % "@!0 H
M 4 * % "@!0 H 4 * % "@!0 H 4 <\F>[>Y,><1Y<B#:)[.6!H6?TZN%@:C
MDDO6EJ2%K?/K)*MX[=K-D[LLEO+RZ8&QBRID3IQ2;*TDF&ZFGDTPCYI 08^/
M10GT2-.:=ID6:MN1D>?(9;4Y<F9YGQ[,C@'6SB#[]M_6OAI[H3-/D;SHR=Y=
MD6+K@]]>AX0;$>O%KY20_GNQ$U[1,^F4M%##B56H,TBZXM-IQ-,T14TDX<+A
M'DH8$ _8(J26DI)$9:)&>>9GL(L]O]6?+D.IF@ICB$XA.T^SK#W.G]HL;8Z>
M68U$5XEP$9L-.7Y!;K>20!F^BFQ@4Q%1W"332 0QLP8-"AE2P6 A@<8?.UQ1
M<\LO,U\5ZNQ+JK$>+6JM&CM/,DTQ'J,QEELCB1U&2&FWDH01J4:C)*2(U&9G
MM,Q][-R7@[A'<>YWPQK=PX68<5ZLSZ54W)U7K-D6S5*G-<;N*L,(<ESYU+?E
M25H9:;90IYU:DM-H;(R0A)%33TUMR>MKLUV\RGWKK5.N>Y?"&N=+3_:!Z*X
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M-)_0AOZT]"SWJ X%ZVSC^'&;W@JRX):3X1._0QO7C9^V38B^)>E=*UWW:'J
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M % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
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M+2P_VEGB>6>5I)VYF<_88D6L&.MA0 H 4 * % "@!0 H 4 * ,SCC_NAL/\
MTS:__P"\(U<PO^&1/\I8_P"]0,#=7\V+C_S#6/\ _/D#_2MKVN/RFA0 H 4
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MCN'H* X"^)I_N[]DO]-B?^JS?KRAB!_/"M_X]C_4XP_1EN,O^3)A-_F>K?\
MB:N"B=:</3P4 * % "@!0 H 4 * % "@!0 H 4 * % $=2+;E#9GT1_?_J_;
M=_\ &!?P0[<G3/I9_P!-N5]V_P#-ZW^7^65G*'L.K;:V7]A*A_Q*69[2:V57
M_P#"_IY]XM4.28MEFUAUW.%2LL5;//\ ^*JM%I.1U#NL/]I:6)Y?]4D[<SW_
M +#$BU@QUL* % "@!0 H 4 * % "@!0!WG\)W_>]-:/]&'1__17C7J[#[^9U
M$_Q,G_7I0_.9NS/^4UBO_G>D_P#ABAC8C6Y#S$% "@!0 H 4 * % "@!0 H
M4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@
M!0 H 4 * *F/C?'3",ID!UZD79^$V+-I@ZWDT&,W=(" WG7FH.TH2/-<EXN5
M3A7+$TX"JDGBHX&6>(JC<\4#*XBBF L,PCHJRTLCRY<M@(V^&F+@FXYK8D;/
MPF<GT@XE=H&8BM(#?!?F+K0<C&*PV@6^8. GC2\GW*&KF$@J&,?QQ*F,[%\L
M0!<L :*LB/(\C[^6P6SH(#0=/6TG"48DQ2$TM@X(1'7,:*X3 #X<)J#D9TF%
M,^.$";(BB+YD7$=2N$C&$TO842UKAX@V+V_%!M7+:_7L/HE7FQZO26I%2:6V
M4IY5*:?-Q9LM*29O*/27DV:"S/BRR[P^A&#N$&[2N+#6U:UAGB)4:-8T^)+<
MMZF,XA3J0U$C-U.:S(0BFM)-N*2YS4ITT)/)1K-SC68B/TTN!=U9FY^S>W_M
MJP_7/A9S&ST*QZ0Z7P#?"&>->J_6I4O0#TTN!=U9FY^S>W_MJ=<^%G,;/0K'
MI!P#?"&>->J_6I4O0#TTN!=U9FY^S>W_ +:G7/A9S&ST*QZ0< WPAGC7JOUJ
M5+T ]-+@7=69N?LWM_[:G7/A9S&ST*QZ0< WPAGC7JOUJ5+T ]-+@7=69N?L
MWM_[:G7/A9S&ST*QZ0< WPAGC7JOUJ5+T ]-+@7=69N?LWM_[:G7/A9S&ST*
MQZ0< WPAGC7JOUJ5+T ]-+@7=69N?LWM_P"VIUSX6<QL]"L>D' -\(9XUZK]
M:E2] /32X%W5F;G[-[?^VIUSX6<QL]"L>D' -\(9XUZK]:E2] /32X%W5F;G
M[-[?^VIUSX6<QL]"L>D' -\(9XUZK]:E2] /32X%W5F;G[-[?^VIUSX6<QL]
M"L>D' -\(9XUZK]:E2] /32X%W5F;G[-[?\ MJ=<^%G,;/0K'I!P#?"&>->J
M_6I4O0#TTN!=U9FY^S>W_MJ=<^%G,;/0K'I!P#?"&>->J_6I4O0#TTN!=U9F
MY^S>W_MJ=<^%G,;/0K'I!P#?"&>->J_6I4O0#TTN!=U9FY^S>W_MJ=<^%G,;
M/0K'I!P#?"&>->J_6I4O0#TTN!=U9FY^S>W_ +:G7/A9S&ST*QZ0< WPAGC7
MJOUJ5+T ]-+@7=69N?LWM_[:G7/A9S&ST*QZ0< WPAGC7JOUJ5+T!6K97=/A
M*XEX/\S&L.J0HU]BXPM)OI%:XC8EPX?ODM>6XL+^3)C'++8'"WBWS;8KO*V[
MWNL^-;7M8&KZ#<^'^<KJ;0W\]Y2"G[RHNWJ;W.^M]:@_^!9:&OUOY RT27QI
M&I7;@)NT5(MWK[Q7I6@FZJ.JTNNK%5LD]>Y'(Z@=;_55.1W/F<KJ25/_ +*?
M\(WI_=!97TTN!=U9FY^S>W_MJL>N?"SF-GH5CTAMO -\(9XUZK]:E2] /32X
M%W5F;G[-[?\ MJ=<^%G,;/0K'I!P#?"&>->J_6I4O0#TTN!=U9FY^S>W_MJ=
M<^%G,;/0K'I!P#?"&>->J_6I4O0&91ULOP391D%B1FU=9&B(Z)%>388K;#/Z
M\-XF1S7G<MD6^CX'3E\Q+%2F2@H%\3)FX>=@ ;YBWPRMCX-[F%7,,9\R)!CT
M*.;\R2Q$9)=&82@W9#J&6])69Z*=-:=)61Y%F>0P5T84;ONT+:N*[*QBS6TT
MBUZ%5[BJJHV)]2?D)IM$I\BI3E,,$23>>*+&=-IHE)-Q9)02BSS&USU?ND'5
M1@;LU;'R^M_ZT;7Y@I/D+'H#QOV2FZ \<F(WG75_:0]7[I!U48&[-6Q\OIUH
MVOS!2?(6/0#LE-T!XY,1O.NK^TAZOW2#JHP-V:MCY?3K1M?F"D^0L>@'9*;H
M#QR8C>==7]I#U?ND'51@;LU;'R^G6C:_,%)\A8] .R4W0'CDQ&\ZZO[2'J_=
M(.JC W9JV/E].M&U^8*3Y"QZ =DIN@/')B-YUU?VD/5^Z0=5&!NS5L?+Z=:-
MK\P4GR%CT [)3= >.3$;SKJ_M(>K]T@ZJ,#=FK8^7TZT;7Y@I/D+'H!V2FZ
M\<F(WG75_:195DL=G1LUDAD,!LHC.9Z ",71&TW4\LE(J4 8-F#PX1!/*8!%
MRP8QPT9-"8A88VR''%$O:^6>5[YJ+%C0F&XL-AJ-&9(R:890EMILE*4M1(0D
MB2DC4I2CR+:9F??'*:_<%<NJL3;@N2K3ZY6ZDXAVH56J279D^8XTRW';7)DO
M*6ZZI##+3236HS)MM"2V)(AE57 PX4 * % "@!0 H 4 * % "@!0 H 4 * %
M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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M'@9_T<O[-_[J9'R'\QAF7*7SD(YD;#+FV7^(P;\L@-NUO.!:]@^7E.<GD?\
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MW[(':Q+C\<=*\T9_X@#VB1B=5)Q]J2/W%IPQ1.8'O+V_9 [6)<?CCI7FC/\
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M5D:#4JZU;..!A0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M@#XY<-?/&A^V!Z!&[75/V"[*'G\HIUI7/X/U?R"3ZL.R0P!\<N&OGC0_; ]
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M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
M* % "@!0 H 4 :&VYQ09\-<1F0=0I02H!UW;J))[C:D0L&9FC.Z/*VR$9HC=
MR/D)<AJ9RE\X(7S3C4/!$3(P,)1)<Z)SR7BX#"R6&QQ"<TD2246WE,N))Y\1
MEQEWLCXC^;.)M=.+#NJI0;HKMWL;&.L"EK9NU-S1U]Q(0L+*38E^(7A(KT=C
M#9CF5$Q\+SR;#[:MUUI&+N$BBJ",O)Z>?+G" *G<N9 Q?Q_'\?\ I$T%FI)9
MYI(S[VW+:?)E]HZ/:"F./#>'B3[LPIMA-T71A.1]K,1HNW FW4 )E1JIAII8
MXC):H9"Q/+;,4E0Q84^?-F+Y'#QC/&XUP\,L0L P\//-XWK<],N6JP8-56Q$
MCNLI99*-"62$JBL+,B4[&6L\U*4?=*,]N7%D0^UVYAW*F -^X$8=W==N'L:L
M7%6Z;47ZI4EUZZXBI3K->JL1I9QX%=B0VM"/'9;R8CM),D:2B-:E*.J?K>N(
MMUDE/L\B#[OJUGA#O+GISR2G^R#O/82[E_Q5Q/.>]_Q*'K>N(MUDE/L\B#[O
MJ<(=Y<].>24_V0.PEW+_ (JXGG/>_P")0];UQ%NLDI]GD0?=]3A#O+GISR2G
M^R!V$NY?\5<3SGO?\2AZWKB+=9)3[/(@^[ZG"'>7/3GDE/\ 9 ["7<O^*N)Y
MSWO^)0];UQ%NLDI]GD0?=]3A#O+GISR2G^R!V$NY?\5<3SGO?\2AZWKB+=9)
M3[/(@^[ZG"'>7/3GDE/]D#L)=R_XJXGG/>_XE#UO7$6ZR2GV>1!]WU.$.\N>
MG/)*?[('82[E_P 5<3SGO?\ $H>MZXBW624^SR(/N^IPAWESTYY)3_9 ["7<
MO^*N)YSWO^)0];UQ%NLDI]GD0?=]3A#O+GISR2G^R!V$NY?\5<3SGO?\2AZW
MKB+=9)3[/(@^[ZG"'>7/3GDE/]D#L)=R_P"*N)YSWO\ B4/6]<1;K)*?9Y$'
MW?4X0[RYZ<\DI_L@=A+N7_%7$\Y[W_$H>MZXBW624^SR(/N^IPAWESTYY)3_
M &0.PEW+_BKB><][_B4/6]<1;K)*?9Y$'W?4X0[RYZ<\DI_L@=A+N7_%7$\Y
M[W_$H>MZXBW624^SR(/N^IPAWESTYY)3_9 ["7<O^*N)YSWO^)0];UQ%NLDI
M]GD0?=]3A#O+GISR2G^R!V$NY?\ %7$\Y[W_ !*'K>N(MUDE/L\B#[OJ<(=Y
M<].>24_V0.PEW+_BKB><][_B493$?$)V\V$VCTPCJ:)6@20F<8VUAQ2Q2-EH
MVB;R?(JI52/EBRQ&"D28A160I[+E#IXI#RNBGR"D&ZSP!/ U8L=- C;C8MWW
M#6+@8AU.H5&9&-EQPFXD*!JT.)4VE+DY:8J7&H))6M*W&EH63ZXZ=+14HC\R
M;KC<S8)89X,U6Z+#LVS+9KC51AQ3FW)==Y[\D0W8T]UV%:,5^XGH51NMQZ/'
M?C0I\>1%72(]:?4R;L=E:.Y*N]CXYA0 H 4 * % "@!0 H 4 * % "@!0 H
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M$:[92K;J[]7DRJ5,@4BI,LR*\E]-9=I3M1I\J30UU+?,A4M5$>I^M<?==/\
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M"JP8E-J%SS$3I4&FF^<*.XW$C1"0R<EQU\VS1&2M6L<4K34>1D61%M0K*#0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * ,$E*0T.(XTD*57. I&FW&K)=#]7R
MR, 7-*YA&:*(=7E,%++'#9 H84121 ; D 9/$RXIC(/ 8T7#RR%PM)\QJGPI
MD]\EJ9A17Y;R6B2IPVH[2WG";2I2$J6:4&224M)&K(C41;1L5H6S4+UNNV;.
MI+D1FJ777Z/;E-=GN.LPFI];J$>FQ')CK#,EYJ*A^2VJ0XU'?=0T2U-LNJ(D
M*I.E\2..ED^GHJ=!&T [D<L3$9O8#;M';6\:R'&AG"PAUR-T2T@Y)28 C898
MW/ O53:8YO,8B @AK)E51P%#66[TAN+0TBE5PWWZ>BJ1&-YQ]9,@J+-3[)E,
M-M!-%^>4E<=2C-"62=4XTE??)>Y8NB#&E5"5B)A&U2J5><C#^Y*J=T5C>=L7
M8THTL4JJ).V2F2W)RB/>[E B5IME*)#E15 9A3G(U0]I.(([3[TU!4((FQ4B
M"&-AXID1]GW1Z/UYN=I8^V\<;)"=G'Y  ZN9&\%4$=OJ]DD_=.("7,*@IPPG
ME+&L]=KUW2%R;<72JHY3J;68$R4M_J1U4D$M@BU:#B(2MTU$X2F7=6O01W3A
MJ4A.D?;,(=S518U!QNC8BV#$O>^\,;RMBW(U(X2RP_HKL:J&K?TI-RR7&*>E
ME4-;=2A',C[ZDI)J(AAJ2\;)1<]=[-RDUB:"7D5RG-;W)/86Q&,HK*?KT8D]
MRFTJ./)L:.W01AP4L;=!$RXRAZ^:@EI8A8+ LK9N:P "( 5*%["5=5RHBVEO
MR0JBOU8JSOYU%'.<^IN$;)PWTTU25/H4\E7=H;-)$3AOY$T24IV^@;G? N7<
M6Z1ZUZ4QBG2L.%X8':$&5B:U:-)9F73U41=%)D7RAUFD2&J6]'T8TN8EU2G8
M2:3K%SW'GW9!GW;S9J.&#K(Y$R77N!!CM39$-3!MVGZ?Y#N9,<"0[5M-;B0Y
M8+<YL@''3<*E "I+-4,@9J;F*E15I#L/>PI8Q>5>XJY"B4-]%1E%2I")BJE<
M2+<S?0\W(=;9;?I3ZDE"92DDI-Q1:;Z4FZSGM2K6<-\$\)[IN3%FE2[*M]S$
M.BR[8:L?!*3C>ENDRZ9-HM/E52;2L0Z2S)5=%4>>==D)B,N)B4EUY%/J!MYH
M=;V7,B;S .HI&=@'RQ=@#!!A*KH!?",?1(39<@73#9\((<P<?"KFA1H+? MB
M0< ;D4P2C>6RJD6/=$Z/D7!W:+5#*W454I42KJ1$<?*4TINEQ9FK4LB-2I3A
MM03[G0>)]9)9=2M*]'1-)>4:_A^TO&N1AVY;UQ8:MR;CATARWI\>??U>MK?;
M,=:VFV+?AIJ-UI)3IR*8NE1%O5. ]%>CZ[6DZN,-6=VUG8Z1%-BJ$91PS0$]
MH*3HQ56CMMKW.RF,(05D),Q(BL^*G&KN,B2%Q6<QQ7":+8(Y,8L73S(V)Q5(
M8"6-!NAVM3'(BX,*,2(ZW]9&N&D59PS0XTC0.- =<>2D]:9F\HB;2:4H4>DX
M@CV[%_ &#A;;$2X8UV737')5;BT@X=;P7Q+P[B(3)A5&6<A%<O&F0J7(D(."
MEM%,9=5.?;==DM-FQ#DJ3%6X[PVWC^?X";D/;((B:E;%RXW6(WH8SA%GJRJV
M&6W6X$KR]( DAJZJH'U4L@$B8JUDGY-@+F,ETH1P-6 )<Z-C[DD7##J](9IM
M:;0W6:BS$9IATN,XMB,RR3E1EG,<6M;B6DI-W0-DC+7)02LD9GN.!E$P6N7#
M;$BJ7QA9/E3<+[*J=Q5.^TX@5N%#JU>JE47!LBVDVQ"AQH\-VI2'T0"DE5EZ
MQ-.?D*9-Q_0;E7B$3Q)4%,.+#C$=9&*D)\RXALN29W4V,)(Z?#;..):L=R<(
MS3^DF8%5%0D01@%!8Q$2"5S(@(^.!PZ1,E\A>%6FTJ) 5%D)@-2J@U%FU5<4
MYJ*;'4VXO7''_,4:W$(;);I&VG2R/)2T*+3MS/AU:N(EQW@Q<-'D7A4;>LJH
M5ZU,.XEPHM:5?5=8EPHY4QNLG^7;1#AR),]R+!-$Z1JDK;4;$>2TYZ&E>S;K
MEW2M$V*EPN$:4DQ*DL^KK+<1KHX+U0(X7G*G NU&;QTP#BFF'$E('2+IHADL
M3LJ7,7+=!("@ EYK9KDBH6RU6:B1*6VW.6ZZRUJRE,PG7T%(:949:!O-LYZ!
MFE.LST=!!D16V/6$U&LK'JHX864ZMF++FVI&@P*I/*<Y0*E=--I,IRBSJI':
M6<MJES*EJBEI:=?.&36MWQ)0XX[B[6XE49/$W'J<B0?LV*I3&PU"0(73Q8]:
MN(\KIB+B4%<!!L"AR"*333J"3-^,3YYZFFHVQT\+$VEKZB$HHEU6BQ>T&2J&
MAJEUPUU*(J93$'#8)50;;T3>0P>_#2A;*5::U251V306DAY9+:UF7K&Y4NRA
MLW-)GX@X3(B6-<<:V;\E(N:L*;LV7/-]%-D5="K90_+CU%]@XT>/0&:S56Y*
ME,3*;%7%J!0\@2.(E#;N;,.K$;,N8)/=$VHCX<C6BUGM=O82&E(<:*QY ?:@
M["SH>#;:Z(&WU]-.(F 7E4:,+RH%B6; 2WSF&=ZK=XTV2Q37(4:HSI%4:E/,
M0([#)3&VH+BV9:Y"7Y++#1,NMJ:(M\*-YPB2P3N9&,9-W,5]42K7S"NJO6/:
M-(L"H6_2ZQ>%<J]35;$RH77"8J=NQJ,]2*'5:O4%5*FR6*@:^H[+=-AKUU77
M3]%22\4YQ,H(,)C#5&(SYEED&18:=DYH0,=L]#.&"K,8:^<;;U 7,'&[FU@C
MK3954Q6+*!8R)T 8PG9IZ8IGU4\CD%*FJ]Z2I$1<2-4J@4RFR*JT4.,TI28T
M1Y3$I+I/R&-6ZPXVX2TJ/0,T&AMQ;BVT+OV-RAB*U+N.'<5;L6RW+7ONC8>5
M%=T5RH,-NUVXZ:Q5: [3SI5$JRIT"K0I<)Z,ZRC?+;4I,J7$C0H\Z3$^R#Q!
M4!\3[$$31O$<G/UJROK\B3T"]D1,1 !$1OO%Y-AKM]45$I<<:*( UV[B?7L9
M 42F:FK)JN"EIJ&C+-L5,<N:N]F55J=3X5/G2X]0I#56*4TAHC:9DR6&&7'&
MW7FC3'9TGM]K3K'$.$A#3;F3AE"H[FFI6_AO?%Z75>MIVY6+,Q+J&'"[?J$J
MHN)J%3H="J]7J4.',I]*GI<J]4.-33MJ,\42%+A.3)50GP#.&V["NE7$B ?L
M9P>C;")$BEI+E! GMP)LFVCU-2XP?'F6<#Q6'&AM7-!/>,C:RV8\2TX8YT5I
M@I1\^3.IQ55.K^!@G?&6S>A2X-+:K#<Q,Z<U5G43MYH;@RNICTEQYJ.;2]8M
MQB&ALU&F.3:UI4VEQ3Q*2-^Q[W+#EMW9B%.PSFVN[:=H5/#BF2[3.YI4N[K?
MZ_:90X5*J%8348^]&8%6N:9);8UU:7-C1GV)3T)BFJ:D"\.K^T[)VP9YY^1Z
MVW@C-<N*0P3E-T#L(R$N!* (X^.1/R%?3WLEGR. &.*TW'3=O.M#%,E E9!*
M9F,+5M-#KT6OQE2X;,AM@C1H+?.(HG261F6CO25*U:T$7Y5E_4R&C4DG&DF8
M\^XN8/W!@U7(]N7-5*).J[B)"I,2D-W&TNGJC+;;,G^N*W;?.7&D*<,X%5HY
M5.BU!#3ZX52?2THQ9FLV.3A0!X+H/F4MN+:B3SQP-$DTV9+YY88B8XB@@Y9X
M7RPSM?'*ULK6Y<<K7M?^:]1+:9%RF0@H\B,R%7// ^?Z^4_5Q/[.JF@7*?V?
M<*6FKE^PON#SP/G^OE/U<3^SIH%RG]GW!IJY?L+[@\\#Y_KY3]7$_LZ:!<I_
M9]P::N7["^X// ^?Z^4_5Q/[.F@7*?V?<&FKE^PON#SP/G^OE/U<3^SIH%RG
M]GW!IJY?L+[@\\#Y_KY3]7$_LZ:!<I_9]P::N7["^X// ^?Z^4_5Q/[.F@7*
M?V?<&FKE^PON#SP/G^OE/U<3^SIH%RG]GW!IJY?L+[@\\#Y_KY3]7$_LZ:!<
MI_9]P::N7["^X// ^?Z^4_5Q/[.F@7*?V?<&FKE^PON#SP/G^OE/U<3^SIH%
MRG]GW!IJY?L+[@\\#Y_KY3]7$_LZ:!<I_9]P::N7["^X// ^?Z^4_5Q/[.F@
M7*?V?<&FKE^PON'S:7WS?_Q\I_-?_P G$_\ ):]_\U30+X_X_8&FKE^PON'Q
MYX'S_7RGZN)_9TT"Y3^S[@TU<OV%]P>>!\_U\I^KB?V=- N4_L^X--7+]A?<
M'G@?/]?*?JXG]G30+E/[/N#35R_87W!YX'S_ %\I^KB?V=- N4_L^X--7+]A
M?<'G@?/]?*?JXG]G30+E/[/N#35R_87W!YX'S_7RGZN)_9TT"Y3^S[@TU<OV
M%]PT$S]%F^6TW%?WTCG5J:WQ&]X1.\/-PM]_J.UTU,!AP&CNEDF'-(/B;69I
MI#@C>>[RNDM):3%EOO01L)28?  -#&%#!R*PI.D+LC22$F99YZ1?FEF>667=
M9D99?%GGQ;!6-N3#L^V^(\OR@N3%-;,U[(\<^1=8'/+9O9&5';'20SQFH15&
MQJPYM5E8_A%;=C^05=<(DV_-@)L8TRE<Z(4%14L-%;YP^$3(M$BR+/0TN+(]
MAGF>D6WB+:1[/C':G041P%\33_=W[)?Z;$_]5F_7E#$#^>%;_P >Q_J<8?HR
MW&7_ "9,)O\ ,]6_\35P43K3AZ>"@!0 H 4 * % "@!0 H 4 * % "@"_O"T
M_P!\ UB_T[.?ZJN&MNL/^=U#_P J7_J[X\V;L#_DU8M?_P#/1_\ _:I8[XZ]
M9#\X0HUO+?D):I_C:48\NZL#6_V:^/A$[\N;H_%U=_%RY-R;_P \&W^CDRLY
MOIM01+O\?$?%_M^+E%Y:" 4 * % "@!0 H 4 * % "@!0 H 4 * % & RM'2
M++\82+%#D-JA%O28QW4P5TZB#%"ZR32'>AGD!2-))@^24B("D 3/C"DA3B>>
M*AF<0\QR9D*V0.=I/AM5&#-I[RG$,SHLB(ZIHTDZEN2TME:FS6E:2625F:#4
MA:241&:5%F1[)9USS[)NVU[RI3,.14[3N&C7)3H]0;>=@/SJ)48]2BM36HTB
M+(<B./QFT2$,2H[RFC6EM]I9DXF$V[J''#9>T8OPBNO<97BG6^^K[?+&U!!S
M3CK#OFC9^.%D(%N &1W=RH97^7$C:>C<@AC_  #RY!W"Q;-NPF)4&6AV4;D"
MB]0F4J6T:%1,VCUCA$R2CD?DD]VE2&MI_DN++?:KC9=-7H%VVY(I]OMPKRQ3
MX7*FZS%J*94>X]&>G>,%;E5<9;HF50>_D\AB3/S0U_9+8O3P>+]!(@B9Q:S.
M9NN:23Q[55D/]A1^"M*S8,%%I)D:ZG=;-/' BT$X8^HE/&ICQ4*B#M\L#X /
M2RAWP<^<M8-I4ZGO4-]E^:I= BS(D,G7&%)=;FDLG5221'0:UIUBM6;1LI+(
MM)*MN>PW=ND+WO.EXL4FITFU8\;&*X+;N.Y5P(57:?@3;7WKO!JA*D5R4W&B
MO;S:WXBH-U-YS2<U+\?-.A,4C:XLJ39NU_GI=5G23=VN6<DYLI,23B2 W%:\
MHMPDV%^SI*'$4\IG+$R!$(9(\4JZ+< WD)F=N?!OB!ADIE%BSJI2*LZX^F11
MM^[V0VILF7-_,I8=UZ5-+<5HH21MZMQK)69JTRV#1K7Q1K]IX?XDX<4Z'1WZ
M)BBFU$U^7-8FN56&5H55^KTWJ.\Q4(\1@WY,A;<[?L*?K&"2EC>SA&XKPY\U
MH\^AU/4B<YSU#1TJ@J374L(@>*0C)#F0543(0R5<C?<C:=*,?-@6%,8)JN"3
M**J?@:,!@F[@BY!7I5:B=55(6FJU:FJ2RXPLJ=);:;?:</-27V7V)#2U$6D2
M'"2E:"4HB49'D,CAQBOP>L28K^'N'-],/5&+5XJKWH<V=-I-1AI)+3U*J=*J
MU'GQV'#0TJ7!<??A25,M*6P3B"665P]KK%,(P<VM=VDW@U*+FTCJ"+BB.ZQ9
MRV7 %E3/K2\.X\#Q6Q!4&7%A445%1!N0!3KC'! 2A$J2P *A5Z=1J?2Z4Q1H
M[).0&&EM:J227]:3BUNNF\2DZ#ANN.+6LM D9J,DH2DB26&OC$^\;_Q!JN)]
M:J:XMWU6=&GG4**;U*.GN0(D:!3FZ6J.]OF&W3X,.+%BK*0N22&$K>D//J<>
M7E+0AN((^4Q5MA15&[(63!(5-'5V@QFPVE,9.'&+F1R I]&2R1H0D,8*%!Q2
MN8N0 @Q4N+F'?,$/+&XC4RFPW#=B4^%%=-)H-R-$88<-!FE1H-;3:5&DS2DS
M29Y&:4F99D0Q%;OJ][FB(@7)>-U7! ;D(EMPJW<-7JL1N4VVZTW)1&GS)#*)
M"&GWFT/)03B6WG4)427%D>-+4!LEP3ZR=BU<RO''K'D?NF/6BDC'BF321RSP
M4B)U=<A5,NGW/!.LV3)601%$-5P*"H8XI0=.%&P+F0*#M)BO5>+67%/*E0X;
M\..V:DG';3)6E3KZ4:&F4A24ZHUDX23:,TF@SR465@8CU^F8;U_"^$U36*#<
M]RT>YJU-1'>36ISM#BR8].I3TLI)1UT9E^0=13%7#4\BHMH>;E(;4ZRY@KPU
M=#>493Q%JC-\YV29]=BZOK*N.ZTE476,WG+@F%UF-8S'5F\=)->/S"<0,I)=
M'R(J!@D065>Q8]@:,X&@K630BDP:M 75*IJZM(=>=<-]MQV*R_JR=A03<94E
MB(:$*;2V:%FA#KFBK25I%L%#Q=50KLPZN^+A_AYOW#>C4ZG0(+=&FPZ=<-3I
M2I;L&Z[L;A51B16+E;E26IKDY,F*T_)@03=CJ9:4RN6P(D9*;$%X.;Z=DV8_
M"C\>,TU.1,@@1T=L#( C<P#3QC8)P/II=/%OF&;.@'+C&[=).8&L\Q;"9 J=
M%13CI;*-1#*&J"A#61&VP;)LY(-1*+22@\R4HE9J[I1*,SSTQR]*_*O8L0:G
M**K7*NY6[KE2J@2W&YU7;J2*HI4E#+C"M[NR4$E3+#C!(8/5,*92E&C"3'TR
MC)@K.KZXD+[[-&]3HX=T8QX&I*3?%+K:$\T5'0E,X\\"K9*"'U<N41"HA =#
M%;Q,,R(8S,$#(608(6,BVU!B.T)UMZ6I5O0Y,*&2ULF3K4IIMEQ4G182:W$I
M:2:#:-E)*,])"BR(M^N#'6[;D@XN4^=3;=:9QFNFB7;<ZHD2IH=@5&@SY]1B
M,4%3U7?1&A./5!Y$ENH(J;ZVD-$U)962UKC%O<.:+V*AQ:6C.3YFCIYQ$!*:
M6V)1;ZFP#CT-MF8G2K.]XM9>+.&.UEF*:2&KK)DPWA\6F66$ < H<**=SN!@
MP9L6;-@Q&H!09U2AR:<4]#$YER(J2IBHON2)+#R7H;D9;9..*-D][DXT9)4E
M>F1J/;:GNH;NN*?=[MV6E8ET4*]7+/EU>T:E$N5B@LU6QJ/#HE#K%.=IET0*
M[$FJA06FZFV=:=@U)MQYA^(3!M-M9"RN'Q \=",W%F&7PB$&1KX_]<DE+#6D
MDT3,M23'$.[':YU(4ZWS!\R^#[A.'U.R@&=+H08QXQA9NW L $#6BVA281QM
M[*E-(BT>716VR=;4E4>:^<B0^LULJ6J4MY2UZ9*)HC69$SED18RO[I?$6Z$U
MPZZU;T^3<&)EMXI39BH$UE]JLVG2T46BTF*F/4VHS5OQJ8S'B'&7'=J"VX[2
MNJA.:Q:_XM706/6"YX%># D^9&<OP1%"/!H!Y)668+E(\4(KI*O(%H2$"HL4
MZ6%+G%XI850/-(!J*(Q4P9+ &BV71!RD(]I0XC])D1)U2C/4JGM4HEMN1C.;
M3VGTR2C3"7$4DTJ=3FM<<HZS2I2247<FF>L;I"Y[DI&(U#N2TK%KE.Q%O.=B
M$['F0*\@K6O*?2'Z$NMVRN+<3#K;K%.?-$:/6G*U%0\TTZXRZ6N;>^S#X?T2
M1TEZRIC<>4J!WU1M/&4;*(ZTU,E(\/L&47RKM-.<8!EEP39E#\HC8[2S1RZ'
MB1,%R>:O@MX!C!CHEHT^&BAH9DSRZ@=5CA+-V/IK56$O%(4^:8R24;6N4<?5
MDUH&2=9K<CTH7'NE+UNF7BS+JM#L]18RGAT5UQ6H%9*+';PT?IK]%9I"'*\Z
MXPU4#IC+=:3.=J)R&G7TPE4]2FU-YYK5J*QM95F5G0W70[G@ZIE4VTIO5;<Y
M)@(@9@1HDE,@B]";T9,>/VH4-YAK"@96U?%"S67"HF,CZN?-#8A^!=T6WHM$
M=J#[+\B3(J3C#DIU],1K2..EQ#6BS!BPXZ5&3BU.N$UK'EGIN*4>0UW%;&NX
M<68-FTFJ4BBT.CV+$JT2@4^D2+DJ"FDUN1$DS]?4[LN"Y:R\RE<&*U3X)U$H
M-+BM%'@QF6U+TK75GQQL* ,5?/\ M.<W_P %4/\ \?.HIXR^4OZQ*O\ -/\
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MZQBD(<3/0?8]ZHD<0MM/%+W?;G+'336:@"N:15IV!)H8HRCBTR;D(HV;H,$
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MSX\\C(LSX_B$ :UZ#;^N/6GACZ:2UK2T8!0M&]E&/L4^]DEF;HY?;A5B4>R
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M % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
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MUAVKD_'D7U:'_P"8 >T:VZG-_P!H2WW(4X9O\&_],?[K#M7)^/(OJT/_ ,P
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M4UE#I+;2B:39QR3JSD1%FZ@^Y-8\[+M,V6* \Z4Q)SID"-5"4T;;<=-5-#\
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M+4R%'Q=_QVTVQ+V@#;*1BYF(07VVUQ'.SY334T1ZJ8IK<.;D489^XA-1I K
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M$\RF,[2L(G8Z#0:6'+)J*V4FT9*;-+2KF-!&VHB4@R26@9$:<C(AES.?<[O
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M69)R]65T[9."E-/1YCBQ>C115L#XB2 \6BL(F*IBE&_%ZM9-'."AEC^:2?\
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M7-4PTZI3CAI4K1(VEI(]%"5*/:9%L2?'R"WT(3Y!S9A&.U=UR4.@K\50/LO
M2O#:0@N@=Z/Q8GEVN!4;<FM-6Q;YF-@RK93'YBI*HSK=:.LD5B&6T6)(JKBJ
MHHP>"J-,J3U1E-L0R=:FU.D5-NH..LE'C-TQAI#T-]O6IF&;RXQH03##C:VZ
M@\:G6]!PAG*=4Z<S3HJWI9MNPJ;5Z8N VV\<B2Y4WG%M3&'-4J(2642--PWW
MFW$N0&22TYIMF4O;;[(:ZOYYQ:\F<^(440(]V>F[:58:<:-*<D%#DE ?3O@<
MTE$GH')#&Q&OLZ^R#071'R61AD2"DM";)0%%/H*F;Z M6-#I-5BQYD>1'J*3
ME4>G45M^8_377(CD9BIDXN.<23EU&C*D-%&-PG*FMUY6L2ZDM-N_KE5I4E^'
M(8DT]91:Q4:RXQ#8J+3<MJ2_3#0F04N-GU8DI8=.2EO5TU#;*2;6TH]%RJ>X
M<G14J-)FL%@2<FSN:QG[:F?E)\%T-\(8"4@S^9A\LTF,H!/A :RR([DL*+%=
MVO(%.*JC83UI]9D4=Q+1H%5-5FJ#"FH?D2I,-5,(Z71:8F,;L=TUNTM,\WY*
M#C.O-DPLYK;$<UJ0\MN-I.--D:$C"5Z7"<8CQHLQ-2/JG6:FN03<IHD-U,X!
M,1EE);8<-]!0EOR"2E;*'))I;=<,EJ/_ $5(9UBB" VY++5C-#4$E%FV6Y1F
M^0BYU=5E<14D.8SN*@_%0H8431@9+)J1G#',JE$,P"";C;P"( .-[VKR /71
MF9Y9]XB(OD+B%3(&X1.DFO+CBMRM%I2:[!X(,&ST&(,MSQ,LL,.&E,_8QTM9
MC2-WP]5=@--;SS,C& %A.;0:DGG,[GTTR3/<IBX1-:CSS,MO'D1$9_*9$1GQ
M#9I02CG9V.X)CCV=G&2IW);#(C.*R(XQE()M&HV/+0Z59.+%D'($14">::&;
MN+FE9&;9XD2]L,1[!7QRN'?/+D=Q88O5RM3JJFL-1DS%MN$PJ$MTV]!AIK(W
M"DH)6>KTL]!.6>7>S/Z3X);ONF82X66AAV_AC/KCML0ID1=5:NN/ ;F')JL^
MHDM,-=!EJ8)!3":-)R'=(VS7F1*T2A/V=-V=:QN]D2E]X-87@;D<_L]'+]L'
M5.V@T;Q-U/SVB_A@/9TW9UK&[V1*7W@TX&Y'/[/1R_; [:#1O$W4_/:+^& ]
MG3=G6L;O9$I?>#3@;D<_L]'+]L#MH-&\3=3\]HOX8%J=*>#"X=2MEH[G\_L
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MI#/R5& B^6$(*"#YN3L3]*\8N"8N<6!_(%HN[HN7F^73/30G3SI?F02W.VY
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MZ3R],B @>7,(*+;\UHT+=,\:J$Z<ZKF/-JD/;H>7FR/'.GXO'GRW,8%>>MR
M,LL]I;,N(R///DY<N_R!&F][0D[T9_%\![8-?TGUV94%O^7,'J+;\UHT+=,\
M:J$Z\\KF/-JDO?H6?FR/'.GXO'GRW,8%.>MR ,LL]I;,N(R///DY<N_R"<M<
M9X1]E8C;TP(3!EB,DQQ'G*0 9LVL<S'4CIN;8<JJV3!A9:1LX>'3RBH821%1
M#'R,YV4D,XGJ6%@\#5@\0&61Y9D?R'F0G*@@% "@!0 H 4 * % "@!0 H 4
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MF>61=\3#5@+\* % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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M_P#I2M<VQ6_FB[_E\+_]UCHV%G\[&?\ (9O_ .B1_H'5Y@'IH* % "@!0 H
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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MSR&?U:BZ"@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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M1&:3(E%FDS(R)1<699\99]\M@@2DF9D1D9I/)1$9&9'QY'EQ'EWC'U 4"!G
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M%7W#^P;D;Z5(#Y@R,&]%$KQP455-@MJP8.RCAEQU-#,JD*29*(TE1S%JFVU
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MAR<F>&-\;\EKU@KBO>SY%.)O?YU#*7$7O>$])B/EH/H5KM:;*<VV<M-QO/\
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MRF-Y$5XOCM51FCS_ ))I"DRFT>3&QTD/FC/D\0-)@I5%Z0%>X0_BT(MSH=_
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M["$C$:-%0;<:.Q'0I1K-##3;*#6>6:C2VE)&H\BS499GD69C+:H"N% "@!0
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ML7!3:/\ 13_+5^@-?X5+L_I('D2?3#VB_B3?G##O92G_ #.G!3:/]%/\M7Z
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M9+U,./#E(?=)J2^MPT)(\R0E41"35MV$:DE\9#LAK@8[N% "@!0 H 4 * %
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0
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M$)B"9Y9Y97H)#XS_ -O'^T2W0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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MWV_F!C'!I&B--/+K<;B<X'LCNR16@]5I-/J;E L 2BYJR*X<"J8L&3"(!S)
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M%=I.DDCN-R-%3/("\2&3E8B4<S/5D%SHN9PB8'+9'D-935 ,,7.P!H*^5[T
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M@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
M% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
M 4 * % "@!_/_/0!\8XXX8XX88VQQQM;'''&UL<<<<;<EL<;6Y+6M:UK6M:U
MK6M:W):@#^?, \E\>9"\&^6.5[<WAR7RPSYS#*]N3DOE@)^4QO\ SXY_CVY,
MOIH ^]\,,LL,\L,<L@[WN'E?&U\L+Y8WQROA>]N7&^6-[XWO:]N7&][7^B]
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g383050g10r11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g10r11.jpg
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M3:,0/A.C]K-?:03Q]=,EM)/:X3'(N:S39(T<UXRD-;VI)1.MFN08]2&X]IZ
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MB\Y%KNX-LL]>4BPL;>Z9MR&477B&L?*1DJ=)(H")Q8MY0)-80YRM&+DP 80
MH^#>J)T;OM(.AZ\V'Q///@&)V^-S01*7DDLHK:\M+QD0;3O>.\%W)EM$-O*0
M"<A7O'J=])+'1[HA1PXA*D$&/X9<8)%/(P2..]FN;.[LP[G8HN);/>B<1FN(
M@2!M'A!C\[J_1*F%*SA%Y\VR'B:; LV[$L-4*S-P)(\R+=1*8>RBU\<,9N54
M4:G6=*P*U\=KQ4:NHO%HN6*3HK8CETY5-Z!:=$7&;*RP/#H8K<6."85?X<ML
M8XF2]GNWTBDM[^[9X6DEDPZ32*>2SM9'DM(Y;=)A$)997/GUWT.<&O;S'<1G
MEN&OL;Q:PQ(W(>57L8+1-'8[BPLU298XDQ&/1Z&.\NXUCNY(KAH3*T<,2BY+
MY_2+R,1CWE<CP6"IGK"TG'*MHN435.>OJ.9B,D6T4,BR=3JE?!2UMW+R2:S2
MDS8%&Y(HTLN.-J3HD74]HEM/A=L'&#-A+W=J\5I=HS-AK2WMI=16F^;>;$&P
MT-C$4L]U#?M?8DT:V9O9:U(^AM;6]V]S;XK<[F<9&+I:74<MY:,JKB2Q65U:
MRW@M9X<.7$BN#216]K-8+8X:LC7@LXZN3_:1DW_+@4IU?*$FA,H2  =8_+22
MP9H*)\I$Z0F7ZG/<R$9%H"@F KVH5Y?M5$"G1V[GHIW=SO@-@>&*+N.^BN1K
M.V^%O?7:Z[L2N<@MKC2E+F$,<A/@N&2;'B5DU;;H5VEMO?5QW$F-K)926V:H
M-P-F=$E;<0K@1[YM]%I+68J 3!C>)Q[4D99.Q':,W9H)IQ0XPWT#8([J.SF'
MK&O%1L,\,P]7)"D;*LU'CQJHO%2RSPKQ&23Y&]*V9O&#=0)CZ)^5\+Z31VT.
M5MB=KO&"]N+?#!'B>)&^GD6P6)X6GFA>2SO'F$R72;A.(X)[:)A1^A<=X;PB
MTCNU^N,-N=_3V,%SB9?#<.WE;Q&_:9)UMX)ECO+..!H7M7W> RS07,JG!MQL
MR]QLDG9'+5%DM)G;&.U0.=1)+DS-NS*!#J=N;>(W*<PFT[8P@  &F//L<Q63
M&\4N\4EA2![HQ$PQLS(FY010 *S]<<UB#'/C)XJ]#P+"8\"PJTPJ*9YX[190
MLTBJKONL\LY)5>M&32E0!Q 9G/.HSCBJY:O1O@YZ!,2&8MBS&.V62KM=KSN!
M2>F(8J3R>F5V*@,VYS !%A9QC=RX>@F8QFQG4=Q@%!TF(_4/J7]&[ZYTHQ/2
MAHG3#,+PR?#DG*D)/B-]);L((V.0?<+2.62XU23$9;4, )E-?+WJH-)+&VT8
MPS1=94?$\3Q*#$7@5@7@PZQCN%W>51F4W>[EBCM];(2B&Y*$[BP'K?:C&*P:
M"41*(S$2 B B Z"\3U#F[P]_'W0/U'] -?"YXO='Z3E\A-4,&<YK=;RF,8Q2
M,ZR)2B(B!1.28WA !Z!-H&OAT#$GVJ_G?+55X7]WRUY_\)#0)F6KE$S"C6RK
MJ-JCB7A;"*1#*"Q;SQXQ2*D%0* \4T!XP78N%S]H5R^CTM0%4-?D[U4NC=]>
MX7H[I-:Q/-:X/+>V&)ZBEM[Q8BUHUI<OD.LA$]N]O)(W6B6XMDS!?;]9>I;T
MDL;+%=(M&KJ5(;K&8K*^PS78+OB7#A=I=VR$GKYC!<I<1QKUQBM[E\B$.7D'
MCXFK[9IA2LA9?YD3F6Y[0ZKQ6Y)*QUU& 2D%T4'!X@4+/6[.G)-&[M!RU5>)
MN*XB@@99(>3"X%V@9-TW04+V71K2G$-%FQ>;#!$MUBF&1X:ES(D<K66YXOA6
M+I=0131RPO.LN%1QQF1#N6ZF>(I-%$Z]9TET5P_2H81%B;2FUPO$Y,2>VC>2
M);T2X3BF$O:SRPRQ3) T6*222"-QNNYB&0-#)(K97B-I64:*PRTW5(ZR*PD8
MTBVR[Z3?$<*HIQE7BI$KHXIKIO&TVA7%CR;%\BZ:JK3+QP1,CMNR<H]RLNBK
M>0O8O?X/:XH]A:0VD4EQ=W"R.BV>$6=R)FU76>*_CPN1KNWG26%WOII%59HH
M)4Z9>]"BSE2^3#\9N<*2_NYKN6.WL[=HT=[S%[RU,*AHV@EL'Q2-;2X@>*9(
M["")F:&2>)[',Y[+RU:D*V6I1#(C^N0=?6DDQ:+OG"<(VDVB!W9'$2=D1JFC
M()*L6<,UA%&,A'M97ECF26D'3WC[[HAR7N$W.%#!;*!;G"\/PR2Z7<)+B5</
MBNX8FF62R:!8D2Y1[>&PAL'M[FUAO-WENI+F:?D+#H=166+6V*G&;V=K;%,0
MQ-+5A/';QO?RVDT@A,=ZLYF9[:1+B>^EOUN+:ZEL]PBM([:&#%,_9EY^,ID8
MLU2;DIE9<5ELJF<YCO4'%MM-M%TN4P:)JE<6EPT B>I!1:HG'YX<^.G8EBTF
M)6F!6DD*1K@6%2X5"Z,Q:>.3&<6QDRR [%<2XM)" O6F.%&]LS5W+#<(CPV[
MQZ[29Y6QW%H\6E1U51;R1X/A.#B&,C:R&+"8YBS==NDSK[55J,8XFN7IA2O7
MK@WJ!,15?OF84BV6:QMH7B(2O"J0R?+T(,\DM*OT@, <:TY6];L4%R:D,Y9R
M"6HF1'3[7]2UHW?6>&:1:3743PVF+R65AAFNI7?$>'-=/>7*9C-X=WGCMXY%
MZTRP7*9DQG+XH]5+I)8WF)Z.Z,VLJ376$1WM_B81@V]Y,06U2SMG()U)MPMY
M+B2,]<(I[9\LG&?HI8#&*K7MTPEUGT0'01#4.IDH.@Z=[4 '3P@&/K(<?N?K
M%?)IX5]W]1JWU(YSNK@!C&,!+6L4NHB.Z7J+"CNAKT!J(CH'-J(CTB.!^Y]S
M]9J%X#[Q_P"D5Y9\)!0)A&X4[,Q%LLM7Y"O(U%\Z3()TF$Q&2$K)M".3@&B7
M5-E)J<D W,H:,=AJ!@ #?$GJI-&[Z/&\#TLCB=\-N<,3!;B55+);7UI<WEW"
M)6 R3?=O=L(<_;-:3<!R!^W/4MZ264F"8YHG)*B8E;8F^-V\3, ]S8W=M9VD
MQB4[7WI/:*9B-JB[AV99D>9N/E&OJZF%*G^7^8DSEPYL3^!3;#(SU;5KJ;MR
MB@YZF<9-P<V61;MG:#EHNZ16@TDT2N$3D3XXRY!*NBD<O9-&M)[[1:7$[G#E
MBWUB.%/AB32QQR[TUK_#[\7444T<L,DR/AZ*@EC(3=#(N4B(PZWI+HQ8Z4Q8
M7;8B\PML-Q5,4:&*22+?>K88AA[6LLL,D4T<,D>(.SF*16;4$;9QNZG+D)M,
M3+%Q7W4Y5XZT.*\FQ*W<24D_(NY.@FS3D^7* 54KQM8BM5"SK%VFX;/2.E#"
M0KE%HY;]TL.BO?6\N&S8AA%KB\N&I;K')=75P))C&D"7>^#DZSQ8HL++B-O,
MLD4XE<ZJRI#+%TG$.A/8W$>)18?B]SA$>)O<-+':VEN8X5D>9[06ZZT;0RX8
M95.'W$+QRP-"H#&)YHI;%)9[+/JR\K*51B6J;NI0E4/)@9FYD%6\&SGF#87!
M7$.=@5F5"<(X1:Q;**>(R\3&SII5:7!V\=<?==$-[C"9\*7!;*)9L%L,'-WG
M!+=-%A\&)6\6ZB6R:V$ CQ!9$AM+>SG2]LK3$3>27PFGFY"TZ'4=MBT&+/C5
MY,T.-7^,K:ZL\5LDM_-AUQ*(S'?"Y,YDP\Q/-=W%Y ]E>76'"SCLC#!#CF?M
M[68J=-JK2$+%)U0)A9=V227=!-2,XLT4?RCAHHBFDU>*),&#'>1.<!CHV-;&
M 3-166ZMB6-0WV#8'A$-@+-<&%\\DRW4DPO[K$'A:YO)8614AG9+:VM\XV(W
MK:6D)!,)=^TX;@DUCC6.XQ-B!O&QG>*1P-:QPFPM</29+>SBG61GF@5[BYN=
M5U4[ZN[N7/*8(D'QP%=AIA2O<?@_Z!,4_)EY.3;99DM>["I/QC9<ADU>H*#!
MI'QKPZ9P Y D%47KML(ANK,%&3E,3)KE,/Z">IMT;OL#T%GQ"_B>!](L3?$K
M2&12C]+H[>"VM9V5@&7?+QW$T68R>V:WF4E90:_/OU2.DECCFG<.'V$J3IH[
MAB8;=S1L'3IC)<3W-U K+FIWLDD$$H!)2Y6XB;)HR!N'+F,6<KP 80 R<OO
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MOQ??^CT^;_\ !<>SM9?>8S@_X+PZF&F7<V'XPL?2*=4S0[NE+\7W_H]/F_\
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M;G$L$LY+HJHR DEM<1M!*P&6<DJ/*YZYW9B6-D^:J<$!XE[</D_E5YQL:'U
MN ]O7/Q^_P#E^M_ZN;2?M2R^(E^G*?-5." \2]N'R?RJ\XV'U N ]O7/Q^_^
M7Z?5S:3]J67Q$OTY3YJIP0'B7MP^3^57G&P^H%P'MZY^/W_R_3ZN;2?M2R^(
ME^G*?-5." \2]N'R?RJ\XV'U N ]O7/Q^_\ E^GU<VD_:EE\1+].4^:J<$!X
ME[</D_E5YQL/J!<![>N?C]_\OT^KFTG[4LOB)?IRGS53@@/$O;A\G\JO.-A]
M0+@/;US\?O\ Y?I]7-I/VI9?$2_3E7J!X6O@>(200D'&5NV/80;G*H1A/5S+
MU6/,<@[Q!70C,V8L[@@& !,@NJHW5 -Q9%1,QR&W\.]0EHY87,=S+'#B8C8,
MMOB..WSVS,IS&Z1VF%V;2*",S'([1N.M=&4E3H8CZMG2O$+62VCF;##(I5KG
M#L$LTNE5MA$<MUB-V(F(S DC194SUD=6 8;B,/R2CP>$6R:1L9EQM-1T<P;I
M-&+!CEIEFT9LVJ! 30;-6R&;Z:*""*92D222(1-,A0*4H  !CW"VZ"ND-G;P
MVMHVC]K:V\20V]O;SW$,$$,:A8XH8H\.6..-% 5$10JJ   !7B%QT5\&O)YK
MJ[&-W-S<2O-<7%Q'#-//-(Q>26:62^9Y))&)9W=BS,22235'+?DE+8$>GB3(
MT7:@ &,JF]6XS+W+DHF1*S>MQ!/3-\P&4WW*8@4PE+N@8=[4  <XZ#VE.WZY
MP7:.V[OE![0[U8#T3M'MGUOBNP]K6W(1VYWZI('\DE[ \8O8%'%%VGS%E)Q2
M2;<5E]ET82MSQT<T JH&S?(!505:*B)2B<NX)! XB(E*/0>TIV?7."[!VW=\
MI/:'?H.B;H\!]@Q7B_!K;D [<[U55@_)('!Q6J'?U^R97;2LY"2: MW\7)99
MY9NV;I(1 P HBKG 8N^FH4BJ*I=U5!8B:R)R*ID.70Q+H%XUC%C<X;BJ:.XA
M87<9BN;2ZFN9H)DS! 9'P\C-6"NCC)XW571E=58;V&]&##L'OK?$L+EQ[#[^
MTD$MM=VD<,,\+@$$I(E\#DRED=#FDB,T;JR,RG3V3X6#@>7[Q9TWRWVTH=)4
MQC%81D#EV=FCO"([J0RF:TF[ H:Z%!1VIH'-KCQ&[]09H[<SO-$V\4<DBVM-
M(+UH(\SGDAO,)NY\AQ!YWR''7MUIZM_2NV@2&4QWSH #<7> V:SR9#+-Q:8G
M:09GA)6%<S5!\U4X(#Q+VX?)_*KSC8UOJ!<![>N?C]_\OUL_5S:3]J67Q$OT
MY3YJIP0'B7MP^3^57G&P^H%P'MZY^/W_ ,OT^KFTG[4LOB)?IRGS53@@/$O;
MA\G\JO.-A]0+@/;US\?O_E^GU<VD_:EE\1+].4^:J<$!XE[</D_E5YQL/J!<
M![>N?C]_\OT^KFTG[4LOB)?IRGS53@@/$O;A\G\JO.-A]0+@/;US\?O_ )?I
M]7-I/VI9?$2_3E/FJG! >)>W#Y/Y5><;#Z@7 >WKGX_?_+]/JYM)^U++XB7Z
M<J65#A?>![J,JA+CE'M<6=PT4*LU;VNI9=2<:DJ00$IU(QOFTP8OB@(?29)!
MXW$1U%$1 HAS.">H<T>P6\CO=ZV&+2PL)(8\9QB]N[5'4@AGM(L,MK:X ['=
M13Q'A,9(!'#8WZL_2K&K.2QWY=85%,K)-)@V%6EI=.C @JMW)B%Q<0$Y^WM9
M()1P!P"0=NR?DEW@_$R%33H.U$0A"E(0A,NLMRD(0H 4I2E+G" %*4  "E
M     - Q[6O0<TH50JW&"*J@*JK=7055 R  &'Y  ; !L V"O%6Z*&C[,6:'
M%F9B69FM[8LS$YDDF]S))VDG:3M-6>0_)*&P*ZDXEXG1=J $F)'Y5@-E]ER!
MQ%T5L"?%@&;X@;043;^\8NFH:;VHZ6'0>TIR(WS@NW+\+N^(_P! JIZ)NCV8
M.X8KLS_!K;C'],JFK'Y)*V"(=BZ;.Z-M/&47EI-\04<OLNCE!%XZ.LD!A/F\
MF(* 0P <H )0-J!3&#GP/0>TI/X3@O /PN[X@!VA4+T3='@,C!BO#VM;=[^6
M5WV3\D=<&]<(5]7+1E9M*ST')I<2^C)++3+5RU7(!@.0PD/G"(D614*55NX2
M$B[=8A%D%$U2$.7CL5Z!&+XW87&%XO%HYB.'W:;G<6EW-<RPR+F"I*MA_6NC
M /%(A62*15DC=756')87T8[#!+^WQ/")L>P[$+1]>WN[6."*:-LB& 9;WKD=
M24DC<-'(C,DBLC%3I_(<*]P/3UVLY;Y=;:D4DJ83%8Q\#ER=H@ B([B)I/-2
M1>"4-= XYVJ;0 U,(ZB/B-SZ@O1V>9Y8G:S1V)%O;:07C0Q@G/50W>$74^J.
M :\SG+A)KVVV]7#I7!"D4@AO'10#<7. VBS29?=.+7%+6#6/'J0H.]5%\U4X
M(#Q+VX?)_*KSC8P?4"X#V]<_'[_Y?K/]7-I/VI9?$2_3E/FJG! >)>W#Y/Y5
M><;#Z@7 >WKGX_?_ "_3ZN;2?M2R^(E^G*?-5." \2]N'R?RJ\XV'U N ]O7
M/Q^_^7Z?5S:3]J67Q$OTY3YJIP0'B7MP^3^57G&P^H%P'MZY^/W_ ,OT^KFT
MG[4LOB)?IRGS53@@/$O;A\G\JO.-A]0+@/;US\?O_E^GU<VD_:EE\1+].4^:
MJ<$!XE[</D_E5YQL/J!<![>N?C]_\OT^KFTG[4LOB)?IRIC3.&#X'VF2S>:)
ME#M:V9XS5*NT);:CEU*L$%B" D4-%HYML8YYNB&I4Y%J\2 VAP3 Y2&+SF!>
MH?T?P*\COA:8?BT\+K) N-8O>WEM&ZG,,;2/#+>UGRXENH9T!R8*& (X3'?5
MF:4X[926#7MYA4$Z-'.V#85:6=S+&P(91=OB%Q=09@Y%K6:!R.M+:I8';</R
M2_P?I0 I:'M1@4    ,N\MP   -   #.'0  .8 #F ,>TCH.Z4@ "YP0 #(
M7=V  .  ;PV 5XL>B?H\228,5).TDV]MF3RGZ]JS.?R2AL"JRQ'Q:+M0<26,
M69B Y?9= IQJBHG*(%#-\2[FG,([VNOI1#GPZCVE/;."^-W?H%0>B;H\<_8,
M5VC+[6MN_P#RSOBOBM?DD[8&B(5G'NJ-M/F70,[$YD<OLNCIB"[UPX)NF/F^
MF8="*E VI T,!@#4  1D]![2DDG?."[3G]MW?'_P%!T3='@ -PQ7WK:V],JA
MNGY(GX-',2!<UFZY2[2MB@W8E.HQ?Y<9<FXM8@&*FZ:.$LY$G3%ZD!S@B]9+
MMW2('.":Q0.;7AL=]3[B&DV'383CUOHYB>'S$,]O<W%X=6100LT,J6*36\Z!
MF"3V\D<R!F".-8Y\S@71N@T9Q&+%L!NL>PS$(056XMH;4%HV(+PS1O=M#<0.
M54O!/')"Y52R$J,M2'7"M<#XX7462H.VTR3.83%:M8'+0Z"("/,1,SS,YVY$
MH= "LX5/X3B//CQ:;U!&CTDC.EQ+;JQ)$,6D%PT: GVJF?!)I2!P#7E=LN%B
M=M>T1>KCTICC5'BMIV49&:7 ;=9'/\)A!B\,0)_B1(O(!71\U4X(#Q+VX?)_
M*KSC8Q_4"X#V]<_'[_Y?K)]7-I/VI9?$2_3E/FJG! >)>W#Y/Y5><;#Z@7 >
MWKGX_?\ R_3ZN;2?M2R^(E^G*?-5." \2]N'R?RJ\XV'U N ]O7/Q^_^7Z?5
MS:3]J67Q$OTY3YJIP0'B7MP^3^57G&P^H%P'MZY^/W_R_3ZN;2?M2R^(E^G*
M?-5." \2]N'R?RJ\XV'U N ]O7/Q^_\ E^GU<VD_:EE\1+].4^:J<$!XE[</
MD_E5YQL/J!<![>N?C]_\OT^KFTG[4LOB)?IRLBY=\,SP0^6\PVL$9D_M7SDT
MQ5(O'/K73<NY@L>NF8#IN&K ,W6L4#E$Y2J-W2S!9RV5(55LLBH&]CL^C'J+
M,%T6OHL3M+/"\0O[=Q):W&,8I>WPMI%(9)8;;I;%9B9&"M%,]N\L+J'B='&M
M76-)_5?Z1Z56,N&W=]?X?87"-'=6^#X;:6)N8V&JT4USO^6\,3J2LD*7"12J
MS)*CH=4>E6R]PZVPOM59OU_).L.LS\N+=;A.TJ3O-ZM5>LUNQSXG2(RJC":@
M[Q:4T+'+[Z@0K241CFLJZ1"*9/59I[%QK_TG&NAII+@EA+B,ZV5W;P9-.MA-
M---#%D=:=XY+: F&/(;HR%V13KLHC5W7S/"M/,!Q:\CL8FNK::;9";R***.6
M3,:L*O'/*!*_W"N%#D:BL795;UG)]E<K]R(G^??X\_XA[I^1:[D/;-^;\E?D
MF8^YZ^(:84IA2F%*84IA2MN>#_\ T>&Q5_"SV=/[7Z?C@M*/WM:0_P!28K_@
M9ZYO1G]\>C_]=X5_C[>JGA ?T>&VK_"RVBO[7;?C/HK^]C1W^H\)_P !!7.Z
M0_Z?QO\ K;$?\7-6HN.>KAZ84IA2F%*84IA2F%*84IA2F%*84IA2N0'00'F'
M00'00 0YN?G =0$/" AH/0.%*]G,\-LW8:S90D9"7R@O-JL#NO0[D(8:F;*W
M*<MRJN5&UO"U)O#4:G9^3-CJ-0:9F9E;/L]*0+',*6C6<95[W'T]A 5\C6KV
MSSS#='M);%D5+^V@B660;KN^_;_>\]]@4DYEN;C#(XKB<V=GBD,<K6J.SS6K
MW#32ZT\'=K_&\!O [/9W$KM&A$>X[TLQ/%:8ND(2W@Q"22*$75SA\CQBX=0L
M4ZPK'&!%+(G=WX,/+K+="\5;+%"8C\T+)F+ 3=2C+[99;/2#ROG,VK_(UNJ.
MJW/W"6J5/4CLIHFD0LU=#K%L<99%:VI49?,)I+WR>B<(MM,[N[-K->&.2RAM
M)8[A[6*/#)+V*QM4FG6:*W2>X#WSW,D=N 8GA$V^([1H[:.3*9]%;6V%Q%;"
M1+M[F.2%+B5[^.UDN[AHH6BDG:&'5M$@22?,2K*8C"]PKW$B:[9>[0>PKE-M
M"R6<M+R,S9ZGU*!LKK+"N/K%39RH/+I*T^.I]==S%*OL'=G4&:K2TC9\T"S<
MM><S(B0LD96:N3+IA"&=R2/+7>%:37^%)A]QB5AK7$L*WLJPW$=PMLEP]Q*L
M=S:RVRR[O&D-F8DMK-TA>:;?C2:J'C+?$<!L\1:]@L+O5ACE-K&989(6G>%8
M8B\%Q',T>Y.\MUKO/<QM(D40MECS8<7//#@[7%HL4K4MEN;DXRPOLR+JB2Z2
M-VCWU?L5FEF<K1<N6#*@YYUJN*Y;T9O+66$<2Z<0QLTZC7Z6_,DR(XL$6Y6^
M&Z6K#"D^-1(\2V=L=[K;LLL,,;)=7;-<X;+*+RY,<,@C+M#&TMPNW5B<3/?Z
M-M-+)%A4CK*;J<"=IU:.:5U>WMU6WOXXC;0!Y8RP19)!' VP&13"4=H'9RRZ
MVH<B<V\@,O;5ESEM3+48^:E6725L3^VTMGGY=)1HU:L;K>[L@]E9W9V4R^K=
MK8KSL/!NKPSL0,$6L:N67?;)PK%[O!<4L,5NH+R\N(/K&<$1+!<MA=NC%FM[
M6V*I%BPNIH&$4DBVS0ZQ9P8UP#$<,ML4P^[PZWEMK:&4[\B(,AF@7$9W4!9Y
MYPSR8;O:.92Z1F=9-4!3KM+HW:<V6K'+R\WFME9:;!;KV^S=2OV9C8DZ>SEK
M$N>-ALHZQ 5>'SAI5'"%A:IU02MR!HN.F7+Z+K;6(LJ#8LLZ>X&P7&X8XXK&
M]@A@M4L#:V9,0@W= \E_/+-)87%QNDD^J8"'>,*\S20EMS5<RXKA,DDDEW:2
MR37#7@N+H;INNY.52SBCBCO8(-1(=83C460E(E24#7+2S,;/'@W)J@62A4K)
M3-.,8-XG.FQY:+/&2;=Y3LU[[DELG5>LR"\L&;<K*62L(YKY/9NSC^*LB\@P
MKU<S :.:_#N7I'$$&"SPW2^.ZBNKG$;)W:3#HKP*Q9;BQM<2QR:9!'O&-(9C
M8XA81J\(1Y9K4K+(%(EK+=7^C+V\MO!8W2J$OI;4E<C#=W%CA$43:V^V:2(7
M=E=NR2YK'%< QH6SCJ[Y?[9V3^SYD>VBZ/EQ1\P[;;\D<IJNSKMPK367KE:N
MU=M^>_9M=9DMTIB&F9AY;S7*HV.MEXN;@9^IEK=9EW3=.E)0L;CNM'<0Q7$B
M]S=W-I!;XG?SF:WF*336TL&&=+19DQR1QK!O>>&;;%+%/NTT8)N#(^2WQNRP
MZP5(+:WN9IK"SB6*:(-'%/'-B&_S= /&[M-N\,D?V2.6'<XG(W (N/8W-S@T
MW*DPE8ME[,!FP:6?+!&!4JMNMZ,O,T.*+'O<S5I=6>S=EV$7?;'**3D8R78M
MEZR6J&@ 81M=L43)R=CVFL-,5$9BQJU=V@O#*)X(#''=.66S$8CL(VDMHD$3
ML'*S;ONNL\L+HD6LEYHN2XDPJY55EM1&8IIMTDMT"M=:YDO'5+B1S(JE08MQ
MW,*L<J.\D]S-VD=@*^59E74\H;@C)5>DS,+3)#K-EXVD1MD"E[-%7BI=>C0^
MTLTLCT%$LN\Z$VKV7S)EWS%]:Z?-6-.Y@W7C8#6L\'TIM9VE-_ 4FN8Y+A=\
MQO<O#OC&)GC%S)A#1+MN\.++'9QJZP7$<1MR5>78NL3T>N(5B%G,'BAD2!MP
M=8$DW#"XD<VZ8FLC9[VO0K/<NRM-#)+NVKJ1VF3SEX+V9==47NS;F$S=NKU3
MY%=I70FH&&C:"SC\KD9>NMXLF>STTM)-W$/FBE-/RR%==7-&S0SEA)4N62ZK
MPMX\/TTC747%[5E6VN$#3&.61[EGO3'*7.&J(T(DLMS4I*+<Q2!DN(_8Y,;W
MNBKG7;#;A6:>%BL0DCC2W5;4-&$W^Q=E*70D;6C,XE0JT,G7QWK+_;%V6ZUG
MIGM9I.D61GE!F5DCE!EI"Q54RM@&U^CY3+O*:FU.;<U*8D,XU6^7#>=N597?
M.QL*V=4;;JZ\,C>H"4E@(\)2[T?QF?#<,A2XA:_L\2O[R1Y[V5K9DN[ZXGC$
M\:8>#>-%;S!5W+I<\$RYVTJ)UM9+?&L*BO\ $)6AD6SN;&SMHTAM$$X>VLX8
M9#"[7AWL))HRQW4WJ31$BXC=\F$ ?YJ<&<6,<MXC9PS*Y8]J%=ADWLM8+,Z>
M0TV3+[,-I9+(U48YQ1<<[L1LQW^7C]FL]B'56=5Z&D5R5*'<K+P;W:6RTQUP
M9,7L]59Y9-6.*%5DCWU:M#"P;#W=8MZ)=(P5Q,LLB#=W4"1==KO1?5(3#+K6
M:&),WDE)C?>URLLHRO55I=\M;."R&(QHQ$,9)1LC/MHO@VV,;+05/R$S!CXT
M7-JL%4-88Z4L9Z;8)=ULBR#1*MJCGY'/V:AQRKSUCD;*]>R,C&-[3349B/NT
M0O8XHNFN$:7LZ2SXI:L^K!%-N3I$+B*-<>4F8=+'5@-_88QA541S!<&-K9Q"
M];38EHRJO'!87"IG+)"95>7<9'.#L-R)OU=2=Z7ZB5BSJ)81(LZ&1:H*QM+\
M'?%64LL^V:+NLULKU.0S%1D9.;M$;-KML[*/)L6J5<?YLQK5>(#*^ER-VEHY
M[)&&4S8S L-33<-,OX2LN6%I\'TMDAU%QBV!A4K:%$C@>-6PVZ1F,R6+LLN_
M;E+:-T4!+&UBG*M=23!ZQ8IHVDNNV&3D3$-=!F>5'(OH&4")KM05WI UPZEN
MON[B2$,MND13%T[=MB.GYG[)D_$Y11T]4H]HWNVTO%1,G<;-&RZ\C(%@8:G1
M-4LV8ZY&@Q54K$5FE8:NO?7ID\P<S+=E\_N#^I5B!9Q^[%;:23V6.QR7[QW#
M,UM@[R+;PO&$4RR7$D\-F-;7GF>RAG%JN=K9P72VZ3S2LVI)/@4%WA$B6:20
MJ!/BB*T\J/K-N:0I#+<D+J0Q)=R1&=B+BZFMVF:**-5B-UMVP?-J9),ZSESF
M54V<=?:RXSQF8=D]ZJ2N7B+&$0O;6L1=GSGN,?(SDS-(V&9HC7E5+)48%[&5
M>RV"]2*"MJ2V+:WTGB&)--=V<[/:S##8Y'74CNRTIMFF>##K=DBCB,,=TVK<
M&XE5YX8K9&$%8)YM'Y-X+%;W4(6XB-^Z*VNUL%03B)9;V=6DD<2/ ,X=QC98
MI9)V!EK<*U[=NR1=[]>LSJM0K_LTYCYEY<P]27O-*RFR8S7/EC*4K,)U(Q)Z
M+57\SE5!@POF4ZE>RYLLQ'=:UJKXT*.6ZH7!M=+><_ 0:,8[;6MM9375KC%G
M9WDEPMM<7V(V._4N;54D%U.D=]+KVM\);N%'W:";?3@I ;> 5S,N/8////=1
M07&&75U;)";B&SLKO>K07+,FX0L]HFK<69BM9'7<IHM[KUTRS39XWSIVQ]E;
M-/9OIF2;_*S,&6GJ%(U>;)>HB*RTRKLEWE4"Y^M[$=])-V6:$;0F"CN]99V:
M1B*Q7)-O>0@Y"I23RO$JE,M6-O#M'L;L<7N,12]M4BNEGC-M))>7T-LAZ5F'
M51GLGNF"VUY"CSS(UL9$G19C-<05KWV-83=X9#8M:W+R0-%()T6UM))W'3 2
M%F"W26PSGM962&)Q.(VA9H]RAFJ0.MKW8RD*+<X"TT7,N\768V;\G\I$,Q5:
M!3:Q-3-EH5HS5M\P[(1',V<)7$)2??Y!NIR7LO971LU<RVM^7C*JU*IS512K
M6(8!I"MS;RP7-G;6T>+XA?&T%W<3QQPW4-E!&I)LXS,4B7%%BCAWB89;NWNV
MFGGCG,^0XS@C03QRV]U<3R899V>^3;PQ.\MO-=32$ 73[D'D;#VD>4W8ECMI
MK80PPO"(_B[[=&S ]VK,Y,\8/(I&XY?7K9UD\KH?+:]4.O1<'*6V3LL"NHI,
M1\/=I66K$86DL'=?;V^$N,M<Z_+$;/ZB$'%-H.)K\VVC.-+@>'X;)B9M[NVQ
M>.]DO+:YE>2.!(90-S9[=(YGWPRRFWDMX[>9"RW&Z.TLDM;C'L+;%[R_CL!-
M;3X:UHMK/!&D;RO(A.LJ3N\2"!3&LR3/-&X#0ZB"-(_JV;47!QYN6JL7G-39
MHM3*4!OD+%W.MY;1)Z;5T8&D5?9T@;M7\O6E?SC@&,#"$+4=H5JF><B)VT76
M/N^7RQ;-E].1$C-,$&":6V$$]M98Q T>>*/;S7;BXG:6YFQ:6WFNVEL)6EE]
MGPEB(WBAMGM[H;C=12)&\S8KHU>313W>&2JV6'K-';(88@D$6&QSQVZQWL:Q
MQ@0XB.OCDEG6>W(DMW1G7'U1SFX-.*6JE@GMF6ZO9=A/Y5S=IK39W8W]:?!"
M_E?%;_%5Q><SP="WK$BK6MHT%H6VQ=K?V?LA4=%">I;.(61@=J?#M,9!/%%C
M-NL;17T<$S"%9EW7IJ+5YA%AJZTR";",I()(%@WI<$Q7#29RZ\-]HNAADDPN
M<NLEH\L2M(T3:G2\W"QF2^.43&+$@T<R3-+OF +)"L9"29SM!\&_9$J3'WO9
MXN$J%!KRU:BI:IL9VCM)IHX>9[RX)62#)GQ8'3F(BYBR91*01DIL]M;MF=K)
M/6:S,HJ*A9S"N%:7PFY>VQ:W3?4N[.D[Q7)C8+AD><4G2R(*[QPW^ZYQB EH
M-QAA9WDCRG$=&91 MQALS[WC,2/")(!(I-^^4J;_ )"4C>2SW/)MV 6;=)95
M5$>!Q&9?!N2"EJAYC(*\0,8;*0\#1+#'N;A*6P^<4M2+"V4NEQ7?[0+6KMJY
M5LP&],>Q4/"5DQ9J#>6M:7(WY-'0;[9>RTO0021XI;RR"^W6YA=;=(-X1W,1
M%O;A,+:8S3VC7"N\DWL<JP!-;6:5=>.YT:8RQOA\\:;T,<$H,S3&\>"0;O,6
MQ$0K'#<B!D2.,!XVFW3(!4::[1LIP;S2$VEV^2>6;52PU2?8T/)28:W/,-M%
M6"4E<TL[$W]UB:]*9GYA.;+1:ODHPRVY/;)2P08R^9R$0_6IIJY9Y2(2UL(C
MTO:7!CB-ZPAGB>ZQ&-K>T9XDCLL.*6TDJ65HL-S/B+WFM D4FYV1D47&[0I(
M<V)MHT$Q/>-JNZ12+;V3K/<JDCM=7H:=(GNKAI;>*Q6VRF>2/=+H(QAW.5T&
M%\Q<V]C.U9++0<1E!<TL\R959?U^-S'D'LX5&/O%*J.R!5E"HLR9INJV>H2*
M=.VMG#@SJCNY85;CE>9FG&(-W+2I<E:6&D,&(B62_MSAIOKJ5[1%CS>VN+C'
MI\RQLEEWPN^,"4:MRJ96][K%RP:?2N;S!)K$HEG.+\6EO&MRQDR6>"'!8CD!
M=-'N+"'&"=: OG-:ZNJ 5BV(-MA;&DYE_7*=?,LKC;::>!R%A2Y')Y7T"JU;
M)N8RQ@HMGF?=Z-G)4<PX7-&^RN=4K&RCB=:2K.A/7"-YFGECGYN5JU;=.N(]
M;^D,5U+<6M[!!<"7$Y#B1O;J>?$8[R5VLK:ZP^>TDLK5,.C=!$R-=*#;1K#%
M%'-*J\F<:P22WC@N+6>: Q6";P%K;PQ6,EK&JW4]O>PW"75PU\ZL9 XMV(G<
MRR2/%$3B)?,S@Y7(P#AID7=(=8W7(ZLS!TTN4XS+8)/)EM&U96%>)[24,OV.
M:KG89].R-+>,S72>K:;1<<T"(K*4MKOBSTN&[!L2MY!["L#*]O$VY)B#/.)%
M.$2#?<^'!8EN%;>T4I8"R) N#I&ZT:.YE;"=#G*TJE9I )'L@L)0],TSMH;X
ML[P,-VDC"G?61, SS);76PU+Y71N5,1ESF)7XJOS6T1$9;QJ%<952)@:?FAE
M_M&U_+UQFM:V>:]VF[[8*Y;\S\MG3VV1%<@I]C1(.<K-K#.0U2J2T]QB8!I+
M'>O?27=I+)+'A,EVYF:=Y;BRN\(FNQ90-96\=M'-;V5VJP232Q-<R130=+]W
MG$7(-C& O:):);7,2QR8BEL@B6&..&ZM\1CMC=S"\GDGECFNK;6ECBC<6Z/'
M-OPPP[I3Y_3/!;46YR=*JN43*=@W9E7,=?,JKSF3F*:)A23<(I""[+-YY0=>
M5M#UG'VCKC@&#Z78)UF6JB;6TUZXN;"UJ\X7'IM<VZ7$U^T4BY*]M?6UI::\
MFY2"75W/#991"K/#N,K(CF9)BT$MNL331B#Z*03M!%9J\9&:W%I/=76HFO&4
MUMTOXXS*0LNZQJSJ(GB"S1S&010>U9L\%K,-$X* R+S*K,.$[/RH2Z=<E).V
ML23.2>3\.V0;2JNTHR2E(F*SGIV9\XE7YMJNBG"9A1#R&D8$T//0%CV8;#3:
M,F63$K263<HDW,S(D#[GB.(2$M'TH<I(^'W%E&98V&<MI(LBR[I%+%KS7>BC
M@1QV%U&@DD?6W-VE&Z6-F@ ?IF-9$O8;IQ'(I 2X0QM'J2)+$)+-O@V74U=&
M;#9BN\=5PHLBAE_*HV:ZC:3WR5LJBRSJUM'N=$I"IQD#4FT<UIRT242)S+B?
M"W1=D0D8B0K.=+#3!8[9GQFV>??*&ZC,5ON(MDA  @9<.20O+.7:X#Y9QB+<
M'B*2++A:\T9+SJN%SK%O=A;ONMP93<-*23*&OG0*D0582@R#F3=DDUD:*0UC
M;,V8J_DAEUL[!L\3,IE;)YI24WG<I=Y6'N>9S/+M2Z90VQNRRYS"K+?*5@^M
M[\:1;(A>8>4VG2$%3[._IT!8&RT]+VM/'-H]C,N)7F+=-8TO4L4BPT6R26]F
MUT+>_@9KNUF-\Z6Z;Y@D6-;B=9+B!+B6(B)(#EBQO"H["VP[I;(]J]T[WV[N
MDUTMON]G,%MKF(6:M,VX3(7,$#1PRM#'(#(THZHS.S@XZY&2CN%R(S*"X&2F
M8P'"#F<:5JQQ=@V:EZ5/,%XM_G7,R-9@G6?AUK=$LT9>?F6U*F'K%_+JGC8^
M!6/ANETSHLF)VF]\XWR81M-"\6,"XB;73#XTFE7#,H';4BC:XC5EC&NTJDOM
M&HE=H["ZW8ZZ$@NL4J288895*&^=HD?$,YD4/(ZP.RL_6JE5=_V@.#HLCV>(
MELX7J3BF03KK+YO$/IO+9E#=<>;UX?NZ^:"0S?O+*/C([*Z^M;'%NFKIRDGF
MWEE6(P(='+:S6B&/6TPK2Z%8B<7MD=MR6[,BQ7C2&&PMD6;=386S.[7EJ875
ME!-C>3-NANX891-SB.C4K2Y8;.Z+NAM@C26JINM[.S1",7MPJ(MK<"52"0+R
MUB0(+:65#;<M]K/9=V?=H/.K-3)3)217I$_D@:FY4T*]-7,Q',\PQS)RVL@R
MEG5>7Z4L$5 O:I59UC*GA[1*OU)"37AD$35Z4=+(Y+S L:Q7"<.L<2Q%-\Q8
MEOB^NK8JCM:;TO(=2$+:QQ/*L\\;1B2%$"(')W5 #2VQ?"<.Q&^N[&R9H)+'
M<;."=2ZBYWW:RZ\A:X>5(V@AD5RDK/K.4 W-R151F>G!Y'I[64FLBI\F<UCI
MU\&]2D=3) M"C,P9ZWY*72LR%"KS7:(B35UE6$JWG32X=W%$B6Z<;=JU)/ZX
M[B8YW3$*OAFE@N#'%B<1PZ&>UWLKW";Z>UBM\2MYDN93A3B5IC-AUQ(LFNVO
M;3(DRR,MP96_T<,(>2P<7LL%QN[I PMTN9)K&>)H(QB*[FL6YWT"% @"3Q,T
M91#!5SFL\># DK0:S'V:,T)E20DYN3FVUDG[.<)-[.9UUJ;>O776]G9 '*+;
M*!.W1U=08NVJ;.RRK1A/DL!625L-2/#-,T@$(QBRC")&D9ACA&HL6'31(JB7
M#I1D;\P/,6#%H49HMRUC!5Y+_15I3+TLNI"SN[K+)+US/?12,S;G?1\%GNRQ
M!2 LC*L@DU1,:JI9O\'V]G:,>MY7/LN;M$N-F)M"76PPSTE0A%:-:XMOM!26
M:;%YFW;H2^P68E(1G95P1EE^G)/5E6E.1JLHO*.Y(L7%AI4L5SNUXMW;R+C)
MDMHI%,\@N89&PI;)EL8);:6TN3%&NM=:B*&N#.@C5#,-YH\TD!BM6MIT.%A)
MI$80IO>5!B+72M>31SI<P"1SE;AF)6$0N79AY>7-S6WMPM;RF,7473W=EG7-
M4C'R@JOHZMKRCI6"8O%146%5TTBSM6[A05E1.LF<PJ'UWA[I;"9;>!;AE>X6
M&(3NHR5Y@BB5E&0R5GUB!D-A&P5U6<Q--,T*E(3+(8E8YLL1<F-6/&53($\H
MJ-8S5BIA2F%*84IA2F%*84IA2F%*84IA2F%*SOLU[.F<6U3G#4LF,C*T\LE]
ML;PBC<Z)U6D96XQJJD:1MEDF"$.G UV!3.1S(2JH"8AA0:,4GDH[8,77&8QB
M^'X)A\^(8E,L-M"I!!R9YG8'4@ACSSEEE(U50<.UF*HK,-_#,-O<6O8;*PB:
M6XE8$$9A8E!&M-*X!W.*/,%G/!L50SLJG],?9LRXON466E"RSS0S2E\ZK_2\
MNJO!VG,^=:H-).V2;561WW:R:)0662:)&2C&CZ36>STDS9(2-ADI.<=2#]S\
M:XO=VM_B5Y>65E'AUK<7$DD-E$Q9($;5ZT9G(%CF[(@6)&8I"B1*B#ZAPRVN
M+.RM[:ZNWOKB"&..6ZD4*\S@'KB!M.0R0,Q:1@H:1GD+,?RN<?:M?%],*4PI
M3"E,*4PI6W/!_P#Z/#8J_A9[.G]K]/QP6E'[VM(?ZDQ7_ SUS>C/[X]'_P"N
M\*_Q]O7Z1%^S$R,HY+%8+_6:+!143)JI3MLM;>GQ$41VZE21J;F1FIHK=LDK
M)RKI!L@H\<E5=OGB"!1.Y7(0WRO#AM\UO%,,1W*)HHW4-+,JHK*NJOM@HRS"
M@#9P 5]22XI9K<2P"P:65)9$.K%$S.T;,'8#(L?:EB3MRVGCJUUO,G("Y13>
M>J%0H%J@W0$,UF:VTI<Y%.2J(I.4S-Y&+(Z9K =NX07(*:Q@,BLDJ74BA#&S
M+A6(.,UQ,L.59IR.7A#$<!!K$V,62'5?#F1APJT42GA(X" >$$>Z#5U9VO)R
M19M9"/RWJK]@_;(/&+YG!U9TS>,W215VSIJY0;'1<-G")R+(+HG.DLD<JB9S
M$, C(PC$B,QB3$':")9\B.7AJIQJP!(.'D$'(@QP@@CA!&6PBJD;!E. "(Y6
MUX #G$1KM:T /"/T)ATGQ+NBW.W'EITZP_M#_H@\E1:G9L;.68D&A9\OZ[EK
M>JTZ441:V&G%HEG@W*J.[QR2$M"<N8+*);Y.,(FX,9/>+O &\&M4PK$)%UDQ
M374\#)/,RGWPQ%7?%[.-M63#7C8;2KQ1(V1X#DP!V^Y4@;6O)QYRCDF6]5=<
MD<JLW7)H.K+\F=H@45FKCBFQN)<I <@JH*;JJ8'*)BAO!K;I1B1X,28\7V6?
MAY.&J'&K <.'D9C,9QP[1R\'!53U?RG]BVO>3E;^*8=)\2[HMSMQY:=.L/[0
M_P"B#R4ZOY3^Q;7O)RM_%,.D^)=T6YVX\M.G6']H?]$'DIU?RG]BVO>3E;^*
M8=)\2[HMSMQY:=.L/[0_Z(/)5;4H#+BTVUZ];9?55LBC @@**];@3"*G+D#<
M84$V8DZ-0UYC?]V-*_MK^PB1WOI) \FJ-2:8$'5)VYD;-E;MA=V5_*Z1V:1E
M(]8EXXB"-8#B!V[?T5E;L=9?>(E-\F(3XCCBM]W?;-QSTGG5RN][?L$/-)YM
M.QUE]XB4WR8A/B.&^[OMFXYZ3SJ;WM^P0\TGFT['67WB)3?)B$^(X;[N^V;C
MGI/.IO>W[!#S2>;3L=9?>(E-\F(3XCAON[[9N.>D\ZF][?L$/-)YM.QUE]XB
M4WR8A/B.&^[OMFXYZ3SJ;WM^P0\TGFT['67WB)3?)B$^(X;[N^V;CGI/.IO>
MW[!#S2>;3L=9?>(E-\F(3XCAON[[9N.>D\ZF][?L$/-)YM.QUE]XB4WR8A/B
M.&^[OMFXYZ3SJ;WM^P0\TGFT['67WB)3?)B$^(X;[N^V;CGI/.IO>W[!#S2>
M;3L=9?>(E-\F(3XCAON[[9N.>D\ZF][?L$/-)YM1JU9>4 K!H):-3BB,Q$@(
MEK,* B O$]0'1D&H#WPZ!Q(N[O/[9N.!OOTG(?XU0UM;Y?8(>$?>DY1_%JWP
M>7E -;K>4:-3Q*5E6!*4:S"B!1,28WA* LM WM UTZ= UZ,2;NZU5^N;CC^_
M2<O\ZJK;V^;>P0\/8D[_ /%J:]CK+[Q$IODQ"?$<5WW=]LW'/2>=5][V_8(>
M:3S:=CK+[Q$IODQ"?$<-]W?;-QSTGG4WO;]@AYI/-IV.LOO$2F^3$)\1PWW=
M]LW'/2>=3>]OV"'FD\VG8ZR^\1*;Y,0GQ'#?=WVS<<])YU-[V_8(>:3S:=CK
M+[Q$IODQ"?$<-]W?;-QSTGG4WO;]@AYI/-IV.LOO$2F^3$)\1PWW=]LW'/2>
M=3>]OV"'FD\VG8ZR^\1*;Y,0GQ'#?=WVS<<])YU-[V_8(>:3S:=CK+[Q$IOD
MQ"?$<-]W?;-QSTGG4WO;]@AYI/-IV.LOO$2F^3$)\1PWW=]LW'/2>=3>]OV"
M'FD\VG8ZR^\1*;Y,0GQ'#?=WVS<<])YU-[V_8(>:3S:CE@R[R_*K7MVC4X-9
M]$!TK,*&H=3)0=!T8\X:@ Z#S:@ ][$B[NMOUS<<'9I.4?QJ@VUOFOL$/#V)
M.0_Q:H*EEY0#.[CO4:GFW;6L4N]684=TH0L*(%+JR'0-1$= YM1' W=WDOUS
M<<'9I.4_QJA;>WR/L$/%]Z3^"/XM3+L=9?>(E-\F(3XCB-]W?;-QSTGG5;>]
MOV"'FD\VG8ZR^\1*;Y,0GQ'#?=WVS<<])YU-[V_8(>:3S:=CK+[Q$IODQ"?$
M<-]W?;-QSTGG4WO;]@AYI/-IV.LOO$2F^3$)\1PWW=]LW'/2>=3>]OV"'FD\
MVG8ZR^\1*;Y,0GQ'#?=WVS<<])YU-[V_8(>:3S:=CK+[Q$IODQ"?$<-]W?;-
MQSTGG4WO;]@AYI/-IV.LOO$2F^3$)\1PWW=]LW'/2>=3>]OV"'FD\VG8ZR^\
M1*;Y,0GQ'#?=WVS<<])YU-[V_8(>:3S:=CK+[Q$IODQ"?$<-]W?;-QSTGG4W
MO;]@AYI/-IV.LOO$2F^3$)\1PWW=]LW'/2>=3>]OV"'FD\VHS+Y>4 LY7@"C
M4\ ,G+[P!684 '0C+34 9:#IJ.FO1J/AQ87=WJM]<W'W/WZ3E_G54V]OK+[!
M#]U]Z3D_FU0T7+R@'BI 3T:GG$+#.@ FK,*80 'Z@ &HLA'0 Y@#H#O8@W=W
MG]LW' OWZ3D'\:H2WM\C[!#P]B3D'\6IIV.LOO$2F^3$)\1Q&^[OMFXYZ3SJ
MOO>W[!#S2>;3L=9?>(E-\F(3XCAON[[9N.>D\ZF][?L$/-)YM.QUE]XB4WR8
MA/B.&^[OMFXYZ3SJ;WM^P0\TGFT['67WB)3?)B$^(X;[N^V;CGI/.IO>W[!#
MS2>;3L=9?>(E-\F(3XCAON[[9N.>D\ZF][?L$/-)YM.QUE]XB4WR8A/B.&^[
MOMFXYZ3SJ;WM^P0\TGFT['67WB)3?)B$^(X;[N^V;CGI/.IO>W[!#S2>;3L=
M9?>(E-\F(3XCAON[[9N.>D\ZF][?L$/-)YM.QUE]XB4WR8A/B.&^[OMFXYZ3
MSJ;WM^P0\TGFT['67WB)3?)B$^(X;[N^V;CGI/.IO>W[!#S2>;48>Y>4 +$F
M4*-3P+U#<&W0K,* ;P.!T'3D6FH>'IPWW=]LW'/2>=53;6_7>P0^U[$G\;^+
M4390F6U7I<*_>9>55X#EZ_:@5&MP(' W+I%4#&,JS !*!4MW0!UYP[P8W[)+
MZ_FDB2]F0HID)>:8@C6"Y;&)SZZM&\FM+"&.5[6-P[[F D<0(.3-F<P!EDIJ
MW]7\I_8MKWDY6_BF.3Z3XEW1;G;CRUQO3K#^T/\ H@\E.K^4_L6U[R<K?Q3#
MI/B7=%N=N/+3IUA_:'_1!Y*=7\I_8MKWDY6_BF'2?$NZ+<[<>6G3K#^T/^B#
MR4ZOY3^Q;7O)RM_%,.D^)=T6YVX\M.G6']H?]$'DIU?RG]BVO>3E;^*8=)\2
M[HMSMQY:=.L/[0_Z(/)3J_E/[%M>\G*W\4PZ3XEW1;G;CRTZ=8?VA_T0>2G5
M_*?V+:]Y.5OXIATGQ+NBW.W'EITZP_M#_H@\E.K^4_L6U[R<K?Q3#I/B7=%N
M=N/+3IUA_:'_ $0>2G5_*?V+:]Y.5OXIATGQ+NBW.W'EITZP_M#_ *(/)5Y@
M[O0XAX!H*C,H1R\XMHJXBXR&CU5$E%2"":JC-%%11(% *?BS&$N\4#:;P (8
MIL%OF0F6]$JH&<*[3.,P"3D&S )&S.LD6.68=1'9M&SD)K*L2G)B!M*Y$C/(
MY=ZLGD^RN5^Y$3_/O\=;XA[I^1:[$/;-^;\E?DF8^YZ^(:84IA2F%*84IA2M
MN>#_ /T>&Q5_"SV=/[7Z?C@M*/WM:0_U)BO^!GKF]&?WQZ/_ -=X5_C[>O[Z
M-K6*ITQ2[FVOL_.5NL-,RJ#..G]73L2MH>2%:SFJ-BK];K"=051MQK)<+%%Q
M52@!JAPLY9>;9FKY5)<&:9OG.W"'#;0.S*NX6AS76UB5W)E5=3)M9V 4:O79
MD9;<J^AI2ZXG=F-59C/>J Y4( V[*S-K]9JHI+MK];DIUMF=>=D?D?DP^>62
M8K^>S/**G4ES#U^:R>S/K#JIHTN=ALPJ)GI$(W)K8;M4Y:8C'T-48-HU<N7*
MK::J<M8IB'LAUY=\\2@0Q$L5F$2IDK12*5"$.DPUPSJ2"$ S)R9"Q#',FLQN
M)@$5H#,[ LDT3Z^N#') 2A6-@""[9@9%7"@J-4 R1QDGE]#BC68W;2"*L[FO
MHPDY)/["B_&0;JY;N,EV!Y(R5[CVT79#'S")8*0B[D2.G%O7;R;"+GBQ\@4+
MF)%R479#:H5B6SS]CW$$]> &S<,F9SU\B V1JN[R-FQLLU#:R@*01[*)SE[&
M25(CU7(&6IF"5S6I_4LN\M,HV2V9\7M$7"UQ\5(QU!F241Z6\R%GN$LUR(KT
M;3U8>/4O!W,U*6.D2TTXAV,6WEFB^<]RDNJ,(V5?3+JRI''G()V8 A#J'7+.
M=Q75R&OF2R$E0,P9G.SVU8GDEF.Y-;HA(+@R#4"(IG)?,A,E"NJYDE3N*#(G
M(#"M4V9\IZ=5*M7&FT[(T>,J]7E(:4IV;,U9ZK>&4E=,N*QETG+V!8,V:+?V
M+UYV-I%S4C3DO,)-:+(2-)R\DX^C1%16@L2V\:(J"X*A5*E9"RN"\:IFQ$L;
M@^QDKF2 A9(R$"%<[W4KNS&U$A9PP>(*\9"2O)JK[%)&0#* ^J!G( \@+E]:
M6&V?:,1TS1E=L&FRTI7H2)K,FUFU(04%[=D=<:/F;9'C^ 89EQ;&O(5B+KS]
M.SU6L-*TXAX^UI2EQE)2.K50CXF^XJ,L[I254*=8CVT+)(Q($@"ZH4ZRIJY!
MLW)"H%H;AR#E9NH9BP*@CK9T>)0&,1+%F9=1F+9E-5 "[DR>!V(BSE,KC@=H
M20O("WK\K#6%*)<.:39(!GF+;<W(B)7@8:^%CY&A2TG9:VR=1,#-1;9]4Z76
MXV+?QZ3=@XCY%IK(OLY?VI#9'58"1YE!"OD4)91DI&:(H!&PBK7Q5V&]PFU@
M5)&NCF-(2P9HR1(H5B"RDAW8D',@^CI=X"E XE,<"AO&*42%$VG;"4HF.)2B
M.H@43F$ YA,80U'>KC:YPI68,F_KU*_<L/Z6ACKVD7VM!^7_ /&]=AT=^V9_
MR'_D2N^[WFSP]HDXV.D2H,VW(N)2%HR5$O'1[1=3YXLW44-O*JG-VQATUT#0
M   IAF&65S90S30EI&,FLVZ2KGJRNHV*X49* -@'!F=N9J^)XI>VU[/##*JQ
MIN>J#'&Q&M#&YVLI)S9B=I[W!44#,VYZ?74G2/\ @$?WA$/M7'('!,-[7/ /
MOT_&!^,K0Z=XEVP.9A^;IV3+GZ[%]P1WQ7$=)<-[7//3?.5/3O$NSKS,7F5T
MCF?=0 ?S6)T#^E\=\5Q(P3#20-[G:1]^F^<IT[Q+LR\S%YE=!LT[N :A+DZ?
M6^.]O]BXR=(<,[ W/3>?4=.L2[8',P_-U3]EB\^NR0?ZNCO_ +MAQ9<!PLD
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MLP#IR-X/SS<U B.FGJGT_P"EAX>Z_6X5&?#L.S]/N4Y6;4H<C><YQ)KN(Z
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M.[,W,R^93I'B/8DYV/SJG&6L')U^R23*50*W<*0H+D(59%<!3Y:@7>WT3J%
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MM;RTM5EF9R20:P4=$L%5GC] Q2@?M+SQQMJN2O6@YY$YYB0Y9*"1JK$[,3D
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MB&6DI^$J]X/NOB_KXT4[L0<S=?,51]"])R-F$R\/9[3O_P HKX'91VA! ?\
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M\@W]['77](/M.#^D?^.6M;;'EQE_;W@R%JI57L;XT:ZAS/)N#CI-R,2]B;'
MO(T5G;=506+J%M]JB5VV]Q*L=8YMF<AD))V17MK1HQS9%8Y99LH.S)ERVC@U
M7<9<&3,.,UU19)$&2.ZC,')6(&8*L#D#PAD0@\14'A K#6:>3F1U?I%WN"NS
MK3LP'L=5GIUZS#T.*DINR,V<3'1G4=NT:1$A(O2K1$+$QCEI&1LM*O86):13
M"'FE&L=#+8I(H@C,8$<A3UHC4E@ !ED%).P $ $D  *V0%9HIIW>./?+Q@N
M&:1@JDL3K$ZP VL3F2 "22RC-ABMKF]L5YIQ5*H\Y$Y?6UW"I5IG"4^)R^F\
MQ*_6WUQI9[6O'U::BJ2XAGU=;55JZ6MLS% A 14*W EW"%37*RQC$MK)JH1&
MY&J%41F15UTULD(3(KJ^V89*J^WU1LK,8;V%G=6D0,6+.9%C9@CZH+ N&#:^
M6H#UQ8^QYG;74.;.P:=.2*O#5!NE(QTG*3G5')"Y1Z(QK++WJ^JZGS/Z W39
M(RN6W%.:]U6%N-L@G+)I62RY7S-NO&ZV>W8@S!8YPL-FIK$L2@RSCVKGD67(
M+GL%-QOSEDSG5( RG0G,R:N0RD).K)F&RS"$$MED341>YC[)=30K5^5V?&<<
MNLEM VVMOF>4;U6R1<ILPYI-ZTH*T$PJJUDJCR2L,RXL< I,1D0A4G)G",J,
M5+.2I*5,ELH#F#+[,P(B)8&WEU?:A=9<V)89A0IX<B:MN=V^LF^"0#;HP,PU
M2+J(M[8N%<!5"MD27V$9@9U76?//9>O%JI-40RCC,Q;-F%=9FH2Q9&@/6YZK
M<T9K9_D;0G8G<E55'QFPQECH%O1M\:@[JTNYH]=W+"D9",DXZ6GMW9%$0D+N
MR'.,]:^<!;6)3/+)HWUQFI*+UVP$%M[J-9&,K1B-%<92 Z\>K<!=7)\MA61-
M0Y, [=;PAHW8[5L\5/,B8RZD=D2D.9AAF*[(_?QD3EX_B5XZWSN2M&7LBRRS
M%N0UIDWN;F3SFQ9?NB%<-*8[BY<\D^<Q\/!NJL\"2&,VR9A]I"QD9.88RV9
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M>'WE^05"<'OG]5345T UU62#0 $=5"<P#T"//S />$>GO8BKTX]$-=5D@T$
M'YX3F$>@!Y^81[P#T]["E..1]62Z=WZ83NAZ"]/3[73A3,<O>]_DIQZ'JR7.
M(E#YX3G,'27IZ0[X=(84H"Z Z:+)#KKIHH0==WNM.?GT[^G1W\*4X]#U9+G
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M@WTMF%F1.+-(_+BU(W.B-E1F;<_*^+5YUNW-&'D"NE0C$$8%R=Q!I)QQ9%K
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MMT>QM>):9HF6$E:5+4US"2MD959RF,6U7KY*UQ.JN!:2K-;/#=6MO;QWV+W
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M;P8H2&6:UN EO)=3V.N4*RF%)0K(P76T[*ZP);:**^M)YV2ZN&)!=2MO/-8
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M_IH/K@U9$S,<7.LM\NY6"MU0G2OI&&3:5:PSZTXP?QE:?3,/&,I)NL"*]KK
ML5;&,2QBVOY8I##%'AEJEQJV[,;,6\S7<<L$\6JDA,\40C=))DC=VC(UA6WQ
M?#UPRPPRXLXY$$DC7]PT.M,%WT9XA;M'-#)FR!8I)-T5EB+HJN" <D=FG@NV
M3B6AH_)3,=&@23V9CG+-C'3+6^2E;>[3N5F9D0SD[3(9T2S12.@LEH2SY>MF
M[5DPLSJ2CTG*MK;KSYIUAJ=+M-&$<CXC9FZ18W5F=&M8YEP:]LY&2!</C.O+
MB,D-TQ9FA5'($!$6YMM;]T44NBV-SO=F="JK(MP\38I:72AY6O775CLHY;<
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M&U<E!)(!8YN40+$A8I$JQJBCZAPRVN+2RM[:[NFO;F&&..:Z<!6F< YL0-I
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M%-O['_U0#R&I=6S, WC;^CU<1 O/N"76/+O&'FWBCN@7GT,;OJ4 \AH75LR
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MRSX,LQD0"+# ]*A,\YM;9G>2.4AI;4J'B,IC*^R@KJF:3@8:P.JVLI(,W:;
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MXA-;7,$9<YZJM++$L:%CUJZS@%B%!S(%9[QP5=QIA2F%*84IA2HW8OIM=_?
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M1I/X8E?!]P,7&F&%#[U>\)^]1<9)[8K&_0MTC(V7&$\/;-SW_P"15<H38JS
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M9_PZH^E4JY96<?%PS-QG+L=42N>CU(!'K=:FTY_K@J'@_8H^'%ND299[Y;A
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ME[HP:'YRE[XAS!WQPI7/5!AIKRYGIN<9KRE'3B_5.[[C]=W/MX5&8Y109!@
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M6RABDDCR.NN)0Y+&1P9"QFZXONFZ^R52CP?V2@LH9@68O94*^QA6,44Z](<
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M</O>YDMS!*5VJ)5BMHF9 <B4#@-EJMFI93M>1)-,A$TTR)IIE*1-,A"D(0A
M I2$*4 *4I2@ %*         8ZN2222223F2=I)/"2>,FO1@ H"J %
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M<RW\X^'4LTV[HV'QG>^B4]?&A/<F3XJL/GJH8W\D5<'7$6=Q+1E&V@8U@O#
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MXW<>A4ZINCO8L3\6@]*JRR'Y)%X/YU)Q+Q.L;27%,2/RK ;+JE@<1<E; GN
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MN";4G.)- W1'7=T#33&"L^0Y/V_8FG(66NO(VNHG!01Y.CJ*A0T ^NYW8
M!NZ .@<*4Y"QUUY&UU XJ /)T=04'F$_<=V(=)NZ'OCA2@,6(;NC-J&X)A+H
MW1#=$^N^)="<PGU'>$--[4==<*9#D_;]@*C$LR9EFZZ0K1L4G%3!=PJ"0%W>
M+9AIN@0 TT,8----#&#OCK8>U;WOEJI]LOYWR5149HU5BGXJ-FZ@A.SJ "=%
M,X@B$@KHB&\4=$@U'1/N U'0.?$'A]Y?D%0G![_DJ9BP8CO:LF@[P%*;5LB.
M\4O<E-J3G OI0'F#O:8BKUR+%D.]JS:CO"4QM6Z([QB=R8VI.<2Z!NB/.&G-
MIA49#D%.0LNGD;77?!37DZ7TP.8#]QW8!S ;NO;PID.0<.?O\ONTY"Q 0$&;
M4! PG >3HZ@<W,8X=IS&$.DP<X]\<*F@,&(;NC-H&[O;NC=$-W?[O=T)S;_I
MM--[OZX4K@&#$   9-  ""F  V1  (;NB!VG,0>^4.8>^&%*<@8B&@LF@@)
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M-!:J?;SP.W V@"UZ ])]2]P/?]/X#AA3W_D\'!_[[] :J!I]'/![83:"+7G
M?2#HU#M0[VFAN;G,.%1[Y_1Y* T4#=^CG@[N]KJ+7MM[HWM&H=QZ7=W?UV]A
M4TY(IH <O>\Q1+KJUU$1]..C7N@[VFA?"4<*>_\ )Y*CCA(R5B3WEUEM8%<-
M5A3U 2N#:F#BTDPU/KVW-IS!N@7GU54_=?S?+6.Y" E;#0J\VB6P.5D).175
M(*[=#=2Y9)I[V\X52*;MSE#=*(FY]=- $0YG![N"TN)WN'**\952%=\VUU.6
M2*Q&P':1EWZX?%[2>[M88[=-=EFUR-9$R75<9YNR@[2-@.=0(^6%V$1TB"<X
M>N,9X-/MS'8QC6&@@[X)R(X(9_UQ"NO=)<2[7'/0_.588S)&QP359E"5>/C&
M;B2FIE9LQ=Q#9%26L<P_L$](J)D=%*9Y+SLI(RT@N("HZ?O7+E43*K',-UQS
M"EV"8@$L3E#-EFS%F/V/A+$D\I)-4?!,5<AC &( 7,SPDZJC54;9.!5"J!Q
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MJ;M".&6,?[Q?+5,;-W*@G=YG9>E_^*YUPO\ MD@QB.DVCB^VQ_!1[N*60_\
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M03P</"/T$?+Q<ONU;X)T;KMMIN2.M3LJWJ3<3WD]PDP <8'&Z!QFOSO=$VH
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M;#M[W![O[?HKGE9N?Z">?2]_3<1Z?4_I_P!,#P=S^NPIG[O!GP?MM[U<"\.
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MMTCU=S?+?^6NFHFHWMEU%R(U1E.\K[@W*3+8<M=>$<!]OQ<7)7P&R'M;@EQ
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MNOYH_P"ZH6E#N)NAQ+)!FF^(=U)@Y;JB@*2C91Y)HJ$5(X,5)5-0%.+.F8#
M<IA Q1*(XT,3@EGC585UV6;6(UE7(!7&>;%1PD<!SK&RLT:A1F0V?"!R\N51
MMYELO(-CLG]7C'S,_'[[1XC$.6Q^5+E=.=]!8YTC<H<D(X7U(/&KE*LIO*%
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M,?=73#F;_P"C:VGR&/G)*P\K,YU1T3%VEP\*T:-HE-%)L,,V22.U44*W=/"
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M *=4Y+UQ?>ZW'PF&YQ]C3X*^2F0Y!X!3JG)>N+[W6X^$PW./L:?!7R4R'(/
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MDFHJZ\C?=.V;'C-;>(HB;TU$5-:TB9M50NLQSS8Y 9D\9.VOY0,Z/SXLV/\
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M3(CR,AFLHX=I(+0:X2&,XSBT=M)=386D45M;+<S"1IXI92975K6V26% ;G4
MW-7;5>1D521*-2N^;@(SM  J1AVUBZECF<XT#*,WRRU03D6R&W6R6(4MMLGP
M67&>3ZXH3%XGDKT>IY,*(+OHBVN:^^J&8HP]S=1;6[0</!L6EFCZ3)V%Y)U_
M,5)L@LK5F\$"\TG8(O8N6QZ6\PQ+<QVT1M-\8D"JR6XF6XM!);J[6LLDK-"]
MRD*)-9%B!.TN49B>[F[:6 +JHNYZ\W 4UP\>:9E&+'5+A0K1Y^WULEU3,H+9
MHV>;G<92GT_/]^_7+FZXRSKZZL16EG]@9(W*B5J(M$% -;+RZRQ%X8VBT2\
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MR <A#@15,Q0.4I@#4H""E5I2E(4I"%*0A2@4I2@!2E*4-"E*4-  H
M !H'-A2NI=NW=)@DY01<)%507!-=(BR8+M5TW358"*%,4%6SE%%P@H ;Z*Z2
M:R8E4(4P*5W84KI;MV[-N@T:((M6K5%)NV;-TB(-V[= A4D4$$4BE31113*5
M-)),I2)D*4A"@4  %*[L*5TIMFZ*CA9)!%)9V<BKI5-(A%'*B:*;=-1PH4H&
M6.F@DDB0Z@F,5%--,H@0A2@I7=A2NDS=N=9%R=!$[AN15-!<R1#+($7XOCR(
MJB43ID6XI+C2D,4%.*3WP-N%T4KNPI3"E,*4PI3"E,*4PI3"E=*#9NV!0K9!
M%N"RRKE4$$B) JX7.*BZZ@)E*!UECB)U53:G4.(F.81'7"E=V%*84KI;MV[1
M!%JT01:M6R2:#=LW2(B@@BD4")(HHIE*FDDF0H$33(4I"% "E    PI5+'1,
M7#I+H1,;'Q:+EXZD'*,<S;,DG#]ZH*SQ\NFV32(J\=K"*KIRH!EEU!$ZISF$
M1PI5PPI3"E,*51C'1XHBW%BS% 7@2(H"V1XD9 KXLF5\*>YN"\+)%+( Y$O'
M ^*5V!^/ %,*5684IA2NENW;LVZ#1H@BU:M44F[9LW2(@W;MT"%210012*5-
M%%%,I4TDDRE(F0I2$*!0  4JE;Q,4T?R$HTC(]K)RP-0E9%NS;(OY,&*1D&(
M2#M-,KAZ#-$QD6O*5%>3I&,FCN$$0%2KAA2F%*84IA2F%*84IA2F%*84IA2F
M%*84IA2F%*84IA2F%*84IA2F%*84IA2F%*84IA2F%*84K3W@M_\ \ZG\,;,_
M_<\=BTW_ /PW_P#IVQ_[JW,3_ OZ'%^NMVG.T#L]M+=8J1*72KQ%JK$N[A9R
M.GF#F$%"2:0]=L#D$'TO',V$FV+$6B/?]4HUT\CE$V=D CLRE0M9(;H^N_\
M";X1\M<;FW#F<O=/N5516>60<_6[!::[<J;8(VKTYO?9UM$"T=3<=5GM;7MT
M?).X 4TYEKU0K[9>09MG3)!RL1%9/BBK(K)IM=_X3?"/EJ,VY3X37R_SLR>C
M8RX3#D) 6-%1EE[%R?+^TNI!%. MLQ29Y1A"MZ\K-S"$-/PCE-Z[BHYXRZFN
M8N;;.7$/*L'R[7?^$WPCY:G-N4^'_P!_L=G#7:\SRV>HUTNPD\Q,N(N09RD?
M!R$?)RD0P?QDS++NF\7%RK-V*3B+?R2C!\=@V?IMU'C9B\>-BJM&JZZ;7?\
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MKH,5)JTU:/9R05P8^56;:PCTMNCI^5K!FLVFT/$KDGF=9EQBC)/# ]<ILV*
MG>RL6W>-=_X3?"/EIFW!F<^3,U8FVT3LW.I61B$LP\O^.C'LU'+O#O8LD0J^
MK<&C9+$V93!AZFOE("$5/)37)7*I8QLSD%7AD2L'0I-=_P"$WPCY:G-N5OT\
M?!X:KF.>^SV^,BEU^T%BZ<NYUHV8RSV+BI!P:MSC^ F%TF3\4')F;)Y'+N5W
M7%@BA$':S3@R,6[;NU&N_P#";X1\M1FW*>3A/#R5>:=FKDSF'/NJU1;)4[=*
ML(@)J0)7Q92C>.:"Y0:<1(.FA%$&,D55RCQD4Z.E(HD."BS9,H@(M=_X3?"/
MEIFW*?":RCU*B_6UA[C;_!X:[_PF^$?+3,\I\)IU*B_6UA[C;_!X:[_PF^$?
M+3,\I\)IU*B_6UA[C;_!X:[_ ,)OA'RTS/*?":=2HOUM8>XV_P 'AKO_  F^
M$?+3,\I\)IU*B_6UA[C;_!X:[_PF^$?+3,\I\)KL3CV"0B9)DT2,(:"*;9$@
MB&NN@B4@"(:@ Z=&H8:S'A9C[Y\M,R>$D^_7;R=OZ@C]Z)^+B,SRGPFHIR=O
MZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C
M]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)
M^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+A
MF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4
M^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$T
MIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=
MOZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@
MC]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z
M)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+
MAF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>
M4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$
MTIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR
M=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ
M@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]
MZ)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^
M+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF
M>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^
M$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TIR=OZ@C]Z)^+AF>4^$TJ
MF8Q49&<IZFQS"/Y8X.\><A9MVG*W:GTQTYY.FGQ[A30-]=7?5/IVQAQ9I'?5
MUW=]50JZS%M51P*N9.2CB V"I))RS).0R&9)R'(,^ 5CB:R,R?L4^K:IO+BI
MR-E75*JYGEXE )9V4J;E!1L\?I@1R\CW31](,'\8Y45CI&,DY6,?M7,?*2#9
MS2HJA-DCE9!U2Y04-3V45#6BKO8"=C8]W*-&CZ)&KGJ_)>*0?$*V$( B<:5P
MSY.Z*BDD<JX+))JE4S/+5QC\J,OF4O<12K;=8MOCS!84'[R2E&C\L[.6"9FD
MR,Y)Z[:,4I>4=JO9)*.1:)O5BMA<D4*R9E04S_5^C@K#F9.S5D4J2G)]C6OH
M$?9VT^Y2 ,^7,!DK"Q:6U@T=29F3QN:2:-XVT3\4G#OA<0P1$HYB1CQC1(U(
MIF>6LSM,F,L6,>WBVM3:)-&LI&3C;1Y*&=(S41%+0#.83?G?&?EE3UUPO6I"
M0!SRN8K"IZW+K/H,PL,*5:VNSYDHQBUH5IEK5VT<NT38F018B11-LW4DU69&
MSH%.5LS1JLQ(JQ"S1=!>(5<<;&*-#HH&24SX_EVU0V?(C)]S S/'Y?5U42UF
M?C#',U/QBK&1DU;6^;N%05!1T5S9B$L"IG)E5!F2%D@.#LI504J1!DQE69U
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g383050g11i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g11i11.jpg
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M 0$! 0$! 0'_P  1" $) ET# 1$  A$! Q$!_\0 'P !  $$ P$! 0
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MF62$SQ"6.(#DR/'W=Z1@$$NRA0#R3QEDYGOSI+8Y.MW6<[7P%CD;<<LJMO\
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MYAA@R9OA7^[1KMH?I:9:0OKMM+)7>5Z\31V+;--92,2&M$OL(+3,I7M3R!+
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M'LB*CS%5Q_LS;\:OZL"UB]4J-C^_NB>U]Q1CV.TV>:W%3TUUQV7@I?<TFJJ
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M6>>Q9I31RR5HI#70)'59)I(%B:P74M$@0<6^N^#S95$IPM>IPU*74NMW-:K
M9YVJU:5+:5IX(;T\"6Y&EFV"2UH;33I36-U6Q(96)L(GV3W9QO5UIUQ_XA=5
M4<]%X<NP/#_FM3FJ'0U]MVQ)NNR*/=)O.[U="]\9]-%1^4-+7$:UQ6CM;&^2
M_$B<E;)<#K.HMU+?LMR42;6KLY89I(F2D*U26L:VO\_-9#+YR.( (HTB\(GX
MXLF^##9/K9-?[?K(##T_?T5>S7AG27:&[?AN"]N.5Y$D(A\HHVM%[$LDWC(#
MX9V0^';PT,Z#[/\ $KIZ7\%*G"=RZ?K"^QF)R-5]" Y"+%=4YW!7D<]8,()4
M0$7=O2S6R/JXU2>&:-YKE+]:)JNSVQV5/4PR&:2S0AN16+$[^(TYL79K,9#E
MF<B..01GO/D0>WXO&= Z?Z=&BV/4-B'V6.EMK.NGJ5*L?@I5%365Z,X:-56)
M6FFA:4&('D,"_P ;G,MN87-IS!KQV_D#C/ZWR?Y+8<\]?A%?X<T/^=M_06<]
M _@\_P"(][_DB_U];-7G/(F>M\<8ST'YS\GJ']35?W&#GTQU7R7K?V"G_3QY
M\U-E\HW_ -MM??R96>7^66.,8XQCC&:WD]H5'3WGB)?L.B>Q*SK_ *-[ZRG0
M0VZJ[CKBS'OM7JKCJK-5XQ-*[=CZ((DFP[+;IH98:4BE@Q-<Q3;F':3R9&#:
M?]F2Z:L0;&J]K8ZV;9M6=+:&*&%+LK$2"LT+ +3,)!E64V&/;&:X\<\]_P!O
M!#-OS;TE^*CIMW5T:W(Y=?()[5J765XU:'VT3HS/L?:01"85IQCOE%MC56Z+
M+Q_XU-LSK;)]1=M;[=F=\]R^'BGSV?\ _#JN?;;3I/KND[+TUG%9:W?YRH#S
M!=!=Q_1YU@<-8>_!/;/51>D1#*2]-6/9_:Y[M*M6774-G)++[6_97V%J2I"I
M2"K-(TRRQGO55*<,I$A^-VW4G7-3VP:^KJMI>NOO-OH8H(/8(S+<T]"'8V)!
M)9NP1+6>"8=CNZR<H_=$.%[[/S7M0NE;?/YW;:+K_M[K_K[8],=H=TX[9ZJH
MQTP6EJ>E'5T/:6="ILUM;_2A:#-FV<%<&ES3UE5HRH29**R, ?7'6->;I'81
MRRUXK-&U:@OT]?/!!).&BDV'<:4IDFKQ0O%,J%CX<CO$"HE16[E2TK_"3IY(
M*]RQ1VM&C;U&RV]6W9BJLMB+3F-=E D->W/82>N\@C3Q8HX[#JQ@=T,;R<MM
M[3'K3+!DQ;7J'NS+:^"VZ(@'Z^?5X?1:NVSWB*--K^N]131Y/<WE780?'5QE
M=>T$5DFGKK2)H(U18*0-+-!.D[<S U[VOG@,>R8VA)8B@275*KVH9#/6C=#V
MNKQ2%/!="6,B\$":7X1-?61A<U6XK6UETBB@8Z5BS)7W\C1T+,7LMR>)QWH\
M<T D]ICD7L6*3N4M=GB;\2G:77?1'2G:60Z[U.2U^[\071&"O>J]8+BB-PM%
MN>Q!LWH<A'*NIGQ 6BO %<-1V\FM@J@I3@C#+6OC:1(-0U.JIVMC?ISVH9H*
M^LV-F.Y ; K^)6J--%.1X LM%&P!DC$!D8*RJC'@&YZCZBV=#2:C9U*%FI;N
M[W2TIM9:6FUSP+M]:\]7GVDTTL31GMAE-I8T+HSRQ@,5C.W]HKAH-7@+FYGW
M76.:ST/C'J>\>N+_  N5T5S3ZKPO9G%W^CKC];0;LZ$&>H$OXK',NQ(NVK=Y
M#>CC&&Y^02-9+M.E[)AM1QBO<EE_$4FNM16)HHY(=O+/%$R02UE+B1D[)O:&
MK/6,3%5E#'C'2]?4ULT9IFNZVM .K(MUKYZ5:Q-#9Z<KU)YT>U!<<(T2SK)7
M]D2W'=695=X"@YN,_P!I5U_2 DPZ/ICNFCW#W]#ET'6Q#.L2=/JLYXCKV7-]
M::&GL0^R9\<-%+=PR5>AKKW3T]C0G(C)X915^,Y27I2S(X\*_0DKC\9++;!N
M"&&751B:W%(C5!.2(V#Q-%#(LB^A#?%RX?X0Z,,;"QJ-O#=_^"/#KF_%S6;-
M?J"<UM=/%(E]JB@S QSQSV(9('_.4KPV?$OM-.JPSL3G[?K7L[.Z_2]O[WHW
M19_3E]8YP+ =C]<SY5MYFKS<778@/7MK;6P6SH[?%U^8U5R3KJUY?T:WX\=@
M$X=)W66Q+':J2P0T*VQBEB6Y*UFI;$WARQUXZK6DC1H)([#S01B!PO?\0]X'
MX1=8CTX)M=L:]NQM;NFGKV7UT"4=A0:L)J\UV6\E&265+<,M2.O9E>U&6\,=
MZ]AE3I/QO===[=JG=+Y7(;ZM[ RM;V&=VC4WH5!!'U.5@NP)NNQJ;9% WY\2
MVVYL1R;S$CTBVS+/+02794H,*>CEG?Z?MZZFM^>:LU:=JJTWC:5C=%FJ+320
M!HD/AUD*QV&D\/LG81*&/GF2T_65#=[-]16J7H[U:.^^RCF6 #5M1O-06&VR
M3N/%NR*TU-8?%$E8&9BB\<YH<P6;?CC&.,8XQE?R_P!O5_Z<WW:;F0U7RA6_
M6?[M\QNW^3;7ZJ?>QY-/-XS0<<8QQC'&,<8QQC+0.O31BR((VP*R*16M5S'J
M[R3R^M4D1%7^9$Y45 0#Y_Z/U93+D$CR\B??_?.K^$=A_ &_9O\ ^[R/8/>?
MY?VR'>?</Y_WQ^$=A_ &_9O_ .[QV#WG^7]L=Y]P_G_?'X1V'\ ;]F__ +O'
M8/>?Y?VQWGW#^?\ ?'X1V'\ ;]F__N\=@]Y_E_;'>?</Y_WQ^$=A_ &_9O\
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MZ(_+6=1JQ<U2Z^OSN=W->?B<L0/N\S5T^Q8ZHB;]-K&0:PG,0[[:UTIQQ65
MU_B"HS5:<DD4<JS))"9I*[RRUV6Q.#6F>2 ^(?R?DG;K-KH_IZY+LYK%*1FW
M'A'8*E[810S2PO6DBM)7AM)!7NQO3K,MVO'%:'A*/&X+!N]A?!YX=NM[[-ZG
M(X$H/29/L#>]J4M[9[CL/2VK.PNT,6'U]OM58FZ?67$][9Z?) #5QZWK[(=I
M#9;@: >[))L9I;&\VEJ*6&>RK135:U.2-*U6%#5ISM9K0HL,$:Q)%.Q=?""$
M@]A)C 05*72F@U\]>S5HLEBK>N[.&>2Y?L2B_LJ:4+UJ1[%J4SRV:J+'(9S(
MO=S*H69FD/S7^#;PT5M#@\O!U75SYSK3&]H]>XVDL[G4W596XSNF4:7LZ@,$
MN+TZ&_#U;Q($)=HFVQ ,;'15,]?%)*QY][MGEL3&XXEMST[4\B)#&[6->"*<
MJM'&IB: ,>WPNP,?-PQ (@G273L<-*L-9$U?7U-E0J0RS69HXZ>W*ML8'269
MQ.EHJO<9Q*R <1,@)!I=%X(?#)GH!X@^NSCB!-?U=N!K?2=A=FZ[1PWO2A2F
M]3PMT^IV5QHOP;P4ZO7/8QUFN.$CEGA=12PD3LDGDZ@VTI/=:50T%RN4BJTX
M(C'L%"W3X,%>.+Q;0 \6QV>.Q /B @$4H.C.G*ZJJ4'D9;6MN++8O[&U8$VG
M;OU:BS9MRV/9Z+<FO3\3V1.6'@$,P,O=N],=<=ZY</'=H415_05NFSVRK8 -
M'J,H?7:C*'ML\[=@7F/NJ"]".J+!C#!)!K*)K9XXWO8]6-\K&E?M:Z9IZDBQ
MR/#+ Y:*&96AF4I+&T<\<L;*Z$JP*'R)'SG,MM=1K]U62ILH&G@CL06XPEBS
M6>.S5<25YDFJS03(\4@#H5D [@"0>!D55'@J\,-,'G@8.JP;"'-0=P0"/T6B
MV.J*ME[]#"K^XB]D;I=#;&=@66^!K@A+FUW4^BLFCCQQ EAL]35O'WVWD:5C
M<93*:)81100J@UK,U!:ZPQ1K52LS,T<=81)R>65CYYC(NC^G(4KQC6)(M8;4
M(;%BW9:4[Q$CVSVWL3R->DNI&BRRW3/( H",F0?VQ[.?J71]?@XOJX<W%F$]
MG]":G5:?0[KM+8:NPP?2&J%MZO!4.TOMC;;/*5U;3-/K<:'G+VHK<J67\?5P
M!$M2=,C2ZHNQ66L7"M@"GLH88HZU*"%;.P@,;V9:\5=*\[O)V/8::*1YPO:Y
M9?BYAMIT#K+%!*>M5ZCOLM):LV;%W96K+TM/:2:.C!;FM2VZT<<0>.HE>:*.
MJSF2)4;SR79_ MX8B<M38HG"7Y&6J=;:[LRFF[6[?D%VNPN[VGTUIH>U5=O%
ME[@LBK[/TME[_M*37^XEK1XQDA'1\+[$=0[<3/8%F,3/ E99!2H=U>"..2)(
MJ7^Z\4$6.61 *0K\AV)Y8\YE#T5TXU:&FU*=JT5J6Z\1V>U*W+4TT5B2?9_[
M[SM9&F@BD[MD;7!C4+P.0:QX?/#L[J':^(GM'1VE/HNQ_$1VM+M+ZXIZA:@>
MLQ>>JA<SUEAF,=(^0U<IGAII+"VE2*6XOKBXL7Q1MGCC9)L]I[=7U=.)'BJZ
MNF*\4;R>(7L2NTURR3P.WQY6';&.1'&D: G@Y6T6@.JN;[96)8;&PWVS-N::
M*+PECIP1+7UU( DE_9H%)>4\&6:660J.X 90\Q&;)CC&.,8XQE?R_P!O5_Z<
MWW:;F0U7RA6_6?[M\QNW^3;7ZJ?>QY-/-XS0<<8QQC'&,<8QQC(WM?M$S^F=
M_<G*R?FC]_VG*#>I^L_;E/Y-D,<8QQC'&,<8QQC'&,<8RGVUO54-<9<7EG7T
MU37PO)/M+8T:NK@1XT\Y"##3)81AH6)\WRS2LC:GS<Y$Y$ L0J@DD\  $DD^
M@ 'F2?<,>GKFKSO#VV/LQ>@[23/:OQ68?5:EIC:YN:ZE&O.VSEL%(05P1%E@
M*R]S=61%,JLG2ZO:U@ZM<DSV*GDL9%:*!;,BE*[N(UE(/:Q[!)RH +.H1E8L
MBLOQE'/<0#0%F D@2HQ !/:>[R(Y'!7D$D>? Y/T>8S&3O[_ &B?P2^'KM_L
MGI+2==^)71['JS;ZCK_2DY?%]=29Z70XZV.I+V.KLKKM>F*(&&. >D<Y-:$L
M\$PY$<:QO<K+ 7ZCI(Z3*P@9UMKQ(KU627P@) Z*LG>W:4-=IEX95<I)R@Z(
MOP?WOQ93VLN[Z;K0;&,/06SLI(/:F6&&:>%;$M5*,5BI[36BM0SVHFADL1\\
MQB1T@V+_ &J'V?K*K17=IU1XK:ROS2.:7ZL9U,4<7.D<,D8P%?#W0A,KIDG1
ML9)#1:_U1R->8S]S]XFNB&6K"\$YDM)XJJJKQ'7/;VV)'9EB"$L4\-)'L(ZL
MCPJP(SGUN:.M8CK0^+L3):, GU]>>2DD')$=^2],D%5:TQ5_!B$K;!PC-["J
MCG)YZ8_VE#V3G;\@0MAW7KNFK*P2+W /<O6.KH8(WR^G\0W194;9X^N]"N1L
MDUAHQAD5%5L[FIZN7'CQ\A>2"21Z>[WD<\#W$YD?Q?:[.\(". Q 8 @'CYB0
M>?/T')]?=FY/J?O3I;OG/LU?27;76_;F;D9%)]-];[7.[.NB29%]VPDG/V-A
M&+,JM<U8"5BF8]CV/C:]CFI.&5O1@?J.6CHZ'AT93[F!'VY*G)LEQQC'&,<8
MQQC'&,<8QQC'&,D2E^S!/T9/\:3E!O4_6?MRNOH/J'V95.0R..,8XQCC&.,9
M3KC[)M/U<;]VEY;7?T.W^S3_ '3Y<TOTRI^TP?>ID$<T#.CXXQCC&=<L6 X4
MD(J/WHI@\PI,7J>SWD!$;HIH_7&YDC?7&]S?4QS7M\_-KD<B*D02I# \%2"#
M[B#R#Y^7K[\E=5=61ARKJ58<D<JP((Y!!'()\P0?<<PLK/9T>#RIS-SCQ>J;
M":ANLCG\$H]IVAV_>&4.-RVLK-Y19O$W%WO;&YZ_J@MK356J>+A[#/L,O@!K
M([XDF)KTSS]4;UYHYS> ECGEL@I4HQK)/- ]:26Q''66.T[5Y'@YLI-VQ,R)
MV@G-/CZ Z3BKS55UDA@FJP4NV39;69X*E:S'=@KTIIKLDU&)+<,5GMIR0!IT
M61^Y@#E1D\ 7A9FI"LR1BMB5FK+<778UYG#.[^]3*#4:_16U-?W=CL*4KLJ:
MMV ]G?T%7>E5&G&M::2YB(M/H]#;&RG+D'4FX$BS"Q LJ5DJ1RKKM:LD->))
M(HT@D6F'@*12O$LD)27PRJ%RJ(%JGH;IHPM6:G;:O)=FV$U=]QN7@LVYY8IY
MI+<+; QVEDGACG>&PLD)F#2^'WR2,UYC^#_P]C';DF'$V*5?9,NR)VN(?ONQ
MY>K+L_L, NMV]L_J.76OZQ"NM,&><RUNJ[)"6DTIA132V%DS3OH'=[-A6YL)
MWTQ *]CV6H+D:U65ZZ>W" 7&CA95\.-YVC 4#MX  NUZ4T*/=9:<GA; VVMT
MC>OG63/?1X[DIU9M'7)-921_%FCJK(S.[]P=BQK72WABZ7\/MAJK?JS.7=3;
M[:LQU+I[;1=A=C]AVEI4=?"VP&*K%L.Q=;JRPP<U7WEE7U8M?*)#!7R#@JQP
MH $0U._MK^R2%+DL<B5WL20I%5J541[3(]A^RI! K-*T:,Y8$E@6_.9BU;4=
M.:C1/9EUM>:*6Y'4ALRV+^PORRQ45E2G&9+]JRRI72:2.-4*@1E4X*H@6/R?
M!SX2Q;K9:,_"UL4UC7=C_3X!V^VJ93*P=TU1E7VA<9K'$Z[\$.L;3L*IGL!M
M%I<92Y>XM()SGOLE=.4]]TN]W1C@A6RY"/4\)EK5S-,=>ZO3CFG$'CW$JN%,
M,5F2=$(4!. H%@W2?2ZS6[#TXP7CV GC>]<]EJKMXGCV,M>HUKV772WXFD6>
MQ4BK2R*S_E/C,3*7672W2V%MTW'65  )9$==X;J)MW7:.[O!I<!U2EF#C,W&
MAMU9USOP<6PLQGV+(OIHV621MQ8&RP1^ZL[=^_93P+<K,@M6+OAM%'&19N]C
M6)3VQHWY7L0]G/AJ /#50?/)Z[3Z>E+[;K8(UD:A2U7C1V)IE-'6>(E2N.^:
M2/\ W?Q)%,@'C.21+(Y XQ7Z@]G3U%F)>S+CMRLC[2TF[[)\26D >9J.PERV
M=QOB*MKYFAI:;#EZAV/S^G/QUZ1E-'L<Y15FAM 'RP);?#N1O,Q>ZHO3"I'2
M<TX:U34Q,%AJ^-+/JXXO"DDLK#[1+"L\8GA@FE>)&X/A\CG-9U70&JK'8R[6
M,;*Q>V'4-B,M9O\ LU>IOYI_'AAIO9]D@LO5G:M/;KP13RH2OB]IXR^!? !X
M0Z^OOLG'AKU?PO\ _#VW/89W3W0;HU+Z8BJZWKS2T-T?V.1H\]=840>FIZS2
MYH^LM0JR*NI9K!U<@X?+=NI=VS1S&S'^1]JC3MU^O6+MOEWM121K4$,L=EC)
M(\,R/&SEY @?N;+Q>ANE8XYZ@IS<V_897#[?;/9[M0(XZ%B"9[[6()::+#%'
M8KO'(D:QQ%^P*N7F;X*O#:= :R3"6P]D;L\]V(NJKNR.T:O>!;G+XNOZ\I]3
M3=@UVT%V]#<-QE6'1615+?@+>CMGGO6V1AII)%NN^VJE>+*%5KRU?!:K3>LU
M::P]J2&2J]=JTD9L.TB+)$WA$@1=BJH%X_1_3TBN#2E61[<%_P!JCV&RBNI=
MK4XZ$5F*]';6Y#-['&D$C0SIXR]QF\1W=F[%UX-/#CI*[75FCP1V@@WN&RO6
M^S)O-_V5;6^DQ^*UEAN<Y7VM\?L"+PDT+5VMA<DWZV":&VG)?%<6IXK60,1[
MW:0M T5E8C6L36H!'6J(D4]B%:\KI&L C :%%C6,)X484&-$/GDTO273]B.U
M'8HO.MZE6U]QIKVPEEL5*=J2Y7CEG>V9F=+,LDK3]_CREBLLKIPHOW&=!=5]
M>]C[_M;&T%C1;'M$I]ANGC:[92YF[N)H:<<N_P#P"*T$^$K=)8#T%/!9:2IS
M8%Y8P@QQFV$[))TEMI]E<M5:U.>598*8"U@T%<311@R%8O:5B%EX5,LA2&29
MXT+$JH\N+ZIH]90V%[:5()(;>R8R7>VU;-::5A$K3^Q-.U*.PZP1+)8BKI,Z
MH [D$@S'RQS+8XQF#7CM_('&?UOD_P EL.>>OPBO\.:'_.V_H+.>@?P>?\1[
MW_)%_KZV:O.>1,];XXQGH/SGY/4/ZFJ_N,'/ICJODO6_L%/^GCSYJ;+Y1O\
M[;:^_DRL\O\ ++'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,K^7
M^WJ_].;[M-S(:KY0K?K/]V^8W;_)MK]5/O8\FGF\9H..,8XQCC&.,8XQD;VO
MVB9_3._N3E9/S1^_[3E!O4_6?MRG\FR&.,8XQCC&.,8XQG6,,#KA"K"P*&!
M!'F+--,GB%$#$&C=,0443.]D(X\$3'RS32O9'%&USWN:UJJ@D $D\ >9)] /
M><>GKGF(]H9_M(G5G1]C<=7^"O+4_B&[#KD('N.S;<HZ+J'-+$TN(@Z@&JU@
MNNT&U1 RH>15'T6;8DHLX5_<P3/8RVDM0Q1).Y/@2%U28<&,O'+%&RLP+/&'
M+NL,IB:*66*2)"S(X7 W.H:-9GB21'F#&!&9EC@:XPC\&KXKL@::;Q 8E4\2
M=KJKAE('C+\6?C[\7'C+V1%IXC^Y>Q=Q5 >@F7$PV*4'7U)/+/,J,SW6M8E+
M1U<@8J1P/MGTQ)DZLB4VRFFG9+)D];O7I/?77K4:6R[#4WYXW6:!EB18@A1;
M0+6I4+10NW/#NQ "EX[5K-BW55VG@[K#DP$ O&BJJ\'OA\2)V+^87GN"DGD^
M&QR+LT5ELU94P4-4#\.?=T%R/J8[)D\8]:#:EUAR$CSPS_NQ$:^Z.$@F6*,^
M&!(6R/18TT>5=IL9+-Z]-,\E=Y:TD%FN_P :_,@DBKH(5"JRE)):_B!%$<3"
M0=G&:A:KWMI<AFK[&V@KUY:5[4/4,)ENV8Z-M&KV8YHP(8V5_9[$D)E>M8E[
MQ%P2V:7M(I'U_M _&([2SD"26/C3[\2J1H SG1UX'9.FL*PPH^=RJD1S9Y@1
M15D&;.'&])'N;")"^7=30B:XNE662-M7&E]Y7EA4[,SCVB.&M$ZP3I'X,3-/
M.LCF1>]40DMG8Z?4&LNT=MTHD]MM78V^DM[RO+ ;>NKTJHV=/>3T;,'M.ZU]
MN&PYL7(-9"*=UI>ZP%G@B\'#7-U>!DN]5FR'_3=/>T07TJ+,<0+*)[VZ,IW$
MB%UD$8P-B(/;2&C0%NF"D;#\.22DLJQC6[W-YM8J,EZ.2M:JK(M UU>5K'^[
M+=598[-EVEBL2Q?E7C,;+(QDBA8H ]/X5UZ7UEG12_!UNM]LJEW53I:O#4I[
M1'O(+$UV"FVEV-*O>72W(M+2[H]=8VVPBJWHI/;I)DLPQX4'@_1=A9U"SCE/
MI[(VK<2+.A Q#@2'C)/ 0C&-GAF2/WL4J-:CXWH_R1%\N; KB5(Y>UD\6-)
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M>2?)4_/^]_R__CDXCD/HC?\ VD?:/Y9(;$0/!9>1](_U_KYOF_?3)\OW-_\
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M1UCY'J'5U%0"Y[W+[D,"NK@(%<YR_P#EP"B"#1*J_P"Y%##'_P +&_+?P H
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MR%7NJ!CD<CYLW=$V M67*CFM1KC/HV<N)K/4U1)AGJ[U/<UOO2EL:FQ-T59
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MUDBM5XIXW4@JRRHK@@CR^?YOGR[.6>76.,9@UX[?R!QG];Y/\EL.>>OPBO\
M#FA_SMOZ"SGH'\'G_$>]_P D7^OK9J\YY$SUOCC&>@_.?D]0_J:K^XP<^F.J
M^2];^P4_Z>//FILOE&_^VVOOY,K/+_++'&,XZR/XK65C%3U15=98V3U^?E$8
M4\>K <ODGEYR"SW36HJI_NN7R7R^6Q=.Q=T\\Q_].-4!_P#\C$M_ 1C]Q^;-
M8ZEEXAKP#UD=I"/H0 #^;_3Z9)GU<V[-.SB;/"]5:R1CU:Y6.1BH[T.;];7^
MGS]#D\_FCO)?/Y?7R4.I) 8$CU /)'U@<GY_7)S'(O :-U[@".Y&7D-QVGS
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M[_YJJ^]<]K7N:K&/1/+/=K$>?'/ 'T'@ >0'J/+D^_S'GZ9S9G3N<J.T,\C
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M.L<^LU:CE]2*BNAK;)&HC'(OI=YN9Y(C[;;AC%&P] [=Q/TKY?QX/K]N;C\
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M*,MN7.:7CC*Z^@^H?9CC(Y:6^J3[[#;&EJA*T^UMLO?5]6#=23PTYED75E0
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M>F.)C(XVJKG*UC&HUJ*YRN<[R:B)YN57+]:JJ^:\Y@2223YDDDGZ3YG.@@
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M6CS22>7KDE@#ABD>_P D:GK>]KG.\FM3S5?)$^KF94<*H]P _EGG*=E>>9U
M"O+(R@>@5G8@#GY@#QE6Y'*6.,8XRNOH/J'V8XR..,8XQFD3/X^T*]M3K;-W
MO'"T_6Z:YSYO/T_1I76E!E(6C^?FCF)9VK6)Z51$<R?S^;7(O?;-Z%?@%IP^
M0>;;FEP/7Q4VMFZ2W!'!,,//GSY,O/J,XK!2E?X9[<Q![(M2+G)YX\-J5>H
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MIUYD@FDD]DC,',Y+M(L(CG8.K]KLG(*.+'<64B3@K;5P\4"KJX7@K1^(\;>
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MFB@G<,^2//54REE$%:&UAF-[KU'O]3\'6D@TNECC_&+Q'V:$A7:/N^+)L;Q
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M17*ODB(JJO\ (G(9'/(G[;CVP)MB;H_!%X2="0465/-E.[>RLK/-,7,7/,X
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MHJ25]>^.P4OWK'M@1)74Q0L^QR7VC>.LDL4"R21R*LTLOC?$A<IX;M&()#(
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MF*!"='H<_GNKL2:*);Q77N1\<?A>M9LU5YN:G+-SD&MN6B:$FJ$JJ42N.H)
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M:GRR=MDHP?(P?"%IYWTL:5;H?>M**?,^E,06&>&NY:RFW>I/+WSJ?8J,]O8
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MPF56D=.PE1FP/M>I%K2Q+2A>P=M%0@V)KR)4\)MO#2GE?6^UM<*PU#9L+,+
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M2?*R@2 XEIM:0\B974;/4>RFDD[)(H8&@V%5*\56K#$E;9'_ 'L>'#$J>-.
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MHY&M@];>LQI&T+2&<I+$Z"&+M;XR%EY=9/(IV\E@!QVE.".6S%J%[7_*%2K
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M5K8U=MN76)4I2.@*57K59Q)1LV98JU78/1DXF6(U9<J:RK!R]!74E3$Y@=2
M)5UL4LCYI7I#'&,.I,\CG3$32O1LI94KGS32.F)F>^1SWKO,$2UX((%>61((
M8H5>:5YIG2)%C5I9I"TDLA507D=F=VY9B22<YA;LO9L6;3I!'):L2SM'7ACK
M5TDL2M(R0UX52*"%6<B.&)%CC0!$554 5>")((HXD55]#?QG+];WJJNDD=_]
MTCU<]R_ON<J\JY1 X 'N^?YR?G)^DGS.4R]JUN*R<%LB12/6*2*1R*K$EAD;
M(Q)$;\U8_P!*L<J(JM1WJ1%5J(M6&7PI%?CD#D$?/PP(/'TCGD?P^?(Y$\^5
MT$#E1:U\S47R]X-.-*Q?Y6M65DWE^;U0M7\[4YE%M0-_Z@!]S*P/\>"O/_U8
MSIOS]RYKF25!KVN16N:HSGM<UR>2M<B(YJHJ>:*GS1>3">(<$2H#Z@]P!'_<
M''/'G]G_ (RWY.OHY'J^3-'*OS\T04Q&_/Z_)&)]2_OHGR\OY.7 O$#@6$'T
M]Z<_;D_B/[Q_]J\_QXYSO#YN>M:K!:$L5OEY.6*K*:JI_P#?(D"J[ZO^)R__
M )Y3:PLAY:=&/S=TJG^ +>7\,E))]2?]?1\V?DC71.1LS7PO7ZF3-=$__P!$
MB-=_^.1!!'(((]X/(_B/+(9UR1AS!Y12H8YQYV.CFAD:CF/8Y/)45%_M14\G
M-5$<U45$5)E9D8,I*LI!!'J"/]?4?0X\QZ>1S%K=]5D5Y$A%8\EU9,]TD3F/
M?ZAWO8^)8B%;Y(J^[D?$R1R>4L3W,<OJ<]J[)2V2R +)VB0#@@@<, 0W*\^?
M!*@D?,WG\P.5@5;U YX'S#YO3R^OCS^8^O/ED.-ZO5)4=[A4^?S_ '-/Y_J_
M_KZOKYESL_+CGR]W/]S_ ./,Y-V_^WR^KD>O]SY9>5/TYFS+"OM[#.!V&AK'
M-^B+6>O&G+K6L]3VM&F?&Z=OO))7JB-='\,]$FC];WN1M-NH=E7K3T:VPL04
M;7Z55CG=(K!/ )D13V'A553R#WCXK  #G"W>FM#L=KK]Y?TVLM;?4AAKMG:I
MPRW:8)9N*]AT,D7:SM)'P?B.SO'V,S,<F,ODY:]T$\[%A2)S9$:[Y2.>U?-B
M>E/]QJ+Y*[U>3E1/2C?GYMU6S:$G(7SY'!(]//CGS/F3]7ES_/-.ZA2JGDGR
M)^;Z?H^CR_CY9+])1%W9",B1T0D;D0HQ6_B1HB_C1P^I/3*2J?)K$]38O-'S
M>358R3%33I"O)X+G\U.?,_2?G"_3\_H//DBWR;A!8 AH!!F)' /&V*-OUJC6
MI];E7YN>Y?-SWKYN>]7.<JJJKS#LQ=BS'DL>2?\ 7S>X?,/(8SL<EQGQ)&R5
MCXY&HYCVJUS5^I6JGDJ?_P!_6B_-/GQ@CGR.1Q8A.!*?"OFK%_'B<O\ Q1N5
M?3YK\OFU45KOY45?J5.5U/(Y_<?KR@PX/'\,Z/(Y#)$I?LP3]&3_ !I.4&]3
M]9^W*Z^@^H?9E4Y#(XXQCC&.,8XQE.N/LFT_5QOW:7EM=_0[?[-/]T^7-+],
MJ?M,'WJ9!'- SH^.,8XQCC&61?R.;L<%&AE? V673>H0D-9SC?13>I$K2DKR
M4"<.O[J6JG5OQ$'[BCB__(YK^R8C>]-KX]:,,VVYAE@,EBQVT.0*LPK2B Q?
MGS$V*OBQ_$!F/Y/,[KU!TO4+&"S(435\313B.O7[KP!-J'VF(SB4?$A KVO#
MD^.1#_Q,O?FP9@L<8QQC'&,<8QQC'&,L3L2=@]#7/D,/":[;];PI-6M1Y#WD
M=@YD>,25'%"(@![Y&A6;DE>K*T@I[1C%:@D^N=42+'KJC--9@!ZAZ5C[Z@#2
M,TO4VIC6%P98?]VL,XKW#WL5JRS,(IR!!)GNG(VDV%E5AK3D:#JEREHD1JL7
M3.WD:9.(IN;-=5,]1>Q0UJ.$&6 $S1WWS8\P..,8XQCC&8->.W\@<9_6^3_)
M;#GGK\(K_#FA_P [;^@LYZ!_!Y_Q'O?\D7^OK9J\YY$SUOCC&>@_.?D]0_J:
MK^XP<^F.J^2];^P4_P"GCSYJ;+Y1O_MMK[^3.U9V@-0)(:?.V""/Y(J_-\CU
M15;%$Q/QI)7(U51K4^34<]RM8USFYFG3LW[$=6I$TTTAX55'H!ZN['R1%'FS
ML0JCU.8JU;KTH7L69%BB0>;-ZD_,JJ/-G8^2JH))\@,QRU>R-T<ZQL5XM;&[
MS@$:[Z_+Y>](<U426=WU_P 7"U?=PIY^]G([%H.FZVE02OVV-@Z\26.#VQ C
MXT=8$ JOS-(1XDGF?B*1&O+-SO;&V<H.Z&DK<QP<_&DX/E).0>&;YQ&.43R'
MQF'?D#=D;@3(X':Z,$\&6RH:6T^!A;./._\ "!HTD557O'1[E<3-9O%@01S?
M>2.>D?H\U\N7^WV*4=9L;<4D;35:\_AJ&5C[4$801%>?-VF*+X9^,2>.,M]3
MK7O[/74Y8Y$AM6(!(_:R_P"ZEP9Y5;@<*L(=O$'Q5XYYX&=?K[K//XX(*QDK
MX;#:E!0OT>PM$2QTMM:3P,=92SVY22F1C2D.E2$ >6$$6#T#CCQQ,1O)-7IZ
MNOCCE,2R[%XU-O83 2W)YF4>,7L/S($+\]L2LL2+PJ(J@#)MIN+6PDDB$K1:
MY)&%2A"?"IP0JQ\$+ G$;.J<=TKAI7;EW<L2<[6SU#@_.AJ$BGN"H_.=\C6R
M058KT1?B"&N1S'3O:J*- Y%7S5LKVJU8F3;EK:"LOMUON2I&?B(#P]J0'RCC
M\P>T$?'8>X@$<,5T[9WV4^Q5.U[4B_'<@%*T9\B[\^7>0>$4^?/F1Z X<W7?
MAU+WSTUT5U8PR_[!O>P<,/K"*=99)<_E1+H S22'/%>JH0F>&L2;&*>3W(%8
MA9%@K8V^YFR>RZ?JR])=2]0;H05]?7U6Q_%Z60GY:]+!)'16+N'//M3Q)#V#
MO>7L"#T.8_6[JQ%U-H=-JVFL7Y]E1]M,!?\ (THY4DMO*%)'Z.DC2!R52,L6
MY/ S>SSR%GJ+'&,<8QQC'&,MW2V98 40M2D;[VX(;64K)6>]AA)E8]\]F7%[
MV#W@%*'&1:F0^_@>7&(E<+*AYH<<D1_(>9^KW?O] >#P3R1P#DK$@ #\YCP/
MH]Y(\O(#DGZN,A_N;JTB^ZUK:[*02G7^#N!-?0C3RQ/-T)XL%D)?"DDSS!0D
M7>FJKJ^=$6:6&*3IC!#;0J$?XF9N5TNQ&MV,-EP3"0T,X4>8AD':Q4>?_#(5
MPH!Y[.T>HRUMUS+7[%'<\?QTY]6(!##GD?&8,W!/EW$<^6:^:]U7< :5"A[F
M*H)+F=8/OICJU\$TZQS6 L3B61FUSJ4L"4.VJ"Q!2J@N D(^-)X2(&=R2PTB
MZ^Q5EK3%HE\#V15D\E)53(O #.X?E6));UX4\9A26#1E64N/)5"CN':2 KIZ
MASS\YYY\N 1R:@<,$8/464=U*'45C2SY'C'L=2V0!$K6(T^>1WO9_<>38%;)
M!(Y[G/B:C'/]Y'&-I$:Q :RO/-VHH=")8I "Q* #@%R>X\, . Q)'D09@74K
MW.Y5/C#\HK $?%'/EZ\\@@#R^@9>O46"(["[%!:":?9YJEO,WK]4?,Z,BBJ8
M:-1[R@RU/,BNAG/TEDRI+*K_ '*-&R8Y95@T,PNA6PU/J_=)4U_XM$<4=V:.
M2!P@XE$3L!+)8'J&(#Q)R26+NR_$7+FK$TTJ H%2!N7;MX+,K JK'T+<CDJ.
M1VD\\!EYVA\Y%F=ROY?[>K_TYONTW,AJOE"M^L_W;YC=O\FVOU4^]CR:>;QF
M@XXQCC&.,8XQCC&1O:_:)G],[^Y.5D_-'[_M.4&]3]9^W.(%[(S17R*B,9/$
MYRK]2(CT^:_R)]:_F1.1;G@\>[ XY'/OR345%1%145%3S14^:*B_4J+^^B\H
M97QQC(AQ'3M)C=5=;1]I8Z'37"70WTO:AT8Y\%7=W;+PBN(.J:JO/NFCSCUX
M0$]Z5925M76! 5: 0?%M*UC4=+5-5L;>V-F>]?M"W'[39BII,E>Y<%V2"2:M
M6@FM]CQP0PO<DG:"O7BAKB%#*)-TWW6U_>:>AHA4JZW54C0E]CIS;"2O);U^
MO;7Q68Z]RY9KT3)'+9GL1Z^&JMJW;GLVS8D$)AE%?W<Q$^N,-/4OYE*F8J-3
M^>$=SE5%^2_$L5/FWFSYI/JWT+__ -$'[%/_ .0]V=WC)L<8QQC'&,<8QQC/
MB2..5JLEC9(Q?K9(UKVK_.UR*B_\TY$$@\@D'WCR.,H)64H"_-75\0[E^?K"
M5X:^?\)6#NCB>O\ 21O\_P!]%Y66S.O_ *A8>Y^'\OK8$C]Q&,MLOKT>1KD$
ML96HY%\XS1XB6*B_6SU0J+Y-7\[F2+^?SY<)?8$=\8/THQ4_7Y]_G^\?NQEI
MS=7D,>KXPJ6=//S3T/=&Y?Y5CD%9&G\J(]4_G7ET-DI'F\R_6 ?W<AB3]? R
M?Q'].X_Q_P"_KG:&P=PSR9&/6B,_?_=T8GE_(T8>7S7\R+Y)_*G)6NPGS+2.
M?U>?YLP_?DI)/F22?>3SET5^"%B5LED4\QR+YJ/ U1AU7Z_3(_UOGE1/+ZV/
M@1WS1S%3Y<MI+K'RC4(/^IOC-^X<!5_>&(^8C(9?<,,0\3(((HX88FHR.*)C
M61L:GU-:QJ(UJ?R(B<LB2Q)8DD^9))))]Y)\SC.3D,8XQCC&6=II(W3#1M5%
MDC9*LB)]:->K/=HO\OXKU\E^I%1?W_G43Y_W?Z_GE)^.1[QZ_P"O]>N6QRID
MF2)2_9@GZ,G^-)R@WJ?K/VY77T'U#[,JG(9''&,<8QQC'&,IUQ]DVGZN-^[2
M\MKOZ';_ &:?[I\N:7Z94_:8/O4R".:!G1\<8QQC'&,LB^<Y-C@FI+6,:Z73
M>J,N".2QE]--YHE5.X>60=S%_&-]T0-[T;\1ZS-_<^:_LB1O>FP'J*"VWY2:
M-&M/Q1!'L<AB=HBI\Y^R6'OB^*WB#XN9W7@'2]0DK;)":OAH9&6JG-X<^V1B
M5%E##R@[XY>R7AE[#\;+WYL&8+'&,<8QQC'&,<8QQC(V[1T%7GJ&KGL]*F80
MC982*,MA< LQ43-I02' K[ZQK?56E@-('OI4FE8)1S6!9 A@\,@DVJ=8;.GK
M-=3DM[8:@2;[IQ5F$T<,DR+OM:]BN>^S5YJ35Q)%LG$CK!KWLSRPSQQM#)L_
M2FMN;+86XZFJ.V,>CZB=X3#)*D+'0[):]@>'5M\6H+)BEUR&-&FV*58(YZ\L
MB31R-'(R5C)8GLDBD8V2.2-R/9(QZ(YCV/:JM<QS51S7-54<BHJ*J+S:5975
M71E='4,CJ0RLK#E65@2&5@0002"#R#QFM,K(S(ZLCJQ5E8%65E/#*RG@A@00
M00"".#YY]\FR7'&,<8S!KQV_D#C/ZWR?Y+8<\]?A%?X<T/\ G;?T%G/0/X//
M^(][_DB_U];-7G/(F>M\<8ST'YS\GJ']35?W&#GTQU7R7K?V"G_3QY\U-E\H
MW_VVU]_)F"7<?>>:[#MKC 9_6!UGX'::QJK1@%T*!JH=)GCC*DYL@SWH<"+!
M/&5# Q1_18"3QF.>\8L5J>@.B.E)=76K;ZS$TTNQII)67L9ZJ4[*I*O<1\66
M5QV,_) A8>&!WJS9P[K'J5=E8GTU9Q%'1LLD[!U6RUF$LA[1YM%&I[@I'G*#
MR2$8 Q9#:=CUR(H.O&N86JBL&T=5!,YS4141);0'W1\OGY_-57\R_6B)S>V2
ME)_Q*QC/SM Y7CZD;E1Q[N?7-+6:[%^98$@]0LR!OG\^7'QO/Y_Y9;R,I(M
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M3/Z9W]R<K)^:/W_:<H-ZGZS]N4_DV0SN0V!L#49$3*QB?4WU>IJ?S([S1/\
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MXR3^QG_3CL7W?S/]\<GWG^)Q]+S_ ,9)_8S_ *<=B^[^9_OCD^\_Q./I>?\
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MBC:Y\DCW-8QC5<YR-15Y$ L0J@EB0  "223P  /,DGR 'F3D"0 22  "22>
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M":0H+FEL[4_4%,3[22O6MZ36V:E6Q6BA-V2<M[0BQEF"6&9!(YA9F1>$4F)
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M9+(T"R=47@8)DU:3)#)!\7!')&,2WX4WX8E\<3Y$GCD=XU)\2, NC*RLH;D
ME6 /F01Z>H(]0<VCK#X/NKN@Y*$?5.H;6_C.!K%&1;5*[#.B%1(!/0LV8EDC
M++WQ2.L@#!PI0ACD;RKFF8XQCC&.,91M'HJ/(9Z]UFGM J/-YBGL]!H+JQF:
M/7U%)3!3V-K9G$/_ !8 P 1IRB97?*.&)[U^2<B 6(502S$*H'J6)X 'O))
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M/[U\_P /#[^3W7O)O=1^]?[CU^Y]<GI];O<^\D]UZE7W?K?Z/+U.\W)XXY/
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MXJMPX5S9WX509>3B6UZZ*>_+BN;VQO%??6<;62W]RV6RE98Z6P1]WHR6ON=
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; )VW]!9ST#^#S_B/>_Y(O]?6S5YSR)GK?/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g383050g11m11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g11m11.jpg
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M 0$! 0$! 0$! 0$!_\  $0@!"0)> P$1  (1 0,1 ?_$ !\  0 " @(# 0$
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M)H9I)FBQRJ,+!,40D8\3Y$@5NJ?E&MT=PW&OU7U.]3:Q6-V7Y_W!3%[7*8H
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MZ;;;%KM1325)6DADB[@:G<KW8P.8=<-)75'RI/!FXD-@BPL]S)MLW6Q4PE6
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MBF?-*P*O/'&;+,[[:61L:.D=\WJJ_/K9?)=3J3=)PO-5KRN;MT%Y((G<@2*
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MW ;3_'6X_P#5=;_S/3\(-X'_ %V?+GW@\;_?7T^[S>OXFVO_ *UM_P#E>GW
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M9_KF.K/][H?\=C_\"SKH>FO\.E_Q23_QH-83Q+?\*)O_ +'I_P#L[NL_3/\
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M""=@%=ZG;*]Q8PK=^7N$JC/#SY#9+B[1ZNZU.]CO':TJE5*"WS)5]D;#&UH
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M[9/\;E_\*'5>H_\ ?!/\6C_KRZU4TY-V'FM"7F0H+/2"T=L3GZTIR,&L+N
MB6I"(>Z<5&0%GM'@F<I0R-CD<JSPHGJ-ZB,(9(Q(Q6,NHD8>JH6 9AX/D+DC
MP?L/IKG9"XCD,:AI C&-3Z,X4E5/D>"V ?(^T>NM=!>4^0J70@9X7.:3D"OO
MHA9JFXT^=L^/]!&; ?5 :L22E&R#&_ J&&^J+86]M:ZDKGQ+94ZWUM8#CDS[
M UJ[QF0R1P,A(=8W6>/B0[1$.TOTW[;(45G;Z+]M5)&H0L3JZH(Y)U<*5>1&
M@DSR5904$0'! Z.'944CDG-V .LE5\K\N$H/+/PX8\:5<\\N5Y=_6$#MLZ6T
MLK=@-<=CV%$-IBJ5U8OO[P99[&]J(Y$@A[R2VM5JCP+:YQ)CPC \755Y,LN!
MR#\O&1Q1B,G5RV+)QFJ<$1EB6=<<D9G"JT.3P*<?>XY9U] ?/M"Y/Y2-Q^EU
M_P!:^]@L@8J!U+AIQ;$6R/D^JJ]JKAL99=)$:YI=&'5W*=ZE[JV ]C%21R.E
M=0UJPECB]I0JW<YS@@JOWJ-D. ^/$C,A][WN)]-%L6#%)+[.X953C"0P9CW7
M5L,4!.4"O] \0V/.N%;\J<Q"WDL(O$EE(%45NQ<2&(ZW+9HCZ6]J0*0FMNG9
M=H 5?>!QW$M>*^66\DC<IT]0VO96F65R5JA3)M*"[188\ 8PZ.75D[I8LAX<
MCX0'W0_+D%HUBR'(%9B%28D L>XR.JH5?M\55QR(!]_'O<.(#-S">6^2I+*6
MN!XIMG!Q+4-2]]PV44!K[.GLCI&5X5EB@28D!- B%,(MV #B^_#C%.'.?!$1
M:*M?CR:TH/O^YF(D!751R*S$'DK$@(6)XD@$ ZK[3.6*BLV!P]\B4!N2,3Q#
M0J1Q90"7XJ,@$AB ?"+F+E.<24M.$+6%L(YKWQS':1)W%194N\&$@%=AHC"5
M;=C)DRR(AU$E/DB/J"+.M)'F>]DK @>V)Y(&<1XP9 A)/>('N$R@$Y"CBP5@
M1H+-@J6]D;P&\%G!R(RX '9R??':) P20R%E(SG=+RCOJPX8&@XEN;WWO&AZ
M1"9Y;BO#$M9YQ6$9HPJ'-6,++*$<B:5(FO<0D@;XIAHDF]2"R.M REGM(F)3
M'@!6)4 XE ,BDJ2,?#UR"<>;I+$RL%CK/)F'N9)90&R!VV/;8<L$G'KXQCSX
M]8?(W(:A;.W,X^L(&UF@I:BCII0]&^5M=/83 V=U/+7Y4VTN&0#^[V,T>7J-
M %%ZK((+*8:,VQ&JU>OF%%G4ED=I'S'C(4,J -*JH2<J.XZ'QDJ/ (3S\96,
M!'!U5%(DR5Y$,Y*QLS ##?>TD4$X#D L."3RORFZ0EE9PL80@SSFOD-M[ZO8
MCX;6CJQPD]7$*I1K(K8FW-+JOB>:EKJHE:'17CV&NKJBM6P"UL#(7T6-O578
MGQ-X&4"@-B0,PYQKE>5ILV<GC4)QRR6=U]&10N##[S8<L2A:,JIX2/Y*X 7E
MOF=C[)B\.VEI[H1O9!))7W--$1!7:5Z9BLF]?)OE4^7-I$^$ZLCLJ6VD*']W
MLI31[6"NR&K4/']UHH(A!^@QR8QW&&)?"]S.0W%EP?= *<K19M>]^Y6;!GQD
ML@/&3[VI)B/DQX/)0R-D88L'"Y$GE_E!3K2,7AN]4.K)O(Q/-'H6$Z#X2..6
M.HTDN44( .P:5&'$1-/).47',M5 >@Y<$%HJ5L+FW'E@N?*83D2#G$G(D8S@
M  #PY7()J;5C+XJOA2_'Z8+\ ", Q8 ;(4'.2P/$, <<R/ESDQS?7DX8MD#4
MF0>.6(G1O+*C@T.;J_?8:PC%"&C#6%1=GWP++9E:5!!1V MD.(1$]K+35K^G
MM:9QD@B/ )CD8 L)F4E714;AR!YJ5)!\W"S/C/LK8R1G+Y.'C4$*800&5V<<
MN) 1@P!UL7U U-UNKX3/R'L?W36?R1'7 =6?X=7_ ,47_P :;7;=-?X%-_C3
M_P#@PZW#ZY;71:=--8]UM5-<YKK.O:YJJUS7&#(YKD7LK7(LB*BHJ*BHJ=T7
MY+U'-RH"0;5<$$@@SQ @CP006R"#X(/IJ2*5P@$5+)! ((@E((/D$$)@@CR"
M/77Y\8J?T4KOXZ-_]7JGMM/\;K?T\7[>J^PW?Q.U^CR_L:?&*G]%*[^.C?\
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M3>]HBC::7=MMBA4,C2O?K)&O!@'#2-,%!1L!@3[I\$ ZIBUXJ\.6?Y$X_ON
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M\M27+_>;:UQ]7EF:$@[453]6;=)N%"*%;$MVI'7:0Q+/)9A2%I0,F-96<(9
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MRB<^* M[S.G$ $/R%G<=NXS\2&#/QP%E-C8\7#G[RLWJN;+]36K&KJVG>5+
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MG7E-5@:1I(8[5A56*258N/)1Y7PQ55(U/>(+/BHBHCL+\9\^WD^),N/6A)2
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MG^IY&R]G/DE5?*OJ21JUZ])3W;VG;XXT>/ '-NW(KLIE3!B9D8 @9SEAD_'
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M/:),;E8DOW2BM5J2I#%6 !8R.Q*!W0N5QR;("@LRJ /;]UV?Y/J\&_;MM/\
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MIU>K1R^"4# ,0KYP2%R ?'CR, _!O!.NQWA;V5'M/\WQK+B=5X2[P.QJ1'Q
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M]$BY-JNU+'>1>4LF,/.GB@P20+"X68P5\1A, 43BVD2I)994@B9Q(88PD 4
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M>3U/,YJJ[Y.@[4*5?<X=[W6J=R>#VJ6-)9#)'8>>1E"RH0QC*(YD!(RQ R"
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MNCV+I;J;JB2U#TST[OO44M*'VFY%L6T;ANTE2N25$]E*%>PT$)8%1+*$0L"
MV?&N2=O<-69ZXUUEM,G7Y3/&6E=?Z<[14XF>H["DM9J&Z!N+J<R.MK#*B\'(
MIK08TF"<"U@FKBV1&1/A;5K$"QO,T\*Q1LRR2M(@CC9',;J[E@JLC@HP8@JX
M*G!&-8J_3O4%O<Z6RU=BWBSO&Y05+.W;37VR[-N>X5K]--PHV*5".!K5J"[M
M\L=ZI+!%)'9IR)9A9X75SB[?ECBS/VY6?ON2L!27P-!-JC:2WV.=K;8/+C03
M%$:,JN-L83!Z& 8<@F:WFA97Q0033/(;'%(YMCW*D;F.2U7CD6,RLCS1HZQ
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M'BA "Y;S="."VW+:.R51V;2E=/(5;# Q#BV]2Q]X$&(HMH./U>R[E-: JWE
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M.'HK_-)7$N:PV!%[]D^AI,2=^R31=_H^B2/S1KV56N9%N5A8C\>)$!*'Z_\
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M2J>YKI9('O;&=56H)E;8B/5LX9PI I$<<T+V-O>-XV"R(R,51PKJ5)210Z,
M0,JZ,KJP\,I# D$'5J.D@+1NKJ&="R,& :-BCKD$CDCJR,/564J<$$:RW5FK
MM.FFG333IIK3CQX^(ZU\+GAOU?)N:95S;.6PI,MC(+B-TX+[V]-1DA#Q&21.
M,?64P]O;QBJ](Y9 &MG1T'J,=NNG]L3=MTAJ2EQ!QDEG*>&[<:DX!P0O-RB<
ML>.7CSC6JWK<&VW;Y;,85I>21PJ^2I>1L9P""W% S@9\\?/C.OE,+\='BO.W
M\?),O,>C;L(D6 <Z""KAB@$?*Z1:R$%@""-K7.>YB@^BL#F+Y7,7Z>O7!T]L
MRUS6]AC[)\D%I,D@8YEN>>?@'EG.?.O-#OV[&;O^UOW!D#"H  3DJ%XXXY\8
M^SX@:^HWV=GB;TOBH\/ VWW"5GU<YO57&'U4E4,H(YIE6)5V8=FX'S.C$G.J
M[@)Y,8_E$4IA#AXH(U]"+RCJ3:HMHW)J\!<UY88[$/,\BJN70KRP.05XV )R
MV,9)]=>C;#N4FYT!/,%$T<KP2\ 54L@5@W$^G)'4D#QG.,>@WMZT&MUK7#Q0
M<Q6G#7'<-SGXPY-'=W(]%4J=&Z>$3U!2S"[!1D<Q)U&A$2*-CW>FA!,#I&2,
M1T;O*?E@ZZN=!]+QWML6!MUW&_'MU(V$,L< :">>>T8@R]PQ1PA$5CP[LL9<
M,H*M[I_N?ODQV_Y4>MY=KWIK2;'M.US;ON(J.(9;)2S6JUJ0GXL81/+9,DC(
MO<,$$RQLCD.O4X)XB>91M*[4P;(M]X0YC)IG UCVDPH]'-#EA:$C9!N_VK8$
M^2(O9O9?GU\60_*?UU%NQWF/?K!W&0JKRF"HW=C# B!T]GPT)(QVL8QX&-?H
M]9^1/Y+Y]@'3LO2]5-HB#/'$MN^C02E"K6HYC:+)8 ]XRDGR,L"!C7<7P!R8
M3RWQ=0;&PB&@N)GG5UU"&BM'995I4@\DD4;GR.A85 @YK87/<L:$HQ%5J-5?
MNOY,^K9NM>CMLWRTL,=]VL5-P2 %8EMU)FB9D0LQC$T7:L",L> E !(QK\P/
MEFZ"@^3;Y0=YZ8I23R[9$M2]M4MDAIFH7ZZ3(DD@5!*U>8SU6E"@.T!8CD3J
MY^N^UY9ITTU?''^N^(Q-I;&7N? Q?=)GJOF+'8WNL;G+^.(A:B_2OFDB3S?-
MS'JNBOU.VW>C'WMC[P'[QB<9_P#A8G^8_:-;FG9[BB-V^^#T)_?#_21\?B=2
MR#\M]G^]NC_G30]:WX#[3^I=3OB?L'ZVU).J:KITTUKD?^3C?W63_+/Z\\G_
M  \W\K)_7;7J5?\ P>#^1B_J+KB=8M9M.FFG333IIITTU\]/X(AWX/&V#\".
MELAHI06\Q\MUTI9#%>-526&0HX(K(A$:[RQ#JKE>[Y*C7.\O=W9%[_I*Y6V]
M]NNW(%L5:]WE80KR=(6?A+- OJ9X8V:2''[]1KP'Y;NG[?4VP;OM5&9HK,D5
M::)4;C)8:!>[[/'@@\Y./N^HY!<C!R/D0YNXBLN0^:ZK1Y@ LFJT@#XQ2U#'
MK(7R#2L&!G#@]5$)BLE,%<+$CW&$-5Z/8Z1%5.^Z/3:H>NK\,MF?<J%N6Y?V
M:Y$[6+1K3P2F,W$C[DBA"3#,7*X"@D#T'CO0/5>W],=$2[7NMR)KVS.\-B(3
MB:92W-GCF'DQ20E6$N0%0X(P"->?,Q_+&SPA&%I<B[1)0Y2,2S(A@DDLZ;+U
M%N.V.-1$D2="UL@B&SK-"XEH4<KFQ(,WU%TN^01])6;FU;-N\S[-NM;:[.[0
M_A:YO--89*B,.8C2%XS(RJ5S(Q!;BIUBZ%V_I?9MX7?[>Y^Q2;M;DGI133+'
M!:GF65WD#X59(UBG18V#]OFZGZ3*JTGP_P D#BX*7B>VF2L)'L;!JU1\,C7$
M.N(C!+!R>J^-C"&(@(<H[U1'M8KF-1?55T[I1MBD=J%BLD-K?;J06=W$F?\
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M$)916"KR8+.BK'(RL(Y(_?1WE5I*H2ZI2VFUQK9/2E].8>6.4>:04P,P,J.
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MN^>:7\7VO^L8O_+=3_FJY^.UOT"7_P PU%Y?#=?<;9D30\>&":7<BRVQ_(5
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MVVD2*:-GC#%U21&( 8$_H/U?N->/IWJVK!<@&YU>E-WOFJDT9N00/0O)7MM
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MC!E.&4Y!^HZOC%7S]#;GF2QK&1#GZ00GLG:.2:*PO7NEB_\ 0D;(URI_B/\
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M#N\Q!A36DF3*V,>*'L:.S[?LLM;>.H*!MUV$L<$,Z%':8KDM7C?!(4$*[9!
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M%W:DU"Y;H6 HL4K5BI.%/)1-6E>&4*V!E0Z-@X&1YQJ"@.;]=K5,21%=];K
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M5B>6+D&+*95;D?&0"<:@UO[7KV<0ZGR:;V*?A]#L128$%C*NJDN2Y;(Y_K%
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MW1V8H+JU^%>K''5>01\A$S,6B (]T*RAB.7[X>/J^S4+\AB?N:#^29UZ3!^
MA_DH_P"HNM;-^%E_E'_K'7)ZRZQZKSB)BQ<3\81JQT:Q\>8IBQOB= ]BLS58
MU6/A?64CX7-5/*Z)U-4.C5%8ZL 5%$BDW3FY;.<YLSG.<Y^^OYSSDS]O-\_P
MV]3&I>*=0>F*T'@C!'WI/4<(\?9VX\?P%^B*9Y^X:'W6HQV[DJ[^P*R=584P
M1^/("BV.7?:Z++W!-U2#6A$-;8PEAT)%+;P*DUE  <^2L$.>^<99="XT$4T
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M.AA59$]5$<DGVFWZ-FB]JM=,[Y*D=R>_)8%I6\ST;<K]V:6,@+VW+*1Y()#
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MUNJ*"#V?<[EDV9(@MAI-TN23+%'(5!:ORF7R,KQ523X(''; FT=([W\HEJU
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M)0M\I9@ZR2LF]6013'(2L20LAC;#JE:LK6KCS3VIS$&[IP!YY *%(0+R)XD
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MMFNN(Q$UN/D QE,O"/*MEO5<G)U:5IKE!.C^K4GN-(IK5^H8UB62:/+=E96
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MIY4C%LO0Q\U08=Z*>E!(ZP9?62S/@@9(R)I(LB.22%C9AV>;O<(6'GO5SGU
M)4^,#S](Y_T?7C.J-,A\"&<8]/1A\?0'C]OK]7CSXG5;;K8R21K57%?Z<:/]
M2R#:-&_NY$\D;VS2^:1._=4[(G9%5%7MU5EXX]Y&S_!.<?;X&K5;EGW77'\(
M8S]GDZB("M^NYJD\[%>G'.!56(^%9&M73<D^5[F)8/(:QZHYK'R58T+W,>V&
MP.>R8>NS-_@</^,V?@<?@JOQX@?: Q(\95<@OA4_NR8?_JU4_#/X6WCQRS]?
M[P#ZF8@A;&ZC:DZ=--.FFG333IIITTTZ::=--.FFG333IIJ*V^*SET2XXD.<
M:Q>UK)+*HL+&CL9F,[^1A!M04$02QG=58PA\K6?XJ)W7O>)'4<0Q ^K (_,0
M<9^.-4(!QD X_F/P]2,'X#XZQ7UMZ+]$]G_KYL/[:ZN[TGUC_H)^SIQ7^"/S
MM^UKWP\759#O*.7N9W+_ (L.WV<B_P"9EPY>K6LLHRTB*/RB,?K&KA%R^C'G
M[.?[6N)<^%/.;<BH*O\ -Z^WGHRF&5,]ILM?$HDS#:^R1K7SWD*2C.L:BHL9
M I_5#F/J:LR6!Y->%+#:N\FN'$=M5$@*N$"-D%63X*<'B[IR&&"NZ@X9@4FU
M+9,;2U%<QMRC+\AQ(*M\6&5+(C%3E2R(Q4E%(L<?PUSS=EEL]**B_3ZO(NQ>
MY/\ (/;3)W_Y74-MYC'T2[_9$@_K ?[?7J8NVR'&1&OVLYQ^8_ZO/Y]9T?PO
MTZ]E*UFO;^:T?8;)_P"WV?)H(_V?\3]GY?1U@;?'_>Q9_P#BX#_((S^3XZS#
M;%^+@?8&/ZW'^WUZDM5X;./:\J$TU]]?$CN;(.^_O+*ZC'E;W\LPT-N4?&/,
MWO\ :30HR5OW']8'WFVRE%$: XSQ7SX_*,>"?./369=N@4Y/(G[<?F/DC^8C
M/QU:$. RL/;_ +F^JJ?=F)*?W_95J3-8O\%$_8ZB-?M-_P +Q_(JJ/\ 1G_+
M^H:S+3KK_P &#]I)_P!./]O'C69@SM",B)#3US>WT*HD+W?+Y?CGL<Y?VU7K
M"UB=OI2R'_YV_4#_ +>?KUE$,2^1&@/Y%&LI&/!$G:*"&)/S(XV,3Y?1\FM3
MK$68^I)^TD_KU> !Z #[ ->WJFJZ=--.FFG333IIITTTZ::=--.FFG333III
MTTUK_D<DMY:$GFL5*H0N55:J*B&SME<J0-7_ ,TSY.(<GTHK8D^;U<S>VK?8
MA2.,CNM&O_R*5'O?:?WO\Y^&M/6K=V5I''WM7.,Y'(Y/I]8'Q.?R?9?[6M:U
M&M1&M:B-:UJ(C6M1.R(B)\D1$^2(GR1/DG6B]?76X]/37[TTTZ::C<'Y;[/]
M[='_ #IH>J_ ?:?U+JGQ/V#];:DG5-5TZ::UR/\ R<;^ZR?Y9_7GD_X>;^5D
M_KMKU*O_ (/!_(Q?U%UQ.L6LVM*/&MQ=SWRCF,2#P+I;G,W-5:ZHFX)I=U<X
M69RG8JZK,P00737-+-8"U>K)JK.8::<R.!@SBTJK1\2 SZ/>ZNX6HH%V^22-
MT>4NT<[0'WH'6(EDDC+!92CD98#CGBV.)]W^0CJWY.^DMVWZS\HFU4=UHVZ>
MTQ4H;W3]'J!![/OU"WNL<<-ZC?2O+;VB*Y525$@>1I1";E17-B.&4? _BEAY
M1I=Y=<V::3*,\0A^RN.)Q='ZV4CPQ>2MJMTH=U/!%HBZ2*P=4LKN,R7Q9\0W
MWS3/&=8R0QB8$H;J+4=A[LO9^<3.]02YB$#1.I(<@2% Q3C6.$#<I,<C@;W<
M/E"^2.3I*_T]0Z#VI=X;Y-JVQTNL9ML,>\-U!!O-.V$GH1R/M<-]ZPN&SU5$
MK[E-!V-J6455=INPKKH]?->G3373O[=RS=6^$+@+LY&Q'^)X0 M5F4=JB+Q/
MRT;(GK)*QL;V3A#S0O?$2UD\43T@5S6O9Z!TA&\T^TPPQ4);4VYK%7.Y/%%6
MC:0NKR&24JB.J%N!SGEC )QKYD_W1%-;FP3Y*AX+-&6$L 5$@XJ RG 965F5
MEY*2I(Y#7Q:Z3G?"8;0F8\X5Q]B=L;DT@P)?0/2>W(E6*SMC6QLADE@9964G
MEB15=ZD2D*Y8VJG:3[E;Z&LU=OVB*#=+^V7Y]TW&XQ,C=U9C+['5*<BR(@)!
M7W1D$$Y.O&:/074_5.WU-X:\M1(=FJ5(:\R&19141>*)&Q)5)FBC+.S'(9N
M"DJ=9_$!6.B^#\KYJODIC*C20P^HT>2%>ZNF,KBF2O8WWA8C*XE%D[2HKYXO
M,YK71L7??*/-0W^WM/6.V0+!4ZGVI;%FHP"LNX1A1,Y4##]X-QYCR_:Y'Z0
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M<%"1#))/-!:38=6ZJ,:3R224BH<U%A^?4&0;@8Q+(+ B:$V%<AD1H!8-0RC
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M4J_^#P?R,7]1=<3K%K-ITTTZ::=--.FFNDC\$$V=)5^$?PI3:.P=74D_C1J
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M?&U8T:]'>5=I8?M2Q/7#%4821?\ (<CZ1^H8\$XQYR,9U:M>.W:JQ2,L<;6
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MYJ^?"BR9?6GF7F0M'RRJGE5[E6B=\U^E4;V:B_-$3J;!6AK1K%"@2- %51Z
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M.T3+(F6+);Z7$-A%H1F9_;C&ZM==49:% 41$[-6(CDW".[),KUU*))P4I$4
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M<94*,%78"Y_X>N.?_NBYI_\ C+@/K5Q_[VV_\>V[_P"GW36RD_WQJ_XE?_\
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M:95@,4J\)HMPE@5I9I(D626:NB3J(6:(12H5YC$C]AG7+:Z;517/_#UQS_\
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M22=7QQ7XHTBB^;HXHT6..-()D1$0!51%64*JJH 50    !C64]#GC]$^(_\
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M((!X($69;":229B#L9*DGJBK)7KQS@RSP3.\SQL (([*!5"1K]+VDDDGQQ
M\^$4-HV4L6)(#VX)X42&.1<]^2N[,S/(WT?9P  //(DGP ;>Z@ZG:=--.FFM
M07_CW?\ K._ZUZJWJ?M/Z]47T'V#]6O'JFJZ=--.FFG333IIITTTZ::=--.F
MFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG3
M33IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333I
MIJW^*?IO/VJ[_K-ZK\!]I_4NJ?$_8/UMJX>J:KITTTZ::=--.FFG333IIITT
MTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ:
#:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g383050g12s26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g12s26.jpg
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M 0$! 0$! 0$! ?_  !$( 58"70,!$0 "$0$#$0'_Q  >   " @,! 0$!
M       &!P4(! D* P " ?_$ &$0  $$ @ $ P$+!@D(!P4"#P,! @0%!@<
M"!(3$105%@D7&"%65Y66E];7(B-56)35&20Q4U23T]38)3(S45*2F-$*&B8U
M69'2)S1!0F<H-F9HI6%EHJ2FIZCF0T9(A__$ !X!  $$ P$! 0
M  0  P4& @<( 0D*_\0 ;1$  @$" P,$"!$(!@0)"@(+ 0(#!!$ !1(&$R$'
M%"(Q%2-!4515E-0(%A<R4E-687&1DI.5T=+3U1@D,X&6H=;P)31"5['!8F1E
MHT-CHJ2EX>+E\0D9)D1F<G."EZ;7Y#4V16=TL\+G@[*T_]H # ,!  (1 Q$
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M0 +DFV%=K/W4/5F'V\@]KRE8-L;S<.S;#J\AV3A16QQVMF&\')"*-H)R2/(
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MY(^7IL)B0)<&UB0R7%<26VN/$!&MFUP(K91)VS@ E)RVK A ,G;:;H@@,/\
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M@RSE7V)JJRCC$M1 N7;1QND3")A*IFHHUEC(GA[9$SKVQ03?@&W_  L.F?\
MP[-/_77%?\/O OJR93XGS'YVF^WB>_\ -M<H?]XVQWD6>>;XIOS;>Z5:IS+W
MO_(<CFLL3]-]J^[Z;E>-R?/^<]F^WWNSI6IZ/*^5?V^KS'5YDGAVNE>Y+97R
MG9=FF_W66UL6XW6K>20'5O=Y:VECU;LWOWQ;%!VY] UMIL+V+Y]MQLS6]E.>
M[KFM)FJ[KF/-->\WT2WU\\33IO;0U[<+[3<%-IQNH\<AELM6Q#KBE TM?%QC
M"RVS2DM&-*M->GHAN!4B5O>Q0Y;2%ZA1$F5TF5D[:YF.8QLW'#MVO_:-OA[W
M=[W\V/4<8]#8:/CQ)([1^#WHY^-R&!G6C<9K@"E.BQ;2!+\UC60UI8$@9@B@
MJJR*Y5I"0/6[2/*M+3+KM8]NUKW[O&U[CND=1Z@3W[6]X#&S[%XFBY6,X[)/
M0>Y\*:115!S+D8\'@9"I2U\<A%OH,:@%'AW*O<OJD0 A!CSN^$0V,8UJ+&/3
M_P!+]^$US:U&DC\J_,L"!3>Y[QIQM!;A%"D8Z7$G9 "637N0LCFHVAJ!&=<"
M*YCZQ!%&19K0HPC'>#D&K 6HZH L"::< KZX$Q.+KQ'2'6.(X]W$SL[)NMH,
MBE=$D2+.<KD>.<VA=4KH&9)B0P$3 $2$J0%))!'#&A+WC=?_ "HY6/\ =I/_
M %<:(['U?AF<?)D^]Q]2?3UD7N6Y/_GZ/\.Q&W.D=?AJ+4J91RT*HJV<1$J0
MTAK559%*[PK!>*]VP^+^)C\%ZY/;;X+X\9QY?5;Q/SS-CTUX.LN@](<'[=ZT
M_P!KWKX8JMN<C:FJ%&S&PJ%H)0'IYJ,U"$QL-4 .6D&9>N+@>F%X'JPHL-U%
MK^PRJHCKFVG&?]DXUH@;D&/"QN0]\2)#?#L"'M+.<7)0M>*48$8WDFJ"1.(:
M1(F.ES3IZ"I$,@$]:"9B R++OE&LOT-+HNZ/%;D%K$*-*J%6LY9MEDXS&E=L
MGV:D5*!'YO45%'S"9C D!YQO:6JG:M4".4K'*(@ZO,^\FFDED=_O&Z_^5'*Q
M_NTG_JXCNQ]7X9G'R9/O<6WT]9%[EN3_ .?H_P .P+7VEL"CWNO4;DG*^1LC
M+IP2]IM,H6,3 <W.CYO@OAY;N &QG5\7G'Q/_FZ>'X:"J"5-ZO-S>!1Q63A^
M<TYNO;3QX6_]TG$5F6VF235&36V9V#01YG)(VB:DLZ]B,UCTRVR\=#5(KB]Q
MO$CX7L0>>\OK[Y0\J?\ N4G_ #X;YC4^%9O\F3[S!?IQR+W-; _/4?X?@-S_
M %#K^%BL^2W(N7;Q9(J6_P#9./2&OU[MQ %X01))B]:+U^$EO>_*B*=%%)15
MC%?IJ&IWRWJ<S/!^$RR;O]&UM7;#U'B.'KK<1UB-S?:_)'R^95V?V-A8O3]L
MR^:DYVH%3"2(K4*>N *OTK&,N"L@)C8:UMK+ +:?E49;_0ZLJIBQ&R,JKJ>+
M!F+[097_ !G'BDM;%\R"HVB ,SF@<VNCU(RN>=A@1'*K+Z@+$14YB"PN1$')
M':H1:0!E )(+6%QJ9R+ @D+)=L<FWM<'R#9&8(^A36O3+'?GF8R%J4O3SEXR
MLB1*W1(IX*96+,K*C7]Y?7WRAY4_]RD_Y\"<QJ?"LW^3)]YB?]..1>YK8'YZ
MC_#\"L'!M?8QLLHB'Y6K8,O!F$1Q/1&0 D%?N:J(J@D-68]K_'^1KD"W_P"*
M+\12P5,%*>W9LY:H'<DU"T?_ +YX<>_U_#B"J,WR;-,Y5URK8>C6'+"NA9*1
MHY&>J!U<*2,!U"VZF)4]8M8LCT[6WZ.Y2?ZRA_=_#-ZGV>;_ "9/MX*UY-X+
ML-\JE^XPL=@ UU%L,><,7+M#\867*KZ!E&:G\643E:M]T>GJDEKE_P"SGB1R
M):N[BNCH+S RZ85!64$YD>E!;>!PXO)_P=R_#VWAZSAQO;$/FDF4B6D*Q;)Q
M6CK[FGYLU.?S;@:JPALZ\32<3:?I733J']U+%US(Q-Y"1M R7)>WS.YL)M"#
M(4:.Q,UH^CR\KPKQM1&0?SK5:-%&Z/$>QT0/E8*D36#9@!NXS:FUM'ZT7-]2
M](GBW#K[I'$K(I,H-!=H=EY#SFJ&K-#2K5"TS@*1NY.U*.$8U<%Z)6,@QHS?
M3M;?H[E)_K*']W\"WJ?9YO\ )D^WB8UY-X+L-\JE^XQNIY)F44?W.KF\2'[)
M0J-A]ZN*_74A8^/ C^\%AKIAJN54)%*"2S\Z22>$HI09R%>(B':C^-L;+:^P
ME+K,Q;747-0")?ZQ+;5<DVMZWCZVV.$N6\P'E(SHTR9>D7-\HTKEF@T0/8JC
MU;K0JK<M<R67])JO<X,@YC'DL-%OJ0!6"9;2!3*_F4YD+,4^2/'W)7074UIG
ME3Z:.=9D/"?=+<69%C]$"110HLLU]"L.-36/>/Q''E2Y)%-E%.ZVKJNOH'75
M.MU9CY@N95+F'6)>426,ZK\OL>P23/@5 2V,!#CBJ6RK1@5@FUE<6^6%8]X_
M$<6[]?Y8?G6VC]N7,S]]N%A6/>/Q'%6.=')>6N-R\Y'(A[5V(IPYOI$BK8[J
MYAY,-D=F\];NEF**XS(M>B@B(<P3%9W8YF#D1'#EB 1H]7N333"H,8@*$2F5
M@L86X]>S$ #JXDC%AV42J?:/*%I(ZAZDU:B%*5)7J&?0_")(096<B]@@+$7L
M,:YO?+Y;/GGR'[:MP_>[BM:-G?;,L\I@^]QT=S/:WP#:CR#.?N,0V0[.T&.D
MLGT&W+:=;I&?Y&).W3M]T8Y%5K7L(-V<01G7M*1PHQ;"N#**C(Q[&O$5\P""
M;.W';,L\IA^\QA)1[8!&W>7[3E[< U!G-CW_ /@EOPO8%E!-@64&X#,0VOK<
M^06@LKV"*EQORA#5LNIWON.19&G>:$P,>8Q,X*-[&P>Z0DA  \3(QC&M:B]7
MI39TCC+EI/OU,%O_ .;\&&HJ3;4NV]RS:1$M=2M#G)8M<  ]J/\ 9[MAU =6
M&9[Y?+9\\^0_;5N'[W<>:-G?;,L\I@^]P1S/:WP#:CR#.?N,)3/LZTI/V3@:
MXUM'++-0X/LU)KH.U=N64B.A+[5'ET5WM+(D1PF[9U(T2L"9X1*='D#'5DOD
M]+LE42S1UK94U.(PXUU<:()@P$?2293JT--I4FQ&HV.FXKN>R;;Y=)1RT4.T
MU-4NE5'JYCF8=H-5*T@430&ZB182Y4<#H!(U 'U]JM>_+[8?VA[D_?W%@[$\
MGG>R7Z0__-8A.SO*=[;M3Y!6>:X&,IR^A#$@OQG*LPMY2V+&S8]ILG<8!,KE
MAS5,4!ER,?;DJ=(P&.Z)*=!R(^.HW/,'%LJY/Q;0,D)OQOF-NC8]1%5UWM_/
M$>'/>4[A:3:DD'NT%9[_ %?FW7W/UXQL*S"I-5R5S#)<LI+$=B442/2[)W&6
M-)JV1HGE)AQIDLIL.:1RF#)@,ES PW 0$>=81V"G24F5<GY%Y%R0-?A;,;]'
MN$_G9L>NXN0#U$CB?%SSE.MQDVH''J%!6=5@!_ZKWA;]5L&'M5KWY?;#^T/<
MG[^XR[$\GG>R7Z0__-8R[.\IWMNU/D%9YKC6QS&9/@Z;KO7LS3*7B?B6']!9
MV:[$+(>K29 CT4UA;OEO&Q5\&-<]1,57=M$ZG^/0_([2[,09)FD>7R!*;LKJ
MME]?7[G>M24X<L:2H*&32J!M1U!0O<MCF?EGKMI:C:3+Y,Y-4]7V'B53FE+$
MM0(15U90*M7"L@BU&0J5&@L7L2=6$S[581\M+[ZY9O\ O;C;VZR7V^M^D,Y\
MXQJ#?U_L:?R>@^ZP-W&7U3)#DJ<CFS )"$X)9>;9NUZ6"SPH49?&^"K8K:]#
M%8X;"$64@T^-K58\*H6C5R*9IY$W2E6DS'.0=]OE#!OSM;1B'6P*AFWFGN @
MD135!7MK1HVLW"4U!8IH-B.TF[[S2""0--^-^(F*[*L16!"6;EMS&F+% LN.
M#,LU0(92B;Y@849=':@FEZT$B&+^1T^+W+XJI,,>4F*(RRUB2F--XBYAG&E9
M-(UA;53=$-<+TFX6XG#4D];O'T;ADU-H9J>@U%;G23>%3<BU^ X]P8S/:K"/
MEI??7+-_WMPYNLE]OK?I#.?.,8;^O]C3^3T'W6.VOW*(T>1[GQR^GB2"RXIJ
M[8Q(\DTB1**<+]M[ <,I),MY)1WO8J.<601YGJO41RN55XXTVP$8VJVB$)9H
MAG%>(R[2.Q7G,EBSREI&-NMG8L>LDG&\LF+'*,L+VUF@I2VD*HU&!-5E0! +
MWL% 4=P6PJ]8X[B)=4:_GY"3E,'91]=Z\DWAKG*\RBW$:;/IX @/LABL1+%L
MGVK3M<R.P:Q[%I>RT3T:O%;Q)^\+VZ_^NWP88>/U6OHDROAXA*Y*ZV2Z][U7
M"Q+*\DK!+DP[2R@%-!B4,^-&2^=:OL:^88(TL#2'>1EO?X@#PL><?\O^K%DL
M,]^E,2QM,*-H:;B"4M=[,RZ^TS^U@2:/RH_3#0K(KI9)T0D3M.CRG23]X*L>
MA7M5'*L+"!YXJWF"NN3#FTIK-^G(];;<MN[:R?(@+FQ9P(<_6^1Q9)H8Y#&
M)*$$KW@&9[!/*UK2/:Q5<@E>@DH:V,D@24E2A(%R \+J2 >!(!N <6'9&J>A
MVLV8KHT662CVAR6JCC=BB2/3YE33*CLH9E5V0*S!6*@D@$BV.4'^#<V3\Z^#
M_5.^_?O',OI4H?#:OYB'[W'W0_*KVI]Q>0?3F8_AF/"5[F]L <62^;MK !PF
M1S/EODXK=LC,BM&Y9#Y#RWR#8!HD>I7$5&-&CE>J-15X]796B#*4K:P.&!4K
M!%J# ]'3:6][VM;C?JPU/Z*C:.6&:*HV(V<>GDBDCG27.Z\Q/"Z%95D#99I,
M;(6#ANB5)OPP&UGN>$HUO7QZS=FJ3WDN"V56@'2W)[*3!?$<9DB,(F2/D'$L
M/ND:5K7J@?,N1R)YC@J39E6B=9*ZOW.OIKS:%8PVH'B%<*.D!PX D+WEM T?
MHE7IZZGJJ38/93LDL 6GG.T.9S59AW)0,KS4$DKV@>11(2SA)*@!AO9]1S_!
MN;)^=?!_JG??OW@3TJ4/AM7\Q#][BQ_E5[4^XO(/IS,?PS$'/Y1MBZ"R37^P
M7YOA63.!E5A4AJV4=[6-<2SP/-6*<DI;*:J,"(151C0*YY'#17-:CO$JGR6B
MRN.LJQ454P6F5"ACA2X>KI1<-K;B#;@1Q%^[;%;VAY;=I^4F;9_9D[.Y#E)D
MSJ6M2K&9YA5@-29!GI,;0FB@.ET=[,)+JP7HD$V:GM7LG^@X/^T7W]CPSSNA
M]A5_'#]6/.P^U7MVS_Q9C]6(>^R;+S54D>10M=I3N?%\TL^;>@B=39D=T5#$
M<P;419B1T:UST:]ZM&Y'-<K5<AJZ;>+N8ZTRV;2$,);UIU6 !/K=75U"YP'F
M&39X:27LE/LPM%JBWQJ&S".$'?1[K>,Q50#-NP Q"LQ"FX)!A,4O;"')NEPZ
MMU8*460GKR4\RY<1TMDZU\7SV"8[IDOL7W#R$(B%/*=+(1Q'JYW#M15QE8N<
MIF&G3VG>F(#3IC/0)'4$W? < ND"PP#E.1UB2UW8:;9 3&4=D!1&N+"83U8O
M4JA.F5JCGA9F =Y=\S%FN<&?M7LG^@X/^T7W]CP-SNA]A5_'#]6)KL/M5[=L
M_P#%F/U83.9V&P;C/JI2!PT!8^(6/3T$NR#<,EU7^/CU,:Y'HYB>'AXM5JKX
M^"HG'E2]#/0J2*M56K[FY8DF$]^P L/AOAS(Z;:FAVEFTG())),B[IS%4"+7
MKW@6+EF^"WOXQ_*[!_VL-_\ RW_RXBMWEWLJWY,'VL7WG&UWL-G/EYG]C UD
M4"Y*T*9*;7C&I$M^SY^3=1O&#Z>1UYX*I1*Z*VM:1U@JJHF1D5QO!G@O!-,L
M"EN;-F).N*^B*!^GO (>ZUGWA&[MQ+=5R,0V;OF4HC&<KLBHYOF CYU59E!>
ME-*QS, WC+0<S5C5W)00 F2R\<9E#7Y,"O0>/.P+TYLF8WPA$NRA24.44<UB
MNZGJA12F%$0;G>(G#[2-:UC6IA4+2O)JJ'S R%4]>D )0J"AM<<"I!!MTKWN
M22<$96V>0T@CRF+9448FJ !3RYF\8G69TJ%+68ZTF5XV4GM93=@*J!1,^5V#
M_M8;_P#EO_EPSN\N]E6_)@^UB1YQM=[#9SY>9_8QU%^XK,LQ\J>:-MU@K.3?
M.6=Q:[S'E.E<#UDH^CS/Y[J[?3U]7Q=?CT_%X<="[ B(;+T(A,ACWM;;>A0]
M^=S7OI)7KO:W<Z\?(/T6;5C\N6U!KQ2BJYCLV)!1F4T]AL_EVC09@)+Z-.K4
M/77MPM@_V1DV$T>Y=\LR.TQPLYN>X8:#CMGS-7^D)SY!=):V8"[?6P\G@U?I
M5>T)89+8=#-NYIK=0PRR(U1+CLN6.;[$]P^]8?S_ )]["G7*\#;#9+BS=7>M
M(4W>%)YQ\BAQ^PQ,+"SRUA%WI92#&/"2X8U)$6(-A<:APB.2+'JI]VL+2>\?
MB/U?7BP.L,ST+*QMY-B[KH<0O6V!!1ZG&><S8EA ])%"@LA&*5FUGC%*&Y#P
M7 $4PFQX48@W,81H1+"TGN _%;Z\,7VJY2/UE"?\7NQOQ5X6%8]X_$<<CO,K
MO';V/<Q>_*C4&V-D2M;1-T;0=B<JCR_),HJY4"3F]Y+-*BY">9;'MTD3CRS&
MFFL9A2R'E5YG.143GS;2MVPBVFS2/+*:MDH5:EW#Q9/#51D&BIC)IG:BE:2T
MI<&\C:2"@L% 'UR]#5LGZ&G,>1+8>MV]SK9>DVMFASTYO3YCRE9CD-9&R;3Y
MU%1B;*8-J,OBI"V7I2.@2CAWT;)4$.TID=)_"+YIOG1V]](W_P#9\5?LCM_X
M)F/[/T_X=C>GI&]!S[HMBO\ ZPYM_&F &]W_ ,W19YWQ;_/[@:R1N;,GV$]#
ME"^I)&.5RG:XCI#"/9 8CT&A8"G"YS!]#B2%/6[8-&IG[+Q/H8E$V;B<!Q*-
M N,LMI,6IR025?38&[!:=F^R/H98JN9,J/)UF%**B$1U%1RW5].[TS9?(9Y-
M+;=:S/'7&*"-&2)):;?AGCTQ22'WPB^:;YT=O?2-_P#V?$?V1V_\$S']GZ?\
M.Q<?2-Z#GW1;%?\ UAS;^-,8%KS$<T9*NQ87:&W'#? F,(U]C?*US'1R(]KD
M4?@K5:JH[Q^+P\?'C.+,-O3)&&I,QTET#?T!3CHEA?CV.X<+\<#5NP_H/5HZ
MMHMH=BS*M-.8@.6#-G)D$3% %.V9#$M:RD$-U6-[8VRX9+Y)$P_%$E;RQ<4E
M,:HDDB=S190!PCI5Q>\-P&[+8T*L)U-42,8@U3H1C4;X)LB6* R27IJ8G6]R
M8(R3TCQ)*W)]\XX@I,QST4E*%K\WTBG@ M55@%A&MK6?JM@E\YR.?/MBW_%1
ME/XG<8;J#P:F^8B^S@CLEGWA^;^55OWF%)22>5(\RB)99YJ^E(Z48]U,9S1V
M\I((Q3+SM^G'B;E=+?*E0"5JBE.B.04J78*>.T4AS8;[)3V8".%A:P&Y07N%
MX$%+6%B"+\;"QX<8^*OVE+1%Y:^)@Q9W%14MHLTWK"L^K4R,MFMP+R77I$*V
M_.<CGS[8M_Q493^)W#&Z@\&IOF(OLXD.R6?>'YOY56_>8K5S>&Y/Y&@,O!B>
MXL?N;\EWK5L*MB<QV2Y!(D,7:6%K.45238<YDE05Z2I+G^5(Z(P+IC'"?':8
M8U;"AHJX0TL#2FAK BK31.S$TTHTA=!U:A<%;&X)%L3^R>:9@FUFRCYEFV9T
MU"FT^SSU-1-F5;21PQIG%$V]:I$\1@",%82B1"A 8,"+XU7>E:9^53/M/R/[
MS\:NYGF'BH?14/FV.^_3+LM[NW_;[,OQO&#9U6HO3YOD\ACS)*QC(&*?9U^H
MI#U8J((C"96 1&O\?!1$D1QE\>V21'8Y3,<BHZ[>QZ\L*('4LZY5$&4 WN"*
M5B".^%8CK"L18B5^TFS9HJI8-M!53-3RK'3S;>Y@T4S,A7=R))GT4<BN#8QR
M2PI(#NWFA5C(L145.L4FE6?9UD$!8S",-$V=>=T9?+5O7#D$9EY'R',DNGC:
M9@ A4$.,[P1Q4:C\])5F-0E#)(RL05DRI"I&J6SJ#2 *-(C.DL6U2,.X3B.R
MW:+)%JI6J=J*6DBDA1UEI=O*T2*^XHM5-,Z;0L\Q68U48D6&.,Q4L+=;A02^
ME:9^53/M/R/[S\"<SS#Q4/HJ'S;$YZ9=EO=V_P"WV9?C>*Y[^K]8"]D_2\@9
M)ZO7N_X9Y=V/1X>C=K_3WLCL]7B3_-Z.YT_E=70G3:-FJ:N3GNK+Q%?FUOZ.
MBCU6W]^J :K7'?M?W\:)Y:\^V>F]+/-]K6K-/9G7?;"OK=WJ[%:?7YK+NM=F
MZM.O3QOH%NN?7>Q*6-J3%*[W_P"JK7OQ3&9*T%-6T\O%I*DM!2TF1IB\P994
M:9,Z762 ;2#?75;*Z$\E:G;>/I7'Q6()/4?B/[^'Q\../&OR*#:A))D;VHF+
M!Q<Z2(US*J*]++TN+1Q)]4U86W1S9V0'A,++K)S&!#;4U8"GJK0=\R)A58L(
M@WZC[W D=_N_YXV;8AMO&Q8EBXEYJ>3V(H\=I!K%R''(4N_C*RMC-6/>2R<S
MKB2;@*IV[.0]SGFFM.1RJYRKPL>6/>/Q'ZL5[YYMJ8].Y*.;^$+F>Y/+HLSE
M?WY%'38_C$$-];$D:JRL3*VD,WF+MW"MYSGI%K2MJ;-PYA0O2OFJB1B 9H+Y
M9F("LY-!5C2AL[?F\G14Z6LS=2G2W$CHGJ-KV#;=[<[&2-)% $VKV=<SU"WI
MX0N<49,LX,D(,,=M<@,L5T##>)ZX<-'K</Y<Z\_8A??'CC_FD_B7/?G7_"L?
MI'],M#_>+R5?1T/\>XQIMW#6'+3VWP1_C&.G3$B";*=XB?\ DQG>V2=,A?Y
MN\4\"*U?%/#QX<AI)M[%_0V=#MB<99',8Z0XR#L5Q0?VQW5O@/,-I*$T%<!R
MA\FCDT=2 E%0PQUK$PN M))Z?ET53'A3OJ&F4HUQ:^ :ELH[+J$7VMH@L;71
MQJ68(7IKU; Z$86)[2@[1 =*A5W1"<XS1$2,J$)T2]732FDE7L76N3.[!(F;
MG !FO=9!E[ZE>X>VJ6RZEU]$7UWL_G5+'G^7S>GC9J"-<JIHFFKX(>Q$C+EN
M[$<]$=KZ;=34V@P:MWE[M.()!2$2RB-A>MP_ESKS]B%]\>(3FD_B7/?G7_"L
M;0],M#_>+R5?1T/\>XLCR?YW68MS,:HO)6RM05((<S,T?99)#CI21/,ZSS:*
MUT_N; JV*AGF;&C(MA&_CIXRHI51(YK/LG'+3YC-*V59M"!12#542MNR3/3#
M2+Y=%TCQ(Z1X \#UCGKT2V8TV<[ 4%#!MKL#F4C[4Y>XI\DR^,5@$>6YRQD(
M3:_,&:%;6D&X U,C&1;:6WR?"7Q7]8+E)_8Z[\<N-@\\/@=3\\?-L<*=@)/&
M^7?1S?BN '9W,=B\O"[,#-]<MTMSI5(Y 8>"M#D3NU?5AE=7E7<T[MJ-!J20
M](Z*R(P[DDP%1)\9V"K)D4&EF46;C)-T/6G@1S<7OU 7Z^X>HAU^S\AI7MFE
M+)THNA39<PF/;D]8>R;6MUL; !0260 NHAJGF.QP-_L(IMZZ+"V39C,.=FT:
MO6NFH2_S O3BH#;4HY42O$PHY+XKQE .-/K>UU&=*G6#M1562&U,[77BL<W2
M6R1_I"('!)-P#?CI/<L -EV0S&:MOF4:C6")*O+7"2 S5/\ 5PV80LJ@68J0
M0%DCM<EG=V_"7Q7]8+E)_8Z[\<N!>>'P.I^>/FV)7L!)XWR[Z.;\5PBLLV[C
MV7;8A2 [UY9RL@:\,%TJMK(,B"CY&2,>D<K6[E*C)?@%2,<LE%4*N3L*B=SC
MRH!JZ5;TM9T*@\$DN>,8XG\U/ VL.'</'!N2J,DS6HWF<Y&G.,OCL:JDW0.Z
MJ7N(PV;I<]L!:Q-AIX#KQ(^U]%\^W+C] P_QFXC^9?ZIF'R__P IBV=G(O'N
MR_S*_C>%;L/)J:18XXK=TZ>EM;"S%CW8]1PEKF>8H'!:"[#[Y]LKR3U=Y*H*
M@A^5E%,?Q*K4$XJGI"JRVIJM;M">V/TNC)>Z'FR^M]<XXW  X=>(K,<YB>6F
M_IK(GM'6C\WA7<].G*Z:A>RTUR]]$!TC2[,>EZTYFK,DIH6*- 3=NG8CO5KD
MO8S2JAS+Q&GGE*TA)*[9@O+&.UZ'CM>,C@-(Z,V0886.X\JJ37+JYK5GH(.T
MM9."VZN:M8CJ/'CUV%\993G$45&$.=Y$IWU0UJZ-'J.E,[ E^S$9*L#J0%3I
M!T:F"@X8WM?1?/MRX_0,/\9N!N9?ZIF'R_\ \IB3[.1>/=E_F5_&\;;^3R>L
MWD$YO)M3=XCF!5E;K6%9XQ_DK%Y\D6@,):*.PD:SR]T-@SM2+/DBE69!E8<S
M8?6B1$VOLM'NLEI4T21V>HZ,IO(+U$IXG1'UWN.@.%NOK/#/+74+5<HN=3+4
M4E4&@RD;ZA4+3-IRJC4A%%14@%;:7[<UW#<%]:(NIRVFD(>/59P0P.FY<E+)
MYD=QVD<(TQN"&;(@4]WR1SW1)4&K/'""TA@#<I(N@U_G3LMJV(6PXU60.^>'
M#UH_R.)/",NJY.=8Y#H\C#?7X\HQ=:VJL>8'<P:H]S/RJGE4$>WGCY(JH'IM
MW;XJM(05M;"K+$+SU\CKE0\=)5K"L.^?B'<_^;_KZN_QV4^O\R/S4:0_X@\\
M_P ,O"QYP[Y^(?7BD_NB,SF!N>4C8-9:ZWT[5P9F6Z-$2=7[PS6WE!(F_-8/
MBHROD\O5*$S"RF@!(>ZR Z-'(64,<H@61#PNT:J^1YDCLR*U,P+*H=@-2\0I
M= WP%U^'&RN1ZJDH>4W8VK@A2IE@SB.1()9FIHY"(9AI>=(:IHA8DZA3RFX
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MV" V*]I6E,1YP*!@Y-PV2V:3.Y*ZDIZ]HFC2"H9YJ0:=*-+%I 2J<DDS7N;
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M TZCQ#Z)7::FVNVTRG-)Z>?*V39VGHQ3Q&/,598LPS"3>F9VR\J6,Q7=B%@
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M.5  D0D]BZX6&H7-[<+=_ E?MSL U#6J.6/*&+4E2 HVXV7)8F%P% #7))X
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M'5E)%F5EN#QG>\/!^7N<?U>$?<SCD?FN7^+X?GZWSK'Z#^SFUGNKS'Z-V:_
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ML+\XX74$'N6X'A@:LY6]MZ>G>:JSV-H$:+4#DV42#4TT:QG0:$W*RLA%@6!
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MUC4O4V1"Y4?G,M[&1Y'X]9NQXGA86&.!N783#E+SK?U,U7*:;*"T\Z4R2/\
MT52!05I(*: !5 4:85) !8LUV(YM/-<=Q_<>^JV\S6KJE=G^#6,+'9F8\L-&
M619MTEKP$&W-7[LP7(L@CPZ\23 ^N0[ T(;K,T:GJ5F>L.EV3&H;$]P_$?Y_
M\,*NHV?B,ZUCENLMP&G8!U&P-PNS^1>R/&::TI8\A0CA\OI)H_9^&1UT]!M0
M9A0X\2O(2QAV(*Y8]TGO'XCW/U?%^^V+%ZMV;K8V.'?/YN*?5S_4WH''H&?\
MFY!20>G5J^I$95Z@@B 9IU/4.&4'<(VI9*"0D&1$7A8\L>\?B.&3[Y&J/_$
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M0N=*G1O3KZY6!8L9$EFCBD/CO@*K13 C'*#X*JM89!D\"C(UODKB)] 2EDL
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MFYN;  $]1Q [2[$;59+E+9I6Y?2\UH\PR5Y=UF,$DA#YUE\2A$*J"2[J.+
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MV,0(T'YQ);TA-1!2[;Y:A4MT2LF9:KWX ]-KBU[\!8]5[FWID/<9?U[O^?\
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M:ZFU.JFWYT?6@EC<6 !N0+D1.*<IW+YD<_(HDW3V?X['I)RQ8-A;;3W7'CY
M!9UK%9-K62<UB'0/8KX\HC2C1[&V 4;W *"5)];+<O4*11T#:A<@4E/=38&Q
M[6>Z2/U?J#<'*!MQ,TRMM1M9"(W*JTF>YL!*-3J'354J;60,;@$:AUBS,;?
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M?]+B3_CPZS;&U7'-16DO'J&4WE7Y4+1LFFJY#;.7G]E&E6*&@@(DZ3'!RLC
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MBM:)LN0,2; <>!((5R C!VJ=+XU<7N>@707+5D[J^:$;HTF-!KZBGZ\CS43
MT<X.E[A]E'***.,]333/"&OAG:L<<YM= =J8*1$@.EH]2DW%-$S-T(KEU,Z!
M3QOP47N0;Z=1$RK.]H'GK[3K4E74%>S%=%%$!45H589%H)3*A T]*1M(0,-
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MOEU:]$Z]I$ 8C2"^]TGUH*DNGAE*CG,=.K;PZA%!DUC#NVMIO$>V;TB^HA=
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MT,M.>?.=GLB6KI:I8=0$<4459#/!--91:=7ANZL95B2>H)O!W\Z?]H/_ &G
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M>?/GB\R-[U7<VGE]MU^W/AYP.M6^7Z?8_P >WZ7@5?X]WJ3K[_>\.TWM=O\
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MN<*,T Y!"E:B=OH:0KFQVF5&Y?1=TN8J(_2!6J8#SD&+:F.-[HK1\&[!D_\
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M2Z14\DE#)I!L*F1 &URJ73\!S&OG2V#^QX1]UN(_L)E7M$WE+?8Q:O5AV_\
M&&5_0\7G&(R[Y(,;#36YDVAL!RAJYY4:Z'A/2Y1Q"O1KNG%VNZ55/!?!47P_
MD5%^/C./),KWD=H)KZUM^<M[(?Z&&*KE?V^>EJ5;,,KLU/,IME$0-FC8&QW_
M  -CBOF,XWD#L<Q]R9K8-1U)5.1J4U"J-18$=4:BK!551/Y/%5\5_P#C\?$=
M42P\XG_-E_32_P#"R^S;_2Q?<II<X.5985S^H5>Q]%91E^6D*.;166YIR38<
M+DDGN\<3?LUD/RVL/H6@_N/#.]@\&7YV7[6)#FF<^Z&H^CLL\VPJ*>DLQV-
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M)')IWB9UF*OH)*:A52 Z2RJQ6_42H-NL8WMDLBS9/E<J!@DE!2NH:VH*T*,
MUKB]CQL2/?P"ZKV[F;=0Z[BX_P SG*W459=;Z]%4QKK)*AV1T,.+15[_ "CB
M]YT 5D6 H:V<MI5WC(DB.L@ 7$[C"UK$I8^Q/Q&W^'^>&9 VKE46X@FG<WW+
MK;4HY\>18PUR3!:R3)A-FE(:OC%!62EC,6(K N.\QY!D40QE@FB'GVJPK'V)
M^(_S\'[[XL#C>]]/P*&HAY%O_4UW? @1F7%JW/,(BCG6/;199@QX<R#'%'4R
MO;&8R(!R :-2M4JO<JPK'O'XCBN?/)O'2UOR6\VM55;<UE9VEGRV;N@5U;7Y
MWC$R?/G3-;Y)'B0H42/:$D2I<HY!ACQP#>8Q7L&-CGN1%$S %J"M5068TE2
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M:R%=B]CQ+F*+/7LT<;K7#<:HY*>G*Q NAH!()=;5*S,SX-.??JR%_KM&_?\
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MXA:(1'L:K^ITAK%8CG(-7([P3C=W(]2+&N>J%>GN: ]J85>KA5#I%!)N[6X
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MS"_2(4\6PS_8#&/D;N#Z!WQ_=>,?3!DOCC,?+L]^\P3V"S/Q1!Y#0?=8A[K
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MV;>Y7MKV<@FAFU*2$K&Q-E) 27Y_S21$V[L! )(]5_REWD'T]SSW\:ZO'O\
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M1YF%PHQ&NEH!AU))&K([BD&A",8)]PV WGISV=W00R=D8M D9E0MI>VIE5F
M]\*3[V(3:31V"S/67"\U>^E06M=>H%@"?A(QR.]W-OZ%BWTI;?N?CM2V:^U9
M?Y34^:XT-JH_9U/S47WV(;(39.E)9+9P\;;!\N[S"AM+/N=*N:C43NTZQU:K
M^A'I+182L5R346(IN!:T9@*6<SQT(BT'64J9]5KCV=)HL38-O.U:;[WM>K#L
M#4QFC$;5!?5T08H[>_U3:NJ]M'3OZSIZ<#&(GL'6-KZ&RE/)57.F><M;9S3+
MW&=1AN)1L.Y&OZ43K<C6H15:SQ>J\ Y:T[35 I!2N]R9=[4U)#$, 64M2!R
M> OP%S8<3@FKT+'$9]\JVM&%BAZ(() (6<@</U\!<X8'=S;^A8M]*6W[GXF+
M9K[5E_E-3YK@'51^SJ?FHOOL26%Y_FNO]E55NF/XO:%E8/F=<V.M];0QL&2_
MU])(9QDH)+E>UT43&#02-<TA'.(U6-:^J[0Y-F>=5>74Q>@IFCI\QG#AZB8,
M%DRZ-E(W,1!O(I!!(L""!PQ9-G\[I<D6LJA#45.\--3E#NX=.H5$@8,&DO;=
M$$6'6#?A;%@OA-YW\@<2^N-Q]T>(;T@9IXPH/FJCZ\6+U0Z;Q9/Y1']W@(SK
MF0NYD"K9D.$T,6,*Y$:(:NS6\$=DYL"Q:-SGBPYYD$T#Y#U4*(]'M9U*H>ZU
MP5=L+5PQQ-4YE1HAF559(JDD.4D8$A;M;2K7*@D?!?#L6WL,S,(\KG+*A8CG
M,:W74JD7,8'61P)'Q\#Y:]YB[FLIY<;&L&QXD)UDLB0V;F=FJAFGK*PA!QQQ
ML.%$!'<!8QVAA#9!0IC/AM2,02<>4&PE7)$YILRHF19+-JBGN':**2PTG3IT
M.A!2Z&]T)0@E3;>Q0L%DRR<$J67\XCXJ'=+\8@?7*W @,.I@"" >?";SOY X
ME]<;C[H\'>D#-/&%!\U4?7AKU0Z;Q9/Y1']WBL^9[,S/+]B9';KCF,0"I4XS
M#?'2_M9(^D [0C",-Z !RJ_ON1S5$B-Z4\'.\5\+%LUDF9Y2V94HDH)R9:><
MN7J(@-<.@*%$4G4(KDD]WJQ5-I,[I,XEHZMX:FGM#)"(UW4M]$I8L6+1VOKL
M %-K7OQL(CVES3]$8O\ 3%M^Y>+3S;-?89?\_4^;8K6^H>_5_-P_?87F6Y)-
M2;(==0:<)TI(_?9$N;56DK4O(KQ-&WT%Y'2'6+1.<D;P.H1._P#@C4="9E%(
MDK\[-*KBD1F$<]58P"KCTA0*4DR&?22(^V%$/< O)4<B&-=P)RN_8*7BAX2F
MG?42=\ %$6H=/HZF'OD%6/93DY:.K6MK,=) '##'B/D6]FTRABM\LSN=NC:)
MRH@NE""3M%1$()SQN:]TC0PU\E)3M3BA:$1*D1>:H#%(QNQ>U*%/K;:EZ+#I
M*2I!(E3)2+42B4U(D+EG"1Q:;OTS;5,6 Z5['B.H@$6Q,^TN:?HC%_IBV_<O
M!7-LU]AE_P _4^;88WU#WZOYN'[[';/[E&60?W/GE^-*8$<DM?L8AQQR/*!A
M7[;V XC0D(,1'C:Y51CWB&YS?!7,:OQ<<-[;!QM?M,) @D&=YB'"$LFH54@.
MDLJL5OU$J#WQCH?(2K9)E)35H.74>G4 &T\WCMJ ) -NL D7ZC@-U7-S.?J+
M7BUF]-Z8_5VFM]>N!35_*7N&U!4Q(]%7RX]?6Y '%$EN @BMKCV5+-@+90 B
M($HU416U?$MAEU!LK@Q)$>RWMS"7<DUHDP=C(Y4M[0I,>"TN1R&58P5V,1ZU
M1BD6]6]LET!2F!0A@SVS8$@<:$L(_!;%@<9V]CM-CE#47#=Q9#:U5/6UUC?%
MY<]_Q#74V%##&DVIHQ, GO >P*)THXW392M*5_YY_P#+PL+%8^?[<6)6?(KS
MEUT:GVJR3/Y6=^PP/G:*W=5PFFDZLRD(G2[*SU[#K:^,CWM4\V?+C0XH^HTD
MX0L>1H.:"^69B!:YH:L"Y '&GD'$D@ =\D@#K) Q;-@I%BVZV+E?5HCVLV=D
M;0CR/I3.*-FT1QJ\DC6!TQQHSN;*BLQ /!;ZDW]&Y']5,G_=''&/,9_9T?TC
ME_G./TW^G;(O:]H?V.VP_ L>9IZD"48X62@(\;V#,W$LE>X+W-5K2M:^G5CG
M#<J/1KD5KE3P<BHJ\9+12JREFHG4,"5.8T # &Y4D50(!' D$$7X<<-5&V>2
MRP311-M'3RR121QU";&;6N\$CHRI,B/D)1FB8AU5P58J P()&(*"*?%F"E2)
M>6S!,CM ^$_#LG9&<YH6#[S>JO*5"*X;2.<<DAZN4BJ_J*YW!<T0DB:-*?+X
MF,A<2C,\O,@!8MH-IU72 Q "*@MI%K*!BMY=G4%'F$%94[0[6U\$=(M-)ETF
MP^V"4KNL"1<X1FRN:<2LT22LU3+5REC,3+JF=\$/J3?T;D?U4R?]T<!<QG]G
M1_2.7^<XM/IVR+VO:']CML/P+']@3''R?#QAJLE(3UJ>J#9B>3N(_P ,3R7Q
M08TJ.LCD3Q<K1M<Y&->141C'N:;29?4/%7HK4C,U&@ 6OH#U5U$QO:IL!8'B
M;"]A>Y -*VRVUR'7LJY&>HL6TDKNTFR6UD8L=E]IHP%WF2+K8M(O034^G4^G
M0CLKL_C_ ,GLP^I67?N3AGL17>QIOI#+_.L1_I]V;]LSK]E-J_P3&!9Q;B;"
M+&AUF:5L@C@.'-%@V6E(%!2!%>C1K4#1W=&-X5ZG=*(15<TC44;G8,KJXI5>
M2"EF0!P8VS'+U#:D91QYPUM)(86%[KP*FS ',MM,CK*.6GI<PS[+YW:$I5Q;
M(;5R21".>*60*ARB,$RQH\)U-I D+,DB@QMA4];D%>Z6MA'S2V20]Q!(3 <N
MCI&4DV?*<P?^33HHF"EQX0&>#5''@!ZW%(][T=J<NJ)A'N:2DI]"A6TYEE[Z
M[1Q1ZCV]3J+1O(QN07E:P4 # >4;6Y70&J-?G>?9J)W>2(2;%[5P"F,E9753
M)'_1DUXDBJJ>C@2RF.GH8B[RR.[XG/X_\GLP^I67?N3@7L17>QIOI#+_ #K$
MUZ?=F_;,Z_93:O\ !,;'_<S,OKL2VAM@M[4YQ&;.P+%QQFQ=;;$MBO4&0VSB
MJ\-1B\\P1M0C$0IV#&]R]#'N<CD3:7)YE]5#2YJ'6*[3TA&BJI9> CJ ;F*9
MPO6.!L3W+V..&O1>[391F><[!-2/F!$&6;2+)SG)<ZH2#)59(4T+79?3-*#N
MVNT0<(0 Y4LH.YCWY<,_H6Q_L8W%]Q.-A\UG]BOSL7V\<?\ 9.D]E/Y'6>;X
M",PV#6Y ^O?19)M'%4B0\BC21Q]%;DFCGFN*@M;73"*/%:THS4$DJVD)J%>,
MDIK.MK'#&5F2TTHOJC5N*V[=$+6-S_:-[C@;X9FKH)+;N>HBLL@-J&L8$NFE
M6/:5XQGI 7XGO=>)/%]G45+ DQKFSV=DDH]G.G,F'T=N*&D>/+*A!P A7#IK
MT"!>LB>,E0L(8@8$:NK!0JV'XU-,3P11P _2Q'B.[Z\?SUW-R?8J^FC4AYJB
M4EF;4:*L%@QN% ,+&PZ^+$ DA0J!44D]^7#/Z%L?[&-Q?<3CSFL_L5^=B^WA
MWLG2>RG\CK/-\7IY&KR#D>(;AMJT=H*)(W45@V7-%=XY/10:?T^$BEJ<BKJN
MU U7L<HGGA#8<?28#B!>Q[K=E*,E#$K !@TEP"&ZY&(XJ2.H]_'/^WDJ3;3U
MTD98HT5&!J1XVX4D(-TD5''$<+J+CB+@@X4F?4[;/=^^FP=78MGUT7,<4& N
M1:4Q[9"PX(],:L2=.%:2)L&]<^O/(JA1J;NLI0K82Y)R,E3 H^2Q3[>^/W_Y
M X6L2IAQZ]16.H\#/-E-,*%9-T)J",!7>>U^1#B@>R"H<T6 ?)H;Q)->(TC)
M,<F.2.A@182PK#OC]_U8>>LZ?43L99[1\M0-@739A13[JCY==71ZN/( "* U
M?$#4B"P;&E&^<\,U3SHQ9[XI))P CD585AWQ^_ZL,'T;0WZF$_\ X?,$_P"?
M"PK#OC]_U8T-9?AN,3=@[5DU/+5;#K2;DW(D( ]98C%9%CCVCEPAPDB^:&D9
M82,\HZ.QB# X*B'XL8U5U-M'%F#9U7&&L:*(M!H053QA?S:&_0! 6[7/#KO?
MNX[=Y)LPV6@Y/MG8LQR>.JK%3,=].<FBJC)?.,P9":AHF:33$43B3ITZ.&FV
M(+V"J?U;+G[.L1_OO$)N<U\/;RZ3[6-B]E=B?<_%^ST'W.%+D^!Y&EC;/I]3
M0*6O'/A/C L]<8$I:T \:G// G(81G.\_:NBW76^4.0&K@R& *@I2^5+BBK=
M"B2HF=]+ LM?-9FWJD$ 2#J2Z6L068$BXXQ%5F6S9EE-/EU#!%O$*+)LW2EH
MT6EDU1O>D)(DG*3DZPRQ1LJL _0;7L%4_JV7/V=8C_?>!-SFOA[>72?:Q+]E
M=B?<_%^ST'W.(J^P2I;1W+DY;[D:MJ;%R$][O$F]M4AF7KZFS%<WI\.KQ3XT
M\/%/CXR2'-=:7KV(U+<<]DZKC_2PU/FNQ6XFMD$0.ZDL?2] +'0UC?<\+'N]
MS&KW'-"9,7'J$J<O-H="TU61#IB^'N0R/@@<A4<^R1[D(B]:.<B.7Q\7(BJO
M%2GR_.C/,176&]DL.R#"PUM;AKX?!W,=695MUR3IE>6I)LTC2+04:NWI/@:[
MK3QACJYOTKL"=7=Z\3/O 9/^KG:_57#?WGPUV/SOP[_I%OMX/]/?))[F4_8V
M#S; !$T'L8AZ=K]1#.\4I_J$>/BFOB-M8OG[!C^R-LEDB.<* 96,8 _2AHTD
MIBD/'(*0:U!F($MI9!J7M;',I08GT(.)WQ5@3J<DK?B%"@$%:Q#MIL(7R\RT
M= QAG)KHX]AZ I6TYJ*ECH7L:LL$J1B*D18Y0MT>621Y(V6<_P#> R?]7.U^
MJN&_O/@+L?G?AW_2+?;Q9_3WR2>YE/V-@\VQ-XIJ"7BN<ZUR#).7RSBT-;M7
M59;0C\.Q.6U\0FQ,9CDC+%!.,22LSO)$2.@GM,XZ"(B#<Y4G]E\OS<9[0;RJ
MWJ$U(,?/C)J)I*@*-!>QZ1!X]5K]S&K>6K;'DUK>3/:6ERG9]:;,)>PW-YAL
MM#1E-WM!E4DMJA8%,>J%)%X,->K1QU6QNC]5T9^KC-^Q?&_[/C<'8S,?:S\]
M']YC@CLGE/@K>1+]6(7([;324%PZKT$^HL&5TM\6TFZ8Q5D2 5@7O25(+)AS
M(P!A1JO=)D0IT>-X>8/ G"&^(;T9;F%Q>,D7XC?1\1\X/\1\(Z\829GE9C?1
M3E'TG2QHELIMP)NK 6[Y5@.LJP%B X5/PL626297JZFR& R"1C*"GT3A\>7
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MQ-O6T<V.U(3<Z4T:];,=[JUZ['2#8*6 U-[4-*'7FK4ACT#5OADVK>7;4!I
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M8TZ9!<)),:'(FPP23B8$LJ.-[BL!S-BF6YBX9D*4-6P=1=D*T\A#*"0"RD7
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M/1I%#HVJGEE>D,*BG8HNS))CB@=N;/&J*D51*J'=2Z<&7J>7_)W'_K9/^Z'
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MG6.7HSR#3(@RF0 K;2O2'0"W1#T0W5UC+.P%=F,=ECZ,8+(+Q(;JW/%O?K/
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M>;39%)+B2Y=/ +%DVL./J](V/R2V_F71H8C#!#LFFCP7N(#QXK.);X/U>_\
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MCVKK'5D?&B2@W.H)U;-%D$B3+MH5$[(ZDUE7T%W%A1H8MD#LG!B2Y+:3%DA
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M61X/0K6M&SH57;KY*]O,QY1<MS;/H<MHLJ$68QY<::2IGK"QIZ2&;>B58:<
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MU=7<L/?(PV_F[7JVPS#UW;B,\SZVG4_&/\[)N4T6U#UVJ_!N@W/'E _^I_\
MY<TO_+AGTKYMX@?Z,A^YP3Z?HO=CF_T[G?G.$GS"UG*K=ZQD5%+7[*M;&QSC
M4,45::)S+3&30EV[@S9L=(MD,D4Y20?,H 2L=(<?MI"19OE^,TRS/\C+9M1T
M%3E-701RU%-F5/3I13T<ZQ.(IHJN-(W@<.0%D612";7L<(;19/M)+29%G.=U
MF>Y5F=?E]-7Y179AF^94=?3&NIWD@J*&66:.IC(348VB<=$$"X&$Y[PW+Y\T
M&SOJ/S%_NW@?U2N53W=[4?M)4^>8O/J6<AG]WNS?[+5/F6(VXT1I%E58/H].
M[#)<-B&=6CGX-S'.AOF(Q5"V0T<.,]XU?X(K$DQD>O@UTD#54S,DY2N5'6N\
MV[VJT7&K3M)4!K=VQ-61?]1^ ]6&YN2WD1$4A@Y/-F#-H;=B39:J*%[='4!1
MJ2+]8#+?JU+ZX#./:-U\6VDMR?2>4QJ9L-JQWU6%<RY)KIZPZ-58KSQRC?%9
M/7)&N>^-'(Z*RE<U.ZLU.'I>4GE+"#=;>[6,^KCKVCJ --W[@JAQMN^Z>.ON
M6P-3\EW(X96%5R=;(K!IZ)AV7K3)KT0<"6H])42&J!.A24$!'$R8./>&Y?/F
M@V=]1^8O]V\#^J5RJ>[O:C]I*GSS!OJ6<AG]WNS?[+5/F6*1<Y&H=-4_O<^B
M:USVL\S[7^:]0Q/=<3O]GV7[/9]<@L[G;[I>YY7QZ.XSO^'4'Q.HMN>4#,-[
MV2VNS^LW.C<\YSR>?=[S7O-&JI;1KT1ZK6U:5O>W"H[5<GW)'E_,.Q6Q>1T6
M^YUO^;[/U-/O=WS?=:_S1->C7)IZ].MNK5QWGX!L>$/3V,5+.8>OJ7GP_'"I
M24+<?+C1D/9#E#FPK%W,.6Q@V,MJ/L1A90#?4UXZV"8E6SRYF7#'(MC>]C^L
M7^/AQ/OVZ^/OXQZ;8SX-4D0F]@(Z-2&(%YRTLD\*?*L,08\/G1;?BSC6<(%4
ML6!<5\2VE$Q3_)TU6N?-J,56%I/<%A?O'X^HFQ_7[^-GF'[DI1XEBXS\V?*
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MYO;=+5@;_P"S/_U&_P#XN<7;^CO_ &@_^ZL4O\__ -E_]!X';=KU,3T-^6M
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M!9X FP59 =R\3V.];:"-(B(X9(WC=TDC:-H'19%W>#CX;VX_T+K/ZOY3]^>
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M4J321D9/$"L(C;#LQ5>DV(RE@S2S9PW2Z1?,*1B6!-NN@)8])B"+\&9AP).
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MB-DU@1^=XB./$I=C<PV$QPRCZ2U?W+&6'5TUN+GC0QQX@SM="]I9KI@V$DI
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M8ZR$$T(@2RD9#.]!DNR$<JO%F%.)%#Z2,TA<BZ,&.DNP-E)ZQPZ^%KB-S?E
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MV$T/EZ+I03MKH_J[$SK4O0O>_P!GH4_Q=/CVOR4=P+2IEYK<P,BYZ3:DL?\
MTF+6W;^NM=NOJU=R^GAAVH-5S:DT'++7J+W.3:?71^MU</AT]WKXXGNYCO\
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MS9\M7.XZ8UM-39.L"U)RUI1&*2/*A.9#"A;7OMV$%M&HZJ<>H.^4>R?J,/\
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M$JGL0;JJ*H4W-P!Q.);TH']/S/ZU9U^]N'?4E]#IXGV4_:&K_&,+\IST6O\
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M&RT^8YSLJL$KT^5YS4 !Z7/M:2(L3R*69(RJ,I8LR(VV7X1>$_T_F-^D,/\
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MJ[*.&3#E4;.:5OG8- PL4$XHL>&5SIS[PQZ>+*A6).<L6OAW[?'W1W.CW?\
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M[.X-CE8U_1X-1R+%Y9%.*VH-(]*LYC?>234-9H9#(A8J6S(F[OI8:E!(4VL
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M"MHZN3*H*NEDVK@:.6E?.<OYP'W=:KJBPZW9U93&%,FI=-P\_93DR^>S&O\
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M)CI^B R$$1L!+ ST$*-+L)\ZPAACQ)@8XECSAWS\7_:PVO7M[_-AJ[[:<G_
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M[?<].7E)+Q%D)5[$0Q "> +RIMK/^MP@D-(>(;G>*M&\YG-3P12/5.I>$]N
MXVQVG$C*\@SS,@[(AC1F%5+<JC/(R@GJ!=R/9''2.SQ4Y%DY0,$.6T14,0S!
M>;QV#,%4$VZR% />&!'5> WH]1:\'2<DNGLCC+K?7J4>239&LHQ;,'H=>DBW
ML*N6T<LY9];V)L>,:?52$FE*&:4355XZMB8PQ(&O<K/"(>PY&](5\Y+Z#"97
M!?K&>/T EC=MGWJ6"&BM)*CU4:E(*F=#CO).GN8DYX5DK5+'O#O_ +O_ !_S
M]^V+"8IHC4UAC='-RC0>JJ/(I59$/=5#,&PTR5U@03728BO@LMX74(BJU[(E
MM:QAOZA@L[ 3&RS+'F*S<_VC-+57(KSF6E7J36U=95W*SOV=7V$'"<;BS8,V
M+JS*3Q9<22"M8:/)CF8PP#B>PHBL:0;FN:BH#FA*Y;F+ D%:&K((X$$4\A!!
M[A!XC%LV"CCFVZV+BE1)(I=K-G(Y(Y%#I)&^<4:NCHP*LCJ2K*P(8$@@@XX+
M/1:C]%P/V0'_ *..,^R>9>'UGE,WV\?IQ](FQ'N/V8^@<K\UQYFIZQ@2O#3U
MYC-&1PA.C@&TI6M51C4BC<@T>Y$:KU:Y&(O4J+X>'&2YGF!90^8UJJ6 9A43
M,54D78+K%R!<VN+VM?#4^PVQR03/3[%[+33I%(T,+9+E<2RRJA,<32FD81K(
MX53(58("6TFUC"5]=)-*8V?C5-#AH ;WE0<4IWF4*(4:#$4S0N;(^-C462)\
M=7>,IA1,;(*FS"5(R8<VS"676P"[Z=4"ANB;MI+@IUFT;!P.UE6)2 RW8_+J
MBLC7,>3K8VAH130R/*,JRB:H>H: ">+=0B9*=HZGC&BM6PR4S.36QRPHE3/^
MBU'Z+@?L@/\ T<!]D\R\/K/*9OMXLGI$V(]Q^S'T#E?FN+:<B.N=?YOS=:6Q
MG-,'Q++L;L9N?.L*#)L=J+ZEG.AZDV#.B.EU=I$E09"Q9L:/+CJ8#U#) $XU
M:4;');=C*NJJLUEAJJB:IB-#,QBGD::,LLU.5)20LI(/$&UP>K',?HLLAR39
MSDOI<TV>RC+<AS./:O*8H\QR:AILLKHXIJ'-TFC2KHHX*A$E3H2(L@5UNK C
MACI2^!YRE_JP<OGV-Z\^[O&S^;4W@U/\Q%]C'S:],^TONBS[Z8S'SG [E?*3
MRV5]%,EXIRD<NM_?"+ 2'4R=3ZU@!E#+8Q SW/F2*2.('EJXDN6USB*YS@-8
M,,@KF1RY)34A8!X*=5XW(IXB1P-N 0]9L.KNX;EVIVI6-C%G^>R2 KI0YUF"
M@W8!KL:H 64D_JX FP,/B'*IH.TL<F'EG)IR[8U60IW9QB2W5VJ["1=0?/VX
M_.2A5]=.2"_R *@_ERH)W7,*GBKV$CQ<GI:(!=$-.Y(Z?YO&-)L. O&+\;\;
MG]76<(MJMK&:42Y[GL:JUHCV;KV+KJ<:B%JFT]$(;'C=C[X!U\#SE+_5@Y?/
ML;UY]W>&^;4W@U/\Q%]C#_IGVE]T6??3&8^<XT_>Z4Z+TIK[8VGX^!ZAUEA4
M>UPG.368,3P7&,=#8FAWN*,B%G"J*N&R66*R3(9'(=I'!:<S1JU"/1W5OH7Z
M&BEJ-L1+1TKA8<E(#4\1 )?,@2 4M<@ 7QR#Z*K.,WK/24:S-<RJVC[.B-JJ
MNJJAD#=BBP1II7*AB 6"D D D$@8UT^QN(_)C'_H>O\ [OQUUV*RSQ?1>2P_
M8QR#SNK\)J/GI/M8A;?%ZN,H/2<%QRP:\-@XZNKZ@+@G%%<^N&UI_+H]DJ7T
MB*]'KV1HYRHGBCFBU.74R%.;910S K,7)@IE*LL9,*@/NP1)+96.KHK<FU[A
M^&ID8-OJZIC(:,*!),=2EP)3<%K%$N0".D>'O'TI<6J)4)"W6$8U63E(]'10
MU]7*8T?@U6JA1"(UW@Y7C:[J1QF#;(>&*XRQ >TN74LD(:KRB@IYM1O&L-/(
M .%NDJD&Q)4&X+!0Y2,L8D\GJ94DM!75,L=ATVDE4DW(ZB01< &UCI)TZGTZ
MVEO8W$?DQC_T/7_W?@GL5EGB^B\EA^QAGG=7X34?/2?:QUQ>X7085=R<Y5$K
MXD:#%9OO-',CQ "C@8Y^&:W<]6B"UC&J]RJYRHU%<Y55?%5XX_Y6H8H-NLUB
MABCAC6#+2L<2*B G+J8DA5  N22;#B3?&]-B7>39RB:1V=C)5@L[%F-JN:UR
M22;#@+G@.'5AK;/RBII]R;ZA6>9BJT7/L'FP\>7.>6_'7GM$TEKL4.V/7[CP
MJ_O(\2 %LD#[N'//&:MHZ-45*RF7#I6ML6S"IJ,]HTD=Z9DU!3)$D5QQGB[6
MY)I<SS,B5B8)4R".+H\8W.KJ^+!EH4DV'(D%QF-7M0"5$64JQ[P[_P#/O_\
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MV,Q.TKN\.^\F^03P[3Q--F]=6(U'5KN:V%U@OH5@Q+5E0"RZ>B-WUF^H6XZ
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M..4RBV+:">NV63:$9@)(HXS-$.:FG*N[C?4-2.VB55.D)^C%RW"WW\(%J/\
M48Y8_KIC/X"<3GY.6=_WDTGS-7^)8AORB\B_NMC^?H_P?"QV'SZZSE'IGPN3
MO0=$T-;F S"I\MQTT6:LNA)& ::X.F:DK)U:1ZRL?5AW?Y549/$*B:9@\_(#
MFU$4$O*'#+O5E<-'3U)""F3?,K%LT #3 ;N-1?6QTDJ+D>CE]R>LXQ<FT,&[
MZ#*U32KKYQVI7LF3@D0$F4D$% -0NUL3F"^Z#:M)0N67R1\N\XSK>\D))M\H
MQV%,05A;2[,$- ETK:.2/5AG,JHK4E-0 (3(GEHCH[HPE2^A^SBNBW\?*)%
MM]WHGIZI)+HJ@DA<S(XGUW'4KAT<!U8#*3T0.2T9W,G)I3U#7>3>1U-(X DD
M=E0DY/?H A5[A0*5Z)&#+^$"U'^HQRQ_73&?P$X(_)RSO^\FD^9J_P 2QA^4
M7D7]UL?S]'^#XWF<BNQ<?VO[G!S;9Q4Z_P >UG16TG? O8O7LQ]I4UPJW0V'
MULPE/)H,<Q:2:;8OBEGO964<:<V?)>..Z3*1IR:[S_9FHV0S6HR"IS1,YFHU
M@=LPC5U6854$=4H DEF<;I91$;R-Q3A8< T^TU/M>W9^ERD9'#6 (N6JT;"
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M,)=73:67)-)4 @VTRMQ+:2+  "X/'!)T8G_1<Y_8=H?V'$A?+?89W\SM+]C
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M:,O"BQ,5ILN*EHP$8@G,@2+@VN!P[F.OT]"MRC5"+.F8;*!)U69 V8YB&"R
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M7^'CUG$G@V!86_8F*6^/Y<&IRRON*:12R9FH=B5E:^1)S7"H$$<_M<R+(=D
M][.K6S8$M)<MU60[YL9(P,442PN-O>O^_P#F^-FWHV_/G(U!]BF9_C]PL>8U
MM^ZZU6YP^Y\[T)=YWK"PK&VVD/,1*K4V5T\\KG<PFJ6QE#8R]T7D<#12E 8[
M25<E3QQEC#=&(9DH%TY.A(=M]FQ$R)(<RCT-(C2HK:)+%HUDB9Q[PD0_Z0Q
M;4E!L]FY<,R<SDU!&",1=;A6*N ??*L/>QQS^6R[]-8Y]6+/[W<=R;O-?#<O
M^C*G\6QSCKH?:*ORN'S+$/D$7(5IK!+&UHCPE J2!1\8L>ZYG6WP\%)F(PM:
MUW2XCI+V1&C1[I;DC(5>!:Z*O-)4"HJZ%X=V=XJ994:BMQW6S=4 !L29"(@
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M!DK)E,<_R_BPQ6)&8<HV*CT3>95ZK'-L?EQ6%Q.NG-ZQ&#JK1@ADI@UP)&L
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MFH1\9X)&#6>8V4&M32RWO):X=F#:G),C^R31 +9+VN"%F46X);B8S<=87JL
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M0!V-<)[-0N6&&3<09JDNDZ&DHMI BGNDGF[Z>%[,4<*;,T;@%2Y"U;O4WLE
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M24C&"<Y!*]-Y0UJ$$AZ2I0@&Q.J%Q8$\ 3>U^YUXG]E*DT>U.S56KB-J7/\
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M":K-(9$,ZA=SD]061]W(P=@F=*VD*K7TZB"0=-@2":7;+>NXARLJRQECKS)
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MKRZ+S#"_RQDMTJ3ZY)J9AG4@6&6'BM\B2*[UF,YD(3 Y^!326SD'+<(+%.H
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METY!]W+1XWNN+9^J:6\N>]PGF?@U;&KOS5R24DRLKI04(W/B]\<9)I6O+*<
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M=0-V8DD=5L$U#2;E-QN$DU#4\L^4:66S7M:9A<G2195%@?>P2]O#_P!'9?\
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M40I5B85RU\LN\)1H*7:'0(M*:%:]-'>2^HNP4*Q.I%C4K$F54U077FQIHTT
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MEC;BV&)\@4(DN>^*,KFJ]H'S9;A(J,6054ZUYBVEJ'J]H,ZJ9 JR5&9UDSA
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M7=XUJ'FD,M4TP)YSIEJ5J";X/V^?FAR[^NQK[P<!>H_M_P")XOI/+?.\6?\
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M)9YLN16-T 2W8JVLZF-@S653<@W57).7+:NE42Q4^S$DC'=LL5+6,P7B;_\
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MJ]-240HTE3U*[N/7535#6?4ZSYR%DO(0" E+8:+A+C@Q&DV)N#STJE^:C_\
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MG-:/W+?\WR'S[$?O9_'8^=S3S7%?MZU]6/V6[6NEK?'UOJ\86&L[WAZ1X?\
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M7PS+/HM?PW'5E[E,&0SW*3F6%&#,K)2VG,2D=M[++?FCG=I_&NR:65MQ*+,
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M+/T=L88I(8]AA$2.!ZWFV15T5\9^4R+R#,&YD*+%K<VG@LP7K\R@ 6/> _\
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M7.+5;X+_  K[_O\ P?OQ-T-/5#EU+,DPJSE 9>(2U?4:)YP0/+0+;8$1\6/
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M(J];&/7)6N&#+0]S=D$$&^J]Q:Q<WOR;,_G<%^JU_P#?GAOTKYAXVH_HB?\
M&,2'IPB\5R?2"^88#\SVUE\N#7COX6*645EJ(L<=?C&4M*"8V'.1DHGD]AQ3
MN",#I#51KB])'C)VE5B$''YCLS4+'#SG,(9D:<!1!D]261]W*0[!,[1M"J'O
M;58D'387!-+M6)7<19?NV6,L3)F* ,NM!I%\N8:B2MKV[H# FQ\<$V[EH*R=
M[/5^*U$4MH]\D-EC&2/-(F"@5\198WDV-.[D<L2-$8(PS(&0@EDB0C#(<V&5
M;-SR02M2U\=.@G966HR><.[K%$N\4]G) T;($".K:9 N\34C*[Y5FU0@D1):
M 2L8PP,68J0JEWZ+7RU"'#:M2D74G2;$%0;>_)LS^=P7ZK7_ -^>)/TKYAXV
MH_HB?\8P)Z<(O%<GT@OF&$K<WN;Y;F^1V<JSQ6)('7X[#<P&+V[@O8(5B4;F
MM)F2O8_Q.]K_ !(]'>#5:C/!45[*LNS.AJLR@CS"@>YI)&9\KJ.):)U "KFX
ML $%[EKDWX#A@#-<PI,SCHJF6CJ(R$GC"1UL1 "R@W):A-R2W< M[^/YY7,/
MT[C7U3M/OGQ.;K./#LM^BJK\9Q#?T?X/6>6P?A^ #*X,U\J1ZP:!8&=2A85T
M#%;SHE0?6(ZLKQ,#L&,II39G1-<(8^ZL<3U[CO!@7P6:0S[V3G;T]0YHT#;C
M*JZTL(JT*P($S^/7*)B)2H&K=J26M96E*)HA&NX6:-14,1O:VGNDG-W!D).6
M-I0QWCN3;4PX 78$F.1,B2E@)6V5'!@]IZQXLS%+99(VJ8BN4KG9U(4BD(KR
MM*TY6%8]I!O<-S5XD:"+,11P<WJJ&&'2=W'+E57O%!=B=1.>2:M378,'96!#
M*Q4C =6:0U$IFBJ9)+C6Z5L 4D*   ,M6VD64@J"""&%P<3?E<P_3N-?5.T^
M^?!FZSCP[+?HJJ_&<#_T?X/6>6P?A^.X/W)QIV^YY\O+91 FDI5[$0Y8X'Q@
M$*FVL_ZWBCDD2R!&YWBK1ODG<Q/!%*]4ZEX2VX$@VQVG$K(\@SS,@[QHT:,W
M.I;E(VDE9%)XA3+(0.!9NO'2&S^GL%D^@,J=C:+2&8.P7F\=@S!4#$#K(103
MQ"CJPMM9X'K^?JG7UWDNN^6Y]F+76NYM_9W'-AL"DGPYDRH@.C2;2('5O8QZ
M6:X20H(@C,%#LVFCPB*0".XJV)GX.KJ[U_A_DX8E;A&KP54RDJ=?<K8Z>1</
MGS*V#S@Y\D/UMA<H 0S@!U5T!G-D'RD;VL0;VR84M'-0U('R*PC?N][O=S^2
M/W8LM@YMH4F(8[48)K32*8;6U42%C3:K?^:VM:RGCC0<,<&P=H68LJ*,348$
MGFCIVVM:UZM:B(L>8K_SU7N[Q\E'-V2RUUJJ/7#Y9]Y/GR(.Y<NGS0PV:TR5
MTDL2%(T16@F21A1[@1C6$$1R(T9)<=KE,P_*E+9IEJK;4U?1JMR0+FHC N0&
M(%SQ(!('4#U88JG"4U2[7TI!,YL 398V)L"0+\.%R/AQQ]>_=D_R$H?KW8?<
M'CMGL-FOL<O\LJ?P_&D?3#0^UU?S</G&,>7NB_D194>9@6.OB'CF#*87/;!H
MG1BC<P[2.]@F](W"<Y'KU)X-55\4_EXQ?)LS*,'3+M!5@^JLJ ND@ZKWR_JM
M>_O8]7:*BU+ICK-5QIM%"3JOPM^<==^KW\!]1M.LAVD>34X/B3[=0C)'<W:U
MQ.E%#Y!0C.@CXC(=(1:\SE:=S"*\)5-UKU]:A0Y)*)D,+92TY160#-*F21DW
M?1<*:-BP,37#V-U;5<WO@B3:&/=MO(,P$88JQ--$JAM7%2V^ !#BVFXLP(M?
MA@X]^[)_D)0_7NP^X/!_8;-?8Y?Y94_A^!O3#0^UU?S</G&/JS.LOS[-]=8[
M$Q+&Z^4;);:4$\C-K0H%=%P#-GO&7M8&A!HX*D<PC&%7N-8-1HTCBCU3RR[%
MYGM'L3-D[5%#1<[S++R*E9*BJT&G=ZFQA--3:@XA*7$H*E@;, 1C=_H=^56A
MY/>5+)]K1E%5FXRNASE3EYJ(<OWPK\MJ,NN*K17;LQ&J$MC3/K"%+H6U"R_L
M'LW]%X)]=,@_#SCD3\GS,?=+1?1\_G./HK^730_W:U?[50_P_B&O]>YD>IDB
MR*!KH5.]\1)3YN?Y!!B]:3([HC2R?8*.C.Y-2.-C%*U#D<P"M(A5&[)>0',H
M&$B[3T*%;@,<OFL-0*?VJ@BYU6'=N1;C; U9Z-S*,PIY*2KY,*N:GE,9DB.U
MB('W4B3)<QY"CV$D:L0&LP!5@5+ X6.X%D;76+,:CZRED!)?'M?([(OK0L:6
MZ5-G/C3'>PTHD8OFYTZ0L<JC<TL@[D8G4O";D$S*?KVIH'T64A<ODZ)"JEB$
MJ!8Z44<>-E%^K#=)Z-C):#><UY+ZN(S$M(3M<)&?5-/4&[2Y$[6W]542  A0
MTKD 7P3>P>S?T7@GUTR#\/.,?R?,Q]TM%]'S^<X-_+IH?[M:O]JH?X?Q4+F#
MJ,YH,YQ)D^IQ-Y9.*7KA-B97<%8C!W%.CU(\V$QG-?U/:C6-&]')U*KVJB-=
MTSZ'#8/,M@ZO:N-:RAS9LSI\I>Y,^7B 4LE<MN$-<93(9^]&%"];:N'$?HPN
M6VBY:6V$J!D%5LT-GES^'2:Z+.#5G,CE3ZK\WROFXAYG:UIMYO+W31TDSYG+
M/T)COUHLONAQU1O,U\"R_P"DZG\)QQ-HHO"*KR.+S[$%<MG271UNJC%!O8"R
M;&4^;6L%_ERPW):="LQB.YXVPFO?)=XN0 6N*JC1JO0*L$\AC-9296I5*@1E
M\ZJH3H>(BIL5RR,LNY!,G6$0%CIM?!$!C0-N)ZP@M$7TY?#(-2O>&]ZQ@#O"
M @X:FL./5CTH?48D!H<?IL3?7M(Y&NAYE9S H0;6!4:'7%CK^9&,8&"[G2 0
MQA8U@QL8F5#SF* )04>5&G#$ PYO4RI=0J:0_8M_6*JH%U6155% 50 JG=/*
M6JIZT2D<=Y00QM8DF^GGB];%F)MTF)))))Q,^9RS]"8[]:++[H<%[S-? LO^
MDZG\)P/HHO"*KR.+S['7O[A(^:_DRRAUA'BQI*[\S;K##F%G :U,-UPC%;(-
M!KB/5S?!7-6*Q&.56HYZ)U+QIROF9MO<V,Z1QR[C+-212M-&!V-I;6D>&G9K
MBQ(,2V)(!8#4=\[#B,;-T(B9W3>5=F=%C8_G<U[HLDH%C<#IFXX\.H/;8M0&
MTVIS!BL:B+.K2Y_@Z.>33VPL\/9RQ:/P!L/'V7F%;FU^/LF%)M)$K'["E6L>
MPL>=<VDIJ5H:S66+;@*QZ'%C@KS5]$ZH6-9Q4AQY^H=G!F5TL>3:DGAD)#+S
MGGE1(4*V-A^7LDC$E>(=#E-['>Z86Y]66/?B^+X?>_GAWN%I-*1MI6F*3).(
M6^)X+6+>'[M/G/+UL>HMB22UE3)9(AQK7F3L2K11Z^1 J*5D*0E- A58Z>C
M"HK88FK"/\_R/Y/7W<-_T7?GSEZ@^P_,_P#$)PL>8X8>=>'G+.;WF99/R+$Y
M,YN\=EMER(>&7$&*>0F5V:&+&AFSVP-%"]_4X<<LZ803%1CI)E12.[5Y*4S
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M_P"T!GO='6"Y.EN,Y'\1T1Z?F5>K?#Q7P[_9_P#CX<"S1Y?%598_.MEF K9
M0-R%L<MS#C)VTC3>P%_^$*=VV,Q4U4M/6(*;.E/-T((WFOA5TOK.U^NM>_\
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M%1/CX:FY>LZJ(GAER#*&CD%F FKE) ((LR3JP((!!!!!&'(N33+89%ECS+,
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M-^U6X:>%L27_ %?L_P"MR+[ '_C;P]ZOF>^(LI^=K/O<->IGE?C"O^*G^ZQ
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M!&8Y@""""!3@@CB""(K@@]1Q'Q_^CO5L0PY,7FDJ(T@3.V(\?EQ $PQ]M!=
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MWE[MH+3F/)DS3&,D7>PD*4TR;,EE(_J>23+DG>JE.5[T=EZ=NNKJ#;@+A#8
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M;N'9_)(D!9@D9JXT#,Q9CI64"[,2S&URQ)-R<>/R<Y>[:GS+,'8@ L^X9B
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M_ \)!D&P08Y2:[7*X\^#GE[8(+7<JUS#+O3VCU^[)8 ]95>>)49':K"X=_\
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MZ6=--IHTN(^/B<G((LX,>XD&NCU^-U8+O'Y<FXS1JPN'<'&W&_?[XL>YW/\
M#OQ&=:?YZ9E9E\G7O,K1U61^V&53=>1<DKL9F8S78O<W^UIE,[(&0=-MM9MK
M0T&4:YHHM)//DM T>$29JF+=30W3%A<.Z#^K]7?_ %_'AR:/P7F#PW)LJ9M'
M/ZC+<#E(>1A=5!LQS;#'Y$ST>1,B6)IVN:F]MP-GMO"U<R9FTCTR/*+%)66$
M.=2Q,'6%P_7W?^K%7<KY+.8*UJX4^AYFL]JLRK=<::JHS"[)S8>(R=DZYQ$5
M)D][.C5E?"OS8UE\BEKP+7/MS2P6N9YWL26Z9<)"QBP6%<<+]SWA[W_7UW[U
ML/'-<!YSK;*\8)@^X]>8'@T'4C(&0U-=11;29*W'"I;A(4^K9EF"99-%KV7D
M!:(=L&9E!<A=C<&6"O2'=R%MB+"N.]W?W<.]:YZ^]@>71?,A:8E7UF8;'B9%
METSF Q#/L@RVIV9F& 3:77F/8CAM-<P<(#AN 5],&9D=SBD][L"NL?E4$/%<
MQR&JGYI?96:1G-@L+AW.]WN[_/=[_5;A8;T?RI[\T]L75U_.WQ<[%PNGH\KA
M;'HMA9KF^26LNTNK3-[?&9F,$C H*"7[#0,BJ<"@#N::#0V--&MLP!BE#DTB
MMB5JPKBW5Q[_ //5W[_JZL"5UR>\R-S&QYL+>]EB-CB.1XMD=C9U&T]I7*[K
MO\/HMFL=E&;PKN)V-9LSN\R?%HV283KI]A64M+",^OR&X3#]>T],L*_Z_A]_
MZNY_@,,7EMU7M;3.T8>#9IM:[V1!+KC*<PMY-UD-[:O6YOUT?1UM9#BV0FQ7
M5F-9)ANW;:JL&LKYI8.QF+9Q+"_DY!=S5CP]9[F+]<+"Q]PL+'W"PL?<+"Q]
MPL+'W"PL?<+"Q]PL+'W"PL4LWEAFPLWW%2TU%=>=IPX;295"U[+S_-M;8[ED
M/&;//*#8M+DN6X+"L[JD;:6>Q-(Y=22X^/Y6RQD:HL,9GPZ.KOYD^>L>C@"?
MU<1U7XW_ ''"II]"<_&'U=[3XGS.XU+23&Q]M-:9Q';F3XEA!TM9XA8S7 O]
M=VF2MC/V8'%,L)"ML_RB=>QZJ=8S;RNFVU]3Y L+AP[G_C^JY^KXC.9JCGT=
MC\<U;S1XG&RLD(B6=?98!A5GCB2H>(8M6UXJ&UAZRI+2M+;Y4',[_(;FYJ,F
MBQR3L<2BQ2%50+'&IRPC;N#^?C/ZOB-^O&7$T_SB%QK9Y+3?-('8^15>"U^!
MY-!2.6BQ<V,W.?VT^8S%0ZZIJ2,LJ+E6/U,P-I79H[*9&,%M+J3%HY]3@^-+
M"N.'#O\ #X>KC>YM^K_$XA<UJ^=&VR@FN-;;KQ.IO\4TOC%I=9-D=+C#HMWD
M^47>Y,>K;\]2#4ULUUJY,:Q*XL"5I\>QB%(I+:LBX18Q\H%,QA80M;C>_P#/
MOCW_ -WOW**76W.@6NW/[5[MQQUKEF(VE?J9,=)118.O<C%D^26U+*.23I%"
MS6RZ.ZJ<9EW,R/=DI:_&(D@V/9C=V!KR*L+A\/[K_5_/ZAFRTOSN2+_7;F<Q
M%!:8JF18]D&W85F.#4VU@*E+C]NN/X*?&-75@(%.R[JYT4:F=4R;>AF/BY<[
M(W23"$L*XX\._;XCQ/'KZO\ *W=_F\^67F"VGDTF]Q7=UIK\AM28QC,*=6YY
MF("U&?560@L;"Q-B]#2T&#7E>YKC7[,H908_E,^X@P*"/#QS'W +4K"N.OX>
M'<ZO?OU=[]^"+(=#[VOHFKE)FU/$N,?P'"L8LY]-LC;U'"UQEV.WS+*^V)B%
M8PMD_=5GDM/Y3'I=7N2P@ +&H$\_-G4V<9WCEHL+AQ_</KM;]P^+%4[+E,YE
M=-X%(S&PYG,QRLVMM>Y%"@Q)6=YBQ<DM<MU=D.-6<^Y.L)K89L)V3?5>:8/+
MBQY0[$.+0)V15:9A)#D-4L*X[W=/<'5PMW^][_PFYQN+&CT8Q".:\B,:A'M:
MK&O>B(CG-8KGJQKG>*HU7N5J*B=3O#Q58\Q^^%A8^X6%C[A86/N%A8^X6%C[
MA86*S2^3;EBL!"!8Z<Q:R$*_I\EZ+)UK8(>SQ^"ZJHAS/.6)UGTU/4N;3UF-
MS5D8["IPQ:J/5#KXD6,%86,I.4;ET\Q%F.UA5DGPITZVC6);7)#68[NVLHUG
M=Y MD6Z?/)DF1%A0X.3Y$60^[R:AB1L:OI]CCH!5;5CV_P#/\_R.Y@DS#EST
MIGV.5&(Y7@-99XQ18HS!:ZC',N*RM;AP5J7Q<;EQJFQ@LLZB >BJ)=9#LTF"
MJY]?'L*](TUJR%6/+V_G^?UCNXBY_*UH&R!+CR=;531V+Y9K)8<^]K36DJ98
M5EQYZTDUUK%D65E O*:JR*CLIQ9$_'LEKXN1T,FMO!-L$6%?N?SW?K.#^MU7
MKZHJF45=C$&-2CLZFZ%4(682L#<TF;SMDUMN&":22,&T!G5C*R8M@(3)<RR4
M#YII H<,0%A8$[_ERTEDU@EM<:]J#6B)9.]0BGM*N9YBTS.PV*2P6153X176
MU?GEO;YACUPKEM<6R*WMK;&IE3,LYQ3K"Q!DY3N7=]-(QQNKZ6-CDN3(G2L=
M@S;ROH)%G,IKW')MP:E@VL>L)=S\>R2VH;"Z=%6UG4I(55+F&@5%/'@+"O\
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MO!R+"PHIW+-HNU/&FW&O:ZZLXMS37_K5Y8WUU?S+:@B08%7*MK^TM9=U=-'
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+"PR>%A8^X6%C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g383050g13p30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g13p30.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ T@)> P$1  (1 0,1 ?_$ !\  0 !! (# 0             (! 4&
M!P() 0,+"O_$ %H0  $$ @$! @@(!PH+" $$ P4#! 8' 0( "!46"1$2$U63
MTM04(5-45EB4E1F2EI?1T]88(C$U.7B8M+75%QHT-D%7='6SM]<C)#(X47)S
M=B4W87'P)B>1_\0 ' $!  (# 0$!              $" P0%!@@'_\0 31$
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M(K[,<- 6@#:0-I'N2"U<V2E1H\B1,EPFO)\0@PFVDO+5Y:F=#7.9=BOH9<0
M\QNS'WB!FS.EW=%D(<LWM7%DR(\>)$F.;^!.F..J:0GR)4*6B"ZW)96\VN[+
M^\#^19RY6MT74O%;?IKOPEE0$(/6I.9[24L^?U_TUG[@L2&P-P)JRL)%U.,!
MF*P:R9L:EA:4 VTQ)D6NS%F+[\XC \F*5EQI@DYT=J3*V1GIDS$,!EM*)6+M
M0(DB4')LUK!E.>6*9+;"&73'0VK.M8C!Y:' PVHI*1$7:R"J/$6^77%*BX2[
M.E1XRD0X;N+I1Y(EU+C[CS8?6M.5*/*=RA:"^XD*"CMRI>NRG;CL\55<>!6:
M%+21U=0Z(R"5Q)L+B4P+=/DP:0NU!<=*MC1%RY<1XB1'N]7+L<R&/6+O";5^
MH6:$1;/1G;-SX$-<UUR&XAD8<I]IE\K?CHQ6.J3!6Z@MI2$NH0M-DK4M*TW4
M@(4A:MR%M'!GS$0VFY;:WCB"6'7F AB0O#'TQYJ&EAQ2B6E+0K,I"4*2JR5E
MQ*T)FCSS]=^G%*<4IQ2G%*K7'^2,/_8X_K&_('%7K_D*5".4=$53S_JU>=5-
ME!(79+C6F(E5,=@LZKB-2IE$BL3G,AFC:P !L_DDH/.K]O[BM=&(EDY:HM\.
M$RJGGLMT_0L[13HN!IP6(Y(B).(2)STB-+>84^B1&9C&*ZVUD"VAN<_G+4%%
M1!0+7/!>V?A2L;.,RVX\M0@,0FH\F*T\EA;$EV0)33CN<H<.]R62A)2$W"S>
MPT08\&:#?V1=DP;6;C:/W))+CGJ8@_&9:<DT!GUUU(9J:4E(F:;VT&@. FHX
MVZ<I,252O)7L.VVC&LZ0"^83;=)O:]Q,3#F##_38>S B[QMYAMF3%PZ<W.90
M^T8*Y)=SM@%:)R6,_P"F,8NW)YJ]DFU2\0?$N[4]V?)"'6GW'HLG$(+D)Y;#
M@FMQMWE<4H)7"4^4_H1)#=@,J6\'TRBR'2N6I*P(U6,[Z8*V/5@U+DZ>"S2'
M3X5,(E#(M+Y">A"4GBCH?-RF8.)(-I2QEBCW359Z+.ZR0<OA'3"-J"^<;;Q&
M*],BXS,:FEM$]R._%<8?D/L--22R^%QT>4K0IA;&4V2MK<K%ZSG9E+(P9>'R
MFHDG!XCL-*UP6Y#$E#[$=E]UR.'F5)D+\G0L/)?S:J0[OD&U:UD?@L 9PUU!
M+IVQX@-ZO.HR2-M#41E9R65W->IFN)%7\Z(1HCI;PNO%HXAF2OBC$0M5"$JV
M:),X\O/MQ;1MYK;9VS=:;PH>1?I<,3A#*MV^PVQ+C8/,:EQD/(\@7*#Q+*$*
M<$TLA69U,4+4;ZCNQS3CF)D3?T6(JQ5T!QE]Q^+(Q>([%DJ:6)R(I:&^6M*#
M"#U@EHR2A(ME$E\&X@_?R*11.X<Q65+S_H^LN%O%ZX9&P$8D_2'"LP@"F7CJ
M<L#*28)+QZBRI <V,1IP(\39NU(O$FWC5PL[6E"&67X&_8$7'H<A(EJ;=?9Q
MV1Y2Z4.EAP,N,+ "5EMX.><5)25:9GME0I;KK$[</&5@<R.3%2XTR[@<?R=H
M+:#S9=;?025)2XRIOS0E:@G7?'4ATH$+ZUI&: K<-U+U!=/1@F?K2Y8W%PIQ
MJU?RJ-Z1:P!AROCSA809B<W$ZX1) LE&CMKYEIHT-:I)NDWO,PG&TX8<1CN0
M6YV%XHVAJ9A[SSC94AA[?Q5M2F@'&WXZ]4.Y%)-U9FR2,O1Q7!E8E^3Y#<YR
M%B>&.+=B3VF6W$I4\UN9*'(KI+;C,AO13>=*DV&5RP4%:PD'1=<\O5JV=S7J
MLTFM[5')K7(Q6<2*B8LE7C:)W%6XNMY-#-:EB\MC*N^@UH,VD$;D3^>D3#,Z
M4+HEMS<<>Y )[C6T&'L";&CX*8^&SF8*'XS6)/&4I^!+7+9D&<\P\ 5J7NGF
MD14-J:0V6]V\G>G4<P&>\8<E_&?*,2@O35,R'<.9$4,SXJ(CK'D3+S)L@(WK
M3JI*W ZMP.;QE>Z&L(]X*.$1**%8> M<_D<[CW1/'1C\W%V!8X+0Z.+")6"F
MML03,#]'&;*>$<L'S9JU&M(NW;-MF:)9)%%JENN[;27WT/NPFLX>VC>6EMY:
M&EJV@B(B$9"VL@0THS(*E+4\5*"BW<DZC6QL=AE;#4QS(IK9YI"G&4K<0,!E
M+E E06B_EA7E6E*4)9LDI"P D>9=X+$+*T+#0VN<DPQ/V?7<T5VT@K1?(O'7
M!*XS*""FF,RE'X7_ (.-HYHQ9:[9;]YM'6RZ^P/*.$E(C[9N,&*1AZ%>2JV9
M4+R5#.=FV7F4#_PG*)>^S*]]N2FPWM[@_L>V\)0\O6GRE.TB3_\ '2K)[HGV
M7E$?IA?R0M!*>&^"KG=VL=L3KP>L!E3DSV <&0<23Z'[4Z+V@0' A.K 6VL[
M:-84LM!-N38)[E0K:-HM- 7FDNT$5_)4/-M4-=5-*-M3*9#9=;7)<1M'"V@4
MXY)7F6J'OK1"2A9"'%/%6]N<A&C2KZ;DG9B,^7-VXB.A>STW  VW&1E0F9N;
MRP M(SMI9"0W;S@1=P6UUK/_  74;FBST@RMLM&2S:.='[")*"HPNR&AI)T@
MXFB,<-&6P"8QTP9$RQE-';1\%"R&(%X_EBP> 9:B^;-G+;;C;9/1TH;5!;=;
M+N/*D!;P4MQG'O)R\VV76'FVW&%1TJ0XXU(;=S*2ZP4D@ZLG9!J1F4F:MIP-
M8$E@H9*4-NX'Y0&G' T^TXXAY,A25-MNQW&LJ5-/A0"AB5@>"CS+(J< 1F[0
M]?NK HN8T):.PZI"LD EXW++AD%W[&X*PEMPEY5"Y'WTE!I0\_/SJPN]#=WA
M<AJB7;,RC;/%VUW#[3KV'.2TQ,2CXI"SSD-.MO,0&L.W<E3$!#,AKR=EO=):
MC1=RI-D7;4I!P2MC2^RXTSB#<8R<.D8;,R0G'FW&7Y[N([R,E^>X]'=\H?<W
MJW9$K? @JLX$K$S.I?I7S?#JGIM$++.4U=W3](3,BJ.U H$/+$PVTJC^T4F@
M"10T_LF+DT7ET?VT9%AWPT4_T4:LUF1=KJFX1=<#!\:_)B9\9^&WB&'8HRVS
M.A..N,%S<.A^.ZU(:NME]AT%3:\JTV4H*;5<%/>Q;!_RDJ#(8EN0,0PQUQV#
M,;;;>#>^:W,AIV.[YCS+[1RK1F0L$)*7$V(5%>2^"Z8V3$[1S<MYE;3MZ[K-
MHJ<VE9)JMXT/CI6*T";1(Q&JX]5HXHF#C\0<C]B0TILY+G'Q)<JY)%U2N^J;
M;':9VR5#?A_D_#40X.'0\3C0HC<MY;J'\4:*)$UV:M!<=?"@A: &VT(#:4-A
M NH\9W9!,MF9Y?B*YDW$9>&R)DIR*REI;.&.!;$-N&A0;:84C.A9*W%++A6X
M5V":]>W@H*T5UCT)=R\:6Z>X=U6&^IJ(4"=K409B$>'RR(&P$JIQGL\/;#\0
M%T=-N92!1UCR>L<74=,$6+WX3H^;S[MI@+LE+"F\4?P1O!G\3:EN-ONK9D-/
M,X@K*UF\J2VTEAT[T[T!*BI-LICW%PSNHZGT+PQC&7,68PQV(VXPTA]AQMZ
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M2E2T[2*NYYV\-E1$V2A1"M[8$AL"U;5L7HSD=M]"IGHQG]QM'CXM#HM!];5
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M#=11=JR(ZZOVC=7;=%L]UU=(Z:+XPIB$O/( 2AUQ"4J4M*4N*2$K4G(I0 (
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M9K54!!OG-K$>L@Z:>D&QX<+W(MKK6D;DZIYC>]"2"X%YI6-8794EE6$"I?\
MP(NGG8A(E-W;FMX!:]ACQ)I6!6+%J>?1&02ID9,1YDK,VTO L\/VR.R;2 3<
M7X'6UN=["X]&OVU*DI 4  2D@%6;C8:D"^H)O8CT<Q0DZM''7'XXHI=-.0-&
M:!6TUP&@'4/<M>=0;9Q'!J?_ .2VE,.:=//3H.8NU$$2,_K0S(),>P(\U)3
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MX3O_ %20?\\-<_W]Q^='8[^W2?W"7]W3\V>UW]BC_OT7[RG^+Z>$[_U20?\
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M=@I8<AV"MB5LHIN7>XWWWWQ@;OG&-MMML8S\*;?'CQYSS"\ $BP \X='H-+
M$6%M#P]8KYL'A'_Y0'K6_G27G_S'D7/K[9+X+[/?,V'?[1JOD;:GX2X_\\8C
M_NW:A;ST-<&MW"NF?J..UJ^N8)05T&*A&LWQ$A:0NKYL_KQD.&85R3(NIFU"
M*QU >,\RKVB]4(ZM6.4]L.U4<X\7.<O&,):F)P]S%,/;GK4E"82YL=,I2UVR
M)$=3@=*EW&1(1=5QE!KH(PG%7(BI[>&SUP4I4I4Q$20J,E*+YU%\-EH)18YU
M9LJ;><16L(K$Y3.I&&AT(C4@F,ND;] 5'HM%0Q&0R,\4=;>0V&A@8AL\)E'[
MC?\ >H,V+5=PMM^]33VS\7-Q]]B,RY(DO-1V&DE;KS[B&F6D#BMQQPI0A(Z5
M*4 .DUILLO2'6V([3K[[J@AIEEM3KKBU:!#;: I:U$\$I!)Z!5D525054073
M41614W2615TV35253VSHHFHGOC&^BFF^,Z[Z;8QMKMC.NV,9QG',H((!!!!%
MP1J"#P(/2#5"""00002""+$$:$$'4$'B*]?%15</&$BY%@'%#GQ,N5>,QXL6
M/:.'I$D_(*I(,&+!BV35<O'CY=9%%FV;I*+.554DT=-]U-=<U6M"$*<6M*&T
M)4I:UJ"4(2@$K4I1(2E*0"5$D!(!)(M5DH6M:6T(4M:U)2A"4E2UJ60$I2D
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M-J05)"TK(*20#8T3"F+=CL(B25ORD(<C,I9<4[(;<ONULMA)6XA82HH4@$*
M)!(UJDB59V+/FY!W!X),)>T$E(P#*NXU'"YIH,,S8MV##1)%T.:.$&1*5F__
M ,1&V3E1)R;)XRQ&IN7.,IXL_-B12A,F4PPIQ#SC:774-J6W'1O9#B$J4"I#
M#?Z1U0!2VCSED#6JL1)4D*,>.^^$+9;66FEK"')"]TPA12"$K><_1M))!<7Y
MJ 3I6)D![\2_?"BK%X,*#'CD>2&D&RS)^/?LEMVSQB^9N=$W#1XT<)J(.6RZ
M::R"R>Z2NFF^FVN,Z%H<2E:%)6A:4K0M"@I*T* *5)4"0I*@04J!((((-JPK
M2I"E(6E2%H44K0L%*DJ22%)4D@%*DD$$$ @@@B]4G+56OHS>#T_\AO1U_-WK
M;^QM.?)&UOPHQ_YUE_ZAKZTV/^"^!?-L;^ 5IWKW%6-+9[T@U[7>Q%XXFEDV
MHW,1U#J+NCIA%'6@2C9P=9*FK(H@2=G7D ";)L=&A412K(F48MF[IV-TV^'H
M>:7>Z .DG2Y2#H3J1KZ:]* #>_0-- ;:CH.E1"C75?;G2,:<51:=OQ6VI8RZ
MEJ<JZ?&K+7,,2DEC:%%^#HKJR9Q 2Q28 XY"& B87<<M,R"T8S,J7(FWKQ*)
M,QJ\XGD=KF*+ F_G &_'WJ+VU'2;VU)X\S4VOP%K@G3G=1UYW M_VU3#@/5E
M8:W2?U<77*CM-R^SNG=WU8KZ0&$M2HKNGBC3MG,8;&+/&N9E(3C4K(F$&9&,
MNO-Q=9_'BS1TS'>5GM)S8*)2I6ETYM.5KVOK?6WHJ+:@:BX3Q]/=IZS6*6%U
MBWU5-XU'34S$44FYG0V"2M4F[D V C)T+L&UW\'?U_5Q"R[:C!$M8E219J/D
ML@TCL6LI_/RDHA@1M!ZX0DS8HV%:@H).7H-[V!!-K:D:CCI?E:ENG\;:=-AP
M)T'"VI)-JT0$\(E9LICBDH:/:.>3N)B>I9B10&SML&HE@=@XKIO.19BO8*MJ
MOZXL=NX&VKET&EY&<5LBNJ^' 9:+HZ1/)>-CE=X3U;^=T^;H$]-['CQN!SM0
MBQM8]'KUTX6OT>GT7TOD>OA$YFLL0-+6QTWQ:,2#IZZ7["JEM,X+*Q,DF\PO
M"SIC7!TN,!OKI$(.8D&+QY@+<(=YNZ(!Q(HX9/7&QB.'4G*3O#KJD>:DCTDF
MQ/$::<].9&M+<=#<*4#ZDB_+C;6_HX7T&35'U_6_;NE3RL5'JB90R9->E@')
M!*&TC.G6\VZDX+)7[_(J4L)(D$:"ZSG0- 60#N@!8D?'*E6*A:-E1";@E(6H
MV-DV.7GQ4+\?0>(M].FJVI'2"1KIP/+T@'U:<>%6:<]2,\M7P2!>^3EFUTA9
MQ>!563G1>HY?)*D#UK)CLAK9Y,:_E$M$2Z5RVM9'$D3C^/S\@B19F8^GL\<]
M@C]M,,=H4HEN]Q?S;V)%B2+@V-Q:^O30C4BV@-M1>_(VL ;]'HM?6]0,*3GJ
M'LV*AJZH^82:WCT<F76JI"WM4=;=ZE8"3'LZNI>>5[I3W4B/^#3/J<(TV[G#
M@2SB5KNXS'2-DH2JO"4DC47&#%=:W4187)!5:RS8Z7%E"Q5:_ VY5;S1J;"U
MN*1<#6]QIE!MQ'18Z],X'ERT%9=D:F>J;JID<$I9]1=,2?IED"M]3KI%@EI[
ME@YS>W)ZXD$$G-9*G;E#RQHW"'ZQ-21Z3J<4S#O!\2#OI$5*O+723YRK"P*=
M2D'F="-;Z6T(Y=)J+VX:@F^@)&@TX'3IN.)N. %6JQ>I.U6'4%%+KJQG<TOZ
M+^E5G":RM.?,)3 G=7RF/3V*M3=[V59J,LL<-:\K*T<!,T7+PLKCM>3+882C
M-[QTP_'O"Q[LX5',"+Y$V!.ECIYQ-R#IIK8\#4@"VI%SPO>XZH&EO.N1Q'ZM
M3'ZO^IJ[NG\U" U4TCB['UKAC8ZN!P]4DSSO9D)<-)M)HM)C"&5V(QE)*-'V
M-*H(]V;HI+2RMW<>).]LR</A&RE*' 7N-/6-2"?2+VTXBH !Z;>&NH]1L#_>
MOT&M=TOUAV;:MX4:U/O*IJ^F[]JFQ[5JJ)3$0=%7%94<9S5T.K7(%T8F(MDW
ME!&N%XA:DHB;6(&B  )(WXA^BBNU;F6D!9)%[ $$@'B1?S;>DC6W(T(M<:DB
MP-M0.CE<ZW%]!I?G6YI'(.I]/J,&B) .*QSIUV/@-8;(:6C,7G).1+J,VGPX
M7?Y>9D'$G@4>?&]GK31*KJH(L6 9LW,GKOCBC]0,QDE6;I";BQ !OSS7N0/4
M!IK>H^WLZ3PXWTM<DC7@.FM,=5$W#!.L[HL!PZQ\,[,,6$@)L2M@-ZSAO.7]
M0/XC9BPDHCTO-36*YF%=/I,B47LJWI %;FX4VBD>['<FWX\7I&84?/18ZWU%
MS>QO^KPMH;D\+#T5('OCT:6-M K32_,@BR?23I6/=1-\3:I>KB6HBB)8D#TK
M'I&6915S(SK.,M"11OX3Z0G278S!ZBR67D7^"R&#C^-DM,EVL?C^7VZ^\=#?
M!"B03ZD<^:[]MA?_ /*@#0GD3V61IWD]O.M72?PBUZPN+ $Y, I(8>E#JG3.
M+((J=TJCA$=N"B95;06,RY2R;D@@KO(I)H@Z@(J3O[0B@PVD4;&A\35D#9G
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M&V^5TL;1<:"XN> N-?5SI8ZZ<./H]=7EU9U:L9Z,JM[8<&9V>:$.#X:N'4L
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M&-]_92#-@8 J'BL2>[+;$A,IJ9*CS43EJSEPP_\ Y3R!'DA5LD@Q\[JW%.(
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M[ W"K:6N+#B#Z32^B?\ %PN-"!>]^!(TTTT'3Q[NN9JBG%*<4IQ2G%*O.O\
MF\M_OEO_ %%URG_L']P_Q)J.D^H?:JK-R]33BE.*4XI4/>O2O[&M/I;L"OZR
MTD2Y63EJX82P?#LQS,Q-5)K9L/<W5'XFWF#MC%"1\_4R$R#L0DB=(BI!E[N"
M<;ZY):9Q58)20.FU[<;7UMSTZ.F@X_\ [QZ.&HUMKT5"L%%>J[O#TM3%.N;>
M&7,!--:]*EEHOTTAJ/7Z25.HIXLZ87>!&%2!NO;F%=/4="2P<.HC D0WLLI&
M@(YN[!XF,2CM %>;H01IP3ERW/$#@H :6X&PZ3:=->'H]]>]N TU!5TGHUX@
M7WC<*\EL;J+Z6]4NEVUF$+C<X:6[.;29Q:M]C;";"FLGK"NX>?)8G:10?&A
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MHT&MM;ZFQ.A]70-20->D5N3I5Q<"PFU-+,;6HK!%)@RUJ!M?.M?J6^O%]X:
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M[_%T]OC>(ZPI6<P(*5&DW:S]BNU2W8;):;JXUQKLIEPAMC7'BVS\?DZ[9_\
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MK6?_ %%/P@?7I]=SJ[_I)W+^VG'N7V9_9W OJC#_ .GI[IMH_P!H,;^M9_\
M45^VKI1M:T9'TE]*\DD-DSX[(I#T_5L:/GC,QD10T<,/PVJKXL8*/B*[XF2>
M*_\ :.W[U==TX4_?K*[[?'SYDVEBQF-H<;88CL,LM8E*;:9::;;::0EPA*&V
MT)2A"$C1*4@ #0"OI39J1(?V?P9Y]]YYYW#HRW7G75N.N+4BZEN.+4I:U$ZE
M2B2>DUOCO]._IK+?RC,>^<XF[;^+1[*?"NWG7UE>T?&G?Z=_366_E&8]\XW;
M?Q:/93X4SKZRO:/C3O\ 3OZ:RW\HS'OG&[;^+1[*?"F=?65[1\:=_IW]-9;^
M49CWSC=M_%H]E/A3.OK*]H^-._T[^FLM_*,Q[YQNV_BT>RGPIG7UE>T?&G?Z
M=_366_E&8]\XW;?Q:/93X4SKZRO:/C3O]._IK+?RC,>^<;MOXM'LI\*9U]97
MM'QIW^G?TUEOY1F/?.-VW\6CV4^%,Z^LKVCXT[_3OZ:RW\HS'OG&[;^+1[*?
M"F=?65[1\:=_IW]-9;^49CWSC=M_%H]E/A3.OK*]H^-._P!._IK+?RC,>^<;
MMOXM'LI\*9U]97M'QIW^G?TUEOY1F/?.-VW\6CV4^%,Z^LKVCXT[_3OZ:RW\
MHS'OG&[;^+1[*?"F=?65[1\:=_IW]-9;^49CWSC=M_%H]E/A3.OK*]H^-._T
M[^FLM_*,Q[YQNV_BT>RGPIG7UE>T?&G?Z=_366_E&8]\XW;?Q:/93X4SKZRO
M:/C3O]._IK+?RC,>^<;MOXM'LI\*9U]97M'QIW^G?TUEOY1F/?.-VW\6CV4^
M%,Z^LKVCXT[_ $[^FLM_*,Q[YQNV_BT>RGPIG7UE>T?&G?Z=_366_E&8]\XW
M;?Q:/93X4SKZRO:/C3O]._IK+?RC,>^<;MOXM'LI\*9U]97M'QIW^G?TUEOY
M1F/?.-VW\6CV4^%,Z^LKVCXUEAF;3-*-0U=*72=-=TV.;.5DSY715QLB9722
MV74U=XW6RDEC":>5-MLZ)XQIKXM<8QRH;;S*\Q'1^JGEZJL5*RI\Y73TGGZZ
MQ/O]._IK+?RC,>^<MNV_BT>RGPJN=?65[1\:=_IW]-9;^49CWSC=M_%H]E/A
M3.OK*]H^-._T[^FLM_*,Q[YQNV_BT>RGPIG7UE>T?&G?Z=_366_E&8]\XW;?
MQ:/93X4SKZRO:/C3O]._IK+?RC,>^<;MOXM'LI\*9U]97M'QIW^G?TUEOY1F
M/?.-VW\6CV4^%,Z^LKVCXT[_ $[^FLM_*,Q[YQNV_BT>RGPIG7UE>T?&G?Z=
M_366_E&8]\XW;?Q:/93X4SKZRO:/C3O]._IK+?RC,>^<;MOXM'LI\*9U]97M
M'QIW^G?TUEOY1F/?.-VW\6CV4^%,Z^LKVCXT[_3OZ:RW\HS'OG&[;^+1[*?"
MF=?65[1\:=_IW]-9;^49CWSC=M_%H]E/A3.OK*]H^-._T[^FLM_*,Q[YQNV_
MBT>RGPIG7UE>T?&G?Z=_366_E&8]\XW;?Q:/93X4SKZRO:/C3O\ 3OZ:RW\H
MS'OG&[;^+1[*?"F=?65[1\:=_IW]-9;^49CWSC=M_%H]E/A3.OK*]H^-._T[
M^FLM_*,Q[YQNV_BT>RGPIG7UE>T?&G?Z=_366_E&8]\XW;?Q:/93X4SKZRO:
M/C3O]._IK+?RC,>^<;MOXM'LI\*9U]97M'QK+$YM,\P9V[S+I/EWK+![;5UD
M^5RXU;[ARBNZ&JWPOSF$=U$TU-DL;>1MOIIOG7.VNN<4W:-X!D1;(3;*+7N-
M>%7S*W9.95\X%[F]K'3C6)]_IW]-9;^49CWSE]VW\6CV4^%4SKZRO:/C3O\
M3OZ:RW\HS'OG&[;^+1[*?"F=?65[1\:=_IW]-9;^49CWSC=M_%H]E/A3.OK*
M]H^-._T[^FLM_*,Q[YQNV_BT>RGPIG7UE>T?&G?Z=_366_E&8]\XW;?Q:/93
MX4SKZRO:/C3O]._IK+?RC,>^<;MOXM'LI\*9U]97M'QIW^G?TUEOY1F/?.-V
MW\6CV4^%,Z^LKVCXT[_3OZ:RW\HS'OG&[;^+1[*?"F=?65[1\:=_IW]-9;^4
M9CWSC=M_%H]E/A3.OK*]H^-._P!._IK+?RC,>^<;MOXM'LI\*9U]97M'QIW^
MG?TUEOY1F/?.-VW\6CV4^%,Z^LKVCXT[_3OZ:RW\HS'OG&[;^+1[*?"F=?65
M[1\:=_IW]-9;^49CWSC=M_%H]E/A3.OK*]H^-._T[^FLM_*,Q[YQNV_BT>RG
MPIG7UE>T?&G?Z=_366_E&8]\XW;?Q:/93X4SKZRO:/C3O]._IK+?RC,>^<;M
MOXM'LI\*9U]97M'QIW^G?TUEOY1F/?.-VW\6CV4^%,Z^LKVCXT[_ $[^FLM_
M*,Q[YQNV_BT>RGPIG7UE>T?&G?Z=_366_E&8]\XW;?Q:/93X4SKZRO:/C6_.
MGF320W+##8S(#9=NE'EETD"95^_136P2&IX6T2=.%=-%<:*;Z84UUQOC3??7
M&?%MG&=>2A"6P4I2DYP+A(!M96F@K*RI14;J)\T\23TCG7SN/"/_ ,H#UK?S
MI+S_ .8\BY]=;)?!?9[YFP[_ &C5?)VU/PEQ_P">,1_W;M0MYZ&N#5Q3#EEA
MK@RB+(JB&BVC9T538N5!K9PIY/FT'#[5++5%;?R]/(245UWV\O7R=<^5CQT+
MC86&RM <4+A!4D+(YA-\Q'I JX;64%P(66TD K"24 G@"JV4$W%@3?6J1NV<
M.UTFK1!9TY7WU30;MTMUEUE-L^+5-))/7913?;/Q:Z::YVSG^#'+$A(*E$)2
M!<DD  <R3H!ZZJ 5$)2"I1-@ "23R &I/JKU9QG&<XSC.,XSG&<9QXLXSCXL
MXSC/QXSC/\..345XXI7+77;?;7337;???;&NFFN,[;;;;9\6NNNN,9SMMMG.
M,8QC&<YSGQ8QX^.'&G'A54_'$!3M9@48O!KYOG3"[)^V69NT,[Z:JZ86;.-$
MUD\[I[Z*:8WTU\K3?7?'CUVQG-4+0XD*0I*TG@I"@I)L;&Q!(-CIQXU92%H4
M4K2I"AQ2I)2H>L$ CLKEH+)J+#VZ8Y^HN7U3W%(:-'&RQ/15RLR2W'IZIYW>
MZJ/&Z[1/9MJKC=R@LAKG*J6^FHK0 LE:0&[A9*A9! "B%F]DV20HWM8$'@13
M(NZ1D5=8!0,INL$E(*1:Z@5 I%KW((X@US;!R[S1JHS%D72;Y_@4R4;,7*^C
MPIMJGMJ-:[I);ZN'^VJR6V&:.=W&=54\X3\6^OC@N-IS9EH3E3G5=21E1KYZ
MKG1.A\XV&AUTJ0VXH)*4+4%*R)(2HA2^HD@:JU'FC77A5NSC.,YQG'BSCXLX
MS_#C/_IGEZI3BE?OGZ./_)CT?_S;*K_L+7GR=M5\)L>^=9G^J:^J=E?@U@7S
M9%_@K2O6E)K882GIKAE5$;.;N; G-@CC@NI3U9QB5F&@"IY5)1FNIVV&)"*,
MQHPP.9E".BS9=TZ:ME&[=F_WWPS6\XLD% %]2;@9;FR3;571?4\^1KTC020L
MJMYJ005 D"Z@."2";@V^GB*T;7G5E=U2.EH-?"45M.?)WI454SMR#D) "[BZ
MDEJ/HHC,HD4$BP*LC \]$6MQWP6/EG\O.5D'8)&F@H857+&8]%=04H6"A<DH
M2;=%TM D:6L%+N;E(U&NMJL4)4+IND95*%Q>]E.D7)-P<J+  *.AOP)J3D2Z
MF9HOTU7AU"3JNXD,S4W[HL@(B<0L,K(5),&H616!'E$RY,Q7\:S%RIHC 2+'
M75LQDS71#9$QMN@NX7C@V<YR*64VRYS:]SYI((-P+&XL=./95"@9TH"B<V07
M(X9@DZ:F]@H<N7IK&B_5U8<<L^*56;H5%60$@D+FTLUC$\D\G3CM?6+9!>OH
MR;%/6U.M8^6-A$P1&16.%DT@@8>-L\,A\4EE@DB;!%>,Z@H)*=38D DV!5E'
MZO'G>P&@!-ZD-@I*L]@"0+@:E*0H_K7MK8$ D\2 *UJRZYIZ92;O&M-O=)^)
M%79J0H<//,/"RIB#CJ4,1H;*R)NGAA=,Z8$V<F7C^:OVF<6D(1TT)PDQ;>9!
M'6S,%D@^:<X"KH!X6RV"KIU)"KC*2+<"JXM.Z%[9M#E\ZW,JO:RB.BQS6-]"
M$V-7\;ULSHZYDSX! *7)187573_,011Q=5CCUY!-;VFTQA V&L1B73<3ECK5
M$O##(MFT2AB<_7/-!P'>O\FCA$9#P63P"2,J2+*)N5$BP 1?B+6M>^G'0"T!
M:ZE7NL$91H$@$D^?;I&M\MM;V )]T(Z[3D_<UX\"TRQ:Q2;C>G_#PJ8LMRS/
M I+U%0@Q)HD*3C3>N'K<F'"F1B &3'%I )(-FC_0T-C9-5LN%Q <U RVN$=.
MH*TYDBUOH)OIQL:@M6O=6HSVTXA"K'6_$BY L?21QJ@G/4+;DS\'*EU%-1HZ
ML;%G=?51- 3&MIDG*7(@?8IB".6B+4Y-(9&!PN2.@LC69NF)(03$@7JV-<'C
M+9'M'<I2MUGT!(218WL%6/$@:V-B.@Z7/&I2A(>R>^ *@<PMJ+\B=-..A] J
M#\[ZC>JUJ$V@<;DMW$[1KN6=4S4I'XP1HHY/A8Z+5O5MDT^I.I"-C)BOK+8Q
MH%/&IV2!H%&2<V(#R&D2VCLFE@U1R8H5. 6NHJ!<! RDBR4J3?0@VS:@ J]!
M(K($(XD)RD(L;* N5%*K"X(O:UR0/UK@<)Q")Q(;^M@Y%'W4R5K")1"E*:L:
M$[TT\@H/%PM;$"%RQ^Z6YV>167NBM>BR([2.1T&)2:"!KEH4>3;)O8N ;"[@
ME:B,V494J3EL,P-[J%P38'0=]S:V*P2D')F)4I)S7.7*19)"2-3<$GZ!TU@5
MA=7$TB/4G &L=/R^9=.E3H5]6]Z3EA7CH]#Y=)KG!MR"D_/V;$XXE 8?O4+5
M[2\Q)_ W0,&0C=M3K&HYMH""IZP5D*'$H&4%5M"5=)4-!E!0=+ A1Y"K!L%!
MO8+5<H%[$!)M:QU.;SASND<ZDYU)]4,@H<V@,!UB.GK5C5DON"4NWT_5AKH=
M%87,*_B1-D 8IPF5(GY$YS/42(]B1(Q@8KH*<-G)IINY15UNM13P .A.I(X$
M V\TZZWZ.!JB&PH7*BGS@D>;?4@FYU%AIT GT5B$3ZL[$D-QQBK2U8UO%D&R
M?4+BV#CZXC;EC%,42?I!@J0ACY:I12,O;&0UX1TK\%D3> 9;*-SC==^W3!-E
MY) 62K+E'ZUSF-AE*=1YNMPH<<MC?EK); %PI1ODRC*+G.%$ C,;>]Z+^KEL
MOJ6ZDMNGT1$#C.,A)LS//5G!9AM+2XB0H1-@] -#$AB8@% IQI)-Q>DA9.':
MDA?02',]5638O.A3TR&;OY6O( ; \]2#86X )-_IL.9N154(S7%R+:< =3?C
M<BW#HN?16E7_ %T2$.]E#LG2:*D/ J]2I-H8!V,X,2-U".DCJ-B=%79*"<2V
MKQ@F/=L 4HWLN)QX3()(YDC0"7B[EZ#(;BGY.-YQN-++.A)-FUA"KBP' E0
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M^?[I^T5\]/PC_P#* ]:W\Z2\_P#F/(N?7&R7P7V>^9L._P!HU7R?M3\)<?\
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M:%S) 1+1;,=)9073$/)1*!<E >3GP\;Q+8."G#&S*1)BOS,90AYY&)S,6<E
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MC5[BNJ_0@C:Q9_;2,9KIU $G;.KC)*.6?-=DV\4":6 WAL@&/P,GD<;UDJ;
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M"> &49CH+@JL3T^K6'D&Z68_;U$](5363TYQPH45M.U9)(K#F%'HAG5?]/\
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M1UNF*$'V!DZ)3J$*'6 *B;)78BX "KD*N$ZV%KZ\KBK;Q'38FP%RBX(&:Z;
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M"Q%[:9@5<-!F%[D5<.C+E(N%!16K4',H@YK7L<I";::V/"]8$]Z%+G"Q&ZU
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MZUY?\UU'?],N/S<[&?(C?[YB/]93\X6V'RRO]SP[^DI^'$\*;]:\O^:ZCO\
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MVJ'C,2$S#4E9*D?@Z,1D4MK^G8[=TDBD9 C[0D<[;EG<)/X>!,&P3:/K$!Y
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MP0=ACK&R=VI%U6RQH">&O V\[]7@+VZ+WZ1K4::7_F.C2_$C6W1I?46N*VH
MBG68J G<DE4UZCY#K!NFN&O*TB@/2G:@DUHV@ZG/5>PD8N2M7&UTMQ$K'5BO
M0FO:>\@<;.2.@F5N0:<SR_C 2;*L=5:)%@+"Y\[GFL;6Z?203I46]-M>/G$<
M$\/>W%\W1W<8^AYMUU[S&'5AL6Z@,6_'81,RT8&[-ZKTB!@>EU@SV.U[+K[W
M.;OM7,(?].[6*MCKX2[UGZ^K,NJ*\=CK#5W=;K\T'-?773H5Q5Z,OHN>5SK;
M3Z-+\;ZC6WT_0#;H!J>/1L6NZ7RN^S5AV)M-:OKNR)C15+/T$T4]IPP@L\EC
MZ6V%)E=!K/+R31Q^8%]/+M5LIV>Y-T9+98V3QB;^;;73<DW.@)2/38\3Z>CZ
M#0VTMRN>GC8CIY:_XK=%3UY>HIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MKR__ (J!?_$0_KRG*)]^YZT_PBHZ3ZA]JJLW+U-.*4XI3BE.*5QSIIG.<YTU
MSG.N=,YSKC.<Z9^/.F<YQX\ZYS\>=<_%G_TXI8<O1]'*N7%*Q$7!HV&EDMF@
MQCEF;G3>.HRK*2N^&)AU%FSP>(+N1_C^"]N:"G2 5V8U3P^(!@T=&/%EFD?$
M)-%NGG_*GHK+-D]-L9QMIIMC.VN^<;:XSC.^F==M-\XSCX]M,Z:9UV_AUSIK
MG&<9UQXE18<A7G;77;'BVUUVQC;7;&-L8SC&VFV-]-O%GQX\K3?77;7/\.NV
M,;8\6<8SQ4UXQKKKG;.NNNN=]O*WSC&,9WV\G73RMLXQX]MO(TUU\>?'GR==
M=?'XL8QA2N7%*X[::;XVQOIKMC;7.FV-M<;8VTV^+.FV,XSC.N<9SX]<^/&?
M'\>.*5BC2$1UG-35A)L]E)8<CP*)N2BZRBN6T:CKTR3'!AJ&V<(,&NQ20%B3
M_=NGJZ*.EVN"+ARW$AD!ZVM^G^7_ '_O"G_?L\/MYFLMXI3BE.*4XI3BE7G7
M_-Y;_?+?^HNN4_\ 8/[A_B34=)]0^U56;EZFG%*<4IQ2O&VNN^NVF^NN^FVN
M==M=L8VUVUVQXMM=M<^/&=<XSG&<9QG&<9\6?BXI7GBE>,8QCXL8QC&/X,8Q
MC'^GQ_Z/_P!_C_\ YXI6).X/&WDV$V&HRRG+!$:-P](DBKNEAY&3[\.5?!RC
M;&<MB+=$H"'$!BKE+=T(7[1T&N&K8V;0(Q87O;6UK]-N-J?]^WQ^SD*RW&,8
MQC&,8QC&,8QC&/%C&,?%C&,8^+&,8_@QR:5X\C3RL;>1KY6OEXUV\G'E8PIG
M&RF,9\7CQY>V,;;^+_Q9QC.WCSC'%+#E_P!/&O.==<[:[9UUSMKC.-=LXQG;
M7&WB\K&N?X<8V\6/'XOX?%CQ_P &.*5XUUUTUQKIKKIKC^#77&-=<?'X_BQC
M&,8^/X_BQ_#Q2O.===L8UVUUSC&=<XQG&,XQG7.-M<XQGXO'KMC&VN?]&<8S
MCQ9QCBE>,Z:;?PZ:Y\>VN^?'KC/[_3R?(W^/'_BU\G7R=OX=?)U\6<>+'%+#
MEZ?IYUBL5A,=AJLJ<@V>Z3Z;RPC-I42<+*.B!N0D&@X3H[?.U<Y56T%1T* B
MH5#.?-BXS'@89MC5J.0UQ %K^DW/_?58>H4_[_/[23ZR:RSDTIQ2G%*<4K8U
M:?QP^_W;O_6FW,+_ +P?WA]AJ.D>H_:FOFQ^$?\ Y0'K6_G27G_S'D7/KW9+
MX+[/?,V'?[1JOD;:GX2X_P#/&(_[MVH6\]#7!IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2OHS>#T_\AO1U_-WK;^QM.?)&UOPHQ_YUE_ZAKZTV/^"^!?-L;^ 5+%R(
M$O'XTJ\%CG90-\,R').639=^*R10PV(9&O%4MW#'X<VUU;O/@JB7PE#7"2_E
MIXQKSSU>DJX\4IQ2G%*<4IQ2K=@0)P6V/8%CL'-QV@C<UADVP6V$IN=WJ8O8
MCYKX9L.T>*J.]&65LMM7*FZ^J6%=]M\J5X$!@\?'H"0(H:$%-=E]FPP0Q:C1
M[?9TX5>.=D&3-)%LCLX=N%W2^4T]<K.%E5U/*54WVV4JY<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2KR_P#XJ!?_ !$/Z\IRB??N>M/\(J.D^H?:JK-R
M]33BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI5YU_S>6_WR
MW_J+KE/_ &#^X?XDU'2?4/M55FY>IIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4K8U:?QP^_W;O_6FW,+_ +P?WA]AJ.D>H_:FL<D'1YTC
MRPX7D\IZ6>G*2R60$GID_(9!2%9F3APN1<*.R!4N6(QAR_)$G[I55R]?/7"[
MITX4467544WVVSN-8]CC#;;+.,XLRRTA+;336(S&VVVT )0AM"'@E"$I "4I
M 2D    5RW<#P1]Q;SV#X4\\ZM3CCKN'Q'''%J)*EK6MDJ6M1)*E*))))))J
MT?N&^BGZGW2W_1^J;]DN7]T>T/R[C/UI.^_JGN>P#Y#P?ZLA?<4_<-]%/U/N
MEO\ H_5-^R7'NCVA^7<9^M)WW]/<]@'R'@_U9"^XI^X;Z*?J?=+?]'ZIOV2X
M]T>T/R[C/UI.^_I[GL ^0\'^K(7W%/W#?13]3[I;_H_5-^R7'NCVA^7<9^M)
MWW]/<]@'R'@_U9"^XI^X;Z*?J?=+?]'ZIOV2X]T>T/R[C/UI.^_I[GL ^0\'
M^K(7W%/W#?13]3[I;_H_5-^R7'NCVA^7<9^M)WW]/<]@'R'@_P!60ON*?N&^
MBGZGW2W_ $?JF_9+CW1[0_+N,_6D[[^GN>P#Y#P?ZLA?<4_<-]%/U/NEO^C]
M4W[)<>Z/:'Y=QGZTG??T]SV ?(>#_5D+[BG[AOHI^I]TM_T?JF_9+CW1[0_+
MN,_6D[[^GN>P#Y#P?ZLA?<4_<-]%/U/NEO\ H_5-^R7'NCVA^7<9^M)WW]/<
M]@'R'@_U9"^XI^X;Z*?J?=+?]'ZIOV2X]T>T/R[C/UI.^_I[GL ^0\'^K(7W
M%;\!0>%18()C49A\7CD< L&XH& !1\2("!1C33S;4:)%#VC=B.8-M/WC=FS0
M1;HZ?O4T]<?%SF.R'WW%O//O//.J*W'77%N..+5JI:UK45+43J5*))Z373:8
M98;0RPRTRRVD(;::;0VVV@:!*$( 2A(&@2D #H%77L4-Z)&?8&OZKF/.OK*]
MH^-9+#D.P4[%#>B1GV!K^JXSKZRO:/C2PY#L%.Q0WHD9]@:_JN,Z^LKVCXTL
M.0[!3L4-Z)&?8&OZKC.OK*]H^-+#D.P4[%#>B1GV!K^JXSKZRO:/C2PY#L%.
MQ0WHD9]@:_JN,Z^LKVCXTL.0[!3L4-Z)&?8&OZKC.OK*]H^-+#D.P4[%#>B1
MGV!K^JXSKZRO:/C2PY#L%.Q0WHD9]@:_JN,Z^LKVCXTL.0[!3L4-Z)&?8&OZ
MKC.OK*]H^-+#D.P4[%#>B1GV!K^JXSKZRO:/C2PY#L%.Q0WHD9]@:_JN,Z^L
MKVCXTL.0[!3L4-Z)&?8&OZKC.OK*]H^-+#D.P4[%#>B1GV!K^JXSKZRO:/C2
MPY#L%.Q0WHD9]@:_JN,Z^LKVCXTL.0[!3L4-Z)&?8&OZKC.OK*]H^-+#D.P4
M[%#>B1GV!K^JXSKZRO:/C2PY#L%.Q0WHD9]@:_JN,Z^LKVCXTL.0[!3L4-Z)
M&?8&OZKC.OK*]H^-+#D.P4[%#>B1GV!K^JXSKZRO:/C2PY#L%.Q0WHD9]@:_
MJN,Z^LKVCXTL.0[!3L4-Z)&?8&OZKC.OK*]H^-+#D.P5SV$"MM=--A@_;1/&
MV$]-F3;.J>-]O*VQIKE+.-,;;9SMMY.,>/;X\^//&96OG*UXZG7UZTL.0[!7
M#L4-Z)&?8&OZKC.OK*]H^-+#D.P4[%#>B1GV!K^JXSKZRO:/C2PY#L%.Q0WH
MD9]@:_JN,Z^LKVCXTL.0[!3L4-Z)&?8&OZKC.OK*]H^-+#D.P4[%#>B1GV!K
M^JXSKZRO:/C2PY#L%.Q0WHD9]@:_JN,Z^LKVCXTL.0[!3L4-Z)&?8&OZKC.O
MK*]H^-+#D.P4[%#>B1GV!K^JXSKZRO:/C2PY#L%.Q0WHD9]@:_JN,Z^LKVCX
MTL.0[!3L4-Z)&?8&OZKC.OK*]H^-+#D.P4[%#>B1GV!K^JXSKZRO:/C2PY#L
M%.Q0WHD9]@:_JN,Z^LKVCXTL.0[!3L4-Z)&?8&OZKC.OK*]H^-+#D.P4[%#>
MB1GV!K^JXSKZRO:/C2PY#L%.Q0WHD9]@:_JN,Z^LKVCXTL.0[!3L4-Z)&?8&
MOZKC.OK*]H^-+#D.P4[%#>B1GV!K^JXSKZRO:/C2PY#L%.Q0WHD9]@:_JN,Z
M^LKVCXTL.0[!3L4-Z)&?8&OZKC.OK*]H^-+#D.P5S[(%>1E+LP?YK.^%,I_
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LBCOMIG.-LZ[;)Z:YSKX]<9\G.?%X\8SXO'C'(*E'BHGUDG[:6 X #Z*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g383050g13p40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g13p40.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $6 EX# 1$  A$! Q$!_\0
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MYHZ-Y^^?SST>8O[:3^.[^7@VC[H_-'1O/WS^>>O3;RID)_<I^7I>]_7\)#F
M3KW.Z]$A8CT3KUZ]$X^:/Z.*9',Z>XS(^2^7C_[HO[NOKG_^[6B"IZXY1$_J
M:E\XW_\ O]K[^NGR$_;'_P 9W\O'!',_UQ?Y4_S]?5+@'ZT?\F/YNCR$_;'_
M ,9W\O!S/]<7^5/\_1P#]:/^3'\W1Y"?MC_XSOY>#F?ZXO\ *G^?HX!^M'_)
MC^;H\A/VQ_\ &=_+P<S_ %Q?Y4_S]' /UH_Y,?S='D)^V/\ XSOY>#F?ZXO\
MJ?Y^C@'ZT?\ )C^;H\A/VQ_\9W\O!S/]<7^5/\_1P#]:/^3'\W1Y"?MC_P",
M[^7@YG^N+_*G^?HX!^M'_)C^;H\A/VQ_\9W\O!S/]<7^5/\ /T< _6C_ ),?
MS='D)^V/_C._EX.9_KB_RI_GZ. ?K1_R8_FZR(@)L^7&@PAR9<R;(#$B18Z$
M*>3*DD:&/' )G5Y#&*]@QC:BN>]S6M155$XS7#G,6E7<8UI@M:PDB,V&4" "
M,>9(BF!&(\S,Q'6MQUZZ6V'DI*$*8YSF<06I2ADV,89;0(  D1%,Q C$S,[1
MU)7;W*KLW5.7X?AD9\?8MKFT&Y6H3 &6%UWY%BL^=6YGB" 9'24>^Q*5!=\7
M#'"08PG 9CU12-'-]1Z!SNG\CC<:LQS3\HJS[?Z)AUG>YCVM3D\=Q@>9VL>Q
M4^X$(*($A*)^<156BO6#2>L<+F\ZT6Z8IX&Q1][^$95J''&9BO7M8+-2PF2I
M>.S*;$>R8PQ(C6P)CP,DW3-&;L)86M2/5^?OLJ.L@W%M!9C5PZ3"K+.'+L*Z
M6421E<HY\&!82H:,1[Y(*^P(%CVP9:A9HTMJF7/KQ@\Q+JJ%6;"HIV9-2'+8
MY+"'AO,-4ES%Q&\F*72,3"F<9.7J#H$:U.X6K=-C5R%M]&G8G*484^W5>FM9
M2!RW:"KV+-9+Y+B*F6:PL(9L)Y[21HS-29MJO7U&:+?Y+MS%<'RG'(T4I8P8
MXLZC.E0H=B>6T; .K0L>6SEIW10A&4S7N8Q>-YZ5RLY3 8>JP+=W46/Q5^D
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M%3&\Q)*E)$13HNZPO7JUJLU"@BPW)&));95"UY2TRY828 V!> O:9*[N^T3
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MMNY8%#-EPJ2=4N%C2U2QDCOS9L MM_'Y1],(3VFW\8F$5&PR52Y:Q %RQ('
ML-<3N(DP3;T:FM(QXT8K5S8JC?QJ+ARV6KI9)TOM+E<,[#&29,A;C7) +)B8
M*1602(/ZO^QRYO#SF)I'7./V,C<>QM[YD#&,LVK61\ZV!M; L,P/.%OPS,SM
M81L2N(&%P4/@Q84G$SP))H$VJF26#M.&F-!U(K36+)6VB-"KC:Y.12.:U6E9
ML6:_:D4 4/65@MK,%#H.(,3$9D.G.=<6_<18''U5D5^UD7PIUP!L6;E=%>QW
M8)YB2&"@=Z\C*9&>) 4Q!]1%U'SDY-JC8V\\I9J_5.5:VYDH^0U.X.7VVIKJ
MKU)<XS>Y8W-*^AQR)C-]2Y+A:8/>"BR->VN/Y#&M,6]E&8*1*%YQ'?K^ 3>J
M8U'O;J+>(E1T,HMBSO+<M$UR:TG+8JQ[E4E%H&JD'<IF8&=IAEI9UM*UD713
MINJ96&A>QC%L"D:6.]P"E0IBVH]NR!FL:FB:>,1$S&\2^U!ZI&UL#VKI',M5
MZMU+K;5G+WB.PL)UQR[T\/*+W6;J7:1'6&=2<SF9CDF19AF]]D.1QL?R>=;W
MF0%7XQB.+GC1HWPU_N&UNBZ5JCD:]V[>N7<J^K8MY5A)5<AE*.%8:XUTJ164
MI4M2*UJCZM[HDIYQLX+U?<KW,>^G3I5*>,3:KU<6L7,J=NY/.Q+R>UK[#&MA
M3B-C)^L0F8&.'DUMZG6;:\U)/UB_2NI\FMLBOJK+L[V;9ORZ!G6Q<TQ_F!JN
M8F@S#-Y])?UX<@OJS*:P=,,\\9XWT=#!KX\6(%MP.]\MZ-KVKPW(R-Y(*4:*
MU,(KG7JUVXIF):BN+%%*E&@^Y,#L7=DRDBF5RKVIJZQ5I'3^CZ33:P'6;9=\
M+%IZ\D&36^P2VC#&@X>W$E$CVH$8&(YPQ)8UZB.;UN5;3R/,]5ZTVQ V]S.U
M?,]E>+;'%?9%0$OZJHW'41,2%$F6I1R<:BIN:WL8(K5EBX%G0T)) YL)MC G
M*':4KFBDFM=MT2HX<\,AU3MJ;"C9083Y(0&1<4X]8E(2$2#6Q'$I ATIU18!
MUQKZ=2Z-[+AEW)MPQJ^Z 7@%,"1S!)'WQD,'!;&M>\$/,2=N[]7':EMF&O\
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MI)F%EI+CD=&L E,X<F.YXG?[8]SH^[5V1G+X/-4UHH6]/TL;2H0GN-7"\6)
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M]9T%P*8G;F$DLO'D3*/MZ:\T%=F,LA:K)N(+L]RM8'DIFUA4CS'[>!P)C_\
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MI/\ TJ:W_E /Z/H^@?+[^35IW\PD_G^#Z.TC^XC37\4/^DZ/PA]2?^E36_\
M* ?T?1] ^7W\FK3OYA)_/\'T=I']Q&FOXH?])T?A#ZD_]*FM_P"4 _H^CZ!\
MOOY-6G?S"3^?X/H[2/[B--?Q0_Z3H_"'U)_Z5-;_ ,H!_1]'T#Y??R:M._F$
MG\_P?1VD?W$::_BA_P!)T?A#ZD_]*FM_Y0#^CZ/H'R^_DU:=_,)/Y_@^CM(_
MN(TU_%#_ *3H_"'U)_Z5-;_R@']'T?0/E]_)JT[^82?S_!]':1_<1IK^*'_2
M='X0^I/_ $J:W_E /Z/H^@?+[^35IW\PD_G^#Z.TC^XC37\4/^DZ/PA]2?\
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MR8+C/#=4<]B^&>.\1/CI(SUITFE2'MEBDV6@FLQEBD /<PH%:DR3X[C&%,0
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MA\^FWW^-/44Y05)W=O8W;%.YW=\OET:Y?V4_R?-%^SC?&B,A,S$6Z<S&V_\
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M6)325>I5KE,$2*Z$D0[\2)2Q"9'>(G:9&9C>(G;YQU35^P-N_=M@)"%JW9L
M);<A%[C8(EM,QRB"B)VF8WB=IVZ6/"CI)T<'1T<'1T<'1T<'1T<'1T<'1T<'
M1T<'1T<'1T<'1T<'1T<'1U&?BM^K8Z.#HZ.#HZ.#HZ.#HZ.#HZJC]?)JO]%#
MGE:U.JK#TM\NJ)]G,3IA5^:]$^2(J\2K ?\ H[__ .M'_P"H/4,U-_Z36_\
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MK$XB\_B06\3/CIT]=S:,W))&H[&M982:KF-=?2^[VZ]*CZ&P '$U4<V0]XV
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M)<I0LEQC#&-\D?F4:C62Z)T?F?4+4+L+B[E>C5Q08^_F;3.!6%*:\X6M-<C
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MNA/4!BQTCF,DHTY4KJZ3]+Y%II%]Q5TX,5T\BM,HNTNTQ;[,U6A"W*(B0UN
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M5HL"I-PMXL();0M+LAW1L@<>5@(,")979V[%5C!KL7!J:*_L7\@'_ /Y)_\
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MB8AG*0GS$PU1JFO5PV#U-8HQD,<WXK%0B2R!&RRJ2S55$'NM9&JQ0$M2?[T
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M606QLJY+XK3#@UE0Q\&^'+,%EE JF*XK6-82U=722%1)8S%<%):1#OB]6/\
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MU;63BS,,7R6OG7;W8-L1$!7:/DI'J.57+HL.J\5S3'+ T#(X,CX=DD-JH-P
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MSQ%*QXN(RY2$+"5"0#AAK]K3F5H9?%73J6Z;C8[L :;-);)[;)6X]B$Y6PY
MDQ#U1/."Y1)"FY]3(!)EW#2QY8FSV'%)>][(4P<F;*4DH!7(@5[) $:>.[H5
M&KU[.K']K>=="TE"[*VR,)%8\7#!"P=S:/.!#C7/M+:)Q\1-B8&.,QUA;IVQ
MLNR#(!BILFX+13^I[<'9>$O6>PC.[$L(E1$,&(G<?@*(^Q_R)/:3D@Y-GL:K
M6OY5.7E[6JB(K6NU'B#FM5&HUJ*B*B*B(B?+Y(B?+C1,S,S,[;SYG;;;>?GM
MM$1M]VT1'W1MU''R,N=(Q,#+62,3MO R<S$3M$1O$;1.T1'W1'4J^#K5T<'1
MT<'1T<'1T<'1T<'1T<'1T<'1T<'1T<'1T<'1T<'1T<'1U&?BM^K8ZAYORKW)
M,V5BLFCKMQ7VIAX7:!=5:(S# ,-RN)M%UU%)7VF7R<YR/$TLL47'VOC5<:!:
MS:R-:ML'Y/13HTFM-%9L@-TK*I ;K*G8..&/<A+AM<XD3=+V)Y)[?@8$R&#Y
M2Q91([79Z=6]#HTMF%9"UHG':Q+.TSBYZA834>;P[M)11:-FIA5:?Q>9FKF(
MR4BVVVQ3KVVTYKCB<@AJ[2VM3?%YO[S5%UJ>@Q'8=%L2\W=GXS;CL<PU]55=
M'IF5MS.,NH)F,7D/(,KR*+9%UK%Q; Z0$S R2:8]Y'*:)X:F3)"D9.894.HM
M-E=@[SX*X3JX"%*;;W 260QK(*:T*0$$B9"3WD=@WZE^-#T5Q^L*6L<EFM-9
M#36/T%IPEZ(K834MRWD-<IT9@,+D49:@_&X?&-J#JEN7U#?8C4(*O+H,$'\[
MJEFBIE7SS7]Y06-C"V-03+?2-WB68IC5UKIM#@.QZ;"\UJ6Y]KZ$?:%?29_+
MS7,/@%O4XSG6+8[+I63J.8/8=# K[RLBIY'/,8HR&TLCI&IT+.OVZ]@$.#OU
MQFT*WDYW!@*>M9#R646%B+!A]3;] ,=C\C6JOTQD4TM>T,SA)RM#4Y9#46E[
MV=P5R=.:DL!I.S?TZG X3Z1I7,KI[+9--\J^02>FLC8LX^TU\L/KN9(G+3C-
M=;U>04FW8FWM;K/8;+PVMU/UK6\P.&RLOMYEA;91DY*V/=:DCY)+GXK+S3*K
M2'5R#T(;2QL" A-<$CDIQBA,&KMQ<K<HEW)DUAR"9<1$;6R,'4ADDHGM(1F0
M@RF8CJ 9NUZ7#ZIY6S2MXZ_HQVB]416(,*=2C6U3:]-\XG"TT5J>(Q(6FT=9
M-Q::^73@L14=;6O(G4K5A98F;G#YU0W4!_5OU6N[/2SYK-7?%&4K<N)J*(6U
M(!DAD $+>6J;:1(<$A!#<C 5Y/F\C6LZ^1W5&JBN7TK]!Z?RN5[$VO9R+(KC
M$R3B*5*$!@8(I*2.-HB)F9VCJH?5W4Q:.P%S4850NGCZ]6%U66(J+:R[DZV/
M7W+,J="5@=H6,/M'L %\/7SR)%'O_P!/#+BR<=QV-LC6ZRZG)*_+#4;;6L!"
M.\T:5&9:0S2(E%82@#=#E2!%8XS0@*!&=K6(T+R&']0<4^A8MWL8TI8FYAG/
M=3[CA$# W4R[1. =Q-6^TR$[<MYZYT7.A_6VMC;F5LU].:SJ):M5!.3JVG T
MYDD-41)6K*55F)D("(&!]]<]LQYB_59ZCF#YU.+DECJVMQR=&;+#<VUA'J;6
MQ>*3&<&K/%M(514V+'TY'N:]HVE=-B/*(SF/02-LK26<N>G];&8O%5/I#%XY
M4%CJ3K3K*Z5NP0SEW58N$V$%?&"[+(9!4V'N,/V\U#JO]#3JYZVUXUJ.3FQ8
MEZZWMSQE2P2& RNMU1#FU",5!"I?!*D]A[HD([Q'7=G-]@>08/9T>#0)<[+9
M5--I(UZT$D$&."_A/K\H>L!PHT-I)E8:170WI%*Z, YGA\1B.,V1VLOCQQUR
MKIZED,4G/6RN9ZIFKJ\T^>W 2H*619V#5'-C^\7MC-H2L.02O<YCZ3>A>I]+
M:E9E,Y;IKQ1VAN_1PDFP^3IS)8V%VH@)5V7%WK!#!>[D5@8B*@Y5Q6UUEU?C
M@L*M2VE?0?$ENFP)4<C!K8O"-GFZ.Z)U>%&,:UJ/1O>KOJ_-%B0+J-L>]7P8
M[M=B7;CSE0S^),1,[;3XWDMYVC[/$]6KI8MN1++UTI9D9K12FV)#+1KK83(3
MSCE,@+"(RC<?BG[?'4G.3?&WYSD%YB_GAJ.-7OO9$.VEI5TAH(7MCR2S[8R>
MU@K'*2(X"R6,;*,]D0:O*882R)&N6Z1P>:K(IVG6,PE=6LRK7FV])#R+E[6-
MB9'GE!B4<)'E,3$3U57K/>+#8.IDP@Q;[U50+J%)?;JN,3</8KL8HF]Z%FI@
MK/EPF9XE\I3',%JBUTOF6?:\GDB3QQI5+D5>8)!2AFH+F.VUK3P)['D$1@!3
MF@(@41"(UI&=G7Y+-#ZC;JGTRSAUFPYJLC3L746DD%FNNFYM>RY/.8)9>YB.
M\$A,!!1(R1%.TST3GUZHP&(S(J958Y#46%-(28%FJPJ[H* F1D6DJ6I+F4]I
M@3,<O'3W:(W!440:O7>Z9M[;8#;8NZ *@J25KXN25UB&0RKA7;I;@N61C[I2
MFI3J7RPU&P$=8SD[UV:GTQJ.,5@-')/3].,G;3J7"9JZXEKQ#<A$3;;;):R)
MIV%CVV#)JA<[3'=B9"(/KS1=B'-U+HFM21GIR%>W=MLEJ6KFN7=L0B $US%H
MH@;<$$"T281<B(B%C,FUD[6LZZRG <C?81:>..>V#9QX\0_P2>9!Q7M>V2K;
M#Q(X39@QLAF$3L*+S,:I6[KV/RFB&8;*4\Y6<ZYWTULEA;,RI=RN3%-6/,"E
MBF2N3&6"$<)B##Y3,LPVH)U)1KU,]C@JVK,L0TZ%@S%=I S#XWA0FGXMY7,F
M<$$QN<;Q$\*#F>V(3/=>9GEK#9/5:ZL//3U:E]I6Q"$?%$62#M%*%&F*D6,K
MY?@(]SH@G/ZJ/M6O\S0+*4KM5]J3== @9<=O8M&);[K:S=9-"=]I$ICQ,[3&
M^TI;7IGIQ. U-@L&LL&[4\-+(6ZG-C9:P9CN\9</(8W*)4!K H(AC:2F>KJ4
ML(^P[S6]_JO:YXUB*D!E6W[3*[@\RGJL6C5C[#(8+);8S"3WQXEX4R$D"[7%
M !"2 E8]C(IJ+06I\!HJEF\I@*V3TTVX.*TT&"0@+HY:^^;"0M)!K.2B=7[:
MKFZ0B),96/ >7&=+3T8 =1X;4N#>9YE>1Q^%OVJ2466ZA01KKY!,A:=816;6
MK<CKB-EK2(U+)YM,>H\DTYAN,;<V-DMI98SE^%BQO&#V68-E'FUQ:^^QT]VV
MPIU Q$),CL;7R7QQ2"KVM5PV(,C>QVT73S67TWEM0+&Y@;.E$6; 4FS71:??
M]R--..F'=Q1Q96QIRT?B6KE(K84Q'4YSFIM25=&Z)TO2L6J>>NY:SCD)J5S,
M2;4LU$2EDME!]NNJVV"%JU$1ANR=ADBC]LO4]!LR]R.HUO46\BNF"K#4^44E
M,&FK;:?+AVMI'27&*8(9D*?7C8J*I4L811H=7#7SPC73.HL-FM"+L801P66J
M8=F6USC*LO>$,J6F5=GD,UZK"/D#H.%1P(C!8LCD?5IZ6UH_2F%Q8ZTR-9>3
M&QD*+Z=BY#;(+JV55UV($18Q>\R1<-NW(G'UA1 GU6%<5$['IY8=A#E0)H">
M(H)(G"<]&/=^-:CVJUPW*SM8YB*U43JUSFK\Z^6U30!B2@A(1("B8GE!1,R4
MQ$1M]TQO/S^<;;3T,AZGJ58KM!JV!!@8%!#/^.-XV_)\X^4^8GKU%^GMEEOD
MOH@;T@Y(*RRVOPWU"\ 3'JX[B60J@#M"SI31L#)G1FBJ8\EJF2(TC@#/(>]H
M%<5SFKL+CL7%G)-?AE7P=3L67H5741&]:Q6-N>4A M6)3$/\L 9V'SM(WQ^A
MOT[IO*:\U".6TE^$H%HK4V57C:M2NYAY>E5K>VODMT0!,4J&([LSW0AH<#CC
M'5:]E!P<\N1F3K)*2_R3(OATABQ2' &DF23Q@'K8DA354R=\+CN,LF.8H0%%
MW "'QM7B 8K-E@L;<1A<EDUW5HMU64Z\NWM5#CC[>W8A/:-,<BAJQ$F')1/<
MVF>ES=(>F>2] ^]IG60L]7TSD+3M(7KC*G9,K+B1C;5 U\)2*]QAX6Y*=XCL
M#M,RMK:_J.7"KM,DUG7V^75].*1(A3+&4*R$V/<-CA9.MYH5:H"M-%&LT2(Q
MA!B$R-';',5R*]$:P&B*G#2I+U'9AE:XZS68:R0#E.$:@R:IKP2B8D>,D8G!
MDTV;B,P+TJ]:M,Z'TCAGX+!(Q7K?D[I8C5J\SQL8<,51<5AJ\&0#)P-WBOW/
M%L'(\(Y%QWE)8YFF3[(@8]MB=E-,V5$+*K#X;$FB\HZ&?:+-]K#C?74;QRYD
MIX6R2JDEA48QXQJ,?$HTK&7G7.4MZ>12K9+,6#M17L6$UZCI: @P#>PR/EN
M\0BL<\1Y;D13$]"^GFEK6)Q^<_1!(U;HJ,GJ?+7AN^G"L@RI=O+EL3%6J<#D
M6UT\A(^R5%G,-XB2YSRW^"9%\7S&YQ\\*LQ/&,ALFW]4EY$@DE0C8Y&CA7VC
MT404^($B12F;[AS6HR6H@L82*O&#[MYCL_I'.6\:DK-RT5WL*[DU;>XGPJV)
MX )<0 9/A(F(S(SORB91Z!9+]-ZQZC>DNMCTGIG2VK;.2RE^A80J;V*="Z\P
MG%/:5&13Q2H@.5!$B%@P@2F8ZVW+ULC#KS:FV,4O\C,ZW'B-;6XE+=<U6.P9
M9:_((T>Q2 :Z!.ARI;:8GFB0B"$:57I8"$ DQH9#*IRN)U-1KXE6FS4<6\L9
MW)>@&B]0]V*Y.B37P7W@Y%'Q1R(/''X)H[TMJZIT)ZPX?TO]+->Z1TOI(-;F
MYF4U)BXR5"Y9QBI&@2T#*VR=ML$DB3DJKY,@(;$Q':E6[MJYXMCWAL+7)'D+
M6X_#JG3Y-42PLZJ+25<*QM8$>.5(5:V2=IT,R6>*)X*]W:KGJ\:.UK!YK%7,
M:C645X;F;=J^QM$%@!'<LE,Q"P(I'L""P@)CP6_D(^.*S_1$>F/J@GUA=1];
M!T[>C4&<M:E1;P0Q4J'C77B)S8$K+BF26+93481&ID]MLLX]TX\9I)GV,N'6
MX_9CEVH:$@FUCO'=6,=Y6,B3;F?&J9#Z['S0%*Z3#DV<N(=A(PT9#D*9CUD-
MW$:2Q^2H6"7D%Z?>*DWK1 H;+[E>"5:)%8W"PEN:)R*Q,^0SO,R(S),FMLYZ
M>86[@\?Z=W,[C,1C6)'(7;]TD8M-@/!=BJY4-LM*8B&KK*D8CE$,F($BVVL.
M7/(-A22IF6R,C-BE9&I[/( 5.2LGQ++XNR 8\.*V"XPX(ZNH2:_(%?Y#0'1
MP?"I9('<13/ZEPE$$A@L.E5P^^"WVJ@5Q$ERP5"(26Y$ZQ*Q1N<0V3(XXBLX
MFB/57U-T]@$4[F%Q=W(:GR%IRG.RE4 6M21DCOKKII&X1$AY*Y-(#F!*.7$A
MZVMUJ.OJRU-.*J/JNTLK",ZOI)&+.M[(,>@%(#?VAGA)'N94..CH$H4R2\OQ
M6QDGC5,$K1L8U*S*T9J56JOV<ZWL.G)/[H4Z27VWC%&C2"3>+3(.X+&Q"8&
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MN1(QQ.>8[I+ L64X?B2V'M"Z#%W%VT0R5Y%M:F^'2]8Q62M@L)S) 06G9@S
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M*_?>3D?+$Z2J%5BQ'R0-:)&L=-?$;W*0@AO=M6A/N\98F&2"5/YCQ9VFP9+
M5$01M!<I@HY3$R,$7XL&0W1J;3LV:J-1"ONSBR?3>"9*Q;]@=>+UI@X\&0SV
MJFTZA7+LK8I%:6K/9IH$X;SLMQJLK*EV2Y&6EL&Y!*BA,ZL=-%$D-4HUKKF/
M&9[F(@K 1XQ9?A.01Q$9)A*,3WB@1T,Q%ZPY:2?6*@I\TI: ,V(18)U29,*.
M&)8# GO+68%X+?C),&(T_P"F^6T'/IKAM(@OU6IZWH+1ZD)SKJ>D\YH;-T*M
M:'VQ-CGJNT7#7RZ F@1!6N6H8U;>*([<BM9-#>Q+B/'D4<^#(BK*G /81Q6
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MN8H3DZ%],_0]>L:V2M:OL9"E:IY4*BJ2+1IM50I6&C>0Y!<IA=A;0&&\BCD
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M,BTI(L95-CDL0\7M+=CX4<6.1145'$V#:(R=853#H112S1JVCCL3W9C2#B?
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MT:+9.#%N55%#(0JP*V&)+$=B<J5<N!=Z8GXB@8%@Q//;<.,^.IWB+5S&0C*
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MR(2Z8AM5:-G-35IC?78BUC\6W) 3+=%4O%E7*)*FQ*PRX"N8$YAJ DVS"2F
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M5S!@Y1>"8N2F5G,<@+8AF(Z[*T_FJ6J<+C,Y3GC7O5460#>.:F,&)-4Q'F"
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MB.XXI$.F/7/HS^AOTEC-4:B].?4:[J+-TXT_4TZI15$"Z,E,7,O%T5U5Q:K
M<'*QKJ08N$)LV&GQ$ZMI&,W(WRI0HDU&!')EP3]O:8T"',DAE2B/9V/$4+A]
MB]W1$(B(J+T:BSNO3BWCRLLG@Z% 252,2-G:2A\C,[;PKX/$Q,SO/F/,=5%%
M++FA-I2F0)I:\+(3 _4H9*C+:=^40<$!>=XF(^V=XNUYB[*+CWHD>G/9XU&C
M*E/SQ\R4^+YH\H@IMA#Q_!9GEG"EJQ9;B2&J&6T+0Q"(-P8R/$QL@K*I9NI/
M39,HEON$LB#&)4)K)<@!#&X<1G<=]SC?<O,[0QY&A,UW5WL<47Z;"84I*K*P
ML+8HQKP7,I6,04PV9."9SF-QB!B!/,3DL[-*JQ'!H"0CW]G,RR/ @,6R(*=8
MS!$MX,1L9@XU?5!D*63W$8:0L@Q'>[,A/JQK K.@4"ZRV2KK10<US9 #2M4^
MW)ALYDUQ0L!7Q(!A8[0.T1U2_I_IM>G;CGVLI%ZU60G"/<2UU0.K0)S*3;G+
MN/M9+LO77,P:JOV$I$*:I")ZB1CMIE6#2WD0EC'$KR-2N+#EECJ3O:8S#HK4
M:,*.&UIF"<CG=S%<]JIT2<+KXJXNR%UXS! '!E<5.GO<#-+Y;,3, !SQ(8VD
M^4[3(P0E;=RCC\DB"9*'B43$, HYKY<Q&>41\)$/+C\]X^\?'4CGY]L3%H-)
MLN#55%58X\DSK:4Y8MP6LBY-4'J72YM-=QIL6'<Q$F_[%W8!K85,\SGK('+0
M!6L$:;3=I$-B3LXUQC[A4-!%D0IWDL$G%6,+ 4[;IE*X>$U;D 2@@U@:Y@88
M;#/LV\!:==?6R0*(*5Y)(58&DT3)=>XD5&VHV%R+JIF2F@KDJ( #CK<46V-;
M7M,.C-+M85K:QBE*2,\_N5DQC)[2 P\QIT>$[7F&P)CF8_J^.CT\O7AH9C;]
M2V^TA"6UTFSMA9[+AA#8(.XP!%8RQ4$,RU8 4&,.$8@8Z9LCI?5=;,IRE%F,
M?1IM2I%6XCZD*[0F+=D_;$.UD36B0)2!#C'(@V';J/NTZJ-%(V]Q]R-%#EP(
MEG%]T)#L]W$!9UQ#1 D<1S@L&^++EN:OZL ]KRJ9>JR3$W'@(J>^7FXW--,@
M[LL%-B.X)$4PM@.,18*X@=@D9B-N/5C8=[9B:S_CF1<0&L&2E@UWE7:8LD("
M084"Y03L4I."@>/RT]5M4^/0;2/'K075A9I(\5K:(:0Z&&:AG2(KX4@I8<\
MR2"JYL@7B[VH\@S_ %.Q3F,?3LWI?3>2ZIR+2K*K!66LSX-E*I&9-?MF1-<&
M+D.0+B5\(.1Z+^!3D&UI*S8K5T,6PJU681WF)-9**;"A&POCVX&84P)()D)G
M;>)2>N\PDX5E<.[ YJ (I(-Q'>%9,6?33^V-:5\B-Y@H>/*A/(!P_(/N[D7N
M1R(Y--Q$7*[4E$<N/-1;\"6]?Q+8![3(D)Q$[[3/W1\NE6:Q:,O0?3<,\MQ?
M5;'"&U;U<H;3MI(P8(OK/$&J*0.(,?(E$S$R_P AS&%0LUOL/![.&,],*MDS
MZBDAP\;<Z!9#GU"B<HA1X[Y=2C),84J2,J/^(OD>=$D/9Q&0IN=.1Q=T2:$B
M0JM&9VEB0R%B-MY+8'<P,@&1GDO@4<A\5GCM/G>C56GL[C[)ULA<M#7LY+(V
M\J##3-2^NP$FXGI3::8-FNABP5-*%0 =L2FRO3&9Y9NW1<A^ OES-=UQQ83E
M^%Y#'?+!*#<K&DW(;2.)A/B%<(]J-*Y*U(LJ# ,T"$>R,#Q5AFJ&*PFH4?2J
MZZLRX3OX_(*F!,2K@R%RAI<92V5)*6PS=;&"1R,291/+NN,5F-#ZNMQD+5_O
MMJU<S5R6"LM60]FTRMB&!5(B6-MUFO VF7 N=UH+@) 6-(X(;(P;2W+=O$UU
MCFTTR?$$K)&;ZQPRG+'N$K,HF./7UN/YI*+<+%I04Q'I+^,E8^VEP6#>T0)"
MK)XG.'R.;U)@NU?Q'M+XM&AE+;9FL+4*D#;<HA%>66_< ,A[8)6H6D4$TA'@
M71U'(:I]0M'3CK&#9BKUDTX?4.7R"_:/9BI%3KEG&5E)(G6K 0^O-<)*I7LD
M+)AJ3[<)PNS^7W"JVVP&-BE%D%,2TFGN,CQAQDRK+F>U#$F40,GE#6=5XI*E
M#*R'[&: <J$\QBUTAAVJ9W+%Y&[%?)C?OIR,K!8T+H)^C:83R:%^5*=Q._!'
M$&EM4NU(C'NAF)& =->I><.GG6Y]F+R,J7-'$7JRFXS"P;8)%EU-4PN]E54^
M/>BRHI7;.>W9"%"*G[RJ'94=!5+CSL<PO'=@44&\ADP6QKKR#AM#=&/8?[*R
MXPH3Z ]>!_MR^4(^ZP,>0DE%D.1([1GWK;9&-JX[$N[%H;B&UV7'I)5822MI
M$5H',D"^J(HXS P,B$\:\H4Z5K,D6=7E-1Y73EBRA :EDZ+\[D$+["AHU.[;
M5?FV[N&I=B>ZNHJN)5I6"V&SU+L:'IW*Z66"BM-IXH"!:Y=D&0P\=>ZVG'A7
ML^&V_G..:9%KF0HH:F++<9[0116I@OG&848GN]BBS*8YRS:G&6GFFK44RP&R
M0E+(]JJ1$&3W6FYPA 03"4#86.W+J>933EK7&G[]!EBKI++U\ACJ-*A%P&5*
ME<\7CGOP^U3VQ7*MLGW#!4#'-E*JP 6:SCJS[GPQ:-GOI=>E'<LJH['"Y;MS
MV-9#!-;&="E%WQEDH,2%![2,D?BW.$!C&M<K!.&-SV*X2[\O>9C<YIY/<;*7
M5V(L,D0.# 25!$QA3!A.^Q<YW#>?B&?LZOP6CF7- Z@U(9X:/P>N8BF-[(:C
M3C<LT22UE^OC\,^=\P;JJXL'($#D0AA+[A3(13+RVVK:O))(7GC+$+$D@FUU
ML1_86(8J5TR&9O8T4<RH9DX+W/0:EC-:]R=RL0UB)_1RGK:X&J8+$,IS(6%&
MED/20EM/*9D.,Q&\<#GY3$;I=-Z,G6&8BK4/3;+2\5EG8Q6J:CWXJ;;ZCL2#
M'E6-4UKM-.1?=QUXV+&K=K(<)]T5Q-@%-K&#64-OKWXS[2JO*F;8I*KQ#<*.
M^T$*'&=')(8Q@A(QD4G1HQM*02H1W:?O6OXUG9L$C4,5FV<C1N5X8L^VVQ!H
M;+8>Z?BED0<%)FT3.2*>7F"+J$^HWZ&+76E_T1VD=%ZDUIZ?84<OC<=EM%>H
M.HLGDL5H/4==>)7F5XL<B54D+RUDK)4X]VP*]06U[3FRIB(.NV^P6;A=P?#,
M@(8\R5,",=C.<"+'L0N(;P2XL\I'#( BO$;QN5P!HGC*41QN5O7>CL[A<]I]
M-JW?&P%I('D R:R&S48#SN,J)LFV&M:7(FS1-<*>90P7S\2PEN,?C\E>;C,=
MD<?D23?=A[EA.3IFA>519;2:!W%,M4HK+:N#&Z#V5BJ0MRS[;!.57J8Q\2V)
M1U@1N+$R*02HDBDD<\*(.0JC0@X3&%D))D"?$9V]KG!*<8$*BH]\/]2<52RV
MDK3*"&VPH,MVZ&21[%2XJH(FDA1)7,V#[+4LAEEM:>2?;J5 H(B05,VC3^7P
MVK>./6G3F8JOO(S-ASL+=H=L*>51EG8_MVYP=VI<N*M>R6;_ &\3,=R8+=<W
M>(W.8RG:XML8>Z'!DVWT0E^[2HCTTF38S)TCI*4#TF#GC1Q!!G'CST>]@/\
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MIC=D?"(\_J@$I:6\@.Z3H]J[#QK!\CUY19!9U>(Y;/I;'(:R(4P1V$FE622
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M<7C,'7N6K>1/+)&LP[.6N56JE"6E-BL;)3'*1D5L%GE3C.%:_D1BG <^-,R
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M2MT776C<NJ5=B,:RR_W<KMD@)"M4K/DY. $/W>N[[)N%9GC^;T.31<QS76N
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M&6;F02P$I&I0KD($P>Y.T%$R(KA8\X'C QM,QU!8R==EAE=*5*Y-%*ZR5 I
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MZZ&;Z;X/4/I_@,IZ;V7Y?5E03C4F&8R6W+_<< K#'8U,%8EJ.6\L@362E-9
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M858VK*T?M 0PG.HK<*)QTOLBF66*TUMQ&'=F#(A(_K/AEXUU>+2U(L\:K67
M<JN-L=1F<E35"T5ZE1S*:2-M(^#385DE)@>TO]4-8LNG2QR)E5+E5/CM#27$
MC%I<<-E:W\+*98X F0XUI!'+/<1AS8D,56ED=T=2>=@["9)%U(@R"X97+QMB
MA=ONR59&2KFA%/',QD0RWWX6-B0B2XKD92)-@MB<,08P!<=H)GK^G\EI_)Y7
M,9"D&90UE3'X>WA%-NL-MNC?FL&)LE5MW+-_V-<.837+V:TF(Q$]TXJ\U6B
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M]LHK0O@C%[HRN2+V*&E\;E9OEE\SE,'EJ=H%Z<?+59#'Y:LJ3KVV2?8J :K
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M9&WF,V'CF4YW.-38948E7P(L*#08W2UKG ;7#&"/"6XL+":>9*F"BMBC//<
M"221PM]LQC6D8GTRO*8.NE-BZ>;O@(BR;SJMVD$9!$6WFNM6 :8A%RPA]=<D
M2TM@UN,B3\5E:%PU_&852WY>YE)LV;-ZP^]>99&NZPR28-(-B$$%(CNJ3+8^
M1[Q)=L8VD;U<'PJL=P!&3JTJ*<C1G1HQ>V$,9F- 1KT>YCBJYB(J(Q6JBR1U
M98@(,:M"TTVC)$2R>]07&5Q4U"@!D<&K,W3!N9*N)B,Q$1,]F1XS'Q$7+<BW
MCAMM\$C,1$1.TS'SCS,1&VT[[4$><V&V.LE#!'7R$.\,Y&(4!50H'/ -Q%\
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M'CE/%C5X8TR181PP0 AL%$$"?+ES@C P;!3)4B2Q&F.5[O1J5 $!"M7$0B(
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M>('>0@H^>[#H6F[#^IFO]/#<&,==!UNC5AQDVL;GS;8X%&&ZU$RX2XD6%!-
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M2YD7,M6FLJ&VQ.!BNM!$O'66/:DK)%A&K5<TX(I3WV1/IHE>!EW6BDRK![9
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M"6">/S+%*VPC'B4Z>F7:,S+6,OWQQF;M8RK5<@66(4JMR[%2YR."$T2$#3(
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M@=/X26U<G>QMBM?,[*,M3?=S56V56A,U;%JR:[%@ .P>1I,OIO4>Z^W.09C
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MH60\J"D=DN$!I$CA$GC.0(E9Y%:YTMT]CLAD,76ONLZ<4U3Z3[ Y>Q54<O\
M:N=-9KGG+["H 2$ZZ#<'?[0S$$0E-DUK3GX_'1>J15N,J*?:2B)/LV6PN7I(
MQF1*4',B)>8D8*8WB2Z0MBBA.4+%D(,O8-D)A&JK"3$(CGD1&HJ-\K"D8CE1
M5:H$>GU51$>8B:EMRU]^M5(0X4I=$&EEOD1PQ>^X(-X.< %/*$,J0R9F9V6@
M4\-YD9VY;%/C>(GY;_/Q&T3O^7;QMTK(ARP0FAQ"O= $,(GFCF&1'-D1U0@'
MN=Y%8\RN:Q/QR"4KG 8/N(T;I4BW%*K=JH9W\'42N)<#:S:S&V,<9L'9ON#2
M\G$,2<N!7?,ZH#),6J$LB+)@R'9DSN,%R^8E$Q/V;Q&WW;\?B\;=::P)#]T[
MHT( O;[=[PG&B$&U4;T.-K5<%9#&*UY1M^9D<T;1L55X9+[L>=H'#737J,7%
M8YJO6J;%<# >;PA4'6FRH#%I@N))H&("M7B%821!M)SO^/,D,\1G:9^':=RV
MF=A\QXG>9Z0.3R/,$<<(P"!$?XT8Q&H1SF*]%-]9W>Y#,5A%5J=%55[D^2*L
M4N.YR"0E4HK2:E]F(XE(EL;>6W(^Z4<^13MY\1$=;F$)@$P(C,",%M'F9&"\
M_.8WF)W+Y;S$S/V=?8WY"O\ @M<A/_,-TW_X=Z7X1_9/[\?Z"Z3?X?\ \/\
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M)KF)+0?N) !]XFF<Y7=45W%@9FQF<%ARQAUJ/M,E$6Z#8!<W:HV_K& F1XD
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MV;]+O)_4"Y>,3LLBKK*3GT@6)6^>4>26]7KS);&EJ+/64[:@LWCRK"/%5B_
MZ;1^V\L*0#2LDXY@\TL)TFUN<6J;XZ.,_P"C[?OV_GC\_2QW!SF:-T=D.28C
MG=KD <JQ7%ZK.[FAJ\9L["5%U]<759C$?8DB4C!54' 8>4VL?'+W,;.Q@T&-
MV +$^0SZRJJ[&RC'7G61MWFZU7IC(86)Y)"S>VR2UQ;$LNIJ?&,7+92KVMS7
M95#JFEC4*RY5<"ZL@99DM0W(8=::4N)UUC3S<G)4_2;$Q7QT?\?\?O\ V?\
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M.M3E>A=*9U+CS\RU1K_)YL/%VX5!E76*4U@>!B@Y;)P*&O)(B/= KHDUC94
M,-0^PD=Q82@>][G'1O/W]=4SE_T;8)A23]0ZXFIKBRG7&!)*PZA.F'V=G?0\
MKL)F/(6"Y*LTW*JVLRB2L7QM+DE34WSVK;55?+C'1UK)_++R[VM(/&[+2&K9
MV/A!71A4TK",>-6CC5%3@-!5QQPWP%"P$&CU7K6FC":Q!CJL$Q2O:WVE'7B
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MMD07=L K@3U)&9F8[@P9S^?AN?6^/VF8186 M;5V$F?VS3Y!\.Q:N"*> <F
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MR@B.)'GVYD83$E L^8EQB>$QO/+;C$SM$U_KBNRXAM1)<&V<;90HXF8X,;#
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M(A221R0GIW6]'*!(J;VVARS:?NG\T]><H^^//Y8Z967R1\J)\0?KV':913X
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M&.2UYE&CG";U5>J(JI*-*X[#Y]5>NQZT9#(Y&,?2:]_MZB9V;S;8.0*)"#5
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M>JZWZ@>EN0Q.+59JZCTG]'Y;#VENF66:\L9:JF'![FI>"(L5RH=Q1 :41"$
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MM?Z\BSFZ9833F0PV1I8[&'9*[496?C5*,8Y&(&BT]06VK[8+4R.,"7;':+Z
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MII'5,&]H94.=!K0/B170FP63*ES9,Z.<<D$=A"SQDDG(99#G2Q=&1)2M=$<
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MD+!T:VT47K:N>4/&162VAP-9A$CM(Q,L_P T.W6;EV*')52(6QCU%7#N;."
M4:/<7S1A/;VR#",(D65-(17O8QHBN:XHD:,B)QE5Q./Q!VJF*8R<:-TAQBW1
M(]C'0 C75,3^+/@YF)^7R\;>9UZ9:0;HS /QS[+K$V<M>R BXN3*Z++B)""+
MC&Y N(YEQ@B.2DOBGJ3.]K?8EEI;3^QY22I!L!CXI00['X62(^"R52,)'BED
MJC!6C9#HK71Y(1D[6M59A&J6.XSSI_'UO3RQI[/X&P7TWF;V7RAJ@28J"K6
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MQ$@, YM]80,(O!993W\?.!8QYL9".<0-1'S2O99"98>S@!&YA)DBWD&Z6'0
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M=O,9Q'#1S_K/&+W#E<0HQ.&-(NW&]^I[8G,?8(.(LAT*F"^8RPHVCY[QQ\S
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MB0DN/;O;*D>2.UK+$PLUK]S45G*@=K(T["U8WMA6;2D")C'71R*'=UG8:,
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MA8R2O 0T@GXBG>8C<=HGS<4Y<.S;JH-; <A3!D?(_$,L H*8@A)<RP(@I#E
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MJYT8;G":]>C.'1=RM%>YD5$0+B$!7J2&^[RJFADB8\5[B9R<(:P5DGD7%A!
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MWV;6!#,VX+/_ -GRA7?V&0&>(/*.R7,=N4[SM&Q=*2HWIQ5C-*0;*E-ZZ[R
MUQQ:T>0Q(2<'\IWB8&1\3$^=XF\_),C)K/T/^1O+!LC+*J^<CF^@5H2SS0C^
M7(L0Q''WGAR(YFS/(&++F%-[="M?$<<)/&PJ.;7NHL6P6CC;*03$V5F8FJ+-
M?A6*6 V8,248,8H&I*2XP<@0\I&8ZB^I<'^$F/K89[W4D9&S3L.<M(.":]1P
MW)6\3!B^S8.N*IY[;R4;04;A-)]Y2UHL7IL@;:9):YCE-T>QOH1:B= HXU3,
M80$,X9<Z/V6M@>4Z80,J*IX31'5GR.)?*DQUMOT@U;TKKXNC* "*]I!7+$24
MS:@!&"56$53*Q!@R43L4C*XF.IDZO3QR<?\ 06H,3F<=.%*,WBZ]3(U;FF,]
M5NVDIH7/<!%"_6;BO;VT6*A[I>UU=@[@!2K[W3N38%&?D."7]J"QCJRND0XI
MID2[.0T5'3)%8:$X/NJ]6GZ$:WJ]@R((O<UY%3!#U9"%+:%1ZFU2O-,R65>D
M(.:*JUWO_!7M%-<86)%'>)@ N)E@C-34-7XC4-IV(S&/K'3(9M*LV5U[&+[:
MK1K2JU-GE%>Z#T20PP8$B"36<$(Q+<?17(Z9U5DN2V%Q J[@9GNLX"RRV+;.
M&I@I5S'%5CHEBKWH)'2G]$&?N1[FN7CR'I=W:]0$L8DQ7"V2 !(' E#8X[P2
MXC>=AB-I':=MXGJ5!E,?;9:QM,:SK5,4D=8X6*?:VA@EO7$1LZM(@<3*=QDP
M(-QD9CK=9_<V0+.GB75<Q ?0F-1QU,Z0Z"'VT9M4DV*H2L:MB%E5%B32+Y6%
MD1#->T@T:J.&)6%2U=01E6DGVT6^#)F1EJR*!;*3F6I[[(LPOD02$AXF/AZ4
MZ4FC01E20I%Z;]K(LDK8D;:C;]B+T-KS)1*B2US6U>?(018(8">>_20/1MNZ
MJ)%ACD3+\AHC8DA)+B#?!#&*+VSXCU<016J2((#_ "-CLC1B-8%6H-S9%=KG
M:]BL+%1TE5JH6;'68MND377%K)L,FO2K54_J:>Z2U0FE+AD$<2)SLQ[:%V"8
ME5*5LEG(-CAYF)KGNB4+$(7+(,)"2)A1,%L.Q)6KL\EP*[;)K9$^DNH3QL?X
MR$C%[&O$7PR6=4\L8OA9WA.UXBMZ-(US57A@4YBG*L5WFIR&2RO:JN);DMB2
M&'5K*2%BV#O/!J# XB9D"C?>4EBM0RU0T6E(NU'#,;% L"9D2#FLHWD3&"GB
MP)@Q\2!1XZ4.1;(R'(J5E#(L[1M0MM*NB4CYQC4PIIB27@+'B/7M0D9DV6$9
M'N>]&'(B*BO?UP>;+5A=RV0VKJZHU)R#AYWGI@I/:S:+=KI&>(C)S,B +7'P
M+ 1]5B,-5:K(5L>E>8FK%*WDNVF+%BL':A2^X*Q= [(7W1,R$R6N1@1"(Z;Q
M?FJ*OS5%[O\ X_/[?^GC'_7TKZ[!"-((( 6$,5[F""$;5>][G*C6#&QJ*YSG
M.5&M:U%5RJB(BJOSRDIF/BV^&-^4[1L(QO.\^(VB-YF9^S>9^77A% C)%,"(
MQ,D4SM$1'SF9GQ$1'V^(VCK>54(<6SBGLX<F=6Q319%O&B$2+,'%]V(4F&,A
M6IX)SFJHQO5A/$5Z/<U6L<G&!=R5E*I@&&) HS&2"3D>03,1,<AF)B=HF.0_
MDG?K!O=E+(00K<Q; K,8,L5#S2<J80B0R:A*(,Q@ADA&1$HF8GJ:7,7N[3>_
MM=X2N*:<R+'-X8O K*7*<GBS06%;<8=BE*"IA3;5D,7GL;-T:-$\\R7%BEK6
M1""?9649X61X-IK3^<T[D<I[O-U;F NO;:HTC4Q=FK>NV"LO6DS.5K1S,Y$
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MJ9RLI]5@%)I2TQCD/"7*AG&1/8HD=Y@AG8AGX9B)B8A\L$1LK79JJ($9WS2
M:26Q5(2.)'G4HT\2+V/\A2(0KNOR[&HB]J*ZYM%W:J_3W42*6$==:67QS<M9
M+@R:U487+;-=<3WQFND-XD!Y;E,B)S$\8SEVDG*P]H[C7V,I/B/"-H[91RF"
M+>1D8 =YGF6Y1^+*^UQA<'!+LEO-1[VV?GCA\Y I[;S&7PHJ.:?SE<QBC(I!
M(!A",8]Z>3JC-C_3[\*\S7S.$U"C&Z:9E[!5;=A@D^Q"SF"4D2(2$IB2"6.
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MHIM+'VL@*KXDNPE/=6IPJF8VLA&T%'QSPYQ [27'\NC#C KE13#3'/D'.]&
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M-W:" XP4'NLDB,L"8Y"T_LG<RB67+.*PPJ;"JX$F/;K'N0\VPM<]M*//%HB
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M!%S80S(R01 *$B@2GQ$% Q$QL6W6H6%*>6>Z1((288)%52*)R$;Y'.Z(K_\
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M'C;6,!G+"6+:\RR9&<0VL4N4V8F8B2L$GVT#M,[L&8\1/7?F9"&4&"1[0T"
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MWZY4>A1(]JN5HFB\)E#WD;\D2>W,S.BM-YK3N9Q^3H9#/#3R-'*XZWPAV/\
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M$^BO3 >WSF?62V$@FF=&(U)1:J3&A&D.1S)<F(Z2BM85J)(L2 T<B8VW(MU
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M8_CV9-$2OF6.33W7L<T)@K.7$65!JGR'Q62*]#^T*(;DE(1R.(J0H]IE1U#
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M)%,QXWF=_E,_Z/&WCSUZGDA\6:YR+ VG:8WC[_E,^?/V?O\ SWB>NV^S<-K
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M"5A8S*H.8^(0(^,28[\1WD?&W3GGL3:PD&BM8I9"TS&1=I&I\'68QZS-"FM
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M5-DB]U-='R!L:*R#7V$QQ?<=1RAED1VN?YO"Z&V]-6%YJGD\9"0]SE!LY<F
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M_0LYG_ZKN#\';7[/P'^<.&_KO1^$%;]@9W^0<M_5.C\-K7O\#W.-_H6<S_\
M5=P?@[:_9^ _SAPW]=Z/P@K?L#._R#EOZIT?AM:]_@>YQO\ 0LYG_P"J[@_!
MVU^S\!_G#AOZ[T?A!6_8&=_D'+?U3K5V_.MKN57SH7WF^<AY),.0$?\ YDG-
M*4:/,)XVJYS-4O:G1R]515[D3Y].BIU/P=M?L_ ?YPX;^N]>?A!5_8&>_D#+
MS_HISUY&L,]-3.L?YL\9WQ,B\S#\;H>8"IW 2M'R#<UJS9%;5;"CYK\(:[Z$
MJ@SR01_8))4+T$]_N%BO1O@6WVZRL,P+<)%+!C+,0>+]U^&6$F(DZ4U._P!G
MQ,Q$SS[?<C?\7G'XW54*TA75G%YKWN;F%Y8,I[;\#\S$S W(M]CNQ,[3.W;[
MG;G;\;A/XO7KQC\[FN>QHQZ;YR6(QK45'<DG-(%OV=/EY-5,1?L^?;U5/U^*
M@_!VU^S\!_G#AOZ[U:_X059_^X9[_'@,O'^FIUD?AM:]_@>YQO\ 0LYG_P"J
M[@_!VU^S\!_G#AOZ[U[^$%;]@9W^0<M_5.C\-K7O\#W.-_H6<S_]5W!^#MK]
MGX#_ #APW]=Z/P@K?L#._P @Y;^J='X;6O?X'N<;_0LYG_ZKN#\';7[/P'^<
M.&_KO1^$%;]@9W^0<M_5.C\-K7O\#W.-_H6<S_\ 5=P?@[:_9^ _SAPW]=Z/
MP@K?L#._R#EOZIT?AM:]_@>YQO\ 0LYG_P"J[@_!VU^S\!_G#AOZ[T?A!6_8
M&=_D'+?U3I58GS<:BS7'X=_CT?9LDLO+\LP5^+2=/;/KL\K\HP<$.3E%;;X-
M/Q:/E%2ZJCV$$QCSZL$=[)0E$1ZH]&134UY.D[-&GDPL6+.363J*L-6?G2LI
M!<--R_HE=N.V 3$D<S$1,[=372.#NZUJY.[B&4*M3#&I>2L:@R5'3:JKGNE"
M4F><?1B7-8)0"PY%,1,[1'2L^_WC7[R-X?YB-L_T2XC_ .&%']J=6?YHZB_L
M[J3?I=Y7]OM _P#6%HW^V>C[_>-?O(WA_F(VS_1+@_#"C^U.K/\ -'47]G='
MZ7>5_;[0/_6%HW^V>C[_ 'C7[R-X?YB-L_T2X/PPH_M3JS_-'47]G='Z7>5_
M;[0/_6%HW^V>C[_>-?O(WA_F(VS_ $2X/PPH_M3JS_-'47]G='Z7>5_;[0/_
M %A:-_MGH^_WC7[R-X?YB-L_T2X/PPH_M3JS_-'47]G='Z7>5_;[0/\ UA:-
M_MGI&Y_N''\FPW)\>BX-NY)EO2SZ^*\V@MNN"P\J.\8W.>W#G(C4<Y%<K5ZI
M\T^2\:7:OH,4U/T5JT98LU\OP-U*<1S&1W^'&[3MOO,;Q\MMXZ4U?3W*IL5[
M'T[Z?E"7*;PGU&T4$E"F"<CN6:F1Y<=HF1G;??:8ZIAY<^6_8VL=X8%GN3XA
MLM<?Q.]6RE^TTEN&3*E ;&E1VL9&7"FHUS_,UZ]7D1O16KUZ]W% :/\ 3ZKI
M34F*U 60U3>'&M>V:H^G&IZY.[M5]:![W%_;V[W/>5'O \=HF=XZ^]2/6.]K
M_1.?T>&'T)BRS2*R8R!>L^A[@U_;WZMV2FM$U9;R]MV]H>O:3Y[E \9O-9OW
M&%3HS!MXM1OR1%T)ML:)_P"Q'8@WY?\ L3HG'0D:RH%\L1JW_'H_4@__ *V-
MCKCF?3G*C\\_H#S]WJ)HLO\ ]7-3M_CZY_?[QK]Y&\/\Q&V?Z)<>_AA1_:G5
MG^:.HO[.Z\_2[RO[?:!_ZPM&_P!L]'W^\:_>1O#_ #$;9_HEP?AA1_:G5G^:
M.HO[.Z/TN\K^WV@?^L+1O]L]'W^\:_>1O#_,1MG^B7!^&%']J=6?YHZB_L[H
M_2[RO[?:!_ZPM&_VST??[QK]Y&\/\Q&V?Z)<'X84?VIU9_FCJ+^SNC]+O*_M
M]H'_ *PM&_VST??[QK]Y&\/\Q&V?Z)<'X84?VIU9_FCJ+^SNC]+O*_M]H'_K
M"T;_ &SUU?A$Z[+'QT];&SR]+DU5;75?78[K3/+VWC5U)=OQRT-<559029U*
MZ+=C)7/%9@C%60-R-8K5:YV/X;84@I&A>8N%?K6+:44L%E[=D$5;4T7E9KHI
MFZK*[8D@A>"RYQ,1&VTSG^EGJ8&Y-=IFGL<&*N4Z-FSD]5:=Q])MF_0'*5 I
M7+>257O0Z@86A.HQH0LXF9B=XCM^_P!XU^\C>'^8C;/]$N,OPPH_M3JS_-'4
M7]G=8?I=Y7]OM _]86C?[9Z/O]XU^\C>'^8C;/\ 1+@_#"C^U.K/\T=1?V=T
M?I=Y7]OM _\ 6%HW^V>C[_>-?O(WA_F(VS_1+@_#"C^U.K/\T=1?V=T?I=Y7
M]OM _P#6%HW^V>C[_>-?O(WA_F(VS_1+@_#"C^U.K/\ -'47]G='Z7>5_;[0
M/_6%HW^V>C[_ 'C7[R-X?YB-L_T2X/PPH_M3JS_-'47]G='Z7>5_;[0/_6%H
MW^V>F1YB<]K=IZ:V#@%%A.Z17638].J:\\S0>WDCB/)&K&N>5N'+T8U5ZKVJ
MB+_]I.O7AHSVH*&:PF9PT8_5M:<KBLAC8L3HK4SA1-ZHVM#I6./"&PKN\Y"&
M!SX\>8S.\2/2.E,KIG5.FM2EEO3^Z.G\]A\W-./4O1-<K48O(5[TUH<67;V)
M?".UW92WM27.5GQXS6SR:Z1SC1^ZZW8><X=L]::MI[F#[>NT?N&=(.>QCM -
M4:["AM&T:IWJY4?U^Q.GV\5%H#1M30VH!SIV]59,1I6:OM@].M452F;';^/N
MRNS$<.'XO;^+?YCMYZ)]7_4R_P"JFCRTJO':$PA3DZ.1]\SUBT/D!B*</B5>
MWAM*9EG>_'[WP\?Q"W\7)-W[C+DZMP?>2(GRZ.T-MMB_+_[KL1:O3_+TZ?\
M1Q><:QH3&\8G5O\ CT?J,9_,6-B?^SKE2?3G*C.TY_0'W^/431A1^<<U,?XO
MGUR^_P!XU^\C>'^8C;/]$N/?PPH_M3JS_-'47]G=>?I=Y7]OM _]86C?[9Z/
MO]XU^\C>'^8C;/\ 1+@_#"C^U.K/\T=1?V=T?I=Y7]OM _\ 6%HW^V>C[_>-
M?O(WA_F(VS_1+@_#"C^U.K/\T=1?V=T?I=Y7]OM _P#6%HW^V>C[_>-?O(WA
M_F(VS_1+@_#"C^U.K/\ -'47]G='Z7>5_;[0/_6%HW^V>N!>8#%@C(8V%[N$
M(3'E*1^BML-8,8VJ][WN7$D1K6-17.<JHB(BJOR3CPM98\!(BQ6JQ$8DB*=(
MZBB!&(WF9GZ.\1$1,S/W=9!Z<9=ABL,[H(S,A !'U!T=)$13$"(Q&9WF9F8B
M(CYS/3MX]?5>4T%'D])(=+I<CIZR^J)3@FCNDU=O"!80)#H\D8I '&B2!$4)
MQ#,)7=A1L>US4DE*Y7R%.I?J'+*MZLBY69(&$LKV5 Y)R#!$PDEF)2!B)COL
M0Q,3'4,R6.MXC(Y#$WU0F]B[MK'74P:VPJW2>RM95#%$:F0MRC&#69+/;D!$
M,Q,[CA3TBZ.#HZ.#HZ.#HZ.#HZ.#HZ.#HZ.#HZ.#HZ.#HZ.#HZ.#HZ.#HZ.#
MHZ.#HZ.#HZ.#HZ.#HZ.#HZAISZ_\'J%_SC^2?_YTN7_A_P!,_P#*L_\ Z*U!
M_P!P9/IBU'_R8/\ ^E=/_P#?^,ZF7PP=/O5".@_4HYOBPJ#8FY.7A^<ZBWP/
M)\PT"?!$P3%\S=KK V;KS_8.6Q*BNVOLB;G&'TNG,:TR_&&WU%JW8V6;+S:[
MH8.'2*3X/;M.LI&/LGS$>?W_ !X^R(\SY\SMM\^M9GGK=0IN :4M->ZH'BF0
M;<S+!IS[K-,_P&_Q8.IH^Z,%Q[:$_ F4%XVQV?FM/K.;FT^^QZJC57WKK&K%
M=9;(DTI:%V3G64!\]Y^_;Q/SVWC?[OL^_IR<9]6^YMJ/6<%^K,%7+YVT^6/2
M6U39EMK&=23Z+,=TX329;DV5P]0$F;.S7$L&,6=,IM2DS+)"_?#O_:4E%<W0
MY%/<9$=8R,>?G]LQ&V\^/S?9YG[O.\1MMTW.2^MN#-M7X1,TMIBQQK8&Z]AP
M]=ZJL-GYC@;<;CS;'+>7?%05MK45]\E]:;IB2N8O'_C/+Y!BLRRCBXIGF16%
MLN)8]'O+<_X_XVW_ ./R=>\)C??SM$S.WY-_R3X\?/Y?=OTM.;[U%.9?1G,E
MM37& Z[QC)-01;/EAY<\+SD='<7EU@O-WS"7M3<X\#8,"'91X\G5^2Z[R:#
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M!4[^TD83VJW@ZPGQ,Q]W5;VP?^&7<_\ /\Y4?_DGV#Q/JO\ ZOK_ /=G.?\
M^PU.H-:_Y<9_[RX;_N%_5R'$!ZG/7XYS6-<][FL8UJN<YRHUK6M3JYSG+T1&
MHB*JJJHB(G5?EP='5 O+WZFO-V+#,;VIOWERDYGK/>>M[#?&C"Z]9@F,YP[3
MV#8YEFQMMY6#&J[;&R9.:8U4:XL=*?>VC6L#6NS,VSO,<@QZ=@]96 I+HQUG
MQB9VB?MVG?[_ !M&^T?.=_R1$;]86Q?6[ 3&M.EU_JJ-BMSGLJESZ_N<NSS
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MD:WPZGMH=]%J#KSC^6/M^^=MHB?N_+M^_P!78\'6/4'N7G_=UBW_ +LMQ?\
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MYQC=MJ5==:?I:S(,UR^FUWE-5NFYJ<3/B#J#/</O2'7O&/'GY_X_LB?R??\
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M=K4^#KSK49!_Z!N__P"D67_Y(W":[_Z';_\ RS__ -D?2W&_\HT/_P [5_\
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MX>__ &=T?IMZ>_8&9_@:/]?Z_?[YUY&/X'.;']#M/_UW\'Z3NH_VPPG\/?\
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MRC>Z#2H5LBR'%SC@(*,)VGDP?MEY_=:^7K]XVYOS'A']8'%3?W16C/VIU/\
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MUJ)T1$1,_P"B(B?)$3Y(GR3@_NBM&?M3J?\ BF*_MGH_N,O4S]T&A?Y0S_\
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ML1>J,[OI_P!>U%^:-Z].OSZ=>#^Z*T9^U.I_XIBO[9Z/[C+U,_=!H7^4,_\
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2Z.#HZ.#HZ.#HZ.#HZ.#HZ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g383050g14s30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g14s30.jpg
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M 0$! 0$! ?_  !$( 2 "70,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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M<A$[BJQK[U\G:0\GG(W0=TJWK9:XJS6W2."U*[B)(^7#1(TTXC$C3MQVR$-
MD X 491%U5I'<C-@*[YDC!5M>8!-I-/O"3'BNU'E2DX8">!(1H=VJJW5$_<6
M53(H '%(P(U,,9=\T?=(@K5/%*I8D,<WB!8T\6#\R3M,DA!\F<QQ,I/8X6V$
M!::GA299.WDHH*]I+$*_QB?K:>?N"LZGCN'/;MATL#2LQ**KID%@LT?$#*,9
M5Y&/8XRZA1*HW(S]9Z94H*)';J?$B)B98W($Q,7MMW):A7!DC]:LB+QHYI(G
MC^+R B$>*60N0&Y6,J)".%)"KY":3M5_"C+]C(&5N%;@DGXO#=H\O-@Q \^
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M.ESJ^.+7)"\QJ%8D%4<A^UBI>,^\=H<, A<$D<\'CJ8D-K.U#(1/(SHH8-)
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M6R/32N9-94D+R.SK*SO*%61I#/*96=5EF56,G?R!*_!Y!X/*CBT"+$H( X*
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M4\_M(=M<D)%%PHVLB+9THURR-.[3/,0.9G62U&!Q';>.9IHFE4>:>%XD\2+
M8E$5FP""S(\?C2 1P+64 QQ,#79E5I*X$+0LJ2$<N)%*-)X_BEW@@)/$?#0G
M;/)Q:9M+YP_]E%^BCNUZF]<M$D]?3L8>4J=0W+2$YE&+MU!L+)G+RT'NJ9-)
MO623<R<K7*O,Q1(R3)8'-@UHT\.K4J*SB*E66K 5;LD2-:M&LQ62,(T<CM16
MTSQ%#ZU9MRJ%$H5=Q+DB-,W9$YGGN6)!(ID1WN["#82!XV8I(B-6AK(LJN#4
MC2*3Q&1'7*;5VHT]9/[O**WBY7V1N\VG*N9&\&K;N2B6+,'*,-68R0A*[!.C
MUROL5RL89C)J2"K8A%WZSEQ,2LW)26<R$H$[5'UV6=V4%3)-,(Q)(Z@A.XB)
M%'8BJD:1PQJD$4,<>F0.5/GPD,<$8)Y[(HNXH@)Y8CN=Y&)8EY9))6)DD=FE
M_,><XQC&,8QC&,8QC&,8QC*FQ]S/]'_9#-J#XA_;'^08R#);Y*R?\H/?]I5R
MQ0_F47[FG\T9!S?FLO[H_P#..4_,F8\8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,R0ROY8,8QC&,CZ8U+JVPC;AGM<4::'8#JL/;T,K58-^-R>4H[)2G.K
M2+IBKY^<552.CSUU:4\4I#'9-#1QFXMTA)M1WKL7@>%;LQ^JK,M;LGD7U=;
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MV]9M3O)W#P?5Q)%8ED#RABY>?PRI:7-9;73+% B:MH4[)TL*E,PI.O@5XE0
M^+XY22&-&2,J$[(N\-VQY*VF7/D_(._U6&T"PX9HG8]FJZ4_44]50%%96"1J
MDE2:U+I.XQ[5X]-9..=Z\)39 &X.4NY4U*NX% 8MQ$&4TM@.J):LTFT?;O4A
MF,4YNRV6B2=+,T95UF<@NMOUA">T\3B=>>\2<;5,]/I8B37KK$LRQ"2+U2.!
M9&B:&-P5:)1[)K^"W'(YB,1X[2G.;.5W)O&,9YC/6971&)G;8KU1(5DV9ET@
M='1 3 *Q&XG!8R0"0X"H4@D 2&#GZH\N>UN.[M/:#P6X/'/S<^[G];..Y>[M
M[AW$<A>1W<?/Q[^/U\[E%4T2]:JA$B=1"=:ARD+UJ'*FF7J,(!U**'(F0O/F
M<YBE* F, #QP3[AS[S_ !R3_  #S/ZV"0/,D ?.?+WG@?;/E^SG/&<XQC&,9
MT.7+9FBHY=N$&K=,"]UPY53013 Q@(3N*JF*0H&.<I2]1@YF,!0])@ >0I8\
M*"Q/N !)/')]P\_+S/V\X)"@EB ![R2 !^R3Y9Q.DS?HE%1-L];JD(<@G(DX
M153,)%2'+U =,Y#"5-0A@YE$2D. ^@HAT=%;V716X/FKJ#P001Y$>\, ?UB
M?>,Y#'WJ?>/(@^\$$>\?(02/UP3\ASM5227241733615(9-5%4A5$E4S@)3I
MJ)G 2'(<HB4Q3 )3 (@(" YRRJP*LH96!!5@""#[P0>00?E!SD$@@@D$>XCR
M(_8(]V<$D6S- $D$D&K9$IA*FD1-!!(O,QSB!" 5,A>8F.80  YB8P^D1'"J
MJ@(BA5'DJJ  /U@H  _8 S@GWDG]<DG_ "DG.!NR9LJJAVC$60,H51+H$BI3
MIB8B@')Z#E,!NHI@$0$!Y@(@.<.H57''!X;D<<'G@\\_K_LXYY^7GYO/G/5G
M;&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S@I[FI
M] ;[D<ZO\1OVK?R'&4+-'&?.YY;R)L$U>- E$L@XK4+5KC(-D6R0KHM9A[/5
MUI,2?:[2Q15:P[=EW5115.W:]PY"<CJ<_,O27+=AUT<E/Q.^.*:2/P^SGQ%>
M/N),A6, *069V"JA<D@$D?8O]2A4UMB?J=[#55M*:P(M,5C>)*5^6K"Y5XW4
M3VE=(^'4-,L8)8@*=$4\ZMU+J+:R$!_&1%HE'$2R8JO7#9FQ8O9)W&>=VSD
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MN=]T\S1CX(\.&.T]IHXZ&M*S=]**$0$2B22*M%8B9Q$9YY)4GDD:PDZ(YZ?
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MBT/B.5/!Y4KVD@$GD#G;6?I1R17Z3%F3CDQV]9K[$07D<N([CUH@X/ #"0N
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MK",_//'U)NJ_[F?QQ_Q?'U5^E?FV?\33\8Q^F1/)S_.]^_:PC/SSQ]2;JO\
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M]C$RO)G'ES@ZRYE(;9,@B8P)G<4"/5./-N00W==8]5NUYR2$60"3CWF)P4E
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M.1QR.1Y<^[GYN?DY]^?U1VU1(NHLY;I)M0 SDZBR9"-RB4#@9<QC "("00,
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MF-_@GG\8HS_OD?R3/C'ZE/7W]MNC_C"_\$RS_DBU'ZFD^Z/XUEK*HCW5.J3
MP]P_,Q12$IAZAYB4?&DY@(^D!Z"<P]/27V@\FM](;V*U9BD;<2R1V)HY)8*R
M-#(Z2,K20MXT?=$[ M&WAQ\H0>Q?BBQQ;?6F.,AJ2@HA"M/$&4=H\F!B8AA[
MB"S$'GDGWYVHQ39P3N+2C,IN8EY+N2I'Y!RY#T%%R %YB/(>X B//U0]L=FK
MZ.]K?B\=Y;,9#&/MN1O'-[/!![8ZUI2A[O9/B\\\@JO'GT??TXF*H]7M/!]B
M6(CDCCW_ %OS\OD7C]?GGCN"'13'J;RS7J'T&\,L+@_3[?K%(T5$I>8!ZW2
M<^0<^8@ [L?H\V% EWVL-(2#L$DU+:7E<CVNP1T=':D0^7=WNBIP"O=W$ X7
MWM>8!4ABLD'DJLT"]H\QW$M9A'R\<=Q/G[O+D6Q=VAFM0LKA63%1)&&?J*$.
MF<I3$(W.)BF,HP3(4!#VQ,<I0]L1#/4?0STK<A]*WH^E&_J6RG56H85HM'U%
M#).1:3B-)9^G*T,;,?(-)8A4'WR+[\I'I%VT Z$ZM,E%(4&AV)>4V:I$:^KO
MRY!O2 A1YGV&_8.80>?(KYZV_P"^9_@S]B_@K9?J6?\ Q5G/SL^&-3^J:_\
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MD(S!XW"MQX1APAVMJT5.,B\T261P:X13@R8B)2KK0:97I>[T\C*I)212&/U
M04RB %NR>D"X$XDUU%Y>/S0>,BDCW%HUE(Y^<*R@GW!?("O-TM3+<K:MK'SY
MI]:8\'GD!RO\X'W_ "Y!$1P^[2X9^(R)V;ON[FV):7[-POJ^T13,L%0ZPT5
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M^^$?[#W>9N97<L.?E6\8O]UUQ3_SCMX??-L^?:6@_.+2_P""==_J<.?&N_\
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MN<:__P"Q-4_W$PSXDM_9=K^^)O\ 2-GVG4^Q*O\ >\/^C7+VS7S8S@I[FI]
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M!_$C%RO902\*5Y15?L+>UQR,B&[[0LK>H61>F6-@[M:,.^4KS4-2WED*\J1
MQF:0.S0*Y6XG5 H J9)0">V)!ST7T*[C?[?TM>CO5[\ZJ32WNK-/6V:#J!;!
M>G+:19E$!WDXE)7D=AAE[O=V-[LJGI>T^EU7HOZ]V5'2[6&Y2Z7V]FK,]_1%
M(YXJDCQ.PCHUW*JX!/;/"W'ND3WC"7X.G'9_!FWV+W'\R,_9WZGWHH_4&O\
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M!'<.QC'JL'$=\DL;J#L]FV2S$V%XE)8\OYG.?A/9$NQV%TM)4&O<^M3\O1
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M X'<G(\^<^@/)?/:,8QC&,8QC&,J;'W,_P!'_9#-J#XA_;'^08R#);Y*R?\
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MO_Q'/<%QB$0!$M344*D )%46A+$JL<J8=('55*R*514P!U**%*4IS")@  $
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M,>QZ ]XX?^K&7XC'C2_2R?=M^''AQ_1I]ROX,JX !0 I0 "@         <@
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MO-7SCY)?)#_K?[&_ZEC&!3G?3R=1/R0ZPYL'GR*]/Q ?UR],A[7ZK#DV]O\
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M_P#;^4XW M:!,88)60"$$PC#@ZX;A5<A%"/./!PJ66*55<&G9[R@%*!U.HP
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M!K0*5=(+GQ(5A3Q\[>-_S[ .B L_Q(8_8VFJ/6S*J<^2:QYTCU+D86K5P(G
MK&?J"8QD1;YKTG:]27.OPUG"FR<DR8I-+,+2/?A%'2F(YP=46DJ4T>MWDD5&
MO2Y 2E[_ %DY*%((26HV4.HV-78V*<5^&JSM)4GN2T(I@\3Q!7N05K<L 5G#
MADK2EBH0@!BRUSJ[7OM.G-I0CM+2>S#&JVGA%A82MB&3N,+6:8DY"%>#9BX+
M<\GCM;5G^AJVO_C7I?87K7\5E^^JAHO[2M/_ .-]S_[7SY_^IQ>_MNJ?>&#_
M -TYZRZ8WBB4$26ZLR!$@!(K]2!9$4?%3#H*\.1NL5N0[D !8Q4 !$ICB"0
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M]-U7]^*O_"\?#4>)[^"ZR^Q.2_.3'Y8'KSZ+0_>^Q^/8_*A^B?Z;JO[\5?\
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M)+O*]"/TG3V7618.F,T:\07E0'%.)3M2--3;5VE":VBW5-FJ1+[GI]<B8M]
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M^NF]GY_(^7R'W8ZGZOT\_3?4,$>RZK=YM'MHD2?1PQ0L\E"PBK-(-]*8XF+
M2.(Y"B$L$?CM.]7/U6S\_<@#=/[=>&/Z?+K[Q>[,I_5'YY]"_ON?_P J=49Z
M/T)^<?I7_P"[J/\ ]0>@LG_+AGG&?'CO+]VO</TTM@_^+)?/S6ZK_P"=/4O^
M']Q_M&SG[9>C_P#YA]$_O1Z;_P!C4LBW(#+=C&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,^T&J?M6K7\@0_^[FV?I[0^P:7]Z5O]"F?AAN/SVVG^$;O^
MLRY7\V\CLX*>YJ?0&^Y'.K_$;]JW\AQE"S1QC&,CS:6RJ_J:E2UTL1CJ(,2
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M1[>0?C!O,<@>7\/R9=U0D+#[)X/NR,H*?G% 3_KZH(](&YCR#NFYB'[W2/\
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MB* $"@ #%_=#-2#V!H"4;$Z75TUE&0@'Y>A-C4I495_T@  (\RWYOU!Z0Z
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M5HX::=LM>4)X]QIWSAY=\(K*AOYF*))Q:UDL98Q)&TM]IN=QOK\U;0ME.V;
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M)5W3&<>/TE9M/+F+L-:KJVDH=02[F]0AMW:VFT.YW,6L,K456E+:U.HN0^/
M=7%5NDO"DDU>::/FO:C?/GD[[0G5U+VRN044V3W9];!9VU.!VTZV-A!2OS&>
M,EVV4MW:7Z0('&M?5V@&\;L$I,N+/>U@BF%LKKJJRE8FD"/V)(,]?=OVK-<
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M+P*O\'//ZWORJ5VG69"P02ZSJ8%%&9C%5049N2IBFF]0.<#F$>12"4! PCZ
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M!X\+U^QTD#@\+("0Z2Q-S'-&WM12JZ,JLA&7BIHV#@9K5U$>6EG)WW8FT*E
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MMB)E%=>2SQ1L(6AC=BW$CP]CQ/-)XLDOB23=R%HXX<P\QYUQC&5-C[F?Z/\
MLAFU!\0_MC_(,9'KW]F._P#25_\ 6GRMV/LB?]VE_GMEJK_8\'[C%_,7/-F'
M,V,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&2QEPRGXQC&,8QC&,8QC+'V'
M0HK8]=2KTLZ?,"-+'3K;&R<6G$*2498*);(:Z5U^S"<BIJ,[B$U!,15!S&N
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MM^GV\TXK5.NQ=>GE)*E?;I22#@D'XKRL.?+W\<_K^><LLQ'MVFXY^24#S_\
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MS%(8PD@5U8H3VLIX(QR;N22-XS4K .C(2/$Y 92I(Y<CD<\CD>_)/SWK(3(
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MV^#\Q^T<P8Z#_,F^I'\&.#\Q^T<8Z#_,F^I'\&.#\Q^T<94F0""9^8"'K_+
M0^4'[^;,/DIY\O:/\@QD>/?V8[_TE?\ UI\K=C[(G_=I?Y[9:J_V/!^XQ?S%
BSS9AS-C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g383050g14s40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g14s40.jpg
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M 0$! 0$! 0$! 0$!_\  $0@!G0)= P$1  (1 0,1 ?_$ !\  0 " 04! 0$
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M8EL41V]J]5.A3C.L7HZ=_JAR4NRR+KT,?7K88LL):Y./WW^)LXF8%F_=.O\
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MW+_8SM3_ (6SL_Y,.8_Z!7_ZA1_OU\S?E-X?_K"?_D+G]RG^$!],'_/+<O\
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M3\FG(1\Z?#-_VLI"/L^:GY1\ ?2#,N^D8N8C_P!6_P!B_1Z\G#,GQ<4'E@T
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M^KW'ZW'^U.AG^2W]4?V+ZBR9F*8AFC4Q#E$IR"W2$IRF 0,4Q1)V,40$0$!
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MZ%T3V& &5K6SNE>6=#8^O7R9NS6!X]Y/I6W^3H?ZE/\ W<^:MGXG[ROI#0^
M^X)Z5M_DZ'^I3_W<;/Q/WE-#X#[@GI6W^3H?ZE/_ '<;/Q/WE-#X#[@L!\H[
MSKK5_'W;EKV-:JC1*VE0;7&#/6R6BJ_%C*2T!(L8F,2>R:S9!:3E'RR3.,8(
MG.\?NU4VS1%98Y2#M,+6MW,K1AJ03V9O:H'^7!&^5_1'*QTCRU@)#&-!<]Q
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M'EX_D#1U9+&//9IGD +[-8G7F%X>\ZW*V;3'P\]R/&+V%LRYSAKFP3N=YE_
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MBN3")A$PB81,(H%\D],W.G7%MRNX[,BCM&LM/*V/1FX*$8[BHZ!4A?Q[IJW
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M,Y:YE>Q*QDDAL3SO=,YH:'EKF,/2.F-IWO4\;?8FP>-M6K<]RQ=I5;DLM@0
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MG1.Z'O=&^1C8VA\C9(R7%W)=$SFMJ?DQP_UGJ2NV!=3;?&O6E#U]LFL24&,
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M%$SE Y#D. E.0Y3 )3%,41*8I@$# (@(" Y4$@@@D$$$$'1!'<$$=P0?0JA
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M\Q0 $ZGA+^\;L)%K!)@_!F^!-F]!, <Q[P"(N0(5=,/"X9N.Q_""R1@[*H'
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MA&<Y)0'M$KE<L3%)O2]& :WUM!/Q&R._T['?UWZ_>5.SI1J;)'A'K]GM1;8
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M?'X0/X1*4!#Q@0@'[=O%X"]^_A#L1?4             [  !\   #X  !\
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MX$HO<>E_A"K_ "")^DR*J1)[CTO\(5?Y!$_281/<>E_A"K_((GZ3")[CTO\
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MB81,(F$3")A$PB81,(F$6%>0U!NVTM16[7=!LT;4)FX,BP;R?DT'CDC2 >'
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MDUXH@=DVY3WBFN8\5[-#N785GH"3'G*L8'IO3_:VL^&IY)-: K,])6:#YF:
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MYO%]G_)SZ5;/@[_9\6X?'X?;\,T%CA_*ZN_/XYFV >KQC+CXQ_\ W(X7Q_\
MQ+<P\EX[8UY.<Q+R?1IOU6O_ /TWRM>/M:LQPUOJ=B IJ_:*[.E.'<IH:;C9
M0#!]O<HLG*X"';X]P[YI9Z=NM_XFK9KZ]?/@EBU_^HUJVD5JM/W@L03#XQ2Q
MR?\ H<5V+,9>Z81,(F$3"*-^VN4.MM-[7T?J&UO/+L>\)R1AXA0%TB-X-)LT
M.C%OI8I@,H5*Q6=>+JT.3LF5P]>.W'F@C%N2C)<1Q7)YK$YW,5&;K8*"*:8=
M)+IRYX,L<)[#=:JV6W,?E%K&,;T[E:1HLER&AB\EB,99?J?+S211'8Z80UI$
M;Y/>!/8,=>+T#GN<=ZC<I(9&EO4PB81,(JB-8\Y*7:^I3LW5:/H25J=I5>TW
M5K0581++7G4LQ=[(Z;B<Q_2@SE9"[W:$C7"9SED'$'7_ $?C-,=@[%E."7JG
MACB\J[S#:KWK.;MU"WO#0S$-"JUVM=?7#'0HSRM('EMGL]>A"N8X[E]2SSW(
MXYO0*\]2#%U[&S^=N8R6W.YN]](9(^W;BC<"0]T,/3LRJW?..KIR81,(H]\I
MZIM^^:*OE%T<\KL7?KI%C6$)JS2K^'80L)+CZ6QOF[J-BI=Y[4/#&=L8L46Z
M1FKQZE(%<$,R*FK(^)V\-C\_C[^=99EQ]&7VIT%6&.:2>>'Y=6-S)986>4)P
MR27J<X/9&8BTB0ENCY'6RES#W:>(=!'=MQ^SMEL2OB9%#+\F=[71QR/\PQ=3
M(] %KWB3J'1HX/Z?&CM^\<=/R.HMV2-+F8V!GEY#73ZI3LM,G90TV9=[-0+]
M.4@(/TS=E-^=*1JB(NS+FG)!!3TR3)J57>^(N=X]R7,Q9C!Q789;%=L>2CN5
MX80^:#I9!8C,5B?K=)!J&4.Z T5XW#J+W$:CA&(S6"Q<F,RSZDL<,QDHOK32
M2ED4VWRPO$D$/2UDNY&$%Q/G/:>D,;N>F<_4S3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$56O4PHW+K;4%KC7G&BB2DK#Q]A
M:;!M]L87&CUA9*>K3TBU*A6B=DM,)(*C&22:EG=K$9J,ROVM<4;N3.6CI)+J
MWAA?X=A[&2R7)[\44\E=^.ITY*5^VTU[3"V].\UJD\8\V(BJP%X>8WV@]@8]
MA=SOG]/DV3AH4<!3DDB9.V]:LLM4ZY$U=X-2)@GLPO/ER V'$,+0]L!:XN:X
M"PC4\O>Y[6M)EMH58:5L5W7H_P!]:SZ^(DTHRRH) WE@:/H*1E8M>.=NT5'\
M:+9^N=./=-DG7E.TUT$^=9>''U\G>AQ5OV[&LLR>PVO+FB=+5<>J'KCL10RM
ME8QPCEZHV@R,>6;86N,VQLMR:A4DR%;V2\Z!GM=?KBD$=@#IEZ7PR2QNC<X%
M\?2]Q#'-#M.#@.2LFO*!<BF+;Z-3[44X>$Q;)686<*8O;MX3!)LG0&#M\.P]
MP[?#[,\ZV1R%(@T[]VH1Z&M:G@(]_;RI&:[]UZ6*-*UOVJG5L[['VBO#-L?
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M!VBL4JR3A)4JR:Q2K$.4X (;%_B9A9(W0R<);) ]AC?$_DN3=&^-S2TQN:Z
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M!_\ 4X\IGZ7Z[_WD3V6T_-?,'_U./*9^E^N_]Y$]EM/S7S!_]3CRF?I?KO\
MWD3V6T_-?,'_ -3CRF?I?KO_ 'D3V6T_-?,'_P!3CRF?I?KO_>1/9;3\U\P?
M_4X\IGZ7Z[_WD3V6T_-?,'_U./*9^E^N_P#>1/9;3\U\P?\ U./*9^E^N_\
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M_>1/9;3\U\P?_4X\IGZ7Z[_WD3V6T_-?,'_U./*9^E^N_P#>1/9;3\U\P?\
MU./*9^E^N_\ >1/9;3\U\P?_ %./*9^E^N_]Y$]EM/S7S!_]3CRF?I?KO_>1
M/9;3\U\P?_4X\IGZ7Z[_ -Y$]EM/S7S!_P#4X\IGZ7Z[_P!Y$]EM/S7S!_\
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5$3")A$PB81,(F$3")A$PB81,(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g383050g17s56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g17s56.jpg
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M 0$! 0$! 0$!_\  $0@!I@)= P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
M       ("04&!P0# @$*_\0 61   @(# 0$   8! 0(&"P$A! 4#!@$"!P (
M"1$2$Q05%B$7,2)!4515E!@C)"4R4Y*3E=+4U1DS<7B1N-'3-U=88626H:36
M\ HF*#0V0G>!-3A2L;.TM__$ !L! 0$!  ,! 0             ! @0%!@,'
M_\0 2A$  0,# 04%!04%!@0$!P$  0 " P0%$2$&$C%!41-A<9'P%(&AL=$'
M%2)2P2,RDN'Q%D)3D]+3,U15E"1#8J(E-'*"@Z/BLO_:  P# 0 "$0,1 #\
M_P!_'B*"/0[/]G9K]5UH-!:S6B"I1@WK]@KCPBN&UDLZ(R,;5[2TV7;%@("K
M95L3)P-3Z_7(K!"46V8MX 5X)A48YY]9_ER*[SP [NA]8LDO?DZQ+:M+HPC2
M"IYTA*[>M925^;:1:0E8'[3HXK7-:@JJ2^T66XJHAH"K8J#L$Q^-R''+UZY\
M->&B[KXHO\T7XD7T3]%H?Q1%' J+VOKE%Y/%\&T?KN]0YI]*_,OS!'+T%E]
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MELL2HU.@F!':,1Y@A9X9"VP DY&?PD\,ZCN59?R'^)/V9H__  T5O<OJ$P=
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MD6S+>=<^2TK/-D]%IJGG651J+-!6UA(!2LI&6L^C%/FJB@Q(OZIAH45J:O\
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M_9+#(AGB_7IIO^B37]6NNWYXP465\1/$3Q$\1/$3Q$\1/$48OK[_ .8K'_\
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M,:8*$EQ)/$KN/BB>(GB)XB>(J]M'E*W^^C*AC@WSS_F,5?2OHNR:3<@D[?\
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MS]]<=K4'/0OI'F'S':B^>\AIC&[6_CW.5G0)^M?<-%K*?@G7+$<)W:U,^5)
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M*UQ))UJ].;'T4BNUOX!L/0HKC5/G&#F_)N1=PI7#]79=TNL?</G1S%>2NB]
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M=F7M%G3,NV?=Q0;0W^UTTE';KC4T-/)(^5S*6ID@=VDC86R/;+'&V6-SVT\
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M8XN8YS"0]N6N+7%DC7,>TD<GL<YCQP<USFD$$@[%C#+&/RQ@'&,?Z8QC]_\
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M:LL'PDO0YH=S/4WL%GHNP[U_>/3DUPO*[*DF]W#GGCKO 9^7)3=XK\?G?/\
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MGZ#XXXZ\,\PZ]\>=R^ON:W7F'U=] @5[FE_KYU?=<7^9JG/3ZX>M9:?HG6]
MZK=F5DZ;?QX/RQO'_@\?!5++7\@[%6W(&9QB?I"Z-DK'31&:)KLOB$AB,C<'
M\/:!KBSD<@$Z+$@>6.$+Q%*0=R4L$FX[D[LR0UV.A/O71/PY_G2A?*OQAPCC
M?,HBAJ6NJ>;BK#,*/.G"*Z@Q,Z4\$_F,SV1Q,,+^UM-1=R"]]]1?V8<:ZZQX
MQ[L;Y!34MWN-)1Q/AIZ.MJ:2-LDIF>X4T\D/:.>6,_%)N;Q : TG T7!M4]1
M56ZBJJN5LL]52T]3(YD0A8#/"R3<:P.=@,WMT$DD@9.JDEUR_5[F/.K7=K-:
M1*:K0IS6$KTH6!CN+L+!O/C :F:<?^W.DUCVT%6Q28E*ESKII_K_ *XS9[=4
MW6Y4E#2TCZV6HGCC%.Q[H@_?<&_CF:UW8QC.7RD88 25;G6P6^AJ:NHJ&TL<
M,3WF9S0_=+6EWX8RYO:O./PQ@Y<= M)^8>G$]BXG2NA'M\N&CX#];B3-=DJ^
M@+L;](KE4.LE(*WW# 9Q%P@G_ORZL OXY6N^V),9SSMJ;4RRWRNML<(ABIY,
M0CVD59D@=^.&9TH:P!\D3F.DCW08W[S" 0N)L_<'72TTE<^7M9)F9E/8&F#)
M6_AEC;&7/.XR0.#'[QWVX<"05W[WGEW2>(H9TU?PE1]7VT!E7.@N/I76LF%I
M>B7^OWJU"_[)[!( \8 <SNF5!7,^;T85_P#M51K4Z^9463M_5PBK*L?,IU;Q
MJ5Y=Q_GQ_3^JDQ?4E@L"(4*LNMT306V4-]N7H48'@Q36+Q7K'8$$Q .?W]1;
M.A5,JV7'MK*-,*UFA-@(#DGAD*#Z_+]%7^]^4?J]Y+<#L?2;E5/9KL5;%ZI=
MT_KXZVNI9B]R&-!7F+3%,\"FU;%!R[.%@*C?G4=,"54-'"LOUNC#+0('+/\
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MYUV#ZI;?3/3DQ7 >F#T@9$=O7!;U9=Z[2E[(!RHCDG@MT%<>U-S_ '03K&X
M57;OR ($1N8()],,YX;<K-LG#LO:IV;0VM]>^>,5+Z"E%1721203$-=1NJ8*
MN#L)(,2OJX:=LCJAF\YI[%KOG0W3:.6_W"%UEKVT;87&!M9/V%+&]DL0WA4M
MIYJ:7M6RDL93S3EC87EH(WR/Q]2\V^P>O%\L)KO,N##15)\T;%#2V1)T[?\
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M/%<:FMH:JFNIDVKKG4D5+'5,FA%->=H[H^3V@SQDM95P4)$1-7;ZV9M)-1;
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M*01Y7#[;:)1-+LLR5AL9&=()N=%F&(C0>(G@MX\1/$3Q%'[O-M[M5DKB?AU
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M%3+M<2]8Z%*5R)/6^K,N[5M%\_F;O\D\81H.TMS^GK55*D7AZ6J;20B(A9!
MMC*[[M->'<.F,GKIIK^IS,WYW^>.9?+W,%_)N4 NAZX*[M-J:-+39'5RN-NN
M=YL+&V76ZW2WV,P]Y9K5:K(V8-W#9B7))).1B ;08$<42 H22<G^0'( <@%W
M#Q1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%&:?M%VG^E8
M>+J:I2YJBK6+FEMLC&_#+KI )8*M:6R(FLT.<'0VPBC/ZONFL9,!.H@ CI0P
M6EMYQ;:!4R>O7P4F?$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q%P:M]F>67N%Z
MY.)RZQ156@1ZAMNM;N:\16I[216*!;Q*K H#,(=B,,)+S&2;_<PK)=-(5I"D
M5T$Q9%UXKRSGGP_5=Y\43Q$\1/$3Q$\1/$3Q%QICWOG*KL27@QF;]KTFPI65
MC3BC\=[ =4"T2;"C#AKMU$&B$\N%"4SOT2]G,9<A]0&[E6F+_::GBARE<'&=
M,>(SY9SRZ+D'X@%O44OXS^D&#D6S%#L>.]&1CZU:DW.]%Q&LZ8]T&G8+Z0@L
M)ZI/'F/;^?8F@P=?58S'LT9AZS19W(T9(\1S Y]ZE;7W85E1J; NA;C .EXK
M,,>P5]]4WD(QD.L\,;:LVE:FLB%AIIOC4I2]4KFH,V-QS0QY]-XM2BR_B)XB
M>(JUJ_ G(_$CO9@^RZ)J#5E()T9R?E;5T7MOS-$5#*FLK6C!]EK2.$0J&.6L
M5JZMJ&2TPV=RX&;O;*J%*ZX'P[^OD0._AT"L1<6*OUW5;M8'J=%JY<+Z\GV<
M,PEFK9^VDVB5(UN39X,'.&<NF\:]8+F4TR37;0:"3;7.,%%J977^2A8/R;U'
MG0F%4KJ!IDJ[5H?"V>MG@JK%"?F5GI_#E0,V:U:ZC(_;W5'L 0SM8""X(Y"8
M/3T>'FNB?[_]WB)XB>(GB)XB>(GB)XB>(N(=Q[7OQ!/6G>_+>D=-%LMNK5'B
MBYT1S"$E78+I8DM2J [37I72^<19@L%D?+U0Q2N9G"OWVE,>;*5L63<E?>!X
MY_0%=KADVEABEWAE&WDBCDW'FS#M-!MOKC;:&78>6<?:6+.<Z29@GFASOKG,
M4LFGZ=]BB^GB*M;[S@3F]$^6PV&RZ$[_ "*Z'+R7:?E=G4Z1B,N:1&0:5[KM
M&M2&-Z1N6'A3:*ZWKEZ0"QM@D.&8#]Y(K*C@?H?=P[^NGDK$75BK]:@#*L;U
M,@&8-%R, ATS"50'.FY.H:E.',=/!&2T:%[Z"KE\.VY9I.^L T,LNV-<E%@'
M/3.;UPLD"P]!I"$X*$\@P)S:T*LL0=6,K,9SDC''P300K@WB4H^6733009PK
MG(VCB8";S$6ZZ;Z2::R1[:[Z;ZZ[Z;Z;8VTWTVQC;7;7;7.<;:[8SC.NV,YQ
MG&<9QG\L^(OUXB>(GB)XB>(GB)XB>(J=/QK/JRN?(WS?RB]-$G<[4\L_TQQV
MG):M\]];Z!RN^-TD;[_->B!R[<[MU4;V)/8J#3GO.\#3[,(5=AOM=/'U!/\
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MO/2A-('=K4IGG-&JRNME91%A95:9$.!_1%6VP0Q?O@2+ UA7/KUQ]^> 4R@
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MJ^X\RQ4]8OH)BBGN2JZ61TPOUT=\Y=PBM&^%=BM1S6RT>BK;1E@A H:4H6C
MS #;)0 OY/\ 7AE>_P!W#']?FIG^*)XB>(GB)XB>(GB)XB>(HX.^F]67?35(
MX^'5.>D<ZMO.;[T2:VDVRR074 7GK?FM<9K8JO%49T9)![GIRN4";>T01ZK%
MK"0C70J0<?8KC0GP^.?HH)]_^KPTWW_#\N\&<H7GUS>_G);7J^C> ,)ZURM6
MPM[.W..O] SMJ *WKM)IPI%@ J"EKJYO5DEKE+A(1C/&-E0%<?ASR#B#XD#
M^'?CBI!7_B]4X+\_\LH-6G:-Y,?5/RY8K=<[(3&PN?1[]9/J#F+2Y=%O+:*
M;5K;+<ZF(9M)X1Q5X>NXZ=&O55]8J5 E"<^N'<%/GQ1/$4,/HUYP'GW3>.VC
MN-2UL^+BZCJ%%9V=RPLE8JO25[!852=*QRYX:33@[Q8-FCW<>^H$XMX'C1CJ
M]C3ETL&BLKR^/#7SZ*9_BB>(GB)XB>(GB)XB>(O\\?VET.Z]O_$T^5.5_,O'
M^>W 9&%?>?==^SX.8H[]8?G.TKCE[=\JI5ELP>:@RZ/R53_$:J1?W[6'RN]W
MT8ZU5<TS!U79%L8#23U&&ZC/'CW<^6<8!!U4^JDGX!\__6_SUPZAO*\E8 <
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M=QS734%+$"'8P989& _O,<,@Z)\[_-%L"YE2E7U'82NKV:F1_P!2@JK*9/\
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MRJX"8?7J\5R^NVI=1V+>^7_<B;IE50/$*&E!5:V/-+_3WKUZ_ELMW0"2#G4
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MMREJ,;U"H=BZ/0ZB9:+:U_25:>96+2L_.$$(P6HBNTUUXU;L;U8SC6KX857
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M>TTUBN<]QI8VS5=+%2R.?10N;OBHKG@=E0TP80^2IJY(8(V9>]X:"5#7Y!^
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MTLRJO;J8JA4KA971<(!RVLJ,U4NJ<OY)_-"(:K6N)"9X=WKUWDGFO#V#\/\
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M%82:AFLPWN BN.IQCUY]WCJ I3?/O6[3V*L69];>;-^7')+NRK B!WN?(P(
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MZA?.C[7ZN84]FY9_3/R8[C'7H]I(COV%\#/&=Y/[/34,MM?AN[^+B3EKMWB
M,'0]%CK1^#>)<KI<;PUZ^F2V2_\ UO\ 2_T59+?4.<ZI;Y#3?HKY';_,<O-$
MMKDLI3$22GLG9O0%;8J0Q9*1G5=A .3M(UW*!V!C&= -=>#M[RY$<^*Y+5OP
M2^@K5^I;SN_$M+'4EGP,+S]/2/G)O5.66 GX'MEU?5O';Z-/U]S-?0^LB6J+
M%TB2N:KJF= +FBJ$_"<> PM;_<?[V<NR?Q <-!C&-./>K0?D;Y.L?RSP;H_-
MP.E*670.F]4[SVXFRIZ-NFYS0+WW*V.KEE+SSF1-G93+^=4=HT@T55HNW2$N
M,C'FE,ETSF2((L$Y/D./( #C[NBW_P"-/FM3\@_,/'?G14]FMDW-ZK@2RW0D
M38 N]WYZP.M/1KZ8%(6PE$*NU\=V*T3"3L6,XF[7(TK W>'),I''))Z_ <A[
MAHI-^*)XB>(GB)XB>(N:A=BY<QZ6TXX!>:\9U%(KRZ<T<8[69^I5_P =.5$6
MQ$TQG^%H4*]7$@:$;QRL8-C)@="(U;38,F-,\N"Z5XB>(GB*FW[^_"Y>_8WT
MWRGZ,5N_F!N/S?BMGY#-R[ZK^;7'T30&,UCN0=LUN8"I3UOENZNQJM OZI<5
MN0;B$-@UUSIM_,U_9+;7[H(UU(.6NW3IRX%:ZW_"#Q8^DMNJ,^G4E%;[!]<_
M.7TH>XH/*Y*NU25CB7RO'\Z.>4TIS+;6KBNIWK.5C<:Q/(>Q#J@Q4:8E6]*T
MF<$E-[0#&@!&">KB<^[./U"CQ7OP);F%5U]9<?0G(XH:!\_\ X3SC_#OG-C6
MU%MB^;/I%?\ 0=0L_P!%5^;KS07J95_F6QU_J *LJI1LYI_[L,C!8N(RBUOZ
MDXXDDZZZC!P<:8Y9SCO5A_*O@%Y2/E;[&X*S[-(GNOV;>/HKH]BO7*:J12:[
MQVR_0%7$JNP?(JD79W+!>FI\"T)SIDNSQ,;%9R; _P!R4<[O6!>6=[5I _=Q
MH3G.#GH./P7W_#9^"F?P;2.K5H^[4=U'U"[U:W#T;D/.CN4<:Y_O5>74KF),
M].I+.XWDX>Q=!VIFEZZ.[D=QQ.[8V(DA7#ZBY*.(YV]CN&,DY)U)U.!UP!R&
MBLE\64\1/$7#>=]NVZ%T;J'.=>5=,J$W*6<*=W:[7+S':K-SS@53I+#7\53I
M5IM$VKRM.5]E E;UA-&,MFV"<[*K!%*DU)[_ )_1=R\1/$54U"I213]E&\^;
M]$UNSQ?:K+TJR4ZQ4'Y!K]5&S8P;%=ZR9142F9%]*D6:NRN:)OCJA*:XK]R*
MK95YUD*;N7;!"6M<9X:=^H&!KR]VGRS9A;:35+V""LMZ(%^ L<+[  ,?IOO&
M([4[[RK&<'Z-]-M"P99-I1I<;?G%)G$FOY;ZZYP65S*3Y@^=9QS!2>*<T,B8
MDEGLLG5%.=,S9'RB3EMF9)8LQ#%Q-,%!+EN;+.SUD_?VT*UR65F8B[I''I%I
MI%%II'''IK''''KC32/33&-=----<8UUTUUQC7777&,:XQC&,8QCQ%^O$5*'
MXEGX33O[U[?1>P+;SP5:-5. ]!X5/4^]?/[?N*H.6^OQW.O2J=HJZKS3-<O]
M4T'S%5VTVS.("8DN;<>;$V-(RVU^[GCJ0=#CAG3@=#GN7AYQ^&C]>?./7$O6
M/G?[%Y:Y=Z?)'!/EFXM/IG@-[ZR_M>G#Y7Y45XT95'Z%YI.O,?EO9,96L2+%
M(O &&$D:LB-)&$Q-X'BT_O.<,$#&]C35IX87,;O^!9ITUEW"NW;Z+BVX_84O
MUY+\Z5=%S#(5MX[>_L[IM([!?['<;.7># .E)*3=*$L'I-=&15 HJO'&!NWL
MAT$!^Y-_AI^7.3D$-!  TTR"<ZGNPI J?PNKD_XI:><]C[V@MEC[Q]XTO[5^
MLBJKRTRM4;K*JF'T0P7@]6K+"_/6=+II>>4\VR>Z:/K>P/U4/AI0(\6&(A.4
MWM<@$8;NC7AG.<Z#/$\,:G/C<5XLIXB>(N5=.[EQ_BV*_MUGI-/YYBUEDKZU
MFV.@TV'IX?\ $_DA*_Y<D?\ ,*B_G!_J'A_7+G^1%^G3/ZO%<$\ 2NJXS^>/
MSQ_NS_KCQ1/$56GVI71D_6Z=8V?4RJTPZ6H$IE-K&M*^1\50G>IF[3-HNA6O
MZ)(KUHMJIHRNJ.:/G5!N@SALK6.(4U=TDD>/L%>7@<\3\O@3WA6,-^=T9[6U
M-.:U5*554)5?-25[ <8ZA234RQ3ZQ(N!%Q# 'BOF@@E)XQ](XETX0D@ND6PT
M&="BT*7YIX 1IIJ9R"@L9=)BRM3&M>!:L\G'+E2@EENU91E,I&NZQ(H"T:R%
M[,81UXVD!,>(_P#4F3U7:!!!0!1@01AP@@AX1 PQ(8QA1!1H]81QAAX==(8!
MX(=-(H88M-(XH]-=--===<8P1>CQ%7!^)O\ "+/\0#D'(>;*K9SJL3\I^DN<
M_0,H/6N9G=<YO>AZ @O">3G]SI"ZY4,II6[)M;X]'<4=B%R0K%+7Z_HW.T*&
M+37;ISKP(T.#KS!P5 OFWX,_>N& ?,=BX]]7<K7]+^;_ *.^J?H.LJ;1\]6U
MA\^U43ZAYZMYT?Q[E7)E'>U%BHO,:,OB>NZ\JQTEAM)9;"<SEUBBD(!)+6^#
MO9!PX '\0SH<Y)W=2<:Z+LUM_"T[#U+Z)JG=^G_1G.YA;=<ODGJ7U+2Z/Q%]
M7Q.E='^(+A?[1P\CES1[UZU&<SJ3D>XJ572$;S6^LV6*KH8B>J/[J85<4W@!
MC'Y@#D:!W'.FO=C'$K@:[\"6QC<WZ=S4WZA5&I!.-UWYS^<0]>1&C+:YPI)]
M63?6+6C?0 <72OW>PZ7AUA7RFW25HKFBX[G*G?>15.S=,XLO!-_AIS).O/&
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M+@WT\U[?T7HE1_V6-ZC6:>0]UK]P:$VB&>U *['A,M8SU^P\^JFJ.*R+9(;
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M%V]-D[%9L.G\(880(FJQ.[4.C7KQ1$4<%M>:G*3]M5&ZDKD_#'N]!3' !$6
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M1NWS@[[6Q[HX![P25<9S+YYXAQRLUNH\VY=3JPFJ4A)*/(Z<8YQ"T/(V-;6
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M$+K?SO\ AK_+/RO]$];^FN(U4ZE7WM"::O7!&G_QU1SX=-LU4M@E]<IZ&MJ
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#1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g383050g19a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g19a20.jpg
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M(E&G&B-!<20E)C0X5&%H=+*SYC(S17-V=[;_Q  = 0$  00# 0
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MS$:YY[PYS)(X@O?K6O?SZ>!0?FD-J'7N#PN+\YB-<\]X<YDD<07OUK7OY]/
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M73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\
M'.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU
M%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF
M;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-
M8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXY
MB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$70
M1V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC
M73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\
M'.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU
M%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF
M;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-
M8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXY
MB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$70
M1V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC
M73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\
M'.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU
M%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF
M;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-
M8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXY
MB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$70
M1V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC
M73CBXYB-@/HF;:V1\ '.;$701V>_=-8'Z4YU%L'IMC73CBXYB-@/HF;:V1\
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MA$GGJF*BO?0KG;=/\5'.=L+S]A]AU/P0;C^IK[@HW:A$GGJF*BO?0KG;=/\
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M% * 4 H!0"@% * 4 H!0"@% * 4 H#GYVZG_ )OIK_\ WI3_ /D85:3MS_\
M-J5_]..?^P3$Z*?_ /)G/_MT_P#];9SVU%LQ04 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'6)L<O\ T-RO
M_P#9SY_^5&J7-C/_ )E._P#I./\ YNC,9)_R%/\ VKS_  )5*VN=N* 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!SE_[0+JF
MEW2@DZ87I#IQI$UUP*,IM=2$>$?LJ1".22.68RL)@62GPAKR<2-W.))/+%0*
M%@3N(.(Q;$>P!@<,3/K/Z4D-6S&,@J@E[J8PT/!+%.73[E<EA^R_<.4>)R53
M*CM\\9^II375H\]F,AE<#$2UZ[=/7T>RY;5[#N(AE7:P\0VJ(P_8>,HO*897
ME(B-7(J(MRJB\U/VS>N?W[!_=?T]?+FMKXEK-,UX+UO/?-.XQJJ\[A-F2_=A
M]LWKG]^P?W7]/7RYIB6LTS7@O6\]\8QJJ\[A-F2_=A]LWKG]^P?W7]/7RYIB
M6LTS7@O6\]\8QJJ\[A-F2_=A]LWKG]^P?W7]/7RYIB6LTS7@O6\]\8QJJ\[A
M-F2_=A]LWKG]^P?W7]/7RYIB6LTS7@O6\]\8QJJ\[A-F2_=A]LWKG]^P?W7]
M/7RYIB6LTS7@O6\]\8QJJ\[A-F2_=A]LWKG]^P?W7]/7RYIB6LTS7@O6\]\8
MQJJ\[A-F2_=BN-[;#ZXU91Q+#."$, < LQQ?5TP:>K9YX87PQMAA>\<7M:^6
M8F/IOZ+^C"V5[?U]%:IMDI.@+.Z->3F6T=+8B91DPAI1 +$(^;AH9_$N8J):
MBG[MEXPKU'4/!ON]N^6RRT_:=<OE.T;8:E)W(%'S/N@K7W5'U%.T@*<D]/S&
MK)ZQ+X"5N9C,8&71LKESN6040\@WK,,W%1TX@UB8A'3QX[@7<5WGO<0TY>NZ
M^X]KKK:32%CA-PPK:X8UL1<!M,6GG.V> V=_5]6]HVP]%PKWQPM;T7]8.WIS
MO?.U\\M,V'O:>JZJL%JIIF4S!(^$BXF CH>$9@W\*_@W2Q#;E\Q"][</(9[#
ML/49;5TCYA\RZ17C;+Q428?=K=SG2]E-E^,ZS!^^I]N1324R^>2..>,3B!F<
M#-XEB7.HR#>S1W$Q\/,H>/?0S;QTS%-0;Z#>1+3+APVX85NQ/MF]<_OV#^Z_
MIZ^7-2\Q+6:9KP7K>>^>3&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+U
MO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;
M-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK
M-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39
MDOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U
M\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:
MJO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L
M']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+U
MO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;
M-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK
M-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39
MDOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U
M\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:
MJO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L
M']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+U
MO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;
M-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK
M-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39
MDOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U
M\N:8EK-,UX+UO/?&,:JO.X39DOW8?;-ZY_?L']U_3U\N:8EK-,UX+UO/?&,:
MJO.X39DOW8_T#HXC.+G''K#<*K%L9BJB\S&NM*0H;!:H(8A]40R)XX(&"&E6
M#"PS,#B98A86M@'C>V&-K8VM:HOQ<ADCJ*B73$HEB,.HA\[818&%5498>-,L
MHJJZO5;D3*O22:A&';V%AGK;IRK;V'<O&U1TPB*TV[9::5$1FY$O5<B=!>?,
MU$'"F-NHS7\+KY_$LF]$RSV"%^$?1WAQ_L76K8_R+R1&^@MDCBEMM$2&^F8B
MB#XIR(FDDHCB,->UQAL2A $N7L*+>UKB"6#MGG>UKY7OZ+5]KB'AX5VCJ&<.
M8=TBJTCIPZ8<NT::RM*C#MEEE%5>E;KU\I>RRRPES+++*=3*(B>I+D*O7,7"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 03
M;:6&-/$V#:<V_J.'F<NU$L*5EE%SA)78Z.X;N$/..B06*H.^VXYDT5&^C3JE
M<0(H4 /7/6(YXF; 8#A"==,K7\3;AB?>+?&?C)\S*.\\CE\COC#R,[Y=X9!W
M7>!<F_EM?WO[GE9R^C; XGN@IC$4Q#3AQ)FY/!-SUI^_;>,,O673^'EZN45W
M QRJTJS%EM$5VPES"_OHJ(RU!AN [+#WEM .O&G3Y3UTG/K_ (3_ "/ZX;(_
M9F3;/N7:^)^71N [+#WEM .O&G3Y3TY]?\)_D?UP?LS)MGW+M?$_+HW =EA[
MRV@'7C3I\IZ<^O\ A/\ (_K@_9F3;/N7:^)^71N [+#WEM .O&G3Y3TY]?\
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ME'VD?U<<LO\ RRD[_P##:]__ -$;'_"UZV_8ZJ).YG>MW_T4W_VN$-1VP?\
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M;N7DM7+<MUQOQ6VB.8H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MK2%TKM*?7E[_ "WI@'":0*!VI-.##&],-#ML79Z0_- W6D+I7:4^O+W^6],
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M-/&5N1J>2I8'G>* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M $B$J8E1#8N> 8&(F>5K7 O2@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M85[#O&'K-][#2+E.D:IIGEN* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M79X53 *M\T:CV-'_  !C>LJTCT1VGD^^#=8U+< 9B[.79X53 *M\T:CV-'_
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M4!R*\I9'1!D:YU1L3QP-#B!!8V.F+9A88">O:^5\<9A69O96W14F=2:+B(^
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4!SK[?G59)FDI-TR/:+TR.U18<)Z4VL?!DB/
MV](:4&F#EV*K9B$DIR%C10DH6-)!7'!0 #Q,XELC):V?LC EKYM1%%TY6T?%
MR^I9:XF<)"PBQCAS$.W3UAW$LOG+A'K++UV\1&D=/WK%Z(BW-*E]RK?B575Y
M5E 0<-,Z1G<?(XZ,B? 8B)E\5$0CU["-.GD0TX;;AGKEMIVKZ'<O%8::5GE.
MV5NO1%3FZ^VJU>_=#2MW8(K\(K9G-_LHS2EOLD'NQ@/.5MMTA5+MF:[Z/MJM
M7OW0TK=V"*_"*<W^RC-*6^R0>[#G*VVZ0JEVS-=]'VU6KW[H:5N[!%?A%.;_
M &49I2WV2#W8<Y6VW2%4NV9KOH^VJU>_=#2MW8(K\(IS?[*,TI;[)![L.<K;
M;I"J7;,UWT?;5:O?NAI6[L$5^$4YO]E&:4M]D@]V'.5MMTA5+MF:[Z/MJM7O
MW0TK=V"*_"*<W^RC-*6^R0>[#G*VVZ0JEVS-=]'VU6KW[H:5N[!%?A%.;_91
MFE+?9(/=ASE;;=(52[9FN^C[:K5[]T-*W=@BOPBG-_LHS2EOLD'NPYRMMND*
MI=LS7?3N!V9DMNB=M">G*6GH5;9)T/1GJ:@KE6BWT]JMP$<H[G&E!V2F\E!A
M)R6!D6( YB % \ LC&0PUL;9"7M6F*CDLMIV=S"2RB&=P<ME[YES"0SIEEAV
MY=M.G;U6666&6&43EO&UN991,IM20S^;51*(*?SV-?S&;S-VV_CHZ*>O'\1$
M/67KQRC;UZ^;>/&VN]NV&;VVVEN91+[D1#>RND.W% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"!_;60C ,Z":<F[J%7)@06N
ME82LM(YF&BS+-+XR^'E'9$(!3P>^6*=BD73CRB()D5O<[RT,E;&WL+CU\L9:
M_#V..F9[$RY],F)D\24,NG#MAXTPT\9;C$>*CR-@D1E$@U9O1XTM[2)R%15:
M9R>E;!)GW0,<_IF5S6!E#Z3PC<]>/X]]$.73QTZ?.)>KIAJ'ELS;5XK<P8;1
M&G+#/)8:7OB*B,M03?9W;,?B-KO^$:?OW:ZWGU2K-68>RPW'S/?V9U7YZTW[
M?-/E0?9W;,?B-KO^$:?OW:<^J59JS#V6&X^/V9U7YZTW[?-/E0?9W;,?B-KO
M^$:?OW:<^J59JS#V6&X^/V9U7YZTW[?-/E0?9W;,?B-KO^$:?OW:<^J59JS#
MV6&X^/V9U7YZTW[?-/E0?9W;,?B-KO\ A&G[]VG/JE6:LP]EAN/C]F=5^>M-
M^WS3Y4'V=VS'XC:[_A&G[]VG/JE6:LP]EAN/C]F=5^>M-^WS3Y4'V=VS'XC:
M[_A&G[]VG/JE6:LP]EAN/C]F=5^>M-^WS3Y4'V=VS'XC:[_A&G[]VG/JE6:L
MP]EAN/C]F=5^>M-^WS3Y4.O/9^,:/(UT<02QHH/O-3CUNM=1*-D_(0:("\S)
M05SKQLQFNA-O_P 28&;*!DW@#BGWN%R3$OZ][C>TO?MG%8.Z_<NZQ<PS<([G
MJ>%,0SQEEAMTCM5AN2TRR_B6455<*UD?O$6^^]+^2FL)W9_%6636,L_C8N'C
MHJF7C,$^BX5X\>P[]I\[8C4;=-O8:#>-,HS%,LKRX9TJ-(J<E41&FMQJYCJA
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M^^Y$0HU#\]*10"@% * 4 H!0'5OH._\ 1'A+_P#CBE__ *==J?UE/_-[2_\
M[B]_[9%'COW1'_/17O\ TI"_]U2\VYK81I<4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@.<7_ &@O55/6DQ'TP/73\_/J YG"
MI2DUEA3^J[,=7+$(8JQU84CR)ZMUR)Y?UE!)3S'*BI0 YCR?V6)BP HX8FQK
M-Z>DM1S2.A9W .IA#N8!J(=.GS3UEEA\D1#NT>)WIX[56D8>-LY55+FER7W&
MOK0ZDGE-2V"BY%,7\MB7\<D.]?.$=JVVX5P_>J[7OC#Q.2KQT[:R(BWLIE.:
M'[:3:7])3_DY /RKK<>*V@,V8+6QF\FH\;%HF=<Q_P!V%W<?;2;2_I*?\G(!
M^5=,5M 9LP6MC-Y&-BT3.N8_[L+NX^VDVE_24_Y.0#\JZ8K: S9@M;&;R,;%
MHF=<Q_W87=Q]M)M+^DI_R<@'Y5TQ6T!FS!:V,WD8V+1,ZYC_ +L+NX^VDVE_
M24_Y.0#\JZ8K: S9@M;&;R,;%HF=<Q_W87=Q]M)M+^DI_P G(!^5=,5M 9LP
M6MC-Y&-BT3.N8_[L+NX^VDVE_24_Y.0#\JZ8K: S9@M;&;R,;%HF=<Q_W87=
MQ]M)M+^DI_R<@'Y5TQ6T!FS!:V,WD8V+1,ZYC_NPN[G='LP)9D"=-!6FV693
M7_K1(#T9RJH.5?\ HI$1/I(X5>+E2P!OHINIJ0BD_4(D"H-PT]-*A97"]KGA
MD-F()G'FKI=!2FHYK+I=#L0L%"OV'</#L*VTPZ85PZ;5EE7C3;:IRFFERM+T
M]5R&_*4F4=.*>EDRF42W%QT6Y;>1,2\1E&WK:/WK"--(PRRS?R6&4R,IT==Z
MF^M8X9"* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0$&&V;B_3[*AK3JC:B6Q(CJ:R>!*RFC$HX>:8R58NX,!(Y*A&CJ@J-MS
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M+'>F)@T^2^'>HTKM&+F>5RV>INMFD:A0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!'5KOTD/O5(IQ1]4%9%1
M2;*(/WZ5-J^0F669E?,,KZ-+ERX5\<\[9A(ZD*,-ZWJ W!"#RQO<?&^.M;3J
M(C:[DT#+8&-A8)["3-W'-O(ME\TPV[8A8MPK#/>66VN7RHAEK*B)<RN6^XWG
M8+:M*[)*EFT[FTKF$T<3"1/I4[<RYN&8>NWKR82Z+1ZVL2\=L=[1B#;9N956
MN4VSDN15-!OLD9C^_P S?RQW]ZM(<W6H?3\FU4=\$E9SUJ,S/J?7RK>3/VEW
M9WR9 TZL:5UUTMY;2VI=RW,I:2"(&H&OIMH+[<!L!F<-!%\?8F%@(P+<3.WI
M!!$QPM?.^-JRZ@[%YQ2=5RJH(N<2R*<2_P .Y;B'=Q2/GGA4NC()GD*]=LL)
MR6XEEMJ]?[K*HF54-;VN=U#3-HMGM04;+J:GL!&3CQ5WJ+C7TO:AG*2^=RV:
MO.^,N'[;U>^.X%MTPC+.1MME6E1E%)?N7&O<RE^*C^*U(LA0.7&O<RE^*C^*
MT Y<:]S*7XJ/XK0#EQKW,I?BH_BM .7&O<RE^*C^*T Y<:]S*7XJ/XK0#EQK
MW,I?BH_BM .7&O<RE^*C^*T Y<:]S*7XJ/XK0#EQKW,I?BH_BM .7&O<RE^*
MC^*T Y<:]S*7XJ/XK0#EQKW,I?BH_BM .7&O<RE^*C^*T Y<:]S*7XJ/XK0#
MEQKW,I?BH_BM .7&O<RE^*C^*T Y<:]S*7XJ/XK0#EQKW,I?BH_BM .7&O<R
ME^*C^*T Y<:]S*7XJ/XK0#EQKW,I?BH_BM .7&O<RE^*C^*T Y<:]S*7XJ/X
MK0#EQKW,I?BH_BM .7&O<RE^*C^*T Y<:]S*7XJ/XK0#EQKW,I?BH_BM .7&
MO<RE^*C^*T Y<:]S*7XJ/XK0#EQKW,I?BH_BM .7&O<RE^*C^*T Y<:]S*7X
MJ/XK0#EQKW,I?BH_BM .7&O<RE^*C^*T Y<:]S*7XJ/XK0#EQKW,I?BH_BM
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MD74,$FT?9R$T<7O=4$!Q,!IMFI=7LO74!"^>(^!/D'*,P<L1<0[X7ME<#*E
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MTWOZ/^RUK?UO?_A;_MH")+9_E[KVJW71+#79SJ2HCD!!TRI3 <+DTV/S2ER
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MG*9L07-=/3]66^Y$Z,J>3Z/)<2^4+10"@([CD-$95VAB5(A^*R3=9.E&/!7
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M"@% ?E[VM>UKWM:]_P"EK7O_ %O?T>GT6_X_TM>__=;TT!^T H!0"@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MOF2\+MRYUSK[< -"N+)G"8B-+-YIELPT5\B-;(,+%NB/%-71$0,$ %-R+!
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M9997]-[BTN2@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M-I0:&J\(ZBK8BU'X0[+4UYS:?R^+;!;JN+RUQ**3@?7/JO\ 2I,^*JS=DO\
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M8%(+,=I*!'E:&W2R"UE!D)!8F2'SS#$+$FDK*3?P -V, B)ITP -@);.]ZS
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M44E6,E6V2^EE0T[@DH\?1[7S+FR!,.2MU]R]"JOT7+<M_P"'K/#$6T)A]Z1
MAS#*B@TX/156-(+?ADHO2$C+YDJK3N7=0S;990B4))CD45?,5JG $6_U:*&G
M=?$\(AI@F",I^P!4NO\ K5/490-ZY=(9'ZUV,:A(S]HR(L&FMS  +X9HT0C
MLV6^\C#K"*E<!C"D6 :KM::\,02@CJN$FNML&!$_'%PH_+ N7J7+T9.G*J?S
M14^M%/&A:W=.JVEN=Z9R<Q4>*6['L52#C)*X\$5(3SI267I*+!;Z<,@J0Q1P
M))HTZ8O4T%!R4"0=WBX#!E ;(2@J(JB!B%R]2WY<ERWY.G]>L]ZQKCT?("$S
MW.K:D8@*-Q_)3@7&BN7>B2,EK2*T5Y/:[Q5@3I8<8 NG,IPJI%'>IP[F6+L\
M\(("Y1$O(J:]@%R]7Z_71UFU-"@H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MG+U;Y>KZU[>F_H]/H]-_]:%IZ: 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
+"@% * 4 H!0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g383050g20a22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g20a22.jpg
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M#?9BGB>WON,YDH+A&P*]I(0"L];V S;M:LFWP 6W'3;X0+/*%<:V-GQ?*59
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M_<N!JW9<?<()R-(4M65(E2B$@PE(U4HP$C4D"M;KS3""X\XAIL$ K<4$)DF
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M2F*4Q2HY<+,RI=5L=ND6LF_8UJ%DIMS'PC!:5FI!.-:*NACX>+; +B2EGPI
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MI>SSFXLH5;IBE,4IBE,4IBE,4IBE,4IBE:\;%7F=C[%9:0AIJ6K=;CJHRO\
MM^<K\@ZAK,ZKD_+3$!1J'7IMBJWD8#PWDJQ<WEDL\*Z;ST- U \1#KQLE;F=
MA@NK:ANTM58BXVAYU;RK6Q;=0'&0\TAMVXN76U H=XNAYA+3+B2VXX_G6%H8
M4TY0N"NXN$V:%J;;2TE^[6VHH=+;BUML,-K20IO;J:>+CJ"'$(9R(*5O)<;I
MA^_G:1#[])I^)T3K?6/#PJX92NOY>@K%3OJ[#6-8VK8GT_9(BSU^/I$=,1=M
M2A(V27J=M=-7;)U<Y@;$R?%K"-]*6[A>&<>7B-U=XH I%TBY'^3!5V[9M);9
M6RXJX4VM@N+0'F$J2H,(V:D[8TU*<91?"T18V]KA\I4PM@P^4VS5TX7'$.-I
M82I#P0E1:>((+Z]HE0:$Q>PL7HSP3VQK6+6IVL;7,U..VKJA)N$;7(AML&3C
MH>.V-7JVF)8RDVBJV2;CG6PTH8L;#V*JN+3,SS.2M,+!O@T(<7B6VL;M8?NV
M6WEV5Z25.K-JA2U6KCL9[AEYIM2;4N9W&G@RVTI#3CB:W*0FRV5S;H+-LXMI
M-U:@96T!]:4)N&VQUK+K3CB3<9,J'&BZMP+=0VH;>YPJZM,4IBE,4IBE,4IB
ME,4IBE,4IBE,4K56LP+WB-2<; N4[9&>I9!\^1U?KRK6.;J+"S5=B[68L]C7
MV6K+Z+G;02]%06FZQ4UY5.F,Z3(P2TY7I*T+NG$;VGG485EMK=II5\E*3>73
MS3;ZF7E)"E6MLAU*VF3;DAMY\(VZKA#@;=2R %\QMM6(2^\MP6JB1;6[3BVD
MN-)) N'UM*2MT/@%;315L0PI!<;4Z24U-?M*O)/8+G6O#/:IO0DK6*6E;]@6
MB#G+0]K,@2W'L,-1Z#X"+3H5<'=B>UZ=FK?>HQG'[$IM>B8IM3IF)E[NSLD!
M=M<02BU%WB[+>)-O7&PM67&V4O)+&R<N;GC ;VT-)=;;8MUJ5:W#JUE]"T6Z
MFG*K]FI5P;?#G5V*VF0Z^ZA;JFU!TN(88V!<#4N*;<6Z^D)N66T(2RM"GPZW
M8.KM-Z<V/0(6X-ZM;Z?;ES2T/8I1CM?99]B5V[5*;DJG=()WLQ*U)6FR&K]O
MA)J(.^D))W'SR3(7*S5PQ>BB>K>W]_:W3C"GF'V $+:0JRM.*NV[[:'[=Q-H
M62RT'&7&UA*4)4T3 (4F1OM;2SN&$/!IYEU6=#BA=7)N&WFG%-/-JN=J'72V
M\VM!4I12X$R04JBK.U?8K9$VNTZ=V#,&L\]5HJ&M51O2[-C'/KUK^>=R<8W7
MGV48V8Q*5XJ<U#O(>WF@F#&$D&;ZIV9G'PREF7KL-3O&F%LLWUJWL6GEN,OV
MX4I:;:Z;2A9#2EE2S;O-N)<8#JE.)4EYI2W T'7+-LXZEUVT?675M)0ZT^4I
M2I]APJ2"XE(2@/M+04/;-*4*"FG0EO:EM%Z9SJNTQ2F*4Q2F*4Q2F*4Q2F*4
MQ2F*5&U[?6FT^\JJTPT)8F%;+;W<08QP=HUHSUS'%F#AT.AV0SYFY; 8#B?K
M43 ) #D([@PZ6DOA"MBI[8!S3*70E*RC?.;*H*W1!WUK+K8<+16 XEO:E.LA
MO,4Y^B,P(WSI6A/"KQ'/&7#3P')W=NYDK5O2?=Z9E'C^34%]#6*FZ\W%9)"1
M>"LDZ5EEC2NHRUA=%1PV.5S.IOC.CF:=D=>DQG"DJQ;A&;<I0SAS2;]"4(&5
MQI^YL6DH3! 0,E[M@0%:-D 02I/"PS$2G#L##X*G;Y9LU%2NN0XS;7;BE*D$
MJ.:TV1$B"L&3E@^B#=\R=JOD&CQJY7C'16,DBW<)+*Q[T[-I(D9ODTSF.T='
MCW[%\5NN":IF;UHZ @H.43G\N4J2$E25 +3F02" I.92<R2>R3F2I,B1F2H;
MP17H 020""4F% $$I,!4'H.5250=8(.XBNUD:S3%*8I3%*8I3%*8I3%*8I3%
M*8I5&2'$7K9A*2T2@VVE8E8.5D8.1D*1H?>=^KJ<S#NU8^9C&UJI.NI^LR#V
M&DV[J)F$(Z6=GBIAF^B) &\FP>-4.BC"KM2$+*K-H.(0XA%QB6'6SI;<2%MK
M+-Q=-O(2X@A;96A.=M27$RA25&DK$+9*EI N7"A:D*4S8WS[>=!*5I#K-NXV
MHH4"A82LY%I4A4*2H#62Q6G4^QMS6R=V7J[>UJH[76NLHFBIS7#'Q/.XIA9T
M++MIYL \=!$UC_N"0=QC[7I9.65CT!E6[:+9HO'80ZJ#+L-,WMI8,-VE[AK-
MPJ[NUW!;Q;"$K4R6K)-L%N<;E24K3=9$9CD)6HI&<%7-<=M+B\=7<6U\ZRFV
MMDLY\-Q,H2Z';LOY4"VZU10JWSKRC, A(4<A"?NM6[5FM]S5B6UIK#>]5U\_
MUCLN.OC>'X9.)UK$/KD%JU$YUNL]@E=8B9U)-H1+:!&4NUCU 9-G#YF_>(B_
MCD'&'F+R[L'D7=YAKUTF\M%VQ<Q?""M-OL;X782X+O1"G#9E2%*ZXA*DI.51
M!MVVM[QI5M;7S5NJVN4OA&&XF$*>VMF;<J0;:2H(%SE4$]:"H*(S)!V<B.(;
M7$O-0T"9OLVO/;!(IQ$.ZO.C=VZ\@GDLNDLJTBPL]ZU[7:VWD9#J%$8QBZE4
M',F\ZMC'I.7JZ+=3D.87=-MN.9K-U+22M:;;$</NG$H! 4O8V]RZZ4)D%:@@
MA"94HA()'31?VZUH;BY0IQ65!>LKVW0502$[5^W;;"E00E)6"I4)2"H@&[\Y
MU7*8I3%*8I3%*8I7C3\+@0#>3]SY>;QK_&'/X_%M^[/4\&B1QV"1[F__ #UR
M\2$['28VG-/O=>D?# '+AIX> ^;1FI0^Z@U_.#?ZWU[_ .;N?]\NNBT(;;'0
MA ^9(%7GE2ITQ2F*4Q2F*5$KG9)BKQ:$A"T&W;%=*ODFBD'3'=&9RC9NH@Y6
M/*+J[ NE%AC,4%$$FJJ;:7<20KO&QD8]9L5VX:[[=EMY92Y=,6B0DJ#EP+A2
M%$$#(!;6]RYF()(E 1"3*@8!U/.+:2%(8=N"5 9&2PE0!!.8FX>81E$ $!95
M)$)(DC5/7ERVUQ \)<DR=TBV5+8=XX>ET(:ZW=;59*Y:;G;J,\:-)1DRHMON
M"\>R[V=-W[M*;JD*W1:+E(G&K&(LP3[5U;V6%XVA0N&'[6WQ0%RVMQ>;9FW8
MN$J*%&X88"E9$E*2V\X2H:K$A1YC#UU?X6I)8=9N'\/A#SQM=FZ\ZP0%I2P\
M\4ISD*(6T@!)C+,I&RVI[+!V[7%0G*XPDXF)4B$HU*$FU$E9RONH!16 E*Y-
MJH/9)!2:KTI&/82641D9!$\@P<F2?.R"5=3D7K3C%V^VZI#B]H5EQH$-NAT!
MU#K8*4$-NH6EQ *$D)4)2G<.C;.(=MVEMI4A!3E"%ZK;*"4*;60I8*VU)*%D
M+4"I)A2AJ:ZX<%5I:OW^\,D'#2D[,VE8;_K5H]5;+/QILU#5MLK-.#ME7)0:
M76WQULOT @J[7<M*O:H-FZ3C5VZD/'6L5 ;=M;<D*N+2S:MKM200GC"''E;,
M2 9MV%LVSIR@%YEP@K!"UUL/)6A]X I9N;E;]LE49MBM#0*S!.CSR7;AL$DA
MIU (21D3VGQ2Q?%+6#LPZ!KQH&]EL8EY?Y<-5[$UR-,ZWEY_]R#N*^=1T@_]
M,<='_P _,).?!G@HSQ?$[;9#HXY:W7&(^-Q&VGXHK*NMQ-J/Y^P?VGAXK<6^
MQGXO''X^,?#5_9S*OTQ2F*4Q2F*4Q2F*4Q2F*4Q2M4K;9GVKMT[/GDX!]9']
M\X?XF8UO 1P?[X7:Z:0<[-E[+KZ,6$IB$G9:)O%1>5F* %7<DD2X2+5!5K 2
M9T.TPRF\P^S;VJ6DVV)K;NW%=C;V^("T0U=+ UV;:[=]+R^Q0=@DD%Q,\QUP
MVUW<N;-3BGK%*[=M.JGGK(W"G6$GF6I+[):1J5_GE $-KC74FO=&7%HZG]WZ
MYXC=E[4M#&"&ZW4FJN(RLH ^@G:DO#QM)B:XQB6M0K%0EW+@]-:,$^^&I")R
M<[,SMF<RDZ_ZG&L184EO#KK"K2S94YQ>W-[A;QRN)R+5<+=4LOO/H XP5'9J
MDH;;;9"&T\\6]D\"Y>LXA<W3J6]L]Q7$6QF0<Z$LH:0A++;*R2R$]>G1:UK=
M*G%3.3N%LMVD;/J2RM[J]L-VVA':0UE/WRH2%)N=_I5@:5VQ2][D:[(Q4(8L
MAK.E.[P>S2[:.8,IYQK-[86+-@O86,.GH0PPSB+-\RJW2U;V:\1O&K9]+]O:
MOM%UI%NEU"W)1=OIM]BV5*4V+M+2E*#2G*W*=<=LW;5S;*6]<ILK9Q]I3#UP
MRXEMQ;ZFU(1UULRI_:K"4ASBRG$I27$H'H)GF*[M,4IBE,4IBE,4IBE,4IBE
M,4IBE,4K2S7&R5=7\.E?H3*.;R^VM0'I7#:E2WCHS 9*_LQB:/1IF1,DDX>1
M])M\&,1M(\NV:/7#'73Q]))M',A%.XY/T%U:"\Q5RY4M2+&^%QBQN$IS9+56
M>XN6T20E5PPYGLPV5)"KH(25!*TJ/'M[@VV'H82D+NK38X?L5'+F?3D996K0
ME+#J"BZ*P%%-N5*RE2%)%;JZNU_K_;]VE.)VZ/[<78E"AKO&[!MEAE*71R6+
M7S"?1V35X*K04Q'5*KHU>J)UBRU)N\+*7>2K!;2Z>62S+4ZQ3@VQ>75U8VZ,
M(MTL<5N5VZ[5AI%Q<%JZ6V;1YQYU"WWBZ]M6GLN2W0]L0EID/M-BOQ9BWNWE
MXD\IWC#"'DW#KBF6 Y;A8N&FVFUI::#38:=:S9GUMETEQTLN+K*Z7BKEP_4Z
MIW9=[:#:HVGLZ??637-Y=/Y2S:F:;KVE++:KL<=,3AW5L2<)!::= ;?J%KE9
MA")?2<C;8B1KX5>P1=LUWZF,3??M@EGCMG:-)9N[<)0U>G#[-L7C*FVPEDC\
MR^[9/LH05I0EA:7=LTMF=FAZQ::>*G>*W-RXIRW?*E.6HO+I9M7$J6"\"-JR
MW=LO+6$*4IY*F]DXAZ_JZ^1O?$19;-#&*YK>I:&]U8O--Q [&5OUPL<+9[C7
MVZX<BNEJ#&4VG)22Z K-6TQ;9.",LG,04ZR:<QU!ML+:9<ZUZ]N4W@;/9(MF
M&G&6'2/T1<K??*0844,H<@MN-J-UM0?OW'$:MVC"K4K'8J?><0X\V#SEA++.
M8B0%NJ1(6AQ(V(SEUT*8I3%*8I3%*8I3%*8I3%*8I5#\2^YEM Z8M^T&5?4M
MLM!!$-X6K(*F3<SLE+S4?%$;(=6!E3%9MG;F7> B4QTXZ.>+B $1.8O2PFP&
M)7[%FIT,-N9U./'<VA#:ER9TE2@EM,[UK2.>J.(WAL;-ZY2V7EHR!#0,%Q2U
MI0 /$"5F-R4J.X$UI-MZWJ,.)G?VRHU\=2 K_ CM.E)'05%1DYLU&94W=;%9
MOT3"3M2U8VR#@#I\A4:((F'S%((^@LF O",-LU(&U=X1V=P9'7!JY5<8>I)^
M"'K(#4Z*5H-3/&NW<N)7URE7YMO [IG0RDN,!F\21S3LKN?"D57*D&2IO>'6
M@  %4TEQ$[/L#<P?R6[J>XP>'NJ]8?EYDR!0.)>Q%*H/1#LO3 W^34..6]H7
MTXI<\V(879M*U[(-8%B;P\?^484T8YSX16C)LCA]OSV>(7+@/-+F+V#4^ ;#
M$G!T1X#6R'#A?8VI7?C7L=]LS"$JSS;DEMIU,S[]NQB:["1D]<^&$".7SDZ:
M#1H53A7,^ %5 *49(#AR%<"YR<5M7'[? &K=E3CR;)%DEMM)4MUQ;3&+Z)$E
M2B,8"=TG+NTKH8<^EI_&7'W4H:5=JNRMQ02AM"5O8;!42 $_]%YM3O5TFO0?
M/,5WJ8I3%*8I3%*8I3%*8I3%*8I3%*UAX?KE4(NCV=A)VJMQSYOOOBG!=F^G
M(MH[1%3B<VZJ0%F[ATFLF)TCD4(!R%Z29RG#F4P"/8Q.VN%W#*T,/+2<-P:%
M):6I)C"+$&"$D&""#!W@BN;8.M)9<2IUM)%]B<A2T@C_ *2N]X)D5BIF_P!U
MW-=FE+U [V%3*33;Y)Q&R]V5@^C9&%D2,=>+R[>KU1M<7-_GG2_A-8ZF22D#
MZP9M>C'RB+.?(@0POIMVUOA]NI^^3:W%P_;(7:8>\,12XC-=9%//E@6S:?S3
M3Q0CCBE=>@J:)/6Q6^]=O!FT-PRRR^I%Q>M<24A03;E8::#QN%D[1QK,HVH'
M6J < [+]K^P[IJ"[/*!N1:_VJJ7+9)(75&\+.KH^/@N[5=0L+<O6K8WIKZC3
MC&32M54V6WCGWBM*Q4:J0#9S..#."+)X=M;>_83<V MF'F+3:7F',C$%.9Q?
M*8#K!?3<MJ267K0J2;S,%!TAL1!-W#UH\6+LONM/7&2UO7.))1EXHEXMNADL
M+2H.M7(2KBL$%L%9F1DM\W"I2T+KAC%6BNR;Y7?NA!29Q\W&/72H);6JZB@I
MMVSI18X)ID,H<2D$"$*8YN10$0QAMN^VN[4XP\A(PS$@5+;6E()LW8$J2!KS
M:U*^=:4BW2EQM1-]8P$K228NFIT!)K:#.-72IBE,4IBE,4IBE>./PM) -X@.
M?+S>-7XPY_'XM_W9Z;@ZK+QS29XO_P#GJC>)"MG,Z9]WZE>CW#&'+ALX>P^;
M1^IP^ZA0 9PKW6\NSTW+_P#O5U=2( '0 /F%7AE:LTQ2F*4Q2F*5&+J]M$;4
M;')4F(96&VQ\._?5ZOR+P8YG/2K- [AK"*R/,"QQI91,(]&05 [=BNX3=N$E
M4$5$C[K=+*WVD7"U-,*<2EUQ S*;0HP7 G]+).8I$%0!2""01J>+J6G%,(2X
MZE"E-MJ.5+BP)""K0)SD90HZ))S$$ BM=:3NHUVK4-$\,.K#3%8AF",(,]=U
M)'4>MZ:YB [L?TA%)6N3MOF[54'3=:$G8&N4Y:O04]%2M2G[C 62+?QS7JW&
M'BW><<QB]R/.*+@;MPB]N[A*Y4FX)#K;#;+Z8<;==?VKC;B'FV'&EI6:#-X7
MFT)PZU*VD)"-H]FM+=DHZU3(!;6\MUD@H6VVR6T.(6RX\VXA21W]8(2-$UU+
MTF]1=L6N]AL.RK+80I5&L*E<4G-FW"QVV03I<TP/8(1E#)O["NA$2%HL<5*'
M!,)NU,*VY>.F#.-V4W-TW<V[C MVFK1IOC%RUM@W:,-,HXPVH-.*<*6@5H9:
M<0/:V5.I2DF5L%,6ZV7DNEYQRY=<V++FS*[EYQY096G.A* IPA"G7$J,9W4M
MJ*@,)K^?W'H[7U-KFR-7L;'2:=6H>MDM>G5WDQ:(2"@&",9&O[7IL6CE\EV6
M)9LPEFFJ;AM=\64.Y1AX-Q#MR21IW35AB-T^[:7BFKA]YQTLW^5MIQQU6=26
M;Z4I,K4K(;UFS3D"2MS:$IJ#"[NR89;N+9+C++2&]K:%2W4(;2$I4[9Y2H0@
M#,FU=NE9Y"&R@!52C3<PSVY>+AOV'7!]0)*!A-=:?DP*?LUCJ\*^DIRW[#AS
M*%35[DN]HDV<)$+&3,VFH/7$);(E=S#6-@X5U7[:K&W8PQP9;E#CEU?(YVGG
M$I;8M5ZD!RW907' ""ARZ6RX ME0&RS6F[>=OD',PI"+>T5S.-(4I;MPCGR/
M.J"$2(6BW0Z@E#J2=E<Y%=&F*4Q2F*4Q2F*4Q2F*4Q2F*5"K[K^L[)@>X+.U
M='10?-)>(E(M^\AK#6Y^/$YHVQ5F>C5F\G!3D>914K>08.$E#MUW3!R#B.>O
M6CBQ:W3UH[M62F2E2%H6E+C3K:NR:>;6"AQM4"4J!@@*$*2E0TOL-W#>S=!@
M*"T*2HH<;<3V+C3B2%-N)DPI)!@E)E)(-9)4SB1BB!'P^]==S,:@'5M)/8NA
MY&<NBB0!YCS,K0MR:MJ4B[_-UT70ZZA\1CM%!Z72N<8PE<J<PZ[;69)1:8DA
MNW!Z$(N;"\>0D="[ET^$56V.(IZU%];K2-$JN+%3CQ'PUL7EJTH^%%NV.E)J
ML=D\--KDX-:_0&QK=8N)*!>Q$C4MBO).&K"D/!-YA@YNFM:+!IP$O0*A7K_5
MTY>N+JV*H715Q+KU6T75Y;)6BU9_#V[3%F4."V=M6&L)=2M#]JE#CP6X4*#%
MW<.%U%R^[;/9'0&GV,J \S;I93</)<KW&'.J07V[AU>(MJ0IJX4I#90@+27K
M9E&S4PTW<-9VB7&7B5%IUXO+8:4G+:!XASVM=MKS8ZRC*^HNY*%AYF2BT:XM
M<9* :%?3=7L-?256:TS<]8C3$D[916[AQ#V. .CL[5C^?UY(KFK<,3PL,@W5
MH,UL4H<<;2HNAA+BLK;S3D OV#R^M9N" MIV;.\2W=(&UE8W^U(8N"4O@J0A
M:DALO*; 4XTML$AJ\:20IYE)*'$?Y3;*7;J_-[=9PZZM,4IBE,4IBE,4IBE,
M4IBE,4IBE:=\66K*Y*LJ5NL&LU#V;3]PK]@F[E1G"\7=VVM1),U^W'[4R1<&
MG8JDQ%ME]@DKTG'SK9?N*1:QL0X?2ZK=YW<%O'4*N,/S-N-7UNZTVQ<@+MU7
M?6.L )41LW+AQE%MM4*;(+B%+6$H!3R<4MFUAF\A:7+1YM:WF24O"VZ]M[5(
M)6AE#R[C9J2L'(H(05+(5)G/#3K794=%OMF6Z];ZBO\ <4[5E[C<42UR/<"B
M#F%M==AM:L:/41L,<"J<C5;R$2ZM%>="E*UF>C79NTFU#%KNT4M%HQ;8:N5-
MO!A@[58DAQEUR[5</;)>J7K?.EAU/6.M+3I6PX=;7*4FY=?OD]:MHO/#9I($
MH=;1;)89VB=%M/Y"ZVJ%M.).M5!Q!::3=UNOZB;[DW=/N-J6BOUJ UZ_N[)T
M5&L1\[$2FP+1(6AO7V^T'L-2*6WD91:0L%_<MWD^>MUYR^6FK-$MWM[#+\I=
M=OC88>TFS9<==NDVZ@2\IM:+9E#*G3:)<N'RE&5JV"DM;5T)#;*RFI?V<MMV
MJ;R]6;EUMIM@O),-I6A5PZIT-BZ*&60I14Y<$%PMME6=U 5O#6JS7J;!1E8J
M<)&5RNPK8K.*A89DA'QK!L4QC]4V:-B)I)@=0ZBRI@+TUEU%%U3'54.<WG77
MG7W%O/.+==696XXHJ6H^%1).@T W   0 *[3;;;*$M-(2VV@0E"$A*4C?  @
M:DDGI)).IK.9KJ=,4IBE,4IBE,4IBE,4IBE,4K7%_1]H[%NU*<[-A];15"H<
MU9+.UC:S:;+:I2TS,E4+'0XAI.,IJCU6-8Q+.$N4_*.2)/)94TXWA1;D(5J9
MT'53<V=HQ<"S<NUW%RVTR5O,M,H90A]FY6IM3=P\M2U.,-H$AL;,N3,Y:YZF
M;FX>9-RBV2PPMQT);=<=4ZM3+C" M*V&D)0$/+61*^O"(W37FU:Z%?\ 7G#U
M5F.R8AW"W?8NS-@Z(D$WKIF\7E(-UPER^@(2R NR<NT01O0:0J=LCTC* XZJ
M>:"Y21>=)$/6,W-K<XF\JT<2MBUM+7$490H!#HQI&).LPI(,VW*#["C&7\VK
M*2F#7G76'[?#VDW""AZXN7[%84I)*VSA2[!#I*5$2_Q)EU(F?S@! )@6%?$E
M3[;^$7?J)J)ETSKZE[1@BF(8I/\ ?_7VN+^HLR.)>B)U[+PYN#J] 1$CM,AC
MB3I)Y5MB.)<%4@B;^Y?LW#(_FKFZM87XFL4$ _HD@<]6'_=7"!1!_P CMV;I
M U_G+>W?ZV.V=P]6:-<T$U**GIRS[.C^&B52K#:=U#N^G#?^(-X]<Q16Z+1K
M?WO$MK6'=Q3QR1_-%ME_OTG'2C9HQ=M4X7OY*6.@F]12=Z7[YBT5BZ"\6[[#
MW^+88E(<)*C;)PFZ<2L#(WL;:V0I)4H*V@;* HIE.UJT<N4X<L-)7:7K.WQ
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M4I"@ <I2E*4I2E%2E$J4I1)4I1,E2B9))))))DG4U? "0$I 2E( 2D    0
M -  - !H!78S%9IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K63?'#7%[@(ZEJ_8
M"Z]O3UBSBG]H1AEIII+L8Q99Y774O$L9VKOS6J@3"WA/JZ\0UB@[;0;*D*L9
M++5V6M%:L/7PW%UV,-NM<:MDJ4M+)<#:D*6 '4H6IMY.PN4#97ELXTXQ<M'K
MVPZAEUKFWV')NY6VYL'RD(4X$%:5)22IM2D)<:5M;=9VMJ^AQ#S#@ZU9;6ZV
MYLHU1.W;-T%7"SQ5%!%%1VX!$J[HZ:92'<+E;I(H LN8HJJ BBDB!S&!-),G
M1('))!)( 2"20D3 !.X228&X22>DFNB!  ))( !)B3 WF !)WF !T"N?,5FF
M*4Q2F*4Q2F*4Q2F*4Q2F*4^/X\4J@/)[AX59R;6.P-F::CWSA=T\KE EJV]I
MX+N5#K.3PU.V-4[_ %BFD<KJ*NG2%%BJPW=/5G$@Y26?N7#E7I\J.. "\M;.
M_4D!*7;EMU+\ 0-H_:O6SS\ !*3<+>*4@)20D "CQ!"">+/W-FDDDML*:4R"
M22<C-RU<-,@DDD,(:!42H@J))F5$U)4: _DYYAWU/W"=;H-)V]7.<D;5<)1D
MV4.NWBPEI598(>OMW2JSQI5*VWA:JQ>N73QC"-G+IRJKHN;Y^Y0AI6S:8:)4
MW;6[:&6$*(@N%" -HZ4@)4\Z7'E)"4J<*4@#:Q:M,*4M.=;RP M]Y:G7E)!D
M)SK)R-@DJ#380TE14I* 5$FS<IU9IBE,4IBE,4IBE,4IBE,4IBE,4IBE5AM3
M45/W'&U.*N2<D9M3-BTC9\(:+?"P6)9:%,I3,01RH"2H.(IX8BT=,,#%*#^*
M>/&H*HF5*L2Y97S]@MY;&2;BUN+-S.G,"S<MEMR!(A:00IM7Z*TI5!B*K75H
MU=I:2]FAFX9N49593M&%A:)T,H,%*T_I))$B9J>3$+$6"*EH*<C6,O#3T8]A
MIJ+D&R3MC*Q,BV69/XV0;+%.DZ9/&CA=LX;+%.DJBLJF<HE.8!K-N.-+;<;6
MI#C2TN-K22%(6A04E:2-4J2H @C4$ \U;UH2XA3:TI6A:5(6A0"DJ2H%*DJ!
MT*5 D$'0@P:_8:'BJ[#Q5?@8YG$0<%&L8>&B8YNFTCXN*C&J3*.CF+5$I$6S
M-DS01;-FZ12IHH)$3(4"E  ..+=<6ZZM3CCBU..+62I2UK45+6HG4J4HDDG4
MDDT0A#:$-MI"$(2E"$) "4H2 E*4@: )   &@ BLED*E3%*8I3%*8I3%*8I3
M%*8I3%*8I5!CHN0CGLTI2=V[>UU"S=AL%J6JE:1U#+0+.?MLR]L=H?1RNP-2
MW:PM23ECDY2==,1GE(UL_D7?=K-BU.1LGTQB25);%QAUC=N-M-,AYXWR'%-,
M-I:92H6M[;M*V;2$-A6SSE*$YU*5)-'B2DJ66;V[MT+<6Z6FQ:+;#CJU..J2
M;BT?<&T<4I:D[3*%*.4)$ ?7B>OWVI=]?@G#5_\ IWQQ^V[S89^TQ;UI3BEQ
MWSOOV>&^KJ>)Z_?:EWU^"<-7_P"G?''[;O-AG[3%O6E.*7'?.^_9X;ZNKZ;:
M/>NI>OR%VW/MG94=6IQA9XVKVM'4T57SV&'.=>#E7X:\U51IF0/"OC$DX]B[
MF58D)-LR?.H]TNR:F1PK$4AMU%OA]C:+>;4RMY@WJW=DYHXA/&KVY;2'$]8I
M26PO(5)2I(49"R45MJ>O+JY2VM+B6G1:(;VB-4+5Q>U86K(KKDI4LHSA*BDE
M*2+XSFU>IBE,4IBE,4IBE>0?PK!.EXAO-SY>-'\_+X_%U_2'S9VL(6$\8F-=
MEO,;MKYZV-I"IGFCIYYZ >BO1'AK 2\.>@0'XPTIJL!_K"BP(9R[@S</GI>=
M/SK56'1#K@Z%K'S*-77FFH5VV+8'CI-N)Q3 X''I@7I"'0(8_P 7,O/GT>7Q
M_GYY%:LJ2J)B--V\@>'IJ2$YE!,Q,Z[]P)\'16?\&R>EF]2'\3-.W^!]K\-;
MMA\/[/XJ>#9/2S>I#^)C;_ ^U^&FP^']G\5/!LGI9O4A_$QM_@?:_#38?#^S
M^*G@V3TLWJ0_B8V_P/M?AIL/A_9_%3P;)Z6;U(?Q,;?X'VOPTV'P_L_BIX-D
M]+-ZD/XF-O\  ^U^&FP^']G\5/!LGI9O4A_$QM_@?:_#38?#^S^*G@V3TLWJ
M0_B8V_P/M?AIL/A_9_%3P;)Z6;U(?Q,;?X'VOPTV'P_L_BIX-D]+-ZD/XF-O
M\#[7X:;#X?V?Q4\&R>EF]2'\3&W^!]K\--A\/[/XJQ,G'!'BB *BKUH''SD
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MB7I>(GS /+QG_'R_]GGSYT; D;6"1[7_ 'ZM6R<V?6(R_P!ZO0OAN#EP[Z$
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MT[I,3NGGK837>RJ?M2"<V*E/Y%Y'L)R:K,DWFJW9J?.1,_7WIV$M$S-7N4/
M66'>MEB%5(E*1+07;%=G)LNT1KYF[7D"%:CF,'0B".8@P:B04F#T [P00=Q!
M$@_)XM]3O,UBF*5%;)_+:?V5O[TLL,?I_J_WJKO_ *'ZW]VHSEBJ],4J:5_Y
M";_2%/V$\J/=F?$*ML]@/&:SF:JVTQ2F*55F\MJQFB],;7W1-1,O/1.J-=W#
M8<A"0+-V^F)=I4(!_.K1K!!DT>K%7>D8BW!T9L=JP*H9\^,DR;N%D\*.4$]
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M8IB0Z+^\'_W#E6SFZJ%,4IBE,4IBE,4IBE59=@0&^Z9%4&@JA:+4+;KSPA7
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MME\0Y0DXQJNGSY&.R.JW5*'YS=!8[@B@_P#X>DB _P#*#-3F#MD'9.K2>8.
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MVYHRH4UOS;-UPYMJ&G&L;!V(X[<[HG)9S.1:<WN2)S+2YNRYVD#+LRXVYV/
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M.EU 37*4I5D^ZVZ1RE* OG@])LRX#^'V%]C%P+VRM+S+A5HA(NK=A_*AVYQ
M.)&U><4$N 0M/$VD+ CC#^K5OW6;Z^LL(MU6=Y=VA5BETI1M;FX8*EM6U@IM
M1V3+:2ILDE"N-NK223Q=@977\IX*U?K.N\&X#K>M%?K>YX[K.O%ZXDA6Z?9^
MEUHR+MT_%3GTQ>N7#H3=>LHH:YR+@^?:<E8;G#A=S\1MLVU-P[=%S-LIVANG
MGKG/.;;NN/3M%J4:G+.+Y<G*N)9,@;R<>NLNS%NW:!O+M8R"U99M@B,HMVFV
M8V;:4CA\#:AU?4^"E;ZGJ0;=5W'%]7V<&*48#?J^R]'J0C4$8\$N75@Q12:
M7J$R)A#D# \FSY&PK9[,-9.3[3+LA;HM WEV,! M6V[;)&7B[:&8V:4I$^7<
M;S[3EC%=IM"[GY0N\^U-PN[+F;;9MH;IQRY*YS&X<6].T4I1YO!6L=;UW@Y
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ML_+&*9\X=S\H7>;:!]JZ#F;;3G%RRS<!<YMNTT].T;0H<HU2KB?K!K< *G6
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M8@H+XC9 I/%VUYI=LKMH$+LK-9+MK<MYK2V4NW>#"&ZZ6"XSC"L8PE)Q7$U
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ME+&P"+<E14VA,F<XLZI]VT=6YMG58;8[1PJ96M2TLA'YU;24E3B4I2@E\KN
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M*Y@;N# !BH+&*( (""1Q 0'XA 0+R$!_,(9,-K(D(60=00DP1T[J@7$ D%:
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MOZ*O-0N-'>M'TD^?P5'B5\L<NHK#OI6NKG.)U213Q9H@HH;S]-PP$19+F_.
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M+D*)CHJD*'+F8R9RE#F/(.8B  ',?,'].8*%@24* &\E) ^<BLA:"8"TDG<
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MO<^U?K#^VI7G0KGTQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2L=*_(5OZTO\
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MV,]D-@;\B5#[>4H;*=:P=HB-=M])65TTUK)5.N.99TW-U+19:Y4F.PO9@=:
M5$P8*H$!))3,2"<PZZ3\P-23FGKIB- 0)WG?&XQ&Z >;<16\^:JG3%*^%/YM
M3^P;]D<PK<?$?NK*=X\8^^H%G(KKTQ2F*5-F/R-M^A3_ &0SJ->U(^**Y3GM
MCGQU?Q&NUFRH5Y$Z@)QT&T!M38[Z_/8%J\UHYGX&O;1K[O:&S).U0S#;[NY2
M>OS5VPT-QJYO9TG>IFM%B;2ELPL#)56QJ>+]DE.-S/K"]EG"0 85$IZU,$B
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MO.+?/F2%B%6SQ]FG>&)G&6]Q:Y2U$;4N07/?DW;VW6"Q2*VNU&^9">>4>+2
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MC);9O#U";*C9-W4W]I9OX2J4"7XB;/2IBKC2IM<]>K$?*-[FM'LGVQ\*V(F
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MIQD[+O\ O=8*!'5JJ0>K4(ULG#VJ?DKN4]G)$$[& 3"3*9'7GP*CF$=E)S=
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M#[J['9[7@^9P# STX1AI^>R9KP7"3_.+'_Z:Q7^O/U/LZ]<6N=K\I;_IT?\
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MW" ><'2MM8S16D85VL_AM.:KB7SB >55=[&:]J+!VM5Y!\M)OZVLY:Q"2RD
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ME8O8VNE=57.M.)22UN]=NHV:I2<-&J2SY1W<V:M:AG<?:FC@\R>7;96G6HT
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M BXF*;V))E%1R+;/&DR#M$R#(.42#,Z'+,3)C=J=-:QQ9?O9W1$Z?-,3S3O
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M^0_& Y0=(4XH@R"=#\@J^T"EM((@@&1\IKJ9KK93%*ST2Z;H(J%65*0QE>D
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M>G>++T@GW&]G&W:[<?7YJ;!WM#]7GKI2+QJLT5336*<YA3Y%#I<QY*%$?C
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M^N5WZ:4?8KU;[/7DSIF5KTH6L-VDHFB<JB+2=>PU;BY:78$,0A5F*[\C:50
M[:PIS*"[@BTC@BW@EF]Q;$;ZS2H%5F^+!MNX"2%(;NW;:R8N+EE)2 II;P1<
M(EN\%RA2PK6GA0W;J7<X9P>P3"<26E01B5H<7=>M%K24K?PYB^Q6\LK*X4%*
M*'T6RG;-PI=PQ5@XVTI%EYW:\I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI74?L&,JQ>1DFS;2$=(-EF;YB]03<M'C1PF9)=LY;K%.DL@LD8R:J2A3$.0P
ME, @(AFMYEJX:<8?:;>9>0IMUIU"5MN-K!2M"T*!2I"DDA25 @@D$5NMKFXL
M[AF[M'W;:ZMG4/V]PPXMI]AYI06VZTZ@I6VXA8"D+2H*2H @@BH$G0I9@0&D
M'LF\1,44.@WCE@JUA-'H@ <DF,M:*S-3JO1'GT!FI.:!,O122(FB0B8<A.$7
M#(V=KCF*V]N!"&%<GWA93VK5Q?V-U=JC4#C3]T$B$I 2D)KT:^$=E<JVV(<%
M>#][>$YG;I'+&&"Y7SKN++",5L,.1/Z0L+2Q*U2M94M2E&0UVI1E;,]=(*OY
M.9E>H&8L,TZ%_-2G905[,DNXZ"2#5BU,NX.RAXMK'PL>HZ=G81S4SIP*MRRP
MYBQ+KB%.OW-QE-S>73FVNKC)FR)6N$H;:;S++5M;MLVK)6X664%Q95S<4QJ[
MQ4,,N)M[2QL]IQ+#+!D6UA:;4IVJVVLRW'KAX-MI?O;MVYO[E+3*;BZ=2RT$
M2?+]<BF*5!YW95$K-KK-'GK/&Q=LN/7>#,(Y.J#N6Z@1*?J1(D=%+IJ 9)#M
M*J/:ERF0;=:L42!RKO&\)L;^QPN[OF&,0Q+-Q&U65;2XRF#EA)2F52E&T4C:
M*!2C,H$5Z##^"O"+%L'Q;A!AV$W=W@V!Y.5<0:2@LV6T *=I*PXJ$D+<V2'-
MDV0X[D00JHS<-]Z@H%B\%+E>XFNSI6S%XJSD4WZ:;=I)*G19.G;\C,\<S;KJ
M)G*"SIVBF3HB*AB!Y\HXEPNX.81><GXGBMO9W>1IPM/)> 0V\HI:6XZEI3+:
M%D$9EN) CKB!76P3\G/#;A)A@QC N#U[B>'%VX80_;+ME*=>M4)7<,LVZGTW
M+[K:5))0RRM2I&4*)BN*8X@=-5^VJT:;V!"1=G0<Q#-=@\!ZBBW<3S-J_ATU
MY0S3NA'O%F]:KMCJOR)G*L4.D!P,4L;GACP9L\05A5UC%JQ?)7;MJ9<VJ4I7
M=M(>M@JX+?%D[9IQ"T%3P20H:S($K'\FO#K$\&1P@P_@W?W>$N-7K[=RP;=Q
MQQK#GW;:^4W9A[CKG%7V'6W4HMU*24$Y<L$SZOW&M6IS8F=?EF\FYJ4ZXK5B
M10(N0T7.M$45W$<N*R*13K)(N$5#&0%5$04#HJ"/, Z]GB5C?N7K5G<(?7A]
MTNRO4H"P6+IM*5K945)2"I*5I)*"I.N^9KSF)8'BN#M86_B=D[:-8SA[6*X6
MMQ39%YA[RW&VKIO(M9#:UM.) <"%RDRD""8:]WGJ..I:&PG]\@F5.=2+R(9S
M3I5=!-]*Q[QTP>1S!HH@60?/4'3)VF9LT:+*B1NLL0ID""H',=X5\'6,,3C+
MV+6K6&N/.V[5RLK2'GV7'&G666B@/O.H<:<!0TVM1"%* *!FKNL?D]X:76.N
M<&;;@[B#^.,VK%Z_8,I;<5;V=RPS<L75R^EPVUO;N,W#*PZ^\V@%U""H+4$U
MSPVZ=6V"D3>QXBZ13RE5L[Q*>G0!V@C$+L$&[ETV?M7+9%^W=IH/&BI6AV@.
M5BNF_4I*"ND!IVO"? ;S"[K&K;$V'<,LBXF[NX=0FW4TE"W$.MN-I>0XE+C:
M@V6\Z@XC*DYTSKON ?"_#<?L."][@5XQCV*)87AV'RPXN];N7'667;9YIURV
M=96ZP\@O)>+2%,NYUIV:X2.Z-815*A-BO+<R+2K&LDA"S[=K)OFKY99%ZN1,
MB3%DY=I&!..? KVANCU"K91!<4U@!,3W"? K?"[7&7<1:&%WJDHM;Q#;[K;J
ME)=4$A+32W$D!ET*SH3D4A2%Y5PFL6O 3A;>8]B'!AC!;@X]A:%N7^&NO6MN
M];H;<8;4HJN+AIE8*KJWR;)Q9<0ZEQO,W*A'HGB2TC.1KR9B[_'NHM@O#MG3
M\(^<1;$7GY L5$)D4<1:0+"]D#%;)BAUA2''FL*9/RLIV_#?@M=,N7#&+LN,
M-+MT..AF[2@+NW@Q;I!7;IS;5XAL9<P!/7%(UKIWGY+.'^'W3-C=\&[IF\N&
M[YYJWXSAZW5-X;;&\OEJ0W=K+8M[8%U0<R%21" I6E9"Z<0&F=>3Q*Q<]AU^
M"GA3;K+1KA5PNLP1==#LRLN=DW<HPR2Y5$U$E)95D0Z*A%RF%$Y3CNQ/AAP9
MP:[%AB>,VEK=D(4IA9<6II+D%"K@M(<3;)6%)4E5PIH%*@H'*0:KX%^3;AUP
MFPXXO@7!G$L1P[.ZVW=-(:;1<N,Y@\BR2^ZTY?+;4E2%HLT/J2XE39&=)2)4
M?9-#3M%?IAK5#^$UKA3V*LQ970'//0I 4.+^)<D S)\D9)%9=,C=R=99LDJZ
M23.W3.J6^<<P@7]GAAQ"VX]B-J;VQ8"Y-W:@*.VMU@%IU)2A2TA"RI2$J6E)
M0DJ''3P5X1JPC$\=&#WW)6#7XPS%KLLE*<-OU%*>+7K2B'[=86M#:E.M)0AU
M:&5J2ZI*#');>NI(*.EY65N\6T9P=R>Z^D1,E(*N272.01<OJZU8(,U7\C(-
MFZZ2ZI(UL[3*B85>L$A#F+2N.%G!VT9N;BXQ1AMNTQ)W!W^M>4X,392E;MFV
MRAI3S[R$J2I08;<2$DJS0"1T[+\GG#3$;JRL[/@_>/OXA@;'"6UA=LAE6!7+
MCC5OB;URX^BVM;9UUI;:%73K*BX,F7,4@SJK6JO76!86>JRK::@90K@S&2:=
M8"*XM':[!V3HK$2626:O6KEHY063360<H*HJD(HF8H=:PQ"SQ2T9O\/N&[JT
M?"]D^W.5>S<6TX(4$J2IMU"VUI4D*0M*DJ ((KSV+X/B> XC<X3C%F[88C:%
MH7%J]ESMAYENY95*%+0M#UN\T\TXA:D.-.(<0I25 F09<KFU63>@3,<^G7</
M?YR-)8)Q[/O$.YJH]-VMX5% B8NWD(J[608L6K*+8 X554;QK!FUZPY4"B/"
M1@]TR[=N6V,73 O+IV[=1Q7#W3M' E(3M';53BTM--M,,YU*4AAIIN2$ UZQ
MWA)8W5OAS%]P;P^Z5AN'V^',.<>QE@;%@K6I098Q!#+;EQ<.OW=R6D(2Y=7#
M[V5)<(K,5:H+UV3L4N[L4C//;(:)4>B[90\>W(O$MEF2;Q-O#Q[%-1\Z9&9L
MG;MQUJJK.)BFY1(FT*!K.'X:NR?O;AR]>NW;XVZG2XU;,H"[="F@Z$6S+0+K
MC1;:<<7F4INWMT" WK2Q?&V\3M,,LF<+M<.8PH7J6-@_?7+JF[UUM]3"G;ZY
MN%)MV;@/W##+>1"'[V\=(4IXD=><I3V3LR-IC;9*P+]&"[@(DWCH&1;I-#R!
MY%VHV"7C'JS1>16*P+(B@L5-VG$1733 S,IC:[O"W7[].(,8C<6CR+3B:4H8
MLWT);+Q><4CC+#JFU/J#(>RJ"7!;6\B6Y.S#\>8M,)7@]U@UGB-LYB/*2ENW
M6)6KJWDVR;5E+O$KNW0\W:H-PJUVB%*95>WF54/$#K-*+)A9(.RR]VF)EQ )
MRR#5NI%5J/37;3+4C=XS=N(R(:O%61UF\?(BT*X324D(N-<* ?LI2C!O"7Q?
M6E]<XI<W3EFFX0VA5O8LA2+EL(=:<6Q;-N*:*DM/%L+ +S#"S.2#M>X0VAPK
M$,*LL!L;!K$EV;CSJ+S%;E3;MB\IQA]EN[O7F$/I;=N;8/%M2TVUY=-I(VI(
ML;.W7EZ8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I6 LE;C+5'%C)07Q$4GS"2
M07C9%[%/FSZ,=)O&3EN^CUV[E$Z2Z11$"J=%0O2(H4Q#"&4[VQ8Q!D,7&U"4
MO,OH4P\[;NMO,.!QI:'65H6DI4D:!4$2""#72PO%;O![I5W9\74XNWN;1QNZ
MM;>\MW;>[:4P^T[;W3;K*TK;61)1*3"DD$ U&3ZTBE"'34L>P5$U"F(HF>_V
MHY#D. E,0Y328E,4Q1$#%$! 0$0$! <I'!+=0*57F+E)!!!Q>_(((@@@OP01
MH0="*ZJ>%=ZE25)PS@TE22%)4G@U@H4E0,A22+,$$$ @@R#J*Q\5K!Q6H]K"
MU+85X@(%FB1LSB%5:Y94HYN0 *5.,D+;7IR8;IIE J;9FYD7L4Q0(1NPCFS<
MA4\T6^ KL646N'8QBMG:-I"&K92K*^2P@" EA[$;.[N4)2(#;2WG;=I("&6&
MT )JS><+6L5N7;_&N#7!_$L1?6IU^]2C%,*7=.*,E5W;8+B>'6+BE$E3K[5J
MQ>7"RIRXNG7%%=3"N56-K1'IVRCV0DY59-S-3TNY[=-3#A%,4T3O'70222;M
MB&.1C&1[=E#QB:BB49'LTE#ICTK+#V+$.E"G7G[A25W-W<KVMU<K2"$EUR$I
M"$ D-,,H:MF$E26&6TD@\3%,8NL54PEU-O;6EFA35CAUDUQ>PL6EJ"EI89S+
M6MQU02JXN[EVXO;M24+N[E]:4J$ER]7*IBE,4IBE,4IBE,4IBE:@\5A>EX!^
M?ER\*/\ 9W/BOY8%9?8[I,\K_5R97VK\CZ<WLBUB.2/KY3K8C6?_ !<:_P"?
MQ^!-4Y_@3#/I?!3_ #6X-?T!@_\ PZVKYIPKTX4<)!T8_C'_ !&XJ;9WZX%,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE><&U= [YVA=-M;$:-:E 2;%[78_3J<VN+ZU,X_6KE.QPLO
M5Y6(G#0=?\-K(J][4C945';9!<2O6D:0I5C_ !3A!P0X68]BG"'&6V\/LWVG
M;-G@XF[6'L0;9P1:;RVN,/N+>Z-K9<J7I<*TWR2XVE9#B&$C.K]2<#ORD?DZ
MX(X#P+X,O.XUB-K<6^)W/#A>'MBVPA^YX5-*PN_L<7L[W#^4,3Y PI%OL5X4
MXEEUQL*MWKM1*$S!_P /UMW#M2R6;9C2W4*HV_4&OH:P1%7M=7(E+V%BZ<O+
M'3I@S,T\_<1,>NJ4$WK [!%X0>DWDE!$Z9.F[P0Q'A)CU[?8XWB.$X?B/!W!
M[:\MK#$+ )N+QIQ;E[AMR6C=NKMV5D976BTAQ)ZU\DE(XEM^4K!> _ ["L)X
M)O8+PCQK!.&_"6_PR^Q;!L74NRPRX9:8PO'+$/C#K9J\N6T'.Q<IN%L*$.6J
M0$J5V"\+ 7#;^[GEU&TPVJ9]YIA2M5V"L4,VKUZ:T6I,6:[2R,$DI"Q$:U^7
MC&J+1-5S!*KBHJX04>$ZMPC(< >4N$?"EW%#B%K@%VYP9-C9VE[;(L\6;PK#
MFVEM7S24O7@;L[AAM+84NT6HJ4M"G!E6G3U7S@? K@"Q@(P>^X8X:QPZ3BN*
M8CA=\[B?!Y[A#C5P^V]A5RM=MABGL2LKMYQY2&L02WE0VXEA6=I<AU?';:UM
ML/<#=QIV;FZWL;=$C:XZWQ]OUXW8,*]*(Q4;WB\B7UH0GS=E2:+/U6B,:9\H
MB (HMCN1!(;N!,\(<$QCA&A?!NZNK+&N$S^(,XBSB6#(::LWTL,[9RW=ODW9
MR);4ZIM+&U*>M2@K.6N;PNNN!G"K@QP(=:X<6%ABO!?@':X-=8)<X)PF<N+C
M$[-R\NN+,7MOA#F&C;+?1;H>7="W2X<ZW4M K%/5+1>XZ+ Z)N:=$86NQ:GM
M&XUY?63ZR5]HY=1^P;#(.HFR5Z;.\>5I&;C6G9G@(O'B:QDUDFY%&CM)3J_-
MX=P4X283:<$\33A+.(7O!Z]X1JN<"=O;-MQ;.+WCRV+VSNBX[9)NF6]F[E<<
M"E I0%-N),>VQG\H7 ?A#B/Y0\"7PAN,&PSAEA' 9NRX66^%8D\TU=<&L+M6
M+W"L3L$LL8JO#[I_:L%;+"D!3:G5)>86DJL_;$#O3=]1KM01U9%ZY8S^Q6<K
M=QL=JKUC9FI]28Q\S&HVEK69%J\=GM5A;-8KN^ <RSAHPAB'D'\>D[3%OW.$
M-GPKX4X?9X<G@^Q@K5YC+=QBAO;^RO6CAV'-,W#"<0;LGFW73?WB&V-C:+N%
MM-6J2\ZREP%'E.!N(_D\X 8UBF-KX7W?"BYPW@P_9X ,+P?$L+>&-XU<7-C=
M+PA[%;5YAD8/ACKUZ+K$FK-IZYOE"VMKE;*@[)-#Z]VEKJ*VWKRU1<,M67,M
M*V;7,O6W*#>  +HW=OYZHQL,_E74["L8&=4.=AWH4R*Y)%RH605*F !=X)X-
MC^"V_"+!K^WME6+C]Q?8+<V*T(LQRFAQV[PYBU=?7=VK-K=*EGC *5!UPAY0
M KE?E%X2\$.%%YP+X38/>7Z,6:LK/">%%EBK3CN)3@3K-MAV-75];6;.'7]Q
MB.'(2FYXH0XA5LTE5L@J-5\KI;99N#[6FK"UL!O=?FJ.[EX/OB  &C>'OJ<U
M(J=YC*=SN.S1A1<]!K(+'6Y=2@55QR2SE*X,XX?R<X'@(L9Q:SNL+<N;7C-G
M^;1;8J+EY6W-QQ9>1@9X;>65=B@*7UM>E1P\X*#\MW"SA><4(X.XGA_"%BRQ
M#B.(_GG;[@XNPM4\4XIQYO:W9#69VV0E$[1PH;E=9 *=N#6-@WQ'5[4$9M^'
MW1:9BUQMF5MM:A.[B6"+3CC5*Z1UA51?.H&OF(L,<$2$BFLP<N$BIMW#H44=
MG)O"/ [SA8Q:<'&.$EMPFO[F_9OEXC96NQ3>,ADX=B;-X4O+M+.%;'B^V2IE
M:DI"''"E%;ES@3PLPW\G5UB7#:[X$WW /"+'![K"48-BM_QI6&WB[H8S@-UA
MB'+=K$<2"FQ=<=XLI%PTVM2W&V@MRO67!W:',SJ>OV%\\[!0="O(%ELN#E6R
M+VI[62O!;+ N()JJ];3;EO"I+KMFBYF"3)U$(BS668N'!4T>.W^3?$'+G@_:
M7CKNRPG@DY:-8Y:W"$N8?CZ<5-]:*M6RZW=.-VJ5J;;664M+MD[-2FEJ 3Z5
M_P#+AA+-CPSQ+#+=CC/"3\HUOB-QP4Q"S=<M\9X'+P!>%8BUB+R;=VP:=OUM
MM.O-BX7<,WJP^VBX::*EX^&T%MA+7UJ3V-1[#/["<\0UNV3$VG5%^JE/LT8>
M4K->8H7BK*RKY&)%I+2+%^BYKLNM%239N*:Y8](Z3<N:+;@CPA3@]^,:PJ]N
M\8<X88AC3%_P?QC#\.OF"_96K2<5L%/NI8V5P^TZE=G<*MWVT%*PR@I0!:O_
M ,I' Q?"7!U\%^$&&X9P9:_)E@O!:]PCACP;QC',)NQ:XMB=RYP>Q=%E;N7H
M>LK6YMG&<3L47EJZX%-FY4%.&MV=$,=GQNK:RRW$Y1=WY$L@$JL16/7<=F-)
MO#Q*<FZB0"+=RZ<69H22=,!50<.RJ*"X=K&5=+?4>";6.LX#8M\)'$N8ND/<
M84"RI807W#;I?7;_ )ARX2P6P\XT5)4Y)*W%9G%? _RB7'!*ZX7XL_P'96QP
M<<-L;-M2;EMK:BT83>*M&;S_ "MBR5=AXVK-P$N-LE*0VR@(9;M[/1UXFF*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2M0^*OG_Y!\N7_K1\8\O^;O\ 0.?$_P L7_9W_:__ "NOM?Y'
MB![(I/>C_F=4G6^**_PM=@89K#T]1K$PL7&-E'$?-'7.@P8H-43KF3L"29EC
M)I%,J9-),ACB82ID*(%#YYA7Y8.$UAA>&V#-C@2V;*PL[1I3MMB"G5-VUNVR
MA3BDXFA)<4E *RE"$E1)"4B /?XK^2+@W?XIB5\]?8XEV\O[R[=2W<V ;2Y<
M7#CRTMA6&+4$!2R$A2UJ"8!4HR3FO*UV/]2TG\-G?>3+_5KX5=[^#_DN(^M:
MH=1?@MW?C_E6'>JJ>5KL?ZEI/X;.^\F.K7PJ[W\'_)<1]:TZB_!;N_'_ "K#
MO55/*UV/]2TG\-G?>3'5KX5=[^#_ )+B/K6G47X+=WX_Y5AWJJGE:['^I:3^
M&SOO)CJU\*N]_!_R7$?6M.HOP6[OQ_RK#O55/*UV/]2TG\-G?>3'5KX5=[^#
M_DN(^M:=1?@MW?C_ )5AWJJGE:['^I:3^&SOO)CJU\*N]_!_R7$?6M.HOP6[
MOQ_RK#O55/*UV/\ 4M)_#9WWDQU:^%7>_@_Y+B/K6G47X+=WX_Y5AWJJGE:[
M'^I:3^&SOO)CJU\*N]_!_P EQ'UK3J+\%N[\?\JP[U53RM=C_4M)_#9WWDQU
M:^%7>_@_Y+B/K6G47X+=WX_Y5AWJJGE:['^I:3^&SOO)CJU\*N]_!_R7$?6M
M.HOP6[OQ_P JP[U53RM=C_4M)_#9WWDQU:^%7>_@_P"2XCZUIU%^"W=^/^58
M=ZJIY6NQ_J6D_AL[[R8ZM?"KO?P?\EQ'UK3J+\%N[\?\JP[U53RM=C_4M)_#
M9WWDQU:^%7>_@_Y+B/K6G47X+=WX_P"58=ZJIY6NQ_J6D_AL[[R8ZM?"KO?P
M?\EQ'UK3J+\%N[\?\JP[U53RM=C_ %+2?PV=]Y,=6OA5WOX/^2XCZUIU%^"W
M=^/^58=ZJIY6NQ_J6D_AL[[R8ZM?"KO?P?\ )<1]:TZB_!;N_'_*L.]54\K7
M8_U+2?PV=]Y,=6OA5WOX/^2XCZUIU%^"W=^/^58=ZJIY6NQ_J6D_AL[[R8ZM
M?"KO?P?\EQ'UK3J+\%N[\?\ *L.]54\K78_U+2?PV=]Y,=6OA5WOX/\ DN(^
MM:=1?@MW?C_E6'>JJ>5KL?ZEI/X;.^\F.K7PJ[W\'_)<1]:TZB_!;N_'_*L.
M]54\K78_U+2?PV=]Y,=6OA5WOX/^2XCZUIU%^"W=^/\ E6'>JJ>5KL?ZEI/X
M;.^\F.K7PJ[W\'_)<1]:TZB_!;N_'_*L.]54\K78_P!2TG\-G?>3'5KX5=[^
M#_DN(^M:=1?@MW?C_E6'>JJ>5KL?ZEI/X;.^\F.K7PJ[W\'_ "7$?6M.HOP6
M[OQ_RK#O55/*UV/]2TG\-G?>3'5KX5=[^#_DN(^M:=1?@MW?C_E6'>JJ>5KL
M?ZEI/X;.^\F.K7PJ[W\'_)<1]:TZB_!;N_'_ "K#O55/*UV/]2TG\-G?>3'5
MKX5=[^#_ )+B/K6G47X+=WX_Y5AWJJGE:['^I:3^&SOO)CJU\*N]_!_R7$?6
MM.HOP6[OQ_RK#O55/*UV/]2TG\-G?>3'5KX5=[^#_DN(^M:=1?@MW?C_ )5A
MWJJGE:['^I:3^&SOO)CJU\*N]_!_R7$?6M.HOP6[OQ_RK#O55/*UV/\ 4M)_
M#9WWDQU:^%7>_@_Y+B/K6G47X+=WX_Y5AWJJGE:['^I:3^&SOO)CJU\*N]_!
M_P EQ'UK3J+\%N[\?\JP[U53RM=C_4M)_#9WWDQU:^%7>_@_Y+B/K6G47X+=
MWX_Y5AWJJGE:['^I:3^&SOO)CJU\*N]_!_R7$?6M.HOP6[OQ_P JP[U53RM=
MC_4M)_#9WWDQU:^%7>_@_P"2XCZUIU%^"W=^/^58=ZJIY6NQ_J6D_AL[[R8Z
MM?"KO?P?\EQ'UK3J+\%N[\?\JP[U53RM=C_4M)_#9WWDQU:^%7>_@_Y+B/K6
MG47X+=WX_P"58=ZJIY6NQ_J6D_AL[[R8ZM?"KO?P?\EQ'UK3J+\%N[\?\JP[
MU53RM=C_ %+2?PV=]Y,=6OA5WOX/^2XCZUIU%^"W=^/^58=ZJIY6NQ_J6D_A
ML[[R8ZM?"KO?P?\ )<1]:TZB_!;N_'_*L.]54\K78_U+2?PV=]Y,=6OA5WOX
M/^2XCZUIU%^"W=^/^58=ZJIY6NQ_J6D_AL[[R8ZM?"KO?P?\EQ'UK3J+\%N[
M\?\ *L.]54\K78_U+2?PV=]Y,=6OA5WOX/\ DN(^M:=1?@MW?C_E6'>JJ>5K
ML?ZEI/X;.^\F.K7PJ[W\'_)<1]:TZB_!;N_'_*L.]54\K78_U+2?PV=]Y,=6
MOA5WOX/^2XCZUIU%^"W=^/\ E6'>JJ>5KL?ZEI/X;.^\F.K7PJ[W\'_)<1]:
MTZB_!;N_'_*L.]54\K78_P!2TG\-G?>3'5KX5=[^#_DN(^M:=1?@MW?C_E6'
M>JJ>5KL?ZEI/X;.^\F.K7PJ[W\'_ "7$?6M.HOP6[OQ_RK#O55/*UV/]2TG\
M-G?>3'5KX5=[^#_DN(^M:=1?@MW?C_E6'>JJ>5KL?ZEI/X;.^\F.K7PJ[W\'
M_)<1]:TZB_!;N_'_ "K#O55/*UV/]2TG\-G?>3'5KX5=[^#_ )+B/K6G47X+
M=WX_Y5AWJJGE:['^I:3^&SOO)CJU\*N]_!_R7$?6M.HOP6[OQ_RK#O55/*UV
M/]2TG\-G?>3'5KX5=[^#_DN(^M:=1?@MW?C_ )5AWJJGE:['^I:3^&SOO)CJ
MU\*N]_!_R7$?6M.HOP6[OQ_RK#O55/*UV/\ 4M)_#9WWDQU:^%7>_@_Y+B/K
M6G47X+=WX_Y5AWJJGE:['^I:3^&SOO)CJU\*N]_!_P EQ'UK3J+\%N[\?\JP
M[U53RM=C_4M)_#9WWDQU:^%7>_@_Y+B/K6G47X+=WX_Y5AWJJGE:['^I:3^&
MSOO)CJU\*N]_!_R7$?6M.HOP6[OQ_P JP[U53RM=C_4M)_#9WWDQU:^%7>_@
M_P"2XCZUIU%^"W=^/^58=ZJIY6NQ_J6D_AL[[R8ZM?"KO?P?\EQ'UK3J+\%N
M[\?\JP[U53RM=C_4M)_#9WWDQU:^%7>_@_Y+B/K6G47X+=WX_P"58=ZJIY6N
MQ_J6D_AL[[R8ZM?"KO?P?\EQ'UK3J+\%N[\?\JP[U53RM=C_ %+2?PV=]Y,=
M6OA5WOX/^2XCZUIU%^"W=^/^58=ZJIY6NQ_J6D_AL[[R8ZM?"KO?P?\ )<1]
M:TZB_!;N_'_*L.]54\K78_U+2?PV=]Y,=6OA5WOX/^2XCZUIU%^"W=^/^58=
MZJIY6NQ_J6D_AL[[R8ZM?"KO?P?\EQ'UK3J+\%N[\?\ *L.]54\K78_U+2?P
MV=]Y,=6OA5WOX/\ DN(^M:=1?@MW?C_E6'>JJ>5KL?ZEI/X;.^\F.K7PJ[W\
M'_)<1]:TZB_!;N_'_*L.]54\K78_U+2?PV=]Y,=6OA5WOX/^2XCZUIU%^"W=
M^/\ E6'>JJ>5KL?ZEI/X;.^\F.K7PJ[W\'_)<1]:TZB_!;N_'_*L.]54\K78
M_P!2TG\-G?>3'5KX5=[^#_DN(^M:=1?@MW?C_E6'>JJ>5KL?ZEI/X;.^\F.K
M7PJ[W\'_ "7$?6M.HOP6[OQ_RK#O55/*UV/]2TG\-G?>3'5KX5=[^#_DN(^M
M:=1?@MW?C_E6'>JJ>5KL?ZEI/X;.^\F.K7PJ[W\'_)<1]:TZB_!;N_'_ "K#
MO555+M+>EMO?<7>\=7&W=7>?9^[6DFCT^W=W];UW:I=YTNCV-+J^AU?+I*=+
MI\R]'Q'#'\HN-\(^3N/6N%-<3XYLN*L7:,W&.*Y]IMKY^8V",N7)$JG-(CVO
I _\ )Y@O![E'B5UBCO'.*;7C3]HO+Q?C639[*R8B=NO-FS3"8RP9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g383050g20a23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g20a23.jpg
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M3 /O4%)G:-<?A&!+KYZ, 'O$+%")(5F+,KY,4Q%DRO5>:FC)$'V5[)1B7)Q
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M$S%;LMO0U (9?:Q<6GQ6KBFK;N,:^5FV%@FFBPV9E:S+GL[>!XYYF(FL(OI
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MS(D,P0S,3$YC:IJ&M0];$O2PU.2T"6U35E(,6Q9Q!@P#&1,"B"$HD2B)B8S
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M(]H)IG06D$%L.YRF1RUUO5'7QU%LK[#J'8[)W1/6=_K"I?TBZB>E^HJ-%K-
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M(UZWG8FN5-MI7+=L%=C2G7!$?/AE7K6(2^3K^,9SA"'2;4A?QQTYQM_0V_\
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M2YGU',W'3]&;CJ6VP-V@N;?=P,[IGPWKF=J70]7E]4'NNA4-"1+JA>W3JQ)
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MDJ+CB?I",QQQ[^I_)M5K;6C\HVIN)2]?[O=UNJ,. 3]+MM%:UFP1<KR0R2K
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MS1,UI:P%1$L,%F8K@IF!DR&)@(F8F(DICF8GC.A-6! !L #9,PL2,1(YCWF
M&9B2F(]Y@8GC/B]:ZO'9@2'[( 8CE8C,\6^\8'-LDH$F1!BQYL!U<E*)D1^4
M4&1F9,=3C+L@C!90M3DN.ESF*[YDQA#IE92)Q"SF0*((I$X@>1*! RF)XF(
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MQFQ=3UZU;Y'_ )&F)/R/5L.L>F5J*2*[<<>]+=OLSPL$R*1V+[=HN1(B?_"
MIDHCY]K/22]ABARH6'KF,LVL-503:(D:Q7.C Y#>U2/M491<;B0=7-8&1JW6
M!.Q2Y,/%1'-02-;##2#^"=N#PQ,&[U/+:NQLZSF$ZVY;U_J'"$)MW:$QZH%$
M7=!5E$+JQ,&0,[:#2$\2)%-Z9Z5Z;K]1=*=+]4 ^]O.K.IM9T\[74K<H+1U-
MFDFEL9>J&"V[4"!82F0=3W\,PPYF8[Y-:W*'L/7=$OP^3!F0;I3ZY:8TH8^B
M2.?9/"(91#D*0AQU#L7.)7@RYAQ?K(QC.5*SXYSN2F0U2VC_ %6 !QQ\.#&"
MCB?KCB?:?K^.>6["H>OOW:#>?)2MV:C.8XGOK.-)\Q]4]P3S'U9CJCN'5-^L
M-GJ5(V-2[99Z7,>'VROU^QBBIBORX[B&)#)0?#DNR8OL\E>(<A:V\-,3DN07
M5HELNLH"U1&:Q8!,7Q)A!1)A$_"2&)YB)^J9CXQ,?5G9^MV%6M6NV:-M%.YW
M14M.KM77LR''?"'&$+;(Q,24 4S$3$S'$Q,V/S)D+'&,<8QQC'&,<8QQC'&,
M\?GIS-NVON;W5Z]^C1TY/7+9KME"$;]F)ZTF(UL6Y0?-9DDV&59\V-K'64B?
M9):VE84AJSEXSB/:("<)]W^3BFCISIO;]:; (B6):JG!?1(JU<^V1"9^!7KT
M @>8GCP 43VG.>0=<VG;S>ZSI:D4S -6=J1^D(O</,$<1S/%2I)N+Z^&G''(
MQGJJT5J*JZ%U!KO3])@H'5G7M3"5<5'3A/KYC"(#$)+\EQ*4^T3)'DY?F2EX
M\R5*<>D.Y4ZZM6?$KUQ^QN6KUHY98MO;8<7U2QQD9<1]0Q)<",>PC$1'M$9Z
MO4JII5:]2N/8FLE:5#[>P+" 'G[9F(Y*9]Y*9F?CEL\BY(RG2?\ M&=_BG_\
MQ7&,X/&,T4['Z V#L'?V@=KZ[JNOG9VOBU>AV2Y7:QLSF&*(W?P-HN%><UB6
MUG:HI4O\'A6C.M+M4[QK^WU78<8?(G$WJPB=#G;3IMM3J:G;4+EBW VUM)->
MLF1(K4U6HKNB\NZB5K[FDJ[6L5;==]0C@0A\@0:]M-=9L[+6W*R:TE6-0M>]
ML%$5_4+:]?I#JN$V2"X.I838KN39$)(I3!"6EVG^H36Y:#;KE79 RT:RG=HM
M5BNO]>O3,=5> ]-=%=MQNVK=7 45 ^>V0 WTY$OB*5$)QELV+6E?TV+(36!<
M&.N)LNQZA^;;:*[H--X=%>9MG59GRMZCVFA*A7<TNX)!M14U9LD!<INNV)@,
ML*8*CI:7UU=SU2#JI;>F&M78X\2]'K]T%UZEQVE!KL,&Q%>"B8;571 B@!CB
M\PO36Z47=%$V>"UKI.WAJINCLD7&UDL4Q6O<^C[NL^L+=5K76'4:[LD:.>HI
MRE68K[LP8PS"2EMD3Q)]B2^0><JV=15;6MM46W=E698UNF6;UKEWJ+6L3>0^
MNZ/5I*56E64+\Y$?T*XBQ4B(1$\-'8KWJ]M=6@]:;^U8*C/Q>"O?;4<ERI],
MV(:AB&GXA@?I.D@;$R4Y4COHX-C1])Z]U]6,:MJ5D#]3AFK=@NB75CQ&PMDU
MW>.EMMLB;-+CTV8LS3+B-I&P:E8;"9!&IL.)>RCSE4.L$R<"38?ME2+97+;_
M %UA+>H&7Z<,B#94I.UFRH>1 E8"%6:S+-1Z4K:H9*J$0]4@!Q#GI>U%&O73
M-1#0TXU+,A/:%FTO84;L THKG)H>"+*6M-;"&+!SX609#,]IW3?8%5M&H-G,
MZ0T]-.53:^T;-8:):-J1;#'&#]CT_7 6+<JW8QG7BL@ A8#9*&[87:77:-"A
M/SBDFV,69VUF#+?(=GJ*H]&PHSM-B*GT**4VDT"3)E3L7&%6>DML]S5M3:A,
M6763* "$2F$+7,R4:2REM*W&OI$Q-RVUM=MP6P 6DU@AZFAK4J6:FUY9*%5Q
MB2,G0V7&><C3O3_;&HK9K8_8=7Z)WHQ&UM0=>S7;K:Y8\KH\G2]N;)OTVUZT
M42U?<(IN-985Y"%2$:)FF'46R@U]#A*9!5!GUSK?ZAH7Z]Q*KVTU<S=M6QBM
M7$U[-=FA3JBB[ 7J\K)!5FK BBRJ:]MO "4$#N:6EN4G56,J:_81%2M6*7N(
M#UYHN6K!.J251T&+1L 90/@9#JZ_ID,B2KA[A]5]A=AK _+IU@K]>A/=8-Y:
MB4^8E36_;;1?=H=<+T##%(L8230Y2+('U%:*O=9?E3I,48;;0R .MR7XJ:_I
MW>T]0F!LJ<THW>LV$0L1GM15H[BJU@$3 XLI9L$/K#R$$:IY:J8&9F[O4V=D
MR90Q:XG4["ER93'+K%O5V%@<0!\UVA2:E\\%, R(A;(F8BA@'3'8H4GK+9+>
MBM,S+-4=YV>_G-:VK;,.P IPRUZ5C:P<L8>PB.MM6KM4*C3H:K&Y%:"Z\>8,
M,@&[3)/YMTG(]JU;U)38%VG.UV0IL:Q%15U% DM$Z^R*]"6I/<O=86:F/5#V
M6X)9-E,*]./=->O1VEE4M1KZ)-3L&V6577!8LA=1BI+5L#5J4DQ8"6$H*\P<
M+ATL\\]N?EGHILNIT[7JJ34="RKN!U=VAJUZ9L4"-(!W@[MG>FJ-FT5PWB13
M2$6T*#B*:?EQI-N%%!H.X+"KD!S8ETDG+]J*3[%N+-C:C6;=T;ZLJ,A;650U
M=ZE;A4C8$D0QEA(R-=BS;7AD"Q3(#.(Z?MI15\"-<5A53;)L0T8E=AER_3M5
MY9R@H;XUI80RX#!;_',@82661U@ZI[=U3?M7'[A'I0ZNZ[D]Y6680"QM%)'P
M5V4W!IW:%%;B0!.O-?UL>H8S5;:.L0\(#"AH,QD=(!C\0BJX0F)N]]K[]2\J
MN5DW7!Z8F2:F5CY--0V%*U)&RW;<??+T&DVM8PADX:?<$$<K4Z>[3LU&.A J
MJ_/XP*VP<]FTNT;=?@0K5E#VPEPL%:U@)0$K"!/M"06#K3L=W=78(]#I6JCL
M'?;J2%4[&$; ]"W?UV6UH\5JF.%J0&30#."D"OFQ4^YU%T!?J>G$V]6Q!1F-
M*2X1/84[JE&MU"BLWU'J8D7Z<$P>LW'.S.]+;#8MK\9N685[$.J6/HU:_CDA
MX!61FJLS?V31148.QF"3LR;([#63% *D E<US[Q6P">F564?2>Z#B"CN;K9-
MZ#;5M5477L:GZWZ4B"-.4[3IP#K6R%3@/?<H1N?3%]F7/8+<C6-31#'5JN:W
MMS%-'&XUQL\LIM&UPRQR%!5)E'KD>JZ"'PWYPW.S)FQL;%;KJ04W5"S6[&J-
M:I,7;!$QSKE>;!J*N@5TD$M9'VPJL+IVXY/C]'K*,!2128JJTF+V,KO4;!/L
MQ-1,"*E5G0@60]I':<)F(S,LM:Q]+[<%V8O8M-U=HZZ!J]VZL>Y*?K2R$&ZD
M#9U[=NIE&TT61%F,:ZM\&N&H&W@$S8,H-" 2X11AAHZV119%LQ<0$]25V48I
MV;VSK-;H$ZZQ=0$V&S;K;^UL5\C-RL3EGKW#4%A.$@*95(2GDLEMT;UVYM(J
M4'K7N6745&GX5Q6?IZ]%G:45GBHQNJ*S*Q7(G$0SNAO Y6E4Z([9JT79X4IK
MO4>R"1:J[OIP.^W#:,R$(V+!W3L,?:TDMEZ_K6CA%J=GB5L0K4?DD-NV@K%M
MM8:]Q"@YRRJ.5N<_JG7N*DU=W84P!^LLMJ5Z DRF>MJ'7D*5MVS8B!9$DA4!
M00!5WSZH#\,*=$3T]<5%L#K4[1FF^A=E]N8"R-^R+>^W650!TD' N9)77'#E
M1%<QELL5G W1G:U$K6JQ\RL:@['VC2O96S[>>N^U+ 3#6OL-6]AZ7V%KLC/V
MB9-4[9[P:^TH_:ZDF.EA%AKIFHZSJ;@ENND!XX$-Q,ZHH6G7CA^QTZ-EIDZ^
M*U%*V5]0ZIL:EP!HK59I0RK94BQSS*G*L7'PR7 9M/(/3]RNJF)*I;1U#:MN
MS8N-(';-5BC:K$5MAHMRNPAKD\1$,4::J9"%$(+'M\3ZWJX];&,*\,>MA.<J
M3A7A\>,*RE.58QGXL9RE.<X^/*<?U<\\_N_U_P <W7/[QC'&,<8QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC+ IW^J3/\ $(_R\<8R8<8QQC'&,HGLKU[I7:?35GT;L.?8AE0MA.CE
M"DNJ21,0XEVA7ZK[$$L1WS@:P#,19IFICX15J0)DJD")$Z/&<ARG6)L>RU&T
ML:78)V505&] 60 7BPE\6JKJAS,+8H^X5O,@F&1PR!F8(8D9K=MJZ^YH-UUH
MF@AQUV&2" 6<UK*;01$L6T.TF)$3B0GD)*(D2F"C78'Z.#0];OX2ZA3.PH(6
MM=A;SV5K>JVY]-5JP!>=EZW):VO@,17UTA1.#0K)$+$+/+JK)U+$>V2Y4T?)
MABYDT/)M6]6;-U9E=BZI,=JJVH==[+$76UJ=L+=9C&Q9@"M))8)%\JYE B)P
M1B+(JU]*:U5E=A;+0K3M+.V52@J_HE6+=0ZEE8*]-WC6<)DXDPSB'D1#(@1+
MFJJ]Z';J%65QQ M>U8^LHO8*R=E8^F8=Y9"Z]C;%-4&/KT$U"D5T&&OPVNZZ
M&M22>OAHR\PY04L0E-S2)4&W!"PYK>O=\[EA^BFX6K5J)V!5I9;FHNT5ILE#
M6,K&VV<P%LSK$+%@,B -DF%#5T+HT\+#UHU!VC=M% ;,+JC:96BJN!E2EV05
M5").J 61E9F7<9K@%CN'UEZMZZZF52XT+4Y*Y9HEIV-9=DBZE:CS=B'4*=;4
MPG3==I<Z1 9/LU>25BR;!B'9#%D)I-F#$O)=3<S##5#N-S;WCT6KP5_4IJ)J
M&]"I4=H4=T+;8&#E4N$"%7<E:0\:UCX_H\S>:C3U-(E]:D5CTSK;K8(<V&C6
M)_;+%5RD8;"9,9;VM8X_(QA>3@N(V1Y4Y;8XQCC&.,9I+NOH#U]W]N.M[KV%
M L4RP ASHDE7HY(<NEW$<["6-5'M (H&)N+?P-4D<DH"G BZ1R5P$S\0Y4YF
M5 /75SNC?X,;$+6N2!A#!"HC-<F,3$202PX$HGG@RB8F..-EJ=6;>GJJNG65
M5E;7V]E>UC+%53[.KM;BK6I;-M%K(F%';K5*ZS,@,U>.2KDDF-D[/["ZHK5G
MZW[6U\(I(:5'SK:Y)JE9&U^"['CV)@+/GUY803'B*;:*-'V84L<N"PF6@FEF
M1&5B5A"^==C25;U]NI*%&+4-@5RL"'R\2:C$)&1\@N@6 7'(L$3CZ41.<=);
M:=1U=TWNW.((UW4&IV#WF124*KWT-L$9\]TQ*A9!^_)#)1/,3.=#O427WNWM
M2B&G-4[#NE4H0)(K5UTV'<Y<*/,H@"K'*U$+A*4"EPR#P*R,1+%M+(".D<-D
MFJ37=0P);HP$VS-54Z8KC]0*Y*RNS/I$\V E45ZX+F+?;'9S-CR%(I&>>U2U
MR904Q$6756J9I^I^O=O8V-38S>ZMW)]'5X96MK/6QO#:.YM(2)I*C9K.M,U8
M,(UWTJUY&!()QE--5:J-^CM[RT:3LTR =H.QJA8!#FT$9?B,GH:8EA-VR=.J
MX4:4*0K([L'X$LYM,_PK(.J6D8-A6)X9KV0\K%MM@C7=2:ZW;-=2I;J3JZ_<
M?,0<,H(J5X$0EAMEA<RR1[9%A,,A$6%F]CM#ZE^1[KKSKGS:'JGI;J)]F87
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M72IXD,$))8Q@@P2$A*)"2B1*)B>)C.$T+UAC55Z5M[43,.6FLYK$R,R,PT
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M,&,+Y'N'Z0]T1S'O'MF.&];.Q9D:4,A]!;J*AP9$R(-%ANK+S.&ARU=E/0;
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M)+(P63(X@Q$O2LP!TZ7Y7L\20XWB#>:5D,D-QJSA0>1LAL*A0M?<(>1DPZ8
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M5O5C8MY!0.RMTV\-;K-+KMFLYJRDVK2,C!:H1O$>%'UF+!QY.;@1(71EO(3
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MR1-,Q6$2,V/3-1>L52U>UZ-O6-VK90RQN_0U;59SRN2X-O.X:R&1"@D6R/\
MTXR'8"Y*9C(.^LLOLM;#7=45$ZIE&01J?66*]A:8JPLM9\V+"5S+"B5]T_P2
M[N\F<1$YL!W WGI>[N:-M]1VWH Y6JQ"Z1MV(N/[L7GWPA+I-FU8W;83O5J(
M35K":BMNPI3YDK,B>W#1PV?;7E()"&UIJNG]9L:P[&O8H[13G3U'XE'TY6\!
M>I1=E!1NR"+H>:"&%K$NTS,41R#.,LMS>I/]"Y-S7&M0Z.&&.]?YHE#:D.&=
M5!^DF%2,R9S'(")/F8(,JOTIW;?1?9;KAV INGMD5=DG0._Q.^FZU8MI$MD3
MMST\O4B54J>UM R[ 5S$J]0@2ILZ+:=;T43)'0V9,>R8+Q1Z9$,A.Z*T6ST^
MWU5B_3=(6NE@JK<JD%,=?878%[Z.T%2^YU@A$21;LL$RF"5XR+@AA]5[BAL]
M9L44[*H.OU"5@U,ME9*ZDTDE5O72P^%)&9F&UJX$,1,,[Q#F"X767MA6M;::
M]&*(H>T.MRKC3-%]]M?[BH^Z]DEM>"8X':N_1)>#32.P:K'FE]/W:X5IC)^C
M6TDD?"PR/>0Y,0S/3YG.YT;[>PZR99I;?T]C9],6M?9UU-=LY92UC *P%1\B
MO85J[IA5FN$D7<<?1F1GCC5[=56ETN"+6LER:'4%:ZB]:.L$+M[$#%)6501T
MGN4/D0XHB.!F.>#C--^W-TZHTCTB>A+[4[G8-^Z(ISO7VU[?JI;9Y?L(%JKH
M:T-G-DZ0H.S[8EJ1LZA5\,UB,%G2WW8!.26)#''VF4O,Q]AT-?>6>DMI5?75
MJ]G8C:HH/"DO5,?#$RNILK5)$=M.TUD\L$8[PA8'[S,3-+N'ZA'4FOL)<S8:
M],Z]MQ1VV;$$^-W?9HU[3OI6JZPB("2F1.3(.>.>-@>YC%_WKL;<MUA^EKT;
M<.NF_MB@8]0U=*WU?H<^-0+=L^NR*E6;;H:<&A5W7@G3@]V$?.2[*X$&C(E-
M?*1I3AF9F+FJZ>FKK*>OK%T+LJ^WU=5I6+HZRL03:13:+WHV@,)ML]@4$I8H
MAIF5B%R/C'NRPW46;]JZ^.KZ#M;L;(0FK.P?!17=:625.H$ KK!3&18PFRL!
MA)'!2PN)V%[H;\Z)=D>NF_\ JAKCL/%7'ZN5Z@63IT.N-&!T2E0_^#]6H>L-
MB4ZC[=S?C"]MD-\AGR-LK,1RJTOX0-1X1%I)Q;:92:GIW5]3ZC;ZO>7-2?.Z
M;:3OS1999L%\Z.FY4L6:'I5^A#6,@$.+SV>Q<D/\*.1FQW>PT&SUNPU%78CQ
MJEUVZ87H770/S>N*ME*+LV#FX6P"2<H94GN9$%'D]IC/']K]8L]XMI^E)9[9
M:$E:JN760B/!Z4C60LYV67L<EUC$:19UU-U6H$B3"E-V. _+>LCI'W<:A.1W
MUS<05/D(^-5'=?LW1Z*G1;0;U?<@;-B25QI_2!N6;&;8WH;(E$J*!A,!+9+F
M(&2X&<AV]5&]N=51M]>51^K,5T8:?SG-DM8NC%::GCB1GR#,RV2\?$Q//;R0
MUH=WMI[:'0.F-;SWQJJK;,U3HG0NO]-N]>^R%]9.;'%5TO6GV=,=A>IL^!%K
M\"33&6I#MMV-AI(>2<$MG I1X=%'L2)BM9L*75%B=;K+SZ5[9[.UL(VNHJRJ
MFQJWC.PU6\ R80V)F(14Y[X4SQL7!D11&/84K73Z/7WZB;52AKZ]*=;L[$,L
M@LU3Z+9:@AA8RB(F76>.R6!WK/M$8G:3L9V'T*9[_P"DMU"-T]=I.J1O<'4U
MO(WT'W=NU[(9JXZNSQ\\J9Z^%"KVK]?!8$W.')UD",LOC<1(_JNI]X26%TNI
MU.T7TML=<>OVT7CT-Y U6=-UZH^8W"8K7M@"+MMA#_52R9@^Z?;^$'%MLMCK
MSZAHW0O:R:@[BHXK"]Z^P7B%1"1,UQG-2N E_6:$1(]L>_\ $+G0KLCN&K4S
MJ/WCUAMWMUKOM5:.PV\Z!<.K&O*#L@[NM&E(E8V2<LEOV#/L\^%D#KS)ZA$8
M]*:K8,L]/)>8J.[!^#L3)#&SZC7OL;[IJ[0T-O1IU.LM5]W;M4U:Z=B3JBDH
MJ"D2AMOQ60*Q+F+[ ]B@^_MB=>V=U2-1OJMS<5MLW8WZ[M36KVCO12A5EC76
M9:0RNOWUR%'B ^XO<9CMYF-OO19]I-%:KZD]4!EKW5IBE']>;P[ &=A1KGV/
M+ZKMM#IEV&M!H]K$ZN%03@?<I-Z$_-DUZI7L 1 ?"4:')8;;>?7*8H>MM+L[
MN]WAHUVQLJMZW5KJE7U"[U>U8K'+"0RZ9+9KP@H&&OJM!O;)#,S$0,W/2FUH
M5-/J0=>HH96O[!EB'[,ZCJZ7CV0X*@"P+IS$S*TV%DONB)B.9F8T@ZF=Y!VA
M^K7?2D5G:M1)F=-&L6/T?5CV&-%Q=H@">WK@;UEM&SZCC3<1IX$R2U633<"@
M,/&;A 3SLDRZ/QF42:E;)O>FCV>ZZ8LNI/!>P5X>JDU#,J3 H5UW:2;TCR+5
MA>#TX-9,DU<"ON^B$Q1ZC?#0U/4%==Q)'2/R].LL  VEE<<RM;;3@N"6953A
MQ+".U;"(^WW/FA/12;!K]8MO=:!8]T4W2ULVMT5W1KC7%_V'?F]?0%;3M=QU
MI(KS3=QD/MRH)9:X,XKB9%6Y/99'S)S>%*CKSBSZXJ->CIPDZZQL44>IM=;N
M5:E6;11117N0V9KC$B2^"%?:40,R8C/QROZ2LJ4W>@V\BDZYHKE:M8LV/3C-
MMK:\K_CS/(GS$GW1/=$#)1\)S8#>G<XAH6M>CL@U#LQ6NP_;[K'9]HG-A[RJ
MQP[>ZG UQ>["+57]'%ME6"&,G[5 9K^#<:P1_-DB:\.(R@(8AY+Z9"*K6=.C
MM'=6$_3.U.@W*:*JFM<I55YVZJC\NR7341C1;#?'*IX@W&(M8/(R.6&PW14%
M=-BK:*V6XU;;1V;ZF'82-9[ \= [+($K:_'WPR.9  *5@7$Q.7_;^\T2!Z4N
MZ0-&;!ZKL]6]8:1L&A=+U&UW@AJ;0)/5UT"TPSL*O439M!C38VO-CVRSO%B2
M-D9]C;5*KZ D\BTTP-815HZ:(^BJY[.INYW=W9*VFQ>BL%[:A=KLL+J-LT[4
MB5JFA,+#T?TI@6RT1GDYFP?O1'JMXT+&IC55*+*%%+7E4UYU7K0=E:+5>"BO
M9<V3+U/MS*X611$#$6RUVEZ1=<5=]9U=W);MQ5RT4WT=LB-KD9VNNQ.\,6*N
M[4OTW;&LM!=@FY$&\; J.G QP8?;*C)689&++G 24^$,ERE1H,Z3J3;_ +,"
MW7HH.38ZM$K;-'7"M*FTJ@T;FTU4P5:K8V#%&KL,9("$6@)F(\RXVNBUOS^2
M[KKBFIZ;D:P;9YOAB[=B;E77['D;%A-(#%O>$Q!01*(A IXL,QV)TA8I7I!F
MX_8;K#>R>X^V>J]N:X6YVDL?5('8-:_S00Q\9]JV:Z-XN+=@IJ?8ZE;P<UUM
MLY:!Y0R4CM+=AXS%7J=DH>E>[5;FL&OT=ZC;_P#(BMVQ5SU\G,2BVKT\JL?2
M?78,<J28+"9X+))[&BPNHN-EJ;!7=M4N5N=LW4K96]' 1,.K,\T-1]%3EE/#
M&B1G$3(QFH&K-KT*_P"@Z3H77G;[7W5FSZJ[A;UO':<#CLO:-0-]FZ3;+PU(
MIUQUUVHS6[6[?LU2L0Y58$2;3&*%3[+<"YD TV0R%Q/OKM&U5VEG9V]!;W:;
MW3^LK:1OS.F_\S6$59&Q7MZ3S)BKYWE#C%! M4R5<6#$MD*>I<KV->BA7W-?
M5-I[F_8VR_G1M/YT0ZQW)=5VOB;-CQ*B5A+>\V1 O("GQ]V,VF3ZS=A-6]S>
MH6K>Z%,^%&NYVK^P.LMR]NMEEX$'<U.":-:UA;4R=O$JRADG9P=C>F.,/%Q\
M19X-&@NB'BS:WIZ,E(-SJKO3V^N]/6.R>GKNJNZ_0TUD6NL,V4W:\Q0!W():
MF!@H69>)I'#("8@,ZVSU>QJ;K35-VCN^>ZNQJWMO:,1NI"@-5T3<)7TVK;SQ
M)C$L"!D)..2RX+UM_KGMRI]MNM=+[-:+C$!7H_>AO5>I;,O5U:H&L-D[!T)=
M)1R_3::>L,5B41 0XJEM1B"!RT2Y"$KC>;!D1IKU?5H;>@_1;BSIMG(LZIZG
MW;Z=:M-J[3J[2M"JHV%)*1!I%Q,A)\B,\3P8D,2[%S6W4[?6(VE 2#I[0:E-
MJP^*]6U8U]@F6"0QL01+@?:"[?>?A]&8F:GZ);*ZY^C)UQL.W7CM/K\AO?9.
MZM7UYF7UN&5SLRA&A-8/5K9MOKLK#=XURBO!-S%R3NO[&6?FR)D9FL.I%BI;
MJ5S(D[J>GM^LKE1%;26AUE/776S&W)VGF=G=AU-#1YK6Y:S7K"+2EP,#,NB3
M,8F!F)H+.MZ7JV7/VU8K]F]55$ZP5;2/F^KXK3EEP^MXPN&4UV')3,0KZ E[
MR,7ZW[2TGU8]*A>(NKNS8$;TPME;WCL:D2AFR'!6M1KFS=&6>?4JH?%M%&1$
M"ZTZR3!E C1B\9)YN=7PJL>JZN%G&;;TMCN^B:Q7=,T^HD.UM2S!TX.X<4]F
MD7O4<A+"K6$B=J2"?'(M9S[068M;:HZGJNP-3:+'2M5?LH(+795&;5!I)4P8
M. %Z6R%>(./)!+#Z^W,MZ/KL76S/2SL#4]L[IH9?;]E[&:]LHL3OCN!L#KL>
M-5$#K^6*?+1=DU@RF\3X0J4^S 9!^T+#RE.+]H2ER#'QCIU5J7+ZBU3Z.NLK
MH)U-M)LUF@J[92WMM"<+*FY?IA)@C)2SB&#Q''L4YWZ=V2CTFQ3;O5SN-V5=
MHAL-S8UK&)77D).+2F0\A"9@8#F0GZ_ZL9**_?5FNLW7*JZJ[\Z/ZQ7G3G</
MM-=MIS)/9>P+F9J1_9(N;73H1R'@C:]XB)<066G I1N)(=O$&6Q,G+5@[-<Q
M@=5\>YVS[W2^RW-;8=/Z6M2$=,KM]0JH8M6R"[$:U@D8"T5D,5B&1'B5#&95
MV)9JM8FIU!0U;Z>YVK[<SM&<^%EH248<=SKP3 F2Y8,R\9@BG^(4Y1VK.S?6
ML[Z>$?V=JIROZTZY$]WVJQ1[;9DLTVOHBO:P. RERGH))A? K%XN&9UC::)L
MPY^';$RV0BQ2#CT=NSNZ;<*^3(],];;FW#6I5*$\V&R7K5M"N/9W>2:R.U,R
M$D/"9D2D(B<@5=IK&=?#M%,56UI7FLAS>$*[?2&LW%W]O9#W=S(@H$N61!1!
M3,9>_7#TI5#V!O(3%OP,3J/4/7WJCW.K]!7<-[W2U7W8-OVXT(..U][=UP>;
ML\::?F5^")H P*RA^L*==4'5)RW CPJO;]%6:NM,JK&7[^UWG3S;45]9715J
M5Z$L5#8UM>)3(J%I':-DS#N(\G')25AK>JJ]C8!#UA3IZ[4[M=>77W-L677.
MUGCF\Z8;$L)8A7!?$JY^ASP,#;)/N=U\O.S*]<Z7V#IFE+#NKT8XGKOU]V?:
MK8<M-_ZD[AK=HDRK=2-W[,<>L&PQTZW>WSXH'?,J",F-@Y3;XX:QY,Z>0@AT
M]MJU-M>QJK&Q3KNLV;;:4D(4BKO=>Y(Q7LZVG$*JD*.T9;K!(Q\L3!F7(B$P
MMWKGVE/1L4467NEPUVNM-<QUC3W5,F7(O6>66!)W<4+OD(%V<2(1Q)%HCVPW
MU,UETQTIHP]W"#]FNX%2[$7':0+<^F]HVO8/\R>CK!KO-1(:JC[SD(&$R\B[
MVE2+/,KP4C-A"HL%<,CF.W\&HF;-H]6-WJ'8[-6A9IM _4UZ3=;L***GSCLE
M6O.%Z=;$F"XK)_@BY@"1D7<'/TY&@V^P*KI*5!FY#:;E6R=;7=I6VV/0T65O
M"52+\]I'+W3Y26!$(P/!<1V=VW8SNE0IWI>>E5W.=F!LWK[3=*ZI=N)TILUZ
M5K"O; A]9+96S\HVJ45<K\*U,V4JX()S)+:2?PH0=C2'LOR7,+HBZ=M#T'U'
M67IS':V-C>BNL*<#=;5+<(<H5\!#21*0A@",R'8$3$<#'%N.[076&C>S: 6O
M31IRYAVN:J[ ZMRV2R9.5BZ&G(&4_3[RF)GF<BPW;VJ:9MW>QBS[-T2$%6_T
M<?=#7=874>Z=\[1PBU\M(NMMUNMN&MH$I4FJ62T.9]F 58(M*#^8,I]+*WH6
M/#,5"\^CJUII[-IU^KNG;;H?T[6TI+JH-TN=XZ0##U)CW:]L?PNX8YB"G.@W
M*B;NP-MK7K!_36[K*E.[L;43L-%7B7)VC+PM;\%I7/#.V9XY&,VGH/?#I-9N
MQO0?7>[[=0HP3K_UVZS7/3W96ME!:D:NVX'UYD-MC1FW2S*G6%4NS,#H.?\
MCJF)E'O,2&_,<R-*/+&4=KICJ-.HZHMZZO:)FTVVXK7].T#_ *;09:AE'9T
MGB?4)(S_ *G(V:Q% _3".^TK;_1MV73]:\ZO :_6ZQ]+9K,)BK<"M"[="X<3
M,0EL!'];B46(&2^B7(=/_H_+;UYHO>+;/:+>6R*S7*/H+.U-L:ZC.MC[&8V#
MLX@>G!M8QJ53G3(-^Z2@<PTO8+4:"8&,I=K(W$PH/BS/:V]^ZIK[:STS0TFM
MIN=9VD4:-N8[U+J4P4#+DV;$+:-<60N*LD2SGAQ]H'(\9IW3SM;7WUS:W[2E
M(U\V[=:)[6G9M$P@JPA/>N7R$L]1$"8Q_"'N(1GNCL7B]H.DQ#M?U5[L/=B!
MIJ\6S1-_ZY;8VC==?"Z[L77?8FI4)-.U+VUN.F1]CO<B/ L8B6P+FE118P'%
MR T2?Y@Y2GH\'4BTO48:/>=.QJ6+K(V=7;T:5:TQU2WJ7V?/?T5?8$FL)$HQ
M[Q68+8<,(>#XB2V.-KHRVVIWD[$#>VA8UENTZN"[-;9)1X:FX?2%KR@6@4 1
MB9@$@)<C/,#U7]H2_9?404&6/>DUJ_8TP0O!*<$"Z3[/;1VL9!XEB)[)6]SR
MTR(+@TYLTP['#NBT$VK 5Q)]4F):BC6UXW?2KTU]C05T:[4+"L M9LM+2HK;
MVL"0JBL2,K$KF)9!R$J#M^@<D<QFJ;4]G3!9LZH5LS)Y$L*.TM6S7W 4&\C*
M %/?$P$A!=Y<\$/ 9V@J[GZZ)^G.UKL<OV5$$.LE<I41^/9B6RUR]0@[-(Z)
MFZ40DQG))1RLCS3]X+3JY+DLMM3'3Y*9"><5+EOI<TR.GK8?)K;J!IV!N6V"
M&4A3@;[$QU*NR(S A#C7%98N$9F1A0"41VC'&U%NZQ]>5;);,"U:TP4-*US3
M!LZ)B2F.3\0LEQDJ9B(*6'(_UBF)H'J_WWTS3>CK^P;].CJ[S]*Z;L'1/3R;
M(EL(+E:1V10T.&65I#R%2BTKKTPC82A6,.)'5\&=#B\MJD'HWJV>ZZ7V%CJ6
M*M42_9KJ*Q4V>_&!GQA9U$R9IF8^B$;6?2]_MWM:MA\\++*[5=04D:*;%@H^
M?M(FQ0TQ2409HV? BV(GF3G71%CM_P"JM; #XLC(78.T-= G?0VNT?>S0.-K
MS7>LZWV 75[[(%-5F)$[$RK":![-^"R,=+$1D"^X6(#CWK,?![RY+S66EJ5F
M0K2M:KY08LZR6S;MW7:J'U8.7$6IA2VTN\)Y*6Q"P-7OWQ$1/,9A9M5+9T5*
M-A #7KU5['Q6)&%0.QEC M=A1Q$+F3(6>W;,S,<3F';[MG0GIA+;?D;M8MW7
M2Z=K]AZTL<BXVM^VZ;*=5]P[7^ [Z/7%+$9-<:U[+HKL8\QEA+0>(X"!&,-J
M2)C83EGIM3>@45?FV:^VKZ.I<3%=$(V"]WKZ/DK'!+ 73;&S$JGF984-:OG^
M).=/GUB^LG6/7P[6OVUBLV7.)U(]5<M]E@>TCE?IY1,,CCZ$2M9\3 1&:4>D
M2WS.[ =N]R'XM@!G-;4>X']2Z(C5#V=JB -$:W.DZUJX31HD%:QL:NO5J)%-
M(<'>K%)$"T\NA*<D,XQL726K'5:'7J)3%7+*%7MF3^9M-V=M8.NLLD7TR;#B
M)?!\D  *YGZ&474>P+8[BXR&+.LAS*E 4\1770K,-54$",]L+E40SD?8R,C_
M .MQFD?-DRCQQC/=I_)E_P#\ FR?_P UVP?_ *5Z2Y\S_+'_ .=%/_ZCJ_\
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M7D]$;V7IW?VN^O5ML&8:2\=-PUI9P@P%:)<#,F&B?*/5&;3[B9&>T04,E3!
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MJ&Q?K%5_$7'[?]'??U/\G_HX_8WJ?[GM?FK]3'Y)7TC7[J&Q?K%5_$7'[?\
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MHM9L;/[.4G6/E$K=%%96S;V];N:S>9]3I K5FW*EJ[',:_YY%%+M43K;TBT
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M+OE-Z,1J:6\G96G:F\AMH+M32[RZJM6KV2IV'[*:FN<6K!%H#KL^<8K%#08
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M.<*U]O>OE+FJ%G+P0<,?#FP*VT#K]!V/<#TPUJMVKM[#A#@50J)PN3S4V[B
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M\Q,G$3$Y]2';_KR()[$$F;W+"R-6U6TW>URC5&V((#/52D$QP2X&Z;8"-3C
M=EQ*R;+B AO^;8E;'1QHL+$R6FR)&'&?X#I[;L"FQ=46Q>>BK7%=JFQD6+(&
MRNJRD+!-I$Y:V,5ZP*\&M;&#,@!%');K6@=D#L$N:B76'2=>R 2E!BM[$-),
M+MBIA@MGI3=(F8!,01#$_ ]W$Z_U8/7#EDL]K Q;*+L!]J&7U#N0>?K59JAA
M("RV[9-6E4!JS:FI8(NM$0I<MH":A5X>58?>+(C9P]SE73NV>QRDH0TDFI4D
MO8:XU.<]<M37IO&W*;]EJXDEUJ++#RXF(7,^V=6;O6I!1M:Y<-!K($Z5X&*4
MD_&UUI15H;30L_HF^V"%1\9/CWRW-D[3HFHZM[Y7TVL2#<)"0L#V 0<LYHZ<
M/S&H ,!6*M51INT6NP&);J&1@*M!RI:=G#BHT-QMIU2*^E1M;!_IJBH8V 8P
M^]BD+4I0R36O>\U(0I8QR;7,6L?:)*)F.9MJW7I)\]ED@ON!8]H,:QC&% K6
MI*08YS#*8@%J S*?@,^^:G:N[Y:OL05V5L"87KA\WLG?(&AU,7JG<4NW%Z'I
M_;R-9XL!JDM5 I<*\4@(+5F5=81\0#?KJYQ$B3%AQ(@JX-V"_P!*7DL$:@K>
MI=+5.M6#O:X:Z[>QH3<\*[,V KN6<K<-8E,;#NT 6;&,7!TU3J*HU<S9(U,.
MUL5UTA3O$\Z]*Y%7RLKP@WJ,8-1/%@+E7<1&  !R%DU;MYIZ?6#YJTW6M"2%
M58R5/0P+%[,PD BNW[EIFH2@;QBAU<U:2!FYTZ95IPNOU^>^/N&4AH^2$(A7
MBYV$_IW9 ]2D57L!\^-1-FJLI:O7U]C8%L+M/4@%UK O%C7#!U_XD]A"U:I:
M=U2)33<]0$F.YHKBP8PL[KZ*)7)UU,<3'IE) M92+OH1W"2S9'D=Y-$@0[<S
M85RA"2/AL,Q.Q2JIMZ_5X#2:'MBV:JG7*T6"%JX=BJ 0YBL.0KM8+1 "U2K&
M$S4XL)*M)%6@OEGI?:-;(TZQ,"/1K'U-C7U7-LV]?7OC62HKQ^=K%O@JRD&Q
M[U]O\$'>1"\4;_7K7!67B!_TDR\";MA2T5[CJ9/:R*@^%8&F1L,<*TI9W?Q"
M5V-.SX79O2Q/;C.C1=H*E-CO2K#!3!%T/89&LHGU(9$+6D?(V+"JC^N8I"N1
M2 QHY!DVQF6*)%1(::RP8*CX,F$6DV8:^=H:%KIP*BDV6J8/[7F2T'%,GQ<D
M'$!^(HKR+ 6Q@S*P,AECM:)W(H TSLR31[0KV25W)"#<,V13-6"5!!#!ET2!
MF"RB#,1F^^5.6..,8XQCC&.,8XQCC&6!3O\ 5)G^(1_EXXQDPXQCC&.,8XQC
MC&.,8XQCC&.,9UW>DY[X?DZ^N$'L!_-^SLW,K958U]BJNV%=86_FRBK+/]NC
ME4BS&$O#L <RE15P5(FQT/QL2(:W$2V(.PN>A1#^R&<L$.V2[?ZT%///$_#M
M^SWCGX?'-FZ3Z=GJ?:%K8LS4XJNL^;Q>:(\1J'MD.]?L7DXY@OHSQ/!1[3KW
MZ$RAPB?6$UV\MA0K;^PG=6[&=P[ONQNJ62JNYEI(3X=3H-6CV@8,D2]?4,,Z
MY$KDX+\(5:3+(&/=HM.!LC4QL&H")KS:*9-]LR:XY$A^$S  ,%$<@$<]LQR,
MS,]LR/'%EUY9(-L&D2()UFA0%'7H6Y3H[>T2=9=*2*(LV61W-$^UL0(>4!.2
MY[E>6N:/GGEZW]I>OY'TZ'<D &V:#(E-I:<TWK.JCH4<N_-,;.U,P6CWZGIC
M(&Y=B%Z=#$%7S^""(L<:P.EKD2$)8<RFC191.XM##(F6*4L8XGF6*Y@P^'M(
M\3W<^T<3[YZ7M-1LA^3[1M.HP0J7KUMQE(0(5+LKFL_GNX);R,(5(S,E)1Q$
M]T9Z&N7F>:9IMZ0'JS![E]1MS:$7EJ-9;)6EF-;F7'/9G*]M.IO-V/7IAJ<G
M*7H#3=F'08163&<:>6"G%8F%X;DN85$O5HMU7(^!$/*Y^':P?I!/,<3'THB)
MF)Y[9F/KR\Z<VY:/=4=C',J4V M+CW\M1T2JRN1^!3*C(@B>8\@A/QB,J[T9
MO=0#VZZRZKGVJRA(?8X!5R=6WAK285'1[Z&OFK2T6B7P^3J67\%X HL<6+.)
MD9B*A0/>L8+>DXG>+/,>OMQ9KK[BB+ C(N7,QY(-<P!E(\S,1,\3S\([HB>)
M]LE]5Z%FEVUP$J86K8X':^V('-9E:V$V:RQ=QV$8+[ER/=W%X3.([??.QKD_
M-8QQC'&,<8QQC'&,<8SJ6]-OI/\ GK]'9O.-%B>U&M>BH>TPRD-^8^PNA363
MQ;,=.,9RIV57(IH?A*?%:DS%);QES*<<W/Y/MC\V=7:=LEVKLOF@WWXB1N@5
M<.[\!<:C]_:)")GVS5>M*/K^F]FN!Y-"?6+^N8FJ0N+M^V24# XXYF"F(]\T
M;_DS.[/?+J7M?24Z7YQ/2VUE%AL;+GCF)3]H#,%1S26\YSE.%VP#>)*E)\$*
MS(QC"<+2M2]J^6+6^FW]+8B/ ;*C G/_ &K%(_$<\_A795C_ '9K_P F-[SZ
M:U1(N3HW)(8_[*+8>0/;\7+L3]GO]N>DWGD6>E93I/\ VC._Q3_^8KC&<'C&
M4S?*!/LFPM<W-F%%G1Z S:,I'2Y3#3!5VT#6QCK;Z7HDGR$CTQVI;+B4/><X
MKU,H:\O#F?.>J>E+6YZMZ/ZC761:5THO><4WO4M5X]Y3&D8-AE=WCBH*@>LX
M%GE,NV17V=Y>B]+]5UM-TEU?TXQ[ZS>JV:3NN(0PVT0TEP[H&J5V$^2;<M8A
M@22_& ]T$??(Q\RU2L)6_4J]J CV7:2+L8R$,2:96R][PL0XRY"9&1251%Q&
M8JFVTM,K\QM]QO*D)\<*Z7]!M[W573?5$ZJHH^FJ.XI5J4;)9+9&W57231;-
M")KE76B0"%K+O!IA)"/,3S0Z@U5'I7J3I<=G;8OJ2]I[MF[.N8+%SJ&V'"J5
M1?D7C88^#.6,CL)0E D7O%>R-*V)\K/3CU6Z<5V4C;!&KX*1%2W[8E;$EUMN
MPJ&^<R"DS8S,IX<D>J4GU<LQR3#:L\U-WR;[=MZV,0(=.WNL@Z[MZ.+U>7LW
MT$MS!#;>BAB]8^RE;V5(J2\>V5JN+ IS;4_*3JE4:I3!'U%2Z-/H2IO/1O%"
M]#(M2!EJ8N>-FS36<Q"[DVQ3/,,;3:<1F/):)LQ05<:])D-*KMBN4K8 @:N0
M*?=K]IF%6BKSS\I\4X@\*RM+\/(F;%80N%*>;=?<?2S(;B7/DOW=VCU#J7-"
M=1M^HG]6:^F3J+#U.\L7@O,:Q[:!CM*,D+:_H;"% 59[!-AMA;@ET_E1T]*]
MT]MDH8.WU'3J.D]A<%5U8;;1UZ)T5J6A5X"U=Z!E5CU]=[3&PA9+4"I-1\QC
M2]HA+KQ@5"JP&W58^2."2@ :*$@<_# 5H"4AD*W'B^:03-@LH]>8^<]N9=0C
M$5]B.C$?DA?R<[RN6HV%&MHM7U!H]K<V="]JJ5"AJY^<-:O5W:]O3)1#+<6*
MRQ[K#=GZE9B$):M00K([/E'TM@=OK[S]YM-!O-53UE^EM;UZ_M(^;]BS:4K%
M3<N?(5)KVF%Q75K/3,61>93'%+LR%0TZ:IYRIGXT5,Z;7F;NX05*-149.E;W
M+BS2A%?D"FVAS<=V*E$2$PRZA+'J(<>6XE;SLOI[Y/-ET]M-#MDHBU9U =2L
MMR_9)&=I?ZH>BS=N%XJ !4!3$"**REL&%=HFPC$F'$Z@^437]0:S?:IS9JUM
MNSID*@IUSBC5T>ET/K4:@^6^1W":MTE8LM8LI;W$"Q A6'!#Z3/B0NK0R6VG
MT:P;NS<=]11A"B_OG *07LOMX@JQ$]@P34XUAM3_ )^6<)5Y>%Y4F+K_ )-=
MM0UO0^N$%M'HD.I02V;RAG81U'5NU62P8JS%>:L79,.TF^65Q!=G=,Q*O_*5
MJ[VRZWV,RQ1=:ETV3E128<:_]G;5&RN%G-H9L>JFE 'W"KQ0R9'O[8B>."TM
M>J>_6B--*M!"X>EPZ*7ER7!I>(=$0)SI")(1 E0&_@LFR\\XE,AN3*CJ;PVE
MR(O&'/-PZOY..J.GFZ:YT[>#6[#7=-U^E[[W'3V%?::^K:.W7=%5]4?17%L8
M40T'O5(0 D@N#\F7:?*/TSU K<T^HM>S9:_8=26.J*"$C;U[]7L+=8*MA,VD
M6C];2:M83*C2AHE)R#QY#QS/:U"N6RF:FJ(U$K!&GV>-:1L]N?"-)5.AL/-1
MT.PIPMN*XVA;N'<I>2\VOU/+6TI*L\V/KOI;J/K->AFN"-);Z>W:-Y2MA;K;
M&)M5U,!0G6M4@00"3(9,,A@%V]A!(E.:YT+U5T_T:S?0\G[JIU#I7:.[5.K8
MUTQ5L-6QI!9JWC<)D*Y7$K)9CW=PG!1&0,3H.PP%M$)TC)4^]M.K[1,E5SA8
M^,2FU5,]$,7&$#@\>$,CR,$'U2)+.7G5+]7/EYPE*4ZM0^2O;U27;M-F]M6=
M<Z3K?8WBM4:B;EG1C:%%%.OIZ]->DIT6VRUZY8<EQ/9,1$1M-_Y5-3:$ZE5$
M4-4KH?=]$:ZB-:[;=3K;R:Q6+SMA<V#K%UJIJ*A*&0L!'NB#B2F9YHK1]A&R
M:_"5E$FGU"RG;;5JUDE#:DP#)O,Y?A/.I&J?)CQKY*:_ BXAPW\K=0B;-EM-
M)1F31^3/;TW:FL7:[I[I_<[3?:/3>MKK=5V.SFT7%K:13)MVI29=LLJ(BM6;
M)&(VK-D @9C7OE,U5U.VL0))Z@Z@TNLT&\W,4WFFUKM;%8.:NKFX*J5NXJG6
M7:?-BPJ! IK5ZY')1EJQJ2PUK.G,MQF)?\T$&W0HOKEF6OAQ-L@XA.N2/5@+
M]BS"QCS&TM^T8>S_ $59;Q\?+#2]!;?3S\G<BA3Y^3ZKOZR.[8+7\YQOJL53
M-O%0O336B.\(#S0R?:9"/?*_==?:K<Q\H<&UJ/W@6M#9?VT6,^;)T5J;( KF
MV/J8LS/84GXI7'O$'/MD#)]<;60K<2J_"^<!X\&XQG8$J7'FCES;4<E'&CD<
M>IEF.P:$N2<P8\Y[$MSV/"O8_@V4YF2G5;OR/;ZWIZVC]?,:Y-;J%)U'V$V*
MA6=[LW;->R55E2TJV- G>F599%@IKQ,UHI/.71M5/Y8='4W#]Y.NB=BRST\Y
M=M"&UK8UM%K$ZP]8ZW#6-;KKXI]2VLOTX>HD?4>L2$)FSJ=KBTU8K;C4F)",
M$;=6:C6Y+ZR,:#[&U50\L1B1'PT.>SE)%,AI]Z-E24MKBLI4Z^K'F)W7I[H_
M>Z2_U!LG5ZVPN=0:70:9S)N)J^F#1:Y^O\J8"HV9&W#0:Q,R, 2%C)MGZ<:5
MU!UCI-W1T&M2ZSKZ>@W6_P!RE8U'6?4'O-@C82ITG;7$34E)J6Z(*3%[)@%1
M]":W$]:IH@"8K+"%? MJIPZLV^*V8C-J+D@3ZGP%IANK'/9%$QV<-LO14IF#
MI[#></QTON*?QIU#Y&K5#5;#2J@OF[>]/5-+U @-@D)V%S6,EFIWE<RJ,FA=
MI_06Q$18J6U#,.5#3EL;A?\ EEKW]KK]TWM^<M'U#;W6@>6O:<:^GLUPO:Z.
MP VUQ>I6X[V+?,U[=5I1*FRL(7.79T2>4/@PIHRHH<AVFE6-UX ("5Q)1%,E
M39+4,LU$@ON3G"?MSK<A]<C$.+C&<P1;&7Y.'K%7R8;;TE:M8H]/B5?>=-;A
MC-5KM9IXNCTX^R]=>^%>JPK)W/4D#6FWTZ(@IJT5>5W? ;\J&LBW:LUK>_(+
M.CZDTX+VNQV6X*D74:*R&6*!V+2@JA3],!J4*9L/GB+-YL*3XY;;=8V:X;$I
M]Y?BC V:M/$RT9'2(R3\AD?)??>&N61J)'DN@B&'U-SP\N',;<:S(;BO1,RW
ME<OM_P!%;KJ'J[I_J=J*6NG1VJ#XFFY,;1JZCV-93+<+KI<>LMPR0M:]]>R!
MAY10Q$O864.@ZUTW3_274'3*VW=C&\JWD%%Q;IU266TK4NX.G.PY(;.I*X.K
M?18KF!PHG+?"%CD9[ ]92^WC).TTK9R]966RZ@MVB;>_-ID*^!3^N[=)Q/6V
M@4^:K4X38P<YR>\%,P#:8F6BT]@P&+^6,<&_0&IW:]>L$6:,7D)V%?:5X&R=
M5BKE<>R)E@K<+$M" ABS5W<K"5L7R<'X/LM4=UANKVYJ.;2=KW22!L+96<7=
M/ 2Q4@U9=T@P3XX,H,#X'MC>O^F BA;#K>P&;X0)OUS:KFT6ACP&+':DR7.I
M%&ZH9$*E()/+:9P+I+5R]L2RIS,XBZ%\CV=A,]W/;ZD9;INIS4 (=1BC+(:1
M2(QO[.^\G;V1$EY+,UNWF([ AG/<7;&.OHPKVE6HL$4JN>K[)7$1,_,M?3=G
M=WSQ'97A_=Q,]Q2OCB.Z809]'G1#E\VJ6(%*=,U_N$KLP_9P<_2]%(;7$F-N
M4HU3KLBF[YEY<LU<#3?>$R7A14 IAP8\3GAH5D:K<CX';DKZNLJJT%@NR-O7
M!24EH;.T%!B]?958K38U0Q"7,'PK692T5' "PDRZ(9D=G35=EBV9&B:UT[;&
MK*A7.X#+J&)?X=C/\90%Y3,8A<L"3(!;"I[(F4_K%N<Q6-70S?9$>4N^CMBB
M;WJNZN:4$18\9F%J_8.HB0V\5B%=X\2V3S54V2<??+AY]-APSL47/A 6H;,L
M9-CCO-:M]XU:4PK;.HRK?K1LV%)2=VI? ZKRK25<%/IKB%L&R1*)@DV2D3',
M6IO&JI#-H)OU]H+%-_H0B!@:EFD86%"^(<3$VF3)@2!%@@0K@8("J"=TWC3=
MS=;Z>1%$[+2--[$[*]H[3LJ;"6$A&K%N#>1';%(TBF+#GOQ30T9L8T-V678F
M-NQVI>D=?$G6(LDZW'8L ZC(=;N; ,!%K8T]+HT4A+R$I.OU@4+.S[B""69T
MU'2"1F"D=G:")(5<S"+1P5[5I(3:BE:VFW=:(?&+&7;YW$4.T2F&"%I@6C@H
MF(FA7*8@F1$;K7S3L2];*UCL=X[('/ZT [3!1Q3<%N2R61L\,"#R)#TI<EI<
M10A -#[+:&7\3%2%(<6QAO"EZU4V)5:5VG"H.+C:+99)3$KFBQK!B!@9@H9Y
M9B9F8[>(F.>>,OK%$;%JI:EDC-5=Q<! Q,'%M:US,S,^W9"^8B(GF9]^./?4
MX[Z.ZI6'7M$HI"_S'U:YZ\=?](5LI,IP$O#48Z[7(3>:G>#=:-R"0,\/,EPT
M:'9J(38?&$ <@@.24:=DM3(U\GJ]Z;EJV%08]9M]MLW -EJRA>XK,JV*RG*@
M&J-:V$2;0%!@T0.5S$2)4S.F4,JUZQ6"GTNLUM!1DA9CWZQPO38-3));!880
M+:YQ($N2&#B9@HP=H]'R>LE9%5QC<%(J\".158B=;I?7T-3-;.W6'=*)<@-X
M#Z]J-_!06+9$Q0XE:*6&W$KT=EUHJ6@@2E5>?3*1F1U<I#C=.NLO.0A(.L[9
MEF[%8J]JNVLRW8J-.4%ZHG+4@*RA<L#:#XB1SH[IMC5 J+J$C!^4E(UJT59>
M-BN]=@*J+"QAT>G%1M<=ADJ,Q6:9GF)(2Z(DR9_;UI_GE;"F-AW?5.S*_%JV
MM!]?J@?8NG=N#MO5:^WJH1[4\&V%<9Y *'J5LL0QJ@$;33H6(Q=V0?3#L,'"
M'52P5KT?-LM74K7J3B?=-SV4]A0/7OJU;$HAM2N(,8]"3FV";!=P1"NY192Z
M?,V77>N@#LV*=M<)JBI(6J-T;JK-A,.D++S( 2YHQ6)R!B#F60+1L+574=[7
MVR@&U3VS)-RM P[V(LA3"*C"K@XF3[#SM4D"R(<6.8)+%#ZPYJYB,'CK?)2Y
M<,NI!&>[*A*F3X=_J"+=)U!5**R&*TZ YL$XP7J!OBN2*5!Y#?%Z99,0 B2^
M0"!.!"33TOIK2[C+4O<#-FT_X(J SV94R9VC!G("J:D0N.2F1/@BF1[BQ^GN
MEP+36VB5^!%J'.KKEMV9=@ ^9I"BHVJ#+;6+&SMC%N;T0XJTD:Q$)V0RD/!P
M)@G6PSD&O%;,8#P<Q9'?8]2MV6O"HU=H'>GI5FF.SM30:N@M2DL^:YCP \@2
MN6'Y"7+8-RTK8?,=:.B71N'86=<E2ZT]8E0KQ<6=PS8T)V$?QC5!M9V#V0R
MD5FTP'MG[[7ZB$]D7':I>#M=RM5#<T?4DB[U)RD0S9#-ATX=@%*Z3!6A5@&*
M%C9\(?&A& T@*2>=E--$(A>&SF0-D]:'4"Z=>BLZ$/L:Z;\5K$6B4'AV*C!P
M-1"3@S$CDELA@1$3(DLIX,>;FF*T^VP;DJ3>BE-A/@%A>6BP34:V^0>P2$8$
MPD"F9B"$QCD9B^T.AP/8%SM.QXMO M7,SNJ?MX0U?=5US:5%'QSFB=3Z,L-/
M-4D\3@MGHLV%J0%;!I^"7K9L,;4B,P\^+;GQ2V>CU4VI713*NV:R]:&O9-2^
M^C:,E;2_LTV%64@4J(2V#4&HUN4Q?)3$'(R&&WT\NP]]H7+A[+Q70BS35;KA
M#-?3U[$FAA##((:2W P34P&3Q$R'=!W39NN VP:,HVGX-@C5$CK4CK6STFUT
MZEU:O"*_=-66 1:*X2@:Y'16*C%K3A40F).I\5J/$^ 9DL?!(09^(IB-6IW)
MIVEK8$DK 75W4646;+W,;6O)8AP'<,IL$^ 9W#8*9+RB)D!!W+F>W6"S7UZ0
MMA)U2JN0Y"$J!;ZC0<HAJA$)A4F':2(B(\9$(D)<,BC!W1LS\)&;59-NA[-=
M+ _V#EFI$W4 9^D%']_!M. BL$E0#5J/PR%>&#M018DP)-+/XL$2Q$F5S!:X
M\=Y5H75"X!:$Z]B:R8U J@=@R+2XU+=BY9A;6A1 XV;$B%HKCQ$D)[6=Q1E>
M&@/O-S;H.>R=G+)*D$USG9!268G6-S!)0#2@261SY!:4203$3D'_ ";,!H'K
MUK^<FK66RTVM7^ASG=J:.K.WJ"_K^[W>3=AM1I]$OMD*SZ1 UR[*>KNO_7NE
ME9@55Y8 _$L8^.)8%ROVS*6VY]$]";+JEH8H;1^OMQ;K5HK'8L6JJ5A9.Y B
MVWQ63W/'RJE)DPCC_LN,+K?TI+6H38KE-R@J[6FN^Q+P2BO8:95QJS,JK?QV
MP*9E;(:,! 3%71BQ?SD'M@N;H$'/A2B;MUE#$733PRVQV=?[C*:W-LT<M#G7
M-BID:71)&LQ0&MU(53ZX 52RI\5(@XLA65<7(_[4I]&JI&L8KLM:RZ3*VQ97
M*;>N7<5-H#"M-@+-J+K&OL'8<[U(*9!^$!KQF_9]OJF69O SOK7Z@@^D#HBM
M>.JR$&)/A)HKS4!:D@A2Y0; D?*<OF%8]&J/9#T5&=DU6SV*L5*ZZ]+.;5T7
M5MP49[7]JO16\A:I2*3?[&7G46#KE9HA6J*B1;[9$CU-] *PP;#"@"&QLG]M
M"EEJ?1/2E[ZUM?H-K8UUJ+:*JZK'VK-1*PM%<A0.M<5ZY%8B6I-)&R3PQTL,
M!7YM)<U27UC]9KTW:\UFV#L FNBRTRKC6EA*K\N<,)F%L%@B$#L-;>F>LIF%
MV#6__P!UNT&]B5?:\2_CH:K!'=O%5;L42/(,4TK/0 E R0JX6L22"!$UO#<0
MVXX'FB)D 7*A4]?J2Z,^*['KZ,T[% JAEXIBM8E)%"[(#+A:#*Z& ULNF25$
M,%@D<%9.T=0OXM7^B6XLIN#8 99$O3#1B3010J5F#W :U^+V9,@0$($/#T?U
M*D:FV"*V<=V0J[6N.+['Q3*HM/9JHHH2['[EH^Y#I"'!Q83[PF-7R5+0''#L
MSB.9<,BJ3(FM.Q4MO=]IU!&PJ'153]*B3T\KB;$O,%Z;76M<H"+PJAA-"S+#
M/M#M((B!F"F8ZZ_332LC;9:]0Z!V<,F$0D#/9WD76$(^1DA"R1 "/<7<)3,E
M$QQ,='="]=LD^NYHM8S)4GU]V!M.ZQE-1FQD"]PMC7\UM<96;; 8ENIF#Z#L
MU=+O-6>=>E>RV"D1)C<6.HK+\K*?5=R0W"UI6L-O4HUBY*3.J5.HN@;ZYR,2
M)VZ46:KXB![DVB&9* 'G&/3U:#UK#:9GK;-Q\<# C8&U99<%3A@IY&O:E%A4
MS,\,KB7$=Y<8/_@!A/<[;E0_G**^5MC1'8/1LF=[MQ/,"P]^[:V=M:;8F&/A
M?U9LFM2=E2 T4<XY':),"69CTJ(Y+7'8R_M8SU-"QZ(.:&TU.S$/.7#"U6OI
M:\4S/C^C#AIPTCB)D)9(P)0,3.*>G%RBZCU1_P!-UVRUY%XA_ACLKMNX38CO
M^E*BM2L1F8@H""DHF9B-6J_J7M-#[#;B-4>F9J%MOEGWA$I5RM=>L<NA==1K
MM40'I>TZ@1E[#.::V#(W>:HE'-WZOU_1@+:XQS8%CC6RX&8E4>C2[UVPT1:C
M7JLV?45ZJ-85FLAR1M;@XL2RS1L"--6RJ1K%V[2ZC6[1M XJ)E%=4O@AJ5T]
ML.RO,KH\+K#K\5WN6TJ^L"4=B+:2FRRC9F^RM7984J@NX$V6PYQPJ8+NK3A6
M$IPO.%+PG&%*2GU4J5C']+.$Y4K*<9SXYPG*E>&/B];/AXY\TGXSQ[1]4?'C
M-[S]<8QQC'&,<8QQC'&,L"G?ZI,_Q"/\O'&,F'&,<8QQC'&,<8QQC'&,<8QQ
MC*=W+U_TWV%'4P+NO7X#90&@7T7LVM5VU1UDJZS=0H8^"$ER@)QSX*L#8^!9
MB^8PP]$)"4S78Q%4%4\? D1L34*? 0Y8L$#A@B4<CWP)#$R/P+B"GV*)CGWX
MYB,FT=C>UIO90LMJLL5SJM:F>QLH8:V& ,B.]<D2@Y-9 ?;$AW=I%$V^TTVR
MVVRRVAIEI"&FFFD);;:;;3A*&VT)QA*$(3C"4(3C"4IQC&,8QC&.9?A\,A3,
MS,S,\S/O,S\9G[9S\NR&&/5\Y]EGU_'U?-<0WZWAX>/J^NK'CX>./'P\?#QQ
MX_UXXQG7C0/1PZ8U_P"D(VQZ0,*TPFY[.UD&J:*TB"U@>"N\B2]%V#L2 \E6
M&V2EQK(>GB',,1VY"92KP1ERY2[6ZW'@A04%YMV/Z[%P,#Q["<\PQD?5R8P$
M>T<\]\S,]\YLUGJB_9Z:I=-LF9KU+;'^7NGN97@8FM5*/K!#3><<SQQZ<1$8
M3$SLY9>R>HZML(QJF:=)DMA@*Z M9BIU>KV2VF1]?LL^>-%DY4*M"RC[494N
M!ZDI:VTX@IGB')?E-EH"G^0V--E]VL!X3>KUU6FU_?O%#C, 9]DQW!P41/(P
M2YF(A@S*ST=U)4Z2UG75C565=*[C<[#I_7[<ACT]C:ZRM6M6ZP^_='";42IA
M#"W'7N+41'3L0N7";U4]A/GJA"S;8TE(F6@IB0#NU)F1HDI;@M_V$\[#"3!I
M5"W,KB.BR,4S%QEDH/<:0EB9B9,<Q,3SQ,3'M,Q/O]DQ,3$_9,3$Q\8GG-:
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M.O,'_1>(!BW#)U^]H9 Z@2U5-B:-]QWUV6UDHF@XC75A),/RKO%6B)%T2/\
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M;93KBYQ 1N(136GGTRH,:Q=T/MD-4EKJ8$9VU/-D7E*J/IT+&R<IK641%_\
M1ZE@0=0]96)JB"71$P4PE=6:URV,6NR<"-9B17--C+*K5Q%%3%K7;*4_QK"9
M)=STSX6R"\4S!#$SL/?:DU*IR+C9]0;G!"ZSL4OK+:J2"=0MN:@L0J75V4>]
M3Z=N+'6E!>!<0=@"0-1SMDGYX!<Z;\#-/CY$/$9/2EFP^*Z-CK6FZFN[0D/G
M"8V"60__ *"/F_OK^,ZS5,/8#34+>T?),'!9G;U$A"9>ZE>6"K)U;?=Z+FDP
M)3'\:?6]K8,7K8 TBM,)?<7CB1F,@57[E6879=S4S853O[4-'8+<FH]3;B;"
MZ^SK*(<K-.D6RH:\(M#;/B]H,+A"2V8MA.Z_76B1)48&_:WRC[,+DIW3B&)U
MMFI8J24ZK77[^NEMOUI*=8A%BX$FGTOC[F!W)5;AP!W-%$!$ED9.\<++Z+*;
M$#&ROTJ=V K^E%B4RU%8X%OJ(9(@?:QE>5&7:N72<P.<35'I%];J%=>Z'L64
M8,[+NNN>LB=CV^!(UH*!@]F]@J;4B58'S*E*N@&_DO>$G: \R?,UUKBRU2GP
M[()DV$B"&-D'1?>_T=<\FWM4Q6NE6N;OT5<QNL:VEJ+-@'F-@:S:@>($,$!N
M7$OL$ED*!IR$'Q3ZFJR&MKV2,[;ZNJ]4X9J@M=K9(2:AE,O78/R&T"(JM5J4
M"T)82Q@NW:;=796NZ)LE #VZDWN;7KW9Z;3\["#YHK=2K-@V!;X-'J@XI%L%
MX 70]*FG2411"-KZHW637@SF3UA9&"L8E*HM;I7;1%MM>U5%U5-BQZ1GJIL.
M54KE9>8$JLVLH14!=DV[%:',B5)DV?1RVO[56O;6!Z+!*L-0CU(>G\*FV7C7
M2!BRPNPR288]T5D/E03Y&P >^1C7G<"G;$V/!U[$U[M&N1CMRWGKVI7RRP:.
MW3+=<^O%P-T[8P00D%?#MOB9:D5XN6!D+#4P8LP)@RL-S&2[*Q6,]SIZQ3IG
M;*Y1<2J^KMOJ).S-FO6V]=5BFUDMJJKES#EK:"GL8MAC,C*YAF8JVZ19M#6&
MM;7#'["LFRT40AS]8]B+2P\=ACH]U,-9,2L# 9X*#B0C$;.[SZ8U5NB+I&P-
MG)9YLAKD19C< EKZ*)J!;;)=L+1(! )8;V"V'9%$I4D?)+R]>4>YCJB)*0#-
MMF!!BY$J-WI=+[*_K2V:94*I"XQ"S"V1V%T%RRT8-35;43V#!0L;=FN=A@&N
MN+#B!+I:Z@HT[T4&]\L@JP-8)UH!)W#A=<26RPNRV3F1DYK5WBD#$W$ \S']
M =UZ7;R5QK5-U7NZSWS6H<C.VE08E9J8L]K,ZP?;  :3<"5CO(2G1[+=DXFV
M:I2!%I,5670AS^P"=F$TZ8%,E>6]-64!6?9OZQ%6ZT HVB?88JZJ4RYMFNM-
M5MB4UOHH>+$*?%LXJ+2RP+5K+WR'&]**=]UFJLRMUA4D&560R%KKO-MA:(:_
MW:F0<Q,UQFR;000,/$5_O92KP&H[^M=2[DV9<+DUL^7,UM36]4/V:EB].7O.
MM;^7LY\QM8/K&3 A7+RQ%?74=@6EZZY>3,J+)D>S-EQ,C>E;-9EF+NPUU*M7
MFD(W;,WA39/8UO65%I4NBRZ)E6Y:V+%5$5HCML2LY$2QKZA18"O-6E>MO?%N
M9JHBG+4!1L>ELFUAW J2 OF%KE-ETOY[DPP8*8MS2>^IFYK)N )C4U\HXK4^
MQCVMVK?92>O9@*YE*XJ*R36$AUFZG+./<9<D)E>4>KXV&X+E#7V"3Q-XF'#U
MVSU0ZU&O;\X5+3+]-5R:Z MBVL#H*0\I.K*2<3$=O*G&7>)Q(0$ QDVAL9O-
MNKBG8KA3M,J^9I5Y6\U<0?C%3V-&8YB>&+") AF"DI, I/'?:N3)[(\!U_["
MV91B;O 92Y F!IUJ-?"'72\$*+MB."47W*,<&)!S1LDH,>N356:LPU/LU>41
M/_\ V)FT_91PC).VVH1XQUAV18>QDJH;>J%JA+?'KC@Y:)BLQKR^4G[N[%?Q
M<@_M$HB@5:[9.[ROBB0&E$6"UM@J]R%RR\$AXR"3&7PF&A[+[F?0R00>\&OR
M=KUY6QNO]GRQ^XM=.;%T];<MZXA!-G1F]3HW-\!5L21V/#O$.>JG>TLI/6>H
MU^A)L@\C77;BV1C>HYA+I>V"+;CN41/7W(I["OS<)E*9O_-OE<P*952'U';/
MB18=:\)@[T_:69!W]8G5E!6MD-ZK-FD[BL*[4>C]=XU 5H; E*(*/*Y"ZT-$
MER^"C,#0^\R;]4-.& _6S?)"Y[AUM"W"/UP#DZ5)EPNJY<&K2&=CD3T[;X6K
MIK!:;:HPVK!Y)6#M \_ )J7K8;[#+;8RVNE_26=BIFZU05M?<+7G=;&R!;+P
MD^)IBH->U_G6*"-[(6=)4$$>L/N&9QU^H/4IHF&KV)/NU1NC57-$F+ID*IBT
M3"NK5XC)T H),;;)$^:H=LQ'$Z^=L#=FO!?66RZQ=OA"P]CNV&LM:;(4+HT6
M@&(^F-AWM8FB,-AK)BXMF0VN*TZ[\-FZ3%$F'0!5MRRSC:<MR>VWT*DU0NTG
M5NQ.FT%V[3[[16EELJ=3R6IEB?3RMEQ\1XE62-<-"82"_AUUNX8VP=2TI_<W
M:;BI5M=M<:YQ1LV)"O$ WS^0*JIGR'7@#E9\M)GQG6X^\&DM"G[-6MFJM8(I
M6K%J8-EI(B#*P;"[<:L,F!L "EHQE^50J7!I&QR6Q3$MF#-K0W6UPG(%$([
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M\:9*5.5+/_E"R)"R27/<!B M4#!Z6NGJ-LW&9V0*P5DFRM@1!>J&H+8&&*9
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M-MM6S)&"@KP9>\FVVV7N*/\ VHA P4_'AO$3[SGM'Y\_9[1E.D_]HSO\4_\
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M=]UF%(@RYU=4^AV%S C2K5U5K]/#@L)L6]5*VV*\R!U]DFK:3ZBJ%@9F839
M7*"S$24&(.XX+,SMH;.G[NRE9I:BOL(8M+H@A=1;8KM\%@TE$1+$$26'7F8&
M1(E<\CD>?[KVD-?B$:R:J!Q=20.P&T.NN+6(OI,OL%ZSZZTU;=THL>:"NAC@
MJ0!4/22P#V5B\R2[)B7 D(BN04.Y7FCIJNVJ,IOM+8%JJ6WE#*@+J0BWLD:V
M4Q:BT;/*L[*W<S6%<K$Q[N[CC'\^N"P4-IK&D.QM:WS!9-EGRUJ+K_E]/-<0
M\9@@U\18)D&0SVR/,SKH0[H[DJM\&[ANU!&Q0&PNM&GC&I=15'9MVN@N6:WI
MORITBDE;\V)UEE RR#F;>,18I=!JNQ"+P]N8%JB;',R+BE[<.F]<^J>NJVV$
MVINMBO87[%*K68*]7JGV;2ZDLN_Q$G-<Y2-M],(.1:^4AY"75GO;J;07;%<8
M59U5(Z=)%I[PD]ALD5ZYV.RI/8T(>,-*LFR4C! GREV"=T8[I;\EEJ]4Q?6B
MOQ[DFA;XV3;8.PMC;"U*+G5'1]BU2%^%-;N7'0B;*7]]HFUALP0B]U77T 61
M#FA) PN-%:-R:[]FM4*G6&;ITUO5ZNE7*G3J;!@V-FF\SLN16VO@7-8J)BST
MK[9,!BF N"*5#/\ GW8D:TAJE0^*VPM/&S:LT@)-!M-??5E^N\I^<;H$$6$U
MA EL61\1#)YE$[\F=K;&$B]:Z-MEAU<X3U"$L5I6-V-[U I&X]44?;@ZPRH(
MG5YG6 VKU 'LBH1;8FR[<K]D3ARPEQ@.4.#A_>OK:Z350IL.[M$)O0&P8E$'
M3\#8UU^SKV)$F75WF/L-IV"KRC7M3[*6QHDQDH[5^HCN60"K0<RIWTEM=(VH
M<N;U.O=!LB%1E05)7:2+O+=6WW88+D0#S0^J^D1O4S7%6O5NT76AL_:VC-*[
MDT_7ZUMB>:9)2]V;/HFG@-4V =+ZUK;--;AV_9=-($[$+'VN'!KDDV_F'(FA
M&&#&=_2%4;;ZM?:.,:&TV.NV+74 5(#K:-K8-L5%+N.FS)5Z5@ 29H(G0J.Z
M!9)+P)ZEL%518?KU"5W7T+U)2KA,@IOVJU-:;+#JJA':ZV@S: N$52R>V97$
M'#P7;;>>M=C;QH-EI(N\;<N/:4R"K57%VS<]VUC0*=1NG75F\EH5<G5#2MUV
M$F,8*7%DJV"&ZL&"(=CM=O/3R+C8^1,/R6]/ZN[4UEM%EE775]$MSGL1K:UZ
MW8M=1;RJLG#8V5:IW+77E<M.\;"2BNH B3$58%[G85;6PKM0%BZ_;FM2@=>L
M5*R*^CU%@Q62*+[,09O@_&%,0AKGL(OHR3+<C]Y=DR329$KK_&JU.!VWJ12M
M@Q+G?2P3:=5L7;.52:\*&-T9.NY0N0_KNWWH; M6)]L%O3AD.=,%QO:L-P\U
M\]+TQ7(CMB?9;7W]FH5:HMM%Z= -ES#FU-P6#%RO5,T=E=D 9"+)[>2R;'4%
MJ3B9UL*0MVF19A]@UVU-W)(4 Q7]+(3-9U@!=WN"2 2((YX'+]ZL;EVAN#59
MC9.UZE0J@RW<-F" $>@6FS6U<D+0=A7.F27#,4U3:T["(L9K"6F/@Q\RV>1X
MELQZ\],Q78-3O=;1UU]=*A8MV)]/28V;:$U^UEJI6L#"R59?!@7GYGOA4JG^
M'RV!\Q6.HNV[M,[5Q-9/#[0+BLYKN5U[+T3)PQ"I$H\7$=LG#(^GPN9\8Z5[
MF[U[GSUDM&Q NKZMK]K=75+=VZNL]Q&[;DV:T"XM(U0]LN/.V/66M:0!]3M+
M="D+MP"'6[#L"N^]PV-1+'8@6"$6Q.[+K>EM;\]HILO/MSK=]K-;NJS-?"$,
M*U?&E(TW>M(WHFU'IW$Y51WIS*TE+>PE117^H+T:IUI=1-:+VGOW]6\;LM:$
M5Z<VH*TF*HBEL5Y\RQ4VRKS#%=K5]T-G9NZ;1)=1>L^H)+P886*SI].I!DQM
M#>%_*T6GG+2*+FR-CV'O>WU*[[!EUERQ1<U<":)TYZ83L5CI]=0,K@Z<W\$T
MM:BOJ'=[$88Q:P"Q96NCK*B[5A:&+4":FK18JU!="B\[5A8@02FP[O<8SWVS
M[9:;5TBE8F9$A#&6[]DZZ&. V&VSL7IL625+8\*V&B2-K4+[%"7T*=IG?K:M
MO-T@,QUD.9GKJ6CK9M@$)7MH]8JA'WM-E/CHX#X.T<NLNYH51:8M5P<V59M8
M*G.-F@-<9GR@JYDNQL=*4*Z[+"W:NV+&TKT&G&O4FP6K$8*6^39P_P#I5B91
M7BFF[ <K8Z1%D",!'4=QS$!&I9W>&@ZXL/6,:F-A)2,+[*$J_HZ8%KYM-J=W
M#%J@R7W3QE>D6LU<IS^Q]@:5#P*:;U;V,V'KYFH;&*6:SE)O739%:UT3!6T9
M-UR!A5QFXRK<*)"B84C;?@6'"(Y)PWW%L-)[1T<A]F*=/9,.RJ]IZER;%,$H
M6.XIOM@VN8VVDZ:XUS!@,!'D(@["B(F9XGJ9JD3:LT5@AE/9V:WAM&YIEK+2
MJQ+<$U5"J'RX3 UD[QB)=\3/&2!KMUV6)633=,A]?J: L-_W>:UH0G7NP;JH
M]0/5V#H*\[FCG:+-NN@JM=5284BE'*\<47U_F&T5!Q(4#,P?</>.GX)Z?TH)
MV-DMM9<BIK57 &JG6VK*G'M:NNE5D*VV?5[3&RIJ_';[I!I&<"=?PV,D;K:D
MVC7'7(6VS?95*;#+]=+%#KK%Z&5R?KDO[A)#%,[ZW;!K@1[A=Y4\S47:;:.P
MC(O6^KM?A+7884[=ESOIG<&W)8'X,I-<[5;=TJ &5*55=2FWK&7G.:].RAXV
M8$!":57H%<!F+&?GD6C,CC8Z*A46R[>MMKI(=;5J*UVO%O?9=HM?LG,L"_8*
MA*PBVH3,6-99<;FK2H0E<=Z6VMV6!5J5@<P9OOL,NW"7V(7M[M%8)E-,Y893
M680 2U@A0J6;6$4,FV.W7: YUE%5^P"JG3[D-R//62UAB=TL86]*JM:(U6$9
MG4:K5O7=XP:0-8LN)1NPVHE2Z979.*^),6%A^VP9$&OZ>T:MV;DLL6:S.]2:
M[ K)95A[@>:QM/=;J^.3E/:I* L671Y6+5(US@IFYVS-4"V E#Q[6-<LWM78
M\*C2+"KI55L>2 AO<QC20A4^,#;$N&1UZH^_=["]^F]75<75;V(O7;W?=>GD
M-E;!MXN73*3KO5>I[&D'1XP^IV^,RPSDX3*#Q;JH(MV>AT;Z@M)B2>@6]K5:
MIFI5>>Q]5E7I[4M *52NP;%FY>OIEMF3L5YF9A0+,X[C@9@_XDK%15E?8[ -
MBRHD4V L;K8K(K5AP2A%:G2;XT0*71$1+#,1G@)+Z' >26#Q0GI&;V:UR?VW
M'ZV'GZ#-K(RV:W+8F;$!Q2<<KMJD:T%U>Z6*Z:@JU+&W&PC+LS<0<>A678X)
M" -G EC@]0N 9-=F]'557%4"W*XM XZ]U?;3:2Y"A9NF^LFML+%DZZ65IKMF
MTBFV?*AJUGWDM?"^IK#*S+D:MDUR4#JI]UE<&)W*]4%/:^DFN+F"_P RXKNM
M+CQM69CV"P[;LO:W;VN=GZIUULC6.H&9%YM=4J-FCZ_W'>KM8:H[L:S6ZOT&
MR.CI&B:Z(@54BJO0&UR[D?J) T2>M4&I#S:J6^HO7IT.NN4;URG=V,Q60]Z"
MMZZK62^*:$-M(@XVC6&\?*4P-95@%+A!6"5ZF/'-;M[M:U3K6JE*)L.4EL5K
MUA[$S9:]=9O;.O4$)+Q#R3V((SEPI%DHGOIL?W>V&(I>O=R[NI0FN5E9+MZ:
M6*T]?REB03J'7:J;2)3V;/7[3K<$\1,>K1%Q0,<39Q\262S'L\^0,9><J<.Q
M+IFFRS=UNLLFY\!T\N&;"H"?'8V]BBL90Y%QL O^E03B-!$(=R $YB'G"'?6
M016O7T I7?NF2%&R;8-&L3<,H:IU5<F?]'F%P#1B3X:4C$RF)]=>[.VM8-*!
M;"T+186Q+$(T]:-;@ZKO*=::H9K^TM_ZNT&0AW*W.:C"3:C8:B8VO7B^<!ZM
M=*[9X*)^ 1YU0V;AJ+6Z9U]Z8;3VMHJ:6;%%UK]8*+"G4=5>VH%7KQ?8-A-A
M=%R_XCJSDEV^54=X\Y[&^N5(\=G75QLM"DVJ"=@3DL7;V-37%#W>B626(.XH
M^%I>MP]WC9]&<_!7N[LROX!QS^G:6&0)WI=M(;AO<W8UQ=U-0BU=Q19E1D8M
M8C4)<O :V4+O36 QJ\5JGTNOV,)*K-CM45XR GS2^F*3O*2MC:9+-76V>NJC
M3KQ?M+=ZH;$2@]@"SFD=6?(NJZQ9:EHO4B86T!'OK2_'#*5<(#86-?>LE9?Z
M.L:O3DF?,%(S&+06/H,>I*%M7*FNB6+(NR7FF9M&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQE@4[_5)G^(1_EXXQFN=<I,I"@4<%1"%,NT"^6<M8=D_ H<0A%;E
MV2R3)+<@DXO,FVI."ID.+"&2(A,>Q)<BE)Z8V1+"\>*ZK0.&=<K7].V='OZW
M46WN;/JGT%&E ZMVUVCVBRT<RW=1L*;ZZ45&(MUEM)-RQ"II+*/:MIOU3&P;
ML.HJV]T-GI[4T]9TMZ^[=*=HG5ZM"B75$?%I9U]Q#VOM+=4LL4+J=>6Q<8,Y
M>O6?<AD?KVS.NR)D*R39ZYPJM"Q.!:@2880<&L;A@H(F2&QI-Z$7N;0M3@B=
M)$V6- B&%3@$<0<FZS;=<7Z_3.U,VOK[6Q9*Q3U5.I%2=="*%:CLSO6Z3VA5
MMG7N[T*A%1L-I[559-Z;&N52OP=GJNAZ-GJ74@"T/U=>L->[M;=R;<;"7W[-
M[6!1J74K*W4!]+1';@+M=5S5-LNHPC8LNT.7F=N@1C7L@F7,2(DT*&,W&4X!
MK#D> ;<<"KLM=+QX :.^,!0AZ2CXF>S.B2HLIZ<HF>(IA#1TG--CKNE'3++=
MV\Q-BA0O;QQ:[4FNM?(Z!;76755J*SJZY%6+AT["WH:EQ/*WL;4)JU6X/3]"
MW)ZE74I4EN1?O4=(D=CMA;9H"-X=5LZ3;-YB[>P?9FHNY6.N]3DBB*FNJD^S
M:5"JUL+<12M&2<688L!J35K,J$&CUB"S, 6<A5Z[-H<MV+,JU;<R#)EV;=*@
M/N.6(8D<H7 GG2A!MU2J'5=3=;V]5>MJ==V=YNHVTHH*U5=;];MK.HUECIQQ
MIL:C5E.OMW5[IU9LGLJ<5IIUK&PN61.9OMKTUT14VM&HU-+6T5;C518O-VM@
MT;+4UMOM$=1)!R-OM1C85*1Z5-A8CK+<VHMV:^OJ5B"(D24[9#%LA0$*R0!I
M(_MN5)>;@@9 I'O)8=P%:T7CO2@DV7'(LE4T5]3D\S'$)&&F,K!$DK*3!%I$
M=9T;OH=:C:5ZMK8]9N<8U]<VD/SILNMKFJNK-U![UV@N#T\PBL7ETHJ7U<ZZ
MU!7'TJR2Z-O4XO;)^KL6JNNZ,2H"L;%5POFO6=%4]K28";Z$-JG3+J%<#7HL
MN^KH,XV%61J(N_N.6WLE<9L8FPR\MTQU8EJT@ +3!JP-UT[YF+-)A#!#H8FQ
M;FAC45:2 T;+ 8AJP/(RY\XG#*N_*'!*&I&S=(Z)A4@V^NUP+O;(=7L>Z-NU
M%2F5&VO=#4!)#9J57:V$3%:VZQ9MHX;3^3Z8:5N=:F"WH#=/4;'8&RCK2V>O
M[9U*GV[H7JC-,=LVQ-:U:3LI='J*J*]>I8LS4< S$QL*:959'UF[U&)0I]L'
M"Q)HC$9UY0 SLA^ %@#!K+3!,21'1\QH3276H*7<N2LKS+?VOHNM>3^TUB].
MU9.PZA5;KV-S5IT[]E"^F.FZ!M97H5JE4 7;I6JRI57"#"O!R39+S,U7K.S1
M=^S2*,:I8T.GVU7U]-:N7*%9S.INH[X+78OV;=HS94NUK+8:\Y [$AVI@?"O
M([3+3H==DA8E,O=M;M(\V%E/4)5:;)@V7Q4C&9JG[,9%Q8[[R5+9%O):GM))
M883+9;97Z^=VS2LJ/4TF_P"2!6=9<6.H/'7AP0)'V*+R7F36  _S&4^U0KG*
MCP21-P@0*2(2)"HDB:X1BA\YCB5>NSC\/]?_ *>/_?GU["4P]8*N/D$+0$@N
M"R*'QLZ%#L-5G1R<9;1P;'9L V\,3(*3A0".K4I$9;2Y<(U,A+4XS*<CK9SG
M45WN$]P[/)U<OK46OL76IAQFT7DN(([ FF5)>S(&3/>,'+,%V&JD+9P2CR@Z
MH0R59"+TJ1F(8AB94\7I75M/JNW9TD=.W%TZZ[PE?9W1# Y]@:Y9_0L4@7Y(
M97B>6,(8,2'M(/J7_P"#IU'_ /!\Z>TGRIG\M&@N;_<W.EFU^DZ1)EE.T/$$
M^AJ[2>7Z;J>U>BE-/='V+ITD63384?E1;W=H\78%:@UPTJIO3]B$"@NIF'"-
MBQ;TP[#"H!N:6Q$',UJ$1J60[Y,U*9AUL*FIHBC4118J5'5$DR=U^SDNZ8B(
MDH&!YF(XY@8F8CGX\<^W/QGXS\MLD9,R6$K"3(@61^20"9GM7+.T9.0CB.^0
M'NXYF!YF(IZU;1!THH'L@VJ"X!"9?KD633K97Z>2CGZL/ID$;-CQISS*K0MQ
M^0P#"OS8R<R!F8C9 A!RI]T;+[1$3SSQ'P^OB?>8C_?Q]?\ J8Z_G_?_ *_O
M_P!<9M+J/8](5J+!&E5)%:GVZ1%V9=R;E1G!:XP5+%8DB5,8^!A?@=%A8\"*
M!@$%N#H>0HB&Q/-1";;T9/$QQ[>W^['/Q^/MQ[S'Q_N^W^?PYRL=F7%ZW7L2
M.KUZL8U+EG#GA>62,:G/6PRTR\,,Q$B2$3,<#3IM:]:?DP38;(.#4H,-$++\
M(,Q8+[?;GV_OXY_\?[_^./S^,?5^,?\ =]N6U'TY3"ID$)//#+Y*@2J_,L9R
M5(R9\\O&G H(@.->G/SI<855!AQAT&^[)?EOS)A"=+>412I;/']WM_+'/^^?
MKXY^O_W_  ^S^[+J';;?,U<Q&$YP[:( 2TX$R("1ME(F"M-P]'EO)J$0F/(>
M85=81(&CW9$9+JI30Z=+%$5MQE=3+L C[2/M$B[0CDR[8F>T8F8Y*>.!CF.9
MF(YC,]9,6;%>OYDUXL.2GU%DY771#6"'FL,@3($+@N]IP!2*X(H&9CB>JOKK
MZ2WLEN'L16]06'K_ +'K-=(G8H@D>F:)L<.6*0W+5F;/MJ'[UB)2ACH[PR[+
MS(L.0TGU'UH+1W/)3I.LZS;L=F&N+IO?4X,R#U-FK(K5V\_3L1,0*0YCB2AC
M.)F(XGVY^K^O_P#X+-'H;H*SUNKY>?D<ZF;5JJM3T_I>H0=?V/E(!]-HS%C6
M;.W'=)"DJE3N &$1+[>,[UN;QGR5CC&.,8XQCC&=%?\ *&]V?S6>CTL%,AR_
M9S&]+_3=;QL-K]63\$Q)3]YL+B48SXYBOC*BL/,7G&6\(,(:SX./M9YZ1\E6
MM]=U;7>0]R]95LWBYCZ/D[8JIB?_ &H99AHQ\>53/U3FB_*)>]'TVY(SP>PL
M(J#Q\>R"FPW_ '$M$K*?APSCVF8SC_R>+2?\UWH_@MUF1,1C&[[W;-A2,N(\
M)/P5%DLTROI4O./',60+J[):(A*LMI056[C"7'W<<?*ILO7]6V$"7<O65J]$
M>)]N_MFR[Z_ZPML$LO:)Y7Q[Q$9S\GE'TG3:&D/!WWOMES'OV]T(5[_'B5H$
MXCX1WSQ[R6=[G/-\WG*=)_[1G?XI_P#S%<8S@\8R 6G5FO+O*,3;94A!Z6?H
M%CU89?GL*<<(Z\MSD=ZRU*3E+B?7$&7(L=<UC&,*<4RC.'$^'QRT7[E85A7L
M,4*;:;ZH"8B N5XF$V!]O^D7!3 S\(YGVR,ZG6L29.2#)96;3.2CF2K/F):F
M??\ J,D8DH^OB/?(Q;NN^D;Y#/0;?K6L'F+*U2VS&9T1>9+ZM<YGJHDJ-.:>
M:FC"%3R4(Y!DQ<B&1@>VR?)E)PZOQSU]QLZI*.O=>HDS9E?:4<1ZSL]4)#,2
M)A8[ \H'! ?:/(^T9B=K:%@6"^JED-A$'W#[SZ;N]/,3$Q($GO/QD$B0]T\3
M[Y@%]4.N:I%"F(U'4XT[63.8U)(0H\J 2$Q%'W+6[!D$84N/--CY%I>D665
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M\@H1<(19*'6)6)DAMUM33BD<QMN6G68N,>TK4$HXL=TBT22("HA,>)$EBL(
MHXD>V)B>8YS(%9"T36!017F&#*>V)7(MDB8,B7,2)R9=T3S$]TQ,<>V594^J
M772C"B(6J:AIX<>6.42Q$&V83STB23U?9(-OUQZT^7(D3T#J)9AL,S4PC4I
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M-Q&@!4H$1'P+)38C\J>HMW-B;4[%_FE)HDHA<"2F,%Q@2H"%%W. '$4A)2T
M;SW@)1'^9-5X?3^A3XH:+H'Z<E#0 EB<,DO)$BLS7$0<1"S-?'81#.6-]5NO
M%B16DE]3520NGE;89K<IF/*@3Q<V]VB5=KHVT1'RHL]X9:;;,D6 \$E27PI,
MHI$F7 =6RSY?16^W"?/X]A8B+ (6X9(3!@U4#6K3(&)!#$5Q%*FB,- (X$XY
MGG(S4:UOB[Z:9E)N-11$B0%8=+WQ!C,%(.<4L8N9E9GQ,C/$<2':6@M.[K5
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M!Z^/VFH&1VG:TFPL 1-+Y9C-1'JA&$DF$/0BSH4\0'X"J9:;EF(L5\-Y@:!
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M2WR5UA,164I-6RJ8EHFZZH1>L[&RNW9LS7D[B2HNIVX2S7\0NF?J#$:T&U<
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M"*L165D5+GT9%J;,E4Y#QSZ:9JS*.5_PY\79]#Z/]7VSK'1'60P\108C:_\
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M=!,&E!S#0,P;$EPP3(3Y@IB<C.ENOVKA+6W6)&5S"F;D37$J(35, 5J1B5F
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L8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g383050g22j00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g22j00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4WS:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(R+3 X+3$R5#(S.C S.C$R*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 X+3$R5#(S.C S.C$S*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,BTP."TQ,E0R,SHP,SHQ,RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$S,CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%H045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q>%$O;#59=#5J9EA8
M=C=R,28C>$$[;755=6QT:TUA44%X.49+:$XV.5=.86XV34YQ>79!<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<B8C>$$[
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER1F)J>70U;&LX,$QQ:659
M<&\Y35=33GIP45$X0W%-4WE6-2]T06=D3S)&5CDO-28C>$$[,VIS+U K;655
M1&%&,S%+,6MU>&5C=T%G:D5N=SA/3SEF4S8X<W1'2S1'6&,Q;DI5:$AV6E!L
M3%DW1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E=.6$AL>GI(2G)Y
M,WEA+TI(<#9Z>'I(5"8C>$$[:$@X2E)3955F34].;7%/,V(U-'$X;R]05'I"
M<69L,SAX3E Q<E,S5T\O<SE)<D$W<4A597!C=$4Q5D]X*T-1-7-T2D%39U%E
M5B]O8R8C>$$[1%9:1$-814]92#91.74P0S=N=DY#,#8W;E!+931T65I:5T%!
M0F0T,5IJ464U>EAZ1D5H>FAY4C)24S=&6%EQ-T9867$W1E=!9FY*<28C>$$[
M97!A9G!F;'@W0S=M=$AN.'<V8D)/,$5J4FPT6DI'1'AS54DU23-D5'-C5E-:
M3DA5+VYJ3&]*,4Q6=C!1=FPY9%5&;BML=%,T9E=Z9B8C>$$[96YZ+T%.-DLP
M-&)C2SAF8D972UA8;F)8,#AR95ET2FDQ3RM/<C9X-3!V=$DP*S1H3GAC6%9R
M6E)02$I-8F19:$I+1FAI0D-R1TYU5R8C>$$[=WA6;'8U6BMF.510;&TR,')5
M03DY<D]M-G=U:#,P=6]Z1WEU5V=L3%!B,V)*94):6DI(:7!32VY.=#A6569Z
M44AM9E50>DDP4%%T1R8C>$$[=35O:&5A5F9396=U<%AM;5$K<VA!:FUD-TU/
M>G1'5%5+5F]E:'A62V]03B]M<GE4-70Q2U!8<GE86#=44V1),&AD56(Q,FI#
M>51Z928C>$$[9S@X14)6:V51=38X<6Q#=W%3,61I5EIP;S)P86I**V1(;4Q4
M-4QQ6C=#1%-B1U='>F%2:D-K:G4T6C%J2C1Q>E4S24="5V4T<3=&6"8C>$$[
M67$W1EA9<3=&6$5H45-4441C:SE+67%H5'$R;$--4T<Y9T5B3#9G9C%5-&Q/
M451L5W94:U%T9DAB1E56:7)S5F1I<G-69&ER<U9D:28C>$$[<G-667ID95=V
M36MV;4-$54DO34US5VY2>F5Q*VQI4#1(4W%N9UA$9S K1VY3;G0Q<7$X6"]W
M0V-L=CA!;$M99BLR3VXO56)M,3!(,"8C>$$[+T@Y1')D9'HK2#91.4\O2GIZ
M<&,K63E(=DQ783)3,UA1-4DY4&E:1TQ'4EEK-#@R<C!*-#ES=SE4:31#4%!D
M>3A'6&I".&I4,$1-6B8C>$$[=F1I<G-69&ER<U9D:7%395EF2U=N-B]E8590
M<44P-70Y2G5K=F]B1D1'24I,;4PK-FML<6AK4'!K:W%O8TPT9S=9<6U%;6LV
M93$X*R8C>$$[;W)B>%(V;SA"=&8P:W-C9C%K43AU66I%:DMX-&@O:31N-&$Y
M<U939GDQ*U@O;')116IE0S-&-7%+6$9Z9&Y6<GA)<$QW,T8T9CE):R8C>$$[
M16EO;D%Y1%IG9U55,G!I<5IY95A03#!T*S)O4S9885!F=3A5<C-B45)M67E1
M06E&>DE6-49O=U-%3F9H-UEQ<GEA6G!S;"]&<4UL<"8C>$$[0RMO44DP548T
M,&%M6D5F-U-*25)Y5E<W9TA&5D,W.'4K6#=Y5S1L=DY-=$QM5S=33T\V:VUG
M:FMA5DE7-7AR25=5;&=J:FMO4%$W:B8C>$$[1E522'!U;E(S.'5O4C)S2U@X
M-DQ&3F5,1V]M94Y.,5)P04]42W1D9U1I<4EX5C)+=7A6,DMU>%8R2V]85E5T
M;C!U.%,V6FMT;6=K128C>$$[-W Y;TE525ER<V0V93)#56A%16YO>6A!>6M)
M:FU8:T=K+VQ.*U=U<S962F)1871F=EIA9#9C=#(W;4]%,5=35UI736AI1$)A
M4$E#028C>$$[869T9F$S>6Y"<6]:8C1E:FLV=E$U9%!81TLT=C!05#E(.'=E
M6%@P>4%16#9E:$1'<V%V8T0V=3=+9T-"=45I>&)';S-#.&9$3#-%4B8C>$$[
M9C9F,%0V-4A::2MG3GI+:E-2>&E24U-Q3D5J2%DP*S%C4FHS-41&54YQ4&Y$
M>79P,FU(5DQV531&,#574D=U:V-34F=Y0W$Q369+9R8C>$$[23-Q9'%B-'%J
M>G%M;4-14FTW:#E2;31Q;G%*5716;&]"6')Y4F@Y0GA664Y:,&,P<&97-7%!
M4BLY5&]15T(V.7=#8U9284]J;W)O=R8C>$$[6D=!6E=5,4)",T)"1TMT-'%H
M23E8,&U854I.3FEV8F0Y4FA54$Y:3$MH;5)4,%IO=V592'52:7%3,TU(;G,V
M+T4Q=F-7-C9/2G<P>28C>$$[<U9,1T-O<6EJ,"M19G)5;#9E1D]P2W9&=BMC
M;'8K57!H+S=9-F8X055B;3 P2# O2#E$<F1D>BM(-E%Y=B]N2$0O95!Z4B\R
M,&HO>"8C>$$[1352<G5C9F,S85 K3"MS6'-E64QM3WA6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<48O0D9C5TYX0B8C>$$[
M2R]P>%124$A)*W<T<7EK13<W8D1)6DEG>$E054YM2UIJ345C=U%X-WEV-5,P
M1%1R8E5B83)U:'%.=F9O<V0S1S=)-CA+3W9%.$]Z0B8C>$$[>C%Z1C!E;FAI
M=FA.,C=$=$Q7-6,O1'AX-&%V=CAU.4,S2#52*U-,<'56-6(S1C1X9U<R3%A.
M,V-Y;C!K9FUI,651+UE),GI.9%=L,28C>$$[=BM1+S5C>'9Z;7-(;F105%,S
M3'I41# T25=I84M)568T9W!G6&1T>G98<FEQ639:*U5(-68V8F%85FYB85HO
M;S$T,74Y>$4X<W)H:B8C>$$[84E9-%!T35-/0W-F,3EC5E-T=GE"+TQF-CEA
M,V%757%'0C)E5U V>$U6;41.22]&+VHW4U,X<6IW<#!X5D949FMD*U=K.$-1
M>F%7>B8C>$$[<6I33U-:-2M43DMH4GEX1#<Q1$UF;6-66FIP1VQ73VMA5EHV
M5EE2*VQ9,DU+5SET2%5S5FII54MO3$Y5;EED5&EQ3'A6-5HU4C!/.28C>$$[
M=%!Z1S%#92LP>35:5%!D=%I/8EE*83)Y4U-/-EA#,T)9<DQ*34AC3E-R<4=!
M-E9O5EIB8U<S;C@K645K9W4W46%(-GE&-%-0,S-O9R8C>$$[;FU+.$0X5DMD
M+TA&6&DO+T%$:W0O=T%P5$0O,G@P+S9J8S)M9RMN-"]O9&)R=69W+U-&=C51
M9FU4;W9L3S@Q4%0Y55(P:#%054HS828C>$$[.2\S6$-S0U9*6E%#>')8<TUD
M5&=-=T-/9U1P.'=G4T0Q:U@P6%HS9'9E5VM&-6)0-FQT8WAR3D1)05)Y4C%$
M2S%$43=G-7%Y2TY/>"8C>$$[0E9C0W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%93=6]43F)446<P36E-9THW8VA427E&9VAN
M:FQW>28C>$$[0C=I:V5N95=*-UA4.5)T5W5&-5@P4FE34E%F9TI6,355,B]N
M>6I4-$1J=2MR;#8S5D1.5D-Q=&@Y="M62&Y3>%,T<SE..#8S5G)P4R8C>$$[
M5WEX-F)A96U7359Z>5(U2EI(3#AM:EEH>#9A.%%!=W!3;2M5-$QR9CAO=DUS
M*VTV=EEA,35R;'9%,4)R0DQ34T])>'1B5SEH3$I*-B8C>$$[86MU,5,O<F1E
M,5!L4E9S*U$O>F1J,7$Q=58X.$=A=V$Y371Z82]69VEX5S-",D-,5C)-;G@X
M56]X-F)K-T5%2W)Y+VPY*UIR2F$K;"8C>$$[-3EM:&MI5C%U5RMQ<39Y:W9Y
M4F=R4#A!0U9"23A$=#)&34MS-3AV,D]P5T=H,DYN<60X9%,Q0S-H4T\V=GEG
M:DTP:6EH9FE/;&-#<"8C>$$[:&ER<U9E6BM7+TUL-68X034T95I.35156DHY
M3'1.4&HY1WA-:FU*2FQA1EI85D](<"]A67)8;GER>39I;D96;&5Q86PU=F@X
M>3)D<"8C>$$[66%:2&-A2$EK4G4W.6Y!94YM:V-304M75W9&07 V9#A694IF
M.#5,9CAP5$0O=T)S9% X07%.>F$V1#9F:BMH,75U-2]$.4EE5E@O*R8C>$$[
M.44O+T%$139H+WEB6$UY4#9N16QZ4'9L.7HW2SAL+SAO9&]0+V)/=% K5$-:
M;V-V,4@S=3=H>4-C-4)K-T9867$W1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T952G)-3GA0<$8Y1&)!;31L=#55:$%)56PR46AD
M>5)49DE:051%9V,V45=%9FPW-6,X,B8C>$$[-EI:83-(<6EY450S555A,DQM
M94YY2$-Y9VQ757IH2T9L,TMN-4A-4%$T<'=V:CAM14%2>E,U=$@O4&5/2S%T
M-$PW5&I&0C940U-35R8C>$$[5C-,3$A%0W-P369.,#5I4716:5=R,C)Z64YI
M=F%A1"MC56YL2T]W,64O=%IT5G1R;4%2,T9L8U17>GDR>5=V0GI,4'=::35N
M26,O0B8C>$$[.%9$.'-656]D4#A!*V-H3%I40TY1,%<W:E5Z,'5*1FM75C9X
M5FEA;D5Q=C<V=G<Y;#)X5FMN;$YF>E O045Q-RMA1S P85<Q=DHV8R8C>$$[
M3FM:1VQ7-$YY-6I(2FQ11D)B.%%D='HY3T)75S1Q-T9867$X=CAR,E0R2#4T
M95DW95 Q:W-P9%!7-&E34U=74E=K;&5&-6U54U-Y528C>$$[*TXK>6=B,$9+
M8FQ786%P<5!M94A7-T\R<TY-4S0P=5%X9E<W-7!&0E%--VE3:49L4'=Q<6YV
M5W9T9U8T8B]Z:W0O>6Q-4#A!,G@P+R8C>$$[-FIC,G5G*VXT+V]D8G)U9G<O
M4TAL5B\O04PP5"]W1$U4<4@O04-B6$UY4#9N16QZ4'9L.7HW2SAL+SA!2TAA
M1"]W0G,V,"\U34IM:"8C>$$[>2]59F4W=4A)2GIK1U1S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U93,WI,3F5195A.5FUS:7=V
M67)/-"8C>$$[93%+1&LS<7)%>%1I2T=P-55P:V]!8U%T1754>2]W1$I86"]Z
M2#%45"]->#AW3F136&-%54(P;UAC26DO94US.6502E5"*TI5<EA-=B8C>$$[
M5U%H1W5&=SE*4$I+*TY-8FIZ8BMB=FPO45AU9%8P2T166'198FE3835T,DE:
M:DA#2EE166]Q;C1N9C!Y55@Y:VUI9S=98FUR-%!/+R8C>$$[-79Z43)5.$AK
M,D,T=#=Y0T\T.5584&]L4%5N0T9':6TT=7)E:BLX,S9D1'9T:7%,,&9Z3BMB
M<GEA64Y3.'%12D1D,T51=C56=30K5B8C>$$[=$)-6#5N9T]P9S1$>#5";#<Q
M;T91:V5T+VY.86%N338V3"ML3E!-<G@K:DTY=&)-:"MU0D9-5&]Z8S1V<7)"
M9U@K3&Q7=%)H5E(O>"8C>$$[,2MD,W Q2&M'37EE9TA+9EA9-F5R43%7=DQC
M8D0V9'8X<D%R,4="-5AG:F5A4#!P;5942D5'-6-723-8:TM6;V4K2W(X5F5C
M*U0O3"8C>$$[+VY73#AY.6,Q-UA.4'1,97EU-'!93&$V9V%S:VEP3D=,9FMO
M9'5S369X17%/9SDV<7-P,6)Z3F173W971VQ285)D6&-6-7@Y5%5),28C>$$[
M4#%E2&LO2#0R06)C9%17;C8V2W9$=CA!;DIB+T%*4VU(+W1J<"\Q1S5T9$(Y
M4'@O438S6&,O:"MK4$MR+W=$,V]N+S5I9%$O-4YR;28C>$$[6D@Y5&E3-6XS
M>2LU:VYL-SAW9DUN;&I65%!:6%5K;'-L,V5.3%EU-V5J2TEO>'=6=T0Y;&$W
M05I44$1'63,W9S-2>GEI9DLU9EDK<28C>$$[=DQ'=E<R=&%.85AI5%%V8WE7
M.$UL,T1#-&(P<$I%1$UJ045L84=O;V0X,#@T8TIP,G-4651824UN67$W1EA9
M<3=&6%EQ-T9867$W1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3@U,$\S:%@X.%!-8R\Q,D=36G1/:%5786@O5E)1
M<T9A<R8C>$$[,$%88EII1FY.3V%K<%4Q>%9L5W)E6DQI>#$R>#!U3%1P8G1,
M=W V;'I%2$MW:&Y+;'!09TLX4E0K8C5G0VA+<G=R+VY*<#)8>E1B."8C>$$[
M63)K<G!#5C0X9'8Y3C<X:75B5%$O5#AF,$]U,6\S*T@V43AP=C5(*W1823E*
M<4,T,4%H<7)1+W4Q,DAX5BLO37E**S1/2DEB+T=8,R8C>$$[3&(R850Q6E0V
M1#%.>F8Q5W%62#=T979X52LW1THR*U-Y1S4S-GDK-4]T33@R*UID0G4W<S90
M9%A.;'IU8C935#!N54I+,%51369*4R8C>$$[,4<T:VMJ:TM:6$M%6D1C6'-'
M=UI$16UJ,6PY>DU&+S5Y0R]-05=E;7)':V9/2T=56$QV2$<W5'1&8G!+2&LK
M26-A;'1W;$YV9DM0>28C>$$[:TQ/,S1T=2].4V]C=5@V3%1F5&8K8VPO37%,
M1#EF,%-#-%1I-U-.0S-P37=I:%=6=4Y88V9&>3=J66505$E3,%$S<3)C9%ED
M<D@T<28C>$$[,E4V9"]W035+*U8U=V]V9$EV-U=49VIY8U!1;5)1.%IL-BMP
M1U121G)S=55Y,%4K:F%.6$$O:GET:W1L*V-V:RLV=&9R1$=A,41,1R8C>$$[
M,$M84G0T5VQ%;W%O471.>$HT-S!*<FU*14=5-5%'-6IZ8FAM:E8S>E1R5"]!
M1'AO5V]T04Q+5DHQ;4-&;5,T=$0V9DUK2TA55&,K,28C>$$[9FA"<4]L8UIJ
M9RMR6FM*03AK>4=O6%IJ:V8X05)L>4=19TQ'5W1U5&<Q<58O9F-D<6(X:4U$
M2F5,-C5-<U-F;RLT0WE+0S!H83,T;R8C>$$[5"MY,S<S;%5F-4E)>%993E)V
M1$-Z+V]U-D1"9T)&>71E4D)"*TEF=G5.0E1U831Q=48Y9$=652]2,7=&6E%X
M;$Q7+T935C5C5"LY-28C>$$[5G(X3W=P6'949D96=C92=E!2.50Y1C-83&QX
M.4QL83AQ57)Y+W8X06I4=#%R-UEQ=DXW8RMS62]Q12]!3'E%,TM$9U1X-6-2
M*SDU5B8C>$$[<CA0,F%6-S S>%9:*VMB>C!22BMI-W)M5TLK:GET=5E!05!+
M=G)C84AP.7%V=&EQ.#-T>4I:12]2.#561DQ,2T=G-'512SA6+V4X<28C>$$[
M;G!U05!E;4MR1'%.-$E6:T=L,U)D:5%99S%T>55#;GA'<S-':'(R3TMR,G9R
M;U-Y;TY0=4=7345P24=T*TUL3WDQ;$1B+S511TMR1"8C>$$[<48S=VIB.4=8
M2DQK:&PU5S%5;V%68CDY5&8X07E38U981RMU9S!W+U(Q=U)&6&<S2S-P3%)Q
M9D(K.7%+:F8T*T\S=G1I<G9R.3%32"8C>$$[+V-B8R]V9G1J;&(O04QV-'%F
M2"LK.$XO:')T-S=9<3<V+V15;2\S1S-0-W(W0357+W=#."M+;G=F=G9$9C1Q
M8F4K,DMU1CED1F]2*R8C>$$[:G)G0U=N3G56=E-+<E4K4#DW53!'+W=C='9F
M8D97=C!H9#A:5"MJ3&US6D%2959T5U-P<%9F,S%.=79X57A6<U@Q,%I):T]N
M6$%7428C>$$[079)5W0K36144VHP;#5B9&9H0GA684Y2=D1%-R]O=39$2U%"
M2'ET=51!,7%W+V9C84-M.51I<3EB-C5-<4ED4'5!<G%'855T8CA52B8C>$$[
M1F5,56PU5DA4645E*TMR4#!J965I6E P6&1C=W=8,&56='I)24HU5CEB:E%D
M4'16.7-65D5V3&AR;$EJ67IP1W="3G=79S1+4W1E2B8C>$$[06M,,7(X3WEN
M9C(S>%8U+S54:'5)=GIH.'I09E@Q;$QF>E=Y:S)D<5I05E="1$-)1VM6-$)1
M*VY4:T)C3G4S,F0V-%9:-7%U<%172B8C>$$[<VA(85-86#%U-FIT;DU92D53
M=4=*;&5G4'=R>' Y3T)8:E U.653+TY7=F59;UHY2#!Y83EH1VU,05I)9T-"
M24QV,4].4U)V>#-Z628C>$$[85!,1TUD>C$O431/<GA3;'E(5#E)96189C57
M9FU(2DY+>6%$9$5.4&5/<#1J-TUY04EE=F-J36]A;D@S.7IJ>3 P-S5D6F9A
M,61F;"8C>$$[6BM98GEY<W5G,U)$5#-J9SA2.6U604506'52:4Y4:C<K-45T
M3D\K6%=8,G(U+WEU+TU&<%I76%%R;VAP<C5X.$DK>E!%1FI06#EO:B8C>$$[
M16%N2#,Y>51P-3-Y-GDK,$Q6+TMZ.'=H2$5$;TXQ5EDU,6(T4C%E,%-*92]D
M,4EX+TTT*R]W1$9R*U=N='0S+T%/-4%C=C579FU%228C>$$[-&=D0G5Q<DA/
M<F9#3W(R:5),,S=U<$=0-6Y(,R]I,2],5#(R-R\X06-G3DHK5FXU:&AP0V1"
M=7%.06E$-%(Y;U=J>$5D9C4R07@O328C>$$[-"LO.%=G86%F9# O,W1*='%N
M-6)E935T3#!Q2U!28FQP241B1UI1;W%V<%)"6#<Y:FUS,&-H2%!L:V55=51D
M4$1->&E+-55I4$MV-28C>$$[965E8DMA9#4Y2'594V9Q2E)U3SE926U6-E50
M-TQ(2T\R9C-O:'=B,%-N0FAL16UX+TXK-4].33AS9FU21G)L-5!,83,T9UHW
M37=S5R8C>$$[8VEI4FM454A,*V)R-#5J86E-:G X46HY435T<TE4-'E4>3):
M6F$V;BMB9'192D-,86534E="85-325-/45-X8F1Q.5!H<&U.:$]C128C>$$[
M06IA.2]C,UA*1BM84$Y8-7)J4C=9879O4FPQ075F<DUJ4CA+2UA98DQ'479W
M;T8K9&-Z9%AK;$A)4FIJ8TYT+W92:FQ0:$A%3C R<R8C>$$[4$\O;D9R=C9V
M9F558FQ)*TA,-C%%-$MC=5%(1&=26'!V5W5%4VPT66M2-G(K;CE,25-.,5-*
M2&YB6"]R4FDO=VYQ06I#8WA.5T]H828C>$$[=$]&4$AV-&94:$UJ-&9&6'%V
M-F5Q94DS>5I&6F%K3&U%>5!B6$9U4650<'EX<T<V1&-C95<R1TUR2$MM878X
M05=9+T(O=T1K5R\X028C>$$[5$I+-S9Z2#10+WE,9BMM2W%%,G)78TML<$)-
M<6IQ9E%N22]"36E:9TI)<$PR.#<K5FQ*0G9G0T-14C9C=E9E=C=08DLO=T%X
M1'99,B8C>$$[1DTK9G9+0VMG-FMG24Q!9W)*<U5&5T@R93-F0BM:>#DV.%%D
M+W=!<D$X;C!"+U-C9$15:C1:3W<U2#EN=TYC9GI/4'9#.%%5;V9Z228C>$$[
M.&M4339X871'-6I*5G=&:S)+:FMF,F5W,WEY95--041),7A#=V=40C9U:R]-
M;GE21DI(2$IQ,%-Y4R\S86Q:2VXT95@X=CA!3'9J1"8C>$$[2D=12D)S4C4K
M4VU9-S%8+T%"+S50,R\S2DIS050X36Y1<5=(-U X04M+-5@K6G@Y-%1X0C,K
M4"]!0V8O04Y82U Y:V9::R]B1E8O6B8C>$$[-VI(.'IJ-W=V14<P."ME55AD
M551555HS6E950EI.,FLS469:+V$W62]M8V9E;TYM9W(S2&TO>35B<6I46'%O
M<G-%46Q8,UDQ;U!S*R8C>$$[,D4V:4AE,C5-56]F54M85R]M>GDO8W=R3D)E
M0U-*>E)(5EAO5%5J*UAX0GA';V=E<5E92GE&9U=(4RMA+TPX4VAP3'A65FE!
M0U9F928C>$$[<' O3&=/<'AJ;5<R3VEZ2&Q%<&HY6FHX2"\U1G8O5$PS1F57
M5U9N9C-0.$%Z:TAQ5$QD4S)T=&%78V1Y,%%$1#8P=F]242MM5'=#;28C>$$[
M2DAL-55,;6HQ*TAE;TMS=#%R.'DO3&5J,SAL;F5E<TAI66\W;W%S0E%+5U!%
M3C9L1C5D95!J4W1$4G!75C1&9&ER<U9D:7)S5F1I<B8C>$$[<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U93:6)Y:#59;5HS:S!Y,UHU1UIN8F=!
M4WHO84Y2,V)V;$HP*TTY06IH0VPO9R8C>$$[9GEL440Y1G<P1F%B2'5/2C<K
M07!G+TLT*S5E14E#."],4'EL2F%8359L67A73GIC0G%835E9;%=C8U,S2&M!
M9F@R>5=F0TUK4D4Y0B8C>$$[43AM4$%'2#9R*U)5,#DQ85A.<G$V.')92&MK
M<TI!8CDQ-E%O5EIQ9&$Y36AG=V5(:FY'-S1X5%A,1%I"=FMT=69Y;#AW>%)S
M64IR928C>$$[-%IK0SA!>DEF9V=A269A1DYY,F$K5V=M3U9F9TUV1$Q$3E%S
M8FEW=C5B2S5!5V4S;719<%9"<4%Y>&M(8UIH5&E9;6HP<&=24S=49B8C>$$[
M*T]J6B]W1$U4668X47AJ>DAV:7IW+UA(,VAK6&UJ+V5+=R\U:6]V*UIM5WHU
M1#-U-S=9*VU0.$%7+U%I=DM0+T%"=V)(+VI)4"M4,"8C>$$[=4A&.4DO2&4S
M9&XO04YW4&1,-S-A-2]V1F(O-C9F.$%*=S56;BMK3S8P=C%N-"]C.6EZ<$AI
M6&U(:S=5-4Y3+TYN5S<T-EA&6E<X.28C>$$[=&-1,FPW6&Q.9&EW=5ER4U=4
M;7,W<'A$>#AA0T55*T@T=D5Q;E=V968O23)L-G)066%H05=U:7A.>31T=S9N
M9W-93'-X*S-X<7$W5B8C>$$[230Y2U5/2W-T=DE,>55,.5=U9G%X1F52-$Q*
M6'<K,3!W2W-A,C%!>7ES3#)K8F=I2U P;%!!;F]A+W15>%998E!64%1J56%H
M4C%*328C>$$[:BMI;GA!,&]+5C)P:7$T,G5O*W!-=W9A231):%0P;"]D:VM%
M1W8W5D)T=FEQ,S9P<6Y'269P1#1L2CE1*VEN>&ET4CAT='-68V)4528C>$$[
M+W=".2]P+S(O=T,V+V1*.$AX02M0>&)B8C1Q,DQ856<P2DXY54HO9D0P:R]E
M9D98+UDW8F)9<3$Y53%0:$M0<B]W051K96LS;W X028C>$$[0C-&2S<Q1TMR
M:&$V:C9K3$<Y<6E!0UI04U@Y-%%34V$O<S%',C)+<E):-G V8VEN54MU>$)J
M9C!5*T5#=%)3=3EC5EA#,3%$,5EM3B8C>$$[-U=.5D%L5#!L*TUJ<6$Y<31Q
M<T9N<3-O;%1Q3EI#=TEK.49.;$%.5G!8=G1I<3A7=7!E<7)F6'8S655";R]3
M6&1U3D,Q83DR,W!I<28C>$$[>C9N<79O.&8P:BLY-58Y5#!5*WI4-U!(-3DX
M5E90<3)O97-8*W4O=6ET0D8V4S=.>'!Y-61F=&9&5$9633)E<2MG12]32#<P
M35-:9B8C>$$[4E1D84-I.&$P-CDX5E9$8F%H-C!J0SEP1WEK2D@V4R]#>$9!
M,64Y1'941E9-,F5Q;4951V]5:T1%=$HV2V)G,&]+5C=9<79A,3%%>28C>$$[
M>7-T.7AJ8T@P:SE*1'=*-D=V96U+<F9Q97%C27@K:U!I56MY3C9+9D5$,$AT
M5$96>'1D4S5415@Q03EF4DAP3"LW*TMO-R]&='1V:28C>$$[<E@Q5%5Q42\V
M9'5N.3AF4U0Y-3A69D@T9'1T<U9D.54Q2VLS*VYB=B]C;C!K+V0O1EAX*TQB
M8F9&5WAA-FQY:$IV<6A+97-04U@Y-28C>$$[.%94,RM(8F)B1E5(8V58>F-2
M,TM4>7A33F-B0GIB>#AL0BLQ=C%.4G1826U%5'I#<TLQ:CAQ<G5057)+.#!E
M-#5)='A"2F0R-VA%428C>$$[2D)T*S<W-VIT;4)L,%<Y>#<P4FI59V9-2D8U
M,C!,5SE/=$Q/3S9U3U).-4-)-6QJ6&HP:TI!.&9T1$U84&I-2W-D6% W47IX
M>5%I428C>$$[97)V2TU&,RMH.5!B-GHK-T1G3DAW6&,K<DQV6$E9:4]%3UHR
M940T03DP=G9783-B,W<P-D)49#%C>5)K4#9A:6<Y4G1Q6EAN26]B3R8C>$$[
M-3!O4$5D+WA4,DY,92M&>6MJ6&9+04M!.%!P<4]2-#!R>39J9F9/:65-465M
M954O3#)M87!D-G)9,E-W6#DX5TYX34=C,35V-FHX5B8C>$$[66Q5-78X5&-!
M3U1B;F9&54IQ9FUF>5):,U9X6C9H9%=Q5"MO;C%Q2U)A+T=Y<45A5#133VEQ
M=DDK1D\R2W-H>%8R2W5X5C)+=7A6,B8C>$$[2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<&1R=6DR97(R3%%8
M15-34TM'83)A4W!#4R8C>$$[.%-&9F)W<FQE6$=*:6EG:3)#5W9L=2LP1WIT
M<DLU26M%8W%!5&]#15ES>G9T6'<U6G%J9T]/9UAE9&YY2&A#3C=G4RLY2V1C
M+W="-"8C>$$[<F8X03$P+S5/2$U44#E)9#-P9G)0>"LU-T9N4U!%=7A6:$]U
M6&8U5DQQ.3-:-G@Y52]35&Q8=7964FEW-4%)2WE5;W%N;V%%0W1A-R8C>$$[
M:S166G1G5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A61#-T:B8C>$$[8C-C45-:03-%
M.&]Y82]#,4M!-4-C0DEB=&U,3$M"<U!,+T].9V)!>#)H9C%$1S!8>&=5<GEF
M;# S.&,P5W-X.$=Z,6Y:=6)X3&Q66"8C>$$[8C%J3V=E4&1I<D=B,U(O>3AV
M8FPW:3=J,"MA-79Q17EV26AE5&)I06@U5F]E2C)866UV8VY#<DIS0W5X5C)+
M=7A6,DMU>%8R2W5X5B8C>$$[,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8U="M9,$UR86=75D=:955'-$))-UIP
M3S!1928C>$$[3#50561J4T%H.#-P3V)T-614=692*W)Y*W0O8SA'.5-L9G,P
M,S9B.5!$1EAK*W!F.'%F+T%%9F(O6%!R4')F5F\V,#E8,794-70Y=B8C>$$[
M:BLU-65P>2MZ,RMZ,G=O9759175X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>"8C>$$[5C)+=7A6,DMU
M>%8R2W5X5B\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP
M.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @
M(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%!O=V5R4&]I;G3"KB R,#$V
M/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@
M(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C
M.F9O<FUA=#X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA:&5S:"!4:&%N87!P
M86X\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+V1C.F-R96%T;W(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z
M<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP
M5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P
M87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*
M(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM
M<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DUA
M>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T1&EM.G<^.38P+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @
M/'-T1&EM.F@^-30P+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T
M1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @
M(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$YA;64^1VEL;%-A;G--5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D=I;&P@4V%N<R!-5#PO<W1&
M;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO
M;B Q+C8U/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^1TE,7U]?7U\N
M5%1&/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D=I
M;&Q386YS350M0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1F%M:6QY/D=I;&P@4V%N<R!-5#PO<W1&;G0Z9F]N
M=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O
M;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B Q+C8U/"]S
M=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^1TE,0E]?7U\N5%1&/"]S=$9N
M=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D-A;&EB<FDM0F]L
M9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP
M93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/E9E<G-I;VX@-BXR,SPO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9I;&5.86UE/F-A;&EB<FEB+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G
M/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0
M;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE
M;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!4
M4&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R
M;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \
M+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'
M<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D9$0T$V
M03DY-C0Q045$,3$X.3!&1C<P13!"-#$X.3<W/"]X;7!-33I$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D9$0T$V03DY
M-C0Q045$,3$X.3!&1C<P13!"-#$X.3<W/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,30Y
M1# R138V,C%!140Q,4$U03%#0C$P0C8W,#4Q-CD\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E
M9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ
M1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" \<W12968Z:6YS=&%N8V5)1#YU=6ED.C=A8S<Q-&(Y+31F,&,M-&1D
M-BTX,#DV+3@X-C,R86-E8C0S9#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HQ-#E$,#)%-C8R,4%%
M1#$Q035!,4-",3!"-C<P-3$V.3PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C$T.40P
M,D4V-C(Q045$,3%!-4$Q0T(Q,$(V-S U,38Y/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD
M969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$T.40P,D4V-C(Q045$,3%!
M-4$Q0T(Q,$(V-S U,38Y/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 X+3$R5#(R.C0Y.C$X*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#I&1$-!-D$Y.38T,4%%1#$Q.#DP1D8W,$4P0C0Q.#DW
M-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R,BTP."TQ,E0R,SHP,SHQ,RLP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MYI:KP@!K'Y$M8(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MJJAX-X;2=7J'5Z[J\5)T]WK>KI;_ ,3.>KCSQC@67RT%W& , 8 P!@# & ,
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M^C)XA_5TX_C:59R_M]Y8:[ZW'W>B=,[!^2.A^JS]XKFS/,0,N& , 8 P!@#
M& , 8 P!@# & , 8 P#H)UQ_^;\<?KPM/_<\E^#TO^P^:/\ $CNK\S_F><K_
M +-5Z_E=*<'GCS7I7VG4Y]QP?LIV@7](>-'W;>>#[5^<?0_M-BWNJ;Z*Q=]H
M>GOZF6X*:/QUZ&1)P=Y?(N"_N8>M>1W5)B)5%JSO!CK%,H\L>W"UIIR1MR*U
MZ2%*/6]KDZ"2.J-]>$Q81#U'VAW4B\!2<TP 2CO56N^7'T=IUD^QW[0CB/PA
M8>7"[E30UY<@)3RJA@JC<ET*;8FY-@*E>R'L=DLSFZRF5,KBK<; >'- -[V
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MG\C8+@^4N;]+^TNG@@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M9QK4_M*G_/+^)G8E/^SI_P#)'^%')Y05C & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!I^[
M8#]V]/?TW??N$&<Z?TB_D/9SVK<^Z';/]"?RIVW]@:?^(R-4O#CYTM$?6/'_
M .TYH#HW\O-E/;5G_&=A].']T72'^Z^I?='::MI]E\7JJS9+7S"&53Z.U],W
MV$1@19IH9'+VB..3A&F$11 RSS O#TG1-^RR3"S1Z4;"6,(]Z%K]"C\8US6>
M7::P>'U8<=GVEN/?,-]Y)73:=QS-BA\RD]G+>5%O)$-@6B]M)"R3U4*BVZQ&
MZG4B!/(5+A#VR@D=;)@1=4@2L93*3*VXUR$*FVFUA)=V$W].,OAV^EK@R/7K
MM4+AC-10VXGFF*:7,_(#C/*^3''EAB-R/TC?F5GB[C6(?9.]0:@")*T&K6BU
M&8ERE\%-D3-&9TVN<%/0.PSF9]=',G=7++RFD^'#CW?/G&<97'O2F%CYN<D6
MBY%=>V75])AC$0Y>,'$";OT'FTY5/KA)K&XU1ODS!9M%F9^BB- E8&-EFT2A
M4J:W9W4.3P[&R"0M)S,B:&]G?A3A<./-9^O'UX?9_,J0^]H#?%R4'0)<_B<+
MK*2<@F;LU.6D!?Z.LF7N"IHK*S^>W$*&2VM;*;G=@CSG'W)V9[, RI53:]/L
M<L9B#8;,<D0)X\M)=Q4XI-K.<.2XK')/BN+_ -.'>9Y*.T^Y.KZ8Y$W+ ^/L
M';(3$H/R)>*KELO>I.!''9)0=I)JZ,9+21] @#(7B5-!4FEAC-!U"8$!?8P.
M!RER6%N14N($87!9>7CZ^/U</3GS<9_-YO<D47)(RA2Z,A4R)J]XX\1B_'R'
M/LH*T6KO]R G/FE?JWYL1M"&$5HUK4CDK*EZKURPW)EG,3C1+6_QYL)D8C"[
M7C*;7I79\_+S93*N=KJMO!5>L 8J7C5N3EW:>!_,VR6UAJCD39E#.4(F,4LK
MBNS1F]2&^MG!.NMQ[JDF5NRMNJP] [J)BA=W9G;&UQ7*26M=#_)_EVKN_,JC
MC#SCG'FD_P#]NU\OUW%@U?:!V9[X]>5M2$(8>2D/8:*XLV_8ULHERYC6V?#>
M0+_(8V985<$)4>HE&V=@8X8]3XY7+'$MMDSJI][M!J-K$"E_#)#6$\Y3RTDN
MQK&<\<]O_DX(':&<CECL[5Q[UM,16\5W*&O*8C==3)^L@A,QUI:)-ZN$!MA[
ME#7&U;#/XA.V:F1K89-*N7NK.M=S9A$7]HC4B@RY(O#=[<\,9[..,<.?/CCZ
M.\][+VE-Q6(CD+77%04@US6G:QNBT+M'9MZ/;%6[NCH^^[<X^/C;1TX:ZT7G
MRMA>I%2LJD:NQ9*PL#97["_0%/)(\O<I,H*9PQW]O!8]">7S[UP7T]_,0SM'
M+,G=A-CJT51#6Z@EU]\7Z-V;(9#)&ZZ"U/*?BK3_ "$CKZL8 LAT3:MP5YME
MLC$A:3G=6I>$('!2F.9%;(45(A+BDN+XXSYN$G'TO..'!$;M/:=7^OCT(A3E
M2D!8N3T[O)PJERJP\VRG%'41*&G7VYTY4@VD8"]VTKE3"QZU6<PJA[40&QHT
MJ=9PWN;4.(/D.&(PN]XQGLX^-COX<._MX&W"D9W([.J*N+ F,)45M+Y9$65X
ME=?J7=%(#8;)5*,OUZ-A?6\!25Y(:74*M&E<P)T1BY,42I4-[<H--0IQ22E@
M# & , 8 P"-KF.?T]/VLHBHG0$H(K:='1L3&%2)Z"_E1=T&SB9PHM"6"=-.(
M4^V\*0(E.U>B=$:V;L&L$KFL\LK)J5Y S2[6M97*"GWOD\EY$'<*; E,B\MK
MN>3U>_2H=!R=IK:MFZ,GLCI2;;?#A;@P6CN72$#;+VPR HH3)WDQELUA8E(G
MAE\L9[\=OFXXQP^?*Y%\N%BR2+*ZG.UJRTW*O$]P3-+1;K=FK"%:3E4I:*/B
M3J92HMLHFT5I1<],GJ.*N$\ )\7PA+&58#U34:VJCA#^;EQQC&?FX<L?.4&]
MT+?1CV=]850?CIMS8G1;Y86?JM_[M,UYTH>2-WZU8^\0.D#(_F1TY]JCDI^4
MG%#.BZ7E#?\ L;2??M:.>JOD]8>V=6]QT4\N47ZEQD^RK6GW_.<IT7XVL>V[
MW[NW&L?%TCV-9_>7!_4C9?\ $S3_  Q!_92LXUJ?VE3_ )Y?Q,[$I_V=/_DC
M_"CD\H*Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , KMR)XQUYR;98ZQ6$NE*%'&'14[-P
MXLY-S:H&J6)-(S0JAN+.\ -)T5K6P +*)'H?P[,%KXN8=MCL/H^W%K9VFL5;
M^G2L:]2XHNQKT:$W4J4^JEUCK6]PI14>2BHO/%M\C9O1ETL;3=%%_J>H[,V^
MD7%?5K2C974=7M;FZI1I4:W7P=&-K>V4H5-]M2<ISBX\%%/B0'7'9KT!5\[B
MMAQUZLX]]A[RD?6HEUD,?4MIBQ$/QDA6ITT21GFI]B_OP%*B!BU_,8',2T;H
M4V0T+5;#6+*XUR5WIUS3N[>->\M)T75I/,55A"PIRE!OFHS@WV21L;:C^E/T
MC[6[/:QLSJ=ALG3T_6[&MI]Y.STS4J5U&A7CNS="I5UFO3A4Q\64Z-2*[8LV
M"YMXYL*\HN(O%)LM8Z]V[C+Q_07<H<#G8^X$=.5XEL\YV4>/J'8R>$QT$H&Z
MJ=#&%0Y;=-K3PBV$T\8>[6"<O&,O'=EX^@^EDXI<78VLL)QCW&^AF)?;8MBM
M18T5#7[<ILK8G'U<7MZ>DCY)DNT)WV)V&%_$O")T$-Q%K:T8SQ!E\.+X<N/+
MT=QGRVJZT7+')S/KZ#&/#M,$%C+WDV(L!KHLL9HBC?!&:P5:X:#:I5-F>%-#
M1$&N5''#?4$7:FV/I' EI0I4A0C+[_-\W=];^DK5Q5X%<<>*U 5Y1D:JFI'<
M<7B%,-$ZFI51P>/.MOSFD4S IB5K3I&B;U>W2;(IC'TL_9G9U<'EUCLNV![;
M';3L2%Q$*G)MMY?%OMY9YKT=A+A?%GC(3++#GI7'6BRYQ;K*\1NUID"I8$&4
MV9'9"643(&&?O^F#3K,69^)((*>FR0JG%$[%D$ 7D* DEZ"(R\)9>%R6>"]'
M<<2CX=\26YSK-Z0<7N/*)YI=.4EI]W2TQ7)#I5B9.\*I$017;@7' JX861(%
MRU^)!'3F[13VM5NQ?A7J3U!@9?'B^//B^/I)N.B<542ING2B,Q\^;,[ \Q1I
MF)S,W&RIKBTB<6)WD$:;I"-,)W1,#Z[1>-.CRS)EA3<YN,=8EJU,>I:4!J<1
M^OU]+(:<>(_%-X4U^L=>,O'YR5U.M6N-7*5]-UTK.K=P<7TR4N"V"&'QP8XD
MJ72<XV2JU##M :HD!@GHX0W/?58)R^/%\>?'GZ>\A>V.SHXKV6W1AA04K2<*
MC!%_Q6_K1B[)2U?^@W<]1=BG#.0V60V$-C>AD!BA1.%KN%Z>T[TJ2+B3#2DX
MCEQYX04FNU\L+B^'+^1-TIXG\6IQ'Z]B<TXVT++8K4@2@57&I+4%?OD?K4LD
M*8!14"9G./*6Z($EA1(@A)8$S>5K2-)KP?R8GP!EKDVL\^)(2BJJO5KG%S55
MO 5+D[S"/V$[."B'QXY<YSZ)LC3&8M.'%68W"4+9A&HVP,4?C\F4F&O3,R,K
M2TMRU,@;4:<D01.7PRX@$UZ]U&5Q6XY%55)9&GF,BK4JDZV+@3Y+4A11".4.
MT1!&M,#A(41"=.G1O*IO-<4B<@@A,H*))+ $3EYSEY[\O)/,9C$;A<>98C#H
M\QQ.*1IL1LL=C$9:4##'F!F;B )6]I965K3I6UJ;$"8LM.C0(4Q"5*06 D@H
M!80AT(.<P!@# & :S>3?:%R^L[)?J)XJ\/+PYOWA#2FDVQ&FOE+)6U15>H?F
M=!(F2/6%>T] &(-,U>8X[-4C;X>SHY [%L#@D<W<#22L;]+14HY67)179G+;
M^99/5QF[0^8V194?HGE?PYO#@]=<T Z;KEOGZMCLRGK/6,K2ND#O&H%>\"+]
MD7"<-D?:G60*H@](H^YGLC>J7,^W;IEA24'%+BI*2[>QKYGA_.N!LWP4C &
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MCE+7A**]WHSB_&'&/U!84?KF A8)_*4?'&2(:;4AL=["R3-ODZE$_7Z^WO\
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MT92KY?4ZQRX*TE+:(JU,Z!KZMS#4,GBLR:69R=)^!(:C4+Y G3&(5$=41IN
M>(]L4%EB)YSQ4D\?[SWGS?;A</,;G,% P!@&D7W0M]&/9WUA5!^.FW-B=%OE
MA9^JW_NTS7O2AY(W?K5C[Q Z0,C^9'3GVJ.2GY2<4,Z+I>4-_P"QM)]^UHYZ
MJ^3UA[9U;W'13RY1?J7&3[*M:??\YRG1?C:Q[;O?N[<:Q\72/8UG]Y<%JG/Z
M7/D']I3F)_7W!ED7D)I?L?0/X; O4O+C4_:^O?Q7Y>'W,7\_&VOLF3C\WJ-S
M'NF'R:L?;=M[CJ)D'1%Y2WGL2Z]^TT[U><W'1HP!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MXZ-& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M::333364UQ33Y-/M3//()& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MY"O!;95>[N"9BHLJ]]V;NVRJEVBC^DX9?JZA"MTL.Y]J?&14JQ-ZD)4''&
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MWS4X<:WO6^6G&;6]?!O6[XJSOUO_ ,-__=6!A]S^ADB32]:0K=JCC[8=R55
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MI0:60048:,(=AA]S^AF13OD=QZJU]U%[-OBF:ZDNT2=RU'9W:$(B+[MN5B-
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MO.JV-D]0V?;L[5NKK%SUK=O1;J9T'6YOK'N>/F<5-[V?&2ES29:M*O[Y:?M
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MAM5UO$GLLDY,6\1F#QAA=0)U =!4)P.#4UI%823PZT$XH)VBS0ZUH81:UK6
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M+DNSEH(G9EAV40]!AJT2M8KL&+5C%U36:EVLT24F;2:R1JTZ@!@C3S75268
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M2M%4V-VFE.ZM(W4J<;:2G;N=:O25"M&5%.-5*BJCBTO$J0?)Y?QJ:I4AN?\
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MM.4F\KEPPG%-)8Y8YMK@^"9VN\D^0P!@# & , 8 P!@# & , 8 P!@# & ,
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MR/\ 68\7?G4X\.+WIRX]V%V&3?\ 9E\9??7+N7R9[[9ER@F7A%[6!]+]8(4
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#7
M_*>+A,";;!L8,V,=!IXK/U7I H\%&$?K<>>46P==I[5;#TWJ'FZ%T@O-\KP;
M"7YGC!J6]V%6E4=6UCX4==T[#5ZBM_ U2SX397-+#J^%5/B*LY9ZOQG''BYX
M=(:3TN3VBNMF]F'H$;-5=8V;I>&K4W7<? -3L:^]X/X!13ZWP;=QUZW-_>S/
M=PZ5LO[OIU_&(3_MDN:UMODG4_6--_[PWO?>4FS_ *EKWV:65 Y9_L=3G\3L
M_P#X"S6W2)\G;-_Y^N_9I!NOH:^7=N?4]D?MVD.P=Q+^;'0GU40C[A1YU[T?
M>0VR7[OZ7[I2/S8Z9?[V.D7]\=?_ !&N6%S,#6@P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , XI\96V1LSHP
M/!&U34\H5+:XI@G')]GHU90B5!6CTYA1Y6QEC$'S"3"S =_> 81:UO7PNK:C
M>6U>TN(;]"YI3HUH*4H.5.I%PG'>@XRCF+:S&2:YIIGLT^_NM+OK34;*HJ-Y
M8W%*ZMJKA3J*G7H352G-TZL9TYJ,HI[LX2B^33113DE4%?UE4ZI7"V0QI/=I
M5'4Z\8W5W<='%)DSV82'07)<K"5X!FCWXBM $+O[A;%K6M:U9MGL[I&B:#.I
MIMM*A.O?V<*K=>XK;T80N916*U6HHX;;S%)OM.A.BW;;:3:O;&E1UV_C>4[/
M2-3JV\8V=E;;DZM6PA-MVMO1E/,816)N26,I)MFFSEG^QU.?Q.S_ /@+.;.D
M3Y.V;_S]=^S2#N+H:^7=N?4]D?MVD.P=Q+^;'0GU40C[A1YU[T?>0VR7[OZ7
M[I2/S8Z9?[V.D7]\=?\ Q&N6%S,#6@P!@# ,.L5=*FNOITYP5N*=YNW0Z3KH
M<TGZ\1#I*DC(N41YN.#XR_$4M=RT:8S7C!W@-%KQA_GT!UT'RO.8DPFC5,ZK
M%><IADFI& N),@97&=MKY.:F>^(T76S]V9+7]\!LKI$[SNVE<L:6FDBX(T7D
MDOEU2<AB;<;8)HN,IQ6L<O.O1S[GSX9XOAC":R;%N&!5G1>X5$/6(IVTUP[5
MK<DQ1PZPE3ZHD=>0??*25D<3TCL@D2Q:[QURE=7.UFD)69Y,*DC9"H#"(;(D
MR!; RVAK?K]?K@4O'FX87U<?H:^OF;2L$# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P"I?,_P#<^1_3!D_L;OF =)'D]#VC
M;?=7!N7H+\MJGL2_^_LC1!RS_8ZG/XG9_P#P%G*/2)\G;-_Y^N_9I!^AO0U\
MN[<^I[(_;M(=@[B7\V.A/JHA'W"CSKWH^\AMDOW?TOW2D?FQTR_WL=(O[XZ_
M^(URPN9@:T& , 8 P#YDB)&WD:2H$B9$F"8><%.D(*3$:-5'FJE)NBB0 +T8
MI5''*3QZ#XCCS33C-B,,$+8 I$C)4JEI*1,4L6A("M5E$%%J584H1@2A5'@!
MHU0%, PP!&C1CT2$8PE^'0A:V!]. , 8 P!@# & , 8 P!@# & , 8 P!@#
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MTO5=IM8O["ZC3K45<6ES>UJM"LJ5Q3I5Z:J4Y1DH5:5.I'.)1B^!,V9*8,,
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g383050g23a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g23a01.jpg
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M ?_$ !\  0 " 00# 0             &!P@$!0D* 0(#"__$ &<0  $$ @(
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M*H$)2K7;BHQ(Q),&,2264$DDM9))XDGB37QY/O%V3/FI3=+BE*9<D)2)LD
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ME*FY#+B5QUJ<2EP:N(TG'3SK/M=;[Q;K*_>'C)N:D(BOM72:Y$WBGEQUMK>
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MI@:C,F>IF"UD@I3)M2[4>=!FP1'1ZJ_I5)*R=2$E*@0I)4X0<D*R,K)1@I&
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ME 2E*,)  SWH25*X$DDY4LDY)\ P*E#"4K#A4M:\J45*T]\5)2CDE( "4I
M2!QR3DDYR_Y9J_4QAW]4O/\  )_]YGFUM7[H[_,3_>K1WS]R8_I%?W:G_-W7
M-U^4;=G]>:W/\IT]_P!:BW/N2W?O?!_J<7_H(KXKN/[X3OZY*_ZZZM3IC=<
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MXVJ4DA6I#JBI2%DFH],O$UKZ65:7BKFLK-W)SR$=/ZXED,:6*Q 5E78+JF;
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M(8[:M4T\ \Z#D+5G&./'K*N1R,A2BH'F"200:@L-$8*!C.1C(P=(1P(((!2
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M_P"DYTL/$N(XY*CWQ4.%%;(=D%3R)"KA$+S<B7*0YTI.I,B>T&);HQ%QJ?9
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M:GLH9^#V7YJC^AQT>/\  ,_1(_5ITN7]\R/IG/UJ>RAGX/9?FJ/Z''1X_P
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M_6I[*&?@]E^:H_H<='C_  #/T2/U:=+E_?,CZ9S]:GLH9^#V7YJC^AQT>/\
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M-&XMC'V#79JN2G3UY. .6."<X\/'CQ.?Q5+CFO& 0 I:N*M1*ED%1S@8' 8
M'#B22235LQOK%8==]+$NL54WKB#VMK BP#/8[:N]3+QO8,S*OI!8UKC:ZWFP
M])J?D$C/RF2 A[J:D4(V<*,7;YW)T1B[8H"2$Z0>..>.L\SCY^./MJ"L%>LI
MR,YTYZAP2DG'(  ' !(Y8YC>^D/6DKU ZS5MUV+3\79RE<-"@YK,A->M*S3+
M,WQ=\6T<D8XUDDN4<R%TN^</I/)B,B)EY;(G921E%M7I)9/0D:4@9SCKQC/'
MP?:>OF>-0M6M15C&>K.>K'/_ #CE66/*JIIQ2G%*<4IQ2G%*<4K4(?\ Q_\
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M[F0VWH3[6CW*?XJ? /DKX^N-ZO*;A.2F[7-*4S)02D3Y0  ?6   [@ #@ .
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M]]"5BX6Y(6$.K4D*"5*2% 9 4H9P37?,Y\O5[Y3BE.*4XI3BE5)?W]8BZ_\
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M\Z--I:+!XC\P'R=!5N5::Z+L',CB-_WA U1KRB[-J;M^EME3C%O:F--PM[T
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M*DO,-M34:6$K::<RI+J5-K5,E>LO6Q--Q&H7"76]?6%X:$B[!O;8D<]A=@*
MKHK>GHE;.2457"QH3)Z\>B;/5*TS84:(EG0N7>ZG00S #"@,>DVQA>KN2'I$
ME/2XFV3-I3!9BR(@=MTRX/P E]+CSC,M+D((N,5Y*$K8W&\4\M#JR;QM%H&6
M6(ZNBRMD7;FJ<])CR2W<(L!B;K8+;+;T4HF%=OE-+6I#^^W:6D+:2$\'O/2:
M\[IQ2G%*[&7U,Y_TU[8_S<9%_M!KOGDO9C_@U"_MAC_"3*]F[#G_ (Z^?U.)
M_P!=RN\=SYIKWJG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*V*4?\V9%_B(O_Y>XY=8_=V?Z5O^^FI3
MS'SC[:_)Q._\N&?\:D?_ !:W/NE'N$_S4_8*^*[E^^,_^NRO^NY6U<JK"IQ2
MG%*<4IQ2N1KJ57U>*]?;=MF01^,2^4L^Q/4VE=VTI%C#(^ 5K9D@FTFF\UPQ
M,(NA[9[('-<@X"VD"B&BX449D35JY0<&DUD>1OTJ6+K @-.OQV56B^W$%A:V
MURYL-F,Q&C:FRE92TF8[++040ZXTRI22EH@]78XL4VR=.=:9D/)NMDMY2\A"
MTQ8DQV0](DZ5@I"G3$;BI=(RVAQX)4"X".5"\ZV\,XP.\1>P(,QJR#.81:M/
M57(*@4U&YQ$AL<[>P8!([JZU'8^(,F6$%M.G\FTY<&K\&0+PHDU.L6 XM&#4
M>:[\5;)FV+:]D8DE4V4),"XSFIX*_;UO;/RG6;;>&G7&VU2H-PW1CN2G$-R4
M*:4I;;[3RAV=RA[(K3M5)CHAQC&FP(;L Z 6$,WV*T[<+0XTVMQ,:;!+@?;B
MMJ7'6%I2A;+K2:XA^S@#H\K-*A&==)GL&AA-\2:VU*&2EMS]S&1ZI  DR+MP
M-D5O4#LDY9#E#KMN(!.W6A55#5L^)!LY:K+=Y9G=I!'GKN\;>2$)0J RH0(J
M7EA#I4V78<R>E"5+#25..I!0%:D(<PH#AKPULX9$!%JD;N.M2TSGTF=*+*"I
MH)6&I<. I92@N*#;14%D84MO@3DATHIRF<]IZV'U#8U2=F8 58EY-<P[L#U^
M QG:"U1$G\:-%P:(:X)*8KW-NV0FD1@,45A\JD20)V68D&TV%:O"3^/ZC:.X
M7#M),7/B3[-+;6VS;E6JZN/=*G2$/M-N%R RW+-OADHER!(CLEU+:D*C+TH0
M[M]GK?;^W41$"7!O$5Q+CMP3<[6VST:$PMEQQM+<]Y<7ITL!<9@L/.AHK"A(
M1J6INKY>-@M?=9'TN85G5HNX8?XELZ$Z0THUAUDOV$"CM=@R#"M"KO;8UI.Z
MQ829)T+RELY*120NL.W*"KO=[LLIFQUR9=Y3'5-FK@2-CHKG2&U/Q$KDO2W4
M*F-I&[Z+-6R4KR$H?9&E)"=  PGT1HMG4^F'"1/8VODM]'6EB6M$9J(VI,-:
MO;.DPTO!2,96RZK44DE630G?&JX/27<'L!5U;I99PJ)S]ZV!AMG>[[>+)D&;
M(P]A*CQ7=1PY5@Q(B\AZJSM11[NH$VV>J;N\K;YV>S$Z3<MG[5-F'5)?BI+K
M@3I#Y0I3:9(2  D2D(3( 2 D!WO0$X%:S:6%&MU^ND.(-,=B4H-MZBHLA:4N
M*CE1XDQEK4P2K*LM]\2K-8D<WU:.G%*<4IQ2G%*YX/J='_K%6?\ D5LW_P!!
MYYEV6OX(N?VC"^UVO6.P_P#PAN7]AO?_ %&VUWX.?+E?1%.*4XI3BE.*5!+3
MCC^8UC8T1%J-DB<J@<OC@Y5ZHHDS3?G(^0&,U':J*2ZJ;;1PZ3V742064T2Q
MOMHDIMC&F<J$^B+-B2G HMQI4=]P( *RAEU#BPD$I!44I.D$@$X!(YU*>8^<
M?;72.S]3>=T,YS_[T.O'[^?_ .XYY^S[GT@>R_LZ23T"]<>/[A!Z_P#]0KY_
M[D$SQ] ^JR_-7CWMYW0^%#KQ\HYY^S[CNO;._>%Z^@@^L*=R&9X^@?59?FI[
MV\[H?"AUX^4<\_9]QW7MG?O"]?00?6%.Y#,\?0/JLOS5*H1]3Z=_*VE86<06
M[:&C4KCSK9V(,CI-.=7#915!9HZ1435KM5L\8$&+AT.*#'R#D<5&.W8PDU=,
M';ANK9D]E;9:6PY&DVN\/,.I"7&UL0<* 4%)((N *5(6E*T+20MM:4K0I*TI
M(O1^Q3<XC[<F-M%"9?:5J;<1%EY!(*2""DA25))2M"@4+0I2%I4E1!B^_P!3
M?=T5-]]]K/Z[8VWVVWSC203E/3&=LYSG&B:=>ZIIZXSG]SIIKKIKCR:ZZXUQ
MC&+W=>V=^\+U]#!/VW"K)[$,PDGM] X\>$26!^()P/F'"O7WMYW0^%#KQ\HY
MY^S[CNO;._>%Z^@@^L*=R&9X^@?59?FI[V\[H?"AUX^4<\_9]QW7MG?O"]?0
M0?6%.Y#,\?0/JLOS5-('X 'B"5B8?GX'=]!QLP3B\NA3]\S/S)55S%IY&R<0
MEP??5Y6[E+#<W&S),4YWT3U<)H.U-VRR"^J:VF/*[*>RLQM+4JUWAYM#\>2A
M*F88"7XKR)$=P:;BDY:>;0XD9P2D!0(R#D1NQ7=(;BG8VT<)EQ;+\=2DQ)1)
M9DM+8?;[Y)&'&G%H40,@*."#@U"_>WG=#X4.O'RCGG[/N9'=>V=^\+U]!!]8
M5C]R&9X^@?59?FI[V\[H?"AUX^4<\_9]QW7MG?O"]?00?6%.Y#,\?0/JLOS4
M][>=T/A0Z\?*.>?L^X[KVSOWA>OH(/K"G<AF>/H'U67YJ>]O.Z'PH=>/E'//
MV?<=U[9W[PO7T$'UA3N0S/'T#ZK+\U/>WG=#X4.O'RCGG[/N.Z]L[]X7KZ"#
MZPIW(9GCZ!]5E^:I8"^I]N_L8 3&,1^[*$#A+!'# \T9L9'-D-I&%$&&L@8A
M2+S6N?7E NIT>,,N1&CG0:_*" SY^V<N0XQ1I8=[*NRSSL=YVUWAQV(M;D=2
MF(1#+CC:FE.(3VQTAS=+6V'"DK0VXZA"DI<<"K[?8IN;+4AEK:*$VW*0AN0E
M,64"ZVVXEU+:U:=1;WJ4.%L*"%+;;4I*E-H*8G[V\[H?"AUX^4<\_9]R_P!U
M[9W[PO7T$'UA5CN0S/'T#ZK+\U/>WG=#X4.O'RCGG[/N.Z]L[]X7KZ"#ZPIW
M(9GCZ!]5E^:GO;SNA\*'7CY1SS]GW'=>V=^\+U]!!]84[D,SQ] ^JR_-7+-X
M//A,]@NA_8N;VI:TPJN0QZ1U&7A#1K!R\E?%42SV51(R@LN@9BP5MAEZJ%>:
M**Z.]U=%LH:X0WU4VW3X7L@;>6G:>T1K?!C7!EYN>W**I;49#9;;8?:4 693
MZM>IY& 4@$:CJR #W6P^Q;^RK]P>=N,::)C+#(2PT\T6RVXM>I6] "@<XX<0
M>==D?GC]>BTXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI6V&FBI ,68([::K/1C]HELKG;5/55RU513V
M4VUUWVQIC??&=\ZZ;[8U\N<:[9\F,UMJ"'&UG.$+0HXYX2H$XS@9P.'$5(X$
M'P$5T<2/U.+W.>$'[O6S>O.FKIXZ<ZZ;2.=YVTU77W5QKMG%?>3.=<;>3.<?
M<SG'EQ]SGTJCLO;.Z4_Z!>O<C_40? /#< ?Q@&O!Y?8FF/RI+XOD%(>D/.A)
MBRR4AQQ2PDD#!(S@D<,\JT?O;SNA\*'7CY1SS]GW*NZ]L[]X7KZ"#ZPK'[D,
MSQ] ^JR_-3WMYW0^%#KQ\HYY^S[CNO;._>%Z^@@^L*=R&9X^@?59?FI[V\[H
M?"AUX^4<\_9]QW7MG?O"]?00?6%.Y#,\?0/JLOS4][>=T/A0Z\?*.>?L^X[K
MVSOWA>OH(/K"G<AF>/H'U67YJ>]O.Z'PH=>/E'//V?<=U[9W[PO7T$'UA3N0
MS/'T#ZK+\U2R.?4^W?V)"Y@$CMVT(-#3\ G&)H(3D4V7&20&@7&GVC(HP=5R
MNU7R/.AQ9D6[]%J]%%&#5^.<M726JN+#W95V6?7'==M=X6Y%=+T9PL0@METM
MK:4I"TW$*&MIQ;;B<Z7&UJ0L*2<5?:[%-S80^VUM'"0W*:#,A BRRAYL+0ZE
M*TE)2=+C:'$'&I"TI4@A0S43][>=T/A0Z\?*.>?L^Y?[KVSOWA>OH(/K"K'<
MAF>/H'U67YJ>]O.Z'PH=>/E'//V?<=U[9W[PO7T$'UA3N0S/'T#ZK+\U/>WG
M=#X4.O'RCGG[/N.Z]L[]X7KZ"#ZPIW(9GCZ!]5E^:M\C'U/!WIATC RV.6WU
MV'R",&!I\&_V,2]]AB7$/$7XYYAF1K9VQ<;M'C=%?1)VU70VW3U](EOKY<9M
MO=EG9F0RZP];KTMIYM;3J-U#3J;<24K3J1<4J 4DD$I4#@\#5QGL37".\T^U
MM! 2ZRXAUM1AR5:7$*"D*TK0I)TJ ("DD9'$5HRWU.EWD/%29TY<-#&#1H@]
M+&"Y26V&_)E2A%RH\($2+YU E7+Q\^=K+.7;MPJHNX<*J++*;J;[;9J1V6]F
MFD(;;MMX;;;0EMMM$> E"$(2$H0A*9X"4I2 E*0 $@   "J5]B2>ZM;CFT,)
MQQQ2EN+7&F*6M:R5*6M2@2I2E$E2B22223DUM_O;SNA\*'7CY1SS]GW*NZ]L
M[]X7KZ"#ZPJGN0S/'T#ZK+\U/>WG=#X4.O'RCGG[/N.Z]L[]X7KZ"#ZPIW(9
MGCZ!]5E^:GO;SNA\*'7CY1SS]GW'=>V=^\+U]!!]84[D,SQ] ^JR_-3WMYW0
M^%#KQ\HYY^S[CNO;._>%Z^@@^L*=R&9X^@?59?FI[V\[H?"AUX^4<\_9]QW7
MMG?O"]?00?6%.Y#,\?0/JLOS5R9>$WX//8[I'VR;7;9LTJ,_%TZ\F4548PTS
M*7AK#T]J-]37T;EXD(:;MD]F>VKC.7NJFF-]=M-%,XSKSC=N^R#9]H[$;9#B
MW)E]<N.\E<IJ,EK2SK*DE3,MY040<CO,'&"179[$;"R-E[E+GNW*--2_;EQ
MTRR^VI)7*B/;PET!)2 P4D#CE8/(&NSWSQ>O3*<4IQ2G%*<4KYK?TI7_  >_
M^CGE*_<*_FJ^PU*>8^<?;5=\V5:ZL7Y[W(Z\U?;DAI:?3QO&)=#Z#DW9:7O"
M;)XE%8M4T2*HBC!8Y)M4MAK(KKC=T5;1WTFYER"&$"Z;3U--%1>"H X)XX*C
M\@'7500H@* R"H('AU$9 QSXU2\V\2[KW6<1%SJR(QV"@,9--Y6:&.IA0=C
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MX]Z,#. <ZE'YN X9.">&0*QILGJIVBF87M#&WE330W?EGV/8+*&=NG5^"5(
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M-71,+#HO#(VG3S&>-@,^+M)>-*RB2;0@"G,BDN,D71D= 1C3QXC!)\.!@ >
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M/C5B1&C2VRU*CL26CS;D--O-GYT.)4D_BKC4N'P4/#:N/UIR\ZZAZ[,.?/\
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MQRD:D"5K71:Q#)&!:G+QD8(]M:U02>CI<%$O)I;<H-5?$%H5,#RP>'UF4BX
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MQE4/XIU9G=!4' J]UDTBCGNGLF]%K<^N%,I!9,ME9IL:JXK(91,X428[+O\
M$L9QMFUP-%>U/2XTW8Q,E49#LA<Y+][BW6Z2I999>W,.V)@=$C-0H\=LM34,
MLQY*%:4='4\I6MS=XR8>V*HPD.-L(A+8LLFUVR-%WSK.^EW(SNE2'9;[S@<A
MK=>D1UI)5OTLI3H;W@5Q!YSG.<YSG.<YSY<YS]W.<Y_?SG/]G.>=Y7"USP?4
MZ/\ UBK/_(K9O_H//,NRU_!%S^T87VNUZQV'_P"$-R_L-[_ZC;:[\'/EROHB
MG%*<4IQ2G%*J2_OZQ%U_Y)+(_P!3C/-A:?WUMG]H0O\ $M5*>8^<?;7Y3>W[
M^?[N?Y>?<*N9^<_;7P]7CD4IQ2L]/#O;B5+DL=ZEJDK:03K)V,/]>4=L:[NM
MKX#UD9>PQR"1WQMJM,1(].0&X$GIKL\Q.1L<5%Z[%TV&,\OM87!;X:3D0G;U
M:&KL1D#M6Y-;3(2Z1Q$=Q99;E'(3T5;P6=V5UTNRH09\M0P9K=GNSMK' J[9
M(AN*CEH$$&0A(=<C8[[I*&BCVP)KF)J#O#T?7EW2X=:9H*%EG7?H8#"0J]P#
M(ELJTLH_0]FUC9'7>W]=6"JY$*FH?%2B#FVC=3,:F21$7A\H,F3_ "AP%PV:
MVEZ/M$J"TXZQ=]J'7)-L>6@!4-JZ0IL.[6_*@$.'=.,2FE*P]'*'- 7&23WD
M#:+9TO;/HFN-MOVK9I#<>Y-)62F8[;9L.7:IW>DJ;&]0]'<2#NI 4C442%8X
MAK[O?J;..OT3@E5TUB'VP+VAF3TR^M7#8Q[1P("K,Y'CW5"+'D)E][4);INO
M_:8XT]H^;ZPZ]15UPAGO;7;+Y&NLB5.N'2(*Q(W,?ITA_1O'0IGVAR(TVG0@
M%/>O*T9PG4.-</<[E8Y-K8C0K>8\Y'1][(Z%'9U[MLI>]N;E.N*UK(5Q:3KQ
ME6D\*Y*.L/:;H?!J7ZB16-RTI6T@K#L#*Y;.49[$F(<R:F)OJ3.8TYL Q.HD
M:FI%C&B-P&P44@DV9@AYJKP28TII'42<0<2F0<=>K)M/)N-_?>81,:FVIAB*
M8LA;C;<=J_17DQ6XTAJ,A3R+>TZ_*C*=6W-=*T%THD!AKJ[/>=FXT"Q,LO+B
M.P[F^_)$IA"%N/N6.2TJ2Y)8<?6EI<]QMB+(2VAR&T$+#06P7W:*>BNOO;CQ
M/+8).EHK:M9NNO4YG2S@M(9V!A+JR:BZ<Y,O7!V<QU>&3V4Q\+9\/<JR6?8P
M)+6"DT)R=VFZW-;KNMHA=UL.Q<!"0_!F)NL6,$MM1G90AS]H=VD-1GA(BLO.
MPI"0S%[]$0J0PDIW>$ZXMVN^;8S5*+$V&JUR)!*W9+<<RX-AUJ+DEHQY+[3<
MR.2]*]K7*"5O*!WF5>9!#?"FTBMO*!748>V DE&D5 XZP;=80R%.7G7L&YDI
M'KM(Y&6W(SL. [%K2EELA9(RT#Q:,"@#,.*6&E7,LU-2-N-_;PXEY,4EXAQ4
M6 J1)2F[.!E%W9:1HBN.V@,*S#7!:;>6ZIQT+;#%'8^Q09G%M3*I(#(+:)4Y
M,>.I5K;+R[4ZZO5*;;NI>21+1,=6RAI+;90LOC$:_7?2)?L74\&JZ(8B77H
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M=6;/U+='<YSG[,\U]W__ $4Q_:MSVT]FQPDGV-HX_P"]E>KJ\A[C]F\:W/\
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MPR?.HL2,&D(FL#'&2C)W.D> =?YSJ^WB/ 2<<S4:U^^/\7EP]RG2.7^SP^7
MSG J!&O#LZ<25D492>GL2CVY-<STZ1D]@6C(Y =,;QMW#5!!N3FIL^D1BOUH
M@_?11Q51$HYK!Q&GCD$O$%!:RC3:"A)YC/'/$D_^O+_9Y?)4AQ8((.,# P
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M)RX^&LE[*QQR4F#<A*MWA<T5>/!0DC&,  C )' \P<$9_#_ZT#BP2=7$G/$
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/2>' 5)^7:M4XI3BE?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g383050g23n00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g23n00.jpg
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MN4:[G[)97"YC6Y_,*]0_="Z*VDYV.Q5T'K6.S&I;]],J;!O2JW$D@'OQ;$@
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MY"NI6C*\99T8M>,8^+'<O/NQQA.<YSW8\7=WYQG&,_%GK>VG NW\,!Y#<;1
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M!#/B:$%D'L,N+#=9Z28R_B+<]1Z]JV><\/9[M!H4E)D0+Q=IMF4L55F4-QY
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M2?+KI>7P:\7*]C(5K>CA4DQ.G(=49,SY6OPH8RTLLE-;311RF&Y=CADDK5&
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M)D:QLRKN1R([)(7RWW/P??\ +K^+#^$0=E!)U0)VU3>Y)*JVQDIE4?.Z- D
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M&<4U3)1QI2V(H1I:FG$X\+C>5)SE"T_$M.<*Q\6>N6KL$!N6R<EC 3:G\C;
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M%6,$;-"++2!FX;?P9=E8(VY/FVR*3L=B3UF9$Y!8]B6/DH*@D[_ #L2!Y;[
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M/!"SD @DL/+I%J;1^:@O8V.'*PUY=-6#/:2&8.,BG9$4D<TBMZT; E@57RD
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M_IRC?1&?_??HXX'Y'E_RK2_<W1[D^+/W5^'?]0-2_P#:5UM_[/[F%R;U%QS
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M1C9F5Y'/[&B!:#!U*!'@3"F,2;4W8QH1P,4$7$CD=*62$H0\2S@9D"*$D'F
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M?P_X[/\ [\Z/>MJ[_3'XB?DGPB_[+.MYW9I]GK5MT<68J_S7(;D369&1V3N
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MK$ZEHZCU_IO5>I,KDTL:EHXC.M>@S%2O.QR>.R=HM!(EB[2FE[]T/'(C$<9
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M5 GG'2N9',Q&C2 $6D<I6&UQ!$* @YU\EIY"U LL9P0IQQ"<+RXRKSH]@%U
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MC?3%&HLB!,XY.):FLS^LUDW4V$ 82X0S'/6=N:BHPV*@#3HW'P[?!\ ^+?\
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M8;$@D^SJ,,^Z*Z^8.VP(\P"0=R#YC<#SY#R\QY^?3@AZ L<FK$D%"LF8EH)
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M2V,S>/RUN3L6EDMP5:52M<J7)CF9)A2R[T[&5FIHT(K7<O-'%;EIX^6+-,F
MX[\HXZ'!#/XY;8?-9:5ZEWU]&/0IYQUQU>&23+TV4H=&5^ 9M]*ECCI:'RX]
MY6'5M-O163FL2R13XQ8V8<%[S1$*%"CDD<#('.V[LIV=RS[+RXB?X#Z)?1..
MP]&G?QNMY[D,3"S+[G)>1I9)9)7$-BWDX[+5T+\*T4P9Z]=8JQEF[0F?,>\)
MR7^;9M?_ )>O?W]Z3^\;+_*<9\YE_9^GC_"D\/?M/K;\AT_WMT>\)R7^;9M?
M_EZ]_?WH]XV7^4XSYS+^S]'^%)X>_:?6WY#I_O;K<UV:'(DS2_%]C7%JX_\
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M27?:I:6"/4';(?1:>0H9-I;=E,;$;9@MM)-5BM5 #7N7*..=9I8Z\VTMD&<
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MASG"%J$<=0G*&<X[\*&5A'J$9\&7F\9RK&JQE.%FKEJ\VUR&6&8TUKF.FEB
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MLDBLT3RF CE*Q/-,JWJ=B"_%8BC?*X]J629 76W79HY_1U4D<.U8A5T=@60
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MVT[A*'.];S*'%N7R4^-BB>O6>T\\R5WC0D<(79>[.WEL5B&S%=P3\!\CLRZ
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ML^>LK*490A&%X<2M"<)RYW(RG*<IPE:E)5XN[*DX3E?5J2N)?18FD2")YI>
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MSD>(_P!B?<G\?_1T>7Q'\(_-TM=T4_G*C3VV%G\BN)Y("-:7M1HP?#';X)9
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MXV/I)=H>'OH,64Q\M6M>P>N9(4M14:<5"RT4WBM)$:\6*:A6]?<)06#'V(^
M:MT[M;]G_8K32H.P4_D14&J[)MFOQ[1?'^P^J:RF2,9-;(2YR++6AYN0;*0X
MTHAS+2DY:_(\'@2U7-'85[$C6'S#S>H'9;U!00L:JA 7#*NW +YA1O[?,G<S
MK3_T0OB77Q%2+#1>'4&.!L/7BDTGJV5T::U/-.&>?Q)FE)-F28E6E;AOP7BB
MJHG'XN#9'SBZ1]GZ>_B"Z3>\S3WQYG\H4?W1T\_X1GB]\?AO_5#4_P#VB='X
MN#9'SBZ1]GZ>_B"Z/>9I[X\S^4*/[HZ/\(SQ>^/PW_JAJ?\ [1.O;QVXZ;JA
M:=:8*$W3JYH&!VSM>&\<KH2V2)91(%WEV2C?-$Y$1#+#!;^%O#A>F><#94@=
MPXY:,DN267%8J&.I#V\@RPT:D2'TVL"42%0O+_%Q!;;ZY@%!/F%4>75-T-;Z
M\R=C/9)KND89<AJ;4%NQ&-,YEXQ8FR=AINSOK-62$ON8HW:62-"$>:4@N7W[
MPO('Y;].?9TNW\3G6GW.Q7V+(?/JW[MZ<O?5KS[8Z1_JMF?[Z]'O"\@?EOTY
M]G2[?Q.='N=BOL60^?5OW;T>^K7GVQTC_5;,_P!]>JY7'5%DB)K8Y=HW+K<,
MF&B3"[%(>\1L4>/E_)A*"S(Q,*.SRY::Q)D!6'6H+@JPHT>;DB8)H5Z1.BRU
M@.,-"KVX%BCNE>8$:^E4RRGG.ZNS'%$E586"#R;@ID! 5MFB.0U-G4M9:>Y<
MTTLH@D:Y(-/ZB2*<"MC(IH8(TU^J"66*3$1/&(HDLRK4V,LL#-'.=5ZCV=,Q
M\LW3-N:LB!1B8U;H\KQVNJ"S@T0H,-!38@SW*X\[$$=#P0P<+($-BCRK$8Z4
M%@EO#A3B>SCZ!93,M]VV;S6[6V!:1Y)%)&+5>?<D9G W*EMCMY .F%U7JL0S
M)C;6E:\8>!F273&:9Y$2I!3K3H'UW-)V&JTX8H)&X+*D!= ^[.S4]X7D#\M^
MG/LZ7;^)SI-[G8K[%D/GU;]V]/7OJUY]L=(_U6S/]]>CWA>0/RWZ<^SI=OXG
M.CW.Q7V+(?/JW[MZ/?5KS[8Z1_JMF?[Z].3A;J?DQ'\A^1$=6]WZ*!DDZ7XU
M&RI\YQIO\V"8"3>.43$4''Q@'*VNOQI0#X<N]('DRLLS*,R$<.-'PZXDDF:E
M^!KTX:+K"ED(;<K$2V(I&Y&&L"0R58AQV"[#CN"">1! 7FSQ?S.HK6JZDV1L
MX66P-/48E:EB+U.$0KDLPZJT4^>ON90[R%I!.J,A11$I1GDV:>]AS+^</QD^
MR!M3^-[IZXP?Q)?QJ?J>JM]TLI]DH?,K'[QZ/>PYE_.'XR?9 VI_&]T<8/XD
MOXU/U/1[I93[)0^96/WCT@=JZUWXK86J8^[;QT,99)#%C&J<K#<5=TQL="-%
M2]'CB'YUN,Y^Q2BO46L^BMP#V(V;+A9] ,X)B&;CRY<?8BQ\7XK)L-B=Y$.^
MP;;;> [>7+?S&X)'GOMTFFOWFDA,CTBPYA"M6TH7DT0/(+DU)W?M<#LQ5P''
M'B6$ U3I7;[6T(T^L['TS%7INN[)C1[19N,^V[.G(E2V2<+<8XR07VCML<D9
M%ZX7J6E&YAU@UAU^8FXXB:'GP)2# ]81\""'*[J>(=%\RHV_^;+ML% (!^ '
M8CSZUPV[:S!T]#$H25>X]:TYV69BZDG*OR;N2,P8@GUF!8,"HM[[V',OYP_&
M3[(&U/XWNM7&#^)+^-3]3TM]TLI]DH?,K'[QZ/>PYE_.'XR?9 VI_&]T<8/X
MDOXU/U/1[I93[)0^96/WCUI>[=&F<AX#B5KLS9FV=,7."=Y%5(82+HN@+QK>
M7'EUZTVXZP>1.3_)3:89<<T&R>.]%-5\,E\DH,Q$R.T"\%(+\>(Q,_!7![3>
M;.K#;FGP"-#OOMY[_P WQ1O5-N[8QT*V'JE%NQ,!#7EB;EV+(!+/;F!78MNH
M0$D@\@ 0=\G5\=<Q='1T='1T='1T='1T=:<.UCCJ[+[&XYQ5N*5&5Z2TS.CN
MF9%*+S(SC>T[D]5H2-PL,N($ET3J1+ ,86R24G$'AL=##2WU/\G>/5ZP,G'C
M\703(9@^AVHD#P02Q49(UK6W:=YZ\K02+O!) K\9.Z0=E+NO<7A9IC-ZU^A0
M\3],:6T)+K755S4D,V"FCO:?Q2:9DB.'%W.V<AD[M7("O#5;L/6I*RS+.^ZR
ML&[6D6QP] L$U5:]EVWR5>DH%J+,LSF*G'0&4^V\%?W:"2(<0R9 #B8%*BRV
MXUE$:V(['/JPS'N&5U<C\2L!IQ,=E8,=3IX6Q#J#'8R009&>NU['H()>[4F5
M;,5E+(8E>Z\;!_22I/U.59737T?6D-%+!G_#WP^O:8\$LGC==U,+4H1WTU'5
M-%Z$V/HBI/*UN*>"2WE,C8988Q?EL,\H;@CZD>4O&_3TM.34WI2RV$R4R&;8
MIF(FU1;XK@CYH88CD(N)C0AG 1TR,=A9;\F^:^@G#C,,E@8AQF;:+U9F5I5H
M<_5ILG?CI1VZ:RQ*T@A#%G@9Y)(9"0Y6 1]M0 G>+^J>5,C%XI9/,7-5:VT-
MI[1]36.:R)Q..P&3QT]7%Y+:3)W\/-7CR5J6%ZT4PCCE[4=;DK1I(6"J=7#
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M/1Y'K5)(XI&FV+,\T:S1Q*K,6D7@X$K-LHY +R];CE+W)565C(&5@I=V1LC
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ME:-+4=Z."+*7F :IAI&9Y9VDED9FQ9]:21F8A0J G9%5=@+2_B^87YSO)_\
MIN@/X?>O?<O&_(H_QMK]?UI]_P#KC[IKGS'"?NKH_%\POSG>3_\ 3= ?P^]'
MN7C?D4?XVU^OZ/?_ *X^Z:Y\QPG[JZJ5<.,.JJK>-M"3&Z]R R5+@W)%^UV"
MQ\=H]^PEQU/JDJQ&S:Q>)\S-@XF(.[2,/1_0LVN1L^:CL*-#AQ6H-:#=@QM'
MBH%4<?/9>_;V&[;G8>D[#S )]GGL3[=^D#Z]U:LT\K9U^]QW>=L;@!))QB"
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M"L9\"YA2,_E8QG.,XSC.<8[\9Z\]\.KO/_%VFO/X?3LGOYJ5]OH&X\CMY?\
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MHZ.CHZ.CHZ.CHZ.LEQC_ -P/5O\ P7'_ /:">GO0G_)# ?[ G_X<G2+Q8_\
MC'U?_P#>\O\ U473VZEO5>='1T='1T=<[=#O]4K+^W2P:Q6[,:QOKEG O5ZQ
M<0-F;%85<\\V>8<G)VMS8%=U@>#-@+;*T_"3K(UCEW :6+<<UEG%TC@(HXZR
M.V_G\0_Z!_[?[/9[>LW([4B2Y \V3U^ &@FLXAAP=9<)KJW$14RW=8:.%N
M>P>.CLI+3"*T!.W<Z"E+!&UTP&:BM=8RF1$/MJ#KSR^(_P"_P?\ JW_G\]]A
M$S+X;Y1Z@845#N?<&ME!?!FTR Z@P1L"[G"$#&XW5PI4K;;#Y<WJ$@BQ1@T)
M2D&1MD/J5B=% ;.CU?/V_#M_ZA[?P_#U<_5.T.)<4%:2ME49Z6D9RV/R<)$-
M\)MO2 52@FX6$BU0D;*A\9ZZ1)1QL]'3MHCURH;DI'Q]A$A3"'G8M3BSKS_?
M_?\ W/35]^G@+\D[OV'=V_<-T='2YW#N3@@_J/:3$=JMUF0>US=V@7?@4;H
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M,UMQK#[ 2AV",MNOH4^VXI)!&,^<MGNT\R]F1JEGMP;1A5.H*3>N(D$K*6R
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MQ@R)#&H:0^U2/5/D'<D;MD=^5(>]9B]1E1XVC"J64Q\Y"$:1R53X&!&X.Y5
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M[I='M;;_ ,W>_?3/2OWG=''4WW'Y/\IZ;_?71Z+HO_27IS\B:\_NET>UMO\
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M#G/57$+[T\MQ7?BONMISBNX*G8>[>PW#,#L/,,1[">O#0T,6+'Q'TP6.V['
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M* WH6+L$]&Q+HR6W(X";EPPU,CR1C;V!;5)WWTGECON#OE=.'<$@D'?->>Y
M)W]I )\QUF*&AAMMXCZ9&VVVV!UT-M@0-O\ O1\M@S ?$&('D3U'&N/U/8@V
MJPQV>U09K3,^S:V:\U7.+3<&U:1ADA#V5J)1<, -SXX:4B,S*!\2+0R4L-DI
M:QA&/3)JPGD=*9<L5*ECE].D\2=RN_NWOQ)\R/9O\'6/N=H3;C],72_'?EM[
M@:YVY?QMO>CMO]_V]2&1U6U+QTG$2W!T&3B9H*7C9B+D1>-9L=+1U@LSEUG@
M),(F\NC'A3=R>>MLN*4TZQ)69UR>,;>E5J+SX&U4""-)Y8$$$$9;3@((7B"#
M[M^1"^J/B7R'EY=9&AH8@@^(^F2"""#@==;$$\B"/>CL06]8@^T^9\^L-K33
M<KJ2U[*N5*XO[ C9K:3U':G,8NFC6HV(KNM*;'T>@T:HQ(6Q0XZLT:IQ AI,
M-7(X= HTQ8;)*>)9$N_W>N^J9%16TCDR$Y[?XSTUN6D<N[,?=K=F8D;L220J
MCX.L8\?H>-G9/$K3@,G'?_$FN]@J*%5% TD J*!N%'EN2?:>G+[6V_\ -WOW
MTSTK]YW6OCJ;[C\G^4]-_OKK;Z+HO_27IS\B:\_NET>UMO\ S=[]],]*_>=T
M<=3?<?D_RGIO]]='HNB_])>G/R)KS^Z71[6V_P#-WOWTSTK]YW1QU-]Q^3_*
M>F_WUT>BZ+_TEZ<_(FO/[I='M;;_ ,W>_?3/2OWG=''4WW'Y/\IZ;_?71Z+H
MO_27IS\B:\_NET>UMO\ S=[]],]*_>=T<=3?<?D_RGIO]]='HNB_])>G/R)K
MS^Z71[6V_P#-WOWTSTK]YW1QU-]Q^3_*>F_WUT>BZ+_TEZ<_(FO/[I='M;;_
M ,W>_?3/2OWG=''4WW'Y/\IZ;_?71Z+HO_27IS\B:\_NET>UMO\ S=[]],]*
M_>=T<=3?<?D_RGIO]]='HNB_])>G/R)KS^Z71[6V_P#-WOWTSTK]YW1QU-]Q
M^3_*>F_WUT>BZ+_TEZ<_(FO/[I='M;;_ ,W>_?3/2OWG=''4WW'Y/\IZ;_?7
M1Z+HO_27IS\B:\_NETZM$5J=IVG]?5FS >RY^'KHHLM&^J#-R"9XW77!5%Q[
MY0)"V?,PA;HA+XZE8SEIUQ'<K,STE1MXS3>'H7HNQ;K4TCL0]R.7M2<F8H9(
M7DB<KR +1NZ$[\6(\^H'XAY7'YS6^I<MBK'I>-O9.::G:[,\'I$'%$240V8X
M;$0?B65)HHY ".:*VX#:ZD74,Z.CHZ.CHZY\J'&[(L:-NQ(4!IN,$5N_E!A$
M];N9.S-0M$U1CG1S:BZP5+5@G@]MG54+;C;1;KW[!]-?K+=!":?5[C7'JV?$
M][9UG["/;[!\&_P#RWW!^+R_F]A\_5,5^\URRM1#PNE%64^&CP88^#YW[7M4
MP"]:K75\U(JO7J$[+R:DQ;;$1#]!J]5%&L:I.(HH]<M9<:Z:>7=I,Z\\M_/?
MX?(C;V;[_P"</O\ LZS0RMC"TV2:%J>D7H^IP0UT9G$<N-P2)U<A-<8XVN 6
MF/C,]E,3%2[,75:1I%D23,@IS,U0;)(6,19\5:Y*?6='M^$_%[!\._P\OAW.
M_5C.*[7(Z@UR[5_3>G.,]MB(F[R$%+*L7-G<.7Z_(0S#+2*W'$I[-VNN3<1&
MM$*]'9S/=%(S>7GLF6V;R&WZ0Z\\OC/]$#_U]6E]V?/#YMW$?[;&Y/X .CH\
MOC/X!^?I:[HN'.5>GML(/XZ\3Q@%ZTO:320^9VWSBQQ%5>5P2^*$]P,CV3"6
MF<K<8%=/!:(=2EEPP9"\O(.CR^,_@'Y^M.&H>UIW= :FU?!#<1M5R T+KNE1
M(Y[_ "RMP#YK$;6HP-HMX%OB.>V$Z2VREYP1!YJ!EKRRDLE*,/+KF;7F)BFE
MB:KD2T<CQL5BK%2R,5)!-L';<>6X!V]H'7:^.^A-\0+^/HWHL[HY(KM.K;C2
M2[FQ(L=F!)D5PN!90ZJX#!690P.S$>?3$_&_[T^9WJ;[7MP_@\ZU_3 P_P E
MR7XJK^U]+/\ !"\1/M]HOY]G/[O]'XW_ 'I\SO4WVO;A_!YT?3 P_P ER7XJ
MK^U]'^"%XB?;[1?S[.?W?ZIW4>TBL-;C*4Q"Z'@2A(/8U1L5?;(Y7.E&G350
MU>)1(>)=:3V>J9#,"?K-BM,&2 * "9 0"'F Y]A^:D"II6=:40S@T,D"D9D<
ME:055[A0[L;W$,)%9"F_,.CJ5Y*VS#%]#%JITKR1:LT9(+-M:E=5GU*TLT_H
MB645(!I?OF)Z4D-E+'#L25YJ\T<Q2>)I+&:V[6K:D%1JW$5?B1K.4A@(_P A
MJ7E>7EQQ,S1N'WE3$Y/K5PPCUD6.;F%'RMB+=!$>-FS#RWF&W7EIQHEUYBXI
M&CDIY)74@,O;J$#< C8K<*D$$%2I((((.W3I2^A.UW?JPVZ>H]&35I@QCD-O
M4$;-Q=HWYI+IR.1'6165U>-&#A@R@^74X_&_[T^9WJ;[7MP_@\ZU_3 P_P E
MR7XJK^U]*O\ !"\1/M]HOY]G/[O]'XW_ 'I\SO4WVO;A_!YT?3 P_P ER7XJ
MK^U]'^"%XB?;[1?S[.?W?ZK[H;M9MRU&'V0$+Q,UE+)EM[;KL[[I'*JU1>1"
M[)L&:EBHMEMOBC*8+&C7B5B#R:W W9%IM)3D9'+<R(WE:U]B:KQH]7(L9*\$
MX*QUM@DT:NH.]H>L =FVW&_L)'GTCPGT)?B!F8+D]?.Z.C6IELIC)!-=S89I
M\=<EJS.G# R Q/)&6B+%7*$%T1MU#R_'(;O^9QJK[7EN_@^Z3?3'PWR/)_BJ
MO[7T\_X&OB1]T.B/GV>_N]T?CD-W_,XU5]KRW?P?='TQ\-\CR?XJK^U]'^!K
MXD?=#HCY]GO[O=5*V#VE\]9)W<1<YQYK<(3>:O8("V! <MGG!(B/N-+UW2YS
M-=S,\ YK)DL2'5-82C+!#]A(B)X>(6&&&)938R851Z\Q\BQ-'CLHPF8B,A*7
MGQ[GFW\-!11VIMG?BI$4A#$1MQ8K7T*6KJDN0BM:OT/#)1B$EM6LZDV19$IC
MC$PTNRV9MKN/#5ZS33H]VDK1J;4*RN^B=K_LMF0NDS#<4M>V.5GIR/78I66Y
M<6C#S!<+78BOCPH2AN%,2*/'@MQCI[\6(TI@*QS%C(4@8N0*';US>(&+@X=V
MCDT[B\T'"D24).S;+=) ;VJ6VY*0R[J0>EM#Z$C7.2])-'5.B+ K3FO886=1
MHL=A57G"&DTTBL\?ULJQENS,'BDX2JZ!C?CD-W_,XU5]KRW?P?=:?ICX;Y'D
M_P 55_:^G#_ U\2/NAT1\^SW]WNC\<AN_P"9QJK[7EN_@^Z/ICX;Y'D_Q57]
MKZ/\#7Q(^Z'1'S[/?W>Z2=4YS;^W9R?VW=(7C9I^'/$T+Q[J\A"RG*&Z+#:#
MC=A<FY:.E YD3BB\\62>]/28AL8_"@M1C46"4Q*2JY<@2&NKPIR1U15S%G%0
M!$JV*D$RY"4UW+M'-(IC%:*Z'78D-R,9! V# [CDSZ(?PUROA%GL!AM37\?=
MLY/$39.O)@C9M0+ ;DE4I,V0@Q<B2B2LS )'*A1E/,-NO5B/A&<H_F\:"^U9
ML3^#WJVO<K+?8L=\^L_NSKGGT_'_ ,>Y\U@_;>CX1G*/YO&@OM6;$_@]Z/<K
M+?8L=\^L_NSH]/Q_\>Y\U@_;>DALS<^[IR]:R*L.H]05VR XL3%4#B.4MT<#
MDW2)&GR"B)0D_@S--@+BK!#U1V)<4?#BR4D2S G-S@\KF(?2SXG(&:#N>@)(
M>8B NV=F]:,DDG%,%(?M!=V4,Q";-RXE1#?J=J8H+;H./<)K0@KY./(#(*6W
M4ORV#%0.7J[;]0;1^[]@0]B;C:-JW4MNL$)3QW&AISE#L1C$;6I*+I%:CY)?
MI."5=!P]+5S7M(&BB"5./RD+&HL$8V\S/2LM*Z:F,N&3A":,KI$K<6N6AQC9
M8T1]O<A "Z11\?XZ#N*"KECLL7:X3E*MJ-6D(W6M7/)U+LR_\8.3Q9WY;>2L
M>+$%546H^$9RC^;QH+[5FQ/X/>G#W*RWV+'?/K/[LZ1^GX_^/<^:P?MO1\(S
ME'\WC07VK-B?P>]'N5EOL6.^?6?W9T>GX_\ CW/FL'[;UJE[8+;6[KOQHH\3
M?-2ZKID0/O.LR(TI4=YV[8$D_)-4#9HS(#\-,\?=;BC NBEF$.R;<X4^R^*,
M*F*?;-=,!BFL*5ZMC('LI46,WHD!@LS3/S->T0"LE.NH7BK;L')!V'$@DJ_:
M=LU9KLJP-8+BJ[$2PQQKQ$L .S)8F);<C8<0-MSR! ![F^JWZE71T='1T='1
MT='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1
MT='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1
MT='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='7
M//1H@V1(VV!9=GZ]IL7C<'+B<:F9GBSLB^%BU%SF=SN";IA5ZUSR9J5BF'&H
M6/W?8K0$UK^$K*:#*2#%D,DPQW<).L_BV!]@'M'MV7[W\FV_L/L\^OYL+U3J
M@%A>'WOJE^EO4&Q),EX#BUM.NT^P1LY:8V>N-&CX>8YV58DN8:S8&RK&A5?'
MA(ZK0DEKLF>9;II%&BCH\A\!&Q\]_/\ G/JD?R?V=,N9UEL2$JU@)S>XDB-"
MU]R$:.@J]QOV03)2-4U#L77FH]F5H&/C>T/1DEQ[-,UZNLC8=;&:UU6XZ#$,
MA4ANU3HZ\_F/M'M(^$'8^:]/OC+7]X60/;Q&E]]Z5K0@&YK3$W4B2XBV9WW5
MW.,CH,(RV0I*>9]@695I&.8C1*\4EV.#<&CG4@Q0K*,J=.@[>7D?9\8_M]7_
M '&WP=6<][SFS\Z/0OV0K5_%AT=>>7Q'\(_-TM=ST#F>WI[:[AW)S1983>M;
MVLP4?B7: WR145>540.P8OE06@5YYG"VVR5"%)86I+JAWL)RVHZ/+XC^'_V=
M<\&K>$6T)/6.N9)CD)5A&9"B5 YD5S1AA3@S1=?CR&QUDXW&-@A;*',-J?P.
MQA[*<N89:PKP)IZS@,.]B=FCO<FFE9MKD0'(NQ.P-(D#<^0)) \MS[>OI3B/
M%KQ%KXG%P0V]*B&#'4H8A)IS(NXCCK1)&'<:G0.X51R8(@9MR%4'83OX"FU?
MG&5/ZA3/OIZT^][#?8[_ ,]A_8>G'Z;_ (E?+-)?U:R7]Z>CX"FU?G&5/ZA3
M/OIZ/>]AOL=_Y[#^P]'TW_$KY9I+^K62_O3U3TGBO#1U $OQFVRQ:G$VRIC.
M$8T7+$/P+\K6JO8ZC83$!<ER5-03\!,U# ;++Q!C#[5?@WH9F3B8R/$=/<6H
MTCH&MEWCD5OX34 =6>02KYXP L7,I9O+_*2MSVED+08^)FHHZ<-AHM/+6K7:
M4T9]Q<^6K31P59*,Y*ZY8K"D H+%&&94%:A"8 U*HD-BM<<);O*TV(-K6^8.
M%B7%RC28B7T,9[7BY 68D!)J/ETYWQ)J;E1)IB08DF'3B'F#FWV7U)>;6A"&
MQ@,4\SM,MYY#QW87( & 10A4"@HX\ O'90-MO+J48KQ8U]6H004)M*UJJ&;A
M!)IS*O+'(T\KV%E:35TSF7TAI3+SE=A(6!.XV$X^ IM7YQE3^H4S[Z>M/O>P
MWV._\]A_8>G'Z;_B5\LTE_5K)?WIZ/@*;5^<94_J%,^^GH][V&^QW_GL/[#T
M?3?\2OEFDOZM9+^]/4ZXA]DI=]PZWMUSSRGAZZ[G=V[H%^/1H!<JVX16]CST
M*](-D*W1'J9;D5AY+0$IIW(6'?3Y++\OSUR4:#PF2AK6I9,BC&K!$JQV(-@D
M,8C3<M4)+<5!9O($^Q0/+JB;7T5WB?HO*9O!4:6CK429K)77GLXC*B1[&1L-
M<L<5CSZJD0EF98D)=E0 -([;L;3?B0KO\\6)^S;G[]NCZ6FG_L^4^<5OV/K7
M_AM>+?VJT-^2,Q_>'H_$A7?YXL3]FW/W[='TM-/_ &?*?.*W['T?X;7BW]JM
M#?DC,?WAZJC>.R4K\18=R,S')*Q2<MK.JSUWL9$3QW$99L#%#J6L[?81:IAS
ME7%I&FX>$N.LRW%RS%7#E)!$6N.DY,VL//12J/0.(B1(TMY,)&&"@R46V#F0
ML"7H,6![LHV8D!995&RR.&8[7T6GB'=L6+=C :*>>V\4DTB5=3P[R0K42.2-
M8=51I!(#CZ#EX%C=YL?1G<M-3JR1MK6O8B.M2&PH2J<H&JX[1[8)2)I!W')I
MT8XA-5KU^ *@O)Y'R_EP;D?L)A]MM]N)+Q+$3"B8MM:\%%^6/#_#VBIL6\K(
M5+$$S5%.[!%+,5HJ68K&B\FW/%%4'90.MF)^B[\1<$LB8K3VA*:3+&CJN-S\
MB]N*2Q+''&LVII1#&LUJS-VX@B--8FE93)*[%J?B0KO\\6)^S;G[]NDWTM-/
M_9\I\XK?L?3Q_AM>+?VJT-^2,Q_>'H_$A7?YXL3]FW/W[='TM-/_ &?*?.*W
M['T?X;7BW]JM#?DC,?WAZI);^&VX.*W*O85$J?(:FV$B=X^:%MLE-3NA3VT9
M9*V/R7AP(L2+"W6WD=82X4\L@]R0)]=B3''0&%[.4^?>'A#IZ/ U\Y6Q-ITC
MEFH3S&]$+;LY2U&H0PO3"*JQG<%9"Q;?==MCS!X]^+6>\6LO@<YJVCC([F.Q
MUC$U4PB6<?!Z,EDW.4R6[&3>28RVW')9(T"*HX$[L97[D>2ORX:K^S]._?SU
M<?:R7RVI^3Y/WAU07=H?(Y_GJ_LO1[D>2ORX:K^S]._?ST=K)?+:GY/D_>'1
MW:'R.?YZO[+TG-AUG;.+IKL"T[6HQ\X?B>8KLI%Z-M (<(V_(52/)=E4A<EH
ML@CU$Y(5;V2Z/'S),1+,#3C.(C,<J5'1V([??K++:KL[=P1NM&953=H5)<+D
MU+;R&'CLLA1PLGJ!>85025NS.T=6547@75K:DN=I".)-)@-D$G+=D#*2GK<@
MI7>H8N[25O $I]YKU?DQ*FT9#R]CT1:R(%Z.EXBKG,1<6^_REG 2Y]--<II>
M1V1ER4'4,0L,2_&CAIAADU-9VF"PS11L(0R/+0F,95TB8(A.5D4R"'LD@#E'
M#P0E0. W6GA6,F6!G!DXLJ7$Y@HTB\FVH(0G=[HW)V>7FP#$EC:?W(\E?EPU
M7]GZ=^_GIU[62^6U/R?)^\.F_NT/D<_SU?V7H]R/)7Y<-5_9^G?OYZ.UDOEM
M3\GR?O#H[M#Y'/\ /5_9>M9_:IP&Y(_CW3GKOLNCVB*5N6O-#Q]?U1)T\QF0
M52-AK:,=DS-H6YI\5L9!;"P4QK#CKI#)&#FTBJ8)A.O4N+AZQL6()4]TH0%B
MJO P;T6YLQ=K4X*@!@5X DD'D.)#272KUFR$PAKR1-Z'(2SV!*"O?K[KQ$$>
MQ)V/+D=@"-O/<=\W52=3;HZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.
MCHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.
MCHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.
MCHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CK0!0:N"D':Q%SDN3+M$>WWRDLK9VO;=
MK$BNHM9'.?FA['I<13KG0LK'>BAZ ?+P9SMQD#)2\WN(JM?B6IRR1S9QUGO[
M/)?8!N1]X>W\/Q?^OK(3I,'!SIAE?<YA+"D*C*"2TI/WC6-/MZ(]^\J9NT/8
M(%O2$SX:D_<#K?&">*P&&W[;P!M?A:K(-V*.MYIT;^WR3R^][?BV\_P_$//K
MR$4BKEP<O(D.;2<)S5K19L0TUO#34*](-JL&AYBWQ$B39N-L9'C2^3MH2JK3
M'N$%E%;6U!9Z9@>5FV&I4$Z]W_\ LGV [#^4;#S\_(>7L\B/8.KFZ*T!'W ?
M9Q-7W_R,J0$3M>QPC[M6V;2L.VF3%BX F7LMJBG-'U65K]PS+FGUZ?AYP T]
M!=?R>/-3$0?&'.G7A;V>JOL^+_?^SIZ_!2E?G7<N/K'IOW;='7G+_P %?P=+
M7<_%J4$T]M<O/*;E>7@76M[(R(9L.GNB%89J\JYD<II&N6EN#/83Y;[:'&U+
M:4I*5HSG"L'1R_\ !7\'6OO2O#V(D--ZE/5O?D>*H[65#,4*'?H!H0;)-6BG
MLL"M+I3JVAF<K\MAM3CBD-)2E2UYQE68J\-<NY->$DLVY*G<G<[D^M[3UT+5
MRN96M75<Q?55@A55#5]E41J !O7)V \AN2?C)Z9GP,H;Y?N3'UA5[]Q^L>Q7
M^3P_T3^EUO\ =;-_;K(?TJW[-T? RAOE^Y,?6%7OW'Z.Q7^3P_T3^ET>ZV;^
MW60_I5OV;JCD5IC5Q%9@IYZ7W #+F[ KD,/4A=E5$NPK9FJZFXF3%=&1HP=4
ME;ZXY)76!DJP\F'>)V!6;=2H6>D[:4'&26\P1;D=M#ZIW)#;>T#8_5/K3LIW
M_BE20!YAK&7R/!']-G#=Y.*;4^>[*TA=!Z!N94+3 IZI,JRQJYD.S65TUQ3@
MK5K2K3C6R.3&N$E,2#"J1[MX8!-==C9>0C'PFQ2]5UM]#*GPW"6%+@X[#S+Z
M'VV5-N(=<U/!!R.\$+'^,023Y>1WY'X/O]+:V7S/8CXY2_ H! A45D$>S$%0
MOHB;#<$_6+OOOMY[],[X&4-\OW)CZPJ]^X_6/8K_ ">'^B?TNM_NMF_MUD/Z
M5;]FZ/@90WR_<F/K"KW[C]'8K_)X?Z)_2Z/=;-_;K(?TJW[-TB>-.N;W7JWL
MZ!K?)KDA7H>'Y#[[CQ0(NX5)+*\C[,GT.G$**H93KLA(.^,L][S$MNE.N+;9
M91E+:=LN0L52D,/;2-(H^*\-]N2@D D[[;D[?%TVU-(XC.BQD\GZ59NV+MOO
M3&QP,ACF>-6*HBJ#Q10=@ 2/8.K&>Y';'SMN47TSI/W==:O=B[_&C_%C\_2K
MZ76F?L%KYT_Z/1[D=L?.VY1?3.D_=UT>[%W^-'^+'Y^CZ76F?L%KYT_Z/5<;
M[ 30VT8:GV/<.ZIEG88+;5EM]DLNL<.FL-UR]! COC&:7D$V<"-'CLU.:5(S
M "(-&R*S'#L2#=E=$ZV+E+C(S\X]U/UHB!)&Z^9/(;>1)4;'?BWLVZ1RZ%TU
M%9A@-6SQD&YE:ZZA=UF8<5[9# -$J2$NG!IX?KBX'4NTC7[W8:9BY1.^=_4
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MKMQD*#=I"HW )+$ ['JGGE<4/UJU9]8\=^\G5T>CZ'^S8+\H5_VGJL._J?\
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MO0=%WS6U@ +(D]31E@<B<S4Y[E8F[PD'8*U:APD*.L]A\/Q#X0/@'P$C[_\
M/M\'66L>Y]UR<E[5$C;VT\F&6 1#B\#.>\74I-V/LHK<1X 8KBM'62(+F(^-
MQ:+1/@6=)P(5AE*!$!R+49'3SQUYM_)[?XR^S^7?_P!7W_O=9+WX+UBO6"->
MBM^/R\IKZX14;((X1\TU#0^PY 33K<3:A<#\18*84$NS0&X[.)%YF&HZ"KUP
MKE2!C!@Q2(^*.C8>7L]OGZP]FYW^'^0#JS6HN1>OX;.QU[,H6_)+$SL8^9I
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MSSHYNP]?(DA#>.MUUB'.'V"R;)0 @&TS%OC<5V"M\&NM2L.%),'69^#V^P?
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M^/JH(RG,EQ(6#!0$(8LM@>&ZXX9RV:DMV27W*GY"S7@A0)Z91W(:*U,Q?EQ
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MDQW!()/:D1M@"3R 'K;CK?)X29N+,X'3S86^<SJ<PC T8[-6:3)>D9:[@X3
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M]?\ C1^AT>[N<_F"_HZ_[;H]W+O^I_%G]/H][N._U_XT?H='N[G/Y@OZ.O\
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M)?C,A/%MVR7;>R(Z(X.GRY(MMM#26D.^%&$I;;D=!+4RST&:7ERD9;DB*S.
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M=*^@9W[?Q_D>O^T=<\^E8S[5-\_F_5='N>V#\HPWT*COVGT>@9W[?Q_D>O\
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MO _$-PF:.)N#;\6XNZGBVQV.VQV.Q.QZQDU+@86VERM2)@%)$DG;8!NX4.S
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M.Y)\_:2=^K+B\8?$ZO%'7@UIFXX8(TAAC6>/C'%$H2-%WB/JJBA1Y^P=-/\
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MO)<P%2[&O?H3QOOWV8,51YE6-'15 VB&YW\NK4T7X2/5R=/4.>R%Z2.@]>?
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MEW(.X)=/MGLM_P!;^$'TWTM^V>E/;TU_%PG_ *#UHYYGX\E^"S^;H]L]EO\
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M4DR+VWE20[E0I4W'_32[C<MA6K8>/:[M$G50[\:;ZG!I-K).(QZPUPL5]!3
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M:R\ 0'FU>K=2X\0X@(@"#?B"7UHN>]T&X-K:SF9B/JD#=8V9&=(E8SU^8J>
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MA,?RGJQ%/-^(;PIPIQ/F9:;RASP]Z7DMJ3GQ81C*&W6CMP212R"%)(V(<D*
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MCHZ.D[RM5X>!G:.*^/\ )[/WENK\G^^^+35HS\7Q9^/XOB^+/Q_X,]1O5/\
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M9,P<$$,*/$?/.,*+*<:8'%"!&(,+?=<0T.*P\0ZI#32UIVDA02Q  !))(
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MQN%A2A0S0C24MNXA<DR\K-OM-H6Y**<9&:?3AK"^MV0T;K_&5,QE]2Z2QE_
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MR3X;0+)DB6^\X0<>L9)4@6X\:<Z0:002[I?2\+L6-N0$GV"-=A\  !<D #R
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M348''/\ D.L=71IO,935&D,CI+*UYLMJ#1V'R>8CR-8+'-G9+%BE%BJ[!&Y
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M8<5G,KU'B99K>6K:&66)I,OJ&F,"(S4RT./L)6>SD+#S$/[DNTB%2\A$(97
M]<;1.#+8S$8UZK*L,T_=>1?57E+(6&[AF4@D!%9CZW\8DJ=G3N1H(#6LC:#Q
MF9.(D4"0,8UE*D^2<2T\H=_*/*&:80RT&L@=0S[S2TKPE;*\.*<;WZWHZPPO
MAQH_ YVU5@*Y"%T2O8#V)JU>O.J0O L:?P2,, DZ,R,1'N-W4FL- 36#JPZ?
M5&Q]NO+:S=M#%$IL1L\<1;N]R6696:=4+2Q1L!N(Y=HN!U=XRRX^*EAI7FX5
ME+J<J\6'59=RI.4)SX<HQY:DHRGXL94CO[\*SG.*CV+;@#S.X']H^_OY_P!G
M]O2X]OMV_P!]_P"SV]7GW=$$0&@^)!#V<,8M.O[D^Y*N)=RDH).RIX? _BP\
M^EWT.6W6E+PRPM*?"RIM333+JF_3>2LME-2X])WITYK6/IVI) [(L1BBD=P
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MJM9F6WNU>%CMDLBHW,:D[!;04#<^0  'L  ZJ^QEKBV)U!K[+-*!O2ID[!V
MW)@))^,DDGVDD],#WH /E/Y*?:JY'?>ATH][^-_BW/RGDOVOK3[KW?CK?,:7
M[/T>] !\I_)3[57([[T.CWOXW^+<_*>2_:^CW7N_'6^8TOV?JIGI[2J%B2A
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M"2&01O!W-M<^W]@F3,J76F)IZ1K$0>2N*#;,?7&I<><\QTEIGN6UA;GB\&?
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M:\[,"">9V?;VJ%W5[A](-GZV2=W4\ID>LP;JH].8K#&"FK!(&V!^65)/DI
M5' L'7FY^,_A/^_X/@^_OTY_+[##]7.S ^A/&7]B]'1N?C/X3TO=MM]B-[U.
MS?8-=[,],Y[WMT]C*BJ9QL;DTRWN;DO9RHY8L,DE!^#/)R&L=27TD>7EG.',
M)ST=&['X3^$]<^&ND=GK[WU%]K1G$94K[C:Q[3R?!:E4?F0]B ^LR:H@'+ZB
M\D^9DE3^<O9>\>7,Y7XNNCZ?O0]#J=R/3YD]&@YEX:!?GVEY<B4W+<M^6_GO
MOOY]598;/=^?@^6X=Z3CQ>WQX\VX\=CMMMMMMY;>SJ9>#LY?T7P[_J'4'^H=
M*=M&_8]._B,?^AUJY:@_CY?^G<_/T>#LY?T7P[_J'4'^H=&VC?L>G?Q&/_0Z
M.6H/X^7_ *=S\_5;VC>-6(V)QFF\-W95$]%/GX*C.-HHI +K%9S,1YI(B#U"
MUU@S%Z2&;%1Q=J9!51%N-2A7NG1TS!L)PC_@VG.YW8R_*+#*I0B#NH[*'*PA
MA:"O'&TX0U=Q(W?V7'W3Y-M-F./!P-FR)((,G J"5WD([/(,ZQ%N_L5':Z<5
M$QP355(GW>1'#!%L2DMN7R# Z9](ZXT>4T*2PD8)3+:"@4"D^2E2E,9=RRXK
M+B%YZ<:OO5]'C]*BTV+&S"3C#C>)(=@K#BA Y*%;8'RWV/F#TEF;-]QNR^9[
M?EQY/<Y#<#<'S]H.XW^';<>74N\'9R_HOAW_ %#J#_4.E&VC?L>G?Q&/_0ZU
M\M0?Q\O_ $[GY^CP=G+^B^'?]0Z@_P!0Z-M&_8]._B,?^AT<M0?Q\O\ T[GY
M^FEQ2 [,)[7-C<OE=X1DS.=O;?P*[::KI4J1S 8OTUB 2.[*1;A'LI$5Z9,2
MAM7I&P<,H$2EA*$XY<UL]E=4Y@8MYDH>E'T=:+.E4)P3_(K 1$%Y;^2 #??X
M>NP?#%=--HK#G.QX5\IQL^DME(J4EX_PJ;M]YK2M.?J?'AS/DG';RVZLQ[*[
M(W]5>S_^AF@_V/U%>YF/LN1_&V/TNI]PT']@TK\WQ?ZOH]E=D;^JO9__ $,T
M'^Q^CN9C[+D?QMC]+HX:#^P:5^;XO]7U7VQC]G\W9=AL0NON"1-;<AR&**5&
MU7B PZS*XK]5)B#1%SP;A6%+L.;Y'VA-DC2Q4#II#E=!RTJQ&IWK)DN,?*;(
M!M_7WDN'RW8$$*=O(<"O$@GUPQ^M'39,NDQ+:$=72YB,9%8K!@1L_:A*,#(I
M;SE])2;NHR@>CF)2.ZW4FU8'V<)"[+G95%X! M^97W8'#M4XNOJ\UV!%Q91A
M<5N,<\$4-/-$+C,RZWY53!*L/%D-(:PUC+)DQQ[<V1/UW+ZI;^/U2>3#S*^W
M;8;CV=;::Z/)F]+K:54;Q&+>#"GS,8[P7M(=D$@/#N$OL?,GX&Y[*[(W]5>S
M_P#H9H/]C]:NYF/LN1_&V/TNEW#0?V#2OS?%_J^CV5V1OZJ]G_\ 0S0?['Z.
MYF/LN1_&V/TNCAH/[!I7YOB_U?7LXWR'8V0')??"=E!]G/$TTG1?&Q5.:NE?
MX[B5QVS-7_E)B[N5UF:CD1V9O$4NB)LSL<C!JP,59$FI3#<7A,DPD&0LP3=R
M*Y8=)1YNDTS(A1=AN0Q520VP\@2&V\]^J>\1I,)!E*7N0^+KUVH+W!0-6")I
MA8L<BX@X(T@0Q[D@MQX#V =7S]V/X/\ ?Y5V37]3\4?V?T]^YUWY#:^;2_H=
M5YZ7#\KA^<Q_I]'NQ_!_O\J[)K^I^*/[/Z/<Z[\AM?-I?T.CTN'Y7#\YC_3Z
M1VSK_P!C(#>M8.:Z [*&8I2,68C8K \7P?;P[Z<BKYAP25V5Z+ET*-A7+G[!
M<K*\)]V#%;1:BP*LN1>6>Y]WY#:^:S?H=>BY7V.]N+?SV_A$>W]C_?W_ )O+
M?SZC&M-A]CZ7? V+]%=E]&5(:(VNB3/DHKL]LPDD:O;L@C4;D8+49&6N <JW
MJL1M^?R;G,'EJ3@F'67;2W87H\]SKOR&U\VF_5]!MP?!;A]@_P#G,?M^'_/_
M )3\'_JZLQ[L?P?[_*NR:_J?BC^S^CW.N_(;7S:7]#KSTN'Y7#\YC_3Z/=C^
M#_?Y5V37]3\4?V?T>YUWY#:^;2_H='I</RN'YS'^GUIH[<>?[*Z4XG:]'X=N
M<%7MF(Y$5-Z<3QVC=&L7;%%3K7;:)-4HO78C4UFK8L#E8P:DI68O,MF$R^G)
M> <XUR5;$"AYJTT*D\0TD+QJ6()"AF4 D@$[;[[ GX#UDL\<IXI/'*0.7%9D
M<@#8;[!CL-R!O]_KISY"?[=@/^#0/_.4OU-]+_\ %\O^UR?]5!U!M0_\.C_V
M:/\ ZR;I%=2/IBZ.CHZ.CHZ.CHZ7^_90N#X<\\YJ/:+?/A^#_)R4"8CW,LGO
M%Q^K9\L9H)Y+!*FBW'F4(&<2,1E#RD*PP[G'EJCVI&A6G5:S6AN5UOPM8IV"
M1!:A$4YEK3E2&$,Z!HI2I!".VQ!\^EE>E4R5+.8Z^8Q1OX/(TKIF_P B*EJ+
ML6#+Z\?U,0R/S^J1^KOZZ_7#YV6W8;E!NS19DM/Q])@:=(3,3)14$3-$MW$G
M,>(:V*P(@LAF,D3'W521APH0Z9+)STCEH(3U!3+M<X7#9XM#IS$XG4N2H8D7
M<GV*U O5QAF$LC33L"TE:)X&<5VFE821KPC+,5WY\T)8\%= >($]7$9'-W-2
MI5-*_?6'EA>4\D3M89462;@"PKK*99HX511)(X02]2#@OL: FM?2>DY&/@(F
MTP&9&1AB+6,*5'RTRVHYV-*:;.;;:;*AY/N>>&7Y_F,H4[XF&F7^G[267P&
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MG??R"[>0  '\@V_M^'_<]>N)<\J0$>RG*\(>1G*>_&,93G\G.%*[\XPG/?\
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M"WY++#.%*==2MUQ/8ABGF::.)*HDE[[Q0+VT>7@8^3!3[6!);R]8DDC<]3O
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M28[N[/?C\VJ_C[O_ ,_CZV>_W#>8]$U%L?:/>SF_V'R_FZ?OI5ZD^VNB//\
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M;_XUT1Y^?_+W2/Q#_P"M_O?>_DZTS[R_!^X3<3=J!'YJ[FK,-<+4[9Y6(<X
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M,YQE?/\ VRO/=\><]FMM?OS^?N[_ /9S_P![^?O[L_'\?Q>>_O##V5-1 ?\
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M]G73SV'7 BL]GGI#=&H(#<QVY29[;85PF)"4T-8= 25?))HE:C18PJM6.W7
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MOD9!%'N;I"!\P@/DI?<;V$TVX\EOPX=6VTTA:\*4AM"<X3CKW'IG?0*/"SB
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MD+1LG",M^.:$A:62X]M@D+AW7) IS:>.)2#RYR#;8 LJFOB<6-[,(R0-5XY
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MO(F2'BA=9'!D(1D:%2I':#L29XMBB.OK'=AL>O!D(VV BEY-Q*+]3W=7$I#
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MXA;!J")5NK<W.2< B<E79R73%:XX+!XD99T40!1Y>&>&Z?.?2!'@ ,J5WX'
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M?($^W;8$^P$]9-:KJ')FC^I@EP&!*@$+N0"3[2!_*1TR"-XZ6$$KQY6WM8#
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MFFTMFHXH88D#/)++(RI'&BL[NRJH+$#I._"!T+\MNHOK)IO[:ZA7OKTM]TN
M_+&._:>IW]+?Q$^X+6G]5LY^P]'P@="_+;J+ZR:;^VNCWUZ6^Z7 ?EC'?M/1
M]+?Q$^X+6G]5LY^P]'P@="_+;J+ZR:;^VNCWUZ6^Z7 ?EC'?M/1]+?Q$^X+6
MG]5LY^P]'P@="_+;J+ZR:;^VNCWUZ6^Z7 ?EC'?M/1]+?Q$^X+6G]5LY^P](
M7D,%P_Y.U.HTG:.Z-:&5JH;9U?N%B+!V5K98<Y/:GMH%Q@H*RA3:IL&6J,P?
M'M@6>'R*P]*0[Y0;!X*W<$(VQ:QTU"S-'J73X9XY(B?=C'[A9%*DJ1:!# '=
M3\! .Q]G6J;PQ\09U57T%K7BLB2;#2V;\RAY '>@05)]H^$>6XZKSN+C+P>W
M3M"J[*GN4":X#2JX15*UJJF;BTM%:EA(24UGM74%G%@:P?69>1J^;C0=OV*&
MM#E4GH)<@N&I<@UD60JD62WMBUMIJ*-D746G#S8,SMEZ!D)$D<BDL+8#<7C!
M7D#MNX\PQZTR>%6OY) YT)KA0J\1&NE\T(P"DB'93CB5Y+(P;B1OLI]JCI>2
M?![@78!X%^T\M3;;:ZR'JJ.AKO9MF\8I:49C=/TK;NM:O'&U5_5N-6S8A>O-
MT6FH3B9W7TDX8&!7Y@1P"U!&V"2S&N=-CEQU#IQ5;N$JN9I@;R-&[$-Z;W%(
M>)64JXVW8>:D 8'PHU^=N6A=<,P" ,VELP3M&KHH*^YG ^I(5.Z_ I^N&Y]T
MMPB[.^6@)&O*Y$BQHAX&\ FG87<.E8E42[O@C19MB.AP0JNW"A.U@_CSKXND
M 9BG8&+[I@&6AYV*+# C_%USIU2&]\FG3MVO;F*!W[7="@GTO<[B9PQWW/D0
M0=R0^$^O2I7WAZW (D'EI?,C;NF,DC;';>J8EXC;8>8((.W3AY):-X,<N*CJ
MRK<@=\UF]DZJ&G& K:C<.LZQ:;4Y8J@JNRI5L<J(T# J<<L@=2VP&+5X"KQ<
M3M775 LD1'@@5U$(1KAUKINNSM#J33R=S;=?=?'L% ;D O*T3]:6C/(L3&[J
M22Q/6V;PLU_.J++H/6[< 0&]Z^;5FW78\BN/ ]H5QL% =5('EMU (/B;P/IU
M@UU:]?<FT:_L>JSM*&TV6K^XM*GNA8TCJ?:6E8\<X:W5>SQ\Q[O:%N.]B;&D
M90,N<E)B3:L=>E:Q.,8.7FVM]-N'5]1Z<=7$H8'+T!OW9(Y205MJ1P>)"@!"
M@#BP8>76 \*=?JR,FA-<(R=KB1IC-'_)(\8!Y8YM^2R,')\R3N"I\^I'K;CA
MP1U9KG:.L*UR%B'*[MSC/1N*EH(DMR:K>E6-=4 '<<?#RT20)& BCW,IG>%O
M7*RQ@1\62\' +8@Q$AG(D\7UMIMY$D;4FG>4<S3KMF*&W-S$2"#:/JCM+L-]
M_;YG?RR3PKU_&DB#0>M]I(5@8G2^;WX*) "-L>!R^J-N2"/9L!Y[K>U\(NSY
MM:;;X^33\([?(RZ5>WOPF[-,)<F]>;*T;HCC[L77"VY:KRPT=6[E1N.>MB3Y
M:'8CK[$6$>9/J=SKP<HJ-9S77.G%X[:BTV>!5DWR]#9726:9'\K8W97GDV!W
M0C8,I(WZUGPGU\>7_>)KD<@RL1IC->:/''$R>>.("LL2[D ,#OQ8 [=./>FE
M.%^^;G6+K,\F8ZF%P%<UQ3I6'HVWM/M0MWJ6I-P5C>FO8"T)N$'<984:O[$J
MH<C@ZFRU2FI0 R1B9F4D07!6@]<6M--0J5&H].MN78%LQ0W1I(VB<KQMJ#R1
MB-G#*" 0 1OUME\+/$"5E8Z$UNI"HA"Z7S6S+'()4#<L<Q\G4'=2I/F"2/+I
M/6GA+V?=CU;J_4D?R8Q2J[J_76V-4,R%.V[H@2>NM$W3;J5>[[$7<J8IDY'E
MDR-MU[5)EF<KT96I]EX$D=R4?"E)48S8NN=-K(\AU%IQV=XY-FR]$A7B5T0K
MM<4^2R,-F+#;;R\AUK/A1KXHD8T'KA51'C!72^9!99&5FY;XT@DE0=P ?P]>
M?AIJNLZ"VKR5M>S.1?%F?J&Z3+3F"CZKM0(V5@XJR;=VOLI%9K8LLU7Q=5:Y
MCFMGRKZ=<1,KL#U=YE[+<G+DV1).B$%C6>DY8X%34F##1JH;EF,8 6$<<?(D
M6CW'/; YD1[(%7@=M^O*WA;XD123,^@]8E9.0 72^>) ,CN -\>." .?4!;U
MBS;^>W6)(X+\*)"+TK R_.[9$U7N/]*K.O-8UZ2WCQK<A(.HU&K;%H$/'(CF
M-5#L-'.:[V9,46;L8. K/9H.&J)EDFI6RUL"?Q[[^=-;RL,_ID-,[/(1EZ6Y
M9F1R=S=/ESC#@'<*2P4!6(Z/I3Z_(C!T/KLB)0J Z8S.P55=!Y#& ;\'*$@
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MYL0PN\R2)7!#LR$;;K\>7TJ-?EN;:%UPS%F9BVELN>7+M[@K[F<0 8E(*JK
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M0WC"4)3C'=AIP^;\,$BNBS:TB&;+91XN[%CB37>[*U<IRB/U(Q%3%MZH3;B
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@PF46L<;,J&[).\7?-JF4"B5V42=M9=B!RXA]CMOU_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g383050g23r43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g23r43.jpg
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MJ1_*OCN\T^F/5IW^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:?IQ
M?!J1_*OCN\T^F/5IW^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:?I
MQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:
M?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\
MM:?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1/K
MT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1
M/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>
M/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW
M^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5IW^>/1/KT\M:?IQ ?!J1_*OCN\T^F/5
MIW^>/1/KUXQB9D>:$C9$J,,9,BY0Y"PHPJ/=9=CBX9C"59?F)-#K;J)1><XP
MAI2%-)SA2L*SC#NVWC?QQY=_'O[T>;3OWVG;Q3Y-O%M[\^?6I_I#"20^D7:Q
M(A#XI#2:AEM\9UQAYO*KQ7$*RAUI25H[R%*0KNJQVI4I.>W&<XYSCV6FM3['
MG$C4L8I@HH\K%&2S'?*41GE,9@HW&9B=IC>)F/%.NW_,Y5T6O9IX'190FPAE
MG+]1+U@Y1\O#N7,>=;!("Y3$2C>)V(8*.^(G7J_>R>R_5#.?=8_\8Y\*>VN4
M^V5_\<L?K-?K7\[^!^TF(_)M+]3I[)[+]4,Y]UC_ ,8X]M<I]LK_ ..6/UFG
MSOX'[28C\FTOU.GLGLOU0SGW6/\ QCCVURGVRO\ XY8_6:?._@?M)B/R;2_4
MZ>R>R_5#.?=8_P#&./;7*?;*_P#CEC]9I\[^!^TF(_)M+]3I[)[+]4,Y]UC_
M ,8X]M<I]LK_ ..6/UFGSOX'[28C\FTOU.GLGLOU0SGW6/\ QCCVURGVRO\
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MX^O_ %BX<_>FGT^/S,?W=7OZI<5_N?3Y:[IM_;>A/@[L#\C^/I2?9X^X^O\
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MB8*#:V(*8_@Q@C+P8G;-M^KD_L+4USJ@1C=)M5UU[8($.0?8%L+-1L5AKI8
MIKPW:V%.M0$F6V^ZQVH%E$"*;[4LO^U&UV)KW4-,9LUT6EL,!(DE82IHD0P4
M>&J6@,Q!1X2Y+?QQK/<#75F@!0AS4, "*(9"6FN8$I'ZUD+.8F8\11&WBG7-
M[T1?07N+H,TM?J5O/8%-O]SN&R9>T D4=^;DHB*@"1A.XP1.6."K<Q)2,I-9
MF)TH=^+P-&.R3C8I12R2EIV;C/.8K/9)%G$5;=6NJFM+(MD,,8T9+O%2W/6L
M07TU00LW. B2$8$=X#A;$Y'$47(R=FM8<RR;0FJ)<@+*![B8:U&9F?.PH(-@
MDIV(IF9U?==.],BO2Q=0,;7!]*IW2#TK:*//;B(^FM[$'N#VP^H$C8YCY @R
M9[%E)H]CU*NY/Y=S*DUF1I*9E3D;B)2W=MQF?G'Q1NG(SCRS>2$)8=B:DUXJ
M8L:@Q!3*NB-E5Z*\;<@N&STX@Y/>W6G%_/;D!5%'MPXFB10 IBS#ILY";)3,
M1U.K*&U.M._-*R1S^#R:ZD\TK6U:<::<::<::<::<::<::<::<::<::C\]^J
M0'UP"?Q0[C34@XTTXTUX2/[W?_XEW_L*YX9_!L_S"_\ QG7M?\(O_/'_ /*-
M:V\YUKJNG&FHY<+,#2JE:;E)LE$QM2KDW9I <%#+ASX,#&%2I;(:"'AF%E.L
M"N('0^0PRIY2,./-(RI:;;FBE+7%$R*5FTH';FD5C)S [S$;S$3MO,1OXYC4
MGA<4_.YG$X2J:56LQDZ&*K,L28H6_(6E5$F\E@U@I!CA)DK6PX""D0,MAG1N
M#])5T_R=>K5JEHV_UB G[E,4LR4-B:_8PZR7%4:O7Y,Q//Z_M%Q0FOG15HB8
MY!\9F2?C)Y1D;/AQ&(\U]F!7Q-CS6IIA84MCC212*V0J00M_.R:[7?4R%H#!
M#S2)[BP0Y2F._P!_YEKV2*N2RF(IVN',KD<=A*6<341<R6,=EDW.(,EPY-+'
M!Q'B,))9*O<Q-VR5>WV5=K'BFUC7W9LH6S.&@NJ6C=1!)HM1KUW@7@:?#74A
MFYQ,=#E-1TW?MHZZ' ?#%F)(L28&FM36$@\$MEG H)L3WG5'.2 ,?G8_*HR,
MS"5O7,)%\PX1"8$[%JM R,&4P<'49)#,1L)!W\W- Z![(OL29_V-%H;F<E@<
MB%C-7<$MF#N6KJCLT.'.$N)FV%O=2JI=2;1XRQBZ]A)LZMA%W8(KC6L6=E^2
MFN6:<::F4#^MVU?\2'_UO\F*'^(93_1J_P#=U Y+_K3#_P"D;^E>H;R'U/:<
M::P?O_?-7Z=J2!>;9$S4S'R5K@J>*'!$U@(C$G8%$H">*/N-CJM? CVU"K\T
M8?-#(9PI&>Q6,JRG!R%]6.0+V@9B35I@0E8SS,WY9DG,4L1C;ODCC;6_>QS[
M'F6]DS/6,!AKE"C9JX?(9MS\@K+/5V3&PF7@FOA,9F,E8LE#AZ2:]%I'L4;Q
M,1OK#,>DRZ>H2-=/.B-I>.]1==W^ BQZ:T899XS8<.//IC8PD.8(A@IJG0Q&
M).ZB3TK#CQ@#))<<9+L#/K1%GQ-CUAS2%K>45["PA,230L!#.49$Y 22$\SH
M880(Q,B1[3KK%+YE7V2K]H*Z+O"737Q!Q-PYDK;,V:4XFWPS=;CIM6U/I*O/
MH9NZJ:N!=CJEUMJP:DVD4C:N"V[HFTQKQ;=DTQ53M57E]9RD.!)+L'L:?!F1
MK $3(PTG#&5FQV)MM!D>,F0<B)OU-9(Z/D(<J4A0DR@J52]>W#W64=%R3JF
MEU.E(G#!D@,)4UD;$,<T@?(P1()((YHUQ?B#A%N PW"V=C,8C+4N*JEZQ5''
M>VJ[%%N->JM>JWD97%XPB)%EI5ANT)O8NS9K755+SYJ-F,I\R]:CIQIJ9*_6
M.C_EK/\ JE<EY_ZE'_YW_<G4%'_:$O\ Y#_?C4-Y$:G=.--:Z[[ZHM6]-SM/
M;V6].L)NOK]<4[#1:)3#(]9]2YEWR6?.#EO*9Q/Q^1H^*&DY>04IUN/CB7F_
M#5'7\I5QLIBS+(Z_4Y) 8+:%<G/,QS1,[=0=A"",N^!&9C;73/8[]B;B[V4
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M'&T;1MDPC:(C:(C_ */[HV[MO-I/L.-G??B,9WG>=\64[S,[S,_](=\S/?\
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M, B"DU1'UTQ$3)3/6#FCZVW3C33C33C33C33C33C33C33C33C34?GOU2 ^N
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M0_$/''%7%56K2X@R[<C6HVF7:JF5Z:83:;B,'@3;!5JR3*2Q'#6$I\ID00%
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MQJ-&6W;9\MO*+8>DJUYU#$=$01<++'T$EX"&FB/6VV&''Z_"#X&PEUD"9?\
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MG*NM?I:1@@?)3"G-FUMM+H^,+SXC:EEIPK&<-N=F,9RI7<5C"<Y3GEDN"\B
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M'A"L,RZ\CDM9]IQAW"'49]I2,<K/LC9Z-MZ^.C>-XWKV(WCSQ_A7?'OZ\C[
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M@A*1GQQ,Q,3JIY77C3C33C33C33C33C33C33C33C33C33C33C34?GOU2 ^N
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M^UDK;A#IM.PE.3794X^2''7.2+I0!9-EK:).8T1*K[7F_P $I$2<1],:^W=
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MD(4L1[IC<Y\*.Z!*9&8[H[]IC??R3MZTL35YHYQ) XMA7#L5@NQN6V!KDIB
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MN6TB M0NU:$_?YFN3%E%K%K&MBX(9F:9JD5'3H4M S.6XY\X8-\?Q4E,;4G
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M]AQ+*"$1KLFG(.0VLJ:>5DES*6U.(;2E3J'<)QAU2L?1[6YS+\-F.1L8K'Y
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M4PE[+ U[@EN<ETB@=@F8&95T]G1W1$ 1%,1.^]C@(=(L2S)G23CDQ*SP\+A
MDKY67CHD:)4N6:RP5G N&3!C6PV_'<9;SA#C*<]U:\\U; 8.*N/KVLEDK+L]
MELY5P8S2RLU<KC<17Q3G9*O$W9% P^L\:G(^5@,"M2SCJ3.LFP^3<2EJCH*K
M=HF33SI:XG<J=B#<N99+DYD8DMB$M]XC4@!K$K<(Z.)0W%UR.8;DGF9T]8(
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M+, CZI!9)TZ+;)6)6H+.TI4(ME1%(>$4=/F@3Y)G<9B2VB2WG7LX>C0;P;Z
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MVMQLA*L+SOE+BSC+AS#,PDX"L&-K-6JQ-_'Y$P"]< ;M5KF%="LNW*& U$"
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M:>MVI$V5YF#D#Y6%9>G:?ZS>9B925AJY*2,8TX4IL$Z2K\">6,EI\R&BR''
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MXEQR#[LOT-_5:=I=_,+?X=']MUD:@,-8];=AHR^WR'Z5!F.S^_?F]X1/S?\
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M<Y22Y=>02+E,O,J%D&O-#2H4J[$N7 +94)E9M@+$BJ[V.KU5]EFM9N8=6J,
M7.0D; F:^:F;B\0\HNPOQ5D=!CJX$0Q#VIP2+%DB"$R<3 SI7A'$LQJ(E_<[
MN-R..8]'"G$O#O$.)R>1M6G<.-K7#!;(D+=G&E6 ;=?'450)+K6C"HM;&P+2
M7UHVLX_-YE*:.;#"'Q-F<K5J92_<PW$IT,(B$@J@JUCZ5VY8MOG(8<K%IM2
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M@H-H!MIS#UL>G&FG&FG&FLD:^_\ >_\ ]!_^[S,J?RG_ (/][6K\2?\ <O\
MS/\ [&O90YT37Q_IQIIQIIQIIQIIQIIQIIQIKQ/L,DLO#$LM$#D-.,$#OMH=
M9?9=1EMUEYIS"FW6G4*4AQM:5(6A64JQG&<XY28B8F)B)B8F)B8WB8GNF)B>
MZ8F/'&O0D0$)@1 8%! 8S(D)#,2)"43$B0S$3$Q,3$Q$Q.^L?U+4&JJ%4Y6A
MTG7-*J5*G7)1V:JM=K43$0$NY-CX#EE246"*R&;F0"2@$GS+3GB M,A9_N5A
MEE&.FG4KI.NBLA*&2<L4M0 LY9'*<F(Q$%S#L,[Q/@Q _6Q$1+Y#B+/9;((R
MN4S.3R&3JP@:U^Y=L6+=>*IRVO";#6$Q71;)-#D(=G$;?X0R*=;]03A_3K=8
M[IAOYY3]&EUDYZ7;_*ON/-RM?&;62]HRQ29"E=V\:_$0I%.<*>4Y<Z$.*H=2
MYJNS#3L9286->.+L%,USF?:JP<[\ZXCFF@TI_EZ\;PC?^&KQ&V[%'ON?$557
M&.,=QQB$K#*5X#Y^L17"!E%PR@!XJIH"(CVJR[)B<D(#$8S+&R#B*MRL<;J\
MG-<STXTTXTTXTU1'R4=%LI(DY *.86YAE#QY3 ;*W5)4M+27"'&T*<RA"U81
MA6592A2L8[$YSCR1",;D0C&^VY3$1OYMYV[^Z=75)<\I!"FN.!DI%2R84#$Q
M$E(A$S Q,Q$SMMO,1XYC5FM*BCJ;8U03#TN:969C,.-&33L(_)E$19&8]B/L
M03S3T0\:\MEL2:$(;=CUN-G,/(6RA>/#MR0WIQ)D2CY($^23F0GE@61,2$E.
MT0<3X._-$]VLFATU9*EVHAKJ7>K]I-]4;0(6#PZQ.IL$ALBL8*656 0N@948
MS!3&N>7HOQ>H@?4^Q'.HZM;2K]F>V9**@5;5M]^L,L7 J&:(P/%QFP9R<DHJ
M(BC22 19,1YL>S-);.(<D#AB9,S7.%HR44[,Y-=M;9M'T^UNL-.5[1.PC88P
MP "F1@HVAL1!3S%$G/7_ &<CX.+/X>.#;N"N4APB(MQ@<=B*===N#(.=[\/5
MJHL6+"@!K$,$CHES*"$J8"%=,^;1KB6G&FG&FH_/?JD!]< G\4.XTU(.--:<
M=>C0+W37:D2;4<1'^R"BJ*&):K)4P2E%PAU-,TT*YL%U0^ZY(PRJNB3@A0CI
M2<Y:9\ZD5:-;XL@9PEB#@)#K5>82A$L*(LJ[JP6A*N=J9VZ(N&1DO%'/ S'<
MOF=#L![*N'FH5I=GVMXAA+5'EDT53.#O0;,[8P3$YFO@(7)QE'8YRG@F8@SZ
M$N$LAT+*E]*E.RI^ND*5T_P/]T4]]LJJ/?\ F[%['JR2RI3)$"YCL7$/,K4T
MZ!D=;:LH4G/)7$3/M9C)F4%/8:<[UY@JT_4%]Z2C>)3/C7,3,2&TQO&N?>R-
M$#[(''<"K*+B.+^)MDYM9*S(;9F[]3RRCB#5DAGP;JS&#"SU!*.:)U\N#-MA
M:I[*I6MV67?T]$U""A$:Q,F?+R$BF6*#(EYJKXFX\M;,/B\1[!9Y</X9"!B<
M,H.;0WG+79N!\RJMB.)V9;.D7#^,JMIUN'F&I5NX.2D8-V+"R%K>$VS9#(!:
MS8OF<+T0J5G^<%GA[+<0V\5C<U@*JO9!R'$&8R+N.ZB%V*V/9C4R.*Q^9["^
MI!VCPSU"BC?"!%:H&5V3(G%8=@:BUS98R$;TI(VDL&L0U"FK0-=RQ(<5T*ZQ
M$1($R5;P4VZ0U',SAY49-K<<:C@C \%-*6T:/C$)Q3A>&KU6E'"-BTQ^,IUU
MY)5]\]*56>8J]JD10,@)D4"U,+. .9F&,C4YPSQ_Q9P[ELB7LC+Q7/GW9VMA
MK6 H':L*R.#L.4[%Y=-:ST"-592FXM@@=RY7>,/A7*2USD/7-7IE4N%1A(#8
MR;A!.3T3U H?A6G8V'"'(:?H<X-..$M1C4?&GR1$PPQ&$/,S7JA&7E*C@A9>
M5UY&"I,1DJ;J]R[;I4&DT%C$U!>%H 5<*Q/<"E**8CZD7- FSFB-MXC+\7\0
M7\O@\S?R?#8X_(/J6N %A<("M6&5UIS.)934A]J;6116.B5R\*PJG=8%54/;
M(+RK9K17Z+,C:9K%B@9(6GT3,4&^[)C"MPEML@9#L,8&))B%P&R(*3[L0X$1
M-L^R&ICV1N,:G6$P(TH-.87%%VT<!O3=>J]>S1LM)J;F/NB!N5"6!)5[=6X(
MHF19 FDS&(= QR1I",0?%>-9Q]F\?<Y,[F&L?T:*33D,5C\@P;HLOUR3DN&;
M=&669,T0M5WLA$=6.419;88>T7Z-G[[3*0)8JPC5>V\FDD3!@TK)V,N4JS]G
MEI1A*6369 8HD8"-C2/$$4$RUX.<K\3"9_"YO.8\,TRK3ZQ\6XFYAHLA82N$
MY W5UVW6.JIA=9Q2U(5YVY@9! \2F!U@TW5.%HC@_,Y^QB\Y6XAX0FW%2E49
M1H\+I3DZ^+*N]K7HLTP0ZI;MM6M+SN24L%D0PBS?J/6&RU.Q^H]N1FO85BT,
MVHM3=9D7HFT(8J;=,MT5$F$C",O!I8(FAX,=?=<(;0'8 7DLY%20_K/$7L@Y
M_P!@S@L,;6HXBM9QN=NED+#&78R-F5VL>QU$65=I-CEW6 DB @2N8.?!*-];
MRD\*YS,XWB7V/,YQ3-X#770_B$*UBHFY8P^95=R 39=9%3[1X^'0D@4)V;#'
MA*3ZB$\S+3=VK*[U"0>OZ)8:^#*$T_P&XJQSAL-!#T8*>.G\S4H3*OBR3\RV
MS(/1SAB^^^.*0H)H5QTA&69XCJ\2>V'$14<BMEQN$FM/7LN364(&#8NM9/4E
MC83RBR9CE@BGDYHF9^L\+@K6%1[&-_BOBG%95]=&8FR=W'T49'*VN('X]&([
M%CUU@8E5!S*XV.46E5<U8M:T/#GW.*12Z?'?(]77=1(FG/:\C(.,L;=FBA"A
M$DKE1J+I2Q34K&39;R@;(X6,XQB%F?,*(M&&0G#"/7IQJD8N:BOD,R)8&LP2
M;62T4*YR/M*:\M=T2Y1-LQ*YD3B.9I1,C$$41K8?8DRN<CV.<UEKN1C,7K'$
MV7G%V+J=E&JQ9ITZ";-.B;2Q]4K!21J2H8J5&Q:"N\.]WHG7*7JL[4@G:_$1
ML?:S+, V9'>L2Y?(4$Q6T966X\T]C!31<L:5EGQ@I"=BT!-@/RA#[+3YFT9[
M)9[()K56A0R%I=6FRQ7PX#;AB(J@*+60)',5N_U'R+6M G56B"N>('F'<</1
MXBH\0FK)Y%EO!(PARJUV2M4E^49F'SR$(035%6QRJZV0#%5;1,-ZT+@V+"CK
M1T+*HUE /2VR@9M^QRSMS.:DHZQQ; C[S([4E6*LO !C,LS$#O#2PLN>\H[R
MHKPY*1GL!CPO#SN+4WAJX&K>9Q+%IS,**[<@,@%:4Y.E<HW(*KU)A$&LS)',
M 0MX<HK86;=1D*1\19"ECN'+ +Q55>&026XZU8>F'M[%D<E$& TBL- ZI( 1
M0370P.<8;.1-F5*JZLLE>.$;D#(29H7GJ_/@6R%G)F9+EP2A8RVO1\7'1F8R
M'7(LOMOU26:*G:Z8R5%2\BLA@93N\8_B2EC[RN(FMRG;*N-R>(9!"FKQ$O.D
MDD+]M<:9!7M4:MMA#597BRJ2B.=S.1):U#A;.\4\2XZZ-H:^/S-;-(F_C+6,
M?6QM2FFR$W<*-X[&1"QDEH+FC(UF*JW0E+44TCVGH3'6=+MT=K\#:6MM4V23
MME"-D2;I?X6^N!QV(;()Y$C6E5QH4.1+)&KJ/&GGH&:>.C0VW,2;;3)*61X+
MB/BO@_A0>&*MN4KXTN0I></&6#.K3IVK!5:>/O3<I7:-7*Y""4(6765-)M=E
M<2."(5X/%-[%Y'.V.&\_QCCJ^%S]1",7PS:X?6VT.04Y;49964EC!!!6$ME(
M7:15W][*[1)4MF*WNDRE?I47=['4':O#S'J:)C;%0'69^&+:F(UZ1=)MT\DF
M:CIJP2,&M]LF!!F*V^&X&HTB(RM]YYR7=FKE#L-"\Z>'.VJ7:M!B\8JQD_:+
M(UFI1:R;)W5F%VJ1/B:4.H+I&A;8J'U8E<CPSGHO9J[A<?F&Y1M&Q=/(HXBJ
M'CK2;%5L5NR8.A*J%FECJUI*WHLVE913UV!6F\7)N'D%L.IY2D1T856Y7#Y$
MX8*58Y&X0;\J+$+DQU0'EV&H DF"!#CVB1W#_5 3#1+S+J<^"Z0AR6)B>(J.
M)I<2WLA37BK3+^.XLQJVR]N.5:Z>/3=HU3LKQM":O-V,3K*%-T4D!?PP.\V,
M7QD'%!W_ &Y0-:GBUM#'5\-E#HV;452&\,Q&2K(L6'6BARZTW+C27') #*PF
M(I8IYNO2EJC*W:QI%,HW'1)\@A].8.U5"! BS0Q,D):7)LR!,I'8?>\K)@*?
M=;;PEMU?EU<KG5XO-9?V\3FF222JG35E$WZM;-XG%4D(496Z=V+17KMNM/-4
MAE"Y <I- 3; 3.X[&JRR,5>RN)A!46V;E:L^FU5_'9N[8M5WOZ74E$JFI;D)
M%J[([F9=08$I+V-=<%IIOR-;"D3\C.0CI?I"K0/Y>"D6&)!MV1U]8@50TP-)
M#&ME %,)(69"FL/9+!=&<7E6%8[8?@_$TG>R"_'<7(?C13CK1)H6+;!L)MCT
MFUJM=QOAH<LFUE93BL%"!$6@SPCB[QSCBXAX?JTZ6/QF3&OQ!C7%&74\*^U5
M960NX^Q68IJ+:G&D*]Q)> </5RE$D,^M&'60)R4JKD%?AU2D<,:1,JFF),7$
M'&Q><EX4,[)L/ $MC *)4P(RV,GS"?!9:<<?;YZQG"R;U\+6%S(8Q^'*S<R2
M\J9E:FO69VBWD*JHIE4Y5U&S(RT08QT1!!$[%-^+URI6ST9+A>:]"20=$,=9
MI6CRSK(<MB356[,Y+B>*Q,W,,F#,G+.XHU10NSY.F'MR=-LI6%DL3U;F@)=E
MXD67JTZ7E4A&R,<X-ZM5%2PN&?.ABO9=;,_11\MNH0^FMCBFDE/#C\3EFY!]
M*_?JY&IFHM6U-Q]RWS-YZQJ'&C0LU^0[%>JR&K=(PH!VE@Y^1X9I9NHJIF<>
MLXK.I9*HRJ7(=3)4E3V:Q7<!P_K53F>D;H*#7&S.:)F)G-_=T_";'/FM3E2!
M$8/78*8'8+23A->V 7W%R*:S*QKH*?8_!RF&28DD]A1"&W6(]4>0L=12O.3Q
MW#M7BWB5>/QN)XAPYU>9LJ>U%'$NR3I!=C'O3+ D*LOKI)9]7D:R06/17'+
M\/1QE;P<TN+ZE(K#,IE*3'5#$%W.'E[Q5;=KNZ[)MVUM-;5@81,1+C<)%MJ:
M3LSL&1AEW*M&WZ>VG8YJ83MV2#6$JE&%ER$6?",U 6)\N#*R<@ (,S.Q/JR1
M1W@T*8;\NM.4V>'Z/'?!MSB#'8^D#512IG9RN/L$H:-*0KW+"Z+CZ=!UTA3R
M.<%:[,]P+*)%DGK].APOC<D'#>3K\-8[AK&8ZI8X0K6"GVYK)0NRG(V+MBT1
M/H5:S[9#4N'8K3!/D 9,R4#B-G7ILY'JQ7I6#M=B/#"-<AH R7'D1)&7D4AB
MAFA2H +1\TXZXO#<?#(6PEQQ*>^I:F1WI6KASR^!O7<<6*+(5JRK=AT9>UCR
M0VUX47KC,MR5K#I65DN6G%>NNP,B<1)K$MO3Q&"7M/(8J]@,7C[%FK&1RPT.
MA9J4DRPK54ZURQ**!\HE%BR8M,1[TB$$P+Q5*C'PDO%UNWW. JCTBM 5J@)]
M%D4F-<<>4(\B7:;&1(1DR(\AI1$>WEC.482Y@EMOO(:E>#\?AJS,>RSQEP[,
MY*FOVUQ/;GW$61F90$1=AW,C)*<40RNBPI!#X2RA.Q1BW\BW**L9'%8E^1"H
MHK6+RR)J 3CB8,5TBE;UVJ=A<3,65P[EGE$D$<[:5_5-$D=M@ZPM-IKU=!S,
MR2B[[*'D!5#U2MMS,(OQ&1)"3!\=Q3>7DE..X;0K#>5)4C+KL2/"&!PO&A8'
MB2I#ZU=UB_;M4+85Z?M?>CEQ8EU&DY)P]RUM!EGFC:9B3VB6>,YQ5GL-PO8X
MHJ86_G933HBO 8ROU<U-PF0%YA%S+2]20GGCLU46SRF<++<5Q]5[T10C<?Z,
M;H9!:=8?;"Z;];BH?&7ET=](\*TUAX=Q24*6R[A'B-*4A"E(4G.4ISVXQQS+
MUU5,ID*J>655KEA"Y!I/"04P@$@<4"31*(W%A",E$Q,Q$SMKI%&Q-NE4M2MJ
M9LUDV)2\8!RI<L62IH#,B+%R7(8C,Q!#,1,QM.M]R?UU0WUOV;^4:ER/\D_#
M'Z"UD^6/@G](ZK9/#V4B8'6TA[)S/<6\VMUK&?#>[>^VAUE:NU/;C&,.H[%9
MQG.<XQG&::KK\^'-_1D5]S2_C7C33PYOZ,BON:7\:\::>'-_1D5]S2_C7C33
MPYOZ,BON:7\:\::>'-_1D5]S2_C7C33PYOZ,BON:7\:\::>'-_1D5]S2_C7C
M33PYOZ,BON:7\:\::YL&X)\X7VK8[?-/]O8TYV=OBK[>S]&S[7.MA#.0?"#Z
MT?Y,O-'WS7-3E7.7@L^N+^,/GG_(U2]A'NV?M2_PW/6S/L@^++]9KSNK[%GX
M0_(T["/=L_:E_AN-F?9!\67ZS3=7V+/PA^1IV$>[9^U+_#<;,^R#XLOUFFZO
ML6?A#\C3L(]VS]J7^&XV9]D'Q9?K--U?8L_"'Y&G81[MG[4O\-QLS[(/BR_6
M:;J^Q9^$/R-:XRW3J-*RLG**M;[*I*0,/4RF(;6EI1A+A&6TJS(8RK",N93A
M6<8RK&.W.,=O9SFUOV.%VK5FU.7,)LV'6)"*0S 2YA,D8F;43,#);1,Q&^V^
MVOH'&>S[:QN-Q^.'AJNT<?1J4A:638)-&JA:(80Q3F!DX7!2,3,1,[1,[;ZM
M_P K,)]5Y'W&;^,>8_T,%?;EGXB/[5K.^F*N?<M6_*C?V+3Y683ZKR/N,W\8
M\?0P5]N6?B(_M6GTQ5S[EJWY4;^Q:?*S"?5>1]QF_C'CZ&"OMRS\1']JT^F*
MN?<M6_*C?V+3Y683ZKR/N,W\8\?0P5]N6?B(_M6GTQ5S[EJWY4;^Q:?*S"?5
M>1]QF_C'CZ&"OMRS\1']JT^F*N?<M6_*C?V+3Y683ZKR/N,W\8\?0P5]N6?B
M(_M6GTQ5S[EJWY4;^Q:?*S"?5>1]QF_C'CZ&"OMRS\1']JT^F*N?<M6_*C?V
M+3Y683ZKR/N,W\8\?0P5]N6?B(_M6GTQ5S[EJWY4;^Q:?*S"?5>1]QF_C'CZ
M&"OMRS\1']JT^F*N?<M6_*C?V+4GKF@AH7SG=LSY'F?+]O;%MM=SP?'^9V'+
M[W>\7_)V=W]GM]KR7L>JJ;;95C.IOXZ8CMR;?_$EOOS>]MM[^L.W[.=K*]/F
MX=KIZ'/MMD6'S=7E\>]4=N7I^_OOY-N_M[S%UI&G&FG&FG&FG&FG&FG&FG&F
MG&FG&FN;<SU!UCJ)ZHMI=!FP-!69RJUVN-6)&RGI4H9QJ2C1HB8BK+&CB1(9
ME2PT>>WFEW2*L[LDF:!%<'''68M(.LGD59+*V\!8Q[92M4,[5)%&QC &#1B
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MB(^3%#-;"B\19#!60'#7X#*3P[QIB<F_B8";FTQ2?1N/:UE3)V88RW?L6P:
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M+R>YV:WDLF^8R%_'9V*/#6*(J/#LX>!19LV35$=.VFTX,F-<5L8)VF(E)0)
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MR4-:;P!@]F<(+8$F)L*(Y0G:)D>;OCG[N7Q\T:Y$[/Z,?2?;0AK0J=D6X[8
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M&H8DF><9$00)SM/-$UR:8=/R?5);(LF9C8!VB"DO!R2N 0N\ ^8R?(>+EF+
M)674[]]UPKF#;?<BWF8@?"W]YGZC].--.--.--.--.--:A]9W2U']76O*#K&
M=?C$U.&W;K785VCI)R4'S/TZHGFO3\!&&PRV3XZ:DPS%-Q4DR0(L M*"FRAW
MFFG4X=ZI%Q:U%MR"]3&1.\<P!,\PQ(]\%,3W3$QM/ECQZS*5N:;&-&)YR0U0
M3&T\IG$<I3!;Q(Q,=\3$[QW;3KF-:_0Z;0NE=M=:M/4N39GI.X=5UDC;Q*#R
M EQL(>Z]1]/^MM>Q>S/5@K(5F0"G2SXNVG@G(YZZ1DNN1C78V9,>\E%GA6L
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M4-J;SC.%<::YI:0Z?.I^E;'HELM-M2=5I*>U=+RD,?.-3%AI4'5.G*W4.QU
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M]E_^YW_2_P#PW&FGLO\ ]SO^E_\ AN--/9?_ +G?]+_\-QII[+_]SO\ I?\
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<MS_Q]_'R_P"3'FUE5J7+S_5=]^7^)_G?Y>O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g383050g23s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g23s23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X8C0:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(R+3 X+3$P5#$T.C4P.C Q*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 X+3$P5#$T.C4P.C Q*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,BTP."TQ,%0Q-#HU,#HP,2LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M,CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C(U-CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T)!040X07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$U6FY4=E!U>%9K<V9K*TPO
M04$S828C>$$[87).9'DO5SE217)A9%IW,C5M4FA$25EM13 S3E)%,TE'9S1T
M='5A5GEK-6965F-M*T]#-#-F4'E25&9L3#4O45)M5%15:CE74S1I:B8C>$$[
M16PS84E783!,:65G85EB4BMK,50P;TLT4'I74'8K=W(K5VXS9F-T5#AQ4%!Z
M4$5G,'9E84@V>$544&)!3D=84TYE2DUL0U=A5D%Q+R8C>$$[86%O;T182#AZ
M:C<Q+TQ:3S5&84(K5T9Z96$S8V%:<2MO439:.5@P>5!65VUJ93-N06IL845+
M:VY+93-32G%805DX,TA4645-<$U:-B8C>$$[9T-.9UAV4UEA8VU613%T840Q
M2#AS=DYL<4PR94,S:G9D4'-O9G)J6#!%,$Q),6\T-5)4.$$U9%),2#AA<7<U
M57)T<V-L2%523F0V2B8C>$$[8651=G584"M72&UT3%0Q1&$Q=4EZ8T<V9U=A
M,&(P;S=626YK1$9:>7=M6#%V:6A:47<R-C%O2#AX1R\W9C%,*U=L*TLO5S9F
M.')F3R8C>$$[479:26)E=UHT5FYU64DU<'!B841A,6%53S!L6FU7355T-4YY
M+T4X5S1S,4U2<5E6>E4V86912S-L+SA!3%<V,4AL1F985%=&-#)P3B8C>$$[
M;W-&=7-$6$)&-F=(251S:D0P;WAY<'HK3'9T44A"4%5!8W0Y<BM#8V5N=FUA
M,W!!>B]L>C5U9V=J=4IB4TI,5U-$-C!,;')Q,451:28C>$$[<$5W3'E'6&I'
M5T9X1GA6>4=0255'*U-'94(V+V5X3T-9-DDR4#AQ=DY8,4LX:W5)4'$Y-V%T
M8FQ,5U(T46I25$QC=$Q).#5K16-8;R8C>$$[9E4R1&AZ.$\O3&E2:V9Z36)(
M9"]:*W1K3DY+:F%N2"M5,S5H4U=J6%DP:&A"1SAK8VI03F)O5DU-:&EL6FQA
M44U%4G=1>C T:G)7;28C>$$[2#AZ:G5R4BM7>61Z96EF;')Q*W(K4V11.#!7
M>DU6<S5E159O26UB,551;TIN.5=V1F5(<7)S4CA61W Y:S1*-F=2;4EL66%C
M>6AX0B8C>$$[969Y9R]-351*0BMI,4TP<W)W47AI-G1#,&MK6D%K15E%,W@K
M;50X6E=O5V@U531M:BMA>#DO,W(K5WED,S-)5U X<R]/<VIW3$AP-B8C>$$[
M=CE9;4YV0S8S3G-Y1U%">CES4V-1<#E&=T=*-&MQ>6<Q0D=3+TU1-S!F;#4Y
M>4XP>CAP9DYL-V$V:7IX2F(S=&UV.$%O.6<X,75*<"8C>$$[-49U>&%/;U)P
M5EI12#5H6#1K37DX5G%4:UIA<4E)-W8R5WEJ<'!%2'91;#DK5G9N>7=T<#=M
M.#!S=U)7='0Y8W5#,#!(2DE2<U-6.28C>$$[5&QY2&1+8V@S1RM%86U"3D%S
M5' U9U=1:C(O2W952F)13%E86#%V5T9J<UIP8D@P=E-H2S9L=SE"66)P,S13
M35!66&YS;T<Y0V%(228C>$$[+VU292],9C=02G-/;$YB8R]W06162S4O2V9Z
M6$1O-E@V44-76EAU9G(Q=7-K2$=#0S-H:6Y79C%22U9E3C0U<3AL*T5B8B]%
M34DQ328C>$$[8G!I9$Y)0S$X+S58,W(K5S=$5V1+=3%V>&-23$QF.$%,,$QA
M,W,K4SAU13 X,#8X5S-!+V5)9V%V=T9S03%)-&E#2R]3:S99.$EK128C>$$[
M3&$O;%0U-G5L:F5+=U1H26)95BMS,C%6*W5&4%),;TI#-CAV5E1Q=3%D.&MD
M5$%D5TDP,"LU5S!N.'%F36UO3F525F=J=4EB9#5R1R8C>$$[15A&<35U;6IU
M:W1/2V9V9U%J3S="2DMC5UIE27%49VQQ66EV>#!T361.26MH4G5V>78X04]%
M87!*8C)$>7=/,71%=DXW9$I43&-P028C>$$[=U@P:$LW8U$Y,T=V3' X435C
M4V5)23%-3R\X04@T0TIA85DV27)34'EK.'I8;6\S=&QE4&)A93)N;&\W:WE8
M3G,U13,Q4U<V:E%5;"8C>$$[0VUO:&\Q1RM!2&M24E=P1V5Q:4%#3C<O048P
M;4]M:U12,E-B5E!),VUN4V)73S@Q4W=E>G1*3' W1EIN2VME=D5X5GAX47-X
M04M.."8C>$$[449$43!R;&MC,%I'9U="=WE(34HY<78U3RM::S%L9% P2D<Q
M:4-14BMH959G=#!L37%3>4M9*U5Z9V]6='!#1S5D<45"='-Q:G%O,28C>$$[
M8W1M>65L:T11,U$W9FQ4-6LO=WI.<D5A<E!08E14<&,R8T5T=$E)-$Q73EAL
M;$QR3E9Y0S1(0TY',G%34G-$3#AZ2&EP0C P=4<P<R8C>$$[,4PX=B].=6TV
M8F1A;&0R4W):5U5O9W4U:VYG;#E/56M!>'-S8VIS1U5S031P5E-A3E1*>'IW
M2F](9&A,0DU#>4YM4%IA,4]X5CER+R8C>$$[05!L3F8K,TXO=T)I=6,W+T%*
M5#1U*S90:DPY2% O=BM$+VMA=61">$]H9"MJ,R\S+T(O>4Y82&E61W=83W0R
M.6A,<#!'<6U,5#5Z>28C>$$[;G,P=6ES3&YX94U.>&)P,T=24$-49&(K-6M*
M:T-R,E)&,W)F;74X84IR=E@U-VAO1FM307DS<VIL1FQ4,#5&5&LU-&@P4$9G
M3V\R3R8C>$$[4D591&M0<U-C:VHQ2S),5B].155C16-7=7I2>#)Y:$Q:1G98
M0WAQ<G))<6]!,W=G4$=R041U064R17AJ,V99=FE3-WEP4S-M=7I+128C>$$[
M;#%D<$5&=4Q-2SDP>D0V<W)",6=O5R]U=WEG:$]L8TE%93<W16-C=3EY6&UU
M;TI65%8R5F)I0F)38TQD34)*8F]O4DE8;S-X4G%O028C>$$[0VY91$=O.3,R
M3'AY-S!3*W8K8C5),6EK.'A81'A,13%U<4YF4T920R](;$5!6'!W8F=T5C9B
M1'=Y4$)$*V(Y:69&;#-L4V)69DUR9R8C>$$[<3)U4W-#,'IK1SAC:FQC9VED
M=G1D6F52-6XY<74K2&AJ,V99=FE3-WET:3%$>D1#.30X5W-V1RMO16TO6DQT
M;$TU66MS6FE'+V562B8C>$$[2E!+=4I%9'1U6&MG5&M/<2M(5G9-.$%1438W
M3$5),$UC65,Y9&5+1TY):7$P8EEE;D5I52]L541O0FE9>#=V<U--:V@Q3%DQ
M;GI3<R8C>$$[>51$6'!H3D@V66IK1C8O2F921$Q&4G564C9A>4]&.$]2<#%X
M-%ED,S),-&MU.'-G;B]-9GI23#5F9E)3.6=%:W0O<7(S;G%Y;69I=R8C>$$[
M-'E-=DM:;VMA5F%I56]G.5-P6G%T4FA5345E2SDR,#9M6$141W)3.3%U,&4R
M84163T%S=S97>4,U259%;$I-<4M!,GEY8VIZ02LQ6"8C>$$[9DQ326YP.6I6
M1V-H>5!*4'17+TU4>G1F4EA#=G))=$9U3"M857!(=#=U5TUH-5)'16E"36@O
M9%$K:79P3"MZ-#5534]/4%1P6$IS3R8C>$$[95HR=G%K3G)R1W4R:V-C9'(U
M:"MR>'=U.'-+4F%H=U9*2D9+3S9H6$9'6E=)66IQ36M:-'IZ2#)-45IJ=E1F
M5')J.'AT46=F-FAR;"8C>$$[,V-7-6Q%.&YP-F<U47I">$E*1%-3:&9M=DMV
M5W4K0SA88U!K>&QM;$AM5#EQ26PP>C@P<'):<E=B54QY4S%A25%003DX>E)M
M161)>28C>$$[<&MP=T@X=E1#1&HU,%!K=T]O4#@T+V%O<&]0-6IW,CET0VPS
M8U(R.6DT;7,T;'9#<5%Y1&-01V]E:4U01F-01FHW=69K=FHK6F1"2B8C>$$[
M-3!H<TPV>&4K:6YJ=F]"84\P.39S:E)W:&]I>7A6;#1R>E<R:5)T=G-Q1C99
M0TE71%A,>5I$54=I3#4K.51G9GHO8G!B2F(V-TQ#;"8C>$$[:W!3>E=0575)
M:%9H46E)0U5C05)T.$]%:4(V9EEG6GE/<"LQ<4EE9DE9;FEH,7533TM8:#9K
M86%K1E9V5%955&M"3%$X56I65CA!028C>$$[3S)0;S=V<U5:>C-N-U9W:R]-
M14%G83E-05I$35(K:RMS<&-3;50K.2LQ-FE+.65V24$Y8V%X.3,R3#0X=3@O
M86ED2'8O4&5M86A$928C>$$[1%55=2]30E@V=&,S+T]*9U5204-&;5)H>$55
M6E5Q=TML14E)2W)14VI!:7$K>&Q(56M'-RLY8G%.,S4T=DY2,4,K:C%#3W=/
M<4)5=B8C>$$[;TQ/*T5C8W%P2#995U%'6FUK*TAQ6D=9=%5K:VMN1TU904%6
M9&532F%G:VLS5BLY05AD;#5W=DE41&0V<#E9:$UZ6$IJ;'8Q9&988B8C>$$[
M-U5V1G!#3UIR=3-82D%W2$EF67A/66YM5#EQ2VEU4'I%:75P8G5,>D)02&14
M<7%46$,V;E-2,6IR=U8S179*9W1D<3E-1EDV<79S5"8C>$$[-#AU."]A;U=K
M4&YE>G1:3%,P,6AR93!L3&U7,VDQ0E5J67E#:CAK5U%+95%&1SAC2C1#8DDK
M>%)M239N-U<W=5!Z>&57,&QT9#9Y.28C>$$[>&)40D),0DQQ261(15@Y,WE6
M<$-$=R]:<C!X2$%.=U!S535I95I0,G!B+VA45E U-V(O<$IH+S5Q>69I0FAX
M0D5R-4$X>G-!>3(V128C>$$[2&-%4WAK2#AC2&EX4GAH.6(K;% O=T%Q-3E,
M:"LO.$$P4'<Y3V\K,SE6<%1L,#8Y.#!0*U4K4#989F-8;W9Y9DM7:$PU270Y
M1C K*R8C>$$[,75&<G%:<C8O:79,83-K4')M05=C6#%6=E0Y4TU"5G582C5B
M5F]2=E-M8G5F1UI%4C=H.2LO,D]R:'=#24UU+SE#9&57.4DO3'DO1R8C>$$[
M;U-W1S%#=&5Y0T-,6'(Q-TDR.6=S6$].,2MR<T1,33=K<%)E9D=G<7!R;&53
M5U%6-W5G=F1T>'AX;2]F,4Y)4F9Y.3AR;E$T=%%B>B8C>$$[;%IF6$IR551P
M66A9-G).-DUS>E%Y17I+-E4Y15(Q.4]P9&=/3S1*;#0X=4MU17-006I6.%%2
M3VUA6"M73C,U4C!M>G9B9U=0;4LY9R8C>$$[=7)I-3%.0UI206)A860Q4UI(
M=55J-5-W>$MK8UEJ5FE75G5867AL3$E*:VIE239F9TIJ2$=904AA4E%*.&EE
M5VI"851X96$W5UIB<28C>$$[>FQU>D%O:&IN4U-.,%9B9#%N=4E9,6-Q+TDX
M-48K>3-!4'179FI3+VTY9G@P62M$2"MD*U!M;48O=T-29DHP8C-4>&5:=$TT
M6$TP:R8C>$$[5G5Q:VQB9$4Q1T<S5U-0:F13=5$P3'9**SA$9D%#4E@W87=J
M;6YT-E0K0C=M8W--4#5W+T(Y-E4V,35,.'4R1VLS.3-B95HW82MU-R8C>$$[
M5U%R1%EX<DAY;&I6<F1347EZ4V9'1&-N6D%Y:U)U435!>6--,&E11$=M=65'
M249I5G Y9BM69GDS=5EJ1D)Q;')P:U-.-FQJ<456>"8C>$$[.6)N=6):3&%7
M5U4S3G,X<V%W>D=223!22W!5=%-H-C562$QK2%%L=6QI>&YK45!I;&QT*UAF
M;'57-$5-=FTK>6I(<5A-8EA!3G59=B8C>$$[,T5Z4DE2>755:R]E2W9Q,31C
M94@R1V0V26)$;FPO3E T*T17345F-7<O2'A256XU9BM79%=V1B]1,G4R;'9Y
M3FI%3$QK2FU#=%HR."8C>$$[;#5C37AK-55J6C5P2"M(:6]2=WI)47%M27IY
M:4YW978S;6U2=U)K9E-1;"\U9V9L-5EE53=E,&QH,6]A;3$V-T-#35%E:51'
M9W$P="8C>$$[9E5K56\S3D1'>6MH=U-A:FIV4$)N37IY<&AM=T-!-3)W<DUH
M>#!03F97,%=X9FLS.'$W;DLU6EEH;DA&26]2=%-U6G!"1F)2175X;R8C>$$[
M;T$U350W05I23%5(;S-$0T)Z6D1P2#5A96%D5DMY,W1,1T$O=%A&961084EB
M+SA!0E5Y;S)E8D-7;VA(:WHW4E!Y>3AS86)X:VUI3R8C>$$[;UA!-GE81D-L
M9F%-9D0O=U9C4D9X6C9Q579*;&E"15%)9T-O;V]Q<4%!04]W07E4:C)U-64K
M2W!0-6MD+W$X0U8O8W9*4UAW3D9*528C>$$[2#)R:V]S;TI/0T)S36LR2FHU
M9D9I*W0R85@T:6%Y9596=5!86C!J0TYS>D9O,E)V:$)Q4&DV-4A*9D-A-7,X
M44A%3#5*=G%6:C5F=28C>$$[271+93).=G!Y,S$S26LW>#-(<G1"8D\V:4YP
M;S)K6FQ:4GE0-T\Q2S<Q>75-<$,W,V].,#113E91<SDO4D9W950O3#!-,75:
M+TU6;"8C>$$[2R]Q4F5T05-H:31S65))1$I(3T-E2FY0,E1U15DQ1DUI8W-V
M-7 O2'=::E1W2$]1+TAX875F275L=W=R3B]I1S(Y2U-!,T5,=4DQ5R8C>$$[
M44PV>6M2+W94>2]E47%T0CA8>#=Q0W!'27I%+W=O3VUI3BM)9FHT;V1F2T]I
M;E@P,#,O159R.51E,T4U,45E;C998W1X.4UH<%9&928C>$$[+W="<710,F-0
M:7DT8C13>#A#4$9814MR;BM#:F@K6%9I<5)V3G)S35DK<7@S9'=E35)%46Q-
M45%K;6-$9V973D-A3650=W%A:7-F>B8C>$$[0C=U<E X;U U,U0X9%5U:3AT
M95AM.5AN-6AJ45%1>%-Y:U)O86U33#%75T]S>2MO52MX4F9I-4AD44MK5$]3
M6#@Q9TU-4#4S-"MA328C>$$[<R]+=FQM1G U-VI88E<X:71Z3D593U-X8S)&
M;SAI4U)N,4]B0EIU2VHT9FE0,UI%-5ID>"]"6GAW44A/45 X05EK4&U,4W),
M4S<V3R8C>$$[,W1.46HQ2TYO56QA94QH>%9M<E=0-$AL1E9P-#5B:FM:1&-5
M-"M706EA0G1+<35.<E1B>3(W:&)M34@Y=VI,=TA935%3-$@T2$EY628C>$$[
M5&919B]41R\Y=3<O04IK6G%F-"]I.40O04I,+T%$9C!0:34O2G9N:T]W6%,Q
M2V=N:697:#9F.$%)>DYX-#!U-3%01FDW,78K1&909B8C>$$[+U9R6"]K9$0O
M=T)6369';#-,>%EU.3,K1&909B]6<E@O:V1$+W="5DUF1VPS3'A9=3EV+T%!
M8C4W+S9T82\X04DV2"]!2W%9*TY,=28C>$$[6&IX9#=8*T1F4&8O049A,2]W
M0U(P4#A!,55X.&%88W9&:3<S9C1..#DO.$%6<E@O04I(42]W1%942'AP9'DX
M5TQV9"]G,WHS+W="5R8C>$$[=&8X06MD1"]!3E9-9D=L,TQX674Y=CA!=V(U
M-R]W0W)7=CA!>4]H+S9Q62M.3'58:7AD-U@K1&909CA!,6$Q+S5(42\Y5DUF
M1VPS3"8C>$$[>#1U.5AS+TQ8-6HR5GI(9#)6:S%T9%%N;$9C43--56-I2'!6
M5U=516929T]34D9%0DEY67AU2D95,4Q24'I2,5-66G139VQV6C%5<28C>$$[
M:W1Z9'!-=U5S6$E"955M;DII9FUC15IK8V=!;5=81V5C:55S;#AG969*:E-3
M>6]P-FHQ;T%0=40U0U)K96)/3V)%3U):0F]N-5%$-"8C>$$[6F1:=2]C,C%T
M+T=2:#DY1BMN04E.53E:+TY$4&1*,$129$E4:' Y<$A!855-9T9:1#@S87)(
M-SAM0E1H>GE3;'I+63AS85E);7ES3"8C>$$[,BM-9W195$PV4SAP3TY.:#E0
M8SEH,7=%,'IJ07DU9$5.6$I-1W572V],5G)U0T<P26QI12]Q;F=K2C9-974O
M9T)3=45";$5-9352.28C>$$[<E9"-V5T4"]!33%:2G-P,TM0.$$U6FLO-4A4
M+T%03E=+=352+W=$3$UN+TDV9CA!-7%X5G-C1UE+3%9#4V%!9710,R]!3FQI
M;T-:-B8C>$$[:G!/<S)Q,T56-6%+53!L,'0U;$8S2DMS3%1L,U9"=VQ98G-R
M:VAE:')89DE2;D4X=7)B3$A-8R\T9F-G-4Q/84]Z9W98<VM&=&-V2B8C>$$[
M2$1*-C@S>$Y$>$QI;D]U,W%,,7E81G9407=)1CE#,#)O,U1+-G-'6EI),&AK
M0G5B:VAO-#9C15!X-W%V0F5)-D-G>#11=D5E.5(U4B8C>$$[+W=$3$UN+TDV
M9CA!-7%W<U=U568O3$UN+TDV9B]M<D9A9'EJ+W=#5UI0.$%K9% O04TQ67)4
M=55F+TQ-;B])-F8O;7)&850O045A-R8C>$$[=#5B67AX4D-!=VYI.%$S07)V
M54AV6$EK3F-G.3@O-EEZ+W0S9CAY33%(.&9X96HO04UJ+T%*=C9(:#--6G0V
M95ID>D=.2S=M36%6,R8C>$$[35DP:#--63!L,TU9,')U67AP6&-X:E-U-6I'
M;&1Z1TY+-VU-858S35DP<G59>'!88WAJ4S)J9$PP=2LQ4S=3,',Q0FQK255-
M>$E55B8C>$$[-W1113 R-T1)5&U):7DR67-C<&UG.6%S+TQ-1VHV2$1B469V
M2EEI5W5*-D)427IB<WAP-&1"-$1-05IU2UIV<3<S.'5)67=",%E8-28C>$$[
M<SAT07$K;S)39D=0:75)4E%#9T93-#9B-V(K3UIM3V92,65O=S=C45EB>7DQ
M=VMV,6DP:W5O56%':&QH8FMQ;EE-0TM%5GE16E)L4R8C>$$[4RMH940O:C-B
M+V=O+W=$;7)*3FY%2&5H9"\X04Q/,R]!055F+TY72T])3SE#."\U6C(O-$M0
M.$$U<7A4>$)T27)X6%9V<7I(:5%A1B8C>$$[:W!T.&YX55-#8S9P-6LQ,U5L
M=FQN=$9586<Q<SAX53%99E9%6DDV33AR<V%H+VE,16MN=FQC8U%&95@V5S9E
M;TUR.#8K>$]*9GI0."8C>$$[-79B43(X9'1(07--.&1W1VI,5EEX,$E1:'!M
M55)M;C)&04AH5$MH<%E7,FY8>7)P.7%9,D@U;S9H8396344P,%)A;#9S8E%2
M>$%#,R8C>$$[2U)2>%)2<3=F5U!6;W%23CA/.5-2=4%#1$=7;',X.6UY3W9Q
M4&XY:D%R>#E1=3=Y93=L=&E*3&E2-5A#;$MC;EES859C*T]:449#;B8C>$$[
M0FQ/>F%J-D8U+WEZ="]W568O3E=&2$5(96AE9CAS-V8X1D@O04TQ67)X0C-O
M6&XO04-Z="]W049(+WI6:79%130P87IL=&MK:VYO<R8C>$$[<WA(=T$Q-'%T
M84%K9#EZ:U,Q>6QB-D(O-EER+T%,9'8O36I.4"]L4&DY2B]K9CA!3B]1.$LU
M6G58;#-C<U9D>7A6,TQ&6&-J:7)U5R8C>$$[2W4U67$W;&ER=5)X5C-)-'$W
M;&ER=5=+<F]K:VQL4TM.4SAK:D)55613>D=G07=&249M:W=/:&%R1F-#2S1T
M,VI7;S539G-$+UIJ:R8C>$$[=&-J>$-M,W=:03!1.5DX;"M7261,<VQN:VI!
M=5I11U=V,FM5:G959F%09C=S,6UF3GA'=6IV=$IP>&IJ9E9K<F]R;U595E9G
M45(W2"8C>$$[364S3$ET:7@T5E!",6M516=/<$)5,#(R27I00G-/<VM+2U=A
M3&]7:7AE65%Q,G%";35B1W)#:&I*24%9:T0V0C!W-5IN9UDT34UF128C>$$[
M-5!.9GI1,$MF46131FY'4TQ'-V-Y44]T9C=V-'%216YU2V(W.5!N;5)P<VY(
M2'I$:#9N5"M(:W)P>D1#9E)G+S,R=B]!04EZ26%B6B8C>$$[8G K:RM5;G-D
M3&$K4S!I=4I%=FIC:$IQ;&Q3,4PR>GEF1W=2+UAQ079W,3)(13DX955P,F$X
M=G8S8W5%655,<G(Q.'1V=%@K5W9Y.28C>$$[,')69$A/<#9J<7-/;$E826IJ
M:VA6-GAH:$@V<$IK:C1O6E0V9DDW8W1Q-#5--6EA071C3VU%;SA2;'=Q9BM"
M+TQ82S-8+T5.;5=K;"8C>$$[84]A:5)55E(V+T9L67EG2&PY6$@R=4MJ;79X
M8C0K3DPK858X0U X05!(-'9Z6%1E4V9+:V%Z0U!Z1F%Z4W=O<D%E;$=S8VI.
M0S S1B8C>$$[2#EB:U(X0E$O1%5-5D9..6M:<&9Z5D]#2#@X9FHT<EIF2S-L
M<5!78E1J<49L3&%81V]345-G8U!Q.%5#5$]Q<W@K<V5V>%I&1%8K>B8C>$$[
M46HY-%1I36MU13=(;"M/;C0W:TA&2&E'-'$O>#%V.$%(3D8R+VMR>6)B,V1Y
M.#)T,FPY87=15&Q)+S-53%!+1FY21'1-9&<X4TUV128C>$$[<U<U3%9E2DIY
M2GI4235%9F=--#1)03=Y0D@Y=FTW+T%8;%<U,4-613$K=W1O1V5B9S8K:#9+
M0DI3:4PK.'5F5U!)56%T0TMF=$YV:"8C>$$[.&%12#!N.&9"9GDX0V9Q02](
M=F%F>5(U4V1,2TM06$Q+27I+,&LP.&YO<W=0<%%N9V5--55+2&0O=$MR-TY4
M;CA.6'AP8BMK+VHT2R8C>$$[8T5.=E50>%AM9UIV2G9L,4E3.&5U,G-R3%IY
M,TQ,=VE8.3E(2$9)<T,Q;'%E6FTT9S!R5E<K2&)*1$Q,*V(Q87IH:B]!1&AY
M+TA6:28C>$$[+V]W9C<W6"]!245:930Q<'9O17-N1V5%:VU+27(V9&0V8V=A
M<5!U<CE/071C,S!6+W="35(O,C=0*WAF3DXO;%!J*VPV5"])+W=#8B8C>$$[
M*V@T3GIZ9%4X=&)U94Y,8G573DQB=65.3&)U94Y,8G58=FI3,C=L:E,R-VPW
M-#!T=34T,'1U-54W-#!T=34K*TY,8G5E3DQB3R])3R8C>$$[:'1%1'$Q>6YX
M4W)X<VM.2S!R.%5L2U98=T(K9FE->&,P-S)$<V1(:7(Q2#104F1.<RM497$T
M2$%B:C-/64]79E(R,DA(,5(Y,V57="8C>$$[;D-:<FE14E)J<7@X9EE$8S54
M1TI*;T]22UEI3$M4>$YE835)2%E.8C9/3C!!3DAN,W!2<4=O5"]!1"M6<'%!
M+W!F8S!!;DHU42LY5"8C>$$[=G)945A,26]P2#%4=V]F-EID:FQ98V9,1&A+
M:F\Q=5<Q.'EK8DI%5T(Y.6PO:F=Z2#!,<'@K."M#2"].1S(P5V9Y>38V;$0V
M.'I/1B8C>$$[,#E&2#=W>F9A;W!Q=D=Q<6%M=7<S.$UQ,#!I2F)/4G%S46Y#
M=792.#E89'-S37(O04]J4TMO3D-V,6AJ>$DR25 W=GAZ8U).=6=L128C>$$[
M9V]E<U@K*U@O=T-2-2\U;WE41S!B1&5A<%!:;E199G)C=&MG85IR2DQQ5F]G
M14)D-41'130O0T%72G!T:U1'24XW5WI%<&M51'-O,R8C>$$[9&IC,F)R2&57
M33ES-W%*15-A4C1Y56)O=T12:6]0:FA"0C5);$=5964S=U5+>&8W-68X035(
M;B]!2F]W,'AT,5EV.$%F3"\X:GHO,28C>$$[5'AP8F173"]!2'DO+TDX+SE5
M.%9T,5EV.3AV+T%-:GHO=T$P67)B<7AF-S5F+VME9BMA359D5TPO9DPO05!)
M."]W1$Y'2S(V<U@K*R8C>$$[6"\U2&XO;6I&53<P;64P83)+,C9'3&=A4U)N
M9&=X,W%4,W(T-$-'<5AM*VAF*VU'+W=#,UHO,DPU<&8X<"]N9G!E;B]!36HO
M04IV-B8C>$$[2&=03$XT.'!B=5=+,C=L:71U-5ER8G572S(W;&ET=359<F)U
M5TLR-VQI='4U67)B84(U2%9%0EHS2596559*2C)!04=+:F1M369K9B8C>$$[
M,#0Y3TYW>$5K<%IR>5!V*WE6:5=N43E15R]S>D=/8FY4;D13,$)F>"]5>FI4
M66YE-U-W=&M(<4I'<&Q)*WA"14YL561D-F9:6#9C>"8C>$$[36MQ1G5X=W=U
M5D0K>$]T63$K>3!I1EEW=G%Z,$A#,U4P,CA73D116FI9.%)M6$YY-30T=VLK
M;39B9C8Y8W)Q1W%/4F%X="LU="M.1B8C>$$[6E1V4F8X;G!V,WDV8WAJ1E(U
M=4YJ>'EY;FEL>5IC:4EI2VE!2VEG2W%G54%!,D%!>D5D9T)303%M079!<V<V
M>&YF-4A,<TUQ3&HV;28C>$$[3FDK-4)A2$=X,4-:+W=":%EL2#!S>"\U<'EZ
M54A90G P;SE22T,O34118B]!1D]W=')I=U0Q<FEX:V%1,C1)0FMJ9%-R8V$P
M2$EB128C>$$[94]6-%IG2&1Y-6DS;%8U<$XQ23@V3G!T-'!L2$=59E9P<3%P
M5'-H>EE13S-.,2M735-4-7-*,4Q48C)W=6UT-6)E-%5G0FPU=U-O4R8C>$$[
M<#<P6F-Y-&UX8G%C:V5%,')A3'%C*VU4,TUV,5-76#9X85A&;U8T3W10<D54
M4F-V<VXW4$MT3RM#8T],-7!X-65'+TU%9DY03E<X-R8C>$$[:E9.9G,Y575T
M1EHT8F%'4TIR5FQ,:&UK85)Z24]52FIQ<GDQ2$].<3 K3&MD.'%H9TU9:T%T
M.#E72E-%:4)T-2]J-VM3=FYJ46Q7,R8C>$$[03AN>$TX55EI;&0T-'E:05AJ
M6GEW5S%247A73C%$059(3&)P:V9!;"]/4#0K3$PX,VHO;40W4#%,-V)Z,V]%
M6$PQ4$IK33-*;VU!6B8C>$$[14A%4FUP4F%7,65"+W=!<7)(.7!N1D%%-F58
M.#0O:C1Q3EAJ+VU$-U Q251Y,S5N<UET475O.5<P;4DR3V]Z=TY/=W12=VAI
M:DQ",28C>$$[4TY96%!X23(S1&E1,418<FMS;4DP2T\T4F@Q36)014)24G,S
M;2]Y-4A$<&MQ95=O3&UD6EHW:3EH*W)E:W%"<%IX2$1542](4T]3328C>$$[
M,5EU=G=J871C9TU-.2]59GA4239N2%$Y351Z+T%%<$(U:S%U>C%63$Y,2%$O
M=T)&+U969%I41D=36E,W06=S5FEJ*WE.:%=U6%DX6B8C>$$[:F1M,FI.;6I/
M<4%J4U-C2G8Y.'DO=T1)="\V6F$P5TAC2B\Y.'DO.&DS+W!I=&A.3DIT-6]6
M:VQL2$)P4TM)96]683!R-VUU3%A/5B8C>$$[=F\S+T%+650O=#$O.6DK84PO
M2R\U,S98<5 X04DO-78V2&QA*U1R0U<R8U<Y,4I*8T0T;W!L151O>3 V4$9'
M-W5M.5!I0F%N.'5B528C>$$[-7!$;4YV:CDY53@X345#2T).+T0W9U-F=EDS
M2G!M;W!)>4-",W S4E-W+T1,*TU/3'=&14AY+W%W5E,P458R05!P<W=69T=&
M45159R8C>$$[1&(S>4EY>$M406IM<VHP3%=:2D-I5W)T>"LP=W!W559P5FYR
M>%9F.&]M;44U26IQ<V-C<&-G:4<X<V%O<V=5;45P4F%Z2DMK<4M71B8C>$$[
M94I-4F9C9% Q6DAX4EA637-D9%(X3B]U4CAN;$=#24%3,VMI=59$1#EW<$)*
M.$0V,C0Y.')'66YP.7)+8TEX-6LO3#EQ04AL<2M,:"8C>$$[4DQ$=6%,5FU(
M,S=51U=(34=O8G!T<'9L,U-B6D<O4V=E+W5P4&=J=#=6*TM29S=&:DE2.&)G
M;7%Q;TLK2DYA0VUE4U5J-E1W:GIC:28C>$$[4&AW*V]C8W4T8V@X97!B:3AQ
M854O<G%K,#AP1D1#>$UC3$PQ<41%42]Q168U3$1%-7 K4TEX>&UW3% R9EIV
M9GI3>30X=$](071R9R8C>$$[4TI49'!%35IR.&Q-;C8X=6IL=F\P4TEV6E!F
M3%AL,DQ49CA!8VYQ25=3654K;U)#=$]89'E#0C!Q2V8W5U9:36PW0GID3FI!
M2$5F9R8C>$$[>D-Y:&U)3C5-4%5U6E(K-FHR5VQD;%563D)8,WI';$E">C12
M2C,V;V4T.'E2-F-R5W5L0EI.4FUA=#=E:C0Q3#E!:U@X=U-V1F%J="8C>$$[
M,W)82VAJ-&IC=51/96-9>'=W*W)Q57DP:GEO3&XP-W)5;6%6:GE-;UIM2F-N
M6F%T,6]V-B]B0FQZ8T\P5S-$<'5,,5-:87%O:6A6028C>$$[5E9!0W%.9T%/
M9T=9:G-!14IE-GAP=&Y55'IQ<FHO9%DK2G5L9G-I<$@P-4]/3U(U0G%N;6I(
M;55G=F9/0FQ6;W)7,V]R0VAA6')1:28C>$$[:$A&5"](36E';G)C;'<X=71S
M54%M;6A83G-X84Y$5V%18RMM,T%502]&<VAN0C5T,FUK3UA6:6XU,"M99%4P
M;GDY87<V9DLY<SDY4"8C>$$[-F-T>D=E3'%I2U@T<7<S57-2,4AA=5,P<T%:
M8G1U95)%6&UL:C56=#=V>2MT*V)U-4TP;'9*8TYF97%0<7-C>5--:3)S9U!X
M*W)*>"8C>$$[0D(U1#=1,DDS>DQ/46E69FHS=4U-64ET9')(-5)A:4Y.4U4V
M;&(O<$-/4S9A85)P<%!1*W$R9D):1TA+35!Y:FM,.'1U9RM'=F-W,28C>$$[
M479L<S$U=$IX0S<S4WIY;C5),$15=DQY-FQQ,3-D5W)'-6MH9316:7-+4G!%
M2D$T0F=K-3A1<VI.>&9A:7%E4%!M2C5C.&A+9S!99"8C>$$[3D-58FPK4'-1
M1G K6$]S6#)R86Y9=WE#,4]N8T=:3&QY-VQ:1C5)5TU!:U)15D976FE%4W9X
M34UM9%%!064Y:$A3;55I3U9)-C8O3"8C>$$[4G!8=F8P6F0X;W1)<W)3-78S
M;6M9;58W<3-A-2]D8UEL5TYE2VM$,4<V,#-Q,T511W U6#%*6FY30WI84VM:
M4"M45W-7-'5:8FDU:28C>$$[+W="2&=--71O;FYP>$U5-T)J2S!,8T],,CE#
M2%5!.4]12E=S4G%X*U!G>FQO=78R9E!R4T9G+TIJ>D\K;VUY;3%'>&A:9E)Q
M-6QL628C>$$[151*2DI685(P*T9)2$HU141B66Y*2%=2<39,5TY"2S9S24,V
M+TQ45V]B>E1,45AC6F96<FUA,'1'9%IO9TAT-5)#>E-#4D9:5DQ(828C>$$[
M9THY<VM.4TM*<FMX3VI.9UAZ.&M5=C50*V%:3DU4531B,GEM=$I,95<V:FMJ
M;&U.631V*V5D2W8R<C V3GA/,D0X,T<V;W!':&U2628C>$$[22](=U5R=CAP
M=DY&<F-8:T0S5G%7<V]V5VM):VU7;W)+=E(T:UI2*S1A:G5&4G%R>%DX;'%2
M<6]M=6%$;W!J=5).-2M5*W%A6'!7<R8C>$$[86AQ5C=&2VQH8G,Q<V)/4U)U
M53982W=-<C@T;&]O<$EU+T5S4CA024)S03%1:U%",5I(4D5!:SE","]S4R]Y
M8D1Q97!I4S)/+W!-<28C>$$[:6%3=7=C2%DP1$UA53=!;DUI57="8G)*-"]5
M0GET.4PO5D<O=VHY57(X6#90.4QL43EF4C0Q-#EF;WI26#8W.#-P-B]D5B]2
M+U$K4"8C>$$[=% Q4'HQ<FPW.51S=%)V3&PT,5HV4&1-:V-C4SE76C5(5T].
M0G1U4T)M.5!$16(W3V\X4&I.05=O,V9M3'IN<'0O2D).<3DS2&0R-R8C>$$[
M8U=A3S9:-D5F>7E2=7EN-7%C4D-%:'DR57A-5#5O9"].=FUM4C)E5%8W>#-9
M:W-Z5'E%:VYQ4U-D.&PT8V4U9U%#8DE(>5)7;5@O;B8C>$$[:E9*;6ES3#(Y
M;F16:V1Q5'5&06II961Q<WI"82MN0S=!5G%A1VQC175'4$Y9-%),64%,9$\Q
M5'IP<55K,&1L<48S2SEV0DYD5$0V=R8C>$$[>3A98F1$2DLS>$U0<V]P3D]P
M-UEY-%DX,6IH0C5!3C9L<3-N8E-B,#)L-W%.-4)D0DEP4V=U5V(T2C0Q;6I.
M56-J-&\U1E V.3A%628C>$$[=VM,05-C6$-A<&1"<69N:65W8E5)=%%V1W1&
M=4ER4G!F<D1!*W9/<G9';$,S23AL:5DQ<%1X>$EG1%-J1%EU:'I5-R]!1C-Z
M<'!M;R8C>$$[,T9J9&%P97<S=&Q-.$4X675867!,17A6:'E6:7!O>3E18TEJ
M16EX>4M$:D54>3-#:DHU=C@Q>4YZ9E=,,6TO;4YX2U0Y+TQ#355E-28C>$$[
M6D%(;6E*9%HX-R]O,E!6-4Y3=D1:>E1Y5WE80G582DTP4TDW<E1L>3)75E15
M:6XT-4AH:&16=6LT-TA&4V=F3U!M,'5*1')6.%A7;B8C>$$[1FIC4S%&3VQ$
M>3=:3'<T.7EB6%,K9'9/37-::FPQ>2]E3G9T23%Z2U%F;4]71'=O.7E436Q2
M:C@Q*UHT;41X-G1E27DW:&A024-0*R8C>$$[1W<K2$AU66IB:W%Z9FUT-3)I
M,B]X4'%B2"M68G5C+SAB-6IY:FA(44]61V55.55-=C5L9FUB<6MO<W)05V16
M=5I*9&QG4S1U2FUB9B8C>$$[*U%-82]D;$I-96M11WIE=E579"M8=DMF-758
M2E=86'9-575I,G1/4E)P;W!,;6A&4BLV36MD2VIX879T:TYZ>2]3,6U734@K
M>CE,,28C>$$[9E%D1G1,1S!D53%3-S%+9%8U4%!D4U)Z:V=D94ET,VQ!,R]Y
M4&UC1S1/-"](>'!Q:UEN:V58-#9%<VXX<C9V64LW3SAO06EJ8U5/>"8C>$$[
M;U=5.2]L;&5O9V1G,V%43$586E%V;6EB461F:&PP+U9'<D='*T911T)J6F5J
M27=(,F@T+W=Y5TM":4YM3UA64DUT>7<P9FQ6-6%L4B8C>$$[;F@Q3V1K5&1I
M>E%G2T0O35-G02MN3&9&239)16=2661:*U)D1'1%=5DP,5<T:FIU;R]Q.#AK
M9F]Z2U5,0BM(3D5E:'%G<E%G.75M2B8C>$$[;50P-4UF2$5E9C8O=5-Y-2],
M5%$W95IL3V]8>#5D0WE21E-T9&TS*S-T-T1#37A044].4$M):S=N-6)F9G5H
M9BM68C97-2M#*VM"2B8C>$$[0594=U-T9'9T1F%$-E1K+T5)-6AO.%5N;%@S
M2G)P9FM,5%5S-4Y-1B]D4TQE>4DY>F(R-GA%25E/65-2-4A55G V:&]%86@W
M;G!L8R8C>$$[<%-*=6<U96YZ0W5(;50S9%!-:R]O5E<O2F92>$1Z3B]D8WA5
M:U)I3CEV04)U1R\K>7<K3V4U;#11<CAF<D-1+SAQ.3 R<$)U6E%!9"8C>$$[
M=&Q"+U5C=#1Y-% U:SEW4CAN-59A6D9W861R>4=*:4(V>G9'5D)06G5%5$=V
M=#%Y2&I(<"M0=&)J635X24AV+T%&0F-N-5DK6#%L1"8C>$$[,BMP6%!/16AW
M46=+17)V.$PX0S%F;D=-:4TP=6]$3&EH,%!,>5 S+T%02%5.92M28D\O=C=I
M.75B>60W:39L96%E46E)5F52:7I.428C>$$[2VDW:SEG371%-D9">'IM:UI7
M46IB5#AN<F$V4DI)=%-A2EI72U%R2G=H:V-J8SA+<%)I0B]+>'EU5V]!,DEC
M>DAJ>5-&>$E(,D@X9B8C>$$[1E!.33AT,G5I,CAL:F%E:D]257E*2WDK<$DQ
M84YV12]X=#=(9G='4DTW,TYG9FIY8351;%I(<$HK1B]96' S1G8X3SAF4RM,
M-FY4,"8C>$$[84AR-E@R859R-UIR=C0O:3=Y=C-8*V(K:#A184PU=D=H,S%Y
M.&%W,T5D>$4Y<&4R9'=J=$9,17I";5(K0E)V=$EP<7)!,4A83C-/528C>$$[
M2D-I951R8UEL2&-$;7E/>2]/-U4W0WEI=$Y0=&)#,%,S36XQ9#1O<F=01W)P
M8W%Q<51+4BLW3CE+>6UN2W1+:VIB2U1J>&LR4V9X6"8C>$$[;#5.=WDU04M!
M2#0K3&PO4%1Z1V)7-G1:-4QE-FAU<D]'=UI:-'!8-$I"1TEX26@U5C5V5&LY
M87%7,S0Y369$>%AD.59'6$PS27@O*R8C>$$[8VA036MS;#0X;C%53F9),&-R
M<70P0V]C,T9#3TUY."M#,UI61FLU2T%Q8E952$DK1&DW+T%-8F58:VYX<W9D
M*U!M;#)U+VUW=#,U,28C>$$[=61F=$92-U8T6DQ+2WEU26ES8C)K<V)2>7)*
M2$56-&UB,4AD*T0O85DP3U1G24-(0U-X;DM:;GA!95-/<R\X06Y)1'I$87-X
M4T]Y828C>$$[37EE<7-*:75&4E=#=TI&>#13268S561Q<4E383A3,5-A-44T
M8U(V;CAF0FM-,EAU2#0K2S!F;C-R2VE"571R0TY)3#)B545227)L4B8C>$$[
M-G1W3&=/0E-58U Y-C-O>55F-U!X9D--9D-X9#4U5CDS;#5).%A*,T0X9D95
M:2\U>40X>'@S1C%+63=&,'5O<&]8=#-H;4UA:31U2B8C>$$[8FU2:W!)1T):
M<'5*2$QI>7%V245I=5!G-'4X+VHT2CAB3#-"5"\U6#-R678O<G=G<U),.618
M54]*:75'6#%%<WA:2V\U4W-1;VDS0B8C>$$[0C5!+W15,G@X3$965V569F)F
M8VIX8VPS42]',V5K,VUR.#!R>GI,<#%L<#DV;'1$0EEY4U-W:3)J;%1E54MP
M2$9M9$9!0T1:1D945B8C>$$[:E9I5&QM35DT16M(;7=Y>7E41D5-62]35FXO
M=GHX1R]P;#-J4C<R;G=P26%B5BLP2V8W2G8V1$MP86IU8DDT3SE8,"]1+TU/
M<W-$1"8C>$$[13-O="]U-2]G:4@P.2]O<FQD5&UW>39N1&@U;F8W5V1A1"M7
M2&QQ14Q,<FPY3&139%1B5S9M3U U1GHX8D0U8V-M3D]86#5/,DDO=R8C>$$[
M:#98;W5S958Y1'1J8C986G!B2U)34C0P84HR02]M36)R>2MB66Y44V%4,F]$
M>C,O04(W,%A(-7@P94]S<TU5:T4U<4)*1U=5+W)R*R8C>$$[3T@X=DDX,$1T
M2TUE46)F>FAO8E-#6F]8965T5$LU8W-7.&%G9R]J:"],4S<O=T%F2D(W4VE4
M9$YV-30P-S%"2VEL6FPV4SA$2V8X028C>$$[:W,X9S(K5T0X=$QK95,O>6Q'
M-T$S+TAE5DXO3S)N4TUZ5$MZ=3=&;F9G05-4+W%L4CDR16%9:EE-6F$R371Y
M1G X-&%/>'$X8VIE1R8C>$$[=S(K.&Y$*UAK,6Y74C=I,%!.*VEJ+V15;3-1
M:%%0-&Y"-$5L1W%H,TMK6&YR5%EX>%$S0THT3'0K;S5!-F,K5%I$5FIK3%=0
M-3<P528C>$$[>#A"8G158CAW1S5M=FE3.5!W=T1"3'9B5&LV8TMM;FYN4S%:
M1U=+5G!&24MG9T)A,3)R,4]3.$5S4FLT9#%S=FYI,6LK2U-%8RLX:28C>$$[
M:FDS,T%H9G=W+VQI1W(X,WA(;'5V:C@O,E5B:5))=55G4'<X;S T+U13:"](
M265!6$EJ;#1D-EA.*UI&>3!H95=E86I$:C9A,$-5+R8C>$$[,4)X2&9B=FA/
M;$-9839C.3=+<$@K6G%O<DM2231);W5W<79Y2DIY0C!R6DA64T-X4'I*5TU!
M>&UC4T1Q5TMU<'(O:W-$:"],2D=P228C>$$[-S!&8RMC-U,V;#E7-3E785-L
M3V-H-45$=S-*,GEY3TEX1D)H3$YX1WIU5EI04#125E@Q2EA24GA%8B]%=$M5
M<%)Q:6U23T)0-6=V828C>$$[=G)I+S1/*W5C4G@O4C-R8V%B53E$;%-M86UV
M,VQE8C!L+W5V.#,Y1#513VYA85-38E-%:S=K;4Y0-EHP2$%/-35B>%ID-60K
M:F1-+R8C>$$[-5I)4"M2868P=V-!-VPX85AE6&9O,U10*U=31"]K5VXY365!
M9'DK3DQV3'8P8G!N+TQ*0B]W06DP+W!J=T1U6'AP9#5D*VID32\U6B8C>$$[
M25 X06M7;CE-94%D>2M.3'9,=C!B<&XO04-Y468X:3 O<&IW1'58>'!D-60K
M:F1-+W=#5T]$+VM7;CE-94%D>2M.3'9+27-T07-R<28C>$$[6&=L;D1X1D]B
M*VML1D(K:D%9>$A2:DQ54TA5<# R:F58-U-%4DQP.7,P;C=43D-H4%1Q86I)
M:D=$,&-397)Y9GIJ.#!),FTV3B]Y=R8C>$$[,C,O26U0.$%P;'9H4C=M:CAZ
M:R]N4RM:57IP;6HO.$%,1&(O05!)<% V669$:C-"4#5J3"]/;#AY<T]M855+
M1F)+,T)(4VM35B]6:"8C>$$[.$]08W@O35I0-3!V;552-FA'=S)P:VU(1&$P
M>44T5C1':31(53<K1TM20F5J8VM.9F]W:&I+3D943$A&;4ER0DEA-$=8:'5,
M-' T2"8C>$$[0CA51T,W;'1I9U%C96Y89G1G<%%.,$\R>'E"1&TT-3DW46-J
M8UE+8D8W4S%J-U9R46HX8TQ42$5"2S%N3$)49F)B>3AJ6'!H65%I228C>$$[
M:')L9W!N8G573DQB=5=.3&)U5TY,8C9A+W=$2V-6+S=5+SA!,DLU;V8X<B]!
M2C,V6'$O.&HO;2]O9DU(25HP1E!*=35$1VQD>4=.2R8C>$$[-VM-858S25DP
M<G51>'!58EEA9$YD3414:D18-&XO9TU",F$U-4%%.&UU27)3,T5-6#)G=$9(
M-%9/05)T>$1);$LK8VIT=%9M2BM:2B8C>$$[>7="<F],=G$Q-'=Q<U)0>F]V
M.$%X2VU&245E.5-:3&].4FQ24C0Q0B]55&AO<C9/.'5,24]P0BM68TM/06Q4
M.59F1$9K249$,T8P528C>$$[3D9&2S<Q>4IB;U$W,4$S8EDR>C1%9%E(,6\R
M66UL1%1P-UI+26%-=V]R-VE-<7!91V\W-&%20U$U24MR1'!G<'1B375.2S)*
M0E1';"8C>$$[6$(K*TY+,%I!8V%7;6UC34M(<C)/4G!K1DQL43!06'1K4T<V
M37)D>4=#;6)U47AP6&-H:E-U-41';&1Y1TY+,WI'3DLQ>4=.2RMN=B8C>$$[
M+TMB9CEU8B]!3$9C-2\X07DS*V0K;#9Z+TDO-78V2'DY>4=D1%1Y3'51>'!8
M8VAJ4W4U1$=L9'EX<%5D6C)K6D%M;5!W9&5*,GAA<"8C>$$[-41Y0TQN.'=7
M54-!0U)#4G-Q<%9Q52\Q46-$6$A$23E&2WHQ>E1'16MK-S%9;F%S8G0P.%!H
M>5E)4E!4>79:8S-M4%-K<3!B04XP*R8C>$$[1TYG9G!015I,:41%86))9S5V
M36M-9W!Z3E!!<3E0,5DX45IJ4VQ$3G)&=7@S:THO,DQF,'@T9WI'1UAC<T]Q
M5W8X-2\T1G8V63)%*R8C>$$[1DIO-G!A+WIN+V=7+W!J>$)0:%-5<#E1=&Y4
M6FI59C5,9C!W16AL1$A)1D1I-VDO;4DK9R]W0DUI,F-"5$A4.55T25E75FY*
M2F%O;R8C>$$[<BM(>7EC4T=J3&AL27%L>')6;WEC451V,2M&=C9994E-239E
M45%F-E-T-B]A,B\Q5R]P:GA"=#A!=$A58EEN-U(K9D9V-EE/24M-2B8C>$$[
M8D=O,G9D:B]!34,S.4UE24HX1U1J<4YT+T]F*T)B*VU(:4,K1$IR.4E7=C@U
M+S1&=C993TE,-$UN9G!#,B]N4"]!="]42&E#*T1*<"8C>$$[=%%T5#%9+SA#
M,SE-:5-'47A38E,O=&U.3UE".39R*W9)<RM#4W5'0D92=5!(1VU$9DE9,')U
M47AP6&-H:E-U-41';&1Y1TY+*V]F+R8C>$$[04-M=B]B;2\W1F,U-R],9C4S
M-EAR=CA!22\U=C9(>3-83VIE4V181EA6>%8Q8T-R2DHQ:G!51FU*,E%B131L
M26IA>31U6G!V:75'-28C>$$[1#EM26))4&\W+U1K3V)+34)(:VPX.'A:-E8V
M8E5W,#)!3U-2=4A%+S4O4FAP0D1823!W,&AA6&]+:S=9<'!W87941F%605%"
M:6AA=R8C>$$[-VI&2WEU2W5R:7)96G5X>%=L449Q8FY&0WAL-V<T<$,P,5AR
M:7)U5TMA8U1I=$YC:FET3S59<E1U5TMA5W-4,4A806M+<T4W<'9'928C>$$[
M2C=R,E P64531C@P>70W;%IL.$A(,FQY46%:4G!7<FA9=7)I<G$T<39U2W9Q
M4#A!.'!P+S(U=BMX6$]C+W=!="]N9G!E="]Y4"MB*R8C>$$[:#AS,7IO,VLS
M5GA6,6-52W-%16MX8FIS<4-R=65G1TM#85%,3714261Y,U-V54PR1U$U=#%5
M;WE3,$)9-VYS36Q3,&A2,7%D>FI4328C>$$[<G-+2$TR,DLP;U-3,4Y",'=.
M:U$S1DM&,D,X;4]+2D,P4E4Y>%0X8TQ">$\R2TM5-C1S;E9X5E55,$=,1C%C
M5G Q8U9P>$\R2W%B1"8C>$$[1FU&=%1I;'%U0F%D6$9A9%A&86-4:6UL4&MY
M;79H9W!+2FAN2W-*139R,4AI3S1W34-/:6)+-%I1=S-"1E%C;30Y3C%X5C%C
M5F181B8C>$$[6#%.+S544"]!3&-V+UEP;D]F-6(O3R]3.5HO:V8X,SE$-5AQ
M8S9.-4HQ5&EQ-49:,D-R=7A.04U)0VMP:'%,2D)P:GAX-T%G25-/+R8C>$$[
M26=%;C9-36AS=W@W>5DK.&Y)*S)1<'EA6GHU33%(>5)"-698.4U7,79,9GAA
M;&)(,'!H05I*,&%E1C9H-5A4:$A(1$1-<FAG23(U:28C>$$[<#)Z0S%!;GAE
M:S=5-TQ394AW96]#-R](-#5)-C5K.'!36"MQ-F1-*VMC<F=Q3$16:VIG:&EG
M9#1696IW,C1K42MI26U4;$A*=UHS,R8C>$$[-3=C44)/9V96-VTP*TA:2' X
M:G0K3G8P<U4X=F%.-5IU.4AU3'95-SAW6%545&9U;&UI:4MP2$(V:U)%8G%Z
M>F5T3"LV<$@Y:C=2,B8C>$$[>DEY5&U*54$T;4Q&:DUB:U=34#5D.&XV+W=#
M8B]-82MS;&YO3VMR0W1R4&%45S!-26DY94LS85IP0VA34VEU>F=F86,P6&M7
M3E12-"8C>$$[:S11:C%K9F4U4&A9-7IL,&E+-55H62]*,S5E46%D1E!*<6MD
M-614869,2CE81V]7.$E&,'9O4$=/5$HX1EDU6E!G8T@T:TLQ2DEW;B8C>$$[
M3&MV;%<O8V57-FI":4$U,W0S:FUJ6B]+9C5C5&95<G(O14YT1UIZ<'E85555
M.79'62]61G9(3W9P:4U+3TMV2DDP=DEG155913AJ:R8C>$$[635S9W-C4&8K
M;&-M;GA(9FDW=6\X;$5E5R]Y-&LP*TXT8C4S;75*<E)M-5@Y<7-K14QY>G=Z
M+V)33DI$*S92=5!W;%$V:VYI0U=L-"8C>$$[=5<K6&8P4&MW.$1$6%!U-FIZ
M4W92+TQ(;&$W,6)8<E,U,6%+1S%S=E984S=K,TU566Q997 V5&9V14%L5FEI
M9SAE4#)Q.4US;FQM0B8C>$$[16=C*V5Z6&IW67I+44HR2$QD151E5B]Y.64P
M,40P3F%A3SAS<D]'85 Q6C13:S P='(V>DQ%1E0T*TTQ26EN3&M+,2]:;S!2
M;'E73B8C>$$[=&EF,"]G=&YG67%.4S-(;C5)2%%V3&YL83DP,G=L=7(X4C-&
M,3E:5S9D<GDR='AB>7!(3#E7:4U%<6U2;&QD67E:=5%103!.1'9K<R8C>$$[
M;5-92F]D,U$O2"MX:&IW=TE&;FYF56)D>6%,-54O3&U'-W1,5S0Q:5(S=6(R
M0S)K;6AU-U%X4E).83)S,#!R=G=98U),3$Y'<#966"8C>$$[9C=*<E@T=5=I
M44]N8V4X+W-B4$%X6%)06'9(8T=R4'EZ*UA6>%DR3CDK;5AI5V8Q>F-756QX
M06QW;G!15'5Q;7-D14IK:&E!3R],,28C>$$[3TEO4E9P2$QL0DER.&)F:C1-
M4F=W:T$X6#)J>E1#,C!8.'5R2C=E84,U:'5Q<F4O5TAU<GDS8TE*9$Q%,79'
M65-I*V]Y>GE&1F1A528C>$$[9&1X>4MH87IK>6XW3V@O;F(O63)2>%E14E)V
M;GI)-VMO,4QY=#52='9-3VTV670Y4$9"9E=B,VMS='I*1D8V3'HR-U17541U
M-DEI="8C>$$[6&=*1TY".%@W4%A,635P;4I.8VI8-C)Q96YX:5E&;F-8*W!'
M6&9K,SAV-#104VDQ>%=V94-.-FAV3%IO47=&:TI%4$)#9#)U<'%-1"8C>$$[
M<TEZ<V%.:U)N>69Z9'9C9E Y42MB339B1B]/*S!E6#8P9&%E5F9Y.# W55HU
M,3%3,W9O4D)0=VIN=DQ.,&@Y4W=F:7I$:5!R3"]71"8C>$$[=U%2:%=5:%<W
M:DE3>35*1&Q8=U!F.6UZ3T](1D4S65!X2&0Y=39J<2]L+SAT8F911E0V-G).
M679D4$9*8EAD;DQD6%-V3F%24D\O0B8C>$$[0WEP=V534EEM2$I+3C%O8UE:
M37!L>34Q,$\S4#A7;5=00TDX*UAM3%!*0S9H-4DO3"LS9W979SAW4C-,>%<P
M:W1O574W8W%Z2G5N<28C>$$[06]K;DM12&%*15EQ9&DQ4&E%;S4X:'(P+UEF
M>#A73710:6\Q3#=1=6)Y3"M82F4W<#5N:FAI:6U65EHU-&YK4TUX4G98,#0P
M2WIS6"8C>$$[6C%0<'928617>#AF2G0V9G@K:% U9D8O3RLQ5T=N*U,W9GI$
M-65S,49K,6MT:'%A6'9Q6&1N3GEL275V<35M=6M544-2<7AM37-+<"8C>$$[
M.$DW6D<U;4UJ=F1J;V9+.6QR1TI21S%E<G%03VMO.'=E5G9+3VXK6#=R5DQ+
M.6YU6D9U:%DR,%)E3U-*-65%8SAJ0U)%-'E*16IT1R8C>$$[>%4W=E)H.$IP
M;'503$UY04DV5S%:<T]-44I"4$]M16U)<#AC5S0W;V-Y86-+*SE-<D-4;F)$
M+TI*56IW,S99:&]Y1&1%5D]&9S9P>"8C>$$[5C%4:7(V;B]!4$M:9CEU6"]S
M57IN4#A!3&8U,S98<F8X:B]M+V]F2S)D1SAK-T965S)L5TM537=Q4&)Q2S5+
M2TI#,6UQ6&%Z,C4Y2B8C>$$[=55A:U9)3WAO8VY-8DIX0W!*6%5!5D]63U%L
M<S!X:VM,9F1L6F)2<VEO;352<69B2FA"1&).5&)V:%=L,%8U8WA25%)2>D]K
M5G=O4R8C>$$[-&I6:49K5E=$:%A!3D=!6E$R+V-9;4E:06YK:#-1<V$X=F]X
M47--56<V54]+1U4K6'9Y-3AW83%P,71F5U9X8E)I-W50<3AC36IY2R8C>$$[
M*S X1G4P:E5J6D]#=F52,2M,;#%O<'!L1U154FEA3B]I+S%/4D13>6U!4E<V
M85(O;%(U<&UH:6QT2DQA.&IM:U=+3V%&<%!4671-="8C>$$[=7I#4F\P:BM#
M6BM"2$QL<U-!5D9C:BMB9T]E,S1T;BM3;#!P6F(O;'IC,S%V869O*SET<'!R
M:#=W3$M8;59*=G%I=TAH0D4X0U1&>B8C>$$[-BMY,$IA;7=&3C V:T%M>#-F
M8F9M;S!P249(9F8W4&=I3#,X<4Y:1W-Y5T9P3F)R5S1-5455<W)S+W!F5S%S
M9E=:,6E60V=N:T%/=R8C>$$[8G5&<&M9-G501%HO1S%S<#9/6$91+TA22C=J
M>5!Q8T]Q=V%F.5IT<$9N=$I.45<X4G!04D9V04I05F,X;S%L*T0P2$9!;%14
M874R5R8C>$$[:D]+=GIP<4]M:TI6='ET331V>6\X>4U&0U0R:GEY4TMK14%K
M:T1Y2WHR>4-687AH46XK;GA(-&U$8CE.<W(O3G@X+WAF-FEZ3VEN-28C>$$[
M9FEV,7%&;C5"=G)P5$Y$95<P.7-(;45B4FU:1VU3,5-/4S5A25-X25(V85-J
M*S@T,2]:<FMJ<4%/;C102FA$4VLY4E@T=F]M=7,O;"8C>$$[<')L>G(Y+TA&
M9E)Z8THU4D4Q-4Q).7EB5T\V:W,T<%I'5TUH>7IW.$%I5F-M;$4V6D-'<&E)
M:F(U9#E7,E0P:VI)-R]!1#4Y>55A.28C>$$[*UA'<F%0<#%Z<55T-UIZ,FQQ
M>5)34$,X=&98:T--24]-:U5B0U%*3'I+<T)103EX5$IW,4%K86\R=VYP<%)"
M2DDR66Y5:DUH>&UQ;B8C>$$[1DQ2<5)I<3%Q9S!W;V-(660X85-I1W8W;5,S
M:71P2EAA,VA,3D1#5TI20SE/6E9384%T>$9A9&%93TAQ=#-S,'(K0BMJ1FE1
M;4YG:28C>$$[1T5V,$Q-86ME,C(K5U)'>FHU3V%*94YL1F5Q+WI$<&M41VU#
M>DEQ-G5+=G%N+WEM4"]B;"]W0WA43V0O>3,K9"ML-C,O22\U=C9(>28C>$$[
M<FY24$I,-$EZ2DMQ1'8Q*U=%0D).3')U,6DS4DI'0VY9:U5R.2M70TM9:W!,
M1F1O:6U)-TLK>FIT."]N:U)K0D9&=6QJ3C)&2S5N<"8C>$$[1GA"*TIT:CAS
M<4IP=4%13F-G>51#,U4K:7!Y=TU3<VM"<E5D1"MV2DI767$W1EA6>%90679.
M5W5X84Q:-E)B,TPR='!:6$0S:UIG928C>$$[4TXR;6-X;%=F:3%#66I%1$=A
M5E5K-S558U5E27E)-3=.;FI3-%)%2&MH53%V5TDW63)K9"]C2F)C>$MB9%I8
M0V5O0T=$.%%A8W51<B8C>$$[6$IC16)U;4EY4S=Y<G0U<3@Q4$LX>F%Z9DY.
M24A6-41C>D9M5U5+<V=*-59)8U))1SAE23A":V9#:#-$-4UV1FXS;C5Q4CAX
M*UEQ;"8C>$$[:G%L,E-::&1%+U=*86UC34=%,S)V-W=-06585W5(=S0Y=UAX
M6F0U42]W0VPY5D4P1G=,;35793%8:&%Z3$LS3TI3>DY33F<Q5DA*,B8C>$$[
M3S-C;GAW.$$U57@T-5AD-W%G,6Y7,D1(.4HS;GAL,F5S.&TW4TUJ=515.5=A
M1D=0:595.6AG.$]08T4K3$QV4'I23"M:4$U%+W(K=B8C>$$[<6PS26)K<3%Y
M6&YK8C%39T%5>59B-&E!;W!8=WA'3TDV0D)Y>C=Z.#!4<'9N2'I$<#DO2&1I
M.&QU=E1L930Y0S5L;&5*<'!!=V%59R8C>$$[3W Y4W)L=6%K34<K24=U*U)L
M:&E25DUO6C523C)V.$%-9FY85F1D9U=#-U='2TU41S1K.4E0>6MK.4I)5F%2
M-4AK6GEQ4F)%;713>"8C>$$[2DI/1$AH14]43$QN;$U55U!-45(P*U)Y-6]5
M<%=+9TU/>'=P6$DT8F-91F1.,4)W:%-P-%5/>%8Q5#(V;G!I<4]T<F@T84%B
M<E-H2"8C>$$[:FQW,D122TXW<&QA86A'6$,O>F)&1#,K6&II43%%14MK+W!I
M46A"4419:C-Y9W%&4$%R-G O.$%+668Y=50O<U5Z;E X="]N9G!E="8C>$$[
M+W=!:B]M+V]F2W1--DHU3VMF<'-7>E-N+U9(-CAS:4=%,'0Q2UHT-6I%1%)E
M=%(Q-FM:84=B2&IT;4<U<E1B.2MM2W%:8D%Q8E%!3"8C>$$[8F]P<E5Q1%=H
M4#9S<W1G96%L8U!%=$-'2'5$:4-%:3%,,4EJ*S!0=G<R;'-54%1F-5E66$)'
M2F]&4'IP5$9&<G=$,#A/*T)79T%#4R8C>$$[3R]5.3A5:'--3RM+=4\R2W16
M>%9E4',T;U<Q>%-G>$\O2W!9:V5'1D-Q2EEY84$Y8U5Q,T=Q1'AW2V]Y8F]C
M2T9+1C9%:D9685)I628C>$$[=U(Q0GA3<&AQ*W@X355.,7A65FI3;GA.,3=$
M=WEY35=*5DUM:6MD83(S0VMJ:C0Y-D1W0GEQ8VUQ57)25U9S5W-54'%R+WEM
M2"]B:R8C>$$[+W=#>%1/9"]Y,RMD*VPV>B])+S5V-DAY<EA/:F554FUN4%5S
M<#-O2W(T1'AY-6A*3'1B6&IE5C=&469X3U-$3TA*:GIU07AO86UP>B8C>$$[
M0TQM2UI9;G9I<E%Q8V)#<#-.4' X64A#9&E/=S0Y4'8T6EE:4C<R;T-2-6AU
M,%-/+T5Q;SE%4V=*2SE382LO=&AH-FQK949Q9E)%5B8C>$$[1'=91FPS030Y
M9F)R:W!9=&U)>F)O2TE0169H654W:6TS-CAX>$MM.&DP>6AT,6U8:VMW.7AX
M,T(K+TUI36)'>&%*5')M1D,T:$M/528C>$$[1&<P-C=E4# U3'<O3D%Z95-L
M-F)F>D0W=C=C4&@K869'.&QK<$59<5A&97=P=CA!<G='1F1756-L.49"8F@K
M:$\S>39:2&A:,G5%-"8C>$$[<G8P.%%0-V-E1F)22U-13U W,$MA9$-+9FI8
M1'=E8E=:161&3UI325=93T-/,4(T+U1H3U!Z55I,3E5O5S%N3F--5FIP54-P
M<G--028C>$$[:7EL34)9.%5K57!2+VAD5'5-5$9);&%9<$,S169%4'4O='E8
M:&5B56,Y9$9/5S-98CAH43ED=C=C9D-73V$K:4-20TI+13 S<&ME1B8C>$$[
M=71%0T4P235$>#9F,C1E1D9T96=/-V9D:G=R83E%4F5N6'AY44%#<G$T8E%I
M3%-%<S19:EEB:D)),$=U8W5I659Y;')D6$%R<31Q*R8C>$$[<78X07EM2"]!
M1S50*WA43V0O>3,K9"ML-G8X07E8*V(K:#AQ6C!B>6DK0U8T6#5,43%&2TA*
M.&%#149R8S9Y3VIT.$%:949E=E$Q+R8C>$$[:FMH2FYJ0E-&;%5%,$YE=$1M
M2UA,57A5;6YF07$P>55/,U5:16Q+,'539'E4.#A#5U-E6&Q63$XR-W,K+W="
M04(O:FU69S5/2FXU;R8C>$$[>3=U;TE/2FQB:GDV8D4Y4&QL.3 P:4I02DHW
M*S9T3U)L4C9H=6]O979J,'I&>E)(34]8:'9K54I&<D-W='IJ5G$K0C)"*V98
M2UE:3R8C>$$[13=.:SA9:TXQ8CE,0V52<$-L06%F0T1U3S):8TUO3%%C3DYV
M96]&*T%%:RM08DHX8D59*SE#=$E73E-A:SE4:V)B86$U-$5U-31Q-R8C>$$[
M;FER=E5.2U8R.$\R1S!5;61L8TQ:,F)Z35 S:W!P1W W:&4O,VY*1%E.57AX
M4W!,;FUA4C)D:E9M3E-F;FM',$-K,FDK1T=/=F119B8C>$$[=WDX3TI,;392
M>'A).&-3;4%S;T)O2D1)5T)&2S%(6$LK1GEB5F5*-S!X<%<K2GAP6&-7>'!6
M83%G-45V3'-I.79(05=%<#E!;4595"8C>$$[:4-L3THV160X<71R6%EO9&ER
M<U9F5F8O04I41"]T>68Y:6UC-2]L=C@W.4PQ9CA!:W8X04XO42M5.#9.-58Q
M8U91;7 R,&QX8FA9>"8C>$$[5C%91VQA8E5)>%IW;%)9.4Q$8W=.4FQ.979&
M:%$O4C0U55E%8C@S2D5G5F]U:%-L3TIX1U5C=5-40G!9,6)C4%@R1TU903E6
M2EAE:R8C>$$[=FEC;4U963A3.6%!54A42FIB:V=T,7E6;W!6:71,:6-F0D=7
M53DK9RLX-UE#:7=&94AY-#5A<S!O0S$R0T-P22M:<%0W<W@O0U-C+R8C>$$[
M8T5D0F]T:$-394Q/9D9Z+T%%;TUN1T%$5DQ+4W%N5&));BLV+T9H+TA*,G@T
M>71B4W)).49++TIJ+T=U1S X6E$Y>G!-2U%/.&)-5R8C>$$[559!2D9.=79B
M=WAT35IM,'%R:'1T9%A',6181S%62EI(:T%9+UI10D9(9T)H=$%J4VY80F)*
M4&Q51T92,T%(-G-Y0GEC1UA-;V%2="8C>$$[+VQK4U<O1TYL;T]#,GAO:G=X
M5G990W K+T<Q541E4C%)5#1Q9%0R+W1Y:65C1&QU>FIJ=$U,93-K:T-V8V)!
M54M21'!4+TLX8V=,;"8C>$$[=5=Q56=.;V\R=51A;E9X5C)+=7A6.58O*U5V
M+T%/,THO=T)I;6,U+VQV.$%/+U,Y6"]K=C@S.40U57IO,VQ(67$W1E9R26IR
M>&11>28C>$$[*T)&4FEO2T)U=$5S<#9L4C94-S=R,'(W:DE39T,R=WEK2E).
M;U8Y15-24C%(47!U9G4V-55-4G1V1UE&570Y2W9:4#)3;S=T2G0K2"8C>$$[
M6$PT:6U%<V=40TA226AV3$E74&=U=R]J:&%Z:S=K6DA:,G-D3TU3,4A1:U90
M,VY&<DUI<C1O9&ER5T)7.$MU>%8R2W-D,4\S348P,28C>$$[0E-.>GE4=S,V
M:C9-6$IG8D-%<6-75'%N1E5614LR56YJ5W8S57E84FEE848U2$ES;5%U+T9.
M=FM->65J9VE.;$-3-T-U4DQK>%5X228C>$$[1D)*3D%/<%!426MS:U!0<55A
M8DHX8F508BLS2UI:9T]435%+1#E7-75P3T9382]S<C K-TUE57E766E!;BMN
M-F%S2V@U5D)F<7$Y428C>$$[4#=C<VAJ<F-U4&MY,W-%9FQJ4S-H5C)+=7A6
M<D98,5HO=T-5=B\W8VXO67!N3V8U8B]/+U,Y6"]!2DPO041F,%!L4$]I951D
M:7)S5B8C>$$[9&ER<U9D:6PR2TA9<&1I:#)+=7A6,DMU>%8R2W5X5D%A>F%V
M4&%C;R]W0SAH<30Y>%1D9G!Y37)R6G5W>4%.1FIA,T-N<G-C:$A+0R8C>$$[
M-5)X;&9Y>7DR3DIJ048K<D)4*S!.+W!Y635-0VPW5D1&5#%'>'E$2VLW;6Q5
M16MK0E8V:S=$36=Y,F%-8U5V=615:#1L639S9DAO328C>$$[;VQN2%)U1TUP
M8DIC4U-.5C)R-$1S37AZ36YM,FE)1&]9<$HU5FIJ2$HR3D%-:4XQ2F]7>6I4
M9$QJ=$5"86I48B]&,DAY>39%2V-42B8C>$$[;'998VMD;&I3-T9867$W1EA9
M<3=&6#%:+W=#578O-V-N+UEP;D\O-6(O3R]3.5@O04I,+T%$9C!0;$MU9$4X
M<E1Q-')4<31R5'$T<B8C>$$[5'$T<E1Q-')4<31R5'$T<E1Q-')4<31R5'$T
M<E1Q-')4<31R5'$T<E1Q-')4<31R5$5T67-46C-*-&EK36TX6C8O36918WA-
M:TM,<R8C>$$[34TK24E32GI7;&1S3T]2=6UC9VTV16A&6'=!2#-$37-&>&EG
M<%5(,6QH6#1E<%!T,4]24$YM3U16,6103V5),FE(4W95-5AK>6-7,R8C>$$[
M4FQ'3DEE4V=553AC<$Q+2S)#3U-A5EEO=U=D>E%!64)U5U))03-:6'!E;7A7
M8TEB<DY);SE2:C(W,$AT;51#1D]$:WEC4CAK9%A*="8C>$$[5D]R:71/<FET
M3W)I=$]R:71/<FET3W)I=%!Q,R]W07!F+S(U4"MX5$]D+WDS*V0K;#9V+T%#
M6"MB*V@X<%HP5'ER<U9D:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-644]R,E Q=7I:5D@W,D]R>#=B:V=F6BMN25I),D=Z1E!H:WA'
M2W!K03=K,'I&>"]5-28C>$$[.'538D8K-3)(9DTR,T=3*S=U3V-G0S=+3G$K
M3UDR4V1N6G5H1V<Q6$DR;6QJ.&Y+;V]Q>#9!64]A47EN4CE,5WEH-4]!6C-O
M5U!D4B8C>$$[5#=/6DU),#176$IX2'E42$IT5'-69&ER<U9D:7)S5F1I<G-6
M9E9V+T%*4S<O='EF.6EM8S<O;'8X-SE,,5@K4R]W03,Y1#53>F]N;"8C>$$[
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E=,87)9
M:3 Q3E=285%31&MT3V=)1S0O:FU-63%/,TYX-4]+2"8C>$$[;6=,:3@U+T%U
M>3DO9D)02F5W8EE9-E%X8U959#9J2S)D2W!K4%%D8VM%57E$44Y+2T)B>5EF
M168W<$0Q+W="62]W04UV>'AC6$YL-B8C>$$[0E!-=&-6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8Y5R]W1&Q,=CA!='EF.6EM8S<O;'8X-SE,,5@K4R]Z9C!0;$Q/
M:6569&ER<U9D:7)S5B8C>$$[9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-654QY,&EU-%1$2U-%2D)02%DW6D=58D9-;U1-5%E3+W=$=WAP,S@X=C-R
M+W=!,"8C>$$[-58T06)V>DUM,3AS85=0=$(R4&E7<"MO1$0T155F;5I)<5!2
M.4YI;%=73T5",4Y63E=)2#!%,'E99T=(:E1)<3!::S)T,DMU>%8R2R8C>$$[
M=7A6,DMU>%8R2W5X5C)+=G$S+WEL,R]B:R\W1DTU,R]!0S,K9"ML-G(O2F8U
M=C9(>6QN4E!+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>"8C>$$[5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMV
M<3,O=T%P9"\R-5 K>%1/9"]Y,RMD*R8C>$$[;#9R+T%#6"MB*V@X<%HP5'ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69"8C>$$[:7)S5F1I<G-69&ER<U9D:7(V="\X<&0O,C50
M*WA43V0O=T%T+VYF<&5Q+WE8*V(K:#AS9E5R>B]!2'A*+W=!03,Y339(:41Z
M2$),=28C>$$[9#E3=E Y.%-F.$$S.4UE24QW4S=N9E5R>B]F16XO04XO5$AI
M0SA%=34S,4LX+S-X2B]W1&8P>#1G=D),=60Y4W90.$%F16XO04%$9B8C>$$[
M,'@T9W9"3'5D.5-V4#DX4V8X03,Y365)3'=3-VYF57)Z+V9%;B]!3B]42&E#
M.$5U-3,Q2S@O,WA*+W=$9C!X-&=V0DQU9#E3=E X028C>$$[9D5N+T%!1&8P
M>#1G=D),=60Y4W90.3A39CA!,SE-94E,=U,W;F95<GHO9D5N+T%.+U1(:4,X
M174U,S%+."\S>$HO=T1F,'@T9W9"3"8C>$$[=60Y4W90.$%F16XO04%$9C!X
M-&=V0DQU9#E3=E Y.%-F.$$S.4UE24QW4S=N9E5R>B]F16XO04XO5$AI0SA%
M=34S,4LX+S-X2B]W1"8C>$$[9C!X-&=V0DQU9#E3=E X069%;B]!041F,'@T
M9W9"3'5D.5-V4#DX4V8X03,Y365)3'=3-VYF57)Z+V9%;B]!3B]42&E#.$5U
M-3,Q2R8C>$$[."\S>$HO=T1F,'@T9W9"3'5D.5-V4#A!9D5N+T%!1&8P>#1G
M=D),=60Y4W90.3A39CA!,SE-94E,=U,W;F95<GHO9D5N+T%.+U1(:28C>$$[
M0SA%=34S,4LX+S-X2B]W1&8P>#1G=D),=60Y4W90.$%F16XO04%$9C!X-&=V
M0DQU9#E3=E Y.%-F.$$S.4UE24QW4S=N9E5R>B]F128C>$$[;B]!3B]42&E#
M.$5U-3,Q2S@O,WA*+W=$9C!X-&=V0DQU9#E3=E X069%;B]!041F,'@T9W9"
M3'5D.5-V4#DX4V8X03,Y365)3'=3-R8C>$$[;F95<GHO9D5N+T%.+U1(:4,X
M174U.55C5R\U5FIX;V58-D5P>#<Q*W%D334W+TQF-3,V6' O.$%*9C5V-D@O
M+S)1/3T\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB
M;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F
M.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C
M97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z
M9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @
M(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/D-H86YD<F%S96=A<F%N(%!A<F1U(%-A;FIE
M:3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M9&,Z8W)E871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD
M969A=6QT(CYG,C-S,C,\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT
M/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I
M;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @
M(" @(&<R,W,R,RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(S
M,#<R."8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3 M075G+3(P,C(@
M,30Z-#DZ-38F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,3 M075G+3(P
M,C(@,#4Z,3DZ-38F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C
M>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XS)B-X03M'<F%P:&EC
M('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B(#$@<F%S=&5R
M(&EM86=E<R!H879E(&$@<F5S;VQU=&EO;B!B96QO=R R-C4N)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M
M96YT.B8C>$$[(" @(" @(" @($=I;&Q386YS+4)O;&0F(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[
M)B-X03M4:&4@9F]L;&]W:6YG(&ET96US(&AA=F4@8F5E;B!F;&%G9V5D(&9O
M<B!#4SHF(WA!.R8C>$$[16UB961D960@:6UA9V4@:7,@;&]W(')E<R8C>$$[
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @
M(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z3E!A
M9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z2&%S5FES
M:6)L951R86YS<&%R96YC>3Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L951R86YS
M<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \
M>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T1&EM.G<^-3DU+C(W-3,Y,3PO<W1$:6TZ=SX*(" @
M(" @(" @(" @/'-T1&EM.F@^.#0Q+C@Y,#$S-SPO<W1$:6TZ:#X*(" @(" @
M(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @
M(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT
M<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$YA;64^1VEL;%-A;G,M0F]L9#PO<W1&;G0Z9F]N=$YA
M;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D=I;&P@
M4V%N<SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q
M+C P,3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/D=.0E]?7U]?,"Y0
M1D([($=.0E]?7U]?,"Y01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @
M(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.
M86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA
M9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L
M871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA
M;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'
M.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM
M;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HV0C4Y,3-#,C8R
M,3A%1#$Q.#!!-4(U131#13E&-3-"-CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HV0C4Y,3-#,C8R,3A%
M1#$Q.#!!-4(U131#13E&-3-"-CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @
M(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C8Y-3DQ,T,R
M-C(Q.$5$,3$X,$$U0C5%-$-%.48U,T(V/"]X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT
M/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HV034Y,3-#,C8R,3A%1#$Q.#!!
M-4(U131#13E&-3-"-CPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HV034Y,3-#,C8R,3A%1#$Q.#!!
M-4(U131#13E&-3-"-CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C8Y-3DQ,T,R-C(Q
M.$5$,3$X,$$U0C5%-$-%.48U,T(V/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT
M/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I
M=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C8Y-3DQ,T,R-C(Q.$5$,3$X,$$U0C5%
M-$-%.48U,T(V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(R+3 X+3$P5#$T.C0U.C0Q*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HV0C4Y,3-#,C8R,3A%1#$Q.#!!-4(U131#13E&-3-"-CPO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,BTP."TQ,%0Q-#HU,#HP,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@"
M"0'Y P$1  (1 0,1 ?_$ !X  0  !P$! 0             ! P0%!@<( @D*
M_\0 <1   0,# @,$!04(# D%"@<1 0(#! 4&$0 '"!(A$S%!410B8:'1"15Q
M@9$6%S)2DK'2X1DC0E-78I26P=/6\!@D,U566).BU$.5E]7Q-#9&9G*"A(:'
MI HE)D=48W6%L[0:)T5T@[+"P\1$H[;&XO_$ !P! 0 " P$! 0
M   ! @,$!08'"/_$ & 1  $# @0#! 4&"@8'!04##0$" Q$ ! 42(3$305$&
M89'1%")Q@:$5,E*QP? '%B-"4U22D]+A56*4HM/Q%R0S0X+4XE9R<Y7C)31C
M@[(81&2CI,((-45&U29UL[2U_]H # ,!  (1 Q$ /P#X=7-_WQW!_P#;=5__
M  ^1K]V,_P"R:_\ #1_](K\AO?[5W_Q%_P#U&K)K)6.FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*^A&O'UZBN$KF_[X[@_^VZK_P#A\C7K&?\
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MGO[4-CZYO'>EJ[<5>BWE?]R[ 7-1;IL>XZW5$WE(B^GO2J!3X57@PZ=%M[T
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M/+EML)I]-<8G\1R[CF(-A=]AW9]> X=A3/R?>,-JNVV IM^SN XA^X+2F_\
M:.%+2W2I4/',L&/QM#>$V2RBTOL91C%[B+OIMJ\M-NX\4N,W3!0IED.!S5"
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M_P!/H5"I-3N.FTVAQXUQ59$HYV80]9.V3V-8XZEY396\NXLBXIMIMYL,%H6
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M>+:ZFTVC6U?=N2;FW!N:D09YH])@TN53)%&FVZS";>:I%&I1F352/.V?X/\
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M!Q6VW_,N-_;W3\8+G^BW/WQ_P:?+%P-\,>'_ ,W_ -&AX(-IP<?X5MMYZ?\
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M>OBIW!^]9L'9#M_WY\Q56Y306J[;%NJ%#HGHWSI4%5*[:U0*0EN)Z7'*VE5
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MTKSJ>,?I+\3YT^8*".ZB4@?_ '-A_P!3IQ%G=:S_ ,1\Z<8G<K/O_G78MH\
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MM(N&EN  /-)SYM!G0D>L#KJ0-9ZQRFOH)S@=R0/K_5KD$ [@'VUPJ=I[/?\
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MSNO7RE@KXIED&"EQ9(S*R98<'.\/"QO_ &UQ'WA=&Q'"-MKQ(6S:VT5G\/\
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M=+_AI\ZTO_.4#^61_P"LT]+M/UFW_?-_Q4]'N/T#W[I?\-/G6E_YR@?RR/\
MUFGI=I^LV_[YO^*GH]Q^@>_=+_AI\ZTO_.4#^61_ZS3TNT_6;?\ ?-_Q4]'N
M/T#W[I?\-/G6E_YR@?RR/_6:>EVGZS;_ +YO^*GH]Q^@>_=+_AI\ZTO_ #E
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MVMO^8J/[#YOQC/WR=HL>?IEY8_\ \2U'H#_5'BO^"I_TF81,>@XC/2+6?_\
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MB 2EZ&[;"QS%*F5A.59F[ #5TE7]5((3MS/SCKTRUP<5_"1>O9F\+MF[)!!
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M$(;0@)2VE"4@!*0D$    8U\A4I2R5*45*)DDF229))/MK]%H0EM*4-I"4)
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M<#F#:?50G'PR]O';VX6^ZI1*B0 3HE,DA(&P ^)U.IK]68?86^'VZ+=A"4A
M&<I$9EQ!43 DGX"!M6<]<^S'O_O_ '\M2MZFE*U3NU26JE;CDI00AVDN":AU
M?( 6T@H?:"CD\SC:SA)P%$<O4]-=G ;@LWZ 0K(M028TUW$S&FA!,Z3.U>;[
M3VB+G#EDJ0V6Y67%R$I0 0J2 3I,B =CI7*OV?4<CZCXCVZ^CS.HYZ^-?)PW
ME,9DK2- H20H#0*&8 P=Q(!C<31(ZGQY^5)R,@ <P[O'\(]_F?,ZKPP5!0T7
MI)),0-1&^ONK*RII*WTN)*@IH)0!E@*/,@Q(&\:ZSI7.46MB/6*O2IBQRMU2
MH)A.J4<-\TN2I#!YCZJ0I("5=R4GDZ) UTD.\)MQPYEI2@RG<\QZLD?7\=O-
M"0HVY2D97<R%)V!<5!S: \N7B! KZ;1K)H-T[2L6-<U-CU.@UNT8](J\!Y"5
M-/PJA"0'4$$='$I<*NT2 I+J0X@\P!U\<?N5,8F]?,K4E:;@K05'8I60) ,<
MXCD-M:_03.',WV!,X9?M(?8N+-#+S8'JJ2M )(D""/G9M"")!G6OQZ_**;(7
M5P_L;B[>5$RY4)E=-GT:LA*DBO6A)JT9<6I(P$ O*QV-10TCLV9S,IGU4!&?
MTAV6QEC&V+%]N0ZTSD=2L@D.!.50T), R03N-1O7XQ[2=F5]D.V9PE2#P+XO
M7%K<)20PA'#<4D**X(7 *1E2L9O5G0D?/YA;?9-%GE+!:1V/(?4[(I3V?)CI
MR\F.7'3&->GR$DR=>?6?A6B%$$S)]I.]"[Z_+GQ\%>?L]FG#/6H*]3ZT:[3U
MY45SD]%$=/QB/S:LD0-8WJ"2=R3[:^T6\*=Z:M\E],^_(_NQ'O2S^(R@IN5C
MB#I52CRE0GZ-4*1:U,V"FU8QYC%OP:0]#?N* Y%>:+IN!RE/1:4A+<SYMAWR
M8UVY1\FC#S;7.#/< X0X@C,'$.7"\72W*2\IP*#*@08X(<"G)R_7,6&+N?@X
M7\K*Q--W:8^R+A..M.)5D++C5LU@BW84EA#10I]!21/'X2DM !?/O&[S'8'Y
M.\I41GAJF$G)ZYNM[KT[]=?LO_\ M?MC_P#WI'_^"N%VQ_\ V'V#,Z?B\N/[
M4K[(K/N$7ACX9+WV1MO>+>N55WK=<W1O"R]V[JG[G0=KJ%M32J):+5QVNBV*
M5/MNH5#=FY[F+J79M&MBI2*E3(ST-"Z/';+M0<U.T..XY:8H_AN&);#PL;:Y
MP^W19+OG;]QVX++Y?<0^A&'L,P0EU] ;6H*APF$#?[+=G.SEY@]OBV,*<-N<
M2NK3%+ES$48:SAC3-J+BV]&:7;.+Q2XN9E;-NXIQM)0.$D%3ASNU^#GA8J.S
M.TM]5NL7I%5Q Q]T*I0Z]0&MV[\J.WTVD5FITVQ+,H5M;=;(7C0;PFTMYFFP
M[^;O2ZK.KL]#E1F6[&A%AM"=)_M%CR,2Q"U;;ME?)"K%MYIY6'6B+M+K:%W=
MRZ]>8I;/6Z5@K5:>BL7+2"$)>4N36[;=E.S:\)PJ]>>NT_+B<2=9?8&*7J[%
M;3KC=E9LV]A@UVQ=K:(;1?"[N;1Y<N+MT(R@5[H/!YPT5FC[7V4[;^XK&X6Y
MW 5,XG5WTQ?L842WKRH]+JTYJ%$LY=LN*J%.JTNF2&ZHU*KS2(\%,-FF(C2U
MR9^I<[18VTY?7(>LS9V/:Q.!^BFT/%>MG'$(*U7(?]1;:5I*"EDDJS%9*0E%
M2SV5[//M8=9FWOTW^)=B5]HO31>IX%O=M-NK"$VAMR7&W5-J#H4^D)0$!L)6
M5+I"X%MD7Z72K%53-Q7)M4X,7.*%[B=1<S:=NJ?=/S<]5!:IMS[G541=EQ2T
MBE2I#UR-W2J4\E8<C#E!E?:K%0MR[#EF$H[2# Q@99/IBK?.$>D<;C!T7*IS
MI 9+&4;&H1V+P93;5EP[\K<[(GM&KM$+A/R>W=<-3GHQMS;\'T-.7A*4;E-R
M5G=-7*W^#_A2J-S[5[2U2U]U6;GW)X%[<XG*CN'3-R("6*%="K5J-P5"F4>S
M9MH/QI42I.TB<E]52KKK3++T&-!BPW&)4^31[M'CZ+>_Q%NXL2Q9=J7L$19K
MLERZQQT-(6[<IN0I*D!Q!'#:!*DK*BH*2E.2W[*=F7+C#,+=ML2%QB'8NV[1
MN7[6(-PS<FV<><;:M%VBDJ0XII>;B/$ *0EM*"E2U7_ASV"VFJ%<X4MZ-HG-
MT]H6M[=M>+^F7)08NXD>X:I3INT5O3:3$G4ZZS:U&<6U<\>8ZNN0E49B.RH-
M)I*8*V1(7AQK%\0;:Q[#,1%AB)PV\[/.,/*LU,MK3B#R7%)<M^.X 6%)'"4'
M"3KQ,X.49L!P/#''NS&+X2<2PH8QAW:MNX83?A]U"\*8<:0M%R+9DE-R%DOH
M+*4I(3P@@IS'E[=3AOVSVHX;-G;GI.T>[^\%W;Q;)-[M53>^W+HDPMM-KZO)
M7(7(M%ZWZ795<AU/[CFHX9O,5VXZ/*8<693$R*AQ4.!W;#&K[$,:Q%AS$<.P
MZWPW$_D]O"WV$JO;]L0!<!YRZ:4CT@F;;A,N)(]4I41F5YS$^S^'89V>PFY:
MPK%<5NL6P<8HYC#%RI&'X:ZHDJM3;M6;R'/1$IB[XUPTH$E06D'(W4<(VVT'
M</A@WAIU<N2\8E"JG$MPE6=6;:HU;$"@UJF7A?+]%GR:E#5#?<>J4&)+>72I
M+;[+<:4&7WV)2HT8-5[17R[/'<.6TS;*=;P3M!<M/NM%;S2[>TXJ$H5F "%J
M2 XDI)4F0"G,J;=EL.1?]G<5;>N+M##O:+LO:.VS3V1AYN[O%,K4XC(HEQ"5
M$MJ! 2H)44JRIC>MS\$O#/==2OVU['%^[92-K.-JPN&ZM7;<M\P+JC7%:E\U
MI^CSZHFFNVY18M!J-'EM*1;Y,N<V]'2PFMO2GY#DB-RF>U&.6Z+-^Z-K?)O^
MS%WC3=NS:K8+-Q:M!U",X><4ZA:?]MZJ2#);"0D!7:N>QW9VY<OK:S]-PY6&
M]L+'L^[=7%XW=)?MKUTM..\,V[*6'&E"&/76%)"0\5*45)Z6M7;"U+-L&-M=
M9&W.Z^R-%HGRHVR%AQJW<EURZC=-T(I#SU#8W!MVH3;4HT2DOU",EFH,,4]-
M>HS+CD=R,^_'44O<2XO[BYO#?75[88HZYV&Q.[4TRP$,,%T!TV;R$W#BG @R
MDJ7PG5 $* .H]!:X;;6MBG#;*PQ/!FF?PD8/9)??NEKNKD,E;(OF'%6K*&5.
M( 6$MAYH%0*5*2=>4]S^&#;.V;*O[>*J;9;X<4-Z;A\3O$9M^^+(O&333M8U
M8]]UVF4VIWD]1['NZ?7KVNOD%RA%3BT^E5&#(!2B$ZD.U#T%CCE\]<VN&MWV
M%X%;6>!8-=I]*MTK].]*M&EK1;!RZMT-6MO/ ]12UH4G7,-$>:Q+LYAUO9WN
M+NX=C':2\O\ M'C]BH6=V6_DT6=Z^VVY=EJRNW'[RY(%Q^52VTXA0@((ERE=
MX%["_P $J]+]JFWE\VWN[9^S>TF\-'3 W"J=X5.[:7>U3BQ:Q)K5OP=L(UCV
MM1ZK$16)UJT.DWE<][4*GQ&9UYQ6.Q6S4+#M3=GM#;6C=[:O8=<XEB.'.%=H
MBW1;KM6U*;2VZJ^-T^XVKAH?=<MF+9U:BFV4J914]B['\5[R^=L+RWQ2UPG"
M\69R7[EVY=-7CB4O*>81AJ+.V9=2'56K+=W<WC*$!=VE,$.=.IV1VSM_BEVM
MMG:C:S<[9N@RN&"H5N+O!:5[3TT:Z8U3V(N2NNVVT\[9;-+G7!,F^DRKBN%%
M>F5"M*C3'V:925I:<A</Y3OGL!OW\0O[+$7DXXAM6&W%LGBL*1BS#(>(%R7$
MLH24I99X24-2@%QP2%^B.#8?;]I,-M\,PS$<(85V;<>&*VMXL,W27,%N'C;!
M1LPVM]2\RWW^.M;Q2M0::(24<Z;><"^R%PT[8RQJE3-Q)\S>GA9K/$'6^)>G
MW,W'V[VNN2)2ZY4Q9\VWON=D4:11K6>HT6BW@JJW#'KKD^LQEQI%&*T1VNQ>
M=JL597BMTVY9H3AN/-80U@BV"J\OF%.--^D)>XZ7$NW <+MN&V5-!+:@H.05
M'@6'8S!WT8+9.-7ZUXOV9=QY[M"BX";##;A+3SHM%L<!32F;4LI9NRZ^EXK>
M04J9D)"D\'?#35*+MW9*J!N*QN'N)\GR>*I5^-W]&-$H5ZTZE56:FG1;.<ME
M:IU,J\RF24U1$JO($> F%'I3<66J54%'.T>-H=O;D/69L[+M<,!]$-HKBNVS
MCB$9U7/'&5QM*TE!2UZR\Q<*DY4 UV4[/.LV%GP+]-_?=A?QF]-%ZG@LWC;;
MJPVFT-L2MMU;:@Z%/C*WD2UD7F<.E.(+A?VKM/A-V_WLVDH]S2UE>WM)W'N&
M]Z[<ULW?1[QN>VYM4JE*=VTK]C4JB5.UJA+##UJW39]VU -T^.CTEJO1IKE9
MA]/",=Q"X[07>&8@ZPD?ZXY9LVK3#UNY;L/)0AP7K5TXZA]"9#[%Q;HE:CE+
M10&U<C'>S>&VO9BPQC"V;A?_ +@UB#]X]<6]VS=W-NMUQHX<_9-LN6RU93;7
M-I=KA"1F#Z5EU'S.PY^.?RE:]O7SRF'/QS^4K2E6>H&1\\60F*2:F;VH)IO+
MDNB0'UE121Z_*$<P5CIDHR<\HU(^:Y,Y>&K-J?JV^WE5I :?S&$\%S-I^;EZ
M[SW>VOHDI[., CZ\?FUHE9(TT]]>5KSVI]OY1^&JR>I\32J9#@62 ".F>OTC
MXZE(S&)CW?SI4%/(22DGUAX>W4E($^L)'+;[?#K2H=NCQRGRSXZ@)G<@>WG\
M?92IP.0"/$9^W5LG?\/YTJ"CA*CY G[!J"WH=>1Y?SI5.E[&<@GZ\_GUC (F
M23[?\Z5,2Z%*"0",Y]P)U8"2!UI4TG )\AG5RB 3.PG;^=*D>D$?@CZ<XUCU
MY?5/VBE3.<E'.>_&2!]FKY/5F>4[?S-*DJ>R>@(Z>>/S:QD$Q!(^_MI7KMQ^
M*?M&II7DO>MG!QD=,_;T[M5(,SF,::?<\Z5Z[<?BG[1JU*\A[ULX.,GIG[.G
M=J ""3),\NGQI7KMQ^*?M&IWI4Q#B5DA)SCOU?(#LJ?9_G2O"GDI401C!P3G
MIJ(]:)'M^-*@9./P,$>.?/W^&-0H$'0@CK'/Q]E*]H=0LX2<D#/U=!_3JV0'
M90/N_G2H*="5%)!./(^8SJI$$CI2O2%A8) QCSU*4YA,Q2I/;84<@D=>F?;J
MF4A1U)U(CW^VE3DK!05XZ#/3Z-9 F1,]>73WBE> \#TY3]O]_I^C.H2DJ!(.
MT?&3]E02$B3M6YMB-HZOO=N'2K-IO:1X!_\ C"XZH$A::30XJVU2Y'<I!E/$
MIB0&5_Y>8\TE2"RF06^=B=^C#K1UX+27Q"&V^:E+(2K76,J2I1D: :ZZ#N]G
M^S[_ &AOK>URENW*P\\\4E80VR0Z04@IDK*0V/6@*6"08(K]!GW'4FE6G2;3
MH45BF4VAP(5/H45&.S8;A,(8C(0M/K*46D9=>42X^M2W7%<RR=?+V;ATWCC[
MQ*PLJ4K3+!F28U^J!KN!7Z:=LF+>RMK>U0E#;+3;9:*0K/E !,^KI&H@#6:\
M-;:6K56&8U9H%)KDQ:>P$F; 8DR IU02IB&^$=O'1S\J!V+C94O"UDJ&K76(
MOZN!TMH )RE1T'4R0)CNC4QWX;7 ["X<R.6R75J4GU@D3(/(Q(C4Z*\*Z7V?
MV3M7:J#4)%!@(B5.OK:?J3CKCTM3+;2#Z/3X[SZU.HC,K4MQUOG_ &Q]Q:U=
M4H"?G>+XF[B#YS*46D*.0'23H"KV0/5F8!/6OIW9[L]8X&R^JV9"'[LA3BS!
M*   $#G B3KJ=Y@$;M0DI2 2"<#) QD@8)QGN\M<C[BO0@$;ZJ.YZ]\$GZ]-
MMA7HG'V]>N,#ST/W^\&?94UKO<7=&T=LJ.Y5;GJ"(Y6AP4^GM'M*C5'TIZ,0
MXP]=7K%*7'E\K#(/,ZX@8ST,-PN[Q9]#%HV5E2TI4N/4;"E!)4HF-$@R1O&N
MTD<K%<9L,&8+]Z\E'JJ+34@./* ,(0-3*C"9(@$CGH>*:A4-RN("-)O*LM2[
M;VMI,^.[2:!'><;<J[K3W*B?*D(2TY)1$>PE<H=BPV[ZE/ >:<E+]A9L81AC
M_P G+_*XDHY5.R  1!  U(F= )V];E'S:[N<>[2LOWT>A8&ULPJ5N.@3*PL!
M,Q!$D0#HD$A1%[   ">X# ^CP]VO0!.4!.V498]FE<73EMR]G*HCI@^1_,1\
M=6^: KJ8[]= :QGU5%6\A(CQY^ZN3:S$7,O.IP&\!R9751&SW9<ESE,I0.[!
M5VIPK(P4YP?#.\8L7UD[-G3NUYG8 =VW3<<)"5.8BVRD&774I!WRPHG4<YF*
M^T,&.(L&,PD)*&XT9D)QT"6VDH'3.,8 P!W#IKXPZ0XXX2-%+4J.6JB8Y>_X
M[U^DV4Y&64 SD0A(/_=3'\AWP>ZN"?E"N%"G<3.SU2;IU+9E7W:\.<_0D@(0
M[6J9(84W6+:><.%<D]A*7X*TJ2XS4XL52'&D..J/JNQ_:%S \22I2R+=>BTG
M9)W"P-HDD$ #0R3._P ]_"5V/':?!E.6J4-XK9'BVMP4%2H20HMP""9B0)U.
MFQ-?C?N3A[WDVU<DQ(=KR[VMJ,XZBG.49YE^XH##:ECT"92^8.R%Q>1;22P,
M(0V/6Y2EIK](V^(6EV 4N!"H&8'5)/4*$P#WP>@K\FMW##SKC#BQ;W+0]=#@
M*4+(&I0HD =2"<PG8G4ZOYKQR?\ \EVX?>>^WU ]#XCMNA\QX'IK=_)'9]HC
MJ%:&H2ZR1)N+<'73B@[$C>![=M-J8O-?=MAN( /_ !>6K\SXQJ8;.SR#[ZMG
M9.UU:CVNBLSN;<G?2](%*I5Y4K?6[:90D=G1*=<TFNUV#1T=F&N2E0ZI5)4>
MG([)*6^2(VRGLTA&.4 :U6++#[5;CELU96[CIEU;#+3*W#,RXIM*5+,Z^L3K
M6U<XI<7B&V[O%EW3;(AE%Q?.OH:$1#27%K2@1IZ@ C3:K-4[FW2K<2CT^LV9
MNY5X%O0C3:!"J<2H3XE#IRG"ZJ!1XTJ:ZS3(1=)=,6$AA@N$K+?,<ZR-L6C2
MG%M&V;6\K.\IM*$*=7$9W%) *U1IF428TFL3EYQDM(>Q!+J&$<-A#ERI:66Y
MG(TE1(;1.N5 "9UBN_.''Y0W='AVVZL^PJ-PTW]*79-RW%=$>I6Y7KCL*#?D
MVX'67A&WFH%&:E1]S8-(2PU3Z5'FRZ5Z-1&FJ5S%I*W'/)8UV/M<9O;F[<Q-
M"1=,,L%#UJS=KM$L@C-AKSBTFR6Y)6X4I<S.$N1.WM\ [?\ R#86EBTQ;*-G
M<OW*7+?$GK%%ZM\I.7%V&4+3B2&@D-M)6IK*R U) )/'"MX]_HWW6LT&A[U6
M=0[VJU5K-P6C9@KULV?*>K,AQZ5%-NTRK,TQ=/0AWT2/%?9?0W":9C<RFVTC
M7I!AF'$6ZGFK2X<MFVVVKFY;;?N &TA*5<9Q!7G,9BH*$J)5N:\H<9ND^E!C
M%A:,WCKKK]I9WKEO:J+RB5)-NVM+90 <@20H! "=0*L+6XV][#T"0U2-\V9-
M+MU=GTQ]I^N(>IUI.(=;<M> ZFJ)<B6ZXAYY"Z)'+=,4AUU)C$.+!RFRL"%)
M+5D4N/"Y<!::A=P"/]84,A"W@0"'52N0/6TK7&)O@H4,54%-VYM&R+UP%NU(
M(-L@A<IMR"064PW!(RZFB=Q]\46FJPDTC?--BJ>,A5EI?K@M-4@O>DE]5N"I
MBCEXR/V\NF&5]M^V\W/ZVAL\/-QZ66[(W0$"Y++7I$1ECC9>)&72,T1IM4_*
M;XM?0ABJ_0B<QM/37/12J<V;T?/PIS:SDF==Z](W#WP;F0JJW1]]&ZE3+=1:
M-.J"':ZF;3[3;8=BHMB%,34P_$MU$9]Z.BBL.-TU,=YUD10VXM)DV5B4*;+5
MF6EO>DK066\BWR0HOJ1DRJ>*@%<4RN0%9I J1B+X4AT8L0XW;BU;6+YP.-VH
M!2+9"@N4L!)(#*2&P"1EU(KS3=QM[Z-'H\2DTC?.E1;>;K+- BTU^MP8]#:N
M,<MPM4=F-5&6Z8W74GEK*(2&$U0=)P?&H<LK!Q3BW&K)Q3Q;+RG&FE*=+'^Q
M+BE(47"U_NRHDM_FQ56\3?:2TEK%5-)MPZ&$MWKB$LBX_P!N&@E8#8>_WH1E
M#GY^:HPMQM](%K3K%IE,WWIME5-3CE2M"!(KT:UZBIX@O*G6]&JC5)EJ=(27
M52(CA64CGR0-2JRP]RX3=+:LEW3<9+A3+2KA$:#*Z4EQ,;"%"*E&)7"+9=DU
MBZVK-PDN6J+YU%LX3OG82L-+)YYD&>=6ZDW=NY;\%^DT.V-Y:- E5&EU>5 I
M3%4IT.35Z*_Z51*I(AQ*@RR]4:/)(D4N:XVJ5 ?_ &Z&ZRYA6K.6UH\L*=3:
M.K2AQM*W4(6M+;J<KK8*DDA#J?56@'*X-% C2L;5ZMA!99Q-+;:G&W5);NUH
M;4ZTK,RZI*5 %;2M6UD9D$2D@U/F7OO+.CUJ)4Z!O7/BW+5V[@N&--36)$>O
M5YE3BFJW6F9%2<;JM7:4ZXINI3DOS&U.+*7@5JS M+)LM*0BT0IELLLD-MH+
M+)B6FB$RALP)0G*DP--*LN_=4EY#F*!Q-PZ'WTF\6I+SP)(>>2I9#CH))#BP
M5@DD*WK(*AO-Q+5E4 U:9Q'U7YJG4RJ4OYQK=V3_ )MJ5$YC1:C $FN.^ASJ
M1SJ^:Y<;LY%/YE>B.-<QSA;PO"6\X:M<.1Q$.(<#=K;ISH=T=0O*V,R'- XE
M4A?YP-9EXS?O*07<>N'.&MMUOBXE<+#;C,\%:,SIRK:G\DI,*;_-(JDHVZO$
M%;AN#YAC\0%$5=LB1*NI5'GW)2U7-)F*<7+D7 (=79-9?E+>>5(=J1DN/J=<
M4XI1<43=W#\->X/&8L73;A*;?BV[*^"E,90SG0>&$P,H1E @1M4-8M=VY?X&
M-.LFZ4I5R6<0>;%RI9)4I_(X.*I1)S%S,222=ZJ#N_Q&M49FW65\13-OL41V
MV6:&W5KI;H[5MO%M3UO-4Q-93"10W2RTIVDH8$!PM-E<<E"<5.&87Q"\JUP[
MBET/ETVS!<+XF'BLMA1=$F')*Q)@ZFI5B]\&4L#'7PPEDVP93B3_  A;J@E@
M-AT(#)*02T$\,D"4Z"O#&[W$1&I]#I3">(5FF6S$E0+<I[55N9J#0(4Z*Y F
MPZ)#16!'I469!==ARH\%MAF1$<7'=0ME:D$<.PM2W7#;X>7'U)6\LV[!6\M"
M@M*G5%$N*2L!25+)(4 H$$34)QB\2VPT,:?#=LA3=N@8@^$,(4DH6AE <RM)
M6@E*DH"0I)*2""15J8W#WRAVM+L:#2M](-D3W%/3K-B/UV/:LUY:PXMZ7;S-
M4;I$EU;@2M3CT-:U+2%%14 1=5GAZ[A-TINR5=($(N5,M*N$@" $O%)<2 "1
M 4!!K",1?3;*LD8NM%DLDKLTWKJ;5:B9*EL!8:42=R4$R*])W%WQ;>A2&:1O
MFS(IUM&S*?(;>KB7H-G*0ZVJTX;J:HER+;2D/O(50F%(I90ZZDQ"'% C9X>0
MI);LB%O^DK!9:A=S(/I"AEA3\@'BF7) .;05;Y3?!0I.+*"F[?T1"O3791:0
M1Z*@A8*;>"1P00W!(RZU&M;C;XW+0J/:]R4C?.X;;MX(% M^MOUVJT.B!IDQ
MFA1Z3/JDB!3 U&)CMB$PR$,$M)PV>71JSP]AUQ]ENR9?>GBO-,M-NNR9/$<0
MD+7)U.8F3KO1[$W[AAFVN,66_;V\<!AZ]=<89@91P6G%J0W"3E&0"!H--*Q#
MGO+^"_</_F!7]=K9_)?IF_&M7B,?K-O^]%>&V[W6X$,[8WZ7%GE0)-',5@*5
MT':2%NK2T@>*RDA(ZGII^2_3-^,^%5#C ))NF"-= X#'L'.MU;6[55MBOQKV
MOQN-'GP6W$6];D9Y$IJDKD)"')TZ0D%IZ<4=$!LJ#:N1S]I<92WK \ZDCA-F
M02,RB(S= -X G7ZSK6C>7R%(4Q;R4JCB.D$9P/S4@P0F=R=8TV,UTRZLIY<9
MZY\<=V/CK56@B(41OR]G?7)J3VI]OY1^&L>4_3/Q\Z5+[5?[X/[_ %ZWN$/I
M'Q/\5:W'/T1XFI1>RYRGKG *L^P>&/J[]5X(.I)&_P -.>NM3Q_ZOQ_E4%NA
M!&!S9]OZCIP!](^ IQ_ZG][_ *:@AWF."G'3.<_J&G 'TCX"G'_J?WO^FIN1
MYC[1IP!](^ IQ_ZG][_IID>8^T:< ?2/@*<?^I_>_P"FO*EA*21@XQTS[<>W
M3@#Z1\!3C_U/[W_34$.!8).$]<8)^CKX>>G 'TCX"G'_ *G][_IKWD>8^T:<
M ?2/@*<?^I_>_P"FF1YC[1IP!](^ IQ_ZG][_IID>8^T:< ?2/@*<?\ J?WO
M^FF1YC[1IP!](^ IQ_ZG][_IJ6IY*21@DCRQ@],]^?MZ:C@#KI]^4?;4>D<L
MA\3]>6*@%AS.<)Y?,YSG[.['OU/ $1F//D.<>5"^>21[S/V"IH*0 ,CI[1IP
M!](^ J>/_4_O?]-,CS'VC3@#Z1\!3C_U/[W_ $UX6X$ $ *R<=#W>XZ< ?2/
M@*<?^I_>_P"FO*7N90!3C.>O-["?(:%@?2/+D.OV4X_]3^]_TU.R#W'.G 'T
MCX"G'_J?WO\ IJ&1YC[1IP!](^ IQ_ZG][_IID>8^T:< ?2/@*<?^I_>_P"F
MF1YC[1IP!](^ IQ_ZG][_IKRM82,C!ZXQG_MTX ^D? 4X_\ 4_O?]-$K"D@G
M SGIGVD>S3@#7UCX#704X_\ 4_O?]-5,:/(FR8T*$P]*F3)#,2)&CMJ==D2I
M"PS'8;0@$J=>>6AMM ]9:E<J 5E*31Q3=JDNK5HD$PJ #'4\AW]]5*EW*V[1
MA"EW5RM*+=I(S<0R,^HU&4$1"3).XY_?_ACV5IW#[MFR[6 A5YW.B#4;H? 0
MI]$M<?,.VHI2I2WF:0'WFV^4$2)TJH26REEUM"?E&+7RL5Q!:FB4VZ"I*0"5
M),#YP)B)/3DE,B=OT_V8P1/9G!;7TIL*Q"X;0XXW 249DB6Y$DY08)( U41
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M;U%=M[BY<:1A>$/7)&$VN*/LJ:Q!]Y9NDYT6=O\ )]C=H0J)2FZNBU;J60F
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ME*0$A/3E'0#YB25J+BR2M4DDDDDDG4DZDGX[U]M2E+:0A"0A"0 E*0$I &@
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M;+3*DOHPD<YK!\-98OK9%HSZ/B=Q<75^RHEQNY?NPE-PXXEQ:A+H2D%*<J!
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M!S$&=N6^^@2JVOKJQO65M.ME0;GU8C:=IZZ^\5*,DY("AD=Z<94/:0.H'D2
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MGF65?2K)BUM&/]5X=NRD:Z D;;DC,#J3KKK,<Z^&XQ?XI?FU>O5KN+EU2,Y
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M2$QKH<Q&WSC$NV*;FW>M;.W5F45-*=6K*@(VA)$DJC143EV,'2OGZ/E>>)\
M ;8;&8'=^W7M_P ;KW7XLV7*XNXY0ED>Z-(C:(KP4.]$_OE>/^QYU']EZXG\
MY.U^QA\/\O>W=Y?]VD?:#JJ^R]@M,*?O)Y$!D1[I@U*2ZDSD0>1!=4009'Z'
MOTKA_B+XR]W]Q[A1N'4MO]KZ-4'8\>G544!ZY2Q++94F),DM3'5D/I0I,13J
M5GG;1$;*?VH'7J,%M6;-OT1+[RTQ*>*EL'38$I,SJ3KIKKTKYIVR[,,W+R<5
MAQM<AMP,N!0]8G4I6T$B=$SN/5 U)%<T_P"%9N0>@MVR\XS^'6?S]IW>T:[_
M *,!!*E08^C\.?C7@AA%H3E#MP2)YM<M]>''A4/\*O<O_1VR_P#:5?\ 2U/
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M]+3@-_27X)I\BVWTG_VF_P"&G^%7N7_H[9?^TJ_Z6G ;^DOP34?(MM].X/\
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MA35JLE).A]:X2XF1KN@$>X5]B=POLIA+I#?8;M=B)2=L9>"6C (U^3."HID
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M"E"4CKDDX&,JP.NK);=<,--*=.FB=22=A UU[JQ.OLL)S/.(:3]):@ .\DZ
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MX%+1JCUQW/<U^5>=!:4Y1:7"V[JSL=,SE"TO/.RS&0EU! ;CX);9</;J4L
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M;<CYDISCE.IW:_@.UFMR"Q1:'&5_]+K%0@Q02 7@2 =823"05*B<J05*('0
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MUT>!@7ZC8_V2W_@K'_\ U=^OXC_;+C_%K\:_$'&$+?O>^&D )B;O;E1@$G(
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M"XOL\]B=QB3F#VDAT8LZTVMFS20C,&.!:*0MXM%!>N,I?R1SFF^S)P6XQYS
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MRJ^@Y! (*2-:APG$RAP-V3"4J@*!(!(@Z 1K&O6)!/?TVN$AULA"U%HC=.8
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MNY:Y4*PB NVGI2X:9KZGA'5(37&$O%L*Y2X&6@K&>1/=KLW?9E=U=7%P+Q*
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M().>GW"2^F//_P"5>MG\37HTOD$]!;JD?_E?'I6'_P"TI:C?LA<=-,:;)_\
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M<A)_*_.CE$[S'-1@>VKA3'>65@J2.W06^[KS %2 59SC(P1@9[AWC5DC7+!
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M:^R=/@-_8=>DS6-25Z2)W^<(]^BM>733OJK$I)ZJ6D*/?G)P?'P_HU=*%YA
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M22I#O,V%=BWT">G,,9!SC(*0<X(/7 5@=3H$JT(UF#]NVY/L[QSFL[*LQ!4
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M_LG[^WIXQCU?NMKT,L-K82J0L-%2WFU*"$@$X*4@$K2,=%''?DZQD3(S#0Z
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MXK*FW<7("5((YY5:C:.6VE2US&EI![=!6""K#B00"![>@]G=UQG.L"B$D@$
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M52._OSW8SQ$'168?U@>X]Y,3&A^R*N65H_)4QPEF!F9.4:Z Y3ZO+3U3&T;
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MFG:K\_>?CI0&5 D"21KKYU$.*)QZQ)("0">_V]^KJ2!&O7?[_??K0N$#:23
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M$=W?GKY=^E64D!.P2=-S$=VNG+ZSO7D\AZDC[?@=*QB)&J=2)]9/V&H<J.I
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M3EKTC7VF->1V5$@1*5';CQTE2B.=]T_AN+Z=2 2$]V.4$].Y1&1I))UC8 =
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MX35*M*?W8'U]?S:0 3$Z]Y^J8K.A141&P!Z:?SF*IRT2 4X'B<YSTSG'74$
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M&<0-A;-6]Q=/XI8J6ZMBUNL0;59(LN!<.) 7Z/=*-N'$*65Q!8Q^"YO";/%
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MZ7:,W%VM;6(7EHPS;V:WN$2I>=]:' V E+:WOF?Q?<.4OA/W^O79-Z\:)N#
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M-X&VWGW;=H*2VA+*"9N4K1?$NP&"6%EA+MUVA=1B6/8)97N$8<FQ4XI_$;Q
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M[PX;7O[>L;A5ZBRXDVF/7/Z7<=P-F)$G4RDU&-"IC-.#<BFP6ENKA1F8B-C
MNQ.'V&(L8\_B6.8UB%NP[;6+N-7XO18LN<1MQ-L$LLD*6A;B"I:E@I<60D*4
M5&<9[;W^(86_@3&%X%@N'W%PW<WS."8>;,7SS90XV;@J>=2H(6AM82V$0IM
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M37^#? EEUCTK%DX,]B'RH]V>1=M#!W+R0HDM^C&\2PI20HVR+Q+(4$E*4A(
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MN$>H,JH@UX;&L2LU]L<1Q>W2F]L%8^_B#:,JD(N[;TXW 24NH2I*7T:$+0"
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MY;FKDU4\82ON\^A!S[>N/+KTZ_;3)S&O=$$>/VQ/=I5E+2203'.9T/4;=_\
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MZG'<,$IY>I2$IS@]WD5)5;NNVZA"FU*2-]4DRA4:@@IV)C2"=Z]FEINY;;N
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M8#QT$G3O)JV29"E^J@@(!ZGKE7T8/<>HR,8P<'NU<#;0GZM^?33EK,CV&2D
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M>W.#]F"//2??]_;RF?O!$)/SDD](C0^T[3MI[ZNC-2;#9$A:6L8_;"H)1U(
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MJ""G*  9GH)'C[P8/*I*2V@<H4._SSW^'34$'32.0'\B9\:N"D2 >^J99RC
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MYZZ9E=?JJ0D3H-3]OPKP]R%/(4CF)R#G'=GP!^P>/U'4IF9G3F3K]_LY]\D
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M89(48!DH&O=/+W3R_P I4912\@@D=<9QX'P/L\_UZL/G;[B(&_..1WV\:BZ
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M#[-QW_?:B-$.(@9]T])G7V2#/AK&]DD1T%UQM2<<JU#*2//(ST&>A]O7O&A
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M\V5O_P"B1_Y2CXZ?)]_^B;_>I\Z?*5GU=_8_G3YLK?\ ]$C_ ,I1\=/D^_\
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M0Z5D&)V0@9W9.;_=J'(1OTWG[:H/FNO'NBQ<D@#$D9)/<.O]^FAL+X:\)O\
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M7VR#R(JZ,0L<I'%<(WG(=S',QW1"8T/*L<JL&>W'[5UII(;4E9*70K 7AL9
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M94[^%X^.OI]BRIFWMD$E65D F)DJ,YNZ)@@])KYO<N)4+I 4F57.8$;0@#U
M"2=<H@\A\<ME+262H)QR8\NXGP^L=?MUO(00=#O[N_OK14Z$QH3X>??5B>[%
M]MQIT)6EU)0IM8"DE*^BD*"B$\J@HA61CE).KJ;S!04,R2D@STCE.NG+V4"5
M'(M*RE0A0)&W/63[8UCG7-5Y6X;=J(#*5&G2^=V"O!PVD96N,M1Z!QH$<J?W
M:%(*>_7@L7PU=J\IQ)"FUI+DI20$G.L93KO"09@;B!O7N,(NTW+*4+4$K0HH
MDF2H!"59@--"5$ 2=I)$Q6'<Q42 ,8SDYZ$=QP<>(.,_3KA%Q:4$MD .>HN>
M:-R!!WD#78>VNP&R7,DB ,Q.\C00(ZSH9Y'V5?*'<%1MN09=/</4<DB.20S*
M9R!V;B1CUTCJTX"%-J.0#K<PW$3AKC?#)X!6%/I609$F<LR$G70UIWN$HN4J
M+<)<*2 8.I)F!!'0:<S71]N7)3J_!;?BJ*'DC$AA:OV^.X0!R.#O4@*.$N(Y
MDD8SC.OH]I<MWC27FE"")*01(T'3KL3 KP%^P[:N*:6A05)RK(@&)ZZSH-]1
MRJZU!?+3Y9QU2RZKH?%"%'&?_-UM;*"N4P.LC3GWBM=EHA$$CUH^.8?_ *5:
M04^7B7%CF4O"CDY[^H'<>@\ .GB-$N @Z$>LH0-=E$<S762CAH2DF=.D:'N\
M>M0[3V>_]6ISCH?AYU:H%S'[DGZ#U_-J0L$QK]_?4@28J!>0$*6LA" ,J4I0
M2E*>H4I1) "1XG)/7H-25!())V!,<S'+W[35N&HZ?2,"-=#,GV"M?5RZU.J<
MC4Q2D-]4.2OP5K&.526.\H;(&.<X6O.0 -<QVYS#U0I/<HR-#W  QUDZ\M9K
MI,6JK?57Y28V29&\]=AH-HUTUTP=1*B223DDY/4Y/4D]3DD]Y[R>IZZU^).I
M$G77;NTWCRKI@R- 4@@:'?3K0**>XX\?K\]07%?F@>\G?W"F9P"$%(!W!$Z\
MMC4U#[K?,6UJ0I8(44GHM)QE*T]RP>\A61S ''0:CB+.Y[]^>T=XCF=:A4J2
M 8!'-(CVC?;7W\Z\<YP1WYR 2!T'<!C![AH7'"")&LZDF?"(TWJZ77$I4@98
M4""8U@@B>DZD])J<Q,E15!<>0\PK!&6G5MY'D0E7*1WY!!'D!XV0\XG<S[S]
M^_O/LJ@0W^<D== -^_J/?65T^_;BIW*$R42&T8PW);YPH  8)0ILCH <@]X\
M<YUF1=N@G/"DZP)A0Z:D'EI.ICV5IKL&2HK;)222H@B4R3.P4!I_+;;*4[B1
MJDZV:C%5$6$!!<:4'6B0K/7U4N(3C&!A03COUG3=IG5*N\J4(]Q[YTTG0]9K
M7<PYTDK1!!$>JD@$B>4G6=]SK.U7]$^,]&5*CO-NM)0IWG0H*Y A)620"<'"
M2GOR,]0.XYR^D@[Q!&_7G]S-:C;;R5A*FU(S$@*.H$=0)Z\ZT2\Z7''7.I4Z
MM:R?'*EJ5U/B<'J>_/?U[N:\J5GVD_?N]AZ[5V\BFV0V%',2GKIK,$S),>Z>
MZLJL>DBNW/3(3B N.AX2Y:2,CT:+^W+2KI^"ZI*&L8)/-CN)S=MM3P)2H)RD
M&#K,Z" (._70ZCV8L6<";= 0K(I8T5RF 1,:Z;D#7;785U#<5H4"YTDU&$E,
M@)*43X^&)R0,E([9*#SI2,\K;X=;QD#D)"T]%24*04'8@#4SOJ8Y[[D 'G%>
M08O,09?XC;R5)!G(E!F=P=3&D1J"=H/.N1*["A4ZJS(4"?\ .,6.\6D3.S[,
M.*3D+  <<"@A0Y XE7(X>J $XURUJ2A2DI'J@P-1 [O'30:FO:,.N7#+;SLA
MUQ&98(U!&G+0Z"=!M4RWW^QJL5.>7MEEHG&<!:%H'3OSSJ21[1[-9;9T!] *
M3)VU]W2L-\T7+=1"LN61M/SH^KKOTKHQ*LX&,=,_5G&NR(.8<SKW"#[==Z\J
MI'KC7?,=!UD?97KNTX??\(\Z%N00%:D$;?SJCGQ43&%,JP"<E!QT"@.F<8Z=
M<$#O)'3IJVPW)Z'28TG4Z>/=SBH:;6@0I84-X$@2-B!M]XK6-3C*7%FQBG#B
M4.("%?A*6T<I(/7F"5(!SY#.L#[9<0H@@1,[\I$=TS(UT)]]="R<X;R0H29Y
MD?G$1$;\A,1,1I%:R"CGF(\^AZ>8(^H]/JUPU'0IZ+)GVZ;>ZO4J@+"CS;1H
M-=B5<SSG[>=950) +3S6#S(5S8)Z87D]/H/0^TYUM-7 R!$$Q&L@ZQ$1[IWY
M[5J.M>MGS;D\CSCF=_FGQ]M7YQ>4$8QW>WN(/=C65+X!!@CWC;G6)39(("M2
M"!IS(]M0?>[9$=1_#2WV*_\ ]624$G'4\A2/J^K6;T@:^IH-1!&O7X@Z\ZPA
M@B0".[?7?PC:>@[J]I<Z#IX#Q]GT:P%\ D93IWBL_#[_ (?SJ/:>SW_JTXX^
MB?$4X??\/YT[3V>_]6G''T3XBG#[_A_.G:>SW_JTXX^B?$4X??\ #^=0+F 3
MCN&>_P#5H'P2!E.O>*</O^'\Z@ETJ4$I022H# .3U.!@ =2?+WZL'1S$>TB:
M@)'-03[08VG_ #Z>\5G-(I7HJ4K6D*FR%!*4]_9<W_)@],D_NE$9() Z9!U;
MFX"08,@<I'2=^DZP8UUWVT7CJ?7!'+38<N9U&F@W\:V/'93'90TCJ$ @J&/6
M)[U=/QL],Y(&!DZX3KO&5F@B!EUYP29^,>ZM(C4R08.ACERCNZ&IVL=*:4H2
M3WDGZ=*4TI32E-*5E&MBN/6+ZUZ[%1!Z?1GZ\@#W=_M]FK,J"'9/=/("(Y^_
MI0)^<9DDR1&P@#KKM.VGNFO)4KNY<X[O6 [\]<>W^C&NL%I<!DA,D;F08$:;
M1\=8Z5!<"8!1.40/6UB(G;G'MTY:&L]M:\&J'$7 E1'G6E2%R ^TMLJ3V@2%
MI+2RDG*@5CE<)ZX"?/-Q&_5!6E.5.63,'F-AT[C[8K1<MTJ"U(,J4J2D 2D:
MR(*NL3$3 TYC)Z]7Z/7K;KD.+*;[=^ES4MLNJ4PZIP1U.-(Y7$IRHNI2!V9<
M2<C)(Z'(R\R%)EU,Y@ (*A*M#[C.Y C4[[\]3;J+AD<)2DE]L*7\TA <22HB
M" 0 3\Z#(!($FN&JRS*>@.1V6U..N.H;Y<H3@(=RI65+2, H(/4#!^@:SO%!
M,H.;GMRC<@C:#S[O?ZRQ6WZ3F6<J8B2!&Y .A$DR3[M*T]48,AB?)9?"4.I<
M]9(4%XRA"QU02GJ%9.#CP!.O XI_[PX>KJ].GK'_ "]U>R:<2\A*4?-0D!*O
MI)3(!C3??0G4\]ZDIC82<N*'K$82< C'?\=:!&J03'J \O/I4A4J UT,23MJ
M.A[SS!T-6TKP>[Q4._RQ[/'/NU8*DD1M/UUM%, &=X^(FH=I[/?^K4D@"3H!
M5=Z=I[/?^K5<Z#LH&K92-Q'O'G4H2BA7, GF2#CJ.A[\CV]/U:U,R9C,9GG!
MVGEO&NHZ3I65;3:@ #'_  Z[C;;;?G/UT;LI^1U=?4K)SRE7JC'082"!W>8(
M/EWZU'7#G4 9&D=V@[S.O,S5&VD(_-"CSTCKMO&]2A@9RH'/M_7JJ'<LZ3/4
M_P JS**2!"<L#769^ ^VKA2V3)EH&,);0MU1]G*M*!UQGG7A/LSD==;#"\[[
M"2@92\V-]LR@ 8CEORF!L#6K=SZ,^4F"EM:ICDD$QTUVUG7D=J^EE,;]#IU/
MAI2$B/"B,@=.G9,(0KH?-22>AZ>W7V1M 2VE,R4HC]D:'0Z1'O&O6OBCBG7'
MS(("W0HB9&I$G72),\H&E7%1"T+!Z8!/?G/?^KZ\:HE4G;:/?\*W5M2/G;2=
MOYUCRSE2C[3K9W TW$Q61(A*1T2!\*LU=I$:NTUVG21R\V7&9 RI<=X =FXV
MG(ZI(PH9]=M2D=,@C2OK1-XPXT5A/$2$)5E"BA4DYA"DDG7;,F(F9K:M[D,K
M0D A045E0/SDD 9(C35),Z[Q'.N8*A$D4F9(ARVPB3'66UH!YO5SE#@(Z<KB
M<*3Y@D=Z=?,+RW5:7"[('B!'Y3C$<,'=.4)]:.LYHB-.=?0+2Z0[;MNB2H^J
M4@S WS3$Z;1'L)JC,@$* 'K=V <]_P!1\._IWGNUK%"AJM(R<_6W'3;2>4Q6
MYQ#E*DR% 2G2==]3RT!Y&1M573*^_0)K4]B2W%<;("@\Z$LO-D#G;>;64I4@
M_N3T6A6%I4% '6Y98DY8JEIXE&I"-?5'_>$@]-OMC1NL/;Q%,/,@*.SDSXB$
MZ]Y,Z^^MP_?;MF9;,V5$F1'*JT@QQ22]VCJY#H[)13RC*V$I4ISM1S<O* L
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M1M\:=I[/?^K2HX??\/YT[3V>_P#5I3A]_P /YT[3V>_]6E.'W_#^=.T]GO\
MU:4X??\ #^=.T]GO_5I3A]_P_G3G]GO_ %:K!S9@K332.G?/ATJR<Z= N!TR
M_'>/A4QN4\SS]BXXT'$*;6$.*2%H6 %)4$D!22!U!SG67.J ).D\_N/?OWB3
M4E*5%)4D$I),Q$]/9WQOSUB)0<P"2"< G/3( ZG  &3@?7]F,)!S9BK0<H\-
M0>6G+;3V0M <6@SE2% 1O,F!)$<S.WG70^S%'2B-4ZZZ "\Z*?$4<@AI@H=E
M.I.< *<+;">F2M*P>@&>M:ME"5+.H/+D=X$P3',GIRYUYCM$5+N6;)ITISB0
MX$R4'33+(!/($* U/?%9N??II[2[<I+H3.DMXJ4EM651([@.([:TGU9#Z %+
M4,*8:7@%+BP48KI_A2 ))&FI3OHF=#OKN>\[@TP?#2XL%TP$J@RB9 ZB=AK(
MU'@:YMYP.X9]N>_V_P!_J [M<]))2"=^=>G6TE*BE!A(@ 1W#OZ_YU64W+M3
MI[8/*IR=#:2<9P7'TC/AW<O=TSGO&LUN8N&SR@_;YUKW:/\ 57-9DCNTT!^L
M;[;Z:FNFR2A1![TDI/TA1SKT"1 S#7NY[]?Y5Y/)G= )B$J,D?UE#J.M.<^0
M]_QU(49'JD>/E60M  G.# )B!K'+YU>5.XQD#QQT_7JT@\P8^%8@"=A6OJO(
M0_4G>1*0$89*L=2H9YQX#O\ 5\?/KK$\O(RL?.*I]62-#RC<::G8GI&^XPUF
M<;)) 2 3IN002#K.A) (Z:<HU')'9R)#8!(;?>0"<]0EQ0ST![^_OUYY>BE2
M")),0=B>6FU>I0D/(2O.$P D!43 Y[C0S_G5;2)(:E8) "TD$Y./5]8="!D^
M6KM228!.G.0-X.XUD$]_?6.X:4VE)"@N51H8C0D=9FLL#X(&%<V1D=QSX^.3
M^?68!1.Q'?$1X ?96L"H&#H.<&8]PT^/QTIVI\A[OT=7RGZ1^/G5M/IGP/G4
M>V5Y?F^&HX??\/YTT^F? ^=.V5_?'PTX??\ #^=-/IGP/G3ME?WQ\-.'W_#^
M=02!NX1[9\Z=L?'H/J^&K);23ZRB!!U"9UY:35AKH%G7;?ZYBI*YK:%I;4HE
M3BDH;0@<SBUK.$I2D ^LKH$CS/EJBRRC7B$QRB).\<]XWHI)2"5*)2$DF.@G
M-K,  #?^5;:MRTFH\=F;4PXJ6H!Q#1*0VPDX*<H;Y0I[EP>8*4$=Q3S9 YUS
M=MDD(44Z]ZSWZ'30S'+ESFN!=WC8 *2J-Q)D&-CZTDZ'\T1J.<BLT:AQ6E)<
M;90%I'JK]8J'@5)YE*Y20<''=G&N>7%KDJ62%:P0!]7=I'A54*XJ&W 1ZR0K
M0:&>8$P-QRTTJJU6JE)23)F3.T0#RYSMO32HII2FE*:4II2FE*RC6Q7'K%\@
M=YQK7KN9 -U1[OYU#(/B/MU0HE4R1,Z>W?[Q[9J@; 42%DDF8D1[M9T^%>LG
MZ?I /Y]9 2-)/C5U-A4:QIKZHU/,ZTS]'V#X:@^L())'M-5X400L@CF D>[;
M:O*CT)/4 $D=W0#V?T:A*0%""1ZPUGO^H5;)EDDE4:P1O&L&.OC7*,NO3:35
MJG!<6)+42HSF U) 4ZE*)+H'(Z %Y*<'F(4#@#H,:ZR'TMB5*G6==AJ>FPV]
ML]QKT#&'MW%GG2G*O(-4@;P-=>:O;/LBL,JE3C3*E(>',RITH5V;A!R>S2%X
M6 D8 02"K!)Z=Y UY/$W&UW"RE0]9Q9CVJ)@>R?MVKK6S:K=EI ]8AM$DQH<
MJ0=CM(_SJ0720"0.XX&>N#TSU\,=Q&?SXUU(44!1("0E*==_5)UUZZ^<UL!'
M,F.6O0>_J>=6DYYE@#)*L@#J>[H.GB=84.!:\H!*@(,"=XY;UE2L*!21',1U
MVU[OC54U"DN@*".1)\5GE.#TZ#Q^CID?9K>1AUU<^JE("%#YVQ&Y'/J(T!YZ
M<QB==X8)&4D<CO,]QT[IC45;:@H1WBPV[DH2 XKJ$\YZJ"0<= !RD^?B>F>7
M>6_HAR%:E+WB?AH)\=NF];"&UJ;"S$D3 '+ES.XWZ5:.=7T_5\,:T()W4?<(
M^.M9JCSGR'O^.HR#J?'^5*AVA! ..OV_G\>OUZHH00!J".?7NTCW58))!($Q
M'V_5'WTG-+00PY/AH?>:;$JHQ&"7'$([-E3S:7%+*U#E2E!6OF.$^.0,ZZ%@
MUFNK>%)3#S>J]H"@8S:;\@9Y#2N?>.."WN$I;4HJ:6D! )5)03I'UQ'/4Q'?
MZKGMYM24FMT; 3GF^<H9.3E0& ^3ZH(0,CH1UZY.OKF=,P5 $Z@$@$](','6
M#WZ5\R3:7"H6&%$)22<J%$YHF.]4P/;I$@"J5=XVNWGGKU(2!T/_ ,91"<^P
M!S!'GRJ..F=6]7Z:?$G[_9TK$$W,QZ#=S_W!OTU GW<M>DZ6KN\;T*I3H=,I
ML*9'CR'&6)JIJW6I"$8Y7DH9:0.18.0$O$#H.=6#K47>+2I20E*@E12#)$A)
MT.T\N[7D17?ML$#S#3BUNM*6VE10I*<R"1JD]XV//NK&_OQW&XXGFBTYN.">
MT1':=#ZD$]0AY]V2&E8P X&5!."0DDXU0W:Y_P!FD"-I)&;KH4^\ 1 @'6MQ
MO!66OSBM1/SE!($<DP1!C<#O/(P,%O2]*I7$HEPJ?"@OQ6BT V7I+KL<'F#:
ME.J;2I;9YBE194<$@GKC7F^T#*KME+J$!#J7 5+0(*TY%R%1$#,0=X[IKLX3
M9MVSR@5%3:D0E!( !*@93$B8G?KSW&EI%Q5N22':A(2GJ"VT?1DCV<K(:[OW
M05G)SG7SU;KZ5*:63&HF=1&O3F>_3WUZS@,@)R(!2KG$ 3[#OKS^VK4J0\M1
M4MQ:U*[RL\Q/7/><D_\ G$XZXU23U/C65#;:-D CW:?"ID>8]&=2\RLH=0<H
M4#T)_%4#T*2,@@],9\0-9V;A;#B7&I1EU(!,$\R0(W.O+7VF5PVBX$.)&T @
M"0.FVV@D:3KJ)K8E*K#=10<D-R$ =HUE/4XZ*1XE/3N&2D]_JZ]KA>*(NP X
MK(]\TI3JF!\TB=?6&IVUK@WUFZRG,VO\GK"5:;Q,0>L_ ;FLDA56?!5S17EI
M3G\#)6V<9Y@4*RD=_>GE/?U\O0!UYN0%:&,I!DD:[R1MR]O,"N,Y;-+ XC16
M=9+8U![^>^LD:ZBDZK2ZBOM)2POD "$#*6FQW8" < GQ43S*/4GPU"WW7$E*
ME&#J=>^1LH_5&AVY6MF6F!E0PL'Z:TQ'<3&QUTZFK>5D9. <=>O7!Z=!UZ9Z
M?;K%&H,G3OT/MK9*M=-.X?;[:CSGR'O^.LF<]!\?.G 'TCX"G.?(>_XZ9ST'
MQ\Z< ?2/@*<Y\A[_ (Z9ST'Q\Z< ?2/@*<Y\A[_CIG/0?'SIP!](^ ISGR'O
M^.F<]!\?.G 'TCX"G.?(>_XZ9ST'Q\Z< ?2/@*<Y\A[_ (Z9ST'Q\Z< ?2/@
M*<Y\A[_CIG/0?'SIP!](^ ISGR'O^.F<]!\?.G 'TCX"O;?,ZM+83S*60E*4
M@DJ4KHE..OX2L)/3N)U!S._D]LQ&H!G0@]_3I55,MA*BMQ24I!45"-,HD#WD
M 'VUTO5*]'V[L^ETI@MNUIR&$L-* 44ONI4N7-=_B(?<*4()':K2$IYDM*QV
MEK##( (5" (.AG4=9T@JG0=(._BK=I[%+QR[<24"W<4E.7UDK2)U5)TD'8:>
MS6N:Y$MZ4\[(D+6\^\XIUUUQ:EK6XL@E143GJ1E7F>HQUSQ'%*<4%$Q'+E]X
M_D!7NFVD-(R(2 (B0-8[^_OZ;SO4GG/D/?\ '5LYZ#X^=4+ .N8^ J\6^2NN
M4CS^=*=T'?A,MM9/CT!2,^P^&L]LHJ?0# G3QCOZBM:^:"+)U<DY9$:1!03)
M/N^-=0U)H(<$A/1#@)6 ?5"R>\G'3./W7?T\0=>@&OJD[Q!/4#W>R/#;7P[:
M\ZLQTD:0>O63.O+3NJVEU.%=W<?W0\M6R=_P_G691]51&NA[]8JUSYHC1UN$
M#J D=?%708\?'/=W?3T@RC5.O=MKJ/;&Y'^5:X+FOJ:0".I)&FF^DDQTUY:X
M(M9622 %DE2E=<E1.23W>.2?IUA*<Q)420HDY>0),QUTVU]]=AH$--Z'_9HU
M@Z^J))]N^G4UXYD@84E!)[RH#)]OA[\]<]=3PVN;:2:QNK=0J$J6 0# *H&X
M^RO(0SWI::!'<H(;R/H(2,9[L]^,XT*&_P UM*=Y@#7X<N5&W7E*]9Q<#EM/
MU=/CXP[-&<X'T8&/S?W.JEI!$1OSTGR_E6Y"_P!(J.FG^?QJ)2D]Z4GZ0-8S
M;)ZD?\*?M!J,I^F?CYU MMGO0G[-3Z.GZ2OO[ZGU_IGP%2E(;!([-'V>SZ=1
MZ.GZ2O$^=44I0)$[<X% $#_DT_5T^.AMD'=2C[2?.J%V/SAX _4*]*9:<24D
M'!'7LU*2H].[*5)4!Y]1[=!;-\R8^_WY5B](?)A$3, JD")@\QRV$Z[5EMJ6
MO!B2FJRN,0ZVE1BI?4IX!2NZ2D.%0)00>7/K=2$COUHNVJ2OU2F)U*E;ZZ@]
MT3//OYBMQ?%M$!2G"004I&D$$<@=2">8/4\ZS6HW3"ISC;"GR[*?6E$>GPVT
MR9CZE8"6T,\I"5K4/4[120 ,DX&N%=W>&LO>B*,W),0!ZFLZS'4'GK&O.EIA
MMT^P+MQM*;8ZRK58&I^;(V&ITYC3F+[ ,YQH/3D]@MS"D1$E"S'"@24/.H"0
MZX>]79H#3:QRI6L@$ZY4$Z0--(!D"(B#K\=>FE8"0E9"-4 D(TC3OCJ-O9!Z
M57ZLDYA,1K%6@KU)CEM_/OIJ:</O^'\Z:4X??\/YU#(\Q]HTJ,H^F/AYU'2I
MR?UOA_.F1WYZ>>E,@WS:=8_G4,CS'VC2HRCZ8^'G649'F/M&MO*/ICX>=<C*
MCZ7Q%8D5$C!QK4KK%1(@Q4!WCZ1^?2H&X]H^NO:EX/3!Z?3^8Z5=2X.D'3V_
M4:ASGR'O^.E1G/0?'SJ(6<CH#U'3'?[.ITH5D@S ',C>.>YCQKDS<JGM-7=5
MDGF0'UM34.-N%I8]*8:<46UIY2?7))_"220"#C13*7 (6X@\RVH).P'0]!W\
M]Z]G@[X]$R>J1M)/K$&3.^7F#MOJ-*TG4C5HDMY;)$]E& .=LE]I ./7+:4\
M^"""M(*CCF6!UUXG%VKZU?*V4!Q&<F7 I:B)T)*2D209/4[;UZ.V1AS@"7%O
M)<(2 0M 228!(E"N??/QJIIU9;Z*F=K&1@<R6SVZ?+*@K]L3GN(\ ,CQ&KVV
M(6[KJ4WI?:.4 H:(2C0F#"TN:DSKFB!IJ=3^&/'UVE)+8$)DG-(U'0'ER'OT
MK,8<FFN>M%=8658)*E J.<8]57*H'_S?#7K[-6'Y@62V0H 2[!5O,)*<HF>4
M'O&]<=]%XUH&D1FB4I7//?UHT[AX'45$^<W#CK<*AS'*&T@]><COR%#& <C.
M ,# Z8.UB%TFVMW PK\IE]4#:28)$:[:C72J(9S+3Q M)D] DD]9!5'OU W-
M8$I+LASG"77EDY44I*B>I(.4@YR.IZ]^>OCKP#B+M;Y?2%NJ*I*5R4[3H!!Y
M=3OO78:*DMY)00)@P9,SN09UF3I[AM7@4^:HX#+W?@DI*1]I(S_3GIW'6PS8
MOOD!#9$DR5 C7Q%8PIHE6JM.9.GCE.AZQ\:JD46:H$GE3T&.9P C/L3SDX\O
M5SYCOUO)P&[) /#]Q5KST]8_'?NTG&MUM*B-2.H4#]2?9TY[[U4HH#AP5RP"
M,92VDGZ<\R@#Y=2/'Z=9_P 7GDE)6K0_1/3?=)/L@^8@7"DR&2@@GULX48B0
M,L$0=YT/+3<5<H](886VZ7G77&E)6D'D".8'Q&"3W^"N[Q\^FS@K#.5U2EK*
M%!612DE)(5(E(0#$\@H35%/K$D !2DJ22$Z0H0J 9W!U&NN_07@+RH$I2.OD
M0/S^TGZSKJA8+@<R(!C*(S@"8U "YS#<:G7D:U4RAHM!1RDYB2$YB?;ECX5Z
MYT^?N/PUFSK^DK]H^=->O]U'\-.=/G[C\-5))U)D]33[\OL@4YT^?N/PTI3F
M3UZCN/>/,8.,COP2/'OU/J0I*XRJ!&O(]T@B8GE4$@0HYCE,P(Y=="8]D5@E
M>IHCNF4T"&'OPB!D-.>T =$N8R"<X423T(&O XY9*MW5/,I4M$E2@8)()U (
M">9'U"N[8OIN$A"UMH4 ,F:1$===>IB.8Y$514N@UJMN!JCTNH5)1QUBQ7'4
M DXP7$I#?CZQ4M 2!S$]XUQVFGGP"AO)/T@?KF(_G,<LK]U:VQAU])U@Y"/J
MDGF/=K6VZ+L+=M0*'*H_!H<=1]9+SWIDT)\2(\5"FB?)"I+9_C=#KJL8/<+_
M -K GZ/JQ^T3U[_97 O.U%BT"+<*4H2/RAS>MMH$A.GOK<5O[&6E1G&I$^1/
MK,EM25@NNF'&P".GH\3D6M)5U4AZ4L%.04K3D'MVF%,VQ#F9PN#<YDY=#I R
M?::\]<=I+J[2 $L!K\V$.A8Y*G\J4F?8(W@[5FZK L\9Y:*P.;OQ(F>K_P"3
MB3A/?UQC(P/#772M:9E14#$!4$")VT'6N:<0NDF4/*3.^51U]LD^&W=5 YMK
M:#A4?F]Y!5D^I.F8!)SD!3RDY![L@@>735^*KHGP[HZ\QUGNJ4XI>@R7BL22
M4K$I,]0G*=#J-=]Y$BJ%>U%KK!"7*JUD 91,;5C'B [&<&?I'@.[4\=?1/@?
M.LGRO<R)2S$C9*_?_O.?^4:51N;0492,,5>I-K!3U=3%<3RY];"0RR>;'X/K
M$9[QJ>.?HCXUL?+B_HM>]"OA#Q$^V/KB@>V>CG CUY[/CV]/;Q]2D2TC[4CZ
M.FG'5]$1SWGN@?6?/2WRZ0-+5:C]))A)]FI('?)[ITJS5#:>H1(LJ5'JL:5Z
M*P\_V/HSK;KO9-J<Y&\.N)YE)02"2!T5U]7K(>GE[/O-9&L<0XL(6R6E'DLF
M2)B1 U Y^P[5J4G&0KH1WCR/3I](SU\O'&LJ5%1.W\YCK7?2DEH.R"%$  #J
M"9W[NE0YT^?N/PU>HISI\_<?AI2G.GS]Q^&E*<Z?/W'X:4ISI\_<?AI2KY;D
MJ%"JT>HST]K%II5.,<8"I3T<!46*DJ!'[=(+9<5RD-LA:B%8U=IPM.!R$G+,
M9AIJ"!(!UWZC6-(K4O6G'K5UEJ,[@2E,SL5IS>\)F-9W,:0::LU:=<$^55IR
MBXZZOKU):CM%?(PRT%E10V@$)2>BRK).2H*-7GW722,I!/($P)V&LZ:0#W^Y
M;6OH-DIEH(+CA"E*<]8YB1,92F-1IORF1I5LYT^?N/PU%;=.=/G[C\-*5?;7
MPNXZ*D=0:C&!QW@=JE7C[$$^/0'RUFME%-PV--^?MCK6CB9(P]\""3I'<1!.
M]=8N-AULH7CE(]8'IX8Z>T$@]>G0YUZ,&#/2OG:5E"%*$2%)!F=('M&H(%8B
M^RJ.Z6E_N.H4/W2,]%CSSYZOF)Z:@]QF# &O=\>M;ENLK G+H!SWU&^IT,DF
M!I6'UF4'I'HR3E+',%$'(6XH)SU[B$X]4X!!SU.L:U%(F1ZT$]VY_G_+?=0
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M\NZMVWOG[9.1M24ITG,C,3 @?  <O&M15G:.I1BMRBRFJD@$E,>06XDOJ<!
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MK7SB]Q9Z[?6')X1D)(3E)G2% <M3I!C3V5E']_[_ -\:Z!U,[=PT'A6I.D
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M/7"E@&8_-2L)TT$@"-SKOE;:W VD+>[98'K*#83D^![-(40/ $*4"/(CKZY
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M1I6*QF9$Z0EI"@E)',ZM7,0$J/5:AG ."0#GF..ASC/#=60HI"E%<"25$_.
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M]AII6+.KK\!Y4TIG5U^ \J:4SJZ_ >5-*N@DS)Z?;32KTTI32E-*4TI4#X=
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ML;D1RW/=&[;X3</+/%;+38$I4(];42.DQW_RUC6;TJE3"V4O&'% .&&%E*E
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M>FAWY"NIABE$E(48((B3&_3:*P/F))()QD^/D=<C.OZ:OVCYUU5I.8Y2 -(
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MJ4"I20"DD$$D $$:@C0@[B)KY^[P6@JT+ME)CL\E)JG/4:;ZH2E"5*3Z9%
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M#DN.D8Z%:N7\5*05 ^0Q'&;N]GB*4UO);44Z]Y!]_3IL#7?M<(MK,@."2.9
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MF!C!&?IS\=*0>A\#4O2D'H? U.[8XQRCNQG)U!$QW$'PI!Z'P-1#Y 2.4>J
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M''.S RHE. $G.%$CN'>>['TGIK69_++*1).92=CJ08[N?2M]MOB$!)("!"U
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MCUL=,CU>;!QC&#[<'(( \!X:K'JJ1&BR<T&)!))).G68U.PZU=*RA:5I^<D
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-4TI32E-*4TI32E?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g383050g24m45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g24m45.jpg
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MDL2N6.1&N5J21J]K'JQZ)S,5[&.Y53F:U=T3]A4T
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M5GVJ-:Q9I)<<K[#:=B2-98$>]RO3E<JQOV=$K'-:K=^W3N/CR'QE Z[5L/\
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M=>&.%BR/=+(K(F-8U9)'JY\CU:U.9[U5SW;N<JJJJ5(/B?8
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M3$<]RN<C(HFLCC9NJ\L<;&L8FS6-:U$1/V%30
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M:L5JJ]62*K^:.-O9NDR4"T2[
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M9CZN%@CR-^ED)Y8K\\]>*O)0LMA[1R]BLW83Q[21,6%)D=+$R3D:DDB8FCX
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M=:2Y7M8[+U6V+S+5!74:MN?XNXC:
M $3.0[LF-X1^]'.:%,I2FN>L^E:3C^&1">A*WAU2V<\1"+&N.JA:MRI>C&E"
M1LZKBMDY"M7G<XE$DTVP3J*JFVWSHBEG^?K6ZC0=;V'S=?<WIJW$2.A(G?.9
M!4%:26M<4R]RR?R&'-5420I]L6Q<RYME+8P/+_!92L,BDB6$PR6'.D?]45M>
M$3^_^P+MMNF^^ZIU7?R^9#(F!0        *"L6K:XMY@(BMHP>,6!&TKRTR)
M.QRUG1/C60_,*G"QE=RD:\HXC1P:U>,*$*K73!J8['GE;:[??&YJ7;="59Z5
MF:K,L<D2R02.C>L4K>62-7-5%Y7MZ.3N5.BFVM4ZEZ)(;E>&U$DC)4CGC;(Q
M)(UYHWHUZ*G,QW5J[;HO5#\W^IJQE,[@]HR2 1%\LBM"WTFOITZ,#:LED,)D
MS>8U2$B./QR?=R:B'IM..1.)*1064J3FF%FZ;8WV\M8KUR&M9I0VIXZEQ8EM
M5F2O;!86%Z21++$B\CUC>B.8KD56JG12DM*G-9KW):L$ENHDB5;+XF.GKI,U
M62I%*J<[$D8JM>C51%151>\MG&^0.5X<Y3AWBG/%.QQSLEC?XO.5K-7\;;SY
M'&I7N>9*8ZNV3-Y?D8I*>I/4R!H3X(;WI6;LK<DZE3Y#<;R;/9JPRM'/E;\K
M*DL4U9LEJ9Z0S0(B0RLYGK_.PHB-BD7=T;4Y6*B=#:0X+#5WV'P8NA$^W'+#
M9='5B8LL,RJLT3N5J?S<RJJRQILV1R\ST5>I7L8I.H86_P =E42K6%QN21&L
M&VE8N^,T?;F]T8*C9ER5S::V:5B<C0]##&YP0HUJ./D;Z-R=2F(.+(UW+USC
M:S9&_8BE@GMV)H9[C\A-')*][);TC7,?;>U55'6'L<YKI5W<J*J*O4W,./HU
MY8IH*E>&6"FS'PR1Q,8^*C&YKV5&.1$5M=KFM<V)-F(K45$W0^A53U5+9X\6
MBMKN'*[%D$$,J]]FJI@;E$D>*Y-<,.IL'<G4U/NJ618URQA::RJ##$!BG_.[
MDYV^^*-OW6U8Z3;=AM2*REV*NV5Z0QVT;R)98Q%V;,C/DI(B(Y$Z(I5:%)UF
M2XZK ZW+66G)8=$U97U%=SK6>]4W="KTYEC5>57==MRT#IP[QX]1N$1!VYFI
M1PC%;)W=% F157L<-01)MD#BJ=W]G9"<H?(B8WQU7+'!X8R\X:'-8I.4+41Y
MF^=AOV:CST<UBPS,9!LUM8W69&VI4=.^)C8XI)%YOE21QL:R.1?YQC6HUKD0
MV+].X*2*O _$8]T-1)&UHUJQ*V!DKU?+'&G+\F.1ZJZ2/_NWN55<U5*/M_@C
MG&Q(K>NL2JBJJVMRZ:3LRFONRM%;L)\FC22Q:Y<*W,=TY:/+.>H]09E2-,J1
MHG-G4.[2WE,A[F0CVQDO<4-3Y:I/C.WO7;E''9&GD/B^2W*D,SJEMMOLU5W:
M(G/(CE:YS)$CD>LB,5W?\+VFL5:AR/84J52]D,?;H>GLJ1+-"EJHZHLB(WLU
M7EC5K7(U\:R,8D;GHW;;[^<^%>;^=JB2UBQU!4JY8^UC$:YN.2IJTCC9FY](
M]&DK"ZK)FUG%NN%[;(E6C@[JX\Y+G5 6J=ENQNZQ0>H5J-&6U)ELK?=<DOWF
MMCN3VZ$+KDS_ (O[69TK&UWHK.1\35:QLK&L<J,;MRHB-35BM.8G%T4IQT:+
MG2U(*M^9*D3/3TBB;&]UABH_F9*Y'2+$YSV(Y[E7F55<M<1SCWE>(Q0^#1GG
MRHV2)*Y7')TM8F^#L)"%=,8>>2IB4E7ZX1Y,7/$7-3I_BZM5F'',I9!)+;LF
M)+T+UVTN>S4\Z69LI>DG2"6LV5UF57-KSHK9X6_*V;',BKVK6HB2*JJ[=553
M<Q8+#00K7AQE&.!TT5ET;:T2-=/ J.@F=\G=TD*M3LG.55C1$1FR(B'WS#E'
MFBP&J8,<WHBJY4TV!-D=DS1$^PMC<2I'8+>@):D,V<\J$>YATI3-9!;64^XW
MU<M6WTB#UCU0XXG?3!F\O5?7DK9*[ ^K7=4KNCL2,6*J]RO=79L[9('/57K$
MJ*SGV=MS(BIJGPN(M,GCL8VE,RS8;;L-DKQN26TQJ,;8?NW=9D8G(DGU_+NW
M?951?!7<4\BN,'C]:J^;*7V@42?W:4Q.*DU]'$C/%9$_&8,?7>-)DB C# M>
M<XUU=C6G9'[1*UU(5X.)UU+Q]6ZASK+,MQN7R'I4\3()YUM2NDFAB3:..9SG
M+VC8_P# 1_-RKNK=E55/D[3^#?7BJ.Q./]&@E?-!"E6%L<$LJ[R20M:U.R=)
M_AK'R\R=';IT+G0ZD*=KMZTD4"J^"0M\*A3%6Y+E%HNSL*DB 1@]0JCL,(V;
M$B;4B-,BA6J/:V<K71"B-4';D$Z;&;9SL[&1OVH^RLW+-B-;$MM63322(MJ9
M&I-87G<JK-(C6H^1=W.1$W7H;R#'4*LG:UJ=:O(E>.HCX88XU2M"JK%73D:F
MT,:N<K(TV:U5543J>%3O-7/O/69'M1E,UM4VTN.0G27> Q%FC)CU[+PIU:DZ
M\QK2)]S4+5A:MPU-WG80-GKBSU%,G]:/])]+^7RF5['XRR%N]V".2'TJ>29(
M^?;G5J/<NSI.5O:/^O?RMYG+RIM\J&)QF+[7XNH5*7;JU9O1H(X5DY-^1'*Q
MJ;M9S.Y&?6,YG<K4YEWO<...1
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M/&(Y,;#?<^=R7/BY'O2A)8226FCG>C/BYEW^24<C<^O9SH_M-0UC&[ ,@2Z
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MR3J4YY*'8O(JG?UZ]_BB>'FO3_;W$H@*
M
M                                   !%/L!NE+G7<'(B2"X'!P*O:DU
MBTFE;EC]'28IC23YI.>E3_*)(I2HI!7R9!J:=/*Z2&;NT_CNJR-M9!RM:7ID
M53O\.Y>_JG<ODB]?+R7J2L H
M
M                           $(N]OBI]RBN/CAGG[#=_*6YV]1_E'XFN8
M;[>^Z<R>Q,17$$SJZXMC+AZ'[EV7'.8YB7>S\R#&6WTV *MWWZ;[[+W=_<O]
MU^;N)N@4
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MLLD36>2L1EF8%4[^NR]%[^G@OE_=258%
M                                                         #FO
M>,_^,]ZY_3F._5S#!+;A]ZG8/\GF]\LD3M>^M^<_*8_=8">7P8WW];6_5,G?
MUN4:+;XP>K%+Z<J^X9(N3A%ZRW/H2U[]C3>O$;21H
M              0^[62%K:S@)1L?)DFI?0=#J,(C^AOY->J7<BQ6<S5VUFGD
MS\:S&O.OK>E2?_>GL7B(>7_M "J=%_0OAOX+X?WV[R8(%
M
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MK%+Z<J^X9(N3A%ZRW/H2U[]C3>O$;21H
M     0M[I<(PVU;79\K<:F;$!O1_/B1$?<5+2*](X<]*K+926=&QQ:-(7!;'
M9XK6[%$PBQU9);17S_LDDKJI3(T1AVHJG?\ H7Q1/#S7]7CW$T@*
M
M         6#ZMB$XL'ESI*!5B>8ELF;T'<40KU24JU0FIYQ):\D3-$SRENYA
M6J,PE^6MYFBK8TO5/MK@W)FF-,[8%4[TW\S%QQ=/X;OT*FMF)US:-3TXGX[X
MNXX=&Z047:T(,5='M$VM)0VUT;&U<)1N'F4C')&EC,LL)0@+KV,;3%*UFS#5
M,W+<HA5>[9515W5>BIX[;KOW==DV3OZ+TZGG\/<E656?:I:=LF,W?N5N&Z'L
MWF>F7:=U W59(I+(KHL"NY\^0Y')R2DKO>L.J6.US'TJ^VUS0R,$IFLBQM'M
M7Q\9YS('$5<[=%W1-W+NJ]_=OMY[=_=\WD9TP-  '->\9_\ &>]<_IS'?JYA
M@EMP^]3L'^3S>^62)VO?6_.?E,?NL!/+X,;[^MK?JF3OZW*-%M\8/5BE].5?
M<,D7)PB]9;GT):]^QIO7B-I(T                                 (N
M]::RW: 0O$-UZ!W<?NW4UE?CF]1#T\SPP8G37E\VE6\UT,;-JGU;_2YM$IOQ
MB0FQ'VAHP[:N.2<X%4[_  \>_?;N^;K][Y_F)1 4
M
M     .:]XS_XSWKG].8[]7,,$MN'WJ=@_P GF]\LD3M>^M^<_*8_=8">7P8W
MW];6_5,G?UN4:+;XP>K%+Z<J^X9(N3A%ZRW/H2U[]C3>O$;21H
M                       0I[N;XNY5771$M;Z;<F\KI+GI4B)N^V))3T8*
M>TMF,IS,KC\BBZI(N?;$2KM2C8# UAF[--Y)JB8'<DY$K-TR*M[_ !ZHO<FZ
M]R^'EY_-U)K 4
M                                      .:]XS_ .,]ZY_3F._5S#!+
M;A]ZG8/\GF]\LD3M>^M^<_*8_=8">7P8WW];6_5,G?UN4:+;XP>K%+Z<J^X9
M(N3A%ZRW/H2U[]C3>O$;21H                                 1 [4
M5GHJT@1A$A5QK<SH*B$^RU%SP1TL8K+/L1G+,:3(4HVTTBB=TUSE(?;FN<FU
M669F8%Z[;-V,9%4ZKW;]%\43P[]U\N_;Q[B7X%
M
M   #FO>,_P#C/>N?TYCOU<PP2VX?>IV#_)YO?+)$[7OK?G/RF/W6 GE\&-]_
M6UOU3)W];E&BV^,'JQ2^G*ON&2+DX1>LMSZ$M>_8TWKQ&TD:
M                     $3^Q&^2N-=08F+-]JN*XJ^*15+":AO"/T'(2F9-
M/VDUW5ODLD:Q"BDD%2HM33IK6:4TQUL9AU5Q=L3J%:XLO(JG?X=R]Z;^"^'Z
MO)>I+ "@
M                                !S7O&?\ QGO7/Z<QWZN88);</O4[
M!_D\WOEDB=KWUOSGY3'[K 3R^#&^_K:WZID[^MRC1;?&#U8I?3E7W#)%R<(O
M66Y]"6O?L:;UXC:2-                                 "$7>QD4*JF
MM]I@9S\6W9Z7YUT0[='H9JX0W+]M9[)ADTBI,%-)=2[8W</0ZU>J<=MHVFEV
M6\V0E[MFI^N15-]^F^^R]W?W+_9Y_-N3= H
M
M<U[QG_QGO7/Z<QWZN88);</O4[!_D\WOEDB=KWUOSGY3'[K 3R^#&^_K:WZI
MD[^MRC1;?&#U8I?3E7W#)%R<(O66Y]"6O?L:;UXC:2-
M                "*_7:^4MU>PDZ)+KH0.!MY4LE7&T75<;MV4FL:J>-13T
MED4>E!1R%DKA2@V-*L&<H]=7F%QK9:_-)FBQ*7M@53]'<O?_ /A47?R_V$J
M*
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M/+UB!F,ZN&0*IW_H7P1?!?!>G^SO)A@4
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M[^MRC1;?&#U8I?3E7W#)%R<(O66Y]"6O?L:;UXC:2-
M               "&'<SC&FVKJ\.E+G6#4@.Z-Y^2(U%L47(.@6 YY564RDM
M")EB4<;719&9LL6[%D0ZSU9!+36[YLEE+HL2)$)A^@JG?X]R[[+MTV7?K_J\
M>XF>!0
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MVP*IW]=O'OWV[OFZ_>^?OZ$H0*
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MT6WQ@]6*7TY5]PR1<G"+UEN?0EKW[&F]>(VDC0
M           A-WBWQ5RJJN2)>@I-P;BND^>%:(F^++D]614I\2V:R',JJ./L
M3.)<'FR4R_4HVO(8MVV9)?)]4+(\%[H5)NN15._;KU1>Y-U[O+I^GR[_  )L
M@4
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M,9O+T^<&-^ *I_J7Q1/[5_5XDO *
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M33'6R6753%6Q,H5KRR]A5._P[E[TW\%\/]?AWDL@*
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M._K<HT6WQ@]6*7TY5]PR1<G"+UEN?0EKW[&F]>(VDC0
M                A#WNJB:.J*W,F)W/Y#=OTQSH0AVZ.89O(8;L_'6>QEL9
M<51P(].[)K7,<,DZU@Z..^T:;);EO5R(HUL+/TR*M[^F^^R[<O?W+_9Y_-N3
M> H
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MF"'/MR)Q?*YY9?\ 3TQ(%4[^NW<O1=T\/F_NO<2G H
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M2/H%7S@C3+$]CLQJ5T23)&849*G9M.UU5M=3F;93V@K++B)^FY;AG7(JG?\
MH7P1?!?!>GZ?#O\  F,!0
M                                "&'?;+9*_F*P7"E53#';61J8 E;+
M!=8I7\N75Y!7"T(4EN&9L;39A6T.7O<6J,V<2)B;7\S1L7/C8W$GZ[[[%ZY%
M6[;IOU3RZ]?+NZ]_D0M\&'>_S(%TU_*$L*2VA)D=[MK(BF3HLHPN*/&T;JB
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M9!N=J*IW_H7Q1/#?O7I_M[B9@%
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MHEAP1,)I;B:3O@53O\/'OW\OFW_1\Y*$"@
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M1+20HKEG;(YJL[*65-D2)W-S<O>FV_7;(R+3+J
M      "$O>;=%'.J:Y(F".BUS<5TKSNL0E= SZ65U$2WY)9S(<R*(R\0[.'%
MTL].X:E&5M%5W_8,FE6J!I>_^SSS0*IW[=>J+W)NO=Y=/T^7?X$V@*
M
M      8O/&$B=>/_ !%+7ZT);<L(A\!LWG^6.LGI2SG2KWR.)R[ZK9JWF<@<
MTS7(F==$ZX]I:V0]8?8N^:LA$1Q)6/V3(F=K>D U-WYNFW5%3JF_>BIMWIU7
MN3J4QX6&_/FBWLIMYZM&Q>DF1DOV'M<GZQL6_=>CUU\2'[@-4..-$%@H65H8
M"DU7-SBDKK+ P*9 C0Z,Z=:>^85N1S&Q@Y57;?IT[D3;;JOA_;X=YEJ T@
M     !S7O&?_ !GO7/Z<QWZN88);</O4[!_D\WOEDB=KWUOSGY3'[K 3R^#&
M^_K:WZID[^MRC1;?&#U8I?3E7W#)%R<(O66Y]"6O?L:;UXC:2-.3A>']=5O_
M #HV!^]CL)MXW['4/R*K^PC(5Y'[(7ORRU^W>;9WP6+^@/97Z7TM_@MC#"/&
M?^DZ?_$9']I4,U\&_P"C9[\?C_V=LV,^QGMZC/(O5$CCCNZ1^0Q_G"\'MA?F
M1>K:GID>FJLI.O:W=H=$!J=<VNC:N3D+$"]&>2K1JR2E"<TLXO3?7%& CCFS
MN%AEC9+%+EL='+%(UKXY(WW(6OCD8Y%:]CVJK7-<BM<U5145%5#*F=DDAP>9
MEB>^*6+%9&2.2-SF21R,J3.8]CVJCF/8Y$<US51S7(BHJ*AS8OY??=O^^KUK
M_P#N.N+_ /N0EM_)C37_ )>P?^::'_+D3_Y3:C_\P9O_ #K?_P"8-Y3P&[-L
MFW/#WBDRM>PIQ9TO46;9R!1*["EC]-)(>A0/9)2%&<^21>Y.AJ1$5G):1/NJ
MV)3EYSH3IIKG.!'+B73J4=4S5Z-6M3@2G3<D%6"*O"CG1N5SDCA:QB.<O5R\
MNZ^*J2(X;W+=[3$-B[:L7)UN7&K-:GEL3*ULB(UJR2N>]6M3HU%=LB=$V,RX
ML OT                       (C=G+7-#6T#-:GV2Q\\R_J,3'*XMS^V]'
MKU2)18304L:UD-="CB(JS.1&VR5WM<K7595Z(PV7)#-#F_7; JG?^A>]=O!?
M'^^_<2Y H
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MNVZ+8_\ R?W&?^[S /\ W5P_Z@.+_DEIS_%%7V2?[YD#_K&<;_\ U'S_ /\
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MW;Q?M&G-/^,TC_V@>_I5?_S A/Z18_\ 'F_RK_\ >/5I\183_$V*_P W5/\
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M]Y*4"@              !H_^-?\ C"[5_1>K/J\CPB]Q-]<,A^(H>YPGH$^
M+]S-H_Z8UA_$V2/9\#SW_8;\WUF?NYN/KPN];:WY'>_8FQ^J"_<VYS\YM)_O
M-#=G$G#H).=KVA[X?5_ZREZ?6?*!#K4WK'J#Z;ROO]@]/' 7[1O!G^JGAY_"
M.(,UOP=;^G?4?Z)5?_C$R&3>#G]+SOY/0_:62!'U3_U>X0?3.K_<<";.$_\
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M<']_UJLZ=RJJJO5>O7K_ /T92@-(
M         '*7ZG]YWHWY^+>^L&0B:V&^P^*^C:/NL1#',_9C*_25[WJ4V:/@
MK7X5[C_]/YR_O-XC#_&GZS3GX66_5C3+G!KZ_47X.)_7DC< &"3.1#;N!>SM
MU85\<]O$)94IO1- I4ZF>4*[=$-2AQ560S$H&]NA[.D6*(O)5ZG;1-';4/+T
M05FY[D2M<>2G0;F8%4[_ -"^*)X+XKT_1X]WB3) H
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MYT0A%_DT>#/]URK/HI7_ ,\+8_D3I/\ Q%0_R;O]\S__ -:[X1G_ *O:P_\
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M+#@S+IA"C5*\I?5TYIF@;+Y?/^CS+M@
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MCCL@5;W^/<O<FZ]R^'EY_-N3= H
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MVE9'&S$-1U04^XFQNZ615I)=BW]^L;"(T^>(R]F8Z/,>F_K>H=/+P\_'?O\
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MII^SA_CS!(N,L<R91$>[XP79SY[L/Q:Y$]'^2E#NF;N[TSO582=_&?!<3/\
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M)]6STI*=:Z,+84Y86-.5[8N KX
M       1([,0NSA6\$*9V:7/BDJ_:-5'I87?K3SHY)T":P6@U<XKYB\GITTH
MC[>GUW4OM5$;[+[.;M#HDA*-4.&FF15._P#0OAOX>6R^WP[R6X%
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MB.SGB7]KCB!^9.J_W%?.D$)GGEE
M                   A%WLX1%MJBMSIFLHA"VG=+\ZI$!O0L*F$ZB!C^JL]
MD)8T\8:X5OHYMMI*'#8DJM)(X9S'X]*]D#F^Z[-Y)N *IW]-^Y>Y=E[EWZ]?
M#O\ -.A-T"@
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M7^XKYT@A,\\LH
M    $7.M5\M;J_A1T-47\G<C;OIE*OWYSB<0F,QV8%,Z:RGPJ4MTT.(;4%4F
MM^QVEGOR#?:0,<2RX.#$68XE$Z9%4[_#N7OWV[E\NN_E\_?T)1@4
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MD:7O,1V<\2_M<<0/S)U7^XKYT@A,\\LH
M                       $,^XT#(X5?7I+^SP1Z2%=%T J3);!OEVYX:"'
M--9+,:W.#9+V=:@42>4(%6NBF-U8>:8@LQUT(BBY,H3K]RMA5._]"^"+X+X+
MT_3X=_@3, H
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M91A[#_9;%_2-+WF([.>)?VN.('YDZK_<5\Z00F>>64
M                                 "&_;RYM05A7YKH]1=B(,Z(H),2J
MEM!+^BV]2L46.S%)&U%#FY,J.BSVXG;:I6:UC2]$E8KC"I:J.)*;]M\"J=_M
M\43P\UZ?[>[Q)D 4
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MMKOIOKC;3?7.-M=M=L>77;7;&<XVUVQG&<9QG.,XSY<9\@&D_H
M                             $7.M6^6N5?PHF&H[V6N1-WTRK7%<^3R
M)UY+BV!+.FLY\429XF)9C<Z5>0WZG&63%D.N'Z317"YI8]M7!03M@53O\/'O
MW\OFW_1\Y*,"@
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MKO+<-Z&0;Z-II^V!5N^_3??9=MN_N7^S;O\ F)N@4
M                                                UF_A&7X/Y"_/
M+W_L*?&$>,OUFG?PLM^K&G;#]2[_ *3QM_$<._VFMS7AY\_K[I#YWJU_?-E&
M'L/]EL7](TO>8CLYXE_:XX@?F3JO]Q7SI!"9YY90
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M='(US'L<YCV/:K7L>U5:YKFN1%:YJHJ.:J(J*BHJ;H?V*FD
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M01Z&1%,7N:X:ZY%4[_#N7O3?P\O]?AWDN *
M   !_.^FAFFY9FFIA9FNVAA>^N-]-]-\9UVTWUVQG7;7;7.<;:YQG&<9SC.,
MXR"HBHJ*FZ+T5%[E3R4JUSFN:YKE:YJHYKFJJ.:Y%W1S53945%1%147=%ZH0
M*;_#7Y9;9 WKB62>FPAHEGQ[9J-5VA.%= M$PPOW==7QOJ0]XWBQ.Q;F::M*
M:]DQC$7N;N1HU81>:EUM-FBL"R5CDBMK5CL>E18IUZT[$1V>97]JS'K(L"*C
MU5Z1JU847HD:-^22-L_"JXOVL;9KOR&G&:@NX7^3M_B%!I'3T/$F]@_1VTUQ
M]K6L=%,P]'5&,KON),W(N:Q)5N+8WF6NI?P]04V26JF>VF1846]:<0NB0NR"
M2KD+RSV1!BD*>.2.'N)&,'1I4C2H-4NV$?EP:F5+BM_YJHP;JSI;$6FY!LL<
MV^1OU\E-(R=[)8[M5&-AGK/3K YK6<J\O>UST[G*6[A/A \2,!/HZ7'W<9V>
MB='YO0>,I6<56L4;VEM0OLRY3%9RK)NS*PSS65F3M]E9+#7>WK"T_A3PW0:E
M$Y)LMDE(6.'3JSKTE\2R58F?6>\%^4?KC\RN!6F-D#4H+1%$'1_4LQK-(W,+
M,(WQZ/)9VEL2YKTY)T<_..U$DK9W-ECRC^7FEB>B?(C<C$18418U3=%1>FVJ
M+X07$>*>K+Z7BI(*W"2'@B_'S8J"7'W>'U=)^PQU^LYRI9N1/L/DCR:N;<9(
MUCFR)\I'29?83#)0>2JDT1C$B4IBLITZA]8&IW/3D9WR9DDDYP2*#"BLF;;;
MY++VUTSOMG;.OG9SD<W+5K3JCIZ\$SFILU98HY%1-]]D5[55$WZ[)TW,3X_/
MYW$1R18K-9;&12O226+'Y&Y2CDD1J-221E::)KWHU$:CG(KN5$3?9-C\)! (
M+*V-%&9-#(K((ZV^@RV,;U'FAT:6S9*C-;TAC:W+D9Z-"8D0GG(TIB8DK9.F
M-,()SH5OMIFDU2K8B;!/6KS0LV6.*6&.2.-6M5C58Q[5:Q6M56M5J(K6JJ)L
MB['TQNI-0X?(3Y;$YW,8W*6^T2WD*&3NT[MM)IV69VVK5>>.>PV>Q''/,V61
MZ2S,;(]'/:CDL=">/J,@$=H"+,$><M6;F=VD#]52-8^."DA ]R5L?&IQ=WM+
M@PM%(G,LF1.:AN<'1*>L;%QWKB$\@W<_)W%5=.8JI#B((89$BP<DTU!KIGN1
MDL[)6/DE;NC9I$2:1S'R-5T;UYF*BJN^0L_QOXA:DR?$K+Y+)U%O\6*6-QVL
M9X,=5BDLT,5;QURK2Q\W(ZQBZCI,74BM5J<T<%NO'V%B.1C8T9Z]F\P5A;2A
MZ<9;F4X?G=W9'1/)6:2KF:01XEABLDAB1BCC@BQIEMCQS#.)^0M:]BE!:E5.
MY0X[;ZKE:10A^MW!T<@Z62QV_;2212)/%.^*:%(J\]9L4+V[<D*Q6K:.CV5'
M/M3OWYW-5FPTGQ:U;HR.A5POQ1\74J5^I)BKV*KWL;DY,CF,7G9LAE*UCF]+
MR<>1T_IN2O<1\;H8=.8BLC5KPSQV+YL3(UQID9HXQI-&]EC[4WLC.@+W-,+1
M-;4D)0-Z30P_<T[?1,D())UW.,,-VUTQL9OOOG.V>4BBC@BCAB:C(H8V11L3
M=49'&U&,:FZJNS6HB)NJKTZJIC[(W[F5R%[*9"=UF_DKEF_>LO:QK[%RY.^Q
M9G<V-K(VNEFD?(YK&-8BN5&M:W9$]4?0V8                     &LW\(
MR_!_(7YY>_\ 84^,(\9?K-._A9;]6-.V'ZEW_2>-OXCAW^TUN:\//G]?=(?.
M]6O[YLHP]A_LMB_I&E[S$=G/$O[7'$#\R=5_N*^=((3//+*
M                                      !"7O-SB3555<'S)=1S>VG=
M*\[HD!U_5Y*K*B1K^LLYD(8TL:98AC9Q:;-4N&Q)5<2Y=Y&*+2G9 [O6<($Y
MH%6]_CT15Z+LO<OCY>?S$V@*
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MJ-5[47=-AP9A.L@
M      "+O6BR6H8!"S88=T"2Y&7=32=?MSA'X?(YELP*)TUEOI<J138XAL2U
M.8W;':V@ZM^VTA:XCEP5L)9CB63KD53O\.Y>_?;N7RZ[^7S[$H@*
M
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M\UMLEZT315Q2JDR_<G85;W^/<N^R;]-E\/\ 7X=_@3/ H
M
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MN.,TT;\[8%4[_P!"^*)X+XKT_P!O<3& H
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MMG1S@B(YM+-.<D4K;6EW93B%*%V;T:],>E+%>1VV_3O5.JM3=4[]D5=U_09
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MQ2388(ZPK4^_MAR<M2$[>1L2>HWT+/)R8*HU7)NFVV^W543JOWU0M18WC-<
M5>^-[7(;.FCFSK:KK:[U<^A-*W!/ZXCE26WYF(%/IA,H;"GMJB3 ];&ED^GD
M&Z Y&JWU1+""%N-D^H(QR^'BJ;*J(NZ=Z;*J*JIOX(90&UQ;WAN0.[4M2N36
MZ(DKBVN*$\M4B7MZX@M2C6HU).VY*A*J3FEGISRM]BS2C-#--MM=L9R-)]H
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MTT>;4Z!P?+,):"CU*G4W5M4%IG).*\S45KMU54:B(FVR;HFW5=_/KT0VAVQ
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M8/HK^AT7^=2LOWL;P!?P
;                                !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g383050g24s24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g24s24.jpg
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M 1$  A$! Q$!_\0 'P ! 0 " @,! 0$           <&" 4) P0* @$+_\0
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MUT_95 ]VI1<YUVH^!(RV5R3SK*Y[;B+DR,B.>&KL9)WV%G+!#1>)63D3(=^
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MR[W4,)/8N[6YJ7IS9L!=8@F#W5+];.Q&]:E:1#:9+OZ@MP6K)K>E!U1<*.'
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M2B2JRUBK7<3L62QK"6G]?P-UG)2$UWNRNU36L=LZD$F@;0Z5=R-L@:BDQ$[
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M8^ AOAF7RVO5?546+B&#%0DC,.,-)Z[H'CH[UJE6Y%88Z68\4JM09S [)$.
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M8"DV#%.TCB9J$$7@_!4+69/&H\&0<4_B5E<.Q\8\,(KX3D?%G^SBO5?9)?\
M"GAPG!NG$MS%Q]0X=Q(NW;),G=VV5QL3#.&;O$Y]ZN'K%9\2*7+\6!#'!)P;
M'?#&=V4B?N/=&AWME4('?-R[XYPZ>Z6=::#K6P1-@.#JNIT 0C5EB"J3H>.I
MF8Z GI.9K;<I&(T^B,<&@K-9YF7@D/CJ1$3<]*2,=@8V2+?>D1=(M8NKR)XE
M:>^W2&&07.I/<;I8DCF*2&_+@R0PQI*0WW2.)$?*HH&F31-,M[:1)&$-IM02
MH8;!8-L<C/%O7N,)B.65WCR.\>1V7#,2:.%T^U]&@#14=8K*!&!15*@@XX.M
MZ9&!%A-;3Y5KUU##",ZG0.Q%4&TG'66EQ[;:1*M8#"YF#9!D2'B5PVU^[=F=
MXH7=I+F5G:6_9FEO(E@NY&8WI)DNH%6&Y<G=/$JQRED %25T:W50JRRJJI!&
MJK'9!1':R&6V0 6F EO*S2P*!MBD8O&%8DUA6L>HN@(UY^RZBL3D05!6^6 =
MFZ/5='Q)43=Z-FY:ZEVT'1.I!7PY^L,V&_4MUYIQLN/CYZSP+;B )61&(DWF
MO:JX$-_$)%EMXV$5S-J,BO;7/<]W'E'OF#13&*UN ""KO%#*071&&FUT?3U)
MELY2ACF=2\$5BA2>#C6[]\EF"LD0DN(200RK)+'G:[ TRR=7J[<A+ !;K_?[
M0%;(F+@+2+8 -4S ]C@X(V1DX2'G&I#5Y")6,AI*7EI&)".P^-&GR9Y@3;)!
M9#CD.'6IK=HG@M;6%H)'E@:)KV,PR2*B221%+P&-Y$C179<%U158D* ),NE1
MS"19KBXE69$CE$BVCB5(V9D20-:D.J,[LBMD*S,5 +$G&J_TKU;5$A(J\G-5
MQ,:6+(1R8.IZ4BL1YP,],VD$L+W'4C'NA(-EL=@L +P_IN!S4Y+R@RFC9$QY
M[;+TBO9]W&2.;>I5^+-J$FY6CCA96W7QW!H88HF!R&CBC0Y5% U1Z':0[>$\
MD6U@R\.*R3:RR/*K+MLQ@K++)(I&"KR.XPS,3@>.AO5_X1FZDEFO(E[&J.O%
MDK35"ZZ-2<\J-79X>*MTY#MZ?27*>XN7"YQ($Z>._@=5ILX#!2/AR69*E?9-
MK6R*<F8QP[[:&8W.JE(MW!D>WBD-_M3=P+>1HD(SP8'*_<XRNCU@TO=)$.&'
MDVSRQ"#3@\FWBHDTB"SR^.-.BR,#CBS*#]T<'-8SI%J6%G@;5$&RT79XR/K<
M3&V("H:3$G(^,IP;$=4@ 99C4B#Q!*Q'"B 0###[;<0$((( E@<5AMN,_2._
MDB:"18WA=YG>)Y]0:-WN&+3LR&^*LTS,S2D@F1F9FR6).]=#M$D65&=946-5
MD6&Q$BK"H6%5<6>X")0%C ("* %P *_-6Z/ZBHR3DTLJ3J29.Q1-ND4UJG:1
M@TG6J (?+@;(5B-U&-A^=@RR22H:6<\QT6020\"^PX\XI69^DE_<[3<!)RD4
MD"&:?49=L$H"RPKOOFQ%*JJLD8[QP &! %8BT*S@W<!GAWR),W"AL8]TT9+1
MRMMLQF2,DE'/?(22I!)K8;54=38J@5X2@'ARM44V>;'R8(T,&B1)DY4^3F3R
MAH"+A8MJ5+G"Y(B;2U% DYF7#U23"9)1><U5\]P]U*UTK)/E5=&,C; D:I&J
MM*\CE%C5!'EV7AA=AV;:LK184MXUMV#Q89E8!%W%G9G9A&B*',A8R=XIW[MP
MW9JA<B5(IQ2L1V!1JWL^A7?6ES"<DJ?L.HV6C6N.9+*CWCZW;88V G0FCP7A
MS@G"HN0*806&^P4,IS#P[S;R$+3OM;F:RNK:\MV"7%I/#<P.55PDT$BRQ,5<
M%6"NBDJP*MC!!!(K3<0175O/:S*6AN898)5!*EHID:.10RD,I*L0""".L$&L
MK;0EIM#:,>"&T)0C'CG/@E"<)3CQSXYSX8QC'CG/CG]_FCKK=U5^^*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI47[#1=RFM-W:*H$',62UGBQ0\=#5^\R
MNMYLL=<_%?#"HNXP=KH4M&FB0N)$U@0&]T=Z=6/BOXN=53**GH^QTI[>/4+9
M[J6.&!3(7DEMDO(U/"DX>^WD@ND=6DV*6:VN1&#Q>YYMG":%J*SO93I;QO+,
MP4*D<[VSL#(F_9,DUNZLL>Y@JW$!D(X?'A#\1>N[7NB^Y[H=;G+?/;<CK-00
M.I,+5P9#?<DN,DQZ?W*W%)=@I&V5Z)VK::[=R9_J?,:^C39#8IMPL=@8:%CT
M2DC=X918_5W>I='@TT5O%8-#=/KLDSII:!T-QT?T]-*2"62RAFMA%KD=TZI:
M+;PQ$LVQ+:3:W.6]AK16)YI+Q9;==(2)6OVV.(=9O&U!IHH[N6.<R:2]NK-<
MM-))A5WO.F1.FM+=D,QY$[O8K9FF]74?9,_NB<O4EOPJ\S.EJT7TE[8:LV%:
M*)>9C<>Q;XY]3%\N%%G(Y0K%*AC&9+-AB]:4X?ZJ:[%2CJ&D[Q%IBV6H7ES:
M1:?%:II:VL>HRKTCT2]M(;JVCT^TM1QK6"YC?<;F12G">\N"()GCBRU((9+]
MKFSM8+F2]DN&U!IWLHFT35;6YEMYY+RYG/"GF@=,"%&W\1+6$<6-*'K_ %WW
M2GANI^W;9*;+GMA727D=@[MK2-C2='TGKB*O_P!13<7%R&O MM5:=;G-6T:L
MQ6(RFCU3<% M=U/V<#8ZY5S[ZO9$/&NKKH[$==L($LXK6W1;73IC:+<ZE=O:
M]TEW2[:PGBX5]<S/ON#/874%LEDT4TZ6O<<DBWM]:D&DWDSW4MQ.[7%]%W2T
M%C;)<<':K6ZW<,F^U@C4)"(KRWEG:Z$L437'=*2Z(T5WX!T\4'.O=@;'M2(L
MFJY0B$$WZU"T;8UTK=7VE%W^?>NH_:QK9L!IV_2T_49"2!JTEJIVK3%>IMEK
M76*7#A+;2;9,DU/HPVH!XAI45E)#>HLATLR7-I;3363VL(MFT0V<NH6J13HC
M3)>B>.:XAFUJ-I(+B"*EAKZV95_7"2Z26T<H-0V07$\<5VES)QQJPNH[.X:2
M%F6%K4Q/'!)%I;A)H)N\M/FRE.58QA7ACS82K*DX5X?'A*LI3E6,9\<85E*<
MYQ\>4X^]CYM7=5_>*4XI3BE.*4XI3BE=),7ISL59Z=KZ5UN)-B[(H&O_ &A^
MLMAV2'M4%5+-#;IVGV\T#<V"17Y>8BY%E5Z@*3?;O!3C#3D7FN.PQCAC+%CK
M:)3Z*^H:5!/=QW;1M:75UT4O+2&2"6>&33K'0=4M]K!$=2+:6YM;:6(D/QA(
MH4F&8Q\0MEJ,L-N]L'%S;P=(K6YECE2&5+V[UG3YP5WNC+QXX+B>-P-O"*$D
M"6/?2++H_M;";'&E*L5NB7A:V/VUINH9<K?A$M&5&1V"C0\[U]V%MT"T[6"E
M-E:\IT[$;F$E(NRC[#N08#M>C/J,E8YJ&R%$AU+1)+-DG&GQR3-H5Q?QC2UC
M>X2U.IQ:I:6#P6+)9W4\4FGLCPFTMV<3/W0CF3=)EL=5CN0T1O72(:M!9NVH
M%UA:X%@^GW-XLMVKW5O#(EZK+*+F<*8TX++L*X=2=-]R+!5 (6U6'L-6PD1^
MU) ^.E-SQU8L05W<U!!QM*S&W6L=J=U7"QU0_:81,]&CS-R@H:/EG91ARC5S
M7QK$0_ON=0Z/Q3O)!%I4S%K)4=-/>:)K<7\CW >VGT33H(9DL6$3F.WED=!&
M1<S7:F0:8++69(D26348EVW;.K7JQ2K-W$BP%9XM5O9I8FNU,BAYT17+ P1V
M[!#^+UISNI<-A4FT.#79[:-9L%BMM&V<;M:D8Z^ZP&E?9\[3U3$QTAIT78;+
MI^P@NTEU<D)FS@ZCN3A5;FGG(V^,5)1%6B<VVH='8+2XA#6PLIHHH+FR6QN?
M76\*=*K.^=TU VA"VC:+;A(X6O[?;-& ]J9P)Y%Q9ZU-<PRXG-U%))+;W37<
M'K=:A^C]U:(KV8N 6N%U28L\JV<^8WRDXBS$GKCZM[?2>J&(2W1O9:Q5@N=N
MN;+JP'<M)I&UG9*4U-$PE7+C=I$=Q;_+6#4@&P1[#.6*NRN\ZN?(3$ZPF,U^
MK7D8+67/1OM!2_,L#Z/#,L=MP;UM/N;BQ")?R23J]B.C]K'%?M:M%'%+'ILR
M)'$=]UW6[3#R+76'M!',NIR1&2?BV@O8(+HN]HB1%;KUYG>2S6X$DDD;7T3,
M\@"6YMTX5;A.PN[=>:FZ5#U.M62PG:L&JL'N[75.MU&C9:2AF^N-YHJ15E6>
MXUBG6"/K.USZ5+FL(LKF,,Q?P_#-RKT6PP_SXDTZ[OND1GFAB6],\FFW=Q!<
MO&DAU:VN2V(;>:XB::Q6XC4\'K?A2% Y(N=E[;6>B+%%)(UH(8[ZWAF@5V0:
M;/!MS+-%#(L=VT#L.+U)O0.5 .F@&O/:"B5F;!$(VJ5=Y;JQH6-G;+;]QUMZ
M+B]H5.(Z_C;CH^K8VN[\3#R]JV1&QFYF\;+L%<U)9JQLQR6D@]YS=)M]-+I/
M0M=]%6FB9A9"WCUO4WBAM["8.]E.^J'3[F]>;2^(D%F[Z<>XXIKZ&:S"(VFQ
MW,%PMS2K;](1$Z@W9N'TJP622:\B*)=0KIXO(+58[_AO+<HM[_U,D=I+%<EV
M6^>"6!H-ECM<[ULW1"_:[+/VNO;4@S9R*M&S%ZC*7MCX%1=<V"&I6+]!;\VI
MY7WJ^V[5X68LV^)B5DX5V/'O]D%*?FE,TZ7>F0])K:[5+$6*&%9GCMGN;'B&
MVX4ESW+-I=ER$I$TD<.F1QI(&-K$P$>;-K:^ET&XMRUWW6PE,2O.D%YPQ/Q$
M@X\=_=<^&.$CRW[LZ;1<2@E\3%ZD]IA=E4NRUZL;V;I0_8ZJ2H-$L6\:F@ 3
M3"]*]1ZC+2^X;3 ]@UVJ=L5-M-3W/*Q\,0SO>OWR01>P[;4B#[SK[8T3,%SH
MAL[F&6;3#<-I,Z-=0Z;.7.H#4==N(X[""72Q!%%<03Z>C2 Z9+;)W,T$ZI;7
M=I)%,.JBY@ECBO\ @#4H76WDOHMJV7<.D0NUY+'J!E>2&:*]<(1?QW#<<31%
MI[>Y3AZ36^\52IF5)J&]K8^#:=X0;2)_<VO3=E6T6[ZEA$:ZV%9@9K?]JUW6
M(ZF;%#D8-Z,HM\CXY!BOJZIVH:1#S)%>C-EQ-T;GN!]WTR -!ILIX6GW:V<#
M6U_+W7:0O'I4%W,UQ:,D@>YM7?:#;7%_<R1K*_B"+7(8#B&_E*RWT8$E[;M<
MRB>SC[FN)0^H2VT2P7(9"L%PJ[ON\-G KF-/S#U'M+4[S>K5V4D=AR&F([5D
MZ_<2$S-<L6JY/6C76^-CINDV*&*[!*($NX&T09^6.GZSUOF)ZR%OY0[MLZGS
MKL##YDGT6>VMH='2T34&O8A ICFBODO#J[O'<PR+I6#;-9-%&L4VK1Q0J,BP
M6XB$LA(=5BGN)=3:Y:R6UD,Q#Q26K6HTU%>"1#J&5G6Z61VDBTUY)6.#=M"Y
M1.Q?K/$7JO\ 7#K_  .T7"'MF0FDM51&Q'3',O%NWF-HD"';7"GE*5ETE<\R
M>HAW*LY<=RM?^VYR>L26TNKZI+9 "SDU&^DM OWHMGN96@"^)>$5P.P8KH],
M2XCTW3TNR3=)96J7);[XSK!&)BQYY/$#9/:<U;N5M3J<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*ZO;EK._V_L7ML$:-^%)8'
MM-THW7#+)-!"]UZ\TZGQ,/(N O2)(R#&8'9U9W))/0H"WY!)4]Z[0*ES ^2>
MSM[RU@TFQ8OL1M%Z1:=)A6;=JMQ/)(@8(&*F6SFL$$CA4VQ8+?<SCEI[:XFU
M*[4+O==5T2]CRRKC3H851BI8C<([J.]<HI+ OD+EQF0)ZT]LF=<Z^ MY'82_
M*!HW2>Y;2JT)VIL,?>K!N*G6K9+/9&,IMP,W54&853M;DJ!).1H=[JFNY@Z!
M"EJX0Y;@7RWI_KQH9O+MH%TJUW7/2*WLIY-$A>UAL+B&S.D/<6ZZ=.TF)4ND
MWM;3W<:RNDH$#!1$];-6%M;K,=0N"MOH<UW%'JLJSR7L,MR-36"9KV$1DQM;
ML56>&V=HU>(\92QY5C3O>F7N&T6IR;W)&B6+9\24S*0NT8^'IDMJ@_M]J6W
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M$D&0*A6,$_F^4_7M^BN17[0'KJVH;"SKXELZNP]]CR5:XMJ!9#5%@;G287<
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MB_: APP) Q6"".T=O;YP?T?'\M3"P>TVKR@:I&5[4.R*Y<KWK;5VV:YB_@U
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M'<5!U+V')^,MO28:NG*RIU.*4XI75EV<V;M2([ V&K5G9EMJE=B]?:^E!8B
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MPPCJ(J)+A+#8\L"&NO(CWW S8Y0W,$ ]8\OER,\L#K^4]=>P#CO2<Y(QC'+
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M&&GD;(I9(7WQM@X96! 9'1@5>.1&!22*125DCD5DD4E74J2*UR1I*NQQD9#
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M\V,+<;RWMU:LH;3E3JUY3A&&T+5E7CC&,^EMI"5WD1*T*S;Y0ZH%=TC +;2
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M$6Y$@D84^\KUAA&G/,\[GS>+B\YVK?7J3-<)>727#C#SK<2K,XY##2AP[#
MP6(Y#Q5X:SM'B6!K6W:%#E(6@B:)3S.5C*E%.2>8 ZSXZSX,,..$%CX\48$
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M0.%.^ZL'XQGKSX_'S^3/96>3V.BMLV/$7V<N.@Y38\7G5D9$'JVA6FS6G7)
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MR;>O?S'ZG^@4!SGM9\,:K\)7WI4M7FE^#=.]XVGH\=>OM[KO1MUS]+L%N.M
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M.$ISE><V3Z?JB!\VR2*2$:.2XXC<)XQ$8R5$<G"<R[I C*K'8)%*QG.@I ^
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MU_-\8SXL*ZG?:7=OW-(QE4U)699H&R7P8F3M)+7I./Q-2&(?""%?2A>,B-V
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M:1ZHVJ6G?7%S%J=JCE)%NB(YE*MM(2X(5BP;O<R\52>K).:J[[H-I.I6@O\
M3K6[M;:12\6HVD<DVG,NTR L-IC"! 6)1H]H!+':I%?2_P!8.VVI>V%)9MNM
MY3+,F.,*[9:3+K'9M-5?*]1+3<F&P^\V\&0ME[ 4H&X\$5AM2/.R4T0*Q]CT
M#I)IG2.WDGL)&$D#\*YM9ALN+>3 .&7JDC8$%)H]T3CD&#!E7YCTBZ-:IT9N
M((=2C3AW4$=U9W4#K-;W$$JAT*NF3'*%9>-;2A)X&($D:Y4G9KSY_@Q_T_\
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MXUX8\F?*G_6\9:QY\^/'3E9XXU8SB.-C$4<BTN(%$;SBW";&W%)N(P;OCWS
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M0GGBC*B214WG:I8X7)S@%CWH)Q@ D$GD,U+BMIY]_!BDD,:-(RHI9@BC+-M
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MEDNHD$C-S.!<"XB\<1(!'KN,1D-:RR6S#^B&:6W88Y*UO(Q15S@DP&&0XQQ
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M_P#3S]+]'(]V@:,2.O3;/GG_ .PGB/\ "OANLRXUC4U&>5]=?TL?^\YZNO\
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MRRR,JI''&I9W=C@*J*"S,2  "359&\TTD<,2\265UCCC1=SN[D*J*HR2S,0
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M^K^U.A%N(6$IQ2LFPSX3^''26I!#'Z\]33I@G2O2!!=2#UZTU4BO$+*&N8@
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M))8AK(1.S8H0[+!D;[DMOX4CGR62V$*3AU@IX8A3B''<9K2ZQJ\CC*QQR2,
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MS]*=%%[ 0ACP!<(TYGN$L@N93'AYE%M;&Z] (EF?=FQDXCGDCM QCQK2#2A
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M9^ZW#1Q1-*P)(#&.&),+A<(,#.2:RXN[BZ%N+B5I1:P+:V^['W*!9))5B4@
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M;HHTJ9I<B8 "<6G"E  2 H.,XQY!TXPG&)*7%K$V^/2=.$H!'&D[NNI0&.2
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M^3G2_GKKGT%V/SL^@WA:X^#IO2;2N4Z7^#8/?T7H]S6Z/63Y-O7OYC]3_0*
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M4A"2P*#O1CO#@1 A0,<E+' SNYFJE7_[C@_^8Y_Z]WEC<_\ ?D\X_5%:(O\
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M0MJ&MP0QR5#*0E(,_#6  ?&0A17%Y4DJ"PYD=>" ?* >P_F.1V5Z0Y4 N'8
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MI'GJ)MYK?4''G,-G+MZLMM'6<&GUE3P;2;^C!?1,_C GBGLE/Q2W4>?$N2<
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MEG>-\':IQY.)GZ6:D8TFMH+!8V7),QF=N^*[7[QT54522=S%BR%, '>)P/\
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M^=$0XSZ+K-D=# 5EN)=::]9'C^O5^GE6OL\M5-7E\,?MN?[9'^V3_N\?X/\
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MKIOEC#X+O_?>G?L]0J%+X0L_>U]^O95;^5U3:<4IQ2G%*B!ORD:Y\R%U^GE
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MEE?>Q=&^#9?WQJM0;3V1JGOZ/]VZ=5TY6U.IQ2G%*U5UA?8G7?7O6DY,L2Y
M;PQ /A#0<G/$-N+-F2?5=&BV7WVF$MBN8]52,X<>4R(RETLH9AV7KMQ';7US
M)+N$?$4$HCR$?<U/WJ*S=A[.OEUG%;>C6DW>L10VEDUL)EMVEQ=74-HC*)!'
MM62=T0N7D0X+#"!W8A%9EY^1[+40"+'FVP[S)QQ)# ;68C65\--R2^OR(2J*
M3"IEDIQGPSE>0<->"DX2XO*'<(H)-7M$B$X6ZEC9E4<*UF=N_P"HE-BN!Y=O
M8<>*NLM^@NO37<EB[:-:W$49ED-WK^BP0*BA68FY-\UMN +#8)2^<#;R.?\
M/P_9$(*K![4JQ75228^M6_7&FXH(DQE42:V?C6<)*LL2(,I@=V/<8^%8Q9(Y
M^&%LNY=9>PEQE:<31?H;2X6'!FBMHKO9(K\0P2SSQ9*\,MN40D%0 RL0"3]Z
MOS/I*QMI-0TL".YOM-07$JVY%S \8N)K9VMYH"Z3[A#.8VA9PR-&ZG:P+=08
M4E;V*O/*SD@.O4\9U\]^%&<R\,HI\:,=(;*QXK2_,FNAC$'.D^&67,H:PD9K
M [F;I]'M^Y85AMKZ]UC<L<DMPTDD,.SB+;&&9#%$< SP-%#'(A5TE:0O+O\
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MQK:L_"F$L#<62:2$R1+$Z3*L?,.</$XD5&$9&PFO]'+]C)8RGV1FEL9QX?\
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MM/N8YFX<44<*"TCBBMFLY!-*RVZM"C(=MPAVO*]Y[D#BK!9J799<^3HY]5;
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M^_XP9LM=:3>"Q,X_M29O7-:=\V%)6*C[C*_?<-H^##JUIM/,)=0WMO.HY_\
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MV[1OG6#Z*?9_H?M.J_-\G\U/M]G2'\6.SOYA+!^O\?:RZ1^W:-\ZP?13[/\
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M"V17X1PA(!T=L6C3-5(&DTH4I\>)FW&B:A<1AU(4A^2I=BGQ UY:'E%QQSN
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I8EF9B2S,3DLQ.222222<D\S5X % 50%50 J@   #   Y  <@!R K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g383050g28m28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g28m28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X43>:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(R+3 X+3$P5#$U.C$R.C,S*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 X+3$P5#$U.C$R.C,T*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,BTP."TQ,%0Q-3HQ,CHS-"LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C@X/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G05=!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ-T98
M67$W)B-X03M&6%EQ-T953DY*-FYW+W-F<GE11$5L9D1,*W<U+W="5G8T2$%1
M:T97=TID:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S)B-X03M6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9A67%&2F(W3DXV
M*T=+;TU!8FUL2VMM9WE9649U3C!%:D9K-55O06%$)B-X03M9:7 W+U!!46M&
M5FIU4G5*5'AQ5'A*,D9+-UE#16=Q-$E)<4152&]29U,W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T952DYC<34T<E5O1#%!3S5(.$UK07A*57DW2&]T1#1M
M;CA-:WAC;3(R2W0O)B-X03MA4'-0>$]"5W=+1W%N:3-I36%4879(8V(X6DYJ
M,F)S8VE1>4)6<T-867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T9867$W1E5.8WDQ4'!J;U!T+S!Y
M44-#549E6'1P6E=S=#-D>7)"8E%+6&QM8SA65E(Q2DIY649S0UAG)B-X03MF
M;G8O04IY23%#8653>3AP;TQE,E5L5'%->6AP6#9I<V%(-%9(:%5%+TQ.:F@P
M435Y9&1M,7934'IE5F%H-78X,#9J2UIB,U8W=61Y)B-X03M+2&Q-.4MF24=M
M6FMC55)Y06-/5V5:-FQ5,'IZ=C5V,'58,6)(5TQU1G4T17IS<"MA<U-P-F5'
M0U='0C5H639I639L-T0U02\U>4IA)B-X03MA-&HP+W=!,TEK9G%%2VUQ4D1I
M;TI0.$%U-DUB068U4R]D;49M,%9B>&,W1')19'!B4&-V6&=-2'(K;VAT>6Y0
M,6%J:'=P6&QY-E5P)B-X03MV6$YE-39V6EA58S!A;4]26EDR2$M+4E-'1$PW
M161C9U%Z0E)/0DQS5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-6)B-X03MD:7)S5F1I<G-69&ER<U9D:7)4<T52;5 W24IP.'-667@U;3AT
M=V593%,R=&)M5F\T;TQQ3S9K35ID2%EX,3)34TYO,VIA<E9$<6%Q)B-X03ME
M;5=-2'HO*V(O;49T2W1R9CAV=$QN1&%D<'!E4SED0G<U>5-Y3DMK3D]49D1%
M<FHU;DYL;W-/,T585S8S3B]#4&DX<'I93W1D:7)S)B-X03M69&ER,T0X;79-
M9#,U;#!/-#AK6&QY<5,R6FEV3DQK;5@Q561)2FQK83-L:G%V<5)607%O669#
M5&UR,75':GA",C)I>F-1-%0P97AE)B-X03M53DXQ<E-,3G10,4(T<FA,66U7
M0S9G:5="6&%E5U=6,$5A16=#34]Q03!Q9G1'<$]90F,V,E=!9VEO,T(V2$E-
M,48W;FEX6&I7;G9K)B-X03MH1D9R9G)F*U(K4#EM4$-J:60Y8B]W06HX9C=-
M949E2C,Q=B]!0U!X+W-X-%8T;F97+SA!22](*WI(:%AI9#EB+W=!:CAF-TUE
M1F5*)B-X03M:<75O<G R:S-M<$Y&2D]T;F)Y6$Q14D1L231I479W460R86Q"
M:U=4>BMB.#9)671/9313>'0W>3555$))-U,X2F=D-$IO:UI6=4HT)B-X03M,
M9&%#2U9P0SE/1D8R6F=A-&%6<E9F>C,X=&%26F%,8V%H8GES,G X5&-#,5=3
M5DE1.$1Y<5EZ2DA#."]X2W$O0V=P6&5H1D-&870O)B-X03MZ-SAS1TLY1C-:
M,V-&-UEM4G!,5E969UEL5C5%9%I:1$-J1F\P1$915'A*-V=&<TY+;4=G9FY2
M-54Q:3AS<D9)8GE#-W9,9#=N:3A0)B-X03M/3D)(04QL;$US6F139E):5TA'
M;TY2-#1&46%F;B\U0V$W;'12.6)-<T9U3'5C<DA'-G!%471#5U-2:'4P:7)4
M>$\K,BM+;W5,.#9V)B-X03M+37-&>&-2=S-P9W1::$)02UEK5D9:<$DT9U%3
M-$1+6&Y58VQQ3W V66%66G$S-3 K5SE0,49R03)L-4I*1DIC0V%1=VM2*VQA
M5'E7)B-X03LP.&MB1&YZ2WEW3T%M>%!%*S%1<4DQ=C@U4$M':7I7.$XX=#!K
M='AA<F5R1W-13$Q#65=U1TQ,>41F0D9'>DY153)P.7)B1EAY,2]Y)B-X03MS
M3'HY+W="5$QQ=B]!16Y84"].961$-$50-6\K5'IV:GHO;D@U=2\U5T8U*R]W
M0W!L,5@O04M4<FXO;79(=TEF>E(X;#AE9C@T+TXS)B-X03LO2W=V4#,O57DV
M<B]!3DHQ>B]Z6&HT15 U;RM3*U!0*V-F;3<O;%E8;C<O<5ID5B\V5')N+VUV
M2'=)9GI2.&PX968X04]0>F0O=T%R)B-X03M#."]F.51,<78O4V1C+SA!3F50
M9U$O;6HU3#0X+W=#8V9M;5AL;GHW-35M.'EA5$1.-6DQ3U-+4SAT,&MJ93AU
M1U9L85915EE&-D5%)B-X03M:1$IH:'=N66-U-7-X6G!M63-03618,EIM:&0X
M;S-B05%N,TE!<'8S<FA#0VA#5T<U53 K+W=$05I.:2M*9DTK;U0V:C5J,5,K
M;E!+)B-X03M7-'5P<$=05'$U,C(X33,K259%0C!'63--*SE/=DIM;V%,8E=&
M,G-T>%DR5W%M5D=3-C%/>DXW0S%S1F)N16E#3S1#=5=O83A.+S5H)B-X03LS
M<GEX2E!5:GE.3C)#55%$9$$K679:37)3,"]+<CE'5W1Z95AH:S%%;WAU<F%-
M6$5A.#-K:30O<T9F:%@Q1#A*039$9G)K0V-T-V-M)B-X03LP1$)6;CE,9&I9
M+VQ/2E9&>F5-.%!P='=,3F-P25I1-$1E<G=H:U95-%9-4E-P3S-+;E1%;DMO
M:F<O1G-:.#!F-%I7-71O=$%6>D%T)B-X03MV03%X8U-/>$QZ=D-H;%AI>7)X
M-%-C:'0Q*U9-=7@X6#A4:EIU0WAW<&XK52MO5#)0-6EA1DQ%-50Q8G!)2DMD
M,&TO9'-$.41:1%5I)B-X03LX6EIA43%K1#=&>E)U-F%J=DQH5E)"67IU05=1
M>4)O855J06\R.&=.2#9$879J5$)8;7IT67-R>6HQ2&EE0C(S355H57-V<V5$
M3W8S)B-X03M(2DU3.&\Q5#AT<FY4.4QN13-M93,P3W=U1TU6-7=15S!--G8V
M=D5Z<S!G-7ET-C-%.4MG1'=Z36IM<SAR3&IY>#!/9$)&3#5!.'I8)B-X03M7
M:7A24BMC;6YT63 T<$]V<4)#:79+1T(Y2UI%24-U0C R-&=F6D9-:C0P469P
M6F5'835P:%IE4F1F;C S55E,<GI83G%L;G%C15 Q)B-X03M:<$9$>&=Q-&Q*
M*T9X>6IK2'=S07<U2V%6,D=23U=.:C Q4U)!-S=O94PX<G!*9$MJ=%1Q<TUK
M36QO:TQ,2$)W:&-,3&14<5972U)+)B-X03M)2'4P<'A.84PQ<61J-"LY,2M.
M:T1&='I:9#53,$M4469,=&QP17,V,TPR:49437%#3E16>7=!444P0VAU4%AF
M2V-K=4M23%I#3D-K)B-X03LW,4\U=3=84C=U-G,W63-L-4)B>5,R,6]$>$US
M:4E74TU(='I957EH=&5A6#-N=GHQ83(Y,2MJ.45I,65'0S!-.$XS2'!T-UIQ
M6C-I)B-X03MV;F%!5S!Z=DLS>#)S4W-64#=7+S)L;U94,DQZ5G)N,6$T;'90
M3&HS3%<X8T%T-V%'1FLT4U1037-S5%!,6&MS6&]O:&5.4T=0>%4T)B-X03MK
M5599-65F;F)*0G%L>G!-=FMY.%A6231,<5I,8VQ*2DI0<2]/3TIK:5)42S93
M=4]!64QT6'=Q47%I9$\O3FY8,VYS;UHO2D8O57E*)B-X03MB4S-%56)O1EDK
M:W-K:5)Y>'%21W9/;C(Y.6=+-VM+<7DO;5AQ<T=H<'%-=FLV-G5*<F<S0E<Q
M=&]:1F(P;V)L65EL4'%29F$T2&TS)B-X03M,:4YV:'(R5E)$9FU$<6UL*UAZ
M<65R*UAN9&IC6$MY>#(X36M627)6039(:31K-5-04VE624)P<V$P0E5+569N
M:E9.5CAW=&]7<654)B-X03M,;CE&,U1X5U5T=UDR6D5A5U,U1G=:2DA21FMI
M26=J3D4W35-4,$=+6'!,4E)-,TIK5FUP4W!!2F]E,D)8>%(U4#@S=RM8-&(K
M2U,P)B-X03ME-"MU2T%(:&U.=2]W<$EN<'4V<7I.0S-Q.&U1159+<G948D]G
M>31U2W0S431-+T)E>6,S2#5N,GAG2U)A54HU5W1O-$AK=C)I=5$P)B-X03MK
M8E%%4T9$16\R5T)G;U!4;'1S;UA+>'!Z,R]*=6QR0EA,-7%52#5J=W=Z86I.
M2%I3>$QE6%8S8W):>%1Q='$O,6]K;W0Q0UEI2G92)B-X03MR4D]G.6@S2G=C
M="LW.$)J2%9!6'0Q4#(Y-DE(-6=E4S0W.3=M,#AO>#)K5%).0TQE3UE-0W)R
M36I&,FQJ:TQ(:DU0045Q2V=G57=E)B-X03M"3W0U36AQ8UE/,%9Z964O259V
M9G$Q=C54:75,84]1:&YE45)'84EI;39Q;G=';G<Y=U)U45@K3$(T37E0<5-D
M5&I",FEL838S<#)S)B-X03LK869,4G-.3VHP;&]*8F%'-$9U27=R>6TT1$Y-
M0G='-35D1W%",$9"=&LK07AJ2WIB5C1K6E1J47)D.6=V<&LX:49(,4<V2VQ&
M6#14)B-X03M#:'%P0C4X:VI6<6YV=E0R>E(X6&LW=6UP<D1I5$XY66Y9*W%*
M06AE<6EV=SA12V9:*TQP:4I+479W<TAX:&5A4EI7;C5G5&%8<FMJ)B-X03M7
M.6Q(<4Q1,S!Q.59I.5=J3411+W,W,6]C,W-:130W:GIP,'-O:GAA;'ET:T5V
M;&)Y-V4S37DS,'5M-D<P14A/1T148C9/-U=95DDY)B-X03M2-4IR:5)!5D$S
M44]'875Y:6AY;UI*1&Q:.31B>F=G5'959F-62%9D2CAJ<')M:G=X>7=X,D5R
M5&985VEN3$Q65E5X3$DO2BM#<R]W)B-X03ML=7=Q93)'17 X2C<Q>5DX9D9(
M=39Q,7@U5#AV,V%A:&0S-U=M:69O>4=&<%ET3&XK=C(W;61P230V>6U7-#1Y
M8RM"6E$U*T-P<%A!)B-X03M-<VA11SDY*WEN1$$R5#9A-VIA=D@U2SAI4$%T
M<DQQ,&-%-GHS1$IC9E=R5U-39496:$512$=8,$EG,THU0GI)3WA7=&%94$=N
M>G(W)B-X03LP:E0T<7$O=$-59FQB<$UT,2M:,FM7,7-F6%,Q=E!7859A54UD
M=5,U9G%246AF2$Q.4DMS6F%D3D0Y-W0P9EAN<'(W9V9Y9S!(,UIP)B-X03M(
M8TEU,T%%0U4R0D9A949D.&=7=TM-<V)M4FE&2D9C;4-X25-J6&9,>C9O=',V
M5'DR9#-:4VUA,759;&IC<7I2=$4Q56Q74D="4U%J)B-X03MC6D]%-EEY:F)%
M,"]*8E1)-W57-&<Q2R]I.55!1T5.1UEW4DMK<$E2:TLQ6F\Y-F<Y=D1,=GI2
M<FM'=G=D-S-1;&PK4G1N0SAQ4'%L)B-X03LW.5A"4F)267EI<TEW;T1E<CA&
M1UE'<%)V,E0X6#)S2C%8:T5$0C5L3G9+=C54-F(U8C%#>79B4S=U-3-S-'!O
M5E,T2T]R975A<S5O)B-X03MO;S%&5F%R*WET36IK,4)K0T1365E21W5E>DYF
M4VLO;$]55S(P=3%+5R]G,&TV;'-)0F,S.%5%:C)L<WIC1FMM5D-9-'EX*WE'
M86=R)B-X03ML8DXU*W9M3#@U-V4X-$AY.41E,F,V4WII9&UJ:6MH8C!36310
M5%=5.'8S9S=T,"M(;%=H=W%H<E!Z9"MC<V0Q2EE495A9<FEE3&Y-)B-X03LX
M>F-&<&)V331J9%-K=U-2;%)F-W(T5V(K8F)K>7%L2#5H+U!)2S$U3C51<T)E
M<$YD4DHK.%-35#9U:V)346=32DMT5FML6D5(*W%3)B-X03M2=G-Q.59T;FUE
M,VEE9%!4;5I&37-E>#1S4CA3,4)),E!V9U95>%9P-#0U1C1U;V1A9S!95D96
M3E%D+T%I=4MT-'$W1EAH=B]!14MX)B-X03MO=CA!,69R;B]K5$@O=T$Q6G-F
M-5)L,T]V+VLK2&553F1F.$%/3EAL;3%K16,S;4<V.5%J;'=3,D5H07)3<#1C
M<58W5GEU9F%V0V%))B-X03LK.75X.6MC67-C=F5".39"6#AH4$ER2S=,-7!U
M1U9!-6-I,4I#:4]N36YW-#AH>3A+-4@K5T(S9EI,.51,*U)F4"]:4EA$.&=F
M2D)9)B-X03MQ4$TY>5=5:%=8-G%A9VQZ1T%F;30T+U!B2"M70C-F668Q2B]K
M6'HO04YL1D<R;B]!1&I0-6)U>31G.'=84F%/;DY7=&=H06%T1%)Y)B-X03MP
M;V%(9DI1-U8T=5$K.7)Y9&MI2$UN-T0Y>5IA6"]Z:DYO.6AQ9'!F<G)L>$DQ
M<$Y(3W%'1D%'36)H-D4X=3E-;$Q8:VEQ65(P15%1)B-X03MB3WHR:DU">FUN
M6&UJ3# U06EU2V]-5G!V<V5H2'5-;3%V;C<O;DEF.'9P-#=W96)T4&E,5SAW
M5U!61E5$-$A(=W!+44]Z0V=0=CA!)B-X03M03FQO<S,X2F1F<F-.*V]01#@R
M3')(67%Q3&,S0S(W,GEY=4QE4FQK945-46I/9TE6:791:T)J42LK0W5R3&E.
M5C!5.$Q&.49F.#0X)B-X03ME46)J5')/8GI2<4580V4K5#!T4&I99D5S1F%T
M2G5.=5I!<#=F4$Y8<F,Q;FA(4C(K:G<X27,X>3EN24Q55617,D=90F,P23!!
M04%$)B-X03M91'!K1V(U;R]-2#@V+WI%,&9Z<G)';#)';U)X5U9P8W9&0D=B
M94)I1DA18VU1:R]4;3)W851(2T%*1'$X*W)N1UI!4T-0.$%0+SA!)B-X03M.
M4C-60G%S44Q%049R83)!1F1T>54R1U<O:W-F8S!J6%I$,TUV9S@T+VYF3G$Y
M-W!A95E.3CE3>6=J=51C=$9'='9):W!O;G!Y;4%!)B-X03LQ3S-*<4PO;%IJ
M;D9H;T=I-5%N;7-I-'!F4#A!;4@O>FM$1$Y02'I%;W0U5VAE5T\R=%=J-4I'
M,'A)8FHY;C P3%8O:G1K>&AW341L)B-X03LQ1CAK<C%F.#90>FXP93A.;'%D
M,$Q3-D-H>D9*83(T4$9U:"MX:S0V6$9)5T=U97)Y>$Y&0F8X05%W6#5P+SA!
M5C!J+T%/:V$S+S5O)B-X03MY6#5,2#--4'HR5'EF5'5L-C9S9FMM,#$O5EIA
M2VUM>#,Y+TU&-T-!4WES1E5F33!!>E1Z1E-).#-C>$YG2D9Q9C5U-D1P1'IW
M-G99)B-X03M8.6AE45<S,3%R4U))2&M-0FIU6E%W34TP<V8R8DHY:3%D,3DV
M45-M,70U.#!#83%U<GAZ3&(R;'!&8C-$>E-X:VAO<G0S4T)K5D,W)B-X03MN
M,5!4<4)X<E)H=%=O0W%&:"].:CAU-6ML94Q824A71U-+1U%Q2$Y(=4]8<$0W
M4#=F03!05$954EEF;5 U23%#>6UV8DA6;W)M,70O)B-X03M3.5=734]W<E!)
M,%591D9Q>%HP26]U2V]E=R].2'EB9G9-,7!D;6%Y:&AE-"]30TQY9V19-45H
M64IX2F1M.5-52T%%,U!4=%965#%$)B-X03LX,B])1FA'2EHY55@P031J;6Y6
M2#125D0W>4U14#)O>6Q"5G57,4]T1E5W4&XW>6M.5FDP;S9G;W9:>$,P2V-*
M3T1I-30K:U9K-"MM)B-X03M1>&M15C5D5U5D5T=+<V=X5C)+<V0X>F%F2F5F
M5S=::$]K3C=A1S(K<U=Y<WIO5#9G67%61$9706M"56M::35B13=R<"MT>G-"
M0G@Q)B-X03M9=7HQ<G5E5S9J*U1.>'%.;4QE8397,#E,5#=V5#17,'I4<FUY
M1"]71FA73U,T0U-T-G1"0CAA;C17<C R=V5*-4@U2#E39D,X-"]-)B-X03MF
M<E)6;"M5,7IA<G%+3&934$AQ5W!W87)*>7-:=6%.8C9I8GA9,&%V,D-J8V%F
M>F9&,TEX.%1Y4'E0-FPX4'IJ.'@K=#9P;WE3+U=B)B-X03MM5F\S4TYK:5)3
M-FQ#4W!C;6=902]T:F9*64%B2CDS-E='<$DT66DY.2\P2G1M4S1B<U9D:7%(
M;FHT<UI".6LO83EJ-#5)1FE1.#4P)B-X03MV4R]-1VLV=6)F5TQ31%5B2%9Y
M3$]E8U1813!K-VMY>4YC4WA/:&=20DA294)P>#9+>#)":T-X64HU.2\U>#!U
M4')%;#DU4FM6;UA0)B-X03M*=$UM8FEY:SE21DED:5!:=G9Z631D8C!K-B].
M;W(S:3AP,4AY1#4Q,#5Q6&UH,W-F6#1H0S=R.%!8-&Q$1&)->4]E0C5%3TA,
M5#5")B-X03LP5DY,+TQN>C%Q8FAB5%$W>&=70S@U26UI444P-G1*>$$V-$I:
M-$1M5FIP<V@V4%EF>3@O-7@U:'-P-'13.#)/;'I.1U$P5VU22&Q%)B-X03M'
M0C(Y5G8R+SE58EIG-71B93!84'=A35(S;'58<'-/:C9Z1C4S9E4Q:T,V1610
M1G%T=#EA=4=!;E=25U8P<RM+,CAF=S%"97)-9'%C)B-X03M2>7)G3V-Y0G)3
M85I#>3-%;'-X1D5A35)L:'5$>2]E2DE+-U4V9$0T.4)A448S,4<U.5AN*VM,
M:FIZ5B]4-#(O2&EV5E W<FQX8G9V)B-X03M8=TEX=GE3*TYV>E52:R]-6'I!
M:E-.2WDS:V=-:CA1>F1.>GA#<CEW>F4V8BLW1&]T6"]E1D%E5DY/,"LY=G!2
M9'E-2&AJ.5,R=#0W)B-X03MI1WIE5U%/<3A6=4IW.&-F1E=,-VIF:E%E3U1Y
M>4E',S8R3T=!2B]!6F9Q4&QV-CA"<7$K9$5U6'9'4T]70S1U5BMT+W5):DM/
M8G9))B-X03MQ8U9K:D%J2DDX4C!P;5!(2E<S0S5C<TYM*TY-8GIY.7$Q<4HT
M<F9Z+W=#;'!T,CAN<$-3-DY*-'$K;5@K1UAI-%5)1$E305%"<T,S)B-X03MW
M:4EM1"]"=7EL:FM0-#EM4"ME+TLQ<F%J54PY=DYC3W8S3G).0F)20EI&;6MK
M:F1#,TQM6D=*5TYE0VMQ1#A223)P53(T8VPP3TAH)B-X03MA3E)H;T=81GA5
M=U1-;'=N,C%O5C=:,D@U8C9F9EAQ;#=+,3!A1V4U4E5-:$U59'%'8T)"6&Q6
M461U*V,W;"MS*SDV5T@P:#4W969M)B-X03M**U5.:'!V<%<O;'A0.4YI:DUD
M;$QB45%#84HT-5=O+TEN6D5N;%4Q2'=L:4YG835":W)W+VU"-4(X>"M73F,K
M<#9.>$M)8G$V=#5")B-X03LY5FAU26].4FM327E82V\T2$IX-FIJ:3-%3U)V
M=FEQ5G8U="],4WIN0S-0:V5Y47IZ4SAB:7IJ:75)6G!O27)I5VM,<$5P:TQY
M5VE,)B-X03M$5E)Z16=99EI967%N:F5B9GEN,#-1-&)I-#AV0S-T9%)G=&YV
M;TER2EI"15)C>4ES339G0C9W>G!,*WIT43DV1$961%1F>D<O2V$Y)B-X03MK
M:C S5&1$.5E8<V%W=D)(0F)K;&)Q56-9=4MU=RM+4E9.0U)4631Q>C9$>4(U
M3VEG4T4V5&)48T5K5#%:63%E46E:,VMK<7A&9FEE)B-X03M:,E!U5&=61TXU
M5CAT3F5W,WIA6&%M.'1X1TE,9W=P>E%19VE,:3%.=49F:#A.=D%9<6UM2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6)B-X03M$>5%-=3AE-B]W079C9DQ*07-3
M1DE%5G S2%5(62]D:%ET4V1!3WI':"M8*V4R2W)S5F%R=E%B=#1$8S1P5F\W
M8S$U4V91;R]J:U-7)B-X03M10W9G4S=&5T)A,2M32#5F87IQ=#%Q="]A5%!E
M6&MH;&YD6C5&0EDY84M$45IK=S%C-&EG6$AN<&-C:EI'-E4S=C5$+T%*5E=G
M5&QP)B-X03LY>DDX;&5%85A%:%DP-FYD9T%"-VY)-4\P6GA:-'5Z8V,K;DQZ
M2UAN.&]F>6=%-6=/;EA1;E5Q1VDK=4QZ0F(W24LK=%AF=&M0-55Y)B-X03MD
M>"MZ.6)B+T%#5&HW-"\W3#E4=BM65"]!2E%0>%0V:F1.>$(T3#ED53!!<7AO
M4%<K6G@O;%1*,T@W4#%R+TI74'9(>FPK<$97;C5))B-X03MF;%!C>4I'3D]U
M;WI+2WA-.7DU5C9#=7I)-VIP=FAJ,FY-;758>5E4-TMX>$8W2#1L2"\Y0SAF
M;&@O>7=Z+SA!4U1,+T%&>3<X-VLW)B-X03LR:CAL:3=V=F5H,D9J8E=.:&(R
M1G5T3&$Q:5-#1E-E4D-2<45516YR<TUX4V).=5-"4S0R9&]50T=#36]"44M6
M5VQ!2U5P5$%L<S(Y)B-X03MU47=-4T5/3TQ$:4XQ<511*S%38U9B14U)04%2
M84Q4:4M$8FIS2V9,1E=P8F$S;&IE3U-*6&IF6C%906<W,3,K;F9&5D\Q,#)W
M=$E))B-X03M93&$S:FEI=#!72T96541I:69:565W<&EQ27A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6<&M2>%)L1&5&4EA&5DTR<T(V)B-X03MG
M+SA!0DXO6$1A2V0Y5V@X1"]W5&8Q>'1A5D925D9&055E049-0U<X5F1I<G-6
M9&EQ5S9V0F-.2D)01D=:5FI$;S9R5&M/6E5G,$Y+)B-X03MJ-$UX.#A464DS
M8W)45&E!4516,2MN.6)Y-F(X<#<R83954U,P=%DW-7(U8G%+,6%,5D@Y4UEZ
M4$A*9GAZ<35O5V]P5E)S0C1:1&I0)B-X03MC5S-H:B]/0T4P8CAM3E$P=3=M
M=5DW,E=8,3=+9E0S4U,R-4)9-31Y=G%)5$M716=B:CA69#%Q1#%W;5HO;6Q!
M:$5F>$(V4C5C,&TW)B-X03MS-$Y,<S)J9FAP,$M2=D\T0T)V5&A-46]T5TY3
M5%A"045Y0G%Q5&ML15%)=7EF,7-M>DQC0C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMV)B-X03LO.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM
M<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!0;W=E<E!O:6YTPJX@,C Q
M-CPO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*
M(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/DUO:&%M;65D($UU;GII<CPO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O
M<CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T
M/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z
M<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW
M/CDV,"XP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C4T
M,"XP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O
M:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I
M>F4^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^
M"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y4<G5E
M/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @
M(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT3F%M93Y':6QL4V%N<TU4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^1VEL;"!386YS($U4/"]S=$9N
M=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A
M8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N
M(#$N-C4\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y'24Q?7U]?7RY4
M5$8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^1VEL
M;%-A;G--5"U";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86UI;'D^1VEL;"!386YS($U4/"]S=$9N=#IF;VYT
M1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L
M9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#$N-C4\+W-T
M1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC
M;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y'24Q"7U]?7RY45$8\+W-T1FYT
M.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @
M(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C
M:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.D1E<FEV961&
M<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M4F5F.FEN<W1A;F-E240^>&UP+FEI9#HY0D,W,3$Q0CA$,3A%1#$Q.$4X0D$S
M,T-!-C4Q-$$R13PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T
M4F5F.F1O8W5M96YT240^>&UP+F1I9#HY0D,W,3$Q0CA$,3A%1#$Q.$4X0D$S
M,T-!-C4Q-$$R13PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.CE!0S<Q,3%".$0Q.$5$
M,3$X13A"03,S0T$V-3$T03)%/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S
M=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D
M1G)O;3X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HY0T,W
M,3$Q0CA$,3A%1#$Q.$4X0D$S,T-!-C4Q-$$R13PO>&UP34TZ1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HY0T,W,3$Q
M0CA$,3A%1#$Q.$4X0D$S,T-!-C4Q-$$R13PO>&UP34TZ26YS=&%N8V5)1#X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.CE!
M0S<Q,3%".$0Q.$5$,3$X13A"03,S0T$V-3$T03)%/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY04,W,3$Q0CA$,3A%1#$Q.$4X
M0D$S,T-!-C4Q-$$R13PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,BTP."TQ,%0Q-3HQ,CHP-RLP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z.4-#-S$Q,4(X1#$X140Q,3A%.$)!,S-#038U,31!,D4\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C(M,#@M,3!4,34Z,3(Z,S0K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO
M;D-L87-S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K
M970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_\  $0@ R0)4 P$1  (1 0,1 ?_$ !\  0 !! (#
M 0             &!0<("00* 0,+ O_$ %L0   & @$!!0$'# T)! L   $"
M P0%!@ '"!$)$A,4(146%S%!5)?2"AHB55>3E);3U=;7&",E,C,U.5%2<7)U
M=R1"5EAAL[2VMS<X0[$9-$1B8X&1E;7!\/_$ !T! 0  !P$!
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M^28QL;0UH])[2>\_?ARY*R<XN))YG[X7[R=07L9O7$2Z,\:E,LDJ)?:#$HE
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MU5"#O]3\;O.&#I/]L1:3D>4ZKRLSP(*.8>2Z]2N8QY*1S_7=I=G*>TFGOJ6
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M*G+VO+&X.ZUK@-YV\3D$\P!R. !V#"W"N 6\(3M^GFD#I.FG>'NE\TU4(X;
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M#VX'G/F7S<,]T+PXF$3")A$PB81,(F$3")A$PB81,(MW/U/5_*<:P_P^V_\
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M/=Z2K$W=ABO=7;5DW+$;^D=(&V%/9_4:HTACZ]K%?3M(C8:=JBP:==K/=+J
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MQS],$U:*2'3MG9ZHBEDC,4VI6HJU=\,@:Y[NCC@KRQODW#&YEIVXYQ#@,6.
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MM!XN)FL1-('$ EW)I5O-:A@EJPR.(DNS/@K@-)#I(ZT]MP<1P:!#6E=EV 2
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M^ V30;@;U*D7+6U@-;W[QX]O+[\.7F5:#.\>[=^O(Q^M71RR5TF$5F#?"/\
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M$EUB( F"J@&IV=G-!N1UH;6D4)H:;'1U(75H^BK,>0Y[88F@,C#B 7!C1O$
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M#,P89*>,C7+BI\AMXI2U<G4]JW8DQ4+;6[[6)()UX#N"N=.KT!4ZM9HU;O\
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MT9WF/:?46N!!:]C@'L<"U[6N! \S6ZEFC8FJ6X9*]F!Y9+#*W=>QPX\1R+7
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M>Q#Q_4[QS-W?;J99&;=\B@JX@[55IF)L5?E$BG9R\+),9)BLNT=(JG(XY/\
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M1(=0LKG-8"7' ^_(=JB 7' &2IA!U\[90DC)^&H^* ^5;$'OMXTIRB0YB'$
M\P_4(8R:SONE*BD8S5F4J9W2[['RS&3AR:.0[_.?1V*ZCC#.)XN/J'H[?2I9
ME%54PB81,(F$71,D/J:#GZZ?OG2>P.+ )N7CE=,#["V8!P(LL=0H& -,F #
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DPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g383050g29k08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g29k08.jpg
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M P$1  (1 0,1 ?_$ !X  0 " P$! 0$!           '" 4&"00* @,!_\0
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MV=+0YC*WOSVS."!6VM[TK=VLS1.8ZH$1*] :I#&[/,JJB+E.*8SZ4)Q
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MBQN7M"Q5'Y4T(WQF4*VEU3HW1K5'-RY,8I;7)(E<$)VVZ5:F(4E&E:#$VT
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MZ<3V5[,-^<&7FEFRR#>P'<J?977),!6(7_V8SOX)['[X/\"UUPI\)TVSDKL
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MJJNX8I,?H4T78TN4QA9L4)+)<&W5O:Y2XM3RWR0!CH7F5>'1GQ^(OD!
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M!>'32L6LJ&4[7MC[S;M;*OVE17(BXQE,Y3L(*&7H
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M0B!B           !!G&[XG(S])S?[?2@9/\ ?+Y/0A"</*[TJ3F,22L?,_\
M56O7^C]W_P"\D4;E,_('57Z(J/2TZQR%?TO\GOZR47H>3]%?_IB.?0+/_P"7
MIQ;J#_$:+^J4W^Y8<XO'\[73](UO_$RG-[JS?J\U+_7/X=_VZQ,7S1'\Z5_Z
MO7_[MG.?ZU_FNA_3]A^\H#I^*<6\             .9QMM\C,:+B]&_&8L7S
MD,@&DU]LN^))I L726PZQ76%>TK*;:-^P&?8_P!F\RG!_@.V5/<9WQC;/$7:
MAUFC942'_P "WE36T)<^_5[\2T>V9M(E EL]C%8M%WHO<>^EKMON2K)Q3*_J
MQNC.3!70.6I7V7=_@_-U&ZP^Q3?8MVHUT&ZXK=W7[V>25+I[(IWSWA[#K'WP
MB0YV5PG@JUOYA3V!S2=(+&<$!1S586T+;WER;7-P>IU#;8<=8PF)9/:4S[12
M,N$<CR^&O2=;)9)EY(=T[ZF*;SM"? OE8(N4:[6FY76*\RQ-=3WCV,AJIH)Y
MJF[6S4$R4,:4OL93=X4,M%1S6VJ9+75JU+:EE4QL+FL[EZ-75/(EIS45BT]4
M:7IJAS*S327ZJH:6KI*:AT[?-&TRW:5]P]GJY+Q=J>Z7.FOE!+!:;7WC)0RV
M^5]2QS^[V7H&=V-,*\F-WS%AE6^LU=ECU7]2IBVO1[CT+8$9;,TM:0EU4LB3
M:12I:B<9"L,=7=,DVPYMY6JA*G(P+MI&ZWJY6>Y:HN5)<,7.HDJ;1IYC8&U5
M';*2-*:G@C9.^FC6MKY8IZR1T]0QCDGA:CXV,1#E7*/I[2]DU-8] V.XV=%L
M-'!0:DUG*ZL=07._7&=U=6U<SZ.*OF2UV>GGI;9 VCHI9D6EJ7K'-+(689UY
MSJTMCFH:W)C/<6]&M.97C"+5V:352<L\QM<\-BYS;L."'??*99A XKT>%!9G
M@RQ23W!V]WIY73T\$[X)J5\T,<KJ:I[DE13ND8CUAG2"6>%)HE78D2*:6-'M
M=L2/;AR\JK:=E)65=)'5TMPCIJF>G9742U"T=:R&5T;:JD6KIZ2J6FJ$:DL"
MU%+3SK$]O=8(G[3&Y$?8\H    !1>*W38K-CE[IX =9$\9>1DK@W'"KG601^
M%FS=2T\:*ILAM@$>D$A,;6M*W&.7MZD#D[JCEN[8WD2%;IHMRWEM^1..'R;U
M\JIDK]4]\\D3^"Z:4VUK)F6ZWSFH^<<9#)79KAC,Y,L5G?4<6<=,R"-M$-D\
MY8676 UY(\Q^%['ODD**>(HUNJAVF$?-(EC^)5$SNX8SN7/^3G_OU;EW)8:.
MVJ:5(>=C#:UL+JXCC/R#Q7-32M0I8VA?#8UG@!QRN)_4052_M#DSK5D;>5MO
M626:[M<A0IUK>_F."-8V-A[:4(Z-W-E>M>/H,%P+OF/6Q2S>DVOA+9D@>76W
MI5"%+O(XJ_6@U4NEL)077^+#,9D25OVFL5A<H@!,N1NK7H^1M<]-+#-_9*2%
M.+JZ@OBYL)XLXW]:HJE+4?+!P\4[E6XU)RG6VB[I+J0-5%/\GF$%<+68JC0/
MU%5Y:,FGK['8@<37D)-EKG:U@%6(ZP&1NE04I)6:SRXNZ-[ TP-O$XWINQN7
M//O3R\>&[IW8YB?^G_>=OSEPBT9LB1NDU22FF; G)+JO5)7PAF,KWE-:E5P]
MS:)HG8(OO842LZKL0Q1"+(,C453VHPUS[KB>)QYRL%^;B1"ICZO0F<]"IT=.
M4SN.J8$   !4WE;7DDGWB^'M&KRICD.O]"\6*VQXHY2[JHI+JAN&G6EW2)2-
M#-C=(!8]GP&TEBC;3;1G0P54_9[,M6-L"4Y_&GH5%W_*B8^4IC#>%')1FJ=Z
MB+QK0I,G*3<.RH\1'IQ.R(4XF<"9)5$PK+V?1J*D*6MR6_76'R1BLE.A(=]J
MAANL3:6(ZY3B%AR<3E,\ZIOX\VUGQ\W'FSSGY8NGY8$2DU>723B/*K%A<JY!
M\D9W7T3MBPFR$VU><SL#D#:%)U(:0Y,;5$D\"K%[Y%2MJ]VETB"6</9$;B!*
MV$M[#HI:T#\=G3Y5&>K<F53?C&%7G5,]"*J;U)YY)<7[6N*T8C+XLJK]!'I-
M&J;B5KXDS]("9' $%.\A8GR 1O-3D-<0=6Z6/TE.:WF(K='UT@!#(N30N;D+
M7O9@/BJT0BX^O'EW;\[OJWD67!Q(Y(VY8$RFK415M1$2Z$P*1S>/ME_7%9L0
MNFZ*Z<:/E\*8IA '^HHE$*XB,3>JQ?:]66W!43I.[!KAU1*)' $)YN\7:1**
MF.=>/-C"?*B[U\2[N;G-\XO4':E:7P[268IFQKPM@-U26P]8HI>7" .-@<CN
M54RO6-PN'2!Z88NX2Y/2+$HE#<[2=9&H[L\NMG*'XIB9%+^Z,;2"XYO$F_&<
M(F,^+*\WBXJ=( ,0                  @?DG9<EJ>K-Y-#BX_[:'FQ*3K%
MC72M$O<XPP.%TW37]/$RM_:6MWCSB]M41S.<R94PHY%'#W[1J]AM9$P>'9>$
M0E-_UKU)DY_3[J#VK'(WP_=V*)P9Q/M]*^NEPJT['('YA;F6(WG0=(N4CC:P
MB;L2B"P"3[7&LG#).G4FU%S0U)XBU>T25D2)PD[$&./DY^E%7]V,=/.=>0((
M,XW?$Y&?I.;_ &^E R?[Y?)Z$(3AY7>E2<QB25_Y51I^F''.XHS%VI6^2!YA
M#JC:FA 7WY:X*]M=-]$R4GMQDX\S&FV"RM>W<S;LT+UVWVUUS4-?4-7<M&:C
MH:"GDJJRIM<\=/3Q)M2S2+A49&W*;3U1%V6IO<NY$551#I'(_=;=9.4_1%VN
MU9#;[;0W^CGK*VI=L4]-"BN:Z69^%1D;5<FV]?<L3+G*C454C2+<K4*!?6D(
MEM&\@X =+WE@KUGD,UA<=:HR9)E;:?NE2&KB)FM68PH+;%AQ?>6XX[O)!ANY
M.NA9F=-+0:^BBFL=KN&E=86A]QJ:2T4U9<[914]"M<^![F1NE9=)941[8)7-
MV87.V6*Y6HB.5+5=^1ZHJ:;55_LW*!R:ZC99:&XZEKK98;]<JRZMM4-5&DTS
M*>2QP0*L3JN!CMNICC[I(UB2*YS4=J_49I"V[YX^L\;I%GC<BL.'7=1UM-4>
ME4CS$VA^3U?8K++E[28_^Q[IHW&K$S=N7H>8C-UTU[O.FAAV"B#>WZ4N-#;+
MI++<9)HJ6HMMRH7RP1=WDB6MI)(&O2+;9MHU79PCDWXSA,JGYIU5;ZVY6R.*
MWQQ2U4%PMU<R*:7N#)4HZN.=S%EV7HQ7(Q415:OR*N$6,_=QZK7R"N/'ID[^
MIP>OV.T5^<UU^@$_O \?LCK3\VK7]/?_ ,)CH?S,Y@1_D[QNX_\ )?B=656L
M_)1=;#5%YG!>0IEE+&MPJJKWRS'#"Y@]SB/:;D+D[2G:R]MG1-DO=?LKUR;X
M'LF49SV"PRV>[72T7NLK9+0VA?-3U-J2D:]E;61T;=F7ON7"M5ZO7W"Y1NSN
MVLIC!?[[%>+3;+O9:2CCNSJUD-1373OMS'45')5OVHN]8MSD8C$]VF%=M;]G
M"]4!2RY        !#EYRNZH;!LO-"4_&;PGN'AO2XA$MMG6EVG+,?JIRXN^9
MGO [%QA2W[%IM26KVNYROPHWV\.2^#]AHE,9WKCQ\2FOC!=4/YMNBOK#R/RD
M@3AOA?94>,%U0_FVZ*^L/(_*2 PWPOLJ/&"ZH?S;=%?6'D?E) 8;X7V5'C!=
M4/YMNBOK#R/RD@,-\+[*CQ@NJ'\VW17UAY'Y20&&^%]E1XP75#^;;HKZP\C\
MI(##?"^RH\8+JA_-MT5]8>1^4D!AOA?94>,%U0_FVZ*^L/(_*2 PWPOLJ/&"
MZH?S;=%?6'D?E) 8;X7V5,!*K9ZD<VCKO%)5TQZ">8^^HS$+FW*>HAKIH>1O
MG7?7<H]/Q-)5HUB8[0I4@<$1Z9>W+B$Z] I3+$Y!Y88;X7V5,_XP75#^;;HK
MZP\C\I(##?"^RIYLWKU-LK-7'/30H#+AHEW1:+\]0A'E9JC,-+/,2:JO%'[_
M *I3#RBCMT^-\%;&EEF;:9WTUS@,-\+[*GI\8+JA_-MT5]8>1^4D!AOA?94P
M".V>I&@DCY+TG3(H(N325N86=[>\]1#4U>N9XN8\GQYHV-.XFF=X:F=5(I"N
M0MR;!*,EP?GIPU(\-=5ZA0&&^%]2F?\ &"ZH?S;=%?6'D?E) 8;X7V5'C!=4
M/YMNBOK#R/RD@,-\+[*CQ@NJ'\VW17UAY'Y20&&^%]E1XP75#^;;HKZP\C\I
M(##?"^RH\8+JA_-MT5]8>1^4D!AOA?94>,%U0_FVZ*^L/(_*2 PWPOLJ/&"Z
MH?S;=%?6'D?E) 8;X7V5'C!=4/YMNBOK#R/RD@,-\+[*CQ@NJ'\VW17UAY'Y
M20&&^%]E1XP75#^;;HKZP\C\I(##?"^RH\8+JA_-MT5]8>1^4D!AOA?94>,%
MU0_FVZ*^L/(_*2 PWPOLJ/&"ZH?S;=%?6'D?E) 8;X7V5'C!=4/YMNBOK#R/
MRD@,-\+[*CQ@NJ'\VW17UAY'Y20&&^%]E1XP75#^;;HKZP\C\I(##?"^RH\8
M+JA_-MT5]8>1^4D!AOA?94>,%U0_FVZ*^L/(_*2 PWPOLJ6ZH"97W-X@Z.G(
MBD(E0DR3214@:HE#KHTO)M<XR6V-*A)(U$JTKJL\-JY4ZJGAL,C^6-9E,G:4
MSC[+'>RF$:$0N.9<^3!.8$  8:11R/2]B=HO+&%FE$9?T"EJ?8[(FM"]L3TU
MK"]B5;:[-#D0I;W) J)VV*4HUB<Y.>7MMH:7MKG. !I!U(4NH4QU8HJ&KSUD
M0>&J0Q-4= (H:IB[^PL;5&&-\CI^[3L:R/#-&F)CCS4YMNZ9:W,;,U-*,\E
MW)$Y($H "#.-WQ.1GZ3F_P!OI0,G^^7R>A"$X>5WI4G,8D@ 5#Y8?_-^)_\
M6VKG[)V$.>:^_P 9Y/\ _6#9_NV\G:>1S_$^6+_4QJC[ZTP6\'0SBP ',#EQ
M_P (CTD_^O/,[^ZA)Q<;'^2NN/ZMI_[[A*??/RIT1_6+_P#<LIT_%.+@
M
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MEPN].8R0P,P
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MSMN:5_AR2.\YRK^\L\+=B*)G@QL;YK43]QG!\SZ
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M3UE/%41)(U&O1DK$<UKVHJHCFHN'(CG)E%PY4PJRD/$>P
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M4+)I^EHY(9(*FS/DLM;%(Z-^S66[9BGV'Q/>Q\>539<CL*N<9:B.=TN%1+:
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M-4;4                               !C&,8[,8[,8^#&,?HQC^8
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MA"Y:[_GR/]#V/[JI2GZ'_F27],7O[TJ3I\*:7
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M<8WHO-OWICJ7)VJ Q     (,XW?$Y&?I.;_;Z4#)_OE\GH0A.'E=Z5)S&)(
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M3]T2*18Y8E58I7PR(L<S(Y6*V6-[51[&JN,IEJHJR\/ >X
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M^>G-HHFY^R5#0V[3[&?YNY7IG5=ZU?\ F.GPIQ;P
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MM;0W.C=M-J**_7B.>%[7L?%W:LDJ855'M3+98962L<U7-<UR*CN*)U.%++D
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M5=?2UH_VN3P<[Y*?R#LW]8OO]HKL=K_PB/Z7M3_U+2/]BM.EO!T0XH
M          !S X*_K5=4_P#K4P#^[W6PN.I/YDT7^AJO[UJRH:<_GG67Z9I?
MNNC.GXIQ;P
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MBV.IJ"@@934=-WQ8[953-IZ>-$CB8Z>:6388B-17KLHB;BT(O1R0
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M<+B\@KA8@
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MV%/\[?+U)YD%!&5"B]UK:^K_ )NR6:/Y-N>NDQY>)T]%.+>
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MPJ>ZQE,VY&B-X
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M(C^HIQ__ +7[8%QJOR$M/ZQW7_@:$J%-^7-T_5RV?\=7'3\4XMX
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M72/JZE9$@BDM]RINZ+%&Z5Z-DJ:.&++8V.=A7HJXPF55$6_HK!9@
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MF*??_P HM%?I"Z_=%0=0!3BX
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M>C5;+'&[>U<HJ(K5WHBY142Q8U1M0
M        "#.-WQ.1GZ3F_P!OI0,G^^7R>A"$X>5WI4G,8D@
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M:Q15SY8Z.6XTCX(ZB2!K'2QQO7+5>QLC'*W*.V5RB*B+B41OBH@
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M;M*^&VW*DK9HX^ZOC@E1[VQ[36*]6[EV4<YK5<B817-1<;29LV-.;<
M       (,XW?$Y&?I.;_ &^E R?[Y?)Z$(3AY7>E2<QB2
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M^5O^E/E(_7K5?WY7$["UG/0
M  #F(>E6%=9E X;H'+V-5=,MP;2735N7&-67$CE(A6FH#70M/L@(682;:J-4
MQZ@HXPK;78O3?&<=MP16KH%S4>S;;J]KU9MM2386S.:CT8J[:MVMVTB*B+N5
M4*BJ.37C7*U^R[23F(_8<K-M+PURM5Z)LH[9W[*JBJG!%.G8IY;@
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MI0;IE XN4;TL*'^RJ3/>--S716E;#W%7'90G9!.-V?QU<>8FD"
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M7")S_(=Q ,0
M                           *B\VOB9C7]9+A]_>LIL"4X^1WH4MT!
M 5'O/]9'A'_2%=']WNP0)3@[Y/WH6X @
%   #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g383050g35a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g35a01.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 14"70,!$0 "$0$#$0'_Q  ?  $
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M*O,P\9JO@D3"B?,.B5\KF$ 3I@^V84),GZ$3,19F[FEC&,ZZ>@E_^*AXP_\
MT[J__GRU<X/])O\ L/N__P"M_P#5Z&=Q^CC_ &ST_P#W_P#],N9_HF9\EY]4
M95#SS_\ <:\SO_M0\BO_ -03#+WI?_:;IW_MW4?^H5\I.IO]G.H/^Q-K_P"0
ML9_EW9]IY\=98?QH\:YGY2SL] X5(83%'$7KJ;6I(I#8)(T+C8F&UZ,T9D[]
MPXCT>E!519F-]XZ2;-0[A1?E%3CC>E/8X[J=SN*^DJJM6$V7BZW6I*54!1N.
MQ;/PT#$.<A<01\#)2R.)F)GTYF+74:BQN;+:U=M=,IJ6+K6VC8"@KU0\1Q3*
ME..9$.2@17,SQ,1Z\1.R7;X7>0=%S8S##4)(S9 /&X],=S6L!<AF<$?124PM
M2P@Y]$ZW"-%A[1:'MB!YRVD \*3'C111\_8-V;)9QK#K>HM3LZR["K(5Y8YM
M>*UTU5[0O18BHQ4J)A0918(%#*38!FQ8B4D41F78=/[37665V5CLPM*K'F*8
M-L5B0ZO-I;88*XD1E$&TH:"S  ,B&!&9R,$Z O925"H-JE[8YF9T)J3AHGU7
M4QYDA2,[UUUN2#P7R;95['^>$U%.C+5HJ/Y334[VX]GCK>MWY5UG@'9^4:/E
MEM\!CXMU_!!W]";?$\,6\S$>&10?,QZ9I_)>R\8*WR?>\PQ?C+1Y2QXQI]OB
M@KP^\E1$3,L$9'B)]<F"X?"2\:=FJ=<.1C6Q)XM9UJU0A$ZJ%3F8&'DDI].+
MK2AT,0^C1W!D2X1E;-8:H&5($DTF))0X,"<<,NGVAK^I-;L:TW!,JE6*=&]+
M[S*M=8IV'C^!!S%DY6<2@H.&0 3)!"S9R7;O7^GMC0L14D(M69N7:4)I!9>P
MFT(3+R"/+AX@3#QD97W'$"<L!? ]T>/_ !;\D1<?B4H?45:[<+.Y6<@L1=;@
MDD[5.S*./UQ1B,,F*8[M_LXV*LB8Q,8HV3=NR 4\S9I.' (NFSVQW6H-KTCL
MZ,LJH7:L#YI,0JLX1-;R*3@/"(# ^^"D1!BB*8AJY+5+3;8%(>6MNPNT]E9!
M>6;,ML**08D1@9+Q(,3" F((B6T1B94R!V*E_#[R"O2QR=812NI.(.1SHTE-
M2,LC$M$1^O702.FY*JRGY%"/$%(@]?M0+QB*:F6C95Z54;,]:X][VJGAV&_U
M6MIKNOMH8IWA^6%#D,;;AKEI@JH2T8L")-$C)9% A!%/LXG-K]#M-E;.DFHY
M;4RR+!O2]:JI+4QLC:.%'*"*%D(0P8DCD1].>8A2.5[/IB*DQV(P>82D)"Q_
M):8F8Y&31P5$Q7>ENN2<F(#&3IH!']<MG'7+PHLU;;T@MO2F])=^S8NMU:YI
M58LUT,LGX==;G+4;V>GT$@9"33^D/T0@B]8]/6,KE5;5@'-16L.77#Q+#%)8
MP$!Z_3<8"0J#TGZ1R,>D^OI.;,YHB\&:,?<.Z:M9JWEBVFT57<UW+T$9*XZ"
M<2;3>/JJA^>#*VXVHG(-)#NG*FPBG!77/P'?+C>&-IK"EL#L:)2B.Y\1;KS*
M1\64\MB&<KCQHE7)\1XL2O\ G^F9IUNQ&%26ONC#YX1,U7Q#I\/QN%3*^&3X
M,PW@.?U?T_YOKFV$O%Z[!PRO%-0*6$);91R:@0-7#X3/E;-17@XB&GWKMY&%
MXFWTX9%0DX#E@W0)\:==C>'#\HU%-%1JQ' &ZUQG;CS2!1357:VZ=FK%.8LL
MLJ$1=#Y[26RJP&>**Q@Y$0(R@X#.>GV !5GRSR?;;84NF->U-R)K+KM,B3*(
MY$UV5FOPR9/9R1B$2,EDIOXD7S :QKRVS4"D#B(6$RDSC:PR.RIRY@A"+VQ+
M:7=QNRM*@&S*'R=_.8699" CM\LZ?)_#)^I(CVN/;^*V]U=J[;H+M*BQ5),<
M&U Q:!]"OL1=3X;)6$#5LK-C1&!&>9]0B#GU9T>RJTZMYE9LHM"Z>04XIK$F
MZ_7DJWRJ!0XK-=@K61211Q'H<R$:B1\<?(41RY[+4/<POAF&.2)YT1J^;LN6
MD?C#GAE)3KGIR#2T@&CSQ3AH<)J[X9"7/?"#]=NKUKC>P&WU+.(7L]<<DQ21
M[+M8NYKQDTJCM;/+'#$DH(^DP8F0B8CG,)ZG:K[I9K-@$"MC2DZ5D>U29@6L
M+E<<+44P+#GZ(3,04Q.81M2]Q/6D1(,ZGLMVPL#@BI WK:"2A=I-N [1=^6[
MB+E(5VC).!;%LY>D>@W;W3%HW7<.=I(I*=\Y)V.O$K %>IB520BT,VD05:6%
M KBQ$GRF3*8$/$@>XIB!YF8C,4:^^0H,:5N1M0<UBBLZ1L0L9)DH* X= ",D
M<KDNT8F2XB)S:N?&#R+V$LB1*4?:;013Z =U9[A_!Y$.5@S8\/=%Q3F2,GP]
MN^&-G(5B\.=.7#;E!L$;*%W:B [V7/6"=UJ(;33\I4I9L)9%(1LJ.+4J,5G"
M2$I$Y%ABKB"Y)LPL8D_HYG^1]KX=MTZZZ*Z$+FX15FA-:&C+ EPD,$$2L29S
M,<0N)84P'$Y]!GCI:\DB, ED'BQRQ=V'S,E1T:@,5FTGDPAI"9#'XL0?&VC&
M+[':9/C4G#,1K@*4-<:=/6S$I\K(/&#-V/;T4V+:++U5/*37@W6GUDI85E+7
M@*R)W?W"M#",6 N>T2(.\!(A!J;SD57UD-M^:\Q(*JHL.< UVJ29,$4]G:3'
M+$)6;([B$3[#(1G0!E<6&:DA:&AX',RTO ]O4SD5&1<X_D@90:^2&$4RP-JQ
M5)CNQY)=$>]X>-4>FKY9)HOI-=3A/>V=NHM(6&6JZT-[96\W+!+(,9,)!A%
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M0(V#.PXI\1A\3SV9AJ=1+#J*CMGI8-:NOR9J&:Y-7396=2.5Q7JTJ\FA#RE
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M,KVFRVRTK+8$1XA8*F*[C/&G1=*V;EQ";5H4U-K&M:QVUUR?#I0=V7;T".K
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M"EO21V&6==>6-FPO9LJNJUBKML^%V4@"S7<:V>:ERW0E20:K)?TUTXH=G,;
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MM*A!*$+4A("M8QF3J?J.QU/LANMJ4M;4JUE:[4ZG7)A-#4ZJL;3K4*PSW-9
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M3#!+U<N$BGYQUMMK?1+HN6*:]GTO<IN^1^HM>YA5W;E*76!T^T1*9?I[=@
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M%FS9L&JK3IUE";K5RVY-6LD":]JUC)1KKJO$S-BB[!-GBI)M&QVTH5$?9VP
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MMPZ:-0P%_P N]M2Q1RZ9/&R#!@JNZ57:N$DTNNT5.><@[K4'7IVQVFN*IL+
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M/?'QC/7]51C[Q@?YP/\ ZC'$^Z?A..8]\?&,U67#JAG[%F+GC&MYL-'D4B[
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MP/\ .!_]1CB?=/PG',>^/C&/JJ,?>,#_ #@?_48XGW3\)QS'OCXQCZJC'WC
M_P X'_U&.)]T_"<<Q[X^,8^JHQ]XP/\ .!_]1CB?=/PG',>^/C&/JJ,?>,#_
M #@?_48XGW3\)QS'OCXQCZJC'WC _P X'_U&.)]T_"<<Q[X^,8^JHQ]XP/\
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MTQWI8R";.U"+#A/105\3M=OQ\)LJ*TZ]SLDQTX8XGV\>GOR1L8QC&,8S'&#
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M%)$[ATB%2)N$DH])NX> RBPITZ39$D&SQHZVU7ZX5Z:.VKI/GMNX14[8S?\
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M'[ BH:\)OW.;"3AAH*.T7=JT4!\>E 7;,K&S8A:-?1$9!EFPT@-?+#9R,'3
M4\8E18KIBR8GC]WL^[UY_OS5#O@G )!&WD->6?<B445)VJX& VQ"MM(1X%>
MV8L+:A@AZXK%R75C<T6FY4FJJ:(F)-''C46UA<CC01IV(78Y]8GB/3CW_5[/
MKS*#?!RI!\Y"3A0]8A)2'3253JO8V0-@_IROB]A6N*N^RVP#EC&&)TD-L"T
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J,6;QDB73==:FCB5]MV2C5B9Y_B?\9^OVY:G&1C&,8QC&,8QC&,8QG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g383050g44x13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g44x13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4\C:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C(M8S P," W.2XQ
M8C8U83<Y+" R,#(R+S V+S$S+3$W.C0V.C$T(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SII
M;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P
M<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C
M.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYA8W)I=F]N/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*
M(" @(" @(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B
M/D9I;&4@3F%M93H@(" @(" @(" @(" @("!A8W)I=F]N+F%I)B-X03M5<V5R
M;F%M93H@(" @(" @(" @(" @(')R,3DR,3 T)B-X03M,;V-A;"!4:6UE.B @
M(" @(" @(" @(" Q,2U!=6<M,C R,B Q,3HR,SHS,28C>$$[15-4(%1I;64Z
M(" @(" @(" @(" @(" Q,2U!=6<M,C R,B Q-#HR,SHS,28C>$$[4V-R:7!T
M(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N
M.B @(" R-BXT+C$F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R
M:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E
M+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P
M97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@
M87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($--
M64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#(R+3 X+3$Q5#$Q.C(S.C,W+3 W.C P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M,BTP."TQ,50Q,3HR,SHS-RTP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z0W)E871E1&%T93XR,#(R+3 X+3$Q5#$Q.C(S.C,V+3 W.C P
M/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!
M9&]B92!);&QU<W1R871O<B R-BXT("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^
M,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIH96EG:'0^-C \+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!
M9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!
M04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'
M5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O
M2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS
M8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!
M.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!4$%%04%W15(F(WA!.T%!25)!44U2
M068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#
M=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%
M04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9
M155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS
M4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R
M>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D
M;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!
M.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%
M0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2
M-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#
M:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD
M65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%
M:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N
M<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3AS+S5Y1S@S9F]B
M>5HK:6\F(WA!.TAP938R>&<R3S1T,&\P>"MN-%4K5$A-=E-9*TM6.7II87I*
M=W=R<5AN6"]/3C-M+SE(95IB:GDY8U!3,3%D959V53=#-6E"239N.70F(WA!
M.TMJ,TE836I7-#=J>&1Z:39(3%(T93DY35IR2&%U>%8R2W5X5C)+=7A6,DMV
M2# O3DQZ=3,U>$AY<BMJ52]2275$8BML-F)E<C9!1F8F(WA!.W)8<58V52M,
M<%-M,UAF37IW265&>%AU-&9J>CA8:'):-T)M1S5J<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-666YR6&YU2S,X,G@F(WA!.RM43$]#438U9C)-='I96&)G
M9E9%:U9*5U9:;7)Z<"LV,S1Q,U5:9$A&-F5).')A6EIA;'<Q=EAW64(U;#AU
M96)R-U-03%8W-3,X=R\F(WA!.V\S5DY.=EI$2DA:2E@Q-'=Y1EI&.45O1FM#
M;V9I<%%C=6=05T]F6#1D4&4R,'548G!E>F,K<4E!4'%J=64U6G%F:W93-V)7
M=DU:,#<F(WA!.WI.8U$V<C4P4EAT2E9J6EER9&)I9%HQ5C5&9FMW8T1G0T%/
M2TA+:C)X:45O44DW=G0U3C!E=W-X:&MY1&)N-SEU9C0K5%!R5V$T+TPF(WA!
M.R]W1$Q:2DY:=5IT86TP94@Y+T]G2FQL-5,P5E8U16UI0G=O<65G>3@O=DHW
M8E<T9R]D=S,Y5DI73F$X-&%Z<6UN83%A,S!/:V523E<F(WA!.S T,$9Z-E-8
M:V,X<V)M2U1C-T]3>49E36I,461+-#5*63AC4TIN,4$O0FQI:&QY>4)G3&E9
M.3(W1&)J.'!,16%*6F543E8X-'IN55@F(WA!.S%!-FA%>7A/.%)%:4-.56]Z
M+T,W54I6=695.4XY>$QT8DA(2T)1<VA-3WAS,#A";%I-66TW6D0O04EF.#0R
M;FTW>DAR96DK854Q5U<F(WA!.T]X:UA4.41L9'!A4W%O0TI*2'E#1&EY9F%7
M;GA(-'%63E1$5EE:,41A=V0V4FLP969(95$S=WE',3AK*S!$>C-083-E9RM6
M+TYS6G0F(WA!.W9/3W%7-WI34GA"5W0O9V%7;C=X5TMH;5-(;TLW;6U'94LW
M;$@V47=J;'%O>2MO<S-Y:'9D:7(U6"]-0R]U9GI&+TXR4%-,1BM6<6LF(WA!
M.WDV8F%/=3172TII6C5T=6]R>F5V.&]'8F)#4$1X,F9E-FI-9D9Y.$DU8W8Q
M<G9Z;3AP=#5(.#8R1W(V26XQ5WIN161X66QE:V1X83@F(WA!.U$V+V=R+U1G
M,#)4:FE1539Q2&AZ16<K:V9+=FU#,CAX95AD4#%Q,C)I=F]6:TM$9F<O,EI%
M<B]K3T-V,%IR6G<T6D5/,&A-4T%)5$\F(WA!.U-33TM.<%I70U)O0WIU>$%6
M5D%Q4U-E9T=16E!'=DY(+T]41V<R1C-*839(<'HV<4DV<6)X-5!1:4Q$=6<T
M=3=R."M/6G-.15-.>E0F(WA!.V<U3F1%1V=,52]+,R]/4W1L<5=P,G5N86YO
M<C)R6%5Q=W!C5SAW;55023-&87AS<UI!,T9F:4](2F]I0EE+-#EC2D=I1V8X
M035L*V8F(WA!.S0O22MH46%T2EI'+T4Y,&QR-DMY0TEG=DA*2GDU1E@O04XY
M57!4369$:31Z5&M:.'=X:7EX9E50*V-G3D)S9DHR;6$U2EI/*W!A<4HF(WA!
M.U=T=$A7549L4T=:-%,X:W9(-%9*:C(K1&9W,DIY,&%1;5)(4617<5=S:4E#
M6&8P5R]L>BMF5FHU<C%I3%),,U18<TY1=4]8,5HT;4TF(WA!.SA4;%%726(T
M5EI0:$AU4&-9-71+64-W9&M93E=*;7%O;VXO;&1K2"]!0W-4+T)N-DEF;CEC
M*W O6&981DLO>BMN=R]$;&<O3&5J:70F(WA!.VXK6DAI8T9,4$\S-3-X*U5F
M3EHP4%5.16ME1#DQ26PK:S1O,$UN5U)9>D@K>651<'DV:DA&<'5/3F=O>39O
M46Q21# V2U=/84I*66TF(WA!.T1X4TM(4C%.47ES2V=G*S1Z1F-P-6PU,"]0
M1S X=2MB9CA.5V5K4V%R940P:UIO-6A(*R]M,U=*5C1053!:92]5,'I+>#95
M>6IX6%0F(WA!.VDU3E5)>31A<W,T.'<K871&.'0V4614,3(T4WIH04%+,4QS
M,&A(,DEW0GEC+TEE-6]-;VA!>4Y"=FY-4D9L-5!E+SA!3U5E:DI/>3(F(WA!
M.U=H6$4X05!W>5-Z2D-X+S)#<DQ4+V=S>7AO5#%,:&Y8>#9!<W X:V9N<#51
M.#!8:V5N3TI.3#%+53!I9W53=G!Y3B],2$M$47-E=UDF(WA!.T-V8DMS=6QL
M05AZ1&1I,55*;7526C%R3V]J5$Y(=G13369Q:7ET-6)G>$$X95AP25@T,6]A
M5C0U:GA&;6Y)2F]7.&PP>B]N2G)Y-U F(WA!.V%8<SDO<&LQ;DIB<6XQ5S-J
M;$5Z>G4U3W<K1TY50S!Q4U1M6DQ24W99=4A(6%))2DM75V8O3U5S5%@Q3'IY
M*S!D9WA!-5)806ML560F(WA!.WIX84Y&8C562'IY6C!/,G@S87@R9TPS1WHR
M=E%T8S!Z6&1*='17,'E95#)6,FY/2U%B2')1<7<W37!&0U!(34=55$4P6%!J
M25-&:$@F(WA!.UI&:W=V.'<O3D5&;E!P+VQ793!U5UAZ64ID3UA53&-G0S,Y
M54Q#6#9%.&PY645:9FAH9'DO;71/5V162&8Q9EEG.4ET8F)29$YH+TPF(WA!
M.V%#-G5*8F]15$Q$<6MN159%<&5F8TMA-T$X9FQM<C%M<4=826-8,'EK3V9W
M9'AO9$5C3TM/;THT;W=03')Z5$A39GDY<VPP0U!3.5DF(WA!.TEU;6EN865.
M-&UD46Y)04963WAO94\K531E>EDK2'=:3CDW8VI59'-33UDU35AP<U9U;4]S
M84QO9')%*W5.<#1U3'93<EIP3&5.4U$F(WA!.U=&=6A:14%R>$HK1VEK:DUW
M85!(2UE.8F@Q+S4O3D=%;VE8<&QZ+U0X,DIE5#1,8GI$<5@O2WDP1C%P*V\S
M9'1,6G!O;'E167%X;FDF(WA!.VI,5EDR8FYX53=E3DUZ9%1--#1M1W@W;D(P
M,%!%:TIN:4$U2'E(96US=6EA,35V,%)%,7=F;W$W=')L:D=K8UI+=$AW6&-Q
M>FLQ<5,F(WA!.T%E6#!:;WIG>6%N2"LX.4)"-W8R=E)2,5=,4EIF,U W>4UO
M.2]7+V-N2RM3=$)&.5I8>GA-.3%9<$9(1S59,%EW<492;4AD:%%:;$0F(WA!
M.U$T*TM-=7-A*WAW5#)N;31*44(Y37EF=#5P6DHU3&TP9&15,5!Y+TLU,6$U
M46DS4U1G5E%.2W)U;S5#:$I#-V-S>'IO5&DT<#1J-GHF(WA!.WDK8FQ$=$U:
M=41(;4$X3U!0;C-%1#A"041N3'!N-D\Q,C1G<R]/=#EB>E$V5F9V14=U249N
M-4I%=VUJ5VEK4%5G0F@Y*UAA4%9(2'<F(WA!.W=Z2#%K.'9,-VUN6#9)6D],
M2G!X*S=I2W9U3F(X.3!6*U@O;4\Q5U=B>5AE-G)*<79M:E)%6G13=6U35&I)
M<D]'1$-29U(X26Q60T,F(WA!.V$Q-E9!>F$U64@V=TMI6%,T<&DK06TU1&UR
M9FUV-710;&9Y4'%';U)0=W9:5BMQ,DI'>$4X=TE$1#-2950O4F=W62M/64,U
M.&Y"06PF(WA!.S@P+VQ:-3,P:GEB<G,K<U@Q:$IF,TAO;4<Q0TUQ96U84'AV
M5F=D*TDT:C5N3FYN>$=9;T8Q5VUZ4GAK:W-P+TTS.#4Y03@V*U=Z<%HF(WA!
M.S!A83)U-'!5;G1,<'!%64DV-TU#04%A36A)*S0Y<W%W86%52EAB9&XQ56-K
M86]P+R]W031Y*V(Y-R]Y<&-V-#-U;F<O47-Y1"]H5T$F(WA!.R]W0EDU6')C
M9DM46F]-=7AI>7(O04IY33$V-C S>4=T;F)/56)68FQ,85IH="LU5E=K9&$O
M=T-55E5F2W5684]&>G9U8G1B36E(=E,F(WA!.W(X:'9Y>3AV:GEX0C5K,5=Z
M:79D43%!=3%S3&A226M-2T]56&EJ1&IY67%7-65&2U4S<DQ66GIX8TDU0FAP
M34%%94EJ8W923E8O3&XF(WA!.WE6<6-T=E!0<$YV2&17<W%445A.=6=H:U8T
M,D1#<E)H95%Q=E)Q:DUA3V%1-G563$9%-VM-1R\U>6,O-5%+=R\W87-0+U50
M8UIK84PF(WA!.S9Z-VY&,2\P1#,O<E%0.$%Z:CDK6'5I>2M6,#AY87!A>#,Q
M,V5V2DA:9E=&5U9)64EN6D1W4G%H5V%14%4O,C%L<3AP-'5%3&\X430F(WA!
M.V5).#-P3VLO;#DU4C!J>D10<BMM-F9(85@Y>$8V3"MK3TU11F%S>5)J-%9:
M='522&@X-C1S<W-I2THR8W%/2TE.9V)V05 X03$T-R\F(WA!.T%,9D]B1"])
M9D(Q,R]):C0O;V5H+W=$3U(O:R\Y2BM7269-1G5L8G92,G!05'%B855G3C@K
M1#A4-T1L;5!O.&Q3<G9C:E<T=4M..7HF(WA!.V8U469M5&$O.'%S=3=J57!/
M52]L84IO-6Q,55HT47!A,D%*-W14,&PY,7@Q1T@Y-70O16Y46G=C9&XK1F=F
M-4=A2&0K8E!Z17903E<F(WA!.W!J,55S6&4X;&-J-%=U-VAM.4U$+U8K2F@T
M54=:1W%K25$T430R:VE:>DUY;V9M6&1A:C4W+T]&4$Q35$=/,'1R:V%D87%D
M,6I#,"LF(WA!.W-3.%(Q66Q74'E!1T]%1$AI-&QZ,VMY.%!2-WIO,S59*U$Y
M2G-)-TLS,%,P;59!03 Q>D1(4$TU<%%S-WE+>$I0,V5!1UE%<S!Y8G0F(WA!
M.S)%8TU):6=(:F8U.2]L9&\R9S)T=C5L,$=)5U5-:WEW6&QN2%52<3=!<VMS
M62]9*WI19V)D2V0X>F1,;DUV4UA",6UN15)X4C)E9V4F(WA!.U8O33EZ-6LO
M2D,X,4,X8WE8,&5M,W1T9'E(<7IW>$]O66YU5U1I>#EZ;4YK:'<U84AE-5=,
M2G@T<E!C.'8O-7AW.',V3'$O;4Q58G8F(WA!.U5R6F)P.4YH:F4Q:FQ!84U0
M27A"8W%246MC9F@X37DY6DUI24$V=4AO24%K:SE(<6XU*V%(<'0W*UA/;UAS
M,$-'-S W,%IB4V9I3V$F(WA!.U9M4D=53C$T<W)N8BMM66UL:U)-1'9C>E9W
M0GAN>5-B+VY'3SAL;#AL-FAA=6%P8C,W1TUK.4)*1D=3;RMK12]4:SEA4%50
M8S$V02LF(WA!.VHT=EE-=S-.95EE5DY6,517+TU0;3-6.4$X,'@V,7!F<$-'
M=S S:38O5G)I;%5)16E*2'@R8T)L<4@R<61S<S%K6E)X5D=.5'!H;W F(WA!
M.U%L;755<G@R3%ID-4UT+TU#-F4X;FU"46(P>4@P;F)G6E!4-&HW5$HW,3DX
M,75H:&LT8GDO5CER='4P-3143W-0,#%V>G$O:7E(334F(WA!.S%J>C<X,G(V
M0U-04CE$="].5&573EEV<GE.<F%24%9R2V=*4FMB,'%52$IH5&UY<51S5&U4
M<'AZ4$1X04]0<41Y2$9W:VQU*W1.1S@F(WA!.S!E8F)E3U!56%<K,'1!='EI
M=VM2>65J25,O<'-7*T4X;3DO=WIN8W-C96]Z:7!%1U!L,T8V<D)K>F%44VYI
M:41'9DQF;%DV:&U.+W(F(WA!.VUL,E9Z1EIZ,TUC5C=C1"]!165+46MC:512
M86M!,$)B8DYN4%51:$E2:V%*9$QJ,'538U1/35-9>#5S52]+<E904#$W8F%T
M2#4P3G4F(WA!.TPK,G5U14U-2F@U;VA89FM)5UE"4U(X2$QC-SEC>G,X64-U
M1&LT1T%Z25!(>G1N5UDW97<O=T$X,G5K-F,X4&UE93)E-79B5C0T-%DF(WA!
M.W952U(X9WA:5V%G4#)4=FUR,3A)44EZ15A)53=R<W)*:WE!-F-%4FA+-S(S
M63%R97(K8E)R+VQF5R],=6Y73FAP=7)S:V5U,VLT=&LF(WA!.VMC1U5!>'9,
M2G=L231+5U1H=50R-D1.=F]S<V-U2&EL9#%S2%,V+T)01&XT23!11'58;B]!
M4'IK5#5M;#%N>F1:*U=,1#DV;6UG2S F(WA!.V%54$\W=4MF1'0Q-')X2'I*
M>EEA3TA$2&E05C%E=&YX4T5!.58P3#AK=DE.;F\Q;&)A:'!-3C5F>%%O=#-D
M3UAR2DQ4-#(R2S=C<3 F(WA!.S(V6FE3,4UY9&DU:V1.04%#9VHO05!L5'8U
M6B\Y5T,S*RM4+T%*<7E0-6EF97DO3#0K-%!!+T\R;#-(-5DO;71"<4=M255S
M5FQ7*W,F(WA!.TEW4T%92D-6;&=Q4V1V=' Q*WI43FAI;#1U3VDV-TQ(=V-T
M:FLY42]0*WDO>$(K5W1L<F5M17HR='1,1&4X;#<R,#A:6&Y4<G-852\F(WA!
M.TMU675K4$1/:35E<VIX63=(=E%V-40O;60U9E!L93,X=#9P95(R3V\V95A7
M,TYW-%)*;UAC=79&,E!(:W9)<G@X2U4W,$]Q=TAI-&@F(WA!.WE+3DIN0FIW
M;FU(<#)Q*V,O2V5L4D-454Y7=%E!86-637%L,G)T.$M+4S=F44UX630U2&M(
M3&Q/235L-3,O>FLU+WEG5F@O,C%99BLF(WA!.V]E-'I*,%@Q;C-/2'(O;TAV
M+U=N+W=#42]W1#5+;E$O*VIR+T%+:DIS<C%8.31F>#!B9$@O9&HX9%=F6FIU
M4RM8=CA!,30W+T%,9D\F(WA!.V)4+TEF0C%8+TEJ-"]O9E16+UI7,2]9,T9J
M9$E*3&$V:F5'94TY1U-24W)$-VIM<T)O,C=1:3-X6C5L,#-6+TMM=#8Q-6)A
M6C!I-6DF(WA!.T<T6&]*;U5C4W=U4C=J:31Z9'=);4)*,%=12$=41CE2+VLU
M-5)(;&YY3%I14W!W=C<T9EAB-G954$M!5E$W9G-*>%5J>')M<3%'5&DF(WA!
M.VU88C9B2'=1039V12]0>5AN:U0X-B\P.#A,4S)S=#!U<%$P,CE72U@K+U)3
M86=-0UA8-VIM9&ER2FEP=TTQ-#@S1C!F42MI96502V4F(WA!.W1A9DAF,D=Q
M5S=W=79.:V%216MJ.%)):DAK:$AV;75L:6Q%,%$W3T=336A93'AN+T%*>44O
M37)1=%0P*T1Y>&\Y=VPV>51R8U@Q,44F(WA!.U$P4RMM1T-X2W<R6G%T5G%D
M2U4X85IU:W=K2&E,9S8S3T-/14UW.&PK6&)R479Y2W9,83=1>#-D>G Q.61Z
M4DYS5CEA2GEG23=(,"LF(WA!.TY2-#52;&YX6F1U.$]2:&=9-'%08W=R+T%*
M>&$O=T-/<G(O+T%"9W0O=T1I8C5F<G518UAS+SA!:2M$,"]W1$\S+WE6=79F
M.%DT9BLF(WA!.V]I4$U85&8S9V-Z52]W0C)72"\X-'9F.&]V<D@O36-0*U1+
M-61R=G%(=6%.0CE".3<R95)M5D=:5DQS05-%1D%34C)&841F34IZ;FDF(WA!
M.UAK1%1K,4AY9#5K:DAL.5!*:6981F%34GIC8TIH1U=*4B]73$XK-T\S=R]$
M53=+36HR>FHT.&1C8F0R1&TX4$YF:#E4=#%E<654170F(WA!.TEV3&QN0F$S
M:3,X8TE:1&-,54%N:U<T,$\T-#AQ04AT;4YO4D599T%E2W5R:SEP;5)Z>4UO
M.$)04D]S>3-!95=F;61W8CAW9DM%8F4F(WA!.U5Z<EDY6E-.5"]F05%F=E%A
M1# R5TTK;E0Q0TI15G Y3UIE1#9*97%N17HO049X.5!&-3EY9"M59%,P4S<X
M,V%Q;'!P6#%3-E531G(F(WA!.W9M>D9W2D%R5E$O0VA9-S=:>G5I>30U6C5C
M36%/*R]X*W@V<G1(0FQH<&]C52M+3S(Q95AF,7!:-7)F>6TO;E!463E14S1.
M.'9P1&PF(WA!.T9X.44Q8VU-4T$O169I3R](=&<Q:'=N4$53=FDR.3-L8DQS
M.&%K85=:9UDX1R]0;GDS<&I0-5!N>5I**UE0;D]F4G!,.3<Y<&U-,S$F(WA!
M.W-+275$5$U835I5;&HK.#9C-DAJ.4]D3'%E3&=J9%4X:G!U1&IN=S-D-W99
M8W=N3E-V>E$K<$IO5C(R;7=,8S-G565N0WEH=V9I2$DF(WA!.VA$<WA!<5%-
M>'176F5'94582GDY0TE(3DAJ4$1(=F5/9FUX8S928V574$LV*V90,&AB6%0S
M8W!I4WAJ:E5T16A26D1+:D91<F-72$<F(WA!.V=R-UIL.6IY>DA'5$E$:3@Y
M=F,T=F)S9%!(3%535$,K;2]V,U0O>34K430P-WIR2#5Q,5A84#!T8TI02F1T
M06)8,%$Q=SE3<FQV5VLF(WA!.RMW-V-G2V1S>5HV<31C249/1D135E!J2G0V
M>&U)-6IS5EE4*V%(-5E79FYU=W,T6'4O,&9E5U5H94LX.4PQ:C9B<E(T>79/
M4%II1DXF(WA!.V$Y<W9W6GIJ3%)Q34%Y0W5362M2=DHX,VQV>7!(-61V<C5D
M670T:DEK8G9!26@V17!Q66Y1=DQY1E=B<65H<%1B235C;D9,:4%P;&DF(WA!
M.W@X365%;3-N9FUF+T%*>&TP4SEU<$QN46129E1&8SAV<6-S9G)X06LW:$<U
M2S9J-3AS>5EA,&IM3&-B2F]9:S)$4U@V5"]Z:3DV5C$F(WA!.TA.<4]V.&]O
M,D1E;&(R+T9M;V$O8F1Y1B]W0T)/1U=U,C)$1T=G;S)3.4PO041/.&=F-#4P
M0S,P;C8O*VIV475K=2]7.4PQ-CA)-4DF(WA!.RM02&Y&+W8R=&$Y<WAS1UAW
M>F17-4]O=RM*1W)P2"M1+TMV*T902VQJ;T@Q<C8W.5,Y6"]!16XP+U,U97)-
M.'8R3U5L2V5P5#=74GDF(WA!.S5/3U),3$1J-$EI2V8U5S)V3"\K5DDO.&A(
M+WAP*VUV*U!Z-C<Y42MR9CA!0V5R-G8T.$UY=GI0;S1A8U@X="LX-#=E;UII
M=54X*S@F(WA!.S=F;$9P,VUJ>FAP2&U'5UI9,'-I;S%#,4MC=G)+4E!Z:E=O
M27 S5G9B36I&<41'2FDT*UA4:6-H3'5E9S5J=5%K4&Y(>50U93@S85HF(WA!
M.RMJ.5IG36E)4S!%.%HT>E)-9&DP8C!.2SEW45%E-'EZ2&Q-1%EA.&U+37A2
M94\S=B]/3%4O<FLR6&U"5$%F<VEA,U!-97A+>550>F\F(WA!.TUZ0G)U.$]#
M97HK-'-R.&MF.#0Y*U=F3#DW2'%'<#-$87IE=VM006MI0TLS4GAV>3E/<FQI
M1# U3E0R>7),<3531D1:=GAA3TU$6C,F(WA!.TPP;E=T3R]396I8*VTK<#90
M,3(S;'1V5G!Y-&5Q:%1L>'%T86-Q,')M3$4P45A+:TQ&34DO2S,X;R\X04%D
M,7%&>"ML=C!J.65J:FHF(WA!.S0O5B]1-&5M4V$Q.5=7=&576D=F565*5S%/
M4' Y4#1D-S-B2B]/+VQN+T9(;&$O,$@V>CE4*W5Q:2]794AQ.$]%:7EF635*
M5W9#;C(F(WA!.W-Q>%0T6D%T,E-(1D5J=E-F.'(O04UU4#A#-EAE5T@V4B]3
M4#%U8U0K<#90;V-A244T,#E35W94>'EE9DXT:'5Q83E0:#A-5F1S,'DF(WA!
M.VAV95-A6&]T=&\S;FI83D0X>BM:<$PR8GIB*RLP;E12-GA+>"MQ-T)I4W)X
M27EC94LW,&]0;WDW531X;G<X3E5">F$Y2FUL<#@O1G@F(WA!.UA,;4%Y:GE4
M<6UN5S)P,VYL87AT<%93=TUR=&1Y=7).23930DA*54MT3GIT-UIP3D1L:D=:
M=WA".4XW+T%'4%%D<5E*>7AX,45Y4%@F(WA!.U=W2$QA=WI03G$V3FA0-6XK
M4V9-6&UQ,# R2%)D86)2,G,W;C$U;5AM0RMW0W-$1U%E4V(P0CAC=G=:67=*
M<U<P6CA5<&=5949M85$F(WA!.W=O-W5K87$X;3=S04%7*UI(6$UC4D$S1&MM
M4DEO;FMW4W@Q935N,6TY=G9-96XR;6UW5U-/3$A63#)0,#!J:U=3:V%M4U)L
M5BLW8D4F(WA!.V1.<59Z5V%4:GDU:5IW-6-J6&TW<E=J2&<P-$=,2CE8,4,O
M3'4V23<X<W)8>E)(<$XU9&5:<E=Y:#%3.'5N;44Y:4E1<SA,04=.,DTF(WA!
M.TEO,C5A:%II861C,U=C>'8P,U1Z,D53<C%69FMZ1$M7,6EF;DE487A44F1*
M,4Y,9E9)6$5K.7)Z94UT1U5R47-O4%IG85IR9&1E6#DF(WA!.S-#5E1(4C-(
M6G199C-U4T8T>GE04&4P;&4S.'AA:C5R,$]Y<W(W4W1A,%!267A(-6EG;$U%
M.#A.-&Y*43%32DIK:R]K*WIU<#5(3G(F(WA!.W T94AH<58X9&,K.3 R<'EE
M2FU-;U9W5V1U-4(K669.4#5V84QQ=6MA9DM03#AJ83-C=&$R:DI(96M)44LQ
M:W))=3%$,G)L.$E9-4$F(WA!.VXQ8F4U>'!Z>4%G96YF,W,Y.'5$>E5,1B]W
M1$5R5TQ8,W%N,'IP;VU72#!E2SAE6')&;34X=59E,4M:4E!H=C S.%<K2$98
M<7!*-U F(WA!.WIX0W9N1'I&;RMQ,T9P6E=7;$-W1FI,2S1I95)R=4HU2D9:
M<$@T=%%O3U!%1#9C;6-8<$)(5S))>65O9SE+6F%#0TMJ8TAO8W!B548F(WA!
M.V,V,V\Q<F52,E9Z9C(P1C5.5#!R85-A3DI8-4=I.%59:&I5.4M$2D-*275K
M5T5B:U5O1T18=$1U2C0W94158F%795AL-E535%)S-V,F(WA!.T-68FEO3E1X
M24E.36M9;G5265)&-6975FIB=&,S='A(83(V535Z5$]S84-U=W%Z141!051Y
M56UM-U<W=&)U0F)I,6U3-&=C5E-A2F<F(WA!.S9-4%IL2D)X27!.;V$O,3=1
M=$]M4T153E)T8D]A46-O-' U;S1M6E-A5D-U=TI&4FA%4V5145I!27E/4T]3
M3EI),D1X=4%Y3W!"0D(F(WA!.T9145(Q0GE+54YQ1W,V4G!V<"]P1RMT-U Q
M4U)&.5EL4TQK4C$T.'E+-%)%;FMG:T1M:6Q:5U5-<$1+=W%R1&-%2'5-0U5-
M9%8P<U(F(WA!.S--:'9)0DA:17)E4#9I8UE30E5I53$K06=F>EEE16]S26E+
M5TMA2DIO6%=32U)1.&-I14UR2W=Q1U5J66=J06Q+9$LX,RM79%=V8FTF(WA!
M.W@P+U5R931U-U=6;TI)16M5=5=25EHK0S%Q>7)Y;U=',6%J=&LU635!5U%W
M:DU(6495,3-6-W)46# P45<P9'=,,CEI=$IJ3&-2,C,F(WA!.W!P24=*:U0Q
M4#<Q;#0W4G(X5&1S67AU,'E.56UM45I)2WHQ,U),,C5E,7-T471R;35I0DUK
M14TP8VIQ06%(:W%K:V(U27A)-6A!:T,F(WA!.W(S;#=:5U9U,7IE6$5D=&)P
M.75A6C%J458X5UEG64%#95-K,#-B6%9R9'=,4&%Z2E!!*S93>$U(42]*;$I"
M>$EP2W)G5FI8;F)1-S(F(WA!.S5S2DY6.'8R5F\O;2MZ5E8P;2MU551L1T,Y
M2D9%:DM305DS9F)P53EU=5<T<$%':694,6%S:U-264$T=6E1+UA99&5T6E!,
M;'!F5SDF(WA!.W8U.71R83)K.'=I3TXT=FE#24IL37E*4FPY4FAS<$]95W8P
M57!12G@K;FE04'9(,W5X-TXW46I$24)L=5%I3UA/:C-G2%I&4V5:9%DF(WA!
M.SAT,T=K84)C=VY56C5%6#%R=FLQ5S5Y<V]#5D<O0F%D8S$U,5=405E9>4])
M.2]X-D\P1VEX87%/5$Y%.$%(269$<C<P96YN>4]F5CDF(WA!.U(P;3)S6EAU
M8DI*>D5A,45K:T%0=SA12VIK4E%(3'@R:&,U445D-#,X86-9.6MM3TM'4U5H
M=WE-9F=#:R]W0F%U+TYF;%,U=61D;E0F(WA!.U)R9E0W9WIT9'%J2VY#3TYU
M5F5B8D)E9E=U55EO-4Y::G%8<'%844]4;6QI-U!Z6$0Q9W@S<SAT+V0U25A6
M63=J>FQQ369L2S0P-6(F(WA!.R]W06E45S!5<V9M4S%K<4=M:$%)-%-+6&HK
M,G9%.64K8B]$2'=O03,V>'14>D]A6&I324DY170W6D1P6&Y(>3EB>7IA2&%P
M37-7:C(F(WA!.S=+<VIG34=3,%AI=T),8VE1<3E4,7I61'1+17!Y1RLQ;C5C
M,V-Y-TEY>'AX;G0V<4AZ-4E#-3@V-G1R4&PR838X=5=S,&0Y0F-*2$LF(WA!
M.V=26FU%8DMX-4M#0T0P04\R,EDP=&103&E*>$$X45!V,F,R2%IM4$)N16,X
M9UE'2E!D=6AD53%63$<P=714,#(Q=#E2+TUI0S-T,FXF(WA!.S!:6E0V>%=1
M>$DU34-S3FA%,TMO1S)B2%-A345X>35"56E.>CA0:S9N5S8V445S3TDX5TU(
M66)D+W=!,#<X:BM69$XP-D]B6'A9=%DF(WA!.V$W-6A32S@Q=45Y3U%T=S8K
M;SA94FIX6&A*23-A=5IE6$E4-F)S1&LT1TQ'0C9Q;WDU<$XK6F%/,VTS>456
M56M,<6I&:4)79S1$<FLF(WA!.SA0,'DY>DA+4%9(,R]O96A::G0W>5A54$Q7
M:C9R-7DO36EF5710:74U8F94<DIB3U-:0351=EIY1FI(6&\Q63$K26)I;5I9
M;5)'1D@F(WA!.W%81D]-1V-R2%%F<%IP*U=,5$XK6'9L-'I&:DE,1T94>G)8
M-%9!03,X04UP>B]79F4S669O2'5E2RM:=$DP-69.,VUU,3@R6#=A8F,F(WA!
M.S9H9&UB5$QH.4YA*VQM='$Q9U<Q;E4X;WEI9TQ154<Q1#!O33)%:G=X-&5N
M;31C-&II;'AC>GDR*S4Y0C9)2$=J5T%K:VML8U<P264F(WA!.U=:945J;F=+
M<S8Q4$9J,4ER,7I8>35L>GAY96(O:SDU2CAU>3913F-V3E!36%8T.5-U-4E,
M<55%=DAW;%I%0U8W1&1H-S<Y8WED4FLF(WA!.VQD03=5-"M$1TMS:F5Z.39D
M9FY(8V%B8BM6-U=454Y/:C%'2#8O07%I-4UV,6%",D1Q3&DT5T@T,VEJ0DY6
M2%=U5C9C2&DR3F)-.#4F(WA!.TA$=4PS4V8X:%HW0T14+TU':G=30G!,9E9:
M<#1K5T=A1E!Q,'-C46ED16TU36ET>&)I<DU7<&LY5EI)4&LQ-EA9165A6&9M
M5&5E5#<F(WA!.U0X,DY0;#@R>'A385(K:$A"5V%&<#$Y5#9W-5=I;W)K2%DP
M3U1W:5)X;F@U,GAZ1TEY1&DU57E,.&HW839G.&\S4DU-,79P:S)P6%4F(WA!
M.W5H,CEW5'I3=V9J-E$K3&8W6$DK+UAV;%=P4'$X-C,Y-UIP9U)(>79B,TU*
M+TTW5#=A4#AY-W$U.'I847-T1G9B0T](5$PR97A/;W<F(WA!.V]12U-2<6].
M66XU,5E-0EAF,WDO0V92-F5D.3E.5UE$:G582W4V,W%0-5HR.%9T-48P;4-'
M-6YV3&5+3C%G=6)Q23(X<GA#5G94<D4F(WA!.WA9<4%L074O,F%::35J8WDU
M3TE614(U8C5J.'=796I1+VU4;T8O2$UM<#9V3SEX<'-+4E-0-C!5<U%(<4)L
M0E5+=D=R16Y-<45#94$F(WA!.VIK2$9Y4V]40C5N.50Q+WEF17)E4SE%:6Q1
M37)A8F%Q-DU+9V=W2T-#1&U(:RMO*SEZ26932&Y8-5AY*U9.23@U*UE.0FXP
M,4Q8>D8F(WA!.TIR5CE*<%1#,#1L9%!:3U-#3UE*4T],:D4Q1G%"=4MD8WEC
M+T599S-T42MB:39C4FI):70W4%1O>6HX>C!D<&9*,T93,TAZ3%EL<4,F(WA!
M.W1!235T>FQ72"M,*W%7-TU.-"\Q=C%P>#4O='18=69*5W17*VHX=C!L2F%3
M3&)I3V]C;6TV<%1F:WDQ0RLK47A%0U%V:WEY9VU*<FXF(WA!.U1"9GEK,40X
M<C)B4S=04TQ!,G9M<4-Z358Y>70U56Q6,5)44#8P<$%2=51J87 K-W!L*V]'
M5&-K*VQP,#5X.&=+;#=K,B]/>4A2-78F(WA!.TQT:75P,VAS1$9E<%!A6&(R
M-75R5EHT:V-Q=#%%031-8F=K8G%F=7)K3DU4>$=M5V]!360K+SA!1F\O.&XW
M9S-(:U=Z;D]L>#94>FLF(WA!.VU0,65"6%-*+VI.6F\P9C1K5GIU1E P8EE.
M45!8>G1L9U!O1S%-,'EH=61I<D=03E!K83 Q4WHQ85A3<$)O+VU(5DEK:&98
M3&--='@F(WA!.WAJ6D-&6FM:1TML66=P1F5M5S0X<$)&-V=D1W%E245'=&EE
M<D<T<E@X,SE).'DV3G!L;5E.53AR,D9G:TXS97EI2THU-4DT,E5L=50F(WA!
M.W9+<G-Y<E1J5F4U-S5A9D--4U1T2S)S94M*06,T,75K169M5#@V-VIY>&,V
M=&%E5F)A>3AX3G%#=T]28BMN3DIA.%-34VMR8VU#=G@F(WA!.UAN5VQ0:U1I
M3E!P-#5,-WAZ+V%G-G)5>7@Q,TA99%!V6FHO9WIZ4G%N;4<X;CAW-FUL>C58
M,4]W:FAU=DQY8S%22G=Q0F=R5DI#.&<F(WA!.WIC;%E%-T$W6D1X26E0<$AQ
M0C5T;FAY36I:.4I(2DU.8C!R5E!,,VM+-# W>4IA;W0O6E)"9$QT6D<U9T%Y
M:&XS;%DX:45::79).6,F(WA!.VI'46Q/-7!L17AH54)U3U1#<D154'I-,#=7
M4$LP9'HU5W0U8FI71D$X,#9M:TI9;TAN6EA$3D4S<%)%43A*1W%+33(S8D5A
M5%0S3U$F(WA!.S4O96U7=#%*:D-%=#1J-U W4#=&=6MA3BMB5W,V2C5G,'1L
M:#AO>E)8,&-M:S-.=6=J.5)&6G95:DQ1<U-5;TDO=T(U43$S1S0V5&@F(WA!
M.VIW67$T0G0Q635-,F]Z6'AN9F]E97HP4%-F2G5J5T=S4#5G84PQ=DUL>F%X
M,FUO86]3=V%D63%J56MX02MK=DPP5E!W<4UR;&M*2$0F(WA!.R]#>6II:41X
M9GAD-F4U5S)/>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C4U9CA!+VLY.4TO-UE%
M=CA!,45.;5%0-V\O=T):;U X065J*W$F(WA!.SE$>DAB,UEQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$O+S)1
M/3T\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I
M;',^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-&8Y,3!D
M9F$M-65F8BTQ9#1E+3DW-F8M,&$X,S4X,C-F830Y/"]X;7!-33I);G-T86YC
M94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C1F.3$P
M9&9A+35E9F(M,60T92TY-S9F+3!A.#,U.#(S9F$T.3PO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S
M<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM
M<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^=75I9#HV-&9C8S8W-RTY-38W
M+30Q.# M83@Y.2TU-3$X.68Q9#,Y-3 \+W-T4F5F.FEN<W1A;F-E240^"B @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z9F$Q.3-D-S0M
M9CEA,"TU.30W+3@S.3,M-68P-&%C-&(S83(T/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z83AA-6-A-&(M,3)A
M9"UF930P+3AF,C,M-#DQ-F(T,#0T8S1F/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 X+3$Q5#$Q.C(S
M.C(R+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B R-BXT("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-&8Y,3!D9F$M-65F8BTQ9#1E+3DW
M-F8M,&$X,S4X,C-F830Y/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 X+3$Q5#$Q.C(S.C,W+3 W.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B R-BXT("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^
M4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" @(" \
M:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^061O8F4@26QL=7-T<F%T;W(\
M+VEL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/@H@(" @(" @(" \>&UP5%!G
M.DAA<U9I<VEB;&5/=F5R<')I;G0^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE
M3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A
M<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@
M(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @
M(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C,P+C P,# P,#PO<W1$:6TZ
M=SX*(" @(" @(" @(" @/'-T1&EM.F@^.#$P+C P,# P,#PO<W1$:6TZ:#X*
M(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@
M(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%10
M9SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U
M<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'
M.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E
M/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T
M8VA'<F]U<',^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI
M8G)A<GD@,38N,#<\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #( U@,!
M$0 "$0$#$0'_Q  =   " P$! 0$!            " <)"@4&! (#_\0 -A
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MP5RVW\83/)K9B/?%2A-I?[(3U&YG*(PN*OY2QMXJ5=CN,SM+&1'%*1G\$YQ
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MQ34%5QDUFE*E..O-/KUN.W1=?O\ S;N74M#T4WSF9@ZXY]HX3:(Z^72R\U5
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MQO"2O[0XZ8^>(_&_ :\S_OB9^\=>'_2O?X6[7_Y_H/\ R[;OG3W:_P S _\
MZ9+_ -U'KF[*?Y&HO^+B_P#V7^O7?JE&&5::Y,DJ;1E]K9NQ6&WLIQEQ#,BJ
M@G'VTJ_TX0ZN-'4M./Y*4RWG/\TX\T=IYGYV8C?U-6M,Q^-X<R(G_P!-Y_\
M[/6_O5$?I^"+;W%RW$3^8B4*F8_]9&-_]T=:9]5N+=UAKAUQ2EN.4.H..+5G
MXJ6M=>'*4I6<_P \J4K.<YS_ +\Y^/BMM^K5F(^WR'?\PNG%2F9I5)F=YFK7
MF9G[S/B#W/5>/3\*WW7V!<7T@M7^/[MINLU_8.VY=8VI*K1'IX5L&JCR[X:W
MZ+JA:<D^^R+G#ZH^@K7!4R#&?@V"78Y,&0(K$R-9,:U%/2NHK@%GUWBE%6"Q
MX-_3'5F2,LJW6!$*ECA)X"IK (I-(JY0QPS5,LBQ?UEI:@P=--QPQ8N$.48G
M]6KVU0<*N8]9S+84DX0PW)48A"GFZ1)2)B0^%<:RNDG=6Z:=JFWZPLEQV 2&
M66-:#<HS&ENM/J.25A/KP!B1OU"9:2Z9$_0E9&$,(ALSW8C3#+'F?L__ "_E
MF:LU7BM-Y33U_*YM]?(+R-IEE;B YMF52#2@4<K%EA6ZT SX[]E"\EB(C[)_
MB#_FS JT'H3.:QPNK<7@]-U;>*;B*":+4+-8X]0WY78M%:XU*2@HW98KY=;D
M]E<7&PSL'\=G7FOJG;8D;;MN]B&["<57#DAG1O)CA30-I,3Z>0ZNU+<;:V*8
M*%K3&(R)AVI4,HV2NS."989'I^!I:L*BR'735OBSY+5+;M/M9DST]<R6-SUL
M[LC9R,RG2Q,JI<:&,:X)I&VO*T'$O\@+:MA6EDA0<8W1%?&9#O1A5ZLQ^,S&
MF:48X&T\1'R-9PF[80NRE2*[(R(*LPRPOC6A3&H:L*31M..9>31\;:H3G%=A
M-0Z!;-X%J[:;.Y*JG[=B +U:5X*R*@HR;K#0X(2ED8Z0T N;A+3&6O+SC<QU
M*,RW%5I%>HZ>A9O7%87)ZNLT<AD";C?@JIYC(3%@\9-JWCQ14L->N*J+-M4P
MLIYD+9B/)+NU^W1^0[H1C:#]1X;0%/)XC$@G,?J;\CI[$#--6;BC0RQVK]5-
M5I7[-+'V!)HQP T!)0@*SKQ7-R&^G/75TWM#@VR[-WTQ?;_J*S;0IEX-U>M<
M\:H*J8'0;]=J*P_8!!!W\?>M@%(/YF:/BYC@9L3$AP[8JG'&,/M-FM697MYG
MZ^N;-#2^281VAPX50EF6\#)FO"Y*P]E1C)KI4Q0.:1#*K$ M1."57WTT[H/!
M=UM-V>V5?):TPREJJ'GF73\>$*RK:WSD:E9-]*8LO>IYH2(%YJDL:X4,B];P
MZY^D[[E$,$]$RY4[=)+10T%::\8(VT9$.$'B#&')0UBO+@UJ3%.2L2IY*&2C
MM05.XQ-%179+2(K;TJ,KN\%4+&CFL=JQ^CZ]/(T;3\G77<<3P@F("B2:#%W&
M^1SU/6*9+]ZLHC&%B3%N[^'ZZRIW"2FOH.KW"M9'$9.C5PMM^/K!69(JM,R0
MV,JIV/3X:]5]5IV(#>O<<*C)Q EM8NX<633G:P/IGF?U[;%[./[NY"J(VW],
MA]L3ZJ!/-CC]<%Q@$BLFA\RKA[*\ I-*.%79&(!PDR[%:%C&$B+=*G>@-&W<
M=G^W^'KOUS77CDMK6<>3J4,L7TNH>2,FPQE=C_$LL6"-9#LAI,!VQDH \N=P
M,=E=,=T-06$]M[,Y9R[M3**1D?'5Q;T9/Q%AE+*'5=J2ZU8%N Y^0@%&CD N
M8R'>8/7?UUM#VW[$[Z[0UC$HU% $K+:-, Y-\U]=9"R,%F-1]1@Y ZF6>PY'
MII%&^:Q22#R(+3ER%CYL=MYZ7+RU8LMJ3#5-'5M/8.W-BPP5*NLBO91$ 4S8
MN,@GJ5RE]C]J!CE/@,XF8@1WJ>&TGGKNN[>J-0TAK5E&U^/65JK9F3"!K4%R
M%=SN'QJT>4BF!B; "8Q)$4QI@\5W3AZAWH32=1Z0TAM+1-[9^I5MITLW4"3R
M6D/2!CA*(M(T] 0YG#?Y6NED03PEQ6<89)CHCWQ_H\[<;?=C+]3(5YV;4>MP
MQOM!P,_6LMO?!H<EG'Y BC\]1^5QM?+XV[C+4;HNUV(.=MY"3CZ&C_MI9 M"
M?P8#/XZI3])W(G:O(5;Z#YHZNU4*1H6U3I%IH%A;O6OK@#GF9S::C=P#M>$6
M4K8F U\KC0,U#8* Q\*'@,99*(8)FT1W+SKK,X+,MQN4Q%PIR"AA-E?Q[*&B
M SYD,\IJ!4G79+%E(,(IYA(20!O"[[=8'46!3E</G*(?ICRE]5L6:EA1,*/C
MV52I;C="[284P8-0"/C9!Q!MVE(;EZH_95Z[=\W';OJLN[%QUA=9"UR-;$;!
M3XAV"$1*D3(E4NE:V?)@TR\P*]]W(B5FV#2J+FU&D3,M0Q,N1*EDIY&KM+ZE
MQZ:>K:\HMHB(BT*WRLF;1$M0VI!/KDSC!-28>#>(W(QB(&N6-#ZOTGD[%_1-
MF+%.S/NF;4"T5P4D*+";DC7LBGE(I>#(L0,EL($12;=\MD/?YM?HC3Q?IX%3
MM-<ZUBV1BVS PA_3PF9<0T.)+PH;]"MF;Q?'E.RU1\YA-S0(:7C.<2W'&D8P
MB&RP]O*>-NABF/O9-J9"J9Q=,4&4C]6[5UZ\1 [^Y%C!G[1$]3V$/NA>RU!F
M:57Q^)2^&7%KF@LK"Q$_HV2RS9G<N/T\E+*/O,QUT?8_P5U+T#[2N%.E-4:Y
MBV73>E97/[FQ[4[=:*#> HHO1-AOMGRW7S]D&6,O^/JL^*13@,*GYF+<S"@X
MD3T+C)QTQJ'$XW2>?QERU*KMZ,C\5,(L,AGGQJJZOW%J-0<G#(?N&/';D6P^
M^LM7:8S>5UIIK+T:@NQ^.+%S;?-FLJ516RS;3ME-<#F<$$)_M@?+?B.Y1,=:
M(/%MTU^L^7ONX3Z@[>K/,H[FG7D6_P O71W:DVWM2;G1Z?@7&LP^AL!7$.76
MQ5]N?F6Z$))4@>N4N/\ ;X5)2REYG+C'[>Z@Q."9E2REF:T6@IPF818?SE)6
M99$PA39':&!_5$1._K?:>E9W/TUF=1HPX8>I%HJC;I/B;%:OP%P5H7.]ERH+
ME*S]!RF-OJVWC>_X4P[&&#HSR?D>CP(;#J/BE7RNM1VVW$_,G.4J^52<X^*<
MY3GX?'&<X^&?%T4Q)%,?:2F8_P!TSTT0B1 (G[P(Q/\ OB(B>LW/37IJ(;=]
MO>JNC1M7A/\ ,=R>%[<WRO,D4W%C;+UTC&?VLZ"=DMSY\#:\X;4995^-%>;=
M7/ODN8_'>1#1+9V+UL-/1EO&$THRJ(.GCXV/E-6S_P#FAD1(B5,3= 1,QMQK
MP,3'+BH<QV^._KVEEP0,X:Q(7\G]00(W*D?Y$JDH,AO&""9(C,3)V2*8G;EI
M,F0XA&)*'D(L>= G1GX<V%+9;D19D24TIB3%DQWDK:?CR&5K:>9=0IMUM:D+
M2I*LXRL!(A*"&9$AF"$AF8(2B=XF)CW$Q/N)CW$^XZ;Y")"0D,$)1(D)1$B0
MS&TB43O$Q,3,3$QM,>IZRB[+]3OL&X$WW<-[>I:]Q"^O[T^XZ5TH8-U>$4%#
ME2GYS=3)BMDO1Z+?:R#<DRT5,[(,#KV$B2G!\=+T[[L^7;M75^G-0XY./UA7
M(+->(@+ZUM(3+:!EP'6B;%=K-HERX J[)B"G8=E C[FAM5:7REC)Z%M"RK9F
M99C6,2)@&Y%"#"W(UK2521>!LL"TH2D!W+DUGD-B<V>_[V.08>G.E7:;SIHB
M=/@/7)*"6O0H<TS E-2<+)U_75@M]]N#D1QI$X;7"LX53Y99B#(DR(+\5@E"
MWULIV[TR17<7#LED!$H3]-EAA)1,; VRM-=$%_2;0$W0$E$043(SHMXCNCJX
M!Q^8FOB,81#-CZJJUL@2@MS34:^U8D9B"!)FM!' S)#,08Z-N3./-<<6\RA^
M=-2-29T$4+,S#5C)ICL&KU>3T3X'+8:RUG$=F43D-QHD.)AU; <)!%!FGW8P
MUIU2SS&:M9S*,R5R8$C(!6H=Y77KKG]M*]_<B$3,E.VYL(V3$2<QTVL%@*FG
M<.O$T(DA6#"8T]H99LM']Q[/>T$<P(B.^RUB"XGB$3U51Z#^$.H>( /3T+I?
M7<6@2=CE]22J>W&NE'N'Y1BK0]B,G%K72K'8&X'VCA\4E*2*HJY/W"LQDO)8
M?RW;^X6H,3GCQ,XNS-F*HW8?,HL(X2Z:OCC]]2I+EXC_ *8F(V][;QO2.V&F
M<UIQ69',5!JE;90*O$6*UCG"!MPR9FLYL!QEH?U\9G?Z=]IV]+[Y>(>ENVM8
M<_5OFR@1K\8HM\MYNSQ9-PI502.&E:\/@09"9%TL%?CS<O2F'6\LP79+S6$_
M.ZVAM259T]OL[B\%;R+<I9FL%BNE:BA+W<C!I$4;(4V1VB8G<HB)^T3OUN[G
M:;S&HZ6*3AZHVF5K3V.&;%>OP!BA$2B;#5"6Y1,;#,S'WF-O?5X&OQ4X%0J0
M$*,XCD@U1K8HC'PZT]AB</#0HDMG#S"W&7<-2&7$8=9<<:<PGYFUJ1G"LT.P
M8LL/8$[B;FF,[3&XD93$[3M,;Q,>IC>/STR*H$JK66<;&M"0.-XG8@6(E&\3
M,3M,3&\3,3^)ZK/[,I:Z;VYPYT]7^4J5LR:!GVK5^T^G[;M"31F^;M8',MC8
MA# :;91-3-O3$7V^OB99T.;D)E?=U8+D><MHF8U;,$_SX#4.);F;%06"FW3Q
M":8V/U6VO<Y'R"DWK@9K5H.%L7$CQ:SDM)C-*U'5^/J;3&;3@:UTU$^C>SEB
M]-6,-1;]$'XC<NNV2BU:)9,6PH+DA7!E@"B>M&6B]:ZW!?\ 5_06^*E<+?L0
MSFS:>I<)<O)*#5V'+"_+=4I06!!$)(P6828%:^_EY:R"(OCW)*'79$CSAI'(
M9G!:HS>G=;ZQQF3RF<M_/TOB%2R+*,<!7B;,S-1"JWF4*A30ES9&:3S21P1F
M?KON!B=/:HT3IO5W;7MYFL+A-,T(Q6ML\\4?$LY9@XU:8'C?LONS6>;RL97P
M)@XR-5=D%$ +6\GC=Z0'50&S>97K%[([41'\<C,ZSZ3Y=>J6^>UA.QRD&Y#B
M]=FQDUVD#Z9--RZY&?;30M9Q'Y$6FK(GHN1TN:5DAZL6$RI;4&/QFK>V>1TK
MF<[<%+;A*1@ZRUJ.$ND6%<5<\!E#%M;8: N-B!,26RN<6(WB-)Y?,Z#[P8G6
M^GM.4#LUZ0V+&H;C6/45BO!)''OQ_P E8RIJ55DL- )M$!@U5I15MX9S;:]/
M<?<G-:W)E]ACJ.1A%]7A3-?3$-7IHM>(UE+3#*)#CP$8U)C*<-&%*PX.BLI8
M1!'Q\*5%BJ1>IBTOVO[;#@;%K.5\0Y-G3U2U1\=O,!9RX7[+;0F1TT"Q<E:M
M;\D+" A20B96N?2^C!UOWL[R'JFI2TU:U!6L4M6WZ.2EU#3YT]/MQ5-%$EB&
M0M&IL#0I1$C9<<LE]ELQ#FQ7+)TQKI[LWUQ\Y$'^QK),TG6+WU30]WTM":QS
MZ5S89CI-JC;*A2F3,N%%;:ID(<[#B%H<E#=WC58AB9%OKB@S@[2Z?+1'::[7
MHYK'YRI>E=;GE4&K*RB^7RUMQM67,FHD0O<@0PW2+$-L[@:>!(7OOJN.Y/?*
ME>R.G,EIG(8[RV"5A;"WX8;.+&*#TY:\-=47[+&X_@VRI:!)5A-7BQ;_ "1?
M[YCUIZ37M8Q<6]:C*Q3M(#-_)LUG$0;539[!0AD>!PMZ7&+_ &0&7#+P%+*0
MF(\:RX?;'@WTY?FX<0M*/%9W8M94<!7Q^*TA7UI&0R-5.1Q3@L/\-.)-H6O%
M38JRF9L* %W^8HIG'-O*)B.GCV'I8,M56\MG-?V^W$XK$W;&'SE=E2M\G(S"
MT-I>?(I=2L1%2PQC<7*RLY!<^-'$HDNJW+3SCIOK?V/[$UT4K';&AYO,G+VO
M]=A[5KZUMT#GVS5HT8#7"(,IA.&&E3DF8+YU0AYJ&36)L^*F8??&0I]01+)>
MB\+89I+0N&1CD::^#8MS"<3*(?<QHU*TU 0:Q8"O I:1@"@.2X:OB9"_8?)>
MH4KUQW)U!;RMO5Q9.M3Y6<W\DZ]++G>MQ>99%I 3ODN:\B8/DD&RMO)8'6W-
MFK9VAVU5-ZZ^T ]P[J"5<-I5;9=UI<I':,QH5(K>K9M3B6!\N_\ V7W%BR#W
M[U!.08"&YR7?FF(5*3]MA3W&G!X-U"SD8SUR$U&U4/B<'$F+;8NE4!'ZK',8
M\#((O6WTSM[]=K]0ZC1DJF+G3F/*Q=1<LUR_F H"4TB0+99/Z-,@<_)5(C$%
M$_5]7T^WPN&RK)KWGZU;@N5,'P[=1M.G=DVG7HFUJ+"XUBK-+EV<U3AMX778
M"R4!HE!DA8=J54X:I<=+995>8RYD<F 3559R*:2'D2;%U=5-DT\"E;7PI;R1
MY2XE(E#)3YBVG</).W+JS6+CJF*?D+%<!?6Q[;CZJWRP(:FL3F5PLRH),8,9
M6+I0/*-C\4;\.OJTQMZM[FH-0N B<#9,'J11[?8:B-L4 ^2I<B[5J!8XP0TJ
M*B+*:>8:FK98D3A@QP@W'5*;ALI5EI'R]2;2L.28LD%O>E3B42P?"&DJ3#?>
M)B9'>8$SXS.TE/WG[CKZ<A5KV%DJ&-K5K#:X-%IUYLI!T+9QV*)B"VB2 .41
MO Q]H][8K16J@,6:MEB!5<,T\S'<+6(M "#&WY*_IQV%SR4B-%0\^YG#;+:G
M<+=7GY4)4K^7G.I37'P2IC3VF>"@)A[1[F>(1,[1'WG;:/SUUM<E 2Q[5I7$
MQ$FU@K")F=HB2.1'>9]1&^\S]NNRTZT^TV\RXV\R\VAUIUI:7&G6G$X6VXVX
MC.4+;6C.%(6G.4J3G"DYSC.,^83$Q,Q,3$Q.TQ/J8F/O$Q^)CK.)B8B8F)B8
MWB8]Q,3]IB?S$]>?'W"HEB+8@7::X2+/099-H6/-C)A%T; )O!9Q!N%&E.25
MP81B.^)ERTM98CDV'H#SB)32VD["0X!DS2T @H"3)9B,&00P1DIB(@B"8.!W
MWD)@HC:8GK4%A##A8/2;)$C@ 8!'( <K(H&"F9$61($6VT'$C,P43'7Z,6ZJ
M5X@%$G[/7@92R2E0:Z-,&AHP@?FIRC"H86'-DL2"DI.76L*CP6WWL9<1\4?U
MI^("7-$S6EK 5')A@LS%8^_9D,3 1ZGV4Q'J?[=?6/0HU@UREFXN*@8P -I?
M]U8D429>X]#$S[Z[$V;#&PY9$C+C0!\",_-G3IK[46'"AQ6EOR9<N4^MMB-&
MCLH6\^^\M#3+2%N.+2A.<XUB)$0B(R1%,"(C$R1%,[0(Q&\S,S,1$1&\SZCK
M,B$!(S(0 8DB(I@1$8C>2(IF(B(CW,S,1$>YZY@&S5NU0UD*O80=D'MO*CKG
M 2T Q#1(0E*EL+DCI$AE+R$K2I365X6E*DYRG&,X^.;$M27%RF**8W@6 2RV
M_OL41.W^NW6*G)>/-+5N&)VDE,%@Q/\ ;D$S&_\ IOOU^;':JQ3Q^"]ML8&K
M"E26(6"=C,#P@_,R4K*8T3$TG(BQLR9"DY2PQAWZKRL9PVA6<9QX*4UQ<$J8
MT]I+@H"87&/O/$8F=H_,[;1^>OC7)0'D>Y20W@>;6 L.4_8>1R,;S^(WWG\=
M=Q"T.)2M"DK0M*5H6A6%)6A6,92I*L9SA258SC*58SG&<9QG&?AYK^WWZV_?
M[=<>/9*[+;$.Q3X62T?>D1P+D<K!>;-OQ&9,F4P(6V^I))Z-'AS'Y#</+RV6
M8DEUQ*4,.J1LE38DXE;(E41+(D"B5Q,Q$2>\?1$R0Q$EM$R41'N8ZUPY10N1
M:N8;,PJ8,9ADC$R4+VGZYB!*9@=YB!F9]1/7"O>RM?:P'"BVQ;G6J2-.6(/4
M@TVS%X0>.4LI^1F,("0')KS6)1"8M+KN&&OF4S#C3"$CZ,&%+DL[*]6S;(PJ
MH;8-:C<8J CD%+C<V% Q.PCZC>?N4B,;D0Q.JS<JT@!ENPFN#6K0LG,%<&YL
M[+6,E,;D7N=H^PB1SL(E,?99K4R"H]@NXN"[;8X>J%;4.&@R 1E^S,CQ$@O$
M@ARIHF+KC3IE#+<<>0+&1P1"Y+,F<3AP,.RF\5)EEA=<RA,FX$D3!9,*DC@"
M(P #;L$S,D( 3/4P($6T3DY\*K-L@,O%:&/ %FN)= +E@BMC#!,2R(B ,V N
M-X(C$=RCH5DRNQ5NOV!T9*"N'0@DRX'G2!DR<)63@1YJQDR6$GE TJ5 4_F+
M(D""9$8^\TMV!/F15-2',6A"FL7!P<+8808P8B< 4CS&#$#B"VWB# 3B)V(1
MG>(S2R6I4V0)<M6#)6<@1+DQ@N!$HV+(AWXS*S,)F)D#(=IGYA%RJ%@*&08&
MU5LV:KCV(UA#B#@PD4!2%*4A+!D?#E/2Q;V5(6G#4YEA>5)5C"?BG.,?30Y8
M QB6K!L;K,UF ,C^X$41!Q_J,S'6*["&FQ:GI8Q,[-6M@&:IG[0P!*2"9VGT
M41/7]#%MJE>GA11^S5X&4LDI<*NC3!H:-GGIC?T_J1 L.;)8D%)3?U6OGCP6
MWW4_5;^9&/G3\?@)<P3-:F,!4032!9&*QG?:3(8F B=IVDIB/4_VZ^L>A1+!
MKE+-Q2*@8P )I1MN*Q*8DRC>-X&)GW'7H/-?6WI;>L>5-0]G:7.:)W>*+EZ*
M:)@CCL<%8)U9*-%JV1:*"WXY6#AQ3:?K-*CR&WXTMA<:0]GZ'UTL/,RN&S%[
M!7UY''F"[*P8N)8H6A(-&0.) O4^IWB8F)B8CWMO$PV>P6/U'C6XO)K8VJTU
M-D5.-!PQ)PQ<PP/<>XVF)@HF)GUOM,59:<V;8S+M6U]T;JO1_,_M/35K^)Y,
MU&-N)>X?EM&T&!+@5>W+D/V&XTMX\D<+V,+!R;D7D3S*:G*M$6#$$*G#Q=:[
MF]MJEXLEW T%4#,:CQ>*BKCM3Y%9(73RMN6<T'49*:36 NY_AGVJ+5U'7%):
MWQ#N5V[-]W[V-#$]J^YV1;@M%YK-S>S.CL0P;+[^$I>+QV0O*&QDT)8V@$W:
MU+)(=>KT'V$(EQ\1?"F]*7S7EKY]Y]WU5BAW<^RJY*(V.V5AD9BMCY"S-BC"
MFG61K34*=-BBQ$9ZWO!<1Q8=;V)T1$F$^E#2MQ>O<Q@\CHG1.LL=9N:KS]!C
M[^2QP5_T]#)M7EUQ(4"*G-77K+/)E4@*]63ARX-1Q NG.=K-.ZFP_<KN3VZR
M]3'Z%TIE$U<7ALLRW.5M*BCC&W# [1G8KUW7+K5X0+\LMWH":[B787)'RS?L
M#I<[5=ZV3JC7EXV&_0KR$I14#+B9KV<M'/R"HEG^]A,69U@"_@9(C,?<CVBB
M2+\"(0'#DS&GO.>WWJQ+M.9C/:;P>8SAX;,5<39IL3-*=K?FE>0\J@OD-(_
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MDC&),I(XB!*(ZLNGZTT\-CZLA=7"$>,%Y$JY75J$S\*WS5(ZXD"N B"R*%A
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-1T>'1T>'1T>'1U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g383050g46m46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g46m46.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_B4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MAP  !M8          0                         !              ;6
M   #AP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #AP    !29VAT;&]N9P  !M8    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   X<     4F=H=&QO
M;F<   ;6     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,     !5_     0   *    !3   !X   FZ   !5C !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !3 * # 2(
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M9IVV5UML>YKGES3HUCW_ )Y+?IM8J^1CL=E,HISA6ZQI=!%9U_1BIK&-]/\
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MW%V9II)DL:2>20%P?U(?OQ:*!+O4R
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@!(0(P P$1  (1 0,1 ?_$ !\   $$ @,! 0
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M/\/]=-,]^Z9YZO'_ ,7L\]@]N8?%XZ_'>S%XCIH_=,\]7_:]WO\ \X;%W_\
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MG%W_ #-PP/M_>?\ 731^2[.?^J>G_P#BIQ=_S-PP/M_>?]=-'Y+LY_ZIZ?\
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MGY_/Y_YSUY0LX\R==YJ;EA68K_,AS#1?V=_Y1^7JVQE>M:+V4NSSF0SW)6_
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M(RK2E>YGL;<OD),,Y)JG.W6IU^UDLDD\08O89S /K!=:S%(!'1R,HZ5:BSF
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M5O&:E+[=6E"LHJ.>R<(;$,-&Y'LC2/1L#=>F1$A;GR)&;4D./;'V:=S]O?\
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M7.HJ/AF$!EJ"E).TI2+:I9N%!89!X!\6C;F-YGY$!<JU*[KF 1*!Y:&G[ Z
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M"=AGG[LZ#>.DD[3%13"K689:$0?R2D*_?OX,LVJR</')RC*]2;ETGI<]^Q;
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MZ.%8QG@@5'3,A+#Y*PSP,#G-S6=82WIHFN7T90_#Y6(6_I_R?,67^\,GPE;
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MR' KX@QJ9IQ-(Z8"*9B^Z6Y5&'/H7<V "Q(') P,D]\<<]_EPOU!F4GD$K@
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M)"^4#L8L2ZD@'5<$9]@IC5FAT-LTY% #*&$PGJ\K'CH0*!A CJT]PP^"[$H
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MC22,)6MM(7W2R/),YR!DR2,V>2223KS=<!Y-741RQ2PLD\RF-QB1"LA5D=6
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M]H2''4_4ZL[DYVG;!4@<^VU0.X;L-75*+PGENE#-N0* 9+;22ICV.V5&4Y
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MZQQQ-:89)Y96(5(O+>M2H=W;"(@0.Q*J@.5S8BCJ]H?$X0 DL&8* ,DD$)M
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M[]_E(/W\?S&M6K,59LJ*"SDK)4!* M5'J2"A.LH&+^:,U(H'6 @8/S>QZBB
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MC+GXUE9@0VPJIA8GA@<[\>Q!QDZV"T5][G65Z=[: A4$R4-MD(') #5=-*
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MU!2&,R)6T%#=*6MD8B).*EUBEV-*V,R[1C"+9B"*IP'KBH)0P!\H&DW*HEV
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MNJ#@'%&SSM4_LAZ9_/C12_U2W?69I+/\53I4+>[/2*S8$%=5&.K0@]Y(E1@
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M-O\ $Y1'0:WH X[)>0C_  WQ'2?3L.)9& %T-!Z2[$'RJ"N6!NQ(<@NV<-E
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M6#B1#YV4>.M^>R@/D/8-=H->/J(>/;BR'373S "2W6<@>ZT]'D\_,0@'&#D
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M#W8-3]01I@\@*20" <'OKECM?+SZU(-[3/,4886KTZI(V43<.BJ@C_6Y2EE
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MUB :UY]AI7KQ!KS)3O!:6C4+(S-4J:<'8=F=[2",YSD$2X+ *I=F"F:&@3U
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M0Z$/ Z$! =?4!#W#AIKZ51,YCE(<IC)B!5"E, B0PE P 8 \E$2B!@ =")1
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M:^43*$((>^AZ@*.@_@[ 0XFJ++XD&.5*6@Z7C9HV6$U%PK6D20H0C.T5.(R
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MF F%IEUW\!=[%9(&,N6.V+C(1HZ>R]]U6#YW<Y5.50A!,Z1<(2+%1PC3U/\
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MN[!&ZWLQ;WV_]B75"5'S*J <<^^I&&F9X3#T,HL/8-&7(([_ %;<)B8?P$
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MY0 *H+/QG#,>=7<4JQ 1Q5E0J+D;4<J,'YA2,?(\#V^W.(#:0:!W&24:"@[
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MBB 9+R2J*JQT%D0!?OJK$$#]9@(0H_*&@XZ_9>INI:JC#QV&VU!#LK&.Y+&
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M>(7&VFH\TQ,49MT"4BA0058/"R  Y)]6O6-AY-LEB3"B3,QCLT>7CES1:',
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MHS@Y@71#J25G3J'J" 2BPW'KFQ(ZCSE-\GE$SHWIDE0QTT8<#*H(F1 , +@
M'%]25]5U7+2S>)?60ZQJJ)9(K3+7]3A7H:>5U-7 F;+>69*BH5*ABTT#,T9?
M#$\2IA[G9'$4R1D["[1EE6Z8/$A!DP>(O.D!5(9@I8I8S50O3\Z'=?=OYA!0
MVQZ<FWB!UK'0I'^ME]=UC56+W&$U'FY]2LSW-7WXQVC.,D@ ]N.UUFH8ZVI>
MGHXWHED)AD02U$7D_P"%A4-14WF1\_WGEQ*==Z]EL#7HZYR?<B81$!27(?H
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M2SE*^WRU3DE I,9BH:G:N -P8H2W(##)'G,#*<B+8J RE353!,I1*@P406
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M2SL<#OP(S_TY[:B5FZT5V:R;1E(:;BI;TKC%1ER1L@S>G3_Z9O">NX5NNH)
M,(" ";6Q 0#8@(<8F>.:*O6HEI:@1+;ZG):+RP7B9)"GF2@1#(<$Y;E5<J?0
M2-R6EJ*?PYN:U%//#OZRLY4RPRIG%GNW(!0$@'DG& !N/ U,L) IQ$2H'$"A
ML=*H"(![[_LHB ?@(!K0<60N18D+12,0,%EJZ+TGC(!\X,.,'@ '[>=:)L7_
M ,P$]_[N4Y'N?J$8'OKX>0* "((J"(>Y 71*)]_4!%0-Z^O2/C?T$?--Z\JK
M%*:5W'_A"X4B,V#[F291Q]AX_P 7L-5!$2,[A@=CL8\'W"J"PP0.ZY^_L>)9
M#10.LT60#^#M=,YC .AW^;6,8/ >!-^/MQ".Y,Z!JJAJ*)5#;#+74^U^?=TF
M )YRH+$$<C(T\KN1)N.<,!$[8^65V''W8^_!UW%=D-M4B3@2Z$0'N;'9?&P#
MN;-Y ? %\^WGBX69'*R)!+(.&$BUB,F,C)SYQ0XQ@\D<$'W&I& [&1>,X'DN
M&_ >6&Y]N.==1Y,0, $07,.C";:R: Z#6Q_.G)O7UUU:\;UL.)*BO>+:5HII
MP<C*5](FWY [ITSGV[@8/;144G!DVG&<-#+V'_$G\M:5S(.C+'$A13 ==)#*
MH'-K\?D'?T_UWXB/D.-3N%TN JI"D"P A=L<T]'*Q! _PQ.['CWY ^\ZNXHH
M]@R<GY[2O'V!@ 1\_M.?EK'!VX+LQDRF 0T @)2@ @.]B.@_O>?[_%BMUN 8
MO)3PN"#V\M2H P3N4#(&/PX^6JGE)C )'!QQ@?+'!_T^_MKK-+%24 JI4"F
M ,/4\[0]("&]?*<#![;T)=>-^_%*7J5(7VSPTQ:/#G=7K3%4]^?)DW]\D9!4
M#D$$8E6G+#T,P!SW4L.,_,Y ]C\S]N=9@61BO^;*8@F  ':3UL(@ !^)3=73
MY\^!XOX^L[96O\/$RNZJ&/PMTH6;"CV*R!]N#D\#L,@'C4GPD@]1XR<$M X
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M66H,;S>2A/J?RHR'DVCG:IR?;4@?RU\T'^HPFO\ CXQ!_P X<7'E4W_R7_\
MT)/]=9_Z+Z=_^:D?_.6O_P#]]8SW./-,@U75;\E<RLN1(YDDASQB(0.<I1$
M$"2 G-[;Z"!UG'Y"_,8.!BIO:JS]GD2#^NI)+;8%0E.I1(PQA/H:N7.2 ?4S
MX&!D\]\8[G5/&#OM#/M<N9+*60L38PPAR;UJTXKI] LM]A<]0/,YANQP4I<Z
MA5[%(5O[MOU)Z2=GKTK87,&C.@1O$65M%DL,,H:.DVJ:=KK73C!)SQDC@>WX
M\::*>Y__ +6:V5NE6J=Y4.2-:!NM<B[;C>2MX9TK[&X,K,-;38'J[F7=B"KI
M["V=C-'*]&+4+#H+G4 5TO3<9&AL4=Y61S) #2DQOYOF^9$LL+RAU,2/MC.W
M;D(Y\PJI&267?>BK)?+DEPELMZ2SF-X(ZUC)5*'C,514P3R0TD$KU,$34SQL
M0ZF"9XP<!SEO^7GFYYOB7>\-.8;"^&ZS6J#2<<6UK7\;V>X??Q((OF)Q&M$1
M:<+:(\9689OCS[5L#YXJ9Q$1I6:YG[D/1QSS4.ONFHNC>D;Y?Y:RFK:..UUL
M3QQM+]6,"=G65%A9A"H<R')<!<LY' Z[?+%U5U$>E^GJVX=*J_4W5(5+O35=
MQBIQ<#:I[>)ZQ*J.6*"CG"RR3SVZ-HUK,^<D3R+(UB54^T#RQ=8^E.V/*F07
M*AY9#*2(Y%FFS>J+ JN->+2W#VE,E[JG(LR(.)-6295,8IP=1J@G(IIE<J>*
M;AUQT<QJ2::JE955:#<M5"LK2(//$BQ=2!HO+?(C)W^Q7;CC,7']'6^62>GB
MN?7'0\*U"R/F"XU54P5/2.(K.X!+D+AGC)'J!Q@:Z#_:!9P11;LW'*'U2J5C
M.WE6;+)5Z=M"UA-0Q#N(I=/$AP?V,I2"<L<J5"%,(#T3QRZ-Q=-U_P!$?#FF
M:.X^4M/&-IDJVB,JE&:,QOU*V4# X9@V#AMOI&L8G@#U!)('CZPZ$,32,5J'
MOD$0\D@XD9)*.*9&93@QO#&X/#*-*:'YW,X3,%;'$=RF+L[ PL,8E5(F4N>0
MD(R7K#H7 /G\[,-L5N',+/,2(IF1BHZ(G(YZ982&F&O9ZE<>/$'HBEJ*5(Z:
MK-+-#.];(LU7 T-0@S3Q+%'>9?,21MH>0.H R"GI&;2Z>"=XMH'F=9]"U$CL
M_DK%?:0J8D6/<SM*(BK LX*D'@ ACN.W9O\ G<N99[(,9"8 D5E&'P=OB]:=
M6S!#-[+)F$A; A?G:&*7S&CLXY0%B1;^&>7<DL":9W"4:"NR6T/6722M;ZJJ
MME=#+-))-=(Z>ZU-33TB(^(13R+U!25-0TB@,\?DHB\[B6 Q/+X']4)1SUD?
M4'1<U.D/FP^7U)8'J)4/?-.M6TP?D>@H) ." 01K>3O.+<(Z1>-U<+L',7^3
ML9>&>IV+(IW[K*:0H&-4)%D..5D8VDBL8Z0W9)T^F!2*54*:!S"F1^O_ $=5
MQ?MZ*X&59Y%=6GKRHHP&<2B1^HG3S"H_NV3)Q@L2<ZM:7P8ZEJO,:"[=-JD,
M:.QGNULISYI!=5+[I<*<?6$;XSMQGG44FW)5GC+N0Z]F@;+CRAPF2T9F_P!N
M:LC560M="L<\5W(1]=KBD[B5I+6MB0[E!I(6&R2=9F42G=*JPCQ5/I<2R].V
M^]/6U\5PML$%PK(WH8)KC3R324%0%DFGGW]3PO33*S-MCV%RP+"0LS;>S4OZ
M11Z+L%'X>5_0T%Z?IRV1=/5E<O5?51H*V>V(E,)(J>DK$H6@D:(NIITCB!&Y
M%  UG$Y%>9Y^IC8UEO\ 1BED"3OY4#%FJ%85J8**I_N^E10D,,19;N253!%2
M8-+'H@11S'!L66[9!/;U?1EIHA,R76VM(/+%(BUMM19!N;S?,+=7R",*FTIC
MN3C@\BTHOTG+?!@+X:4%.6!,QI[_ -84Y) &P'X>XN9!NRN3]0 X[XUAXRY.
M.:/%5HHN49:6Q#*/83(#[[U5MG/,"MVV/WC9W&DL,+-06($9F6M8)OQ7/5$8
M6#CDSI 0+2+<QQ3LKC9K3;J"MK5O<</P]$LE/+!/15,WQLA1!'Y%/?KA-Y.]
MS&95HJGRD)F,3*GII]5?I#4O6O3-=TD.C&M[WB.&DDJQU%?*A*>""H@J7=8;
MD?AY=RTY4)/-E0V5D:4*6E[.9<Y@8*.GU6M#QJ]FBVQ-I4F9KAD<K&8HQ1*1
MS.S\DAA5XK 60A1*=.M-&$['+&,8#6-/I$Y]?I+G93\.XZLO$/G4RO6+26):
MKRJD*?,C2>JJ:+SX0VWUK20M@D[ =<-I^F9JX5+114A$4B")9;M;X2T)VC<P
MDK%)<C<=HW9/&X@D#<S4]S%R;/(#BLU[%;MNDR@G.)33ELM\4M9OB!6ZTZG=
MVWY,Y#[C#%D,L$;\,+<CRADT2NT(D5#E2LQ-8:D4WQ76EUV.\@KD_5YX]D+N
MS*\#I=D\QP-J\#@<#YZM6%)15,D#VQYA2R"/<E?'MD9&VN%9'(Q@>ED9AR3G
MVUMJPAS!J+V(DE7L9/V;>F)/JTX1RM;JHY=Y"].!_NU+QT?C@[9O4C. $H6Y
M%[)2Y$TRJ%JH"H9(,MTK9[%<J>23]9ZJ&I6Z0+4P_&26J);<(SMG)CG4U,[)
M@FD=F6,DCXZHP-U*^7"B2:'Z,H7AB6D9F^)CCKW>J,@+(IG\T1(J\JPX/U2O
M.=+B+99@-*T\DW6\;LXEW5%WEY>L\X7F5DH"ZE07,V@ZW$O:+'L[/7%7 -T5
M9^2?5UZDDHLL6!740307W&7H_IKR*F,=8(S E(%:[S%I(-S,&EW7:([@#P&B
ME ["1MN!KQNE6^W-+ JX!.*"D1@^>0&CIP0, '<#G/8<:ZH=?-YF^/#3=1Q.
MS<RCR:3RJG'Y>L\RC4(Y!<Y:^ZHJC['$,:[/)%N"2THTF24E*+7,HDV=RA2%
M6/9R=(=-0&J%-UA#*K1J*=I)$E8N$56)6>[4?DX()#))*6)Y"_6-$U=0Y7=2
M\ G.Q5 P<G!VQL2,_9\N-1FN.#LZW!E+N']+Y>#O+'DM\SEHQ[<[/88]#%#U
MR98UM TDQ9LI^\]!A$]"?P457E50 1N:)?T:'Z@6-JEJQ>O*.GA^%CGCDBJ+
M;\2M8Y4RQ"&2]+L"@LID:K;OP'.%/7>G_%:ILL%HBAI[W'/;4@B62"]0T 3X
M>,(CQ2TW3<M=3@A0%$=7)*JG:\S+N)T=5Y:,FTN!N2<'1L"*2JE_;MZHSCYU
MWCR*F\=E;$*M9K*:LP=@%A=$E1431K2+29CNT4H!:R@<>FVJ>C>GI9Z>6?KU
M704TH;SZ>AF*RAO,"A(.J0A5MHW;%!8'!#8 UD^I?'#J*]U-/.L-SG%.C1GZ
M5ZBJ[Q(0Y!(IY[A8F>ECR?5$J!7QECG&5;D6GY:K<?-+P]1Q*^;US*?+M^1\
MZUSGV3VYN#9DQZ5ZG?EDZW+C0DVST4VS=U"(Y 5?M3*N%VS10"MN-J\,>EK#
M;^ONC*FCZG2XUL-P9YXOA/*#'$AB,8%VN*%F4NI*K%M! &X?5YEU'U9<+M:K
MA#/%4*U1&Q9FKDEB+N<KMA6V4(0IW $C@@X 4 AX?T?)_+:RJ,2PE*"@[>1V
M#JNZ8/U,@9(:.9G-"<!'EEJQ+L&F.7K.!HOQ,'9$+C%R$])&;$25)3B=8H)^
M^4\TJI&.P.#QW&>5]CSVY_#7'G*$GD$@D!BN3W^T>_OJ?G()E6/D[=9:CC^G
M5.)Q[9(]Y;[$_-DYY)VF&RI7:AA:*L%8K]/L=:@;+::"5K9$7),BE2CDF3U%
MG%RM?C7,Q'&<4I-VX[\9P.W_ "U$8QP, \]L<^_X_/4D;)S/6J!?9#N84^KC
MA#%5GNE1L\DZM*R&3I]UCVD/KA<9RC5,6'PN82AG49)P#2I.)9M9+"E%2]E8
MF;1C2/;S,FHZT3GGQHI+_/5:+I5ULU=BJRI-1-KKB$(Z1MCN,?91^\Y()J^G
M(Y-. K<%B>>G%+/+.XV.FDY"!;0(/UIZN!.M-:JV?:&XGAD8A2)C+"LA-V.0
M:1$U8(].$KT[5:#;30V:;'".B/7DGUXZ@HNSROHIR*@QF7<*JU8JJ-VTH[CQ
MS[?Q_/Y[?;IKN4^T<P&A'C*.VEZ:,&[:_NI)TI"0KEI'DQM!*66S(-Y&/L[R
M,M#UO"(K2!F%'>VAY'MFLBYG4(AK$RR[!I^?SG3\XLYBZQE2XS5%85>\5N?@
M81S//4;3%1#=N+1E<)ZBO$2NX2?GD47K:R5J88*,WIFBJBC%ZFW!9>,E46+3
M4@^&FCAIHX::.&FCAIHX::J%^T,?/HR7YE9*,>O(V2C_ +*/F]>Q\C'.W+!^
MP>M9>IKM7C)\T51=,W;9=--9NZ;*I+H*D(JBH0Y2F!J(Y('S.IAL^2/E768-
M3'PY7A.HV0.8PO; (]0IE,(Z^,>^_._<!T(#OA\OL(8?>.VH 8Y]_G^(;^8!
M_P"ND*'V=7+6P34)%Q-WC&IW3EPG&QN0;0V8MQ=N57*B#9N#T_9;$,J8J:93
MCVTP NS"&QSAZDNBQJH-.VQ$C4M2P%MJ*$4LQ0YVJ,DG@XQ@YP>@Q>)G5,<4
M,*R6TI!!#3Q&2U44C+' B11Y9XB68(@!8^K.6R#SJNC(W*;3<7+3M-G*/#5^
M L6:;=;(K.%_AJK:VZ6,(C$CW(7W3>.0?R%Z:IH6"L34>]=H1#&0=1C=XNU?
M^I?@BKLM)>YZQ8:F.>2:2*W4L,ENI6J*<M635J4OGA2D<',,R2*C$A6VAU C
M8CJMIZYN%[%)74UQEJJNGL-'13]-6V6KI*CZ7J+R+<MPAWQQVV1#35<$BQRR
M,L=3(J.H1(R8]Y[R%RL+1/W=H,!R[$5?Q]@CI";QQB"[*RC9X\ARE@7$=+VI
M@V:-DT7QU3+R$(Z6E6RR:9D>KMF <G;*6];A-4O=5PT3"&LKZ?8$\T&4.L+-
MD[ -JR>A@QSQK:NF[?UD)A6W2JZHVPSTTL-/=;[;?(E\J:3XJ)Z>W2/,S&)"
M%6H I001*P8@!F,0V+';>1RG:*U#6&A5QGBW'CR:CJ3)7R;M44\8\Q>$E'TA
M79)%XC;'4THB8/0(UQRW7*LBG\/.FLJ(\:7XSBK@\.+]OF$T\4-0T4\@HX%X
MI:AHRP+0TZ!'4,3(5[@,< :O.KX:V.BZ8CND])=)!UW;51KC0TLM%/&U+7+%
M%5T,-%<(9$& "LE',[%LL$($B[O*&>ZZY4A_N?G[G9J()E??$ E6?-.0S[8M
M1;BD,C)RP:; "PGZ.SKO%$X*%Z1)\W:.XW>F:5:J))5;:BND_2,K;E56 9C>
M%<$\[%\I6 (X? UUSHZQ6.X_&&Y]#]"7P*T?PWT=9*"D2$$NLWG&GZ<I&D$C
M9"%\@%&5""&)7!FIGV-$[3&YHN$=9'5;;R[6]6C.V5:[-I2*Z":HS$Y&2&1R
M/XAXJ8YS/F3JN$<-55#(K1J1R]!=6DZRZB2[F%:VNEI?CIH8J"**DJ/,2+:Q
M,$<1EIY,>MB8Y&0J,C*KD9'Z.ML=Q:D'1=OJ+6M0\*V4=&V\43T^,+"*].GD
MJ"H4-B850D;!?S-V27]Y'KQ-0[C(Q\B9K99R3<-JX$0D^R5(Y.+7#I'FC/CI
MDNSY0D0:2[C0ISQQRF>%9$*XT5LB ;&>I+\RR?!6Q%P=CS7:CZ9H][$[OV35
M?E.<+@.(RVX^IADYUS+Q:Z9@JX[$>E>CZ7HD12UT=5+;J6MI5N&5A9/-:&$E
MQ!EL+RW[0$>G!6P]E8%'KAO*-JWB,(559%PFX7)'C8"L2'+W% 018*,QD")E
M,+=,C@R1C@GU*ZWQE?UXN=-1LM59K-\3' [-.(NDW8,L9<2##REMB88!=W"@
M@#&W7$)K8T,$U)+<NL_I!4EB*(TWT6T[!@@9C*LPI6)7S28A($+#;N[+QNO4
M+28Z"]<KLIZ0.Z0BD/6E"HBJ/0)R@X5:A\P%*79 .;QYZ0\\4K;UO6U[2I+3
M4($:!O33=(0GU;@"345=!D=@-HD]\[<\Z[)%?;. RW6NHC/Z<K4W6/S-N2 ?
M*5BQ )(W8P"<=]+F(!>+:M6D0@E%1+<YA08L&E7;-$"J*F57[::,AU%!14ZB
MIP*&S&.8^A,(\;+17CJ4K#/1UZTUO#[FACINBB-JYWC?%=S*3D9X)'?((QK7
M*MDJ9I9ZR45E5)C?/))<&D8J  27A .  #NY/!Y[E3#,O%!TG(=(!_#]+%K;
M*'OT%1='. @'C8E\B&_J&]A?J:ZS?LX+\(7(QS;K!4,001^R2GN3MNQ@JSKL
M+=SC5AY$2X+1;AWXDF08[\[D'[AS\A@:TDT\=.&3]NFY=G?+L7*+9TB5JQ3(
MNJB<B!A42?E.W$#&#:R* JE$!.F!SE #6LG5M>HDIYZRJKZAH9$66*S]/A3Y
ML,B MON! VH68[<#*[F^H,75+%%'-!(ZPK3K4T[RQ/YDA=$GCD=&$D6QU95*
M,CL X?:<@G5*%[PKSG42"0FI'+%L735?-F(EHF9>8NUS K.$5U"G5C8ZO)+E
M8AV#=UZ8_:24,@F8 %8 XY0KW"R UE)-&TCX1/-IK!ZT?/J5A52!@0.Z*03D
MYQR/;-EZ_P#!2_U/P-7T19Z"/X8S>?)T9T-0H)$908_B9IBY)5AA77>^ S '
MG6MK=*YO)*$2D R7ELR)C.0,>6R%F1A("1%8Y#]3.P1(RHE#I$$NXF8JI1+V
M0%,Q XQE1>.H*Z9G,U.#)LC[6>-2' 1=PBK8V 8@C*(K'&%!(]6PR]0^!-(3
M O2O2\PC^K++TOTA)RPWXDJ*:H50 6(#( 5 _P RG3]<M3F\N,B+)WF8RE/0
MX5J4.5AD>.S1$5WUY7,<#=0CK+M3K]4&2(F98&:02'Q4R9W!F;=5(CHR>8HZ
M/J.BG^)JZ>V5,/DD*LE98*5&W#( >ZUHIV(^08$#(YSG7*O$RY=(U'3L0Z6M
ME@M5S6Z4K+56.@Z>2XBF9*C>A;IF>JN*P_W9E1J8H"$+LK;1J?@3$0R(5NRC
MJ\DB)>L4V\E! D!QUUFZ6:2[?JV  (F/U:#YBAXXQUSZCEMU6*46;II 0LGE
M"?I,LV]L#$EOI)*=F;GTR2LK<EMV =<"%)6U;"HJZVODG4?7DIJ]B1QV%6(Y
M,Y!P?+P.W!X.= U>C13]*4AX9BG))E6.DJC:&DJX#O;!8Q6;B55;['9ND_8*
M=#P!!*)0UTV"\L(X&CZ:L=$1#$XFHI>@6JY!L )VP&*9<'<B%4C(50!D\G'5
ME3>*J%HJJLJI8 Q&)Z.HA12#Z?6M.O?@G+$L<GOG/VV8DQ?DU\C,WC&&/;A(
MLFI8YL_NE+I%FD6K$BJCDK-N]E4'CA%F5PY76(V*J"15EE5 )U*&,:6>2IO#
M"I5(*98QLVU"]/,W<<CR;A3A5R<88-EB<$>\;=U#U!88I*>U7Z\VZ&:0S20V
MJYW.AA:3:%+R1P/"KR;0HW%20H SC@8IL \OG8*@&"L)CHI"=L,98R4 1(4"
M@ IA%AX "@'N(   &O :VE[XPIQ%%)3--'&BA89>GY9-RJ!_=&XH0!WY<D$#
M(/)%LW4?4CLS2]1=0-N8L2]UNQ!)]RQE.6/S]S_'5.>7#ES<#_77+CA%\/3H
MBOY),8G,F40 3%*8T4H)=^#?HCXT8"COSCS>ZV,GS*"6M9E#*\,=E]/HW8<0
MW5U5@"&SY9.P[@I&JT?4O4L61!U/?H=W?9>+JNX?,@OR > ?;Y^VJ0,@WZ[T
M&Y.*_1;=9:7 )5BBBV@JK,OZ]$M00J,4R1(C&Q#AHQ1*@S:M6:94$2II(-44
M$P*DD0I?6UFQ);*)RAC)IJ4^22"T7F4E-,RML)3.^5OJ$CCY8US>L9I*F65V
M9Y)9'>64\O(Y.3)(Q!W,^<ECR3WY[2:^S_R-?KCS44]A;+M:K*P;U'(#Q!E/
M6"5EFB+I.-9(%=)-W[M=)-P5!==,%BE X)**% 0*8>+V90%&"?K#W^PZI+PV
M/LY^S@'^?&O0EUD_NB_^,'^7BWU5T <@^QBCOVT8//\ ?X::.LG]V7_Q@_R\
M--'63^[+_P",'^7AIHZR?W1?_&#_ "\--<N&FCAIHX::.&FCAIHX::IXYE/W
M^M5_W9^SK_I6YW.(-V/W'^6HCLWW?U&KA^(ZAHX::@+?>6;*%=YG;?S-\N:G
M+[5IW)>(:QCC*2=^H-C6FK;)TN?FY&!M4A/T:;KSN;?LX"295=J-B^(KL(F'
M8LV+A%FF1LFTUKL"0>,+E]GGRUU3)TC2_A<MRI8"C9,; M!+14=*&Q944V4@
MFTGU#-4GD7)F2>Q9G.ED'J+=4I@<)IF+2CN5/;ITK/CHJ5X95W2?%+!C!V/$
M[[U"AU+1N&[!FR,9UE+1<*^T7"FN%O:9*BGE5U,+31^9&"?,B<P,CF&9'=)@
MIR8V(Y'!H<YA6SF@7C/=::6.JR]O5PE(O:39VUWA277(*!N;W"<NA+4)Y49$
MJU+BF5:;QPW*OB_+)LW[!A,@#2*$"EM_$R^V6^>&EUGMMPMM4T=+*E1#2%;A
M-1B6@ACE@*1>8]0DS[T=A&5ES%'EC')KU'T9=NG+MUCX0U=:;'#0GJ^VQU]%
M64,[UUNB6U.)X)/CBT531?$RM*[F,4\\C4@F5S!+B$]#M,W?4X0]CLEPD7EP
M=/FF.4XCF.L3T;@6)(<9Q.LID+<E+"M&*IF^(DB%P%D)%/4HAT"J3Y_U]NJH
M#,5@D7X%8OCDJ>D9B*0S']D:@@4II2_ 19@H8'TYS@_1"JZR\.+>UN7I6[>'
M+TMTCGDBDFM'2]2M6U(_E/\ "/3W*UB18E#"542I"N"7E!!77RN/ZR-JA9%G
M(Y E&TI=75.AW1L^,5H6<N!BKH!5H]Z0Z;^0GSJ& J4,@P+.'5$B:L8D83E+
M1J*6\"*>EDC"&"D%=-&G2U1%-%0 J4JW#M,8J3E2:EXS"RYP^6SJ^K>M.C)K
M *N7J_PNIXZETHE:&@A>3XU74R4D-.;C);7JD*-NI(ZA_*0,R<HH+Q3>>:QB
M9&:6F%'T0UC9L];L:\KEV>F4H"S1YBIJUV=78OH=.O39#.B >&ENB04,8.E%
M/MF V%6PW.YM2100S3S55.U330FU-"]32@DM54B+!&U1"H5B\T0EC4+RR\YU
M"/\ 4OJ*"IK#UWT-%2VF>&CJZEJ/I>TT]+55V!!!4/6U%4HGEVKY:-+$Q!7$
M;!@Q5D1S[.:],/V[M%%DUH1HH]M*]>N4EJM'OBE+%KV9S+7E8T.G(D,06;JP
M1Z";WJ*8$!$_1Q9CHFNGAI98*>LF%P,SV]X**LG^/:#(G%$T<;+5>1C]I\*7
M,9R6*@$:Q-\\-?#AZ2^PU?7_ $A3U%+$WTE#/>[!$+>\Q!C:KI5H8Q2"7($4
M2RPLQ($;LN,NA;N><[F0(QF4I.(D(RHC>%XX\FNT>(457H7+='+>/MD&9"JF
M3 AT[$Z;#$&3,!TGI2"/58KTG5%!-'!4205%2*#S5I)C')6L0C4@,B,OQ+#*
M-3YDE!/*J<8U>R^&?0=.E1%0]<="U9^'6KJ&:Z69A'21H5^):&JI:MHZ;!RT
MRL(5'=S@D7G<N^9<-6K$^ B*92QDG<LH8FA[O4:L^GZJM:K7 M(4CF8G8)BO
M*OIZPQL9Z=X>4EV"LJU9@V<F=O@,@OV_3UMZ)IH.E;?/6RVBCJX+70FN@K>F
M:%7I)6@C+PRS/3BJ$BR%BQ8<$[,[@=?.[Q#EC@Z_ZNI:"JCK[?%U!<THZJW5
M@EMU33K5R>7-1O D=+)32H0T3TZ"%E(*94@Z<2+S-@.?/04X7,^%9I7+!9L<
M7$BK=2WY\D%K1CDL1J&5I+G-< @3IJ%F!K_Q$(PQ#@]['2;5I/T;3JL[N+,/
MAR@J,]-4L @,@'EB8OY:QF4$>7O(+<%,C!UJ JY,C#3#N>)Y#G'?L3K4H9TY
M?92-@I-AG#"SN(MMS'&]6EXZ\4Q9G9LA%5!$U"KKYK-*)3%S*MTHC6(Q1S-"
M<>V++8\8*MZ2.VKB,=!2"" 5,M13].1Q5$-.VT^9YM.S3(CJP5Y%7:R.03M+
M$5DJ2Q&6EDW$#8T[8+$\#:V!GY*3G(&#K1S><.7V*C9^:?Y^Q#$1-.MP8^N,
MH^R!5F4?5;T*A2)TFROUY=-"$MHJ& A:W(JMID3F* ,]B&M&N?1SL]!%1WF1
M)JB!ZM8OHB\F22C0G-1'Y*'="I5LR@[./4P !%[#4@^83#N53AF$D. PX*EF
MY!]AV.<8YX'&1RY@^!=7O[P9YQM$&Q62(=9/1F,@U=@GCM"P]DT">]MW\ZDI
M4T)H'+?X0:Q$8%D060!F9;NDW&AZ+K9WH7^DZB:&N:4TTR6J>2.L\K.\4PDJ
M6DE$9.)-JD(>"0<'5=[DFQXA24P* *6./-'R)(/UC@\X&1G@:7D5E_!C%W88
MQUF?%J$G7J.3*5@CU[I2B/8'&A6Y539$F6;R4[\91NT8J@VMX1*!*F8A_B @
M)1'K/1?2%,L%:YK5F\VJBIUE-JM[*L\<1#1GXT.-X(*M&A=@3@>K!UAJJID9
MD!1E(7.P2R A<X!]!!P"=H[9[8^>T8YJPA+257B(C,^(9*6O555O5&C(ZY4U
M]*W.D((J.5KA5F35^JXGZPDV16<*ST0F[B4T45E#.P(DH8NP5%GIZ<5#/5V5
M(Z244\LAM%N>43,,^2[?!LJ2E3G8"-N<^D$G5NLC\924Y&<>8^!W^9^9XSGO
MG[#IV6?<!3J%!<P><L,S;?*;R8C\9.(R\T>22R(^KZQV\^RHJC9^\);7D(ND
MJC+MH$7R\<JFHF[(D<ABAB:^U1PI.SS6\+2A6J7FL- ZTJR8*O,);=/Y*N"-
MK2",,I]+$$ 54E)(&'!;ZH\T^K'RP03@=\9QG.-<B9_Y;%8AI+)9YP<=L^N_
MY+V;\UUQZ:.>9.#I*?';=Z23(1Q>"F'I&JHG&?ZQ #1X"/2%[^KUB,+*)>GQ
M<TH5N$RU72ME&VE= S54P%+3U"TY4LPJ2L2$^HG;D&3S:@-EEJ3"7V*4J)3D
MY. H+!2>QV#G' 'OK4S>=\ 0[*9DYC.F#8F,J]M3H-DD'UXI#!G7KVN4#HTN
M;>.WHMHJV+%,!DZZ]7;S!P$O2R'>^-0K+ E1/11TU;TUNJ:*2X4T%#8:$R3V
M]=Q>MB7Z.JTEI4P=T\,[(N#DH1J[61U5F\FJVA]C-)(X"L2 %8[QALD *><D
MX[@:;W-F:\&LJI8T'F9L1(N<2Y1Y=GF3VY[E4&KC'#1[FS',@S=7L3/T#T]!
MW'D5>-5IX&!'+1,ZZ1C)%,?C;^BK=0T]_P"F:EJ^TNU14.UO-/:J2%JT0(5F
M-+414M,'$1($DD1D"$^K85(-M5M(8I@(I  HW%G?"@YQE2Q'(!(! [=SG.O-
MW&7VC$8(M3W:I)N(NG,+9)H'LD,"\?5%&2#A.T/D?7=QG75$5"*DFW)4XPZ9
MRG*Z$I@'CU.H 55&1A0,$Y8 #')[D_,^YUJAY)X)&3C'_0^VK;/LI+/1YG(;
MQ&*LF#I:=>0N4K)$M@,25S:\ILK$<L"#>P4B88*KL$<.R3YD1&V'.<23EG;4
MM:+67)#R/8MIOKG[A_+51>  001GOQ[_ )^W]_,BGZZN9N9+*E1JF&(Z,K[K
M)-HQC<,NP6'[=%V1O!M\11D!D')T/FNS0\AA1[:UYTKK!4A$1,3+9$5KL:+1
M63:-X</A5+4VE?+N<)V+EFR#D6I\K--(AB2+CZM'4C( 51.(7K%&J*5>22 U
M0?6IJ>$88^L4S6"5YP9LI8H@5:K, C /2N$VF?MY_KI%9DI.-N7>3@:)"8-Q
MIE6)R*\>U9"5M%>;VZ[KY9R_;Y6)E36E7UL-&%96.+S'D.95JZ*5793<<ZN\
M@^N$"#MQZUI\O]?SG6GY?GV&LJ/[)/7?!6(8K'#5H@P:3+;"E]^$V&SW*+BI
M>4=RN0K"X>0DZ[DY_+>1?6M)6L!9HP;-9W4G*E7D;6K*/ZZAP.>WY'^@_)U(
M?"5UMSW+\3"PU:P7&R$LGD(N8WE0@)]M.J,*W/R5V8SD+.#-NV;Z(M%NSA%6
M6#1E6JR]@;VBZ703Q#^05@&#\_GOJ.K#N&FCAIHX::.&FCAIHX::I\^T9_T7
MS0?]Z:YQ/^4JKPU%>X^\?SU;M&_VO8_[4;_^2)PU#6;PTTS6;L,4;-=%GJE>
M:]&V!F[CY+T'KF+)T[AY)Q$O8M*:@7+U!P$1/LVSUR6-F&Q"NF"BQE$S"43D
M/<4=74T%5'5TTSQ.C)O5#)MFB62.1XY8XW7S0WE[=K!@5.W:>VLS8;W7]/W*
MGN%OJYJ62.:)Y?+D=(YHTECD,52B%?.IV,2%X6)5BN?L-1M6K.:LCVZ2Y;;1
M;*%B"OX@P]C!6>K5WQ7B3,L4Z?0U>JL8294=S  U;I24FL_EF+M[(+K-@2*U
M!NU5*8.-QEFMM'3I=H(:NNEN%?6K%-3UU=0.<R5,OE  [AMCC$1"JJG.3D$#
M7;KA66"VT,/5E#0W.^U?4%^O"TM307:^V2ICBJZFNG^&\N%FR:6-EBEC6%8G
MVEE=XV4BM[,ET7P4GS'2C#(\9<4<,U*CUB/E)"HF9,)%I5.:3E_;OZW 5=A.
M/DT(R8='DJQ4UFC\6GJR@\;,3-RIME,'XH4<5W\-[M230"C6ZTDS2!ZE!M:H
MH:LB22HF\A1*@5)90S*0#@OGG6\5%-4WZ#P_C@A_5RMZBZ\Z99'#SW&>FFO"
MU24\DJPQ15576F)UGG@C@,^]DCVR,Y @5=OM0LA23E9:G5>O5IHK:%I1)M/5
M&\%%E63IL2MZB1U"2D=\27ZTG1U;"\21>E[Z23>-(!5!4\!0>#5D1814U*U\
MRVLTDDT5^LD;FX;GVW2-/I*H=5B#*JPD[ $+F7!('K"Q>#]6OQ1OW6MZB9[A
M;IJ63]3[BX%OA9FK+:9;ITC(4EJ_,(AJ(F6:F;:13SDJ!J5_M%IC(L$7&U]M
MMUK$?:)D\;;)BG55W'MXNHN4DR+05:</U7TZR?LG ?UK;GCJ0=*MNVDXKW<
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M,U<(FJ8)I,A%;:ZNNT;O0<Y$R5U-)*D[M*C*5)$8(P58,K+D%2>. 4))(((
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M-)#/+\32TU?'''6PM'MA"E98%A,+#<S^7-N.%&WN:)N*0^F*=IP1D,Z<@_\
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M/W&2&%@J+EX\BVK!NQKRI,<N'%CGUI&K6)*%M1VN<ZTPMM5G6S4.?L_K[?\
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M)+#?QG)*CVR.=>:V)_M9%?[FLO?W_P!#$]^/:2#"(,8PJC'RP!QK39.#&/\
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MC<H41X R$(&PX"6KJ9BIE0>@%5*32XQSG .XJ"<\=AV.>XQG44V RRHNFYA
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MZQ*NF E =CM4P%$-GT " VM2]$*.IITLU[=7IJE3)#9+BT< ,#@L&S4(-H/
M64A_<C;@U88Y2\;K+ &61&"M-&"6#@@88HQ)(QG'S(SV,36\%C*L'^(2<^>7
M1,06WII :25 #J"4Y5?F1BC=U/MZ#^N!$"G/M,XCLOE&"V]+4$YJ:^KNL\&&
M0Q"VV]7$C'(8^36P3 J0P(>3(YWJ3KL$ERZQO$:4M/1RT) 219Z0WQG947&!
MDU4>UPV3MB"]MI51I6,7>/';8BT9)RC%D8QRD;1:M2*R Q3=*HI@BX<EZCF
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MA^O&UTW0G2C6Z"27IR7#T\1:5Z6W-)ZU7EI!3&9F8GU,26))W<$ZM6K:KS&
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MDI>H:*BAA)R_H@2N7RC(Q,C$ ;F<N>^=1-;)(VYTH96)Y>2G,C'@+ZF*$D
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M94SQG. ?XZ7T)>:<9TR9EQ#2UUPVGUJ,JQM4Q$3F$QB J0>H2E$X?,'D/?W
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M&57;4!<8",_"M4$\84'X>)CCDX0L?F=O)S]F/]==2D ]+L!L3C]JJJZ@C[^
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M=IE.[=2)2EFQC.VXQQ2C(X4*-O![$:6C/!UY1*@/WMHSENF4-'323.LJF)3
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M(^W&(^ ?G]8<=SG)]^-=97DZR$57+-VB00$ ,L[:'+L=B =I==N4_@!UH_@
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M(#O[OU 1 = /F";AYUL-^!\!O6O?Z\=BH<FFB)#*6BC)20!9%)7G>%+("?\
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MW\1IY/[>T\H#4RDA\'<=P!*K@$C.O1^H^*DD<Q(MH)P#Y2]E4 $?IU&58GT
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M$(F&TQ/3^;N(P6^$OOD-_NG [Y4<ZPIJ?C'/QU#YX',9M[BFP3@$OY]'4 \
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MWCCXB3RN)K58H BDAZBUU\&< $%3/- 964=HX&,C'TIZL:QDOAEX65>8J'Q
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MV.@(0_RB!NZ41T$)/$NZ!5S=+!(K;L;:ZT2,_."JKG#,>0%#X)X+ G5"2BL
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MQ%R)Z,!0!43NP*43"(= %*H(Z'Z^UQ%^DKTP>7M%_1"0J/'%"5!8A4# UTP
M);;S XQ\OK"E3]#UT^XM7VBF9?:IJO+9B0>% 61NW^?:?NTX49>(=_&-I'U'
MI/6-D7(LGB1$GJ +I%4*BZ2(L<4W!"&*51,="4P"&]:,/3Z#Q+Z>N%GI+G]*
MT].E=205C4DZQQU,*5$8DCCJ!$TBB4(R[TW9!.,<#.N5-KJZ>IEIC'YI@D>+
MS(2)8W*GED<$ J?8^G(P<#.N[[Y0R?RB\1'Q[ 0IM:_450=?S!^KB@?$_I:
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MP,<W=-#6C<1&1@ <GOWSC*D^Q'V\Y[:732=BT(AJF1T4A$V:)"B*9Q'0)E
M_2, B/MKJ-[^X^_'7+3U=TY2=.6Y(;G M-!;:5(V=&.V)8D5-T9,JYQ@$&23
M!Y#L0"<;)2U+5$A,3$F1B<8[Y/MGY^WMV.D^_FF#@Y#]]$Y2(F*/YQVW$H]6
M_P!!%)0HAH/<1V.A#0AKC3;UUAT_6/$Z5U%.$I74GXJOI%5F;*_L:6FEB8
MG/<@XQ[:N8::H4<HZ9(_PHQSCN"S*>_L/YZ:+-4NV<4>&0372,)\L<O_ &R
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MC(V@C!UN/3UUJK9%11K;[-7I#5I():BW&IG.V9)-NYPR,F%V^6ZR1L#^TB?
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M\1A3("P.01(Q!.=QP"5"\G:^U4*1&O$6*8O5U$@6SD \B&A-\/7 IM@/47J
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M_,-T:BX<"JF4&(GJ5)G'YA,F8[@"N4",_P T!A<%7*BDIK5/X8V17YZRE].
MK;*60D9&3B6X/* ,9)>0C .T#*@9JL_1PIZ.GB-/9.H+JZ,BF%Z.6HV=QN,=
M5 J!R ,LLK,Q;(Y) Y(?:@W26MT0W5P_C2SI.Y2):*V68J5_F9("+.4$3"$M
M/52$>&!D)Q32[S)%)J0@"14Y"=9H2^&5F1VD2_\ GHLBL\X>U L.,AH6KI)"
M%XVCD8X(4$$3)X 1K:9YFNO6_3DJTM:[6."&Z4D"%8)63"TEO>$+42[2[K(^
M$!R03@>HZP/J7',$U&\W&O50622%NT6@VS@I>@XB8YY*;:MQ HDT<"J H)A
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MH9*RBDIKIMP"#-;OC"(Y1_BB2ID"\_M6.0O6QR+<; *GQ5B[I8MN@4@2E23
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MX+\?;COD?9I/#;J V<G9!-N4NPJ9 2$K,SV$Q3$2=)7":!FYB )>DJA %(P
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M3/ 1Y;^;N89SZ%P, XD:>XX@B3$:NVKF+5-I46KEE,HJ=)P$ 5$H*: IQ((
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M9!2)F)!<[D%_3@4ATB)=H53"IU@4HY*5MP QSG.?PY_F-48^_P N/ZCY:O\
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M(LB)2"4HI+%*JD("FH4#E$ ]8V81?1E%Y"+%3?"4ZP0HAC2.)8P$58&YB 4
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M._$%TP?3\QT6^H1S>>3RPA*F2C'Y))KZ.1QECKTIO5)D3**A@0.)TP+^;#I
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MLA>GG@DSY4L4@]<<F"&V,H(.UE8'#!E(SJJQ[8N9FO2BN/H"TR";BG1LBQ]
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MCBDD>XT\YF6G9S&-F\^9Z1WFLKXJ[PGZ4>5U)H;_ &NWU7EO!YZBE_6IH(Y
MI,@7X22D\L2A0RF4#@DEU+E5K?+A'B1W9H_T_J.HM6=10G5[@(;&0^,HJ?H
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M4R]:S=(RZJA$3GV9),7"IB$$H=TP_,.8CK%@I(Y%AHW,<0!$8!9F'?:O&1[
MY_ 8&L/+$):J18_B$C:4[$ED#NJ%B5$CJBJ9 ,;FV#)SA<:RXZ45>D5.D@B<
M$U"$,*B:B'2)@$P:$S[1O ".QZ/IHH=0<92SWNMFCF,=NHY%22(9JQ) H#KO
M4AA7[!M0';N$62H4*.VI*NC%.RH[L-RE@4*M\N2=G)/W?O/&LAVXGQ36%L:+
M*&A%(JS@2A[^ 5Z'!U-!Y]A$0UL 'SQ?5%TZN/FLM38UIU.88WFB9U0XPI+U
M<CX ![2 ?(#DFG#%;M\?G1U1#<2F+:"PX&5!7:2#SV&>P[9UU1KJ>-W0D5(4
MHZ+VP:.5C%$/('Z_4.B#O]'6A'?G?TXIT%WOS!UJ:BR+@+LV2J"22<Y+749]
ML #C[,ZK5<5O!04BUN,$-YP3GY8"+CY]_;[L:VIYB:23.!&+%5-,NBJIJH$5
M4 -:Z3K'*D!E T "=R #U:%3SQEAU3U:B^1#;K1)"BF..H5J:-I8P"H<3RS&
M+UKW+3D,#M#L6!-I\+1-@M/*C'E@X8HISDY" L<'@83@^V!K5J34Z<0'T::&
MMATJJ1JYC;^H&1F4RE#W#6CB(@(Z#QQ8R=0=3N6\Z"V1.OU%,]!.2#D99H[@
M@Q[!2#CYG.-7*TE H(%09 ?\2&I0 $=B&I"6([D\ YXSSINLIR,LK7:ZDN$<
M#8^7, ]P$SD%<H?EVQP</E(LL4IM@&P Y@WL"F/X'C>_"WJ#J&?KKIFDGAM0
MI9;AME-*U,)PFQQEA%-+SC)P3\P,GD8ZZ4U&M%4-&U29?+PI=B8RV[C:61#C
MY\ ]B0,:JMP-<:U2N4-W(V>1RI&M'6<8MFT6Q-;V]-FC.S8M27(G)OW+-Z1U
M%=M$YCLRID/ZH&JP* "8E'W@H.54'V.23D\8]P3DGY@D'OSQK0VR7F)[O(Q
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MY^V/;OJ0U2ORR,".!ZB?_P#(?UUV&'F0,&BT#"@#[[_*[<CAKV$-#@K7G?T
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M+'T]]"KJJ3J+9 '!G[JT2I"IM2(&,*(,Q,J8Y-*$ H[J-(6&"!P<^_\ 4G4
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M_P 0\--?>(#M^+?S.FNH_N'[/\8\1TT']P_9_C'AJ [M]_\ 0:Y_P/\ P?\
M%Q)[K][_ ,SH>WXK_,:ZS_I#_)_@#B8=OQ;^9U'7=Q'31PTT<--<2^X_^_\
M"-PTURX:@>WXK_,:Z#_I$_V8?_WFX:#NWW_T&N_AJ.CAIKJ/[A^S_&/#4#W7
M[_Z'7;PU'7P/<W[?\0<0;L?N/\M-<2>X_L+_ (.(#N/_ %__ $0TU]_@?^#_
M (N)!]?\6_KIK@'Z?\IO\?%737;Q(?KK]W^NFCB?31Q2'U_Q;^NFCBKIHX::
M.&FCAIKX/N7]O^(>*;?X_P#TZ:"^P?L#_!Q.O8?</Y::^%^G^Q+_ (^(Z:Y<
=--'#31PTT<--'#31PTT<--'#31PTT<--'#37_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g383050g91s91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g91s91.jpg
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M=I.8XA<C)#1U>;2XU3(S072SM1DF)S8U0E%R<[)#4U3_Q  > 0$   <! 0$
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MQP<$TX<-B3G$XN8XZUCHC@#@9Z[#';DD,>.7<V$(GAA9XWM".<GY%'!,5$H
MD%THM'-<1Q%3(P^2N[1UQN<WN=@Y5PP2RQ24>E3:PO-/#M8M$4[/D;Y.5,\+
M3YL+#,<\CRNSS37)GVC%^%[F.CQQBV[[OPA&QL_5Q/YEVV9G4F/*R1A$#1L[
M1158F\V3;M5NR71?9FZN(Y'%V_U=N)NMU_>M>2RFOW!5^Y@S"0$6.T6N[M8.
M<S3H6CK[:@YN40&EG+5%BY3E4<34>!RKV-KY"%GIF&Q92QIL'PD0.1+F&:VP
M"-DX@.D6-NLT;&]JB;@YQB3F/(F=AD 9F:1ACL3MRWDY4D2KE'K.;O ,A#::
M]5)Y"'L:V+&PF[,+M+'YH#*-^!RD@A?F,#21RHOR+%Q&#Y1(3KG#-\'%;$90
M0^_ECMSG&GN[=31S4VY7Q0>F';XR) RP!.I# &"+L#;7YXR[5=N9BW101LGQ
M!V+//DN.PR'4*S$, MSAQMZ:]CQ GD?DO&<HQ6B<9.RHHQ86@=W=(<D,,')"
MMYH M#7D*9W>(K]..G=(Q8&YK&(/)7%GC['D-W)YF9F5O;!W>RD;#5L>AT3(
MQJ+ZH+2"1@FDLF3K81Y<Y*B($B8;*2#,-&$VD1;*1H9C'HJP$-\!2K@\3=DR
MYN0E"B\VIC2A*[+8G":>]'%#*5>L-2)HX E"-VBYD[E._.-Y9CD+C9H@$(XX
M@!I=F^THU(X82BBJ'++&TTY69'DF*,C9Y'")FA9X@Y<0@W"[R$1F<A$\O_AF
MJC=A-)E&==6'BF2A=RA&S4P6.9W>2#=4<WF756*M(Z!141O* %F U&P?!5F)
M49>,N2! ;9\ZH&T\Q52KS6^*0N6SS1UVB;AAQTV,C9HRFE?=H9>,WYFQ&Q;,
M GPC6OG':RT\5;A 7D=HCF<WWEO1WS\V,4;;<V-Q%N#<0<=W(AXGM>'\L3L;
MU\2A;P,0<E;S#9<R S0*<"A9(Q=[>"1F/SQD5-$H5)90X;O1T699,'42D\%)
MV=/2=I ^D@Y1@-'3K&"BFMA9&41#L>G7EKR1220F-"2:6J01A8AA9Q.<N,9X
M;(<(ARAA)B,Y4.8DBKE X$Y<^U/'/')&$PE<"..<2D*"65V<8FX2@EKGN1\P
MI!<1&I2SEUF;*).@6N1T>8X?RL+/4;EF.3Z0%-O:0'Z7D<@D>49BT.C+DZH@
MT=25X["Q$ V,/R#G$DR5?NBADGX@P/+!QDN'*3]@L+\L]H0H9(LA#%"\T]B9
MHF=QA$9)Y7C$!<"81",(RYCC-B"L,8L]MR;C'>0K=$:4DDO*AAB>39BE(@AC
M8R)^(>)SD.N7YMEAL@DDMB^O1HV0SN92?:,X5.2!S*!+S9<F9J-U7\8$.!3#
M&,PMFN[).[0]TZD! EXVW9FY:28A +<9*^ML#BA@GMF<56O#2K-%",$@TX7W
M8)I&,WFL$+ /9#-$ .+E' !22N<WR],9)98:PA)8GEM3\R1Y0>U*.W%$#@/*
M@%W)VA=Y"+B83F(0C8/05Y8Q?$:4!L]2DLHX7 [#0(1B0;$9RL"1E6P2MS:A
M@FD;UZN3<"(N5Q;$8E@T+,-CA7[7!ZVVOBY</E'?ML%,YA*5\.=')4<)HJA0
M2A#5CY31@\=M@8YPW"?B ZD@$X/1V8>'QY;Q,)@-,GC..PQQ261FC*:P?,>0
MF.MQ.$1[%#L8V8R;B&WNY;X45D:L:41*(E$2B)1$HB41*(E$2B+V&G];:_\
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MO5,# ^QH3,YL@#XVU.5FM/%9Y146F9HG",;?#+"3E.VT9%/@Q52)YWY<]@"
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M$\9;#RQ9I=DUW4GG/)I34.M=42;:42Y".(+'(G%- Z@D*\=X_,)%LGOS.O\
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MQ[%(O#<L7$=)6C"VPI)WT/8W?(92Q5N-7C:!F8*91PRA(5C(%:LR0314G&0
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M[=N@CWG=I88XW:&K6KG8DKUX(#M3=D6CABCB.S.X!&\TY (O-*\<8!S)'(^
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MZ^YU=7X/P]7]2SXHH)1$HB41*(M?4._]>>?>PYWG_3-?\+((GI&'9_[U@[Y
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M0'B=G:-Q;;PNW@6!8#H]N8?+TLE+D:TT=4Y#*..*5C-CADB9A<GX6V<V=]_
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MB)1$HB@T;OV+/<@A%^#E$;@LJR?VB.T)%A&64$DB3(03D*;Y!PA)WDC!B2@
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MN8.SB$PR2PLTG7N+'-$\49;.QF0,.[&SJLL:.U!4ELU[E&2G9KX.OJ$*M@9
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MC$"DX&;J9R[C.1 +F[<(N8\7=;>=#$QD#R$45=YHHIK#1G($+2.[\3B/61,
M22#&SL<C1FP]QW:/M8L]FX"B!;:I82K(#Y&Y)K%(ZW0N @(NZ"2+2,LC639
MI*'J5D\G1D^1[I)X4<.,!(\<+1;(YVG!QYQJ\UC/6*Y6[<W.#'TP#L3$P< C
M'1CM. 3WY1V>2S;FX1DG,QKPPUQ 7R35DVDRN5J>CZ=T,;CJS59<QE)9/++4
M5QI#.;+3T&EDJ8B W)H:&-J\9P5(XRNV;5PY3&2ZO2Q5*(E$2B)1$HB410'!
M>2VJ-D*!4HB6(D<CVRIKJICW@=ZSM\IH1'2TR<N<[N\$>W')'"1K6:PF1MK.
M!<LB4CBT@$+KCCK1>Y1V?_/_ "_OZE26O)^''3I&.0:([(V,5CI62CILC#X\
M-41@R$8V--]6.R1]T?/ &SW%_*M=2[R0 BBLDFC\,,P.8Q=,:^8+N2?G;]?[
ME6)#R;T8#0/),-E0V:28 _&!7$!@DLB\GGCB1')>$U\#CJ4;:&L7#(D3G4D
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M68Y)'YEBK%$W" N^Q&SOML.[[,M?:-TGJ#$YZM=R%#L>M'%9$Y>RJ4NQ20&
M-P0V9)'W)V;=@=FWW=V;K79%7/ZW.E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41:T(IRYV4ZU=M>9&
MGVN5S+'2.H]R17' ._'B]8%=OEMM"C&O=BMKRMPZD>6A66ML)%L-^W>P\P09
M(2GQD7%$&K15J4=NMN[UO_X_!OOX>KV?2S"T!.)'/(*2>RI\',F8WL;:FOE9
M+'Q^8H+*$-=[$DD-:FV@[,B5LS>*(!L&,B;H/UF24I8G,!^#9ABV:H%!^K]7
MZVW6*W&6!\@8OM;D>F:%6U]JLMRQVEM!B_4:,B\EVP)DL?B(X*T&HN$UFL8A
MS=08L_?&,;J2 P]20&CL1+9N_=.8:EL96_F--A1LUZV#QNG: Y"2(!LWLCD&
MDOB6,X9(WCH5:HE#8L6!<[-DSBA@>",9I#N.EH]+XO3&J3R5*]DM6YC4>0#$
MPRG+2Q&!Q3!CY&SCR5YFFR^2O$,].G1D:*A2ACGM7!MS25H8]A7CGZ*\_8?Q
M5YXV^]/^PZM^S>FWZ_W)XY^BO/V'\5.-OO3_ +#ILWIM^O\ <GCGZ*\_8?Q4
MXV^]/^PZ;-Z;?K_<GCGZ*\_8?Q4XV^]/^PZ;-Z;?K_<GCGZ*\_8?Q4XV^]/^
MPZ;-Z;?K_<GCGZ*\_8?Q4XV^]/\ L.FS>FWZ_P!R>.?HKS]A_%3C;[T_[#IL
MWIM^O]R>.?HKS]A_%3C;[T_[#ILWIM^O]R>.?HKS]A_%3C;[T_[#ILWIM^O]
MR>.?HKS]A_%3C;[T_P"PZ;-Z;?K_ ')XY^BO/V'\5.-OO3_L.FS>FWZ_W)XY
M^BO/V'\5.-OO3_L.FS>FWZ_W)XY^BO/V'\5.-OO3_L.FS>FWZ_W)XY^BO/V'
M\5.-OO3_ +#ILWIM^O\ <GCGZ*\_8?Q4XV^]/^PZ;-Z;?K_<GCGZ*\_8?Q4X
MV^]/^PZ;-Z;?K_<GCGZ*\_8?Q4XV^]/^PZ;-Z;?K_<GCGZ*\_8?Q4XV^]/\
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MNH]8-.B=7I>E_P!_ZW])V5,RTWS/Q7.92'9'RV!OI(N0# 06V)!JLJ* W&[
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M![/9KM.4O)(B6UP_'JB)CL28-9,;C YD/CR=HD CPP<PB;R5 9(4=_8;]?\
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/$2B)1$HB41*(E$2B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g383050g93i64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g383050g93i64.jpg
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M 0$! 0'_P  1" '+ EX# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M  @)!@<$!0H# @'_Q !J$  !! ,  0$%  H)#0D*"@L% P0&!P ! @@2"1$3
M%!46%R$B.%1W>+;2"B,Q-SE7E):W&!DD-%9T=I6SM+74U24R,S9UDY>XUB=!
M0E%887)SLM,F.D1%4E-QD9*8L2@U0T95@<+1U\;_Q  > 0$  04! 0$!
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M4)>JQD/9RUX61Y M(C'X"',6;W%9;$VEJI-(PUY@KZ0#BD8QR'/ ._,GKZL
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M3;[CKS>DAZIWM@DITX[[73;<K]\I]*;2XS5U[OU9;*BGI_I9IIS-:K-<'/\
M"DL0#[I::.Y/C:SO*0AL+JHQ-<7DO:P/(!<6C5N'_H/+9?J.LK!QW74C::_\
M3V9D1L-/4.='P_Q'=+''.Z7PI "^I9;VU#V",-C?*Z-I<&AQP[^O$2+^(<+_
M #_??]E,QO[X^L_JG3?IB7_EZSG[R*V__$2N_P#+=/\ \Y7<QSVN4@/2$"#[
MHX,VY,F18KISS/'JO3?DB^09[7Y2W%N-*;2TMM32>^^-=[Y].^N??[]7-%]$
M/5U=924AX6IF"JJJ>G+Q=I7%@FE9&7AO> U%NK.,C.,9'-6-T^@NMUNMEQN
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M_P!XMR;8+%@?66T\A_[.H^S^Y7\^RZ5_W3R'_'1+_6<CPE<?Z?6_G4_[13X
ML7WEM/Z.H_V*W!4DHDJS>V-K2(ZKM&GY0LEM0L_[^$MP4CNN%4_4XWZ%>===
M:Y4Y]W7.NNM:WK6]^_8^';A7N9Q!JK:MVGARX.;JJ9CI<)J/#AE^SADX(W&3
M@K2>,[)962<':+1:V:^-K.Q^F@I&ZV&EN1+'8B&II(!+3D$@9&P6G_LNE?\
M=/(?\=$O]9S7/"5Q_I];^=3_ +1;MX L7WEM/Z.H_P!BGV72O^Z>0_XZ)?ZS
MCPE<?Z?6_G4_[1/ %B^\MI_1U'^Q6WATHDNZ%F#C<B.[<<6]6Z/"^RY#:W"*
ML,M3M5+E7;CU\IJ=HH]J)ZZUSWTDGUUK>^.=ZV.&X5_THW%_?M7K'$=E:']\
MS:@UULOY<T.UY#7%K20#@EK21D!:5562RCNBV.,6BUB-W!7%+W1B@I-#GLOO
M!S6/<WHM)<QLCVM<1EH>\ @..=0_9=*_[IY#_CHE_K.:YX2N/]/K?SJ?]HMU
M\ 6+[RVG]'4?[%/LNE?]T\A_QT2_UG'A*X_T^M_.I_VB> +%]Y;3^CJ/]BJ[
M_:@V#/1,C\6.!4WEXSAWXT/G3OD?)3++ETZUY*^1+73EQRV>IZ6<::M6S;2R
MFNE-(-T$?5\-)/GG]:/H.X8:WN-4D]9%'5SGB"^-,U2QL\I:VH8&M,DH>\M:
M-FC.!U+\(?H^2;=]$5>J:WDT-,WASA9S:>C)IH&N?;&%[A%!HC#G'=Q#<N.Y
M)*J]^VO:7\94_P#YY2+_ &CGU/X.M_\ 0:/\V@_X%\7=_P!=_3:O\YF_XT^V
MO:7\94__ )Y2+_:./!UO_H-'^;0?\"=_UW]-J_SF;_C7J(L"52A.1(\IR0^G
MSN*P'O?/!@CSSZU()&U%.O=RXUKU**===]]?N]=]===;WUO>]_AMW7JVL@[I
M_'44-750Q1\27)L<451+'&QHG.&L8QX:UHZ@T #J"_I*^AXL]IJ>X?W+ZBIM
M=NJ)Y>#[4^6:>AII997NB.I\DDD3GO<>MSG$GK*PG[+I7_=/(?\ '1+_ %G.
M<^$KC_3ZW\ZG_:+LO@"Q?>6T_HZC_8K;E RB2N+TIINXD1U=!>TH$BN@L7(*
MHK)*2D7PHDJGVXZX434XZWQWQWSOGOG>^>M;UO>LV+A"X5[^*^&6/K:M['WZ
MT->QU3,YKFNKX YKFEY#FN!((((()!&%IG='LEEB[GO'4L5HM<<D?!_$DD<D
M=!2,?&]EGK',>Q[8@YKVN <US2"T@$$$+4?V72O^Z>0_XZ)?ZSFN^$KC_3ZW
M\ZG_ &BW/P!8OO+:?T=1_L4^RZ5_W3R'_'1+_6<>$KC_ $^M_.I_VB> +%]Y
M;3^CJ/\ 8K;M8RB2JQR\.E9$=4Z0J+E9#I0N0[Z16^VI5R/Q4M].-[34^$LJ
ME\3C?/7PU5./?Z>^M;V&Q7"O=1\4%U=6.+.'=32:F8EKO#MC;J:2_9VESFY&
M#AQ'(E:7Q99+*RZ< !MHM;1)QH62!MOI&A[/I0XN?H>!" YNMC'Z79&IC78R
MT$:B^RZ5_P!T\A_QT2_UG->\)7'^GUOYU/\ M%NG@"Q?>6T_HZC_ &*?9=*_
M[IY#_CHE_K./"5Q_I];^=3_M$\ 6+[RVG]'4?[%1<\_IU-AOBA"G@Z8RI@[4
M\AOEE'3*0EVKCMO]K<JK\OVN@\35Z1^+K2GPNNMI_$UKOT^K6MY^A'T#!->.
M/>_CW[T9M71]]_PG1GILZ.FUZ<X&=.,]:_)__:6P06NL[E_@R&*W=+37WI>\
M(V4G2Z9:73TG>[8]>G)TZLXR<*E#[:]I?QE3_P#GE(O]HY^@_@ZW_P!!H_S:
M#_@7Y8=_UW]-J_SF;_C3[:]I?QE3_P#GE(O]HX\'6_\ H-'^;0?\"=_UW]-J
M_P YF_XUZ':-F4O<>(OAV]<2J2+O'M06$L]=K'":KEVLEY7>2#--9TOVZZ5<
M*IM&K9KPHKWWWPV;H(<[TDBGSS^2_P!&+/-1=V>J@HII:2$<.6%XAI9'T\6M
MT=1J=T<18S4[ U.QD]97[F_[/B@H+E]#\VIN-%25]1].W$L?3UM-#53:&16O
M2SI9V2/T-R=+=6!DX R5FOV72O\ NGD/^.B7^LY\L>$KC_3ZW\ZG_:+[B\ 6
M+[RVG]'4?[%/LNE?]T\A_P =$O\ 6<>$KC_3ZW\ZG_:)X L7WEM/Z.H_V*V_
M?\HDK>Z[/0;R(Z@@E,S?"2*)<@DDGQR[[USPFGPXYXXYYU]S7/.M:UK]S6;'
MQA<*]G%%_8RMJV,;=*MK6MJ9FM:T2N #6AX  &P & M)[FUDLLO /",DEHM<
MDC[#;W/>^@I'O>XPM)<YSHBYSB=R223UK4'V72O^Z>0_XZ)?ZSFN>$KC_3ZW
M\ZG_ &BW;P!8OO+:?T=1_L5M^@Y1)7%QU\@XD1U=%20(\J(K%GZJ2G/P%]^G
MM/MQUQWS[]:^YUK>LV+A*X5[^)+.U];5O:ZK:'-=4S.:1H?L07D$>0A:5W1[
M)9HN!N)I(K1;(Y&6R5S'QT%(Q[7!\>"US8@YI':""M0?9=*_[IY#_CHE_K.:
M[X2N/]/K?SJ?]HMU\ 6+[RVG]'4?[%/LNE?]T\A_QT2_UG'A*X_T^M_.I_VB
M> +%]Y;3^CJ/]BN[ R:1N7BB;F0&W'&FW?>N%RK]7C7>E4>==:Y4<=:UUK77
M6M=:U[]:ZWKW^[>\[;W!:NKJ.,+DR>JJ)F#ANL<&3322-#A=+. X->YP#@'$
M XS@D9P2OESZ+>UVRC[G%DEI+=04LCN-[;&Z2GI*>!Y8;%Q(XL+XHVN+"YK7
M%I."6M)&0,>S3/L9?F0F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3"+%YK#(Y8<3/PB7,.BD9DXY84:'<NWK#I
MXP<>[XJ.G@YPT?-M]>G7[:U<HJ\^[[WO7W<L+G;:*\6^KM=QA-10UT+Z>JA$
MDL1DB?\ QF])"^.5F<?QHWM<.HA9>PWVZ<,WFW7^RU(I+K::J.LH*DPP5 @J
M(LZ)#!5134\N,GQ)HGL/6TJ(7];>\.?XJ'/_ $@63_VNSG?[BW<W_J^_]+WO
M_F*[5^^C[N']<8O_ "WPM_R5/ZV]X<_Q4.?^D"R?^UV/W%NYO_5]_P"E[W_S
M%/WT?=P_KC%_Y;X6_P"2JC+]D'^-M-^/G@]7NZEBBL8W+?*RN]'_ (D@DAWY
M[0&HK]V+]WV0ERORORWUDC[_ )3X'Q_F-?,?%^"C\/Z%^ATX*X;X/XEOIX>M
M[J'PA8QWWFLKJOI>]*^EZ#'?E34='H[YF_D]&K7X^K2W'SM]$7W4N..Z58>'
MOISO+;MX%N\_@W3;;5;^]_"-$_OS/@RBH^FZ7O&EQTW2='T9Z/1K?J\;.?7R
M^1TPB]!_B[^!MXX_^JMO^EF3Y^37T;_VU[;^*U!\)JE^UG^SF^T[Q'^.U9^K
M;>MLY\:+]!$PBW'?7[Y+G_ ZK/Z+(9FR\7?9R3UNL/ZAMBT;N<^I6'U[XO\
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MD1A?+32.B>Z)SV/,9<W!+"^-CB.66M/4K.MM]%<HFPU]+#5Q,D$K8YV"1C9
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MA3)=,]KV2GZYXZ2F#3'3X CT/=T[)GZ7MJ-!,23X5N(R^%^!WA@")KFNC&:
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MDG#9R@IPLBLGPHGWSWSK>GTE\(4F:JEX7L%/4TP,]/40VBABF@FB!?%-%(R
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M:.\<_P"[BZ_YP07_ /UUG"/WO/!GWTXG_/+5_P F7UO^_0[J'W@X"_1G$/\
M^T)_6CO'/^[BZ_YP07__ %UC][SP9]].)_SRU?\ )D_?H=U#[P<!?HSB'_\
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M?IMZU]>C?^&:.P36R[/JJF<U(M,[JQAHHY644;:EH;44DCB2^<,Z/&-!!>\
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MA>3^0\_Q%6$90JTPB815_>TIE'EK%/'-L^\,A4Z)VL[LF&,3"E9PRLY_.QL
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M,(F$3")A$PB81,(F$3")A$PBBCYATQ,+SK,'$H3V'X*CIT,D3C9IZLP:['M
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MY<>UE=\E[1(4=?59'H/3LEDTOM\%6I:*!'<KCD?9H.+-4\DTQS,V9=<.DV"
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M]Z67*[;E+MXQEL,E('KL'-I@4>P8F@&;R.*LN?I;,XHP)2!$R0.(.>O 'L#
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M4< C.Y(.LB%S=1U7\DM*-1B!S&)2:7SV!1!L\>221UY'VAWEU-6 ML.(;47
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M$CO<8#2V;\\**(G^![ F=L>7/N\NSGOVJ;.%"KID_A%.N [8C5UT@(;: CR
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M4-,5NF7C,/C/V&516:\NG'<3C:W<14FA]+4C<\';'F$YE:;05P?Y%LR@G/\
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MJIW])!411SPR .:'Q2M#XWZ7AKVZFN!PYH<,X(!V68Y;KV4<O(3RU\>O%;B
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M^E\RSKW"?VM^-_[P>\4ZYIQ)ZNN$_P"P??IEZ3<Y"NEIA%YLO9U_PXOM4?\
MD3?Z6PC.N\5_:VX)_O7>\U*YIPWZNN+/[ ]^A7I-SD2Z6OPI_P &I_Z'7_L[
MPH=R/F/N+S<?L8K\#:]_SHCW]%E69U[NR_9^U^LL7PVM7-.Y;]A:_P!='_!*
M1>DK.0KIB\W'[)X_ GI/\Z6.?T36]G7>XUZH[CZR3?#[>N:]U'[!47KM#\#K
M5Z0&O]K-_P#U"/\ D^<Y&[F?.?=726\AYA[B^^0I5,'M4OW[?9Y?EM*_I;3&
M<4[K'V<[G/K[+\+LJP=W_G%L_"#_ (X%<_G:UG$PB\WGF_\ P_WLSOR1$_\
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M6-=/Q$H&C9Y'C<B8E7H->XIMU&R9'S SU_$1U'VM[;Z9$3:/5!50"ROH7VQ
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MM,P\VN P'="(4=W!5#.Y(.T?U(>H4]!Z0U&M]?4MM_GUD^/FM<_"^'O:OO\
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M Y\Y(!'&G39RVVB3;M5-.&ZZ.^?B)*<\W$M)5P11334U1##.-4$TL,D<4S2
MX.BD>T,D&DAV6%PP0>1"\(ZFFFDEBBJ()983IFBCEC?)$[)&)6-<71G((P\
MY!',%9GENO=<5\^9#&3PD2>-1XX>U</G[]\X2:,F+)HEVNZ>/'2_::#9JV03
M46<.%E.$D4N.U%.^>.>NM5-:Y[FL8USWO<&L8T%SG.<<-:UH!+G.)   )).
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M#9JV0346<.%E.$D4N.U%.^>.>NM5-:Y[FL8USWO<&L8T%SG.<<-:UH!+G.)
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M;,>KQ59>SS_?@\X/RML/THM?/63E'_8'N!><?7['QJTW/)>B81-_N;^Y[_\
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M(VC 9\8!O&47ERNY-$77PP)99/EL0[^79NEO2AWUOX;=7K]SC>=.XDNENJ>
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M' R""KD8-ML53P #'IK'.U&J5APSZ0/(=H3JN(XP,Q@^WGV,Y'Q!3J!Y]3<
M_P#^N,'R9]'F7-JSQI\IT?"FYO&V71VY^I2L#8#8,)L:5>*"]3)*<6F2D;EK
M4I*I-M;+;#E@JS9T04O1^^(>ENP;BUT7OU--Q*@D9'+EC;/W.,G/Q>A7<X5*
MT%Y/^25;^(U(3/R"MSH]Q7\$[CG!WJ,BN31K74IE02'"ODQO;IERXULQ(!^G
M&]N4_@M?C+Z]>TM)]92S6BLOMRI[70"(U53TO1=,_HX_J,,D[]3]+L?4XG8V
M.78&V<K'W6YTUGH9[C6=)WO3]%TG1,UO^JS1P,TM);GQY&YW&!D]2SVIK+C5
MSU;7%OPS;_<0M."Q.Q(MLJTTP)[CLS!,9$&V19<JKZ9OMCB+?YIKI=;2"_K2
MTJIKGU[M:ZCFMU;5T%1I[XHJF>DGT.U,Z6GE=%)H=@:FZV'2[ R,' 7O1U45
M=24U9!JZ&K@BJ(M8TOZ.9C9&:FY.EVEPR,G!VR5L#+57*CG>_E'5WCH:JL#8
MO4AY?W#)E(G#] Q'!1'99)V$9]_5%.GC7Y%M\:0#_<MSROO?&U^O1^U>[K,6
MNR5UWCKI:,0Z+? *BHZ630>C+97>(-+M3L1/VVZM]U<04LM0V5T>G$+=;]1Q
MMAQVV.3AI4C,PZMTPBCGWY1U=QY()>*_74A^VFM&=RWCG0CC<=^DZ&J%=[V8
M^<]>G/RJ7?[3\GO7Q/=QZ_N^K,QX$KC9S?,0]XB?O<GI/JW2:Q'_ ">G^+J(
MWU<M\*X[UE[V[Z\7H@[1S\;.<<L<L^52,S#JW3"*']$><%(>1=W^0GC]77<N
MZL#QE/J1NS.3D?3%A>221XU'>M "7)!UT60^H@7_ +E>FS3>T-(J^C6U/1SG
MKGPY<K3;;5=:L0=ZWF+IJ/HY=<A9T<<OU5FAO1G1*S;+M\CJRL-07VAN-?<;
M=3=-WQ:Y.CJNDC#8]72/C^INU'6-4;M\-VP>M3 S K,K&YG*A4$A\KFYW;G0
M2&QL[*C.V:.G#O0J/"W1<CMJWWVGI=S\HS6^ CM1/2JOIXWWSZO5KVIX'U,\
M%-'CI*B:."/4<-URO;&S4<' U.&3@X&^"O*:5D$,L\F>CABDE?@9.B-I>[ Z
MSI!P.LK0OB-Y<5)YKU"C=M*=27N$KR,W%D]RP+P!+?5(_MKHAKIAP](<Z;_V
M8C\%;YC>U/O_ '\<^G[N3OMBK^':\VVXB$5(ACG(@DZ5FB75H\?2W?Q3D8VV
MW5A9[Q1WRC%=0]+T!EDB^K,Z-^N/&KQ=3MO&&#G=2>S#+*+45[7;"?':KY';
MMB;+:B,74"I%-@V'),GKH\=&QUA\NRZ<->5M?42K32V]K\?#0^(KKU>CT]9"
MUVVIN]=#;Z3H^^)Q(8^E?H9]2B?,_+L.QXC'8VW.!UKV@@?42MBCQK=JQJ.!
MXK2X[X/4"LMKR<@[-@<,L:,[>;CD\BP&7@=D&^FC[8B1C&Q8=\XUTHMINZ^4
M=I?'0TJII)7U<:4[USZMV]72RT554T<^GIJ6>6GET'4WI(7NC?I=@9;J:<'
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MO^#@&?ELM/\ ]J/YOG=:]5TGK=1>Y*M/[FWJ:;^'5?\ Z:OBSF2WY5Q^UF_
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MFJYV@@NMI'GO:2*G?IXZNJ&=M+6T=4\.<RFJJ>=[6XU.;#,R1P;D@:B&D#)
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MJ=6W$OJ)U AO;9F[^6KEB[^$P]R/QR+OC_@TD<W7B?A:GL-IX8N,-5-4/OU
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M_O>$\T/@_BZIXEN7%-#/204S.'[BVBA?"^1SJACI[A#KE#]FN HVG#-LO=U
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M9Z'->4>4N2A9UA$PB81>;+V^O[]7LHOSGR?Z64;G7^Y=]CN./6:/WBYKFG=
M_GW"/KJ[WZ@7I-SD"Z6F$3")A$PB81,(F$3")A%3Q[>W^"O\D?\ E&D_Z>:T
MS?NYAZMK/_9N7ZKK5IO'_J4N?]JA_6%*I=^SG_ !\*/S5:$_HPC.8'BSU4<1
M^OEU^'3K,<-^IZQ^M-O^"Q*9F:^LTF$3")A%YL?(G_XRKX.?FPR+]!/+C.NV
MG[4'$GKW#\(L*YI<_MF6#UJE]XO*])V<B72TPB\V/L3_ ,/CVUWYSR?],_E#
MG7NZ+ZF.YSZRG]7V1<SX'^S_ !OZZ#X;=5Z3LY"NF)A$PB814[^WN_@K_(__
M )2I/^GBM<W_ +F'JVM']BX_JRL6F\?^I2Y_VJ']84JF'[/#\ 7PF_-.\>OZ
M)XGF XL]5'$?KY=?ATZS/#GJ?L?K1;?@<*F+FOK,KS7^WI_"+]D7^<X;_3GQ
MWSK_ ',/L3QYZS1_!KLN9]T#[(<(^NC_ '^WKTH9R!=,3")A$PB81>;+V=?\
M.+[5'_D3?Z6PC.N\5_:VX)_O7>\U*YIPWZNN+/[ ]^A7I-SD2Z6OPI_P:G_H
M=?\ L[PH=R/F/N+S<?L8K\#:]_SHCW]%E69U[NR_9^U^LL7PVM7-.Y;]A:_U
MT?\ !*1>DK.0KIB\W'[)X_ GI/\ .ECG]$UO9UWN->J.X^LDWP^WKFO=1^P5
M%Z[0_ ZU>D!K_:S?_P!0C_D^<Y&[F?.?=726\AYA[B^^0I3")A$PB81,(F$3
M")A$PB81,(F$3")A%ICR/_!XOG\C%H_H.=S"<3>ISB#UDNOP"H7A5?S:H_N)
MO>W*&7LB_P ":$_X76%^E#W-*[CWJ'H?PRX_"GJQLO\ ,(_[<O\ C*LTSJ"R
MJH7_ &1S_!QNORY5=_D9/G3NY)ZKF^MM;[L*T'ND^IIWX=2?^HK@O''\'JA_
MR,U?^A /-!NWV5N?KA6_"95N5N^Q]#^!TOO#%N;,>KQ4Q^RS_?V]HK^7 9^F
M-UYQ7N5?9_ND^OT?PV^+!VC^<7/\('^.=7.9VI9Q04<>SN\>R0";Q"0*V+)X
M;*:SL2GHO%#DX>+"*:KJTY''YC,0%/J,VK(K&55I9#X4? G"A*0R*&N85%&,
M.+ @H5J+T4Y/MY]E<>7^SA\:98<GI1(3((F+LRJ2E0S.(Q%V!&QTE'B%*N?'
MEL19*/8V3DD?,AJA4'Q(7Q')$)C_ &A'HZ^*@"A$2@[V3)[3SSV[YSR.W-;'
ML'P]JZ?W6T\@-DY=$K+1C .*O2\4<1C295I$G,E?PHBX3DT4DJXLW$2,M-/!
MY.,N@*ICE1D+F',F!"Q@IH3)QCJ48C'LP*]9R6O 5:S6Q:[HP9&;S#V1" ]@
MDW!V1NKH!UL#EN@A^1!9,<$HVG]B!N17$8&28#)S,\,O;#!E1\XE$OD!,IU'
MF=SMOYLXY?&I!3'P6H>8UNSK%5B="AP=SG[\B!$0Z#.2<+LB2\2MD5( 64C
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MUEE.^OJ'N;VBU57!UJGJK9;ZF=[[AKFGHJ::5^FXU;&ZI)(G/=I:T-;DG#0
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M^&%,9"R29#!4QD0X>S3Z "%.DVK)F11;-^.E.^U-\))<<[[[Z[WKU=;WN[B
M,;<@=?5Y2O%_\8^Q[@4UR]MRD/XV>#3.9W9(Z2J>U948CU[^0R9L8./ VS6,
M3<O!(@\LF7M"XRMF]GS4<)C*]ADM-WR:J#*#1LR$ETXCA)M;R;/=R S\_;7K
M'NWM.-AV[XZM]AV?$N5,?/.#>-P?<:JNRHEY21&+PB56>ZG-F>2D;=3*PN \
MMYC1&AO'4I$J_D;>];H O=<M/L/.&AYQF>D];PXQ(W+J=HD8M0JPTGJ(]@[
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(1,(F$3"+_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
